PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Arico, S; Pattingre, S; Bauvy, C; Gane, P; Barbat, A; Codogno, P; Ogier-Denis, E				Arico, S; Pattingre, S; Bauvy, C; Gane, P; Barbat, A; Codogno, P; Ogier-Denis, E			Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; NF-KAPPA-B; CYCLOOXYGENASE-2 INHIBITOR; COLORECTAL-CANCER; INTESTINAL POLYPOSIS; SIGNALING PATHWAYS; SULINDAC SULFIDE; BCL-2 EXPRESSION; ASPIRIN USE	Nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase (COX) activity, are powerful antineoplastic agents that exert their antiproliferative and proapoptotic effects on cancer cells by COX-dependent and/or COX-independent pathways. Celecoxib, a COX-2-specific inhibitor, has been shown to reduce the number of adenomatous colorectal polyps in patients with familial adenomatous polyposis. Here, we show that celecoxib induces apoptosis in the colon cancer cell line HT-29 by inhibiting the 3-phosphoinositide-dependent kinase 1 (PDK1) activity. This effect was correlated with inhibition of the phosphorylation of the PDK1 downstream substrate Akt/protein kinase B (PKB) on two regulatory sites, Thr(308) and Ser(473). However, expression of a constitutive active form of Akt/PKB (myristoylated PKB) has a low protective effect toward celecoxib-induced cell death. In contrast, overexpression of constitutive active mutant of PDK1 (PDK1(A280V)) was as potent as the pan-caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, to impair celecoxib-induced apoptosis. By contrast, cells expressing a kinase-defective mutant of PDK1 (PDK1(K114G)) remained sensitive to celecoxib. Furthermore, in vitro measurement reveals that celecoxib was a potential inhibitor of PDK1 activity with an IC50 = 3.5 muM. These data indicate that inhibition of PDK1 signaling is involved in the proapoptotic effect of celecoxib in HT-29 cells.	INSERM, U504, F-94807 Villejuif, France; Inst Natl Transfus Sanguine, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Ogier-Denis, E (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Codogno, Patrice/G-1384-2013; Ogier-Denis, Eric/E-5030-2016	Codogno, Patrice/0000-0002-5492-3180; Pattingre, Sophie/0000-0001-6284-6050; Ogier-Denis, Eric/0000-0002-0057-7593				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1999, APOPTOSIS, V4, P365, DOI 10.1023/A:1009696505108; Everts B, 2000, CLIN RHEUMATOL, V19, P331, DOI 10.1007/s100670070024; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Grubbs CJ, 2000, CANCER RES, V60, P5599; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Jacoby RF, 2000, CANCER RES, V60, P5040; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Johnson AJ, 2001, ADV ENZYME REGUL, V41, P221, DOI 10.1016/S0065-2571(00)00015-7; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Liu XH, 1998, CANCER RES, V58, P4245; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ozes ON, 1999, NATURE, V401, P82; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Rice PL, 2001, CANCER RES, V61, P1541; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; Sheng HM, 1998, CANCER RES, V58, P362; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Shureiqi I, 2000, CANCER RES, V60, P6846; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; THUN MJ, 1993, CANCER RES, V53, P1322; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Weaver SA, 2001, TRENDS MOL MED, V7, P455, DOI 10.1016/S1471-4914(01)02107-4; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Yamada T, 2001, J BIOL CHEM, V276, P5339, DOI 10.1074/jbc.M005685200	58	269	287	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27613	27621		10.1074/jbc.M201119200	http://dx.doi.org/10.1074/jbc.M201119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12000750	hybrid			2022-12-25	WOS:000177189800007
J	McCabe, D; Cukierman, T; Gabay, JE				McCabe, D; Cukierman, T; Gabay, JE			Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HUMAN HBP/CAP37/AZUROCIDIN; SERINE PROTEASES; PROTEIN CAP37; LACTOFERRIN; LIPOPOLYSACCHARIDE; NEUTROPHILS; IDENTIFICATION; MONOCYTE; CELLS	Azurocidin/CAP37/HBP is an antimicrobial and chemotactic protein that is part of the innate defenses of human neutrophils. In addition, azurocidin is an inactive serine protease homolog with binding sites for diverse ligands including heparin and the bovine pancreatic trypsin inhibitor (BPTI). The structure of the protein reveals a highly cationic domain concentrated on one side of the molecule and responsible for its strong polarity. To investigate the role of this highly basic region, we produced three recombinant azurocidin mutant proteins that were altered in either one or both of two clusters of 4 basic residues located symmetrically on each side of a central cleft in the cationic domain. Two of the mutant proteins (Loop 3: R5Q, K6Q, R8Q, and R10Q; Loop 4: R61Q, R62Q, R63Q, and R65Q) exhibited little or no change in heparin and BPTI binding or in antimicrobial function. In contrast, the Loop 3/Loop 4 mutant (R5Q, K6Q, R8Q, R10Q, R61Q, R62Q R63Q, and R65Q) in which all 8 basic residues were replaced showed greatly decreased ability to bind heparin and to kill Escherichia coli and Candida albicans. Thus, we report that the 8 basic residues that were altered in the Loop 3/Loop 4 mutant contribute to the ability of the wild-type azurocidin molecule to bind heparin and to kill E. coli and C. albicans. Because BPTI binding was comparable in wild-type and Loop 3/Loop 4 mutant protein, we conclude that the same 8 basic residues are not involved in the binding of BPTI to azurocidin, supporting the notion that the binding site for BPTI is distinct from the site involved in heparin binding and antimicrobial activity. Finally, we show that removal of all 4 positively charged amino acids in the 20-44 azurocidin sequence (DMC1: R23Q,H24S,H32S,R34Q), a region previously thought to contain an antimicrobial domain, does not affect the activity of the protein against E. coli, Streptococcus faecalis, and C. albicans.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Gabay, JE (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023807] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23807] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMEIDA RP, 1991, BIOCHEM BIOPH RES CO, V177, P688, DOI 10.1016/0006-291X(91)91843-2; Almeida RP, 1996, PROTEIN EXPRES PURIF, V7, P355, DOI 10.1006/prep.1996.0053; Baveye S, 1999, CLIN CHEM LAB MED, V37, P281, DOI 10.1515/CCLM.1999.049; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brackett DJ, 1997, INFECT IMMUN, V65, P2803, DOI 10.1128/IAI.65.7.2803-2811.1997; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Chertov O, 1997, J EXP MED, V186, P739, DOI 10.1084/jem.186.5.739; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOHERTY DE, 1999, CHEST S1, V116, P34; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GABAY JE, 1994, CIBA F SYMP, V186, P237; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Heinzelmann M, 1998, INFECT IMMUN, V66, P5842, DOI 10.1128/IAI.66.12.5842-5847.1998; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iversen LF, 1997, NAT STRUCT BIOL, V4, P265, DOI 10.1038/nsb0497-265; Karlsen S, 1998, ACTA CRYSTALLOGR D, V54, P598, DOI 10.1107/S0907444997016193; Kastrup JS, 2001, PROTEINS, V42, P442, DOI 10.1002/1097-0134(20010301)42:4<442::AID-PROT30>3.0.CO;2-S; Kwan CP, 2001, J BIOL CHEM, V276, P23421, DOI 10.1074/jbc.M010786200; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Levy O, 2000, BLOOD, V96, P2664; Linde V, 2000, BIOTECHNIQUES, V28, P218, DOI 10.2144/00282bm06; MANN DM, 1994, J BIOL CHEM, V269, P23661; MORGAN JG, 1991, J IMMUNOL, V147, P3210; Nakamura I, 2001, PROTEIN EXPRES PURIF, V21, P424, DOI 10.1006/prep.2001.1396; PELLEGRINI A, 1992, J APPL BACTERIOL, V72, P180, DOI 10.1111/j.1365-2672.1992.tb01821.x; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; PETERSEN LC, 1993, EUR J BIOCHEM, V214, P271, DOI 10.1111/j.1432-1033.1993.tb17921.x; Rasmussen PB, 1996, FEBS LETT, V390, P109, DOI 10.1016/0014-5793(96)00639-4; SHAFER WM, 1984, INFECT IMMUN, V45, P29, DOI 10.1128/IAI.45.1.29-35.1984; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	34	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27477	27488		10.1074/jbc.M201586200	http://dx.doi.org/10.1074/jbc.M201586200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994286	hybrid			2022-12-25	WOS:000177055900097
J	Ruehl, M; Somasundaram, R; Schoenfelder, I; Farndale, RW; Knight, CG; Schmid, M; Ackermann, R; Riecken, EO; Zeitz, M; Schuppan, D				Ruehl, M; Somasundaram, R; Schoenfelder, I; Farndale, RW; Knight, CG; Schmid, M; Ackermann, R; Riecken, EO; Zeitz, M; Schuppan, D			The epithelial mitogen keratinocyte growth factor binds to collagens via the consensus sequence glycine-proline-hydroxyproline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; EXTRACELLULAR-MATRIX; FACTOR RECEPTORS; HEPARIN; INJURY; CELLS; RATS; PROLIFERATION; SIMILARITIES; TRANSCRIPTS	The binding of certain growth factors and cytokines to components of the extracellular matrix can regulate their local availability and modulate their biological activities. We show that mesenchymal cell-derived keratinocyte growth factor (KGF), a key stimulator of epithelial cell proliferation during wound healing, preferentially binds to collagens I, III, and VI. Binding is inhibited in a dose-dependent manner by denatured single collagen chains and collagen cyanogen bromide peptides. This interaction is saturable with dissociation constants of similar to10(-8) to 10(-9) m and estimated molar ratios of up to three molecules of KGF bound to one molecule of triple helical collagen. Furthermore, collagen-bound KGF stimulated the proliferation of transformed keratinocyte or HaCaT cells. Ligand blotting of collagen-derived peptides points to a limited set of collagenous consensus sequences that bind KGF. By using synthetic collagen peptides, we defined the consensus sequence (Gly-Pro-Hyp), as the collagen binding motif. We conclude that the preferential binding of KGF to the abundant collagens leads to a spatial pattern of bioavailable KGF that is dictated by the local organization of the collagenous extracellular matrix. The defined collagenous consensus peptide or its analogue may be useful in wound healing by increasing KGF bioactivity and thus modulating local epithelial remodeling and regeneration.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Med 1, D-12200 Berlin, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; University of Erlangen Nuremberg	Schuppan, D (corresponding author), Univ Erlangen Nurnberg, Med Klin 1, Krankenhousstr 12, D-91054 Erlangen, Germany.	detlef.schuppan@med1.imed.uni-erlangen.de		Somasundaram, Rajan/0000-0003-3461-3326				BajajElliott M, 1997, AM J PATHOL, V151, P1469; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Deterding RR, 1997, P ASSOC AM PHYSICIAN, V109, P254; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Farrell CL, 1998, CANCER RES, V58, P933; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; Finch PW, 1999, GUT, V45, P848, DOI 10.1136/gut.45.6.848; Gillis P, 1999, J CELL SCI, V112, P2049; Han DS, 2000, AM J PHYSIOL-GASTR L, V279, pG1011, DOI 10.1152/ajpgi.2000.279.5.G1011; Haseltine WA, 2001, J AM ACAD DERMATOL, V45, P473, DOI 10.1067/mjd.2001.117383; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; Jang JH, 2001, CANCER RES, V61, P3541; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; Jimenez PA, 1999, J SURG RES, V81, P238, DOI 10.1006/jsre.1998.5501; Khan WB, 1997, RADIAT RES, V148, P248, DOI 10.2307/3579609; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; La Rosa S, 2001, APPL IMMUNOHISTO M M, V9, P319, DOI 10.1097/00022744-200112000-00006; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MATTHES H, 1992, GASTROENTEROLOGY, V102, P431, DOI 10.1016/0016-5085(92)90087-F; Playford RJ, 1998, J PATHOL, V184, P316, DOI 10.1002/(SICI)1096-9896(199803)184:3<316::AID-PATH3>3.0.CO;2-#; Potten CS, 2001, CELL GROWTH DIFFER, V12, P265; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Schuppan D, 2001, SEMIN LIVER DIS, V21, P351, DOI 10.1055/s-2001-17556; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Somasundaram R, 2000, J BIOL CHEM, V275, P38170, DOI 10.1074/jbc.M006616200; Somasundaram R, 2002, J BIOL CHEM, V277, P3242, DOI 10.1074/jbc.M110011200; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tanahashi T, 1996, J BIOL CHEM, V271, P8221, DOI 10.1074/jbc.271.14.8221; Ueda T, 1999, CANCER RES, V59, P6080; Ulich TR, 1997, CANCER RES, V57, P472; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; Zeeh JM, 1996, GASTROENTEROLOGY, V110, P1077, DOI 10.1053/gast.1996.v110.pm8612996	45	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26872	26878		10.1074/jbc.M202335200	http://dx.doi.org/10.1074/jbc.M202335200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11973338	hybrid			2022-12-25	WOS:000177055900024
J	Chipuk, JE; Stewart, LV; Ranieri, A; Song, K; Danielpour, D				Chipuk, JE; Stewart, LV; Ranieri, A; Song, K; Danielpour, D			Identification and characterization of a novel rat ov-serpin family member, trespin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; GRANZYME-B INHIBITOR; CRYSTAL-STRUCTURE; TGF-BETA; ALPHA-1-PROTEINASE INHIBITOR; PROTEASE INHIBITOR; MOLECULAR-CLONING; OVALBUMIN FAMILY	Serpins are responsible for regulating a variety of proteolytic processes through a unique irreversible suicide substrate mechanism. To discover novel genes regulated by transforming growth factor-beta1 (TGF-beta1), we performed differential display reverse transcriptase-PCR analysis of NRP-152 rat prostatic epithelial cells and cloned a novel rat serpin that is transcriptionally down-regulated by TGF-beta and hence named trespin (TGF-beta-repressible serine proteinase inhibitor (trespin). Trespin is a 397-amino acid member of the ov-serpin clade with a calculated molecular mass of 45.2 kDa and 72% amino acid sequence homology to human bomapin; however, trespin exhibits different tissue expression, cellular localization, and proteinase specificity compared with bomapin. Trespin mRNA is expressed in many tissues, including brain, heart, kidney, liver, lung, prostate, skin, spleen, and stomach. FILAG-trespin expressed in HEK293 cells is localized predominantly in the cytoplasm and is not constitutively secreted. The presence of an arginine at the P1 position of trespin's reactive site loop suggests that trespin inhibits trypsin-like proteinases. Accordingly, in vitro transcribed and translated trespin forms detergent-stable and thermostable complexes with plasmin and elastase but not subtilisin A, trypsin, chymotrypsin, thrombin, or papain. Trespin interacts with plasmin at a near 1:1 stoichiometry, and immunopurified mammal-expressed trespin inhibits plasmin in a dose-dependent manner. These data suggest that trespin is a novel and functional member of the rat ov-serpin family.	Ireland Canc Ctr, Res Labs, Cleveland, OH 44106 USA; Case Western Reserve Univ Hosp, Dept Pharmacol, Cleveland, OH 44106 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Danielpour, D (corresponding author), Ireland Canc Ctr, Res Labs, Samuel Gerber Bldg,Suite 200,Lab 3,11001 Cedar Rd, Cleveland, OH 44106 USA.	dxd49@po.cwru.edu		Chipuk, Jerry Edward/0000-0002-1337-842X; Stewart, LaMonica/0000-0002-8056-6359	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, 1R01 CA3069-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Askew YS, 2001, J BIOL CHEM, V276, P49320, DOI 10.1074/jbc.M108879200; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bonham MJ, 1996, BIOTECHNIQUES, V21, P57; Buzza MS, 2001, CELL IMMUNOL, V210, P21, DOI 10.1006/cimm.2001.1806; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Chen YQ, 2001, THROMB HAEMOSTASIS, V86, P1563, DOI 10.1055/s-0037-1616763; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chuang TL, 1999, J BIOL CHEM, V274, P11194, DOI 10.1074/jbc.274.16.11194; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; CROWTHER D C, 1992, Current Opinion in Biotechnology, V3, P399, DOI 10.1016/0958-1669(92)90169-J; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1999, J CELL SCI, V112, P169; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Falk P, 2000, SCAND J CLIN LAB INV, V60, P439, DOI 10.1080/003655100448419; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Hayashida-Hibino S, 2001, INVEST OPHTH VIS SCI, V42, P1691; Hopkins PCR, 2000, J MOL EVOL, V51, P507, DOI 10.1007/s002390010114; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Hsing AY, 1996, CANCER RES, V56, P5146; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Maass N, 2000, ACTA ONCOL, V39, P931; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Riewald M, 1996, J BIOL CHEM, V271, P14526, DOI 10.1074/jbc.271.24.14526; Riewald M, 1998, BLOOD, V91, P1256, DOI 10.1182/blood.V91.4.1256; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Schleef RR, 2000, J BIOL CHEM, V275, P26385, DOI 10.1074/jbc.C000389200; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tang BW, 1999, CANCER RES, V59, P4834; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Wimalasena K, 1996, ANAL BIOCHEM, V234, P175, DOI 10.1006/abio.1996.0069; YE RD, 1989, J BIOL CHEM, V264, P5495; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZHAO S, 1995, BIOTECHNIQUES, V18, P842; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	69	6	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26412	26421		10.1074/jbc.M201244200	http://dx.doi.org/10.1074/jbc.M201244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986314	hybrid			2022-12-25	WOS:000176908700078
J	Feng, K; Zhou, XH; Oohashi, T; Morgelin, M; Lustig, A; Hirakawa, S; Ninomiya, Y; Engel, J; Rauch, U; Fassler, R				Feng, K; Zhou, XH; Oohashi, T; Morgelin, M; Lustig, A; Hirakawa, S; Ninomiya, Y; Engel, J; Rauch, U; Fassler, R			All four members of the Ten-m/Odz family of transmembrane proteins form dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR-RULE GENE; COLLAGEN-VI; ODD OZ; EXPRESSION; TISSUES; TENASCIN; HOMOLOGS; LAMININ; BINDING; VIRUS	Ten-m/Odz/teneurins are a new family of four distinct type II transmembrane molecules. Their extracellular domains are composed of an array of eight consecutive EGF modules followed by a large globular domain. Two of the eight modules contain only 5 instead of the typical 6 cysteine residues and have the capability to dimerize in a covalent, disulfide-linked fashion. The structural properties of the extracellular domains of all four mouse Ten-m proteins have been analyzed using secreted, recombinant molecules produced by mammalian HEK-293 cells. Electron microscopic analysis supported by analytical ultracentrifugation data revealed that the recombinant extracellular domains of all Ten-m proteins formed homodimers. SDS-PAGE analysis under non-reducing conditions as well as negative staining after partial denaturation of the molecules indicated that the globular COOH-terminal domains of Ten-m1 and -m4 contained subdomains with a pronounced stability against denaturing agents, especially when compared with the homologous domains of Ten-m2 and -m3. Co-transfection experiments of mammalian cells with two different extracellular domains revealed that Ten-m molecules have also the ability to form heterodimers, a property that, combined with alternative splicing events, allows the formation of a multitude of molecules with different characteristics from a limited set of genes.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Lund Univ, Sect Connect Tissue Biol, Dept Expt Pathol, S-22185 Lund, Sweden; Lund Univ, Sect Connect Tissue Biol, Dept Cell & Mol Biol, S-22185 Lund, Sweden; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	Max Planck Society; Lund University; Lund University; Okayama University; University of Basel	Fassler, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Oohashi, Toshitaka/B-1599-2011	Oohashi, Toshitaka/0000-0002-9302-1913				BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; Ben-Zur T, 2000, DEV BIOL, V217, P107, DOI 10.1006/dbio.1999.9532; Brandau O, 1999, HUM MOL GENET, V8, P2407, DOI 10.1093/hmg/8.13.2407; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Levine A, 1997, DEV DYNAM, V209, P1, DOI 10.1002/(SICI)1097-0177(199705)209:1<1::AID-AJA1>3.0.CO;2-M; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Mieda M, 1999, MECH DEVELOP, V87, P223, DOI 10.1016/S0925-4773(99)00155-0; Minet AD, 1999, J CELL SCI, V112, P2019; Minet AD, 2000, GENE, V257, P87, DOI 10.1016/S0378-1119(00)00388-7; Oohashi T, 1999, J CELL BIOL, V145, P563, DOI 10.1083/jcb.145.3.563; Otaki JM, 1999, DEV BIOL, V212, P165, DOI 10.1006/dbio.1999.9310; RALSON G, 1993, INTRO ANAL ULTRACENT; Rubin BP, 1999, DEV BIOL, V216, P195, DOI 10.1006/dbio.1999.9503; Tucker RP, 2000, MECH DEVELOP, V98, P187, DOI 10.1016/S0925-4773(00)00444-5; Tucker RP, 2001, DEV DYNAM, V220, P27, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1084>3.0.CO;2-B; Van Holde K., 1971, PHYSICAL BIOCH, P98; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200	24	70	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26128	26135		10.1074/jbc.M203722200	http://dx.doi.org/10.1074/jbc.M203722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000766	hybrid			2022-12-25	WOS:000176908700040
J	Melamed, P; Koh, M; Preklathan, P; Bei, L; Hew, C				Melamed, P; Koh, M; Preklathan, P; Bei, L; Hew, C			Multiple mechanisms for Pitx-1 transactivation of a luteinizing hormone beta subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; GROWTH-RESPONSE PROTEIN-1; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; BINDING DOMAIN; DNA; RECEPTOR; PTX1; PROMOTER; ELEMENT	The pituitary homeobox factor-1 (Pitx-1) transactivates a number of pituitary-specific genes through direct interaction with other specific transcription factors. We demonstrate here that Pitx-1 plays a crucial role in the regulation of the Chinook salmon luteinizing hormone 13 gene promoter through a number of novel mechanisms. On the proximal promoter its action involves a synergistic effect with steroidogenic factor-1 (SF-1) alone or in combination with the estrogen receptor; promoter activity being induced by 9- or 35-fold over controls, respectively. Further upstream, a series of four Pitx-1 response elements (located between 1366 and 1506 bp from the transcriptional start site) is also involved in regulating the promoter activity. The two distal sequences have the greatest effect on the basal activity and are also essential for the gonadotropin-releasing hormone (GnRH) response. Mammalian two-hybrid assays revealed that Pitx-1 can homodimerize. Moreover, circular permutation assays indicate that binding of Pitx-1 to more than one response element induces conformational changes of the target DNA. This constitutes an additional mechanism through which Pitx-1 can mediate transactivation of this gene, allowing the demonstrated interaction of proximal response elements and distal enhancers, thus facilitating the maximal GnRH response that was seen in the longer promoter constructs. Our research also indicates that Pitx-1 is phosphorylated on three residues when bound to the DNA.	Natl Univ Singapore, Funct Genom Labs, Dept Biol Sci, Singapore 117542, Singapore	National University of Singapore	Melamed, P (corresponding author), Natl Univ Singapore, Funct Genom Labs, Dept Biol Sci, 14 Sci D 4, Singapore 117542, Singapore.							Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Drouin J, 1998, MOL CELL ENDOCRINOL, V140, P31, DOI 10.1016/S0303-7207(98)00026-4; Halvorson LM, 1999, MOL ENDOCRINOL, V13, P106, DOI 10.1210/me.13.1.106; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; Kim J, 1996, BIOCHEM BIOPH RES CO, V226, P638, DOI 10.1006/bbrc.1996.1408; Kioussi C, 1999, MECH DEVELOP, V81, P23, DOI 10.1016/S0925-4773(98)00229-9; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Le Drean Y, 1997, MOL CELL ENDOCRINOL, V135, P31, DOI 10.1016/S0303-7207(97)00184-6; LeDrean Y, 1996, MOL ENDOCRINOL, V10, P217, DOI 10.1210/me.10.3.217; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LIU D, 1995, ENDOCRINOLOGY, V136, P3486, DOI 10.1210/en.136.8.3486; Liu D, 2000, J BIOL CHEM, V275, P16758, DOI 10.1074/jbc.M000121200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; Robinson CE, 1998, BIOCHEM BIOPH RES CO, V244, P671, DOI 10.1006/bbrc.1998.8305; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; Schaeffer V, 1999, P NATL ACAD SCI USA, V96, P4461, DOI 10.1073/pnas.96.8.4461; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Sheng HZ, 1999, TRENDS GENET, V15, P236, DOI 10.1016/S0168-9525(99)01742-4; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; StraussSoukup JK, 1997, J BIOL CHEM, V272, P31570, DOI 10.1074/jbc.272.50.31570; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Weck J, 2000, MOL ENDOCRINOL, V14, P472, DOI 10.1210/me.14.4.472; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; XIONG F, 1994, MOL ENDOCRINOL, V8, P771, DOI 10.1210/me.8.6.771; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617	44	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26200	26207		10.1074/jbc.M201605200	http://dx.doi.org/10.1074/jbc.M201605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011080	hybrid			2022-12-25	WOS:000176908700050
J	Rao, MK; Maiti, S; Ananthaswamy, HN; Wilkinson, MF				Rao, MK; Maiti, S; Ananthaswamy, HN; Wilkinson, MF			A highly active homeobox gene promoter regulated by Ets and Sp1 family members in normal granulosa cells and diverse tumor cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS SP1; REPRESS TRANSCRIPTION; NECROSIS-FACTOR; ONCOFETAL GENE; SERTOLI CELLS; STEM-CELLS; EXPRESSION; PEM; ACTIVATION	One mechanism by which normal cells become converted to tumor cells involves the aberrant transcriptional activation of genes that are normally silent. We characterize a promoter that normally exhibits highly tissue- and stage-specific expression but displays ubiquitous expression when cells become immortalized or malignant, regardless of their lineage or tissue origin. This promoter normally drives the expression of the Pem homeobox gene in specific cell types in ovary and placenta but is aberrantly expressed in lymphomas, neuroblastomas, retinoblastomas, carcinomas, and sarcomas. By deletion analysis we identified a region between nucleotides -80 and -104 that was absolutely critical for the expression from this distal Pem promoter (Pem Pd). Site-specific mutagenesis and transection studies revealed that this region contains two consensus Ets sites and a single Sp1 site that were necessary for Pem Pd expression. Gel shift analysis showed that Ets and Sp1 family members bound to these sites. Transfection studies demonstrated that the Ets family members Elf1 and Gabp and the Sp1 family members Sp1 and Sp3 transactivated the Pem Pd. Surprisingly, we found that Sp3 was a more potent activator of the Pem Pd than was Sp1; this is unusual, because Sp3 is either a weak activator or a repressor of most other promoters. Activation by either Elf1 or Gabp required an intact Sp1 family member binding site, suggesting that Ets and Sp1 family members cooperate to activate Pent Pd transcription. Expression from the Pem Pd (either transiently transfected or endogenous) depended on the Ras pathway, which could explain both its Ets- and Sp1-dependent expression in normal cells and its aberrant expression in tumor cells, in which ras protooncogenes are frequently mutated. We suggest that the Pem Pd may be a useful model system to understand the molecular mechanism by which a tissue-specific promoter can be corrupted in tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org						Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Bassuk AG, 1998, MOL MED, V4, P392, DOI 10.1007/BF03401746; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Caldas C, 1999, CANCER METAST REV, V18, P313, DOI 10.1023/A:1006333610078; CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Fan Y, 1999, DEV BIOL, V210, P481, DOI 10.1006/dbio.1999.9279; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; GALANG CK, 1994, ONCOGENE, V9, P2913; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Krikun G, 2000, MOL ENDOCRINOL, V14, P393, DOI 10.1210/me.14.3.393; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lindsey JS, 1996, DEV BIOL, V179, P471, DOI 10.1006/dbio.1996.0276; Lindsey JS, 1996, BIOL REPROD, V55, P975, DOI 10.1095/biolreprod55.5.975; Maiti S, 1996, J BIOL CHEM, V271, P17536, DOI 10.1074/jbc.271.29.17536; Maiti S, 2001, ENDOCRINOLOGY, V142, P1567, DOI 10.1210/en.142.4.1567; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Ono T, 2000, INT J CANCER, V88, P845, DOI 10.1002/1097-0215(20001215)88:6<845::AID-IJC1>3.0.CO;2-N; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Pitman JL, 1998, DEV BIOL, V202, P196, DOI 10.1006/dbio.1998.8978; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Rao M, 2002, EPIDIDYMIS MOL CLIN, P269, DOI 10.1007/978-1-4615-0679-9_15; Rieber M, 1999, INT J CANCER, V83, P359, DOI 10.1002/(SICI)1097-0215(19991029)83:3<359::AID-IJC11>3.0.CO;2-6; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SASAKI AW, 1991, MECH DEVELOP, V34, P155, DOI 10.1016/0925-4773(91)90052-8; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Serio KJ, 2000, AM J RESP CELL MOL, V23, P234, DOI 10.1165/ajrcmb.23.2.4042; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Sutton KA, 1997, GENOMICS, V45, P447, DOI 10.1006/geno.1997.4946; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Tomaras GD, 1999, J LEUKOCYTE BIOL, V66, P183, DOI 10.1002/jlb.66.1.183; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zachos G, 1997, CRIT REV ONCOL HEMAT, V26, P65, DOI 10.1016/S1040-8428(97)00013-9; Zannetti A, 2000, CANCER RES, V60, P1546	70	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26036	26045		10.1074/jbc.M203374200	http://dx.doi.org/10.1074/jbc.M203374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986330	hybrid			2022-12-25	WOS:000176908700029
J	Greene, BT; Thorburn, J; Willingham, MC; Thorburn, A; Planalp, RP; Brechbiel, MW; Jennings-Gee, J; Wilkinson, J; Torti, FM; Torti, SV				Greene, BT; Thorburn, J; Willingham, MC; Thorburn, A; Planalp, RP; Brechbiel, MW; Jennings-Gee, J; Wilkinson, J; Torti, FM; Torti, SV			Activation of caspase pathways during iron chelator-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; ISONICOTINOYL HYDRAZONE; NEUROBLASTOMA-CELLS; SIGNALING PATHWAY; NECROSIS-FACTOR; CYTOCHROME-C; PROTEIN P35; DEPRIVATION; CIS,CIS-1,3,5-TRIAMINOCYCLOHEXANE; INHIBITION	Iron chelators have traditionally been used in the treatment of iron overload. Recently, chelators have also been explored for their ability to limit oxidant damage in cardiovascular, neurologic, and inflammatory disease as well as to serve as anti-cancer agents. To determine the mechanism of cell death induced by iron chelators, we assessed the time course and pathways of caspase activation during apoptosis induced by iron chelators. We report that the chelator tachpyridine sequentially activates caspases 9, 3, and 8. These caspases were also activated by the structurally unrelated chelators dipyridyl and desferrioxamine. The critical role of caspase activation in cell death was supported by micro-injection experiments demonstrating that p35, a broad spectrum caspase inhibitor, protected HeLa cells from chelator-induced cell death. Apoptosis mediated by tachpyridine was not prevented by blocking the CD95 death receptor pathway with a Fas-associated death domain protein (FADD) dominant-negative mutant. In contrast, chelator-mediated cell death was blocked in cells microinjected with Bcl-XL and completely inhibited in cells microinjected with a dominant-negative caspase 9 expression vector. Caspase activation was not observed in cells treated with N-methyl tachpyridine, an N-alkylated derivative of tachpyridine which lacks an ability to react with iron. These results suggest that activation of a mitochondrial caspase pathway is an important mechanism by which iron chelators induce cell death.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; NIH, Radiat Oncol Branch, Bethesda, MD 20892 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; University System Of New Hampshire; University of New Hampshire; National Institutes of Health (NIH) - USA	Torti, SV (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Hanes Bldg,Rm 4057,Med Ctr Blvd, Winston Salem, NC 27157 USA.	storti@vfubmc.edu	Planalp, Roy/E-7115-2012	Planalp, Roy/0000-0001-5673-8694	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057781] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 57781] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe RD, 2001, CARCINOGENESIS, V22, P1607, DOI 10.1093/carcin/22.10.1607; Bowen T, 1996, BIOORG MED CHEM LETT, V6, P807, DOI 10.1016/0960-894X(96)00110-2; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fan LJ, 2001, CANCER RES, V61, P1073; Franchini M, 2000, HAEMATOLOGICA, V85, P1122; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Galanello R, 2001, SEMIN HEMATOL, V38, P73, DOI 10.1053/shem.2001.20147; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; HENNING RS, 2000, METHOD ENZYMOL, V322, P91; HILETI D, 1995, BRIT J HAEMATOL, V89, P181, DOI 10.1111/j.1365-2141.1995.tb08927.x; Horackova M, 2000, CARDIOVASC RES, V47, P529, DOI 10.1016/S0008-6363(00)00088-2; Ido Y, 1999, CELL PROLIFERAT, V32, P63, DOI 10.1046/j.1365-2184.1999.00133.x; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kovar J, 1997, PATHOBIOLOGY, V65, P61, DOI 10.1159/000164105; Kulp KS, 1996, EXP CELL RES, V229, P60, DOI 10.1006/excr.1996.0343; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZD, 2002, MED RES REV, V22, P26, DOI 10.1002/med.1027; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martelius T, 1999, TRANSPLANTATION, V68, P1753, DOI 10.1097/00007890-199912150-00020; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Park G, 1998, J BIOL INORG CHEM, V3, P449, DOI 10.1007/s007750050254; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Rakba N, 2000, CARCINOGENESIS, V21, P943, DOI 10.1093/carcin/21.5.943; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RIAZULHAQ, 1995, EXP HEMATOL, V23, P428; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Simonart T, 2000, J INVEST DERMATOL, V115, P893, DOI 10.1046/j.1523-1747.2000.00119.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Tetef ML, 2001, CLIN CANCER RES, V7, P1569; Thompson KJ, 2001, BRAIN RES BULL, V55, P155, DOI 10.1016/S0361-9230(01)00510-X; Torti SV, 1998, BLOOD, V92, P1384, DOI 10.1182/blood.V92.4.1384; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Weinberg ED, 1999, CANCER INVEST, V17, P507, DOI 10.3109/07357909909032860; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; Wilson MR, 1998, BIOCHEM CELL BIOL, V76, P573, DOI 10.1139/bcb-76-4-573; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	45	76	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25568	25575		10.1074/jbc.M110345200	http://dx.doi.org/10.1074/jbc.M110345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980894	hybrid			2022-12-25	WOS:000176747000094
J	Ishii, I; Ye, XQ; Friedman, B; Kawamura, S; Contos, JJA; Kingsbury, MA; Yang, AH; Zhang, GF; Brown, JH; Chun, J				Ishii, I; Ye, XQ; Friedman, B; Kawamura, S; Contos, JJA; Kingsbury, MA; Yang, AH; Zhang, GF; Brown, JH; Chun, J			Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LPB2/EDG-5 and S1P(3)/LPB3/EDG-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DIFFERENTIATION GENE FAMILY; HAMSTER OVARY CELLS; SMOOTH-MUSCLE; EDG FAMILY; SPHINGOSINE-1-PHOSPHATE; MIGRATION; ACTIVATION; EXPRESSION; SYSTEM	Five cognate G protein-coupled receptors (S1P(1-5)) have been shown to mediate various cellular effects of sphingosine I-phosphate (SIP). Here we report the generation of mice null for SIP, and for both SIP, and SIP,. S1P(2)-null mice were viable and fertile and developed normally. The litter sizes from S1P(2)S1P(3) double-null crosses were remarkably reduced compared with controls, and double-null pups often did not survive through infancy, although double-null survivors lacked any obvious phenotype. Mouse embryonic fibroblasts (MEFs) were examined for the effects of receptor deletions on SIP signaling pathways. Wild-type MEFs were responsive to SIP in activation of Rho and phospholipase C (PLC), intracellular calcium mobilization, and inhibition of forskolin-activated adenylyl cyclase. S1P(2)-null MEFs showed a significant decrease in Rho activation, but no effect on PLC activation, calcium mobilization, or adenylyl cyclase inhibition. Double-null MEFs displayed a complete loss of Rho activation and a significant decrease in PLC activation and calcium mobilization, with no effect on adenylyl cyclase inhibition. These data extend our previous findings on S1P(3)-null mice and indicate preferential coupling of the S1P(2) and S1P(3) receptors to Rho and PLC/Ca2+ pathways, respectively. Although either receptor subtype supports embryonic development, deletion of both produces marked perinatal lethality, demonstrating an essential role for combined SIP signaling by these receptors.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Neurosci Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Program Biomed Sci, La Jolla, CA 92093 USA; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Genet, Kodaira, Tokyo 1878502, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; National Center for Neurology & Psychiatry - Japan	Chun, J (corresponding author), Merck Res Labs, 3535 Gen Atom Ct, San Diego, CA 92121 USA.			Ishii, Isao/0000-0002-5367-205X	NHLBI NIH HHS [HL28143] Funding Source: Medline; NIA NIH HHS [5T32AG00216] Funding Source: Medline; NIGMS NIH HHS [2T32GM07752, T32 GM007752, GM36927] Funding Source: Medline; NIMH NIH HHS [R01 MH51699] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028143, R01HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R01GM036927, R56GM036927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000216] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MacLennan AJ, 2000, DEV NEUROSCI-BASEL, V22, P283, DOI 10.1159/000017452; MacLennan AJ, 1997, NEUROSCIENCE, V79, P217, DOI 10.1016/S0306-4522(96)00601-X; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Takuwa Y, 2001, MOL CELL ENDOCRINOL, V177, P3, DOI 10.1016/S0303-7207(01)00441-5; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tigyi G, 2001, MOL PHARMACOL, V60, P1161, DOI 10.1124/mol.60.6.1161; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YANG AH, 2002, IN PRESS BIOCH BIOPH; Yatomi Y, 1997, J BIOCHEM, V121, P969; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	44	200	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25152	25159		10.1074/jbc.M200137200	http://dx.doi.org/10.1074/jbc.M200137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006579	hybrid			2022-12-25	WOS:000176747000041
J	Lopez-Carballo, G; Moreno, L; Masia, S; Perez, P; Barettino, D				Lopez-Carballo, G; Moreno, L; Masia, S; Perez, P; Barettino, D			Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ACHAETE-SCUTE HOMOLOG-1; LOOP-HELIX PROTEINS; GROWTH FACTOR-I; NEURONAL DIFFERENTIATION; BLASTOMA CELLS; NEURITE OUTGROWTH; ESTROGEN-RECEPTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION	Retinoic acid (RA) induces neural differentiation of SH-SY5Y neuroblastoma cells. We show that the mRNA levels of the differentiation-inhibiting basic helix-loop-helix transcription factors ID1, ID2, and ID3 are down-regulated during RA-induced differentiation of SHSY5Y cells. The levels of ID proteins decreased in parallel to the observed transcriptional repression. The expression of other basic helix-loop-helix genes changed during RA-induced differentiation: expression of neuroblast-specific ASCL1 (HASH-1) gene was promptly reduced after RA treatment, whereas expression of differentiation-promoting genes NEUROD6 (NEX-1, HATH-2) and NEUROD1 was increased. Treatments with 12-O-tetradecanoylphorbol-13-acetate, another inducer of neuroblastoma cell differentiation, also resulted in coordinated down-regulation of ID gene expression, underscoring the role of ID genes in differentiation. Downregulation of ID gene expression by RA involves a complex mechanism because full transcriptional repression required newly synthesized proteins and signaling by phosphatidylinositol 3-kinase (PI3K). RA treatment activates the PI3K/Akt signaling pathway, resulting in increased PI3K activity in extracts from RA-treated cells and a rapid increase in phosphorylation of Akt in Ser-473. Inhibition of PI3K by LY294002 impaired RA-induced differentiation, as assessed by morphological and biochemical criteria. We propose that RA, by activating the PI3K/Akt signaling pathway, plays an important role in the regulation of neuronal cell survival.	CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Barettino, D (corresponding author), CSIC, Inst Biomed Valencia, Jaime Roig 11, E-46010 Valencia, Spain.		Perez, Paloma/K-8841-2017; Moreno Royo, Lucrecia/A-8648-2017	Perez, Paloma/0000-0002-7166-2824; Moreno Royo, Lucrecia/0000-0002-9456-9649; Masia, Susana/0000-0002-9807-140X				Alexander F, 2000, UROL CLIN N AM, V27, P383, DOI 10.1016/S0094-0143(05)70087-2; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Asano T, 2000, J BIOL CHEM, V275, P17671, DOI 10.1074/jbc.M910391199; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chiaramello A, 1996, J BIOL CHEM, V271, P22035, DOI 10.1074/jbc.271.36.22035; Cho JH, 2001, J NEUROCHEM, V77, P103, DOI 10.1046/j.1471-4159.2001.t01-1-00230.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dragnev K H, 2000, Oncologist, V5, P361, DOI 10.1634/theoncologist.5-5-361; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Gestblom C, 1999, LAB INVEST, V79, P67; Ghigo D, 1998, J CELL PHYSIOL, V174, P99; Glass CK, 2000, GENE DEV, V14, P121; Grynfeld A, 2000, INT J CANCER, V88, P401, DOI 10.1002/1097-0215(20001101)88:3<401::AID-IJC12>3.3.CO;2-M; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HANADA M, 1993, CANCER RES, V53, P4978; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Ichimiya S, 2001, MED PEDIATR ONCOL, V36, P132, DOI 10.1002/1096-911X(20010101)36:1<132::AID-MPO1031>3.0.CO;2-A; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASORELLA A, 1995, CANCER RES, V55, P4711; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; MATTSSON MEK, 1986, J CELL BIOL, V102, P1949, DOI 10.1083/jcb.102.5.1949; Matz M, 1997, NUCLEIC ACIDS RES, V25, P2541, DOI 10.1093/nar/25.12.2541; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; Persson P, 2000, BIOCHEM BIOPH RES CO, V274, P22, DOI 10.1006/bbrc.2000.3090; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIDELL N, 1982, J NATL CANCER I, V68, P589; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Soderholm H, 1999, BIOCHEM BIOPH RES CO, V256, P557, DOI 10.1006/bbrc.1999.0314; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAHIRA T, 1991, ONCOGENE, V6, P2333; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; TAKEUCHI T, 1986, J CLIN INVEST, V77, P1038, DOI 10.1172/JCI112357; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WUARIN L, 1991, DEV BIOL, V144, P429, DOI 10.1016/0012-1606(91)90435-6; WUARIN L, 1990, INT J DEV NEUROSCI, V8, P317, DOI 10.1016/0736-5748(90)90038-4; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zile MH, 1998, J NUTR, V128, p455S, DOI 10.1093/jn/128.2.455S	80	208	215	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25297	25304		10.1074/jbc.M201869200	http://dx.doi.org/10.1074/jbc.M201869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000752	Green Submitted, hybrid			2022-12-25	WOS:000176747000060
J	Sepulveda, JL; Vlahopoulos, S; Iyer, D; Belaguli, N; Schwartz, RJ				Sepulveda, JL; Vlahopoulos, S; Iyer, D; Belaguli, N; Schwartz, RJ			Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; TINMAN HOMOLOG NKX-2.5; DNA-BINDING TARGETS; TRANSCRIPTION FACTORS; PROTEINS SP1; ACTIVATION; HOMEODOMAIN; PROMOTER; ELEMENTS; INTERACT	Herein, the restricted expression of serum response factors (SRF) closely overlapped with Nkx2-5 and GATA4 transcripts in early chick embryos coinciding with the earliest appearance of cardiac alpha-actin (alphaCA) transcripts and nascent myocardial cells. The combinatorial expression of SRF, a MADS box factor Nkx2-5 (a NK4 homeodomain), and/or GATA4, a dual C4 zinc finger protein, in heterologous CV1 fibroblasts and Schneider 2 insect cells demonstrated synergistic induction of alphaCA promoter activity. These three factors induced endogenous alphaCA mRNA over a 100-fold in murine embryonic stem cells. In addition, the DNA-binding defective mutant N-kx2-5pm efficiently coactivated the alphaCA promoter in the presence of SRF and GATA4 in the presence of all four SREs and was substantially weakened when individual SREs were mutated and or serially deleted. In contrast, the introduction of SRFpm, a SRF DNA-binding mutant, blocked the activation with all of the alphaCA promoter constructions. These assays indicated a dependence upon cooperative SRF binding for facilitating the recruitment of Nkx2-5 and GATA4 to the alphaCA promoter. Furthermore, the recruitment of Nkx2-5 and GATA4 by SRF was observed to strongly enhance SRF DNA binding affinity. This mechanism allowed for the formation of higher ordered alphaCA promoter DNA binding complexes, led to a model of SRF physical association with Nkx2-5 and GATA4.	Baylor Coll Med, Dept Mol & Cellular Biol, Div Cardiovasc Sci, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Div Cardiovasc Sci, Ctr Cardiovasc Dev, 1 Baylor Plaza,Rm 145E, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu	Vlahopoulos, Spiros/AAK-6362-2020; Vlahopoulos, Spiros A/A-1186-2014	Vlahopoulos, Spiros/0000-0001-6245-3863; Vlahopoulos, Spiros A/0000-0001-6245-3863	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albrecht BE, 1997, EUR J NEUROSCI, V9, P2414, DOI 10.1111/j.1460-9568.1997.tb01658.x; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; BODMER R, 1993, DEVELOPMENT, V118, P719; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MA JT, 1994, BIOCHEM BIOPH RES CO, V200, P1742, DOI 10.1006/bbrc.1994.1654; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Simon KJ, 1997, MOL CELL BIOL, V17, P6653, DOI 10.1128/MCB.17.11.6653; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Uetz P, 1996, ANAL BIOCHEM, V237, P161, DOI 10.1006/abio.1996.0220; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4	46	127	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25775	25782		10.1074/jbc.M203122200	http://dx.doi.org/10.1074/jbc.M203122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983708	hybrid			2022-12-25	WOS:000176747000120
J	Angata, T; Kerr, SC; Greaves, DR; Varki, NM; Crocker, PR; Varki, A				Angata, T; Kerr, SC; Greaves, DR; Varki, NM; Crocker, PR; Varki, A			Cloning and characterization of human Siglec-11 - A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PROTEIN-TYROSINE PHOSPHATASES; ACID-BINDING-SITE; SIALIC ACIDS; INHIBITORY RECEPTOR; SIALOADHESIN FAMILY; OLIGOSIALIC ACIDS; PRIMATE EVOLUTION; CELL-ADHESION; HUMAN CD33	Siglecs are sialic acid-recognizing animal lectins of the immunoglobulin superfamily. We have cloned and characterized a novel human molecule, Siglec-11, that belongs to the subgroup of CD33/Siglec-3-related Siglees. As with others in this subgroup, the cytosolic domain of Siglec-11 is phosphorylated at tyrosine residue(s) upon pervanadate treatment of cells and then recruits the protein-tyrosine phosphatases SHP-1 and SHP-2. However, Siglec-11 has several novel features relative to the other CD33/Siglec-3-related Siglecs. First, it binds specifically to alpha2-8-linked sialic acids. Second, unlike other CD33/Siglec-3-related Siglecs, Siglec-11 was not found on peripheral blood leukocytes. Instead, we observed its expression on macrophages in various tissues, such as liver Kupffer cells. Third, it was also expressed on brain microglia, thus becoming the second Siglec to be found in the nervous system. Fourth, whereas the Siglec-11 gene is on human chromosome 19, it lies outside the previously described CD33/Siglec-3-related Siglec cluster on this chromosome. Fifth, analyses of genome data bases indicate that Siglec-11 has no mouse ortholog and that it is likely to be the last canonical human Siglec to be reported. Finally, although Siglec-11 shows marked sequence similarity to human Siglec-10 in its extracellular domain, the cytosolic tail appears only distantly related. Analysis of genomic regions surrounding the Siglec-11 gene suggests that it is actually a chimeric molecule that arose from relatively recent gene duplication and recombination events, involving the extracellular domain of a closely related ancestral Siglec gene (which subsequently became a pseudogene) and a transmembrane and cytosolic tail derived from another ancestral Siglec.	Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Dundee, Sch Life Sci, Div Mol Cell Biol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Dundee; University of Oxford	Varki, A (corresponding author), Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	avarki@ucsd.edu		Crocker, Paul/0000-0001-6230-0293; Greaves, David/0000-0003-2856-9410	NHLBI NIH HHS [P01 HL57345-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Angata T, 2001, J BIOL CHEM, V276, P45128, DOI 10.1074/jbc.M108573200; Brand-Arpon V, 1999, GENOMICS, V56, P98, DOI 10.1006/geno.1998.5690; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Canavez F, 2001, J IMMUNOL, V167, P5786, DOI 10.4049/jimmunol.167.10.5786; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Gough PJ, 2001, IMMUNOLOGY, V103, P351, DOI 10.1046/j.1365-2567.2001.01256.x; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Ito A, 2001, FEBS LETT, V498, P116, DOI 10.1016/S0014-5793(01)02476-0; Johnson ME, 2001, NATURE, V413, P514, DOI 10.1038/35097067; KANTOR AB, 1997, WEIRS HDB EXPT IMMUN, V2; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KOOP BF, 1986, NATURE, V319, P234, DOI 10.1038/319234a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li N, 2001, J BIOL CHEM, V276, P28106, DOI 10.1074/jbc.M100467200; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; Nei M, 1997, P NATL ACAD SCI USA, V94, P7799, DOI 10.1073/pnas.94.15.7799; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Ohno S., 1970, EVOLUTION GENE DUPLI; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Paul SP, 2000, BLOOD, V96, P483; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Schnaar RL, 1998, ANN NY ACAD SCI, V845, P92, DOI 10.1111/j.1749-6632.1998.tb09664.x; Sharon D, 1999, GENOMICS, V61, P24, DOI 10.1006/geno.1999.5900; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; Stewart CB, 1998, CURR BIOL, V8, pR582, DOI 10.1016/S0960-9822(07)00367-3; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; TAYLOR CR, 1994, HUM PATHOL, V25, P263, DOI 10.1016/0046-8177(94)90198-8; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Ulyanova T, 2001, J BIOL CHEM, V276, P14451, DOI 10.1074/jbc.M011650200; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; Whitney G, 2001, EUR J BIOCHEM, V268, P6083, DOI 10.1046/j.0014-2956.2001.02543.x; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200; [No title captured]	63	145	153	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24466	24474		10.1074/jbc.M202833200	http://dx.doi.org/10.1074/jbc.M202833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986327	hybrid			2022-12-25	WOS:000176611800066
J	Mihalik, SJ; Steinberg, SJ; Pei, ZT; Park, J; Kim, DG; Heinzer, AK; Dacremont, G; Wanders, RJA; Cuebas, DA; Smith, KD; Watkins, PA				Mihalik, SJ; Steinberg, SJ; Pei, ZT; Park, J; Kim, DG; Heinzer, AK; Dacremont, G; Wanders, RJA; Cuebas, DA; Smith, KD; Watkins, PA			Participation of two members of the very long-chain acyl-CoA synthetase family in bile acid synthesis and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; X-LINKED ADRENOLEUKODYSTROPHY; COENZYME-A-LIGASE; FATTY-ACID; SUBCELLULAR-DISTRIBUTION; SUBSTRATE SPECIFICITIES; N-ACYLTRANSFERASE; CHOLIC-ACID; BIOSYNTHESIS; METABOLISM	Bile acids are synthesized de novo in the liver from cholesterol and conjugated to glycine or taurine via a complex series of reactions involving multiple organelles. Bile acids secreted into the small intestine are efficiently reabsorbed and reutilized. Activation by thio-esterification to CoA is required at two points in bile acid metabolism. First, 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid, the 27-carbon precursor of cholic acid, must be activated to its CoA derivative before side chain cleavage via peroxisomal beta-oxidation. Second, reutilization of cholate and other C-24 bile acids requires reactivation prior to re-conjugation. We reported previously that homolog 2 of very long-chain acyl-CoA synthetase (VLCS) can activate cholate (Steinberg, S. J., Mihalik, S. J., Kim, D. G., Cuebas, D. A., and Watkins, P. A. (2000) J. Biol. Chem. 275, 15605-15608). We now show that this enzyme also activates chenodeoxycholate, the secondary bile acids deoxycholate and lithocholate, and 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. In contrast, VLCS activated 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoate, but did not utilize any of the C-24 bile acids as substrates. We hypothesize that the primary function of homolog 2 is in the reactivation and recycling of C-24 bile acids, whereas VLCS participates in the de novo synthesis pathway. Results of in situ hybridization, topographic orientation, and inhibition studies are consistent with the proposed roles of these enzymes in bile acid metabolism.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; State Univ Ghent, Sch Med, Dept Pediat, B-9000 Ghent, Belgium; Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; SW Missouri State Univ, Dept Chem, Springfield, MO 65804 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Ghent University; University of Amsterdam; Academic Medical Center Amsterdam; Missouri State University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981, HD24061] Funding Source: Medline; NINDS NIH HHS [NS10533, NS37355] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Carey Martin C., 1994, P719; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Hofmann Alan F., 1994, P677; KASE BF, 1989, J BIOL CHEM, V264, P9220; KASE F, 1983, J LIPID RES, V24, P1560; KATZ N, 1989, EUR J BIOCHEM, V180, P185, DOI 10.1111/j.1432-1033.1989.tb14631.x; KATZ NR, 1983, EUR J BIOCHEM, V135, P103, DOI 10.1111/j.1432-1033.1983.tb07623.x; KILLENBERG PG, 1978, J LIPID RES, V19, P24; Kurosawa T, 1998, ANAL CHIM ACTA, V365, P249, DOI 10.1016/S0003-2670(97)00601-6; LIM WC, 1981, BIOCHEM J, V197, P611, DOI 10.1042/bj1970611; LOWRY OH, 1951, J BIOL CHEM, V193, P265; POLOKOFF MA, 1977, J BIOL CHEM, V252, P1167; ROST B, 1995, PROTEIN SCI, V4, P521; SCHEPERS L, 1989, BIOCHEM J, V257, P221, DOI 10.1042/bj2570221; Setchell KDR, 2001, LIVER DIS CHILDREN, P701; Smith BT, 2000, EXP CELL RES, V254, P309, DOI 10.1006/excr.1999.4757; Solaas K, 2000, J LIPID RES, V41, P1154; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Steinberg SJ, 1999, ANN NEUROL, V46, P409, DOI 10.1002/1531-8249(199909)46:3<409::AID-ANA18>3.0.CO;2-9; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; TSERNG KY, 1977, J LIPID RES, V18, P400; TWISK J, 1995, J CLIN INVEST, V95, P1235, DOI 10.1172/JCI117773; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; WATKINS PA, 1995, AM J HUM GENET, V57, P292; Wheeler JB, 1997, ARCH BIOCHEM BIOPHYS, V348, P15, DOI 10.1006/abbi.1997.0391; Xu RF, 1996, BIOCHEM BIOPH RES CO, V221, P271, DOI 10.1006/bbrc.1996.0585	35	86	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24771	24779		10.1074/jbc.M203295200	http://dx.doi.org/10.1074/jbc.M203295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980911	hybrid, Green Published			2022-12-25	WOS:000176611800104
J	Miura, S; Karnik, SS				Miura, S; Karnik, SS			Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; HELICES; MUTATION; AT(1); MECHANISMS; RHODOPSIN; BINDING; DOMAIN; ACID; VI	A key step in transmembrane (TM) signal transduction by G-protein-coupled receptors (GPCRs) is the ligand-induced conformational change of the receptor, which triggers the activation of a guanine nucleotide-binding protein. GPCRs contain a seven-TM helical structure essential for signal transduction in response to a large variety of sensory and hormonal signals. Primary structure comparison of GPCRs has shown that the second TM helix contains a highly conserved Asp residue, which is critical for agonist activation in these receptors. How conformational changes in TM2 relate to signal transduction by a GPCR is not known, because activation-induced conformational changes in TM2 helix have not been measured. Here we use modification of reporter cysteines to measure water accessibility at specific residues in TM2 of the type I receptor for the octapeptide hormone angiotensin II. Activation-dependent changes in the accessibility of Cys(76) on TM2 were measured in constitutively activated mutants. These changes were directly correlated with measurement of function, establishing the link between physical changes in TM2 and function. Accessibility changes were measured at several consecutive residues on TM2, which suggest that TM2 undergoes a transmembrane movement in response to activation. This is the first report of in situ measurement of TAU movement in a GPCR.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Karnik, SS (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	karniks@ccf.org	Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057470] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL064845, R01 HL057470, HL57470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Karnik SS, 2000, V CH MO CAR, V1, P117; Laporte SA, 1999, MOL ENDOCRINOL, V13, P578, DOI 10.1210/me.13.4.578; MARIE J, 1994, J BIOL CHEM, V269, P20815; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492	27	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24299	24305		10.1074/jbc.M202743200	http://dx.doi.org/10.1074/jbc.M202743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983705	hybrid			2022-12-25	WOS:000176611800044
J	Nakamura, J; Tajima, G; Sato, C				Nakamura, J; Tajima, G; Sato, C			Substrate regulation of calcium binding in Ca2+-ATPase molecules of the sarcoplasmic reticulum II. Effect of CTP, GTP, ITP, and UTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE; PUMP PROTEIN; ATP-BINDING; ION; PHOSPHORYLATION; STOICHIOMETRY; MODULATION; HYDROLYSIS; KINETICS	To examine the effect of CTP, GTP, ITP, and UTP on calcium binding of Ca2+-ATPase molecules of the sarcoplasmic reticulum, the calcium dependence of the Ca2+-activated hydrolysis activities of these NTPs of the enzyme molecules was examined by comparison with that of calcium binding of the molecules in the absence of the NTPs at pH 7.40. In the sarcoplasmic reticulum membrane, CTP, GTP, and ITP did not affect the noncooperative (Hill value (n(H)) of similar to1, apparent calcium affinity (K-0.5) of 2-6 mum)) and cooperative (n(H) similar to 2, K-0.5 similar to 0.2 mum) calcium binding of the molecules, whereas UTP caused the molecules to highly cooperatively (n(H) similar to 4) bind calcium ions with a lowered K-0.5 of similar to0.04 mum. When the enzyme molecules were solubilized with detergent, all of these NTPs reversibly degraded the calcium affinity of the molecule (from K-0.5 = 3-5 to >40 mum), although the effect of the NTPs on the negatively cooperative manner (n(H) similar to 0.5) of calcium binding was not experimentally obtained. Taking into account the first part of this study (Nakamura, J., Tajima, G., Sato, C., Furukohri, T., and Konishi, K. (2002) J. Biol. Chem. 277, 24180-24190) showing the improving effect of ATP on calcium binding of the membranous and solubilized molecules, the results show that ATP is the only intrinsic substrate for the enzyme molecule. This NTP regulation is discussed in terms of the oligomeric structure of the molecules.	Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808578, Japan; Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Tsukuba, Ibaraki 3058568, Japan	Tohoku University; National Institute of Advanced Industrial Science & Technology (AIST)	Nakamura, J (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808578, Japan.	jun-n@mail.cc.tohoku.ac.jp	Sato, Chikara/M-7183-2016	Sato, Chikara/0000-0001-5543-4496				BONTING SL, 1961, ARCH BIOCHEM BIOPHYS, V95, P416, DOI 10.1016/0003-9861(61)90170-9; de Meis L, 1973, J Biol Chem, V248, P3691; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; FERREIRA ST, 1988, J BIOL CHEM, V263, P9973; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2307; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1967, J BIOL CHEM, V242, P4637; KHAN MMT, 1966, J AM CHEM SOC, V88, P668; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAKINOSE M, 1965, BIOCHEM Z, V343, P383; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Nakamura J, 2002, J BIOL CHEM, V277, P24180, DOI 10.1074/jbc.M111834200; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TADA M, 1978, PHYSIOL REV, V58, P1; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANWINKLE WB, 1981, J BIOL CHEM, V256, P2268; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	32	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24191	24196		10.1074/jbc.M111836200	http://dx.doi.org/10.1074/jbc.M111836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976322	hybrid			2022-12-25	WOS:000176611800029
J	Permanne, B; Adessi, C; Saborio, GP; Fraga, S; Frossard, MJ; Van Dorpe, J; Dewachter, I; Banks, WA; Van Leuven, F; Soto, C				Permanne, B; Adessi, C; Saborio, GP; Fraga, S; Frossard, MJ; Van Dorpe, J; Dewachter, I; Banks, WA; Van Leuven, F; Soto, C			Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide	FASEB JOURNAL			English	Article						therapy; protein; conformational disorders; neuronal loss; brain inflammation; senile plaques	BLOOD-BRAIN-BARRIER; FIBRIL FORMATION; NERVOUS-SYSTEM; AMINO-ACIDS; RAT-BRAIN; PROTEIN; INHIBITION; PATHOLOGY; MICE; IMMUNIZATION	Genetic, neuropathological, and biochemical studies have provided strong evidence for a central role of amyloid in the pathogenesis of Alzheimer's disease (AD). We have proposed previously that peptides designed as beta-sheet breakers may be useful in preventing the formation of amyloid plaques. In this study, we describe a modified beta-sheet breaker peptide with improved pharmacological properties, a high rate of penetration across the blood-brain barrier, and the ability to induce a dramatic reduction in amyloid deposition in two different transgenic AD models. In addition, we report for the first time a significant increase in neuronal survival and a decrease in brain inflammation associated with the reduction of amyloid plaques. These results demonstrate that the process of amyloid deposition is one of the causes of neurodegeneration in AD. Moreover, our findings indicate that beta-sheet breaker peptides provide a valuable tool for evaluating further the importance of amyloid in the etiology of AD and suggest that these peptides or some of their derivatives might be good candidates for AD treatment.	Serono Pharmaceut Res Inst, Geneva, Switzerland; Katholieke Univ Leuven, Expt Genet Grp, B-3000 Louvain, Belgium; VA Med Ctr St Louis, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63104 USA	KU Leuven; Saint Louis University	Soto, C (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx,1228 Plan Ouates, Geneva, Switzerland.	Claudio.Soto@serono.com	Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619; , Ilse Dewachter/0000-0001-7202-515X				Banks WA, 1996, LIFE SCI, V59, P1923, DOI 10.1016/S0024-3205(96)00380-3; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Blanchard Barbara J., 2000, Journal of Alzheimer's Disease, V2, P137; Bronfman FC, 1996, NEUROSCI LETT, V218, P201, DOI 10.1016/S0304-3940(96)13147-5; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; CHREST FJ, 1993, CYTOCHEM, V8, P883; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Dewachter I, 2000, J NEUROSCI, V20, P6452, DOI 10.1523/JNEUROSCI.20-17-06452.2000; Dewachter I, 2000, EXP GERONTOL, V35, P831, DOI 10.1016/S0531-5565(00)00149-2; Duff K, 1999, TRENDS NEUROSCI, V22, P485, DOI 10.1016/S0166-2236(99)01489-7; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Halliday G, 2000, CLIN EXP PHARMACOL P, V27, P1, DOI 10.1046/j.1440-1681.2000.03200.x; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; JANCIAUSKIENE S, 1995, J BIOL CHEM, V270, P26041, DOI 10.1074/jbc.270.44.26041; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kastin AJ, 1999, BRAIN RES, V848, P96, DOI 10.1016/S0006-8993(99)01961-7; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lee VMY, 2001, P NATL ACAD SCI USA, V98, P8931, DOI 10.1073/pnas.171311798; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; McGeer EG, 1999, CURR PHARM DESIGN, V5, P821; MCGEER PL, 1994, NEUROPATH APPL NEURO, V20, P191; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pachter JS, 1997, MOL PSYCHIATR, V2, P91, DOI 10.1038/sj.mp.4000212; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Ray I, 2000, BRAIN RES, V853, P344, DOI 10.1016/S0006-8993(99)02315-X; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; Selkoe DJ, 2000, JAMA-J AM MED ASSOC, V283, P1615, DOI 10.1001/jama.283.12.1615; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sigurdsson EM, 2000, J NEUROPATH EXP NEUR, V59, P11, DOI 10.1093/jnen/59.1.11; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Soto C, 1999, J MOL MED-JMM, V77, P412, DOI 10.1007/s001090050371; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; Soto C, 2000, ACTA NEUROL SCAND, V102, P90, DOI 10.1034/j.1600-0404.2000.00313.x; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; St George-Hyslop PH, 1999, NATURE, V400, P116; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yankner BA, 2000, ANN NY ACAD SCI, V924, P26	72	184	196	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					860	+		10.1096/fj.01-0841fje	http://dx.doi.org/10.1096/fj.01-0841fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967228				2022-12-25	WOS:000175425900019
J	Vernersson, M; Ledin, A; Johansson, J; Hellman, L				Vernersson, M; Ledin, A; Johansson, J; Hellman, L			Generation of therapeutic antibody responses against IgE through vaccination	FASEB JOURNAL			English	Article						allergy; C epsilon 3; allergen-specific IgE	FC-EPSILON-RI; SEASONAL ALLERGIC RHINITIS; HIGH-AFFINITY RECEPTOR; HUMAN-IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODY; BINDING-SITE; DEFICIENT MICE; ALPHA; CHAIN; PHARMACOKINETICS	IgE is the central mediator in atopic allergies such as hay fever, eczema, and asthma; therefore, it is a prime target in the development of allergen-independent preventive treatments. We describe an active immunization strategy that has the potential to reduce IgE to a clinically significant extent. The active vaccine component is a chimeric IgE molecule, Cepsilon2-Cepsilon3-Cepsilon4. The receptor-binding target domain, Cepsilon3, is derived from the recipient species, whereas the flanking domains, Cepsilon2 and Cepsilon4, are derived from an evolutionarily distant mammal. The flanking domains have dual functions, acting both as structural support for the Cepsilon3 domain and to break T cell tolerance by providing foreign T cell epitopes. The efficacy of the vaccine was studied in an ovalbumin-sensitized rat model. Vaccination resulted in antibody responses against IgE in all rats and in a substantial reduction in serum IgE levels in three out of four strains. The skin reactivity upon allergen challenge was significantly reduced in vaccinated animals. The vaccine appears to be safe to use as an antigen. No cross-linking activity was observed in sera of vaccinated animals, and the response to vaccination was reversible with time. Our results suggest that active immunization against IgE has the potential to become a therapeutic method for humans.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Resistentia Pharmaceut AB, S-75323 Uppsala, Sweden	Uppsala University	Hellman, L (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	Lars.Hellman@icm.uu.se						Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Aveskogh M, 1998, EUR J IMMUNOL, V28, P2738, DOI 10.1002/(SICI)1521-4141(199809)28:09<2738::AID-IMMU2738>3.0.CO;2-I; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI11849; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Dalum I, 1999, NAT BIOTECHNOL, V17, P666, DOI 10.1038/10878; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; DIAZSANCHEZ D, 1991, IMMUNOLOGY, V72, P297; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; HELLMAN L, 1994, EUR J IMMUNOL, V24, P415, DOI 10.1002/eji.1830240222; HELLMAN L, 1982, NUCLEIC ACIDS RES, V10, P6041, DOI 10.1093/nar/10.19.6041; Hellman L, 1999, HANDB EXP PHARMACOL, V133, P499; Hellman L, 1996, ADV EXP MED BIOL, V409, P337; HELLMAN L, 1995, CLIN IMMUNOTHER, V2, P130; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; ISHIDA N, 1982, EMBO J, V1, P1117, DOI 10.1002/j.1460-2075.1982.tb01306.x; KARLSSON T, 1979, SCAND J IMMUNOL, V9, P217, DOI 10.1111/j.1365-3083.1979.tb02725.x; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOLBINGER F, 1993, PROTEIN ENG, V6, P971, DOI 10.1093/protein/6.8.971; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEVY DA, 1970, NEW ENGL J MED, V283, P541; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Racine-Poon A, 1997, CLIN PHARMACOL THER, V62, P675, DOI 10.1016/S0009-9236(97)90087-4; Talwar GP, 1999, IMMUNOL REV, V171, P173; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Vernersson M, 1997, IMMUNOGENETICS, V46, P461, DOI 10.1007/s002510050306; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6	38	61	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					875	+		10.1096/fj.01-0879fje	http://dx.doi.org/10.1096/fj.01-0879fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967231				2022-12-25	WOS:000175425900016
J	Davies, SS; Amarnath, V; Montine, KS; Bernoud-Hubac, N; Boutaud, O; Montine, TJ; Roberts, LJ				Davies, SS; Amarnath, V; Montine, KS; Bernoud-Hubac, N; Boutaud, O; Montine, TJ; Roberts, LJ			Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function	FASEB JOURNAL			English	Article						isoketal; free radical; neurodegenerative	20 S PROTEASOME; MULTICATALYTIC PROTEINASE COMPLEX; AMYLOID-BETA-PROTEIN; HUMAN BJ FIBROBLASTS; FACTOR-KAPPA-B; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; MAMMALIAN-CELLS; PROSTAGLANDIN ENDOPEROXIDES	Oxidative stress can impair proteasome function, both of which are features of neurodegenerative diseases. Inhibition of proteasome function leads to protein accumulation and cell death. We discovered recently the formation of highly reactive gamma-ketoaldehydes, isoketals (IsoKs), and neuroketals (NeuroKs) as products of the isoprostane and neuroprostane pathways of free radical-induced lipid peroxidation that are analogous to cyclooxygenase-derived levuglandins (LGs). Because aldehydes that are much less reactive than IsoKs have been shown to inhibit proteasome function, we explored the ability of the proteasome to degrade IsoK-adducted proteins/peptides and the effect of IsoK and IsoK-adducted proteins/peptides on proteasome function. Adduction of IsoK to model proteasome substrates significantly reduced their rate of degradation by the 20S proteasome. The ability of IsoK to inhibit proteasome function directly was observed only at very high concentrations. However, at much lower concentrations, an IsoK-adducted protein (ovalbumin) and peptide (Abeta(1-40)) significantly inhibited chymotrypsin-like activity of the 20S proteasome. Moreover, incubation of IsoK with P19 neuroglial cultures dose-dependently inhibited proteasome activity (IC50 = 330 nM) and induced cell death (LC50 = 670 nM). These findings suggest that IsoKs/NeuroKs/LGs can inhibit proteasome activity and, if overproduced, may have relevance to the pathogenesis of neurodegenerative diseases.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Roberts, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 522 RRB, Nashville, TN USA.	jack.roberts@mcmail.vanderbilt.edu		Davies, Sean/0000-0001-9879-8062; Montine, Kathleen/0000-0003-2110-8363				Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Breitner JCS, 1996, ANNU REV MED, V47, P401; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Fataccioli V, 1999, HEPATOLOGY, V29, P14, DOI 10.1002/hep.510290106; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; Gregori L, 1997, J BIOL CHEM, V272, P58; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; Ho L, 1999, J NEUROSCI RES, V57, P295; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; IYER RS, 1994, J ORG CHEM, V59, P6038, DOI 10.1021/jo00099a039; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; JIROUSEK MR, 1990, PROSTAGLANDINS, V40, P187, DOI 10.1016/0090-6980(90)90083-8; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2000, MECH AGEING DEV, V113, P61, DOI 10.1016/S0047-6374(99)00101-3; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; KOJIMA S, 1992, FEBS LETT, V304, P57, DOI 10.1016/0014-5793(92)80588-8; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Masaki R, 2000, J NEUROSCI RES, V62, P75, DOI 10.1002/1097-4547(20001001)62:1<75::AID-JNR8>3.0.CO;2-V; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; Montaldo PG, 1997, CELL DEATH DIFFER, V4, P150, DOI 10.1038/sj.cdd.4400215; Montine KS, 1997, J NEUROPATH EXP NEUR, V56, P866, DOI 10.1097/00005072-199708000-00004; Montine TJ, 1996, AM J PATHOL, V148, P89; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Montine TJ, 1999, NEUROLOGY, V52, P1104, DOI 10.1212/WNL.52.5.1104; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Morris MC, 1998, ALZ DIS ASSOC DIS, V12, P121, DOI 10.1097/00002093-199809000-00001; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; Niu CS, 1996, J ORG CHEM, V61, P1014, DOI 10.1021/jo951651u; Ohtani-Kaneko R, 1998, NEUROCHEM RES, V23, P1435, DOI 10.1023/A:1020763009488; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Salomon R G, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P323; Salomon RG, 1999, J BIOL CHEM, V274, P20271, DOI 10.1074/jbc.274.29.20271; Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b; SALOMON RG, 1984, J AM CHEM SOC, V106, P6049, DOI 10.1021/ja00332a049; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEGEL IH, 1993, ENZYME KINETICS BEHA, P208; Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003	71	85	89	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					715	+		10.1096/fj.01-0696fje	http://dx.doi.org/10.1096/fj.01-0696fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978738				2022-12-25	WOS:000174755900014
J	Keller, C; Ladenburger, EM; Kremer, M; Knippers, R				Keller, C; Ladenburger, EM; Kremer, M; Knippers, R			The origin recognition complex marks a replication origin in the human TOP1 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA-REPLICATION; EUKARYOTIC DNA; MCM PROTEINS; IN-VIVO; SACCHAROMYCES-CEREVISIAE; INITIATION SITES; HNRNP-U; CHROMATIN; YEAST; ORC	The locations of the origin recognition complex (ORC) in mammalian genomes have been elusive. We have therefore analyzed the DNA sequences associated with human ORC via in vivo cross-linking and chromatin immunoprecipitation. Antibodies specific for hOrc2 protein precipitate chromatin fragments that also contain other ORC proteins, suggesting that the proteins form multisubunit complexes on chromatin in vivo. A binding region for ORC was identified at the CpG island upstream of the human TOP1 gene. Nascent strand abundance assays show that the ORC binding region coincides with an origin of bidirectional replication. The TOP1 gene includes two well characterized matrix attachment regions. The matrix attachment region elements analyzed contain no ORC and constitute no sites for replication initiation. In initial attempts to use the chromatin immunoprecipitation technique for the identification of additional ORC sites in the human genome, we isolated a sequence close to another actively transcribed gene (TOM1) and an alphoid satellite sequence that underlies centromeric heterochromatin. Nascent strand abundance assays gave no indication that the heterochromatin sequence serves as a replication initiation site, suggesting that an ORC on this site may perform functions other than replication initiation.	Univ Konstanz, Dept Biol, D-78464 Constance, Germany	University of Konstanz	Keller, C (corresponding author), Univ Konstanz, Dept Biol, D-78464 Constance, Germany.	Christian.Keller@uni-konstanz.de						Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Boulikas T, 1996, J CELL BIOCHEM, V60, P297, DOI 10.1002/(SICI)1097-4644(19960301)60:3<297::AID-JCB2>3.0.CO;2-R; BREWER BJ, 1993, COLD SPRING HARB SYM, V58, P425, DOI 10.1101/SQB.1993.058.01.049; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P31; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; Gencheva M, 1996, J BIOL CHEM, V271, P2608, DOI 10.1074/jbc.271.5.2608; Giacca M, 1997, METHODS, V13, P301, DOI 10.1006/meth.1997.0529; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; GUGGENHEIMER RA, 1984, P NATL ACAD SCI-BIOL, V81, P3069, DOI 10.1073/pnas.81.10.3069; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HEILAND S, 1995, MOL CELL BIOL, V15, P6623; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; Jorgensen AL, 1997, DAN MED BULL, V44, P522; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; KUNZE N, 1991, J BIOL CHEM, V266, P9610; KUNZE N, 1990, EUR J BIOCHEM, V194, P323, DOI 10.1111/j.1432-1033.1990.tb15620.x; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mechali M, 2001, NAT REV GENET, V2, P640, DOI 10.1038/35084598; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; Nickerson JA, 2001, J CELL SCI, V114, P463; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; ROMIG H, 1994, EUR J BIOCHEM, V221, P411, DOI 10.1111/j.1432-1033.1994.tb18753.x; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; Shareef MM, 2001, MOL BIOL CELL, V12, P1671, DOI 10.1091/mbc.12.6.1671; Simon I, 2001, EMBO J, V20, P6150, DOI 10.1093/emboj/20.21.6150; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Stagljar I, 1999, BIOL CHEM, V380, P525, DOI 10.1515/BC.1999.067; TODOROVIC V, 1999, FRONT BIOSCI, V4, P859; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; YOON Y, 1995, MOL CELL BIOL, V15, P2482; Zink D, 1999, EXP CELL RES, V247, P176, DOI 10.1006/excr.1998.4311	76	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31430	31440		10.1074/jbc.M202165200	http://dx.doi.org/10.1074/jbc.M202165200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12004060	hybrid			2022-12-25	WOS:000177718700020
J	Berezov, A; Chen, JQ; Liu, QD; Zhang, HT; Greene, MI; Murali, R				Berezov, A; Chen, JQ; Liu, QD; Zhang, HT; Greene, MI; Murali, R			Disabling receptor ensembles with rationally designed interface peptidomimetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RESTRAINED MOLECULAR-DYNAMICS; RESONANCE ENERGY-TRANSFER; ERBB SIGNALING NETWORK; FACTOR EGF RECEPTOR; SWISS 3T3 CELLS; EXTRACELLULAR DOMAIN; ERYTHROPOIETIN RECEPTOR; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDES	Members of the erbB family receptor tyrosine kinases (erbB1, erbB2, erbB3, and erbB4) are overexpressed in a variety of human cancers and represent important targets for the structure-based drug design. Homo- and heterodimerization (oligomerization) of the erbB receptors are known to be critical events for receptor signaling. To block receptor self-associations, we have designed a series of peptides derived from potential dimerization surfaces in the extracellular subdomain IV of the erbB receptors (erbB peptides). In surface plasmon resonance (BIAcore) studies, the designed peptides have been shown to selectively bind to the erbB receptor ectodomains and isolated subdomain IV of erbB2 with submicromolar affinities and to inhibit heregulin-induced interactions of erbB3 with different erbB receptors. A dose-dependent inhibition of native erbB receptor dimerization by the erbB peptides has been observed in 32D cell lines transfected with different combinations of erbB receptors. The peptides effectively inhibited growth of two types of transformed cells overexpressing different erbB receptors, T6-17 and 32D, in standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium bromide)and cell viability assays. The study identifies distinct loops within the membrane-proximal part of the subdomain IV as potential receptor-receptor interaction sites for the erbB receptors and demonstrates the possibility of disabling receptor activity by structure-based targeting of the dimerization interfaces. Molecular models for possible arrangement of the erbB1.EGF complex, consistent with the involvement of subdomain IV in inter-receptor interactions, are proposed. Small dimerization inhibitors described herein can be useful as probes to elucidate different erbB signaling pathways and may be developed as therapeutic agents.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.			Murali, Ramachandran/0000-0002-8384-2793; Zhang, Hongtao/0000-0001-9173-0049				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; Berezov A., 2001, BIAJOURNAL, V8, P4; CARRAWAY KL, 1990, BIOCHEMISTRY-US, V29, P8741, DOI 10.1021/bi00489a034; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cochran JR, 2001, TRENDS BIOCHEM SCI, V26, P304, DOI 10.1016/S0968-0004(01)01815-1; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; Crouch MF, 2000, IMMUNOL CELL BIOL, V78, P408, DOI 10.1046/j.1440-1711.2000.00929.x; Crouch MF, 2001, J CELL BIOL, V152, P263, DOI 10.1083/jcb.152.2.263; DIVITA G, 1994, J BIOL CHEM, V269, P13080; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1988, ONCOGENE, V2, P273; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hirai H, 2001, NEUROSCI RES, V39, P261, DOI 10.1016/S0168-0102(00)00237-6; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jorissen RN, 2000, PROTEIN SCI, V9, P310; Kamboj S, 1998, CURR BIOL, V8, pR719, DOI 10.1016/S0960-9822(98)70457-9; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Krawczyk C, 2001, J LEUKOCYTE BIOL, V69, P317; Kumagai T, 2001, P NATL ACAD SCI USA, V98, P5526, DOI 10.1073/pnas.071060598; Kwong E, 2000, NEUROREPORT, V11, P2703, DOI 10.1097/00001756-200008210-00019; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Li H, 1997, PROTEIN SCI, V6, P956, DOI 10.1002/pro.5560060502; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; Nagy P, 1999, J CELL SCI, V112, P1733; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; O'Rourke DM, 1998, IMMUNOL RES, V17, P179, DOI 10.1007/BF02786443; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Peczuh MW, 2000, CHEM REV, V100, P2479, DOI 10.1021/cr9900026; Prasanna V, 1998, BIOCHEMISTRY-US, V37, P6883, DOI 10.1021/bi9720989; Prevost JM, 2000, CYTOKINE, V12, P187, DOI 10.1006/cyto.1999.0527; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sitrin RG, 2000, J IMMUNOL, V165, P3341, DOI 10.4049/jimmunol.165.6.3341; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tejero R, 1996, PROTEIN SCI, V5, P578; Tulloch PA, 1999, J STRUCT BIOL, V125, P11, DOI 10.1006/jsbi.1998.4066; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; WELS W, 1992, CANCER RES, V52, P6310; WELS W, 1992, J STEROID BIOCHEM, V43, P1, DOI 10.1016/0960-0760(92)90180-Q; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; XU FJ, 1994, INT J CANCER, V59, P242, DOI 10.1002/ijc.2910590217; Yudt MR, 2001, STEROIDS, V66, P549, DOI 10.1016/S0039-128X(00)00224-5; Zhang HT, 1999, EXP MOL PATHOL, V67, P15, DOI 10.1006/exmp.1999.2266; Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7	71	72	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28330	28339		10.1074/jbc.M202880200	http://dx.doi.org/10.1074/jbc.M202880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011054	hybrid			2022-12-25	WOS:000177189800093
J	Zhang, XW; Shu, LL; Hosoi, H; Murti, KG; Houghton, PJ				Zhang, XW; Shu, LL; Hosoi, H; Murti, KG; Houghton, PJ			Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MESSENGER-RNA; TRANSLATION INITIATION; ORNITHINE-DECARBOXYLASE; CYCLIN D1; PROTEIN; GROWTH; INHIBITION; EXPRESSION; RECEPTOR	Mammalian target of rapamycin (mTOR) controls initiation of translation through regulation of ribosomal p70S6 kinase (S6K1) and eukaryotic translation initiation factor-4E (eIF4E) binding protein (4E-BP). mTOR is considered to be located predominantly in cytosolic or membrane fractions and may shuttle between the cytoplasm and nucleus. In most previous studies a single cell line, E1A-immortalized human embryonic kidney cells (HEK293), has been used. Here we show that in human malignant cell lines, human fibroblasts, and murine myoblasts mTOR is predominantly nuclear. In contrast, mTOR is largely excluded from the nucleus in HEK293 cells. Hybrids between HEK293 and Rh30 rhabdomyosarcoma cells generated cells co-expressing markers unique to HEK293 (E1A) and Rh30 (MyoD). mTOR distribution was mainly nuclear with detectable levels in the cytoplasm. mTOR isolated from Rh30 nuclei phosphorylated recombinant GST-4E-BP1 (Thr-46) in vitro and thus has kinase activity. We next investigated the cellular distribution of mTOR substrates 4E-BP, S6K1, and eIF4E. 4E-BP was exclusively detected in cytoplasmic fractions in all cell lines. S6K1 was localized in the cytoplasm in colon carcinoma, HEK293 cells, and IMR90 fibroblasts. S6K1 was readily detected in all cellular fractions derived from rhabdomyosarcoma cells. eIF4E was detected in all fractions derived from rhabdomyosarcoma cells but was not detectable in nuclear fractions from colon carcinoma HEK293 or IMR90 cells.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N LauderdaleSt,Mail Stop 230, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Houghton, Peter/E-3265-2011		NCI NIH HHS [CA28765, CA77776, CA23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, R01CA077776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DILLING MB, 1994, CANCER RES, V54, P903; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Morton CL, 1998, J PHARMACOL EXP THER, V286, P1066; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; SOSINSKI J, 1994, MOL PHARMACOL, V45, P962; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; WRIGHT WE, 1978, EXP CELL RES, V112, P395, DOI 10.1016/0014-4827(78)90222-7	36	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28127	28134		10.1074/jbc.M202625200	http://dx.doi.org/10.1074/jbc.M202625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12000755	hybrid			2022-12-25	WOS:000177189800069
J	Shields, RL; Lai, J; Keck, R; O'Connell, LY; Hong, K; Meng, YG; Weikert, SHA; Presta, LG				Shields, RL; Lai, J; Keck, R; O'Connell, LY; Hong, K; Meng, YG; Weikert, SHA; Presta, LG			Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN SECRETION; GLYCOSYLATION PATTERN; RHEUMATOID-ARTHRITIS; EFFECTOR FUNCTIONS; RECEPTOR-II; AMINO-ACID; CARBOHYDRATE; RAT; COMPLEX	Lec13 cells, a variant Chinese hamster ovary cell line, were used to produce human IgG1 that were deficient in fucose attached to the Asn(297)-Iinked carbohydrate but were otherwise similar to that found in IgG1 produced in normal Chinese hamster ovary cell lines and from human serum. Lack of fucose on the IgG1 had no effect on binding to human FcgammaRI, C1q, or the neonatal Fc receptor. Although no change in affinity was found for the His(131) polymorphic form of human FcgammaRIIA, a slight improvement in binding was evident for FcgammaRIIB and the Arg(131) FcgammaRIIA polymorphic form. In contrast, binding of the fucose-deficient IgG1 to human FcgammaRIIIA was improved up to 50-fold. Antibody-dependent cellular cytotoxicity assays using purified peripheral blood monocytes or natural killer cells from several donors showed enhanced cytotoxicity, especially evident at lower antibody concentrations. When combined with an IgG1 Fc protein variant that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fucose was synergistic.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Cell Culture & Fermentat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Presta, LG (corresponding author), DNAX Res Inst Molec & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	leonard.presta@dnax.org						Anderson DR, 1997, BIOCHEM SOC T, V25, P705, DOI 10.1042/bst0250705; Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J; Boyd PN, 1995, MOL IMMUNOL, V32, P1311, DOI 10.1016/0161-5890(95)00118-2; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CLARK MR, 1989, J IMMUNOL, V143, P1731; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119.abs; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Gavin A, 1998, IMMUNOL MED, V26, P11; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Groenink J, 1996, EUR J IMMUNOL, V26, P1404, DOI 10.1002/eji.1830260634; HAND PH, 1992, CANCER IMMUNOL IMMUN, V35, P165, DOI 10.1007/BF01756183; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; HASHIM OH, 1987, MOL IMMUNOL, V24, P1087, DOI 10.1016/0161-5890(87)90077-0; HASHIM OH, 1988, IMMUNOLOGY, V63, P383; HOBBS SM, 1992, MOL IMMUNOL, V29, P949, DOI 10.1016/0161-5890(92)90133-I; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Jassal R, 2001, BIOCHEM BIOPH RES CO, V286, P243, DOI 10.1006/bbrc.2001.5382; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; KAUSHAL GP, 1994, METHOD ENZYMOL, V230, P316; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Kumpel Belinda M., 1994, Human Antibodies and Hybridomas, V5, P143; Lifely MR, 1995, GLYCOBIOLOGY, V5, P813, DOI 10.1093/glycob/5.8.813; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; Makrides SC, 1998, PHARMACOL REV, V50, P59; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; MATHER JP, 1992, Patent No. 5122469; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; Okafo GN, 1996, ANAL BIOCHEM, V240, P68, DOI 10.1006/abio.1996.0332; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Penichet ML, 2001, J IMMUNOL METHODS, V248, P91, DOI 10.1016/S0022-1759(00)00345-8; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; ROTHMAN RJ, 1989, MOL IMMUNOL, V26, P1113, DOI 10.1016/0161-5890(89)90055-2; Routier FH, 1997, GLYCOCONJUGATE J, V14, P201, DOI 10.1023/A:1018589704981; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Sampson JH, 2000, P NATL ACAD SCI USA, V97, P7503, DOI 10.1073/pnas.130166597; Segal DM, 2001, J IMMUNOL METHODS, V248, P1, DOI 10.1016/S0022-1759(00)00338-0; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; TAO MH, 1989, J IMMUNOL, V143, P2595; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WAWRZYNCZAK EJ, 1992, MOL IMMUNOL, V29, P213, DOI 10.1016/0161-5890(92)90102-4; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wright A, 1998, J IMMUNOL, V160, P3393; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616	65	1286	2141	3	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26733	26740		10.1074/jbc.M202069200	http://dx.doi.org/10.1074/jbc.M202069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11986321	hybrid			2022-12-25	WOS:000177055900006
J	Tsukada, H; Pourmotabbed, T				Tsukada, H; Pourmotabbed, T			Unexpected crucial role of residue 272 in substrate specificity of fibroblast collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-LIKE DOMAIN; POLYMORPHONUCLEAR-LEUKOCYTE COLLAGENASE; HUMAN NEUTROPHIL COLLAGENASE; BASEMENT-MEMBRANE COLLAGEN; C-TERMINAL DOMAIN; RAT EMBRYO CELLS; MATRIX METALLOPROTEINASE-2; I COLLAGEN; EXTRACELLULAR-MATRIX; GELATINASE-A	Degradation of type I collagen by collagenases is an important part of extracellular remodeling. To understand the role of the hinge region of fibroblast collagenase in its collagenolytic activity, we individually substituted the 10 conserved amino acid residues at positions 264, 266, 268, 296, 272, 277, 284, 289, 307, and 313 in this region of the enzyme by their corresponding residues in MMP-3, a noncollagenolytic matrix metalloproteinase. The general proteolytic and triple helicase activities of all of the enzymes were determined, and their abilities to bind to type I collagen were assessed. Among the mutants, only G272D mutant enzyme exhibited a significant change in type I collagenolysis. The alteration of the Gly(272) to Asp reduced the collagenolytic activity of the enzyme to 13% without affecting its general proteolytic activity, substrate specificity, or the collagen binding ability. The catalytic efficiency of the G272D mutant for the triple helical peptide substrate [C-6-(GP-Hyp)(4)GPL(Mca)GPQGLRGQL(DPN)GVR(GP-HYP)(4)-NH2](3) and the peptide substrate Mca-PLGL(Dpa)AR-NH2 and its dissociation constant for the triple helical collagen were similar to that of the wild type enzyme, indicating that the presence of this residue in fibroblast collagenase is particularly important for the efficient cleavage of type I collagen. Gly(272) is evidently responsible for the hinge-bending motion that is essential for allowing the COOH-terminal domain to present the collagen to the active site.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Pourmotabbed, T (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, 858 Madison Ave,Suite G01, Memphis, TN 38163 USA.				NIAMS NIH HHS [AR 41843] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041843, R01AR041843] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIGG HF, 1994, BBA-PROTEIN STRUCT M, V1208, P157, DOI 10.1016/0167-4838(94)90173-2; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CAWSTON TE, 1981, BIOCHIM BIOPHYS ACTA, V657, P73, DOI 10.1016/0005-2744(81)90131-5; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GROSS J, 1981, CELL BIOL EXTRACELLU, P217; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HAYAKAWA T, 1991, BIOMED RES-TOKYO, V12, P169, DOI 10.2220/biomedres.12.169; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HIROSE T, 1992, J RHEUMATOL, V19, P593; HOLLAND DR, 1992, BIOCHEMISTRY-US, V31, P11310, DOI 10.1021/bi00161a008; HOLLAND DR, 1995, PROTEIN SCI, V4, P1955, DOI 10.1002/pro.5560041001; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; O'Farrell TJ, 1998, ARCH BIOCHEM BIOPHYS, V354, P24, DOI 10.1006/abbi.1998.0662; O'Farrell TJ, 2000, J BIOL CHEM, V275, P27964; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1991, INFECT IMMUN, V59, P4687, DOI 10.1128/IAI.59.12.4687-4692.1991; PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; Seltzer JL, 1999, J INVEST DERMATOL, V112, P993, DOI 10.1046/j.1523-1747.1999.00616.x; STARK W, 1992, EUR J BIOCHEM, V207, P781, DOI 10.1111/j.1432-1033.1992.tb17109.x; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5305, DOI 10.1021/bi972374j; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; YU LP, 1990, ARTHRITIS RHEUM, V33, P1626, DOI 10.1002/art.1780331104	53	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27378	27384		10.1074/jbc.M201367200	http://dx.doi.org/10.1074/jbc.M201367200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011042	hybrid			2022-12-25	WOS:000177055900087
J	Min, GS; Kemper, JK; Kemper, B				Min, GS; Kemper, JK; Kemper, B			Glucocorticoid receptor-interacting protein 1 mediates ligand-independent nuclear translocation and activation of constitutive androstane receptor in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-RESPONSIVE ENHANCER; XENOBIOTIC INDUCTION; CYP2B GENE; FACTOR-I; CAR; COACTIVATOR; ELEMENTS; BINDING; BETA; TIF2	Phenobarbital (PB) induction of CYP2B genes is mediated by translocation of the constitutively active androstane receptor (CAR) to the nucleus. Interaction of CAR with p160 coactivators and enhancement of CAR transactivation by the coactivators have been shown in cultured cells. In the present studies, the interaction of CAR with the p160 coactivator glucocorticoid receptor-interacting protein 1 (GRIP1) was examined in vitro and in vivo. Binding of GRIP1 to CAR was shown by glutathione S-transferase (GST) pull-down and affinity DNA binding. N- or C-terminal fragments of GRIP1 that contained the central receptor-interacting domain bound to GST-CAR, but the presence of ligand increased the binding to GST-CAR of only the fragments containing the C-terminal region. In gel shift analysis, binding to was observed only with GRIP1 fragments containing the C-terminal region, and the binding was increased by a CAR agonist and decreased by a CAR antagonist. Expression of GRIP1 enhanced CAR-mediated transactivation in cultured hepatic-derived cells 2-3-fold. In hepatocytes transfected in vivo, expression of exogenous GRIP1 alone induced transactivation of the CYP2B1 PB-dependent enhancer 15-fold, whereas CAR expression alone resulted in only a 3-fold enhancement in untreated mice. Remarkably, CAR and GRIP1 together synergistically transactivated the enhancer about 150-fold, which is approximately equal to activation by PB treatment. In PB-treated mice, expression of exogenous CAR alone had little effect, expression of GRIP1 increased transactivation about 2-fold, and with CAR and GRIP, a 4-fold activation was observed. In untreated mice, expression of GRIP resulted in nuclear translocation of green fluorescent protein-CAR. These results strongly suggest that a p160 coactivator functions in CAR-mediated transactivation in vivo in response to PB treatment and that the synergistic activation of CAR by GRIP in untreated animals results from both nuclear translocation and activation of CAR.	Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM39360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; ESTABROOK RW, 1971, BIOCHEM BIOPH RES CO, V42, P132, DOI 10.1016/0006-291X(71)90372-X; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Gervois P, 2001, J BIOL CHEM, V276, P33471, DOI 10.1074/jbc.M102839200; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HAGSTROM JE, 1999, PANVERA POSTINGS, V5, P2; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; Paquet Y, 2000, J BIOL CHEM, V275, P38427, DOI 10.1074/jbc.M005776200; Puustinen R, 2001, EUR J ENDOCRINOL, V145, P323, DOI 10.1530/eje.0.1450323; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TANAKA H, 1993, J BIOL CHEM, V268, P1854; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557	35	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26356	26363		10.1074/jbc.M200051200	http://dx.doi.org/10.1074/jbc.M200051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000748	hybrid			2022-12-25	WOS:000176908700071
J	Rattenholl, A; Pappano, WN; Koch, M; Keene, DR; Kadler, KE; Sasaki, T; Timpl, R; Burgeson, RE; Greenspan, DS; Bruckner-Tuderman, L				Rattenholl, A; Pappano, WN; Koch, M; Keene, DR; Kadler, KE; Sasaki, T; Timpl, R; Burgeson, RE; Greenspan, DS; Bruckner-Tuderman, L			Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOLLOID-LIKE; C-PROTEINASE; I PROCOLLAGEN; MATRIX METALLOPROTEINASES; EPIDERMOLYSIS-BULLOSA; EXTRACELLULAR-MATRIX; FIBROGENIC CELLS; GAMMA-2 CHAIN; TISSUE FORM; SHORT ARM	Collagen VII is the major structural component of the anchoring fibrils at the dermal-epidermal junction in the skin. It is secreted by keratinocytes as a precursor, procollagen VII, and processed into mature collagen during polymerization of the anchoring fibrils. We show that bone morphogenetic protein-1 (BMP-1), which exhibits procollagen C-proteinase activity, cleaves the C-terminal propeptide from human procollagen VII. The cleavage occurs at the BMP-1 consensus cleavage site SYAA down arrow DTAG within the NC-2 domain. Mammalian tolloid-like (mTLL)-1 and -2, two other proteases of the astacin enzyme family, were able to process procollagen VII at the same site in vitro. Immunohistochemical and genetic evidence supported the involvement of these enzymes in cleaving type VII procollagen in vivo. Both BMP-1 and mTLL-1 are expressed in the skin and in cultured cutaneous cells. A naturally occurring deletion in the human COL7A1 gene, 8523del14, which is associated with dystrophic epidermolysis bullosa and eliminates the BMP-1 consensus sequence, abolished processing of procollagen VII, and in mutant skin procollagen VII accumulated at the dermal-epidermal junction. On the other hand, deficiency of BMP-1 in the skin of knockout mouse embryos did not prevent processing of procollagen VII to mature collagen, suggesting that mTLL-1 and/or mTLL-2 can substitute for BMP-1 in the processing of procollagen VII in situ.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Cambridge, MA 02139 USA; Shriners Hosp Children, Portland, OR 97201 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munster; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital; University of Manchester; Max Planck Society	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany.	tuderma@uni-muenster.de	KADLER, KARL/ABI-2403-2020; Koch, Manuel/AAG-9914-2021	KADLER, KARL/0000-0003-4977-4683; Koch, Manuel/0000-0002-2962-7814; Greenspan, Daniel/0000-0001-8096-7446; Pappano, William/0000-0003-2848-2219	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM63471] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Arnold U, 1999, ANAL BIOCHEM, V271, P197, DOI 10.1006/abio.1999.4149; Betts CM, 1999, BRIT J DERMATOL, V141, P833, DOI 10.1046/j.1365-2133.1999.03155.x; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Bruckner-Tuderman L, 1999, J DERMATOL SCI, V20, P122, DOI 10.1016/S0923-1811(99)00018-3; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; Chen M, 2001, J BIOL CHEM, V276, P21649, DOI 10.1074/jbc.M100180200; Chen M, 2000, J BIOL CHEM, V275, P24429, DOI 10.1074/jbc.M003440200; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; Clark TG, 1999, DEVELOPMENT, V126, P2631; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Gagnoux-Palacios L, 2001, J CELL BIOL, V153, P835, DOI 10.1083/jcb.153.4.835; Gardella R, 1996, AM J HUM GENET, V59, P292; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; HOJIMA Y, 1994, ANAL BIOCHEM, V223, P173, DOI 10.1006/abio.1994.1569; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; KONIG A, 1994, LAB INVEST, V70, P203; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Tunggal L, 2002, AM J PATHOL, V160, P459, DOI 10.1016/S0002-9440(10)64865-1; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Yamada H, 2001, HUM MOL GENET, V10, P1563, DOI 10.1093/hmg/10.15.1563	58	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26372	26378		10.1074/jbc.M203247200	http://dx.doi.org/10.1074/jbc.M203247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986329	hybrid			2022-12-25	WOS:000176908700073
J	Toth, M; Hernandez-Barrantes, S; Osenkowski, P; Bernardo, MM; Gervasi, DC; Shimura, Y; Meroueh, O; Kotra, LP; Galvez, BG; Arroyo, AG; Mobashery, S; Fridman, R				Toth, M; Hernandez-Barrantes, S; Osenkowski, P; Bernardo, MM; Gervasi, DC; Shimura, Y; Meroueh, O; Kotra, LP; Galvez, BG; Arroyo, AG; Mobashery, S; Fridman, R			Complex pattern of membrane type 1 matrix metalloproteinase shedding - Regulation by autocatalytic cell surface inactivation of active enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; TISSUE INHIBITOR; PROGELATINASE-A; GELATINASE-A; 1-MATRIX METALLOPROTEINASE; PRO-MMP-2 ACTIVATION; FIBROSARCOMA CELLS; 72-KDA GELATINASE; CATALYTIC DOMAIN; IV COLLAGENASE	Membrane type I matrix metalloproteinase (MT1-MMP) is a type I transmembrane AIMP shown to play a critical role in normal development and in malignant processes. Emerging evidence indicates that MT1-MMP is regulated by a process of ectodomain shedding. Active MT1-MMP undergoes autocatalytic processing on the cell surface, leading to the formation of an inactive 44kDa fragment and release of the entire catalytic domain. Analysis of the released MT1-MMP forms in various cell types revealed a complex pattern of shedding involving two major fragments of 50 and 18 kDa and two minor species of 56 and 31-35 kDa. Protease inhibitor studies and a catalytically inactive MT1-MMP mutant revealed both autocatalytic (18 kDa) and non-autocatalytic (56, 50, and 31-35 kDa) shedding mechanisms. Purification and sequencing of the 18-kDa fragment indicated that it extends from Tyr(112) to Ala(255). Structural and sequencing data indicate that shedding of the 18-kDa fragment is initiated at the Gly(284)-Gly(285) site, followed by cleavage between the conserved Ala(255) and Ile(256) residues near the conserved methionine turn, a structural feature of the catalytic domain of all MMPs. Consistently, a recombinant 18-kDa fragment had no catalytic activity and did not bind TIMP-2. Thus, autocatalytic shedding evolved as a specific mechanism to terminate MT1-MMP activity on the cell surface by disrupting enzyme integrity at a vital structural site. In contrast, functional data suggest that the non-autocatalytic shedding generates soluble active MT1-MMP species capable of binding TIMP-2. These studies suggest that ectodomain shedding regulates the pericellular and extracellular activities of MT1-MMP through a delicate balance of active and inactive enzyme-soluble fragments.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Chem, Detroit, MI 48201 USA; Hosp Princesa, Dept Inmunol, Madrid 28006, Spain	Wayne State University; Wayne State University; Hospital de La Princesa	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Arroyo, Alicia G./L-2796-2014; Gálvez, Beatriz G./H-1644-2015	Arroyo, Alicia G./0000-0002-1536-3846; Gálvez, Beatriz G./0000-0002-8082-9323; Kotra, Lakshmi P./0000-0002-7071-4637	NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Bigg HF, 2001, CANCER RES, V61, P3610; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brown PD, 1997, MED ONCOL, V14, P1, DOI 10.1007/BF02990939; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CASE DA, 1997, AMBER 5 0 COMPUTER P; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Dolo V, 1998, CANCER RES, V58, P4468; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Foda HD, 1996, LAB INVEST, V74, P538; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Harayama T, 1999, JPN J CANCER RES, V90, P942, DOI 10.1111/j.1349-7006.1999.tb00839.x; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Imai K, 1996, CANCER RES, V56, P2707; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kiessling LL, 1998, CHEM BIOL, V5, pR49, DOI 10.1016/S1074-5521(98)90056-4; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Li H, 1998, MOL CARCINOGEN, V22, P84; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Toth M, 1999, J CELL PHYSIOL, V180, P131, DOI 10.1002/(SICI)1097-4652(199907)180:1<131::AID-JCP15>3.0.CO;2-S; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 1997, CANCER RES, V57, P3159; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; YU M, 1995, CANCER RES, V55, P3272	62	102	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26340	26350		10.1074/jbc.M200655200	http://dx.doi.org/10.1074/jbc.M200655200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004057	hybrid			2022-12-25	WOS:000176908700069
J	Chantret, I; Dupre, T; Delenda, C; Bucher, S; Dancourt, J; Barnier, A; Charollais, A; Heron, D; Bader-Meunier, B; Danos, O; Seta, N; Durand, G; Oriol, R; Codogno, P; Moore, SEH				Chantret, I; Dupre, T; Delenda, C; Bucher, S; Dancourt, J; Barnier, A; Charollais, A; Heron, D; Bader-Meunier, B; Danos, O; Seta, N; Durand, G; Oriol, R; Codogno, P; Moore, SEH			Congenital disorders of glycosylation type ig is defined by a deficiency in dolichyl-P-mannose : Man(7)GlcNAc(2)-PP-dolichyl mannosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	International Symposium on Protein Traffic Glycosylation and Human Health	MAY 12-16, 2001	INTERLAKEN, SWITZERLAND				ALPHA-D-MANNOSIDASE; N-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; LINKED OLIGOSACCHARIDES; PROTEIN GLYCOSYLATION; GENE; DEGRADATION; MUTATIONS; YEAST	Type I congenital disorders of glycosylation (CDGI) are diseases presenting multisystemic lesions including central and peripheral nervous system deficits. The disease is characterized by under-glycosylated serum glycoproteins and is caused by mutations in genes encoding proteins involved in the stepwise assembly of dolichol-oligosaccharide used for protein N-glycosylation. We report that fibroblasts from a type I CDG patient, born of consanguineous parents, are deficient in their capacity to add the eighth mannose residue onto the lipid-linked oligosaccharide precursor. We have characterized cDNA corresponding to the human ortholog of the yeast gene ALG12 that encodes the dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl alpha6-mannosyltransferase that is thought to accomplish this reaction, and we show that the patient is homozygous for a point mutation (T571G) that causes an amino acid substitution (F142V) in a conserved region of the protein. As the pathological phenotype of the fibroblasts of the patient was largely normalized upon transduction with the wild type gene, we demonstrate that the F142V substitution is the underlying cause of this new CDG, which we suggest be called CDG Ig. Finally, we show that the fibroblasts of the patient are capable of the direct transfer of Man(7)GlcNAc(2) from dolichol onto protein and that this N-linked structure can be glucosylated by UDP-glucose: glycoprotein glucosyltransferase in the endoplasmic reticulum.	INSERM, U504, Unite Glycobiol & Signalisat Cellulaire, 16 Ave Paul Vaillant Couturier,Batiment INSERM, F-94807 Villejuif, France; Hop Bichat Claude Bernard, Biochim A, Paris, France; Assistance Publ Hop Paris, Hop Bicetre, Paris, France; Assistance Publ Hop Paris, Hop La Pitie Salpetriere, Paris, France; CNRS, URA 1923, Genethon 3, F-91002 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)	Moore, SEH (corresponding author), INSERM, U504, Unite Glycobiol & Signalisat Cellulaire, 16 Ave Paul Vaillant Couturier,Batiment INSERM, F-94807 Villejuif, France.	moore@vjf.inserm.fr	Codogno, Patrice/G-1384-2013; Dancourt, Julia/U-1533-2017; CHANTRET, Isabelle/AAF-7134-2021; Moore, Stuart/AAF-3920-2021; Seta, Nathalie S/F-1824-2018	Codogno, Patrice/0000-0002-5492-3180; Dancourt, Julia/0000-0002-6237-1566; CHANTRET, Isabelle/0000-0002-0896-1274; Moore, Stuart/0000-0002-1020-2242; Seta, Nathalie S/0000-0002-9240-8630; bader-meunier, brigitte/0000-0001-8476-8196				ABEIJON C, 1990, J BIOL CHEM, V265, P14691; Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; CHANTRET I, 1994, J CELL SCI, V107, P213; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cipollo JF, 2001, J BIOL CHEM, V276, P21828, DOI 10.1074/jbc.M010896200; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; de Koning TJ, 2000, VIRCHOWS ARCH, V437, P101, DOI 10.1007/s004280000185; Dupre T, 2000, GLYCOBIOLOGY, V10, P1277, DOI 10.1093/glycob/10.12.1277; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Freeze HH, 2001, GLYCOBIOLOGY, V11, p129R, DOI 10.1093/glycob/11.12.129R; Freeze HH, 1998, J PEDIATR-US, V133, P593, DOI 10.1016/S0022-3476(98)70096-4; Freeze HH, 1999, BIOCHEM BIOPH RES CO, V255, P189, DOI 10.1006/bbrc.1998.9945; Grunewald S, 2000, ANN NEUROL, V47, P776; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; JAEKEN J, 1993, J INHERIT METAB DIS, V16, P813, DOI 10.1007/BF00714272; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Kim S, 2000, J CLIN INVEST, V105, P191, DOI 10.1172/JCI7302; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1999, EMBO J, V18, P6816, DOI 10.1093/emboj/18.23.6816; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kornfeld S, 1998, J CLIN INVEST, V101, P1293, DOI 10.1172/JCI3140; Kranz C, 2001, J CLIN INVEST, V108, P1613, DOI 10.1172/JCI200113635; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MARQUARDT T, 1995, EUR J CELL BIOL, V66, P268; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; ROMERO PA, 1986, J BIOL CHEM, V261, P5936; Schachter H, 2001, J CLIN INVEST, V108, P1579, DOI 10.1172/JCI200114498; Schachter H, 2001, CELL MOL LIFE SCI, V58, P1085, DOI 10.1007/PL00000923; Schenk B, 2001, J CLIN INVEST, V108, P1687, DOI 10.1172/JCI200113419; Seta N, 1996, CLIN CHIM ACTA, V254, P131, DOI 10.1016/0009-8981(96)06379-6; Sharma CB, 2001, BIOL CHEM, V382, P321, DOI 10.1515/BC.2001.039; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO MJ, 1976, J BIOL CHEM, V251, P6420; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	55	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25815	25822		10.1074/jbc.M203285200	http://dx.doi.org/10.1074/jbc.M203285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	11983712	hybrid			2022-12-25	WOS:000176747000124
J	Gumpricht, E; Dahl, R; Yerushalmi, B; Devereaux, MW; Sokol, RJ				Gumpricht, E; Dahl, R; Yerushalmi, B; Devereaux, MW; Sokol, RJ			Nitric oxide ameliorates hydrophobic bile acid-induced apoptosis in isolated rat hepatocytes by non-mitochondrial pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	52nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases/International-Liver-Transplantation-Society	NOV 09-13, 2001	DALLAS, TX	Amer Assoc Study Liver Dis, Int Liver Transplant Soc			MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C; URSODEOXYCHOLIC ACID; HEPATIC MITOCHONDRIA; CULTURED-HEPATOCYTES; SYNTHASE; PEROXYNITRITE; GLYCOCHENODEOXYCHOLATE; HYDROPEROXIDES; STIMULATION	Hydrophobic bile acids are toxic to isolated rat hepatocytes by mechanisms involving mitochondrial dysfunction and oxidative stress. In the current study we examined the role of nitric oxide (NO), a potential mediator of apoptosis, during bile acid-induced apoptosis. Freshly isolated rat hepatocytes and hepatic mitochondria generated NO and peroxynitrite (ONOO-) in a concentration- and time-dependent manner when exposed to the toxic bile salt glycochenodeoxycholate (GCDC) (25-500 muM), which was prevented by the nitric-oxide synthase (NOS) inhibitors N-G-monomethyl-N-arginine monoacetate (L-NMMA) and 1400W. Relationships between hepatocyte NO production and apoptosis were examined by comparing the effects of NOS inhibitors with other inhibitors of GCDC-induced apoptosis. Inhibitors of caspases 8 and 9, the mitochondrial permeability transition blocker cyclosporin A, and the antioxidant idebenone reduced NO generation and apoptosis in GCDC-treated hepatocytes. In contrast, NOS inhibitors had no effect on GCDC-induced apoptosis despite marked reduction of NO and ONOO-. However, treatment with the NO donors S-nitroso-N-acetylpenicillamine and spermine NONOate [N-(-aminoethyl)N-(2-hydroxy-2-nitrohydrazino)-1,2-ethylenediamine) inhibited apoptosis and caspase 3 activity while significantly elevating NO levels above GCDC-stimulated levels. Neither NO donors nor NOS inhibitors affected GCDC-induced mitochondrial permeability transition or cytochrome c release from liver mitochondria or GCDC-induced mitochondrial depolarization from isolated hepatocytes, suggesting that NO inhibits bile acid-induced hepatocyte apoptosis by a non-mitochondrial-dependent pathway. In conclusion, whereas NO produced from GCDC-treated hepatocytes neither mediates nor protects against bile acid-induced apoptosis, higher levels of NO inhibit GCDC-induced hepatocyte apoptosis by caspase-dependent pathways.	Childrens Hosp, Denver, CO 80218 USA; Univ Colorado, Sch Med, Dept Pediat,Liver Transplantat Program, Sect Pediatr Gastroenterol Hepatol & Nutr, Denver, CO 80262 USA; Univ Colorado, Sch Med, Pediat Liver Ctr, Denver, CO 80262 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sokol, RJ (corresponding author), Childrens Hosp, Box B290,1056 E 19th Ave, Denver, CO 80218 USA.	sokol.ronald@tchden.org		Gumpricht, Eric/0000-0001-6034-3484	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038446] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38446] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balakirev MY, 1997, EUR J BIOCHEM, V246, P710, DOI 10.1111/j.1432-1033.1997.00710.x; Boer R, 2000, MOL PHARMACOL, V58, P1026, DOI 10.1124/mol.58.5.1026; Borutaite V, 1999, BBA-MOL BASIS DIS, V1453, P41, DOI 10.1016/S0925-4439(98)00082-9; BOTLA R, 1995, J PHARMACOL EXP THER, V272, P930; Bove KE, 2000, PEDIATR DEVEL PATHOL, V3, P1, DOI 10.1007/s100240050001; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brune B, 1998, BIOCHEMISTRY-MOSCOW+, V63, P817; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; GALLE PR, 1990, HEPATOLOGY, V12, P486, DOI 10.1002/hep.1840120307; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; GLASCOTT PA, 1992, MOL PHARMACOL, V41, P1155; Go YM, 2001, AM J PHYSIOL-HEART C, V281, pH2705, DOI 10.1152/ajpheart.2001.281.6.H2705; Gonzalez B, 2000, MOL CELL BIOCHEM, V207, P19, DOI 10.1023/A:1007021710825; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; GREIM H, 1973, BIOCHEM MED METAB B, V8, P280, DOI 10.1016/0006-2944(73)90032-X; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Gumpricht E, 2000, TOXICOL APPL PHARM, V164, P102, DOI 10.1006/taap.2000.8894; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Hou YC, 1999, CURR PHARM DESIGN, V5, P417; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; Kojima H, 1997, BIOL PHARM BULL, V20, P1229; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; KRAHENBUHL S, 1994, HEPATOLOGY, V19, P471, DOI 10.1016/0270-9139(94)90027-2; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Nakajima T, 2000, BRIT J PHARMACOL, V130, P1457, DOI 10.1038/sj.bjp.0703471; Nicholls-Grzemski FA, 1999, BIOCHEM PHARMACOL, V57, P1223, DOI 10.1016/S0006-2952(99)00053-2; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914; Rolo AP, 2000, TOXICOL SCI, V57, P177, DOI 10.1093/toxsci/57.1.177; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schliess F, 1997, GASTROENTEROLOGY, V113, P1306, DOI 10.1053/gast.1997.v113.pm9322526; Shivaram KN, 1998, FREE RADICAL BIO MED, V25, P480, DOI 10.1016/S0891-5849(98)00077-X; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Sokol RJ, 2001, PEDIATR RES, V49, P519, DOI 10.1203/00006450-200104000-00014; SUCHY FJ, 1993, SEMIN LIVER DIS, V13, P235, DOI 10.1055/s-2007-1007352; Takikawa Y, 2001, GASTROENTEROLOGY, V120, P1810, DOI 10.1053/gast.2001.24835; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Tirmenstein MA, 2000, TOXICOL SCI, V53, P56, DOI 10.1093/toxsci/53.1.56; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang JH, 1998, AM J PHYSIOL-GASTR L, V275, pG1117, DOI 10.1152/ajpgi.1998.275.5.G1117; WINKLHOFERROOB BW, 1996, HEPATOLOGY, V24, P338; Wright Karen L., 2000, Molecular Cell Biology Research Communications, V4, P137, DOI 10.1006/mcbr.2001.0273; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702	64	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25823	25830		10.1074/jbc.M112305200	http://dx.doi.org/10.1074/jbc.M112305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	12006578	hybrid			2022-12-25	WOS:000176747000125
J	Xiao, C; Yang, BF; Asadi, N; Beguinot, F; Hao, CH				Xiao, C; Yang, BF; Asadi, N; Beguinot, F; Hao, CH			Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE-C; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; INTRACELLULAR REGULATION; CASPASE-8 ACTIVATION; RECEPTOR; FADD; PEA-15; EXPRESSION; RECRUITMENT	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can trigger apoptosis in some tumor cells but not other tumor cells. To explore the signal transduction events in TRAIL-triggered apoptosis and its modulation in nontransfected tumor cells, we analyzed TRAIL-induced death-inducing signaling complex (DISC) in TRAIL-sensitive and -resistant glioma cells. Caspase-8 and caspase-10 were recruited to the DISC, where they were proteolytically activated to initiate apoptosis in TRAIL-sensitive glioma cells. Caspase-8 and caspase-10 were also recruited to the DISC in TRAIL-resistant cells, but their further activation was inhibited by two antiapoptotic proteins termed cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes-15kDa (PED/PEA-15). Both long and short forms of c-FLIP were recruited to the DISC, where the long form c-FLIP was cleaved to produce intermediate fragments. Of the three isoforms of PED/PEA-15 proteins, only the doubly phosphorylated form was expressed and recruited to the DISC in TRAIL-resistant cells, indicating that the phosphorylation status of PED/PEA-15 determines its recruitment in the cells. Treatment with calcium/calmodulin-dependent protein kinase inhibitor rescued TRAIL sensitivity in TRAIL-resistant cells, providing a potential new approach to sensitize the cells to TRAIL-induced apoptosis.	Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada; Univ Naples Federico II, CNR, Sch Med, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Sch Med, Ctr Endocrinol Sperimentale, I-80131 Naples, Italy	University of Alberta; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Hao, CH (corresponding author), Univ Alberta, Dept Lab Med & Pathol, 261HMRC, Edmonton, AB T6G 2S2, Canada.	chao@ualberta.ca			Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hao CH, 2001, CANCER RES, V61, P1162; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kubes M, 1998, J NEUROCHEM, V71, P1307; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Zhang XD, 1999, CANCER RES, V59, P2747	41	161	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25020	25025		10.1074/jbc.M202946200	http://dx.doi.org/10.1074/jbc.M202946200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976344	hybrid			2022-12-25	WOS:000176747000025
J	Schutyser, E; Struyf, S; Proost, P; Opdenakker, G; Laureys, G; Verhasselt, B; Peperstraete, L; Van de Putte, I; Saccani, A; Allavena, P; Mantovani, A; Van Damme, J				Schutyser, E; Struyf, S; Proost, P; Opdenakker, G; Laureys, G; Verhasselt, B; Peperstraete, L; Van de Putte, I; Saccani, A; Allavena, P; Mantovani, A; Van Damme, J			Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC PROTEINS MCP-2; C-C CHEMOKINES; DENDRITIC CELLS; MALIGNANT ASCITES; UP-REGULATION; T-CELLS; IN-VIVO; EXPRESSION; CANCER; RECEPTOR	Chemokines are important in leukocyte homeostasis, inflammation, angiogenesis, and metastasis. Here, the molecular diversity of chemokines present in ovarian carcinoma was studied by purifying the proteins to homogeneity from ascitic fluid. Biologically active intact CCL2 and processed CXCL8, CCL3, and CCL18 isoforms were recovered. CCL7 and CCL20 were also purified, but their levels were 10-fold lower compared with CXCLS, CCL2, and CCL3 and even 100-fold lower than the amounts of CCL18 isolated. In ascitic fluids from patients with ovarian carcinoma (n = 12), significantly higher levels of CXCL8 and CCL18 (2.0 versus 0.7 ng/ml p = 0.01) and 120 versus 44 ng/ml (p = 0.0002), respectively) were detected compared with those in nonovarian carcinoma patients (n = 12). In contrast to CXCLS, CCL18 was not inducible in carcinoma cell lines. Immunostaining showed CCL18 expression in tumor-infiltrating cells with monocyte/macrophage morphology but not in the ovarian carcinoma cells. Our data demonstrate that biochemically heterogenous but biologically active forms of several chemokines are present at different concentrations in ovarian carcinoma ascitic fluid. This points to a delicate balance of chemokines in epithelial ovarian cancer and to a potentially major role for CXCLS and CCL18 in this tumor.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; State Univ Ghent Hosp, B-9000 Ghent, Belgium; Reg Hosp Heilig Hart, B-3000 Louvain, Belgium; Ist Ric Farmacol Mario Negri, Immunol Lab, I-20157 Milan, Italy	KU Leuven; Ghent University; Ghent University Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Van Damme, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.		Proost, Paul/V-3052-2017; Opdenakker, Ghislain/Q-3130-2017; Allavena, Paola/HHM-5218-2022; Struyf, Sofie/U-2455-2017; laureys, genevieve/AAG-2390-2021; Opdenakker, Ghislain/V-8562-2019; Mantovani, Alberto/HCI-7449-2022	Proost, Paul/0000-0002-0133-5545; Opdenakker, Ghislain/0000-0003-1714-2294; Allavena, Paola/0000-0002-6697-6028; Struyf, Sofie/0000-0003-4558-0769; Opdenakker, Ghislain/0000-0003-1714-2294; Mantovani, Alberto/0000-0001-5578-236X; Verhasselt, Bruno/0000-0002-4645-1144; Van Damme, Jo/0000-0002-6707-1167				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; BALKWILL FR, 1994, EUR CYTOKINE NETW, V5, P379; Burke F, 1996, CYTOKINE, V8, P578, DOI 10.1006/cyto.1996.0077; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Guan P, 1999, GENOMICS, V56, P296, DOI 10.1006/geno.1998.5635; Hieshima K, 1997, J IMMUNOL, V159, P1140; Ivarsson K, 1998, GYNECOL ONCOL, V71, P420, DOI 10.1006/gyno.1998.5198; Ivarsson K, 2000, ACTA OBSTET GYN SCAN, V79, P777, DOI 10.1034/j.1600-0412.2000.079009777.x; Kleeff J, 1999, INT J CANCER, V81, P650, DOI 10.1002/(SICI)1097-0215(19990517)81:4<650::AID-IJC23>3.0.CO;2-#; Kodelja V, 1998, RES IMMUNOL, V149, P633, DOI 10.1016/S0923-2494(99)80029-7; Kodelja V, 1998, J IMMUNOL, V160, P1411; Kusano F, 2000, LAB INVEST, V80, P415, DOI 10.1038/labinvest.3780046; Lindhout E, 2001, J IMMUNOL, V166, P3284, DOI 10.4049/jimmunol.166.5.3284; Loercher AE, 1999, J IMMUNOL, V163, P6251; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 1999, CONT CANC RES, P35; Melichar B, 1998, CLIN CANCER RES, V4, P799; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1999, CONT CANC RES, P193; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Opdenakker G, 1999, CONT CANC RES, P51; Pardo A, 2001, J LEUKOCYTE BIOL, V70, P610; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; PROOST P, 1995, CYTOKINE, V7, P97, DOI 10.1006/cyto.1995.1013; Proost P, 1998, J IMMUNOL, V160, P4034; Punnonen R, 1998, CANCER, V83, P788, DOI 10.1002/(SICI)1097-0142(19980815)83:4<788::AID-CNCR24>3.0.CO;2-N; Radke J, 1996, GEBURTSH FRAUENHEILK, V56, P83, DOI 10.1055/s-2007-1022247; Reape TJ, 1999, AM J PATHOL, V154, P365, DOI 10.1016/S0002-9440(10)65283-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schutyser E, 2000, J IMMUNOL, V165, P4470, DOI 10.4049/jimmunol.165.8.4470; Schutyser E, 2001, EUR J IMMUNOL, V31, P3755, DOI 10.1002/1521-4141(200112)31:12<3755::AID-IMMU3755>3.0.CO;2-O; Scotton C, 2001, BRIT J CANCER, V85, P891, DOI 10.1054/bjoc.2001.2020; Scotton CJ, 2001, CANCER RES, V61, P4961; Sica A, 2000, J IMMUNOL, V164, P733, DOI 10.4049/jimmunol.164.2.733; Strieter RM, 1996, J IMMUNOL, V156, P3583; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; VANDAMME J, 1988, J IMMUNOL, V140, P1534; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vissers JLM, 2001, J LEUKOCYTE BIOL, V69, P785; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	50	169	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24584	24593		10.1074/jbc.M112275200	http://dx.doi.org/10.1074/jbc.M112275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978786	hybrid			2022-12-25	WOS:000176611800081
J	Soroka, V; Kiryushko, D; Novitskaya, V; Ronn, LCB; Poulsen, FM; Holm, A; Bock, E; Berezin, V				Soroka, V; Kiryushko, D; Novitskaya, V; Ronn, LCB; Poulsen, FM; Holm, A; Bock, E; Berezin, V			Induction of neuronal differentiation by a peptide corresponding to the homophilic binding site of the second Ig module of the neural cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; HEPARIN-BINDING; SYNTHETIC PEPTIDES; NCAM; OUTGROWTH; DOMAIN; IDENTIFICATION; RECEPTOR; ACTIVATION; PATHWAY	NCAM plays a key role in neural development and plasticity-mediating cell adhesion and differentiation mainly through homophilic binding. Until recently, attempts to modulate neuronal differentiation and plasticity through NCAM have been impeded by the absence of small synthetic agonists mimicking homophilic inter. actions of NCAM. We show here that a peptide, P2, corresponding to a 12-amino acid sequence localized in the FG loop of the second Ig module of NCAM, binds to the first Ig module, which is the natural binding partner of the second Ig module, with an apparent K-d of 4.7 +/- 0.9 x 10(-6) m. P2 inhibits cell aggregation and induces neurite outgrowth from hippocampal neurons, maximal neuritogenic effect being obtained at a concentration of 0.8 mum. The neuritogenic effect was inhibited by preincubation of P2 with the recombinant NCAM-IgI. Both the length of P2 and the basic amino acid residues at the N and C termini are important for its neuritogenic activity. Treatment of hippocampal cultures with P2 results in induction of phosphorylation of the mitogen-activated protein kinases ERK1 and ERK2. Thus, P2 is a potent mimetic of NCAM, and therefore, an attractive compound for the development of drugs for the treatment of neurodegenerative diseases.	Univ Copenhagen, Panum Inst, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen, Denmark; Dniepropetrovsk State Univ, Lab Biophys & Bioelect, UA-49050 Dnepropetrovsk, Ukraine; Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark	University of Copenhagen; Ministry of Education & Science of Ukraine; Oles Honchar Dnipro National University; University of Copenhagen; University of Copenhagen	Berezin, V (corresponding author), Univ Copenhagen, Panum Inst, Inst Mol Pathol, Prot Lab, Bldg 6-2,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.		Poulsen, Flemming M/E-6848-2010					Atkins AR, 1999, FEBS LETT, V451, P162, DOI 10.1016/S0014-5793(99)00554-2; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Berezin V, 2000, Curr Opin Drug Discov Devel, V3, P605; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Jensen PH, 1999, NAT STRUCT BIOL, V6, P486; KALLAPUR SG, 1992, J NEUROSCI RES, V33, P538, DOI 10.1002/jnr.490330406; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Kolkova K, 2000, J NEUROSCI, V20, P2238; MAAR T, 1995, INT J DEV NEUROSCI, V13, P491, DOI 10.1016/0736-5748(95)00068-R; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.3.CO;2-T; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	23	68	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24676	24683		10.1074/jbc.M109694200	http://dx.doi.org/10.1074/jbc.M109694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983682	hybrid			2022-12-25	WOS:000176611800093
J	Vogt, AM; Poolman, M; Ackermann, C; Yildiz, M; Schoels, W; Fell, DA; Kubler, W				Vogt, AM; Poolman, M; Ackermann, C; Yildiz, M; Schoels, W; Fell, DA; Kubler, W			Regulation of glycolytic flux in ischemic preconditioning - A Study employing metabolic control analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-METABOLISM; HEART-MUSCLE; PHOSPHORYLATION; KINASE; MYOCARDIUM; PHOSPHOFRUCTOKINASE; CARBOHYDRATE; ACTIVATION; MECHANISMS; PYRUVATE	Exact adjustment of the Embden-Meyerhof pathway (EMP) is an important issue in ischemic preconditioning (IP) because an attenuated ischemic lactate accumulation contributes to myocardial protection. However, precise mechanisms of glycolytic flux and its regulation in IP remain to be elucidated. In open chest pigs, IP was achieved by two cycles of 10-min coronary artery occlusion and 30-min reperfusion prior to a 45-min index ischemia and 120-min reperfusion. Myocardial contents in glycolytic intermediates were assessed by high performance liquid chromatographic analysis of serial myocardial biopsies under control conditions and IP. Detailed time courses of metabolite contents allow an in-depth description of EMP regulation during index ischemia using metabolic control analysis. IP reduced myocardial infarct size (control, 90.0 +/- 3.1 versus 5.05 +/- 2.1%; p < 0.001) and attenuated myocardial lactate accumulation (end-ischemic contents, 31.9 +/- 4.47 versus 10.3 +/- 1.26 mumol/wet weight, p < 0.0001), whereby a decrease in anaerobic glycolytic flux by at least 70% could constantly be observed throughout index ischemia. By calculation of flux:metabolite co-responses, the mechanisms of glycolytic regulation were investigated. The continuous deceleration of EMP flux in control myocadium could neither be explained on the basis of substrate availability nor be attributed to regulatory "key enzymes," as multisite regulation was employed for flux adjustment. In myocardium subjected to IP, an even pronounced deceleration of EMP flux during index chemia was observed. Again, the adjustment of EMP flux was because of multisite modulation without any evidence for flux limitation by substrate availability or a key enzyme. However, IP changed the regulatory properties of most EMP enzymes, and some of these patterns could not be explained on the basis of substrate kinetics. Instead, other regulatory mechanisms, which have previously not yet been described for EMP enzymes, must be considered. These altered biochemical properties of the EMP enzymes have not yet been described.	Univ Heidelberg, Med Klin, Ludolf Krehl Klin,Abt Innere Med 3, Schwerpunkt Kardiol Angiol & Pulmo, D-69115 Heidelberg, Germany; Oxford Brookes Univ, Sch Biol & Mol Sci, Oxford OX3 0BP, England	Ruprecht Karls University Heidelberg; Oxford Brookes University	Vogt, AM (corresponding author), Univ Heidelberg, Med Klin, Ludolf Krehl Klin,Abt Innere Med 3, Schwerpunkt Kardiol Angiol & Pulmo, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Fell, David A/B-2109-2009	Fell, David A/0000-0001-6669-2247				BING R, 1954, HARVEY LECT SERIES, P27; BING R, 1964, CIRCULATION BLOOD ME; BUDDECKE E, 1984, GRUNDRISS BIOCH; Cai GZ, 1997, BIOPHYS CHEM, V64, P199, DOI 10.1016/S0301-4622(96)02232-6; CLAYTON CE, 1989, MOL BIOCHEM PARASIT, V33, P73, DOI 10.1016/0166-6851(89)90044-3; CONNETT RJ, 1988, AM J PHYSIOL, V254, pR949, DOI 10.1152/ajpregu.1988.254.6.R949; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Cowan KJ, 1999, MOL CELL BIOCHEM, V195, P173, DOI 10.1023/A:1006932221288; Depre C, 1999, CIRCULATION, V99, P578, DOI 10.1161/01.CIR.99.4.578; Fell D., 1997, UNDERSTANDING CONTRO; FELL DA, 1995, BIOCHEM J, V311, P35, DOI 10.1042/bj3110035; GORDON E, 1992, HEART CARDIOVASCULAR, P151; HERS HG, 1983, PHILOS T R SOC B, V302, P27, DOI 10.1098/rstb.1983.0035; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; JENNINGS RB, 1991, J MOL CELL CARDIOL, V23, P1449, DOI 10.1016/0022-2828(91)90190-W; KACSER H, 1993, EUR J BIOCHEM, V216, P361, DOI 10.1111/j.1432-1033.1993.tb18153.x; KORZENIEWSKI B, 1995, BBA-BIOENERGETICS, V1229, P315, DOI 10.1016/0005-2728(95)00008-7; KUBLER W, 1970, Journal of Molecular and Cellular Cardiology, V1, P351, DOI 10.1016/0022-2828(70)90034-9; Meyerhof Otto, 1994, Experientia (Basel), V50, P382; Morgan HECB, 1992, HEART CARDIOVASCULAR, P1505; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; NETTELBLAD FA, 1987, FEBS LETT, V214, P249, DOI 10.1016/0014-5793(87)80064-9; Reimer KA, 1996, ANN NY ACAD SCI, V793, P13, DOI 10.1111/j.1749-6632.1996.tb33501.x; REIMER KA, 1992, HEART CARDIOVASCULAR, P1875; ROVETTO MJ, 1975, CIRC RES, V37, P742, DOI 10.1161/01.RES.37.6.742; SALE EM, 1987, J CELL BIOCHEM, V33, P15, DOI 10.1002/jcb.240330103; Schaefer S, 1997, CARDIOVASC RES, V35, P90, DOI 10.1016/S0008-6363(97)00087-4; SCHOMBURG D, 1997, ENZYME HDB; SELLEVOLD OFM, 1986, J MOL CELL CARDIOL, V18, P517, DOI 10.1016/S0022-2828(86)80917-8; SPRIET LL, 1990, PFLUG ARCH EUR J PHY, V417, P278, DOI 10.1007/BF00370993; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Thomas S, 1996, J THEOR BIOL, V182, P285, DOI 10.1006/jtbi.1996.0166; Thomas S, 1998, ADV ENZYME REGUL, V38, P65, DOI 10.1016/S0065-2571(97)00012-5; VANSCHAFTINGEN E, 1993, DIABETOLOGIA, V36, P581, DOI 10.1007/BF00404065; VARY TC, 1981, ANNU REV PHYSIOL, V43, P419, DOI 10.1146/annurev.ph.43.030181.002223; Vogt Achim M., 1999, Journal of the American College of Cardiology, V33, p387A; Vogt AM, 2002, BBA-MOL BASIS DIS, V1586, P219, DOI 10.1016/S0925-4439(01)00100-4; Vogt AM, 1998, J AM COLL CARDIOL, V31, P1134, DOI 10.1016/S0735-1097(98)00061-8; Vogt AM, 1996, BASIC RES CARDIOL, V91, P389; Weinbrenner C, 1996, BASIC RES CARDIOL, V91, P374; WIKSTROM BG, 1995, EUR HEART J, V16, P563, DOI 10.1093/oxfordjournals.eurheartj.a060951; Yasykova MY, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1192	44	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24411	24419		10.1074/jbc.M201138200	http://dx.doi.org/10.1074/jbc.M201138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006584	hybrid			2022-12-25	WOS:000176611800059
J	Jacob, A; Cooney, D; Pradhan, M; Coggeshall, KM				Jacob, A; Cooney, D; Pradhan, M; Coggeshall, KM			Convergence of signaling pathways on the activation of ERK in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHOLIPASE C-GAMMA; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASE; CROSS-LINKING; RAS; INHIBITION; PHOSPHORYLATION	The B cell receptor (BCR) initiates three major signaling pathways: the Ras pathway, which leads to extracellular signal-regulated kinase (ERR) activation; the phospholipase C-gamma pathway, which causes calcium mobilization; and the phosphoinositide 3-kinase (PI 3-kinase) pathway. These combine to induce different biological responses depending on the context of the BCR signal. Both the Ras and PI 3-kinase pathways are important for B cell development and activation. Several model systems show evidence of cross-regulation between these pathways. Here we demonstrate through the use of PI 3-kinase inhibitors and a dominant-negative PI 3-kinase construct that the BCR-induced phosphorylation and activation of ERK is dependent on PI 3-kinase. PI 3-kinase feeds into the Ras signaling cascade at multiple points, both upstream and downstream of Ras. We also show that ERK activation is dependent on phospholipase C-gamma, in keeping with its dependence on calcium mobilization. Last, the activation of PI 3-kinase itself is completely dependent on Ras. We conclude that the PI 3-kinase and Ras signaling cascades are intimately connected in B cells and that the activation of ERK is a signal integration point, since it requires simultaneous input from all three major signaling pathways.	Oklahoma Med Res Fdn, Immunobiol & Canc Program, Oklahoma City, OK 73104 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Oklahoma Medical Research Foundation; University System of Ohio; Ohio State University	Coggeshall, KM (corresponding author), Oklahoma Med Res Fdn, Immunobiol & Canc Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.		Cooney, Damon/J-4762-2014	Cooney, Damon/0000-0002-2786-287X	NCI NIH HHS [CA64268] Funding Source: Medline; NIAID NIH HHS [AI49264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064268, R29CA064268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; GOLD MR, 1994, J IMMUNOL, V152, P42; Gold MR, 2000, CURR TOP MICROBIOL, V245, P77; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kawauchi K, 1996, MOL IMMUNOL, V33, P287, DOI 10.1016/0161-5890(95)00134-4; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li XL, 2000, EUR J IMMUNOL, V30, P1576, DOI 10.1002/1521-4141(200006)30:6<1576::AID-IMMU1576>3.0.CO;2-0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Montessuit C, 1999, J BIOL CHEM, V274, P9006, DOI 10.1074/jbc.274.13.9006; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Reth M, 2000, IMMUNOL REV, V176, P10; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SAXTON TM, 1994, J IMMUNOL, V153, P623; SMIT L, 1994, J BIOL CHEM, V269, P20209; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1997, J IMMUNOL, V158, P1125; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	56	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23420	23426		10.1074/jbc.M202485200	http://dx.doi.org/10.1074/jbc.M202485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976336	hybrid			2022-12-25	WOS:000176475700043
J	Lee, SH; Hannink, M				Lee, SH; Hannink, M			Characterization of the nuclear import and export functions of I kappa B epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; REL PROTEINS; DNA-BINDING; PEST DOMAIN; ALPHA; PHOSPHORYLATION; ACTIVATION; FAMILY; BETA; EXPRESSION	Control over the nuclear localization of nuclear factor kappaB/Rel proteins is accomplished in large part through association with members of the inhibitor of kappaB (IkappaB) protein family. For example, the well studied IkappaBalpha protein actively shuttles between the nucleus and the cytoplasm and both inhibits nuclear import and mediates nuclear export of NF-kappaB/Rel proteins. In contrast, the IkappaBbeta protein can inhibit nuclear import of NF-kappaB/Rel proteins but does not remove NF-kappaB/Rel proteins from the nucleus. To further understand how the IkappaB proteins control the nuclear-cytoplasmic distribution of NF-kappaB/Rel proteins, we have characterized the nuclear import and nuclear export functions of IkappaBepsilon. Our results indicate that the IkappaBepsilon protein, like the IkappaBalpha protein, actively shuttles between the nucleus and the cytoplasm. Similar to IkappaBalpha, nuclear import of IkappaBepsilon is mediated by its ankyrin repeat domain and is not blocked by the dominant-negative RanQ69L protein. However, the nuclear import function of the IkappaBepsilon ankyrin repeat domain is markedly less efficient than that of IkappaBalpha, with the result that nuclear shuttling of IkappaBepsilon between the nucleus and the cytoplasm is significantly slower than IkappaBalpha. Nuclear export of IkappaBepsilon is mediated by a short leucine-rich nuclear export sequence (NES)-like sequence ((VLLPFDDLKI352)-V-343), located between amino acids 343 and 352. This NES-like sequence is required for RanGTP-dependent binding of IkappaBepsilon to CRM1. Nuclear accumulation of IkappaBepsilon is increased by either leptomycin B treatment or alanine substitutions within the IkappaBepsilon-derived NES. A functional NES is required for both efficient cytoplasmic retention and post-induction control of c-Rel by IkappaBepsilon, consistent with the notion that IkappaBepsilon-mediated nuclear export contributes to control over the nucleocytoplasmic distribution of NF-kappaB/Rel proteins.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Hannink, M (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65212 USA.				NIGMS NIH HHS [GM59213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059213] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AREZANASEISDEDO.F, 1997, J CELL SCI, V110, P369; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee SH, 2001, J BIOL CHEM, V276, P23599, DOI 10.1074/jbc.M011197200; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; Memet S, 1999, J IMMUNOL, V163, P5994; O'Neill RE, 1998, EMBO J, V17, P288, DOI 10.1093/emboj/17.1.288; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SACHDEV S, 1995, ONCOGENE, V11, P811; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON J, 1995, CELL, V61, P255; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	41	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23358	23366		10.1074/jbc.M111559200	http://dx.doi.org/10.1074/jbc.M111559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970947	hybrid			2022-12-25	WOS:000176475700035
J	Covert, MW; Palsson, BO				Covert, MW; Palsson, BO			Transcriptional regulation in constraints-based metabolic models of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUX BALANCE MODELS; GENE-EXPRESSION; DIAUXIC GROWTH; MUTANTS; NETWORKS; GLUCOSE; ORGANIZATION; REQUIREMENT; DEFICIENT; ENZYMES	Full genome sequences enable the construction of genome-scale in silico models of complex cellular functions. Genome-scale constraints-based models of Escherichia coli metabolism have been constructed and used to successfully interpret and predict cellular behavior under a range of conditions. These previous models do not account for regulation of gene transcription and thus cannot accurately predict some organism functions. Here we present an in silico model of the central E. coli metabolism that accounts for regulation of gene expression. This model accounts for 149 genes, the products of which include 16 regulatory proteins and 73 enzymes. These enzymes catalyze 113 reactions, 45 of which are controlled by transcriptional regulation. The combined metabolic/regulatory model can predict the ability of mutant E. coli strains to grow on defined media as well as time courses of cell growth, substrate uptake, metabolic by-product secretion, and qualitative gene expression under various conditions, as indicated by comparison with experimental data under a variety of environmental conditions. The in silico model may also be used to interpret dynamic behaviors observed in cell cultures. This combined metabolic/regulatory model is thus an important step toward the goal of synthesizing genome-scale models that accurately represent E. coli behavior.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Covert, Markus/0000-0002-5993-8912; Palsson, Bernhard/0000-0003-2357-6785	NIGMS NIH HHS [GM57089] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057089] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya Sankar, 1996, P181; ANDERSON A, 1969, FEBS LETT, V4, P19, DOI 10.1016/0014-5793(69)80184-5; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; CALHOUN MW, 1993, J BACTERIOL, V175, P3020, DOI 10.1128/JB.175.10.3020-3025.1993; COURTRIGHT JB, 1970, J BACTERIOL, V102, P722, DOI 10.1128/JB.102.3.722-728.1970; Covert MW, 2001, TRENDS BIOCHEM SCI, V26, P179, DOI 10.1016/S0968-0004(00)01754-0; Covert MW, 2001, J THEOR BIOL, V213, P73, DOI 10.1006/jtbi.2001.2405; CREAGHAN IT, 1978, J GEN MICROBIOL, V107, P1; Cronan Jr. J. E., 1996, ESCHERICHIA COLI SAL, VI, P206; CUNNINGHAM PR, 1986, MOL GEN GENET, V205, P487, DOI 10.1007/BF00338087; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; EDWARDS JS, 1999, METAB ENG, P13; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; Gruer MJ, 1997, MICROBIOL-UK, V143, P1837, DOI 10.1099/00221287-143-6-1837; IRANI MH, 1977, J BACTERIOL, V132, P398, DOI 10.1128/JB.132.2.398-410.1977; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; KOMPALA DS, 1986, BIOTECHNOL BIOENG, V28, P1044, DOI 10.1002/bit.260280715; Kremling A, 2001, METAB ENG, V3, P362, DOI 10.1006/mben.2001.0199; KUMARI S, 1995, J BACTERIOL, V177, P2878, DOI 10.1128/jb.177.10.2878-2886.1995; LANGLEY D, 1977, J GEN MICROBIOL, V99, P263, DOI 10.1099/00221287-99-2-263; LENDENMANN U, 1995, MICROBIOL-SGM, V141, P71, DOI 10.1099/00221287-141-1-71; Maki Y, 2001, Pac Symp Biocomput, P446; MATJAN F, 1989, J BACTERIOL, V171, P342, DOI 10.1128/jb.171.1.342-348.1989; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; NEIDHARDT FC, 1990, PHYSL BACTERIAL CELL, P87; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; Peterson JD, 2001, NUCLEIC ACIDS RES, V29, P123, DOI 10.1093/nar/29.1.123; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Schilling CH, 2000, BIOTECHNOL BIOENG, V71, P286, DOI 10.1002/1097-0290(2000)71:4<286::AID-BIT1018>3.0.CO;2-R; Serres MH, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-9-research0035; Smolen P, 2000, B MATH BIOL, V62, P247, DOI 10.1006/bulm.1999.0155; Sorensen KI, 1996, J BACTERIOL, V178, P1003, DOI 10.1128/jb.178.4.1003-1011.1996; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; THOMAS R, 1973, J THEOR BIOL, V42, P563, DOI 10.1016/0022-5193(73)90247-6; Tran QH, 1997, EUR J BIOCHEM, V244, P155, DOI 10.1111/j.1432-1033.1997.00155.x; Tseng CP, 1997, FEMS MICROBIOL LETT, V157, P67, DOI 10.1016/S0378-1097(97)00455-2; VARMA A, 1994, APPL ENVIRON MICROB, V60, P3724, DOI 10.1128/AEM.60.10.3724-3731.1994; Wong P, 1997, BIOTECHNOL PROGR, V13, P132, DOI 10.1021/bp970003o	42	233	255	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28058	28064		10.1074/jbc.M201691200	http://dx.doi.org/10.1074/jbc.M201691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12006566	hybrid			2022-12-25	WOS:000177189800061
J	Kubota, H; Storms, RW; Reid, LM				Kubota, H; Storms, RW; Reid, LM			Variant forms of alpha-fetoprotein transcripts expressed in human hematopoietic progenitors - Implications for their developmental potential towards endoderm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL STEM-CELLS; GENETIC POTENTIATION; IN-VITRO; ENHANCER; PROMOTER; LIVER; MICE; DIFFERENTIATION; ELEMENTS; SEQUENCE	Hematopoietic stem cells have been identified as multipotent cells that give rise to all adult hematopoietic lineages. Although the hematopoietic lineage is derived from the mesodermal germ layer in the embryo, recent data suggest that bone marrow cells with an antigenic profile consistent with that of hematopoietic stem cells can also differentiate to cell types of the endodermal lineages, such as hepatocytes. However, the molecular mechanisms associated with these events are entirely unknown. For decades, a-fetoprotein (AFP) has been used as a differentiation marker for endodermal cells, because it was thought that the transcription of AFP mRNA is tightly regulated in a developmental and tissue-specific process. In this report we describe two new variant forms of AFP transcripts in human hematopoietic progenitors that are not expressed in mature cells. The variant AFP (vAFP) cDNA sequences isolated from a multipotent hematopoietic cell line, K562, revealed that the vAFP differed from the authentic transcript, consisting of 15 exons, by replacing exon 1 of AFP with one or two exons located in the 5'-untranslated region of the AFP gene. In addition to the K562 cell line, vAFP transcripts were detected in normal bone marrow, thymus, and brain but were not detected in normal spleen, intestine, liver, or the hepatocellular carcinoma cell line, HepG2. This suggests expression in normal hematopoietic progenitors. This hypothesis was confirmed by the finding that CD34(+)Lin(-) hematopoietic progenitor cells purified from cord blood by flow cytometric sorting also expressed the variant transcripts. These results suggest that some hematopoietic progenitors are in a state that permits them to express certain types of transcripts that have been considered unique to endoderm.	Univ N Carolina, Sch Med, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University	Kubota, H (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3850 Baltimore Ave, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052851] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK52851] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Chen HM, 1997, CRIT REV EUKAR GENE, V7, P11, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.20; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; EIFERMAN FA, 1981, NATURE, V294, P713, DOI 10.1038/294713a0; FARE JF, 2001, J BIOL CHEM, V276, P13136; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kubota H, 2000, P NATL ACAD SCI USA, V97, P12132, DOI 10.1073/pnas.97.22.12132; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Lazarevich NL, 2000, BIOCHEMISTRY-MOSCOW+, V65, P117; LEMIRE JM, 1991, CANCER RES, V51, P4656; MORRIS JF, 1995, BLOOD, V86, P3640; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; NAHON JL, 1987, J BIOL CHEM, V262, P12479; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Paterlini-Brechot P, 2000, SEMIN CANCER BIOL, V10, P241, DOI 10.1006/scbi.2000.0323; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Scohy S, 2000, NUCLEIC ACIDS RES, V28, P3743, DOI 10.1093/nar/28.19.3743; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Spear BT, 1999, SEMIN CANCER BIOL, V9, P109, DOI 10.1006/scbi.1998.0087; Storms RW, 2000, BLOOD, V96, P2125; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WATANABE K, 1987, J BIOL CHEM, V262, P4812; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V185, P648, DOI 10.1016/0006-291X(92)91674-F; XU ASL, 2000, PRINCIPLES TISSUE EN, P559; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zaret K, 1998, CURR OPIN GENET DEV, V8, P526, DOI 10.1016/S0959-437X(98)80006-3; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228	39	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27629	27635		10.1074/jbc.M202117200	http://dx.doi.org/10.1074/jbc.M202117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12006569	hybrid			2022-12-25	WOS:000177189800009
J	Siskind, LJ; Kolesnick, RN; Colombini, M				Siskind, LJ; Kolesnick, RN; Colombini, M			Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; INDUCED APOPTOSIS; CELL-DEATH; CASPASE ACTIVATION; LNCAP CELLS; GENERATION; MECHANISM; RESISTANCE; RELEASE; BCL-2	Ceramides are known to play a major regulatory role in apoptosis by inducing cytochrome c release from mitochondria. We have previously reported that C-2- and C-16-ceramide, but not dihydroceramide, form large channels in planar membranes (Siskind, L. J., and Colombini, M. (2001) J. Biol. Chem. 275, 38640 -38644). Here we show that ceramides do not trigger a cytochrome c secretion or release mechanism, but simply raise the permeability of the mitochondrial outer membrane, via ceramide channel formation, to include small proteins. Exogenously added reduced cytochrome c was able to freely permeate the mitochondrial outer membrane with entry to and exit from the intermembrane space facilitated by ceramides in a dose- and time-dependent manner. The permeability pathways were eliminated upon removal of C-2-ceramide by bovine serum albumin, thus ruling out a detergent-like effect of C2-ceramide on membranes. Ceramide channels were not specific to cytochrome c, as ceramides induced release of adenylate kinase, but not fumerase from isolated mitochondria, showing some specificity of these channels for the outer mitochondrial membrane. SDS-PAGE results show that ceramides allow release of intermembrane space proteins with a molecular weight cut-off of about 60,000. These results indicate that the ceramide-induced membrane permeability increases in isolated mitochondria are via ceramide channel formation and not a release mechanism, as the channels that allow cytochrome c to freely permeate are reversible, and are not specific to cytochrome c.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University System of Maryland; University of Maryland College Park; Memorial Sloan Kettering Cancer Center	Colombini, M (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	mc34@umail.umd.edu	Colombini, Marco/A-1540-2014	Siskind, Leah/0000-0001-5026-5187	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042467, R01NS042025] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS042467, F31 NS042467-02, R01 NS042025, R01 NS042025-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Ardail D, 2001, FEBS LETT, V488, P160, DOI 10.1016/S0014-5793(00)02332-2; Ariga T, 1998, J LIPID RES, V39, P1; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; Castedo M, 1996, J IMMUNOL, V157, P512; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Gannes FMP, 1998, CYTOMETRY, V33, P333; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garzotto M, 1999, CANCER RES, V59, P5194; Garzotto M, 1998, CANCER RES, V58, P2260; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; Hofmann K, 1999, TRENDS BIOCHEM SCI, V24, P227, DOI 10.1016/S0968-0004(99)01410-3; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; Kawatani M, 2000, EXP CELL RES, V259, P389, DOI 10.1006/excr.2000.4986; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LI LY, 2001, CELL, V412, P95; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; Muriel MP, 2000, J COMP NEUROL, V426, P297, DOI 10.1002/1096-9861(20001016)426:2<297::AID-CNE10>3.0.CO;2-O; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Polster BM, 2001, J BIOL CHEM, V276, P37887; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Radin NS, 2001, EUR J BIOCHEM, V268, P193, DOI 10.1046/j.1432-1033.2001.01845.x; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Simon CG, 1998, BIOCHEMISTRY-US, V37, P2059, DOI 10.1021/bi9710636; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Sotocassa G.L., 1967, METHOD ENZYMOL, V10, P448; SPECTOR AA, 1969, J LIPID RES, V10, P56; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; TUBOI S, 1990, ADV ENZYME REGUL, V30, P289; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	71	278	285	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26796	26803		10.1074/jbc.M200754200	http://dx.doi.org/10.1074/jbc.M200754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12006562	hybrid, Green Accepted			2022-12-25	WOS:000177055900013
J	Warton, K; Tonini, R; Fairlie, WD; Matthews, JM; Valenzuela, SM; Qiu, MR; Wu, WM; Pankhurst, S; Bauskin, AR; Harrop, SJ; Campbell, TJ; Curmi, PMG; Breit, SN; Mazzanti, M				Warton, K; Tonini, R; Fairlie, WD; Matthews, JM; Valenzuela, SM; Qiu, MR; Wu, WM; Pankhurst, S; Bauskin, AR; Harrop, SJ; Campbell, TJ; Curmi, PMG; Breit, SN; Mazzanti, M			Recombinant CLIC1 (NCC27) assembles in lipid bilayers via a pH-dependent two-state process to form chloride ion channels with identical characteristics to those observed in Chinese hamster ovary cells expressing CLIC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEIN; P64	CLIC1 (NCC27) is an unusual, largely intracellular, ion channel that exists in both soluble and membrane-associated forms. The soluble recombinant protein can be expressed in Escherichia coli, a property that has made possible both detailed electrophysiological studies in lipid bilayers and an examination of the mechanism of membrane integration. Soluble E. coli-derived CLIC1 moves from solution into artificial bilayers and forms chloride-selective ion channels with essentially identical conductance, pharmacology, and opening and closing kinetics to those observed in CLIC1-transfected Chinese hamster ovary cells. The process of membrane integration of CLIC1 is pH-dependent. Following addition of protein to the trans solution, small conductance channels with slow kinetics (SCSK) appear in the bilayer. These SCSK modules then appear to undergo a transition to form a high conductance channel with fast kinetics. This has four times the conductance of the SCSK and fast kinetics that characterize the native channel. This suggests that the CLIC1 ion channel is likely to consist of a tetrameric assembly of subunits and indicates that despite its size and unusual properties, it is able to form a completely functional ion channel in the absence of any other ancillary proteins.	Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia; Univ New S Wales, Dept Med, Sydney, NSW 2052, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ Roma La Sapienza, Dipartimento Fisiol, I-00185 Rome, Italy; Fdn Cenci Bolognetti, Inst Pasteur, I-00185 Rome, Italy; Univ New S Wales, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Darlinghurst, NSW 2010, Australia	Sapienza University Rome; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; Sapienza University Rome; Fondazione Cenci Bolognetti; University of New South Wales Sydney; St Vincents Hospital Sydney	Mazzanti, M (corresponding author), Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Ple Aldo Moro 5, I-00185 Rome, Italy.	michele.mazzanti@uniroma1.it	Mazzanti, Michele/A-8941-2011; Matthews, Jacqueline/A-7322-2013; Curmi, Paul/G-7185-2011; Valenzuela, Stella/R-6387-2019; Fairlie, Walter/M-8401-2015; Tonini, Raffaella/J-2960-2012	Curmi, Paul/0000-0001-5762-7638; Valenzuela, Stella/0000-0001-5934-6047; Fairlie, Walter/0000-0002-2498-1160; Mazzanti, Michele/0000-0002-1819-3811; Matthews, Jacqueline/0000-0001-8518-3472; Campbell, Terry/0000-0003-0055-4137; TONINI, Raffaella/0000-0003-1652-4709				CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575	14	94	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26003	26011		10.1074/jbc.M203666200	http://dx.doi.org/10.1074/jbc.M203666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11978800	hybrid			2022-12-25	WOS:000176908700025
J	Kruger, C; Berkowitz, O; Stephan, UW; Hell, R				Kruger, C; Berkowitz, O; Stephan, UW; Hell, R			A metal-binding member of the late embryogenesis abundant protein family transports iron in the phloem of Ricinus communis L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GELS; NICOTIANAMINE; ACID; ELECTROPHORESIS; MICRONUTRIENTS; STAIN	The transport of metal micronutrients to developing organs in a plant is mediated primarily by the sieve elements. Ligands are thought to form complexes with the free ions in order to prevent cellular damage, but no binding partners have been unequivocally identified from plants so far. This study has used the phloem-mediated transport of micronutrients during the germination of the castor bean seedling to identify an iron transport protein (ITP). It is demonstrated that essentially all Fe-55 fed to seedlings is associated with the protein fraction of phloem exudate. It is shown that ITP carries iron in vivo and binds additional iron in vitro. ITP was purified to homogeneity from minute amounts of phloem exudate using immobilized metal ion affinity chromatography. It preferentially binds to Fe3+ but not to Fe2+ and also complexes Cu2+, Zn2+, and Mn2+ in vitro. The corresponding cDNA of ITP was cloned using internal peptide fragments. The deduced protein of 96 amino acids shows high similarity to the stress-related family of late embryogenesis abundant proteins. Its predicted characteristics and its RNA expression pattern are consistent with a function in metal ion binding. The ITP from Ricinus provides the first identified micronutrient binding partner for phloem-mediated long distance transport in plants and is the first member of the late embryogenesis abundant protein family shown to have such a function.	Leibniz Inst, Inst Pflanzengent & Kulturpflanzenforsch Gatersle, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Hell, R (corresponding author), Leibniz Inst, Inst Pflanzengent & Kulturpflanzenforsch Gatersle, Corrensstr 3, D-06466 Gatersleben, Germany.	hell@ipk-gatersleben.de	Berkowitz, Oliver/AAE-7979-2019; Berkowitz, Oliver/A-7854-2008; Hell, Ruediger/E-5436-2014	Berkowitz, Oliver/0000-0002-7671-6983; Berkowitz, Oliver/0000-0002-7671-6983; Hell, Ruediger/0000-0002-6238-4818				ANDEREGG G, 1989, J CHEM SOC CHEM COMM, P647, DOI 10.1039/c39890000647; Atkins C, 2000, AUST J PLANT PHYSIOL, V27, P531, DOI 10.1071/PP99129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brait JF, 2002, OXIDATIVE STRESS PLA, P171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG MCM, 1985, ANAL BIOCHEM, V148, P498, DOI 10.1016/0003-2697(85)90258-1; Cuming AC, 1999, SEED PROTEINS, P753; Fox TC, 1998, ANNU REV PLANT PHYS, V49, P669, DOI 10.1146/annurev.arplant.49.1.669; Fritsche K, 1999, FEBS LETT, V462, P249, DOI 10.1016/S0014-5793(99)01541-0; GALAU GA, 1992, PLANT PHYSIOL, V98, P1523, DOI 10.1104/pp.98.4.1523; Garay-Arroyo A, 2000, J BIOL CHEM, V275, P5668, DOI 10.1074/jbc.275.8.5668; Herbik A, 1999, EUR J BIOCHEM, V265, P231, DOI 10.1046/j.1432-1327.1999.00717.x; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; JUNGBLUT PR, 1990, J BIOCHEM BIOPH METH, V21, P47, DOI 10.1016/0165-022X(90)90044-D; KALLARACKAL J, 1989, PLANTA, V177, P327, DOI 10.1007/BF00403590; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAAS FM, 1988, PLANT PHYSIOL, V87, P167, DOI 10.1104/pp.87.1.167; Marentes E, 1997, 9 INT S IR NUTR INT, P74; Marschner H, 1997, BOT ACTA, V110, P265, DOI 10.1111/j.1438-8677.1997.tb00639.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATE JS, 1975, PHLOEM TRANSPORT, P451; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDKE I, 1995, PHYSIOL PLANTARUM, V95, P147, DOI 10.1111/j.1399-3054.1995.tb00821.x; Schmidke I, 1999, PHYSIOL PLANTARUM, V106, P82, DOI 10.1034/j.1399-3054.1999.106112.x; Stephan UW, 1996, BIOMETALS, V9, P84, DOI 10.1007/BF00188095; STEPHAN UW, 1993, PHYSIOL PLANTARUM, V88, P522, DOI 10.1111/j.1399-3054.1993.tb01367.x; STEPHAN UW, 2002, IN PRESS PLANT SOIL; Takahashi R, 1997, PLANT SCI, V123, P93, DOI 10.1016/S0168-9452(96)04568-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGOOR BJ, 1976, PHYSIOL PLANTARUM, V36, P213, DOI 10.1111/j.1399-3054.1976.tb03938.x; von Wiren N, 1999, PLANT PHYSIOL, V119, P1107, DOI 10.1104/pp.119.3.1107; WANG HL, 1999, AM SOC PLANT PHYSL A, P105; WANG HL, 2000, 10 INT S IR NUTR INT, P105; Zhong W, 1996, PLANT CELL ENVIRON, V19, P471, DOI 10.1111/j.1365-3040.1996.tb00339.x	37	181	205	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25062	25069		10.1074/jbc.M201896200	http://dx.doi.org/10.1074/jbc.M201896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983700	hybrid			2022-12-25	WOS:000176747000031
J	Teixeira-Clerc, F; Menez, A; Kessler, P				Teixeira-Clerc, F; Menez, A; Kessler, P			How do short neurotoxins bind to a muscular-type nicotinic acetylcholine receptor?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CURAREMIMETIC TOXIN; ALPHA-BUNGAROTOXIN; CRYSTAL-STRUCTURE; SNAKE-VENOM; DELTA-SUBUNIT; COMPLEX; RESIDUES; REVEALS; INHIBITION	We investigated the interacting surface between a short curarimimetic toxin and a muscular-type nicotinic acetylcholine receptor, looking for the ability of various biotinylated Naja nigricollis a-neurotoxin analogues to bind simultaneously the receptor and streptavidin. All these derivatives, modified at positions 10 (loop 1), 27, 30, 33, 35 (loop 11), 46, and 47 (loop III) or the N-terminal (erabutoxin numbering), still shared high affinity for the receptor, and in the absence of receptor they all bound soluble streptavidin. However, the proportion of the toxin-receptor complex that bound to streptavidin-coated beads, varied both with the location of the modification and with the length of the linker between biotin and the toxin. In the receptor-toxin complex, the concave side of loops 11 and III was not accessible to streptavidin, unlike the N terminus of the toxin and, to a certain extent, loop I. On the convex face, loop III was the most accessible, whereas the tip of loop 11, especially Arg-30, seemed to be closer to the receptor. The present data demonstrate that short toxins neither penetrate deeply into a crevice as proposed earlier nor lie parallel to the receptor extracellular wall. These data also suggest that they may not lie strictly perpendicular to the cylindrical wall of the receptor. These results fit nicely with three-dimensional models of interaction between long neurotoxins and their receptors and support the idea that short and long curarimimetic toxins share a similar overall topology of interaction when bound to nicotinic receptors.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Kessler, P (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Teixeira-Clerc, Fatima/AAB-5499-2021; Teixeira-Clerc, Fatima/C-9884-2009	Teixeira-Clerc, Fatima/0000-0003-1098-9222; 				Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BOULAIN JC, 1982, SCIENCE, V217, P732, DOI 10.1126/science.7100919; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Hucho F, 2001, ANGEW CHEM INT EDIT, V40, P3101, DOI 10.1002/1521-3773(20010903)40:17<3100::AID-ANIE3100>3.0.CO;2-A; LeDu MH, 1996, ACTA CRYSTALLOGR D, V52, P87, DOI 10.1107/S0907444995007517; LOBEL P, 1985, J BIOL CHEM, V260, P605; MACHOLD J, 1995, P NATL ACAD SCI USA, V92, P7282, DOI 10.1073/pnas.92.16.7282; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; Michalet S, 2000, J BIOL CHEM, V275, P25608, DOI 10.1074/jbc.M002362200; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; MOORE MA, 1995, BBA-BIOMEMBRANES, V1235, P336, DOI 10.1016/0005-2736(95)80022-8; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; OSWALD RE, 1983, BIOCHEMISTRY-US, V22, P3128, DOI 10.1021/bi00282a015; OSWALD RE, 1981, BIOCHEMISTRY-US, V20, P7166, DOI 10.1021/bi00528a018; PILLET L, 1993, J BIOL CHEM, V268, P909; Saez-Briones P, 1999, EUR J BIOCHEM, V265, P902, DOI 10.1046/j.1432-1327.1999.00787.x; SAITOH T, 1980, FEBS LETT, V116, P30, DOI 10.1016/0014-5793(80)80522-9; Scarselli M, 2002, BIOCHEMISTRY-US, V41, P1457, DOI 10.1021/bi011012f; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200; ZINNJUSTIN S, 1993, BIOCHEMISTRY-US, V32, P6884, DOI 10.1021/bi00078a011; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25741	25747		10.1074/jbc.M200534200	http://dx.doi.org/10.1074/jbc.M200534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006581	hybrid			2022-12-25	WOS:000176747000117
J	Abraham, MR; Selivanov, VA; Hodgson, DM; Pucar, D; Zingman, LV; Wieringa, B; Dzeja, PP; Aleksee, AE; Terzic, A				Abraham, MR; Selivanov, VA; Hodgson, DM; Pucar, D; Zingman, LV; Wieringa, B; Dzeja, PP; Aleksee, AE; Terzic, A			Coupling of cell energetics with membrane metabolic sensing - Integrative signaling through creatine kinase phosphotransfer disrupted by M-CK gene knock-out	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNELS; ADENYLATE KINASE; CATALYZED PHOSPHOTRANSFER; SULFONYLUREA RECEPTOR; SARCOPLASMIC-RETICULUM; PROTECTIVE ROLE; MICE DEFICIENT; MUSCLE; HEART	Transduction of metabolic signals is essential in preserving cellular homeostasis. Yet, principles governing integration and synchronization of membrane metabolic sensors with cell metabolism remain elusive. Here, analysis of cellular nucleotide fluxes and nucleotide-dependent gating of the ATP-sensitive K+ (K-ATP) channel, a prototypic metabolic sensor, revealed a diffusional barrier within the submembrane space, preventing direct reception of cytosolic signals. Creatine kinase phosphotransfer, captured by O-18-assisted P-31 NMR, coordinated tightly with ATP turnover, reflecting the cellular energetic status. The dynamics of high energy phosphoryl transfer through the creatine kinase relay permitted a high fidelity transmission of energetic signals into the submembrane compartment synchronizing K-ATP channel activity with cell metabolism. Knock-out of the creatine kinase M-CK gene disrupted signal delivery to K-ATP channels and generated a cellular phenotype with increased electrical vulnerability. Thus, in the compartmentalized cell environment, phosphotransfer systems shunt diffusional barriers and secure regimented signal transduction integrating metabolic sensors with the cellular energetic network.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; Univ Nijmegen, Med Ctr, Ctr Mol Life Sci, NL-6500 HE Nijmegen, Netherlands	Mayo Clinic; Mayo Clinic; Mayo Clinic; Radboud University Nijmegen	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, 200 1st St SW,Guggenheim 7, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Wieringa, Berend/A-5346-2011; Zingman, Leonid V/GXG-0136-2022	Wieringa, Berend/0000-0001-9192-8020; Zingman, Leonid V/0000-0002-7566-4616; Selivanov, Vitaly/0000-0002-7937-9249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64822, HL-07111] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 1999, FASEB J, V13, P1901; Aguilar-Bryan L, 2001, RECENT PROG HORM RES, V56, P47, DOI 10.1210/rp.56.1.47; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; Boehm E, 2000, J MOL CELL CARDIOL, V32, P891, DOI 10.1006/jmcc.2000.1130; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Chazov E I, 1980, Adv Myocardiol, V1, P139; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; de Groof AJC, 2002, J BIOL CHEM, V277, P5275, DOI 10.1074/jbc.M108157200; DECKING UKM, 1995, AM J PHYSIOL-HEART C, V269, pH734, DOI 10.1152/ajpheart.1995.269.2.H734; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; GOLHABER JI, 1997, MYOCARDIUM, P325; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Kabakov AY, 1998, BIOPHYS J, V75, P2858, DOI 10.1016/S0006-3495(98)77728-8; Kinsey ST, 1999, NMR BIOMED, V12, P1, DOI 10.1002/(SICI)1099-1492(199902)12:1<1::AID-NBM539>3.0.CO;2-V; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Koster JC, 2001, CIRC RES, V89, P1022, DOI 10.1161/hh2301.100342; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; Li RA, 2000, CIRC RES, V87, P837, DOI 10.1161/01.RES.87.10.837; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Mihm MJ, 2001, CIRCULATION, V104, P174, DOI 10.1161/01.CIR.104.2.174; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Pucar D, 2001, J BIOL CHEM, V276, P44812, DOI 10.1074/jbc.M104425200; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; Sasaki N, 2001, AM J PHYSIOL-HEART C, V280, pH1882, DOI 10.1152/ajpheart.2001.280.4.H1882; Saupe KW, 1998, CIRC RES, V82, P898; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Stockler S, 1996, AM J HUM GENET, V58, P914; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WEISS JN, 1992, J PHYSIOL-LONDON, V447, P649, DOI 10.1113/jphysiol.1992.sp019022; WEISS JN, 1993, CARDIOVASC DRUG THER, V7, P499, DOI 10.1007/BF00877614; Weiss JN, 2001, CIRC RES, V89, P108, DOI 10.1161/res.89.2.108; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; Yamada K, 2001, SCIENCE, V292, P1543, DOI 10.1126/science.1059829; Zingman LV, 2002, J BIOL CHEM, V277, P14206, DOI 10.1074/jbc.M109452200; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	64	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24427	24434		10.1074/jbc.M201777200	http://dx.doi.org/10.1074/jbc.M201777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967264	hybrid, Green Published			2022-12-25	WOS:000176611800061
J	Kraus, RJ; Ariazi, EA; Farrell, ML; Mertz, JE				Kraus, RJ; Ariazi, EA; Farrell, ML; Mertz, JE			Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; STEROID-HORMONE RECEPTORS; ACTIVATED PROTEIN-KINASE; HUMAN LACTOFERRIN GENE; RESPONSE ELEMENTS; BREAST-CANCER; PROMOTER; BINDING; PHOSPHORYLATION; COACTIVATOR	The estrogen-related receptor alpha (ERRalpha) is an orphan member of the nuclear receptor superfamily. We show that the major isoform of the human ERRalpha gene, ERRalpha1, can sequence-specifically bind a consensus palindromic estrogen response element (ERE) and directly compete with estrogen receptor alpha (ERalpha) for binding. ERRalpha1 activates or represses ERE-regulated transcription in a cell type-dependent manner, repressing in ER-positive MCF-7 cells while activating in ER-negative HeLa cells. Thus, ERRalpha1 can function both as a modulator of estrogen responsiveness and as an estrogen-independent activator. Repression likely occurs in the absence of exogenous ligand since charcoal treatment of the serum had no effect on silencing activity. Mutational analysis revealed that repression is not simply the result of competition between ERalpha and ERRalpha1 for binding to the DNA, Rather, it also requires the presence of sequences within the carboxyl-terminal E/F domain of ERRalpha1. Thus, ERRalpha1 can function as either an active repressor or a constitutive activator of ERE-dependent transcription. We hypothesize that ERRalpha1 can play a critical role in the etiology of some breast cancers, thereby providing a novel therapeutic target in their treatment.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mertz, JE (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA.				NCI NIH HHS [CA07175, CA22443, CA09681, CA09135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, T32CA009681, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA JC, 1980, EUR J CANCER, V16, P323, DOI 10.1016/0014-2964(80)90348-5; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CATHERINO WH, 1995, CANCER LETT, V92, P39, DOI 10.1016/0304-3835(95)03755-L; Chen F, 1999, GENE, V228, P101, DOI 10.1016/S0378-1119(98)00619-2; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; CLARK GM, 1983, BREAST CANCER RES TR, V3, P69; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN JA, 1973, BIOCHEMISTRY-US, V12, P4085, DOI 10.1021/bi00745a010; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KNIGHT WA, 1977, CANCER RES, V37, P4669; Kraus RJ, 2001, VIROLOGY, V287, P89, DOI 10.1006/viro.2001.1024; Kraus RJ, 2001, J VIROL, V75, P867, DOI 10.1128/JVI.75.2.867-877.2001; Lu DS, 2001, CANCER RES, V61, P6755; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Murphy C S, 1990, Receptor, V1, P65; OREILLEY GH, 2000, THESIS U WISCONSIN M; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang ZP, 2001, MOL CELL ENDOCRINOL, V172, P223, DOI 10.1016/S0303-7207(00)00372-5; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	52	99	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24826	24834		10.1074/jbc.M202952200	http://dx.doi.org/10.1074/jbc.M202952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986328	hybrid			2022-12-25	WOS:000176611800110
J	Lu, CB; Chan, SL; Fu, WM; Mattson, MP				Lu, CB; Chan, SL; Fu, WM; Mattson, MP			The lipid peroxidation product 4-hydroxynonenal facilitates opening of voltage-dependent Ca(2+)Channels in neurons by increasing protein tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PEPTIDE; AMYOTROPHIC-LATERAL-SCLEROSIS; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; CALCIUM-CHANNEL; HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; CA2+ CHANNELS; SUPEROXIDE-DISMUTASE; POSTSYNAPTIC CALCIUM	Calcium influx through voltage-dependent calcium channels (VDCCs) mediates a variety of functions in neurons and other excitable cells, but excessive calcium influx through these channels can contribute to neuronal death in pathological settings. Oxyradical production and membrane lipid peroxidation occur in neurons in response to normal activity in neuronal circuits, whereas excessive lipid peroxidation is implicated in the pathogenesis of of neurodegenerative disorders. We now report on a specific mechanism whereby lipid peroxidation can modulate the activity of VDCCs. The lipid peroxidation product 4-hydroxy-2,3-nonenal (4HN) enhances dihydropyridine-sensitive whole-cell Ca2+ currents and increases depolarization-induced increases of intracellular Ca2+ levels in hippocampal neurons. Prolonged exposure to 4HN results in neuronal death which is prevented by treatment with glutathione an attenuated by the L-type Ca2+ channel blocker nimodipine. Tyrosine phosphorylation of alpha1 VDCC subunits is increased in neurons exposed to 4HN, and studies using inhibitors of tyrosine kinases and phosphatases indicate a requirement for tyrosine phosphorylation in the enhancement of VDCC activity in response to 4HN. Phosphorylation-mediated modulation of Ca2+ channel activity in response to lipid peroxidation may play important roles in the responses of neurons to oxidative stress in both physiological and pathological settings.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000313, ZIAAG000313, Z01AG000312, Z01AG000317, ZIAAG000312, ZIAAG000317] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blalock EM, 1999, J NEUROSCI, V19, P8674; Blanc EM, 1997, J NEUROCHEM, V69, P570; Blanc EM, 1998, GLIA, V22, P149, DOI 10.1002/(SICI)1098-1136(199802)22:2<149::AID-GLIA6>3.0.CO;2-2; BOLSHAKOV VY, 1995, NEUROPHARMACOLOGY, V34, P1581, DOI 10.1016/0028-3908(95)00127-R; Bruce-Keller AJ, 1998, J NEUROPATH EXP NEUR, V57, P257, DOI 10.1097/00005072-199803000-00007; Camandola S, 2000, MOL BRAIN RES, V85, P53, DOI 10.1016/S0169-328X(00)00234-5; Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; DAGANI F, 1988, J NEUROCHEM, V50, P1233, DOI 10.1111/j.1471-4159.1988.tb10598.x; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Evans GJO, 1999, EUR J NEUROSCI, V11, P279, DOI 10.1046/j.1460-9568.1999.00427.x; Farooqui AA, 1997, J NEUROCHEM, V69, P889; FIESCHI C, 1988, J CARDIOVASC PHARM, V12, pS83, DOI 10.1097/00005344-198812006-00021; Furukawa K, 1998, J NEUROCHEM, V70, P1876; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Guo Q, 1997, J NEUROSCI, V17, P4212; HABY C, 1994, BIOCHEM J, V298, P341, DOI 10.1042/bj2980341; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kavalali ET, 1997, J NEUROSCI, V17, P5334; Keller JN, 1997, J NEUROCHEM, V69, P273; Keller JN, 1998, J NEUROSCI, V18, P687; KEYSER DO, 1990, NEURON, V5, P545, DOI 10.1016/0896-6273(90)90092-T; Kondo Y, 1997, BRAIN RES, V772, P37, DOI 10.1016/S0006-8993(97)00836-6; Kruman I, 1997, J NEUROSCI, V17, P5089; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; Liu W, 1999, J CELL SCI, V112, P2409; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; MALENKA RC, 1991, MOL NEUROBIOL, V5, P289, DOI 10.1007/BF02935552; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mattson MP, 1997, NEUROREPORT, V8, P2275, DOI 10.1097/00001756-199707070-00036; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McGahon BM, 1999, NEUROBIOL AGING, V20, P643, DOI 10.1016/S0197-4580(99)00027-5; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; Montine KS, 1998, J NEUROPATH EXP NEUR, V57, P415, DOI 10.1097/00005072-199805000-00005; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Nilova N S, 1996, Neurosci Behav Physiol, V26, P23, DOI 10.1007/BF02391152; Pedersen WA, 2000, J NEUROCHEM, V74, P1426, DOI 10.1046/j.1471-4159.2000.0741426.x; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; RANE SG, 1994, J NEUROSCI RES, V38, P590, DOI 10.1002/jnr.490380511; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rinaldi M, 2000, BIOCHEM BIOPH RES CO, V272, P75, DOI 10.1006/bbrc.2000.2691; Roy J, 1998, J NEUROSCI, V18, P9673; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Shaw PJ, 1999, ANN NEUROL, V46, P803; Siems WG, 1998, J BIOCHEM, V123, P534; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; Walter HJ, 2000, J BIOL CHEM, V275, P25717, DOI 10.1074/jbc.M910282199; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wijetunge S, 1998, BRIT J PHARMACOL, V124, P307, DOI 10.1038/sj.bjp.0701840; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Zhu HY, 1999, BRAIN RES, V842, P224, DOI 10.1016/S0006-8993(99)01827-2; Zipfel GJ, 1999, NEW ENGL J MED, V341, P1543, DOI 10.1056/NEJM199911113412011	68	60	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24368	24375		10.1074/jbc.M201924200	http://dx.doi.org/10.1074/jbc.M201924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006588	hybrid			2022-12-25	WOS:000176611800053
J	Gloe, T; Sohn, HY; Meininger, GA; Pohl, U				Gloe, T; Sohn, HY; Meininger, GA; Pohl, U			Shear stress-induced release of basic fibroblast growth factor from endothelial cells is mediated by matrix interaction via integrin alpha(V)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN SULFATE COMPLEXES; KAPOSIS-SARCOMA KS; SMOOTH-MUSCLE; INFLAMMATORY CYTOKINES; EXTRACELLULAR-MATRIX; LESION FORMATION; BINDING PROTEIN; ANGIOGENESIS; PROLIFERATION; RESPONSES	Considering that chronic elevation of shear stress results in remodeling of the vasculature, we analyzed whether mechanical load could mediate basic fibroblast growth factor (bFGF) release and whether bFGF would act as mediator of shear stress-induced endothelial proliferation and differentiation. Supernatant media of shear stress-exposed endothelial cells (EC) contained significantly higher amounts of bFGF than medium from static cells. Released bFGF was fully intact with regard to its function as an inductor of proliferation and differentiation. Shear stress-conditioned media induced capillary-like structure formation, whereas static control medium did not. Likewise, only shear stress-conditioned medium induced proliferation of serum starved EC. Both capillary-like structure formation and proliferation could be inhibited by neutralization of bFGF or its receptor. The release of bFGF was subject to specific, integrin-mediated control, since inhibition of alpha(v)beta(3) integrin prevented it, whereas inhibition of alpha(5)beta(1) integrin had no effect. We conclude that shear stress induces the release of bFGF from EC in a tightly controlled manner. The release is dependent on specific cell-matrix interactions via alpha(v)beta(3) integrins. The effects on cell proliferation and differentiation suggest that release of bFGF is functionally significant and may represent a necessary initial step in adaptive remodeling processes induced by shear stress.	Univ Munich, Inst Vegetat Physiol, D-80336 Munich, Germany; Univ Munich, Klinikum Innenstadt, Dept Cardiol, D-80336 Munich, Germany; Texas A&M Univ, Dept Med Physiol, College Stn, TX 77843 USA	University of Munich; University of Munich; Texas A&M University System; Texas A&M University College Station	Gloe, T (corresponding author), Univ Munich, Inst Vegetat Physiol, Schillerstr 44, D-80336 Munich, Germany.	gloe@lrz.uni-muenchen.de						ACEVEDO AD, 1993, J CELL PHYSIOL, V157, P603, DOI 10.1002/jcp.1041570321; Acosta JA, 1996, MOL MED, V2, P755, DOI 10.1007/BF03401659; Albuquerque MLC, 1998, EXP CELL RES, V245, P163, DOI 10.1006/excr.1998.4243; Ambalavanan N, 1999, BIOL NEONATE, V76, P311, DOI 10.1159/000014173; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, BLOOD, V81, P3324; Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BUSHKINHARAV I, 1995, J BIOL CHEM, V270, P13422, DOI 10.1074/jbc.270.22.13422; Cenni E, 1999, J BIOMAT SCI-POLYM E, V10, P891, DOI 10.1163/156856299X00513; Cenni E, 1999, J BIOMAT SCI-POLYM E, V10, P989, DOI 10.1163/156856299X00577; Chen CH, 1997, P ASSOC AM PHYSICIAN, V109, P351; COZZOLINO F, 1993, J CLIN INVEST, V91, P2504, DOI 10.1172/JCI116486; Cucina A, 1999, BIOCHEM BIOPH RES CO, V257, P306, DOI 10.1006/bbrc.1999.0478; Deschenes MR, 1999, MED SCI SPORT EXER, V31, P1599, DOI 10.1097/00005768-199911000-00016; EGUCHI K, 1992, J RHEUMATOL, V19, P1925; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Fajardo LF, 1996, LAB INVEST, V74, P600; Garcia-Martinez C, 1999, GENE THER, V6, P1210, DOI 10.1038/sj.gt.3300950; Gavin TP, 2000, J APPL PHYSIOL, V88, P1192, DOI 10.1152/jappl.2000.88.4.1192; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Gloe T, 1999, J BIOL CHEM, V274, P15996, DOI 10.1074/jbc.274.23.15996; Gu JW, 1997, CIRCULATION, V95, P1165; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Hudlicka O, 1998, MICROCIRCULATION, V5, P7; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JOSEPHSILVERSTEIN J, 1987, SEMIN THROMB HEMOST, V13, P504, DOI 10.1055/s-2007-1003526; Kohno M, 1998, CIRCULATION, V98, P353, DOI 10.1161/01.CIR.98.4.353; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li ZH, 1995, EXP MOL PATHOL, V63, P77, DOI 10.1006/exmp.1995.1032; Lopez JJ, 1998, AM J PHYSIOL-HEART C, V274, pH930, DOI 10.1152/ajpheart.1998.274.3.H930; Mogford JE, 1997, J CLIN INVEST, V100, P1647, DOI 10.1172/JCI119689; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.3.CO;2-R; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; Pepper MS, 1998, EXP CELL RES, V241, P414, DOI 10.1006/excr.1998.4072; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Rainger GE, 1999, AM J PHYSIOL-HEART C, V276, pH858, DOI 10.1152/ajpheart.1999.276.3.H858; REIDY MA, 1992, CIRCULATION, V86, P43; RIFKIN DB, 1990, CELL DIFFER DEV, V32, P313, DOI 10.1016/0922-3371(90)90045-X; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAMANIEGO F, 1995, J IMMUNOL, V154, P3582; Samaniego F, 1997, J IMMUNOL, V158, P1887; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sapienza P, 1998, Minerva Cardioangiol, V46, P141; Sapienza P, 1998, J SURG RES, V75, P24, DOI 10.1006/jsre.1997.5260; SARZANI R, 1989, J CLIN INVEST, V83, P1404, DOI 10.1172/JCI114029; SATO Y, 1989, MOL ENDOCRINOL, V3, P744, DOI 10.1210/mend-3-4-744; SCHULTZ G S, 1991, Eye (London), V5, P170; Shyy JYJ, 2001, BIORHEOLOGY, V38, P109; VILLASCHI S, 1993, AM J PATHOL, V143, P181; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Yang HT, 1998, AM J PHYSIOL-HEART C, V274, pH2053, DOI 10.1152/ajpheart.1998.274.6.H2053; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643	59	91	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23453	23458		10.1074/jbc.M203889200	http://dx.doi.org/10.1074/jbc.M203889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976347	hybrid			2022-12-25	WOS:000176475700048
J	Gonzalez-Santos, JM; Wang, A; Jones, J; Ushida, C; Liu, J; Hu, J				Gonzalez-Santos, JM; Wang, A; Jones, J; Ushida, C; Liu, J; Hu, J			Central region of the human splicing factor Hprp3p interacts with Hprp4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; ISOTHERMAL TITRATION CALORIMETRY; SACCHAROMYCES-CEREVISIAE; 2ND STEP; MUTATIONAL ANALYSIS; SNRNP PROTEIN; RNA; YEAST; PRP4; U4	Human splicing factors Hprp3p and Hprp4p are associated with the U4/U6 small nuclear ribonucleoprotein particle, which is essential for the assembly of an active spliceosome. Currently, little is known about the specific roles of these factors in splicing. In this study, we characterized the molecular interaction between Hprp3p and Hprp4p. Constructs were created for expression of Hprp3p or its mutants in bacterial or mammalian cells. We showed that antibodies against either Hprp3p or Hprp4p were able to pull-down the Hprp3p-Hprp4p complex formed in Escherichia coli lysates. By co-immunoprecipitation and isothermal titration calorimetry, we demonstrated that purified Hprp3p and its mutants containing the central region, but lacking either the N-terminal 194 amino acids or the C-terminal 240 amino acids, were able to interact with Hprp4p. Conversely, Hprp3p mutants containing only the N- or C-terminal region did not interact with Hprp4p. In addition, by co-immunoprecipitation, we showed that intact Hprp3p and its mutants containing the central region interacted with Hprp4p in HeLa cell nuclear extracts. Primer extension analysis illustrated that the central region of Hprp3p is required to maintain the association of Hprp3p-Hprp4p with U4/U6 small nuclear RNAs, suggesting that this Hprp3p/Hprp4p interaction allows the recruitment of Hprp4p, and perhaps other protein(s), to the U4/U6 small nuclear ribonucleoprotein particle.	Hosp Sick Children, Program Lung Biol Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Hu, J (corresponding author), Hosp Sick Children, Program Lung Biol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jhu@sickkids.on.ca	Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733; Hu, Jim/0000-0001-9134-7103				Ast G, 2001, NUCLEIC ACIDS RES, V29, P1741, DOI 10.1093/nar/29.8.1741; Ayadi L, 1997, RNA, V3, P197; Ayadi L, 1998, J MOL BIOL, V284, P673, DOI 10.1006/jmbi.1998.2183; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; Blencowe BJ, 1999, TRENDS BIOCHEM SCI, V24, P179, DOI 10.1016/S0968-0004(99)01387-0; Blencowe BJ, 1999, METH MOL B, V118, P275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; Horowitz DS, 1997, RNA, V3, P1374; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; HU J, 1994, NUCLEIC ACIDS RES, V22, P1724, DOI 10.1093/nar/22.9.1724; HU J, 1995, MOL CELL BIOL, V15, P1274; Johnson TL, 2001, GENE DEV, V15, P1957, DOI 10.1101/gad.895601; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; Kim M, 2001, J MOL BIOL, V312, P711, DOI 10.1006/jmbi.2001.4980; KONARSKA MM, 1988, P NATL ACAD SCI USA, V85, P5459, DOI 10.1073/pnas.85.15.5459; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAMER A, 1990, METHOD ENZYMOL, V181, P3; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LAST RL, 1987, GENETICS, V117, P619; Lauber J, 1997, RNA, V3, P926; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; Maroney PA, 2000, MOL CELL, V6, P317, DOI 10.1016/S1097-2765(00)00032-0; Meister G, 2001, EMBO J, V20, P2304, DOI 10.1093/emboj/20.9.2304; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; NOTTROTT S, 2001, 6 ANN M RNA SOC MAY, P5; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Rappsilber J, 2001, J BIOL CHEM, V276, P31142, DOI 10.1074/jbc.M103620200; Reidt U, 2000, J BIOL CHEM, V275, P7439, DOI 10.1074/jbc.275.11.7439; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Teigelkamp S, 1998, RNA, V4, P127; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; Umen JG, 1995, RNA, V1, P869; Vidovic I, 2000, MOL CELL, V6, P1331, DOI 10.1016/S1097-2765(00)00131-3; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Walhout AJM, 2000, YEAST, V17, P88, DOI 10.1002/1097-0061(20000630)17:2<88::AID-YEA20>3.0.CO;2-Y; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wang A, 1997, HUM MOL GENET, V6, P2117, DOI 10.1093/hmg/6.12.2117; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; XU Y, 1990, MOL CELL BIOL, V10, P1217, DOI 10.1128/MCB.10.3.1217	53	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23764	23772		10.1074/jbc.M111461200	http://dx.doi.org/10.1074/jbc.M111461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971898	hybrid			2022-12-25	WOS:000176475700087
J	Le, MT; Vanderheyden, PML; Szaszak, M; Hunyady, L; Vauquelin, G				Le, MT; Vanderheyden, PML; Szaszak, M; Hunyady, L; Vauquelin, G			Angiotensin IV is a potent agonist for constitutive active human AT(1) receptors - Distinct roles of the N- and C-terminal residues of angiotensin II during AT(1) receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE RESIDUES; BINDING-SITE	The octapeptide hormone, angiotensin II (Ang II), exerts its major physiological effects by activating AT, receptors. In vivo Ang II is degraded to bioactive peptides, including Ang III (angiotensin-(2-8)) and Ang IV (angiotensin-(3-8)). These peptides stimulate inositol phosphate generation in human AT(1) receptor expressing CHO-K1 cells, but the potency of Ang IV is very low. Substitution of Asn(111) with glycine, which is known to cause constitutive receptor activation by disrupting its interaction with the seventh transmembrane helix (TM VII), selectively increased the potency of Ang IV (900-fold) and angiotensin-(4-8), and leads to partial agonism of angiotensin-(5-8). Consistent with the need for the interaction between Arg(2) of Ang II and Ang III with Asp(281), substitution of this residue with alanine (D281A) decreased the peptide's potency without affecting that of Ang IV. All effects of the D281A mutation were superseded by the N111G mutation. The increased affinity of Ang IV to the N111G mutant was also demonstrated by binding studies. A model is proposed in which the Arg(2)-Asp(281) interaction causes a conformational change in TM VII of the receptor, which, similar to the N111G mutation, eliminates the constraining intramolecular interaction between Asn(111) and TM VII. The receptor adopts a more relaxed conformation, allowing the binding of the C-terminal five residues of Ang 11 that switches this "preactivated" receptor into the fully active conformation.	Free Univ Brussels, Inst Mol Biol & Biotechnol, Dept Mol & Biochem Pharmacol, B-1640 Rhode St Genese, Belgium; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary	Semmelweis University	Vauquelin, G (corresponding author), Free Univ Brussels, Inst Mol Biol & Biotechnol, Dept Mol & Biochem Pharmacol, B-1640 Rhode St Genese, Belgium.	gvauquel@vub.ac.be	Szaszak, Marta/G-7957-2011					Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; CAPPONI AM, 1979, J BIOL CHEM, V254, P5120; de Gasparo M, 2000, PHARMACOL REV, V52, P415; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Fierens F L, 2000, J Renin Angiotensin Aldosterone Syst, V1, P283, DOI 10.3317/jraas.2000.044; GARDINER SM, 1993, BRIT J PHARMACOL, V110, P159, DOI 10.1111/j.1476-5381.1993.tb13786.x; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; Hunyady L., 2001, J RENIN-ANGIO-ALDO S, V2, P16; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; NODA K, 1995, J BIOL CHEM, V270, P28511, DOI 10.1074/jbc.270.48.28511; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Reaux A, 2001, TRENDS ENDOCRIN MET, V12, P157, DOI 10.1016/S1043-2760(01)00381-2; SWANSON GN, 1992, REGUL PEPTIDES, V40, P409, DOI 10.1016/0167-0115(92)90527-2; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; Vanderheyden PML, 1999, BRIT J PHARMACOL, V126, P1057, DOI 10.1038/sj.bjp.0702398	20	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23107	23110		10.1074/jbc.C200201200	http://dx.doi.org/10.1074/jbc.C200201200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	12006574	hybrid			2022-12-25	WOS:000176475700002
J	Kane, S; Sano, H; Liu, SCH; Asara, JM; Lane, WS; Garner, CC; Lienhard, GE				Kane, S; Sano, H; Liu, SCH; Asara, JM; Lane, WS; Garner, CC; Lienhard, GE			A method to identify serine kinase substrates - Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; S6 KINASE; INSULIN; TRANSPORT; 3-KINASE	This study describes a method for the identification of the substrates of specific serine kinases. An antibody specific for the phosphomotif generated by the kinase is used to isolate phosphorylated substrates by immunoprecipitation, and the isolated proteins are identified by tandem mass spectrometry of peptides. This method was applied to the identification of substrates for the protein kinase Akt, which specifically phosphorylates the RXRXYS/T motif. 3T3-L1 adipocytes were treated with insulin to activate Akt, and the putative Akt substrate proteins were isolated by immunoprecipitation with an antibody against the phospho form of this motif. This led to the identification of a novel 160-kDa substrate for Akt. The 160-kDa substrate for Akt, which was designated AS160, has a Rab GAP domain. Recombinant AS160 was shown to be a substrate for Akt, and two sites of phosphorylation, both in RXRXXS/T motifs, were identified by mass spectrometry and mutation. Insulin treatment of adipocytes caused AS160 to redistribute from the low density microsomes to the cytosol.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Harvard Univ, Dept Mol & Cellular Biol, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Dartmouth College; Harvard University	Lienhard, GE (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Vail Bldg, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK025336, R55DK025336, R01DK042816, R56DK042816, R01DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42816, DK25336, R01 DK042816, R01 DK025336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clifford GM, 1998, FEBS LETT, V435, P125, DOI 10.1016/S0014-5793(98)01052-7; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FROST SC, 1985, J BIOL CHEM, V260, P2646; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Lawlor MA, 2001, J CELL SCI, V114, P2903; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	18	400	425	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22115	22118		10.1074/jbc.C200198200	http://dx.doi.org/10.1074/jbc.C200198200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11994271	hybrid			2022-12-25	WOS:000176313600003
J	Catalano, A; Romano, M; Martinotti, S; Procopio, A				Catalano, A; Romano, M; Martinotti, S; Procopio, A			Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen	ONCOGENE			English	Article						SV40; Tag; VEGF; mesothelioma	ANGIOGENESIS; GENE; P53; MESOTHELIOMA; SUPPRESSION; SEQUENCES; RECEPTOR; CELLS	Vascular endothelial growth factor (VEGF), an important angiogenic factor, regulates cell proliferation, differentiation, and apoptosis through activation of its tyrosine-kinase receptors, such as Flt-1 and Flk-1/Kdr. Human malignant mesothelioma cells (HMC), which have wild-type p53, express VEGF and exhibit cell growth increased by VEGF. Here, we demonstrate that early transforming proteins of simian virus (SV) 40, large tumor antigen (Tag) and small tumor antigen (tag). which have been associated with mesotheliomas, enhanced HNIC proliferation by inducing VEGF expression. SV40-Tag expression potently increased VEGF protein and mRNA levels in several HNIC lines. This effect was suppressed by the protein synthesis inhibitor, cycloheximide. Inactivation of the VEGF signal transduction pathway by expression of soluble form of FIt-1 inhibited Flk-1/Kdr activation and HNIC proliferation induced by SV40 early genes. Experiments with SV40 mutants revealed that SV40-Tag, but not -tag, is involved in the VEGF promoter activation. However, concomitant expression of SV40-tag enhanced Tag function. In addition, SV40-Tag expression sustained VEGF induction in colon carcinoma cell line (CCL)-233, which have wild-type p53, but not in CCL-238, which lack functional p53. These data indicate that VEGF regulation by SV40 transforming proteins can represent a key event in SV40 signaling relevant for tumor progression.	Univ Ancona, Fac Med, Inst Expt Pathol, I-60131 Ancona, Italy; Univ Messina, Dept Human Pathol, I-98125 Messina, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy	Marche Polytechnic University; University of Messina; G d'Annunzio University of Chieti-Pescara	Procopio, A (corresponding author), Univ Ancona, Fac Med, Inst Expt Pathol, Via Ranieri, I-60131 Ancona, Italy.	mromano@unich.it; procopio@poscsi.unian.it	Romano, Mario/I-7986-2012; Procopio, Antonio Domenico/AAB-2451-2021	Romano, Mario/0000-0001-8512-1458; Procopio, Antonio Domenico/0000-0001-6897-8724				Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Browne K, 2001, ANN OCCUP HYG, V45, P327, DOI 10.1016/S0003-4878(01)00029-1; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Claudio PP, 2001, CANCER RES, V61, P462; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gaetano C, 2001, CIRC RES, V88, pE38; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Orengo AM, 1999, EUR RESPIR J, V13, P527, DOI 10.1183/09031936.99.13352799; Pal S, 2001, CANCER RES, V61, P6952; Paley EL, 1996, CARCINOGENESIS, V17, P939, DOI 10.1093/carcin/17.5.939; Procopio A, 2000, GENE CHROMOSOME CANC, V29, P173, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Takayama K, 2000, CANCER RES, V60, P2169; Zhang LL, 2000, CANCER RES, V60, P3655	20	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2896	2900		10.1038/sj.onc.1205382	http://dx.doi.org/10.1038/sj.onc.1205382			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973650				2022-12-25	WOS:000175063700015
J	Urbich, C; Reissner, A; Chavakis, E; Dernbach, E; Haendeler, J; Fleming, I; Zeiher, AM; Kaszkin, M; Dimmeler, S				Urbich, C; Reissner, A; Chavakis, E; Dernbach, E; Haendeler, J; Fleming, I; Zeiher, AM; Kaszkin, M; Dimmeler, S			Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin	FASEB JOURNAL			English	Article						angiogenesis; Akt; migration; VEGF signaling; PP2A	GROWTH-FACTOR; CELL MIGRATION; AKT; PHOSPHORYLATION; VEGF; ANGIOSTATIN; INHIBITORS; SURVIVAL; SUPPRESSION; ACTIVATION	Endostatin is an anti-angiogenic factor that inhibits endothelial cell (EC) migration and induces EC apoptosis. Because nitric oxide (NO) plays a key role in vascular endothelial growth factor (VEGF)-induced angiogenesis, we hypothesized that endostatin interferes with the activation of the endothelial NO synthase (eNOS). Human recombinant endostatin significantly reduced VEGF-induced NO-release, which suggests that endostatin inhibits eNOS activation. Because the activation of eNOS by VEGF is associated with the Akt-dependent phosphorylation of eNOS at Ser1177, we investigated whether endostatin interferes with phosphorylation of eNOS. Endostatin reduced VEGF-induced phosphorylation of eNOS at Ser1177, whereas Akt phosphorylation was not affected. Coinciding with the inhibition of eNOS phosphorylation, endostatin completely blocked VEGF-induced EC migration. The NO-donor SNAP reversed the inhibitory effect of endostatin on EC migration. In addition, endostatin significantly inhibited VEGF-induced tube formation, whereas endostatin did not affect tube formation induced by NO. Finally, a non-dephosphorylatable constitutive active eNOS construct (S1177D), but not constitutive active Akt, abolished the inhibitory effect of endostatin on EC migration. Endostatin activated PP2A, which is known to directly dephosphorylate eNOS at Ser1177. Inhibition of PP2A prevented the inhibitory effect of endostatin. Thus, endostatin inhibits VEGF-induced EC migration and angiogenesis upstream of NO-synthesis via dephosphorylation of eNOS at Ser1177.	Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop E T, 1999, Angiogenesis, V3, P335, DOI 10.1023/A:1026546219962; Boehm T, 1998, BIOCHEM BIOPH RES CO, V252, P190, DOI 10.1006/bbrc.1998.9617; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chavakis E, 2001, CIRCULATION, V103, P2102; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Clauss M, 2000, CIRC RES, V86, P251, DOI 10.1161/01.RES.86.3.251; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Ma L, 2001, P NATL ACAD SCI USA, V98, P6470, DOI 10.1073/pnas.111150798; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryan CJ, 2000, DRUG AGING, V17, P249, DOI 10.2165/00002512-200017040-00001; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Sim BKL, 2000, CANCER METAST REV, V19, P181, DOI 10.1023/A:1026551202548; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Thomsen LL, 1998, CANCER METAST REV, V17, P107, DOI 10.1023/A:1005912906436; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Urbich C, 2002, ARTERIOSCL THROM VAS, V22, P69, DOI 10.1161/hq0102.101518; Webb CP, 2000, J NEURO-ONCOL, V50, P71, DOI 10.1023/A:1006466605356; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841	57	113	127	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					706	+		10.1096/fj.01-0637fje	http://dx.doi.org/10.1096/fj.01-0637fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978735				2022-12-25	WOS:000174755900015
J	Yu, CL; Chen, Y; Cline, GW; Zhang, DY; Zong, HH; Wang, YL; Bergeron, R; Kim, JK; Cushman, SW; Cooney, GJ; Atcheson, B; White, MF; Kraegen, EW; Shulman, GI				Yu, CL; Chen, Y; Cline, GW; Zhang, DY; Zong, HH; Wang, YL; Bergeron, R; Kim, JK; Cushman, SW; Cooney, GJ; Atcheson, B; White, MF; Kraegen, EW; Shulman, GI			Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE EXTRACTION; SKELETAL-MUSCLE; RESISTANCE; HUMANS; TRIGLYCERIDE; TISSUE; SPECTROSCOPY; ASSOCIATION; THETA; RAT	Recent studies have demonstrated that fatty acids induce insulin resistance in skeletal muscle by blocking insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase (PI3-kinase). To examine the mechanism by which fatty acids mediate this effect, rats were infused with either a lipid emulsion (consisting mostly of 18:2 fatty acids) or glycerol. Intracellular C18:2 CoA increased in a time-dependent fashion, reaching an similar to6-fold elevation by 5 h, whereas there was no change in the concentration of any other fatty acyl-CoAs. Diacylglycerol (DAG) also increased transiently after 3-4 h of lipid infusion. In contrast there was no increase in intracellular ceramide or triglyceride concentrations during the lipid infusion. Increases in intracellular C18:2 CoA and DAG concentration were associated with protein kinase C (PKC)-theta activation and a reduction in both insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1 associated PI3-kinase activity, which were associated with an increase in IRS-1 Ser(307) phosphorylation. These data support the hypothesis that an increase in plasma fatty acid concentration results in an increase in intracellular fatty acyl-CoA and DAG concentrations, which results in activation of PKC-theta leading to increased IRS-1 Ser(307) phosphorylation. This in turn leads to decreased IRS-1 tyrosine phosphorylation and decreased activation of IRS-1-associated PI3-kinase activity resulting in decreased insulin-stimulated glucose transport activity.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; NIDDK, NIH, Bethesda, MD 20814 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA; Garvan Inst Med Res, Sydney, NSW, Australia	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Garvan Institute of Medical Research	Shulman, GI (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave,BCMM 254,Box 9812, New Haven, CT 06536 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Kim, Jason/0000-0002-7185-042X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-40936, R01 DK040936, P30 DK-45735] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BODEN G, 1995, J CLIN INVEST, V96, P1261, DOI 10.1172/JCI118160; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Laybutt DR, 1999, AM J PHYSIOL-ENDOC M, V277, pE1070, DOI 10.1152/ajpendo.1999.277.6.E1070; Pacheco YM, 1998, J CHROMATOGR B, V714, P127, DOI 10.1016/S0378-4347(98)00231-X; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280	21	1120	1158	2	83	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50230	50236		10.1074/jbc.M200958200	http://dx.doi.org/10.1074/jbc.M200958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12006582	hybrid			2022-12-25	WOS:000180177700005
J	Bayle, JH; Randazzo, F; Johnen, G; Kaufman, S; Nagy, A; Rossant, J; Crabtree, GR				Bayle, JH; Randazzo, F; Johnen, G; Kaufman, S; Nagy, A; Rossant, J; Crabtree, GR			Hyperphenylalaninemia and impaired glucose tolerance in mice lacking the bifunctional DCoH gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1; TRANSCRIPTION FACTOR HNF1; PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE; 4A-CARBINOLAMINE DEHYDRATASE; PHENYLALANINE-HYDROXYLASE; CRYSTAL-STRUCTURE; PROTEIN; COFACTOR; RAT; DIMERIZATION	The bifunctional protein DCoH (Dimerizing Cofactor for HNF1) acts as an enzyme in intermediary metabolism and as a binding partner of the HNF1 family of transcriptional activators. HNF1 proteins direct the expression of a variety of genes in the liver, kidney, pancreas, and gut and are critical to the regulation of glucose homeostasis. Mutations of the HNF1 a gene underlie maturity onset diabetes of the young (MODY3) in humans. DCoH acts as a cofactor for HNF1 that stabilizes the dimeric HNF1 complex. DCoH also catalyzes the recycling of tetrahydrobiopterin, a cofactor of aromatic amino acid hydroxylases. To examine the roles of DCoH, a targeted deletion allele of the murine DCoH gene was created. Mice lacking DCoH are viable and fertile but display hyperphenylalaninemia and a predisposition to cataract formation. Surprisingly, HNF1 function in DCoH null mice is only slightly impaired, and mice are mildly glucose-intolerant in contrast to HNF1alpha null mice, which are diabetic. DCoH function as it pertains to HNF1 activity appears to be partially complemented by a newly identified homolog, DCoH2.	Stanford Univ, Beckman Ctr Mol & Genet Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Beckman Ctr Mol & Genet Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Beckman Ctr Mol & Genet Med, Dept Pathol, Stanford, CA 94305 USA; NIMH, Neurochem Lab, Bethesda, MD 20892 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Crabtree, GR (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol & Pathol, HHMI, B211,279 Campus Dr, Stanford, CA 94305 USA.		Johnen, Georg/AFG-8027-2022; Nagy, Andras/G-6465-2013	Johnen, Georg/0000-0002-3773-5946; Nagy, Andras/0000-0003-4311-0413				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barbacci E, 1999, DEVELOPMENT, V126, P4795; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; Birse DEA, 1997, EMBO J, V16, P3757, DOI 10.1093/emboj/16.13.3757; Bogdan S, 2001, MECH DEVELOP, V103, P61, DOI 10.1016/S0925-4773(01)00332-X; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; CITRON BA, 1993, AM J HUM GENET, V53, P768; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAVIS MD, 1991, FEBS LETT, V285, P17, DOI 10.1016/0014-5793(91)80714-E; Depaepe V, 2000, MOL BRAIN RES, V75, P76, DOI 10.1016/S0169-328X(99)00297-1; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; ENDRIZZI JA, 1995, SCIENCE, V268, P556, DOI 10.1126/science.7725101; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICNER R, 1995, EMBO J, V14, P2034, DOI 10.1002/j.1460-2075.1995.tb07195.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAUER CR, 1993, J BIOL CHEM, V268, P4828; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Johnen G, 1995, P NATL ACAD SCI USA, V92, P12384, DOI 10.1073/pnas.92.26.12384; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KIM JL, 1995, STRUCTURE, V3, P531, DOI 10.1016/S0969-2126(01)00186-1; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Lei XD, 1999, DNA CELL BIOL, V18, P243, DOI 10.1089/104454999315466; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; POGGE V, 1995, DEVELOPMENT, V121, P1217; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Resibois A, 1999, HISTOCHEM CELL BIOL, V111, P381, DOI 10.1007/s004180050371; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; Rose RB, 2000, NAT STRUCT BIOL, V7, P744; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; Strandmann EPV, 1998, INT J DEV BIOL, V42, P53; Thony B, 1998, AM J HUM GENET, V62, P1302, DOI 10.1086/301887; Von Strandmann EP, 2000, MECH DEVELOP, V91, P53, DOI 10.1016/S0925-4773(99)00269-5; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	44	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28884	28891		10.1074/jbc.M201983200	http://dx.doi.org/10.1074/jbc.M201983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12011081	hybrid			2022-12-25	WOS:000177342600072
J	Samatar, AA; Wang, LQ; Mirza, A; Koseoglu, S; Liu, SX; Kumar, CC				Samatar, AA; Wang, LQ; Mirza, A; Koseoglu, S; Liu, SX; Kumar, CC			Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; FACTOR-BETA; PRIMARY CULTURES; C-AKT; CELLS; CANCER; EXPRESSION; APOPTOSIS; IDENTIFICATION; INHIBITION	Tumors evade cell death by constitutively activating cell survival pathways and suppressing intrinsic death machinery. Activation of cell survival pathways leads to transcriptional repression of genes associated with cell death and activation of ones promoting anti-apoptosis. Akt/protein kinase B phosphorylates forkhead transcription factors and prevents their nuclear localization, leading to repression of genes involved in apoptosis, such as Fas ligand (FasL). Using bioinformatic approaches, we have identified three consensus sequences for forkhead transcription factor binding in transforming growth factor beta2 (TGF-beta2) promoter. TGF-beta inhibits cell proliferation and induces apoptosis in many cell types, and acquisition of TGF-beta resistance is linked to tumorigenesis. In this study, we show that activated Akt down-regulates TGF-beta2 promoter, and sequences within the promoter that are related to consensus forkhead binding sites are necessary for repression. Forkhead factor FKHRL1 binds in vitro to the three consensus sequences and can activate TGF-beta2 promoter in normal and Akt-transformed cell lines. In human breast and pancreatic tumors, activated Akt expression correlated with down-regulation of TGF-beta 2 mRNA levels. A number of tumor cells expressing activated Akt were responsive to TGF-beta addition, indicating the presence of an intact TGF-beta-signaling pathway. These results suggest that repression of TGF-beta 2 promoter activity in cells expressing activated Akt may play a role in promoting tumorigenesis and escape from the growth-inhibitory and/or apoptotic effects of TGF-beta.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Bioinformat, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.							AHMED NN, 1993, ONCOGENE, V8, P1957; Benson JR, 1996, BRIT J CANCER, V74, P352, DOI 10.1038/bjc.1996.365; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUSHEL P, 1995, ONCOGENE, V10, P1361; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; DIJKERS PF, 2000, MOL CELL BIOL, V19, P1201; Fan GS, 1996, ONCOGENE, V12, P1909; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Grau AM, 1997, CANCER RES, V57, P3929; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Kaestner KH, 2000, GENE DEV, V14, P142; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE M, 1990, ANN REV CELL BIOL, V6, P597; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Reiss M, 1997, ONCOL RES, V9, P447; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schutte M, 1996, CANCER RES, V56, P2527; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wall L, 1991, PROGRAMMING PERL; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28118	28126		10.1074/jbc.M203686200	http://dx.doi.org/10.1074/jbc.M203686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011061	hybrid			2022-12-25	WOS:000177189800068
J	Creuzenet, C; Urbanic, RV; Lam, JS				Creuzenet, C; Urbanic, RV; Lam, JS			Structure-function studies of two novel UDP-GlcNAc C6 Dehydratases/C4 Reductases - Variation from the SYK dogma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE 4,6-DEHYDRATASE; PATHOGEN HELICOBACTER-PYLORI; X-RAY STRUCTURE; GDP-L-FUCOSE; GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ACTIVE-SITE; STAPHYLOCOCCUS-AUREUS; GDP-4-KETO-6-DEOXY-D-MANNOSE EPIMERASE/REDUCTASE	Two subfamilies of UDP-GlcNAc C6 dehydratases were recently identified. FlaA1, a short soluble protein that exhibits a typical SYK catalytic triad, characterizes one of these subfamilies, and WbpM, a large membrane protein that harbors an altered SMK triad that was not predicted to sustain activity, represents the other subfamily. This study focuses on investigating the structure and function of these C6 dehydratases and the role of the altered triad as well as additional amino acid residues involved in catalysis. The significant activity retained by the FlaA1 Y141M triad mutant and the low activity of the WbpM M438Y mutant indicated that the methionine residue was involved in catalysis. A Glu 589 residue, which is conserved only within the large homologues, was shown to be essential for activity in WbpM. Introduction of this residue in FlaA1 enhanced the activity of the corresponding V266E mutant. Hence, this glutamate residue might be responsible for the retention of catalytic efficiency in the large homologues despite alteration of their catalytic triad. Mutations of residues specific for the short homologues (AsP70, Asp(149) Lys(150), Cys(103)) abolished the activity of FlaA1. Among them, C103M prevented dimerization but did not significantly affect the secondary structure. The fact that we could identify subfamily-specific residues that are essential for catalysis suggested an independent evolution for each subfamily of C6 dehydratases. Finally, the loss of activity of the FlaAl G20A mutant provided evidence that a cofactor is involved in catalysis, and kinetic study of the FlaAl H86A mutant revealed that this conserved histidine is involved in substrate binding. None of the mutations investigated altered the substrate, product, and function specificity of these enzymes.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	Western University (University of Western Ontario); University of Guelph	Lam, JS (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.							Allard STM, 2000, ACTA CRYSTALLOGR D, V56, P222, DOI 10.1107/S0907444999016200; Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; Bisso A, 1999, FEBS LETT, V456, P370, DOI 10.1016/S0014-5793(99)00982-5; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; COLEMAN WG, 1979, J BACTERIOL, V139, P899, DOI 10.1128/JB.139.3.899-910.1979; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; Dean CR, 1999, J BACTERIOL, V181, P4275, DOI 10.1128/JB.181.14.4275-4284.1999; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; He XM, 1996, BIOCHEMISTRY-US, V35, P4721, DOI 10.1021/bi952706p; Jornvall H, 1999, ADV EXP MED BIOL, V463, P359; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Leclerc G, 1998, J BACTERIOL, V180, P5010, DOI 10.1128/JB.180.19.5010-5019.1998; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; Liu YJ, 1996, BIOCHEMISTRY-US, V35, P7615, DOI 10.1021/bi960102v; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MUKHERJI S, 1992, J BIOL CHEM, V267, P11709; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; Rosano C, 2000, J MOL BIOL, V303, P77, DOI 10.1006/jmbi.2000.4106; Sau S, 1996, J BACTERIOL, V178, P2118, DOI 10.1128/jb.178.7.2118-2126.1996; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SNIPES CE, 1977, J BIOL CHEM, V252, P8113; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P20617, DOI 10.1074/jbc.M101304200; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; THOMPSON MW, 1992, J GEN MICROBIOL, V138, P779, DOI 10.1099/00221287-138-4-779; THORSON JS, 1993, J AM CHEM SOC, V115, P5827, DOI 10.1021/ja00066a062; THORSON JS, 1993, J AM CHEM SOC, V115, P6993, DOI 10.1021/ja00068a075; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tonetti M, 1998, BIOCHIMIE, V80, P923, DOI 10.1016/S0300-9084(00)88889-6; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P354, DOI 10.1128/AAC.37.2.354; WANG SF, 1969, J BIOL CHEM, V244, P3430; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933; YU Y, 1992, J BIOL CHEM, V267, P5868	56	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26769	26778		10.1074/jbc.M202882200	http://dx.doi.org/10.1074/jbc.M202882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004063	hybrid			2022-12-25	WOS:000177055900010
J	Lener, D; Budihas, SR; Le Grice, SFJ				Lener, D; Budihas, SR; Le Grice, SFJ			Mutating conserved residues in the ribonuclease H domain of Ty3 reverse transcriptase affects specialized cleavage events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND TRANSFER; RNA SECONDARY STRUCTURE; YEAST RETROTRANSPOSON TY1; PRIMER TRANSFER-RNA; ESCHERICHIA-COLI; ACTIVE-SITE; NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE; POLYPURINE TRACT; POLYMERASE	The reverse transcriptase-associated ribonuclease H (RT/RNase H) domains from the gypsy group of retrotransposons, of which Ty3 is a member, share considerable sequence homology with their retroviral counterparts. However, the gypsy elements have a conserved tyrosine (position 459 in Ty3 RT) instead of the conserved histidine in the catalytic center of retroviral RTs such as at position 539 of HIV-1. In addition, the gypsy group shows conservation of histidine adjacent to the third of the metal-chelating carboxylate residues, which is Asp-426 of Ty3 RT. The role of these and additional catalytic residues was assessed with purified recombinant enzymes and through the ability of Ty3 mutants to support transposition in Saccaromyces cerevisiae. Although all mutations had minimal impact on DNA polymerase function, amidation of Asp-358, Glu-401, and Asp-426 eliminated Me2+ and Mn2+-dependent RNase H function. Replacing His-427 and Tyr-459 with Ala and Asp-469 with Asn resulted in reduced RNase H activity in the presence of Mg2+, whereas in the presence of Mn2+ these mutants displayed a lack of turnover. Despite this, mutations at all positions were lethal for transposition. To reconcile these apparently contradictory findings, the efficiency of specialized RNase H-mediated events was examined for each enzyme. Mutants retaining RNase H activity on a heteropolymeric RNA-DNA hybrid failed to support DNA strand transfer and release of the (+) strand polypurine tract primer from (+) RNA, suggesting that interrupting one or both of these events might account for the transposition defect.	NCI, Reverse Transcriptase Biochem Sect, Resistance Mechanisms Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), NCI, Reverse Transcriptase Biochem Sect, Resistance Mechanisms Lab, HIV Drug Resistance Program,NIH, 1050 Boyles St,POB B, Frederick, MD 21702 USA.			Lener, Daniela/0000-0001-8266-8810				Baldwin GS, 1999, J MOL BIOL, V288, P87, DOI 10.1006/jmbi.1999.2672; BLAIN SW, 1995, J VIROL, V69, P5113, DOI 10.1128/JVI.69.8.5113-5116.1995; Boutabout M, 2001, NUCLEIC ACIDS RES, V29, P2217, DOI 10.1093/nar/29.11.2217; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CAO WG, 1995, BIOCHEMISTRY-US, V34, P2276, DOI 10.1021/bi00007a023; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 2001, J BIOL CHEM, V276, P32515, DOI 10.1074/jbc.M103958200; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Friant S, 1996, BIOCHIMIE, V78, P674, DOI 10.1016/S0300-9084(96)80013-7; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; Goedken ER, 2001, J BIOL CHEM, V276, P7266, DOI 10.1074/jbc.M009626200; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HANSEN LJ, 1990, J VIROL, V64, P2599, DOI 10.1128/JVI.64.6.2599-2607.1990; Haruki M, 2000, BIOCHEMISTRY-US, V39, P13939, DOI 10.1021/bi001469+; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kanaya S, 1996, J BIOL CHEM, V271, P32729, DOI 10.1074/jbc.271.51.32729; KANAYA S, 1990, J BIOL CHEM, V265, P4615; Kashiwagi T, 1996, PROTEIN ENG, V9, P857, DOI 10.1093/protein/9.10.857; Ke N, 1999, RNA, V5, P929, DOI 10.1017/S1355838299990015; KEENEY JB, 1995, MOL CELL BIOL, V15, P217, DOI 10.1128/MCB.15.1.217; KINSEY PT, 1995, GENETICS, V139, P81; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYARATSKHELIA M, 2002, J BIOL CHEM, V277, P16689; LAUERMANN V, 1994, P NATL ACAD SCI USA, V91, P9847, DOI 10.1073/pnas.91.21.9847; Lauermann V, 1997, EMBO J, V16, P6603, DOI 10.1093/emboj/16.21.6603; Malik HS, 2001, GENOME RES, V11, P1187, DOI 10.1101/gr.185101; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; Nymark-McMahon MH, 1999, J VIROL, V73, P453, DOI 10.1128/JVI.73.1.453-465.1999; ODA Y, 1993, J BIOL CHEM, V268, P88; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2002, BIOCHEMISTRY-US, V41, P4856, DOI 10.1021/bi015970t; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SCHATZ O, 1990, ONCOGENESIS AIDS, P293; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Smith CM, 1999, J VIROL, V73, P6573, DOI 10.1128/JVI.73.8.6573-6581.1999; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; Uzun O, 2001, J VIROL, V75, P6337, DOI 10.1128/JVI.75.14.6337-6347.2001; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wilhelm M, 2001, J BIOL CHEM, V276, P47695, DOI 10.1074/jbc.M106067200; Wilhelm M, 1997, NUCLEIC ACIDS RES, V25, P2161, DOI 10.1093/nar/25.11.2161; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q	60	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26486	26495		10.1074/jbc.M200496200	http://dx.doi.org/10.1074/jbc.M200496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994277	hybrid			2022-12-25	WOS:000176908700087
J	Lingbeek, ME; Jacobs, JJL; van Lohuizen, M				Lingbeek, ME; Jacobs, JJL; van Lohuizen, M			The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14(ARF) via a variant T-site in the initiator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLT-ORAM-SYNDROME; CELL IMMORTALIZATION; DNA-BINDING; TRANSCRIPTION; SENESCENCE; EXPRESSION; MUTATIONS; P19(ARF); TRANSFORMATION; PROLIFERATION	The murine tumor suppressor p19(ARF) (p14(ARF) in humans) is thought to fulfill an important protective role in preventing primary cells from oncogenic transformation via its action in the p53 pathway. Several disease-implicated regulators of p19(ARF) are known to date, among which are the T-box genes TBX2, which resides on an amplicon in primary breast tumors, and TBX3, which is mutated in the human developmental disorder Ulnar-Mammary syndrome. Here we identify a variant T-site, matching 13 of 20 nucleotides of a consensus T-site, as the essential TBX2/TBX3-binding element in the human p14(ARF) promoter. Mutant analysis indicates that both the consensus T-box and a C-terminal conserved repression domain are essential for p14(ARF) repression. Whereas the core nucleotides required for interaction of the archetypal T-box protein Brachyury with a consensus T-site are conserved in the variant site, additional flanking nucleotides contribute to the specificity of TBX2 binding. This is illustrated by the inability of TBX1A or Xbra to activate via the variant p14(ARF) T-site. Importantly, this suggests a hitherto unsuspected level of specificity associated with T-box factors and corresponding recognition sites in regulating their target genes in vivo.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.v.lohuizen@nki.nl	Pillay, Nischalan/F-9536-2012; Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795				Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Casey ES, 1998, DEVELOPMENT, V125, P3887; Casey ES, 1999, DEVELOPMENT, V126, P4193; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Conlon FL, 2001, DEVELOPMENT, V128, P3749; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Gregorio A, 1999, DEVELOPMENT, V126, P5599; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Kusch T, 2002, GENE DEV, V16, P518, DOI 10.1101/gad.213002; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Li QY, 1997, NAT GENET, V15, P21; Liu JX, 2001, P NATL ACAD SCI USA, V98, P8674, DOI 10.1073/pnas.141234898; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Papaioannou VE, 2001, INT REV CYTOL, V207, P1; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sinha S, 2000, GENE, V258, P15, DOI 10.1016/S0378-1119(00)00417-0; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Tada M, 2001, DEV GROWTH DIFFER, V43, P1; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	45	135	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26120	26127		10.1074/jbc.M200403200	http://dx.doi.org/10.1074/jbc.M200403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000749	hybrid			2022-12-25	WOS:000176908700039
J	Niiranen, K; Pietila, M; Pirttila, TJ; Jarvinen, A; Halmekyto, M; Korhonen, VP; Keinanen, TA; Alhonen, L; Janne, J				Niiranen, K; Pietila, M; Pirttila, TJ; Jarvinen, A; Halmekyto, M; Korhonen, VP; Keinanen, TA; Alhonen, L; Janne, J			Targeted disruption of spermidine/spermine N-1-acetyltransferase gene in mouse embryonic stem cells - Effects on polyamine homeostasis and sensitivity to polyamine analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMINE N1-ACETYLTRANSFERASE; TRANSGENIC MICE; LUNG-CANCER; BIS(ETHYL)POLYAMINE ANALOGS; GROWTH; CATABOLISM; N-1,N-11-DIETHYLNORSPERMINE; METABOLISM; OXIDASE; LINES	We have generated mouse embryonic stem cells with targeted disruption of spermidine/spermine N-1-acetyltransferase (SSAT) gene. The targeted cells did not contain any inducible SSAT activity, and the SSAT protein was not present. The SSAT-deficient cells proliferated normally and appeared to maintain otherwise similar polyamine pools as did the wild-type cells, with the possible exception of constantly elevated (about 30%) cellular spermidine. As expected, the mutated cells were significantly more resistant toward the growth-inhibitory action of polyamine analogues, such as N-1,N-11-diethylnorspermine. However, this resistance was not directly attributable to cellular depletion of the higher polyamines spermidine and spermine, as the analogue depleted the polyamine pools almost equally effectively in both wild-type and SSAT-deficient cells. Tracer experiments with [C-14]-labeled spermidine revealed that SSAT activity is essential for the back-conversion of spermidine to putrescine as radioactive N-acetylspermidine and putrescine were readily detectable in N-1,N-11-diethylnorspermine-exposed wild-type cells but not in SSAT-deficient cells. Similar experiments with [C-14]spermine indicated that the latter polyamine was converted to spermidine in both cell lines and, unexpectedly, more effectively in the targeted cells than in the parental cells. This back-conversion was only partly inhibited by MDL72527, an inhibitor of polyamine oxidase. These results indicated that SSAT does not play a major role in the maintenance of polyamine homeostasis, and the toxicity exerted by polyamine analogues is largely not based on SSAT-induced depletion of the natural polyamines. Moreover, embryonic stem cells appear to operate an SSAT-independent system for the back-conversion of spermine to spermidine.	Univ Kuopio, Inst Appl Biotechnol, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland	Janne, J (corresponding author), Univ Kuopio, Inst Appl Biotechnol, POB 1627, FIN-70211 Kuopio, Finland.		Keinänen, Tuomo/AAC-5630-2019					Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Alhonen L, 2000, P NATL ACAD SCI USA, V97, P8290, DOI 10.1073/pnas.140122097; Alhonen L, 1999, MOL PHARMACOL, V55, P693; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; KUMAZAWA T, 1990, ANAL BIOCHEM, V188, P105, DOI 10.1016/0003-2697(90)90535-H; LIBBY PR, 1987, BIOCHEM BIOPH RES CO, V144, P528, DOI 10.1016/S0006-291X(87)80541-7; Mank-Seymour AR, 1998, CLIN CANCER RES, V4, P2003; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; PORTER CW, 1991, CANCER RES, V51, P3715; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Wang YL, 2001, CANCER RES, V61, P5370	20	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25323	25328		10.1074/jbc.M203599200	http://dx.doi.org/10.1074/jbc.M203599200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000764	hybrid			2022-12-25	WOS:000176747000063
J	Que, XC; Ngo, HA; Lawton, J; Gray, M; Liu, Q; Engel, J; Brinen, L; Ghosh, P; Joiner, KA; Reed, SL				Que, XC; Ngo, HA; Lawton, J; Gray, M; Liu, Q; Engel, J; Brinen, L; Ghosh, P; Joiner, KA; Reed, SL			The cathepsin B of Toxoplasma gondii, toxopain-1, is critical for parasite invasion and rhoptry protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	11th Molecular Parasitology Meeting	2000	WOODS HOLE, MA				HOST-CELL INVASION; ORGANELLES; RECEPTOR; IDENTIFICATION; SEQUENCES; BINDING; COMPARTMENTS; TRAFFICKING; BIOGENESIS; PREDICTION	Cysteine proteinases play a major role in invasion and intracellular survival of a number of pathogenic parasites. We cloned a single copy gene, tgcp1, from Toxoplasma gondii and refolded recombinant enzyme to yield active proteinase. Substrate specificity of the enzyme and homology modeling identified the proteinase as a cathepsin B. Specific cysteine proteinase inhibitors interrupted invasion by tachyzoites. The T. gondii cathepsin B localized to rhoptries, secretory organelles required for parasite invasion into cells. Processing of the pro-rhoptry protein 2 to mature rhoptry proteins was delayed by incubation of extracellular parasites with a cathepsin B inhibitor prior to pulse-chase immunoprecipitation. Delivery of cathepsin B to mature rhoptries was impaired in organisms with disruptions in rhoptry formation by expression of a dominant negative mu1-adaptin. Similar disruption of rhoptry formation was observed when infected fibroblasts were treated with a specific inhibitor of cathepsin B, generating small and poorly developed rhoptries. This first evidence for localization of a cysteine proteinase to the unusual rhoptry secretory organelle of an apicomplexan parasite suggests that the rhoptries may be a prototype of a lysosome-related organelle and provides a critical link between cysteine proteinases and parasite invasion for this class of organism.	Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem, La Jolla, CA 92093 USA; Univ Calif San Francisco, Vet Adm Med Ctr, Dept Pathol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Yale University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Reed, SL (corresponding author), Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Pathol, 200 W Arbor Dr, San Diego, CA 92103 USA.	slreed@ucsd.edu	Que, Xuchu/H-2741-2019; Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X; Que, Xuchu/0000-0002-6751-5493	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060, R01AI041903, P30AI036214] Funding Source: NIH RePORTER; NIAID NIH HHS [5 P30 AI36214, R01 AI41903, AI30060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn HJ, 2001, BIOCHEM BIOPH RES CO, V287, P630, DOI 10.1006/bbrc.2001.5637; Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; Armstrong N, 1999, PROTEIN SCI, V8, P1475, DOI 10.1110/ps.8.7.1475; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Bradley PJ, 1999, MOL BIOCHEM PARASIT, V100, P103, DOI 10.1016/S0166-6851(99)00035-3; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Denzer K, 2000, J CELL SCI, V113, P3365; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; Dubremetz JF, 1998, INT J PARASITOL, V28, P1007, DOI 10.1016/S0020-7519(98)00076-9; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; FOUSSARD F, 1991, PARASITOLOGY, V102, P367, DOI 10.1017/S0031182000064313; FULLER AL, 1990, J PARASITOL, V76, P464, DOI 10.2307/3282822; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Huete-Perez JA, 1999, J BIOL CHEM, V274, P16249, DOI 10.1074/jbc.274.23.16249; JOINER KA, 1993, INFECT IMMUN, V61, P1169, DOI 10.1128/IAI.61.4.1169-1172.1993; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LYCKE E, 1965, BRIT J EXP PATHOL, V46, P189; MAYER R, 1991, J MED CHEM, V34, P3029, DOI 10.1021/jm00114a011; MERCKELBACH A, 1994, TROP MED PARASITOL, V45, P193; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ngo HM, 1998, J EUKARYOT MICROBIOL, V45, P323, DOI 10.1111/j.1550-7408.1998.tb04543.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OGUN SA, 1994, EXP PARASITOL, V79, P270, DOI 10.1006/expr.1994.1090; PAMER EG, 1989, MOL BIOCHEM PARASIT, V33, P27, DOI 10.1016/0166-6851(89)90038-8; Que XC, 2002, MOL BIOCHEM PARASIT, V119, P23, DOI 10.1016/S0166-6851(01)00387-5; REED S, 1993, J CLIN INVEST, V91, P1532, DOI 10.1172/JCI116359; Reichmann G, 2002, MOL BIOCHEM PARASIT, V119, P43, DOI 10.1016/S0166-6851(01)00397-8; Robibaro B, 2002, CELL MICROBIOL, V4, P139, DOI 10.1046/j.1462-5822.2002.00178.x; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; Shaw MK, 1998, PARASITOLOGY, V117, P435, DOI 10.1017/S0031182098003278; Sinai AP, 2001, J CELL BIOL, V154, P95, DOI 10.1083/jcb.200101073; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; TAKAHASHI N, 1993, FEBS LETT, V334, P153, DOI 10.1016/0014-5793(93)81702-2	41	85	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25791	25797		10.1074/jbc.M202659200	http://dx.doi.org/10.1074/jbc.M202659200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	12000756	hybrid			2022-12-25	WOS:000176747000122
J	Mishra, RS; Gu, YP; Bose, S; Verghese, S; Kalepu, S; Singh, N				Mishra, RS; Gu, YP; Bose, S; Verghese, S; Kalepu, S; Singh, N			Cell surface accumulation of a truncated transmembrane prion protein in Gerstmann-Straussler-Scheinker disease P102L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; TRANSGENIC MICE; NEURODEGENERATION; PRP; HETEROGENEITY; DEGRADATION; INHIBITION; MUTATION; PEPTIDES; GENETICS	A familial prion disorder with a proline to leucine substitution at residue 102 of the prion protein (PrP102L) is typically associated with protease-resistant PrP fragments (PrPSc) in the brain parenchyma that are infectious to recipient animals. When modeled in transgenic mice, a fatal neurodegenerative disease develops, but, unlike the human counterpart, PrPSc is lacking and transmission to recipient animals is questionable. Alternate mice expressing a single copy of PrP102L (mouse PrP101L) do not develop spontaneous disease, but show dramatic susceptibility to PrPSc isolates from different species. To understand these discrepant results, we studied the biogenesis of human PrP102L in a cell model. Here, we report that cells expressing PrP 1121 show decreased expression of the normal 18-kDa fragment on the plasma membrane. Instead, a 20-kDa fragment, probably derived from transmembrane PrP ((PrP)-Pr-Ctm), accumulates on the cell surface. Because the 20-kDa fragment includes an amyloidogenic region of PrP that is disrupted in the 18-kDa form, increased surface expression of 20-kDa fragment may enhance the susceptibility of these cells to PrPSc infection by providing an optimal substrate, or by amplifying the neurotoxic signal of PrPSc. Thus, altered susceptibility of PrP101L Mice to exogenous PrPSc may be mediated by the 20-kDa (PrP)-Pr-Ctm fragment, rather than PrP102L per se.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Singh, N (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	nxs2@po.cwru.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035962, R29NS035962] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35962] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbanti P, 1996, NEUROLOGY, V47, P734, DOI 10.1212/WNL.47.3.734; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 1998, J VIROL, V72, P1153; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Piccardo P, 1998, J NEUROPATH EXP NEUR, V57, P979, DOI 10.1097/00005072-199810000-00010; Prusiner SB, 1996, COLD SPRING HARB SYM, V61, P473; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Yamada M, 1999, NEUROLOGY, V52, P260, DOI 10.1212/WNL.52.2.260; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	30	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24554	24561		10.1074/jbc.M200213200	http://dx.doi.org/10.1074/jbc.M200213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967261	hybrid			2022-12-25	WOS:000176611800077
J	Seo, M; Lee, YI; Cho, CH; Bae, CD; Kim, IH; Juhnn, YS				Seo, M; Lee, YI; Cho, CH; Bae, CD; Kim, IH; Juhnn, YS			Bi-directional regulation of UV-induced activation of p38 kinase and c-Jun N-terminal kinase by G protein beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; MAP KINASE; KAPPA-B; PATHWAY; EXPRESSION; APOPTOSIS; CELLS; CASCADES	Ultraviolet (UV) irradiation induces various cellular responses by activating many UV-responsive enzymes including mitogen-activated protein kinases (MAPKs). Various G protein-coupled receptor agonists also activate MAPKs, but it is not known whether or not G proteins also mediate the UV-induced activation of MAPKs. Therefore, this study was undertaken to determine whether the G protein betagamma-subunit (Gbetagamma) mediates the UV-induced activation of p38 and JNK. Gbetagamma overexpression in COS-1 cells amplified the UV-induced activation of p38 but reduced JNK activation. The overexpression of the C-terminal region of beta-adrenergic receptor kinase (betaARKct) decreased the UV-induced activation of p38 but increased JNK activation. Gbeta(1)gamma(2) expression increased MKK3/6 phosphorylation with a concomitant decrease in MKK4 phosphorylation, which contrasts with betaARKct expression. Gbeta(1)gamma(2) or betaARKct expression resulted in corresponding changes in the transcriptional activity of CHOP and c-Jun. Treatment with a p38 inhibitor, SB203580, or the expression of a kinase-inactive p38 increased the UV-induced JNK activation. Expression of the constitutively active MKK6 decreased the UV-induced JNK activation. In summary, although the endogenous Gbetagamma was found to mediate about half of the UV-induced activation of p38, it was found that exogenous Gbetagamma mediates the bi-directional regulation of UV-induced p38 and JNK activation, and that this bidirectional regulation results from the inhibition of JNK activation by the p38 activated via Gbetagamma in the COS-1 cells.	Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Inst Canc Res, Seoul 110799, South Korea; Natl Canc Ctr, Div Basic Sci, Koyang 411764, South Korea; Sungkyunkwan Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 440746, South Korea	Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC); Sungkyunkwan University (SKKU)	Juhnn, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.	juhnn@snu.ac.kr	Juhnn, Yong-Sung/J-2790-2012					ARUFFO A, 1991, CURRENT PROTOCOLS MO; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COFFER PJ, 1995, ONCOGENE, V11, P561; Coso OA, 1996, J BIOL CHEM, V271, P3963; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233; FAURE M, 1994, J BIOL CHEM, V269, P7851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	30	24	25	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24197	24203		10.1074/jbc.M201717200	http://dx.doi.org/10.1074/jbc.M201717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978790	hybrid			2022-12-25	WOS:000176611800030
J	Shaw, RJ; Bonawitz, ND; Reines, D				Shaw, RJ; Bonawitz, ND; Reines, D			Use of an in vivo reporter assay to test for transcriptional and translational fidelity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR-SII; FACTOR S-II; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TERMINATION CODONS; CLEAVAGE FACTORS; FACTOR TFIIS; IN-VIVO; GENE	Eukaryotic RNA polymerase II and Escherichia coli RNA polymerase possess an intrinsic ribonuclease activity that is stimulated by the polymerase-binding proteins SII and GreB, respectively. This factor-activated hydrolysis of nascent RNA has been postulated to be involved in transcription elongation as well as removal of incorrect bases misincorporated into RNA. Little is known about the frequency of misincorporation by RNA polymerases in vivo or about the mechanisms involved in improving RNA polymerase accuracy. Here we have developed a luciferase reporter system in an effort to assay for base misincorporation in living Saccharomyces cerevisiae. The assay employs a luciferase open reading frame that contains a premature stop codon. The inactive truncated enzyme would become active if misincorporation by RNA polymerase H took place at the stop triplet. Yeast lacking SII did not display a significant change in reporter activity when compared with wild-type cells. We estimate that under our assay conditions, mRNAs with a misincorporation at the test site could not exceed 1 transcript per 500 cells. The reporter assay was very effective in detecting the previously described process of nonsense suppression (translational read-through) by ribosomes, making it difficult to determine an absolute level of basal (SII-independent) misincorporation by RNA polymerase II. Although these data cannot exclude the possibility that SII is involved in proofreading, they make it unlikely that such a contribution is physiologically significant, especially relative to the high frequency of translational errors.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46331, R01 GM046331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Beier H, 2001, NUCLEIC ACIDS RES, V29, P4767, DOI 10.1093/nar/29.23.4767; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Brodsky JL, 1998, BIOCHEMISTRY-US, V37, P18045, DOI 10.1021/bi980900g; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FIROOZAN M, 1991, YEAST, V7, P173, DOI 10.1002/yea.320070211; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; Kulish D, 2001, MOL CELL BIOL, V21, P4162, DOI 10.1128/MCB.21.13.4162-4168.2001; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; LIBBY RT, 1991, MOL MICROBIOL, V5, P999, DOI 10.1111/j.1365-2958.1991.tb01872.x; Lykke-Andersen J, 2001, CURR BIOL, V11, pR88, DOI 10.1016/S0960-9822(01)00036-7; Miller LL, 2001, CURR GENET, V39, P77, DOI 10.1007/s002940100186; Mugnier P, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1360; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NINIO J, 1991, BIOCHIMIE, V73, P1517, DOI 10.1016/0300-9084(91)90186-5; NINIO J, 1991, GENETICS, V129, P957; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; OZOLINE ON, 1980, FEBS LETT, V110, P123, DOI 10.1016/0014-5793(80)80038-X; REINES D, 1992, J BIOL CHEM, V267, P3795; ROSENBERGER RF, 1983, MOL GEN GENET, V191, P207, DOI 10.1007/BF00334815; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SALANEWBY GB, 1994, BBA-PROTEIN STRUCT M, V1206, P155, DOI 10.1016/0167-4838(94)90084-1; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; Serio TR, 2000, TRENDS CELL BIOL, V10, P98, DOI 10.1016/S0962-8924(99)01711-0; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shimoaraiso M, 2000, J BIOL CHEM, V275, P29623, DOI 10.1074/jbc.M910371199; SPRINGGATE CF, 1975, J MOL BIOL, V97, P577, DOI 10.1016/S0022-2836(75)80060-X; Stansfield I, 1998, J MOL BIOL, V282, P13, DOI 10.1006/jmbi.1998.1976; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4	43	55	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24420	24426		10.1074/jbc.M202059200	http://dx.doi.org/10.1074/jbc.M202059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006589	Green Accepted, hybrid			2022-12-25	WOS:000176611800060
J	Dangoria, NS; DeLay, ML; Kingsbury, DJ; Mear, JP; Uchanska-Ziegler, B; Ziegler, A; Colbert, RA				Dangoria, NS; DeLay, ML; Kingsbury, DJ; Mear, JP; Uchanska-Ziegler, B; Ziegler, A; Colbert, RA			HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; COMPLEX CLASS-I; HEAVY-CHAINS; MONOCLONAL-ANTIBODIES; ANTIGEN PRESENTATION; PEPTIDE BINDING; QUALITY-CONTROL; CUTTING EDGE; EXPRESSION; RECOGNITION	The class I protein HLA-B27 confers susceptibility to inflammatory arthritis in humans and when overexpressed in rodents for reasons that remain unclear. We demonstrated previously that HIA-B27 heavy chains (HQ undergo endoplasmic reticulum (ER)-associated degradation. We report here that HLA-B27 HC also forms two types of aberrant disulfide-linked complexes (dimers) during the folding and assembly process that can be distinguished by conformation-sensitive antibodies W6/32 and HC10. HC10-reactive dimers form immediately after HC synthesis in the ER and constitute at least 25% of the HC pool, whereas W6/32-reactive dimers appear several hours later and represent less than 10% of the folded HC. HC10-reactive dimers accumulate in the absence of tapasin or beta(2)-microglobulin, whereas W6/32-reactive dimers are not detected. Efficient formation of W6/32-reactive dimers appears to depend on the transporter associated with antigen processing, tapasin, and beta(2)-microglobulin. The unpaired Cys(67) and residues at the base of the B pocket that dramatically impair HTA-B27 HC folding are critical for the formation of HC10-reactive ER dimers. Although certain other alleles also form dimers late in the assembly pathway, ER dimerization of HLA-B27 may be unique. These results demonstrate that residues comprising the HIA-B27 B pocket result in aberrant HC folding and disuffide bond formation, and thus confer unusual properties on this molecule that are unrelated to peptide selection per se, yet may be important in disease pathogenesis.	Childrens Hosp, Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA; Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, D-14050 Berlin, Germany	Cincinnati Children's Hospital Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Colbert, RA (corresponding author), Childrens Hosp, Med Ctr, Div Rheumatol, PAV 2-129,3333 Burnet Ave, Cincinnati, OH 45229 USA.	bob.colbert@chmcc.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR044059, R01AR046177] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60 AR-44059, R01 AR-46177] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; CAPPS GG, 1993, J IMMUNOL, V151, P159; CARRENO BM, 1994, EUR J IMMUNOL, V24, P1285, DOI 10.1002/eji.1830240607; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Colbert RA, 2000, J RHEUMATOL, V27, P1107; COLBERT RA, 1993, P NATL ACAD SCI USA, V90, P6879, DOI 10.1073/pnas.90.14.6879; Copeman J, 1998, EUR J IMMUNOL, V28, P3783, DOI 10.1002/(SICI)1521-4141(199811)28:11<3783::AID-IMMU3783>3.0.CO;2-9; CRESSWELL P, 1975, J IMMUNOL, V114, P523; Cresswell P, 1999, IMMUNOL RES, V19, P191, DOI 10.1007/BF02786487; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Gur H, 1999, CELL IMMUNOL, V191, P105, DOI 10.1006/cimm.1998.1417; HAKEM R, 1989, J IMMUNOL, V142, P297; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Ikawa T, 1998, J CLIN INVEST, V101, P263, DOI 10.1172/JCI471; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Khan MA, 1998, SPONDYLARTHRITIDES, P17; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6; Kostyu DD, 1997, HUM IMMUNOL, V57, P1, DOI 10.1016/S0198-8859(97)00175-4; Laitio P, 1997, EUR J IMMUNOL, V27, P1331, DOI 10.1002/eji.1830270606; LARSSON LG, 1992, INT J CANCER, V52, P759, DOI 10.1002/ijc.2910520515; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Lindquist JA, 2001, FASEB J, V15, P1448, DOI 10.1096/fj.00-0720fje; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LOZANO F, 1993, LEUKEMIA RES, V17, P9, DOI 10.1016/0145-2126(93)90135-8; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Malik P, 1999, TISSUE ANTIGENS, V53, P576, DOI 10.1034/j.1399-0039.1999.530609.x; Mear JP, 1999, J IMMUNOL, V163, P6665; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Parham P, 1996, IMMUNOL REV, V154, P137, DOI 10.1111/j.1600-065X.1996.tb00932.x; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; PERARNAU BM, 1988, J IMMUNOL, V141, P1383; PIOUS D, 1977, IMMUNOGENETICS, V4, P437, DOI 10.1007/BF01575679; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Rehm A, 2000, HUM IMMUNOL, V61, P408, DOI 10.1016/S0198-8859(99)00176-7; Reinelt S, 2001, J BIOL CHEM, V276, P18472, DOI 10.1074/jbc.M101282200; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SMITH DM, 1994, J IMMUNOL, V153, P1054; SPRINGER TA, 1977, J BIOL CHEM, V252, P4694; STAM NJ, 1986, J IMMUNOL, V137, P2299; Taurog JD, 1999, IMMUNOL REV, V169, P209; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; Virtala M, 1997, INFECT IMMUN, V65, P4236, DOI 10.1128/IAI.65.10.4236-4242.1997; WARBURTON RJ, 1994, HUM IMMUNOL, V39, P261, DOI 10.1016/0198-8859(94)90269-0; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WHELAN MA, 1993, EUR J IMMUNOL, V23, P3278, DOI 10.1002/eji.1830231233; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	68	179	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23459	23468		10.1074/jbc.M110336200	http://dx.doi.org/10.1074/jbc.M110336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11978783	hybrid			2022-12-25	WOS:000176475700049
J	Igaki, T; Yamamoto-Goto, Y; Tokushige, N; Kanda, H; Miura, M				Igaki, T; Yamamoto-Goto, Y; Tokushige, N; Kanda, H; Miura, M			Down-regulation of DIAP1 triggers a novel Drosophila cell death pathway mediated by dark and DRONC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE ACTIVATION; APOPTOSIS; PROTEIN; INHIBITOR; FAMILY	Members of the inhibitor of apoptosis protein (IAP) family can inhibit caspases and cell death in a variety of insect and vertebrate systems. Drosophila LAP1 (DIAP1) inhibits cell death to facilitate normal embryonic development. Here, using RNA interference, we showed that down-regulation of DIAP1 is sufficient to induce cell death in Drosophila S2 cells. Although this cell death process was accompanied by elevated caspase activity, this activation was not essential for cell death. We found that DIAP1 depletion-induced cell death was strongly suppressed by a reduction in the Drosophila caspase DRONC or the Drosophila apoptotic protease-activating factor-1 (Apaf-1) homolog, Dark. RNA interference studies in Drosophila embryos also demonstrated that the action of Dark is epistatic to that of DIAP1 in this cell death pathway. The cell death caused by down-regulation of DIAP1 was accelerated by overexpression of DRONC and Dark, and a caspase-inactive mutant form of DRONC could functionally substitute the wild-type DRONC in accelerating cell death. These results suggest the existence of a novel mechanism for cell death signaling in Drosophila that is mediated by DRONC and Dark.	RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Integrated Biol, Suita, Osaka 5650871, Japan	RIKEN; Osaka University; Osaka University	Miura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Kanda, Hiroshi/L-1292-2013	Igaki, Tatsushi/0000-0001-5839-9526				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kanuka H, 1999, P NATL ACAD SCI USA, V96, P145, DOI 10.1073/pnas.96.1.145; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	25	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23103	23106		10.1074/jbc.C200222200	http://dx.doi.org/10.1074/jbc.C200222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	12011068	hybrid			2022-12-25	WOS:000176475700001
J	Nelson, LM; Rose, RC; Moroianu, J				Nelson, LM; Rose, RC; Moroianu, J			Nuclear import strategies of high risk HPV16 L1 major capsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; HUMAN-PAPILLOMAVIRUS TYPE-11; VESICULAR STOMATITIS-VIRUS; RNA-BINDING-PROTEINS; HNRNP A1; LOCALIZATION SIGNALS; MATRIX PROTEIN; INSECT CELLS; RAN; IDENTIFICATION	During the late phase of human papillomavirus (HPV) infection, the L1 major capsid proteins enter the nuclei of host epithelial cells and, together with the L2 minor capsid proteins, assemble the replicated viral DNA into virions. We investigated the nuclear import of the L1 major capsid protein of high risk HPV16. When digitonin-permeabilized HeLa cells were incubated with HPV16 L1 capsomeres, the L1 protein was imported into the nucleus in a receptor-mediated manner. HPV16 L1 capsomeres formed complexes with Kap alpha2beta1 heterodimers via interaction with Kap alpha2. Accordingly, nuclear import of HPV16 L1 capsomeres was mediated by Kap alpha2beta1 heterodimers, required RanGDP and free GTP, and was independent of GTP hydrolysis. Remarkably, HPV16 L1 capsomeres also interacted with Kap 132 and binding of RanGTP to Kap 192 did not dissociate the HPV16 L1.Kap beta2 complex. Significantly, HPV16 L1 capsomeres inhibited the nuclear import of Kap 132 and of a Kap beta2-specific M9-containing cargo. These data suggest that, during the productive stage of infection, while the HPV16 L1 major capsid protein enters the nucleus via the Kap alpha2beta1-mediated pathway to assemble the virions, it also inhibits the Kap beta2-mediated nuclear import of host hnRN-P A1 protein and, in this way, favors virion formation.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Univ Rochester, Sch Med & Dent, Dept Med & Microbiol & Immunol, Infect Dis Unit, Rochester, NY 14642 USA	Boston College; University of Rochester	Moroianu, J (corresponding author), Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA.	moroianu@bc.edu						ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Belnap DM, 1996, J MOL BIOL, V259, P249, DOI 10.1006/jmbi.1996.0317; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gustin KE, 2001, EMBO J, V20, P240, DOI 10.1093/emboj/20.1.240; HAGENSEE ME, 1994, J VIROL, V68, P4503, DOI 10.1128/JVI.68.7.4503-4505.1994; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Li ML, 1998, J VIROL, V72, P2160, DOI 10.1128/JVI.72.3.2160-2167.1998; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; MICHAEL WM, 1995, CELL, V83, P415; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Moroianu J, 1999, J CELL BIOCHEM, P76; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nelson LM, 2000, J CELL BIOCHEM, V79, P225, DOI 10.1002/1097-4644(20001101)79:2<225::AID-JCB60>3.0.CO;2-A; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; ROSE RC, 1994, J GEN VIROL, V75, P2075, DOI 10.1099/0022-1317-75-8-2075; ROSE RC, 1993, J VIROL, V67, P1936, DOI 10.1128/JVI.67.4.1936-1944.1993; ROSE RC, 1994, J GEN VIROL, V75, P2445, DOI 10.1099/0022-1317-75-9-2445; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; VOLPERS C, 1994, VIROLOGY, V200, P504, DOI 10.1006/viro.1994.1213; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; ZHOU J, 1993, J GEN VIROL, V74, P763, DOI 10.1099/0022-1317-74-4-763; ZHOU J, 1991, VIROLOGY, V185, P625, DOI 10.1016/0042-6822(91)90533-H; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	52	29	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23958	23964		10.1074/jbc.M200724200	http://dx.doi.org/10.1074/jbc.M200724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971900	hybrid			2022-12-25	WOS:000176475700111
J	Donaldson, JC; Dise, RS; Ritchie, MD; Hanks, SK				Donaldson, JC; Dise, RS; Ritchie, MD; Hanks, SK			Nephrocystin-conserved domains involved in targeting to epithelial cell-cell junctions, interaction with filamins, and establishing cell polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; FAMILIAL JUVENILE NEPHRONOPHTHISIS; TYROSINE PHOSPHORYLATION; GENE; DIFFERENTIATION; IDENTIFICATION; TRANSLOCATION; EXPRESSION; P130(CAS); CLEAVAGE	Nephrocystin is the protein product of the gene mutated in juvenile nephronophthisis, an autosomal recessive cystic kidney disease afflicting children and young adults. Because the normal cellular function of nephrocystin is largely unknown, the molecular defects underlying disease pathogenesis remain obscure. Analysis of nephrocystin amino acid sequences from human and other species revealed three distinct conserved domains including Src homology 3 and coil-coil domains in the N-terminal region, as well as a large highly conserved C-terminal region bearing no obvious homology to other proteins and hence referred to as the "nephrocystin homology domain" (NHD). The objective of this study was to gain insight into nephrocystin function by defining functional properties of the conserved domains. We analyzed a series of nephrocystin deletion mutants expressed in Madin-Darby canine kidney and COS-7 cells. This analysis revealed previously unrecognized functional attributes of the NHD, including abilities to promote both self-association and epithelial cell-cell junctional targeting. We further observed that Madin-Darby canine kidney cell lines stably expressing a nephrocystin mutant with a deletion of the Src homology 3 domain have reduced ability to establish tight junctions as measured by transepithelial electrical resistance. Finally, from a two-hybrid screen and coimmunoprecipitation studies we identified members of the filamin family of actin-binding proteins as having the capacity to interact with the (NHD). These findings support a functional role for nephrocystin as a docking protein involved in organizing a protein complex to regulate the actin cytoskeleton at sites of epithelial cell-cell adhesion and further suggest that these properties are important for establishing epithelial cell polarity.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hanks, SK (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, B-2211 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	steve.hanks@vanderbilt.edu	Ritchie, Marylyn/C-1114-2012		NIDDK NIH HHS [DK56018] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Caridi G, 2000, AM J KIDNEY DIS, V35, P44, DOI 10.1016/S0272-6386(00)70300-3; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hildebrandt F, 2000, J AM SOC NEPHROL, V11, P1753, DOI 10.1681/ASN.V1191753; HILDEBRANDT F, 1992, CLIN INVESTIGATOR, V70, P802; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Hildebrandt F, 2001, KIDNEY INT, V59, P434, DOI 10.1046/j.1523-1755.2001.059002434.x; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Konrad M, 1998, J MOL MED-JMM, V76, P310, DOI 10.1007/s001090050222; KWAK KB, 1993, FEBS LETT, V323, P151, DOI 10.1016/0014-5793(93)81468-F; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lo SH, 1997, J CELL BIOL, V136, P1349, DOI 10.1083/jcb.136.6.1349; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Otto E, 2000, J AM SOC NEPHROL, V11, P270, DOI 10.1681/ASN.V112270; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; PATCH LA, 1995, J CELL SCI, V108, P1371; Saunier S, 1997, HUM MOL GENET, V6, P2317, DOI 10.1093/hmg/6.13.2317; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WALDHERR R, 1982, VIRCHOWS ARCH A, V394, P235, DOI 10.1007/BF00430668; Wang Q, 1996, J CELL BIOCHEM, V62, P383, DOI 10.1002/(SICI)1097-4644(199609)62:3<383::AID-JCB8>3.0.CO;2-N; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919	33	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29028	29035		10.1074/jbc.M111697200	http://dx.doi.org/10.1074/jbc.M111697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12006559	hybrid			2022-12-25	WOS:000177342600089
J	Tanimura, A; Nezu, A; Morita, T; Hashimoto, N; Tojyo, Y				Tanimura, A; Nezu, A; Morita, T; Hashimoto, N; Tojyo, Y			Interplay between calcium, diacylglycerol, and phosphorylation in the spatial and temporal regulation of PKC alpha-GFP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL ESTERS; SIGNAL-TRANSDUCTION; MEMBRANE-BINDING; PHAGOCYTOSIS; LOCALIZATION; ACTIVATION; CA2+; AUTOPHOSPHORYLATION; TRANSLOCATION	The function of protein kinase C (PKC) is closely regulated by its subcellular localization. We expressed PKCalpha fused to green fluorescent protein (PKCalpha-GFP) and examined its translocation in living and permeabilized cells of the human parotid cell line, HSY-EB. ATP induced an oscillatory translocation of PKCalpha-GFP to and from the plasma membrane that paralleled the appearance of repetitive Ca2+ spikes. Staurosporine attenuated the relocation of PKCalpha-GFP to the cytosol and caused a stepwise accumulation of PKCalpha-GFP at the plasma membrane during ATP stimulation. Diacylglycerol enhanced the amplitude and duration of the ATP-induced oscillatory translocation of PKCalpha-GFP. lonomycin induced a transient translocation of PKCalpha-GFP to the plasma membrane despite the continuous elevation of cytosolic Ca2+. The ionomycin-induced transient translocation of PKCalpha-GFP was prolonged by staurosporine, diacylglycerol, and phorbol myristate acetate. Experiments using permeabilized cells showed that staurosporine or the elimination of ATP and Mg2+ decreases the rate of dissociation of PKCalpha-GFP from the membrane. Diacylglycerol slowed the dissociation of PKCalpha-GFP from the membrane regardless of the Ca2+ concentration. The effect of diacylglycerol was attenuated by ATP plus Mg2+ at low concentrations of Ca2+ (< 500 nM) but not at high concentrations of Ca2+ (> 1000 nM). These data suggest a complex interplay between Ca2+, diacylglycerol, and phosphorylation in the regulation of the membrane binding of PKCalpha.	Hlth Sci Univ Hokkaido, Dept Dent Pharmacol, Sch Dent, Ishikari, Hokkaido 0610293, Japan; Hlth Sci Univ Hokkaido, Dept Integrated Human Sci, Sch Dent, Ishikari, Hokkaido 0610293, Japan	Health Sciences University of Hokkaido; Health Sciences University of Hokkaido	Tanimura, A (corresponding author), Hlth Sci Univ Hokkaido, Dept Dent Pharmacol, Sch Dent, Ishikari, Hokkaido 0610293, Japan.							ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Brumell JH, 1999, J IMMUNOL, V163, P3388; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; SCHAEFER M, 2001, FASEB J; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Tojyo Y, 2001, BBA-MOL CELL RES, V1539, P114, DOI 10.1016/S0167-4889(01)00098-2; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	32	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29054	29062		10.1074/jbc.M201130200	http://dx.doi.org/10.1074/jbc.M201130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11997388	hybrid			2022-12-25	WOS:000177342600092
J	Jurado, LA; Song, SL; Roesler, WJ; Park, EA				Jurado, LA; Song, SL; Roesler, WJ; Park, EA			Conserved amino acids within CCAAT enhancer-binding proteins (C/EBP alpha and beta) regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; DEPENDENT ACTIVATION; TRANSCRIPTION; CAMP; GTP; PROMOTER; ELEMENT; INDUCTION; MECHANISM; ISOFORMS	Thyroid hormone and cAMP stimulate transcription of the gene for phosphoenolpyruvate carboxykinase (PEPCK). CCAAT enhancer-binding proteins (C/EBPalpha and beta) are involved in multiple aspects of the nutritional, developmental and hormonal regulation of PEPCK gene expression. Previously, we have identified a thyroid hormone response element in the PEPCK promoter and demonstrated that C/EBP proteins bound to the P3(I) site are participants in the induction of PEPCK gene expression by thyroid hormone and cAMP. Here, we identify several peptide regions within the transactivation domain of C/EBPa that enhance the ability of T-3 to stimulate gene transcription. We also demonstrate that several conserved amino acids in the transactivation domain of C/EBPalpha and C/EBPbeta are required for the stimulation of basal gene expression and identify amino acids within C/EBPbeta that participate in the CAMP induction of the PEPCK gene. Finally, we show that the CREB-binding protein (CBP) enhanced the induction of PEPCK gene transcription by thyroid hormone and that CBP is associated with the PEPCK gene in vivo. Our results indicate that both C/EBP proteins and CBP participate in the regulation of PEPCK gene transcription by thyroid hormone.	Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Tennessee System; University of Tennessee Health Science Center; University of Saskatchewan	Park, EA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu						BOESLER WJ, 2001, ANNU REV NUTR, V21, P141; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chung SS, 1999, ARCH BIOCHEM BIOPHYS, V364, P30, DOI 10.1006/abbi.1998.1089; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lee SJ, 1999, INTERMETALLICS, V7, P11, DOI 10.1016/S0966-9795(98)00004-1; Liu XD, 2001, AM J PHYSIOL-RENAL, V281, pF649, DOI 10.1152/ajprenal.2001.281.4.F649; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Monroy MA, 2001, J BIOL CHEM, V276, P40721, DOI 10.1074/jbc.M103615200; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1993, J BIOL CHEM, V268, P613; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RUNGE D, 1991, EUR J BIOCHEM, V198, P641, DOI 10.1111/j.1432-1033.1991.tb16062.x; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	43	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27606	27612		10.1074/jbc.M201429200	http://dx.doi.org/10.1074/jbc.M201429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11997389	hybrid			2022-12-25	WOS:000177189800006
J	Almog, O; Gallagher, DT; Ladner, JE; Strausberg, S; Alexander, P; Bryan, P; Gilliland, GL				Almog, O; Gallagher, DT; Ladner, JE; Strausberg, S; Alexander, P; Bryan, P; Gilliland, GL			Structural basis of thermostability - Analysis of stabilizing mutations in subtilisin BPN '	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT SUBTILISIN; ENGINEERED DISULFIDE BOND; CRYSTAL-STRUCTURE; PROTEASE; PROTEINS; SUBTILASES; PRODOMAIN	The crystal structures of two thermally stabilized subtilisin BPN' variants, S63 and S88, are reported here at 1.8 and 1.9 Angstrom resolution, respectively. The micromolar affinity calcium binding site (site A) has been deleted (Delta75-83) in these variants, enabling the activity and thermostability measurements in chelating conditions. Each of the variants includes mutations known previously to increase the thermostability of calcium-independent subtilisin in addition to new stabilizing mutations. S63 has eight amino acid replacements: D41A, M50F, A73L, Q206W, Y217K, N218S, S221C, and Q271E. S63 has 75-fold greater stability than wild type subtilisin in chelating conditions (10 mm EDTA). The other variant, S88, has ten site-specific changes: Q2K, S3C, P5S, K43N, M50F, A73L, Q206C, Y217K, N218S, and Q271E. The two new cysteines form a disulfide bond, and S88 has 1000 times greater stability than wild type subtilisin in chelating conditions. Comparisons of the two new crystal structures (S63 in space group P2(1) with Angstrom cell constants 41.2, 78.1, 36.7, and beta = 114.6degrees and S88 in space group P2(1)2(1)2(1) with cell constants 54.2, 60.4, and 82.7) with previous structures of subtilisin BPN' reveal that the principal changes are in the N-terminal region. The structural bases of the stabilization effects of the new mutations Q2K, S3C, P5S, D41A, Q206C, and Q206W are generally apparent. The effects are attributed to the new disulfide cross-link and to improved hydrophobic packing, new hydrogen bonds, and other rearrangements in the N-terminal region.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel	University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; Ben Gurion University	Gallagher, DT (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.							Alexander PA, 2001, BIOCHEMISTRY-US, V40, P10640, DOI 10.1021/bi010798e; Almog O, 1998, PROTEINS, V31, P21, DOI 10.1002/(SICI)1097-0134(19980401)31:1<21::AID-PROT3>3.0.CO;2-K; Almog O, 1998, PROTEINS, V31, P128, DOI 10.1002/(SICI)1097-0134(19980501)31:2<128::AID-PROT3>3.0.CO;2-I; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BRYAN P N, 1986, Proteins Structure Function and Genetics, V1, P326; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DRENTH J, 1967, J MOL BIOL, V28, P543, DOI 10.1016/S0022-2836(67)80104-9; EIJSINK VGH, 1992, PROTEIN ENG, V5, P421, DOI 10.1093/protein/5.5.421; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; Gallagher T, 1996, ACTA CRYSTALLOGR D, V52, P1125, DOI 10.1107/S0907444996007500; GALLAGHER T, 1993, PROTEINS, V16, P205, DOI 10.1002/prot.340160207; HENDRICKSON W, 1980, STEREOCHEMISTRY REST, P1301; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mansfeld J, 1997, J BIOL CHEM, V272, P11152, DOI 10.1074/jbc.272.17.11152; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; STAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P10371; STRAUSBERG SL, 1995, BIO-TECHNOL, V13, P669, DOI 10.1038/nbt0795-669; TAKAGI H, 1990, J BIOL CHEM, V265, P6874; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	30	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27553	27558		10.1074/jbc.M111777200	http://dx.doi.org/10.1074/jbc.M111777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011071	hybrid			2022-12-25	WOS:000177055900106
J	Dobson, GP; Hitchins, S; Teague, WE				Dobson, GP; Hitchins, S; Teague, WE			Thermodynamics of the pyruvate kinase reaction and the reversal of glycolysis in heart and skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROCNEMIUS IN-VIVO; CREATINE-KINASE; GLYCOGEN-SYNTHESIS; LACTATE; METABOLISM; EXERCISE; FROG; PH	The effect of temperature, pH, and free [Mg2+] on the apparent equilibrium constant of pyruvate kinase (phosphoenol transphosphorylase) (EC 2.7.1.40) was investigated. The apparent equilibrium constant, K', for the biochemical reaction P-enolpyruvate + ADP = ATP + Pyr was defined as K' = [ATP][Pyr]/[ADP][P-enolpyruvatel] where each reactant represents the sum of all the ionic and metal complexed species in M. The K' at pH 7.0, 1.0 mm free Mg2+ and I of 0.25 m was 3.89 X 10(4) (n = 8) at 25 degreesC. The standard apparent enthalpy (DeltaH'degrees) for the biochemical reaction was -4.31 kJmol(-1) in the direction of ATP formation. The corresponding standard apparent entropy (DeltaS'degrees) was +73.4 J K-1 mol(-1). The DeltaHdegrees and AS' values for the reference reaction, P-enolpyruvate(3-) + ADp(3-) + H+ = ATp(4-) + Pyr(1-), were -6.43 kJmol(-1) and + 180 J K-1 mol(-1), respectively (5 to 38 degreesC). We examined further the mass action ratio in rat heart and skeletal muscle at rest and found that the pyruvate kinase reaction in vivo was close to equilibrium i.e. within a factor of about 3 to 6 of K' in the direction of ATP at the same pH, free [Mg2+], and T. We conclude that the pyruvate kinase reaction may be reversed under some conditions in vivo, a finding that challenges the long held dogma that the reaction is displaced far from equilibrium.	James Cook Univ N Queensland, Sch Biomed & Mol Sci, Div Physiol & Pharmacol, Townsville, Qld 4811, Australia; NIAAA, Sect Nucl Magnet Resonacne Studies, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	James Cook University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Dobson, GP (corresponding author), James Cook Univ N Queensland, Sch Biomed & Mol Sci, Div Physiol & Pharmacol, Townsville, Qld 4811, Australia.							BENDALL JR, 1970, BIOCHEM J, V118, P887, DOI 10.1042/bj1180887; CHEER RL, 1980, BIOPHYS CHEM, V12, P73, DOI 10.1016/0301-4622(80)80041-X; Cieslar J, 1998, AM J PHYSIOL-REG I, V275, pR1530, DOI 10.1152/ajpregu.1998.275.5.R1530; Cieslar JH, 2001, AM J PHYSIOL-REG I, V281, pR511, DOI 10.1152/ajpregu.2001.281.2.R511; Cieslar JH, 2000, J BIOL CHEM, V275, P6129, DOI 10.1074/jbc.275.9.6129; CONNETT RJ, 1996, SECTION 12 HDB PHYSL, P870; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Donovan CM, 2000, MED SCI SPORT EXER, V32, P772, DOI 10.1097/00005768-200004000-00009; DYSON RD, 1975, J BIOL CHEM, V250, P3316; GOLDBERG RN, 1994, J PHYS CHEM REF DATA, V23, P547, DOI 10.1063/1.555948; GOLDING EM, 1995, J EXP BIOL, V198, P1775; GOLDING EM, 1995, MAGNET RESON MED, V33, P467, DOI 10.1002/mrm.1910330403; HERMANSEN L, 1977, AM J PHYSIOL, V233, pE422, DOI 10.1152/ajpendo.1977.233.5.E422; Hill AV, 1923, Q J MED, V16, P135, DOI 10.1093/qjmed/os-16.62.135; Hitchins S, 2001, AM J PHYSIOL-HEART C, V281, pH882, DOI 10.1152/ajpheart.2001.281.2.H882; HOCHACHKA PW, 1988, CAN J ZOOL, V66, P1128, DOI 10.1139/z88-165; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; KREBS HA, 1965, BIOCHEM J, V94, P436, DOI 10.1042/bj0940436; KREBS HA, 1964, P R SOC LOND B, V159, P544; KRIMSKY I, 1959, J BIOL CHEM, V234, P232; LARDY HA, 1945, J BIOL CHEM, V159, P343; LARDY HA, 1949, RESP ENZYMES, P179; Lehninger A L, 1982, PRINCIPLES BIOCH; MCLANE JA, 1979, J BIOL CHEM, V254, P6548; MCQUATE JT, 1959, J BIOL CHEM, V234, P2151; Meyerhof O, 1919, PFLUG ARCH GES PHYS, V175, P88, DOI 10.1007/BF01722141; Meyerhof O, 1938, BIOCHEM Z, V298, P396; Newsholme E. A., 1973, REGULATION METABOLIS; Parnas JK, 1934, BIOCHEM Z, V272, P64; Pascoe DD, 1996, SPORTS MED, V21, P98, DOI 10.2165/00007256-199621020-00003; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; SCHULTE PM, 1992, J EXP BIOL, V166, P181; SCRUTTON MC, 1968, ANNU REV BIOCHEM, V37, P249, DOI 10.1146/annurev.bi.37.070168.001341; SHIOTA M, 1984, BIOCHEM J, V222, P281, DOI 10.1042/bj2220281; Teague WE, 1999, J BIOL CHEM, V274, P22459, DOI 10.1074/jbc.274.32.22459; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; Voet D, 1999, FUNDAMENTALS BIOCH; ZAMMIT VA, 1978, BIOCHEM J, V174, P979, DOI 10.1042/bj1740979	40	23	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27176	27182		10.1074/jbc.M111422200	http://dx.doi.org/10.1074/jbc.M111422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11986306	hybrid, Green Submitted, Green Accepted			2022-12-25	WOS:000177055900062
J	Walther, M; Anton, M; Wiedmann, M; Fletterick, R; Kuhn, H				Walther, M; Anton, M; Wiedmann, M; Fletterick, R; Kuhn, H			The N-terminal domain of the reticulocyte-type 15-lipoxygenase is not essential for enzymatic activity but contains determinants for membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOXYGENASE; 5-LIPOXYGENASE; CALCIUM; OXYGENATION; TRANSLOCATION; LOCALIZATION; PROTEIN	The rabbit reticulocyte-type 15-lipoxygenase is capable of oxygenating biomembranes and lipoproteins without the preceding action of ester lipid cleaving enzymes. This reaction requires an efficient membrane binding, and the N-terminal beta-barrel domain of the enzyme has been implicated in this process. To obtain detailed information on the structural requirements for membrane oxygenation, we expressed the rabbit wildtype 15-lipoxygenase, its beta-barrel deletion mutant (catalytic domain), and several lipoxygenase point mutations as His-tagged fusion proteins in Escherichia coli and tested their membrane binding characteristics. We found that: (i) the beta-barrel deletion mutant was catalytically active and its enzymatic properties (K-m, V-max, pH optimum, substrate specificity) were similar to those of the wild-type enzyme; (ii) when compared with the wildtype lipoxygenase, the membrane binding properties of the N-terminal truncation mutant were impaired but not abolished, suggesting a role of the catalytic domain in membrane binding; and (iii) Phe-70 and Leu-71 (constituents of the beta-barrel domain) but also Trp-181, which is located in the catalytic domain, were identified as sequence determinants for membrane binding. Mutation of these amino acids to more polar residues (F70H, L71K, W181E) impaired the membrane binding capacity of the recombinant enzyme. These data indicate that the C-terminal catalytic domain of the rabbit 15-lipoxygenase is enzymatically active and that the membrane binding properties of the enzyme are determined by a concerted action of the N-terminal beta-barrel and the C-terminal catalytic domain.	Humboldt Univ, Clin Charite, Inst Biochem, D-10117 Berlin, Germany; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Humboldt University of Berlin; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco	Kuhn, H (corresponding author), Humboldt Univ, Clin Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	hartmut.kuehn@charite.de			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060889] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60889] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; BROCK TG, 1994, J BIOL CHEM, V269, P22059; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; CRANE FL, 1956, BIOCHIM BIOPHYS ACTA, V22, P475, DOI 10.1016/0006-3002(56)90058-0; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; KUHN H, 1990, J BIOL CHEM, V265, P18351; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PUERINGER RJ, 1992, AM J PHYSIOL, V262, pL454, DOI 10.1152/ajplung.1992.262.4.L454; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Tatulian SA, 1998, BIOCHEMISTRY-US, V37, P15481, DOI 10.1021/bi981062t; Upston JM, 1997, J BIOL CHEM, V272, P30067, DOI 10.1074/jbc.272.48.30067; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	40	63	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27360	27366		10.1074/jbc.M203234200	http://dx.doi.org/10.1074/jbc.M203234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004065	hybrid			2022-12-25	WOS:000177055900085
J	Andrews, HN; Mullan, PB; McWilliams, S; Sebelova, S; Quinn, JE; Gilmore, PM; McCabe, N; Pace, A; Koller, B; Johnston, PG; Haber, DA; Harkin, DP				Andrews, HN; Mullan, PB; McWilliams, S; Sebelova, S; Quinn, JE; Gilmore, PM; McCabe, N; Pace, A; Koller, B; Johnston, PG; Haber, DA; Harkin, DP			BRCA1 regulates the interferon gamma-mediated apoptotic response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; POLYMERASE-II HOLOENZYME; BREAST-CANCER CELLS; GENE-EXPRESSION; IFN-GAMMA; TRANSCRIPTIONAL ACTIVATION; CYCLE; PHOSPHORYLATION; COMPLEX; PROTEIN	BRCA1 is a tumor suppressor gene implicated in transcriptional regulation. We have generated cell lines with inducible expression of BRCA1 as a tool to identify downstream targets that may be important mediators of BRCA1 function. Oligonucleotide array-based expression profiling identified 11 previously described interferon regulated genes that were up-regulated following inducible expression of BRCA1. Northern blot analysis revealed that a subset of the identified targets including IRF-7, MxA, and ISG-54 were synergistically up-regulated by BRCA1 in the presence of interferon gamma (IFN-gamma) but not interferons alpha or beta. Importantly, IFN-gamma-mediated induction of IRF-7 and MxA was attenuated in the BRCA1 mutant cell line HCC1937, an effect that was rescued following reconstitution of exogenous wild type BRCA1 in these cells. Furthermore, reconstituted BRCA1 sensitized HCC1937 cells to IFN-gamma-induced apoptotic cell death. This study identifies BRCA1 as a component of the IFN-gamma-regulated signaling pathway and suggests that BRCA1 may play a role in the regulation of IFN-gamma-mediated apoptosis.	Queens Univ Belfast, Dept Oncol, Canc Res Ctr, Belfast BT9 7AB, Antrim, North Ireland; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Queens University Belfast; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital; Harvard University	Harkin, DP (corresponding author), Queens Univ Belfast, Dept Oncol, Canc Res Ctr, Belfast City Hosp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; GUDAS JM, 1995, CANCER RES, V55, P4561; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; KAWAKUBO K, 1996, JPN J CLIN ONCOL, V2, P59; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Kim TK, 2000, CANCER RES, V60, P1153; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spillman MA, 1996, ONCOGENE, V13, P1639; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	42	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26225	26232		10.1074/jbc.M201316200	http://dx.doi.org/10.1074/jbc.M201316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011077	hybrid, Green Published			2022-12-25	WOS:000176908700053
J	Huang, LP; Kirschke, CP; Gitschier, J				Huang, LP; Kirschke, CP; Gitschier, J			Functional characterization of a novel mammalian zinc transporter, ZnT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DI-LEUCINE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; CONFERS RESISTANCE; SYNAPTIC VESICLES; PLASMA-MEMBRANE; MENKES PROTEIN; EXPRESSION; MOUSE; IDENTIFICATION	We describe ZnT6, a new member of the CDF (cation diffusion facilitator) family of heavy metal transporters. The human ZNT6 gene was mapped at 2p21-22, while the mouse Znt6 was localized to chromosome 17. Overexpression of ZnT6 in both wild-type yeast and mutants that are deficient in cytoplasmic zinc causes growth inhibition, but this inhibition is abolished in mutant cells with high cytoplasmic zinc. ZnT6 may function in transporting the cytoplasmic zinc into the Golgi apparatus as well as the vesicular compartment, as evidenced by its overlapping intracellular localization with TGN38 and transferrin receptor in the normal rat kidney cells. We also demonstrate that the intracellular distributions of ZnT6 as well as ZnT4 are regulated by zinc in the normal rat kidney cells. The results from this report, combined with those from other studies, suggest that the intracellular zinc homeostasis is mediated by many ZnT proteins, which act in tissue-, cell-, and organelle-specific manners.	Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA; USDA ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California Davis; United States Department of Agriculture (USDA); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, LP (corresponding author), Univ Calif Davis, Rowe Program Genet, 4445 Tupper Hall, Davis, CA 95616 USA.							BURGUNDER JM, 1984, J HERED, V75, P480; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; DASILVA FDF, 1991, BIOL CHEM ELEMENTS, P299; DICHIE MM, 1969, MOUSE NEWS LETT, V41, P30; Francis MJ, 1999, J CELL SCI, V112, P1721; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Lioumi M, 1999, GENOMICS, V62, P272, DOI 10.1006/geno.1999.5993; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MURGIA C, 1999, J PHYSL, V277, pG1231; NIES DH, 1992, J BACTERIOL, V174, P8102, DOI 10.1128/JB.174.24.8102-8110.1992; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; PILETZ JE, 1978, SCIENCE, V199, P181, DOI 10.1126/science.619449; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	25	172	181	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26389	26395		10.1074/jbc.M200462200	http://dx.doi.org/10.1074/jbc.M200462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11997387	hybrid			2022-12-25	WOS:000176908700075
J	Mazurkiewicz, P; Konings, WN; Poelarends, GJ				Mazurkiewicz, P; Konings, WN; Poelarends, GJ			Acidic residues in the lactococcal multidrug efflux pump LmrP play critical roles in transport of lipophilic cationic compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; CYSTEINE-SCANNING MUTAGENESIS; CONTROLLED GENE-EXPRESSION; ESCHERICHIA-COLI; RESISTANCE; SYSTEMS; RECOGNITION; MECHANISMS; BACTERIA; TOPOLOGY	The proton motive force-driven efflux pump LmrP confers multidrug resistance on Lactococcus lactis cells by extruding a wide variety of lipophilic cationic compounds from the inner leaflet of the cytoplasmic membrane to the exterior of the cell. LmrP contains one cysteine (Cys(270)), which was replaced by alanine. This cysteine-less variant was used in a cysteine scanning accessibility approach. All 19 acidic residues in LmrP were replaced one by one by cysteine and subsequently challenged with the large thiol reagent fluorescein maleimide. The labeling pattern strongly indicates that only three acidic residues (Asp(142), Glu(327), and Glu(388)) are membrane-embedded. The roles of these residues in drug recognition were evaluated based on transport experiments with two cationic substrates, ethidium and Hoechst 33342, after replacing each of these residues with cysteine, alanine, lysine, glutamate, or aspartate. The obtained results suggest that the negative charges at positions 142 and 327 are not critical for the transport function but are important for drug recognition by LmrP. Surprisingly, the residues Cys(142) and Cys(327) become accessible for fluorescein maleimide upon binding of substrates, indicating a movement of these residues from a nonpolar to a polar environment. Substrate binding apparently results in a conformational change in this region of the protein and a reorientation of a lipid-embedded, hydrophobic substrate-binding site to an,aqueous substrate translocation pathway.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Groningen	Konings, WN (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Konings, Wilhelmus N./C-7063-2013	Poelarends, Gerrit/0000-0002-6917-6368				Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Meuller J, 1999, J BIOL CHEM, V274, P19072, DOI 10.1074/jbc.274.27.19072; NIKKADO H, 1909, CURR OPIN MICROBIOL, V1, P516; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 1999, BIOCHEMISTRY-US, V38, P13900, DOI 10.1021/bi991262k; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Roberts MC, 1996, FEMS MICROBIOL REV, V19, P1, DOI 10.1111/j.1574-6976.1996.tb00251.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; van Veen HW, 1997, SEMIN CANCER BIOL, V8, P183, DOI 10.1006/scbi.1997.0064; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	26	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26081	26088		10.1074/jbc.M203141200	http://dx.doi.org/10.1074/jbc.M203141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994308	hybrid, Green Published			2022-12-25	WOS:000176908700034
J	Richardson, TH; Tan, XQ; Frey, G; Callen, W; Cabell, M; Lam, D; Macomber, J; Short, JM; Robertson, DE; Miller, C				Richardson, TH; Tan, XQ; Frey, G; Callen, W; Cabell, M; Lam, D; Macomber, J; Short, JM; Robertson, DE; Miller, C			A novel, high performance enzyme for starch liquefaction - Discovery and optimization of a low pH, thermostable alpha-amylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO RECOMBINATION; BACILLUS-LICHENIFORMIS; PYROCOCCUS-FURIOSUS; DIRECTED EVOLUTION; BIOCHEMICAL-CHARACTERIZATION; THERMOCOCCUS-PROFUNDUS; NUCLEOTIDE-SEQUENCE; MOLECULAR EVOLUTION; CLONING; EXPRESSION	High throughput screening of microbial DNA libraries was used to identify alpha-amylases with phenotypic characteristics compatible with large scale corn wet milling process conditions. Single and multiorganism DNA libraries originating from various environments were targeted for activity and sequence-based screening approaches. After initial screening, 15 clones were designated as primary hits based upon activity at pH 4.5 or 95 degreesC without addition of endogenous Ca2+. After further characterization, three enzyme candidates were chosen each with an exceptional expression of one or more aspects of the necessary phenotype: temperature stability, pH optimum, lowered reliance on Ca2+ and/or enzyme rate. To combine the best aspects of the three phenotypes to optimize process compatibility, the natural gene homologues were used as a parental sequence set for gene reassembly. Approximately 21,000 chimeric daughter sequences were generated and subsets screened using a process-specific, high throughput activity assay. Gene reassembly resulted in numerous improved mutants with combined optimal phenotypes of expression, temperature stability, and pH optimum. After biochemical and process-specific characterization of these gene products, one a-amylase with exceptional process compatibility and economics was identified. This paper describes the synergistic approach of combining environmental discovery and laboratory evolution for identification and optimization of industrially important biocatalysts.	Diversa Corp, San Diego, CA 92121 USA		Richardson, TH (corresponding author), Diversa Corp, 4955 Directors Pl, San Diego, CA 92121 USA.		Short, Jay/GQY-7343-2022					Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; CHUNG YC, 1995, APPL ENVIRON MICROB, V61, P1502, DOI 10.1128/AEM.61.4.1502-1506.1995; Coco WM, 2001, NAT BIOTECHNOL, V19, P354, DOI 10.1038/86744; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Dong GQ, 1997, APPL ENVIRON MICROB, V63, P3569, DOI 10.1128/AEM.63.9.3569-3576.1997; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; Frillingos S, 2000, J APPL MICROBIOL, V88, P495, DOI 10.1046/j.1365-2672.2000.00988.x; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Hashida M, 2000, TRENDS GLYCOSCI GLYC, V12, P389, DOI 10.4052/tigg.12.389; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Holden JF, 2001, FEMS MICROBIOL ECOL, V36, P51, DOI 10.1016/S0168-6496(01)00118-0; IMANAKA T, 1996, Patent No. 96191138; Jorgensen S, 1997, J BIOL CHEM, V272, P16335, DOI 10.1074/jbc.272.26.16335; KOCH R, 1991, ARCH MICROBIOL, V155, P572, DOI 10.1007/BF00245352; Lee JT, 1996, J FERMENT BIOENG, V82, P432, DOI 10.1016/S0922-338X(97)86978-4; Leveque E, 2000, ENZYME MICROB TECH, V26, P3, DOI 10.1016/S0141-0229(99)00142-8; Leveque E, 2000, FEMS MICROBIOL LETT, V186, P67, DOI 10.1016/S0378-1097(00)00117-8; Linden A, 2000, J CHROMATOGR B, V737, P253, DOI 10.1016/S0378-4347(99)00364-3; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUZAKI H, 1974, BIOCHIM BIOPHYS ACTA, V365, P235, DOI 10.1016/0005-2795(74)90268-2; Ness JE, 1999, NAT BIOTECHNOL, V17, P893, DOI 10.1038/12884; Ostermeier M, 1999, NAT BIOTECHNOL, V17, P1205, DOI 10.1038/70754; ROBERTSON DE, 1996, SIM NEWS, V46, P3; SAITO N, 1973, ARCH BIOCHEM BIOPHYS, V155, P290, DOI 10.1016/0003-9861(73)90117-3; Schmidt-Dannert Claudia, 1999, Trends in Biotechnology, V17, P135, DOI 10.1016/S0167-7799(98)01283-9; SHORT JM, 1996, Patent No. 96657409; Sieber V, 2001, NAT BIOTECHNOL, V19, P456, DOI 10.1038/88129; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Tachibana Y, 1996, J FERMENT BIOENG, V82, P224, DOI 10.1016/0922-338X(96)88812-X; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665; YUUKI T, 1985, J BIOCHEM-TOKYO, V98, P1147, DOI 10.1093/oxfordjournals.jbchem.a135381; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	34	148	194	1	68	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26501	26507		10.1074/jbc.M203183200	http://dx.doi.org/10.1074/jbc.M203183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994309	hybrid			2022-12-25	WOS:000176908700089
J	Stahelin, RV; Long, F; Diraviyam, K; Bruzik, KS; Murray, D; Cho, WH				Stahelin, RV; Long, F; Diraviyam, K; Bruzik, KS; Murray, D; Cho, WH			Phosphatidylinositol 3-phosphate induces the membrane penetration of the FYVE domains of Vps27p and Hrs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; KINASE-C-ALPHA; CRYSTAL-STRUCTURE; PROTEIN-KINASE; PHOSPHOLIPASE A(2); BINDING DOMAIN; LOCALIZATION; ROLES; TRAFFICKING; PRESSURE	involved in membrane trafficking and cell signaling to phosphatidylinositol 3-phosphate (PtdIns(3)P)-containing membranes. To elucidate the mechanism by which the FYVE domain interacts with PtdIns(3)P-containing membranes, we measured the membrane binding of the FYVE domains of yeast Vps27p and Drosophila hepatocyte growth factor-regulated tyrosine kinase substrate and their mutants by surface plasmon resonance and monolayer penetration analyses. These measurements as well as electrostatic potential calculation show that PtdIns(3)P specifically induces the membrane penetration of the FYVE domains and increases their membrane residence time by decreasing the positive charge surrounding the hydrophobic tip of the domain and causing local conformational changes. Mutations of hydrophobic residues located close to the PtdIns(3)P-binding pocket or an Arg residue directly involved in PtdIns(3)P binding abrogated the penetration of the FYVE domains into the monolayer, the packing density of which is comparable with that of biological membranes and large unilamellar vesicles. Based on these results, we propose a mechanism of the membrane binding of the FYVE domain in which the domain first binds to the PtdIns(3)P-containing membrane by specific PtdIns(3)P binding and nonspecific electrostatic interactions, which is then followed by the PtdIns(3)P-induced partial membrane penetration of the domain.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University	Cho, WH (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987, GM57568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Kutateladze TG, 2000, J BIOMOL NMR, V17, P89, DOI 10.1023/A:1008394731942; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Momsen WE, 1997, METHOD ENZYMOL, V286, P292; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 2001, SEMIN CELL DEV BIOL, V12, P193, DOI 10.1006/scdb.2000.0236; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	45	127	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26379	26388		10.1074/jbc.M201106200	http://dx.doi.org/10.1074/jbc.M201106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006563	hybrid			2022-12-25	WOS:000176908700074
J	Stubbs, VEL; Schratl, P; Hartnell, A; Williams, TJ; Peskar, BA; Heinemann, A; Sabroe, I				Stubbs, VEL; Schratl, P; Hartnell, A; Williams, TJ; Peskar, BA; Heinemann, A; Sabroe, I			Indomethacin causes prostaglandin D-2-like and eotaxin-like selective responses in eosinophils and basophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CCR3; PLATELET-ACTIVATING-FACTOR; OXYGEN RADICAL PRODUCTION; CD11B UP-REGULATION; MAST-CELLS; IN-VITRO; ACTIN REORGANIZATION; HUMAN NEUTROPHILS; CUTTING EDGE; G-PROTEIN	We investigated the actions of a panel of nonsteroidal anti-inflammatory drugs on eosinophils, basophils, neutrophils, and monocytes. Indomethacin alone was a potent and selective inducer of eosinophil and basophil shape change. In eosinophils, indomethacin induced chemotaxis, CD11b up-regulation, respiratory burst, and L-selectin shedding but did not cause up-regulation of CD63 expression. Pretreatment of eosinophils with indomethacin also enhanced subsequent eosinophil shape change induced by eotaxin, although treatment with higher concentrations of indomethacin resulted in a decrease in the expression of the major eosinophil chemokine receptor, CCR3. Indomethacin activities and cell selectivity closely resembled those of prostaglandin D-2 (PGD(2)). Eosinophil shape change in response to eotaxin was inhibited by pertussis toxin, but indomethacin- and PGD(2)-induced shape change responses were not. Treatment of eosinophils with specific inhibitors of phospholipase C (U-73122), phosphatidylinositol 3-kinase (LY-294002), and p38 mitogen-activated protein kinase (SB-202190) revealed roles for these pathways in indomethacin signaling. Indomethacin and its analogues may therefore provide a structural basis from which selective PGD(2) receptor small molecule antagonists may be designed and which may have utility in the treatment of allergic inflammatory disease.	Dept Expt & Clin Pharmacol, A-8010 Graz, Austria; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Heinemann, A (corresponding author), Dept Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@kfunigraz.ac.at	Sabroe, Ian/I-5981-2013; Sabroe, Ian/AAE-5858-2019	Sabroe, Ian/0000-0001-9750-8975; Heinemann, Akos/0000-0002-8554-2372				Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; ANTHONY A, 1993, ALIMENT PHARM THER, V7, P29; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Boehme SA, 1999, J IMMUNOL, V163, P1611; BRYAN SA, 2002, IN PRESS AM J RESP C; Culley FJ, 2000, J IMMUNOL, V165, P6447, DOI 10.4049/jimmunol.165.11.6447; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DEMERSON CA, 1976, J MED CHEM, V19, P391, DOI 10.1021/jm00225a010; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; EMMENDORFFER A, 1990, J IMMUNOL METHODS, V131, P269, DOI 10.1016/0022-1759(90)90198-5; Fiorucci S, 1997, ALIMENT PHARM THERAP, V11, P619, DOI 10.1046/j.1365-2036.1997.00190.x; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; FUREDER W, 1995, ANN HEMATOL, V70, P251; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; Gomez-Gaviro MV, 2000, BLOOD, V96, P3592, DOI 10.1182/blood.V96.10.3592.h8003592_3592_3600; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirai H, 2002, J IMMUNOL, V168, P981, DOI 10.4049/jimmunol.168.3.981; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Laufer S, 1999, INFLAMM RES, V48, P133, DOI 10.1007/s000110050436; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Liu LX, 1998, J IMMUNOL, V161, P3064; Monneret G, 1999, CLIN EXP IMMUNOL, V115, P393; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; NOWAK D, 1993, EUR RESPIR J, V6, P405; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; Okada S, 1997, AM J RESP CELL MOL, V16, P455, DOI 10.1165/ajrcmb.16.4.9115757; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Prasit P, 1999, BIOORG MED CHEM LETT, V9, P1773, DOI 10.1016/S0960-894X(99)00288-7; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sabroe I, 1999, J IMMUNOL, V162, P2946; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stellato C, 2001, J IMMUNOL, V166, P1457, DOI 10.4049/jimmunol.166.3.1457; Struyf S, 2001, EUR J IMMUNOL, V31, P2170, DOI 10.1002/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D; Tanaka Y, 1999, J IMMUNOL, V163, P6209; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tenscher K, 1997, BIOCHEM BIOPH RES CO, V240, P32, DOI 10.1006/bbrc.1997.7601; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Wu DQ, 2000, J CELL SCI, V113, P2935; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Ying S, 1999, J IMMUNOL, V163, P3976; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	59	71	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26012	26020		10.1074/jbc.M201803200	http://dx.doi.org/10.1074/jbc.M201803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11980903	hybrid			2022-12-25	WOS:000176908700026
J	Wang, Y; Yamaguchi, K; Wada, T; Hata, K; Zhao, XJ; Fujimoto, T; Miyagi, T				Wang, Y; Yamaguchi, K; Wada, T; Hata, K; Zhao, XJ; Fujimoto, T; Miyagi, T			A close association of the ganglioside-specific sialidase Neu3 with caveolin in membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; PLASMA-MEMBRANE; SCAFFOLDING DOMAIN; MOLECULAR-CLONING; LIPID RAFTS; RAT-LIVER; RECEPTOR; EXPRESSION; KINASE; DIFFERENTIATION	The ganglioside-specific sialidase Neu3 has been suggested to play essential roles in regulation of cell surface functions because of its major localization in the plasma membrane and strict substrate preference for gangliosides involved in signal transduction. Here we show that human Neu3 sialidase is enriched in caveolae microdomains and closely associates with caveolin like other caveolin-binding signaling molecules. Using HeLa cells and Neu3-transfected COS-1 cells, endogenous and exogenous Neu3 was found to co-concentrate caveolin-1 in low density Triton X-100-insoluble membrane fractions on sucrose density gradients of the respective cell extracts, as assessed by enzyme activity assays and immunoblotting with a monoclonal antibody to human Neu3. The presence of a putative caveolin-binding motif within Neu3 prompted us to determine whether Neu3 binds to caveolin-1. In transfectants expressing a polyhistidine-tagged form of Neu3, caveolin-1 co-eluted with Neu3 on affinity column chromatography. A mutation with a single amino acid change in the caveolin-binding motif led to inhibition of recruitment of the sialidase to the microdomain, accompanied by reduction of the enzyme activity. Neu3 also failed to associate with caveolin-enriched microdomains by cholesterol depletion with beta-cyclodextrin (with concomitant decrease of the sialidase activity), whereas Neu3 was activated by increased caveolin-1 expression. The tight association of Neu3 with caveolin-1 was supported further by co-immunoprecipitation of Neu3 by anti-caveolin-1 antibody. These results strongly suggest that Neu3 functions as a caveolin-related signaling molecule within caveoin-rich microdomains.	Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Jilin Univ Med Sci, Lab Reprod Pathophysiol, Changchun 130021, Peoples R China; Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, Nagoya, Aichi 4668550, Japan	Jilin University; Nagoya University	Miyagi, T (corresponding author), Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan.		Fujimoto, Toyoshi/ABH-9058-2020	Fujimoto, Toyoshi/0000-0002-3601-7977				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hasegawa T, 2001, BIOCHEM BIOPH RES CO, V280, P726, DOI 10.1006/bbrc.2000.4186; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JONES DH, 1991, BIOTECHNIQUES, V10, P62; Kalka D, 2001, BIOCHEM BIOPH RES CO, V283, P989, DOI 10.1006/bbrc.2001.4864; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; MIYAGI T, 1986, FEBS LETT, V206, P223, DOI 10.1016/0014-5793(86)80985-1; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAGI T, 1990, JPN J CANCER RES, V81, P915, DOI 10.1111/j.1349-7006.1990.tb02667.x; MIYAGI T, 1990, JPN J CANCER RES, V81, P1286, DOI 10.1111/j.1349-7006.1990.tb02692.x; MIYAGI T, 1999, SIALOBIOLOGY OTHER N, P197; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHENGRUND CL, 1973, J BIOL CHEM, V248, P4424; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang Y, 2001, EUR J BIOCHEM, V268, P2201, DOI 10.1046/j.1432-1327.2001.02069.x; Wu G, 1998, ANN NY ACAD SCI, V845, P126, DOI 10.1111/j.1749-6632.1998.tb09666.x; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; YOGEESWARAN G, 1975, BIOCHEMISTRY-US, V14, P2151, DOI 10.1021/bi00681a017	34	105	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26252	26259		10.1074/jbc.M110515200	http://dx.doi.org/10.1074/jbc.M110515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011038	hybrid			2022-12-25	WOS:000176908700057
J	Yamazaki, K; Guo, LM; Sugahara, K; Zhang, C; Enzan, H; Nakabeppu, Y; Kitajima, S; Aso, T				Yamazaki, K; Guo, LM; Sugahara, K; Zhang, C; Enzan, H; Nakabeppu, Y; Kitajima, S; Aso, T			Identification and biochemical characterization of a novel transcription elongation factor, Elongin A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; FACTOR-SIII; BC COMPLEX; GENE; PURIFICATION; SUBUNIT; DISEASE; DOMAINS; BINDING	The Elongin complex stimulates the rate of transcription elongation by RNA polymerase 11 by suppressing the transient pausing of the polymerase at many sites along the DNA template. Elongin is composed of a transcriptionally active A subunit and two small regulatory B and C subunits, the latter binding stably to each other to form a binary complex that interacts with Elongin A and strongly induces its transcriptional activity. To further understand the role of Elongin A in transcriptional regulation by RNA polymerase 11, we are attempting to identify Elongin A-related proteins. Here, we report on the molecular cloning, expression, and biochemical characterization of human Elongin A3, a novel transcription elongation factor that exhibits 49 and 81% identity to Elongin A and the recently identified Elongin A2, respectively. The mRNA of Elongin A3 is ubiquitously expressed, and the protein is localized to the nucleus of cells. Mechanistic studies have demonstrated that Elongin A3 possesses similar biochemical features to Elongin A2. Both stimulate the rate of transcription elongation by RNA polymerase II and are capable of forming a stable complex with Elongin BC. In contrast to Elongin A, however, their transcriptional activities are not activated by Elongin BC. Structure-function analyses using fusion proteins composed of Elongin A3 and Elongin A revealed that the COOH-terminal region of Elongin A is important for the activation by Elongin BC.	Kochi Med Sch, Fac Med, Dept Chem, Nankoku, Kochi 7838505, Japan; Kochi Med Sch, Fac Med, Dept Pathol, Nankoku, Kochi 7838505, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan	Kochi University; Kochi University; Tokyo Medical & Dental University (TMDU); Kyushu University; Japan Science & Technology Agency (JST)	Aso, T (corresponding author), Kochi Med Sch, Fac Med, Dept Chem, Oko Cho, Nankoku, Kochi 7838505, Japan.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Aso T, 1996, GENE, V168, P277, DOI 10.1016/0378-1119(95)00750-4; Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; Aso T, 1999, CYTOGENET CELL GENET, V86, P259, DOI 10.1159/000015355; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Koth CM, 2000, J BIOL CHEM, V275, P11174, DOI 10.1074/jbc.275.15.11174; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Stuhlmuller B, 2000, ARTHRITIS RHEUM, V43, P775, DOI 10.1002/1529-0131(200004)43:4<775::AID-ANR8>3.0.CO;2-7; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956	33	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26444	26451		10.1074/jbc.M202859200	http://dx.doi.org/10.1074/jbc.M202859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994304	hybrid			2022-12-25	WOS:000176908700082
J	Zawalich, WS; Zawalich, KC				Zawalich, WS; Zawalich, KC			Effects of glucose, exogenous insulin, and carbachol on c-peptide and insulin secretion from isolated perifused rat islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; B-CELL; RELEASE; STIMULATION; MECHANISMS; RESISTANCE; INHIBITOR; BIOSYNTHESIS	Isolated perifused rat islets were stimulated with glucose, exogenous insulin, or carbachol. C-peptide and, where possible, insulin secretory rates were measured. Glucose (8-10 mm) induced dose-dependent and kinetically similar patterns of C-peptide and insulin secretion. The addition of 100 nM bovine insulin had no effect on C-peptide release in response to 8-10 mm glucose stimulation. The addition of 100 nM bovine insulin or 500 nM human insulin together with 3 mm glucose had no stimulatory effect on C-peptide secretion rates from perifused rat islets. Stimulation with carbachol plus 7 mm glucose enhanced both C-peptide and insulin secretion, and the further addition of 100 nM bovine insulin had no inhibitory effect on C-peptide secretory rates under this condition. Perifusion studies using pharmacologic inhibitors (genistein and wortmannin) of the kinases thought to be involved in insulin signaling potentiated 10 mM glucose-induced secretion. The results support the following conclusions. 1) C-peptide release rates accurately reflect insulin secretion rates from collagenase-isolated, perifused rat islets. 2) Exogenously added bovine insulin exerts no inhibitory effect on release to several agonists including glucose. 3) In the presence of 3 mm glucose, exogenously added bovine or human insulin do not stimulate endogenous insulin secretion.	Yale Univ, Sch Nursing, New Haven, CT 06536 USA	Yale University	Zawalich, WS (corresponding author), Yale Univ, Sch Nursing, POB 9740,100 Church St S, New Haven, CT 06536 USA.	Walter.Zawalich@Yale.Edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041230] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41230] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; AMMON HPT, 1976, ENDOCRINOLOGY, V99, P1468, DOI 10.1210/endo-99-6-1469; AMMON HPT, 1991, J ENDOCRINOL, V128, P27, DOI 10.1677/joe.0.1280027; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; BEST L, 1984, ENDOCRINOLOGY, V115, P1814, DOI 10.1210/endo-115-5-1814; CURRY DL, 1986, ENDOCRINOLOGY, V118, P170, DOI 10.1210/endo-118-1-170; Eto K, 2000, DIABETES, V49, pA45; Eto K, 2002, DIABETES, V51, P87, DOI 10.2337/diabetes.51.1.87; GAGLIARDINO JJ, 1974, DIABETOLOGIA, V10, P411, DOI 10.1007/BF01221630; GERICH JE, 1974, J CLIN INVEST, V54, P833, DOI 10.1172/JCI107823; GRILL V, 1978, J CLIN INVEST, V61, P1034, DOI 10.1172/JCI109002; HAGIWARA S, 1995, BIOCHEM BIOPH RES CO, V214, P51, DOI 10.1006/bbrc.1995.2255; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HENQUIN JC, 1987, BIOCHEM J, V246, P393, DOI 10.1042/bj2460393; IVERSEN J, 1971, DIABETES, V20, P1; JONAS JC, 1995, BRIT J PHARMACOL, V114, P872, DOI 10.1111/j.1476-5381.1995.tb13285.x; KELLEY GG, 1995, AM J PHYSIOL-ENDOC M, V269, pE575, DOI 10.1152/ajpendo.1995.269.3.E575; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; LANGER SZ, 1980, PHARMACOL REV, V32, P337; LEAHY JL, 1990, ENDOCRINOLOGY, V126, P1593, DOI 10.1210/endo-126-3-1593; LERNMARK A, 1971, HORM METAB RES, V3, P305, DOI 10.1055/s-0028-1094131; LORETI L, 1974, DIABETOLOGIA, V10, P309; LOUBATIE.MM, 1973, DIABETOLOGIA, V9, P439, DOI 10.1007/BF00461685; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MALAISSELAGAE F, 1987, ACTA DIABETOL LAT, V24, P17, DOI 10.1007/BF02732049; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; Nunoi K, 2000, BIOCHEM BIOPH RES CO, V270, P798, DOI 10.1006/bbrc.2000.2514; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; RAPPAPORT AM, 1972, ENDOCRINOLOGY, V91, P168, DOI 10.1210/endo-91-1-168; SCHATZ H, 1977, J ENDOCRINOL, V74, P243, DOI 10.1677/joe.0.0740243; SODOYEZ JC, 1969, P SOC EXP BIOL MED, V130, P568; SORENSON RL, 1994, ENDOCRINOLOGY, V134, P1975, DOI 10.1210/en.134.4.1975; STEINER DF, 1977, DIABETES, V26, P322, DOI 10.2337/diab.26.4.322; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; Zawalich WS, 1998, AM J PHYSIOL-CELL PH, V274, pC1388; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409; ZAWALICH WS, 1989, ENDOCRINOLOGY, V125, P2400, DOI 10.1210/endo-125-5-2400; Zawalich WS, 2000, J ENDOCRINOL, V166, P111, DOI 10.1677/joe.0.1660111; ZAWALICH WS, 1975, DIABETOLOGIA, V11, P231, DOI 10.1007/BF00422327; Zawalich WS, 2000, ENDOCRINOLOGY, V141, P3287, DOI 10.1210/en.141.9.3287; Zawalich WS, 1996, PFLUG ARCH EUR J PHY, V432, P589, DOI 10.1007/s004240050174; Zawalich WS, 2001, J BIOL CHEM, V276, P37120, DOI 10.1074/jbc.M105008200	48	29	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26233	26237		10.1074/jbc.M202291200	http://dx.doi.org/10.1074/jbc.M202291200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011082	hybrid			2022-12-25	WOS:000176908700054
J	Gummadi, SN; Menon, AK				Gummadi, SN; Menon, AK			Transbilayer movement of dipalmitoylphosphatidylcholine in proteoliposomes reconstituted from detergent extracts of endoplasmic reticulum - Kinetics of transbilayer transport mediated by a single flippase and identification of protein fractions enriched in flippase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TRANSMEMBRANE MOVEMENT; PHOSPHOLIPID FLIPPASE; MEMBRANE; PHOSPHATIDYLCHOLINE; BILAYER; SEPARATION; DENSITY; MOTION; LIPIDS; PHASE	Phospholipid translocation (flip-flop) across membrane bilayers is typically assessed via assays utilizing partially water-soluble phospholipid analogs as transport reporters. These assays have been used in previous work to show that phospholipid translocation in biogenic (self-synthesizing) membranes such as the endoplasmic reticulum is facilitated by specific membrane proteins (flippases). To extend these studies to natural phospholipids while providing a framework to guide the purification of a flippase, we now describe an assay to measure the transbilayer translocation of dipalmitoylphosphatidylcholine, a membrane-embedded phospholipid, in proteoliposomes generated from detergent-solubilized rat liver endoplasmic reticulum. Translocation was assayed using phospholipase A(2) under conditions where the vesicles were determined to be intact. Phospholipase A(2), rapidly hydrolyzed phospholipids in the outer leaflet of liposomes and proteoliposomes with a half-time of similar to0.1 min. However, for flippase-containing proteoliposomes, the initial rapid hydrolysis phase was followed by a slower phase reflecting flippase-mediated translocation of phospholipids from the inner to the outer leaflet. The amplitude of the slow phase was decreased in trypsin-treated proteoliposomes. The kinetic characteristics of the slow phase were used to assess the rate of transbilayer equilibration of phospholipids. For 250-nm diameter vesicles containing a single flippase, the half-time was 3.3 min. Proportionate reductions in equilibration half-time were observed for preparations with a higher average number of flippases/vesicle. Preliminary purification steps indicated that flippase activity could be enriched similar to15-fold by sequential adsorption of the detergent extract onto anion and cation exchange resins.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Menon, AK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	menon@biochem.wisc.edu	Gummadi, Sathyanarayana Naidu/K-2303-2019; Gummadi, Sathyanarayana/W-5354-2019	Gummadi, Sathyanarayana Naidu/0000-0003-0707-5710; Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM063117] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63117] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELL GB, 1964, PHOSPHOLIPIDS CHEM M, P264; BACKER JM, 1987, NATURE, V327, P341, DOI 10.1038/327341a0; BELL RM, 1981, J LIPID RES, V22, P391; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRETSCHER MS, 1973, CELL SURFACE DEV, P17; BURACK WR, 1993, BIOCHEMISTRY-US, V32, P583, DOI 10.1021/bi00053a025; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Devaux P F, 1993, Subcell Biochem, V21, P273; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GOLDSTEIN B, 1981, P NATL ACAD SCI-BIOL, V78, P5695, DOI 10.1073/pnas.78.9.5695; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Hrafnsdottir S, 2000, J BACTERIOL, V182, P4198, DOI 10.1128/JB.182.15.4198-4206.2000; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1998, J BIOL CHEM, V273, P18936, DOI 10.1074/jbc.273.30.18936; JAIN MK, 1980, NATURE, V284, P486, DOI 10.1038/284486a0; Janssen MJFW, 1999, BBA-BIOMEMBRANES, V1421, P64, DOI 10.1016/S0005-2736(99)00113-3; KAWASHIMA Y, 1987, J BIOL CHEM, V262, P16495; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; LENARD J, 1976, P NATL ACAD SCI USA, V73, P391, DOI 10.1073/pnas.73.2.391; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Marx U, 2000, BIOPHYS J, V78, P2628, DOI 10.1016/S0006-3495(00)76807-X; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MENON A, 1995, TRENDS CELL BIOL, V5, P355, DOI 10.1016/S0962-8924(00)89069-8; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROTHMAN JE, 1975, BIOCHEMISTRY-US, V14, P2809, DOI 10.1021/bi00684a004; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; SANO H, 1981, J CHEM PHYS, V75, P2870, DOI 10.1063/1.442360; SUNDLER R, 1978, J BIOL CHEM, V253, P5299; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; Webb W W, 1981, Biochem Soc Symp, P191; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSCHUT JC, 1979, FEBS LETT, V98, P181, DOI 10.1016/0014-5793(79)80179-9	43	44	44	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25337	25343		10.1074/jbc.M203809200	http://dx.doi.org/10.1074/jbc.M203809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000768	hybrid			2022-12-25	WOS:000176747000065
J	Kelm, O; Wind, M; Lehmann, WD; Nigg, EA				Kelm, O; Wind, M; Lehmann, WD; Nigg, EA			Cell cycle-regulated phosphorylation of the Xenopus polo-like kinase Plx1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; PROGNOSTIC-SIGNIFICANCE; MPF AMPLIFICATION; FAMILY MEMBERS; PLK EXPRESSION; EGG EXTRACTS; MITOSIS	Polo-like kinases (Plks) control multiple important events during M phase progression, but little is known about their activation during the cell cycle. The activities of both mammalian Plk1 and Xenopus Plx1 peak during M phase, and this activation has been attributed to phosphorylation. However, no phosphorylation sites have previously been identified in any member of the Plk family. Here we have combined tryptic phosphopeptide mapping with mass spectrometry to identify four major phosphorylation sites in Xenopus Plx1. All four sites appear to be phosphorylated in a cell cycle-dependent manner. Phosphorylations at two sites (Ser-260 and Ser-326) most likely represent autophosphorylation events, whereas two other sites (Thr-201 and Ser-340) are targeted by upstream kinases. Several recombinant kinases were tested for their ability to phosphorylate Plx1 in vitro. Whereas xPlkk1 phosphorylated primarily Thr-10, Thr-201 was readily phosphorylated by protein kinase A, and Cdk1/cyclin B was identified as a likely kinase acting on Ser-340. Phosphorylation of Ser-340 was shown to be responsible for the retarded electrophoretic mobility of Plx1 during M phase, and phosphorylation of Thr-201 was identified as a major activating event.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ)	Nigg, EA (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany.	nigg@biochem.mpg.de		nigg, erich/0000-0003-4835-5719				Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL SCI, V114, P2357; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karaiskou A, 1998, EXP CELL RES, V244, P491, DOI 10.1006/excr.1998.4220; Kinter M, 2000, PROTEIN SEQUENCING I, V1st, P152; Knecht R, 1999, CANCER RES, V59, P2794; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; WIND M, 2002, IN PRESS PROTEOMICS, V2; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	56	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25247	25256		10.1074/jbc.M202855200	http://dx.doi.org/10.1074/jbc.M202855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994303	hybrid			2022-12-25	WOS:000176747000053
J	Sengupta, PK; Fargo, J; Smith, BD				Sengupta, PK; Fargo, J; Smith, BD			The RFX family interacts at the collagen (COL1A2) start site and represses transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II TRANSACTIVATOR; GROWTH-FACTOR-BETA; BARE LYMPHOCYTE SYNDROME; HUMAN SKIN FIBROBLASTS; NECROSIS-FACTOR-ALPHA; DNA-BINDING PROTEIN; REGULATORY FACTOR-X; GENE-EXPRESSION; INTERFERON-GAMMA; NF-Y	The transcription start site of the collagen alpha2(1) gene (COL1A2) has a sequence-specific binding site for a DNA methylation-responsive binding protein called regulatory factor for X-box 1 (RFX1) (Sengupta, P. K., Erhlich, M., and Smith, B. D. (1999) J. Biol. Chem. 274, 3664936655). In this report, we demonstrate that RFX1 forms homodimers as well as heterodimers with RFX2 spanning the collagen transcription start site. Methylation at +7 on the coding strand increases RFX1 complex formation in gel shift assays. Methylation on the template strand, however, does not increase RFX1 complex formation. DNA from human fibroblasts contains minimal methylation on the coding strand (<4%) with variable methylation on the template strand. RFX1 acts as a repressor of collagen transcription as judged by in vitro transcription and co-transfection assays with an un-methylated collagen promoter-reporter construct. In addition, an RFX5 complex present in human fibroblasts interacts with the collagen RFX site, which is not sensitive to methylation. This is the first demonstration of RFX5 complex formation on a gene other than major histocompatibility complex (MHC) promoters. Also, RFX5 represses transcription of a collagen promoter-reporter construct in rat fibroblasts that have no detectable RFX5 complex formation or protein. RFX5 complex activates MHC 11 transcription by interacting with an interferon-gamma (IFN-gamma)-inducible protein, major histocompatibility class 11 trans-activator (CIITA). Collagen transcription is repressed by IFN-gamma in a dose-dependent manner in human but not in rat fibroblasts. IFN-gamma enhances RFX5 binding activity, and CIITA is present in the RFX5 complex of IFN-gamma-treated human fibroblasts. CIITA repressed collagen gene transcription more effectively in human fibroblasts than in rat fibroblasts, suggesting that the RFX5 complex may, in part, recruit CIITA protein to the collagen transcription start site. Thus the RFX family may be important repressors of collagen gene transcription through a RFX binding site spanning the transcription start site.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Vet Adm Med Ctr, Boston, MA 02118 USA	Boston University	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386, R01HL068094] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL68094, P01-HL56386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Biegalke BJ, 1998, J VIROL, V72, P5457, DOI 10.1128/JVI.72.7.5457-5463.1998; BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Brickey WJ, 1999, J IMMUNOL, V163, P6622; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; CATANIA J, 1991, MUTAT RES, V256, P283, DOI 10.1016/0921-8734(91)90019-8; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GOLDSTEIN RH, 1991, AM J PHYSIOL, V261, pL29, DOI 10.1152/ajplung.1991.261.2.L29; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Iwama A, 1999, MOL CELL BIOL, V19, P3940; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Katan-Khaykovich Y, 1999, J MOL BIOL, V294, P121, DOI 10.1006/jmbi.1999.3245; KHAN R, 1988, J BIOL CHEM, V263, P14374; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Mach B, 1999, SCIENCE, V285, P1367, DOI 10.1126/science.285.5432.1367; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Masternak K, 2002, EMBO J, V21, P1379, DOI 10.1093/emboj/21.6.1379; Moreno CS, 1997, J IMMUNOL, V158, P5841; Mori-Aoki A, 2000, BIOCHEM BIOPH RES CO, V278, P58, DOI 10.1006/bbrc.2000.3769; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; Pieper RO, 1999, NUCLEIC ACIDS RES, V27, P3229, DOI 10.1093/nar/27.15.3229; Piskurich JF, 1998, J IMMUNOL, V160, P233; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Samac S, 1998, BIOL CHEM, V379, P541; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; SENGUPTA PK, 1994, AM J HEMATOL, V46, P169, DOI 10.1002/ajh.2830460302; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; SMITH BD, 1988, BIOCHEM J, V253, P269, DOI 10.1042/bj2530269; SMITH GJ, 1981, CANCER RES, V41, P1373; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Tierney R, 2000, J VIROL, V74, P10458, DOI 10.1128/JVI.74.22.10458-10467.2000; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; WILSON VL, 1983, SCIENCE, V220, P1054; Ying AK, 2000, CARDIOVASC RES, V46, P172, DOI 10.1016/S0008-6363(00)00004-3; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	90	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24926	24937		10.1074/jbc.M111712200	http://dx.doi.org/10.1074/jbc.M111712200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986307	hybrid			2022-12-25	WOS:000176747000014
J	Shah, S; Pishvaian, MJ; Easwaran, V; Brown, PH; Byers, SW				Shah, S; Pishvaian, MJ; Easwaran, V; Brown, PH; Byers, SW			The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; EPITHELIAL TUMOR-CELLS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; 9-CIS-RETINOIC ACID; GROWTH-INHIBITION; COLON-CARCINOMA; ALPHA-CATENIN; ADHESION	Vitamin A derivatives (retinoids) are potent regulators of cell proliferation and differentiation. Retinoids inhibit the function of the oncogenic AP-1 and beta-catenin/TCF pathways and also stabilize components of the adherens junction, a tumor suppressor complex. When treated with retinoic acid (RA), the breast cancer cell line, SKBR3, undergoes differentiation and reduction in cell proliferation. The present work demonstrates that in SKBR3 cells, which exhibit high AP-1 activity, RA-regulation of cadherin expression and function, but not changes in AP-1 (or beta-catenin/TCF) signaling, is responsible for the epithelial differentiation. However, cadherin function and recruitment of beta-catenin to the membrane is not required for RA to regulate DNA synthesis in these cells. RA also reduces the activity of an AP-1 and TCF-sensitive cyclin D1 reporter in SKBR3 cells in a manner that is independent of the TCF site. In contrast, in SW480 cells, which have high levels of beta-catenin/TCF signaling, the activity and retinoid responsiveness of the cyclin D1 promoter was markedly inhibited by mutation of the TCF site. These data indicate that the remarkably broad effects of RA on the growth and differentiation of many different epithelial cancers may well be explained by the ability of RA to differentially regulate the activity of RAR/RXR, AP-1, and beta-catenin/TCF pathways.	Georgetown Univ, Ctr Med, Sch Med, Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Ctr Med, Sch Med, Dept Oncol & Cell Biol, Washington, DC 20007 USA; Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, San Antonio, TX 78284 USA	Georgetown University; Georgetown University; University of Texas System; University of Texas Health San Antonio	Byers, SW (corresponding author), Georgetown Univ, Ctr Med, Sch Med, Lombardi Canc Res Ctr, E415 Res Bldg,3970 Reservoir Rd, Washington, DC 20007 USA.	byerss@georgetown.edu						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANZANO MA, 1994, CANCER RES, V54, P4614; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1993, J CELL SCI, P159; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BOYER B, 1989, J MEMBRANE BIOL, V112, P97, DOI 10.1007/BF01871271; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Byers S, 1996, ENDOCRINOLOGY, V137, P3265, DOI 10.1210/en.137.8.3265; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EDWARD M, 1992, CLIN EXP METASTAS, V10, P61, DOI 10.1007/BF00163577; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Fitzgerald P, 1997, CANCER RES, V57, P2642; FLIGIEL SEG, 1992, J CUTAN PATHOL, V19, P27, DOI 10.1111/j.1600-0560.1992.tb01555.x; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hong Waun Ki, 1994, P597; HOOSEIN NM, 1988, CANCER LETT, V40, P219, DOI 10.1016/0304-3835(88)90014-6; HOULE JD, 1989, NEUROSCI LETT, V103, P253, DOI 10.1016/0304-3940(89)90108-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li JJ, 1996, CANCER RES, V56, P483; Mangelsdorf David J., 1994, P319; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OYAMA T, 1994, CANCER RES, V54, P6282; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Pishvaian MJ, 1999, CANCER RES, V59, P947; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Sellin JH, 2001, CANCER RES, V61, P2899; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Shimazui T, 1996, CANCER RES, V56, P3234; SHIMOYAMA Y, 1995, CANCER RES, V55, P2206; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Szeto W, 2001, CANCER RES, V61, P4197; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Truica CI, 2000, CANCER RES, V60, P4709; VERMA AK, 1980, CANCER RES, V40, P2367; VERMA AK, 1983, CANCER RES, V43, P3045; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	57	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25313	25322		10.1074/jbc.M203158200	http://dx.doi.org/10.1074/jbc.M203158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000762	hybrid			2022-12-25	WOS:000176747000062
J	Spitkovsky, D; Hehner, SP; Hofmann, TG; Moller, A; Schmitz, ML				Spitkovsky, D; Hehner, SP; Hofmann, TG; Moller, A; Schmitz, ML			The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BINDING-PROTEIN; IMMUNE EVASION; TYPE-16; TRANSCRIPTION; E6; CANCER; ALPHA; CELLS; IKK	Infection with high-risk human papillomaviruses (HPV) can lead to the development of cervical carcinomas. This process critically depends on the virus-encoded E6 and E7 oncoproteins, which stimulate proliferation by manipulating the function of a variety of host key regulatory proteins. Here we show that both viral proteins dose-dependently interfere with the transcriptional activity of NF-kappaB. A variety of experimental approaches revealed that a fraction of the E7 proteins is found in association with the IkappaB kinase complex and attenuates induced kinase activity of IkappaB kinase alpha (IKKalpha) and IKKbeta, thus resulting in impaired IkappaBalpha phosphorylation and degradation. Indirect immunofluorescence shows that E7 impairs TNFalpha-induced nuclear translocation of NF-kappaB, thus preventing NF-kappaB from binding to its cognate DNA. While E7 obviates IKK activation in the cytoplasm, the E6 protein reduces NF-kappaB p65-dependent transcriptional activity within the nucleus. We suggest that HPV oncogene-mediated suppression of NF-kappaB activity contributes to HPV escape from the immune system.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany; German Canc Res Ctr, Div Immunochem G0200, D-69120 Heidelberg, Germany; Univ Cologne, Inst Vegetat Physiol, D-50931 Cologne, Germany	University of Bern; Heinrich Pette Institute; Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Schmitz, ML (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	Lienhard.Schmitz@ibc.unibe.ch	Schmitz, M. Lienhard/D-9328-2017; Möller, Andreas/O-1063-2015	Schmitz, M. Lienhard/0000-0002-6984-7192; Möller, Andreas/0000-0002-8618-6998				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Boyer SN, 1996, CANCER RES, V56, P4620; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; CHINAMI M, 1994, J GEN VIROL, V75, P277, DOI 10.1099/0022-1317-75-2-277; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fontaine V, 2000, VIROLOGY, V272, P40, DOI 10.1006/viro.2000.0363; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; GILMORE TD, 1992, CANCER SURV, V15, P69; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KYO S, 1994, VIROLOGY, V200, P130, DOI 10.1006/viro.1994.1171; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; MALEJCZYK J, 1994, INT J CANCER, V56, P593, DOI 10.1002/ijc.2910560421; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spitkovsky D, 1996, ONCOGENE, V13, P1027; Tait SWG, 2000, J BIOL CHEM, V275, P34656, DOI 10.1074/jbc.M000320200; TARTOUR E, 1994, CANCER RES, V54, P6243; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; Vancurova I, 2002, J VIROL, V76, P1533, DOI 10.1128/JVI.76.3.1533-1536.2002; Vikhanskaya F, 2002, INT J CANCER, V97, P732, DOI 10.1002/ijc.10114; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	55	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25576	25582		10.1074/jbc.M201884200	http://dx.doi.org/10.1074/jbc.M201884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986318	hybrid			2022-12-25	WOS:000176747000095
J	Yusta, B; Estall, J; Drucker, DJ				Yusta, B; Estall, J; Drucker, DJ			Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CELL-SURVIVAL; SIGNALING PATHWAY; GLP-2 RECEPTOR; CARDIAC MYOCYTES; NEURONAL DEATH; CYTOCHROME-C; BH3 DOMAIN; KAPPA-B; IN-VIVO	Activation of glucagon-like peptide-2 receptor (GLP-2R) signaling promotes expansion of the mucosal epithelium indirectly via activation of growth and anti-apoptotic pathways; however, the cellular mechanisms coupling direct GLP-2R activation to cell survival remain poorly understood. We now demonstrate that GLP-2, in a cycloheximide-insensitive manner, enhanced survival in baby hamster kidney cells stably transfected with the rat GLP-2R; reduced mitochondrial cytochrome c efflux; and attenuated the caspase-dependent cleavage of Akt, poly(ADP-ribose) polymerase, and beta-catenin following inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002. The prosurvival effects of GLP-2 on LY294002-induced cell death were independent of Akt, P90(Rsk), or p70 S6 kinase activation; were mimicked by forskolin; and were abrogated by inhibition of protein kinase A (PKA) activity. GLP-2 inhibited activation of glycogen synthase kinase-3 (GSK-3) through phosphorylation at Ser(21) in GSK-3alpha and at Ser(9) in GSK-3beta in a PI3K-independent, PKA-dependent manner. GLP-2 reduced LY294002-induced mitochondrial association of endogenous Bad and Bax and stimulated phosphorylation of a transfected Bad fusion protein at Ser(155) in a PI3K-independent, but H89-sensitive manner, a modification known to suppress Bad pro-apoptotic activity. These results suggest that GLP-2R signaling enhances cell survival independently of PI3K/Akt by inhibiting the activity of a subset of pro-apoptotic downstream targets of Akt in a PKA-dependent manner.	Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, 200 Elizabeth St, Toronto, ON M5G 1L7, Canada.		Drucker, Daniel J/A-4092-2010	Estall, Jennifer/0000-0002-9838-1440				Araki M, 2000, J AM COLL CARDIOL, V36, P1411, DOI 10.1016/S0735-1097(00)00822-6; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boushey RP, 1999, AM J PHYSIOL-ENDOC M, V277, pE937, DOI 10.1152/ajpendo.1999.277.5.E937; Boushey RP, 2001, CANCER RES, V61, P687; BREGENHOLT S, 2001, 61 ANN M AM DIAB ASS, V50, pOR125; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burrin DG, 2000, AM J PHYSIOL-GASTR L, V279, pG1249, DOI 10.1152/ajpgi.2000.279.6.G1249; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Delgado M, 1996, BLOOD, V87, P5152, DOI 10.1182/blood.V87.12.5152.bloodjournal87125152; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Drucker DJ, 2001, J CLIN ENDOCR METAB, V86, P1759, DOI 10.1210/jc.86.4.1759; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; Goswami R, 2000, J NEUROSCI RES, V59, P136, DOI 10.1002/(SICI)1097-4547(20000101)59:1<136::AID-JNR16>3.0.CO;2-F; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; HANSOTIA T, 2001, 61 ANN M AM DIAB ASS, V50, pP1457; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hetman M, 2000, J NEUROSCI, V20, P2567; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Oka JI, 2000, BRAIN RES, V878, P194, DOI 10.1016/S0006-8993(00)02741-4; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Singh K, 2000, CARDIOVASC RES, V45, P713, DOI 10.1016/S0008-6363(99)00370-3; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Thangaraju M, 1999, CANCER RES, V59, P1649; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Wang XD, 2001, GENE DEV, V15, P2922; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yan LZ, 2000, AM J PHYSIOL-CELL PH, V279, pC1665, DOI 10.1152/ajpcell.2000.279.5.C1665; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459; Yusta B, 2000, GASTROENTEROLOGY, V119, P744, DOI 10.1053/gast.2000.16489; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	64	71	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24896	24906		10.1074/jbc.M201358200	http://dx.doi.org/10.1074/jbc.M201358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978789	hybrid			2022-12-25	WOS:000176747000011
J	Bernett, MJ; Blaber, SI; Scarisbrick, IA; Dhanarajana, P; Thomspon, SM; Blaber, M				Bernett, MJ; Blaber, SI; Scarisbrick, IA; Dhanarajana, P; Thomspon, SM; Blaber, M			Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MOUSE SUBMANDIBULAR-GLAND; RAT SPINAL-CORD; SERINE-PROTEASE; GENE FAMILY; ZYME/PROTEASE M/NEUROSIN; ALZHEIMERS-DISEASE; SEQUENCE; IDENTIFICATION; BIOMARKER	The human kallikreins are a large multigene family of closely related serine-type proteases. In this regard, they are similar to the multigene kallikrein families characterized in mice and rats. There is a much more extensive body of knowledge regarding the function of mouse and rat kallikreins in comparison with the human kallikreins. Human kallikrein 6 has been proposed as the homologue to rat myelencephalon-specific protease, an arginine-specific degradative-type protease abundantly expressed in the central nervous system and implicated in demyelinating disease. We present the x-ray crystal structure of mature, active recombinant human kallikrein 6 at 1.75-Angstrom resolution. This high resolution model provides the first three-dimensional view of one of the human kallikreins and one of only a few structures of serine proteases predominantly expressed in the central nervous system. Enzymatic data are presented that support the identification of human kallikrein 6 as the functional homologue of rat myelencephalon-specific protease and are corroborated by a molecular phylogenetic analysis. Furthermore, the x-ray data provide support for the characterization of human kallikrein 6 as a degradative protease with structural features more similar to trypsin than the regulatory kallikreins.	Florida State Univ, Inst Mol Biophys, Dept Chem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Dept Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Dept Biol Sci, Tallahassee, FL 32306 USA; Florida State Univ, Sch Computat Sci & Informat Technol, Tallahassee, FL 32306 USA; Mayo Clin, Mayo Med & Grad Sch, Dept Neurol, Rochester, MN 55905 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; Mayo Clinic	Blaber, M (corresponding author), Florida State Univ, Inst Mol Biophys, Dept Chem, 307-DRS-4380, Tallahassee, FL 32306 USA.	blaber@sb.fsu.edu	Blaber, Michael/E-7478-2011; Blaber, Michael/ABA-5031-2021; Blaber, Michael/N-1083-2019	Blaber, Michael/0000-0002-6856-1643; 				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; BIRKTOFT JJ, 1976, BIOCHEMISTRY-US, V15, P4481, DOI 10.1021/bi00665a023; BLABER M, 1989, BIOCHEMISTRY-US, V28, P7813, DOI 10.1021/bi00445a043; BLABER M, 1993, PROTEIN SCI, V2, P1210, DOI 10.1002/pro.5560020803; BLABER M, 1987, BIOCHEMISTRY-US, V26, P6742, DOI 10.1021/bi00395a025; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; BOCK CW, 1994, INORG CHEM, V33, P419, DOI 10.1021/ic00081a007; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAYHUFF TJ, 1992, BIOTECHNIQUES, V13, P499; Diamandis EP, 2000, CLIN BIOCHEM, V33, P369, DOI 10.1016/S0009-9120(00)00145-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Diamandis EP, 2002, CANCER RES, V62, P295; Diamandis EP, 2000, CLIN BIOCHEM, V33, P663, DOI 10.1016/S0009-9120(00)00185-5; Diamandis EP, 2000, CLIN BIOCHEM, V33, P579, DOI 10.1016/S0009-9120(00)00182-X; DRINKWATER CC, 1987, BIOCHEMISTRY-US, V26, P6750, DOI 10.1021/bi00395a026; ETZOLD T, 1993, COMPUT APPL BIOSCI, V9, P49; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FELSENSTEIN J, 2001, PHYLIP VERSION 3 5 P; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONGSTRABILEN J, 1989, MOL BRAIN RES, V5, P159, DOI 10.1016/0169-328X(89)90007-7; KIM WS, 1991, J BIOL CHEM, V266, P19283; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Luo LY, 2001, CLIN CHIM ACTA, V306, P111, DOI 10.1016/S0009-8981(01)00401-6; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; Matsui H, 2000, J BIOL CHEM, V275, P11050, DOI 10.1074/jbc.275.15.11050; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meier N, 1999, BIOCHEM BIOPH RES CO, V258, P374, DOI 10.1006/bbrc.1999.0600; Nakajima N, 1999, BIOSCI BIOTECH BIOCH, V63, P2031, DOI 10.1271/bbb.63.2031; Ogawa K, 2000, PSYCHIAT CLIN NEUROS, V54, P419, DOI 10.1046/j.1440-1819.2000.00731.x; Oka T, 2002, J BIOL CHEM, V277, P14724, DOI 10.1074/jbc.M110725200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Scarisbrick IA, 2000, GLIA, V30, P219, DOI 10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 2001, J COMP NEUROL, V431, P347; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 2001, PAUP ASTERISK VERSIO; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; WILSON WH, 1979, J BIOL CHEM, V254, P6002; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; Yamanaka H, 1999, MOL BRAIN RES, V71, P217, DOI 10.1016/S0169-328X(99)00187-4; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yousef GM, 2001, CANCER RES, V61, P7811; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	62	149	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24562	24570		10.1074/jbc.M202392200	http://dx.doi.org/10.1074/jbc.M202392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983703	hybrid			2022-12-25	WOS:000176611800078
J	Chen, ZH; Alcayaga, C; Suarez-Isla, BA; O'Rourke, B; Tomaselli, G; Marban, E				Chen, ZH; Alcayaga, C; Suarez-Isla, BA; O'Rourke, B; Tomaselli, G; Marban, E			A "minimal" sodium channel construct consisting of ligated S5-P-S6 segments forms a toxin-activatable ionophore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; NA+-CHANNEL; EXCITABLE-MEMBRANES; BREVETOXIN RECEPTOR; SAXITOXIN BINDING; STRUCTURAL MODEL; POINT MUTATIONS; CELL-DEATH; SITE; PORE	The large size (six membrane-spanning repeats in each of four domains) and asymmetric architecture of the voltage-dependent Na+ channel has hindered determination of its structure. With the goal of determining the minimum structure of the Na+ channel permeation pathway, we created two stable cell lines expressing the voltage-dependent rat skeletal muscle Na+ channel (mu1) with a polyhistidine tag on the C terminus (muHis) and pore-only mu1 (muPore) channels with S1-S4 in all domains removed. Both constructs were recognized by a Na+ channel-specific antibody on a Western blot. muHis channels exhibited the same functional properties as wildtype mu1. In contrast, muPore channels did not conduct Na+ currents nor did they bind [H-3]saxitoxin. Veratridine caused 40 and 54% cell death in muHis- and muPore-expressing cells, respectively. However, veratridine-induced cell death could only be blocked by tetrodotoxin in cells expressing muHis, but not muPore. Furthermore, using a fluorescent Na+ indicator, we measured changes in intracellular Na+ induced by veratridine and a brevotoxin analogue, pumiliotoxin. When calibrated to the maximum signal after addition of gramicidin, the maximal percent increases in fluorescence (DeltaF) were 35 and 31% in cells expressing muHis and muPore, respectively. Moreover, in the presence of 1 mum tetrodotoxin, DeltaF decreased significantly to 10% in muHis- but not in muPore-expressing cells (43%). In conclusion, S5-P-S6 segments of mu1 channels form a toxin-activable ionophore but do not reconstitute the Na+ channel permeation pathway with full fidelity.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Univ Chile, Fac Med, Inst Biomed Sci, Program Physiol & Biophys, Santiago 6530499, Chile	Johns Hopkins University; Universidad de Chile	Marban, E (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R01 HL52768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; Balser JR, 1996, J PHYSIOL-LONDON, V494, P431, DOI 10.1113/jphysiol.1996.sp021503; BARNES S, 1988, J GEN PHYSIOL, V91, P421, DOI 10.1085/jgp.91.3.421; Benitah JP, 1999, J NEUROSCI, V19, P1577; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen ZH, 2000, J PHYSIOL-LONDON, V524, P37, DOI 10.1111/j.1469-7793.2000.t01-1-00037.x; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DOYLE DD, 1993, J GEN PHYSIOL, V101, P153, DOI 10.1085/jgp.101.2.153; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Hille B., 1992, IONIC CHANNELS EXCIT; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; Jeglitsch G, 1998, J PHARMACOL EXP THER, V284, P516; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUTRO JB, 1986, J GEN PHYSIOL, V87, P1, DOI 10.1085/jgp.87.1.1; Takahashi S, 1999, EUR J PHARMACOL, V372, P297, DOI 10.1016/S0014-2999(99)00208-3; Takahashi S, 2000, EUR J PHARMACOL, V408, P127, DOI 10.1016/S0014-2999(00)00790-1; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TRAINER VL, 1991, MOL PHARMACOL, V40, P988; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; Velez P, 2001, TOXICON, V39, P929, DOI 10.1016/S0041-0101(00)00230-0; WADA A, 1992, J PHARMACOL EXP THER, V263, P1347; Wang SY, 1999, BIOPHYS J, V76, P3141, DOI 10.1016/S0006-3495(99)77465-5; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Yotsu-Yamashita M, 2000, BIOCHEM BIOPH RES CO, V267, P403, DOI 10.1006/bbrc.1999.1974	37	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24653	24658		10.1074/jbc.M111862200	http://dx.doi.org/10.1074/jbc.M111862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11973330	hybrid			2022-12-25	WOS:000176611800090
J	Henderson, BR; Galea, M; Schuechner, S; Leung, L				Henderson, BR; Galea, M; Schuechner, S; Leung, L			Lymphoid enhancer factor-1 blocks adenomatous polyposis coli-mediated nuclear export and degradation of beta-catenin - Regulation by histone deacetylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR LEF-1; MALIGNANT-MELANOMA; GENE-EXPRESSION; DOWN-REGULATION; LOCALIZATION; ACTIVATION; CANCER; TRANSACTIVATION; TRANSFORMATION	The oncogenic protein beta-catenin is overexpressed in many cancers, frequently accumulating in nuclei where it forms active complexes with lymphoid enhancer factor-1 (LEF-1)/T-cell transcription factors, inducing genes such as c-myc and cyclin D1. In normal cells, nuclear beta-catenin levels are controlled by the adenomatous polyposis coli (APC) protein through nuclear export and cytoplasmic degradation. Transient expression of LEF-1 is known to increase nuclear beta-catenin levels by an unknown mechanism. Here, we show that A-PC and LEF-1 compete for nuclear beta-catenin with opposing consequences. APC can export nuclear beta-catenin to the cytoplasm for degradation. In contrast, LEF-1 anchors beta-catenin in the nucleus by blocking APC-mediated nuclear export. LEF-1 also prevented the APC/CRM1-independent nuclear export of beta-catenin as revealed by in vitro assays. Importantly, LEF-1-bound beta-catenin was protected from degradation by APC and axin in SW480 colon cancer cells. The ability of LEF-1 to trap beta-catenin in the nucleus was down-regulated by histone deacetylase 1, and this correlated with a decrease in LEF1 transcription activity. Our findings identify LEF-1 as key regulator of beta-catenin nuclear localization and stability and suggest that overexpression of LEF-1 in colon cancer and melanoma cells may contribute to the accumulation of oncogenic beta-catenin in the nucleus.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.		Galea, Melanie A/I-2236-2014					Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOVANES K, 2001, NAT GENET, V28, P53; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Neufeld KL, 2000, EMBO REP, V1, P519; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Orsulic S, 1999, J CELL SCI, V112, P1237; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SMITH KJ, 1994, CANCER RES, V54, P3672; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2	33	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24258	24264		10.1074/jbc.M110602200	http://dx.doi.org/10.1074/jbc.M110602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986304	hybrid			2022-12-25	WOS:000176611800038
J	Maeda, T; Mazzulli, JR; Farrance, IKG; Stewart, AFR				Maeda, T; Mazzulli, JR; Farrance, IKG; Stewart, AFR			Mouse DTEF-1 (ETFR-1, TEF-5) is a transcriptional activator in alpha(1)-adrenergic agonist-stimulated cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; PROTEIN-KINASE-C; HEAVY-CHAIN GENE; RAT-HEART MYOCYTES; M-CAT ELEMENTS; RECEPTOR STIMULATION; MULTIGENE FAMILY; FACTOR RTEF-1; DNA-BINDING; HYPERTROPHY	alpha(1)-Adrenergic signaling in cardiac myocytes activates the skeletal muscle alpha-actin gene through an MCAT cis-element, the binding site of the transcriptional enhancer factor-1 (TEF-1) family of transcription factors. TEF-1 accounts for more than 85% of the MCAT binding activity in neonatal rat cardiac myocytes. Other TEF-1 family members account for the rest. Although TEF-1 itself has little effect on the alpha(1)-adrenergic activation of skeletal muscle alpha-actin, the related factor RTEF-1 augments the response and is a target of alpha(1)-adrenergic signaling. Here, we examined another TEF-1 family member expressed in cardiac muscle, DTEF-1, and observed that it also augmented the alpha(1)-adrenergic response of skeletal muscle alpha-actin. A DTEF-1 peptide-specific antibody revealed that endogenous DTEF-1 accounts for up to 5% of the MCAT binding activity in neonatal rat cardiac myocytes. A TEF-1/DTEF-1 chimera suggests that alpha(1)-adrenergic signaling modulates DTEF-1 function. Orthophosphate labeling and immunoprecipitation of an epitope-tagged DTEF-1 showed that DTEF-1 is phosphorylated in vivo. alpha(1)-Adrenergic stimulation increased while phosphatase treatment lowered the MCAT binding by DTEF-1 and the endogenous non-TEF-1 MCAT-binding factor. In contrast, alpha(1)-adrenergic stimulation did not alter, and phosphatase treatment increased, MCAT binding of TEF-1 and RTEF-1. Taken together, these results suggest that DTEF-1 is a target for alpha(1)-adrenergic activation of the skeletal muscle alpha-actin gene in neonatal rat cardiac myocytes.	Univ Pittsburgh, Sch Med, Cardiovasc Inst, Pittsburgh, PA 15213 USA; Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Maryland; University of Maryland Baltimore	Stewart, AFR (corresponding author), Univ Pittsburgh, Sch Med, Cardiovasc Inst, BST 1704-3,200 Lothrop St, Pittsburgh, PA 15213 USA.		Stewart, Alexandre F.R./A-5677-2011	Stewart, Alexandre/0000-0003-2673-9164	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867, R29HL057211] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL57211, P01 HL27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aihara Y, 2000, HYPERTENSION, V36, P48, DOI 10.1161/01.HYP.36.1.48; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; Brunskill EW, 2001, DEV BIOL, V235, P507, DOI 10.1006/dbio.2001.0313; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; GUPTA MP, 1991, BIOCHEM BIOPH RES CO, V174, P1196, DOI 10.1016/0006-291X(91)91548-Q; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Jacquemin P, 1998, DEV DYNAM, V212, P423, DOI 10.1002/(SICI)1097-0177(199807)212:3<423::AID-AJA10>3.0.CO;2-1; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 1999, MOL ENDOCRINOL, V13, P879, DOI 10.1210/me.13.6.879; Jiang SW, 2001, J BIOL CHEM, V276, P23464, DOI 10.1074/jbc.M010934200; Kaneko KJ, 1997, DEVELOPMENT, V124, P1963; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V228, P365, DOI 10.1006/bbrc.1996.1667	37	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24346	24352		10.1074/jbc.M201171200	http://dx.doi.org/10.1074/jbc.M201171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986313	hybrid			2022-12-25	WOS:000176611800050
J	Meigs, TE; Fedor-Chaiken, M; Kaplan, DD; Brackenbury, R; Casey, PJ				Meigs, TE; Fedor-Chaiken, M; Kaplan, DD; Brackenbury, R; Casey, PJ			G alpha(12) and G alpha(13) negatively regulate the adhesive functions of cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; STRESS FIBER FORMATION; HETEROTRIMERIC G-PROTEINS; RHO-FAMILY GTPASES; BETA-CATENIN; ALPHA-SUBUNIT; CYTOPLASMIC DOMAIN; CARCINOMA-CELLS; PHOSPHOLIPASE-D; NIH3T3 CELLS	Cadherins function to promote adhesion between adjacent cells and play critical roles in such cellular processes as development, tissue maintenance, and tumor suppression. We previously demonstrated that heterotrimeric G proteins of the G(12) subfamily comprised of Galpha(12) and Galpha(13) interact with the cytoplasmic domain of cadherins and cause the release of the transcriptional activator beta-catenin (Meigs, T. E., Fields, T. A., McKee, D. D., and Casey, P. J. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 519-524). Because of the importance of beta-catenin in cadherin-mediated cell-cell adhesion, we examined whether G(12) subfamily proteins could also regulate cadherin function. The introduction of mutationally activated G(12) proteins into K562 cells expressing E-cadherin blocked cadherin-mediated cell adhesion in steady-state assays. Also, in breast cancer cells, the introduction of activated G(12) proteins blocked E-cadherin function in a fast aggregation assay. Aggregation mediated by a mutant cadherin that lacks G(12) binding ability was not affected by activated G(12) proteins, indicating a requirement for direct G(12)-cadherin interaction. Furthermore, in wound-filling assays in which ectopic expression of E-cadherin inhibits cell migration, the expression of activated G(12) proteins reversed the inhibition via a mechanism that was independent of G(12)-mediated Rho activation. These results validate the G(12)-cadherin interaction as a potentially important event in cell biology and suggest novel roles for G(12) proteins in the regulation of cadherin-mediated developmental events and in the loss of cadherin function that is characteristic of metastatic tumor progression.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Duke University; University System of Ohio; University of Cincinnati	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.			Kaplan, Daniel/0000-0001-8297-560X; Casey, Patrick/0000-0002-7366-9309; Brackenbury, Robert/0000-0002-1332-4018	NCI NIH HHS [CA91159] Funding Source: Medline; NIAMS NIH HHS [AR44713] Funding Source: Medline; NIGMS NIH HHS [GM55717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR044713, R01AR044713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055717, R55GM055717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; BRACKENBURY R, 1981, P NATL ACAD SCI-BIOL, V78, P387, DOI 10.1073/pnas.78.1.387; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen HY, 1997, J CELL SCI, V110, P345; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dermott JM, 2001, J CELL BIOCHEM, V81, P1; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLERNINCKX K, 1991, CELL, V66, P107; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	63	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24594	24600		10.1074/jbc.M201984200	http://dx.doi.org/10.1074/jbc.M201984200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976333	hybrid			2022-12-25	WOS:000176611800082
J	Wang, XT; Grammatikakis, N; Hu, JM				Wang, XT; Grammatikakis, N; Hu, JM			Role of p50/CDC37 in hepadnavirus assembly and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; HEPATITIS-B VIRUSES; HEAT-SHOCK-PROTEIN; KINASE-TARGETING SUBUNIT; DNA-SYNTHESIS; ENCAPSIDATION SIGNAL; RECEPTOR COMPLEXES; CHAPERONE COMPLEX; TYROSINE RESIDUE; HSP90	The cellular chaperone Hsp90 has been shown to associate with the reverse transcriptase (RT) of the duck hepatitis B virus and is required for RT functions. However, the molecular basis for the specific interaction between the RT and Hsp90 remains unknown. Comparison of protein compositional properties suggests that the RT is highly related to the protein kinase c-Raf, which interacts with Hsp90 via the cochaperone p50 (CDC37). We tested whether the RT, like c-Raf, is specifically recognized by p50. Immunoprecipitation and pull-down assays showed that p50 or p50deltaC, a p50 mutant defective in Hsp90 binding, could interact specifically with the RT both in vitro and in vivo, indicating that p50 can bind the RT independently of Hsp90. Furthermore, purified p50 and p50deltaC interacted directly with purified RT. The importance of p50-RT interaction for RT functions was underscored by 1) inhibition of protein-primed initiation of reverse transcription by p50deltaC in vitro and 2) stimulation of viral DNA replication and RNA packaging by p50 and their inhibition by p50deltaC in transfected cells. These results suggest that p50 can function as a cellular cofactor for the hepadnavirus RT by mediating the interaction between the RT and Hsp90.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	Boston University; Queens University - Canada	Hu, JM (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Rm R516,80 E Concord St, Boston, MA 02118 USA.		Hu, Jianming/A-6928-2009		NIAID NIH HHS [R01 AI43453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043453, R37AI043453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Fliss AE, 1997, MOL BIOL CELL, V8, P2501, DOI 10.1091/mbc.8.12.2501; Goes FS, 2001, EUR J BIOCHEM, V268, P2281, DOI 10.1046/j.1432-1327.2001.02105.x; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; HIRSCH RC, 1991, J VIROL, V65, P3309, DOI 10.1128/JVI.65.6.3309-3316.1991; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; Hu JM, 1997, SEMIN VIROL, V8, P205, DOI 10.1006/smvy.1997.0123; Hu JM, 1996, METHOD ENZYMOL, V275, P195; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hu JM, 2000, J VIROL, V74, P11447, DOI 10.1128/JVI.74.24.11447-11455.2000; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; JILBERT AR, 1992, J VIROL, V66, P1377, DOI 10.1128/JVI.66.3.1377-1388.1992; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; Kumar R, 2001, J BIOL CHEM, V276, P11371, DOI 10.1074/jbc.M010480200; LANFORD RE, 1995, J VIROL, V69, P4431, DOI 10.1128/JVI.69.7.4431-4439.1995; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Nassal M, 1996, J VIROL, V70, P2764, DOI 10.1128/JVI.70.5.2764-2773.1996; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PUGH JC, 1988, J VIROL, V62, P3513, DOI 10.1128/JVI.62.9.3513-3516.1988; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; Scholz GM, 2001, J BIOL CHEM, V276, P30971, DOI 10.1074/jbc.M103889200; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; SEEGER C, 1989, J VIROL, V63, P1907, DOI 10.1128/JVI.63.5.1907-1915.1989; SEEGER C, 1990, J VIROL, V64, P16, DOI 10.1128/JVI.64.1.16-23.1990; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 1997, METHOD ENZYMOL, V283, P220; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1994, J VIROL, V68, P8437, DOI 10.1128/JVI.68.12.8437-8442.1994; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; WU TT, 1991, J VIROL, V65, P2155, DOI 10.1128/JVI.65.5.2155-2163.1991; Yao EM, 2000, J VIROL, V74, P8648, DOI 10.1128/JVI.74.18.8648-8657.2000; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; YU MS, 1994, J VIROL, V68, P4341, DOI 10.1128/JVI.68.7.4341-4348.1994; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	54	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24361	24367		10.1074/jbc.M202198200	http://dx.doi.org/10.1074/jbc.M202198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986322	hybrid			2022-12-25	WOS:000176611800052
J	Fauconnet, S; Lascombe, I; Chabannes, E; Adessi, GL; Desvergne, B; Wahli, W; Bittard, H				Fauconnet, S; Lascombe, I; Chabannes, E; Adessi, GL; Desvergne, B; Wahli, W; Bittard, H			Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; ACID-BINDING PROTEIN; SMOOTH-MUSCLE-CELLS; PPAR-GAMMA; FATTY-ACIDS; GENE-EXPRESSION; HYPOLIPIDEMIC DRUGS; HUMAN GLIOBLASTOMA; URINARY-BLADDER; MESSENGER-RNA	The growth of any solid tumor depends on angiogenesis. Vascular endothelial growth factor (VEGF) plays a prominent role in vesical tumor angiogenesis regulation. Previous studies have shown that the peroxisome proliferator-activated receptor gamma (PPARgamma) was involved in the angiogenesis process. Here, we report for the first time that in two different human bladder cancer cell lines, RT4 (derived from grade I tumor) and T24 (derived from grade III tumor), VEGF (mRNA and protein) is differentially up-regulated by the three PPAR isotypes. Its expression is increased by PPARalpha, beta, and gamma in RT4 cells and only by PPARbeta in T24 cells via a transcriptional activation of the VEGF promoter through an indirect mechanism. This effect is potentiated by an RXR (retinoid-X-receptor), selective retinoid LG10068 providing support for a PPAR agonist-specific action on VEGF expression. While investigating the downstream signaling pathways involved in PPAR agonist-mediated up-regulation of VEGF, we found that only the MER inhibitor PD98059 reduced PPAR ligand-induced expression of VEGF. These data contribute to a better understanding of the mechanisms by which PPARs regulate VEGF expression. They may lead to a new therapeutic approach to human bladder cancer in which excessive angiogenesis is a negative prognostic factor.	Ctr Hosp Univ Jean Minjoz, Serv Urol & Androl, Hop St Jacques, F-25000 Besancon, France; Ctr Hosp Univ Jean Minjoz, INSERM, F-25000 Besancon, France; Ctr Hosp Univ Jean Minjoz, Serv Endocrinol & Oncol Mol, F-25000 Besancon, France; Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland	Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; University of Lausanne	Bittard, H (corresponding author), Ctr Hosp Univ Jean Minjoz, Serv Urol & Androl, Hop St Jacques, 2 Pl St Jacques, F-25000 Besancon, France.	urologie@chu-besancon.fr	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; Auwerx J, 1999, CELL, V97, P161; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Bernardini S, 2001, J UROLOGY, V166, P1275, DOI 10.1016/S0022-5347(05)65752-7; BROWN LF, 1993, AM J PATHOL, V143, P1255; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; Celis JE, 1996, CANCER RES, V56, P4782; Chabannes E, 2001, CELL SIGNAL, V13, P585, DOI 10.1016/S0898-6568(01)00184-X; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Crew JP, 1999, J UROLOGY, V161, P799, DOI 10.1016/S0022-5347(01)61772-5; Crew JP, 1997, CANCER RES, V57, P5281; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Diep QN, 2000, HYPERTENSION, V36, P851, DOI 10.1161/01.HYP.36.5.851; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FRIEDELL GH, 1983, PATHOLOGY BLADDER CA, V1, P11; Fujimoto J, 1998, CANCER LETT, V134, P15, DOI 10.1016/S0304-3835(98)00232-8; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jones A, 2001, CLIN CANCER RES, V7, P1263; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVI F, 1993, INT J CANCER, V55, P419, DOI 10.1002/ijc.2910550316; Michalik L, 2002, INT J DEV BIOL, V46, P105; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Miyake H, 1999, UROLOGY, V53, P302, DOI 10.1016/S0090-4295(98)00486-5; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OBRIEN T, 1995, CANCER RES, V55, P510; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PAULI BU, 1983, PATHOLOGY BLADDER CA, V2, P41; Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	64	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23534	23543		10.1074/jbc.M200172200	http://dx.doi.org/10.1074/jbc.M200172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980898	hybrid			2022-12-25	WOS:000176475700058
J	Hieta, R; Myllyharju, J				Hieta, R; Myllyharju, J			Cloning and characterization of a low molecular weight prolyl 4-hydroxylase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DISULFIDE-ISOMERASE SUBUNIT; SITE-DIRECTED MUTAGENESIS; CELL WALL PROTEINS; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; PROLINE HYDROXYLATION; BETA-SUBUNIT; PHASEOLUS-VULGARIS; HISTIDINE-RESIDUES	4-Hydroxyproline is found in collagens and collagen-like proteins in animals and in many glycoproteins in plants. Animal prolyl 4-hydroxylases (P4Hs) have been cloned and characterized from many sources, but no plant P4H has been cloned so far. We report here that the genome of Arabidopsis thaliana encodes six P4H-like polypeptides, one of which, a 283-residue soluble monomer, was cloned and characterized here as a recombinant protein. Catalytically critical residues identified in animal P4Hs are conserved in this P4H, and their mutagenesis led to complete or almost complete inactivation. The recombinant P4H effectively hydroxylated poly(L-proline) and many synthetic peptides corresponding to proline-rich repeats present in plant glycoproteins and other proteins. Surprisingly, collagen-like peptides were also good substrates, the V-max with (Pro-Pro-Gly)(10) being similar to that with poly(L-proline). The enzyme acted in this peptide preferentially on prolines in Y positions in the X-Y-Gly triplets. Correspondingly, (Gly-Pro-4Hyp)(5) and (ProAla-Gly)(5) were poor substrates, with V-max values less than 5 and 20% of that obtained with (Pro-Pro-Gly)(10), respectively, the K-m for the latter also being high. Peptides representing the N- and C-terminal hydroxylation sites present in hypoxia-inducible transcription factor a also served as substrates. As these peptides contain only one proline residue, a poly(L-proline) type II conformation was clearly not required for hydroxylation.	Univ Oulu, Dept Biochem & Mol Biol, FIN-90014 Oulu, Finland; Bioctr Oulu, Collagen Res Unit, Oulu, Finland	University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Dept Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.			Hieta, Reija/0000-0001-5724-6253				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; BERG RA, 1977, BIOCHEMISTRY-US, V16, P1615, DOI 10.1021/bi00627a014; BOLWELL GP, 1985, BIOCHEM J, V229, P693, DOI 10.1042/bj2290693; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; COHEN PB, 1983, PLANT PHYSIOL, V72, P754, DOI 10.1104/pp.72.3.754; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HPAK E, 2001, J BIOL CHEM, V276, P11272; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KASKA DD, 1987, BIOCHEM J, V241, P483, DOI 10.1042/bj2410483; KASKA DD, 1988, BIOCHEM J, V256, P257, DOI 10.1042/bj2560257; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1969, J BIOL CHEM, V244, P2755; KIVIRIKKO KI, 1971, BIOCHEM BIOPH RES CO, V45, P1591, DOI 10.1016/0006-291X(71)90203-8; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; SADAVA D, 1971, BIOCHIM BIOPHYS ACTA, V227, P278, DOI 10.1016/0005-2744(71)90060-X; SAUER A, 1985, PLANTA, V164, P287, DOI 10.1007/BF00396094; Serpe MD, 1999, ADV BOT RES, V30, P207; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Sommer-Knudsen J, 1998, PHYTOCHEMISTRY, V47, P483, DOI 10.1016/S0031-9422(97)00724-3; TANAKA M, 1981, J BIOL CHEM, V256, P1397; TANAKA M, 1980, BIOCHIM BIOPHYS ACTA, V616, P188, DOI 10.1016/0005-2744(80)90137-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Wojtaszek P, 1999, INT J BIOCHEM CELL B, V31, P463, DOI 10.1016/S1357-2725(98)00126-5	51	92	97	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23965	23971		10.1074/jbc.M201865200	http://dx.doi.org/10.1074/jbc.M201865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976332	hybrid			2022-12-25	WOS:000176475700112
J	Jelenska, J; Sirikhachornkit, A; Haselkorn, R; Gornicki, P				Jelenska, J; Sirikhachornkit, A; Haselkorn, R; Gornicki, P			The carboxyltransferase activity of the apicoplast acetyl-CoA carboxylase of Toxoplasma gondii is the target of aryloxyphenoxypropionate inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PLASMODIUM-FALCIPARUM; APICOMPLEXA; RESISTANCE; HERBICIDES; PATHWAY; GROWTH; DOMAIN	Inhibition of growth of the apicomplexan parasite Toxoplasma gondii by aryloxyphenoxypropionate herbicides has been correlated with the inhibition of its acetyl-CoA carboxylase (ACC) by these compounds. Here, full-length and C-terminal fragments of T. gondii apicoplast ACC as well as C-terminal fragments of the cytosolic ACC were expressed in Escherichia coli. The recombinant proteins that were soluble showed the expected enzymatic activities. Yeast gene-replacement strains depending for growth on the expressed T. gondii ACC were derived by complementation of a yeast ACC1 null mutation. In vitro and in vivo tests with noxyphenoxypropionates showed that the carboxyltransferase domain of the apicoplast T. gondii ACC is the target for this class of inhibitors. The cytosolic T. gondii ACC is resistant to aryloxyphenoxypropionates. Both T. gondii isozymes are resistant to cyclohexanediones, another class of inhibitors targeting the ACC of grass plastids.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Gornicki, P (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.							Devine MD, 1997, PESTIC SCI, V51, P259, DOI 10.1002/(SICI)1096-9063(199711)51:3&lt;259::AID-PS644&gt;3.0.CO;2-S; Devine MD, 2000, CROP PROT, V19, P881, DOI 10.1016/S0261-2194(00)00123-X; Gleeson MT, 2000, INT J PARASITOL, V30, P1053, DOI 10.1016/S0020-7519(00)00100-4; GORNICKI P, 1993, PLANT MOL BIOL, V22, P547, DOI 10.1007/BF00015984; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; Herbert D, 1997, PESTIC SCI, V50, P67, DOI 10.1002/(SICI)1096-9063(199705)50:1&lt;67::AID-PS552&gt;3.0.CO;2-#; Incledon BJ, 1997, PESTIC BIOCHEM PHYS, V57, P255, DOI 10.1006/pest.1997.2279; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Joachimiak M, 1997, P NATL ACAD SCI USA, V94, P9990, DOI 10.1073/pnas.94.18.9990; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kozaki A, 2000, J BIOL CHEM, V275, P10702, DOI 10.1074/jbc.275.14.10702; Macreadie I, 2000, PARASITOL TODAY, V16, P438, DOI 10.1016/S0169-4758(00)01758-0; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; Nikolskaya T, 1999, P NATL ACAD SCI USA, V96, P14647, DOI 10.1073/pnas.96.25.14647; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1997, MICROBIOL MOL BIOL R, V61, P1; Zagnitko O, 2001, P NATL ACAD SCI USA, V98, P6617, DOI 10.1073/pnas.121172798; Zuther E, 1999, P NATL ACAD SCI USA, V96, P13387, DOI 10.1073/pnas.96.23.13387	21	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23208	23215		10.1074/jbc.M200455200	http://dx.doi.org/10.1074/jbc.M200455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980900	hybrid			2022-12-25	WOS:000176475700016
J	Lellek, H; Welker, S; Diehl, I; Kirsten, R; Greeve, J				Lellek, H; Welker, S; Diehl, I; Kirsten, R; Greeve, J			Reconstitution of mRNA editing in yeast using a Gal4-ApoB-Gal80 fusion transcript as the selectable marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE DEAMINASE AID; APOBEC-1 COMPLEMENTATION FACTOR; MOLECULAR-CLONING; CATALYTIC SUBUNIT; PROTEIN; ENZYME; HYPERMUTATION; GENE; IDENTIFICATION; EXPRESSION	We describe a fusion transcript of Gal4 linked to its specific inhibitor protein Gal80 by 276 nucleotides of apolipoprotein (apo) B sequence as a selectable marker for mRNA editing. Editing of apoB mRNA is catalyzed by an editing enzyme complex that introduces a stop codon by deamination of C to U. The catalytic subunit APOBEC-1 is a cytidine deaminase and requires a second essential component recently cloned and termed APOBEC-1 complementing factor (ACF) or APOBEC-1-stimulating protein (ASP). The aim of this study was to demonstrate that APOBEC-1 plus ACF/ASP comprise all that is required for editing of apoB mRNA in vivo. Expression of APOBEC-l and Gal4 fused to its inhibitor Gal80 by an intervening unedited apoB sequence (Gal4-apoB(C)-Gal80) did not result in the Gal4-dependent expression of HIS3 and beta-galactosidase in the yeast strain CG1945. Co-expression of APOBEC-1 and ACF/ASP induced editing of the apoB site in up to 13% of the Gal4-apoB(C)-Gal80 transcripts and enabled selection of yeast cells for robust expression of HIS3 and beta-galactosidase. Additional expression of the alternative splicing regulatory protein KSRP increased the editing of the apoB site by APOBEC-1 and ACF/ASP to 21%. Thus, APOBEC-1 and ACF/ASP represent the core apoB mRNA editing enzyme in vivo. This study demonstrates for the first time the successful use of a selectable marker for mRNA editing. The Ga14-Gal80 system is analogous to the two-hybrid assay and may have broader applications for the study of other mRNA processing reactions.	Univ Klinikum Hamburg Eppendorf, Kernklin & Poliklin, Klin & Poliklin Innere Med, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Greeve, J (corresponding author), Univ Klinikum Hamburg Eppendorf, Kernklin & Poliklin, Klin & Poliklin Innere Med, Martinstr 52, D-20246 Hamburg, Germany.	greeve@uke.uni-hamburg.de						Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Dance GSC, 2002, J BIOL CHEM, V277, P12703, DOI 10.1074/jbc.M111337200; Dance GSC, 2000, NUCLEIC ACIDS RES, V28, P424, DOI 10.1093/nar/28.2.424; Dance GSC, 2001, NUCLEIC ACIDS RES, V29, P1772, DOI 10.1093/nar/29.8.1772; Greeve J, 1996, J LIPID RES, V37, P2001; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GREEVE J, 1993, J LIPID RES, V34, P1367; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Henderson JO, 2001, BBA-GENE STRUCT EXPR, V1522, P22, DOI 10.1016/S0167-4781(01)00295-0; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Tian M, 2000, NATURE, V407, P31, DOI 10.1038/35024189; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	37	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23638	23644		10.1074/jbc.M203517200	http://dx.doi.org/10.1074/jbc.M203517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976346	hybrid			2022-12-25	WOS:000176475700070
J	Osada, M; Imaoka, S; Sugimoto, T; Hiroi, T; Funae, Y				Osada, M; Imaoka, S; Sugimoto, T; Hiroi, T; Funae, Y			NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; B-CELL LINES; PROLINE HYDROXYLATION; DIPHENYLENE IODONIUM; PROLYL HYDROXYLATION; HUMAN ERYTHROPOIETIN; CARBON-MONOXIDE	Hypoxia induces a group of physiologically important genes that include erythropoietin (EPO) and vascular endothelial growth factor (VEGF). Hypoxia-inducible factor 1 (HIF-1) was identified as a hypoxia-activated transcription factor; however, the molecular mechanisms that underlie hypoxia signal transduction in mammalian cells remain undefined. In this study, we found that a flavoprotein, NADPH-P450 reductase (NPR), could regulate the induction of EPO mRNA under hypoxic conditions. Hypoxic EPO mRNA induction in Hep3B cells was inhibited by diphenyleneiodonium. chloride, which is an inhibitor of NADPH-dependent enzymes. NPR antisense cDNA was transfected into Hep3B cells, and NPR-deficient hepatocyte cells (NPR- cells) were established. NPR- cells lacked EPO induction under hypoxia, and HIF-1alpha in NPR- cells did not respond to either transcriptional activation or translocation to the nucleus based on electrophoretic mobility shift assays and reporter gene assay including hypoxia response element. In contrast, NPR overexpression in Hep3B cells enhanced the DNA binding activity of HIF-1alpha by luciferase reporter gene assay. A study with HeLa S3 cells produced the same results. Furthermore, anti-NPR IgG inhibited EPO induction. EPO induction inhibited by diphenyleneiodonium chloride was recovered by bovine serum albumin-NADPH (a covalent binding complex of bovine serum albumin and NADPH) as well as NADPH. These results suggested that NPR located at the plasma membrane regulates EPO expression in hypoxia, including HIF-1 activation and translocation. We further studied the expression of NPR and VEGF mRNAs in human tumor tissues and found that the NPR mRNA levels were correlated with the VEGF mRNA levels, suggesting that NPR might be an important factor in the hypoxic induction of genes such as VEGF in vivo.	Osaka City Univ, Sch Med, Dept Chem Biol, Abeno Ku, Osaka 5458585, Japan; Osaka City Gen Hosp, Miyakojima Ku, Osaka 5340021, Japan	Osaka Metropolitan University; Osaka City General Hospital	Imaoka, S (corresponding author), Kwansei Gakuin Univ, Sch Sci & Technol, 2-1 Gakuen, Sanda 6691337, Japan.	imaoka@ksc.kwansei.ac.jp						ACKER H, 1994, RESP PHYSIOL, V95, P1, DOI 10.1016/0034-5687(94)90043-4; Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FUNAE Y, 1987, BIOCHIM BIOPHYS ACTA, V926, P349, DOI 10.1016/0304-4165(87)90221-2; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GORLACH A, 1993, BIOCHEM J, V290, P771; Harder DR, 1996, CIRC RES, V79, P54, DOI 10.1161/01.RES.79.1.54; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Imaoka S, 1997, BIOCHEM PHARMACOL, V54, P677, DOI 10.1016/S0006-2952(97)00216-5; IMAOKA S, 1990, ARCH BIOCHEM BIOPHYS, V278, P168, DOI 10.1016/0003-9861(90)90245-T; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li D, 2001, J UROLOGY, V166, P2500, DOI 10.1016/S0022-5347(05)65624-8; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; MALY FE, 1988, J IMMUNOL, V140, P2334; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; ZOU AP, 1994, AM J PHYSIOL, V266, pF275, DOI 10.1152/ajprenal.1994.266.2.F275	44	33	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23367	23373		10.1074/jbc.M112413200	http://dx.doi.org/10.1074/jbc.M112413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971899	hybrid			2022-12-25	WOS:000176475700036
J	Huff, T; Otto, AM; Muller, CSG; Meier, M; Hannappel, E				Huff, T; Otto, AM; Muller, CSG; Meier, M; Hannappel, E			Thymosin beta(4) is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen	FASEB JOURNAL			English	Article						beta-thymosins; cross-linking; actin	ACTIN-SEQUESTERING PEPTIDE; ENDOTHELIAL-CELLS; BETA-4; INHIBITION; CANCER; SPLEEN; GENE	The beta-thymosins constitute a family of highly conserved and extremely water-soluble 5 kDa polypeptides. Thymosin beta(4) is the most abundant member; it is expressed in most cell types and is regarded as the main intracellular G-actin sequestering peptide. There is increasing evidence for extracellular functions of thymosin beta(4). For example, thymosin beta(4) increases the rate of attachment and spreading of endothelial cells on matrix components and stimulates the migration of human umbilical vein endothelial cells. Here we show that thymosin beta(4) can be cross-linked to proteins such as fibrin and collagen by tissue transglutaminase. Thymosin beta(4) is not cross-linked to many other proteins and its cross-linking to fibrin is competed by another family member, thymosin beta(10). After activation of human platelets with thrombin, thymosin beta(4) is released and crosslinked to fibrin in a time- and calcium-dependent manner. We suggest that thymosin beta(4) cross-linking is mediated by factor XIIIa, a transglutaminase that is coreleased from stimulated platelets. This provides a mechanism to increase the local concentration of thymosin beta(4) near sites of clots and tissue damage, where it may contribute to wound healing, angiogenesis and inflammatory responses.	Univ Erlangen Nurnberg, Fac Med, Inst Biochem, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Huff, T (corresponding author), Univ Erlangen Nurnberg, Fac Med, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	thymosin@biochem.uni-erlangen.de						Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; GRANT DS, 1995, J CELL SCI, V108, P3685; HANNAPPEL E, 1985, ARCH BIOCHEM BIOPHYS, V240, P236, DOI 10.1016/0003-9861(85)90028-1; HANNAPPEL E, 1993, BIOL CHEM H-S, V374, P117, DOI 10.1515/bchm3.1993.374.1-6.117; HANNAPPEL E, 1989, ARCH BIOCHEM BIOPHYS, V273, P396, DOI 10.1016/0003-9861(89)90498-0; HANNAPPEL E, 1987, J CHROMATOGR, V397, P279, DOI 10.1016/S0021-9673(01)85010-X; HANNAPPEL E, 1988, ARCH BIOCHEM BIOPHYS, V260, P546, DOI 10.1016/0003-9861(88)90480-8; HEINTZ D, 1993, FEBS LETT, V329, P9, DOI 10.1016/0014-5793(93)80181-S; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; HUFF T, 1995, EUR J BIOCHEM, V230, P650; Huff T, 1999, FEBS LETT, V464, P14, DOI 10.1016/S0014-5793(99)01670-1; Huff T, 1997, ANAL CHIM ACTA, V352, P239, DOI 10.1016/S0003-2670(97)00133-5; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; XU GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4006, DOI 10.1073/pnas.79.13.4006; Young JD, 1999, NAT MED, V5, P1424; YU FX, 1993, J BIOL CHEM, V268, P502	25	81	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0691	10.1096/fj.01-0713com	http://dx.doi.org/10.1096/fj.01-0713com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978733				2022-12-25	WOS:000175973900023
J	Wang, DG; Patil, S; Li, WH; Humphrey, LE; Brattain, MG; Howell, GM				Wang, DG; Patil, S; Li, WH; Humphrey, LE; Brattain, MG; Howell, GM			Activation of the TGF alpha autocrine loop is downstream of IGF-1 receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells	ONCOGENE			English	Article						colon carcinoma; autocrine transforming growth factor alpha; insulin growth factor-1 receptor; IGF-1R competence factor; growth factor dependence	FACTOR-I RECEPTOR; DIFFERENTIAL REGULATION; GENE-EXPRESSION; TRANSGENIC MICE; EGF RECEPTOR; C-MYC; TRANSCRIPTION; REQUIREMENTS; GLUCOSAMINE; KINASE	The inappropriate expression of TGFalpha in growth arrest contributes to malignant progression in human colon carcinoma cells. Early stage, non-progressed colon tumor cells show a down-regulation of TGFalpha in growth arrest and require both nutrients and growth factors for re-entry into the cell cycle. In contrast, highly progressed cells up-regulate TGFalpha during growth arrest and require only nutrients for re-entry. Given the importance of TGFalpha in malignant progression, this work addressed the regulation of TGFalpha expression in the early stage colon carcinoma cell line, FET. Growth-arrested FET cells down-regulated the expression of TGFalpha, EGFr and, in turn, EGFr activation. These quiescent cells continued to express high levels of IGF-IR protein, but IGF-IR activation was undetectable. Cell cycle re-entry required exogenous growth factor activation of the IGF-IR by insulin or IGF-I. This IGF-IR activation resulted in S phase re-entry and was accompanied by an approximate threefold induction of TGFalpha expression along with EGFr activation at 1 h following release from growth arrest. Activation of IGF-IR occurred within 5 min of cell-cycle re-entry. Previously identified DNA binding proteins which bind to a unique TGFalpha/EGF response element within the TGFalpha promoter were similarly induced following IGF-IR activation. The addition of EGFr neutralizing antibodies abolished the activated IGF-IR stimulated S phase re-entry. Moreover, disruption of the growth arrest associated down-regulation of TGFalpha in FET cells by constitutive TGFalpha expression abrogated the requirement for IGF-IR activation for cell cycle re-entry. Consequently, this study indicates, for the first time, that IGF-IR activation up-regulates components of the TGFalpha autocrine loop resulting in TGFalpha-mediated EGFr activation which was critical for IGF-IR mediated re-entry into the cell cycle from the growth-arrested state.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	Roswell Park Cancer Institute	Howell, GM (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	gillian.howell@roswellpark.org			NCI NIH HHS [CA54870, CA34432] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P707; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MULDER KM, 1991, CANCER RES, V51, P2256; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; ROOS MD, 1996, AM J PHYSIOL, V270, P803; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TANAKA S, 1991, AM J PATHOL, V139, P123; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	43	35	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2785	2796		10.1038/sj.onc.1205375	http://dx.doi.org/10.1038/sj.onc.1205375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973637				2022-12-25	WOS:000175063700002
J	Yang, C; Yu, B; Zhou, DJ; Chen, SA				Yang, C; Yu, B; Zhou, DJ; Chen, SA			Regulation of aromatase promoter activity in human breast tissue by nuclear receptors	ONCOGENE			English	Article						aromatase; gene regulation; nuclear receptors; breast cancer	ESTROGEN-RELATED RECEPTOR; CYTOCHROME-P450 GENE-EXPRESSION; ORPHAN RECEPTORS; TRANSCRIPTION FACTOR; RESPONSE ELEMENTS; MESSENGER-RNA; UPSTREAM; BINDING; ALPHA; ARP-1	Using the yeast one-hybrid approach to screen a human breast tissue hybrid cDNA expression library, we have found that four orphan/nuclear receptors, ERRalpha-1, EAR-2, COUP-TFI (EAR-3), and RARgamma, bind to the silencer (SI) region of the human aromatase gene. S1 down regulates promoters 1.3 and 11 of the human aromatase gene. In this study, the interaction of EAR-2, COUP-TFI, and RARgamma with SI was confirmed by DNA mobility shift analysis. In contrast to the findings that ERRalpha-1 behaves as a positive regulatory factor, these three nuclear receptors were found, by, mammalian cell transfection experiments, to act as negative regulatory factors by binding to SI. Furthermore, the negative action of these three nuclear receptors could override the positive effect of ERRalpha-1. RT-PCR analysis of 11 cell lines and 55 human breast tumor specimens has shown that these nuclear receptors are expressed in human breast tissue. Since EAR-2, COUP-TFI, and RARgamma are expressed at high levels, it is likely that SI is a negative regulatory element that suppresses aromatase promoters 1.3 and 11 in normal breast tissue. In cancer tissue, SI may function as a positive element since ERRYalpha-1 is expressed, but EAR-2 and RARgamma are only present in a small number of tumor specimens. This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue. Our studies have revealed that estrogen receptor alpha (ERalpha) can also bind to SI, in a ligand-dependent manner. By binding to S1, ERalpha down-regulates the aromatase promoter activity. These results demonstrate that nuclear receptors play important roles in modulating aromatase expression in human breast tissue.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Chen, SA (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	schen@coh.org			NCI NIH HHS [CA44735, CA65767] Funding Source: Medline; NIEHS NIH HHS [ES08258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bulun SE, 1997, J STEROID BIOCHEM, V61, P133; CHOMCZYMSKI P, 1998, CURRENT PROTOCOLS MO, V1; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Harada N, 1997, J STEROID BIOCHEM, V61, P175; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kao YC, 1996, CANCER RES, V56, P3451; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; Nakamura J, 1999, J CLIN ENDOCR METAB, V84, P1432, DOI 10.1210/jc.84.4.1432; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGEL IH, 1976, BIOCH CALCULATIONS, P218; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vorgia P, 1998, J BIOL CHEM, V273, P4188, DOI 10.1074/jbc.273.7.4188; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454; Zhou DJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P213, DOI 10.1006/abbi.1998.0641; Zhou DJ, 2000, MOL ENDOCRINOL, V14, P986, DOI 10.1210/me.14.7.986; ZHOU F, 1995, P NATL ACAD SCI USA, V92, P8586; 周茂堂, 1993, Chinese Journal of Polymer Science, V11, P46	36	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2854	2863		10.1038/sj.onc.1205386	http://dx.doi.org/10.1038/sj.onc.1205386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973645				2022-12-25	WOS:000175063700010
J	Satoh, M; Toma, H; Sugahara, K; Etoh, K; Shiroma, Y; Kiyuna, S; Takara, M; Matsuoka, M; Yamaguchi, K; Nakada, K; Fujita, K; Kojima, S; Hori, E; Tanaka, Y; Kamihira, S; Sato, Y; Watanabe, T				Satoh, M; Toma, H; Sugahara, K; Etoh, K; Shiroma, Y; Kiyuna, S; Takara, M; Matsuoka, M; Yamaguchi, K; Nakada, K; Fujita, K; Kojima, S; Hori, E; Tanaka, Y; Kamihira, S; Sato, Y; Watanabe, T			Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S-stercoralis	ONCOGENE			English	Article						HTLV-1 provirus load; clonality; S. stercoralis antigen; IL-2; ATL	VIRUS TYPE-I; BLOOD MONONUCLEAR-CELLS; LEUKEMIA-VIRUS; PROVIRAL DNA; MONOCLONAL INTEGRATION; CLONAL PROLIFERATION; GENE-EXPRESSION; INFECTED-CELLS; INTERLEUKIN-2; LINES	The intermediate state of HTLV-1 infection, often found in individuals dually infected with Strongyloides stercoralis (S. stercoralis) and HTLV-1. is assumed to be a preleukemic state of adult T-cell leukemia (ATL). To investigate the effects of S. stercoralis superinfection on the natural history of HTLV-1 infection, we characterized peripheral blood samples of these individuals in Okinawa. Japan, an endemic area for both HTLV-1 and S. stercoralis and we studied effects of the parasite antigen on T-cells. The dually infected individuals showed a significantly higher provirus load and an increase in CD4(+)25(+) T cell population, with a significant, positive correlation. This increase was attributable to polyclonal expansion of HTLV-1-infected cells, as demonstrated by inverse-long PCR analysis of the integration sites. S. stercoralis antigen activated the IL-2 promoter in reporter gene assays, induced production of IL-2 by PBMC in vitro, and supported growth of IL-2 dependent cell lines immortalized by HTLV-1 infection or the transduction of Tax. Taken collectively, these results indicate that S. stercoralis infection induces polyclonal expansion of HTLV-1-infected cells by activating the IL-2/IL-2R system in dually infected carriers, an event which may be a precipitating factor for ATL and inflammatory diseases.	Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan; Saitama Med Sch, Dept Med Zool, Moroyama, Saitama, Japan; Ryukoku Univ, Sch Med, Dept Parasitol, Okinawa, Japan; Nagasaki Univ, Sch Med, Dept Lab Med, Nagasaki 852, Japan; Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 860, Japan; Izumizaki Hosp, Okinawa, Japan; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Gushikawa Clin, Okinawa, Japan; Kumamoto Univ, Sch Med, Blood Transfus Serv, Kumamoto 8608556, Japan; Okinawa Kyodo Hosp, Okinawa, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Med Zool, Tokyo 113, Japan; Univ Tokyo, Inst Med Sci, Dept Parasitol, Tokyo, Japan; Univ Ryukyus, Fac Med, Okinawa Asia Res Ctr Med Sci, Dept Infect Dis & Immunol, Okinawa, Japan	University of Tokyo; Saitama Medical University; Ryukoku University; Nagasaki University; Kumamoto University; Kyoto University; Kumamoto University; Tokyo Medical & Dental University (TMDU); University of Tokyo; University of the Ryukyus	Watanabe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tnabe@ims.u-tokyo.ac.jp		Matsuoka, Masao/0000-0002-0473-754X				AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Arakaki T., 1988, Japanese Journal of Tropical Medicine and Hygiene, V16, P11; BLANK A, 1993, LEUKEMIA LYMPHOMA, V9, P407, DOI 10.3109/10428199309148542; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Etoh K, 1997, CANCER RES, V57, P4862; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJITA K, 1985, Tropical Medicine, V27, P203; FURUKAWA Y, 1992, BLOOD, V80, P1012; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GREENBERG SJ, 1989, J INFECT DIS, V159, P741, DOI 10.1093/infdis/159.4.741; Grove DI, 1996, ADV PARASIT, V38, P251, DOI 10.1016/S0065-308X(08)60036-6; HATTORI T, 1981, BLOOD, V58, P645; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P816, DOI 10.1212/WNL.38.5.816; Kamihira S, 2000, INT J HEMATOL, V72, P79; Kreuzer KA, 1999, CANCER RES, V59, P3171; LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2; LANGRIDGE WHR, 1987, METHOD ENZYMOL, V153, P336; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943; Mori N, 2000, BLOOD, V95, P3915; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NAKADA K, 1984, LANCET, V1, P633; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; NEVA FA, 1986, J INFECT DIS, V153, P397, DOI 10.1093/infdis/153.3.397; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Ono A, 1998, JPN J CANCER RES, V89, P608, DOI 10.1111/j.1349-7006.1998.tb03262.x; ONO A, 1995, BRIT J OPHTHALMOL, V79, P270, DOI 10.1136/bjo.79.3.270; OSAME M, 1986, LANCET, V1, P1031; PATEY O, 1992, AIDS, V6, P575, DOI 10.1097/00002030-199206000-00009; PLUMELLE Y, 1993, HEMATOL PATHOL, V7, P251; SATO Y, 1990, Japanese Journal of Parasitology, V39, P213; SATO Y, 1989, CLIN IMMUNOL IMMUNOP, V53, P430, DOI 10.1016/0090-1229(89)90005-6; SATO Y, 1985, T ROY SOC TROP MED H, V79, P51, DOI 10.1016/0035-9203(85)90233-0; SATOH M, 1991, INT ARCH ALLER A IMM, V96, P95, DOI 10.1159/000235541; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; TAJIMA K, 1986, HEMATOL ONCOL, V4, P31, DOI 10.1002/hon.2900040106; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TATEWAKI M, 1995, BLOOD, V86, P3109; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; Watanabe T, 1997, INT J HEMATOL, V66, P257; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA K, 1993, AM J OPHTHALMOL, V116, P156, DOI 10.1016/S0002-9394(14)71279-6	59	57	59	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2466	2475		10.1038/sj.onc.1205329	http://dx.doi.org/10.1038/sj.onc.1205329			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971181				2022-12-25	WOS:000174918400003
J	Babinski, KJ; Kanjilal, SJ; Raetz, CRH				Babinski, KJ; Kanjilal, SJ; Raetz, CRH			Accumulation of the lipid A precursor UDP-2,3-diacylglucosamine in an Escherichia coli mutant lacking the lpxH gene.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; GRAM-NEGATIVE ENDOTOXIN; AGROBACTERIUM-TUMEFACIENS C58; CDP-DIGLYCERIDE HYDROLASE; PURPLE ACID-PHOSPHATASE; X-RAY STRUCTURE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BIOSYNTHESIS; PROTEIN	The lpxH gene encodes the UDP-2,3-diacylglucosamine-specific pyrophosphatase that catalyzes the fourth step of lipid A biosynthesis in Escherichia coli. To confirm the function of lpxH, we constructed KB321/pKJB5. This strain contains a kanamycin insertion element in the chromosomal copy of lpxH, complemented by plasmid pKJB5, which is temperature-sensitive for replication and harbors lpxH(+). KB21/pKJB5 grows at 30 degreesC but loses viability at 44 degreesC, demonstrating that lpxH is essential. CDP-diglyceride hydrolase (Cdh) catalyzes the same reaction as LpxH in vitro but is nonessential and cannot compensate for the absence of LpxH. The presence of Cdh in cell extracts interferes with the LpxH assay. We therefore constructed KB25/ pKJB5, which contains both an in-frame deletion of cdh and a kanamycin insertion mutation in lpxH, covered by pKJB5. When KB25/pKJB5 cells are grown at 44 degreesC, viability is lost, and all in vitro LpxH activity is eliminated. A lipid migrating with synthetic UDP-2,3-diacylglucosamine accumulates in KB25/pKJB5 following loss of the covering plasmid at 44 degreesC. This material was converted to the expected products, 2,3-diacylglucosamine 1-phosphate and UMP, by LpxH. Pseudomonas aeruginosa contains two proteins with sequence similarity to E. coli LpxH. The more homologous protein catalyzes UDP-2,3-diacylglucosamine hydrolysis in vitro. The corresponding gene complements YB25/pKJB5 at 44 degreesC, but the less homologous gene does not. The accumulation of UDP-2,3-diacylglucosamine in our lpxH mutant is consistent with the observation that the lipid A disaccharide synthase LpxB, the next enzyme in the pathway, cannot condense two UDP-2,3-diacylglucosamine molecules, but instead utilizes UDP-2,3-diacylglucosamine as its donor and 2,3-diacylglucosamine 1-phosphate as its acceptor.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.				NIGMS NIH HHS [GM-51310, GM07184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Babinski KJ, 2002, J BIOL CHEM, V277, P25937, DOI 10.1074/jbc.M204067200; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H., 1999, ENDOTOXIN HLTH DIS; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BULAWA CE, 1984, J BIOL CHEM, V259, P1257; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; GANONG BR, 1980, J BIOL CHEM, V255, P1623; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; ICHO T, 1985, J BIOL CHEM, V260, P2092; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; JOHZUKA K, 1995, GENETICS, V139, P1521; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Miller J.H., 1972, EXPT MOL GENETICS; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1972, J BIOL CHEM, V247, P2245; RAETZ CRH, 1976, J BACTERIOL, V125, P855, DOI 10.1128/JB.125.3.855-863.1976; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rusnak F, 1996, J BIOL INORG CHEM, V1, P388, DOI 10.1007/s007750050070; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Sambrook J., 2002, MOL CLONING LAB MANU; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; TAVASSOLI M, 1995, NUCLEIC ACIDS RES, V23, P383, DOI 10.1093/nar/23.3.383; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	48	52	55	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25947	25956		10.1074/jbc.M204068200	http://dx.doi.org/10.1074/jbc.M204068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000771	hybrid			2022-12-25	WOS:000176908700018
J	Behre, G; Singh, SM; Liu, HT; Bortolin, LT; Christopeit, M; Radomska, HS; Rangatia, J; Hiddemann, W; Friedman, AD; Tenen, DG				Behre, G; Singh, SM; Liu, HT; Bortolin, LT; Christopeit, M; Radomska, HS; Rangatia, J; Hiddemann, W; Friedman, AD; Tenen, DG			Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; CELL-PROLIFERATION; TRANSCRIPTION FACTOR; C-JUN; PU.1; EXPRESSION; KINASE; GROWTH; GENE	The transcription factor C/EBPalpha regulates early steps of normal granulocyte differentiation since mice with a disruption of the C/EBPalpha gene do not express detectable levels of the granulocyte colony-stimulating factor receptor and produce no neutrophils. We have recently shown that C/EBPalpha function is also impaired in acute myeloid leukemias. However, how the transcriptional activity of C/EBPalpha is regulated both in myelopoiesis and leukemogenesis is not fully understood. The current study demonstrates that activated Ras enhances the ability of C/EBPalpha to transactivate the granulocyte colony-stimulating factor receptor promoter and a minimal promoter containing only C/EBP DNA binding sites. Ras signaling activates C/EBPalpha via the transactivation domain because it enhances the transactivation function of a fusion protein containing a Gal4 DNA binding domain and the C/EBPalpha transactivation domain and does not change C/EBPalpha DNA binding. Ras acts on serine 248 of the C/EBPalpha transactivation domain, because it does not enhance the transactivation function of a C/EBPalpha serine 248 to alanine point mutant. Interestingly, serine 248 of C/EBPa is a protein kinase C (PKC) consensus site, and a PKC inhibitor blocks the activation of C/EBPalpha by Ras. Ras signaling leads to phosphorylation of C/EBPa in vivo. Finally, mutation of serine 248 to alanine obviates the ability of C/EBPalpha to induce granulocytic differentiation. These data suggest a model where Ras signaling enhances the activity of C/EBPalpha to induce granulocytic differentiation by phosphorylation of serine 248.	Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; MIT, Lincoln Lab, Lexington, MA 02420 USA; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Johns Hopkins University; Johns Hopkins Medicine; Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.	gerdbehre@aol.com		Christopeit, Maximilian/0000-0003-4627-0412; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [P01CA072009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72009] Funding Source: Medline; NHLBI NIH HHS [HL 56745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HIBI S, 1993, BLOOD, V81, P1841; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Iida H, 2000, INT J HEMATOL, V71, P153; JIN DI, 1995, MOL CELL BIOL, V15, P693; Johnson R, 1996, MOL CELL BIOL, V16, P4504; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Maher J, 1996, LEUKEMIA, V10, P83; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; REDDY VA, 2002, IN PRESS BLOOD; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Schaich M, 2001, BRIT J HAEMATOL, V112, P300, DOI 10.1046/j.1365-2141.2001.02562.x; SCOTT LM, 1992, BLOOD, V80, P1725; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; WASYLYK C, 1994, ONCOGENE, V9, P3665; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	41	66	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26293	26299		10.1074/jbc.M202301200	http://dx.doi.org/10.1074/jbc.M202301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11978795	hybrid			2022-12-25	WOS:000176908700063
J	Krnajski, Z; Gilberger, TW; Walter, RD; Cowman, AF; Muller, S				Krnajski, Z; Gilberger, TW; Walter, RD; Cowman, AF; Muller, S			Thioredoxin reductase is essential for the survival of Plasmodium falciparum erythrocytic stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE GLUTATHIONE-REDUCTASE; MALARIA-INFECTED ERYTHROCYTES; DISULFIDE BOND FORMATION; RED-BLOOD-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; OXIDATIVE STRESS; GENE-EXPRESSION; ACTIVE-SITE	The human malaria parasite Plasmodium falciparum poses an increasing threat to human health in the tropical regions of the world, and the validation and assessment of possible drug targets is required for the development of new antimalarials. It has been shown that the erythrocytic stages of the parasites, which are responsible for the pathology of the disease in humans, are under enhanced oxidative stress and are particularly vulnerable to exogenous challenges by reactive oxygen species. Therefore it is postulated that the disruption of the antioxidant and/or redox systems of the parasite is a feasible way to interfere with their development during erythrocytic schizogony. In order to test this suggestion thioredoxin reductase (TrxR), an enzyme heavily involved in maintenance of redox homeostasis and antioxidant defense, was knocked out in P. falciparum. was impossible to generate parasites with a disrupted trxR gene suggesting that TrxR is essential for P. falciparum erythrocytic stages. Technical problems were excluded by transfecting a 3' replacement construct, which recombined correctly and transfectants did not show any phenotypic alterations. In order to prove that the trxR knockout was responsible for the lethal phenotype of the null mutants, a co-transfection with both the knockout construct and a construct containing the trxR coding region under the control of the calmodulin promoter was conducted. Despite the disruption of the trxR gene, parasites were viable. In a Southern blot analysis a complicated restriction pattern was obtained, but it was shown by pulse field gel electrophoresis and field inverse gel electrophoreses that only the trxR gene locus on chromosome 9 was targeted by the constructs. It was found that the co-transfected constructs form concatemeric structures prior to integration into the trxR gene locus, which is further supported by plasmid rescue followed by restriction analyses of the plasmids. Northern and Western blot analyses proved that the co-transfectants highly overexpress TrxR from the introduced gene. Our results demonstrate that TrxR is essential for the survival of the erythrocytic stages of P. falciparum.	Univ Dundee, Sch Life Sci, Div Biochem & Mol Microbiol, Dundee DD1 5EH, Scotland; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Bernhard Nocht Inst Trop Med, Dept Biochem Parasitol, D-20359 Hamburg, Germany	University of Dundee; Walter & Eliza Hall Institute; Bernhard Nocht Institut fur Tropenmedizin	Muller, S (corresponding author), Univ Dundee, Sch Life Sci, Div Biochem & Mol Microbiol, MSI-WTB Complex, Dundee DD1 5EH, Scotland.		Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004; Gilberger, Tim-Wolf/0000-0002-7965-8272				Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Buettner C, 1999, J BIOL CHEM, V274, P21598, DOI 10.1074/jbc.274.31.21598; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN G, 1993, J BACTERIOL, V175, P5159, DOI 10.1128/JB.175.16.5159-5167.1993; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Gilberger TW, 1998, FEBS LETT, V425, P407, DOI 10.1016/S0014-5793(98)00270-1; GINSBURG H, 1994, PARASITE, V1, P5, DOI 10.1051/parasite/1994011005; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1977, BIOCHEM SOC T, V5, P611, DOI 10.1042/bst0050611; HUNT NH, 1990, BLOOD CELLS, V16, P499; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kadekoppala M, 2001, MOL BIOCHEM PARASIT, V112, P211, DOI 10.1016/S0166-6851(00)00368-6; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kawazu S, 2001, MOL BIOCHEM PARASIT, V116, P73, DOI 10.1016/S0166-6851(01)00308-5; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kreimer S, 1997, ARCH MICROBIOL, V168, P328, DOI 10.1007/s002030050506; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V113, P303, DOI 10.1016/S0166-6851(01)00219-5; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Luersen K, 2000, BIOCHEM J, V346, P545, DOI 10.1042/0264-6021:3460545; Luersen K, 1999, MOL BIOCHEM PARASIT, V98, P131, DOI 10.1016/S0166-6851(98)00161-3; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Meierjohann S, 2002, BIOCHEM J, V363, P833, DOI 10.1042/0264-6021:3630833; Missirlis F, 2001, CURR BIOL, V11, P1272, DOI 10.1016/S0960-9822(01)00393-1; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; O'Donnell RA, 2001, NUCLEIC ACIDS RES, V29, P716, DOI 10.1093/nar/29.3.716; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; Patankar S, 2001, MOL BIOL CELL, V12, P3114, DOI 10.1091/mbc.12.10.3114; Rahlfs S, 2001, EUR J BIOCHEM, V268, P1404, DOI 10.1046/j.1432-1327.2001.02005.x; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Sambrook J., 2002, MOL CLONING LAB MANU; SIES H, 1989, NATURWISSENSCHAFTEN, V76, P57, DOI 10.1007/BF00396705; Sies H, 1986, ANGEW CHEMIE, V98, P1061, DOI [10.1002/ange.19860981203, DOI 10.1002/ANGE.19860981203]; Thompson JK, 1997, MOL BIOCHEM PARASIT, V87, P49, DOI 10.1016/S0166-6851(97)00041-8; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trenholme KR, 2000, P NATL ACAD SCI USA, V97, P4029, DOI 10.1073/pnas.040561197; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; UMLAS J, 1971, AM J TROP MED HYG, V20, P527, DOI 10.4269/ajtmh.1971.20.527; VENNERSTROM JL, 1988, J MED CHEM, V31, P1269, DOI 10.1021/jm00402a001; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	53	91	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25970	25975		10.1074/jbc.M203539200	http://dx.doi.org/10.1074/jbc.M203539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004069	hybrid			2022-12-25	WOS:000176908700021
J	Seyhan, AA; Vitiello, D; Shields, MT; Burke, JM				Seyhan, AA; Vitiello, D; Shields, MT; Burke, JM			Ribozyme inhibition of Alphavirus replication.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HAIRPIN RIBOZYME; IN-VITRO; EXPRESSION; CLEAVAGE; MECHANISM; LIGATION; SEQUENCE; SINDBIS	A model system to examine the expression and antiviral activity of trans-acting ribozymes in mammalian cells has been developed and evaluated. Hairpin ribozymes were engineered to cleave a specific site, identified by a combinatorial activity-based selection method, within genomic and subgenomic RNA species of Sindbis virus. Transiently transfected cells expressed moderate levels of ribozyme (similar to50,000 molecules/cell) with predominant nuclear localization and a short half-life (23 min). Stable cell lines expressed ribozymes at modest levels (similar to2,000 molecules/cell). Ribozyme-mediated RNA cleavage activity was detected in cell extracts. Clonal cell lines were challenged with recombinant Sindhis virus, and viral replication was examined using plaque formation and green fluorescent protein assays. Significant inhibition of viral replication was observed in cells expressing the active antiviral ribozyme, and lower levels of inhibition in control cells expressing inactive or irrelevant ribozymes. These findings are consistent with a model in which inhibition of viral replication occurs via ribozyme cleavage of viral RNAs, suggesting that ribozymes may represent useful antiviral agents.	Somagen Inc, Santa Cruz, CA 95060 USA; Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Burke, JM (corresponding author), Somagen Inc, Santa Cruz, CA 95060 USA.	John.Burke@uvm.edu	Seyhan, Attila/G-3603-2017	Seyhan, Attila/0000-0002-6264-1482; Seyhan, Attila A/0000-0003-1276-8466	NIAID NIH HHS [AI30534] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030534] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Bertrand E, 1997, RNA, V3, P75; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; Donahue CP, 2000, J MOL BIOL, V295, P693, DOI 10.1006/jmbi.1999.3380; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; HEIDNER HW, 1994, J VIROL, V68, P2683, DOI 10.1128/JVI.68.4.2683-2692.1994; Mahy BWJ, 1996, VIROLOGY METHODS MAN, P35; NOONBERG SB, 1994, NUCLEIC ACIDS RES, V22, P2830, DOI 10.1093/nar/22.14.2830; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; Pinard R, 2001, EMBO J, V20, P6434, DOI 10.1093/emboj/20.22.6434; Pulitz JZ, 1999, J VIROL, V73, P5381, DOI 10.1128/JVI.73.7.5381-5387.1999; Sargueil B, 2000, J BIOL CHEM, V275, P32157, DOI 10.1074/jbc.M005591200; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; Seyhan AA, 1998, NUCLEIC ACIDS RES, V26, P3494, DOI 10.1093/nar/26.15.3494; Simpson DA, 1996, VIROLOGY, V222, P464, DOI 10.1006/viro.1996.0445; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Sun LQ, 2000, PHARMACOL REV, V52, P325; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; Vitiello D, 2000, RNA, V6, P628, DOI 10.1017/S1355838200990964; WENGLER G, 1980, TOGAVIRUSES; Yadava RS, 2001, J MOL BIOL, V309, P893, DOI 10.1006/jmbi.2001.4713; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; Yu Q, 1998, J BIOL CHEM, V273, P23524, DOI 10.1074/jbc.273.36.23524; Yu Q, 1997, Methods Mol Biol, V74, P161	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25957	25962		10.1074/jbc.M111360200	http://dx.doi.org/10.1074/jbc.M111360200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006558	hybrid			2022-12-25	WOS:000176908700019
J	Klein, ATJ; van den Berg, M; Bottger, G; Tabak, HF; Distel, B				Klein, ATJ; van den Berg, M; Bottger, G; Tabak, HF; Distel, B			Saccharomyces cerevisiae acyl-CoA oxidase follows a novel, non-PTS1, import pathway into peroxisomes that is dependent on Pex5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; TARGETING SIGNAL-RECEPTOR; MEMBRANE-PROTEIN PEX13P; ALANINE-GLYOXYLATE AMINOTRANSFERASE-1; PRIMARY HYPEROXALURIA TYPE-1; YEAST YARROWIA-LIPOLYTICA; COENZYME-A OXIDASE; PICHIA-PASTORIS; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE	The peroxisomal protein acyl-CoA oxidase (Pox1p) of Saccharomyces cerevisiae lacks either of the two well characterized peroxisomal targeting sequences known as PTS1 and PTS2. Here we demonstrate that peroxisomal import of Pox1p is nevertheless dependent on binding to Pex5p, the PTS1 import receptor. The interaction between Pex5p and Pox1p, however, involves novel contact sites in both proteins. The interaction region in Pex5p is located in a defined area of the amino-terminal part of the protein outside of the tetratricopeptide repeat domain involved in PTS1 recognition; the interaction site in Pox1p is located internally and not at the carboxyl terminus where a PTS1 is normally found. By making use of pex5 mutants that are either specifically disturbed in binding of PTS1 proteins or in binding of Pox1p, we demonstrate the existence of two independent, Pex5p-mediated import pathways into peroxisomes in yeast as follows: a classical PTS1 pathway and a novel, non-PTS1 pathway for Pox1p.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl						Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; BRUINENBERG PG, 1990, YEAST, V6, P245, DOI 10.1002/yea.320060309; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; deVet ECJM, 1997, BBA-LIPID LIPID MET, V1346, P25, DOI 10.1016/S0005-2760(97)00014-3; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hettema EH, 1998, J CELL BIOL, V142, P421, DOI 10.1083/jcb.142.2.421; HILL DE, 1988, NUCLEIC ACIDS RES, V16, P365, DOI 10.1093/nar/16.1.365; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Klein ATJ, 2001, J BIOL CHEM, V276, P15034, DOI 10.1074/jbc.M010776200; Koller A, 1999, YEAST, V15, P1035, DOI 10.1002/(SICI)1097-0061(199908)15:11<1035::AID-YEA432>3.0.CO;2-1; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lee MS, 1997, PLANT CELL, V9, P185, DOI 10.1105/tpc.9.2.185; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; Luck H, 1963, METHODS ENZYMATIC AN, P885; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Miller JH., 1972, EXPT MOL GENETICS; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; Motley AM, 2000, EMBO REP, V1, P40, DOI 10.1093/embo-reports/kvd010; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Nohammer C, 2000, EUR J BIOCHEM, V267, P1254, DOI 10.1046/j.1432-1327.2000.01128.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; Wang HJ, 1998, YEAST, V14, P1373, DOI 10.1002/(SICI)1097-0061(199811)14:15<1373::AID-YEA332>3.0.CO;2-1; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Will GK, 1999, MOL CELL BIOL, V19, P2265; Yang XD, 2001, EUR J CELL BIOL, V80, P126, DOI 10.1078/0171-9335-00144; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	81	104	105	3	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25011	25019		10.1074/jbc.M203254200	http://dx.doi.org/10.1074/jbc.M203254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11967269	hybrid			2022-12-25	WOS:000176747000024
J	Ouzzine, M; Gulberti, S; Levoin, N; Netter, P; Magdalou, J; Fournel-Gigleux, S				Ouzzine, M; Gulberti, S; Levoin, N; Netter, P; Magdalou, J; Fournel-Gigleux, S			The donor substrate specificity beta 1,3-glucuronosyltransferase I toward UDP-glucoronic acid is determined by two crucial histidine and arginine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GLUCURONOSYLTRANSFERASE-I; MOLECULAR-CLONING; BIOSYNTHESIS; EXPRESSION; MECHANISM; GLYCOSYLTRANSFERASES; STRUCTURE/FUNCTION; PROTEINS; COMPLEX	The human beta1,3-glucuronosyltransferase I (GlcAT-I) plays a key role in proteoglycan biosynthesis by catalyzing the transfer of glucuronic acid onto the trisaccharide-protein linkage structure Galbeta1,3Galbeta1,4Xylbeta-O-Ser, a prerequisite step for polymerization of glycosaminoglycan chains. In this study, we identified His(308) and Arg(277) residues as essential determinants for the donor substrate (UDP-glucuronic acid) selectivity of the human GleAT-I. Analysis of the UDP-glucuronic acid-binding site by computational modeling in conjunction with site-directed mutagenesis indicated that both residues interact with glucuronic acid. Substitution of His(308) by arginine induced major changes in the donor substrate specificity of GlcAT-I. Interestingly, the H308R mutant was able to efficiently utilize nucleotide sugars LTDP-glucose, LTDP-mannose, and LTDP-N-acetylglucosamine, which are not naturally accepted by the wild-type enzyme, as co-substrate in the transfer reaction. To gain insight into the role of Arg277, site-directed mutagenesis in combination with chemical modification was carried out. Substitution of Are 77 with alanine abrogated the activity of GlcAT-I. Furthermore, the arginine-directed reagent 2,3-butanedione irreversibly inhibited GlcAT-I, which was effectively protected against inactivation by UDP-glucuronic acid but not by UDP-glucose. It is noteworthy that the activity of the H308R mutant toward UDP-glucose was unaffected by the arginine-directed reagent. Our results are consistent with crucial interactions between the His(308). and Arg(277) residues and the glucuronic acid moiety that governs the specificity of GlcAT-1 toward the nucleotide sugar donor substrate.	Univ Henri Poincare Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Henri Poincare Nancy 1, Fac Med, CNRS, UMR 7561, BP 184, F-54505 Vandoeuvre Les Nancy, France.		Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950; levoin, nicolas/0000-0002-7731-736X; GULBERTI, Sandrine/0000-0002-9378-4697				Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Beier L, 2000, PROTEIN ENG, V13, P509, DOI 10.1093/protein/13.7.509; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gouze JN, 2001, ARTHRITIS RHEUM, V44, P351, DOI 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.3.CO;2-D; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Ouzzine M, 2000, MOL PHARMACOL, V58, P1609, DOI 10.1124/mol.58.6.1609; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PLANT AR, 1988, ARCH BIOCHEM BIOPHYS, V262, P181, DOI 10.1016/0003-9861(88)90180-4; Pless D, 1999, DRUG METAB DISPOS, V27, P588; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Senay C, 1997, MOL PHARMACOL, V51, P406; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SURLES MC, 1994, PROTEIN SCI, V3, P198; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VERTEL BM, 1995, TRENDS CELL BIOL, V5, P458, DOI 10.1016/S0962-8924(00)89115-1; Wakarchuk WW, 2001, J BIOL CHEM, V276, P12785, DOI 10.1074/jbc.M011293200; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; ZAKIM D, 1983, J BIOL CHEM, V258, P6430	36	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25439	25445		10.1074/jbc.M201912200	http://dx.doi.org/10.1074/jbc.M201912200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986319	hybrid			2022-12-25	WOS:000176747000078
J	Waldmann, T; Eckerich, C; Baack, M; Gruss, C				Waldmann, T; Eckerich, C; Baack, M; Gruss, C			The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; MESSENGER-RNA; BINDING; ENHANCER; TRANSLOCATION; MAINTENANCE; REPLICATION; AUTOANTIGEN; ONCOPROTEIN; NUCLEUS	We have investigated the molecular mechanism by which the proto-oncogene protein DEK, an abundant chromatin-associated protein, changes the topology of DNA in chromatin in vitro. Band-shift assays and electron microscopy revealed that DEK induces both intra-and intermolecular interactions between DNA molecules. Binding of the DEK protein introduces constrained positive supercoils both into protein-free DNA and into DNA in chromatin. The induced change in topology is reversible after removal of the DEK protein. As shown by sedimentation analysis and electron microscopy, the DEK-induced positive supercoiling causes distinct structural changes of DNA and chromatin. The observed direct effects of DEK on chromatin folding help to understand the function that this major chromatin protein performs in the nucleus.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Gruss, C (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Claudia.Gruss@uni-konstanz.de	Waldmann, Tanja/A-5145-2010	Waldmann, Tanja/0000-0001-9276-1592				Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Alexiadis V, 2000, GENE DEV, V14, P1308; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GRUSS C, 1995, METH MOL G, V7, P101; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; VOLLENWEIDER HJ, 1975, P NATL ACAD SCI USA, V72, P83, DOI 10.1073/pnas.72.1.83; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wichmann I, 2000, CLIN EXP IMMUNOL, V119, P530, DOI 10.1046/j.1365-2249.2000.01154.x; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	37	81	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24988	24994		10.1074/jbc.M204045200	http://dx.doi.org/10.1074/jbc.M204045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997399	hybrid			2022-12-25	WOS:000176747000021
J	Schwalbe, RA; Rudin, A; Xia, SL; Wingo, CS				Schwalbe, RA; Rudin, A; Xia, SL; Wingo, CS			Site-directed glycosylation tagging of functional Kir2.1 reveals that the putative pore-forming segment is extracellular	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNELS; ASPARAGINE-LINKED OLIGOSACCHARIDES; POTASSIUM CHANNEL; SELECTIVITY FILTER; SIGNATURE SEQUENCE; INWARD RECTIFICATION; UNITARY CONDUCTANCE; MUTATIONS; EXPRESSION; SPERMINE	Inwardly rectifying K+ channels or Kirs are a large gene family and have been predicted to have two transmembrane segments, M1 and M2, intracellular N and C termini, and two extracellular loops, E1 and E2, separated by an intramembranous pore-forming segment, H5. H5 contains a stretch of eight residues that are similar in voltage-dependent K+ channels, Kvs, and this stretch is called the signature sequence of K+ channels. Because mutations in this sequence altered selectivity in Kvs, it has been designated as the selectivity filter. Previously, we used N-glycosylation substitution mutants to map the extracellular topology of a weak inwardly rectifying K+ channel, Kir1.1 or ROMR1, and found that the entire H5 segment was extracellular. We now report utilization of introduced N-glycosylation sites, NX(S/T), at positions Ser(128) in El, and Gln(140), Ileu(143), and Phe(147) in the H5 sequence of a strong inwardly rectifying K+ channel, Kir2.1. Furthermore, we show that biotinylated channel proteins with N-linked oligosaccharides attached at positions 140 and 143 in the signature sequence are located at the cell surface. Mutant channels were functional as detected by whole-cell and single-channel recordings. Unlike Kir1.1, position Lys(117) was not occupied. We conclude that, for yet another K+ channel, the invariant G(Y/F)G sequence is extracellular rather than intramembranous.	Univ Florida, Dept Med, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA; Dept Vet Affairs Med Ctr, Nephrol Sect, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Schwalbe, RA (corresponding author), Univ Florida, Dept Med, Div Nephrol Hypertens & Transplantat, Box 100224, Gainesville, FL 32610 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055404, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052990] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55404, HL36930] Funding Source: Medline; NIDDK NIH HHS [DK52990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bianchi L, 1996, J BIOL CHEM, V271, P6114, DOI 10.1074/jbc.271.11.6114; Dart C, 1998, J PHYSIOL-LONDON, V511, P25, DOI 10.1111/j.1469-7793.1998.025bi.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kubo Y, 1998, FEBS LETT, V435, P69, DOI 10.1016/S0014-5793(98)01038-2; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Picones A, 2001, BIOPHYS J, V81, P2035, DOI 10.1016/S0006-3495(01)75853-5; Repunte VP, 1999, EMBO J, V18, P3317, DOI 10.1093/emboj/18.12.3317; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SAMBROOK J, 1992, MOL CLONING LAB MANU; Schwalbe RA, 1996, J BIOL CHEM, V271, P24201, DOI 10.1074/jbc.271.39.24201; Schwalbe RA, 1997, J BIOL CHEM, V272, P25217, DOI 10.1074/jbc.272.40.25217; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; So I, 2001, J PHYSIOL-LONDON, V531, P37, DOI 10.1111/j.1469-7793.2001.0037j.x; Splitt H, 2000, FEBS LETT, V472, P83, DOI 10.1016/S0014-5793(00)01429-0; Wischmeyer E, 2000, FEBS LETT, V466, P115, DOI 10.1016/S0014-5793(99)01769-X; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24382	24389		10.1074/jbc.M201668200	http://dx.doi.org/10.1074/jbc.M201668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11991952	hybrid			2022-12-25	WOS:000176611800055
J	Chavakis, T; Boeckel, N; Santoso, S; Voss, R; Isordia-Salas, I; Pixley, RA; Morgenstern, E; Colman, RW; Preissner, KT				Chavakis, T; Boeckel, N; Santoso, S; Voss, R; Isordia-Salas, I; Pixley, RA; Morgenstern, E; Colman, RW; Preissner, KT			Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIB-IIIA; UROKINASE RECEPTOR; BINDING-PROTEIN; CLOT FORMATION; LIGHT CHAIN; VITRONECTIN BINDS; ANIONIC SURFACE; S-PROTEIN	Proteolytic cleavage of single chain high molecular weight kininogen (HK) by kallikrein releases the short-lived vasodilator bradykinin and leaves behind two-chain high molecular weight kininogen (HKa). HKa and particularly its His-Gly-Lys-rich domain 5 have been previously reported to exert anti-adhesive properties by binding to the extracellular matrix protein vitronectin (VN). In this study the ability of HKa and domain 5 to interfere with platelet adhesion and aggregation was investigated. In a purified system HKa and particularly domain 5 but not HK inhibited the binding of VN to the alpha(IIb)beta(3) integrin, whereas the binding of fibrinogen to this integrin was not affected. The region Gly-486-Lys-502 from the carboxyl terminus of the domain 5 was identified as responsible for inhibition of the VN-alpha(IIb)beta(3)-integrin interaction, as this portion was also found to mediate kininogen binding to VN. Through these interactions, HKa, the isolated domain 5, and the peptide Gly-486-Lys502 abrogated the alphaIIbbeta(3)-integrin-dependent adhesion of human platelets to VN but not to fibrinogen. The codistribution of VN and HKa at sites of ex vivo platelet aggregation was demonstrated by transmission immune electron microscopy, indicating that the described interaction is likely to take place in vivo. Moreover, domain 5 and the peptide Gly-486-Lys-502 dose-dependently blocked platelet aggregation, resembling the inhibitory effect of monoclonal antibody 13111 against multimeric VN. Finally, treatment of mice with isolated domain 5 resulted in a significantly prolonged tail bleeding time. Taken together, our data emphasize the inhibitory role of HK domain 5 on platelet adhesion and aggregation; new antithrombotic compounds may become available on the basis of peptide Gly-486-Lys-502 of HK domain 5.	Univ Giessen, Fachbereich Humanmed, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med, D-35392 Giessen, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany; Univ Saarland, Dept Med Biol, D-66421 Homburg, Germany; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen; Saarland University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Preissner, KT (corresponding author), Univ Giessen, Fachbereich Humanmed, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	klaus.t.preissner@biochemie.med.uni-giessen.de	Chavakis, Triantafyllos/ABE-8845-2020		NCI NIH HHS [CA63938] Funding Source: Medline; NHLBI NIH HHS [HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BRADFORD HN, 1993, J BIOL CHEM, V268, P26546; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; COLLINS WE, 1987, ANN NY ACAD SCI, V516, P291, DOI 10.1111/j.1749-6632.1987.tb33049.x; Colman RW, 1999, ARTERIOSCL THROM VAS, V19, P2245, DOI 10.1161/01.ATV.19.9.2245; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; deBoer HC, 1995, J BIOL CHEM, V270, P30733, DOI 10.1074/jbc.270.51.30733; DEGROOT PG, 1996, VASCULAR CONTROL HAE, P147; DELACADENA RA, 1994, THROMB HAEMOSTASIS, V72, P125; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Eitzman DT, 2000, BLOOD, V95, P577, DOI 10.1182/blood.V95.2.577; Fay WP, 1999, BLOOD, V93, P1825, DOI 10.1182/blood.V93.6.1825.406k37_1825_1830; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Fox JEB, 1999, THROMB HAEMOSTASIS, V82, P385; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Hasan AAK, 1996, CIRCULATION, V94, P517, DOI 10.1161/01.CIR.94.3.517; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HESS S, 1995, THROMB HAEMOSTASIS, V74, P258; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Konstantinides S, 2001, CIRCULATION, V103, P576, DOI 10.1161/01.CIR.103.4.576; KOST C, 1992, J BIOL CHEM, V267, P12098; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; MOHRI H, 1991, AM J CLIN PATHOL, V96, P605, DOI 10.1093/ajcp/96.5.605; Morgenstern E, 2001, ANN NY ACAD SCI, V936, P449; Morgenstern E, 2001, EUR J CELL BIOL, V80, P87, DOI 10.1078/0171-9335-00138; NICULESCU F, 1987, ATHEROSCLEROSIS, V65, P1, DOI 10.1016/0021-9150(87)90002-5; NISHIKAWA K, 1992, BLOOD, V80, P1980; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; Phillips DR, 1998, ARCH PATHOL LAB MED, V122, P811; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SCHMAIER AH, 1986, BLOOD, V67, P119; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; Sheng N, 2000, BLOOD, V95, P3788; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TAIT JF, 1987, J BIOL CHEM, V262, P11651; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; Verheul HMW, 2000, BLOOD, V96, P4216, DOI 10.1182/blood.V96.13.4216; WATKINS SC, 1990, HISTOCHEM J, V22, P507, DOI 10.1007/BF01007236; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; Wohn KD, 1999, BRIT J HAEMATOL, V104, P901, DOI 10.1046/j.1365-2141.1999.01242.x; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com	57	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23157	23164		10.1074/jbc.M202529200	http://dx.doi.org/10.1074/jbc.M202529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970955	hybrid			2022-12-25	WOS:000176475700010
J	Colston, JT; Chandrasekar, B; Freeman, GL				Colston, JT; Chandrasekar, B; Freeman, GL			A novel peroxide-induced calcium transient regulates interleukin-6 expression in cardiac-derived fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; MYOCARDIAL-ISCHEMIA; GENE-EXPRESSION; PROINFLAMMATORY CYTOKINE; STUNNED MYOCARDIUM; RAT-HEART; REPERFUSION; ENTRY	Reperfusion of ischemic myocardium leads to a local burst of free radicals, increased [Ca2+](i) and the release of proinflammatory cytokines. The purpose of this study was to determine whether brief exposure of cardiac fibroblasts to H2O2 is associated with transient changes in [Ca2+](i) levels and whether this stimulus is sufficient to induce interleukin-6 (IL-6) expression. Cardiac derived fibroblasts were isolated from adult male rats and cultured under standard conditions. Individual coverslip-attached fibroblasts were loaded with the calcium probe Fura-2/AM and exposed to a single 3-min pulse of 100 mum H2O2. In addition, low passage cultures were exposed to a pulse of H2O2 and assayed for IL-6 expression. A brief exposure of H2O2 led to a large intracellular Ca2+ transient with a mean transient magnitude of 318 +/- 28 nm (mean +/- S.D., n = 12). Stimulation in the absence of [Ca2+](o) led to a 59% reduction in mean transient magnitude (129 +/- 23 nm, n = 10, p < 0.001), whereas pretreatment with the inositol 1,4,5-trisphosphate receptor blocker xestospongin C resulted in a 37% reduction (199 +/- 25 nM, n = 10, p < 0.01). Cells treated with xestospongin C and stimulated in the absence of [Ca2+](o) did not exhibit a Ca2+ transient. Time-dependent IL-6 release was significantly elevated by 4 h (368 +/- 64 pg/mg protein, p < 0.01) and increased further by 24 h (1030 +/- 76 pg/mg protein). The depletion of cellular Ca2+ by pretreatment with thapsigargin in the absence of [Ca2+](o). attenuated H2O2-induced IL-6 mRNA expression while blocking protein release. These data show that the exposure of cardiac fibroblasts to a brief pulse of physiological levels of H2O2 resulted in a large Ca2+ transient with intracellular and extracellular Ca2+ contributions. Furthermore, brief H2O2 exposure led to calcium-dependent IL-6 expression.	Univ Texas, Hlth Sci Ctr, Div Cardiol, Audie L Murphy Div, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Freeman, GL (corresponding author), Univ Texas, Dept Med Cardiol, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.							BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOLLI R, 1987, AM J PHYSIOL, V253, pH1372, DOI 10.1152/ajpheart.1987.253.6.H1372; Chandrasekar B, 1998, BBA-MOL BASIS DIS, V1406, P91, DOI 10.1016/S0925-4439(97)00062-8; Chandrasekar B, 1997, CLIN EXP IMMUNOL, V108, P346, DOI 10.1046/j.1365-2249.1997.d01-1017.x; Chandrasekar B, 2001, CIRCULATION, V103, P2296; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; CHARLAT ML, 1989, J AM COLL CARDIOL, V13, P185, DOI 10.1016/0735-1097(89)90569-X; Chen JJ, 2001, J MOL CELL CARDIOL, V33, P1919, DOI 10.1006/jmcc.2001.1454; Colston JT, 2000, J AM COLL CARDIOL, V35, p331A; Colston JT, 1998, CARDIOVASC RES, V38, P158, DOI 10.1016/S0008-6363(97)00323-4; DIGLIO CA, 1988, TISSUE CELL, V20, P477, DOI 10.1016/0040-8166(88)90051-1; EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183; Frangogiannis N G, 1996, EXS, V76, P263; GROSS GJ, 1986, AM J PHYSIOL, V250, P372; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; McDonough JL, 1999, CIRC RES, V84, P9; NAG AC, 1980, CYTOBIOS, V28, P41; National Institute of Health (NIH), 1985, DHEW PUBL; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Rosado JA, 2000, J PHYSIOL-LONDON, V529, P159, DOI 10.1111/j.1469-7793.2000.00159.x; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V280, pH344, DOI 10.1152/ajpheart.2001.280.1.H344; Shivakumar K, 2001, J MOL CELL CARDIOL, V33, P373, DOI 10.1006/jmcc.2000.1309; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; VARANI J, 1989, AM J PATHOL, V135, P435; Wollert K C, 2001, Heart Fail Rev, V6, P95; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	33	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23477	23483		10.1074/jbc.M108676200	http://dx.doi.org/10.1074/jbc.M108676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11983681	hybrid			2022-12-25	WOS:000176475700051
J	Yasukawa, K; Sawamura, D; McMillan, JR; Nakamura, H; Shimizu, H				Yasukawa, K; Sawamura, D; McMillan, JR; Nakamura, H; Shimizu, H			Dominant and recessive compound heterozygous mutations in epidermolysis bullosa simplex demonstrate the role of the stutter region in keratin intermediate filament assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-STRUCTURE; POINT MUTATIONS; TRANSGENIC MICE; DOWLING-MEARA; EXPRESSION; DISEASE; SEVERITY; GENE; HYPERKERATOSIS; ABNORMALITIES	Keratin intermediate filaments are important cytoskeletal structural proteins involved in maintaining cell shape and function. Mutations in the epidermal keratin genes, keratin 5 or keratin 14 lead to the disruption of keratin filament assembly, resulting in an autosomal dominant inherited blistering skin disease, epidermolysis bullosa simplex (EBS). We investigated a large EBS kindred who exhibited a markedly heterogeneous clinical presentation and detected two distinct keratin 5 mutations in the proband, the most severely affected. One missense mutation (E170K) in the highly conserved helix initiation peptide sequence of the 1A rod domain was found in all the affected family members. In contrast, the other missense mutation (E418K) was found only in the proband. The E418K mutation was located in the stutter region, an interruption in the heptad repeat regularity, whose function as yet remains unclear. We hypothesized that this mutated stutter allele was clinically silent when combined with the wild type allele but aggravates the clinical severity of EBS caused by the E170K mutation on the other allele. To confirm this in vitro, we transfected mutant keratin 5 cDNA into cultured cells. Although only 12.7% of the cells transfected with the E170K mutation alone showed disrupted keratin filament aggregations, significantly more cells (30-0% cotransfected with both E170K and E418K mutations demonstrated keratin aggregation p < 0.05). These transfection assay results corresponded to the heterogeneous clinical findings of the EBS patient in this kindred. We have identified the first case of both compound heterozygous dominant (E170K) and recessive (E418K) mutations in any keratin gene and confirmed the significant involvement of the stutter region in the assembly and organization of the keratin intermediate filament network in vitro.	Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Shimizu, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	shimizu@med.hokudai.ac.jp						ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BEAUDET AL, 2000, METABOLIC MOL BASES, V1, P3; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Brown JH, 1996, PROTEINS, V26, P134; CHAN YM, 1994, J CELL SCI, V107, P765; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Fine JD, 2000, J AM ACAD DERMATOL, V42, P1051, DOI 10.1016/S0190-9622(00)90302-5; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1994, J INVEST DERMATOL, V103, pS25, DOI 10.1111/1523-1747.ep12398924; FUCHS EV, 1999, EPIDERMOLYSIS BULLOS, P280; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 1998, Subcell Biochem, V31, P319; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; Hu ZL, 1997, J INVEST DERMATOL, V109, P360, DOI 10.1111/1523-1747.ep12336051; Hut PHL, 2000, J INVEST DERMATOL, V114, P616, DOI 10.1046/j.1523-1747.2000.00928.x; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; Kobayashi S, 1996, FEBS LETT, V386, P149, DOI 10.1016/0014-5793(96)00393-6; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; Liovic M, 2001, J INVEST DERMATOL, V116, P964, DOI 10.1046/j.1523-1747.2001.01334.x; Livingston RJ, 2001, J INVEST DERMATOL, V116, P970, DOI 10.1046/j.1523-1747.2001.01324.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NORTH ACT, 1994, PROTEINS, V20, P174, DOI 10.1002/prot.340200207; RUGG EL, 1993, NAT GENET, V5, P294, DOI 10.1038/ng1193-294; Sato-Matsumura KC, 2002, ARCH DERMATOL, V138, P269, DOI 10.1001/archderm.138.2.269; Shimizu H, 1999, J INVEST DERMATOL, V113, P419, DOI 10.1046/j.1523-1747.1999.00713.x; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1994, J INVEST DERMATOL, V103, pS19, DOI 10.1111/1523-1747.ep12398900; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stephens K, 1997, J INVEST DERMATOL, V108, P349, DOI 10.1111/1523-1747.ep12286486; STEPHENS K, 1993, J INVEST DERMATOL, V101, P240, DOI 10.1111/1523-1747.ep12365079; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563	42	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23670	23674		10.1074/jbc.M200974200	http://dx.doi.org/10.1074/jbc.M200974200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973334	hybrid			2022-12-25	WOS:000176475700075
J	Ogura, T; Furukawa, T; Toyozaki, T; Yamada, K; Zheng, YJ; Katayama, Y; Nakaya, H; Inagaki, N				Ogura, T; Furukawa, T; Toyozaki, T; Yamada, K; Zheng, YJ; Katayama, Y; Nakaya, H; Inagaki, N			ClC-3B, a novel ClC-3 splicing variant that interacts with EBP50 and facilitates expression of CFTR-regulated ORCC	FASEB JOURNAL			English	Article						chloride channel; epithelium; PDZ domain; cystic fibrosis	RECTIFYING CHLORIDE CHANNELS; CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; CL CHANNELS; IDENTIFICATION; CELLS; CURRENTS; CLONING; FAMILY	We have cloned ClC-3B, a novel alternative splicing variant of ClC-3 (ClC-3A) that is expressed predominantly in epithelial cells. ClC-3B has a different, slightly longer C-terminal end than ClC-3A and contains a consensus motif for binding to the second PDZ (PSD95/Dlg/ZO-1) domain of the epithelium-specific scaffolding protein EBP50. Both in vitro and in vivo binding assays demonstrate interaction between ClC-3B and EBP50. C127 mouse mammary epithelial cells transfected with ClC-3B alone showed diffuse immunoreactivity for ClC-3B in the cytoplasmic region. In contrast, when EBP50 was cotransfected with ClC-3B, strong immunoreactivity for ClC-3B appeared at the leading edges of membrane ruffles. Patch-clamp experiments revealed that cotransfection of ClC-3B and EBP50 resulted in a remarkable increase in outwardly rectifying Cl- channel (ORCC) activities at the leading edges of membrane ruffles in C127 cells. The electrophysiological properties of the ClC-3B-induced ORCCs are similar to those of ORCCs described in native epithelial cells. When cystic fibrosis transmembrane conductance regulator (CFTR) was cotransfected with ClC-3B and EBP50, ClC-3B-dependent ORCCs were activated via the protein kinase A-dependent pathway. These findings indicate that ClC-3B is itself a CFTR-regulated ORCC molecule or its activator.	Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba, Japan; Chiba Univ, Grad Sch Med, Dept Basic Pathol, Chiba, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Autonom Physiol, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Akita, Japan	Akita University; Chiba University; Chiba University; Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST)	Furukawa, T (corresponding author), Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan.	tfuru@med.akita-u.ac.jp	furukawa, tetsushi/ABD-3178-2020	Inagaki, Nobuya/0000-0001-8261-2593				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KAWAMURA K, 1995, IEEE T REHABIL ENG, V3, P14, DOI 10.1109/86.372888; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; KRICK W, 1991, PFLUG ARCH EUR J PHY, V418, P491, DOI 10.1007/BF00497777; KUNZELMANN K, 1991, PFLUG ARCH EUR J PHY, V418, P479, DOI 10.1007/BF00497776; Lepple-Wienhues A, 2001, FASEB J, V15, P927, DOI 10.1096/fj.00-0264com; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200	32	72	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					863	+		10.1096/fj.01-0845fje	http://dx.doi.org/10.1096/fj.01-0845fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967229				2022-12-25	WOS:000175425900020
J	Guillen, C; Martinez, P; de Gortazar, AR; Martinez, ME; Esbrit, P				Guillen, C; Martinez, P; de Gortazar, AR; Martinez, ME; Esbrit, P			Both n- and c-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ENDOCHONDRAL BONE-FORMATION; KINASE-C; OSTEOSARCOMA CELLS; IN-VIVO; TRANSCRIPTION FACTOR; OVARIECTOMIZED RATS; PTH/PTHRP RECEPTOR; GENE-EXPRESSION; PEPTIDE	Parathyroid hormone (PTH)-related protein (PTHrP) seems to affect bone resorption by interaction with bone cytokines, among them interleukin-6 (IL-6). Recent studies suggest that nuclear factor (NF)-kappaB activation has an important role in bone resorption. We assessed whether the N-terminal fragment of PTHrP, and its C-terminal region, unrelated to PTH, can activate NF-kappaB, and its relationship with IL-6 gene induction in different rat and human osteoblastic cell preparations. Here we present molecular data demonstrating that both PTHrP (136) and PTHrP (107-139) activate NF-kappaB, leading to an increase in IL-6 mRNA, in these cells. Using anti-p65 and anti-p50 antibodies, we detected the presence of both proteins in the activated NF-kappaB complex. This effect induced by either the N- or C-terminal PTHrP domain in osteoblastic cells appears to occur by different intracellular mechanisms, involving protein kinase A or intracellular Ca2+/protein kinase C activation, respectively. However, the effect of each peptide alone did not increase further when added together. Our findings lend support to the hypothesis that the C-terminal domain of PTHrP, in a manner similar to its N-terminal fragment, might stimulate bone resorption. These studies also provide further insights into the putative role of PTHrP as a modulator of bone remodeling.	Fdn Jimeenez Diaz, Res Unit, Bone & Mineral Metab Lab, Madrid 28040, Spain; Hosp La Paz, Div Biochem, Madrid 28046, Spain	Hospital Universitario La Paz	Esbrit, P (corresponding author), Fdn Jimeenez Diaz, Res Unit, Bone & Mineral Metab Lab, Avda Reyes Catolicos 2, Madrid 28040, Spain.		Guillén, Carlos/J-9728-2014; Gortazar, Arancha/G-5385-2017	Guillén, Carlos/0000-0002-9370-6314; Gortazar, Arancha/0000-0001-5072-3141; Guillen, Carlos/0000-0003-2717-1929				Ali NN, 1999, FEBS LETT, V460, P315, DOI 10.1016/S0014-5793(99)01370-8; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bilbe G, 1996, BONE, V19, P437, DOI 10.1016/S8756-3282(96)00254-2; Cornish J, 1997, ENDOCRINOLOGY, V138, P1299, DOI 10.1210/en.138.3.1299; De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096; de Miguel F, 1999, J AM SOC NEPHROL, V10, P796; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo-129-4-1762; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Frolik CA, 1999, J BONE MINER RES, V14, P163, DOI 10.1359/jbmr.1999.14.2.163; GAGNON L, 1993, J BONE MINER RES, V8, P497; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENFIELD EM, 1995, J CLIN INVEST, V96, P1238, DOI 10.1172/JCI118157; Hehner SP, 1999, J IMMUNOL, V163, P5617; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Itoh K, 2000, J BONE MINER RES, V15, P1766, DOI 10.1359/jbmr.2000.15.9.1766; Jimi E, 1996, J BIOL CHEM, V271, P4605; KAJI H, 1995, ENDOCRINOLOGY, V136, P842, DOI 10.1210/en.136.3.842; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756-3282(97)00180-4; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kozawa O, 1998, BONE, V22, P355, DOI 10.1016/S8756-3282(97)00293-7; Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; Martinez ME, 1997, J BONE MINER RES, V12, P778, DOI 10.1359/jbmr.1997.12.5.778; Nagy Z, 2001, J BONE MINER RES, V16, P1220, DOI 10.1359/jbmr.2001.16.7.1220; Onyia JE, 1997, J CELL BIOCHEM, V67, P265, DOI 10.1002/(SICI)1097-4644(19971101)67:2<265::AID-JCB12>3.0.CO;2-E; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Quinn CO, 2000, ENDOCRINE, V12, P227, DOI 10.1385/ENDO:12:3:227; RIXON RH, 1994, J BONE MINER RES, V9, P1179; ROUFFET J, 1994, REPROD NUTR DEV, V34, P473, DOI 10.1051/rnd:19940508; Sanders JL, 2000, J BONE MINER RES, V15, P885, DOI 10.1359/jbmr.2000.15.5.885; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; SUGIMOTO T, 1993, J BONE MINER RES, V8, P451; Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Valin A, 1997, J CELL PHYSIOL, V170, P209, DOI 10.1002/(SICI)1097-4652(199702)170:2<209::AID-JCP13>3.3.CO;2-Y; Valin A, 1999, CALCIFIED TISSUE INT, V65, P148, DOI 10.1007/s002239900674; Valin A, 2001, ENDOCRINOLOGY, V142, P2752, DOI 10.1210/en.142.7.2752; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WHITFIELD JF, 1994, J CELL PHYSIOL, V158, P518, DOI 10.1002/jcp.1041580317; Yang CH, 1997, PROBABILIST ENG MECH, V12, P1, DOI 10.1016/S0266-8920(96)00009-4	53	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28109	28117		10.1074/jbc.M111013200	http://dx.doi.org/10.1074/jbc.M111013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12000745	hybrid			2022-12-25	WOS:000177189800067
J	Chang, TS; Jeong, W; Choi, SY; Yu, SQ; Kang, SW; Rhee, SG				Chang, TS; Jeong, W; Choi, SY; Yu, SQ; Kang, SW; Rhee, SG			Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN-TYROSINE PHOSPHATASES; MAMMALIAN PEROXIREDOXIN; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; REVERSIBLE INACTIVATION; THIOREDOXIN PEROXIDASE; REDUCE PEROXIDES; OXYGEN; CDC2	Hydrogen peroxide is implicated as an intracellular messenger in various cellular responses such as proliferation and differentiation. Peroxiredoxin (Prx) I is a member of the peroxiredoxin family of peroxidases and contains a consensus site (Thr(90)-Pro-Lys-Lys) for phosphorylation by cyclin-dependent kinases (CDKs). This protein has now been shown to be phosphorylated specifically on Thr(90) by several CDKs, including Cdc2, in vitro. Phosphorylation of Prx I on Thr(90) reduced the peroxidase activity of this protein by 80%. The phosphorylation of Prx I in HeLa cells was monitored with the use of antibodies specific for Prx I phosphorylated on Thr(90). Immunoblot analysis with these antibodies of HeLa cells arrested at various stages of the cell cycle revealed that Prx I phosphorylation occurs in parallel with the activation of Cdc2; Prx I phosphorylation was thus marked during mitosis but virtually undetectable during interphase. Furthermore, when Cdc2 expression was reduced by RNA interference with cognate small interfering RNAs, Prx I phosphorylation was not observed in the cells synchronized in mitotic phase. The cytosolic location of Prx I likely prevents its interaction with activated CDKs until after the breakdown of the nuclear envelope during mitosis, when Cdc2 is the CDK that is most active. Phosphorylation of Prx I on Thr90 both in vitro and in vivo was blocked by roscovitine, an inhibitor of CDKs. These results suggest that Cdc2-mediated phosphorylation and inactivation of Prx I and the resulting intracellular accumulation of H2O2 might be important for progression of the cell cycle.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University	Rhee, SG (corresponding author), Bldg 50,Rm 3523,S Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov						Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cunnick JM, 1998, BIOCHEM MOL BIOL INT, V45, P887; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Harborth J, 2001, J CELL SCI, V114, P4557; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Ichimiya S, 1997, DNA CELL BIOL, V16, P311, DOI 10.1089/dna.1997.16.311; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREK W, 1995, METHOD ENZYMOL, V254, P114; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mizusawa H, 2000, NEUROSCI LETT, V283, P57, DOI 10.1016/S0304-3940(00)00910-1; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oberley TD, 2001, FREE RADICAL BIO MED, V30, P412, DOI 10.1016/S0891-5849(00)00486-X; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rhee S.G., 2000, SCI STKE; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; RIME H, 1995, EXP CELL RES, V219, P29, DOI 10.1006/excr.1995.1201; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YOU JS, 1995, J CELL PHYSIOL, V164, P424, DOI 10.1002/jcp.1041640223; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	55	200	222	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25370	25376		10.1074/jbc.M110432200	http://dx.doi.org/10.1074/jbc.M110432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986303	hybrid			2022-12-25	WOS:000176747000069
J	Hess, MT; Gupta, RD; Kolodner, RD				Hess, MT; Gupta, RD; Kolodner, RD			Dominant Saccharomyces cerevisiae msh6 mutations cause increased mispair binding and decreased dissociation from mispairs by Msh2-Msh6 in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; ESCHERICHIA-COLI MUTS; CELL NUCLEAR ANTIGEN; HMUTS-ALPHA; BASE PAIRS; DUPLEX OLIGONUCLEOTIDES; TRANSLOCATION MECHANISM; SUBUNIT INTERACTIONS; RECOGNITION COMPLEX; SPECIFICALLY BINDS	A previous study described four dominant msh6 mutations that interfere with both the Msh2-Msh6 and Msh2-Msh3 mismatch recognition complexes (Das Gupta, R., and Kolodner, R. D. (2000) Nat. Genet. 24, 53-56). Modeling predicted that two of the amino acid substitutions (G1067D and G1142D) interfere with protein-protein interactions at the ATP-binding site-associated dimer interface, one (S1036P) similarly interferes with protein-protein interactions and affects the Msh2 ATP-binding site, and one (H1096A) affects the Msh6 ATP-binding site. The ATPase activity of the Msh2-Msh6-G1067D and Msh2-Msh6-G1142D complexes was inhibited by GT, +A, and +AT mispairs, and these complexes showed increased binding to GT and +A mispairs in the presence of ATP. The ATPase activity of the Msh2-Msh6-S1036P complex was inhibited by a GT mispair, and it bound the GT mispair in the presence of ATP, whereas its interaction with insertion mispairs was unchanged compared with the wild-type complex. The ATPase activity of the Msh2-Msh6-H1096A complex was generally attenuated, and its mispair-binding behavior was unaffected. These results are in contrast to those obtained with the wild-type Msh2-Msh6 complex, which showed mispair-stimulated ATPase activity and ATP inhibition of mispair binding. These results indicate that the dominant msh6 mutations cause more stable binding to mispairs and suggest that there may be differences in how base base and insertion mispairs are recognized.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.		Classen, Scott/AAY-8176-2020		NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA92584] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Das Gupta R, 2000, NAT GENET, V24, P53, DOI 10.1038/71684; Drotschmann K, 2001, J BIOL CHEM, V276, P46225, DOI 10.1074/jbc.C100450200; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dufner P, 2000, J BIOL CHEM, V275, P36550, DOI 10.1074/jbc.M005987200; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lynch HT, 1999, J MED GENET, V36, P801; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Schofield MJ, 2001, J BIOL CHEM, V276, P45505, DOI 10.1074/jbc.C100449200; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Yamamoto A, 2000, NUCLEIC ACIDS RES, V28, P3564, DOI 10.1093/nar/28.18.3564	68	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25545	25553		10.1074/jbc.M202282200	http://dx.doi.org/10.1074/jbc.M202282200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986324	hybrid			2022-12-25	WOS:000176747000091
J	Inoue, Y; Hayhurst, GP; Inoue, J; Mori, M; Gonzalez, FJ				Inoue, Y; Hayhurst, GP; Inoue, J; Mori, M; Gonzalez, FJ			Defective ureagenesis in mice carrying a liver-specific disruption of he-datocvte nuclear factor 4 alpha (HNF4 alpha) - HNF4 alpha regulates ornithine transcarbamylase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTORS; HEMOPHILIA-B LEYDEN; FACTOR-IX PROMOTER; GENE-EXPRESSION; BINDING-SITE; CYCLE ENZYMES; VISCERAL ENDODERM; RESPONSE ELEMENT; C/EBP-BETA; CELL	Hepatocyte nuclear factor 4alpha (HNF4alpha) regulates the expression of many genes preferentially expressed in liver. HNF4alpha-null mice die during embryogenesis precluding the analysis of its function in the adult. To circumvent this problem, liver-specific HNF4alpha-null mice were produced. Mice lacking hepatic HNF4alpha expression exhibited increased serum ammonia and reduced serum urea. This disruption in ureagenesis may be explained by a marked decrease in expression and activity of hepatic ornithine transcarbamylase (OTC). To determine the molecular mechanisms involved in transcriptional regulation of the mouse OTC gene, the OTC promoter region was analyzed. Sequence analysis revealed the presence of two putative HNF4alpha-binding sites in the mouse OTC promoter region. By using transient transfection analysis, it was established that high levels of promoter activity were dependent on both HNF4alpha-binding sites and the expression of HNF4alpha. Furthermore, the proximal HNF4alpha-binding site was found to be more important than the distal. one for transactivating OTC promoter. These data demonstrate that HNF4alpha is critical for urea homeostasis by direct regulation of the OTC gene in vivo.	NCI, Div Basic Sci, Lab Metab, NIH, Bethesda, MD 20892 USA; Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kumamoto University	Gonzalez, FJ (corresponding author), NCI, Div Basic Sci, Lab Metab, NIH, 9000 Rockville Pike,Rm 3E-24,Bldg 37, Bethesda, MD 20892 USA.		Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482				[Anonymous], 2001, NUCL RECEPTORS GENET; Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; Bailly A, 1998, J CELL SCI, V111, P2411; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; BULLA GA, 1994, MOL CELL BIOL, V14, P7086, DOI 10.1128/MCB.14.11.7086; CARTER ME, 1993, J BIOL CHEM, V268, P13805; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Duncan SA, 1997, DEVELOPMENT, V124, P279; Garnier G, 1996, J BIOL CHEM, V271, P30205, DOI 10.1074/jbc.271.47.30205; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; GRISOLIA S, 1952, J BIOL CHEM, V198, P561; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HODGES PE, 1989, P NATL ACAD SCI USA, V86, P4142, DOI 10.1073/pnas.86.11.4142; IKEMOTO M, 1990, BIOCHEM J, V270, P697, DOI 10.1042/bj2700697; Inoue Y, 2001, INT J MOL MED, V8, P481; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Kimura T, 2001, FEBS LETT, V494, P105, DOI 10.1016/S0014-5793(01)02320-1; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LARGILLIERE C, 1995, LANCET, V345, P1113, DOI 10.1016/S0140-6736(95)90843-9; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Matsuda I, 1997, AM J MED GENET, V71, P378, DOI 10.1002/(SICI)1096-8628(19970905)71:4<378::AID-AJMG2>3.0.CO;2-Q; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MORI M, 1979, P NATL ACAD SCI USA, V76, P5071, DOI 10.1073/pnas.76.10.5071; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; Naka H, 1996, BRIT J HAEMATOL, V92, P231, DOI 10.1046/j.1365-2141.1995.269804.x; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; Qureshi IA, 1997, ADV EXP MED BIOL, V420, P143; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; Tuchman M, 1996, HUM GENET, V97, P274, DOI 10.1007/BF02185751; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; VERES G, 1986, J BIOL CHEM, V261, P7588; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Ye XH, 1996, J BIOL CHEM, V271, P3639; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826	57	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25257	25265		10.1074/jbc.M203126200	http://dx.doi.org/10.1074/jbc.M203126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994307	hybrid			2022-12-25	WOS:000176747000054
J	Kassenbrock, CK; Hunter, S; Garl, P; Johnson, GL; Anderson, SM				Kassenbrock, CK; Hunter, S; Garl, P; Johnson, GL; Anderson, SM			Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SYK TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; SIGNALING PATHWAY; T-CELLS; ADAPTER PROTEINS; BREAST-CANCER; RING FINGER; IN-VIVO	Stimulation of T47D cells with epidermal growth factor (EGF) results in the activation of the intrinsic tyrosine kinases of the receptor and the phosphorylation of multiple cellular proteins including the receptor, scaffold molecules such as c-Cbl, adapter molecules such as Shc, and the serine/threonine protein kinase Akt. We demonstrate that EGF stimulation of T47D cells results in the activation of the Src protein-tyrosine kinase and that the Src kinase inhibitor PP1 blocks the EGF-induced phosphorylation of c-Cbl but not the activation/phosphorylation of the EGF receptor itself. PP1 also blocks EGF-induced ubiquitination of the EGF receptor, which is presumably mediated by phosphorylated c-Cbl. Src is associated with c-Cbl, and we have previously demonstrated that the Src-like kinase Fyn can phosphorylate c-Cbl at a preferred binding site for the p85 subunit of phosphatidylinositol 3'-kinase. PP1 treatment blocks EGF-induced activation of the anti-apoptotic protein kinase Akt suggesting that Src may regulate activation of Akt, perhaps by a Src --> c-Cbl --> phosphatidylinositol 3'-kinase --> Akt pathway.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Anderson, SM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Box B-216,200 E 9th Ave, Denver, CO 80262 USA.	steve.anderson@uchsc.edu			NIDDK NIH HHS [DK48879] Funding Source: Medline; NIGMS NIH HHS [GM55754] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055754] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1996, ONCOGENE, V12, P2491; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smit L, 1996, ONCOGENE, V13, P381; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	95	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24967	24975		10.1074/jbc.M201026200	http://dx.doi.org/10.1074/jbc.M201026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994282	hybrid			2022-12-25	WOS:000176747000018
J	Pendleton, LC; Goodwin, BL; Flam, BR; Solomonson, LP; Eichler, DC				Pendleton, LC; Goodwin, BL; Flam, BR; Solomonson, LP; Eichler, DC			Endothelial argininosuccinate synthase mRNA 5 '-untranslated region diversity - Infrastructure for tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; L-ARGININE; MESSENGER-RNA; TRANSLATIONAL CONTROL; L-CITRULLINE; CELLS; INITIATION; METABOLISM; TRANSPORT; SEQUENCES	Based on the integral role that argininosuccinate synthase (AS) plays in the production of nitric oxide in vascular endothelial cells and urea in liver, an analysis was carried out to determine whether signals reside in the AS mRNA to account for tissue differences in AS function and location. Reverse transcriptase-PCR and sequence analysis showed that the AS mRNA coding region was the same for both endothelial cells and liver; however, 5'-RACE analysis (rapid amplification of cDNA ends) identified AS mRNA species in endothelial cells in addition to a major 43-nucleotide (nt) 5'-untranslated region (UTR) AS mRNA with overlapping extended 5'-UTRs of 66 and 92 nt. Comparison to the genomic sequence immediately upstream of the reported transcription start site for the human and mouse AS gene suggested that expression of all three species of bovine endothelial AS mRNA are driven by a common promoter and that 5'-UTR diversity in endothelial cells results from three transcriptional initiation sites within exon 1. RNase protection analysis and real-time reverse transcriptase-PCR verified and quantitated the differential expression of the extended 5'-UTR species relative to the major 43-nt 5'-UTR AS mRNA. In vitro translation studies showed a less pronounced but similar discordant expression. Sequential deletions starting from the 5' terminus of the 92-nt 5'-UTR construct resulted in a corresponding increase in translational efficiency, but the most pronounced effect resulted from mutation of an upstream open reading frame, which restored translational efficiency of the 92-nt 5'-UTR AS mRNA. When the different AS mRNA 5'-UTRs, cloned in front of a luciferase reporter gene, were transfected into endothelial cells, the pattern of luciferase expression was nearly identical to that observed for the different 5'-UTR AS mRNAs in endothelial cells. Given the different roles ascribed for argininosuccinate synthase, urea versus NO production, these results suggest that sequence in the AS gene represented by position -92 to -43 nt from the translation start site in the extended AS mRNA 5'UTRs plays an important role in differential and tissue-specific expression.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Eichler, DC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA.		Flam, Brenda/I-5625-2012; Eichler, Duane/A-1906-2012					BAYDOUN AR, 1990, BIOCHEM BIOPH RES CO, V173, P940, DOI 10.1016/S0006-291X(05)80876-9; BLOCK ER, 1995, AM J PHYSIOL-LUNG C, V269, pL574, DOI 10.1152/ajplung.1995.269.5.L574; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Moor CH, 2001, INT REV CYTOL, V203, P567; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FAKLER CR, 1995, ACTA PAEDIATR, V84, P460, DOI 10.1111/j.1651-2227.1995.tb13673.x; Flam BR, 2001, NITRIC OXIDE-BIOL CH, V5, P187, DOI 10.1006/niox.2001.0340; FREYTAG SO, 1984, J BIOL CHEM, V259, P3160; FREYTAG SO, 1984, MOL CELL BIOL, V4, P1978, DOI 10.1128/MCB.4.10.1978; GOLD ME, 1989, BIOCHEM BIOPH RES CO, V164, P714, DOI 10.1016/0006-291X(89)91518-0; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; JINNO Y, 1985, J BIOCHEM-TOKYO, V98, P1395, DOI 10.1093/oxfordjournals.jbchem.a135407; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; McDonald KK, 1997, BBA-BIOMEMBRANES, V1324, P133, DOI 10.1016/S0005-2736(96)00226-X; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; Sonenberg Nahum, 1993, Gene Expression, V3, P317; SURH LC, 1991, GENE, V99, P181, DOI 10.1016/0378-1119(91)90125-U; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25363	25369		10.1074/jbc.M111677200	http://dx.doi.org/10.1074/jbc.M111677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11967259	hybrid			2022-12-25	WOS:000176747000068
J	Zhao, HX; Kinnunen, PKJ				Zhao, HX; Kinnunen, PKJ			Binding of the antimicrobial peptide temporin L to liposomes assessed by Trp fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN FLUORESCENCE; MODEL MEMBRANES; MAGAININ 2; DEPTH; PROTEIN; PENETRATION; ORIENTATION; ANALOGS; CHARGE; PORES	The structure and membrane topology of the antimicrobial peptide temporin L (FVQWFSKFLGRILNH(2)) were studied using liposomes as model bilayers. Circular dichroic spectra revealed temporin L to adopt an alpha-helical conformation when bound to liposomes. Binding of temporin L to liposomes induced significant blue shifts of the emission spectra of the single Trp residue (Trp(4)) and also changed its quantum yield. The observed changes in the characteristics of the Trp(4) fluorescence are in keeping with the insertion of this residue into the hydrophobic region of the liposomal bilayers. Access of the aqueous quencher acrylamide to Trp(4) decreased in the sequence 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC)/cholesterol (X-chol = 0.1) > SOPC > SOPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG, X-POPG = 0.1) > SOPC/POPG (X-POPG = 0.2) approximate to SOPC/POPG (X-POPG = 0.4), where X represents molar fraction of the indicated lipid. Whereas quenching of Trp(4) by brominated phospholipids was significant in SOPC liposomes, the quenching efficiency was enhanced when the vesicles contained POPG. The depth of insertion of Trp(4) into lipid bilayers was calculated by both the parallax method and distribution analysis and revealed this residue to reside at an average distance of d approximate to 8.0 +/- 0.5 Angstrom from the center of both SOPC and SOPC/POPG bilayers. However, in the presence of cholesterol, d was increased to 9.5 +/- 0.5 Angstrom, thus revealing Trp(4) to become accommodated more superficially in the bilayer. The above data suggest the presence of two populations of temporin L in SOPC- and POPG-containing membranes with parallel and perpendicular orientation with respect to the plane of the membrane surface.	Univ Helsinki, Helsinki Biophys & Biomembrane Grp, Inst Biomed, FIN-00014 Helsinki, Finland	University of Helsinki	Kinnunen, PKJ (corresponding author), Univ Helsinki, Helsinki Biophys & Biomembrane Grp, Inst Biomed, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Paavo.Kinnunen@Helsinki.fi		Zhao, Hongxia/0000-0002-1606-5621				ARGIOLAS A, 1984, J BIOL CHEM, V259, P106; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P21, DOI 10.1016/0005-2736(78)90108-6; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; Ladokhin A S, 1993, J Fluoresc, V3, P195, DOI 10.1007/BF00862742; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Ladokhin AS, 1997, METHOD ENZYMOL, V278, P462; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MCELHANEY RN, 1999, BIOCHIM BIOPHYS ACTA, V1462, P1; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Oren Z, 1998, BIOPOLYMERS, V47, P451; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; VANGINKEL G, 1989, BIOCHIMIE, V71, P23, DOI 10.1016/0300-9084(89)90127-2; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173; Zhao HX, 2002, BIOCHEMISTRY-US, V41, P4425, DOI 10.1021/bi011929e; Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3	42	86	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25170	25177		10.1074/jbc.M203186200	http://dx.doi.org/10.1074/jbc.M203186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991956	hybrid			2022-12-25	WOS:000176747000043
J	Greenwood, IA; Miller, LJ; Ohya, S; Horowitz, B				Greenwood, IA; Miller, LJ; Ohya, S; Horowitz, B			The large conductance potassium channel beta-subunit can interact with and modulate the functional properties of a calcium-activated chloride channel, CLCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNELS; CLONING; PROTEINS; TRACHEA; FAMILY; CELLS; LUNG	We have recently compared the biophysical and pharmacological properties of native Ca2+-activated Cl- currents in murine portal vein with mCLCA1 channels cloned from murine portal vein myocytes (Britton, F. C., Ohya, S., Horowitz, B., and Greenwood, I. A (2002) J. Physiol. (Lond.) 539,107-117). These channels shared a similar relative permeability to various anions, but the expressed channel current lacked the marked time dependence of the native current. In addition, the expressed channel showed a lower Ca2+ sensitivity than the native channel. As non-pore-forming regulatory beta-subunits alter the kinetics and increase the Ca2+ sensitivity of Ca2+-dependent K+ channels (BK channels) we investigated whether co-expression of beta-subunits with CLCA1 would alter the kinetics/Ca2+ sensitivity of mCLCA1. Internal dialysis of human embryonic kidney cells stably expressing CLCA1 with 500 nM Ca2+ evoked a significantly larger current when the beta-subunit KC-NMB1 was co-expressed. In a small number of co-transfected cells marked time dependence to the activation kinetics was observed. Interaction studies using the mammalian two-hybrid technique demonstrated a physical association between CLCA1 and KCNMB1 when coexpressed in human embryonic kidney cells. These data suggest that activation of CLCA1 can be modified by accessory subunits.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Horowitz, B (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, MS352 Anderson Med Bldg, Reno, NV 89557 USA.		Ohya, Susumu/AAB-3618-2020	Ohya, Susumu/0000-0002-5765-0667; Greenwood, Iain/0000-0002-0603-0492	NCRR NIH HHS [P20 RR15581] Funding Source: Medline; NHLBI NIH HHS [HL 49524] Funding Source: Medline; NIDDK NIH HHS [DK 41315] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041315] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Britton FC, 2002, J PHYSIOL-LONDON, V539, P107, DOI 10.1113/jphysiol.2001.013170; Collier ML, 1996, CIRC RES, V78, P936, DOI 10.1161/01.RES.78.5.936; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; ELBLE RC, 2002, J BIOL CHEM, V10, P1074; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Fuller CM, 2001, PFLUG ARCH EUR J PHY, V443, pS107, DOI 10.1007/s004240100655; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Greenwood IA, 1999, J PHYSIOL-LONDON, V516, P365, DOI 10.1111/j.1469-7793.1999.0365v.x; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ji HL, 1998, AM J PHYSIOL-CELL PH, V274, pC455, DOI 10.1152/ajpcell.1998.274.2.C455; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Nilius B, 1997, J VASC RES, V34, P220, DOI 10.1159/000159226; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Wang Q, 1997, AM J PHYSIOL-CELL PH, V273, pC520, DOI 10.1152/ajpcell.1997.273.2.C520; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971	19	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22119	22122		10.1074/jbc.C200215200	http://dx.doi.org/10.1074/jbc.C200215200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11994272	hybrid			2022-12-25	WOS:000176313600004
J	Srinivasula, SM; Poyet, JL; Razmara, M; Datta, P; Zhang, ZJ; Alnemri, ES				Srinivasula, SM; Poyet, JL; Razmara, M; Datta, P; Zhang, ZJ; Alnemri, ES			The PYRIN-CARD protein ASC is an activating adaptor for caspase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECRUITMENT DOMAIN; FAMILY MEMBER; CROHNS-DISEASE; APOPTOSIS; KINASE; NOD2; SUSCEPTIBILITY; IDENTIFICATION; INFLAMMATION	The PYRIN and CARD domains are members of the six-helix bundle death domain-fold superfamily that mediates assembly of large signaling complexes in the apoptotic and inflammatory signaling pathways. Here we show that the PYRIN-CARD protein ASC functions as a caspase-1-activating adaptor. ASC interacted specifically with procaspase-1 via CARD-CARD interactions and induced its oligomerization. Consistent with these results ectopic expression of full-length ASC, but not its isolated CARD or PYRIN domain, with procaspase-1 induced activation of procaspase-1 and processing of prointerleukin-1beta in transfected cells. Substitution of the PYRIN domain of ASC with an inducible FKBP12 oligomerization domain produced a molecule that can induce caspase-1 activation in response to stimulation with the oligomerization drug AP20187, suggesting that the PYRIN domain functions as an oligomerization domain, whereas the CARD domain functions as the effector domain in the caspase-1 activation pathway. Furthermore stable expression of an isolated CARD of ASC in THP-1 cells diminished interleukin-1beta generation in response to pro-inflammatory cytokines. These results indicate that ASC is involved in the caspase-1 signaling pathway by mediating the assembly of a caspase-1-inflammasome signaling complex in response to pro-inflammatory cytokine stimulation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NCI NIH HHS [CA85421] Funding Source: Medline; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aksentijevich I, 1997, CELL, V90, P797; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1	27	422	441	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21119	21122		10.1074/jbc.C200179200	http://dx.doi.org/10.1074/jbc.C200179200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11967258	hybrid			2022-12-25	WOS:000176286000003
J	Langevin, HM; Churchill, DL; Wu, JR; Badger, GJ; Yandow, JA; Fox, JR; Krag, MH				Langevin, HM; Churchill, DL; Wu, JR; Badger, GJ; Yandow, JA; Fox, JR; Krag, MH			Evidence of connective tissue involvement in acupuncture	FASEB JOURNAL			English	Article						biomechanics; subcutaneous tissue; mechanical stress; ultrasound; histology	MECHANISM; BRAIN	Acupuncture needle manipulation gives rise to "needle grasp," a biomechanical phenomenon characterized by an increase in the force necessary to pull the needle out of the tissue (pullout force). This study investigates the hypothesis that winding of connective tissue, rather than muscle contraction, is the mechanism responsible for needle grasp. We performed 1) measurements of pullout force in humans with and without needle penetration of muscle; 2) measurements of pullout force in anesthetized rats, with and without needle rotation, followed by measurements of connective tissue volume surrounding the needle; 3) imaging of rat abdominal wall explants, with and without needle rotation, using ultrasound scanning acoustic microscopy. We found 1) no evidence that increased penetration of muscle results in greater pullout force than increased penetration of subcutaneous tissue; 2) that both pullout force and subcutaneous tissue volume were increased by needle rotation; 3) that increased periodic architectural order was present in subcutaneous tissue with rotation, compared with no rotation. These data support connective tissue winding as the mechanism responsible for the increase in pullout force induced by needle rotation. Winding may allow needle movements to deliver a mechanical signal into the tissue and may be key to acupuncture's therapeutic mechanism.	Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Phys, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Orthopaed & Rehabil, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Med Biostat, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont	Langevin, HM (corresponding author), Univ Vermont, Coll Med, Dept Neurol, Given C423, Burlington, VT 05405 USA.	hlangevi@zoo.uvm.edu						ANDERSSON S, 1993, SCAND J REHABIL MED, P31; [Anonymous], 1997, NIH Consens Statement, V15, P1; Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95-043; Box GE., 1978, STAT EXPT; Brand RA, 1997, ANN MED, V29, P267, DOI 10.3109/07853899708999346; Briggs A., 1992, ACOUSTIC MICROSCOPY; Cheng X, 1987, CHINESE ACUPUNCTURE; Chiang CY, 1973, SCI SINICA, V16, P210; Cho ZH, 1998, P NATL ACAD SCI USA, V95, P2670, DOI 10.1073/pnas.95.5.2670; De Morant G. S., 1994, CHINESE ACUPUNCTURE; DENMEI S, 1990, INTRO MERIDIAN THERA; DUCK FA, 1990, PHYSICAL PROPERTIES; DUNG HC, 1984, AM J ACUPUNCTURE, V12, P139; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST M, 1985, PAIN, V21, P25, DOI 10.1016/0304-3959(85)90073-9; GUNN C C, 1976, American Journal of Chinese Medicine, V4, P183, DOI 10.1142/S0192415X76000238; GUNN CC, 1977, AM J ACUPUNCTURE, V5, P115; HAN JS, 1987, NEUROCHEMICAL BASIS; Helms JM., 1995, ACUPUNCTURE ENERGETI; Hibbeler R. C, 1995, ENG MECH STAT DYNAMI; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Kendall M.G., 1969, ADV THEORY STAT, V1; KIMURA M, 1992, AM J CHINESE MED, V20, P25, DOI 10.1142/S0192415X92000047; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471; LIU Y K, 1975, American Journal of Chinese Medicine, V3, P347, DOI 10.1142/S0192415X75000426; O'Connor J, 1987, ACUPUNCTURE COMPREHE; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; *SHANGH I PHYS, 1973, CHIN MED J, V153, P532; Stux G, 1995, BASICS ACUPUNCTURE; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Willis Jr W. D., 1991, SENSORY MECH SPINAL; WORSLEY JR, 1982, TRADITIONAL CHINESE, V1; YANG J, 1601, GOLDEN NEEDLE OTHER; 1994, YELLOW EMPERORS CLAS	36	179	198	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					872	+		10.1096/fj.01-0925fje	http://dx.doi.org/10.1096/fj.01-0925fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967233				2022-12-25	WOS:000175425900017
J	Kaneto, H; Xu, G; Fujii, N; Kim, S; Bonner-Weir, S; Weir, GC				Kaneto, H; Xu, G; Fujii, N; Kim, S; Bonner-Weir, S; Weir, GC			Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; HOMEODOMAIN PROTEIN IDX-1; NITRIC-OXIDE; HIGH GLUCOSE; TRANSCRIPTIONAL ACTIVATION; SUPEROXIDE-PRODUCTION; HEXOSAMINE PATHWAY; PROMOTER ACTIVITY; MYC EXPRESSION; MESSENGER-RNA	Oxidative stress, which is found in pancreatic beta-cells in the diabetic state, suppresses insulin gene transcription and secretion, but the signaling pathways involved in the beta-cell dysfunction induced by oxidative stress remain unknown. In this study, subjecting rat islets to oxidative stress activates JNK, p38 MAPK, and protein kinase C, preceding the decrease of insulin gene expression. Adenovirus-mediated overexpression of dominant-negative type (DN) JNK, but not the p38 MAPK inhibitor SB203580 nor the protein kinase C inhibitor GF109203X, protected insulin gene expression and secretion from oxidative stress. Moreover, wild type JNK overexpression suppressed both insulin gene expression and secretion. These results were correlated with changes in the binding of the important transcription factor PDX-1 to the insulin promoter; adenoviral overexpression of DN-JNK preserved PDX-1 DNA binding activity in the face of oxidative stress, whereas wild type JNK overexpression decreased PDX-1 DNA binding activity. Furthermore, to examine whether suppression of the JNK pathway can protect beta-cells from the toxic effects of hyperglycemia, rat islets were infected with DN-JNK expressing adenovirus or control adenovirus and transplanted under renal capsules of streptozotocin-induced diabetic nude mice. In mice receiving DN-JNK overexpressing islets, insulin gene expression in islet grafts was preserved, and hyperglycemia was ameliorated compared with control mice. In conclusion, activation of JNK is involved in the reduction of insulin gene expression by oxidative stress, and suppression of the JNK pathway protects beta-cells from oxidative stress.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Osaka City Univ, Sch Med, Dept Pharmacol, Osaka 545, Japan; Joslin Diabet Ctr, Metab Sect, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Osaka Metropolitan University; Harvard University; Joslin Diabetes Center, Inc.	Weir, GC (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA.	kaneto@osb.att.ne.jp; gordon.weir@joslin.harvard.edu	Fujii, Nobuharu/J-2724-2014	Fujii, Nobuharu/0000-0002-0974-3033; Bonner-Weir, Susan/0000-0003-4682-0656	NIDDK NIH HHS [DK-35449, DK-36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035449, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; DAVALLI AM, 1995, DIABETES, V44, P104, DOI 10.2337/diabetes.44.1.104; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ihara Y, 2000, FEBS LETT, V473, P24, DOI 10.1016/S0014-5793(00)01489-7; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaneto H, 1997, J BIOL CHEM, V272, P29137, DOI 10.1074/jbc.272.46.29137; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; Kaneto H, 2002, J BIOL CHEM, V277, P12998, DOI 10.1074/jbc.M111148200; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; Leinonen J, 1997, FEBS LETT, V417, P150, DOI 10.1016/S0014-5793(97)01273-8; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Liu WL, 2000, AM J PHYSIOL-ENDOC M, V279, pE782, DOI 10.1152/ajpendo.2000.279.4.E782; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; Mandrup-Poulsen T, 2001, DIABETES, V50, pS58, DOI 10.2337/diabetes.50.2007.S58; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olson L.K., 1995, P NATL ACAD SCI USA, V92, P514; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; Purves T, 2001, FASEB J, V15, P2508, DOI 10.1096/fj.01-0253hyp; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Sharma A, 1999, DIABETES, V48, P507, DOI 10.2337/diabetes.48.3.507; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Stoffers DA, 1997, TRENDS ENDOCRIN MET, V8, P145, DOI 10.1016/S1043-2760(97)00008-8; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; WELSH M, 1985, J BIOL CHEM, V260, P3590; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	77	265	280	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30010	30018		10.1074/jbc.M202066200	http://dx.doi.org/10.1074/jbc.M202066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12011047	hybrid			2022-12-25	WOS:000177509300082
J	Han, YP; Nien, YD; Garner, WL				Han, YP; Nien, YD; Garner, WL			Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; 92-KD GELATINASE; IV COLLAGENASE; WOUND FLUID; EXPRESSION; CYTOKINES; MATRIX-METALLOPROTEINASE-9; STROMELYSIN; PROGRESSION; METASTASIS	The proteolytic activation of pro-matrix metalloproteinase (MMP)-9 by conversion of the 92-kDa precursor into an 82-kDa active form has been observed in chronic wounds, tumor metastasis, and many inflammation-associated diseases, yet the mechanistic pathway to control this process has not been identified. In this report, we show that the massive expression and activation of MMP-9 in skin tissue from patients with chronically unhealed wounds could be reconstituted in vitro with cultured normal human skin by stimulation with transforming growth factor-beta and tumor necrosis factor (TNF)-alpha. We dissected the mechanistic pathway for TNF-alpha induced activation of pro-MMP-9 in human skin. We found that proteolytic activation of pro-MMP-9 was mediated by a tissue-associated chymotrypsin-like proteinase, designated here as pro-MMP-9 activator (pM9A). This unidentified activator specifically converted pro-MMP-9 but not pro-MMP-2, another member of the gelatinase family. The tissue-bound pM9A was steadily expressed and not regulated by TNF-alpha, which indicated that the cytokine-mediated activation of pro-MMP-9 might be regulated at the inhibitor level. Indeed, the skin constantly secreted tissue inhibitor of metalloproteinase-1 at the basal state. TNF-alpha, but not transforming growth factor-beta, down-regulated this inhibitor. The TNF-alpha-mediated activation of pro-MMP-9 was tightly associated with down-regulation of tissue inhibitor of metalloproteinase-1 in a dose-dependent manner. To establish this linkage, we demonstrate that the recombinant tissue inhibitor of metalloproteinase-1 could block the activation of pro-MMP-9 by either the intact skin or skin fractions. Thus, these studies suggest a novel regulation for the proteolytic activation of MMP-9 in human tissue, which is mediated by tissue-bound activator and controlled by down-regulation of a specific inhibitor.	Univ So Calif, Keck Sch Med, Div Plast & Reconstruct Surg, Dept Surg, Los Angeles, CA 90033 USA	University of Southern California	Han, YP (corresponding author), Univ So Calif, Keck Sch Med, Div Plast & Reconstruct Surg, Dept Surg, 1450 San Pablo St,Suite 2000, Los Angeles, CA 90033 USA.	yhan@surgery.usc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050967, R01GM050967] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050967-08, R29 GM050967, R01 GM050967, R01 GM050967-07, GM 50967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Cooney R, 1997, J TRAUMA, V42, P415, DOI 10.1097/00005373-199703000-00008; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; GARNER WL, 1993, J INVEST DERMATOL, V101, P875, DOI 10.1111/1523-1747.ep12371710; GIAVAZZI R, 1990, CANCER RES, V50, P4771; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Han YP, 2001, J CELL SCI, V114, P131; JORDON RE, 1985, J INVEST DERMATOL, V85, pS72, DOI 10.1111/1523-1747.ep12275497; Kleer CG, 2000, BREAST CANCER RES, V2, P423, DOI 10.1186/bcr89; Kurtzman SH, 1999, ONCOL REP, V6, P65; LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x; Lijnen HR, 1998, BLOOD, V91, P2045, DOI 10.1182/blood.V91.6.2045.2045_2045_2053; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Nash MA, 1999, ENDOCR-RELAT CANCER, V6, P93, DOI 10.1677/erc.0.0060093; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; REMICK DG, 1992, IMMUNOL INVEST, V21, P321, DOI 10.3109/08820139209069371; Rha SY, 1997, BREAST CANCER RES TR, V43, P175; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stadelmann WK, 1998, AM J SURG, V176, p39S, DOI 10.1016/S0002-9610(98)00184-6; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; Tarlton JF, 1997, BRIT J DERMATOL, V137, P506, DOI 10.1111/j.1365-2133.1997.tb03779.x; Trengove NJ, 2000, WOUND REPAIR REGEN, V8, P13, DOI 10.1046/j.1524-475x.2000.00013.x; TUAN TL, 1994, J CELL SCI, V107, P2285; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wielockx B, 2001, NAT MED, V7, P1202, DOI 10.1038/nm1101-1202; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; Wysocki AB, 1999, WOUND REPAIR REGEN, V7, P154, DOI 10.1046/j.1524-475X.1999.00154.x; Yager DR, 1996, J INVEST DERMATOL, V107, P743, DOI 10.1111/1523-1747.ep12365637; YOUNG PK, 1994, J INVEST DERMATOL, V103, P660, DOI 10.1111/1523-1747.ep12398424; Zeng ZS, 1998, BRIT J CANCER, V78, P349, DOI 10.1038/bjc.1998.497; ZUCKER S, 1989, INVAS METAST, V9, P167	41	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27319	27327		10.1074/jbc.M202842200	http://dx.doi.org/10.1074/jbc.M202842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004062	Green Accepted, hybrid			2022-12-25	WOS:000177055900080
J	Pawlak, G; Helfman, DM				Pawlak, G; Helfman, DM			MEK mediates v-Src-induced disruption of the actin cytoskeleton via inactivation of the Rho-ROCK-LIM kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; FOCAL ADHESIONS; STRESS FIBERS; PHOSPHORYLATION; TRANSFORMATION; PROTEIN; REORGANIZATION; CELLS; COFILIN; DYNAMICS	Cellular transformation by v-Src is believed to be caused by aberrant activation of signaling pathways that are normally regulated by cellular Src. Using normal rat kidney cells expressing a temperature-sensitive mutant of v-Src, we examined the role of the Raf/MEK/ERK, phosphatidylinositol 3-kinase/Akt, and Rho pathways in morphological transformation and cytoskeletal changes induced by v-Src. Activation of v-Src elicited a loss of actin stress fibers and focal contacts. A decrease in the phosphorylation level of cofilin was detected upon v-Src activation, which is indicative of attenuated Rho function. Inhibition of MEK using U0126 prevented v-Src-induced disruption of the cytoskeleton as well as dephosphorylation of cofilin, whereas treatment with a phosphatidylinositol 3-kinase inhibitor had no protective effect. In normal rat kidney cells stably transformed by v-Src, we found that the chronic activation of MEK induces down-regulation of ROCK expression, thereby uncoupling Rho from stress fiber formation. Taken together, these results establish MEK as an effector of v-Src-induced cytoskeleton disruption, participating in v-Src-induced antagonism of the cellular function of Rho.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Helfman, DM (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Helfman, David M./C-2058-2011		NCI NIH HHS [CA 83162] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1999, J CELL SCI, V112, P947; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Nagaoka R, 1996, CELL MOTIL CYTOSKEL, V35, P200, DOI 10.1002/(SICI)1097-0169(1996)35:3<200::AID-CM3>3.0.CO;2-C; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NOBES CD, 1995, J CELL SCI, V108, P225; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V11, P3097; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	33	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26927	26933		10.1074/jbc.M202261200	http://dx.doi.org/10.1074/jbc.M202261200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011049	hybrid			2022-12-25	WOS:000177055900031
J	Dai, MS; Chevallier, N; Stone, S; Heinrich, MC; McConnell, M; Reuter, T; Broxmeyer, HE; Licht, JD; Lu, L; Hoatlin, ME				Dai, MS; Chevallier, N; Stone, S; Heinrich, MC; McConnell, M; Reuter, T; Broxmeyer, HE; Licht, JD; Lu, L; Hoatlin, ME			The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; GROUP-C GENE; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR; ENCODING GENE; PROTEIN; EXPRESSION; PLZF; GROWTH; COMPLEX	FAZF, a member of the BTB/POZ family of transcriptional repressor proteins, has been shown to bind to FANCC, the protein defective in patients with the bone marrow failure syndrome Fanconi anemia complementation group C. Because bone marrow failure in Fanconi anemia has been attributed to a failure of the hematopoietic stem cell population to produce sufficient progeny, we documented the expression of FAZF in human CD34(+) hematopoietic progenitor cells. FAZF was expressed at high levels in early stages of differentiation but declined during subsequent differentiation into erythroid and myeloid lineages. Consistent with its presumed role as a transcriptional repressor, FAZF was found in the nuclear compartment, where it resides in distinct nuclear speckles at or near sites of DNA replication. Using a FAZF-inducible myeloid cell line, we found that enforced expression of FAZF was accompanied by accumulation in the G, phase of the cell cycle followed later by apoptosis. These results suggest an essential role for FAZF during the proliferative stages of primitive hematopoietic progenitors, possibly acting in concert with (a subset of) the Fanconi anemia proteins.	Oregon Hlth Sci Univ, Div Mol Med, Portland, OR 97201 USA; Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA; Portland Vet Adm Med Ctr, Portland, OR 97201 USA	Oregon Health & Science University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hoatlin, ME (corresponding author), Oregon Hlth Sci Univ, Div Mol Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Heinrich, Michael/AAC-6745-2019; Licht, Jonathan/L-4239-2019; Ittershagen, Stacie/X-7658-2019	Chevallier, Nathalie/0000-0002-1800-2579; Ittershagen, Stacie (Stone)/0000-0003-3834-176X; Licht, Jonathan/0000-0002-3942-1369; Heinrich, Michael/0000-0003-3790-0478; McConnell, Melanie J./0000-0003-3840-1347	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056045, R01HL056045] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline; NHLBI NIH HHS [HL56045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; BAGBY GC, 1993, BLOOD, V82, P183; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; BRADY G, 1995, CURR BIOL, V5, P909, DOI 10.1016/S0960-9822(95)00181-3; Carreau M, 1999, EXP HEMATOL, V27, P1667, DOI 10.1016/S0301-472X(99)00102-2; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; De Kerviler E, 2000, CLIN RADIOL, V55, P340, DOI 10.1053/crad.2000.0445; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haneline LS, 1999, BLOOD, V94, P1; Haneline LS, 1998, BLOOD, V91, P4092; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; HOATLIN ME, 1987, J VIROL, V61, P1442, DOI 10.1128/JVI.61.5.1442-1447.1987; Huynh KD, 2000, GENE DEV, V14, P1810; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kruyt FAE, 1997, CANCER RES, V57, P2244; Kupfer GM, 1996, BLOOD, V88, P1019; Lin WC, 1999, BIOCHEM BIOPH RES CO, V264, P789, DOI 10.1006/bbrc.1999.1594; Liu JM, 1997, HUM GENE THER, V8, P1715, DOI 10.1089/hum.1997.8.14-1715; Lu L, 1996, BLOOD, V87, P525, DOI 10.1182/blood.V87.2.525.bloodjournal872525; Lu L, 1999, BLOOD, V94, P2319, DOI 10.1182/blood.V94.7.2319.419k14_2319_2332; Matkovic ME, 2001, AM J HUM GENET, V69, P355; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SEGAL GM, 1994, J CLIN INVEST, V94, P846, DOI 10.1172/JCI117405; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Tang CJC, 2001, J BIOL CHEM, V276, P19631, DOI 10.1074/jbc.M100170200; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tower PA, 1998, EXP HEMATOL, V26, P19; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; WALSH CE, 1994, BLOOD, V84, P453; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	42	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26327	26334		10.1074/jbc.M201834200	http://dx.doi.org/10.1074/jbc.M201834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986317	hybrid			2022-12-25	WOS:000176908700067
J	Behera, AK; Kumar, M; Lockey, RF; Mohapatra, SS				Behera, AK; Kumar, M; Lockey, RF; Mohapatra, SS			2 '-5 ' oligoadenylate synthetase plays a critical role in interferon-7 inhibition of respiratory syncytial virus infection of human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-INDUCIBLE GENES; OLIGO-A SYNTHETASE; RNASE-L INHIBITOR; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; 2-5A-DEPENDENT RNASE; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; 2-5A SYNTHETASE; ACTIVATION	Respiratory syncytial virus (RSV), associated with bronchiolitis and asthma, is resistant to the antiviral effects of type-I interferons (IFN), but not IFN-gamma. However, the antiviral mechanism of IFN-gamma action against RSV infection is unknown. The molecular mechanism of IFN-gamma-induced antiviral activity was examined in this study using human epithelial cell lines HEp-2 and A549. Exposure of these cells to 100-1000 units/ml of IFN-gamma, either before or after RSV infection, results in a significant decrease in RSV infection. After 1 h of exposure, IFN-gamma induces protein expression of IFN regulatory factor-1 (IRF-1) but not IRF-2, double-stranded RNA-activated protein kinase, and inducible nitric-oxide synthase in these cells. The mRNA for IRF-1, p40, and p69 isoforms of 2'-5' oligoadenylate synthetase (2-5 AS) are detectable, respectively, at 1 and 4 h of IFN-gamma exposure. Studies using cycloheximide and antisense oligonucleotides to IRF-1 indicate a direct role of IRF-1 in activating 2-5 AS. Cells transfected with 2-5 AS antisense oligonucleotides inhibit the antiviral effect of IFN-gamma. A stable cell line of HEp-2 overexpressing RNase L inhibitor, RLI-14, which exhibits an IFN-gamma-induced gene expression pattern similar to that of the parent cell line, shows a significant reduction in RNase L activity and IFN-gamma-mediated antiviral effect, compared with HEp-2 cells. These results provide direct evidence of the involvement of 2-5 AS in IFN-gamma-mediated antiviral activity in these cells.	Univ S Florida, Coll Med, Div Allergy Immunol,Dept Internal Med, Joy McCann Culverhouse Airway Dis Ctr, Tampa, FL 33612 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Mohapatra, SS (corresponding author), Univ S Florida, Coll Med, Div Allergy Immunol,Dept Internal Med, Joy McCann Culverhouse Airway Dis Ctr, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	smohapat@hsc.usf.edu	Mohapatra, Shyam/C-2500-2012					Atreya PL, 1999, VIROLOGY, V261, P227, DOI 10.1006/viro.1999.9835; Aubert M, 1999, J VIROL, V73, P2803, DOI 10.1128/JVI.73.4.2803-2813.1999; Behera AK, 2001, BIOCHEM BIOPH RES CO, V280, P188, DOI 10.1006/bbrc.2000.4093; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Bukreyev A, 1999, P NATL ACAD SCI USA, V96, P2367, DOI 10.1073/pnas.96.5.2367; Byrd LG, 1997, CLIN INFECT DIS, V25, P1363, DOI 10.1086/516152; Carbonell-Estrany X, 2001, PEDIATR INFECT DIS J, V20, P874, DOI 10.1097/00006454-200109000-00010; CHA Y, 1994, J BIOL CHEM, V269, P5279; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Floyd-Smith G, 1999, EXP CELL RES, V246, P138, DOI 10.1006/excr.1998.4296; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hall CB, 2000, CLIN INFECT DIS, V31, P590, DOI 10.1086/313960; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Lehtonen A, 1997, J IMMUNOL, V159, P794; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAVLOVIC J, 1993, CIBA F SYMP, V176, P233; Player MR, 1998, METHODS, V15, P243, DOI 10.1006/meth.1998.0628; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEN GC, 1992, J BIOL CHEM, V267, P5017; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Tristram DA, 1998, ARCH OTOLARYNGOL, V124, P777, DOI 10.1001/archotol.124.7.777; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	46	53	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25601	25608		10.1074/jbc.M200211200	http://dx.doi.org/10.1074/jbc.M200211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980899	hybrid			2022-12-25	WOS:000176747000098
J	Hirai, I; Wang, HG				Hirai, I; Wang, HG			A role of the C-terminal region of human Rad9 (hRad9) in nuclear transport of the hRad9 checkpoint complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; SLIDING CLAMP; CONTROL GENE; PROTEIN; PCNA; INTERACTS; HUS1; ATR	Rad9, Rad1, and Hus1 are members of the Rad family of checkpoint proteins that are required for both DNA replication and DNA damage checkpoints and are thought to function as sensors in the DNA integrity checkpoint control. These proteins can interact with each other and form a stable proliferating cell nuclear antigen-related Rad9-Rad1-Hus1 heterotrimeric complex that might encircle DNA at or near the damaged sites. In this study, we demonstrate that the human Rad9 (hRad9) protein contains a predicted nuclear localization sequence (NLS) near its C terminus, which plays an essential role in the hRad9-mediated G2 checkpoint. Deletion experiments indicate that the NLS-containing region of hRad9 is critical for the nuclear transport of not only hRad9 but also human Rad1 (hRad1) and human Hus1 (hHus1), although this region is not required for hRad9-hRad1-hHus1 complex formation. In support of the role that hRad9 NI'S plays in the nuclear targeting of the hRad9-hRad1-hHus1 complex, overexpression of a deletion mutant of hRad9 lacking the NLS-containing C-terminal region can bypass the G(2) checkpoint and result in cell death after ionizing radiation or hydroxyurea treatment. Moreover, knockdown of hRad9 expression by small interfering RNA (siRNA) results in hRad1 accumulation in the cytoplasm and significantly abrogates the G, checkpoint in the presence of damaged DNA or incomplete DNA replication. Thus, the C-terminal region of human Rad9 protein is important for G(2) checkpoint control by operating the transport of the hRad9-hRad1-hHus1 checkpoint complex into the nucleus.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA090315, R01CA082197] Funding Source: NIH RePORTER; NCI NIH HHS [CA90315, CA82197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cai RL, 2000, J BIOL CHEM, V275, P27909; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Humphrey T, 2000, MUTAT RES-FUND MOL M, V451, P211, DOI 10.1016/S0027-5107(00)00051-8; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu QH, 2000, GENE DEV, V14, P1448; Melo JA, 2001, GENE DEV, V15, P2809; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; TSURIMOTO T, 1999, FRONT BIOSCI, V4, pD649; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25722	25727		10.1074/jbc.M203079200	http://dx.doi.org/10.1074/jbc.M203079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994305	hybrid			2022-12-25	WOS:000176747000114
J	Lubetsky, JB; Dios, A; Han, JL; Aljabari, B; Ruzsicska, B; Mitchell, R; Lolis, E; Al-Abed, Y				Lubetsky, JB; Dios, A; Han, JL; Aljabari, B; Ruzsicska, B; Mitchell, R; Lolis, E; Al-Abed, Y			The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MIF; CRYSTAL-STRUCTURE; PHENYLPYRUVATE TAUTOMERASE; RHEUMATOID-ARTHRITIS; MOLECULAR-CLONING; REGULATORY ROLE; HIGH EXPRESSION; CYTOKINE; ANGIOGENESIS; RESOLUTION	Macrophage migration inhibitory factor (MIF) is an immunoregulatory protein that is a potential therapeutic target for a number of inflammatory diseases. Evidence exists that an unexpected catalytic active site of MIF may have a biological function. To gain further insight into the role of the catalytic active site, a series of mutational, structural, and biological activity studies were performed. The insertion of an alanine between Pro-1 and Met-2 (PAM) abolishes a non-physiological catalytic activity, and this mutant is defective in the in vitro glucocorticoid counter-regulatory activity of MIF. The crystal structure of MIF complexed to (SR)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an inhibitor of MIF D-dopachrome tautomerase activity, reveals that ISO-1 binds to the same position of the active site as p-hydroxyphenylpyruvic acid, a substrate of MIF. ISO-1 inhibits several MIF biological activities, further establishing a role for the catalytic active site of MIF.	N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Northwell Health; Yale University; Yale University	Lolis, E (corresponding author), N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA.			Lolis, Elias/0000-0002-7902-7868				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; Benigni F, 2000, J CLIN INVEST, V106, P1291, DOI 10.1172/JCI9900; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1997, X PLOR 3 851 EDITION; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GEORGE M, 1962, P SOC EXP BIOL MED, V111, P514; Hermanowski-Vosatka A, 1999, BIOCHEMISTRY-US, V38, P12841, DOI 10.1021/bi991352p; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; Lan HY, 1996, AM J PATHOL, V149, P1119; Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B; Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Matsunaga J, 1999, J BIOL CHEM, V274, P3268, DOI 10.1074/jbc.274.6.3268; Matsunaga J, 1999, CELL MOL BIOL, V45, P1035; MIKAYAMA T, 1993, P NATL ACAD SCI USA, V90, P10056, DOI 10.1073/pnas.90.21.10056; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Onodera S, 1999, CYTOKINE, V11, P163, DOI 10.1006/cyto.1998.0402; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Sampey AV, 2001, ARTHRITIS RHEUM-US, V44, P1273, DOI 10.1002/1529-0131(200106)44:6<1273::AID-ART219>3.0.CO;2-8; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Swope MD, 1998, J BIOL CHEM, V273, P14877, DOI 10.1074/jbc.273.24.14877; Swope MD, 1999, REV PHYSIOL BIOCH P, V139, P1, DOI 10.1007/BFb0033647; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wityak J, 1997, J MED CHEM, V40, P50, DOI 10.1021/jm960626t; Xue CB, 1997, J MED CHEM, V40, P2064, DOI 10.1021/jm960799i	52	228	248	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24976	24982		10.1074/jbc.M203220200	http://dx.doi.org/10.1074/jbc.M203220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997397	hybrid			2022-12-25	WOS:000176747000019
J	Somanna, A; Mundodi, V; Gedamu, L				Somanna, A; Mundodi, V; Gedamu, L			Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex - Evidence for the activation of latent transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EXPRESSION; PROTEINASES; MECHANISMS; CELLS; GENE; ORGANIZATION; SUPPRESSION; INFECTION; RELEASE	Cathepsin B-like genes from Leishmania donovani and Leishmania chagasi have been isolated and characterized. It is a single gene, which is constitutively expressed in all the life cycle stages of the parasite. Studies using cathepsin B-specific inhibitor treatment suggested that cathepsin B does not seem to play a role in the promastigote stages of the parasite, however it aids in the parasite survival within the host macrophages. Antisense mRNA inhibition of cathepsin B gene also revealed that it plays an important role in the parasite survival within the host macrophages. Furthermore, for the first time, we have shown that Leishmania whole cell lysates as well as the recombinant cathepsin B protein cleaved human recombinant latent transforming growth factor (TGF)-beta1 into a mature peptide releasing the latency associated protein, in a cell-free incubation system. Mink lung epithelial cell growth inhibition assay revealed that the cleaved TGF-beta1 was biologically active, suggesting that Leishmania cathepsin B can cleave latent TGF-beta1 into mature and active form. These results suggest that cathepsin B plays an important role in Leishmania survival within the host macrophages by activating latent TGF-beta1.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Gedamu, L (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	lgedamu@ucalgary.ca						Adam PJ, 2000, CYTOKINE, V12, P348, DOI 10.1006/cyto.1999.0559; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Ankri S, 1999, INFECT IMMUN, V67, P421, DOI 10.1128/IAI.67.1.421-422.1999; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Bart G, 1997, MOL BIOCHEM PARASIT, V88, P53, DOI 10.1016/S0166-6851(97)00072-8; Bogdan C, 1997, Behring Inst Mitt, P58; Bogdan C, 1999, PARASITOL TODAY, V15, P22, DOI 10.1016/S0169-4758(98)01362-3; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535; Chan VJ, 1999, BIOCHEM J, V340, P113, DOI 10.1042/0264-6021:3400113; Chen DQ, 2000, INFECT IMMUN, V68, P80, DOI 10.1128/IAI.68.1.80-86.2000; CHU M, 2002, J BIOL CHEM, V277, P14829; Chu TM, 1998, BIOCHEM BIOPH RES CO, V253, P128, DOI 10.1006/bbrc.1998.9760; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Farrell PJ, 1998, BIOTECHNOL BIOENG, V60, P656, DOI 10.1002/(SICI)1097-0290(19981220)60:6<656::AID-BIT2>3.0.CO;2-9; Farrell PJ, 2000, PROTEINS, V41, P144, DOI 10.1002/1097-0134(20001001)41:1<144::AID-PROT160>3.3.CO;2-8; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; HUNTER CA, 1995, EUR J IMMUNOL, V25, P994, DOI 10.1002/eji.1830250420; Maekawa Y, 1998, J IMMUNOL, V161, P2120; MANIATIS F, 1989, MOL CLONING LAB MANU; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Mundodi V, 2002, GENE, V282, P257, DOI 10.1016/S0378-1119(01)00851-4; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; SchultzCherry S, 1996, J VIROL, V70, P8624, DOI 10.1128/JVI.70.12.8624-8629.1996; Spano F, 1998, MOL BIOCHEM PARASIT, V92, P147, DOI 10.1016/S0166-6851(97)00243-0; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; TSELENTIS Y, 1994, LANCET, V343, P1635, DOI 10.1016/S0140-6736(94)93085-6; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wilson ME, 1998, J IMMUNOL, V161, P6148	36	86	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25305	25312		10.1074/jbc.M203034200	http://dx.doi.org/10.1074/jbc.M203034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000761	Green Submitted, hybrid			2022-12-25	WOS:000176747000061
J	Romeo, AA; Capobianco, JA; English, AM				Romeo, AA; Capobianco, JA; English, AM			Heme nitrosylation of deoxyhemoglobin by S-nitrosoglutathione requires copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ELECTRON-TRANSFER; BLOOD; HEMOGLOBIN; NITROSOHEMOGLOBIN; GLUTATHIONE; MYOGLOBIN; OXIDATION; RELEASE; PROTEIN	NO reactions with hemoglobin (Hb) likely play a role in blood pressure regulation. For example, NO exchange between Hb and S-nitrosoglutathione (GSNO) has been reported in vitro. Here we examine the reaction between GSNO and deoxyHb (HbFe(II)) in the presence of both Cu(I) (2,9-dimethyl-1, 10-phenanthroline (neocuproine)) and Cu(II) (diethylenetriamine-N,N,N',N",N"-pentaacetic acid) chelators using a copper-depleted Hb solution. Spectroscopic analysis of deoxyHb (HbFe(II))/GSNO incubates shows prompt formation (<5 min) of similar to100% hemenitrosylated Hb (HbFe(II)NO) in the absence of chelators, 46% in the presence of diethylenetriamine-N,N,N',N",N"-pentaacetic acid, and 25% in the presence of neocuproine. Negligible (<2%) HbFe(II)NO was detected when neocuproine was added to copper-depleted HbFe(II)/GSNO incubates. Thus, HbFe(II)NO formation via a mechanism involving free NO generated by Cu(I) catalysis of GSNO breakdown is proposed. GSH is a source of reducing equivalents because extensive GSSG was detected in HbFe(II)/GSNO incubates in the absence of metal chelators. No S-nitrosation of HbFe(II) was detected under any conditions. In contrast, the NO released from GSNO is directed to Cysbeta(93) of oxyHb in the absence of chelators, but only metHb formation is observed in the presence of chelators. Our findings reveal that the reactions of GSNO and Hb are controlled by copper and that metal chelators do not fully inhibit NO release from GSNO in Hb-containing solutions.	Concordia Univ, Dept Biochem & Chem, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	English, AM (corresponding author), Concordia Univ, Dept Biochem & Chem, 1455 Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	english@vax2.concordia.ca	Romeo, Andrea Antonino/AAY-2175-2021	Romeo, Andrea Antonino/0000-0002-1579-2480				Abbyad P, 2001, J ANAL ATOM SPECTROM, V16, P464, DOI 10.1039/b100672j; ANTONINI E, 1964, J BIOL CHEM, V239, P907; Artz JD, 1998, CHEM RES TOXICOL, V11, P1393, DOI 10.1021/tx980205+; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; GARTNER A, 1983, FEBS LETT, V155, P15, DOI 10.1016/0014-5793(83)80199-9; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; IORIO EED, 1981, METHOD ENZYMOL, V76, P57; JAMES BR, 1961, J CHEM SOC, P2007, DOI 10.1039/jr9610002007; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kandori H, 1998, J AM CHEM SOC, V120, P5828, DOI 10.1021/ja980837i; KUMA F, 1981, J BIOL CHEM, V256, P5518; LEI YB, 1995, INORG CHEM, V34, P1083, DOI 10.1021/ic00109a014; Mahalingam TR, 1997, BIOL TRACE ELEM RES, V57, P223, DOI 10.1007/BF02785291; MAUK AG, 1979, BIOCHEM BIOPH RES CO, V86, P206, DOI 10.1016/0006-291X(79)90401-7; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; Noble DR, 2000, NITRIC OXIDE-BIOL CH, V4, P392, DOI 10.1006/niox.2000.0291; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pezacki JP, 2001, J AM CHEM SOC, V123, P4615, DOI 10.1021/ja015716o; Romeo AA, 2001, J AM CHEM SOC, V123, P1782, DOI 10.1021/ja005612y; SAMPATH V, 1994, BIOCHEM BIOPH RES CO, V198, P281, DOI 10.1006/bbrc.1994.1039; Scorza G, 1997, FREE RADICAL BIO MED, V22, P633, DOI 10.1016/S0891-5849(96)00378-4; Sheu FS, 2000, BIOPHYS J, V78, P1216, DOI 10.1016/S0006-3495(00)76679-3; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Spencer NY, 2000, J BIOL CHEM, V275, P36562, DOI 10.1074/jbc.M005347200; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Tsikas D, 2001, BBA-PROTEIN STRUCT M, V1546, P422, DOI 10.1016/S0167-4838(01)00166-2; Upmacis RK, 1997, J AM CHEM SOC, V119, P10424, DOI 10.1021/ja964249l; VANASSENDELFT OW, 1975, ANAL BIOCHEM, V69, P43, DOI 10.1016/0003-2697(75)90563-1; Williams DLH, 1999, ACCOUNTS CHEM RES, V32, P869, DOI 10.1021/ar9800439; WILLIAMS WJ, 1972, HEMATOLOGY, P11; [No title captured]	37	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24135	24141		10.1074/jbc.M202221200	http://dx.doi.org/10.1074/jbc.M202221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11970954	Green Accepted, hybrid			2022-12-25	WOS:000176611800022
J	Tanno, B; Negroni, A; Vitali, R; Pirozzoli, MC; Cesi, V; Mancini, C; Calabretta, B; Raschella, G				Tanno, B; Negroni, A; Vitali, R; Pirozzoli, MC; Cesi, V; Mancini, C; Calabretta, B; Raschella, G			Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; MESSENGER-RNA; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR (IGF)-I; CDNA CLONES; DIFFERENTIATION; ACTIVATION; RECEPTOR	Neuroblastoma (NB), a malignant childhood tumor deriving from the embryonic neural crest, is sensitive to the growth-stimulating effects of insulin-like growth factors (IGFs). Aggressive cases of this disease often acquire autocrine loops of IGF production, but the mechanisms through which the different components of the IGF axis are regulated in tumor cells remain unclear. Upon conditional expression of c-Myb in a NB cell line, we detected up-regulation of IGF1, IGF1 receptor, and insulin-like growth factor-binding protein 5 (IGFBP-5) expression. Analysis of the IGFBP-5 promoter revealed two potential Myb binding sites at position -59 to -54 (M1) and -429 to -424 (M2) from the transcription start site; both sites were bound by c-Myb and BMyb in vitro and in vivo. Reporter assays carried out using the proximal region of the human IGFBP-5 promoter demonstrated that c-Myb and B-Myb enhanced transcription. However, site-directed mutagenesis and deletion of the Myb binding sites coupled with reporter assays revealed that M2 but not M1 was important for Myb-dependent transactivation of the IGFBP-5 promoter. The double mutant M1/M2 was still transactivated by c-Myb, suggesting the existence of Myb binding-independent mechanisms of IGFBP-5 promoter regulation. A constitutively active AKT transactivated the IGFBP-5 promoter, whereas the phosphatidylinositol 3-kinase inhibitor LY294002 suppressed it. Moreover, the kinase dead dominant negative K179M AHT mutant was able to inhibit transcription from the M2 and M1/M2 IGFBP-5 mutant promoters. Deletion analysis of the IGFBP-5 promoter revealed that the AKT-responsive region lies between nucleotides -334 and -83. Together, these data suggest that the Myb binding-independent transactivation of the IGFBP-5 promoter was due to the activation of the phosphatidylinositol 3-kinase/AKT pathway likely mediated by IGF1 receptor-dependent signals. Finally, IGFBP-5 was able to modulate proliferation of NB cells in a manner dependent on its concentration and on the presence of IGFs.	ENEA, Sect Toxicol & Biomed Sci, I-00060 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Italian National Agency New Technical Energy & Sustainable Economics Development; Jefferson University	Raschella, G (corresponding author), ENEA, Sect Toxicol & Biomed Sci, Via Anguillarese 301, I-00060 Rome, Italy.	raschella@casaccia.enea.it	Vitali, Roberta/K-2509-2016; Negroni, Anna/GLS-2306-2022	Vitali, Roberta/0000-0003-4203-0163; Negroni, Anna/0000-0002-2273-8837				ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Andress DL, 2001, AM J PHYSIOL-ENDOC M, V281, pE283, DOI 10.1152/ajpendo.2001.281.2.E283; Baxter RC, 2001, J CLIN PATHOL-MOL PA, V54, P145, DOI 10.1136/mp.54.3.145; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; el-Badry O M, 1992, Cancer Treat Res, V63, P105; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; ELBADRY OM, 1991, PROG CLIN BIOL RES, V366, P257; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FIELDER PJ, 1993, GROWTH REGULAT, V3, P226; Franchimont N, 1997, ENDOCRINOLOGY, V138, P3380, DOI 10.1210/en.138.8.3380; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Gabbitas B, 1996, J BIOL CHEM, V271, P9033, DOI 10.1074/jbc.271.15.9033; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KOGNER P, 1993, CANCER RES, V53, P2044; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; MATSUMOTO K, 1992, ENDOCRINOLOGY, V130, P3669, DOI 10.1210/en.130.6.3669; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; PAGTERHOLTHUIZE.P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Pash JM, 1996, ENDOCRINOLOGY, V137, P2375, DOI 10.1210/en.137.6.2375; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1999, CANCER RES, V59, P3365; RASCHELLA G, 1992, CANCER RES, V52, P4221; Raschella G, 1996, EXP CELL RES, V222, P395, DOI 10.1006/excr.1996.0049; REISS K, 1991, CANCER RES, V51, P5997; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Rousse S, 2001, J BIOL CHEM, V276, P46961, DOI 10.1074/jbc.M104440200; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SAWADA T, 1987, MED PEDIATR ONCOL, V15, P14, DOI 10.1002/mpo.2950150104; SCHULLER AGP, 1993, ENDOCRINOLOGY, V132, P2544, DOI 10.1210/en.132.6.2544; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; Tonner E, 2000, ADV EXP MED BIOL, V480, P45; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wulbrand U, 2000, EUR J CLIN INVEST, V30, P729; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Yeh LCC, 1998, J CELL PHYSIOL, V175, P78, DOI 10.1002/(SICI)1097-4652(199804)175:1<78::AID-JCP9>3.0.CO;2-9; Yeh LCC, 2000, ENDOCRINOLOGY, V141, P3278, DOI 10.1210/en.141.9.3278; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	68	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23172	23180		10.1074/jbc.M200141200	http://dx.doi.org/10.1074/jbc.M200141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973331	hybrid			2022-12-25	WOS:000176475700012
J	Koshikawa, K; Osada, H; Kozaki, K; Konishi, H; Masuda, A; Tatematsu, Y; Mitsudomi, T; Nakao, A; Takahashi, T				Koshikawa, K; Osada, H; Kozaki, K; Konishi, H; Masuda, A; Tatematsu, Y; Mitsudomi, T; Nakao, A; Takahashi, T			Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo	ONCOGENE			English	Article						lung cancer; metastasis; CLCP1	ENDOTHELIAL GROWTH-FACTOR; CELL-LINE NCI-H460-LNM35; TUMOR-CELLS; SEMAPHORIN-III; FACTOR VEGF; NEUROPILIN; RECEPTOR; ANGIOGENESIS; FAMILY	Most lung cancer patients are unfortunately uncurable and die because of widespread metastases, thus indicating the importance of identification of molecules with a crucial role in this process. Our previous expression profiling analysis of a highly metastatic lung cancer cell line, NCI-H460-LNM35, and its parental low metastatic line, NCI-H460-N15, revealed significant up-regulation of both known and unknown genes in LNM35. In this study, we describe the isolation and detailed characterizations of a novel gene, named CLCP1, which corresponds to one of such expression sequence tags with up-regulated expression in LNM35. The CLCP1 gene was found to encode a protein with 775 amino acids with structural similarities to, but distinct from neuropilins, cell surface receptors for VEGF(165), and semaphorins. Notably, CLCP1 was shown to be upregulated not only in LNM35 in association with its acquisition of metastatic phenotype during in vivo selection, but also in a significant fraction of lung cancers in vivo with high frequency in metastatic lesions, warranting future studies for a better understanding of the molecular mechanisms of lung cancer metastasis.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Kozaki, Ken-ichi/M-6281-2014; Takahashi, Takashi/I-7262-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Takahashi, Takashi/0000-0003-0615-7001; Mitsudomi, Tetsuya/0000-0001-9860-8505; Konishi, Hiroyuki/0000-0003-1131-4905				Bachelder RE, 2001, CANCER RES, V61, P5736; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; FIDLER IJ, 2001, BIOL CANC ANGIOGENES, P917; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Hayashibara T, 2001, CLIN CANCER RES, V7, P2719; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miao HQ, 2000, CANCER METAST REV, V19, P29, DOI 10.1023/A:1026579711033; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; SEKIDO Y, 2001, CANC PRINCIPLES PRAC, P917; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; *STAT INF DEP MIN, 1999, VIT STAT JAP 1999, V3, P398; STETLERSTEVENSO.WG, 2001, MOL BIOL CANC INVASI, P123; Trexler M, 2000, EUR J BIOCHEM, V267, P5751, DOI 10.1046/j.1432-1327.2000.01641.x; Veikkola T, 2000, CANCER RES, V60, P203	28	44	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2822	2828		10.1038/sj.onc.1205405	http://dx.doi.org/10.1038/sj.onc.1205405			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973641				2022-12-25	WOS:000175063700006
J	Nakamura, S; Roth, JA; Mukhopadhyay, T				Nakamura, S; Roth, JA; Mukhopadhyay, T			Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells	ONCOGENE			English	Article						MDM2; p53; E6	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; P53-MEDIATED APOPTOSIS; STABILIZES P53; ONCOPROTEIN; PROMOTES; UBIQUITINATION; ASSOCIATION; ONCOGENE; TARGETS	We have recently shown that lysine mutations in p53's putative C-terminal acetylation sites result in increased stability and cytoplasmic distribution of the p53 protein in a human lung cancer cell line. In the present study, we showed that when lysine residues 372, 373, 381, and 382 of p53 were substituted with alanine, the resulting A4 protein was resistant to MDM2-mediated proteosomal degradation but was highly sensitive to human papillomavirus E6-mediated proteolysis. When A4 and wildtype p53 were transfected into MDM2-overexpressing MCF-7 cells, A4 significantly reduced colony formation in vitro, when compared with wild-type p53. Our results suggest that A4 exerts a growth-inhibitory effect more efficiently than wild-type p53 does in cell lines that overexpress MDM2 and may therefore be a better therapeutic tool than wild-type p53 for certain cancers in which MDM2 is amplified or overexpressed.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd,Box 445, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P01CA078778, P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA-70907, P01 CA 78778-01A1, 2P50-CA 70970-04, P50-CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chen JD, 1996, MOL CELL BIOL, V16, P2445; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meng RD, 1998, CLIN CANCER RES, V4, P251; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; NAKAMURA S, 2002, IN PRESS ONCOGENE; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REIHSAUS E, 1990, ONCOGENE, V5, P137; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 1996, ONCOGENE, V13, P265; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	39	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2605	2610		10.1038/sj.onc.1205343	http://dx.doi.org/10.1038/sj.onc.1205343			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971195				2022-12-25	WOS:000174918400017
J	Gil-Parrado, S; Fernandez-Montalvan, A; Assfalg-Machleidt, I; Popp, O; Bestvater, F; Holloschi, A; Knoch, TA; Auerswald, EA; Welsh, K; Reed, JC; Fritz, H; Fuentes-Prior, P; Spiess, E; Salvesen, GS; Machleidt, W				Gil-Parrado, S; Fernandez-Montalvan, A; Assfalg-Machleidt, I; Popp, O; Bestvater, F; Holloschi, A; Knoch, TA; Auerswald, EA; Welsh, K; Reed, JC; Fritz, H; Fuentes-Prior, P; Spiess, E; Salvesen, GS; Machleidt, W			Lonomycin-activated calpain triggers apoptosis - A probable role for Bcl-2 family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE DOWN-REGULATION; CELL-DEATH; CASPASE ACTIVATION; CYTOCHROME-C; T-CELLS; PROTEIN; CALCIUM; MITOCHONDRIA; CLEAVAGE; BAX	Ubiquitous calpains (mu- and m-calpain) have been repeatedly implicated in apoptosis, but the underlying mechanism(s) remain(s) to be elucidated. We examined ionomycin-induced cell death in LCLC 103H cells, derived from a human large cell lung carcinoma. We detected hallmarks of apoptosis such as membrane blebbing, nuclear condensation, DNA ladder formation, caspase activation, and poly-(ADP-ribose)polymerase cleavage. Apoptosis was prevented by preincubation of the cells with the calpain inhibitor acetyl-calpastatin 27-peptide and the caspase inhibitor Z-DEVD-fmk, implicating both the calpains and caspases in the apoptotic process. The apoptotic events correlated in a calpastatin-inhibitable manner with Bid and Bcl-2 decrease and with activation of caspases-9, -3, and -7. In vitro both ubiquitous calpains cleaved recombinant Bcl-2, Bid, and Bcl-X-L at single sites truncating their N-terminal regions. Binding studies revealed diminished interactions of calpain-truncated Bcl-2 and Bid with immobilized intact Bcl-2 family proteins. Moreover, calpain-cleaved Bcl-2 and Bid induced cytochrome c release from isolated mitochondria. We conclude that ionomycin-induced calpain activation promotes decrease of Bcl-2 proteins thereby triggering the intrinsic apoptotic pathway.	Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Fachhsch Mannheim, Inst Molekularbiol & Zellkulturtech, D-68163 Mannheim, Germany; Burnham Inst, La Jolla, CA 92037 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Sanford Burnham Prebys Medical Discovery Institute; Max Planck Society	Gil-Parrado, S (corresponding author), Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	shirgilpa@web.de		Fuentes-Prior, Pablo/0000-0002-6618-3204; Fernandez-Montalvan, Amaury/0000-0001-9156-0000				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Buki A, 2000, J NEUROSCI, V20, P2825; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; FURUYA Y, 1994, CANCER RES, V54, P6167; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAFNER M, 1988, CELL MOTIL CYTOSKEL, V9, P271, DOI 10.1002/cm.970090309; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsumura Y, 2001, J MOL CELL CARDIOL, V33, P1133, DOI 10.1006/jmcc.2001.1373; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Squier MKT, 1997, J IMMUNOL, V158, P3690; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Xie ZH, 2000, METHOD ENZYMOL, V322, P266; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	67	168	176	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27217	27226		10.1074/jbc.M202945200	http://dx.doi.org/10.1074/jbc.M202945200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12000759	Green Published, hybrid			2022-12-25	WOS:000177055900067
J	Radeke, HH; Janssen-Graalfs, I; Sowa, EN; Chouchakova, N; Skokowa, J; Loscher, F; Schmidt, RE; Heeringa, P; Gessner, JE				Radeke, HH; Janssen-Graalfs, I; Sowa, EN; Chouchakova, N; Skokowa, J; Loscher, F; Schmidt, RE; Heeringa, P; Gessner, JE			Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIII; AUTOIMMUNE-DISEASE; DEFICIENT MICE; IN-VIVO; IGG; EXPRESSION; CHEMOKINE; COMPLEMENT; COMPLEXES; INJURY	We examined the capacity of mouse glomerular mesangial cells (MC) to express and function through two different low affinity FcgammaRs, the activating FcgammaRIII and the inhibitory FcgammaRII. Immunohistochemistry identified FcgammaRII as the prominent FcgammaR in the kidney, and low levels of FcgammaRIIb2-specific mRNA were also detected in primary cultures of growth-arrested MC. Activation by tumor necrosis factor-alpha/interleukin-1beta induced substantial FcgammaRII expression in proliferating MC. Importantly, however, stimulation with interferon-gamma (IFN-gamma)/lipopolysaccharide or IFN-gamma alone resulted in a complete down-regulation of FcgammaRII, which was accompanied by a strong increase in FcRgamma chain mRNA and a surface appearance of FcgammaRIII. Activating FcgammaRIII triggered mRNA synthesis for monocyte chemoattractant protein-1 (MCP-1), MCP-5, cytokine-induced neutrophil chemoattractant, and RANTES, whereas FcgammaRIII-deficient MC failed to respond to immune complex (IC) activation as shown by impaired production of MCP-1 mRNA/protein. In a passive model of acute anti-glomerular basement membrane (GBM) nephritis, induction of FcgammaRIII and suppression of FcgammaRII occurred in kidney tissues. Blockade of FcgammaRII, when induced selectively in the kidney, resulted in enhanced inflammation. Taken together, our results define a novel regulatory pathway with opposite regulation of FcgammaRII (suppressed) and FcgammaRIII (induced) by IFN-gamma on MCs in vitro and anti-GBM IgG in vivo. Herein is provided the first evidence that glomerular FcgammaRII plays an important immunoregulatory role in the initiation of IC glomerulonephritis.	Hannover Med Sch, Abt Klin Immunol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Clin Goethe Univ, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; Univ Maastricht, Dept Immunol, NL-6221 ER Maastricht, Netherlands	Hannover Medical School; Hannover Medical School; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Maastricht University	Gessner, JE (corresponding author), Hannover Med Sch, Abt Klin Immunol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Gessner.Johannes@MH-Hannover.de	Radeke, Heinfried H/E-3772-2013; Heeringa, Peter/A-6008-2009; Skokowa, Julia/AAU-3622-2021	Radeke, Heinfried H/0000-0002-4499-2510; Heeringa, Peter/0000-0001-8684-763X; Skokowa, Julia/0000-0002-4399-2324				Ambrus JL, 1997, JAMA-J AM MED ASSOC, V278, P1938, DOI 10.1001/jama.278.22.1938; Anders HJ, 2001, J AM SOC NEPHROL, V12, P919, DOI 10.1681/ASN.V125919; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; Baumann U, 2001, J IMMUNOL, V167, P1022, DOI 10.4049/jimmunol.167.2.1022; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; BRINI AT, 1993, J BIOL CHEM, V268, P1355; Chouchakova N, 2001, J IMMUNOL, V166, P5193, DOI 10.4049/jimmunol.166.8.5193; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Coxon A, 2001, IMMUNITY, V14, P693, DOI 10.1016/S1074-7613(01)00150-9; DAERON M, 1992, J IMMUNOL, V149, P1365; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FLOEGE J, 1990, KIDNEY INT, V37, P859, DOI 10.1038/ki.1990.59; FLOEGE J, 1994, KIDNEY INT, V45, P360, DOI 10.1038/ki.1994.46; Fossati-Jimack L, 2000, J EXP MED, V191, P1293, DOI 10.1084/jem.191.8.1293; FRANCKI A, 1995, AM J PATHOL, V147, P1372; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; GUYRE PM, 1989, J IMMUNOL, V143, P1650; Hazenbos WLW, 1998, J IMMUNOL, V161, P3026; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Heller T, 1999, J IMMUNOL, V162, P5657; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P7706, DOI 10.1073/pnas.82.22.7706; HORA K, 1992, P NATL ACAD SCI USA, V89, P1745, DOI 10.1073/pnas.89.5.1745; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Luo Y, 1999, J IMMUNOL, V163, P3985; Madaio MP, 1999, SEMIN NEPHROL, V19, P48; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; Meyer D, 1998, BLOOD, V92, P3997, DOI 10.1182/blood.V92.11.3997.423k52_3997_4002; Mitchell DA, 1999, J IMMUNOL, V162, P5676; Moore KJ, 1998, KIDNEY INT, V53, P1631, DOI 10.1046/j.1523-1755.1998.00911.x; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; Quigg RJ, 1998, KIDNEY INT, V53, P320, DOI 10.1046/j.1523-1755.1998.00723.x; RA C, 1989, J BIOL CHEM, V264, P15323; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; RADEKE HH, 1994, KIDNEY INT, V45, P763, DOI 10.1038/ki.1994.101; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; SANTIAGO A, 1991, KIDNEY INT, V39, P87, DOI 10.1038/ki.1991.11; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Schiller C, 2000, EUR J IMMUNOL, V30, P481; SCHRIJVER G, 1990, KIDNEY INT, V38, P86, DOI 10.1038/ki.1990.171; SEARS DW, 1990, J IMMUNOL, V144, P371; Suzuki Y, 1998, KIDNEY INT, V54, P1166, DOI 10.1046/j.1523-1755.1998.00108.x; Sylvestre DL, 1996, IMMUNITY, V5, P387, DOI 10.1016/S1074-7613(00)80264-2; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; Uciechowski P, 1998, EUR J IMMUNOL, V28, P2928, DOI 10.1002/(SICI)1521-4141(199809)28:09<2928::AID-IMMU2928>3.0.CO;2-8; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187; Zernecke A, 2001, J IMMUNOL, V166, P5755, DOI 10.4049/jimmunol.166.9.5755	59	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27535	27544		10.1074/jbc.M200419200	http://dx.doi.org/10.1074/jbc.M200419200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11983693	hybrid			2022-12-25	WOS:000177055900104
J	Giannone, G; Ronde, P; Gaire, M; Haiech, J; Takeda, K				Giannone, G; Ronde, P; Gaire, M; Haiech, J; Takeda, K			Calcium oscillations trigger focal adhesion disassembly in human U87 astrocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LIGHT-CHAIN KINASE; C-TERMINAL DOMAIN; INTEGRIN-CYTOSKELETON; MIGRATING NEUTROPHILS; CA2+; SRC; EXPRESSION; FAK; CALRETICULIN	Integrin-associated intracellular Ca(2+) oscillations modulate cell migration, probably by controlling integrin-mediated release of the cell rear during migration. Focal adhesion kinase (FAK), via its tyrosine phosphorylation activity, plays a key role in integrin signaling. In human U87 astrocytoma cells, expression of the dominant negative FAK-related non-kinase domain (FRNK) inhibits the Ca(2+)-sensitive component of serum-dependent migration. We investigated how integrin-associated Ca(2+) signaling might be coupled to focal adhesion (FA) dynamics by visualizing the effects of Ca(2+) spikes on FAs using green fluorescent protein (GFP)-tagged FAK and FRNK. We report that Ca(2+) spikes are temporally correlated with movement and disassembly of FAs, but not their formation. FRNK transfection did not affect generation of Ca(2+) spikes, although cell morphology was altered, with fewer FAs of larger size and having a more peripheral localization being observed. Larger sized FAs in FRNK-transfected cells were not disassembled by Ca(2+) spikes, providing a possible explanation for impaired Ca(2+)-dependent migration in these cells. Stress fiber end movements initiated by Ca(2+) spikes were visualized using GFP-tagged myosin light chain kinase (MLCK). Ca(2+)-associated movements of stress fiber ends and FAs had similar kinetics, suggesting that stress fibers and FAs move in a coordinated fashion. This indicates that increases in Ca(2+) likely trigger disassembly of adhesive structures that involves disruption of integrin-extracellular matrix interactions, supporting a key role for Ca(2+)-sensitive inside-out signaling in cell migration. A rapid increase in tyrosine phosphorylation of FAK was found in response to an elevation in Ca(2+) induced by thapsigargin, and we propose that this represents the initial triggering event linking Ca(2+) Signaling and FA dynamics to cell motility.	Univ Louis Pasteur Strasbourg 1, UMR CNRS 7034, Lab Pharmacol & Physicochim Interact Cellulaires, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Takeda, K (corresponding author), Univ Louis Pasteur Strasbourg 1, UMR CNRS 7034, Lab Pharmacol & Physicochim Interact Cellulaires, BP 24, F-67401 Illkirch Graffenstaden, France.		haiech, jacques J/F-2890-2010	haiech, jacques/0000-0003-2908-8053; Giannone, Gregory/0000-0002-0932-1690				Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cary LA, 1996, J CELL SCI, V109, P1787; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Eddy RJ, 2000, J CELL SCI, V113, P1287; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; ILIE D, 1995, NATURE, V377, P539; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; Kudryashov DS, 1999, FEBS LETT, V463, P67, DOI 10.1016/S0014-5793(99)01591-4; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LYNCH JW, 1994, J BIOL CHEM, V269, P8226; MANDEVILLE JTH, 1995, BIOPHYS J, V68, P1207, DOI 10.1016/S0006-3495(95)80336-X; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nishizaka T, 2000, P NATL ACAD SCI USA, V97, P692, DOI 10.1073/pnas.97.2.692; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Pettit EJ, 1996, J CELL SCI, V109, P1689; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ronde P, 2000, BBA-MOL CELL RES, V1498, P273, DOI 10.1016/S0167-4889(00)00102-6; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Scherberich A, 2000, J CELL SCI, V113, P653; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	41	77	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26364	26371		10.1074/jbc.M203952200	http://dx.doi.org/10.1074/jbc.M203952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011063	hybrid			2022-12-25	WOS:000176908700072
J	Guo, WN; Malin, SA; Johns, DC; Jeromin, A; Nerbonne, JM				Guo, WN; Malin, SA; Johns, DC; Jeromin, A; Nerbonne, JM			Modulation of Kv4-encoded K+ currents in the mammalian myocardium by neuronal calcium sensor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; ADRENAL CHROMAFFIN CELLS; CHANNEL BETA-SUBUNITS; LONG-QT SYNDROME; BINDING-PROTEIN; GENE-TRANSFER; POTASSIUM CHANNELS; NERVOUS-SYSTEM; ALPHA-SUBUNITS; RAT VENTRICLE	Voltage-gated K+ channels are multimeric proteins, consisting of four pore-forming alpha-subunits alone or in association with accessory subunits. Recently, for example, it was shown that the accessory Kv channel interacting proteins form complexes with Kv4 alpha-subunits and modulate Kv4 channel activity. The experiments reported here demonstrate that the neuronal calcium sensor protein-1 (NCS-1), another member of the recoverin-neuronal calcium sensor superfamily, is expressed in adult mouse ventricles and that NCS-1 co-immunoprecipitates with Kv4.3 from (adult mouse) ventricular extracts. In addition, co-expression studies in HEK-293 cells reveal that NCS-1 increases membrane expression of Kv4 a-subunits and functional Kv4-encoded K+ current densities. Co-expression of NCS-1 also decreases the rate of inactivation of Kv4 a-subunit-encoded K+ currents. In contrast to the pronounced effects of Kv channel interacting proteins on Kv4 channel gating, however, NCS-1 co-expression does not measurably affect the voltage dependence of steady-state inactivation or the rate of recovery from inactivation of Kv4-encoded K+ currents. Taken together, these results suggest that NCS-1 is an accessory subunit of Kv4-encoded I-to,I-f channels that functions to regulate Ito,f density in the mammalian myocardium.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Washington University (WUSTL); Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Nerbonne, JM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066388] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66388, HL34161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Antzelevitch C, 1999, J ELECTROCARDIOL, V32, P158, DOI 10.1016/S0022-0736(99)90074-2; Antzelevitch C, 2002, HDB PHYSL 2, P654; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Guo WN, 2002, CIRC RES, V90, P586, DOI 10.1161/01.RES.0000012664.05949.E0; Guo WN, 2001, CIRCULATION, V104, P78; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Johns DC, 1999, J NEUROSCI, V19, P1691; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Nerbonne JM, 1998, J NEUROBIOL, V37, P37, DOI 10.1002/(SICI)1097-4695(199810)37:1<37::AID-NEU4>3.0.CO;2-9; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Romero MI, 1998, GENE THER, V5, P1612, DOI 10.1038/sj.gt.3300774; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Xu HD, 1996, J GEN PHYSIOL, V108, P405, DOI 10.1085/jgp.108.5.405; Xu HD, 1999, J GEN PHYSIOL, V113, P661, DOI 10.1085/jgp.113.5.661; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	41	74	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26436	26443		10.1074/jbc.M201431200	http://dx.doi.org/10.1074/jbc.M201431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994284	hybrid			2022-12-25	WOS:000176908700081
J	Ketteler, R; Heinrich, AC; Offe, JK; Becker, V; Cohen, J; Neumann, D; Klingmuller, U				Ketteler, R; Heinrich, AC; Offe, JK; Becker, V; Cohen, J; Neumann, D; Klingmuller, U			A functional green fluorescent protein-tagged erythropoietin receptor despite physical separation of JAK2 binding site and tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TRANSMEMBRANE DOMAIN; CYTOKINE RECEPTORS; ACTIVATION; IDENTIFICATION; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION; PROGENITORS; HORMONE	Signaling through hematopoietic cytokine receptors such as the erythropoietin receptor (EpoR) depends on the activation of a receptor-bound Janus kinase (JAK) and tyrosine phosphorylation of the cytoplasmic domain. To visualize the EpoR and elucidate structural requirements coordinating signal transduction, we probed the EpoR by inserting the green fluorescent protein (GFP) at various positions. We show that insertion of GFP in proximity to the transmembrane domain, either in the extracellular or the cytoplasmic domain, results in EpoR-GFP receptors incompetent to elicit biological responses in a factor-dependent cell line or in erythroid progenitor cells. Surprisingly, a receptor harboring GFP insertion in the middle of the cytoplasmic domain, and thereby separating the JAK2 binding site from the tyrosine residues, is capable of supporting signal transduction in response to ligand binding. Comparable with the wild type EpoR, but more efficient than a C-terminal EpoR-GFP fusion, this chimeric receptor promotes the maturation of erythroid progenitor cells and is localized in punctated endosome-like structures. We conclude that the extracellular, transmembrane, and membrane-proximal segment of the cytoplasmic domain form a rigid structural entity whose precise orientation is essential for the initiation of signal transduction, whereas the cytoplasmic domain possesses flexibility in adopting an activated conformation.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Tel Aviv Univ, Sackler Fac Med, Dept Cell Biol & Histol, IL-69978 Tel Aviv, Israel	Max Planck Society; Tel Aviv University; Sackler Faculty of Medicine	Klingmuller, U (corresponding author), Max Planck Inst Immunbiol, Stubeweg 51, D-79108 Freiburg, Germany.		Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099; Neumann, Drorit/0000-0002-4805-7511; Ketteler, Robin/0000-0002-2786-7291				Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ketteler R, 2002, GENE THER, V9, P477, DOI 10.1038/sj.gt.3301653; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Silverman MA, 2001, P NATL ACAD SCI USA, V98, P7051, DOI 10.1073/pnas.111146198; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	30	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26547	26552		10.1074/jbc.M202287200	http://dx.doi.org/10.1074/jbc.M202287200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11997394	hybrid			2022-12-25	WOS:000176908700095
J	Masiero, S; Imbriano, C; Ravasio, F; Favaro, R; Pelucchi, N; Gorla, MS; Mantovani, R; Colombo, L; Kater, MM				Masiero, S; Imbriano, C; Ravasio, F; Favaro, R; Pelucchi, N; Gorla, MS; Mantovani, R; Colombo, L; Kater, MM			Ternary complex formation between MADS-box transcription factors and the histone fold protein NF-YB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOWER DEVELOPMENT; HOMEOTIC GENES; ANTIRRHINUM-MAJUS; OVULE DEVELOPMENT; RNA-POLYMERASE; HOST STRAIN; CCAAT BOXES; ARABIDOPSIS; DOMAIN; FAMILY	MADS-box proteins are transcription factors present in different eukaryotic kingdoms. In contrast to plants, for mammalian and yeast MADS-box proteins ternary complex formation with unrelated transcription factors was reported. We show here the first identification of such ternary interaction in plants. A rice seed-specific NF-YB was identified as partner of OsMADS18 by two-hybrid screening. NF-YB contains a histone fold motif, HFM,(1) and is part of the trimeric CCAAT-binding NF-Y complex. OsMADS18, alone or in combination with a natural partner, interacts with OsNF-YB1 through the MADS and I regions. The mouse NF-YB also associates with OsMADS18 in vivo and in vitro as a NF-YB-NF-YC dimer. Other rice MADS-box proteins do not interact in these assays, indicating specificity for the interaction. OsNF-YB1 is capable of heterodimerizing with NF-YC, but not trimerizing with NF-YA, thus precluding CCAAT binding. Mutation of the variant Asp at position 99 of the HFM alpha2-helix into a conserved serine recovers the capacity to interact with NF-YA, but not with DNA. This is the first indication that members of the NF-YB family work through mechanisms independent of the CCAAT box.	Univ Milan, Dipartimento Genet & BIol Microrganismi, I-20133 Milan, Italy; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Modena & Reggio Emilia, Dept Anim Biol, I-41100 Modena, Italy	University of Milan; University of Milan; Universita di Modena e Reggio Emilia	Kater, MM (corresponding author), Univ Milan, Dipartimento Genet & BIol Microrganismi, Via Celoria 26, I-20133 Milan, Italy.	martin.kater@unimi.it	Kater, Martin M/M-9381-2017; Masiero, Simona/J-2898-2013; Imbriano, Carol/ABD-8204-2021; Favaro, Rebecca/HHZ-8978-2022; Imbriano, Carol/C-9376-2015	Kater, Martin M/0000-0003-1155-2575; Imbriano, Carol/0000-0003-2864-4820; Favaro, Rebecca/0000-0002-6195-5711; Imbriano, Carol/0000-0003-2864-4820; masiero, simona/0000-0002-7563-7634; Colombo, Lucia/0000-0001-8415-1399				ANGENENT GC, 1995, PLANT CELL, V7, P1569, DOI 10.1105/tpc.7.10.1569; ANGENENT GC, 1992, PLANT CELL, V4, P983, DOI 10.1105/tpc.4.8.983; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Coen Enrico S., 1992, Current Opinion in Cell Biology, V4, P929, DOI 10.1016/0955-0674(92)90120-2; Colombo L, 1997, PLANT CELL, V9, P703, DOI 10.1105/tpc.9.5.703; Colombo L, 1998, PLANT J, V16, P355, DOI 10.1046/j.1365-313x.1998.00300.x; Davies B, 1996, EMBO J, V15, P4330, DOI 10.1002/j.1460-2075.1996.tb00807.x; Davies B, 1994, Results Probl Cell Differ, V20, P235; Edwards D, 1998, PLANT PHYSIOL, V117, P1015, DOI 10.1104/pp.117.3.1015; Egea-Cortines M, 1999, EMBO J, V18, P5370, DOI 10.1093/emboj/18.19.5370; Fan HY, 1997, PLANT J, V12, P999, DOI 10.1046/j.1365-313X.1997.12050999.x; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fernandez DE, 2000, PLANT CELL, V12, P183, DOI 10.1105/tpc.12.2.183; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Gusmaroli G, 2001, GENE, V264, P173, DOI 10.1016/S0378-1119(01)00323-7; Gusmaroli G, 2002, GENE, V283, P41, DOI 10.1016/S0378-1119(01)00833-2; Hartmann U, 2000, PLANT J, V21, P351, DOI 10.1046/j.1365-313x.2000.00682.x; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Immink RGH, 1999, DEVELOPMENT, V126, P5117; James P, 1996, GENETICS, V144, P1425; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Lopez-Dee ZP, 1999, DEV GENET, V25, P237, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;237::AID-DVG6&gt;3.0.CO;2-L; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Moon YH, 1999, PLANT PHYSIOL, V120, P1193, DOI 10.1104/pp.120.4.1193; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; PURUGGANAN MD, 1995, GENETICS, V140, P345; Richert J, 1996, PLANT SCI, V114, P93, DOI 10.1016/0168-9452(95)04308-X; Riechmann JL, 1996, NUCLEIC ACIDS RES, V24, P3134, DOI 10.1093/nar/24.16.3134; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sinha S, 1996, MOL CELL BIOL, V16, P328; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; Zemzoumi K, 1999, J MOL BIOL, V286, P327, DOI 10.1006/jmbi.1998.2496; Zhang HM, 1998, SCIENCE, V279, P407, DOI 10.1126/science.279.5349.407	52	87	108	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26429	26435		10.1074/jbc.M202546200	http://dx.doi.org/10.1074/jbc.M202546200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11971906	hybrid			2022-12-25	WOS:000176908700080
J	Walker, SJ; Brown, HA				Walker, SJ; Brown, HA			Specificity of Rho insert-mediated activation of phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; INTERACTION SITES; CDC42 REQUIRES; NADPH OXIDASE; EFFECTOR; REGION; DOMAIN; ARF	Members of the Rho subfamily of GTP-binding proteins regulate phospholipase D1 (PLD1) activity and signaling. In previous work, we demonstrated that binding of the Rho family member Cdc42 to PLD1 and the subsequent stimulation of its enzymatic activity are distinct events. Deletion of the insert helix from Cdc42 does not interfere with its switch I-mediated, GTP-dependent binding to PLD1 but inhibits Cdc42-stimulated PLD1 activity. To understand the mechanism of the insert-mediated activation of PLD1 by Cdc42 and to develop reagents to study Cdc42-activated PLD1 in cellular signaling events, we have undertaken a mutational analysis of the Rho insert region of Cdc42 and examined the specificity of the insert helix requirement in the other Rho family members, RhoA and Rac1. Here, we identify a critical residue, serine 124, in the Cdc42 insert helix central to its activation mechanism. Further, we examine this activation mechanism with respect to other members of the Rho family and demonstrate that each Rho protein activates PLD by distinct mechanisms, potentially allowing for unique signaling outcomes in the cell.	Cornell Univ, Dept Mol Med, Ctr Vet Med, Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA	Cornell University	Brown, HA (corresponding author), Cornell Univ, Dept Mol Med, Ctr Vet Med, Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA.	hab8@cornell.edu			NIGMS NIH HHS [GM58516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cai SM, 2001, BIOCHEM J, V355, P779, DOI 10.1042/bj3550779; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Walker SJ, 2000, J BIOL CHEM, V275, P15665, DOI 10.1074/jbc.M000076200; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Zong H, 2001, MOL CELL BIOL, V21, P5287, DOI 10.1128/MCB.21.16.5287-5298.2001	23	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26260	26267		10.1074/jbc.M201811200	http://dx.doi.org/10.1074/jbc.M201811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011045	hybrid			2022-12-25	WOS:000176908700058
J	Figueiredo-Pereira, ME; Li, ZM; Jansen, M; Rockwell, P				Figueiredo-Pereira, ME; Li, ZM; Jansen, M; Rockwell, P			N-acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; OXIDATIVE STRESS; PROTEIN; ALZHEIMERS; INHIBITION; IMPAIRMENT; DISEASE; INCLUSIONS; HYPOTHESIS; INDUCTION	In many neurodegenerative disorders, aggregates of ubiquitinated proteins are detected in neuronal inclusions, but their role in neurodegeneration remains to be defined. To identify intracellular mechanisms associated with the appearance of ubiquitin-protein aggregates, mouse neuronal HT4 cells were treated with cadmium. This heavy metal is a potent cell poison that mediates oxidative stress and disrupts the ubiquitin/ proteasome pathway. In the current studies, the following intracellular events were found to be also induced by cadmium: (i) a specific rise in cyclooxygenase-2 (COX-2) gene expression but not COX-1; (ii) an increase in the extracellular levels of the proinflammatory prostaglandin E2, a product of COX-2; and (iii) production of 4-hydroxy-2-nonenal-protein adducts, which result from lipid peroxidation. In addition, cadmium treatment led to the accumulation of high molecular weight ubiquitin COX-2 conjugates and perturbed COX-2 glycosylation. The thiol-reducing antioxidant N-acetylcysteine, and, to a lesser extent, the COX-2 inhibitor celecoxib, attenuated the loss of cell viability induced by cadmium demonstrating that oxidative stress and COX-2 activation contribute to cadmium cytotoxicity. These findings establish that disruption of the ubiquitin/proteasome pathway is not the only event triggered by cadmium. This oxidative stressor also activates COX-2 function. Both events could be triggered by formation of 4-hydroxy-2-nonenal as a result of cadmium-induced lipid peroxidation. Proinflammatory responses stimulated by oxidative stressors that mimic the cadmium effects may, therefore, be important initiators of the neurodegenerative process and exacerbate its progress.	CUNY Hunter Coll, Dept Sci Biol, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Figueiredo-Pereira, ME (corresponding author), CUNY Hunter Coll, Dept Sci Biol, 695 Pk Ave, New York, NY 10021 USA.	pereira@genectr.hunter.cuny.edu			NINDS NIH HHS [NS34018] Funding Source: Medline; PHSPO CDC HHS [SO66054] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034018] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHSPO CDC HHS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACAN NL, 1995, BIOCHEM MOL MED, V54, P33, DOI 10.1006/bmme.1995.1005; Andersen JK, 2000, MECH AGEING DEV, V118, P15, DOI 10.1016/S0047-6374(00)00150-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; FIGUEIREDOPEREI.ME, 2001, PROTEOLYSIS PATHOLPH, P137; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Martinez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5; Martinez M, 1999, LIFE SCI, V64, P1253, DOI 10.1016/S0024-3205(98)00472-X; Minekura H, 2001, BIOCHEM BIOPH RES CO, V282, P557, DOI 10.1006/bbrc.2001.4586; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYTILINEOU C, 1993, J NEUROCHEM, V61, P1470, DOI 10.1111/j.1471-4159.1993.tb13642.x; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Oka A, 1999, NEUROPEDIATRICS, V30, P34, DOI 10.1055/s-2007-973454; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stohs Sidney J., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P201; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203	42	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25283	25289		10.1074/jbc.M109145200	http://dx.doi.org/10.1074/jbc.M109145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997384	hybrid			2022-12-25	WOS:000176747000058
J	Sterling, D; Alvarez, BV; Casey, JR				Sterling, D; Alvarez, BV; Casey, JR			The extracellular component of a transport metabolon - Extracellular loop 4 of the human AE1 Cl-/HCO(3)(-)exchanger binds carbonic anhydrase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGER; CDNA CLONING; ERYTHROCYTE BAND-3; INTRACELLULAR PH; LOCALIZATION; EXPRESSION; PROTEINS; CELLS; CA; RABBIT	Cytosolic carbonic anhydrase II (CAII) and the cytoplasmic C-terminal tails of chloride/bicarbonate anion exchange (AE) proteins associate to form a bicarbonate transport metabolon, which maximizes the bicarbonate transport rate. To determine whether cell surface-anchored carbonic anhydrase IV (CAIV) interacts with AE proteins to accelerate the bicarbonate transport rate, AE1-mediated bicarbonate transport was monitored in transfected HEK293 cells. Expression of the inactive CAII V143Y mutant blocked the interaction between endogenous cytosolic CAII and AE1, AE2, and AE3 and inhibited their transport activity (53 +/- 3, 49 +/- 10, and 35 +/- 1% inhibition, respectively). However, in the presence of V143Y CAII, expression of CAIV restored full functional activity to AE1, AE2, and AE3 (AE1, 101 3; AE2, 85 +/- 5; AE3, 108 +/- 1%). In Triton X-100 extracts of transfected HEK293 cells, resolved by sucrose gradient ultracentrifugation, CAIV recruitment to the position of AE1 suggested a physical interaction between CAIV and AE1. Gel overlay assays showed a specific interaction between CAIV and AE1, AE2, and AE3. Glutathione S-transferase pull-down assays revealed that the interaction between CAIV and AE1 occurs on the large fourth extracellular loop of AE1. We conclude that AE1 and CAIV interact on extracellular loop 4 of AE 1, forming the extracellular component of a bicarbonate transport metabolon, which accelerates the rate of AE-mediated bicarbonate transport.	Univ Alberta, Dept Physiol, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	Institute for Work & Health; University of Alberta; Institute for Work & Health; University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; Bagnis C, 2001, AM J PHYSIOL-RENAL, V280, pF437, DOI 10.1152/ajprenal.2001.280.3.F437; Baird TT, 1997, BIOCHEMISTRY-US, V36, P2669, DOI 10.1021/bi962663s; BRECHUE WF, 1991, BIOCHIM BIOPHYS ACTA, V1066, P201, DOI 10.1016/0005-2736(91)90187-D; BRION LP, 1994, AM J PHYSIOL, V266, pF185, DOI 10.1152/ajprenal.1994.266.2.F185; BROSIUS FC, 1995, AM J PHYSIOL-RENAL, V269, pF461, DOI 10.1152/ajprenal.1995.269.4.F461; BROWN D, 1990, P NATL ACAD SCI USA, V87, P7457, DOI 10.1073/pnas.87.19.7457; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUCE LJ, 1995, BLOOD, V85, P541; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; COUSIN JL, 1976, J PHYSIOL-LONDON, V256, P61, DOI 10.1113/jphysiol.1976.sp011311; COUSIN JL, 1975, J PHYSIOL-LONDON, V253, P385, DOI 10.1113/jphysiol.1975.sp011195; DODGSON SJ, 1988, J APPL PHYSIOL, V65, P1472, DOI 10.1152/jappl.1988.65.4.1472; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; GEERS C, 1992, BIOCHEM J, V282, P165, DOI 10.1042/bj2820165; GHANDOUR MS, 1992, P NATL ACAD SCI USA, V89, P6823, DOI 10.1073/pnas.89.15.6823; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716; Jarolim P, 1998, BLOOD, V92, P4836, DOI 10.1182/blood.V92.12.4836.424k24_4836_4843; KIFOR G, 1993, J MEMBRANE BIOL, V134, P169; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINN SC, 1992, J BIOL CHEM, V267, P7927; LINN SC, 1995, CIRC RES, V76, P584, DOI 10.1161/01.RES.76.4.584; LONNERHOLM G, 1991, ACTA PHYSIOL SCAND, V141, P231, DOI 10.1111/j.1748-1716.1991.tb09072.x; MAREN TH, 1993, J BIOL CHEM, V268, P26233; MCKINLEY DN, 1976, BIOCHIM BIOPHYS ACTA, V445, P780, DOI 10.1016/0005-2744(76)90128-5; Mori K, 1999, J BIOL CHEM, V274, P15701, DOI 10.1074/jbc.274.22.15701; OKUYAMA T, 1992, P NATL ACAD SCI USA, V89, P1315, DOI 10.1073/pnas.89.4.1315; PARKES JL, 1989, ARCH BIOCHEM BIOPHYS, V275, P459, DOI 10.1016/0003-9861(89)90392-5; PUCEAT M, 1995, J BIOL CHEM, V270, P1315, DOI 10.1074/jbc.270.3.1315; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; Richards SM, 1999, J CELL SCI, V112, P1519; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; RUETZ S, 1993, SOC GEN PHY, V48, P193; Schwartz GJ, 2000, AM J PHYSIOL-RENAL, V278, pF894, DOI 10.1152/ajprenal.2000.278.6.F894; Schwartz GJ, 1999, AM J PHYSIOL-RENAL, V276, pF510, DOI 10.1152/ajprenal.1999.276.4.F510; Scozzafava A, 2002, BIOORG MED CHEM LETT, V12, P1177, DOI 10.1016/S0960-894X(02)00121-X; Sender S, 1998, J HISTOCHEM CYTOCHEM, V46, P855, DOI 10.1177/002215549804600709; SLY WS, 1985, PEDIATR RES, V19, P1033, DOI 10.1203/00006450-198510000-00017; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Sterling D, 1999, BIOCHEM J, V344, P221, DOI 10.1042/0264-6021:3440221; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, BIOPHYS J, V82, p570A; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tong CK, 2000, J NEUROSCI, V20, P8247, DOI 10.1523/JNEUROSCI.20-22-08247.2000; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuganezawa H, 2001, J BIOL CHEM, V276, P8180, DOI 10.1074/jbc.M004513200; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; WAHEED A, 1992, ARCH BIOCHEM BIOPHYS, V294, P550, DOI 10.1016/0003-9861(92)90724-B; WHITNEY PL, 1982, J BIOL CHEM, V257, P2056; Wistrand PJ, 1999, ACTA PHYSIOL SCAND, V165, P211; WISTRAND PJ, 1989, KIDNEY INT, V35, P851, DOI 10.1038/ki.1989.63; Zolotarev AS, 1996, BIOCHEMISTRY-US, V35, P10367, DOI 10.1021/bi9526084	67	128	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25239	25246		10.1074/jbc.M202562200	http://dx.doi.org/10.1074/jbc.M202562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994299	hybrid			2022-12-25	WOS:000176747000052
J	Zako, M; Iwaki, M; Yoneda, M; Miyaishi, O; Zhao, JS; Suzuki, Y; Takeuchi, M; Miyake, G; Ikagawa, H; Kimata, K				Zako, M; Iwaki, M; Yoneda, M; Miyaishi, O; Zhao, JS; Suzuki, Y; Takeuchi, M; Miyake, G; Ikagawa, H; Kimata, K			Molecular cloning and characterization of chick sialoprotein associated with cones and rods, a developmentally regulated glycoprotein of interphotoreceptor matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HUMAN RETINA; PG-M; HYALURONAN; PHOTORECEPTORS; LOCALIZATION; PROTEINS; ADHESION; VERSICAN; BINDING	MY-174 is an IgM class monoclonal antibody originally established against chick PG-M/versican. The antibody specifically stains the photoreceptor layer, where we recently reported an absence of PG-M/versican. In this study, we re-characterized the antibody and identified the molecule that reacts to MY-174 at the photoreceptor layer. Immunohistochemistry localized the antigen to the matrix surrounding photoreceptors. A variety of glycosidase digestions showed that the antigen is the 150-kDa glycoprotein that has sialylated N- and O-linked glycoconjugates having a molecular mass of more than 30-kDa. The peptide sequences obtained from purified MY-174 antigen showed we had sequenced a full-length cDNA with an open reading frame of 2787 base pairs, encoding a polypeptide of 928 amino acids, with 56 and 54% identities to human and mouse sialoprotein associated with cones and rods (SPACRs), respectively, and with the structural features observed in SPACRs. The specific sialylated O-glycoconjugates here are involved in the epitope structure for MY-174. SPACR first appeared by embryonic days 15-16, and expression increased with developmental age, paralleling the adhesion between neural retina and retinal pigment epithelium. Thus, we concluded that the MY-174 antigen at the photoreceptor layer, a developmentally regulated glycoprotein, is identical to chick SPACR and may be involved in a novel system mediating adhesion between neural retina and retinal pigment epithelium.	Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Dept Pathol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Prefectural Coll Nursing & Hlth, Nagoya, Aichi 4638502, Japan; Tosei Municipal Hosp, Aichi 4890803, Japan	Aichi Medical University; Aichi Medical University; Aichi Medical University	Zako, M (corresponding author), Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.							Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997; Adler A J, 1982, Curr Eye Res, V2, P743, DOI 10.3109/02713688209020006; ADLER AJ, 1982, EXP EYE RES, V34, P423, DOI 10.1016/0014-4835(82)90088-4; ADLER AJ, 1981, EXP EYE RES, V32, P755, DOI 10.1016/0014-4835(81)90025-7; BISHOP PN, 1993, GLYCOBIOLOGY, V3, P403, DOI 10.1093/glycob/3.4.403; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; ENDO EG, 1988, INVEST OPHTH VIS SCI, V29, P1390; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HAGEMAN GS, 1991, PROGR RETINAL RES, V10, P207; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYFIELD JG, 1989, RETINA-J RET VIT DIS, V9, P59, DOI 10.1097/00006982-198909010-00008; Hollyfield JG, 1997, EXP EYE RES, V65, P603, DOI 10.1006/exer.1997.0369; Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422; HOLLYFIELD JG, 1990, EXP EYE RES, V51, P107, DOI 10.1016/0014-4835(90)90177-V; Isogai Z, 1996, CANCER RES, V56, P3902; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LAZARUS HS, 1992, INVEST OPHTH VIS SCI, V33, P364; Lee JW, 2000, EXP EYE RES, V71, P341, DOI 10.1006/exer.2000.0888; MARMOR MF, 1993, PROG RETIN RES, V12, P179, DOI 10.1016/0278-4327(93)90009-I; PORRELLO K, 1986, CURR EYE RES, V5, P981, DOI 10.3109/02713688608995180; Russell SR, 1997, AM J OPHTHALMOL, V123, P386, DOI 10.1016/S0002-9394(14)70135-7; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; TIEN LF, 1992, EXP EYE RES, V55, P297, DOI 10.1016/0014-4835(92)90194-W; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YAO XY, 1990, INVEST OPHTH VIS SCI, V31, P2051; YAO XY, 1992, INVEST OPHTH VIS SCI, V33, P498; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 1997, J NEUROCHEM, V69, P2155; ZAUBERMAN H, 1969, EXP EYE RES, V8, P276, DOI 10.1016/S0014-4835(69)80039-4; Zauberman H, 1979, RETINAL PIGMENT EPIT, P192; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	34	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25592	25600		10.1074/jbc.M201279200	http://dx.doi.org/10.1074/jbc.M201279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991949	hybrid			2022-12-25	WOS:000176747000097
J	Chou, CJ; Haluzik, M; Gregory, C; Dietz, KR; Vinson, C; Gavrilova, O; Reitman, ML				Chou, CJ; Haluzik, M; Gregory, C; Dietz, KR; Vinson, C; Gavrilova, O; Reitman, ML			WY14,643, a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-OXIDATION; ADIPOSE-TISSUE; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE; SKELETAL-MUSCLE; LIPODYSTROPHY; LEPTIN; OBESITY; MOUSE; OVEREXPRESSION	WY14,643 is a specific peroxisome proliferator-activated receptor a (PPARalpha) agonist with strong hypolipidemic effects. Here we have examined the effect of WY14,643 in the A-ZIP/F-1 mouse, a model of severe lipoatrophic diabetes. With I week of treatment, all doses of WY14,643 that were tested normalized serum triglyceride and fatty acid levels. Glucose and insulin levels also improved but only with high doses and longer treatment duration. WY14,643 reduced liver and muscle triglyceride content and increased levels of mRNA encoding fatty acid oxidation enzymes. In liver, the elevated lipogenic mRNA profile (including PPARgamma) in A-ZIP/F-1 mice remained unchanged. These results suggest that WY14,643 acts by increasing beta-oxidation rather by than decreasing lipogenesis or lipid uptake. Hyperinsulinemic euglycemic clamp studies indicated that WY14,643 treatment improved liver more than muscle insulin sensitivity and that hepatic mRNA levels of gluconeogenic enzymes were reduced. Combination treatment with both WY14,643 and a PPARgamma ligand, rosiglitazone, did not lower glucose levels more effectively than did treatment with WY14,643 alone. These data support the hypothesis that reducing intracellular triglycerides in non-adipose tissues improves insulin sensitivity and suggest that further investigation of the role of PPARa agonists in the treatment of lipoatrophic diabetes is warranted.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reitman, ML (corresponding author), Merck Res Labs, POB 2000,RY80M-213, Rahway, NJ 07065 USA.		Dietz, Kelly/AAE-3074-2021; Reitman, Marc/B-4448-2013; Haluzik, Martin/I-8190-2017	Reitman, Marc/0000-0002-0426-9475; Haluzik, Martin/0000-0002-0201-6888; Dietz, Kelly/0000-0003-3670-2912				Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Cook WS, 2000, BIOCHEM BIOPH RES CO, V278, P250, DOI 10.1006/bbrc.2000.3739; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Gavrilova O, 2000, NATURE, V403, P850, DOI 10.1038/35002663; GRASSO P, 1993, PEROXISOMES BIOL IMP, P639; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Minnich A, 2001, AM J PHYSIOL-ENDOC M, V280, pE270, DOI 10.1152/ajpendo.2001.280.2.E270; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Panz VR, 1997, CLIN ENDOCRINOL, V46, P365, DOI 10.1046/j.1365-2265.1997.970912.x; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; ROBBINS DC, 1979, METABOLISM, V28, P908, DOI 10.1016/0026-0495(79)90090-8; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Vantyghem MC, 1999, DIABETES CARE, V22, P1374, DOI 10.2337/diacare.22.8.1374; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	34	153	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24484	24489		10.1074/jbc.M202449200	http://dx.doi.org/10.1074/jbc.M202449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11994294	hybrid			2022-12-25	WOS:000176611800068
J	Kawano, M; Igarashi, K; Yamato, I; Kakinuma, Y				Kawano, M; Igarashi, K; Yamato, I; Kakinuma, Y			Arginine residue at position 573 in Enterococcus hirae vacuolar-type ATPase NtpI subunit plays a crucial role in Na+ translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; PROTON TRANSLOCATION; ALPHA-SUBUNIT; H+-ATPASE; SYNTHASE; GENE; PURIFICATION; (H+)-ATPASE	The 76-kDa NtpI subunit constitutes the membrane-embedded V-0 moiety of Enterococcus hirae vacuolar type Na+-ATPase with a 16-kDa NtpK hexamer containing Na+ binding sites. In this study, we investigated the role of an arginine residue, which is highly conserved among the corresponding subunits of bacterial vacuolar-type ATPases, at position 573 of NtpI. Substitution of Glu, Leu, or Gln for Arg-573 abolished sodium transport and sodium-stimulated ATP hydrolysis of the enzyme. The conservative replacement of Arg by Lys lowered both activities about one-fifth of those of the wild type enzyme. We have reported previously on ATP-dependent negative cooperativity for Na+ coupling of this enzyme (Murata, T., Kakinuma, Y., and Yamato, 1. (2001) J. Biol. Chem. 276, 48337-48340). The negative cooperativity for the Na+ dependence of ATPase activity was weakened by the mutation R573K, the Hill coefficients for the wild type and mutant enzymes at a saturated ATP concentration were 0.22 +/- 0.03 and 0.40 +/- 0.05, respectively. The Hill coefficients of both enzymes at limited ATP concentrations approached 1. These results indicate that NtpI Arg-573 is indispensable for sodium translocation and for the cooperative features of E. hirae vacuolar-type ATPase.	Muroran Inst Technol, Dept Appl Chem, Muroran, Hokkaido 0508585, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Muroran Institute of Technology; Chiba University; Tokyo University of Science	Kakinuma, Y (corresponding author), Muroran Inst Technol, Dept Appl Chem, 27-1 Mizumoto Cho, Muroran, Hokkaido 0508585, Japan.			Igarashi, Kazuei/0000-0003-3751-3187; KAWANO-KAWADA, Miyuki/0000-0002-1168-9291				Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fillingame RH, 2000, J EXP BIOL, V203, P9; HEEFNER DL, 1980, J BIOL CHEM, V255, P1403; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Murata T, 2000, J BIOL CHEM, V275, P13415, DOI 10.1074/jbc.275.18.13415; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 2001, J BIOL CHEM, V276, P48337, DOI 10.1074/jbc.M106821200; Murata T, 1999, J BIOCHEM, V125, P414, DOI 10.1093/oxfordjournals.jbchem.a022302; NAKAYAMA T, 1993, CHEM PHARM BULL, V41, P117; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oster G, 2000, PHILOS T ROY SOC B, V355, P523, DOI 10.1098/rstb.2000.0593; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUZUKI T, 1993, MOL MICROBIOL, V9, P111, DOI 10.1111/j.1365-2958.1993.tb01673.x; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Takase K, 1999, BIOSCI BIOTECH BIOCH, V63, P1125, DOI 10.1271/bbb.63.1125; TAKASE K, 1998, 71 ANN M JAP BIOCH S, P1099; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1994, J BIOL CHEM, V269, P30364; WASER M, 1992, J BIOL CHEM, V267, P5396; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZUBENTRUP KH, 1997, J BACTERIOL, V179, P1274	41	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24405	24410		10.1074/jbc.M200973200	http://dx.doi.org/10.1074/jbc.M200973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983695	hybrid			2022-12-25	WOS:000176611800058
J	Mukherjee, SB; Das, M; Sudhandiran, G; Shaha, C				Mukherjee, SB; Das, M; Sudhandiran, G; Shaha, C			Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; BUTHIONINE SULFOXIMINE; NERVE-TERMINALS; CALCIUM-UPTAKE; MEMBRANE; RELEASE; NA+; GLUTATHIONE	Reactive oxygen species are important regulators of protozoal infection. Promastigotes of Leishmania donovani, the causative agent of Kala-azar, undergo an apoptosis-like death upon exposure to H2O2. The present study shows that upon activation of death response by H2O2, a dose- and time-dependent loss of mitochondrial membrane potential occurs. This loss is accompanied by a depletion of cellular glutathione, but cardiolipin content or thiol oxidation status remains unchanged. ATP levels are reduced within the first 60 min of exposure as a result of mitochondrial membrane potential loss. A tight link exists between changes in cytosolic Ca2+ homeostasis and collapse of the mitochondrial membrane potential, but the dissipation of the potential is independent of elevation of cytosolic Na+ and mitochondrial Ca2+. Partial inhibition of cytosolic Ca2+ increase achieved by chelating extracellular or intracellular Ca2+ by the use of appropriate agents resulted in significant rescue of the fall of the mitochondrial membrane potential and apoptosis-like death. It is further demonstrated that the increase in cytosolic Ca2+ is an additive result of release of Ca2+ from intracellular stores as well as by influx of extracellular Ca2+ through flufenamic acid-sensitive non-selective cation channels; contribution of the latter was larger. Mitochondrial changes do not involve opening of the mitochondrial transition pore as cyclosporin A is unable to prevent mitochondrial membrane potential loss. An antioxidant like N-acetylcysteine is able to inhibit the fall of the mitochondrial membrane potential and prevent apoptosis-like death. Together, these findings show the importance of non-selective cation channels in regulating the response of L. donovani promastigotes to oxidative stress that triggers downstream signaling cascades leading to apotosis-like death.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	cshaha@nii.res.in	Sudhandiran, G/AAG-9967-2019; Ganapasam, Sudhandiran/AAD-4264-2021	Sudhandiran, G/0000-0003-0066-7801; Das, Manika/0000-0001-8639-7165				Anderson CP, 1999, EXP CELL RES, V246, P183, DOI 10.1006/excr.1998.4303; Anuradha CD, 2001, FREE RADICAL BIO MED, V31, P367, DOI 10.1016/S0891-5849(01)00591-3; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Basselin M, 1998, PARASITOL RES, V84, P78, DOI 10.1007/s004360050361; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CHANG KP, 1983, INT REV CYTOL, P267; Chinopoulos C, 1999, ANN NY ACAD SCI, V893, P269, DOI 10.1111/j.1749-6632.1999.tb07834.x; Chinopoulos C, 2000, J NEUROSCI, V20, P2094; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Das M, 2001, J CELL SCI, V114, P2461; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Diaz G, 1999, J CELL SCI, V112, P1077; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; Ehlers RA, 1999, SURGERY, V126, P148, DOI 10.1067/msy.1999.98725; ERIC C, 2001, J BIOL CHEM, V276, P5384; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Geller HM, 2001, J NEUROCHEM, V78, P265, DOI 10.1046/j.1471-4159.2001.00395.x; Gonzalez A, 2000, J BIOL CHEM, V275, P38680, DOI 10.1074/jbc.M005667200; Gottlieb RA, 2001, BIOL SIGNAL RECEPT, V10, P147; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Kim JA, 2000, FREE RADICAL RES, V33, P267, DOI 10.1080/10715760000301431; Kim JA, 2001, BIOCHEM BIOPH RES CO, V281, P511, DOI 10.1006/bbrc.2001.4371; Kowaltowski AJ, 2000, FEBS LETT, V473, P177, DOI 10.1016/S0014-5793(00)01526-X; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KRICKA LJ, 1988, ANAL BIOCHEM, V175, P14, DOI 10.1016/0003-2697(88)90354-5; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li X, 2000, EXP CELL RES, V257, P290, DOI 10.1006/excr.2000.4901; Meyer TN, 1996, KIDNEY INT, V49, P388, DOI 10.1038/ki.1996.57; NABI ZF, 1984, MOL BIOCHEM PARASIT, V10, P297, DOI 10.1016/0166-6851(84)90028-8; Nicole A, 1998, BIOMED PHARMACOTHER, V52, P349, DOI 10.1016/S0753-3322(99)80001-8; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Overly CC, 1996, J CELL SCI, V109, P971; Panaretakis T, 2001, TOXICOL APPL PHARM, V173, P56, DOI 10.1006/taap.2001.9159; Pariente JA, 2001, J MEMBRANE BIOL, V179, P27, DOI 10.1007/s002320010034; Rais S, 2000, ANTIMICROB AGENTS CH, V44, P2406, DOI 10.1128/AAC.44.9.2406-2410.2000; Satoh T, 1997, J NEUROSCI RES, V50, P413, DOI 10.1002/(SICI)1097-4547(19971101)50:3<413::AID-JNR7>3.0.CO;2-L; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; Simpson PB, 1998, J PHYSIOL-LONDON, V508, P413, DOI 10.1111/j.1469-7793.1998.413bq.x; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P37, DOI 10.1006/abbi.2000.2194; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463; Ward MW, 2000, J NEUROSCI, V20, P7208; Weldrick DP, 1999, FEMS MICROBIOL LETT, V173, P139, DOI 10.1111/j.1574-6968.1999.tb13495.x; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V374, P142, DOI 10.1006/abbi.1999.1574; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhang GH, 1996, J BIOL CHEM, V271, P29067, DOI 10.1074/jbc.271.46.29067	59	174	178	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24717	24727		10.1074/jbc.M201961200	http://dx.doi.org/10.1074/jbc.M201961200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983701	hybrid			2022-12-25	WOS:000176611800098
J	Hagen, T; Di Daniel, E; Culbert, AA; Reith, AD				Hagen, T; Di Daniel, E; Culbert, AA; Reith, AD			Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; NEGATIVE REGULATOR; XENOPUS EMBRYOS; SUBSTRATE-SPECIFICITY; WNT; AXIN; PATHWAY; COMPLEX; DEPHOSPHORYLATION; INHIBITION	Glycogen synthase kinase-3 (GSK-3) is a serine-threo. nine kinase that is involved in multiple cellular signaling pathways, including the Wnt signaling cascade where it phosphorylates beta-catenin, thus targeting it for proteasome-mediated degradation. Unlike phosphorylation of glycogen synthase, phosphorylation of beta-catenin by GSK-3 does not require priming in vitro, i.e. it is not dependent on the presence of a phosphoserine, four residues C-terminal to the GSK-3 phosphorylation site. Recently, a means of dissecting GSK-3 activity toward primed and non-primed substrates has been made possible by identification of the R96A mutant of GSK-3beta. This mutant is unable to phosphorylate primed but can still phosphorylate unprimed substrates (Frame, S., Cohen, P., and Biondi R. M. (2001) Mol. Cell 7,1321-1327). Here we have investigated whether phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin requires priming through prior phosphorylation at Ser(41) in intact cells. We have shown that the Are mutant does not induce beta-catenin degradation but instead stabilizes beta-catenin, indicating that it is unable to phosphorylate beta-catenin in intact cells. Furthermore, if Ser(45) in beta-catenin is mutated to Ala, beta-catenin is markedly stabilized, and phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin by wild type GSK-3beta is prevented in intact cells. In addition, we have shown that the L128A mutant, which is deficient in phosphorylating Axin in vitro, is still able to phosphorylate beta-catenin in intact cells although it has reduced activity. Mutation of Tyr(216) to Phe markedly reduces the ability of GSK-3beta to phosphorylate and down-regulate beta-catenin. In conclusion, we have found that the Are mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).	GlaxoSmithKline Inc, Syst Res Kinase Biol Discovery Res, Harlow CM19 5AD, Essex, England; GlaxoSmithKline Inc, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AD, Essex, England; GlaxoSmithKline Inc, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AD, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hagen, T (corresponding author), UCL, Wolfson Inst Biomed Res, Mortimer St, London WC1E 6BT, England.	t.hagen@ucl.ac.uk						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dale TC, 1998, BIOCHEM J, V329, P209; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Koesters R, 2001, CARCINOGENESIS, V22, P1885, DOI 10.1093/carcin/22.11.1885; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200	38	76	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23330	23335		10.1074/jbc.M201364200	http://dx.doi.org/10.1074/jbc.M201364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967263	hybrid			2022-12-25	WOS:000176475700032
J	Barone, F; Genazzani, AA; Conti, A; Churchill, GC; Palombi, F; Ziparo, E; Sorrentino, V; Galione, A; Filippini, A				Barone, F; Genazzani, AA; Conti, A; Churchill, GC; Palombi, F; Ziparo, E; Sorrentino, V; Galione, A; Filippini, A			A pivotal role for cADPR-mediated Ca2+ signaling: regulation of endothelin-induced contraction in peritubular smooth muscle cells	FASEB JOURNAL			English	Article						ryanodine receptors; calcium signaling; ADP-ribosyl cyclase; seminiferous tubule	CYCLIC ADP-RIBOSE; MYOID CELLS; INOSITOL TRISPHOSPHATE; RAT TESTIS; RYANODINE RECEPTORS; CALCIUM; EXPRESSION; RELEASE; CYCLASE; DIFFERENTIATION	cADPR, a potent calcium-mobilizing intracellular messenger synthesized by ADP-ribosyl cyclases regulates openings of ryanodine receptors (RyR). Here we report that in the rat testis, a functional cADPR Ca2+ release system is essential for the contractile response of peritubular smooth muscle cells (PSMC) to endothelin (ET). We previously showed that this potent smooth muscle agonist elicits intracellular Ca2+ release in PSMC and seminiferous tubule contraction via activation of ETA and ETB receptors. ETB-R induces the mobilization of a thapsigargin-sensitive but IP3-independent intracellular Ca2+ pool. Stimulation of permeabilized PSMC with cADPR was found to elicit large Ca2+ releases blocked by either a selective antagonist of cADPR or a RyR blocker, but not by heparin. Western blotting and confocal fluorescence microscopy indicated the specific expression of type 2 RyR in perinuclear localization. ET was found to stimulate the activity of ADP-ribosyl cyclase. Microinjection of the selective cADPR antagonist 8NH(2)-cADPR completely abolished subsequent stimulation of Ca2+ signaling via ETA and ETB receptors. cADPR therefore appears to have an obligatory role for ETA-R and ETB-R-mediated calcium signaling in PSMC. However, ETB-R seem to be coupled exclusively to cADPR whereas ETA-R activation may be linked to IP3 and cADPR signaling pathways.	Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Siena, Dept Neurosci, Mol Med Sect, I-53100 Siena, Italy; DIBIT S Raffaele Sci Inst, I-20132 Milan, Italy; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	Fondazione Cenci Bolognetti; Sapienza University Rome; University of Oxford; University of Siena; University of Cambridge	Filippini, A (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, Via A Scarpa 14, I-00161 Rome, Italy.	antonio.filippini@uniroma1.it	Conti, Antonio/AAN-7161-2020; Galione, Antony/E-5884-2011; Genazzani, Armando/AAI-8280-2020; Sorrentino, Vincenzo/A-4793-2014	Conti, Antonio/0000-0001-9150-5271; Sorrentino, Vincenzo/0000-0002-8573-8631; Ziparo, Elio/0000-0002-8776-3515; Galione, Antony/0000-0002-4132-7646; filippini, antonio/0000-0001-8453-287X; Genazzani, Armando/0000-0003-1923-7430				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Chiarenza C, 2000, ENDOCRINOLOGY, V141, P2971, DOI 10.1210/en.141.8.2971; Conti M, 1996, ELECTROPHORESIS, V17, P1590, DOI 10.1002/elps.1150171017; FILIPPINI A, 1993, ENDOCRINOLOGY, V133, P1789, DOI 10.1210/en.133.4.1789; FILIPPINI A, 1995, ENDOTHELINS ENDOCRIN, V15, P219; Flucher BE, 1999, J CELL BIOL, V146, P621, DOI 10.1083/jcb.146.3.621; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GRAEFF RM, 1994, BIOCHEM BIOPH RES CO, V205, P722, DOI 10.1006/bbrc.1994.2725; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Li PL, 2001, AM J PHYSIOL-HEART C, V280, pH208, DOI 10.1152/ajpheart.2001.280.1.H208; PALOMBI F, 1988, BIOL REPROD, V39, P1101, DOI 10.1095/biolreprod39.5.1101; PALOMBI F, 1992, ANAT REC, V233, P32, DOI 10.1002/ar.1092330106; PALOMBI F, 1988, SERONO S, V50, P311; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sorrentino V, 2000, CURR OPIN GENET DEV, V10, P662, DOI 10.1016/S0959-437X(00)00139-8; Sorrentino V, 2001, TRENDS PHARMACOL SCI, V22, P459, DOI 10.1016/S0165-6147(00)01760-0; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; Tarroni P, 1997, J BIOL CHEM, V272, P19808, DOI 10.1074/jbc.272.32.19808; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Tripiciano A, 1996, BIOL REPROD, V55, P25, DOI 10.1095/biolreprod55.1.25; Tripiciano A, 1999, J CELL BIOL, V145, P1027, DOI 10.1083/jcb.145.5.1027; Tripiciano A, 1997, FASEB J, V11, P276, DOI 10.1096/fasebj.11.4.9068617; TUNG PS, 1990, BIOL REPROD, V42, P351, DOI 10.1095/biolreprod42.2.351; VIRTANEN I, 1986, ANAT RECORD, V215, P10, DOI 10.1002/ar.1092150103; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	35	48	50	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0697	10.1096/fj.01-0749com	http://dx.doi.org/10.1096/fj.01-0749com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978734				2022-12-25	WOS:000175973900024
J	Ghosh, AK; Majumder, M; Steele, R; Liu, TJ; Ray, RB				Ghosh, AK; Majumder, M; Steele, R; Liu, TJ; Ray, RB			MBP-1 mediated apoptosis involves cytochrome c release from mitochondria	ONCOGENE			English	Article						apoptosis; Bcl-x(L); cytochrome c; MBP-1	SQUAMOUS-CELL CARCINOMA; BINDING PROTEIN MBP-1; MYC PROMOTER; BCL-X; GENE-TRANSFER; FUNCTIONAL DOMAINS; MAMMARY-TUMORS; MESSENGER-RNA; BREAST-CANCER; INDUCTION	MBP-1, a cellular factor, appears to be involved in multiple functions, including transcriptional modulation, apoptosis and cell growth regulation. In this study, we have investigated the signaling pathway involved in MBP-1 mediated apoptotic cell death. Human carcinoma cells infected with a replication deficient adenovirus expressing MBP-1 (AdMBP-1) induced apoptosis, when compared with cells infected by replication-defective adenovirus (d1312) as a negative control. Transduction of MBP-1 in carcinoma cells releases cytochrome c from mitochondria into the cytosol leading to activation of procaspase-9, procaspase-3 and PARP cleavage. We previously observed that MBP-1 mediated apoptosis can be protected by Bcl-2, although MBP-1 does not share a homology with the BH domain of the Bcl-2 family member of proteins. To further understand the mechanism of MBP-1 mediated apoptosis, we examined whether MBP-1 modulates the Bcl-2 gene family. Our results demonstrated that human breast carcinoma cells infected with AdMBP-1 selectively reduced Bcl-x(L) mRNA and protein expression when compared with d1312 infected negative control cells. An in vitro transient reporter assay also suggested repression of the Bcl-x promoter activity by MBP-1. Additional studies indicated that MBP-1 modulates Ets family protein function, thereby downregulating Bcl-x(L) expression. Taken together, our results suggest that MBP-1 selectively represses Bcl-x(L) expression in MCF-7 cells and induces mitochondrial involvement in the apoptotic process.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Div Infect Dis, St Louis, MO 63104 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	Saint Louis University; Saint Louis University; University of Texas System; UTMD Anderson Cancer Center	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rayrb@slu.edu			NCI NIH HHS [CA52799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052799, R29CA052799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Ealovega MW, 1996, CANCER RES, V56, P1965; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; Ghosh AK, 2001, MOL CELL BIOL, V21, P655, DOI 10.1128/MCB.21.2.655-662.2001; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; Graham FL, 2000, IMMUNOL TODAY, V21, P426, DOI 10.1016/S0167-5699(00)01676-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; LIU TJ, 1995, CANCER RES, V55, P3117; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Olopade OI, 1997, CANCER J SCI AM, V3, P230; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY R, 1989, ONCOGENE, V4, P593; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; RAY RB, 1995, CANCER RES, V55, P3747; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; RAY RB, 1994, INT J ONCOL, V5, P1433; Reed JC, 1998, CANCER J, V4, pS8; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shimizu S, 1996, ONCOGENE, V13, P21; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tu YP, 1998, CANCER RES, V58, P256; White RA, 1997, GENOMICS, V39, P406, DOI 10.1006/geno.1996.4499; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YASUSHI F, 1997, J CLIN INVEST, V99, P2898; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	58	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2775	2784		10.1038/sj.onc.1205384	http://dx.doi.org/10.1038/sj.onc.1205384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973636				2022-12-25	WOS:000175063700001
J	Mathai, JP; Germain, M; Marcellus, RC; Shore, GC				Mathai, JP; Germain, M; Marcellus, RC; Shore, GC			Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53	ONCOGENE			English	Article						BIK; E1A; p53; caspase; apoptosis	CYTOCHROME-C; CELL-DEATH; MITOCHONDRIAL-MEMBRANES; TUMOR-SUPPRESSOR; BCL-2 FAMILY; PROTEIN; ADENOVIRUS; ACTIVATION; RELEASE; INTERACTS	A DNA microarray analysis identified the BH3-only BCL-2 family member, BIK/NBK, as a transcript that is upregulated during induction of apoptosis by oncogenic E1A. E1A depended on wild-type p53 to induce BIK and activate the death program. Further, p53 independently induced BIK RNA and protein, and BIK alone stimulated cell death in p53-null cells, dependent on the activation of caspases. BIK function, however, was abrogated by a disabling point mutation within the BH3 domain. Collectively, these results argue that BIK is a downstream apoptotic effector of p53 in response to a physiological p53-mediated death stimulus provided by E1A. Elevated BCL-2 functioned downstream of p53 and BIK induction to inhibit the E1A death pathway, with the ratio of anti-apoptotic BCL-2 and pro-apoptotic BIK determining cell death or survival in E1A-expressing cells. Cells expressing BCL-2 or treated with the pan caspase inhibitor, zVAD-fmk, allowed accumulation of high levels of cytotoxic BIK compared to control cells. Of note, a significant fraction of either ectopic or endogenous BIK was found associated with the endoplasmic reticulum, suggesting that this organelle, in addition to mitochondria, may be a target of BIK function.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; GeminX Biotechnol Inc, Montreal, PQ H2X 3P9, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Gordon.Shore@mcgill.ca						ABERICI A, 1999, J BIOL CHEM, V274, P30764; AKAO Y, 1994, CANCER RES, V54, P2468; Attardi LD, 2000, GENE DEV, V14, P704; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Boulakia CA, 1996, ONCOGENE, V12, P529; BOYD JM, 1995, ONCOGENE, V11, P1921; Breckenridge DG, 2000, CRIT REV EUKAR GENE, V10, P273; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; HEDGE R, 1998, J BIOL CHEM, V273, P7783; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Juin P, 2000, NAT MED, V6, P498, DOI 10.1038/74966; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NG FWH, 1998, MOL CELL BIOL, V20, P6731; NG FWH, 1998, J BIOL CHEM, V139, P327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nguyen M, 1998, J BIOL CHEM, V273, P33099, DOI 10.1074/jbc.273.50.33099; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Orth R, 1997, J BIOL CHEM, V272, P8841; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Prives C, 1999, J PATHOL, V187, P112; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	54	105	106	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2534	2544		10.1038/sj.onc.1205340	http://dx.doi.org/10.1038/sj.onc.1205340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971188				2022-12-25	WOS:000174918400010
J	Bae, SH; Kim, DW; Kim, J; Kim, JH; Kim, DH; Kim, HD; Kang, HY; Seo, YS				Bae, SH; Kim, DW; Kim, J; Kim, JH; Kim, DH; Kim, HD; Kang, HY; Seo, YS			Coupling of DNA helicase and endonuclease activities of yeast Dna2 facilitates Okazaki fragment processing.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESSENTIAL IN-VIVO; REPLICATION FORK; SV40 ORIGIN; PROTEIN; HELICASE/ENDONUCLEASE; NUCLEASES; SUGGESTS; MACHINES; ENCODES	Saccharomyces cerevisiae Dna2 possesses both helicase and endonuclease activities. Its endonuclease activity is essential and well suited to remove RNA-DNA primers of Okazaki fragments. In contrast, its helicase activity, although required for optimal growth, is not essential when the rate of cell growth is reduced. These findings suggest that DNA unwinding activity of Dna2 plays an auxiliary role in Okazaki fragment processing. To address this issue, we examined whether the Dna2 helicase activity influenced its intrinsic endonuclease activity using two mutant proteins, Dna2D657A and Dna2K1080E, which contain only helicase or endonuclease activity, respectively. Experiments performed with a mixture of Dna2D657A and Dna2K1080E enzymes revealed that cleavage of a single-stranded DNA by endonuclease activity of Dna2 occurs while the enzyme translocates along the substrate. In addition, DNA unwinding activity efficiently removed the secondary structure formed in the flap structure, which was further aided by replication protein A. Our results suggest that the Dna2 unwinding activity plays a role in facilitating the removal of the flap DNA by its intrinsic endonuclease activity.	Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Natl Creat Res Initiat Ctr Cell Cycle Control, Suwon 440746, South Korea; Dong A Univ, Coll Med, Dept Pharmacol, Seo Gu, Pusan 602103, South Korea; Chungbuk Prov Univ Sci & Technol, Dept Biotechnol & Bioinformat, Okchon 373807, Chungbuk, South Korea	Sungkyunkwan University (SKKU); Dong A University	Seo, YS (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Natl Creat Res Initiat Ctr Cell Cycle Control, Changan Ku, Suwon 440746, South Korea.	ysseo@med.skku.ac.kr	Seo, Yeonsoo/C-1605-2011; Kim, Dong Wook/H-8253-2015	Kim, Dong Wook/0000-0001-5351-7597				Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2001, NUCLEIC ACIDS RES, V29, P3069, DOI 10.1093/nar/29.14.3069; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Kang HY, 2000, GENETICS, V155, P1055; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0	24	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26632	26641		10.1074/jbc.M111026200	http://dx.doi.org/10.1074/jbc.M111026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004053	hybrid			2022-12-25	WOS:000176908700105
J	Couplan, E; Gonzalez-Barroso, MD; Alves-Guerra, MC; Ricquier, D; Goubern, M; Bouillaud, F				Couplan, E; Gonzalez-Barroso, MD; Alves-Guerra, MC; Ricquier, D; Goubern, M; Bouillaud, F			No evidence for a basal, retinoic, or superoxide-induced uncoupling activity of the uncoupling protein 2 present in spleen or lung mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; THYROID-HORMONE; FATTY-ACIDS; PROTON CONDUCTANCE; ENERGY-METABOLISM; ADP/ATP CARRIER; YEAST-CELLS; COENZYME-Q; MICE; UCP1	The phenotypes observed in mice whose uncoupling protein (Ucp2) gene had been invalidated by homologous recombination (Ucp2(-/-) mice) are consistent with an increase in mitochondrial membrane potential in macrophages and pancreatic A cells. This could support an uncoupling (proton transport) activity of UCP2 in the inner mitochondrial membrane in vivo. We used mitochondria from lung or spleen, the two organs expressing the highest level of UCP2, to compare the proton leak of the mitochondrial inner membrane of wild type and Ucp2(-/-) mice. No difference was observed under basal conditions. Previous reports have concluded that retinoic acid and superoxide activate proton transport by UCP2. Spleen mitochondria showed a higher sensitivity to retinoic acid than liver mitochondria, but this was not caused by UCP2. In contrast with a previous report, superoxide failed to increase the proton leak rate in kidney mitochondria, where no UCP2 expression was detected, and also in spleen mitochondria, which does not support stimulation of UCP2 uncoupling activity by superoxide. Finally, no increase in the ATP/ADP ratio was observed in spleen or lung of Ucp2(-/-) mice. Therefore, no evidence could be gathered for the uncoupling activity of the UCP2 present in spleen or lung mitochondria. Although this may be explained by difficulties with isolated mitochondria, it may also indicate that UCP2 has another physiological significance in spleen and lung.	CNRS, UPR9078, Ceremod, F-92190 Meudon, France; INRA, Lab Nutr & Securite Alimentaire, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Bouillaud, F (corresponding author), CNRS, UPR9078, Ceremod, 9 Jules Hetzel, F-92190 Meudon, France.	bouillau@infobiogen.fr	Bouillaud, Frédéric R/L-3238-2017; Alves-Guerra, Marie-Clotilde/P-4356-2017	Bouillaud, Frédéric R/0000-0002-7518-9237; Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298				ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Bouillaud F, 2001, BBA-BIOENERGETICS, V1504, P107, DOI 10.1016/S0005-2728(00)00241-3; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hagen T, 2000, BIOCHEM BIOPH RES CO, V276, P642, DOI 10.1006/bbrc.2000.3535; Hagen T, 2000, BIOCHEMISTRY-US, V39, P5845, DOI 10.1021/bi992980+; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; RACKER E, 1950, BIOCHIM BIOPHYS ACTA, V4, P211, DOI 10.1016/0006-3002(50)90026-6; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Samartsev VN, 1997, BBA-BIOENERGETICS, V1319, P251, DOI 10.1016/S0005-2728(96)00166-1; Schonfeld P, 1997, FEBS LETT, V416, P19, DOI 10.1016/S0014-5793(97)01162-9; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	51	136	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26268	26275		10.1074/jbc.M202535200	http://dx.doi.org/10.1074/jbc.M202535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011051	hybrid			2022-12-25	WOS:000176908700059
J	Griffiths, SW; King, J; Cooney, CL				Griffiths, SW; King, J; Cooney, CL			The reactivity and oxidation pathway of cysteine 232 in recombinant human alpha 1-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALPHA-1-PROTEINASE INHIBITOR; HYDROGEN-PEROXIDE; SULFENIC ACID; ACTIVE-SITE; DISULFIDE EXCHANGE; ION-PAIR; MECHANISM; ALPHA(1)-ANTITRYPSIN; INACTIVATION; GLUTATHIONE	Oxidative damage to the sulfur-containing amino acids, methionine and cysteine, is a major concern in biotechnology and medicine. alpha1-Antitrypsin, which is a metastable and conformationally flexible protein that belongs to the serpin family of protease inhibitors, contains nine methionines and a single cysteine in its primary sequence. Although it is known that methionine oxidation in the protein active site results in a loss of biological activity, there is little specific knowledge regarding the reactivity of its unpaired thiol, Cys-232. In this study, the thiol-modifying reagent NBD-Cl (7-chloro-4-nitrobenz-2-oxa-1,3-diazole) was used to label peroxide-modified alpha1-antitrypsin and demonstrate that the Cys-232 in vitro oxidation pathway begins with a stable sulfenic acid intermediate and is followed by the formation of sulfinic and cysteic acid in successive steps. pH-dependent reactivity with hydrogen peroxide showed that Cys-232 has a pK(a) of 6.86 +/- 0.05, a value that is more than 1.5 pH units lower than that of a typical protein thiol. pH-induced conformational changes in the region surrounding Cys-232 were also examined and indicate that mildly acidic conditions induce a conformation that enhances Cys-232 reactivity. In summary, this work provides new insights into alpha1-antitrypsin reactivity in oxidizing environments and shows that a unique structural environment renders its unpaired thiol, Cys-232, its most reactive amino acid.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Griffiths, SW (corresponding author), 77 Massachusetts Ave,Bldg 56,Rm 456, Cambridge, MA 02139 USA.	swgriffi@mit.edu		Griffiths, Steven/0000-0002-9593-4724				Barrett GC, 1990, CHEM SULPHENIC ACIDS, P1; BARTON JP, 1973, J CHEM SOC PERK T 2, P1547, DOI 10.1039/p29730001547; BEATTY K, 1982, J LAB CLIN MED, V100, P186; Beynon R., 1996, BASICS BUFFER SOLUTI; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CLAIBORNE A, 2001, BIOCHEMISTRY-US, V58, P215; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Griffiths SW, 2002, BIOCHEMISTRY-US, V41, P6245, DOI 10.1021/bi025599p; Griffiths SW, 2002, J CHROMATOGR A, V942, P133, DOI 10.1016/S0021-9673(01)01350-4; HOLMAN CM, 1994, BIOCHEMISTRY-US, V33, P2672, DOI 10.1021/bi00175a041; HOYLAERTS M, 1987, J BIOTECHNOL, V5, P181, DOI 10.1016/0168-1656(87)90015-0; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JANOFF A, 1986, AM REV RESPIR DIS, V133, P353; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; LAURELL CB, 1970, IMMUNOCHEMISTRY, V7, P461, DOI 10.1016/0019-2791(70)90228-4; LAURELL CB, 1974, IMMUNOCHEMISTRY, V11, P703, DOI 10.1016/0019-2791(74)90269-9; LEUNG PSK, 1985, J PHYS CHEM-US, V89, P5267, DOI 10.1021/j100270a029; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; Miyamoto Y, 2000, BBA-PROTEIN STRUCT M, V1477, P90, DOI 10.1016/S0167-4838(99)00264-2; MUSIANI P, 1978, CLIN CHIM ACTA, V85, P61, DOI 10.1016/0009-8981(78)90101-8; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PARENTE A, 1985, BIOCHEMISTRY-US, V24, P1098, DOI 10.1021/bi00326a005; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; POLGAR L, 1973, EUR J BIOCHEM, V39, P421, DOI 10.1111/j.1432-1033.1973.tb03140.x; SAKLATVALA J, 1976, BIOCHEM J, V157, P339, DOI 10.1042/bj1570339; Scott LJ, 1999, BIOCHEM BIOPH RES CO, V255, P562, DOI 10.1006/bbrc.1999.0247; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Taggart C, 2000, J BIOL CHEM, V275, P27258; Tyagi SC, 1996, BIOCHEM CELL BIOL, V74, P391, DOI 10.1139/o96-042; TYAGI SC, 1992, BIOCHEMISTRY-US, V31, P10584, DOI 10.1021/bi00158a022; Wang PF, 2001, BIOCHEMISTRY-US, V40, P11698, DOI 10.1021/bi011208f; WILSON JM, 1980, J AM CHEM SOC, V102, P359, DOI 10.1021/ja00521a058; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8	47	70	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25486	25492		10.1074/jbc.M203089200	http://dx.doi.org/10.1074/jbc.M203089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991955	hybrid			2022-12-25	WOS:000176747000084
J	He, B; Lee, LW; Minges, JT; Wilson, EM				He, B; Lee, LW; Minges, JT; Wilson, EM			Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; PROBASIN GENE; REGULATED EXPRESSION; RESPONSIVE ENHANCER; STRUCTURAL BASIS; TRANSGENIC MICE; MESSENGER-RNA; MOUSE	The agonist-induced androgen receptor NH2- and COOH-terminal (N/C) interaction is mediated by the FXXLF and WXXLF NH2-terminal motifs. Here we demonstrate that agonist-dependent transactivation of prostate-specific antigen (PSA) and probasin enhancer/promoter regions requires the N/C interaction, whereas the sex-limited protein gene and mouse mammary tumor virus long terminal repeat do not. Transactivation of PSA and probasin response regions also depends on activation function 1 (AF1) in the NH2-terminal region but can be increased by binding an overexpressed p160 coactivator to activation function 2 (AF2) in the ligand binding domain. The dependence of the PSA and probasin enhancer/promoters on the N/C interaction for transactivation allowed us to demonstrate that in the presence of androgen, the WXXLF motif with the sequence (WHTLF437)-W-433 contributes as an inhibitor to AR transactivation. We further show that like the FXXLF and LXXLL motifs, the WXXLF motif interacts in the presence of androgen with AF2 in the ligand binding domain. Sequence comparisons among species indicate greater conservation of the FXXLF motif compared with the WXXLF motif, paralleling the functional significance of these binding motifs. The data provide evidence for promoter-specific differences in the requirement for the androgen receptor N/C interaction and in the contributions of AF1 and AF2 in androgen-induced gene regulation.	Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA.				NICHD NIH HHS [HD16910, U54-HD35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, R01HD016910, U54HD035041] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; CARPET F, 1988, NUCLEIC ACIDS RES, V16, P10881; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHALEPAKIS G, 1988, NUCLEIC ACIDS RES, V16, P10237, DOI 10.1093/nar/16.21.10237; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; Choong CS, 1998, J MOL EVOL, V47, P334, DOI 10.1007/PL00006391; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FISCHER LM, 1995, DEV BIOL, V170, P115, DOI 10.1006/dbio.1995.1200; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Gregory CW, 2001, CANCER RES, V61, P4315; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; HE WW, 1990, BIOCHEM BIOPH RES CO, V171, P697, DOI 10.1016/0006-291X(90)91202-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; KASPER S, 1994, J BIOL CHEM, V269, P31763; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeo J, 1999, J BIOL CHEM, V274, P5674, DOI 10.1074/jbc.274.9.5674; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Todo T, 1999, BIOCHEM BIOPH RES CO, V254, P378, DOI 10.1006/bbrc.1998.9919; Touhata K, 1999, BBA-MOL CELL RES, V1450, P481, DOI 10.1016/S0167-4889(99)00055-5; WONG CI, 1993, J BIOL CHEM, V268, P19004; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	41	130	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25631	25639		10.1074/jbc.M202809200	http://dx.doi.org/10.1074/jbc.M202809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000757	hybrid, Green Published			2022-12-25	WOS:000176747000102
J	Konstas, AA; Koch, JP; Tucker, SJ; Korbmacher, C				Konstas, AA; Koch, JP; Tucker, SJ; Korbmacher, C			Cystic fibrosis transmembrane conductance regulator-dependent up-regulation of Kir1.1 (ROMK) renal K+ channels by the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; NA+ CHANNEL; SURFACE EXPRESSION; XENOPUS OOCYTES; CFTR; ENAC; MUTATIONS; MEMBRANE; PROTEINS; DOMAINS	The epithelial sodium channel (ENaC) and the secretory potassium channel (Kir1.1/ROMK) are expressed in the apical membrane of renal collecting duct principal cells where they provide the rate-limiting steps for Na+ absorption and K+ secretion. The cystic fibrosis transmembrane conductance regulator (CFTR) is thought to regulate the function of both ENaC and Kir1.1. We hypothesized that CFTR may provide a regulatory link between ENaC and Kir1.1. In Xenopus laevis oocytes co-expressing both ENaC and CFTR, the CFTR currents were 3-fold larger than those in oocytes expressing CFTR alone due to an increased expression of CFTR in the plasma membrane. ENaC was also able to increase Kir1.1 currents through an increase in surface expression, but only in the presence of CFTR. In the absence of CFTR, co-expression of ENaC was without effect on Kir1.1. ENaC-mediated CFTR-dependent up-regulation of Kir1.1 was reduced with a Liddle's syndrome mutant of ENaC. Furthermore, ENaC co-expressed with CFTR was without effect on the closely related K+ channel Kir4.1. We conclude that ENaC up-regulates Kir1.1 in a CFTR-dependent manner. CFTR may therefore provide the mechanistic link that mediates the coordinated upregulation of Kir1.1 during the stimulation of ENaC by hormones such as aldosterone or antidiuretic hormone.	Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England	University of Oxford	Korbmacher, C (corresponding author), Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de	Tucker, Stephen J./ABE-7468-2020; Tucker, Stephen J./ABE-6741-2020	Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000				BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Cahill P, 2000, J BIOL CHEM, V275, P16697, DOI 10.1074/jbc.M910205199; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF723, DOI 10.1152/ajprenal.1996.271.3.F723; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Ito M, 1996, FEBS LETT, V388, P11, DOI 10.1016/0014-5793(96)00502-9; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kibble JD, 2000, J PHYSIOL-LONDON, V526, P27, DOI 10.1111/j.1469-7793.2000.00027.x; Koch JP, 1999, J MEMBRANE BIOL, V168, P131, DOI 10.1007/s002329900503; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; KORBMACHER C, 1995, J MEMBRANE BIOL, V146, P29; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Letz B, 1997, AM J PHYSIOL-CELL PH, V272, pC657, DOI 10.1152/ajpcell.1997.272.2.C657; MALNIC G, 2000, KIDNEY PHYSL PATHOPH, P1575; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SCHAFER JA, 1990, AM J PHYSIOL, V258, pF199, DOI 10.1152/ajprenal.1990.258.1.F199; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; ToddTurla KM, 1996, AM J PHYSIOL-RENAL, V270, pF237, DOI 10.1152/ajprenal.1996.270.1.F237; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang WH, 1999, AM J PHYSIOL-RENAL, V277, pF826, DOI 10.1152/ajprenal.1999.277.6.F826; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Welling P. A., 1999, Journal of the American Society of Nephrology, V10, p49A; Wilson PD, 1999, EXP NEPHROL, V7, P284; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	49	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25377	25384		10.1074/jbc.M201925200	http://dx.doi.org/10.1074/jbc.M201925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994290	hybrid			2022-12-25	WOS:000176747000070
J	Adachi, H; Tsujimoto, M				Adachi, H; Tsujimoto, M			Characterization of the human gene encoding the scavenger receptor expressed by endothelial cell and its regulation by a novel transcription factor, endothelial zinc finger protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER; CLONING; BINDING; ATHEROSCLEROSIS; IDENTIFICATION	The scavenger receptor expressed by endothelial cell (SREC), mediates the selective uptake of modified low density lipoprotein (LDL), such as acetylated LDL and oxidized LDL, into endothelial cells. The SREC gene spans 12 kilobase pairs and contains 11 exons. Analysis of full-length cDNA clones of SREC from a peripheral blood leukocyte cDNA library revealed that at least five alternatively spliced cDNAs were present, and two of them encoded soluble forms of SREC. The transcription start site of the SREC gene was mapped, and DNA sequence analysis revealed an Sp1 binding site in its proximal region. Deletion analysis of the 5'-flanking sequence revealed that sequence between base pairs -108 and -98 was critical for the promoter activity. This region contained half of an inverted repeat (111) sequence with a triple nucleotide spacer (IR-3). A protected sequence between base pairs -268 and +17 was defined by in vitro DNase I footprinting analysis using human umbilical vein endothelial cell (HUVEC) nuclear extract. A novel transcription factor, endothelial zinc finger protein-2 (EZF-2), that binds to the 5'-flanking critical region of the SREC promoter activity was cloned from a HUVEC cDNA library employing a one-hybrid system. Whereas purified recombinant Sp1. alone produced similar protection in in vitro DNase I footprinting analysis, EZF-2 also bound to the 5'-flanking region SREC promoter. Co-transfection of SREC promoter and Sp1 or EZF-2 expression plasmids in HUVEC revealed that EZF-2 but not Sp1 increased SREC promoter activity. On the other hand, the mutation of either the Sp1 motif or IR-3 motif resulted in a decrease in the promoter activity. These results suggest that whereas Sp1 is the major nuclear protein bound to the regulatory region of the promoter, both EZF-2 and Sp1 are responsible for its regulation.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	RIKEN	Adachi, H (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; ADACHI H, 1995, J BIOCHEM-TOKYO, V118, P555, DOI 10.1093/oxfordjournals.jbchem.a124945; AMARAVADI L, 1994, BIOTECHNIQUES, V16, P98; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Han ZG, 1999, J BIOL CHEM, V274, P35741, DOI 10.1074/jbc.274.50.35741; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 2001, J CLIN INVEST, V108, P645, DOI 10.1172/JCI13932; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARUYAMA K, 1994, GENE, V138, P171; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OZMEN L, 1993, J IMMUNOL, V150, P2698; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; RICHTERICH P, 1993, METHOD ENZYMOL, V218, P187; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; Sander TL, 2000, J BIOL CHEM, V275, P12857, DOI 10.1074/jbc.275.17.12857; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; YET SF, 1998, J BIOL CHEM, V273, P1056	29	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24014	24021		10.1074/jbc.M201854200	http://dx.doi.org/10.1074/jbc.M201854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978792	hybrid			2022-12-25	WOS:000176611800008
J	Velthuis, JHL; Rouschop, KMA; de Bont, HJGM; Mulder, GJ; Nagelkerke, JF				Velthuis, JHL; Rouschop, KMA; de Bont, HJGM; Mulder, GJ; Nagelkerke, JF			Distinct intracellular signaling in tumor necrosis factor-related apoptosis-inducing ligand- and CD95 ligand-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; DEATH RECEPTORS; IN-VIVO; CELLS; BCL-2; FAS; MITOCHONDRIA; MECHANISMS; EXPRESSION; CASPASE-8	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in tumor cells but not in healthy cells. Similar to CD95 ligand (CD95L), TRAIL signaling requires ligand-receptor interaction; the downstream signaling molecules, such as Fas-associated death domain and caspase-8, also seem similar. Using cells stably expressing TRAIL and CD95L, we show that both TRAIL and CD95L induce apoptosis in the rat colon carcinoma cell line CC531. The mitochondrial damage (loss of mitochondrial membrane potential (MMP) and release of cytochrome c) observed after co-incubation with TRAIL-expressing cells occurs much earlier than that observed with CD95L-expressing cells. The decrease in MMP induced by both ligands was caspase-8-mediated; no difference in caspase-8 activation by TRAIL and CD95L was found. TRAIL, but not CD95L, induced activation of caspase-10. bcl-2 overexpression could not prevent TRAIL-induced mitochondrial dysfunction, whereas it completely prevented CD95L-mediated loss of MMP and cytochrome c release. The selective effect of TRAIL on tumor cells and the apparent inability of bcl-2 to block TRAIL-induced apoptosis suggest that TRAIL may offer a lead for cancer therapy in the future.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Velthuis, JHL (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, Wassenaarseweg 72, NL-2300 RA Leiden, Netherlands.	velthuis@lacdr.leidenuniv.nl		Rouschop, Kasper/0000-0002-4208-5415				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; Degli-Esposti M, 1999, J LEUKOCYTE BIOL, V65, P535, DOI 10.1002/jlb.65.5.535; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Krammer P H, 1999, Adv Immunol, V71, P163; Krammer PH, 1998, TOXICOL LETT, V103, P131, DOI 10.1016/S0378-4274(98)00297-5; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Seol DW, 2001, CANCER RES, V61, P1138; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Tanaka M, 1997, J IMMUNOL, V158, P2303; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANDEWATER B, 1993, BIOCHEM PHARMACOL, V45, P2259, DOI 10.1016/0006-2952(93)90197-5; Vermijlen D, 1999, HEPATOLOGY, V29, P51, DOI 10.1002/hep.510290143; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	41	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24631	24637		10.1074/jbc.M111572200	http://dx.doi.org/10.1074/jbc.M111572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980895	hybrid, Green Published			2022-12-25	WOS:000176611800087
J	Xia, Y; Wen, HY; Kellems, RE				Xia, Y; Wen, HY; Kellems, RE			Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAI-1 GENE-EXPRESSION; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; PROGNOSTIC IMPACT; BOUND UROKINASE; AT(1) RECEPTOR; TYPE-1 PAI-1; CELLS; CALCINEURIN; MECHANISMS	Trophoblast implantation depends, in part, on the controlled production of plasmin from plasminogen, a process regulated by plasminogen activators and plasminogen activator inhibitors. We have determined that angiotensin II (Ang II) stimulates plasminogen activator inhibitor-1 (PAI-1) synthesis and secretion in human trophoblasts in a time- and concentration-dependent manner. Our results indicate that Ang II activates PAI-1 gene expression through the AT1 receptor and involves the calcium-dependent activation of calcineurin and the nuclear translocation of NFAT. Increased PAI-1 synthesis and secretion is associated with reduced trophoblast invasion as judged by an in vitro invasion assay. These studies are the first to link the renin-angiotensin system with the fibrinolytic system to regulate trophoblast invasion.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System	Kellems, RE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin, Houston, TX 77030 USA.	Rodney.E.Kellems@uth.tmc.edu						Ahn JD, 2001, DIABETOLOGIA, V44, P713, DOI 10.1007/s001250051680; Alhenc-Gelas F, 1986, Adv Nephrol Necker Hosp, V15, P25; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; Burgle M, 1997, BIOL CHEM, V378, P231, DOI 10.1515/bchm.1997.378.3-4.231; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chen HC, 2000, ARTERIOSCL THROM VAS, V20, P2297, DOI 10.1161/01.ATV.20.10.2297; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DEBOER K, 1988, AM J OBSTET GYNECOL, V158, P518, DOI 10.1016/0002-9378(88)90016-6; Dechend R, 2000, CIRCULATION, V101, P2382, DOI 10.1161/01.CIR.101.20.2382; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Estelles A, 1998, THROMB HAEMOSTASIS, V79, P500; FEENER EP, 1995, J CLIN INVEST, V95, P1353, DOI 10.1172/JCI117786; FEINBERG RF, 1989, LAB INVEST, V61, P20; Fitzpatrick TE, 1998, EXP CELL RES, V245, P155, DOI 10.1006/excr.1998.4240; Fogo AB, 2000, AM J KIDNEY DIS, V35, P179, DOI 10.1016/S0272-6386(00)70324-6; GRAHAM CH, 1992, BIOCHEM CELL BIOL, V70, P867, DOI 10.1139/o92-135; GRAHAM CH, 1991, J CELL PHYSIOL, V148, P228, DOI 10.1002/jcp.1041480207; Granger JP, 2001, AM J HYPERTENS, V14, p178S, DOI 10.1016/S0895-7061(01)02086-6; HAGEMANN A, 1994, EXP CLIN ENDOCRINOL, V102, P252, DOI 10.1055/s-0029-1211289; HAHN AWA, 1993, BIOCHEM BIOPH RES CO, V192, P189, DOI 10.1006/bbrc.1993.1399; HOFMANN GE, 1994, AM J OBSTET GYNECOL, V170, P671, DOI 10.1016/S0002-9378(94)70246-2; KETTELER M, 1995, ANNU REV PHYSIOL, V57, P279; Khoo NKS, 1998, INT J CANCER, V77, P429, DOI 10.1002/(SICI)1097-0215(19980729)77:3<429::AID-IJC20>3.3.CO;2-Q; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; Lala PK, 2000, PLACENTA, V21, P593, DOI 10.1053/plac.1999.0545; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; Matsusaka T, 1996, J AM SOC NEPHROL, V7, P2025; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Motojima M, 1999, BBA-MOL CELL RES, V1449, P217, DOI 10.1016/S0167-4889(99)00014-2; Motojima M, 2000, BIOCHEM J, V349, P435, DOI 10.1042/0264-6021:3490435; Nakamura S, 2000, KIDNEY INT, V58, P251, DOI 10.1046/j.1523-1755.2000.00160.x; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; Poisner AM, 1998, FRONT NEUROENDOCRIN, V19, P232, DOI 10.1006/frne.1998.0166; QUEENAN JT, 1987, J BIOL CHEM, V262, P10903; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; Schmitt M, 1997, BRIT J CANCER, V76, P306, DOI 10.1038/bjc.1997.383; Shaarawy M, 1996, INT J GYNECOL OBSTET, V55, P135, DOI 10.1016/S0020-7292(96)02755-5; SKINNER SL, 1972, CLIN SCI, V42, P479, DOI 10.1042/cs0420479; STRICKLAND S, 1976, J BIOL CHEM, V251, P5694; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wallukat G, 1999, J CLIN INVEST, V103, P945, DOI 10.1172/JCI4106; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wolf G, 1998, NEPHROLOGIE, V19, P451; WOLF G, 1992, AM J PATHOL, V140, P95; WUN TC, 1987, J BIOL CHEM, V262, P3646; Xia Y, 2002, BIOL REPROD, V66, P135, DOI 10.1095/biolreprod66.1.135; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855	58	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24601	24608		10.1074/jbc.M201369200	http://dx.doi.org/10.1074/jbc.M201369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983698	hybrid			2022-12-25	WOS:000176611800083
J	Corzo, G; Villegas, E; Gomez-Lagunas, F; Possani, LD; Belokoneva, OS; Nakajima, T				Corzo, G; Villegas, E; Gomez-Lagunas, F; Possani, LD; Belokoneva, OS; Nakajima, T			Oxyopinins, large amphipathic peptides isolated from the venom of the wolf spider Oxyopes kitabensis with cytolytic properties and positive insecticidal cooperativity with spider neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PHONEUTRIA-NIGRIVENTER KEYS; SCORPION PANDINUS-IMPERATOR; ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL PEPTIDE; LIPID BILAYERS; CHANNELS; TOXINS; MODEL; MAGAININ-2	Five amphipathic peptides with antimicrobial, hemolytic, and insecticidal activity were isolated from the crude venom of the wolf spider Oxyopes kitabensis. The peptides, named oxyopinins, are the largest linear cationic amphipathic peptides from the venom of a spider that have been chemically characterized at present. According to their primary structure Oxyopinin 1 is composed of 48 amino acid residues showing extended sequence similarity to the ant insecticidal peptide ponericinL2 and to the frog antimicrobial peptide dermaseptin. Oxyopinins 2a, 2b, 2c, and 2d have highly similar sequences. At least 27 out of 37 amino acid residues are conserved. They also show a segment of sequence similar to ponericinL2. Circular dichroism analyses showed that the secondary structure of the five peptides is essentially a-helical. Oxyopinins showed disrupting activities toward both biological membranes and artificial vesicles, particularly to those rich in phosphatidylcholine. Electrophysiological recordings performed on insect cells (Sf9) showed that the oxyopinins produce a drastic reduction of cell membrane resistance by opening non-selective ion channels. Additionally, a new paralytic neurotoxin named Oxytoxin 1 was purified from the same spider venom. It contains 69 amino acid residue cross-linked by five disulfide bridges. Application of mixtures containing oxyopinins and Oxytoxin 1 to insect larvae showed a potentiation phenomenon, by which an increase lethality effect is observed. These results suggest that the linear amphipathic peptides in spider venoms and neuropeptides cooperate to capture insects efficiently.	Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Univ Nacl Autonoma Mexico, Dept Physiol, Sch Med, Mexico City 04510, DF, Mexico; Inst Biotechnol, Dept Mol Recognit & Struct Biol, Cuernavaca 62210, Morelos, Mexico	Suntory Holdings Ltd; Universidad Nacional Autonoma de Mexico	Corzo, G (corresponding author), Suntory Inst Bioorgan Res, Wakayamadai 1-1-1, Shimamoto, Osaka 6188503, Japan.	corzo@sunbor.or.jp	Corzo, Gerardo/B-3778-2014; Possani, Lourival D/J-2397-2013	Corzo, Gerardo/0000-0002-9513-1622; Villegas Villarreal, Elba Cristina/0000-0003-1795-0427				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; AGAWA Y, 1991, J BIOL CHEM, V266, P20218; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Batista CVF, 1999, PEPTIDES, V20, P679, DOI 10.1016/S0196-9781(99)00050-9; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; CHAN TK, 1975, TOXICON, V13, P61, DOI 10.1016/0041-0101(75)90159-2; Chen FY, 2002, BIOPHYS J, V82, P908, DOI 10.1016/S0006-3495(02)75452-0; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G; Corzo G, 2000, EUR J BIOCHEM, V267, P5783, DOI 10.1046/j.1432-1327.2000.01653.x; Corzo G, 2001, BIOCHEM J, V359, P35, DOI 10.1042/0264-6021:3590035; de Lima ME, 2002, J INSECT PHYSIOL, V48, P53, DOI 10.1016/S0022-1910(01)00143-3; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; Elazar M, 2001, J EXP BIOL, V204, P2637; Escoubas P, 1995, TOXICON, V33, P1549, DOI 10.1016/0041-0101(95)00107-7; FENNELL JF, 1968, P SOC EXP BIOL MED, V127, P707; FIGUEIREDO SG, 1995, TOXICON, V33, P83, DOI 10.1016/0041-0101(94)00130-Z; FINNEY DJ, 1962, PROBIT ANAL, P318; FOELIX RF, 1996, BIOL SPIDERS, P7; FRIEDEL T, 1989, TOXICON, V27, P305, DOI 10.1016/0041-0101(89)90178-5; GomezLagunas F, 1996, J MEMBRANE BIOL, V152, P49, DOI 10.1007/s002329900084; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; Hara T, 2001, BIOCHEMISTRY-US, V40, P12395, DOI 10.1021/bi011413v; Heller WT, 1997, BIOPHYS J, V73, P239, DOI 10.1016/S0006-3495(97)78064-0; HERRMANN R, 1995, TOXICON, V33, P1099, DOI 10.1016/0041-0101(95)98053-X; HERRMANN R, 1990, INSECT BIOCHEM, V20, P625, DOI 10.1016/0020-1790(90)90075-6; Higashimoto Y, 1999, J BIOCHEM-TOKYO, V125, P705, DOI 10.1093/oxfordjournals.jbchem.a022340; Hille B., 1992, IONIC CHANNELS EXCIT; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; IWAI H, 1993, EUR J BIOCHEM, V217, P639, DOI 10.1111/j.1432-1033.1993.tb18287.x; Kuhn-Nentwig L, 2002, J BIOL CHEM, V277, P11208, DOI 10.1074/jbc.M111099200; Lamberty M, 2001, J BIOL CHEM, V276, P4085, DOI 10.1074/jbc.M002998200; Mak DOD, 1995, BIOPHYS J, V69, P2323, DOI 10.1016/S0006-3495(95)80102-5; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P2104, DOI 10.1021/bi961870p; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NAKAJIMA T, 1990, ADV EXP MED BIOL, V247, P215; NELSON GJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P221, DOI 10.1016/0005-2760(67)90152-X; OKADA M, 1985, J BIOL CHEM, V260, P7174; Orivel J, 2001, J BIOL CHEM, V276, P17823, DOI 10.1074/jbc.M100216200; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; Silva PI, 2000, J BIOL CHEM, V275, P33464, DOI 10.1074/jbc.M001491200; Silvestro L, 1997, BIOCHEMISTRY-US, V36, P11452, DOI 10.1021/bi9630826; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SODERHALL K, 1983, DEV COMP IMMUNOL, V7, P229, DOI 10.1016/0145-305X(83)90004-6; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TAKLE G, 1985, J CELL SCI, V75, P207; Torres-Larios A, 2000, EUR J BIOCHEM, V267, P5023, DOI 10.1046/j.1432-1327.2000.01556.x; Veiga SS, 2001, BRAZ J MED BIOL RES, V34, P843, DOI 10.1590/S0100-879X2001000700002; WHITE DA, 1973, FORM FUNCTION PHOSPH, P454; Wieprecht T, 2000, BIOPHYS CHEM, V85, P187, DOI 10.1016/S0301-4622(00)00120-4; Wong H, 1997, EUR J BIOCHEM, V247, P545, DOI 10.1111/j.1432-1033.1997.00545.x; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	57	110	121	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23627	23637		10.1074/jbc.M200511200	http://dx.doi.org/10.1074/jbc.M200511200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976325	hybrid			2022-12-25	WOS:000176475700069
J	Knuefermann, P; Chen, P; Misra, A; Shi, SP; Abdellatif, M; Sivasubramanian, N				Knuefermann, P; Chen, P; Misra, A; Shi, SP; Abdellatif, M; Sivasubramanian, N			Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NF kappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE GENE; DNA-BINDING; DEPENDENT ACTIVATION; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION; ALPHA; SIGNAL; CELLS; SUBUNIT	Myotrophin/V-1 is a cytosolic protein found at elevated levels in failing human hearts and in postnatal cerebellum. We have previously shown that it disrupts nuclear factor of kappaB (NFkappaB)-DNA complexes in vitro. In this study, we demonstrated that in HeLa cells native myotrophin/V-1 is predominantly present in the cytoplasm and translocates to the nucleus during sustained NFkappaB activation. Three-dimensional alignment studies indicate that myotrophin/V-1 resembles a truncated IkappaBalpha without the signal response domain (SRD) and PEST domains. Co-immunoprecipitation studies reveal that myotrophin/V-1 interacts with NFkappaB proteins in vitro; however, it remains physically associated only with p65 and c-Rel proteins in vivo during NFkappaB activation. In vitro studies indicate that myotrophin/V-1 can promote the formation of p50-p50 homodimers from monomeric p50 proteins and can convert the preformed p50-p65 heterodimers into p50-p50 and p65-p65 homodimers. Furthermore, adenovirus-mediated overexpression of myotrophin/V-1 resulted in elevated levels of both p5O-p5O and p65-p65 homodimers exceeding the levels of p50-p65 heterodimers compared with Adbetagal-infected cells, where the levels of p50-p65 heterodimers exceeded the levels of p5O-p5O and p65-p65 homodimers. Thus, overexpression of myotrophin/V-1 during NFkappaB activation resulted in a qualitative shift by quantitatively reducing the level of transactivating heterodimers while elevating the levels of repressive p50-p50 homodimers. Correspondingly, overexpression of myotrophin/V-1 resulted in significantly reduced kappaB-luciferase reporter activity. Because myotrophin/V-1 is found at elevated levels during NFkappaB activation in postnatal cerebellum and in failing human hearts, this study cumulatively suggests that myotrophin/V-1 is a regulatory protein for modulating the levels of activated NFkappaB dimers during this period.	Baylor Coll Med, Winters Ctr Heart Failure Res, Mol Cardiol Unit, Sect Dept Med,Vet Affairs Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sivasubramanian, N (corresponding author), Baylor Coll Med, Winters Ctr Heart Failure Res, Mol Cardiol Unit, Sect Dept Med,Vet Affairs Med Ctr, 6565 Fannin ST,MS524, Houston, TX 77030 USA.	nats@bcm.tmc.edu		Chen, Peter/0000-0002-5330-1718				Acarin L, 2000, NEUROSCI LETT, V288, P41, DOI 10.1016/S0304-3940(00)01202-7; Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Anderson KM, 1999, J MOL CELL CARDIOL, V31, P705, DOI 10.1006/jmcc.1998.0903; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Borgland SL, 2000, J VIROL, V74, P3941, DOI 10.1128/JVI.74.9.3941-3947.2000; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Brigelus-Flohe R, 1995, BIOFACTORS, V5, P169; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Clesham GJ, 1998, GENE THER, V5, P174, DOI 10.1038/sj.gt.3300576; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doerre S, 1999, J IMMUNOL, V163, P269; Farmer PK, 2000, AM J PHYSIOL-ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213; Goldring CE, 1998, EUR J IMMUNOL, V28, P2960, DOI 10.1002/(SICI)1521-4141(199809)28:09<2960::AID-IMMU2960>3.0.CO;2-B; GOLDRING CEP, 1995, BIOCHEM BIOPH RES CO, V209, P73, DOI 10.1006/bbrc.1995.1472; Guerrini L, 1997, J NEUROSCI, V17, P6057; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Haudek SB, 2001, J MOL CELL CARDIOL, V33, P1263, DOI 10.1006/jmcc.2001.1388; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Holm L, 1996, METHOD ENZYMOL, V266, P653; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kaltschmidt B, 2001, MECH DEVELOP, V101, P11, DOI 10.1016/S0925-4773(00)00542-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Koukouritaki SB, 1999, MOL MED, V5, P382, DOI 10.1007/BF03402127; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PENNICA D, 1995, GENE, V158, P305, DOI 10.1016/0378-1119(95)00131-O; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SEN S, 1990, J BIOL CHEM, V265, P16635; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIL P, 1995, CIRC RES, V76, P1020, DOI 10.1161/01.RES.76.6.1020; SIL P, 1993, CIRC RES, V73, P98, DOI 10.1161/01.RES.73.1.98; Sivasubramanian N, 1996, J BIOL CHEM, V271, P2812, DOI 10.1074/jbc.271.5.2812; SIVASUBRAMANIAN N, 1987, P NATL ACAD SCI USA, V84, P1, DOI 10.1073/pnas.84.1.1; Sohur US, 1999, GENE EXPRESSION, V8, P219; Song SY, 1996, ENDOCRINOLOGY, V137, P1423, DOI 10.1210/en.137.4.1423; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; TAOKA M, 1994, J BIOL CHEM, V269, P9946; TAOKA M, 1992, EUR J BIOCHEM, V207, P615, DOI 10.1111/j.1432-1033.1992.tb17088.x; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Vallejo JG, 2000, J IMMUNOL, V165, P419, DOI 10.4049/jimmunol.165.1.419; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Wilson L, 1999, GASTROENTEROLOGY, V117, P106, DOI 10.1016/S0016-5085(99)70556-1; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; Yamakuni T, 1998, J BIOL CHEM, V273, P27051, DOI 10.1074/jbc.273.42.27051; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yang YW, 1998, STRUCTURE, V6, P619, DOI 10.1016/S0969-2126(98)00063-X; Yang YW, 1997, PROTEIN SCI, V6, P1347, DOI 10.1002/pro.5560060625; Ziegler-Heitbrock L, 2001, J ENDOTOXIN RES, V7, P219, DOI 10.1177/09680519010070030401	78	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23888	23897		10.1074/jbc.M202937200	http://dx.doi.org/10.1074/jbc.M202937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971907	hybrid			2022-12-25	WOS:000176475700103
J	Yun, S; Jang, DS; Choi, G; Kim, KS; Choi, KY; Lee, HC				Yun, S; Jang, DS; Choi, G; Kim, KS; Choi, KY; Lee, HC			Trifluoroethanol increases the stability of Delta(5)-3-ketosteroid isomerase - N-15 NMR relaxation studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; CHEMICAL-SHIFT ANISOTROPY; PARTIALLY FOLDED STATE; HELICAL COILED-COILS; COLI RIBONUCLEASE HI; MODEL-FREE APPROACH; DNA-BINDING DOMAIN; BACKBONE DYNAMICS; QUATERNARY STRUCTURE; EQUILIBRIUM DISSOCIATION	In the equilibrium unfolding process of Delta(5)-3-ketosteroid isomerase from Pseudomonas testosteroni by urea, it was observed that the enzyme stability increases by 2.5 kcal/mol in the presence of 5% trifluoroethanol (TFE). To elucidate the increased enzyme stability by TFE, the backbone dynamics of Delta(5)-3-ketosteroid isomerase were studied in the presence and absence of 5% TFE by (15)'N NMR relaxation measurements, and the motional parameters (S-2,tau(e), and R-ex were extracted from the relaxation data using the model-free formalism. The presence of 5% TFE causes little change or a slight increase in the order parameters (S2) for a number of residues, which are located mainly in the dimer interface region. However, the majority of the residues exhibit reduced order parameters in the presence of 5% TFE, indicating that high frequency (pico- to nanosecond) motions are generally enhanced by TFE. The results suggest that the entropy can be an important factor for the enzyme stability, and the increase in entropy by TFE is partially responsible for the increased stability of Delta(5)-3-ketosteroid isomerase.	Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Superfunct Mat, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl Res Lab Prot Folding & Engn, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Lee, HC (corresponding author), Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea.		Kim, Kwang Soo/C-7538-2012	Kim, Kwang Soo/0000-0002-6929-5359				AKKE M, 1993, J AM CHEM SOC, V115, P9832, DOI 10.1021/ja00074a073; ALEXANDRESCU AT, 1994, J MOL BIOL, V235, P587, DOI 10.1006/jmbi.1994.1015; Arunkumar AI, 1996, J BIOMOL STRUCT DYN, V14, P381, DOI 10.1080/07391102.1996.10508133; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Beeser SA, 1997, J MOL BIOL, V269, P154, DOI 10.1006/jmbi.1997.1031; Bhakuni V, 1998, ARCH BIOCHEM BIOPHYS, V357, P274, DOI 10.1006/abbi.1998.0794; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BOYD J, 1990, CHEM PHYS LETT, V175, P477, DOI 10.1016/0009-2614(90)85567-V; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; CANN JR, 1987, INT J PEPT PROT RES, V29, P486; Cho HS, 1998, BIOCHEMISTRY-US, V37, P8325, DOI 10.1021/bi9801614; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; FAN P, 1993, BIOCHEMISTRY-US, V32, P13299, DOI 10.1021/bi00211a043; Fushman D, 1998, J AM CHEM SOC, V120, P7109, DOI 10.1021/ja980565j; Gast K, 1997, PROTEIN SCI, V6, P2578; HALLE B, 1981, J CHEM PHYS, V75, P1928, DOI 10.1063/1.442218; Hamada D, 2000, NAT STRUCT BIOL, V7, P58; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P15418, DOI 10.1021/bi00255a023; Ionescu RM, 1999, NAT STRUCT BIOL, V6, P304; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim DH, 2000, BIOCHEMISTRY-US, V39, P13084, DOI 10.1021/bi000872d; KIM SW, 1994, J BACTERIOL, V176, P6672, DOI 10.1128/JB.176.21.6672-6676.1994; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lu H, 1997, J MOL BIOL, V265, P112, DOI 10.1006/jmbi.1996.0715; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; Mackay JP, 1996, BIOCHEMISTRY-US, V35, P4867, DOI 10.1021/bi952761y; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MATTHEWS SJ, 1993, BIOCHEMISTRY-US, V32, P657, DOI 10.1021/bi00053a034; Mok YK, 1996, PROTEIN SCI, V5, P310; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PALMER AG, 1992, MOL PHYS, V75, P699, DOI 10.1080/00268979200100511; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RamirezAlvarado M, 1997, PROTEIN SCI, V6, P162; RISCHEL C, 1994, BIOCHEMISTRY-US, V33, P13997, DOI 10.1021/bi00251a006; Sahu SC, 2000, PROTEINS, V41, P460, DOI 10.1002/1097-0134(20001201)41:4<460::AID-PROT40>3.0.CO;2-X; SCHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452; Schonbrunner N, 1996, J MOL BIOL, V260, P432, DOI 10.1006/jmbi.1996.0412; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; Yamasaki K, 1998, J MOL BIOL, V277, P707, DOI 10.1006/jmbi.1997.1622; Yun SG, 2001, BIOCHEMISTRY-US, V40, P3967, DOI 10.1021/bi0023192; Zajicek J, 2000, J MOL BIOL, V301, P333, DOI 10.1006/jmbi.2000.3972; Zhang YX, 1996, J PROTEIN CHEM, V15, P631, DOI 10.1007/BF01886745; [No title captured]	56	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23414	23419		10.1074/jbc.M200147200	http://dx.doi.org/10.1074/jbc.M200147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973332	hybrid			2022-12-25	WOS:000176475700042
J	Thompson, TA; Haag, JD; Lindstrom, MJ; Griep, AE; Lohse, JK; Gould, MN				Thompson, TA; Haag, JD; Lindstrom, MJ; Griep, AE; Lohse, JK; Gould, MN			Decreased susceptibility to NMU-induced mammary carcinogenesis in transgenic rats carrying multiple copies of a rat ras gene driven by the rat Harvey ras promoter	ONCOGENE			English	Article						mammary carcinogenesis; transgenic rats; ras genes; N-methyl-N-nitrosourea	MOLECULAR-WEIGHT; EXPRESSION; METHYLUREA; PROTEIN; P21; ACTIVATION; PROGNOSIS; APOPTOSIS; MUTATION; RECEPTOR	Ras protein over-expression has been observed in human breast cancers although the significance of Ras overexpression in the etiology of breast cancer is unknown and its contribution to breast cancer prognosis is still debated. In this study, the over-expression of both wildtype Harvey and Kirsten Ras proteins as contributors to rat mammary carcinogenesis were examined using a transgenic rat model. Three rat transgenic lines (designated HrHr transgenics) carrying three to six copies of wild-type rat Harvey ras driven by the wildtype rat Harvey ras promoter were produced. In addition, transgenic lines carrying either three or seven copies of the Kirsten ras gene under the same promoter (HrKr) were produced. No pathological changes in the mammary gland were observed in any of the HrHr or HrKr transgenic rat line heterozygote. Two of the Ras transgenic lines, HrHr (R8) and HrKr (4334), had a significant reduction in NMU-induced rat mammary cancer when compared to their non-transgenic litter-mates. All five Ras transgenic lines developed fewer carcinomas than their non-transgenic littermates following NMU exposure. The percentage of NMU-induced G35 to A35 activating mutations in the endogenous Harvey ras gene in mammary carcinomas from the HrHr, HrKr transgenic rats and their non-transgenic littermates was similar ( similar to50%). In contrast, less than 1% of the NMU-induced carcinomas in these Ras transgenic rats had an activating ras mutation in their transgenes. These findings highlight the potential of Ras to function as a modifier gene in repressing mammary carcinogenesis.	Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gould, MN (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.	gould@oncology.wisc.edu	Griep, Anne/ABA-9636-2020; Gould, Michael N/C-7414-2014		NCI NIH HHS [CA77527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAZI EA, 1995, CARCINOGENESIS, V16, P965, DOI 10.1093/carcin/16.4.965; Asamoto M, 2000, CARCINOGENESIS, V21, P243, DOI 10.1093/carcin/21.2.243; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHAKRABORTY AK, 1991, P NATL ACAD SCI USA, V88, P2217, DOI 10.1073/pnas.88.6.2217; CLAIR T, 1987, CANCER RES, V47, P5290; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gohring UJ, 1999, TUMOR BIOL, V20, P173, DOI 10.1159/000030061; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; Jin ZA, 1996, CANCER RES, V56, P4927; KUMAR R, 1989, ONCOGENE RES, V4, P235; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; OHUCHI N, 1986, CANCER RES, V46, P2511; QUERZOLI P, 1988, BREAST CANCER RES TR, V12, P23, DOI 10.1007/BF01805736; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schondorf T, 1999, ONCOL REP, V6, P1029; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackney SE, 1998, CLIN CANCER RES, V4, P913; SPANDIDOS A, 1988, BRIT J CANCER, V58, P67; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Thompson TA, 1998, CANCER RES, V58, P5097; Tsuda H, 2001, MUTAT RES-FUND MOL M, V477, P173, DOI 10.1016/S0027-5107(01)00118-X; WATSON DMA, 1991, BREAST CANCER RES TR, V17, P161, DOI 10.1007/BF01806365; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	30	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2797	2804		10.1038/sj.onc.1205391	http://dx.doi.org/10.1038/sj.onc.1205391			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973638				2022-12-25	WOS:000175063700003
J	Senoo, M; Matsumura, Y; Habu, S				Senoo, M; Matsumura, Y; Habu, S			TAp63 gamma (p51A) and dNp63 alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression	ONCOGENE			English	Article						p63; p51; p73L; p300; CBP; VEGF; HIF1 alpha	HYPOXIA-INDUCIBLE FACTOR-1; CELL LUNG-CANCER; WILD-TYPE P53; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; TRANSCRIPTION; ACTIVATION; HOMOLOG; ANGIOGENESIS; PROTEIN	Tumor suppressor p53 has been shown to repress expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. The p63 gene, recently identified as a p53-relative, encodes multiple isoforms with structural and functional similarities and differences from p53. In this study, we show the evidence that the two major isoforms of the p63 gene, TAp63gamma (p51A) and dNp63alpha (p73L), represses and upregulates VEGF expression, respectively, on transcription and protein levels. Transient transfection assays show that a hypoxia-inducible factor (HIF) 1 binding site within the VEGF promoter region is responsible for both upregulation and repression by dNp63alpha and by TAp63gamma, respectively, of the VEGF promoter activity. We also show that TAp63gamma targets HIF1alpha for promoting proteasomal degradation but that dNp63alpha targets HIF1alpha for stabilization. Mammalian two-hybrid assays show that HIF1alpha-dependent transcription is repressed by TAp63gamma as well as by p53, whereas it is upregulated by dNp63alpha in collaboration with a transcription coactivator p300. Our data also show that dNp63alpha acts as a dominant-negative reagent toward both p53- and TAp63gamma-mediated degradation of HIF1alpha and repression of HIF1alpha-dependent transcription. These results suggest that p63 is involved in the regulation of the VEGF gene expression and that modulation of VEGF expression by TAp63gamma and dNp63alpha is closely correlated with their distinct roles on the regulation of HIF1alpha stability.	Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 2591193, Japan	Tokai University	Habu, S (corresponding author), Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 2591193, Japan.	sonoko@is.icc.u-tokai.ac.jp		Senoo, Makoto/0000-0002-0155-0683				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bouvet M, 1998, CANCER RES, V58, P2288; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; ENOO M, 2001, BIOCHEM BIOPH RES CO, V286, P628; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FOLKMAN J, 1997, CANC MED, P181; Fontanini G, 1998, EUR J CANCER, V34, P718, DOI 10.1016/S0959-8049(97)10145-9; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nishi H, 1999, INT J ONCOL, V15, P1149; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Ravi R, 2000, GENE DEV, V14, P34; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Shimada A, 1999, CANCER RES, V59, P2781; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Suzuki K, 1996, CANCER RES, V56, P3004; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhong H, 1999, CANCER RES, V59, P5830	52	64	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2455	2465		10.1038/sj.onc.1205330	http://dx.doi.org/10.1038/sj.onc.1205330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971180				2022-12-25	WOS:000174918400002
J	Pralong, FP; Gonzales, C; Voirol, MJ; Palmiter, RD; Brunner, HR; Gaillard, RC; Seydoux, J; Pedrazzini, T				Pralong, FP; Gonzales, C; Voirol, MJ; Palmiter, RD; Brunner, HR; Gaillard, RC; Seydoux, J; Pedrazzini, T			The neuropeptide YY1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions	FASEB JOURNAL			English	Article						feeding; puberty; reproduction; hypothalamus; metabolism	LUTEINIZING-HORMONE SECRETION; OBESE GENE-PRODUCT; NORMAL FEMALE MICE; FOOD-INTAKE; OB/OB MICE; PARAVENTRICULAR NUCLEUS; SEXUAL-MATURATION; Y-RECEPTOR; MALE-RATS; SUBTYPE	The orexigenic neurotransmitter neuropeptide Y (NPY) plays a central role in the hypothalamic control of food intake and energy balance. NPY also exerts an inhibition of the gonadotrope axis that could be important in the response to poor metabolic conditions. In contrast, leptin provides an anorexigenic signal to centrally control the body needs in energy. Moreover, leptin contributes to preserve adequate reproductive functions by stimulating the activity of the gonadotrope axis. It is of interest that hypothalamic NPY represents a primary target of leptin actions. To evaluate the importance of the NPY Y1 and Y5 receptors in the downstream pathways modulated by leptin and controlling energy metabolism as well as the activity of the gonadotrope axis, we studied the effects of leptin administration on food intake and reproductive functions in mice deficient for the expression of either the Y1 or the Y5 receptor. Furthermore, the role of the Y1 receptor in leptin resistance was determined in leptin-deficient ob/ob mice bearing a null mutation in the NPY Y1 locus. Results point to a crucial role for the NPY Y1 receptor in mediating the NPY pathways situated downstream of leptin actions and controlling food intake, the onset of puberty, and the maintenance of reproductive functions.	Univ Lausanne, Sch Med, Div Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland; Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland	University of Lausanne; University of Lausanne; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Geneva	Pralong, FP (corresponding author), Univ Lausanne, Sch Med, Div Endocrinol Diabetol & Metab, BH 19-707, CH-1011 Lausanne, Switzerland.	Francois.Pralong@chuv.hospvd.ch						Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; Aubert ML, 1998, MOL CELL ENDOCRINOL, V140, P107, DOI 10.1016/S0303-7207(98)00058-6; Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828; Bergonzelli GE, 2001, DIABETES, V50, P2666, DOI 10.2337/diabetes.50.12.2666; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cheung CC, 1997, ENDOCRINOLOGY, V138, P855, DOI 10.1210/en.138.2.855; Cheung CC, 2001, NEUROENDOCRINOLOGY, V74, P12, DOI 10.1159/000054666; Cheung CC, 2000, FRONT HORM RES, V26, P87; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Edwards R, 1999, NEW SCI, V160, P7; El Majdoubi M, 2000, P NATL ACAD SCI USA, V97, P6179; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; GARTHWAITE TL, 1980, ENDOCRINOLOGY, V107, P671, DOI 10.1210/endo-107-3-671; Gehlert DR, 1998, P SOC EXP BIOL MED, V218, P7; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Gruaz NM, 1998, J NEUROENDOCRINOL, V10, P627, DOI 10.1046/j.1365-2826.1998.00247.x; HAMILTON GD, 1986, AM J PHYSIOL, V250, pR370, DOI 10.1152/ajpregu.1986.250.3.R370; Jain MR, 1999, ENDOCRINOLOGY, V140, P5171, DOI 10.1210/en.140.11.5171; KALRA SP, 1992, ENDOCRINOLOGY, V130, P3323, DOI 10.1210/en.130.6.3323; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; Leupen SM, 1997, ENDOCRINOLOGY, V138, P2735, DOI 10.1210/en.138.7.2735; Li C, 1999, ENDOCRINOLOGY, V140, P5382, DOI 10.1210/en.140.11.5382; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PIERROZ DD, 1995, NEUROENDOCRINOLOGY, V61, P293, DOI 10.1159/000126851; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; Pralong FP, 2000, REGUL PEPTIDES, V95, P47, DOI 10.1016/S0167-0115(00)00130-0; Raposinho PD, 1999, ENDOCRINOLOGY, V140, P4046, DOI 10.1210/en.140.9.4046; Schaffhauser AO, 1997, DIABETES, V46, P1792, DOI 10.2337/diabetes.46.11.1792; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	41	74	76	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					712	+		10.1096/fj.01-0754fje	http://dx.doi.org/10.1096/fj.01-0754fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978737				2022-12-25	WOS:000174755900018
J	van Wering, HM; Huibregtse, IL; van der Zwan, SM; de Bie, MS; Dowling, LN; Boudreau, F; Rings, EHHM; Grand, RJ; Krasinski, SD				van Wering, HM; Huibregtse, IL; van der Zwan, SM; de Bie, MS; Dowling, LN; Boudreau, F; Rings, EHHM; Grand, RJ; Krasinski, SD			Physical interaction between GATA-5 and hepatocyte nuclear factor-1 alpha results in synergistic activation of the human lactase-phlorizin hydrolase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL DIFFERENTIATION; RAT SMALL-INTESTINE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; PHLORHIZIN HYDROLASE; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; FACTOR-I; REGULATE TRANSCRIPTION; MOLECULAR-CLONING	GATA-4, -5, and -6 zinc finger and hepatocyte nuclear factor-1alpha (HNF-1alpha) homeodomain transcription factors are expressed in the intestinal epithelium and synergistically activate the promoter of intestinal genes. Here, we demonstrate that GATA-5 and HNF-1alpha physically associate both in vivo and in vitro and that this interaction is necessary for cooperative activation of the lactase-phlorizin hydrolase promoter. Furthermore, physical association is mediated by the C-terminal zinc finger of GATA factors and the homeodomain of HNF-1alpha. Deletion of HNF-1alpha activation domains or interruption of HNF-1-binding sites in the lactase-phlorizin hydrolase promoter resulted in a complete loss of cooperativity, whereas deletion of GATA-5 activation domains or interruption of GATA-binding sites resulted in a reduction, but not an elimination, of cooperativity. We hypothesize that GATA/HNF-1alpha cooperativity is mediated by HNF-1alpha through its activation domains, which are oriented for high levels of activation through binding to DNA and physical association with GATA factors. These data suggest a paradigm whereby intestine-specific gene expression is regulated by unique interactions among tissue-restricted transcription factors coexpressed in the intestine. Parallel mechanisms in other tissues as well as in Drosophila suggest that zinc finger/homeodomain interactions are an efficient pathway of cooperative activation of gene transcription that has been conserved throughout evolution.	Childrens Hosp, Dept Med, Div Gastroenterol & Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Tufts Univ New England Med Ctr, Dept Pediat, Boston, MA 02111 USA; Tufts Univ, Gerald J & Dorothy R Friedman Sch Nutr Sci & Poli, Medford, MA 02155 USA; Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Free Univ Amsterdam, Dept Med, NL-1081 HV Amsterdam, Netherlands; Univ Amsterdam, Dept Med, NL-1100 DD Amsterdam, Netherlands	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Tufts Medical Center; Tufts University; University of Pennsylvania; Vrije Universiteit Amsterdam; University of Amsterdam	Krasinski, SD (corresponding author), Childrens Hosp, Dept Med, Div Gastroenterol & Nutr, Enders 1220,300 Longwood Ave, Boston, MA 02115 USA.	stephen.krasinski@tch.harvard.edu	Rings, Edmond/ABE-5731-2021	Rings, Edmond/0000-0001-8195-4356	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R37DK032658] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK-34928, R37-DK-32658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BULLER HA, 1990, J BIOL CHEM, V265, P6978; Chitkara DK, 2001, GASTROENTEROLOGY, V120, pA304, DOI 10.1016/S0016-5085(01)81508-0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; ESCHER JC, 1992, J CLIN INVEST, V89, P480, DOI 10.1172/JCI115609; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Fitzgerald K, 1998, AM J PHYSIOL-GASTR L, V274, pG314, DOI 10.1152/ajpgi.1998.274.2.G314; Florence B, 1997, DEVELOPMENT, V124, P839; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; Hochman JA, 1997, AM J PHYSIOL-GASTR L, V273, pG833, DOI 10.1152/ajpgi.1997.273.4.G833; Jiang YM, 1999, DEV BIOL, V216, P57, DOI 10.1006/dbio.1999.9469; KELLEY C, 1993, DEVELOPMENT, V118, P817; Krasinski SD, 1997, GASTROENTEROLOGY, V113, P844, DOI 10.1016/S0016-5085(97)70179-3; KRASINSKI SD, 1994, AM J PHYSIOL-GASTR L, V267, pG584, DOI 10.1152/ajpgi.1994.267.4.G584; KRASINSKI SD, 2001, AM J PHYSIOL, V281, pG89; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CF, 1990, DEVELOPMENT, V109, P473; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee SY, 2002, J BIOL CHEM, V277, P13099, DOI 10.1074/jbc.M112152200; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LLOYD M, 1992, J CLIN INVEST, V89, P524, DOI 10.1172/JCI115616; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Martin MG, 2000, AM J PHYSIOL-GASTR L, V278, pG591, DOI 10.1152/ajpgi.2000.278.4.G591; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; Montgomery RK, 1999, GASTROENTEROLOGY, V116, P702, DOI 10.1016/S0016-5085(99)70193-9; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; OLSEN J, 1991, J BIOL CHEM, V266, P18089; Orkin S H, 1998, Stem Cells, V16 Suppl 2, P79; RINGS EHHM, 1992, GASTROENTEROLOGY, V103, P1154, DOI 10.1016/0016-5085(92)91498-S; RINGS EHHM, 1994, GASTROENTEROLOGY, V106, P1223, DOI 10.1016/0016-5085(94)90013-2; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Spodsberg N, 1999, GASTROENTEROLOGY, V116, P842, DOI 10.1016/S0016-5085(99)70067-3; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; TROELSEN JT, 1994, FEBS LETT, V342, P291, DOI 10.1016/0014-5793(94)80519-9; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; WU GD, 1994, J BIOL CHEM, V269, P17080; Yussa M, 2001, MECH DEVELOP, V107, P39, DOI 10.1016/S0925-4773(01)00448-8; [No title captured]	65	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27659	27667		10.1074/jbc.M203645200	http://dx.doi.org/10.1074/jbc.M203645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011060	hybrid			2022-12-25	WOS:000177189800013
J	Hoff, KG; Ta, DT; Tapley, TL; Silberg, JJ; Vickery, LE				Hoff, KG; Ta, DT; Tapley, TL; Silberg, JJ; Vickery, LE			Hsc66 substrate specificity is directed toward a discrete region of the iron-sulfur cluster template protein IscU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE SYSTEM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PEPTIDE-BINDING; EXTINCTION COEFFICIENTS; HSP70 CHAPERONES; DNAK CHAPERONE; PHAGE DISPLAY; IDENTIFICATION; DOMAIN	Hsc66 and Hsc20 comprise a specialized chaperone system important for the assembly of iron-sulfur clusters in Escherchia coli. Only a single substrate, the Fe/S template protein IscU, has been identified for the Hsc66/Hsc20 system, but the mechanism by which Hsc66 selectively binds IscU is unknown. We have investigated Hsc66 substrate specificity using phage display and a peptide array of IscU. Screening of a heptameric peptide phage display library revealed that Hsc66 prefers peptides with a centrally located Pro-Pro motif. Using a cellulose-bound peptide array of IscU we determined that Hsc66 interacts specifically with a region (residues 99-103, LPPVK) that is invariant among all IscU family members. A synthetic peptide (ELPPVKIHC) corresponding to IscU residues 98106 behaves in a similar manner to native IscU, stimulating the ATPase activity of Hsc66 with similar affinity as IscU, preventing Hsc66 suppression of bovine rhodanese aggregation, and interacting with the peptide-binding domain of Hsc66. Unlike native IscU, however, the synthetic peptide is not bound by Hsc20 and does not synergistically stimulate Hsc66 ATPase activity with Hsc20. Our results indicate that Hsc66 and Hsc20 recognize distinct regions of IscU and further suggest that Hsc66 will not bind LPPVK motifs with high affinity in vivo unless they are in the context of native IscU and can be directed to Hsc66 by Hsc20.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Silberg, Jonathan J/A-3817-2010		NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA 09054] Funding Source: Medline; NIGMS NIH HHS [GM 07211, GM 54264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Atherton E., 1990, SOLID PHASE PEPTIDE; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cupp-Vickery JR, 2000, J MOL BIOL, V304, P835, DOI 10.1006/jmbi.2000.4252; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gisler SM, 1998, J MOL BIOL, V279, P833, DOI 10.1006/jmbi.1998.1815; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Levitan B, 1998, J MOL BIOL, V277, P893, DOI 10.1006/jmbi.1997.1555; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; OUZOUNIS C, 1994, TRENDS BIOCHEM SCI, V19, P199, DOI 10.1016/0968-0004(94)90021-3; *OXF MOL GROUP, 1996, MACV VERS 6 0 1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WANG TF, 1993, J BIOL CHEM, V268, P26049; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	46	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27353	27359		10.1074/jbc.M202814200	http://dx.doi.org/10.1074/jbc.M202814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994302	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000177055900084
J	Zakalskiy, A; Hogenauer, G; Ishikawa, T; Wehrschutz-Sigl, E; Wendler, F; Teis, D; Zisser, G; Steven, AC; Bergler, H				Zakalskiy, A; Hogenauer, G; Ishikawa, T; Wehrschutz-Sigl, E; Wendler, F; Teis, D; Zisser, G; Steven, AC; Bergler, H			Structural and enzymatic properties of the AAA protein Drg1p from Saccharomyces cerevisiae - Decoupling of intracellular function from ATPase activity and hexamerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; ESCHERICHIA-COLI; MEMBRANE-FUSION; CLPAP PROTEASE; BINDING SITES; FAMILY; YEAST; TRANSPORT; HOMOLOGY; DISTINCT	The AAA protein Drg1 from yeast was affinity-purified, and its ATPase activity and hexamerization properties were analyzed. The same parameters were also determined for several mutant proteins and compared in light of the growth characteristics of the corresponding cells. The protein from a thermosensitive mutant exhibited reduced ATPase activity and hexamerization. These defects were not reversed by an intragenic suppressor mutation, although this allele supported growth at the nonpermissive temperature. A different set of mutants was generated by site-specific mutagenesis intended to adjust the Walker A box of the D2 domain of Drg1p to that of the D1 domain. A S562G exchange in D2 produced a nonfunctional protein that did not hexamerize but showed above-normal ATPase activity. The C561T mutant protein, on the other hand, was functional but hexamerized less readily and had reduced ATPase activity. In contrast, the C561T/S562G protein hexamerized less than wild type but had much higher ATPase activity. We distinguished strong and weak ATP-binding sites in the wild type protein but two weak sites in the C561T/S562G protein, indicating that the stronger site resides in D2. These observations are discussed in terms of the inter-relationship of ATPase activity per se, oligomeric status, and intracellular function for AAA proteins.	Karl Franzens Univ Graz, Inst Mol Biol Biochem & Mikrobiol, A-8010 Graz, Austria; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA	University of Graz; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hogenauer, G (corresponding author), Karl Franzens Univ Graz, Inst Mol Biol Biochem & Mikrobiol, Univ Pl 2, A-8010 Graz, Austria.	gregor.hoegenauer@uni-graz.at	Ishikawa, Takashi/E-5023-2017; Zakalskiy, Andriy E/G-2685-2019	Ishikawa, Takashi/0000-0002-1976-7477; Zakalskiy, Andriy E/0000-0002-8853-1097; Teis, David/0000-0002-8181-0253; Bergler, Helmut/0000-0002-7724-309X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027015, ZIAAR027015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beyer A, 1997, PROTEIN SCI, V6, P2043; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Frohlich KU, 2001, J CELL SCI, V114, P1601; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jungwirth H, 2001, J BIOL CHEM, V276, P36419, DOI 10.1074/jbc.M104487200; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Muller JMM, 1999, NAT CELL BIOL, V1, P335, DOI 10.1038/14025; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; SINGH SK, 1994, J BIOL CHEM, V269, P29537; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wendler F, 1997, J BIOL CHEM, V272, P27091, DOI 10.1074/jbc.272.43.27091; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	30	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26788	26795		10.1074/jbc.M201515200	http://dx.doi.org/10.1074/jbc.M201515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12006565	hybrid			2022-12-25	WOS:000177055900012
J	Bhattacharyya, R; Bhaumik, M; Raju, TS; Stanley, P				Bhattacharyya, R; Bhaumik, M; Raju, TS; Stanley, P			Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MGAT3 GENE; GLYCOPEPTIDE BETA-4-N-ACETYLGLUCOSAMINYLTRANSFERASE-III; HEPATIC NODULES; RECEPTOR GENE; GNT-III; EXPRESSION; GLYCOSYLATION; CELLS; LIVER; OLIGOSACCHARIDES	N-Acetylglucosaminyltransferase III (GlcNAc-TIII), the product of the Mgat3 gene, transfers the bisecting GlcNAe to the core mannose of complex N-glycans. The addition of this residue is regulated during development and has functional consequences for receptor signaling, cell adhesion, and tumor progression. Mice homozygous for a null mutation at the Mgat3 locus (Mgat3(Delta)) or for a targeted mutation in the Mgat3 gene (previously called Mgat3(neo), but herein renamed Mgat3(T37) because the allele generates inactive GlcNAc-TIII of similar to37 kDa) were found to exhibit retarded progression of liver tumors. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of neutral N-glycans from kidneys revealed no significant differences, and both mutants showed the expected lack of N-glycan species with an additional GlcNAc. However, the two mutants differed in several biological traits. Mgat3(T37/T37) homozygotes in a mixed or 129(SvJ) background were retarded in growth rate and exhibited an altered leg clasp reflex, an altered gait, and defective nursing behavior. Pups abandoned by Mgat3(T37/T37) mothers were rescued by wildtype foster mothers. None of these Mgat3(T37/T37) traits were exhibited by Mgat3(Delta/Delta) mice or by heterozygous mice carrying the Mgat3(T37) mutation. Similarly, no dominant-negative effect was observed in Chinese hamster ovary cells expressing truncated GIcNAc-TIII in the presence of wild-type GIcNAc-TIII. However, compound heterozygotes carrying both the Mgat3(T37) and Mgat3(Delta) mutations exhibited a marked leg clasp reflex, indicating that in the absence of wild-type GlcNAc-TIII, truncated GIcNAc-TIII causes this phenotype. The Mgat3 gene was expressed in brain at embryonic day 10.5 and thereafter and in neurons of adult cerebellum. The mutant Mgat3 gene was also highly expressed in Mgat3(T37/T37) brain. This may be the basis of the unexpected neurological phenotype induced by truncated, inactive GIcNAc-TIII in the mouse.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Genentech Inc, Analyt Chem, San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; Roche Holding; Genentech	Stanley, P (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	NCI NIH HHS [P01 CA13330, R01 CA30645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; Bhaumik M, 1998, CANCER RES, V58, P2881; BHAUMIK M, 1995, GENE, V164, P295, DOI 10.1016/0378-1119(95)00260-D; BHAUMIK M, 1996, GLYCOBIOLOGY, V6, P720; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; Chui D, 2001, P NATL ACAD SCI USA, V98, P1142, DOI 10.1073/pnas.98.3.1142; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Ihara H, 2002, EUR J BIOCHEM, V269, P193, DOI 10.1046/j.0014-2956.2001.02640.x; Ihara Y, 1998, P NATL ACAD SCI USA, V95, P2526, DOI 10.1073/pnas.95.5.2526; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Ioffe E, 1996, P NATL ACAD SCI USA, V93, P11041, DOI 10.1073/pnas.93.20.11041; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; Kohlhepp RL, 2001, MAMM GENOME, V12, P606, DOI 10.1007/s003350020042; Koyota S, 2001, J BIOL CHEM, V276, P32867, DOI 10.1074/jbc.M102371200; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; Miyagawa S, 2001, J BIOL CHEM, V276, P39310, DOI 10.1074/jbc.M104359200; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PASCALE R, 1989, CARCINOGENESIS, V10, P961, DOI 10.1093/carcin/10.5.961; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Scacheri PC, 2001, GENESIS, V30, P259, DOI 10.1002/gene.1072; Schachter H, 2001, CELL MOL LIFE SCI, V58, P1085, DOI 10.1007/PL00000923; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STEINBERG H, 1989, J PHARMACOL METHOD, V21, P103, DOI 10.1016/0160-5402(89)90028-4; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YANG J, 1994, GLYCOBIOLOGY, V4, P703, DOI 10.1093/glycob/4.5.703; Yang XP, 2000, CANCER RES, V60, P3313; Yoshimura M, 1996, CANCER RES, V56, P412; Yoshimura M, 1998, BIOCHEM J, V331, P733, DOI 10.1042/bj3310733; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOSHIMURA M, 1995, GLYCOCONJUGATE J, V12, P234, DOI 10.1007/BF00731325; Young WS, 1998, ADV EXP MED BIOL, V449, P231	52	44	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26300	26309		10.1074/jbc.M202276200	http://dx.doi.org/10.1074/jbc.M202276200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986323	hybrid			2022-12-25	WOS:000176908700064
J	Morty, RE; Morehead, J				Morty, RE; Morehead, J			Cloning and characterization of a leucyl aminopeptidase from three pathogenic Leishmania species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS LEUCINE AMINOPEPTIDASE; PLASMODIUM-FALCIPARUM; CYSTEINE PROTEINASES; TRYPANOSOMA-BRUCEI; BOVINE LENS; OLIGOPEPTIDASE-B; BINDING-SITES; ARPHAMENINE-A; TIGHT-BINDING; SLOW-BINDING	Aminopeptidases are emerging as exciting novel drug targets and vaccine candidates in parasitic infections. In this study, we describe for the first time an aminopeptidase from three highly pathogenic Leishmania species. Intronless genes encoding a leucyl aminopeptidase (tap) were cloned from Leishmania amazonensis, Leishmania donovani, and Leishmania major, which encoded 60-kDa proteins that displayed homology to leucyl aminopeptidases from Gram-negative bacteria, plants, and mammals. The lap genes were present as a single copy in each genome, and lap mRNA was detected by reverse transcription-PCR in all life-cycle stages of L amazonensis. Lap assembled into catalytically competent 360-kDa hexamers and demonstrated potent amidolytic activity against synthetic aminopeptidase substrates containing leucine, methionine, and cysteine residues, representing the most restricted substrate specificity of any leucyl aminopeptidase, described to date. Optimal activity was observed against L-leucyl-7-amido-4-methylcoumarin (k(cat)/K-m approximate to 63 s(-1).mM(-1)) with a pH optimum of 8.5. Leishmania Lap activity was inhibited by metal ion chelators and enhanced by divalent manganese, cobalt, and nickel cations, although only zinc was detected in the purified Lap by inductively coupled plasma atomic emission spectroscopy, indicating that zinc is the natural Lap cofactor. Activity was potently inhibited by bestatin and apstatin in a slow binding competitive fashion, with K-i* values of 3 and 44 nM, respectively. Actinonin was a tight binding competitive inhibitor (K-i approximate to 1 nM), whereas arphamenine A (K-i approximate to 70 gm) and L-leucinol (K-i approximate to 100 muM) were non-tight binding competitive inhibitors. Lap was not secreted by Leishmania in vitro and was localized to the parasite cytosol.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Morty, RE (corresponding author), Univ Giessen, Med Klin & Poliklin 2, Zentrum Innere Med, Aulweg 123,Raum 6-11, D-35392 Giessen, Germany.	rory.morty@innere.med.uni-giessen.de			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001584] Funding Source: NIH RePORTER; NIAID NIH HHS [K08-AI01584-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bangs JD, 2001, MOL BIOCHEM PARASIT, V114, P111, DOI 10.1016/S0166-6851(01)00244-4; Bienvenue DL, 2000, J INORG BIOCHEM, V78, P43, DOI 10.1016/S0162-0134(99)00203-2; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; CARPENTER FH, 1973, J BIOL CHEM, V248, P294; Clements JM, 2001, ANTIMICROB AGENTS CH, V45, P563, DOI 10.1128/AAC.45.2.563-570.2001; Cottrell GS, 2000, BIOCHEMISTRY-US, V39, P15121, DOI 10.1021/bi001585c; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Florent I, 1998, MOL BIOCHEM PARASIT, V97, P149, DOI 10.1016/S0166-6851(98)00143-1; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; Gu YQ, 2000, EUR J BIOCHEM, V267, P1178, DOI 10.1046/j.1432-1327.2000.01116.x; Gu YQ, 1996, J BIOL CHEM, V271, P25880, DOI 10.1074/jbc.271.42.25880; Gu YQ, 2002, EUR J BIOCHEM, V269, P1630, DOI 10.1046/j.1432-1327.2002.02795.x; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; Howarth J, 2000, J ANTIMICROB CHEMOTH, V46, P625, DOI 10.1093/jac/46.4.625; KIM HD, 1993, P NATL ACAD SCI USA, V90, P5006, DOI 10.1073/pnas.90.11.5006; KNOWLES G, 1993, J ANTIMICROB CHEMOTH, V32, P172, DOI 10.1093/jac/32.1.172; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; Maggiora LL, 1999, J MED CHEM, V42, P2394, DOI 10.1021/jm9805642; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Morty RE, 1999, J BIOL CHEM, V274, P26149, DOI 10.1074/jbc.274.37.26149; Morty RE, 2000, BIOCHEM PHARMACOL, V60, P1497, DOI 10.1016/S0006-2952(00)00459-7; Morty RE, 1998, FEBS LETT, V433, P251, DOI 10.1016/S0014-5793(98)00914-4; Morty RE, 2001, INFECT IMMUN, V69, P2757, DOI 10.1128/IAI.69.4.2757-2761.2001; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Nankya-Kitaka MF, 1998, PARASITOL RES, V84, P552, DOI 10.1007/s004360050447; Piacenza L, 1999, INFECT IMMUN, V67, P1954; Rafati S, 2001, VACCINE, V19, P3369, DOI 10.1016/S0264-410X(01)00081-0; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Robertson CD, 1999, MOL BIOCHEM PARASIT, V103, P49, DOI 10.1016/S0166-6851(99)00110-3; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Rosenthal PJ, 1999, ADV PARASIT, V43, P105, DOI 10.1016/S0065-308X(08)60242-0; Sakakibara T, 1983, Jpn J Antibiot, V36, P2971; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Sankievicz D, 1999, BIOCHEM BIOPH RES CO, V262, P557, DOI 10.1006/bbrc.1999.1249; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER P, 1993, MOL BIOCHEM PARASIT, V62, P223, DOI 10.1016/0166-6851(93)90111-A; Segel IH, 1975, ENZYME KINETICS BEHA; Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015; TAYLOR A, 1993, BIOCHEMISTRY-US, V32, P784, DOI 10.1021/bi00054a007; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Toma C, 1996, INFECT IMMUN, V64, P4495, DOI 10.1128/IAI.64.11.4495-4500.1996; UMEZAWA H, 1983, J ANTIBIOT, V36, P1572, DOI 10.7164/antibiotics.36.1572; VANWART HE, 1981, BIOCHEMISTRY-US, V20, P5682, DOI 10.1021/bi00523a007; Walker KW, 1998, PROTEIN SCI, V7, P2684, DOI 10.1002/pro.5560071224; WILKES SH, 1985, J BIOL CHEM, V260, P3154; Williams J W, 1979, Methods Enzymol, V63, P437	50	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26057	26065		10.1074/jbc.M202779200	http://dx.doi.org/10.1074/jbc.M202779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006595	hybrid			2022-12-25	WOS:000176908700031
J	Courtois-Coutry, N; Le Moellic, C; Boulkroun, S; Fay, M; Cluzeaud, F; Escoubet, B; Farman, N; Blot-Chabaud, M				Courtois-Coutry, N; Le Moellic, C; Boulkroun, S; Fay, M; Cluzeaud, F; Escoubet, B; Farman, N; Blot-Chabaud, M			Calcyclin is an early vasopressin-induced gene in the renal collecting duct - Role in the long term regulation of ion transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SODIUM-TRANSPORT; CELL-LINE; PERMEABILIZED CELLS; PLASMA-MEMBRANE; WATER CHANNELS; RAT-KIDNEY; TRANSLOCATION; DEOXYCORTICOSTERONE; ALDOSTERONE	Long-term effects of arginine vasopressin (AVP) in the kidney involve the transcription of unidentified genes. By subtractive hybridization experiments performed on the RCCD1 cortical collecting duct cell line, we identified calcyclin as an early AVP-induced gene (1 h). Calcyclin is a calcium-binding protein involved in the transduction of intracellular signals. In the kidney, calcyclin was localized at the mRNA level. in the glomerulus, all along the collecting duct, and in the epithelium lining the papilla. In RCCD, cells and in m-IMCD3 inner medullary collecting duct cells, calcyclin was evidence in the cytoplasm. Caleyelin mRNA levels were progressively increased by AVP treatment in RCCD1 (1.7-fold at 4 h) and m-IMCD3 (2-fold at 7.5 h) cells. In RCCD1 cells, calcyclin protein levels were increased by 4 h of AVP treatment. In vivo, treatment of genetically vasopressin-deficient Brattleboro rats with AVP for 4 days induced an increase in both calcyclin and aquaporin-2 mRNA expression. Finally, introduction of anti-calcyclin antibodies into RCCD1 cells by permeabilizing the plasma membrane prevented the long-term (but not short-term) increase in short-circuit current induced by AVP. Taken together, these results suggest that calcyclin is an early vasopressin-induced gene that participates in the late phase of the hormone response in transepithelial ion transport.	Univ Paris 07, INSERM, U478, Fac Med Xavier Bichat,Inst Federat Rech 02, F-75018 Paris, France; Univ Paris 07, INSERM, U426, Fac Med Xavier Bichat,Inst Federat Rech 02, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Blot-Chabaud, M (corresponding author), Univ Paris 07, INSERM, U478, Fac Med Xavier Bichat,Inst Federat Rech 02, F-75018 Paris, France.		COUTRY, Nathalie/O-9352-2017; Boulkroun, Sheerazed/M-4459-2017; Blot-Chabaud, Marcel/D-4064-2017; Boulkroun, Sheerazed/AAX-8348-2021	COUTRY, Nathalie/0000-0001-5830-4013; Boulkroun, Sheerazed/0000-0002-8796-7534; Boulkroun, Sheerazed/0000-0002-8796-7534				BINDELS RJM, 1988, BIOCHIM BIOPHYS ACTA, V972, P320, DOI 10.1016/0167-4889(88)90208-X; BlotChabaud M, 1996, KIDNEY INT, V50, P367, DOI 10.1038/ki.1996.325; CANESSA CM, 1992, AM J PHYSIOL, V262, pF454, DOI 10.1152/ajprenal.1992.262.3.F454; CHEN L, 1990, AM J PHYSIOL, V259, pF147, DOI 10.1152/ajprenal.1990.259.1.F147; Christensen BM, 1998, AM J PHYSIOL-RENAL, V275, pF285, DOI 10.1152/ajprenal.1998.275.2.F285; Djelidi S, 1999, FEBS LETT, V460, P533, DOI 10.1016/S0014-5793(99)01408-8; Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805; Djelidi S, 1997, J BIOL CHEM, V272, P32919, DOI 10.1074/jbc.272.52.32919; Ecelbarger CA, 2000, AM J PHYSIOL-RENAL, V279, pF46, DOI 10.1152/ajprenal.2000.279.1.F46; FARMAN N, 1991, AM J PHYSIOL, V260, pC468, DOI 10.1152/ajpcell.1991.260.3.C468; FERRARI S, 1987, J BIOL CHEM, V262, P8325; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; GHEZZO F, 1988, J BIOL CHEM, V263, P4758; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; Guerrero ML, 1997, AM J PHYSIOL-CELL PH, V272, pC697, DOI 10.1152/ajpcell.1997.272.2.C697; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HUTTON JC, 1986, CELL CALCIUM, V7, P339, DOI 10.1016/0143-4160(86)90037-0; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; Klussmann E, 2001, KIDNEY INT, V60, P446, DOI 10.1046/j.1523-1755.2001.060002446.x; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; Lewington AJP, 1997, AM J PHYSIOL-RENAL, V273, pF380, DOI 10.1152/ajprenal.1997.273.3.F380; Liu JM, 1999, METHODS, V19, P403, DOI 10.1006/meth.1999.0876; MANI RS, 1995, J BIOL CHEM, V270, P6658, DOI 10.1074/jbc.270.12.6658; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; MURPHY LC, 1988, J BIOL CHEM, V263, P2397; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; OKAZAKI K, 1994, J BIOL CHEM, V269, P6149; REIF MC, 1986, J CLIN INVEST, V77, P1291, DOI 10.1172/JCI112433; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; TOMITA K, 1985, J CLIN INVEST, V76, P132, DOI 10.1172/JCI111935; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; WILLS FL, 1994, PROTEIN SCI, V3, P2311, DOI 10.1002/pro.5560031216; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25728	25734		10.1074/jbc.M112435200	http://dx.doi.org/10.1074/jbc.M112435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000747	hybrid			2022-12-25	WOS:000176747000115
J	Luo, DC; Mari, B; Stoll, I; Anglard, P				Luo, DC; Mari, B; Stoll, I; Anglard, P			Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA; IN-VIVO; RETINOIC ACID; EXPRESSION; GENE; CANCER; INHIBITORS; ACTIVATION; RECEPTORS; IDENTIFICATION	Human stromelysin 3 (ST3) is a matrix metalloproteinase (MMP) that has been implicated in cancer progression and in various tissue remodeling processes. Unlike most MMPs, ST3 is characterized by a distinct substrate specificity and a specific regulation and is not directly involved in extracellular matrix degradation. In the present study, we have identified an additional ST3 gene promoter that is accessible to nuclear factors such as C/EBP and retinoic acid receptors. This human specific promoter is inducible and controls the expression of a novel ST3 transcript called the beta-ST3 that is expressed in cultured cells and in placenta. This transcript encodes a 40-kDa ST3 isoform that lacks both the signal peptide common to all secreted MMPs and the prodomain that normally maintains enzyme latency. Consistent with the lack of a signal peptide, the beta-ST3 was found to be intracellular. The relative amount of the extracellular alpha-ST3 isoform was about 20-fold higher than that of the intracellular ST3 isoforms, as estimated by Western blot analysis. Furthermore, recombinant beta-ST3 produced in Escherichia coli exhibits a proteolytic activity against alpha1-proteinase inhibitor, a substrate previously shown to be inactivated by the alpha-ST3. Therefore, although it was thought that all MMPs were synthesized as inactive zymogens and functioned extra-cellularly, this is the first MMP isoform reported that is generated by alternative promoter usage and directly translated as an active enzyme. Although the intracellular function of the beta-ST3 remains to be investigated, these data support the idea that the functions of MMPs are not restricted to the extracellular space.	Univ Strasbourg 1, CNRS, INSERM U184, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Fac Med Pasteur, INSERM U526, IFR50, F-06107 Nice 02, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Anglard, P (corresponding author), Univ Strasbourg 1, CNRS, INSERM U184, Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Illkirch Graffenstaden, France.		Anglard, Patrick/M-6618-2019; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013	Anglard, Patrick/0000-0001-5701-441X; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182				Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Ahmad A, 1998, AM J PATHOL, V152, P721; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Boulay A, 2001, CANCER RES, V61, P2189; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Guerin E, 1997, J BIOL CHEM, V272, P11088; Kajita M, 1999, FEBS LETT, V457, P353, DOI 10.1016/S0014-5793(99)01065-0; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Ludwig MG, 2000, J BIOL CHEM, V275, P39981, DOI 10.1074/jbc.M007529200; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; SANTAVICCA M, 1995, INT J CANCER, V64, P336, DOI 10.1002/ijc.2910640510; Schonbeck U, 1999, J EXP MED, V189, P843, DOI 10.1084/jem.189.5.843; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Schulze CJ, 2000, CIRCULATION, V102, P203; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TARABOLETTI G, 1995, J NATL CANCER I, V87, P293, DOI 10.1093/jnci/87.4.293; Vassiliou S, 1999, J MED CHEM, V42, P2610, DOI 10.1021/jm9900164; Velasco G, 2000, CANCER RES, V60, P877; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; Westermarck J, 2000, CANCER RES, V60, P7156; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	45	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25527	25536		10.1074/jbc.M202494200	http://dx.doi.org/10.1074/jbc.M202494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006591	hybrid			2022-12-25	WOS:000176747000089
J	Sevrioukova, IF; Poulos, TL				Sevrioukova, IF; Poulos, TL			Putidaredoxin reductase, a new function for an old protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOAMIDE DEHYDROGENASE; PIG-HEART; P450CAM MONOOXYGENASE; PYRIDINE-NUCLEOTIDES; CRYSTAL-STRUCTURE; SURFACE RESIDUES; REDOX PARTNERS; DIOXYGENASE; 2-ELECTRON; CATALYSIS	Properties of recombinant wild type (WT) and six-histidine tag-fused (His(6) putidaredoxin reductase (Pdr), a FAD-containing component of the soluble cytochrome P450cam monooxygenase system from Pseudomonas putida, have been studied. Both WT and His, Pdr were found to undergo a monomer-dimer association-dissociation and were partially present as an NAD(+)-bound form. Although molecular, spectral, and electron transferring properties of recombinant His, Pdr to artificial and native electron acceptors were similar to those of the WT protein, the presence of eight additional C-terminal amino acid residues, Pro-Arg-His-His-His-His-His-His, had a crucial effect on the enzyme interaction with oxidized pyridine nucleotide. Under anaerobic conditions, NAD(+) induced in His(6) Pdr spectral changes indicative of flavin reduction and formation of the charge transfer complex between the reduced FAD and NAD(+). The reaction proceeded considerably faster in the presence of free histidine and thiol-reducing agents, such as dithiothreitol and reduced glutathione. In the presence of any of these three reagents, NAD(+) was capable of inducing reduction of the flavin in WT Pdr. Free thiol groups were identified as an internal source of electrons in the enzyme. The results showed that WT and His, Pdr were able to function as NAD(H)-dependent dithiol/disulfide oxidoreductases catalyzing both forward and reverse reactions, NAD(+)-dependent oxidation of thiols, and NADH-dependent reduction of disulfides. This function of the flavoprotein can be dissociated from electron transfer to putidaredoxin. Similarity of Pdr to the enzymes of the glutathione reductase family is discussed.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92612 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92612 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Sevrioukova, IF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA.	sevrioui@uci.edu						Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P157, DOI 10.1016/S0167-4838(98)00094-6; BILD GS, 1980, J BIOL CHEM, V255, P8109; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P33, DOI 10.1016/0006-3002(61)90512-1; Massy V, 1963, ENZYMES, V7, P275; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATTHEWS RG, 1979, J BIOL CHEM, V254, P4974; MILLER SM, 1991, BIOCHEMISTRY-US, V30, P2600, DOI 10.1021/bi00224a006; MUISWINKEL-VOETBERG H V, 1973, European Journal of Biochemistry, V33, P285, DOI 10.1111/j.1432-1033.1973.tb02682.x; Patil PV, 2000, ANAL BIOCHEM, V286, P187, DOI 10.1006/abio.2000.4802; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROOME PW, 1988, ARCH BIOCHEM BIOPHYS, V266, P32, DOI 10.1016/0003-9861(88)90233-0; ROOME PW, 1983, J BIOL CHEM, V258, P2593; ROOME PW, 1988, ARCH BIOCHEM BIOPHYS, V266, P41, DOI 10.1016/0003-9861(88)90234-2; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Sevrioukova IF, 2001, BIOCHEMISTRY-US, V40, P10592, DOI 10.1021/bi010874d; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; THORPE C, 1981, BIOCHEMISTRY-US, V20, P1507, DOI 10.1021/bi00509a015; WILLIAMS J M, 1991, Bioacoustics, V3, P121	25	24	25	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25831	25839		10.1074/jbc.M201110200	http://dx.doi.org/10.1074/jbc.M201110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12011076	hybrid			2022-12-25	WOS:000176747000126
J	Vandenbroeck, K; Alloza, I; Brehmer, D; Billiau, A; Proost, P; McFerran, N; Rudiger, S; Walker, B				Vandenbroeck, K; Alloza, I; Brehmer, D; Billiau, A; Proost, P; McFerran, N; Rudiger, S; Walker, B			The conserved helix C region in the superfamily of interferon-gamma/interleukin-10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERFERON-GAMMA; DIFFERENTIATION-ASSOCIATED GENE; PROTEIN-PROTEIN INTERFACES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PEPTIDE-BINDING; INTERLEUKIN-10 REVEALS; SUBSTRATE-BINDING; DISEASE VIRUS; IFN-GAMMA	HSP70 chaperones mediate protein folding by ATP-dependent interaction with short linear peptide segments that are exposed on unfolded proteins. The mode of action of the Escherichia coli homolog DnaK is representative of all HSP70 chaperones, including the endoplasmic reticulum variant BiP/GRP78. DnaK has been shown to be effective in assisting refolding of a wide variety of prokaryotic and eukaryotic proteins, including the alpha-helical homodimeric secretory cytokine interferon-gamma (IFN-gamma). We screened solid-phase peptide libraries from human and mouse IFN-gamma to identify DnaK-binding sites. Conserved DnaK-binding sites were identified in the N-terminal half of helix B and in the C-terminal half of helix C, both of which are located at the IFN-gamma dimer interface. Soluble peptides derived from helices B and C bound DnaK with high affinity in competition assays. No DnalK-binding sites were found in the loops connecting the alpha-helices. The helix C DnaK-binding site appears to be conserved in most members of the superfamily of interleukin (IL)-10-related cytokines that comprises, apart from IL-10 and IFN-gamma, a series of recently discovered small secretory proteins, including IL-19, IL-20, IL-22/IL-TIF, IL-24/MDA-7 (melanoma differentiation-associated gene), IL-26/AK155, and a number of viral IL-10 homologs. These cytokines belong to a relatively small group of homodimeric proteins with highly interdigitated interfaces that exhibit the strongly hydrophobic character of the interior core of a single-chain folded domain. We propose that binding of DnaK to helix C in the superfamily of IL-10-related cytokines may constitute the hallmark of a novel conserved regulatory mechanism in which HSP70-like chaperones assist in the formation of a hydrophobic dimeric "folding" interface.	Queens Univ Belfast, Sch Pharm, Cytokine Biol & Genet Programme, Mcclay Res Ctr Pharmaceut Sci,Biomol Sci Res Grp, Belfast BT9 7BL, Antrim, North Ireland; Queens Univ Belfast, Ctr Prot & Peptide Engn, Belfast BT9 7BL, Antrim, North Ireland; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Univ Cambridge, MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	Queens University Belfast; Queens University Belfast; University of Freiburg; KU Leuven; University of Cambridge	Vandenbroeck, K (corresponding author), Queens Univ Belfast, Sch Pharm, Cytokine Biol & Genet Programme, Mcclay Res Ctr Pharmaceut Sci,Biomol Sci Res Grp, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	k.vandenbroeck@qub.ac.uk	Rüdiger, Stefan GD/G-4906-2012; Vandenbroeck, Koen/D-6845-2012; Proost, Paul/V-3052-2017; Walker, Brian/C-5263-2008	Rüdiger, Stefan GD/0000-0002-1807-2972; Vandenbroeck, Koen/0000-0002-6967-6485; Proost, Paul/0000-0002-0133-5545; Alloza, Iraide/0000-0002-8949-7732				ARAKAWA T, 1985, J BIOL CHEM, V260, P4435; ARAKAWA T, 1987, BIOCHEMISTRY-US, V26, P5428, DOI 10.1021/bi00391a032; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; DUDICH IV, 1992, MOL BIOL+, V26, P342; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; Gottesman ME, 2000, CURR OPIN MICROBIOL, V3, P197, DOI 10.1016/S1369-5274(00)00075-8; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8; Kendrick BS, 1998, P NATL ACAD SCI USA, V95, P14142, DOI 10.1073/pnas.95.24.14142; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; Landar A, 2000, J MOL BIOL, V299, P169, DOI 10.1006/jmbi.2000.3734; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Lee HJ, 2001, VIROLOGY, V281, P170, DOI 10.1006/viro.2000.0761; Lockridge KM, 2000, VIROLOGY, V268, P272, DOI 10.1006/viro.2000.0195; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; MULKERRIN MG, 1989, BIOCHEMISTRY-US, V28, P6556, DOI 10.1021/bi00442a005; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; Schaefer G, 2001, J IMMUNOL, V166, P5859, DOI 10.4049/jimmunol.166.10.5859; Soo C, 1999, J CELL BIOCHEM, V74, P1; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TAYSACO ML, 1992, SCIENCE, V255, P594; Tsai CJ, 1997, PROTEIN SCI, V6, P1426, DOI 10.1002/pro.5560060707; Tulman ER, 2001, J VIROL, V75, P7122, DOI 10.1128/JVI.75.15.7122-7130.2001; VANDENBROECK K, 1993, EUR J BIOCHEM, V215, P481, DOI 10.1111/j.1432-1033.1993.tb18057.x; Vandenbroeck K, 1998, EUR J BIOCHEM, V251, P181, DOI 10.1046/j.1432-1327.1998.2510181.x; Vandenbroeck K, 1998, BIOCHIMIE, V80, P729, DOI 10.1016/S0300-9084(99)80026-1; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WALTER MR, 1995, BIOCHEMISTRY-US, V34, P12118, DOI 10.1021/bi00038a004; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Xu D, 1998, PROTEIN SCI, V7, P533; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	59	13	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25668	25676		10.1074/jbc.M202984200	http://dx.doi.org/10.1074/jbc.M202984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11970958	hybrid			2022-12-25	WOS:000176747000106
J	Arai, A; Spencer, JA; Olson, EN				Arai, A; Spencer, JA; Olson, EN			STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS PLAY; GENE-EXPRESSION; FOCAL ADHESIONS; FAMILY GTPASES; MAP KINASE; ACTIN; BINDING; SKELETAL; SMOOTH; CELL	Changes in actin dynamics influence diverse cellular processes and couple the actin-based cytoskeleton to changes in gene transcription. Members of the Rho GTPase family regulate cytoskeletal organization by stimulating actin polymerization and stress fiber formation when activated by extracellular signaling. The transcriptional activity of serum response factor (SRF) is stimulated in response to changes in actin dynamics and Rho signaling, but the proteins that mediate this phenomenon have not been fully identified. We describe a novel, evolutionarily conserved actin-binding protein, called STARS (striated muscle activator of Rho signaling), that is expressed specifically in cardiac and skeletal muscle cells. STARS binds to the I-band of the sarcomere and to actin filaments in transfected cells, where it activates Rho-signaling events. STARS stimulates the transcriptional activity of SRF through a mechanism that requires actin binding and involves Rho GTPase activation. STARS provides a potential mechanism for specifically enhancing Rho-dependent transcription in muscle cells and for linking changes in actin dynamics to gene transcription.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu						Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Ehler E, 1999, J CELL SCI, V112, P1529; GODDETTE DW, 1986, J BIOL CHEM, V261, P5970; Gregorio CC, 2000, TRENDS CELL BIOL, V10, P355, DOI 10.1016/S0962-8924(00)01793-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Hubank M, 1999, METHOD ENZYMOL, V303, P325; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mack CP, 1999, CIRC RES, V84, P852; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Souchet M, 2002, J CELL SCI, V115, P629; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VAN AL, 1997, GENE DEV, V11, P2295; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wei L, 2001, FASEB J, V15, P785, DOI 10.1096/fj.00-026com; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	53	95	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24453	24459		10.1074/jbc.M202216200	http://dx.doi.org/10.1074/jbc.M202216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983702	hybrid			2022-12-25	WOS:000176611800064
J	Bifulco, G; Di Carlo, C; Caruso, M; Oriente, F; Sardo, AD; Formisano, P; Beguinot, F; Nappi, C				Bifulco, G; Di Carlo, C; Caruso, M; Oriente, F; Sardo, AD; Formisano, P; Beguinot, F; Nappi, C			Glucose regulates insulin mitogenic effect by modulating SHP-2 activation and localization in JAr cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; PROTEIN-KINASE; TYROSINE-PHOSPHATASE; DIFFERENT MECHANISMS; PANCREATIC-ISLETS; RECEPTOR; APOPTOSIS; EXPRESSION; PHOSPHORYLATION; ALPHA	The glucose effect on cell growth has been investigated in the JAr human choriocarcinoma cells. When JAr cells were cultured in the presence of 6 mm glucose (LG), proliferation and thymidine incorporation were induced by serum, epidermal growth factor, and insulin-like growth factor 1 but not by insulin. In contrast, at 25 mm glucose (HG), proliferation and thymidine incorporation were stimulated by insulin, serum, epidermal growth factor, and insulin-like growth factor 1 to a comparable extent, whereas basal levels were 25% lower than those in LG. HG culturing also enhanced insulin-stimulated insulin receptor and insulin receptor substrate 1 (IRS1) tyrosine phosphorylations while decreasing basal phosphorylations. These actions of glucose were accompanied by an increase in cellular tyrosine phosphatase activity. The activity of SHP-2 in HG-treated JAr cells was 400% of that measured in LG-treated cells. SHP-2 co-precipitation with IRS1 was also increased in HG-treated cells. SHP-2 was mainly cytosolic in LG-treated cells. However, HG culturing largely redistributed SHP-2 to the internal membrane compartment, where tyrosine-phosphorylated IRS1 predominantly localizes. Further exposure to insulin rescued SHP-2 cytosolic localization, thereby preventing its interaction with IRS1. Antisense inhibition of SHP-2 reverted the effect of HG on basal and insulin-stimulated insulin receptor and IRS1 phosphorylation as well as that on thymidine incorporation. Thus, in JAr cells, glucose modulates insulin mitogenic action by modulating SHP-2 activity and intracellular localization.	Univ Naples Federico II, Dipartimento Biol & Patol Mol & Cellulare L Calif, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Ginecol Ostetricia & Fisiopatol Ripr, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Bifulco, G (corresponding author), Via Pansini 5, I-80131 Naples, Italy.		Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526; BIFULCO, Giuseppe/0000-0001-7772-8591; Di Spiezio Sardo, Attilio/0000-0001-6485-5735	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		BAHN RS, 1980, ENDOCRINOLOGY, V107, P2121, DOI 10.1210/endo-107-6-2121; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; Boileau P, 2001, ENDOCRINOLOGY, V142, P3974, DOI 10.1210/en.142.9.3974; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; CHEN CF, 1988, J CLIN ENDOCR METAB, V71, P923; Crossey PA, 2000, DIABETES, V49, P457, DOI 10.2337/diabetes.49.3.457; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Federici M, 1999, DIABETES, V48, P2277, DOI 10.2337/diabetes.48.12.2277; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fine EL, 1999, DIABETES, V48, P2454, DOI 10.2337/diabetes.48.12.2454; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; IPATA PL, 1967, ANAL BIOCHEM, V20, P30, DOI 10.1016/0003-2697(67)90261-8; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KHUNE MR, 1993, J BIOL CHEM, V268, P11479; KIKKAWA R, 1993, DIABETOLOGIA, V36, P276, DOI 10.1007/BF00400228; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lao TT, 1997, PLACENTA, V18, P227, DOI 10.1016/S0143-4004(97)90097-7; Li RH, 1997, HUM REPROD, V12, P830, DOI 10.1093/humrep/12.4.830; MARSHALL CJ, 1995, CELL, V80, P225; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Okada Y, 1998, DIABETES RES CLIN PR, V41, P157, DOI 10.1016/S0168-8227(98)00076-X; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Pinter E, 2001, AM J PATHOL, V158, P1199, DOI 10.1016/S0002-9440(10)64069-2; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; SIMPSON ER, 1981, ANNU REV PHYSIOL, V43, P163, DOI 10.1146/annurev.ph.43.030181.001115; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Sjoholm A, 1997, DIABETES, V46, P1141, DOI 10.2337/diabetes.46.7.1141; Solow BT, 1999, MOL ENDOCRINOL, V13, P1784, DOI 10.1210/me.13.10.1784; Tsujikawa K, 2001, MOL ENDOCRINOL, V15, P271, DOI 10.1210/me.15.2.271; Weiss U, 2001, DIABETOLOGIA, V44, P209, DOI 10.1007/s001250051601; Yang TJ, 1998, BIOCHEM PHARMACOL, V55, P1633, DOI 10.1016/S0006-2952(98)00018-5; Zhang QM, 1997, J BIOL CHEM, V272, P23703, DOI 10.1074/jbc.272.38.23703	47	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24306	24314		10.1074/jbc.M202962200	http://dx.doi.org/10.1074/jbc.M202962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983706	hybrid			2022-12-25	WOS:000176611800045
J	Nguyen, TH; Liu, J; Lombroso, PJ				Nguyen, TH; Liu, J; Lombroso, PJ			Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; SRC-FAMILY KINASES; MOLECULAR CHARACTERIZATION; SUBUNIT 2B; IN-VIVO; PTP-SL; PHOSPHORYLATION; ALPHA	A family of protein tyrosine phosphatases enriched within the central nervous system called striatal enriched phosphatase (STEP) has been implicated in the regulation of the N-methyl-D-aspartate receptor. STEP61, a membrane-associated isoform. located in the postsynaptic densities (PSDs) of striatal neurons, contains two transmembrane domains, two proline-rich domains, and a kinase-interacting motif. This study demonstrates that STEP61 associates with Fyn, a member of the Src family kinases that is also enriched in PSDs. By using human embryonic kidney 293 cells for co-transfection, we determined that a substrate-trapping variant (STEP61 CS) binds to Fyn but not to other members of the Src family present in PSDs. In a complementary experiment, myc-tagged Fyn immunoprecipitates STEP61 CS. STEP., binds to Fyn through one of its proline-rich domains and the kinase-interacting motif domain, whereas Fyn binds to STEP., through its Src homology 2 domain and the unique N-terminal domain. STEP61 CS pulls down Fyn when the Tyr(420) site is phosphorylated. In vitro, wildtype STEP61 dephosphorylates Fyn at Tyr(420) but not at Tyr(531). These results suggest that STEP regulates the activity of Fyn by specifically dephosphorylating the regulatory Tyr(420) and may be one mechanism by which Fyn activity is decreased within PSDs.	Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA	Yale University	Nguyen, TH (corresponding author), 48480 Lakeview Blvd, Fremont, CA 94538 USA.	tnguyen@lumicyte.com			NIMH NIH HHS [R01 MH52711, MH18268, KO2 MH01527] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052711, K02MH001527] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; Buist A, 2000, J BIOL CHEM, V275, P20754, DOI 10.1074/jbc.M001626200; Bult A, 1996, J NEUROSCI, V16, P7821; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gurd JW, 1999, J NEUROCHEM, V73, P1990; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kojima N, 1998, LEARN MEMORY, V5, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; OYAMA T, 1995, NEUROSCIENCE, V69, P869, DOI 10.1016/0306-4522(95)00278-Q; Paul S, 2000, J NEUROSCI, V20, P5630, DOI 10.1523/JNEUROSCI.20-15-05630.2000; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	37	131	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24274	24279		10.1074/jbc.M111683200	http://dx.doi.org/10.1074/jbc.M111683200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983687	hybrid			2022-12-25	WOS:000176611800040
J	She, QB; Ma, WY; Zhong, SP; Dong, ZG				She, QB; Ma, WY; Zhong, SP; Dong, ZG			Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of bad by ultraviolet B radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; NECROSIS-FACTOR-ALPHA; DEATH AGONIST BAD; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CELL-SURVIVAL; GROWTH-FACTOR; UV-RADIATION; P53 PROTEIN; BH3 DOMAIN	The Bcl-2 family member Bad is a pro-apoptotic protein, and phosphorylation of Bad by cytokines and growth factors promotes cell survival in many cell types. Induction of apoptosis by UV radiation is well documented. However, little is known about UV activation of cell survival pathways. Here, we demonstrate that UVB induces Bad phosphorylation at serine 112 in JNK1, RSK2, and MSK1-dependent pathways. Inhibition of mitogen-activated protein (MAP) kinases including ERKs, JNXs, and p38 kinase by the use of their respective dominant negative mutant or a specific inhibitor for MEK1 or p38 kinase, PD98059 or SB202190, resulted in abrogation of UVB-induced phosphorylation of Bad at serine 112. Incubation of active MAP kinase members with Bad protein showed serine 112 phosphorylation of Bad by JNK1 only. However, activated RSK2 and MSK1, downstream kinases of ERKs and p38 kinase, respectively, also phosphorylated Bad at serine 112 in vitro. Cells from a Coffin-Lowry syndrome patient (deficient in RSK2) or expressing an N-terminal or C-terminal kinase-dead mutant of MSK1 were defective for UVB-induced serine 112 phosphorylation of Bad. Furthermore, MA,P kinase pathway-dependent serine 112 phosphorylation was shown to be required for dissociation of Bad from Bcl-X-L. These data illustrated that UVB-induced phosphorylation of Bad at serine 112 was mediated through MA,P kinase signaling pathways in which JNK1, RSK2, and MSK1 served as direct mediators.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			She, Qing-Bai/0000-0002-7207-0599	NCI NIH HHS [CA77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Scheid MP, 1999, BLOOD, V93, P217, DOI 10.1182/blood.V93.1.217.401k16_217_225; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULLRICH SE, 1995, PHOTOCHEM PHOTOBIOL, V62, P389, DOI 10.1111/j.1751-1097.1995.tb02359.x; Wan YS, 2001, INT J ONCOL, V18, P461; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	65	79	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24039	24048		10.1074/jbc.M109907200	http://dx.doi.org/10.1074/jbc.M109907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983683	hybrid			2022-12-25	WOS:000176611800011
J	Angove, HC; Cole, JA; Richardson, DJ; Butt, JN				Angove, HC; Cole, JA; Richardson, DJ; Butt, JN			Protein film voltammetry reveals distinctive fingerprints of nitrite and hydroxylamine reduction by a cytochrome c nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES; HEME-C; NRFH	The cytochrome c nitrite reductases perform a key step in the biological nitrogen cycle by catalyzing the six-electron reduction of nitrite to ammonium. Graphite electrodes painted with Escherichia coli cytochrome c nitrite reductase and placed in solutions containing nitrite (pH 7) exhibit large catalytic reduction currents during cyclic voltammetry at potentials below 0 V. These catalytic currents were not observed in the absence of cytochrome c nitrite reductase and were shown to originate from an enzyme film engaged in direct electron exchange with the electrode. The catalytic current-potential profiles observed on progression from substrate-limited to enzyme-limited nitrite reduction revealed a fingerprint of catalytic behavior distinct from that observed during hydroxylamine reduction, the latter being an alternative substrate for the enzyme that is reduced to ammonium in a two electron process. Cytochrome c nitrite reductase clearly interacts differently with these two substrates. However, similar features underlie the development of the voltammetric response with increasing nitrite or hydroxylamine concentration. These features are consistent with coordinated two-electron reduction of the active site and suggest that the mechanisms for reduction of both substrates are underpinned by common rate-defining processes.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of East Anglia; University of East Anglia; University of Birmingham	Butt, JN (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.		Richardson, David J/E-2275-2011; Butt, Julea/E-2133-2011	Butt, Julea/0000-0002-9624-5226				Anderson LJ, 2001, BIOCHEMISTRY-US, V40, P11294, DOI 10.1021/bi002706b; Anderson LJ, 2000, FARADAY DISCUSS, V116, P155, DOI 10.1039/b000946f; Armstrong FA, 1997, CHEM SOC REV, V26, P169, DOI 10.1039/cs9972600169; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; Butt JN, 2000, BIOPHYS J, V78, P1001, DOI 10.1016/S0006-3495(00)76658-6; Costa C, 1996, J BIOL CHEM, V271, P23191, DOI 10.1074/jbc.271.38.23191; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Einsle O., 2001, HDB METALLOPROTEINS, V1, P440; Heering HA, 1998, J PHYS CHEM B, V102, P6889, DOI 10.1021/jp981023r; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; KAJIE SI, 1986, EUR J BIOCHEM, V154, P457, DOI 10.1111/j.1432-1033.1986.tb09419.x; MORENO C, 1993, EUR J BIOCHEM, V212, P79, DOI 10.1111/j.1432-1033.1993.tb17635.x; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pereira IAC, 2000, BBA-PROTEIN STRUCT M, V1481, P119, DOI 10.1016/S0167-4838(00)00111-4; SCHARF M, 1995, BIOCHEM BIOPH RES CO, V209, P1018, DOI 10.1006/bbrc.1995.1599; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Simon J, 2001, EUR J BIOCHEM, V268, P5776, DOI 10.1046/j.0014-2956.2001.02520.x; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; SUCHETA A, 1993, BIOCHEMISTRY-US, V32, P5455, DOI 10.1021/bi00071a023	21	70	73	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23374	23381		10.1074/jbc.M200495200	http://dx.doi.org/10.1074/jbc.M200495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970951	hybrid			2022-12-25	WOS:000176475700037
J	Gradin, K; Takasaki, C; Fujii-Kuriyama, Y; Sogawa, K				Gradin, K; Takasaki, C; Fujii-Kuriyama, Y; Sogawa, K			The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; PROLYL HYDROXYLATION; HYPOXIA; PROTEIN; RECRUITMENT; ALPHA; TRANSACTIVATION; HOMEOSTASIS; HIF-1-ALPHA; EXPRESSION	The hypoxia-inducible factor (HIF)-1alpha and the HIF-like factor (HLF) transcription factors are regulated at multiple levels including protein stabilization, nuclear import, and activation of transactivation, resulting in recruitment of coactivators such as the cAMP-response element-binding protein (CREB)-binding protein (CBP)/p300 and SRC-1. During low oxygen tension these proteins modulate a network of genes that are necessary for angiogenesis, erythropopoiesis, and glycolysis. We report here that the C-terminal transactivation domain of HLF is phosphorylated on multiple sites and that phosphorylation on threonine 844 of HLF is necessary for the transcriptional activation function of the protein independently of the hypoxia condition. Importantly, using the mammalian two-hybrid system we demonstrate that a substitution of threonine 844 to an alanine decreased the enhanced transcriptional activation function mediated by CBP/p300.	Tohoku Univ, Dept Biomol Sci, Grad Sch Life Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Japan Sci & Technol, Core Res Evolut Sci & Technol, Tokyo 1500002, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Sogawa, K (corresponding author), Tohoku Univ, Dept Biomol Sci, Grad Sch Life Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan.							Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	26	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23508	23514		10.1074/jbc.M201307200	http://dx.doi.org/10.1074/jbc.M201307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11983697	hybrid			2022-12-25	WOS:000176475700055
J	Fong, A; Sun, SC				Fong, A; Sun, SC			Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IKK-ALPHA; ACTIVATION; CANCER; KINASE; PHOSPHORYLATION; PRECURSOR; PATHWAYS; SUBUNIT; P105	Processing of the nfkappab2 gene product p100 to generate p52 is an important step in NF-kappaB regulation. This step is regulated by a nonclassical NF-kappaB signaling pathway involving the NF-kappaB-inducing kinase (NIK). NIK induces p100 processing by triggering phosphorylation of specific C-terminal serines of p100. However, the downstream molecular events leading to p100 processing remain unclear. Here we show that NIK induced the physical recruitment of beta-transducin repeat-containing protein (beta-TrCP), a component of the SCF ubiquitin ligase complex, to p100. This event required the phosphorylation sites as well as the death domain of p100. Using the RNA interference technique, we demonstrated that beta-TrCP is essential for NIK-induced p100 ubiquitination and processing. Interestingly the constitutive processing of p100 mutants was independent of beta-TrCP. These results suggest that beta-TrCP is an essential component of NIK-induced p100 processing.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NIAID NIH HHS [1R01 AI45045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Caplen NJ, 2002, TRENDS BIOTECHNOL, V20, P49, DOI 10.1016/S0167-7799(01)01900-X; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; Harborth J, 2001, J CELL SCI, V114, P4557; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	26	117	129	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22111	22114		10.1074/jbc.C200151200	http://dx.doi.org/10.1074/jbc.C200151200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11994270	hybrid			2022-12-25	WOS:000176313600002
J	Hamada, K; Miyata, T; Mayanagi, K; Hirota, J; Mikoshiba, K				Hamada, K; Miyata, T; Mayanagi, K; Hirota, J; Mikoshiba, K			Two-state conformational changes in inositol 1,4,5-trisphosphate receptor regulated by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; ENDOPLASMIC-RETICULUM; RELEASE CHANNEL; SKELETAL-MUSCLE; LIGAND-BINDING; MOUSE; PURIFICATION; DEPRESSION; MICROSCOPY; DOMAINS	Inositol 1,4,5-trisphosphate receptor (IP3R) is a highly controlled calcium (Ca2+) channel gated by inositol 1,4,5-trisphosphate (IP3). Multiple regulators modulate IP3-triggered pore opening by binding-to discrete allosteric sites within IP3R Accordingly we have postulated that these regulators structurally control ligand gating behavior; however, no structural evidence has been available. Here we show that Ca2+, the most pivotal regulator, induced marked structural changes in the tetrameric IP3R purified from mouse cerebella. Electron microscopy of the IP3R particles revealed two distinct structures with 4-fold symmetry: a windmill structure and a square structure. Ca2+ reversibly promoted a transition from the square to the windmill with relocations of four peripheral IP3-binding domains, assigned by binding to heparin-gold. Ca2+-dependent susceptibilities to limited digestion strongly support the notion that these alterations exist. Thus, Ca2+ appeared to regulate IP3 gating activity through the rearrangement of functional domains.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; BERI, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Hamada, K (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Hamada, Kozo/GXM-9371-2022; Hirota, Junji/G-1357-2019; Hirota, Junji/O-9315-2019; Mikoshiba, Katsuhiko/N-7943-2015	Hirota, Junji/0000-0002-5741-0655; Hirota, Junji/0000-0002-5741-0655; Hamada, Kozo/0000-0002-2795-802X				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Furuichi T, 1999, CALCIUM AS A CELLULAR REGULATOR, P200; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Kanaseki T, 1998, CELL STRUCT FUNCT, V23, P373, DOI 10.1247/csf.23.373; Katayama E, 1996, EMBO J, V15, P4844, DOI 10.1002/j.1460-2075.1996.tb00865.x; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Street VA, 1997, J NEUROSCI, V17, P635; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	27	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21115	21118		10.1074/jbc.C200244200	http://dx.doi.org/10.1074/jbc.C200244200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11980893	hybrid			2022-12-25	WOS:000176286000002
J	Crozatier, B; Badoual, T; Boehm, E; Ennezat, PV; Guenoun, T; Su, JB; Veksler, V; Hittinger, L; Ventura-Clapier, R				Crozatier, B; Badoual, T; Boehm, E; Ennezat, PV; Guenoun, T; Su, JB; Veksler, V; Hittinger, L; Ventura-Clapier, R			Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice	FASEB JOURNAL			English	Article						CK; ventricular function; cell shortening	CHANNEL RYANODINE RECEPTOR; RAT VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; CALCIUM; MUSCLE; HEART; MITOCHONDRIAL; ISOENZYMES; COMPARTMENTATION	To understand the role of creatine kinase (CK) in cardiac excitation-contraction coupling, CK-deficient mice (CK-/-) were studied in vitro and in vivo. In skinned fibers, the kinetics of caffeine-induced release of Ca2+ was markedly slowed in CK-/- mice with a partial restoration when glycolytic substrates were added. These abnormalities were almost compensated for at the cellular level: the responses of Ca2+ transient and cell shortening to an increased pacing rate from 1 Hz to 4 Hz were normal with a normal post-rest potentiation of shortening. However, the post-rest potentiation of the Ca2+ transient was absent and the cellular contractile response to isoprenaline was decreased in CK-/- mice. In vivo, echocardiographically determined cardiac function was normal at rest but the response to isoprenaline was blunted in CK-/- mice. Previously described compensatory pathways (glycolytic pathway and closer sarcoplasmic reticulum-mitochondria interactions) allow a quasi-normal SR function in isolated cells and a normal basal in vivo ventricular function, but are not sufficient to cope with a large and rapid increase in energy demand produced by beta-adrenergic stimulation. This shows the specific role of CK in excitation-contraction coupling in cardiac muscle that cannot be compensated for by other pathways.	Fac Med, INSERM, U400, F-94000 Creteil, France; INSERM, U446, Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Crozatier, B (corresponding author), Fac Med, INSERM, U400, 8 Rue Gen Sarrail, F-94000 Creteil, France.	crozatier@im3.inserm.fr	Su, Jin Bo/N-6006-2018	Su, Jin Bo/0000-0002-1823-8928; Crozatier, Bertrand/0000-0001-8557-6911; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594; Hittinger, Luc/0000-0003-1933-5815				BASSANI RA, 1994, J MOL CELL CARDIOL, V26, P1335, DOI 10.1006/jmcc.1994.1152; BERS DM, 1993, J MOL CELL CARDIOL, V25, P1047, DOI 10.1006/jmcc.1993.1117; BERS DM, 1991, EXCITATION CONTRACTI; Boehm E, 2000, J MOL CELL CARDIOL, V32, P891, DOI 10.1006/jmcc.2000.1130; CHENG H, 1996, AM J PHYSIOL, V270, P148; Dahlstedt AJ, 2000, FASEB J, V14, P982, DOI 10.1096/fasebj.14.7.982; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Maier LS, 2000, J MOL CELL CARDIOL, V32, P2249, DOI 10.1006/jmcc.2000.1252; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; Meneton P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/pnas.051619598; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; Minajeva A, 1997, AM J PHYSIOL-HEART C, V273, pH2498, DOI 10.1152/ajpheart.1997.273.5.H2498; MONTEROLOMELI M, 1992, J BIOL CHEM, V267, P1829; NEGRETTI N, 1995, J PHYSIOL-LONDON, V486, P581, DOI 10.1113/jphysiol.1995.sp020836; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Saupe KW, 1998, CIRC RES, V82, P898; Saupe KW, 2000, J BIOL CHEM, V275, P19742, DOI 10.1074/jbc.M001932200; Snyder SM, 2000, BIOPHYS J, V79, P94, DOI 10.1016/S0006-3495(00)76276-X; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; STEELE DS, 1995, J PHYSIOL-LONDON, V483, P155, DOI 10.1113/jphysiol.1995.sp020575; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vendelin M, 2000, AM J PHYSIOL-CELL PH, V278, pC747, DOI 10.1152/ajpcell.2000.278.4.C747; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Xu L, 1996, CIRC RES, V79, P1100, DOI 10.1161/01.RES.79.6.1100	32	45	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0653	10.1096/fj.01-0652com	http://dx.doi.org/10.1096/fj.01-0652com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978729				2022-12-25	WOS:000175973900019
J	Todd, JL; Rigas, JD; Rafty, LA; Denu, JM				Todd, JL; Rigas, JD; Rafty, LA; Denu, JM			Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK)	ONCOGENE			English	Article						JNK; stress kinase; VHR; protein tyrosine phosphatase	MAP KINASE; INDUCED APOPTOSIS; CELL APOPTOSIS; IN-VIVO; ACTIVATION; PATHWAYS; HSP72; SUPPRESSION; MECHANISMS; SUBSTRATE	The JNK group (for c-Jun N-terminal kinase) of mitogen-activated protein kinases (MAP kinases) is activated in cells in response to environmental stress and cytokines. Activation of JNK is the result of dual phosphorylation by specific upstream kinases which phosphorylate the TxY motif. Much less is known concerning the down-regulation by protein phosphatases. Here, we demonstrate that the tyrosine-specific and constitutively-expressed phosphatase VHR (for VH1-Related) down-regulates the JNK signaling pathway at the level of JNK dephosphorylation. VHR was shown to efficiently dephosphorylate JNK and to form a tight complex with activated JNK when the catalytically-inactive C124S VHR mutant was employed as an in vivo substrate trap. Utilizing an in vitro assay, the transcription factor c-Jun specifically inhibited the ability of VHR to dephosphorylate JNK, likely by sterically blocking access to the phosphorylation sites when JNK and c-Jun form a complex. c-Jun has no effect on the ability of VHR to inactivate the ERK MAP kinases or to hydrolyze artificial substrates. The c-Jun inhibition results are discussed in terms of the resistant-nature of JNK dephosphorylation in cellular extracts and in terms of a general model in which VHR may be a general MAP kinase phosphatase whose specificity and activity are dictated by the presence of MAP kinase-associated proteins that inhibit dephosphorylation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785, R37GM059785] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59785] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Patel R, 1998, J CELL SCI, V111, P2247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223	36	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2573	2583		10.1038/sj.onc.1205344	http://dx.doi.org/10.1038/sj.onc.1205344			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971192				2022-12-25	WOS:000174918400014
J	Huang, JH; Hamasaki, H; Nakamoto, T; Honda, H; Hirai, H; Saito, M; Takato, T; Sakai, R				Huang, JH; Hamasaki, H; Nakamoto, T; Honda, H; Hirai, H; Saito, M; Takato, T; Sakai, R			Differential regulation of cell migration, actin stress fiber organization, and cell transformation by functional domains of Crk-associated substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASES; PHOSPHATASE PTP-PEST; SRC FAMILY KINASES; PROCESSIVE PHOSPHORYLATION; ADAPTER PROTEIN; DIRECT BINDING; P130(CAS); INTEGRIN; COMPLEX	The Crk-associated substrate Was) is a unique docking protein that possesses a repetitive stretch of tyrosine-containing motifs and an Src homology 3 (SH3) domain. Embryonic fibroblasts lacking Cas demonstrated resistance to Src-induced transformation along with impaired actin bundling and cell motility, indicating critical roles of Cas in actin cytoskeleton organization, cell migration, and oncogenesis. To gain further insight into roles of each domain of Cas in these processes, a compensation assay was performed by expressing a series of Cas mutants in Cas-deficient fibroblasts. The results showed that motifs containing YDxP were indispensable for actin cytoskeleton. organization and cell migration, suggesting that CrkII-mediated signaling regulates these biological processes. The C-terminal Src-binding domain played essential roles in cell migration and membrane localization of Cas, although it was dispensable in the organization of actin stress fibers. Furthermore, the Src-binding domain was also a prerequisite for Src transformation possibly, because of its crucial role in the phosphorylation of Cas during transformation. Overall, differential uses of the Cas domains in individual biological processes were demonstrated.	Natl Canc Ctr, Inst Res, Canc Signal Transduct Project, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Oral & Maxillofacial Surg, Bunkyo Ku, Tokyo 1138655, Japan; Meiji Pharmaceut Univ, Dept Oncol & Pharmacodynam, Tokyo 2048588, Japan	National Cancer Center - Japan; University of Tokyo; University of Tokyo; Meiji Pharmaceutical University	Sakai, R (corresponding author), Natl Canc Ctr, Inst Res, Canc Signal Transduct Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1999, MOL CARCINOGEN, V26, P20, DOI 10.1002/(SICI)1098-2744(199909)26:1<20::AID-MC3>3.0.CO;2-M; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	61	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27265	27272		10.1074/jbc.M203063200	http://dx.doi.org/10.1074/jbc.M203063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011056	hybrid			2022-12-25	WOS:000177055900073
J	Li, JG; Chen, CG; Liu-Chen, LY				Li, JG; Chen, CG; Liu-Chen, LY			Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR MECHANISMS; OPIATE RECEPTOR; TERMINAL TAIL; BETA-ARRESTIN; PDZ PROTEINS; AGONIST; IDENTIFICATION	We have investigated whether Ezrin-radixin-moesin (ERM)-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF), a PDZ domain-containing phosphoprotein, is associated with the human kappa opioid receptor (hkor) and whether it regulates the trafficking and signaling of the hkor. When expressed in CHO cells stably transfected with the FLAG-tagged hkor (FLAG-hkor), EBP50/NHERF co-immunoprecipitated with FLAG-hkor, and the PDZ domain 1, but not the PDZ domain 11, of EBP50/NHERF was involved in the interaction. Treatment with the agonist (-)-(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclohexyl]benzeneacetamide (U50,488H) enhanced the association of EBP50/NHERF with FLAG-hkor. Expression of EBP50/NHERF, but not. a truncated form lacking the ERM-binding domain, abolished U50,488H-induced down-regulation of FLAG-hkor, which was apparently due to an increase in the recycling rate of internalized receptors. However, expression of EBP50/NHERF did not affect U50,488H binding affinity and U50,488H-stimulated [S-35]guanosine 5'-3-O-(thio)triphosphate binding and p42/p44 MAP kinase activation, nor did it affect U50,488H-induced desensitization and internalization of FLAG-hkor. To determine the motif of FLAG-hkor involved in EBP50/NHERF binding, we generated two mutants, FLAG-hkor-A and FLAG-hkor-EE, in which one Ala or two Glu residues were added to the C terminus, respectively. Neither FLAG-hkor-A nor FLAG-hkor-EE co-immunoprecipitated with EBP50/NHERF, and U50,488H-induced down-regulation of FLAG-hkor-A and FLAG-hkor-EE were not affected by expression of EBP50/NHERF. Thus, EBP50/NHERF binds to the C terminus of FLAG-hkor and blocks the down-regulation of FLAG-hkor. The C-terminal sequence of the hkor, NKPV, is distinctly different from the sequence D(S/T)XL, the optimal C-terminal motif in the beta(2)-adrenergic receptor for EBP50/NHERF binding. EBP50/NHERF may have a broader binding specificity and may interact with a subset of G protein-coupled receptors to serve as a recycling signal for these receptors.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Substance Abuse Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@astro.temple.edu						Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Bretscher A, 1997, J CELL SCI, V110, P3011; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hatzoglou A, 1996, J CELL BIOCHEM, V63, P410; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAW PY, 1984, J BIOL CHEM, V259, P4096; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu W, 2000, BIOCHEMISTRY-US, V39, P13904, DOI 10.1021/bi001099p; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	46	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27545	27552		10.1074/jbc.M200058200	http://dx.doi.org/10.1074/jbc.M200058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004055	hybrid			2022-12-25	WOS:000177055900105
J	Fritz, G; Buchert, T; Kroneck, PMH				Fritz, G; Buchert, T; Kroneck, PMH			The function of the [4Fe-4S] clusters and FAD in bacterial and archaeal adenylylsulfate reductases - Evidence for flavin-catalyzed reduction of adenosine 5 '-phosphosulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; DESULFOVIBRIO-VULGARIS; SULFATE REDUCTASE; PROTEIN; FLAVOPROTEINS; FERREDOXIN; METABOLISM; ENZYME	The iron-sulfur flavoenzyme adenylylsulfate (adenosine 5'-phosphosulfate, APS) reductase catalyzes reversibly the 2-electron reduction of APS to sulfite and AMP, a key step in the biological sulfur cycle. APS reductase from one archaea and three different bacteria has been purified, and the molecular and catalytic properties have been characterized. The EPR parameters and redox potentials (-60 and -520 mV versus NHE) have been assigned to the two [4Fe-4S] clusters I and II observed in the three-dimensional structure of the enzyme from Archaeoglobus fulgidus (Fritz, G., Roth, A., Schiffer, A., Buchert, T., Bourenkov, G., Bartunik, H. D., Huber, H., Stetter, K. O., Kroneck, P. M. H., and Ermler, U. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 1836-1841). Sulfite binds to FAD to form a covalent FAD N(5)-sulfite adduct with characteristic UV/visible spectra, in accordance with the three-dimensional structure of crystalline enzyme soaked with APS. UV/visible monitored titrations reveal that the substrates AMP and APS dock closely to the FAD cofactor. These results clearly document that FAD is the site of the 2-electron reduction of APS to sulfite and AMP. Reaction of APS reductase enzyme with sulfite and AMP leads to partial reduction of the [4Fe-4S] centers and formation of the anionic FAD semiquinone. Thus, both [4Fe-4S] clusters function in electron transfer and guide two single electrons from the protein surface to the FAD catalytic site.	Univ Zurich, Inst Biochem, CH-8051 Zurich, Switzerland; Univ Konstanz, Math Naturwissensch Sekt, Fachbereich Biol, D-78457 Constance, Germany	University of Zurich; University of Konstanz	Fritz, G (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8051 Zurich, Switzerland.		Fritz, Guenter/E-2933-2013	Fritz, Guenter/0000-0002-4571-8812				ADACHI K, 1977, CAN J BIOCHEM CELL B, V55, P91, DOI 10.1139/o77-015; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1978, Methods Enzymol, V54, P111; Chen KS, 1999, J BIOL CHEM, V274, P36479, DOI 10.1074/jbc.274.51.36479; COOPER BP, 1979, Z NATURFORSCH C, V34, P346; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, DOI 10.1016/C2013-0-04130-8; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; Dutton P L, 1978, Methods Enzymol, V54, P411; Fritz G, 2000, FEBS LETT, V473, P63, DOI 10.1016/S0014-5793(00)01500-3; Fritz G, 2002, P NATL ACAD SCI USA, V99, P1836, DOI 10.1073/pnas.042664399; HANSEN TA, 1994, ANTON LEEUW INT J G, V66, P165, DOI 10.1007/BF00871638; HONG JS, 1970, J BIOL CHEM, V245, P4982; Kopriva S, 2001, J BIOL CHEM, V276, P42881, DOI 10.1074/jbc.M107424200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMPREIA J, 1994, METHOD ENZYMOL, V243, P241; LAMPREIA J, 1990, EUR J BIOCHEM, V188, P653, DOI 10.1111/j.1432-1033.1990.tb15447.x; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; MICHAELS GB, 1970, BIOCHEM BIOPH RES CO, V39, P321, DOI 10.1016/0006-291X(70)90579-6; More C, 1996, J BIOL INORG CHEM, V1, P152, DOI 10.1007/s007750050034; MULLER F, 1969, J BIOL CHEM, V244, P4007; MULLER F, 1981, EUR J BIOCHEM, V116, P17, DOI 10.1111/j.1432-1033.1981.tb05295.x; Neese F, 1996, J AM CHEM SOC, V118, P8692, DOI 10.1021/ja960125x; NEESE F, 1995, QUANTUM CHEM PROGRAM; NOODLEMAN L, 1992, ADV INORG CHEM, V38, P423, DOI 10.1016/S0898-8838(08)60070-7; PECK HD, 1965, BIOCHIM BIOPHYS ACTA, V96, P429, DOI 10.1016/0005-2787(65)90561-7; SPEICH N, 1994, MICROBIOL-UK, V140, P1273, DOI 10.1099/00221287-140-6-1273; Suter M, 2000, J BIOL CHEM, V275, P930, DOI 10.1074/jbc.275.2.930; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; TRUPER HG, 1982, PHILOS T ROY SOC B, V298, P529, DOI 10.1098/rstb.1982.0095; VERHAGEN MFJM, 1994, EUR J BIOCHEM, V221, P831, DOI 10.1111/j.1432-1033.1994.tb18797.x; [No title captured]	36	38	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26066	26073		10.1074/jbc.M203397200	http://dx.doi.org/10.1074/jbc.M203397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006599	hybrid			2022-12-25	WOS:000176908700032
J	Addona, GH; Husain, SS; Stehle, T; Miller, KW				Addona, GH; Husain, SS; Stehle, T; Miller, KW			Geometric isomers of a photoactivable general anesthetic delineate a binding site on adenylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTHANE; IDENTIFICATION; RESOLUTION; MECHANISM; XENON; PROTEINS; CAVITY	General anesthetics are a class of drugs whose mode of action is poorly understood. Here, two photoactivable general anesthetics, n-octan-1-ol geometric isomers bearing a diazirine group on either the third or seventh carbon (3- and 7-azioctanol, respectively), were used to locate and delineate an anesthetic site on adenylate kinase. Each photoincorporated at a mole ratio of 1:1 as determined by mass spectrometry. The photolabeled kinase was subjected to tryptic digest, and the fragments were separated by chromatography and sequenced by mass spectrometry. 3-Azioctanol photolabeled His-36, whereas its isomer, 7-azioctanol, photolabeled Asp-41. Inspection of the known structure of adenylate kinase shows that the side chains of these residues are within similar to5 Angstrom of each other. This distance matches the separation of the 3- and 7-positions of an extended aliphatic chain. The alkanol site so-defined spans two domains of adenylate kinase. His-36 is part of the CORE domain, and Asp-41 belongs to the nucleotide monophosphate binding domain. Upon ligand binding the nucleotide monophosphate binding domain rotates relative to the CORE domain, causing a conformational change that might be expected to affect alkanol binding. Indeed, the substrate-mimicking inhibitor adenosine-(5')-pentaphospho-(5')-adenosine (Ap5A) reduced the photoincorporation of 3- [H-3]azioctanol by 75%.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Lab Dev Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Miller, KW (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA.	k_miller@helix.mgh.harvard.edu			NIGMS NIH HHS [GM 58448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Addona GH, 2001, BIOPHYS J, V80, p314A; BAYLEY H, 1983, PHOTOGENERATED REAGE, P43; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BYEON IJL, 1993, BIOCHEMISTRY-US, V32, P12508, DOI 10.1021/bi00097a031; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chiara DC, 2000, BIOPHYS J, V78, p360A; CHURCH RFR, 1970, J ORG CHEM, V35, P2465, DOI 10.1021/jo00833a001; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; Dwyer DS, 2000, CELL MOL LIFE SCI, V57, P265, DOI 10.1007/PL00000689; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 2001, BIOPHYS J, V80, p335A; Eckenhoff RG, 2000, J BIOL CHEM, V275, P30439, DOI 10.1074/jbc.M005052200; Ferranti P, 1997, FEBS LETT, V400, P19, DOI 10.1016/S0014-5793(96)01258-6; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; GURSKY O, 1994, P NATL ACAD SCI USA, V91, P12388, DOI 10.1073/pnas.91.26.12388; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Kipp H, 1997, ANAL BIOCHEM, V245, P61, DOI 10.1006/abio.1996.9909; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; MARJANEN LA, 1982, CLIN CHIM ACTA, V122, P225, DOI 10.1016/0009-8981(82)90281-9; Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8564, DOI 10.1021/bi00027a006; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otting G, 1997, NAT STRUCT BIOL, V4, P396, DOI 10.1038/nsb0597-396; Prange T, 1998, PROTEINS, V30, P61, DOI 10.1002/(SICI)1097-0134(19980101)30:1<61::AID-PROT6>3.0.CO;2-N; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHNIEPP LE, 1946, J AM CHEM SOC, V68, P1646, DOI 10.1021/ja01212a085; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; TIAN G, 1988, BIOCHEMISTRY-US, V27, P5544, DOI 10.1021/bi00415a024; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	38	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25685	25691		10.1074/jbc.M201303200	http://dx.doi.org/10.1074/jbc.M201303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976328	hybrid			2022-12-25	WOS:000176747000108
J	Obst, M; Oppermann-Sanio, FB; Luftmann, H; Steinbuchel, A				Obst, M; Oppermann-Sanio, FB; Luftmann, H; Steinbuchel, A			Isolation of cyanophycin-degrading bacteria, cloning and characterization of an extracellular cyanophycinase gene (cphE) from Pseudomonas anguilliseptica strain BI - The cphE gene from P-anguilliseptica BI encodes a cyanophycin-hydrolyzing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC ACID CYANOPHYCIN; BACILLUS-SUBTILIS; ANABAENA-CYLINDRICA; RESERVE MATERIAL; MOLECULAR CHARACTERIZATION; DELETION MUTATION; ESCHERICHIA-COLI; NEUTRAL PROTEASE; CYANOBACTERIA; PURIFICATION	Eleven bacteria capable of utilizing cyanophycin (cyanophycin granule polypeptide (CGP)) as a carbon source for growth were isolated. One isolate was taxonomically affiliated as Pseudomonas anguilliseptica strain BI, and the extracellular cyanophycinase (CphE) was studied because utilization of cyanophycin as a carbon source and extracellular cyanophycinases were hitherto not described. CphE was detected in supernatants of CGP cultures and purified from a corresponding culture of strain BI employing chromatography on the anion exchange matrix Q-Sepharose and on an arginine-agarose affinity matrix. The mature form of the inducible enzyme consisted of one type of subunit with M-r = 43,000 and exhibited high specificity for CGP, whereas proteins and synthetic polyaspartic acid were not hydrolyzed or were only marginally hydrolyzed. Degradation products of the enzyme reaction were identified as aspartic acid-arginine dipeptides (beta-Asp-Arg) by high performance liquid chromatography and electrospray ionization mass spectrometry. The corresponding gene (cphE, 1254 base pairs) was identified in subclones of a cosmid gene library of strain BI by heterologous active expression in Escherichia coli, and its nucleotide sequence was determined. The enzyme exhibited only 27-28% amino acid sequence identity to intracellular cyanophycinases occurring in cyanobacteria. Analysis of the amino acid sequence of cphE revealed a putative catalytic triad consisting of the motif GXSXG plus a histidine and most probably a glutamate residue. In addition, the strong inhibition of the enzyme by Pefabloc(R) and phenylmethylsulfonyl fluoride indicated that the catalytic mechanism of CphE is related to that of serine type proteases. Quantitative analysis on the release of beta-Asp-Arg dipeptides from C-terminal labeled CGP gave evidence for an exo-degradation mechanism.	Univ Munster, Inst Mikrobiol, D-48149 Munster, Germany; Univ Munster, Inst Organ Chem, D-48149 Munster, Germany	University of Munster; University of Munster	Steinbuchel, A (corresponding author), Univ Munster, Inst Mikrobiol, Corrensstr 3, D-48149 Munster, Germany.	steinbu@uni-muenster.de						Aboulmagd E, 2000, ARCH MICROBIOL, V174, P297, DOI 10.1007/s002030000206; Alford Diana D., 1994, Journal of Environmental Polymer Degradation, V2, P225, DOI 10.1007/BF02071970; ALLEN MM, 1980, J BACTERIOL, V141, P959, DOI 10.1128/JB.141.2.959-962.1980; Berg H, 2000, EUR J BIOCHEM, V267, P5561, DOI 10.1046/j.1432-1327.2000.01622.x; BIRRER GA, 1994, INT J BIOL MACROMOL, V16, P265, DOI 10.1016/0141-8130(94)90032-9; Bovarnick M, 1942, J BIOL CHEM, V145, P415; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER TH, 1984, J BACTERIOL, V159, P453, DOI 10.1128/JB.159.2.453-459.1984; CLAUS D, 1964, J GEN MICROBIOL, V36, P107, DOI 10.1099/00221287-36-1-107; Cole R., 1997, ELECTROSPRAY IONIZAT; FREY KM, 2002, APPL ENVIRON MICROB, DOI DOI 10.1128/AE7.68.7.000-000.2002; Hai T, 2000, APPL MICROBIOL BIOT, V53, P383, DOI 10.1007/s002530051630; HANBY WE, 1946, BIOCHEM J, V40, P297, DOI 10.1042/bj0400297; HARA T, 1982, AGR BIOL CHEM TOKYO, V46, P2275, DOI 10.1080/00021369.1982.10865430; HE M, 1990, NUCLEIC ACIDS RES, V18, P1660, DOI 10.1093/nar/18.6.1660; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; JAY FT, 1976, NUCLEIC ACIDS RES, V3, P177, DOI 10.1093/nar/3.1.177; Krehenbrink M, 2002, ARCH MICROBIOL, V177, P371, DOI 10.1007/s00203-001-0396-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATCHINIANSADEK L, 1993, J BIOL CHEM, V268, P534; Liotenberg S, 1996, MICROBIOL-SGM, V142, P611, DOI 10.1099/13500872-142-3-611; MACKERRAS AH, 1990, J GEN MICROBIOL, V136, P2057, DOI 10.1099/00221287-136-10-2057; MILLER CG, 1998, HDB PROTEOLYTIC ENZY, P1557; Oppermann FB, 1998, POLYM DEGRAD STABIL, V59, P337, DOI 10.1016/S0141-3910(97)00175-4; Oppermann-Sanio FB, 2002, NATURWISSENSCHAFTEN, V89, P11, DOI 10.1007/s00114-001-0280-0; Rainey FA, 1996, INT J SYST BACTERIOL, V46, P1088, DOI 10.1099/00207713-46-4-1088; RAO RN, 1987, METHOD ENZYMOL, V153, P166; Richter R, 1999, EUR J BIOCHEM, V263, P163, DOI 10.1046/j.1432-1327.1999.00479.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RUFO GA, 1990, J BACTERIOL, V172, P1019, DOI 10.1128/jb.172.2.1019-1023.1990; Salamone PR, 1997, APPL MICROBIOL BIOT, V48, P317, DOI 10.1007/s002530051056; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Simon R.D., 1987, CYANOBACTERIA, P199; SIMON RD, 1971, P NATL ACAD SCI USA, V68, P265, DOI 10.1073/pnas.68.2.265; SIMON RD, 1976, BIOCHIM BIOPHYS ACTA, V420, P165, DOI 10.1016/0005-2795(76)90355-X; SIMON RD, 1980, BIOCHIM BIOPHYS ACTA, V626, P277, DOI 10.1016/0005-2795(80)90121-X; SLOMA A, 1988, J BACTERIOL, V170, P5557, DOI 10.1128/jb.170.12.5557-5563.1988; SLOMA A, 1990, J BACTERIOL, V172, P1470, DOI 10.1128/jb.172.3.1470-1477.1990; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TANGUYROUGEAU C, 1988, FEBS LETT, V234, P464, DOI 10.1016/0014-5793(88)80139-X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRAN L, 1991, J BACTERIOL, V173, P6364, DOI 10.1128/jb.173.20.6364-6372.1991; WEBER K, 1969, J BIOL CHEM, V244, P4406; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984; Ziegler K, 1998, EUR J BIOCHEM, V254, P154, DOI 10.1046/j.1432-1327.1998.2540154.x	51	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25096	25105		10.1074/jbc.M112267200	http://dx.doi.org/10.1074/jbc.M112267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986309	hybrid			2022-12-25	WOS:000176747000035
J	Robles, LD; Frost, AR; Davila, M; Hutson, AD; Grizzle, WE; Chakrabarti, R				Robles, LD; Frost, AR; Davila, M; Hutson, AD; Grizzle, WE; Chakrabarti, R			Down-regulation of Cdc6, a cell cycle regulatory gene, in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; MAMMALIAN CDC6; MCM PROTEINS; S-PHASE; INITIATION; PHOSPHORYLATION; EXPRESSION; CHROMATIN; ESTABLISHMENT	CDC6 plays a critical role in regulation of the onset of DNA replication in eukaryotic cells. We have found that Cdc6 expression is down-regulated in prostate cancer as detected by semiquantitative reverse transcriptase-PCR of prostate cell lines and laser-captured microdissected prostate tissues. This result was substantiated by immunohistochemical analysis of paraffin-embedded tissue sections and immunoblot analysis of benign (BPH-1) and adenocarcinomatous prostatic cells. Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was noted in the metastatic PC3 cells compared with that in BPH-1 cells. Concentration of the E2F and Oct1 transcription factors that have putative binding sites in the Cdc6 promoter was substantially low in PC3 cells compared with BPH cells. Mutagenesis of the two E2F binding sites on the Cdc6 promoter resulted in increased promoter activity in PC3 cells owing to elimination of the negative regulation by pRb-E2F complex but not to the level of that obtained in BPH cells. We conclude that an altered interaction of transcription factors may be responsible for the down-regulation of Cdc6 transcription in PC3 cells. Our study suggests a potential use of the lack of CDC6 expression as an index of prostate cancer development.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Florida, Dept Stat, Gainesville, FL 32610 USA	State University System of Florida; University of Central Florida; University of Alabama System; University of Alabama Birmingham; State University System of Florida; University of Florida	Chakrabarti, R (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.	rchak@pegasus.cc.ucf.edu	Davila, Monica/I-4170-2018	Davila, Monica/0000-0002-4638-9766	NCI NIH HHS [CA81329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA081329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltomaa S, 1999, PROSTATE, V38, P175; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRUSCHI CV, 1995, MOL GEN GENET, V249, P8, DOI 10.1007/BF00290230; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Cheville JC, 1998, MODERN PATHOL, V11, P324; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Herbig U, 2000, MOL BIOL CELL, V11, P4117, DOI 10.1091/mbc.11.12.4117; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lei M, 2001, J CELL SCI, V114, P1447; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nagabhushan M, 1996, CANCER RES, V56, P3042; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; Nguyen TT, 2000, PROSTATE, V43, P233; Ohta S, 2001, ONCOL REP, V8, P1063; Pepe MS, 1997, BIOMETRIKA, V84, P595, DOI 10.1093/biomet/84.3.595; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Stricker HJ, 1996, UROLOGY, V47, P366, DOI 10.1016/S0090-4295(99)80454-3; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	45	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25431	25438		10.1074/jbc.M201199200	http://dx.doi.org/10.1074/jbc.M201199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006585	Green Published, hybrid			2022-12-25	WOS:000176747000077
J	Bolster, DR; Crozier, SJ; Kimball, SR; Jefferson, LS				Bolster, DR; Crozier, SJ; Kimball, SR; Jefferson, LS			AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; INITIATION; EXERCISE; TRANSLATION; MECHANISM; INSULIN; GLUT-4	AMP-activated protein kinase (AMPK) is viewed as an energy sensor that acts to modulate glucose uptake and fatty acid oxidation in skeletal muscle. Given that protein synthesis is a high energy-consuming process, it may be transiently depressed during cellular energy stress. Thus, the intent of this investigation was to examine whether AMPK activation modulates the translational control of protein synthesis in skeletal muscle. Injections of 5-aminoimidazole-4-carboxamide 1-beta-D-ribonucleoside (AICAR) were used to activate AMPK in male rats. The activity of a, AMPK remained unchanged in gastrocnemius muscle from AICAR-treated animals compared with controls, whereas alpha(2) AMPK activity was significantly increased (51%). AICAR treatment resulted in a reduction in protein synthesis to 45%,, of the control value. This depression was associated with decreased activation of protein kinases in the mammalian target of rapamycin (mTOR) signal transduction pathway as evidenced by reduced phosphorylation. of protein kinase B on Ser(473), mTOR on Ser(2448), ribosomal protein S6 kinase on Thr(389), and eukaryotic initiation factor eIF4E-binding protein on Thr(37). A reduction in eIF4E associated with eIF4G to 10% of the control value was also noted. In contrast, eIF2B activity remained unchanged in response to AICAR treatment and therefore would not appear to contribute to the depression in protein synthesis. This is the first investigation to demonstrate changes in translation initiation and skeletal muscle protein synthesis in response to AMPK activation.	Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Jefferson, LS (corresponding author), Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, H166,500 Univ Dr, Hershey, PA 17033 USA.	jjefferson@psu.edu			NIDDK NIH HHS [DK15658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; CHEREL Y, 1991, CLIN SCI, V81, P611, DOI 10.1042/cs0810611; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DOHM GL, 1980, BIOCHEM J, V188, P255, DOI 10.1042/bj1880255; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2000, METH MOL B, V99, P63; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; KIMBALL SR, 1988, BIOCHEM BIOPH RES CO, V156, P706, DOI 10.1016/S0006-291X(88)80900-8; KIMBALL SR, 1992, BIOCHEM J, V286, P263, DOI 10.1042/bj2860263; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; KIMBALL SR, 1994, BIOCHIMIE, V76, P729, DOI 10.1016/0300-9084(94)90077-9; MERRIL G, 1997, AM J PHYSIOL, V2732, pE1107; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Musi N, 2001, AM J PHYSIOL-ENDOC M, V280, pE677, DOI 10.1152/ajpendo.2001.280.5.E677; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; RENNIE MJ, 1981, CLIN SCI, V61, P627, DOI 10.1042/cs0610627; Sekulic A, 2000, CANCER RES, V60, P3504; Tisdale MJ, 2000, NUTRITION, V16, P1013, DOI 10.1016/S0899-9007(00)00409-3; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; WOLFE RR, 1982, J APPL PHYSIOL, V52, P458, DOI 10.1152/jappl.1982.52.2.458; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	31	647	664	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					23977	23980		10.1074/jbc.C200171200	http://dx.doi.org/10.1074/jbc.C200171200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11997383	hybrid			2022-12-25	WOS:000176611800002
J	Chen, BC; Wu, WT; Ho, FM; Lin, WW				Chen, BC; Wu, WT; Ho, FM; Lin, WW			Inhibition of interleukin-1 beta-induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PROMOTES CELL-SURVIVAL; SIGNALING PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; PERITONEAL-MACROPHAGES; LIPOPOLYSACCHARIDE; IRAK; IL-1	Calcium/calmodulin-dependent protein kinase kinase (CaMKK) and Akt are two multifunctional kinases involved in many cellular responses. Although Akt and Ca2+ signals have been implicated in NF-kappaB activation in response to certain stimuli, these results are still controversial, and the mechanism(s) involved remains unknown. In this study, we show the roles that CaMKK and Akt play in regulating interleukin-1beta (IL-1beta)-induced NF-kappaB signaling. In human embryonic kidney 293 cells, IL-1beta induces IkappaB kinase beta (IKKbeta) activation, IkappaBalpha degradation, NF-kappaB transactivation, and weak Akt activation. A CaMKK inhibitor (KN-93) and phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002) do not inhibit IL-1beta-induced NF-kappaB activation. However, IL-1beta-induced NF-kappaB activity is attenuated by increased intracellular calcium in response to ionomycin, UTP, or thapsigargin or by overexpression of CaMKKc and/or Akt. Ionomycin and CaMKKc overexpression increases Akt phosphorylation on Thr(308) and enzyme activity. Under these conditions or upon overexpression of wild type Akt, IL-1beta-induced IKKbeta activity is diminished. Furthermore, a dominant negative mutant of Akt abolishes IKKbeta inhibition by CaMKKc and ionomycin, suggesting that Akt acts as a mediator of CaMKK signaling to inhibit IL-1beta-induced IKK activity at an upstream target site. We have also identified a novel interaction between CaMKK-stimulated Akt and interleukin-1 receptor-associated kinase 1 (IRAK1), which plays a key role in IL-1beta-induced NF-kappaB activation. CaMKKc and Akt overexpression decreases IRAK1-mediated NF-kappaB activity and its association with MyD88 in response to IL-1beta stimulation. Furthermore, CaMKKc and Akt overexpression increases IRAK1 phosphorylation at Thr(100), and point mutation of this site abrogates the inhibitory effect of Akt on IRAK1-mediated NF-kappaB activation. Taken together, these results indicate a novel regulatory mechanism for IL-1beta signaling and suggest that CaMKK-dependent Akt activation inhibits IL-1beta-induced NF-kappaB activation through interference with the coupling of IRAK1 to MyD88.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan; Tao Yuan Gen Hosp, Dept Hlth Execut Yuan, Taoyan 330, Taiwan	National Taiwan University	Lin, WW (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan.			Lin, Wan Wan/0000-0002-3207-734X				Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Chen BC, 1999, J BIOMED SCI, V6, P425, DOI 10.1159/000025418; Chen BC, 2001, J LEUKOCYTE BIOL, V69, P280; Chen BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/jbc.273.45.29754; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li XX, 1999, MOL CELL BIOL, V19, P4643; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Ozes ON, 1999, NATURE, V401, P82; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Park YC, 1997, BIOCHEM BIOPH RES CO, V240, P692, DOI 10.1006/bbrc.1997.7722; Rauch BH, 2000, FEBS LETT, V481, P3, DOI 10.1016/S0014-5793(00)01957-8; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	63	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24169	24179		10.1074/jbc.M106014200	http://dx.doi.org/10.1074/jbc.M106014200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976320	hybrid			2022-12-25	WOS:000176611800027
J	Iwaki, D; Mitsuzawa, H; Murakami, S; Sano, H; Konishi, M; Akino, T; Kuroki, Y				Iwaki, D; Mitsuzawa, H; Murakami, S; Sano, H; Konishi, M; Akino, T; Kuroki, Y			The extracellular toll-like receptor 2 domain directly binds peptidoglycan derived from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTTING EDGE; CELL ACTIVATION; LIPOPOLYSACCHARIDE; RECOGNITION; PROTEINS; TLR4; LIPOPROTEINS; MICE; CD14; EXPRESSION	Toll-like receptor 2 (TLR2) has been recognized to mediate cell signaling in response to peptidoglycan (PGN), a major cell wall component of Gram-positive bacteria. The mechanism by which TLR2 recognizes PGN is unknown. It is not even clear whether TLR2 directly binds to PGN. In this study, we generated a soluble form of recombinant TLR2 (sTLR2) possessing only its putative extracellular domain by using the baculovirus expression system to examine the direct interaction between sTLR2 and PGN. sTLR2 bound avidly to insoluble PGN (iPGN) from Staphylococcus aureus coated onto microtiter wells in a concentration-dependent manner. In contrast, sTLR2 exhibited a very weak binding to lipopolysaccharide. iPGN cosedimented sTLR2 after the mixture of iPGN and sTLR2 had been incubated and centrifuged. sTLR2 partially attenuated the iPGN-induced NF-kappaB activation in TLR2-transfected HEK 293 cells and the iPGN-induced IL-8 secretion in U937 cells. One of anti-human TLR2 monoclonal antibodies, which blocked iPGN-induced NF-kappaB activation in TLR2-transfected cells, inhibited the binding of sTLR2 to iPGN. In addition, we found that sCD14 interacted with sTLR2 and increased the binding of sTLR2 to iPGN. From these results, we conclude that the extracellular TLR2 domain directly binds to PGN.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Iwami K, 2000, J IMMUNOL, V165, P6682, DOI 10.4049/jimmunol.165.12.6682; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P139; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Stelter F, 1996, EUR J BIOCHEM, V236, P457, DOI 10.1111/j.1432-1033.1996.00457.x; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Yoshimura A, 1999, J IMMUNOL, V163, P1	39	140	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24315	24320		10.1074/jbc.M107057200	http://dx.doi.org/10.1074/jbc.M107057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986301	hybrid			2022-12-25	WOS:000176611800046
J	Jairajpuri, MA; Lu, AQ; Bock, SC				Jairajpuri, MA; Lu, AQ; Bock, SC			Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING SITE; REACTIVE CENTER LOOP; CONFORMATIONAL CHANGE; BETA-ANTITHROMBIN; ALPHA-THROMBIN; MECHANISM; AFFINITY; GLYCOSYLATION; ACCELERATION; CONVERSION	The mechanism for heparin activation of antithrombin III has been postulated to involve disruption of interactions between its reactive loop P1 residue and Glu(255) on the underlying protein surface. To test this hypothesis, the potential PI-constraining Arg(393)-Glu(255) hydrogen bond and ionic interactions were eliminated by converting Glu(255) to alanine. E255A and wild-type ATIIIs have identical reactive loop sequences (including ;the P1 and P14 residues), but differ in that Glu(255) -mediated, P1-constraining interactions with the underlying surface cannot form in the mutant. Relative to its wildtype parent, E255A had a 5-fold higher affinity for heparin and pentasaccharide. In the absence of cofactor, E255A exhibited a 5-fold activation of thrombin inhibition but no activation of factor Xa inhibition. Pentasaccharide addition elicited no further activation of thrombin inhibition but increased the factor Xa inhibition rate 100-fold. E255A heparin-dependent thrombin and factor Xa inhibition rates were 1000- and 2-fold faster, respectively, than pentasaccharide-catalyzed rates. Although "approximation" is the predominant factor in heparin activation of ATIII thrombin inhibition, and removal of the P1 constraint plays a distinct but minor role, the primary determinant for activation of factor Xa inhibition is the pentasaccharide-induced conformational change, with approximation making a further minor contribution, and removal of the P1 constraint playing no role at all.	Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bock, SC (corresponding author), Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Jairajpuri, Mohamad/AAS-2556-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030712] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL30712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHUANG Y, 2001, J BIOL CHEM, V40, P6670; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705; JACQUES LB, 1977, METHOD BIOCHEM ANAL, V24, P203; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; PICARD V, 1996, METHODS MOL BIOL PCR, P183; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492	26	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24460	24465		10.1074/jbc.M203127200	http://dx.doi.org/10.1074/jbc.M203127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11971909	hybrid			2022-12-25	WOS:000176611800065
J	Lishko, PV; Martemyanov, KA; Hopp, JA; Arshavsky, VY				Lishko, PV; Martemyanov, KA; Hopp, JA; Arshavsky, VY			Specific binding of RGS9-G beta 5L to protein anchor in photoreceptor membranes greatly enhances its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACCELERATING PROTEIN; ROD OUTER SEGMENTS; VERTEBRATE PHOTORECEPTORS; RGS; TRANSDUCIN; PHOTOTRANSDUCTION; PHOSPHODIESTERASE; PURIFICATION; ACTIVATION; ADAPTATION	The complex between the short splice variant of the ninth member of the RGS protein family and the long splice variant of type 5 G protein beta subunit (RGS9-Gbeta5L) plays a critical role in regulating the duration of the light response in vertebrate photoreceptors by activating the GTPase activity of the photoreceptor-specific G protein, transducin. RGS9-Gbeta5L is tightly associated with the membranes of photoreceptor outer segments; however, the nature of this association remains unknown. Here we demonstrate that rod outer segment membranes contain a limited number of sites for high affinity RGS9-Gbeta5L binding, which are highly sensitive to proteolysis. In membranes isolated from bovine rod outer segments, all of these sites are occupied by the endogenous RGS9-Gbeta5L, which prevents the binding of exogenous recombinant RGS9-Gbeta5L to these sites. However, treating membranes with urea or high pH buffers causes either removal or denaturation of the endogenous RGS9-Gbeta5L, allowing for high affinity binding of recombinant RGS9-Gbeta5L to these sites. This binding results in a striking similar to70-fold increase in the RGS9-Gbeta5L ability to activate transducin GTPase. The DEP (disheveled/EGL-10/pleckstrin) domain of RGS9 plays a crucial role in the RGS9-Gbeta5L membrane attachment, as evident from the analysis of membrane-binding properties of deletion mutants lacking either N- or C-terminal parts of the RGS9 molecule. Our data indicate that specific association of RGS9-Gbeta5L with photoreceptor disc membranes serves not only as a means of targeting it to an appropriate subcellular compartment but also serves as an important determinant of its catalytic activity.	Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu	Lishko, Polina/L-1191-2017; Lishko, Polina/GQH-9569-2022		NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12859] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 2001, J BIOL CHEM, V276, P48961, DOI 10.1074/jbc.M107428200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; TING TD, 1993, METH NEUROSCI, V15, P180; Wong HC, 2000, NAT STRUCT BIOL, V7, P1178	25	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24376	24381		10.1074/jbc.M203237200	http://dx.doi.org/10.1074/jbc.M203237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006596	hybrid			2022-12-25	WOS:000176611800054
J	Qiu, JZ; Bimston, DN; Partikian, A; Shen, BH				Qiu, JZ; Bimston, DN; Partikian, A; Shen, BH			Arginine residues 47 and 70 of human flap endonuclease-1 are involved in DNA substrate interactions and cleavage site determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN PCNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; REPLICATION FORK; IN-VITRO; BINDING; FEN-1; EXONUCLEASE; RECONSTITUTION; MECHANISM	Flap endonuclease-1 (FEN-1) is a critical enzyme for DNA replication and repair. Intensive studies have been carried out on its structure-specific nuclease activities and biological functions in yeast cells. However, its specific interactions with DNA substrates as an initial step of catalysis are not defined. An understanding of the ability of FEN-1 to recognize and bind a flap DNA substrate is critical for the elucidation of its molecular mechanism and for the explanation of possible pathological consequences resulting from its failure to bind DNA. Using human FEN-1 in this study, we identified two positively charged amino acid residues, Arg-47 and Arg-70 in human FEN-1, as candidates responsible for substrate binding. Mutation of the Arg-70 significantly reduced flap endonuclease activity and eliminated exonuclease activity. Mutation or protonation of Arg-47 shifted cleavage sites with flap substrate and significantly reduced the exonuclease activity. We revealed that these alterations are due to the defects in DNA-protein interactions. Although the effect of the single Arg-47 mutation on binding activities is not as severe as R70A, its double mutation with Asp-181 had a synergistic effect. Furthermore the possible interaction sites of these positively charged residues with DNA substrates were discussed based on FEN-1 cleavage patterns using different substrates. Finally data were provided to indicate that the observed negative effects of a high concentration of Mg2+ on enzymatic activity are probably due to the competition between the arginine residues an metal ions with DNA substrate since mutants were found to be less tolerant.	City Hope Natl Med Ctr, Div Mol Med, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Div Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.	bshen@coh.org		Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R29CA073764, R01CA081967, R01CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [CA81967, CA73764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Brosh RM, 2001, EMBO J, V20, P5791; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; Ma X, 2000, INT J CANCER, V88, P938, DOI 10.1002/1097-0215(20001215)88:6<938::AID-IJC16>3.0.CO;2-G; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 2001, J BIOL CHEM, V276, P30167, DOI 10.1074/jbc.M100985200; YOON JH, 1999, BIOCHEMISTRY-US, V39, P4909	44	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24659	24666		10.1074/jbc.M111941200	http://dx.doi.org/10.1074/jbc.M111941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986308	hybrid			2022-12-25	WOS:000176611800091
J	Graham, DE; Xu, HM; White, RH				Graham, DE; Xu, HM; White, RH			Methanococcus jannaschii uses a pyruvoyl-dependent arginine decarboxylase in polyamine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; HISTIDINE-DECARBOXYLASE; ESCHERICHIA-COLI; CLOSTRIDIUM-PERFRINGENS; LACTOBACILLUS 30A; BOUND PYRUVATE; NITRIC-OXIDE; PURIFICATION; FAMILY; IDENTIFICATION	The genome sequence of the hyperthermophilic methanogen Methanococcus jannaschii contains homologs of most genes required for spermidine polyamine biosynthesis. Yet genomes from neither this organism nor any other euryarchaeon have orthologs of the pyridoxal 5'-phosphate-dependent ornithine or arginine decarboxylase genes, required to produce putrescine. Instead, as shown here, these organisms have a new class of arginine decarboxylase (Pv1ArgDC) formed by the self-cleavage of a proenzyme into a 5-kDa subunit and a 12-kDa subunit that contains a reactive pyruvoyl group. Although this extremely thermostable enzyme has no significant sequence similarity to previously characterized proteins, conserved active site residues are similar to those of the pyruvoyl-dependent histidine decarboxylase enzyme, and its subunits form a similar (alphabeta)(3) complex. Homologs of Pv1ArgDC are found in several bacterial genomes, including those of Chlamydia spp., which have no agmatine ureohydrolase enzyme to convert agmatine (decarboxylated arginine) into putrescine. In these intracellular pathogens, Pv1ArgDC may function analogously to pyruvoyl-dependent histidine decarboxylase; the cells are proposed to import arginine and export agmatine, increasing the pH and affecting the host cell's metabolism. Phylogenetic analysis of Pv1ArgDC proteins suggests that this gene has been recruited from the euryarchaeal polyamine biosynthetic pathway to function as a degradative enzyme in bacteria.	Virginia Polytech Inst & State Univ, Dept Biochem 0308, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	White, RH (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem 0308, Blacksburg, VA 24061 USA.	rhwhite@vt.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], PHYLIP PHYLOGENY INF; Begley TP, 2001, VITAM HORM, V61, P157; BELLEAU B, 1968, J AM CHEM SOC, V90, P1651, DOI 10.1021/ja01008a045; BLETHEN SL, 1968, J BIOL CHEM, V243, P1671; Boeker EA, 1971, METHODS ENZYMOLOGY B, V17B, P657; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CACCIAPUOTI G, 1986, EUR J BIOCHEM, V161, P263, DOI 10.1111/j.1432-1033.1986.tb10442.x; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Dixon H B, 1972, Methods Enzymol, V25, P409, DOI 10.1016/S0076-6879(72)25036-4; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FRIEDMAN SM, 1989, J BIOCHEM-TOKYO, V105, P1030, DOI 10.1093/oxfordjournals.jbchem.a122761; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Graham DE, 2002, J BIOL CHEM, V277, P13421, DOI 10.1074/jbc.M201011200; Hackert M.I., 1998, COMPREHENSIVE BIOL C, V2, P201; HEERSCHAP A, 1985, BIOPHYS CHEM, V22, P205, DOI 10.1016/0301-4622(85)80044-2; HUYNH QK, 1984, J BIOL CHEM, V259, P2833; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; JACOB F, 1960, CR HEBD ACAD SCI, V250, P1727; KELLER PJ, 1986, J AM CHEM SOC, V108, P344, DOI 10.1021/ja00262a053; Kim AD, 2000, J BACTERIOL, V182, P6667, DOI 10.1128/JB.182.23.6667-6672.2000; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Klein RD, 1999, MICROBIOL-UK, V145, P301, DOI 10.1099/13500872-145-2-301; Lu ZCJ, 2002, J BIOL CHEM, V277, P16624, DOI 10.1074/jbc.M110456200; MALMBERG RL, 1994, J BIOL CHEM, V269, P2703; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Piacenza L, 2001, P NATL ACAD SCI USA, V98, P7301, DOI 10.1073/pnas.121520398; PISHKO EJ, 1993, BIOCHEMISTRY-US, V32, P4943, DOI 10.1021/bi00069a032; Ramjee MK, 1997, BIOCHEM J, V323, P661, DOI 10.1042/bj3230661; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; RECSEI PA, 1983, J BIOL CHEM, V258, P439; RECSEI PA, 1970, BIOCHEMISTRY-US, V9, P1492, DOI 10.1021/bi00809a003; RECSEI PA, 1972, J BACTERIOL, V112, P624, DOI 10.1128/JB.112.1.624-626.1972; RILEY WD, 1970, BIOCHEMISTRY-US, V9, P1485, DOI 10.1021/bi00809a002; RILEY WD, 1968, BIOCHEMISTRY-US, V7, P3520, DOI 10.1021/bi00850a029; Schelp E, 2001, J MOL BIOL, V306, P727, DOI 10.1006/jmbi.2000.4430; SCHERER P, 1983, J BACTERIOL, V154, P1315, DOI 10.1128/JB.154.3.1315-1322.1983; Sekowska A, 2000, MICROBIOL-SGM, V146, P1815, DOI 10.1099/00221287-146-8-1815; Sekowska A, 2000, MOL MICROBIOL, V36, P1135, DOI 10.1046/j.1365-2958.2000.01930.x; Selkov E, 1997, GENE, V197, pGC11, DOI 10.1016/S0378-1119(97)00307-7; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Smith Bryan John, 1996, P369, DOI 10.1007/978-1-60327-259-9_63; SNELL EE, 1986, METHOD ENZYMOL, V122, P128; STAHL GL, 1978, J ORG CHEM, V43, P2285, DOI 10.1021/jo00405a045; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1976, J BACTERIOL, V128, P485, DOI 10.1128/JB.128.1.485-486.1976; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANASE S, 1985, J BIOL CHEM, V260, P6738; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Worley S, 2002, PROTEINS, V46, P321, DOI 10.1002/prot.10042; WU WH, 1973, J BIOL CHEM, V248, P1696; WU WH, 1973, J BIOL CHEM, V248, P1687	59	40	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23500	23507		10.1074/jbc.M203467200	http://dx.doi.org/10.1074/jbc.M203467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980912	hybrid			2022-12-25	WOS:000176475700054
J	Zhyvoloup, A; Nemazanyy, I; Babich, A; Panasyuk, G; Pobigailo, N; Vudmaska, M; Naidenov, V; Kukharenko, O; Palchevskii, S; Savinska, L; Ovcharenko, G; Verdier, F; Valovka, T; Fenton, T; Rebholz, H; Wang, ML; Shepherd, P; Matsuka, G; Filonenko, V; Gout, IT				Zhyvoloup, A; Nemazanyy, I; Babich, A; Panasyuk, G; Pobigailo, N; Vudmaska, M; Naidenov, V; Kukharenko, O; Palchevskii, S; Savinska, L; Ovcharenko, G; Verdier, F; Valovka, T; Fenton, T; Rebholz, H; Wang, ML; Shepherd, P; Matsuka, G; Filonenko, V; Gout, IT			Molecular cloning of CoA synthase - The missing link in CoA biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANTOTHENATE KINASE GENE; COENZYME-A METABOLISM; ESCHERICHIA-COLI; RAT-LIVER; ADENYLYLTRANSFERASE; HEART; PURIFICATION; COMPLEX; MUSCLE; STATE	Coenzyme A functions as a carrier of acetyl and acyl groups in living cells and is essential for numerous biosynthetic, energy-yielding, and degradative metabolic pathways. There are five enzymatic steps in CoA biosynthesis. To date, molecular cloning of enzymes involved in the CoA biosynthetic pathway in mammals has been only reported for pantothenate kinase. In this study, we present cDNA cloning and functional characterization of CoA synthase. It has an open reading frame of 563 aa and encodes a protein of similar to60 kDa. Sequence alignments suggested that the protein possesses both phosphopantetheine adenylyltransferase and dephospho-CoA kinase domains. Biochemical assays using wild type recombinant protein confirmed the gene product indeed contained both these enzymatic activities. The presence of intrinsic phosphopantetheine adenylyltransferase activity was further confirmed by site-directed mutagenesis. Therefore, this study describes the first cloning and characterization of a mammalian CoA synthase and confirms this is a bifunctional enzyme containing the last two components of CoA biosynthesis.	Ludwig Inst Canc Res, London W1W 7BS, England; Inst Mol Biol & Genet, Dept Struct & Funct Nucl Acid, UA-143 Kiev, Ukraine; UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; University of London; University College London; UCL Medical School	Gout, IT (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	ivan@ludwig.ucl.ac.uk	Filonenko, Valeriy V/D-5447-2015; Panasyuk, Ganna/AAF-4350-2021; Palchevskyi, Sergii/K-5333-2016; Panasyuk, Ganna/A-4133-2018	Filonenko, Valeriy V/0000-0003-1839-3335; Panasyuk, Ganna/0000-0002-5591-848X; Palchevskyi, Sergii/0000-0001-6553-1513; Panasyuk, Ganna/0000-0002-5591-848X; Fenton, Tim/0000-0002-4737-8233; Rebholz, Heike/0000-0002-0400-7547				Abiko Y., 1975, METABOLIC PATHWAYS, V7, P1; BRASS EP, 1990, J NUTR, V120, P290, DOI 10.1093/jn/120.3.290; BUCOVAZ ET, 1980, MOL CELL BIOCHEM, V30, P7, DOI 10.1007/BF00215301; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; CORKEY BE, 1988, J CLIN INVEST, V82, P782, DOI 10.1172/JCI113679; FISHER MN, 1985, J BIOL CHEM, V260, P5745; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; MCALLISTER RA, 1988, BRIT J CANCER, V57, P83, DOI 10.1038/bjc.1988.14; Ni XH, 2002, INT J BIOCHEM CELL B, V34, P109, DOI 10.1016/S1357-2725(01)00114-5; RAPP GW, 1973, CANCER-AM CANCER SOC, V31, P357, DOI 10.1002/1097-0142(197302)31:2<357::AID-CNCR2820310214>3.0.CO;2-X; REIBEL DK, 1983, AM J PHYSIOL, V244, pH839, DOI 10.1152/ajpheart.1983.244.6.H839; REIBEL DK, 1981, AM J PHYSIOL, V240, pH606, DOI 10.1152/ajpheart.1981.240.4.H606; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; ROBISHAW JD, 1982, J BIOL CHEM, V257, P967; SKREDE S, 1983, EUR J BIOCHEM, V131, P57, DOI 10.1111/j.1432-1033.1983.tb07231.x; SMITH CM, 1980, BIOCHEM J, V188, P175, DOI 10.1042/bj1880175; SMITH CM, 1978, J NUTR, V108, P854, DOI 10.1093/jn/108.5.854; SMITH CM, 1978, J NUTR, V108, P863, DOI 10.1093/jn/108.5.863; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; TAHILIANI AG, 1991, VITAM HORM, V46, P165; TAHILIANI AG, 1991, BIOCHIM BIOPHYS ACTA, V1067, P29, DOI 10.1016/0005-2736(91)90022-Z; Vagelos P. R., 1973, ENZYMES, V8, P155; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; VOLTTI H, 1979, BIOCHEM J, V182, P95, DOI 10.1042/bj1820095; WORRALL DM, 1983, BIOCHEM J, V215, P153, DOI 10.1042/bj2150153; Yun M, 2000, J BIOL CHEM, V275, P28093	30	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22107	22110		10.1074/jbc.C200195200	http://dx.doi.org/10.1074/jbc.C200195200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11980892	Green Accepted, hybrid			2022-12-25	WOS:000176313600001
J	Mori, T; Anazawa, Y; Iiizumi, M; Fukuda, S; Nakamura, Y; Arakawa, H				Mori, T; Anazawa, Y; Iiizumi, M; Fukuda, S; Nakamura, Y; Arakawa, H			Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53	ONCOGENE			English	Article						IRF5; p53; target gene	PROTEIN; EXPRESSION; APOPTOSIS; ELEMENT; CLONING; GROWTH; BINDS	Interferon regulatory factors (IRFs) regulate transcription of interferon genes through DNA sequence-specific binding to these targets. Using a differential display method for examining gene expression in p53-defective cells infected with adenovirus containing wild-type p53, we found that expression of interferon regulatory, factor 5 (IRF-5) mRNA was increased in the presence of exogenous p53. An electrophoretic mobility-shift assay showed that a potential p53 binding site (p53BS) detected in exon 2 of the IRF-5 gene could in fact bind to p53 protein. Moreover, a heterologous reporter assay revealed that the p53BS possessed p53-dependent transcriptional activity. Expression of IRF-5 was induced in p53+/+ cells (MCF7 and NHDF), but not in p53-/- cells (H1299) when DNA was damaged by gamma-irradiation, UV-radiation, or adriamycin treatment in a wild-type p53-dependent manner. These results suggest that IRF-5 is a novel p53-target, and that it might mediate the p53-dependent immune response.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Arakawa, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	harakawa@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Furuhata T, 1996, ONCOGENE, V13, P1965; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARPER JW, 1993, CELL, V75, P805; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MIYASHITA T, 1995, CELL, V80, P293; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Shiraishi K, 2000, CANCER RES, V60, P3722; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281	25	117	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2914	2918		10.1038/sj.onc.1205459	http://dx.doi.org/10.1038/sj.onc.1205459			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973653				2022-12-25	WOS:000175063700018
J	Yamada, T; Zhu, DC; Saxon, A; Zhang, K				Yamada, T; Zhu, DC; Saxon, A; Zhang, K			CD45 controls interleukin-4-mediated IgE class switch recombination in human B cells through its function as a Janus kinase phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SRC-FAMILY KINASES; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; MICROGLIAL ACTIVATION; INTERFERON-GAMMA; GENE-EXPRESSION; PHOSPHORYLATION; INDUCTION; ANTIGEN	CD45 plays a critical regulatory role in receptor signaling through its protein tyrosine phosphatase and Janus kinase (JAK) phosphatase activities. To investigate whether CD45 also plays a regulatory role in Ig class switching in human B cells, we examined the effects of CD45 triggering on Ig class switching to IgE and its relationship with CD45 JAK phosphatase activity. Anti-CD45 triggering of CD45 significantly inhibited interleukin-4 + anti-CD40-induced switch recombination in a switch recombination vector assay in stably transfected Ramos 2G6 human B cells, as well as Ig E germ-line transcription and Smu-Sepsilon switch recombination in primary human B cells. These negative regulatory effects on Ig class switching were concomitant with the ability of CD45 to dephosphorylate the induced phosphorylation of JAK1, JAK3, and signal transducer and activator of transcription 6, but not on stress-activated/mitogen-activated protein kinases. We also showed that phosphorylated JAK1 and JAK3 were directly dephosphorylated by recombinant CD45 in vitro. These results indicate that CD45 is able to function as JAK phosphatase in human B cells and that this activity is directly associated with the negative regulation of the class switch recombination to IgE. CD45 may be an appropriate target drug for modulating IgE in allergic diseases.	Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy,Div Clin Immunol, Dept Med,Hart & Louis Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zhang, K (corresponding author), Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy,Div Clin Immunol, Dept Med,Hart & Louis Lab, 10833 Conte Ave, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA-16042] Funding Source: Medline; NIAID NIH HHS [AI-40551, AI-28697, AI-34567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, U19AI034567, R29AI040551, P30AI028697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; Blank N, 2001, J IMMUNOL, V166, P6034, DOI 10.4049/jimmunol.166.10.6034; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; Craxton A, 1998, J IMMUNOL, V161, P3225; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; FENGHAO X, 1995, J CLIN INVEST, V96, P907, DOI 10.1172/JCI118138; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Hartatik T, 2001, BIOCHEM BIOPH RES CO, V284, P26, DOI 10.1006/bbrc.2001.4931; HASEGAWA K, 1990, INT IMMUNOL, V2, P367, DOI 10.1093/intimm/2.4.367; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; HOOK WA, 1991, J IMMUNOL, V147, P2670; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Katagiri T, 1999, J IMMUNOL, V163, P1321; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Kinoshita K, 1998, IMMUNITY, V9, P849, DOI 10.1016/S1074-7613(00)80650-0; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Li YY, 1996, J IMMUNOL, V157, P1440; Linehan LA, 1998, J IMMUNOL, V161, P302; Losman JA, 1999, J IMMUNOL, V162, P3770; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; MASLIAH E, 1991, ACTA NEUROPATHOL, V83, P12, DOI 10.1007/BF00294425; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MITTLER RS, 1994, J IMMUNOL, V153, P84; MORIKAWA K, 1991, SCAND J IMMUNOL, V34, P273, DOI 10.1111/j.1365-3083.1991.tb01547.x; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; STEVNEZERNORDGR.J, 1986, EMBO J, V5, P95; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeuchi T, 1997, CLIN EXP IMMUNOL, V109, P20, DOI 10.1046/j.1365-2249.1997.4371334.x; Tan J, 2000, J BIOL CHEM, V275, P37224, DOI 10.1074/jbc.M002006200; Tan J, 2000, J NEUROSCI, V20, P7587; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yamada T, 2001, J IMMUNOL, V166, P538, DOI 10.4049/jimmunol.166.1.538; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; Zhang K, 2002, EUR J IMMUNOL, V32, P424, DOI 10.1002/1521-4141(200202)32:2<424::AID-IMMU424>3.0.CO;2-P; Zhong RZ, 1998, J MOL MED-JMM, V76, P572, DOI 10.1007/s001090050252	46	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28830	28835		10.1074/jbc.M201781200	http://dx.doi.org/10.1074/jbc.M201781200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11994288	hybrid			2022-12-25	WOS:000177342600064
J	Farkas, T; Hansen, K; Holm, K; Lukas, J; Bartek, J				Farkas, T; Hansen, K; Holm, K; Lukas, J; Bartek, J			Distinct phosphorylation events regulate p130-and p107-mediated repression of E2F-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE FAMILY; CELL-CYCLE ARREST; LARGE T-ANTIGEN; DNA-REPLICATION; PRB PHOSPHORYLATION; GROWTH SUPPRESSION; PROTEIN FUNCTION; RB/E2F PATHWAY; G(1) CONTROL; BINDING	The "pocket proteins" pRb (retinoblastoma tumor suppressor protein), p107, and p130 regulate cell proliferation via phosphorylation-sensitive interactions with E2F transcription factors and other proteins. We previously identified 22 in vivo phosphorylation sites in human p130, including three sites selectively targeted by cyclin D-Cdk4(6) kinases. Here we assessed the effects of alanine substitution at the individual or combined Cdk4(6)-specific sites in p130, compared with homologous sites in p107 (Thr(369)/Ser(650)/Ser(964)). In U-2-OS cells, the triple p107(DeltaCdk4)* mutant strongly inhibited E2F-4 activity and imposed a G(1) arrest resistant to cyclin D1 coexpression. In contrast, the p130(DeltaCdk4) Mutant still responded to cyclin D1, suggesting the existence of additional phosphorylation sites critical for E2F-4 regulation. Extensive mutagenesis, sensitive E2F reporter assays, and cell cycle analyses allowed the identification of six such residues (serines 413, 639, 662, 1044, 1080, and 1112) that, in addition to the Cdk4-specific sites, are necessary and sufficient for the regulation of E2F-4 and the cell cycle by p130. Surprisingly, 12 of the in vivo phosphorylation sites seem dispensable for E2F regulation and probably modulate other functions of p130. These results further elucidate the complex regulation of p130 and provide a molecular mechanism to explain the differential control of p107 and p130 by cyclin-dependent kinases.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Hansen, K (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Farkas, Thomas/0000-0003-1903-6081; Lukas, Jiri/0000-0001-9087-506X; Hansen, Klaus/0000-0001-9657-8816				Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paggi MG, 2001, CANCER RES, V61, P4651; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	64	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26741	26752		10.1074/jbc.M200381200	http://dx.doi.org/10.1074/jbc.M200381200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12006580	hybrid			2022-12-25	WOS:000177055900007
J	Liu, XP; Samouilov, A; Lancaster, JR; Zweier, JL				Liu, XP; Samouilov, A; Lancaster, JR; Zweier, JL			Nitric oxide uptake by erythrocytes is primarily limited by extracellular diffusion not membrane resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; OXYGEN-UPTAKE; HEMOGLOBIN; PERMEABILITY; CONSUMPTION; OXYHEMOGLOBIN; OXIDATION; BINDING; BARRIER	The process of NO transfer into erythrocytes (RBCs) is of critical biological importance because it regulates the bioavailability and diffusional distance of endothelial-derived NO. It has been reported that the rate of NO reaction with oxyhemoglobin (Hb) within RBCs is nearly three orders of magnitude slower than that by equal amounts of free oxyhemoglobin. Consistent with early studies on oxygen uptake by RBCs, the process of extracellular diffusion was reported to explain this much lower NO uptake by RBC encapsulated Hb (Liu, X., Miller, M. J., Joshi, M. S., Sadowska-Krowicka, H., Clark, D. A., and Lancaster, J. R., Jr. (1998) J. Biol. Chem. 273, 18709-18713). However, it was subsequently proposed that the RBC membrane provides the main resistance to NO uptake rather than the process of extracellular diffusion (Vaughn, M. W., Huang, K. T., Kuo, L., and Liao, J. C. (2000) J. Biol. Chem. 275, 2342-2348). This conclusion was based on competition experiments that were assumed to be able to determine the rate constant of NO uptake by RBCs without extracelluar diffusion limitation. To test the validity of this hypothesis, we theoretically analyzed competition experiments. Here, we show that competition experiments do not eliminate the extracellular diffusion limitation. Simulation of the competition data indicates that the main resistance to NO uptake by RBCs is caused by extracellular diffusion in the unstirred layer surrounding each RBC but not by the RBC membrane. This extracellular diffusion resistance is responsible for preventing interference of NO signaling in the endothelium without the need for special NO uptake by intracellular hemoglobin or a unique membrane resistance mechanism.	Johns Hopkins Univ, Sch Med, Div Cardiol,Dept Med, Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA	Johns Hopkins University; Johns Hopkins University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Liu, XP (corresponding author), Johns Hopkins Asthma & Allergy Ctr, EPR Ctr, 5501 Hopkins Bayview Circle,Rm LA-14, Baltimore, MD 21224 USA.	xpliu@mail.jhmi.edu	Samouilov, Alexandre/E-4010-2011; Liu, Xiaoping/A-4516-2008; Samouilov, Alexandre/B-5824-2014	Liu, Xiaoping/0000-0002-7516-382X	NHLBI NIH HHS [HL65608, HL63744, HL38324] Funding Source: Medline; NIDDK NIH HHS [DK46935] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R29HL038324, R01HL063744, R01HL038324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046935] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; CARRUTHERS A, 1983, BIOCHEMISTRY-US, V22, P5797, DOI 10.1021/bi00294a018; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; COIN JT, 1979, J BIOL CHEM, V254, P1178; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; EVANS E, 1972, MICROVASC RES, V4, P335, DOI 10.1016/0026-2862(72)90069-6; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Hartridge H, 1927, J PHYSIOL-LONDON, V52, P232, DOI 10.1113/jphysiol.1927.sp002354; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; HOLLAND RAB, 1967, RESP PHYSIOL, V3, P307, DOI 10.1016/0034-5687(67)90061-8; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; HUXLEY VH, 1981, J PHYSIOL-LONDON, V316, P75, DOI 10.1113/jphysiol.1981.sp013773; KLONK S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P143, DOI 10.1016/0005-2736(92)90232-B; KUTCHAI H, 1969, J GEN PHYSIOL, V53, P576, DOI 10.1085/jgp.53.5.576; KUTCHAI H, 1975, RESP PHYSIOL, V23, P121, DOI 10.1016/0034-5687(75)90076-6; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; LIDE DR, 1990, HDB CHEM PHYSICS, P6; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MERCHUK JC, 1983, CHEM ENG SCI, V38, P1315, DOI 10.1016/0009-2509(83)80052-9; NICHOLSON P, 1951, P ROY SOC LOND B BIO, V138, P241; RICE SA, 1980, BIOPHYS J, V29, P65, DOI 10.1016/S0006-3495(80)85118-6; SHAKLAI N, 1977, BIOCHEMISTRY-US, V16, P5593, DOI 10.1021/bi00644a032; Shibuya I, 1988, Adv Exp Med Biol, V222, P219; Subczynski WK, 1996, FREE RADICAL RES, V24, P343, DOI 10.3109/10715769609088032; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; VALLANCE P, 1989, LANCET, V2, P997; VANDEGRIFF KD, 1984, BIOPHYS J, V45, P825, DOI 10.1016/S0006-3495(84)84226-5; VANDEGRIFF KD, 1984, J BIOL CHEM, V259, P2619; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH1705, DOI 10.1152/ajpheart.1998.274.5.H1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; VOET D, 1995, BIOCHEMISTRY-US, P224; WEISS TF, 1996, CELLULAR BIOPHYSICS, V1, P149; WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1	39	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26194	26199		10.1074/jbc.M201939200	http://dx.doi.org/10.1074/jbc.M201939200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006567	hybrid			2022-12-25	WOS:000176908700049
J	New, JH; Kowalczykowski, SC				New, JH; Kowalczykowski, SC			Rad52 protein has a second stimulatory role in DNA strand exchange that complements replication protein-A function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; RECOMBINATION; MEDIATOR	Rad52 protein plays a central role in double strand break repair and homologous recombination in Saccharomyces cerevisiae. We have identified a new mechanism by which Rad52 protein stimulates Rad51 protein-promoted DNA strand exchange. This function of Rad52 protein is revealed when subsaturating amounts (relative to the single-stranded DNA concentration) of replication protein-A (RPA) are used. Under these conditions, Rad52 protein is needed for extensive DNA strand exchange. Interestingly, in this new role, Rad52 protein neither acts simply as a single strand DNA-binding protein per se nor, in contrast to its previously identified stimulatory roles, does it require physical interaction with RPA because it can be substituted by the Escherichia coli single strand DNA-binding protein. We propose that Rad52 protein acts by stabilizing the Rad51 presynaptic filament.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 258 Hutchison Hall, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062653, R01GM062653] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline; NIGMS NIH HHS [GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEBOWITZ J, 1985, THESIS J HOPKINS U B; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	22	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26171	26176		10.1074/jbc.M203670200	http://dx.doi.org/10.1074/jbc.M203670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004070	Green Submitted, hybrid			2022-12-25	WOS:000176908700046
J	Qiao, LY; Zhande, R; Jetton, TL; Zhou, GC; Sun, XJ				Qiao, LY; Zhande, R; Jetton, TL; Zhou, GC; Sun, XJ			In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STIMULATED TYROSINE PHOSPHORYLATION; JCR-LA-CORPULENT; PHOSPHATIDYLINOSITOL 3-KINASE; OKADAIC ACID; SERINE/THREONINE PHOSPHORYLATION; GLUCOSE-TRANSPORT; DOCKING PROTEIN; IRS-1 GENE; OBESE RAT	Insulin resistance is a key pathophysiologic feature of obesity and type 2 diabetes and is associated with other human diseases, including atherosclerosis, hypertension, hyperlipidemia, and polycystic ovarian disease. Yet, the specific cellular defects that cause insulin resistance are not precisely known. Insulin receptor substrate (IRS) proteins are important signaling molecules that mediate insulin action in insulin-sensitive cells. Recently, serine phosphorylation of IRS proteins has been implicated in attenuating insulin signaling and is thought to be a potential mechanism for insulin resistance. However, in vivo increased serine phosphorylation of IRS proteins in insulin-resistant animal models has not been reported before. In the present study, we have confirmed previous findings in both JCR:ILA-cp and Zucker fatty rats, two genetically unrelated insulin-resistant rodent models, that an enhanced serine kinase activity in liver is associated with insulin resistance. The enhanced serine kinase specifically phosphorylates the conserved Ser(789) residue in IRS-1, which is in a sequence motif separate from the ones for MAPK, c-Jun N-terminal kinase, glycogen-synthase kinase 3 (GSK-3), Akt, phosphatidylinositol T-kinase, or casein kinase. It is similar to the phosphorylation motif for AMP-activated protein kinase, but the serine kinase in the insulin-resistant animals was shown not to be an AMP-activated protein kinase, suggesting a potential novel serine kinase. Using a specific antibody against Ser(P)(789) pep tide of IRS-1, we then demonstrated for the first time a striking increase of Ser(789)-phosphorylated IRS-1 in livers of insulin-resistant rodent models, indicating enhanced serine kinase activity in vivo. Taken together, these data strongly suggest that unknown serine kinase activity and Ser(789) phosphorylation of IRS-1 may play an important role in attenuating insulin signaling in insulin-resistant animal models.	Univ Vermont, Dept Med, Coll Med, Div Endocrinol, Burlington, VT 05405 USA; Merck Res Labs, Rahway, NJ 07065 USA	University of Vermont; Merck & Company	Sun, XJ (corresponding author), Univ Vermont, Dept Med, Coll Med, Div Endocrinol, Given Bldg,C-350, Burlington, VT 05405 USA.	xsun@zoo.uvm.edu			NIAID NIH HHS [AI41426-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041426] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Barinaga M, 1999, SCIENCE, V283, P1247, DOI 10.1126/science.283.5406.1247; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAY GA, 1977, FED PROC, V36, P148; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KOLETSKY S, 1975, AM J PATHOL, V80, P129; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAM K, 1994, J BIOL CHEM, V269, P20648; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Mantzoros C S, 1995, Adv Endocrinol Metab, V6, P193; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PEDERSON RA, 1991, INT J OBESITY, V15, P461; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; RUSSELL JC, 1987, ARTERIOSCLEROSIS, V7, P620, DOI 10.1161/01.ATV.7.6.620; RUSSELL JC, 1994, METABOLISM, V43, P538, DOI 10.1016/0026-0495(94)90192-9; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; White MF, 1998, RECENT PROG HORM RES, V53, P119; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Wilkinson J., 1986, PRACTICAL PROTEIN CH, P121; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; ZUCKER LM, 1972, ENDOCRINOLOGY, V90, P1320, DOI 10.1210/endo-90-5-1320	71	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26530	26539		10.1074/jbc.M201494200	http://dx.doi.org/10.1074/jbc.M201494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006586	hybrid			2022-12-25	WOS:000176908700093
J	Swain, E; Baudry, K; Stukey, J; McDonough, V; Germann, M; Nickels, JT				Swain, E; Baudry, K; Stukey, J; McDonough, V; Germann, M; Nickels, JT			Sterol-dependent regulation of sphingolipid metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; ALKALINE CERAMIDASE; LIPID-METABOLISM; CELL-SURFACE; GENE; CHOLESTEROL; BIOSYNTHESIS; STRESS; CLONING; SPHINGOSINE-1-PHOSPHATE	We had previously isolated the temperature-sensitive erg26-1 mutant and characterized the sterol defects in erg26-1 cells (Baudry, K., Swain, E., Rahier, A., Germann, M., Batta, A., Rondet, S., Mandala, S., Henry, K., Tint, G. S., Edlind, T., Kurtz, M., and Nickels, J. T., Jr. (2001) J. Biol. Chem. 276, 12702-12711). We have now determined the defects in sphingolipid metabolism in erg26-1 cells, examined their effects on cell growth, and initiated studies designed to elucidate how might changes in sterol levels coordinately regulate sphingolipid metabolism in Saccharomyces cerevisiae. Using [H-3]inositol radiolabeling studies, we found that the biosynthetic rate and steady-state levels of specific hydroxylated forms of inositolphosphorylceramides were decreased in erg26-1 cells when compared with wild type cells. [3 H]Dihydrosphingosine radiolabeling studies demonstrated that erg26-1 cells had decreased levels of the phytosphingosine-derived ceramides that are the direct precursors of the specific hydroxylated inositol phosphorylceramides found to be lower in these cells. Gene dosage experiments using the sphingolipid long chain sphingoid base (LCB) hydroxylase gene, SUR2, suggest that erg26-1 cells may accumulate LCB, thus placing one point of sterol regulation of sphingolipid synthesis possibly at the level of ceramide metabolism. The results from additional genetic studies using the sphingolipid hydroxylase and copper transporter genes, SCS7 and CCC2, respectively, suggest a second possible point of sterol regulation at the level of complex sphingolipid hydroxylation. In addition, [H-3]inositol radiolabeling of sterol biosynthesis inhibitor-treated wild type cells and late sterol pathway mutants showed that additional blocks in sterol biosynthesis have profound effects on sphingolipid metabolism, particularly sphingolipid hydroxylation state. Finally, our genetic studies in erg26-1 cells using the LCB phosphate phosphatase gene, LBP1, suggest that increasing the levels of the LCB sphingoid base phosphate can remediate the temperature-sensitive phenotype of erg26-1 cells.	Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19102 USA; Hope Coll, Dept Biol, Holland, MI 49423 USA	Drexel University; Hope College	Nickels, JT (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19102 USA.	Joseph.Nickels@drexel.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067401] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67401-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHEN H, 1993, J LIPID RES, V34, P2159; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; Crowley JH, 1998, CURR GENET, V34, P93, DOI 10.1007/s002940050371; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Dimster-Denk D, 1999, J LIPID RES, V40, P850; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kim S, 2000, GENETICS, V156, P1519; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lees N., 1997, BIOCH FUNCTION STERO, P85; LESTER RL, 1993, ADV LIPID RES, V26, P253; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SIKORSKI RS, 1989, GENETICS, V122, P19; Silve S, 1996, MOL CELL BIOL, V16, P2719; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; Voelker DR, 2000, BBA-MOL CELL BIOL L, V1486, P97, DOI 10.1016/S1388-1981(00)00051-2; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Young ME, 2002, MOL CELL BIOL, V22, P927, DOI 10.1128/MCB.22.3.927-934.2002	68	43	44	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26177	26184		10.1074/jbc.M204115200	http://dx.doi.org/10.1074/jbc.M204115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006573	hybrid			2022-12-25	WOS:000176908700047
J	Artigues, A; Iriarte, A; Martinez-Carrion, M				Artigues, A; Iriarte, A; Martinez-Carrion, M			Binding to chaperones allows import of a purified mitochondrial precursor into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROTEINS; FREE TRANSLATION SYSTEM; HEAT-SHOCK PROTEIN; ASPARTATE-AMINOTRANSFERASE; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC CHAPERONES; SUBSTRATE-SPECIFICITY; STRESS PROTEINS; DNAK CHAPERONE	Refolding of the acid-unfolded precursor to mitochondrial aspartate aminotransferase (pmAAT) is inhibited when cytosolic Hsc70 is included in the refolding reaction (Artigues, A., Iriarte, A., and Martinez-Carrion, M. (1997) J. Biol. Chem. 272, 16852-16861). At low molar excess of Hsc70 pmAAT is recovered in insoluble aggregates containing equal amounts of Hsc70. However, in the presence of a large excess of Hsc70, refolding of pmAAT is still arrested, but the enzyme remains in solution. Similar behavior was observed with two other cytosolic chaperones, bovine Hsp90 and yeast Ydj1. Co-immunoprecipitation of pmAAT using Hsc70 antibodies confirmed the formation of soluble Hsc70-pmAAT complexes at high concentrations of the chaperone. Data from analytical centrifugation, sedimentation in glycerol gradients, and partial purification of the soluble complexes indicate that multiple Hsc70 molecules bind per pmAAT polypeptide chain. The absence of catalytic activity together with the protease susceptibility of pmAAT bound to Hsc70, Hsp90, or Ydj1 suggest that these chaperones bind and maintain pmAAT in a partially unfolded state, analogous to the import-competent conformation of the protein synthesized in cell-free extracts. Remarkably, the purified pmAAT bound to Hsc70 or Ydj1, but not to Hsp90, is imported by isolated mitochondria in a reticulocyte lysate-dependent manner. Thus, both Hsc70 and Ydj1 can trap an import-competent folding intermediate of pmAAT, but productive binding and import into mitochondria require the collaboration of additional cytosolic factors from the lysate.	Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, 5007 Rockhill Rd, Kansas City, MO 64110 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Artigues A, 1998, J BIOL CHEM, V273, P33130, DOI 10.1074/jbc.273.50.33130; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BECKER K, 1992, J BIOL CHEM, V267, P5637; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; Jensen RE, 1999, CURR BIOL, V9, pR779, DOI 10.1016/S0960-9822(00)80012-3; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; LAIN B, 1994, J BIOL CHEM, V269, P15588; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Mattingly JR, 2000, ARCH BIOCHEM BIOPHYS, V382, P113, DOI 10.1006/abbi.2000.2003; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; Mattingly JR, 1998, J BIOL CHEM, V273, P23191, DOI 10.1074/jbc.273.36.23191; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Minami M, 2001, EUR J BIOCHEM, V268, P2520, DOI 10.1046/j.1432-1327.2001.02145.x; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; Nagata H, 1998, BIOCHEMISTRY-US, V37, P6924, DOI 10.1021/bi980164g; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; TERADA K, 1995, MOL CELL BIOL, V15, P3708; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	56	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25047	25055		10.1074/jbc.M203474200	http://dx.doi.org/10.1074/jbc.M203474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983713	hybrid			2022-12-25	WOS:000176747000029
J	Lelievre, E; Lionneton, F; Mattot, V; Spruyt, N; Soncin, F				Lelievre, E; Lionneton, F; Mattot, V; Spruyt, N; Soncin, F			Ets-1 regulates fli-1 expression in endothelial cells - Identification of Ets binding sites in the fli-1 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ETS-1; CHICK-EMBRYO; APOPTOSIS; PROTEINS; DIFFERENTIATION; EMBRYOGENESIS; ANGIOGENESIS; ERYTHROLEUKEMIA; SPECIFICITY; INHIBITION	To understand the role of the Ets-1 transcription factor during angiogenesis, we have overexpressed it in endothelial cells and analyzed the levels of expression of several candidate target genes involved in angiogenesis. The transcripts levels of the ETS transcription factor fli-1 are specifically up-regulated in endothelial cells, which overexpress Ets-1, but not in fibroblasts. Analysis of the promoter of the mouse fli-1 gene reveals that the 1-kb region that comprises the transcription starts and part of exon 1 is responsible for the response of the promoter to Ets-1. The -270/-41 fragment contains two known Spi-1-responding Ets binding sites (EBS), which are also necessary for the activation by Ets-1. In contrast to Spi-1, a third EBS is necessary for the full response of this promoter fragment to Ets-1. The rest of the promoter activity has been located in the -986/-505 region, where three active EBSs have been identified. Furthermore, endogenous Fli-1 was found to be bound to its own gene promoter and to be able to promote the transactivation of its gene. These results suggest that Ets-1 activates an auto-regulatory loop of expression of fli-1 in endothelial cells, a mechanism that could have significant implications for the endothelial cell fate.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Soncin, F (corresponding author), Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Barat C, 2000, BBA-GENE STRUCT EXPR, V1517, P164, DOI 10.1016/S0167-4781(00)00239-6; Barbeau B, 1999, ONCOGENE, V18, P5535, DOI 10.1038/sj.onc.1202913; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BEN DY, 1991, GENE DEV, V5, P908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Goltzene F, 2000, EXP CELL RES, V260, P233, DOI 10.1006/excr.2000.5005; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kappel A, 2000, BLOOD, V96, P3078; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Lionneton F, 2001, PROTEIN EXPRES PURIF, V21, P492, DOI 10.1006/prep.2001.1405; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Maxam A M, 1980, Methods Enzymol, V65, P499; Melet F, 1996, MOL CELL BIOL, V16, P2708; Meyer D, 1995, INT J DEV BIOL, V39, P909; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; NERLOV C, 1991, ONCOGENE, V6, P1583; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; QUEVA C, 1993, ONCOGENE, V8, P2511; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETH A, 1993, ONCOGENE, V8, P1783; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Takahashi Y, 2000, GENE DEV, V14, P804; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WERNERT N, 1992, AM J PATHOL, V140, P119; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	52	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25143	25151		10.1074/jbc.M201628200	http://dx.doi.org/10.1074/jbc.M201628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991951	hybrid			2022-12-25	WOS:000176747000040
J	Wolf, D; Rodova, M; Miska, EA; Calvet, JP; Kouzarides, T				Wolf, D; Rodova, M; Miska, EA; Calvet, JP; Kouzarides, T			Acetylation of beta-catenin by CREB-binding protein (CBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN RECEPTOR GENE; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASES; THYROID-CARCINOMA; C-MYC; EXPRESSION; WNT; PATHWAY; TARGET; DOMAIN	Acetylation controls the activity of numerous proteins involved in regulating gene transcription as well as many other cellular processes. In this report we show that the CREB-binding protein (CBP) acetyltransferase acetylates beta-catenin protein in vivo. beta-Catenin is a central component of the Wnt signaling pathway, which is of key importance in development as well as being heavily implicated in a variety of human cancers. We show that the CBP-mediated acetylation of beta-catenin occurs at a single site, lysine 49. Importantly, this lysine is frequently found mutated in cancer and is in a region of importance to the regulation of beta-catenin. We show that mutation of this site leads specifically to an increase in the ability of beta-catenin to activate the c-myc gene but not other beta-catenin-regulated genes. This suggests that acetylation of beta-catenin is involved in regulating Wnt signaling in a promoter-specific fashion.	Univ Cambridge, Wellcome CRC Canc Res Campaigne, Inst Pathol, Cambridge CB2 1QR, England; Univ Cambridge, Wellcome CRC Canc Res Campaigne, Dept Pathol, Cambridge CB2 1QR, England; Univ Kansas, Med Ctr, Kansas City, KS 66160 USA	University of Cambridge; University of Cambridge; University of Kansas; University of Kansas Medical Center	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Canc Res Campaigne, Inst Pathol, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162; Miska, Eric/0000-0002-4450-576X	NIDDK NIH HHS [DK57301, DK53763] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057301, P01DK053763] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BRABANT G, 1991, MOL CELL ENDOCRINOL, V82, pR7, DOI 10.1016/0303-7207(91)90018-N; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chan HM, 2001, J CELL SCI, V114, P2363; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HASHIMOTO T, 1990, ENDOCRINOL JAPON, V37, P247; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McManus KJ, 2001, BIOCHEM CELL BIOL, V79, P253, DOI 10.1139/bcb-79-3-253; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; ROMANO MI, 1993, HORM RES, V39, P161, DOI 10.1159/000182718; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SHI YF, 1993, CLIN ENDOCRINOL, V39, P269, DOI 10.1111/j.1365-2265.1993.tb02365.x; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WALZER L, 1998, NATURE, V395, P521; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25562	25567		10.1074/jbc.M201196200	http://dx.doi.org/10.1074/jbc.M201196200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11973335	hybrid			2022-12-25	WOS:000176747000093
J	Kanayama, A; Inoue, J; Sugita-Konishi, Y; Shimizu, M; Miyamoto, Y				Kanayama, A; Inoue, J; Sugita-Konishi, Y; Shimizu, M; Miyamoto, Y			Oxidation of I kappa B alpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; NEUTROPHIL; EXPRESSION; ACID; MYELOPEROXIDASE; INACTIVATION; PROTEOLYSIS; CELLS; BETA	A band shift of IkappaBalpha was observed in Western blots with Jurkat cells treated with I nM taurine chloramine (TauCl) for I h. TauC1 treatment inhibited tumor necrosis factor a (TNFalpha)-initiated nuclear factor kappaB (NF-kappaB) activation. TauCl did not inhibit either the upstream of IkappaB kinase (IKK) activation or IKK itself but did inhibit NF-kappaB activation induced by IKK overexpression. Deletion experiments showed that a TauCl modification site causing the band shift of IkappaBalpha is Met(45). High performance liquid chromatography and mass spectrometry analyses of a small peptide containing Met4(5) revealed that TauC1 oxidizes Met45. A mutant of IkappaBalpha whose Met(45) was converted to alanine did not generate a band shift upon TauC1 treatment and degraded in response to TNFalpha stimulation. However, a reporter assay revealed that NF-kappaB-dependent luciferase expression was not fully recovered in cells transfected with this mutant. These results indicate that Met(45) oxidation of IkappaBalpha is a molecular mechanism underlying the TauCl-induced inhibition of NF-kappaB activation. A similar band shift was observed when HL-60 cells expressing myeloperoxidase were treated with 100 muM hydrogen peroxide for 5 min. When rat neutrophils were incubated with bacteria, intracellular taurine decreased interleukin-8 production. Therefore, taurine may help suppress excessive inflammatory reaction in neutrophils.	Univ Tokyo, Dept Integrat Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Keio Univ, Dept Appl Chem, Fac Sci & Technol, Yokohama, Kanagawa 2238522, Japan; Natl Inst Infect Dis, Dept Biomed Food Res, Shinjuku Ku, Tokyo 1628640, Japan	University of Tokyo; University of Tokyo; Keio University; National Institute of Infectious Diseases (NIID)	Miyamoto, Y (corresponding author), Univ Tokyo, Dept Integrat Biosci, Grad Sch Frontier Sci, Biosci Bldg 402,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	yusei74@k.u-tokyo.ac.jp						ABRINK M, 1994, LEUKEMIA, V8, P1579; Aoki T, 1996, ONCOGENE, V12, P1159; Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chen JG, 2000, BIOPHYS J, V78, P174, DOI 10.1016/S0006-3495(00)76583-0; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Kontny E, 2000, ARTHRITIS RHEUM, V43, P2169, DOI 10.1002/1529-0131(200010)43:10<2169::AID-ANR4>3.0.CO;2-#; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcinkiewicz J, 1998, IMMUNOPHARMACOLOGY, V40, P27, DOI 10.1016/S0162-3109(98)00023-X; MCDONALD PP, 1997, FEBS LETT, V412, P538; Ogino T, 1997, J BIOL CHEM, V272, P26247, DOI 10.1074/jbc.272.42.26247; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stapleton PP, 1998, JPEN-PARENTER ENTER, V22, P42, DOI 10.1177/014860719802200142; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Xia Y, 1997, ANAL BIOCHEM, V245, P93, DOI 10.1006/abio.1996.9940; ZELIKOVIE L, 1989, NEW PROTECTIVE ROLES, P253	33	125	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24049	24056		10.1074/jbc.M110832200	http://dx.doi.org/10.1074/jbc.M110832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983684	hybrid			2022-12-25	WOS:000176611800012
J	Takashima, S; Ishida, H; Inazu, T; Ando, T; Ishida, H; Kiso, M; Tsuji, S; Tsujimoto, M				Takashima, S; Ishida, H; Inazu, T; Ando, T; Ishida, H; Kiso, M; Tsuji, S; Tsujimoto, M			Molecular cloning and expression of a sixth type of alpha 2,8-sialyltransferase (ST8Sia VI) that sialylates O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; GENOMIC STRUCTURE; SUBSTRATE-SPECIFICITY; PROMOTER ACTIVITY; SYNTHASE; GLYCOPROTEINS; RESIDUES; ALPHA-2,6-SIALYL; BIOSYNTHESIS; ORGANIZATION	A novel member of the mouse alpha2,8-sialyltransferase (ST8Sia) family, designated ST8Sia VI, was identified by BLAST analysis of expressed sequence tags. The sequence of STSSia VI encodes a protein of 398 amino acids and shows 42.0 and 38.3% amino acid sequence identities to mouse alpha2,8-sialyltransferases ST8Sia I (GD3 synthase) and STSSia V (GD1c, GT1a, GQ1b, and GT3 synthases), respectively. The recombinant soluble form of STSSia VI expressed in COS-7 cells exhibited alpha2,8-sialyltransferase activity toward both glycolipids and glycoproteins that have the NeuAcalpha2,3(6)Gal sequence at the nonreducing end of their carbohydrate groups. This enzyme formed NeuAcalpha2,8NeuAc structures, but not oligosialic or polysialic acid structures. Analysis of the fetuin sialylated by STSSia VI indicated that ST8Sia VI prefers O-glycans to N-glycans as acceptor substrates. Substrate specificities and kinetic properties also showed that ST8Sia VI prefers O-glycans to glycolipids as acceptor substrates. ST8Sia VI also exhibited activity toward oligosaccharides such as sialyllactose and sialyllactosamine, and the structure of the minimal acceptor substrate for ST8Sia VI was determined as the NeuAcalpha2,3(6)Gal sequence. The expression of the ST8Sia VI gene was ubiquitous, and the highest expression was observed in kidney, with three major transcripts of 8.2, 3.8, and 2.7 kb. This is the first report of a mammalian alpha2,8-sialyltransferase that sialylates O-glycans preferentially.	RIKEN, Lab Cellular Biochem, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Noguchi Inst, Itabashi Ku, Tokyo, Japan; Gifu Univ, Dept Appl Bioorgan Chem, Fac Agr & Life Sci, Gifu 5011193, Japan; Ochanomizu Univ, Dept Chem, Fac Sci, Bunkyo Ku, Tokyo 1128610, Japan	RIKEN; Gifu University; Ochanomizu University	Tsujimoto, M (corresponding author), RIKEN, Lab Cellular Biochem, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	tsujimot@postman.riken.go.jp	Inazu, Toshiyuki/R-1966-2019					DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; Eckhardt M, 1998, GLYCOBIOLOGY, V8, P1165, DOI 10.1093/glycob/8.12.1165; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HARDUINLEPERS A, 2001, RRD CANCER 1, V3, P111; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Ikehara Y, 1999, FEBS LETT, V463, P92, DOI 10.1016/S0014-5793(99)01605-1; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; KAMEYAMA A, 1990, CARBOHYD RES, V200, P269, DOI 10.1016/0008-6215(90)84197-3; Kitajima K, 1999, SIALOBIOLOGY OTHER N, P69; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Nara K, 1996, EUR J BIOCHEM, V238, P647, DOI 10.1111/j.1432-1033.1996.0647w.x; OHTA S, 1993, ANTICANCER RES, V13, P331; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PRABHANJAN H, 1991, CARBOHYD RES, V211, pC1, DOI 10.1016/0008-6215(91)80105-V; Saito M, 2000, BBA-GEN SUBJECTS, V1523, P230, DOI 10.1016/S0304-4165(00)00127-6; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; Suzuki M, 2000, GLYCOBIOLOGY, V10, P1113; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Takashima S, 1998, J BIOL CHEM, V273, P7675, DOI 10.1074/jbc.273.13.7675; Takashima S, 2000, J BIOCHEM-TOKYO, V128, P1033, DOI 10.1093/oxfordjournals.jbchem.a022831; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Tsuji S., 1999, SIALOBIOLOGY OTHER N, P145; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	47	54	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24030	24038		10.1074/jbc.M112367200	http://dx.doi.org/10.1074/jbc.M112367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980897	hybrid			2022-12-25	WOS:000176611800010
J	Zhang, F; Chen, Y; Kweon, DH; Kim, CS; Shin, YK				Zhang, F; Chen, Y; Kweon, DH; Kim, CS; Shin, YK			The four-helix bundle of the neuronal target membrane SNARE complex is neither disordered in the middle nor uncoiled at the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-SNARE; PROTEIN-STRUCTURE; INFLUENZA HEMAGGLUTININ; SYNAPTIC EXOCYTOSIS; CRYSTAL-STRUCTURE; SPIN-LABELS; SIDE-CHAINS; FUSION; RECEPTOR; BACTERIORHODOPSIN	Assembly of the SNARE complex is an essential step for membrane fusion and neurotransmitter release in neurons. The plasma membrane SNAREs syntaxin 1A and SNAP-25 (t-SNAREs) and the delivery-vesicle SNARE VAMP2 (or v-SNARE) contain the "SNARE regions" that essentially mediate SNARE pairing. Using site-directed spin labeling and EPR distance measurement we show that two identical copies of the SNARE region from syntaxin 1A intertwine as a coiled coil near the "ionic layer" region. The structure of the t-SNARE complex appears to be virtually identical to that of the ternary SNARE complex, except that VAMP2 is substituted to the second copy of syntaxin 1A. Furthermore, it appears that the coiled coil structure is maintained up to residue 259 of syntaxin 1A, identical to that of the ternary complex. These results are somewhat contradictory to the previous reports, suggesting that the t-SNARE complex has the disordered midsection (Xiao, W. Z., Poirier, M. A., Bennett, M. K., and Shin, Y. K. (2001) Nat. Struc. Biol. 8,308-311) and the uncoiled C-terminal region (Margittai, M., Fasshauer, D., Pabst, S., Jahn, R., and Langen, R. (2001) J. Biol. Chem. 276, 13169-13177). The newly refined structure of the t-SNARE complex provides a basis for the better understanding of the SNARE assembly process. It also provides possible structural-functional clues to the membrane fusion in the v-SNARE deleted fusion models.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.		Zhang, Fan/A-3477-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051290, R01GM051290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; GUAM K, 1991, ANAL BIOCHEM, V192, P262; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hustedt EJ, 1999, ANNU REV BIOPH BIOM, V28, P129, DOI 10.1146/annurev.biophys.28.1.129; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2000, BIO MAGN RE, V19, P185; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Russell CJ, 1999, BIOCHEMISTRY-US, V38, P337, DOI 10.1021/bi981179h; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xiao WZ, 2000, J MOL BIOL, V304, P715, DOI 10.1006/jmbi.2000.4255; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174	44	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24294	24298		10.1074/jbc.M201200200	http://dx.doi.org/10.1074/jbc.M201200200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983696	hybrid			2022-12-25	WOS:000176611800043
J	Augusto, LA; Li, J; Synguelakis, M; Johansson, J; Chaby, R				Augusto, LA; Li, J; Synguelakis, M; Johansson, J; Chaby, R			Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE SP-C; A SP-A; PULMONARY SURFACTANT; LIPID-A; BIOPHYSICAL ACTIVITY; IN-VIVO; SECONDARY STRUCTURE; EPITHELIAL-CELLS; INNATE IMMUNITY; DEFICIENT MICE	In the respiratory tract, recognition of bacterial endotoxin (lipopolysacharide, LPS) is a critical step of the innate host defense system directed against invading pathogens. Secretions of the airways contain proteins that have direct antimicrobial activity (lysozyme, lactoferrin, defensins, and cathelicidins) as well as complement factors and surfactant proteins that contribute to host defense. The hydrophobic surfactant protein C (SP-C) recognizes LPS (Augusto, L., Le Blay, K., Auger, G., Blanot, D., and Chaby, R. (2001) Am. J. Physiol. 281, L776-L785). In the present study, using synthetic analogs of SP-C, we demonstrate that the palmitoyl residues of SP-C are not required for the interaction with LPS and that both the hydrophilic and hydrophobic regions of SP-C are required for specific binding of a radiolabeled rough-type LPS. In addition, using LPS submitted to different chemical treatments as well as synthetic analogs of the lipid A moiety of LPS, we established that the terminal phosphate group at the reducing end of the lipid A disaccharide in a configuration is of crucial importance for recognition by SP-C. The N-linked fatty acyl chain on the reducing glucosamine of lipid A also takes part in the interaction. Dipalmitoyl phosphatidylcholine is not specifically required for the LPS-binding activity of SP-C, although a lipid environment significantly increases the binding. These results provide a basis for experiments on the role of SP-C in presentation of LPS to alveolar cells and for the design of drugs for the management of endotoxin-induced lung injury.	Univ Paris 11, Natl Ctr Sci Res, UMR 8619, Endotoxin Grp, F-91405 Orsay, France; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet	Chaby, R (corresponding author), Univ Paris 11, Natl Ctr Sci Res, UMR 8619, Endotoxin Grp, F-91405 Orsay, France.		Augusto, Luis/AAR-2230-2021	Johansson, Jan/0000-0002-8719-4703; Augusto, Luis Antonio/0000-0003-2070-944X				Augusto L, 2001, AM J PHYSIOL-LUNG C, V281, pL776, DOI 10.1152/ajplung.2001.281.4.L776; Beamer LJ, 1998, PROTEIN SCI, V7, P906; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Brandenburg K, 1998, EUR J BIOCHEM, V258, P686, DOI 10.1046/j.1432-1327.1998.2580686.x; CHANTRES JR, 1992, J PHARM SCI, V81, P74, DOI 10.1002/jps.2600810115; CHARON D, 1985, BIOCHEMISTRY-US, V24, P2736, DOI 10.1021/bi00332a021; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CLERCX A, 1995, EUR J BIOCHEM, V229, P465, DOI 10.1111/j.1432-1033.1995.tb20487.x; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; Dankesreiter S, 2000, J IMMUNOL, V164, P4804, DOI 10.4049/jimmunol.164.9.4804; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; Gustafsson M, 2000, BBA-BIOMEMBRANES, V1466, P169, DOI 10.1016/S0005-2736(00)00198-X; Gustafsson M, 1997, BIOCHEM J, V326, P799, DOI 10.1042/bj3260799; Gustafsson M, 2001, J MOL BIOL, V310, P937, DOI 10.1006/jmbi.2001.4810; Hallman Mikko, 2001, Biology of the Neonate, V80, P36; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; JOHANSSON J, 1995, FEBS LETT, V362, P261, DOI 10.1016/0014-5793(95)00216-V; Johansson J, 1998, BBA-MOL BASIS DIS, V1408, P161, DOI 10.1016/S0925-4439(98)00065-9; JOHANSSON J, 1995, BIOCHEM J, V307, P535, DOI 10.1042/bj3070535; KALINA M, 1995, AM J PHYSIOL-LUNG C, V268, pL144, DOI 10.1152/ajplung.1995.268.1.L144; Karibian D, 1999, RAPID COMMUN MASS SP, V13, P2252, DOI 10.1002/(SICI)1097-0231(19991130)13:22<2252::AID-RCM783>3.0.CO;2-G; KATYAL SL, 1977, LAB INVEST, V36, P585; KIRIKAE T, 1994, FEMS IMMUNOL MED MIC, V8, P13; Knirel YA, 1996, CARBOHYD RES, V283, P129, DOI 10.1016/0008-6215(95)00401-7; Korfhagen TR, 1998, BBA-MOL BASIS DIS, V1408, P296, DOI 10.1016/S0925-4439(98)00075-1; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; LeVine AM, 1997, J IMMUNOL, V158, P4336; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Lutz C, 1998, AM J RESP CRIT CARE, V158, P840, DOI 10.1164/ajrccm.158.3.9801089; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Nilsson G, 1998, EUR J BIOCHEM, V255, P116, DOI 10.1046/j.1432-1327.1998.2550116.x; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Palmblad M, 1999, BIOCHEM J, V339, P381, DOI 10.1042/0264-6021:3390381; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PHILLIPS NJ, 1993, BIOCHEMISTRY-US, V32, P2003, DOI 10.1021/bi00059a017; PISON U, 1994, EUR J CLIN INVEST, V24, P586, DOI 10.1111/j.1365-2362.1994.tb01110.x; Poelstra K, 1997, AM J PATHOL, V151, P1163; Rahman MM, 1999, GLYCOBIOLOGY, V9, P1371, DOI 10.1093/glycob/9.12.1371; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; RUBIO S, 1995, J BIOL CHEM, V270, P12162, DOI 10.1074/jbc.270.20.12162; RYAN LK, 1989, AM REV RESPIR DIS, V140, P1429, DOI 10.1164/ajrccm/140.5.1429; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; WATSON J, 1975, J IMMUNOL, V114, P1462; Yousefi-Salakdeh E, 1999, BIOCHEM J, V343, P557, DOI 10.1042/0264-6021:3430557	49	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23484	23492		10.1074/jbc.M111925200	http://dx.doi.org/10.1074/jbc.M111925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980896	hybrid			2022-12-25	WOS:000176475700052
J	Liang, CL; Chen, JL; Hsu, YPP; Ou, JT; Chang, YS				Liang, CL; Chen, JL; Hsu, YPP; Ou, JT; Chang, YS			Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYTIC SWITCH; TRANSCRIPTIONAL ACTIVATION; DIMERIZATION DOMAIN; BINDING-ELEMENT; LEUCINE ZIPPER; VIRAL-DNA; PROMOTER; IDENTIFICATION; RECEPTOR; CELLS	Induction of Epstein-Barr virus (EBV) production in an EBV-positive cell is achieved by expression of the gene BZLF1 that switches the latent state into a lytic state. The expression of the BZLF1 gene is initiated from the promoter Zp, which is normally suppressed in EBV-transformed B cells. The BZLF1 gene can be induced for expression by activating agents, such as transforming growth factor-beta (TGF-beta) and 12-O-tetradecanoylphorbol-13-acetate. The 12-O-tetradecanoylphorbol-13-acetate-responsive element located in the Zp is the AP-1 motif. The TGF-beta-responsive element, however, has not been determined. We demonstrated that the Smad4-binding element site, GTCTG, from -233 to -229, was located in the regulatory region of the Zp relative to the BZLF1 transcription initiation site and was physically associated with Smad4. This association was important for the TGF-beta induction of Zp. We also showed from the results of co-transfection experiments and electrophoretic mobility shift assays that both the AP-1 motif and Smad4-binding element site appeared to be required for the TGF-beta-induced activation of Zp. This effect was mediated through the cooperation of Smad3/Smad4 and c-Jun/c-Fos that formed a complex. TGF-beta treatment of Rael cells induced production of infectious EBV particles that was capable of infecting EBV-negative CA46 cells and transforming normal cord blood B cells, in vitro. Those data support a mechanism that TGF-beta induces the latent EBV in cells to enter the viral lytic cycle through regulation of key viral proteins by TGF-beta signal transducers. Those findings also suggest a role of TGF-beta in EBV-associated diseases.	Chang Gung Univ, Sch Med, Grad Inst Basic Med Sci, Tao Yuan, Taiwan; Chang Gung Univ, Sch Med, Dept Microbiol & Immunol, Tao Yuan, Taiwan; Natl Tsing Hua Univ, Grad Inst Life Sci, Hsinchu 300, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan	Chang Gung University; Chang Gung University; National Tsing Hua University; National Yang Ming Chiao Tung University	Chang, YS (corresponding author), Chang Gung Univ, Sch Med, Grad Inst Basic Med Sci, 259 Wen Hwa 1st Rd, Tao Yuan, Taiwan.			Chang, Yu-Sun/0000-0002-6457-3890				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; CAYROL C, 1995, J VIROL, V69, P4206, DOI 10.1128/JVI.69.7.4206-4212.1995; Chang PJ, 1998, J VIROL, V72, P5128, DOI 10.1128/JVI.72.6.5128-5136.1998; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHANG YS, 1995, INT J CANCER, V62, P673, DOI 10.1002/ijc.2910620605; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Chen HL, 1999, P NATL ACAD SCI USA, V96, P9339, DOI 10.1073/pnas.96.16.9339; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; DAIBATA M, 1994, VIROLOGY, V198, P446, DOI 10.1006/viro.1994.1056; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIRENZO L, 1994, INT J CANCER, V57, P914, DOI 10.1002/ijc.2910570623; Fahmi H, 2000, J VIROL, V74, P5810, DOI 10.1128/JVI.74.13.5810-5818.2000; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FARRELL PJ, 1983, EMBO J, V2, P1331, DOI 10.1002/j.1460-2075.1983.tb01588.x; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FLEMINGTON E, 1990, J VIROL, V64, P1217, DOI 10.1128/JVI.64.3.1217-1226.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; GROGAN E, 1987, P NATL ACAD SCI USA, V84, P1332, DOI 10.1073/pnas.84.5.1332; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KOUZARIDES T, 1991, ONCOGENE, V6, P195; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Liang CL, 2000, VIROLOGY, V277, P184, DOI 10.1006/viro.2000.0582; LIN JC, 1979, VIROLOGY, V99, P183, DOI 10.1016/0042-6822(79)90052-7; Liu SF, 1997, VIROLOGY, V228, P11, DOI 10.1006/viro.1996.8371; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; SHIMIZU N, 1993, J VIROL, V67, P3240, DOI 10.1128/JVI.67.6.3240-3245.1993; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsai CH, 1997, J BIOMED SCI, V4, P69, DOI 10.1007/BF02255596; TSAI CN, 1995, DNA CELL BIOL, V14, P767, DOI 10.1089/dna.1995.14.767; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZURHAUSEN H, 1978, NATURE, V272, P373	49	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23345	23357		10.1074/jbc.M107420200	http://dx.doi.org/10.1074/jbc.M107420200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971895	hybrid			2022-12-25	WOS:000176475700034
J	Greiser, JS; Stross, C; Heinrich, PC; Behrmann, I; Hermanns, HM				Greiser, JS; Stross, C; Heinrich, PC; Behrmann, I; Hermanns, HM			Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOSTATIN-M RECEPTOR; ERYTHROPOIETIN RECEPTOR; TRANSDUCER GP130; MONOCLONAL-ANTIBODIES; TRANSMEMBRANE DOMAIN; CYTOKINE RECEPTORS; EPO RECEPTOR; IL-6 FAMILY; FERM DOMAIN; ACTIVATION	The glycoprotein 130 (gp130) is the common signal transducing receptor chain of the interleukin-6 family of cytokines. Here we investigated the requirements for transfer of the information given by ligand binding to the cytoplasmic domain of gp130. It is demonstrated that the box 1/2 region has to be located membrane-proximally in order to bind and activate Janus kinases. To test the possible requirement of an a-helical orientation, we inserted 1-4 alanine residues into this juxtamembrane intracellular region. The insertion of one alanine results in a strongly reduced activation of STAT1 and STAT3, whereas insertion of three alanine residues leads to a stronger STAT activation. These results suggest that gp130-mediated activation of STATs is sensitive to rotational changes around the receptor axis perpendicular to the membrane. Surprisingly, insertion of 1, 2, 3, or 4 alanine residues into this juxtamembrane region leads to successive impairment but not abolishment of Janus kinase and receptor phosphorylation, supporting the finding of sensitivity of Janus kinases toward changes in distance of box 1/2 from the plasma membrane. We suggest a new model concerning the gp130 activation mode in which the relative orientation of the cytoplasmic regions seems to be critical for further signal transduction.	Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Heinrich, PC (corresponding author), Rhein Westfal TH Aachen Klinikum, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.			Behrmann, Iris/0000-0003-3688-3645				Autissier P, 1998, INT IMMUNOL, V10, P1881, DOI 10.1093/intimm/10.12.1881; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; Kurth I, 1999, J IMMUNOL, V162, P1480; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Muller-Newen G, 2000, J BIOL CHEM, V275, P4579, DOI 10.1074/jbc.275.7.4579; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Rowlinson SW, 1998, J BIOL CHEM, V273, P5307, DOI 10.1074/jbc.273.9.5307; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Szalai C, 2000, GENE, V243, P161, DOI 10.1016/S0378-1119(99)00536-3; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	36	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26959	26965		10.1074/jbc.M204113200	http://dx.doi.org/10.1074/jbc.M204113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011064	hybrid			2022-12-25	WOS:000177055900035
J	Li, XM; Li, RH; Lin, XH; Guan, MX				Li, XM; Li, RH; Lin, XH; Guan, MX			Isolation and characterization of the putative nuclear modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 S rRNA A1555G mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16S RIBOSOMAL-RNA; CYTOCHROME-C-OXIDASE; PAROMOMYCIN-RESISTANCE MUTATION; ANTICODON WOBBLE NUCLEOTIDE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MODIFICATION DEFECT; DECODING REGION; WILD-TYPE; YEAST	The human mitochondrial 12 S rRNA A1555G mutation has been found to be associated with aminoglycoside-induced and non-syndromic deafness. However, putative nuclear modifier gene(s) have been proposed to regulate the phenotypic expression of this mutation. In yeast, the mutant alleles of MTO1, encoding a mitochondrial protein, manifest respiratory-deficient phenotype only when coupled with the mitochondrial 15 S rRNA P-4.4(R) mutation corresponding to human A1555G mutation. This suggests that the MTO1-like modifier gene may influence the phenotypic expression of human A1555G mutation. Here we report the identification of full-length cDNA and elucidation of genomic organization of the human MTO1 homolog. Human Mto1 is an evolutionarily conserved protein that implicates a role in the mitochondrial tRNA modification. Functional conservation of this protein is supported by the observation that isolated human MTO1 cDNA can complement the respiratory deficient phenotype of yeast mto1 cells carrying P-454(R) mutation. MTO1 is ubiquitously expressed in various tissues, but with a markedly elevated expression in tissues of high metabolic rates including cochlea. These observations suggest that human MTO1 is a structural and functional homolog of yeast MTO1. Thus, it may play an important role in the pathogenesis of deafness-associated A1555G mutation in 12 S rRNA gene or mutations in tRNA genes.	Childrens Hosp, Ctr Med, Div Human Genet, Program Human Genet, Cincinnati, OH 45229 USA; Childrens Hosp, Ctr Med, Ctr Hearing & Deafness Res, Cincinnati, OH 45229 USA; Childrens Hosp, Ctr Med, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Guan, MX (corresponding author), Childrens Hosp, Ctr Med, Div Human Genet, Program Human Genet, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Guan, Min-Xin/0000-0001-5067-6736	NIDCD NIH HHS [R03 DC004958] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC004958] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BJORK GR, 1996, ESCHERICHIA COLI SAL, P861; Bregeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701; BU X, 1993, GENET EPIDEMIOL, V9, P27; Bykhovskaya Y, 2000, AM J HUM GENET, V66, P1905, DOI 10.1086/302914; CLARKWAL.GD, 1974, GENET RES, V24, P43, DOI 10.1017/S0016672300015068; Colby G, 1998, J BIOL CHEM, V273, P27945, DOI 10.1074/jbc.273.43.27945; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; DESTASIO EA, 1990, J MOL BIOL, V212, P127, DOI 10.1016/0022-2836(90)90309-A; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; Fischel-Ghodsian N, 1999, HUM MUTAT, V13, P261, DOI 10.1002/(SICI)1098-1004(1999)13:4<261::AID-HUMU1>3.0.CO;2-W; FISCHELGHODSIAN N, 1993, AM J OTOLARYNG, V14, P399, DOI 10.1016/0196-0709(93)90113-L; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GREGORY ST, 1995, NUCLEIC ACIDS RES, V23, P4234, DOI 10.1093/nar/23.21.4234; Guan MX, 2001, HUM MOL GENET, V10, P573, DOI 10.1093/hmg/10.6.573; Guan MX, 2000, HUM MOL GENET, V9, P1787, DOI 10.1093/hmg/9.12.1787; Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963; HAGERVALL TG, 1984, MOL GEN GENET, V196, P194, DOI 10.1007/BF00328050; Hamasaki K, 1997, BIOCHEMISTRY-US, V36, P12323, DOI 10.1021/bi970962r; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUTCHIN T, 1993, NUCLEIC ACIDS RES, V21, P4174, DOI 10.1093/nar/21.18.4174; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Kruger MK, 1998, J MOL BIOL, V284, P609, DOI 10.1006/jmbi.1998.2197; LI M, 1982, J BIOL CHEM, V257, P5921; Menke AL, 1996, ONCOGENE, V12, P537; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NEEFS JM, 1991, NUCLEIC ACIDS RES, V19, P1987, DOI 10.1093/nar/19.suppl.1987; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO;2-O; Schneider TD, 1997, J THEOR BIOL, V189, P427, DOI 10.1006/jtbi.1997.0540; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Skvorak AB, 1999, HUM MOL GENET, V8, P439, DOI 10.1093/hmg/8.3.439; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WEISSBRUMMER B, 1989, MOL GEN GENET, V217, P362, DOI 10.1007/BF02464905; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804; ZIMMERMANN RA, 1990, RIBOSOME, P331; ZWIEB C, 1986, MOL GEN GENET, V203, P256, DOI 10.1007/BF00333963	51	201	212	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27256	27264		10.1074/jbc.M203267200	http://dx.doi.org/10.1074/jbc.M203267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011058	hybrid			2022-12-25	WOS:000177055900072
J	Liu, CW; Millen, L; Roman, TB; Xiong, H; Gilbert, HF; Noiva, R; Demartino, GN; Thomas, PJ				Liu, CW; Millen, L; Roman, TB; Xiong, H; Gilbert, HF; Noiva, R; Demartino, GN; Thomas, PJ			Conformational remodeling of proteasomal substrates by PA700, the 19 S regulatory complex of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; MULTIUBIQUITIN-CHAIN-BINDING; MOLECULAR CHAPERONE HSC70; ATP-DEPENDENT ACTIVATOR; 20S PROTEASOME; MULTICATALYTIC PROTEINASE; SACCHAROMYCES-CEREVISIAE; DIHYDROFOLATE-REDUCTASE; SELECTIVE DEGRADATION; OXIDIZED PROTEINS	PA700, the 19 S regulatory complex of the 26 S proteasome, plays a central role in the recognition and efficient degradation of misfolded proteins. PA700 promotes degradation by recruiting proteasomal substrates utilizing polyubiquitin chains and chaperone-like binding activities and by opening the access to the core of the 20 S proteasome to promote degradation. Here we provide evidence that PA700 in addition to binding misfolded protein substrates also acts to remodel their conformation prior to proteolysis. Scrambled RNase A (scRNase A), a misfolded protein, only slowly refolds spontaneously into an active form because of the rate-limiting unfolding of misfolded disulfide isomers. Notably, PA700 accelerates the rate of reactivation of scRNase A, consistent with its ability to increase the exposure of these disulfide bonds to the solvent. In this regard, PA700 also exposes otherwise buried sites to digestion by exogenous chymotrypsin in a polyubiquitinated enzymatically active substrate, pentaubiquitinated dihydrofolate reductase, Ub(5)DHFR. The dihydrofolate reductase ligand methotrexate counters the ability of PA700 to promote digestion by chymotrypsin. Together, these results indicate that in addition to increasing substrate affinity and opening the access channel to the catalytic sites, PA700 activates proteasomal degradation by remodeling the conformation of protein substrates.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Univ S Dakota, Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; University of South Dakota	Thomas, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [DK 49835, DK 46818] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R37DK049835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Harris DA, 2000, NUTRITION, V16, P554, DOI 10.1016/S0899-9007(00)00361-0; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; Merker K, 2000, EXP GERONTOL, V35, P779, DOI 10.1016/S0531-5565(00)00140-6; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; SELA M, 1957, SCIENCE, V125, P691, DOI 10.1126/science.125.3250.691; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Wang R, 1999, BIOCHEMISTRY-US, V38, P14573, DOI 10.1021/bi990826h; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YU J, 1993, J BIOL CHEM, V268, P4326; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	57	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26815	26820		10.1074/jbc.M201782200	http://dx.doi.org/10.1074/jbc.M201782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011044	hybrid			2022-12-25	WOS:000177055900016
J	Bordone, L; Campbell, C				Bordone, L; Campbell, C			DNA ligase III is degraded by calpain during cell death induced by DNA-damaging agents.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CASPASE-MEDIATED CLEAVAGE; INDUCED APOPTOSIS; EARLY EVENT; PROTEINS; ALPHA; MECHANISM; ACTIN; IDENTIFICATION; INTERFERON	A yeast two-hybrid screen identified the regulatory subunit of the calcium-dependent protease calpain as a putative DNA ligase Ill-binding protein. Calpain binds to the N-terminal region of DNA ligase III, which contains an acidic proline, aspartate, serine, and threonine (PEST) domain frequently present in proteins cleaved by calpain. Recombinant DNA ligase III was a substrate for calpain degradation in vitro. This calpain-mediated proteolysis was calcium-dependent and was blocked by the specific calpain inhibitor calpeptin. Western blot analysis revealed that DNA ligase III was degraded in human fibrosarcoma HT1080 cells following exposure to gamma-radiation. The degradation of DNA ligase III was prevented by pretreatment with calpeptin, which protected irradiated cells from death. Calpeptin treatment also blocked 9-amino camptothecin-induced DNA ligase III proteolysis and simultaneously protected the cells from death. HT1080 clones expressing a modified DNA ligase III that lacked a recognizable PEST domain were significantly more resistant to killing by gamma-radiation or 9-amino camptothecin than were cells that overexpressed the wild-type form of DNA ligase III. These data show that calpain-mediated proteolysis of DNA ligase III plays an essential role in DNA damage-induced cell death in human cells.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Campbell, C (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St,SE, Minneapolis, MN 55455 USA.	campb034@umn.edu			NCI NIH HHS [CA61906] Funding Source: Medline; NIA NIH HHS [AG16678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA061906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEMARTINO GN, 1986, J BIOL CHEM, V261, P2047; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Elce JS, 1997, J BIOL CHEM, V272, P11268; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Huang YY, 1999, MOL CELL BIOL, V19, P2986; INOMATA M, 1988, J BIOL CHEM, V263, P19783; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KIM MY, 1991, J BIOL CHEM, V266, P484; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KULKARNI GV, 1994, J CELL SCI, V107, P1169; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; Li L, 2001, INT J RADIAT ONCOL, V49, P1157, DOI 10.1016/S0360-3016(00)01524-8; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; ROBERTSLEWIS JM, 1993, J NEUROCHEM, V61, P378, DOI 10.1111/j.1471-4159.1993.tb03583.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; Tong X, 2000, INT J RADIAT BIOL, V76, P1387, DOI 10.1080/09553000050151664; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	46	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26673	26680		10.1074/jbc.M112037200	http://dx.doi.org/10.1074/jbc.M112037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994275	hybrid			2022-12-25	WOS:000176908700109
J	Kane, R; Murtagh, J; Finlay, D; Marti, A; Jaggi, R; Blatchford, D; Wilde, C; Martin, F				Kane, R; Murtagh, J; Finlay, D; Marti, A; Jaggi, R; Blatchford, D; Wilde, C; Martin, F			Transcription factor NFIC undergoes N-glycosylation during early mammary gland involution.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; ADENOVIRUS DNA-REPLICATION; PROTEIN GENE-EXPRESSION; PROGRAMMED CELL-DEATH; EPITHELIAL-CELLS; BINDING PROTEINS; KAPPA-B; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; TRANSGENIC MICE	Expression of a 74-kDa nuclear factor I (NFI) protein is triggered in early involution in the mouse mammary gland, and its expression correlates with enhanced occupation of a twin (NFI) binding element in the clusterin promoter, a gene whose transcription is induced at this time (Furlong, E. E., Keon, N. K., Thornton, F. D., Rein, T., and Martin, F. (1996) J. BioL Chem. 271,29688-29697). We now identify this 74-kDa NFI as an NFIC isoform based on its interaction in Western analysis with two NFIC-specific antibodies. A transition from the expression of a 49-kDa NFIC in lactation to the expression of the 74-kDa NFIC in early involution is demonstrated. We show that the 74-kDa NFIC binds specifically to concanavalin A (ConA) and that this binding can be reversed by the specific ConA ligands, methyl a-D-mannopyranoside and methyl a-D-glucopyranoside. In addition, its apparent molecular size was reduced to similar to63 kDa by treatment with the peptide N-glycosidase. The 49-kDa lactation-associated NFIC did not bind ConA nor was it affected by peptide N-glycosidase. Tunicamycin, a specific inhibitor of N-glycosylation, blocked formation of the 74-kDa NFI in involuting mouse mammary gland in vivo when delivered from implanted Elvax depot pellets. Finally, the production of the ConA binding activity could be reiterated in "mammospheres" formed from primary mouse mammary epithelial cells associated with a laminin-rich extracellular matrix. Synthesis of the 74-kDa NFIC was also inhibited in this setting by tunicamycin. Thus, involution triggers the production of an NFIC isoform that is post-translationally modified by N-glycosylation. We further show, by using quantitative competitive reverse transcriptase-PCR, that there is increased expression of the major mouse mammary NFIC mRNA transcript, mNFIC2, in early involution, suggesting that the involution-associated change in NFIC expression also has a transcriptional contribution.	Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Natl Univ Ireland Univ Coll Dublin, Dept Pharmacol, Dublin 4, Ireland; Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland	University College Dublin; University College Dublin; University of Bern	Martin, F (corresponding author), Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.	finian.martin@ucd.ie						ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarkson RWE, 1999, J MAMMARY GLAND BIOL, V4, P165, DOI 10.1023/A:1018725207969; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; French LE, 1996, BIOL REPROD, V55, P1213, DOI 10.1095/biolreprod55.6.1213; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; GRONOSTAJSKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P4013, DOI 10.1073/pnas.81.13.4013; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HAY RT, 1985, J MOL BIOL, V186, P129, DOI 10.1016/0022-2836(85)90263-3; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; Imagawa M, 2000, FEBS LETT, V484, P118, DOI 10.1016/S0014-5793(00)02119-0; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOHLER PO, 1971, ACTA ENDOCRINOL-COP, P137; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, J BIOL CHEM, V269, P14235; Liu YC, 1997, J BIOL CHEM, V272, P10739; Marti A, 1999, J MAMMARY GLAND BIOL, V4, P145, DOI 10.1023/A:1018721107061; MARTI A, 1994, ONCOGENE, V9, P1213; McGarvey PB, 2000, BIOINFORMATICS, V16, P290, DOI 10.1093/bioinformatics/16.3.290; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; O'Connell FC, 2000, CELL DEATH DIFFER, V7, P360, DOI 10.1038/sj.cdd.4400647; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; ROULET E, 1995, MOL CELL BIOL, V15, P5552; Rozen S, 2000, Methods Mol Biol, V132, P365; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; STRANGE R, 1992, DEVELOPMENT, V115, P49; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; Wilson K, 2000, QUAL HEALTH RES, V10, P507, DOI 10.1177/104973200129118606	67	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25893	25903		10.1074/jbc.M202469200	http://dx.doi.org/10.1074/jbc.M202469200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11991954	hybrid			2022-12-25	WOS:000176908700012
J	Li, S; Rosen, BP; Borges-Walmsley, MI; Walmsley, AR				Li, S; Rosen, BP; Borges-Walmsley, MI; Walmsley, AR			Evidence for cooperativity between the four binding sites of dimeric ArsD, an As(III)-responsive transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; COPPER-TRANSPORTING ATPASE; SINGLE-TRYPTOPHAN MUTANTS; WILSON DISEASE GENE; MENKES DISEASE; CANDIDATE GENE; ARSENATE REDUCTASE; LACTOSE REPRESSOR; STRUCTURAL BASIS; ENCODES	ArsD is a trans-acting repressor of the arsRDABC operon that confers resistance to arsenicals and antimonials in Escherichia coli. It possesses two-pairs of vicinal cysteine residues, Cys(12)-Cys(13) and Cys(112)-Cys(113), that potentially form separate binding sites for the metalloids that trigger dissociation of ArsD from the operon. However, as a homodimer it has four vicinal cysteine pairs. Titration of the steady-state fluorescence of ArsD with metalloids revealed positive cooperativity, with a Hill coefficient of 2, between these sites. Disruption of the Cys(112)-Cys(113) site by mutagenesis of arsD, but not the Cys(12)-Cys(13) site, largely abolished this cooperativity, indicative of interactions between adjacent Cys(112)-Cys(113) sites within the dimer. The kinetics of metalloid binding were determined by stopped flow spectroscopy; the rate increased in a sigmoidal manner, with a Hill coefficient of 4, indicating that the pre-steady-state measurements reported cooperativity between all four sites of the dimer rather than just the intermolecular interactions reported by the steady-state measurements. The kinetics of Sb(III) displacement by As(III) revealed that the metalloid-binding sites behave differentially, with the rapid exchange of As(III) for Sb(III) at one site retarding the release of Sb(III) from the other sites. We propose a model involving the sequential binding and release of metalloids by the four binding sites of dimeric ArsD, with only one site releasing free metalloids.	Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of Glasgow; Wayne State University	Walmsley, AR (corresponding author), Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Level 3,Robertson Bldg,56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.			Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI45428] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Barry JK, 1997, BIOCHEMISTRY-US, V36, P15632, DOI 10.1021/bi971685r; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CHEN CM, 1986, J BIOL CHEM, V261, P5030; Chen YX, 1997, J BIOL CHEM, V272, P14257, DOI 10.1074/jbc.272.22.14257; DELNOMDEDIEU M, 1993, CHEM RES TOXICOL, V6, P598, DOI 10.1021/tx00035a002; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7287; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Kintrup M, 2000, EUR J BIOCHEM, V267, P821, DOI 10.1046/j.1432-1327.2000.01063.x; Li S, 2001, MOL MICROBIOL, V41, P687, DOI 10.1046/j.1365-2958.2001.02546.x; Liu JY, 1997, J BIOL CHEM, V272, P21084, DOI 10.1074/jbc.272.34.21084; Martin P, 2001, STRUCTURE, V9, P1071, DOI 10.1016/S0969-2126(01)00672-4; Matthews KS, 2000, NAT STRUCT BIOL, V7, P184, DOI 10.1038/73274; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Ozarowski A, 1999, BIOCHEMISTRY-US, V38, P6715, DOI 10.1021/bi990242f; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Vergani B, 2000, BIOCHEMISTRY-US, V39, P2759, DOI 10.1021/bi9912591; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427	28	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25992	26002		10.1074/jbc.M201619200	http://dx.doi.org/10.1074/jbc.M201619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11980902	hybrid, Green Accepted			2022-12-25	WOS:000176908700024
J	Lomax, RB; Camello, C; Van Coppenolle, F; Petersen, OH; Tepikin, AV				Lomax, RB; Camello, C; Van Coppenolle, F; Petersen, OH; Tepikin, AV			Basal and physiological Ca2+ leak from the endoplasmic reticulum of pancreatic acinar cells - Second messenger-activated channels and translocons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CA-2+ RELEASE; CYCLIC-ADP-RIBOSE; CALCIUM STORES; INOSITOL TRISPHOSPHATE; INTRACELLULAR STORES; MEMBRANE-VESICLES; CHOLECYSTOKININ; HEPARIN; ER; MOBILIZATION	We have studied the Ca2+ leak pathways in the endoplasmic reticulum. of pancreatic acinar cells by directly measuring Ca2+ in the endoplasmic reticulum. ([Ca2+](ER)). Cytosolic Ca2+ ([Ca2+](C)) was clamped to the resting level by a BAPTA-Ca2+ mixture. Administration of cholecystokinin within the physiological concentration range caused a graded decrease of [Ca2+](ER), and the rate of Ca2+ release generated by 10 pm cholecystokinin is at least 3x as fast as the basal Ca2+ leak revealed by inhibition of the endoplasmic reticulum Ca2+-ATPase. Acetylcholine also evokes a dose-dependent decrease of [Ca2+](ER), with an EC50 of 0.98 +/- 0.06 mum. Inhibition of receptors for inositol 1,4,5-trisphosphate (IP3) by heparin or flunarizine blocks the effect of acetylcholine but only partly blocks the effect of cholecystokinin. 8-NH2 cyclic ADP-ribose (20 mum) inhibits the action of cholecystokinin, but not of acetylcholine. The basal Ca2+ leak from the endoplasmic reticulum. is not blocked by antagonists of the IP3 receptor, the ryanodine receptor, or the receptor for nicotinic acid adenine dinucleotide phosphate. However, treatment with puromycin (0.1-1 mm) to remove nascent polypeptides from ribosomes increases Ca2+ leak from the endoplasmic reticulum by a mechanism independent of the endoplasmic reticulum Ca2+ pumps and of the receptors for IP3 or ryanodine.	Univ Liverpool, Physiol Lab, MRC, Secretory Control Res Grp, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Lomax, RB (corresponding author), Univ Liverpool, Physiol Lab, MRC, Secretory Control Res Grp, Liverpool L69 3BX, Merseyside, England.		Camello, Cristina/K-8238-2014; Petersen, Ole H/E-8708-2010	Camello, Cristina/0000-0003-0882-8497; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513				BALLINGER A, 1995, CLIN SCI, V89, P375, DOI 10.1042/cs0890375; Beecroft MD, 1998, BIOCHEM J, V334, P431, DOI 10.1042/bj3340431; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; BROMSTROM CO, 1996, J BIOL CHEM, V271, P24995; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Cancela JM, 1998, PFLUG ARCH EUR J PHY, V435, P746, DOI 10.1007/s004240050578; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FAVRE CJ, 1994, BIOCHEM J, V302, P155, DOI 10.1042/bj3020155; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Jeffery J, 2000, BIOCHEM BIOPH RES CO, V268, P711, DOI 10.1006/bbrc.2000.2194; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; Missiaen L, 1996, BIOCHEM J, V317, P849, DOI 10.1042/bj3170849; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; OVEREND CL, 1998, J PHYSL, V507, P750; PALADE P, 1989, MOL PHARMACOL, V36, P673; PALADE P, 1987, J BIOL CHEM, V262, P6135; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Pessah IN, 1997, AM J PHYSIOL-CELL PH, V272, pC601, DOI 10.1152/ajpcell.1997.272.2.C601; Pestka S, 1974, Methods Enzymol, V30, P261; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; SEILER SM, 1987, BIOCHEM PHARMACOL, V36, P3331, DOI 10.1016/0006-2952(87)90307-8; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; THOM P, 1993, CELL, V74, P661; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wetmore DR, 1996, BIOCHEMISTRY-US, V35, P6549, DOI 10.1021/bi9530752; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285	46	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26479	26485		10.1074/jbc.M201845200	http://dx.doi.org/10.1074/jbc.M201845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994289	Green Submitted, hybrid			2022-12-25	WOS:000176908700086
J	Pittman, JK; Shigaki, T; Cheng, NH; Hirschi, KD				Pittman, JK; Shigaki, T; Cheng, NH; Hirschi, KD			Mechanism of N-terminal autoinhibition in the Arabidopsis Ca2+/H+ antiporter CAX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; H+/CA2+ ANTIPORTER; VACUOLAR MEMBRANE; CALCIUM-PUMP; EXPRESSION; TRANSPORT; DOMAIN; IDENTIFICATION; TOLERANCE	Regulation of Ca2+/H+ antiporters may be an important function in determining the duration and amplitude of cytosolic Ca2+ oscillations. Previously the Arabidopsis Ca2+/H+ transporter, CAX1 (cation exchanger 1), was identified by its ability to suppress yeast mutants defective in vacuolar Ca2+ transport. Recently, a 36-amino acid N-terminal regulatory region on CAX1 has been identified that inhibits CAX1-mediated Ca2+/H+ antiport. Here we show that a synthetic peptide designed against the CAX1 36 amino acids inhibited Ca2+/H+ transport mediated by an N-terminal-truncated CAX1 but did not inhibit Ca2+ transport by other Ca2+/H+ antiporters. Ca2+/H+ antiport activity measured from vacuolar-enriched membranes of Arabidopsis root was also inhibited by the CAX1 peptide. Through analyzing CAX chimeric constructs the region of interaction of the N-terminal regulatory region was mapped to include 7 amino acids (residues 56-62) within CAX1 The CAX1 N-terminal regulatory region was shown to physically interact with this 7-amino acid region by yeast two-hybrid analysis. Mutagenesis of amino acids within the N-terminal regulatory region implicated several residues as being essential for regulation. These findings describe a unique mode of antiporter auto-inhibition and demonstrate the first detailed mechanisms for the regulation of a Ca2+/H+ antiporter from any organism.	USDA ARS, Baylor Coll Med, Childrens Nutr Res Ctr, Plant Physiol Grp, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Texas A&M University System; Texas A&M University College Station	Hirschi, KD (corresponding author), USDA ARS, Baylor Coll Med, Childrens Nutr Res Ctr, Plant Physiol Grp, 1100 Bates St, Houston, TX 77030 USA.		hirschi, kendal/GNP-0351-2022	Pittman, Jon/0000-0001-7197-1494	NHLBI NIH HHS [CHRC 5 P30] Funding Source: Medline; NIGMS NIH HHS [1R01 GM57427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057427] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cheng NH, 2002, PLANT PHYSIOL, V128, P1245, DOI 10.1104/pp.010857; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; Gaxiola RA, 2001, P NATL ACAD SCI USA, V98, P11444, DOI 10.1073/pnas.191389398; Geisler M, 2000, PLANT PHYSIOL, V124, P1814, DOI 10.1104/pp.124.4.1814; Goncalves PP, 2000, NEUROCHEM INT, V37, P387, DOI 10.1016/S0197-0186(00)00009-7; Harper JF, 2001, TRENDS PLANT SCI, V6, P395, DOI 10.1016/S1360-1385(01)02023-4; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; HARPER JW, 1993, CELL, V75, P805; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Hirschi KD, 1999, PLANT CELL, V11, P2113, DOI 10.1105/tpc.11.11.2113; Hwang I, 2000, PLANT PHYSIOL, V122, P157, DOI 10.1104/pp.122.1.157; Hwang I, 2000, P NATL ACAD SCI USA, V97, P6224, DOI 10.1073/pnas.97.11.6224; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Malmstrom S, 2000, PLANT PHYSIOL, V122, P517, DOI 10.1104/pp.122.2.517; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Shigaki T, 2001, ANAL BIOCHEM, V298, P118, DOI 10.1006/abio.2001.5341; Shigaki T, 2000, GENE, V257, P291, DOI 10.1016/S0378-1119(00)00390-5; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; UEMURA M, 1995, PLANT PHYSIOL, V109, P15, DOI 10.1104/pp.109.1.15; Ueoka-Nakanishi H, 1999, EUR J BIOCHEM, V262, P417, DOI 10.1046/j.1432-1327.1999.00377.x; Villa A, 1998, BBA-BIOMEMBRANES, V1373, P347, DOI 10.1016/S0005-2736(98)00120-5	32	61	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26452	26459		10.1074/jbc.M202563200	http://dx.doi.org/10.1074/jbc.M202563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006570	hybrid			2022-12-25	WOS:000176908700083
J	Amasaki, Y; Adachi, S; Ishida, Y; Iwata, M; Arai, N; Arai, K; Miyatake, S				Amasaki, Y; Adachi, S; Ishida, Y; Iwata, M; Arai, N; Arai, K; Miyatake, S			A constitutively nuclear form of NFATx shows efficient transactivation activity and induces differentiation of CD4(+)CD8(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; SIGNAL-TRANSDUCTION; POSITIVE SELECTION; CYCLOSPORINE-A; NEGATIVE SELECTION; KAPPA-B; NF-ATC; CALCINEURIN; ACTIVATION; THYMOCYTES	The Ca2+ signal facilitates nuclear translocation of NFAT through the dephosphorylation of clustered serine residues in the calcium regulatory domain by the Ca2+/calmodulin-dependent phosphatase calcineurin. The conformation of dephosphorylated NFAT exposes the nuclear localization signal for translocation into the nucleus and masks the nuclear export sequence to keep the protein in the nucleus. It has been reported that deletion of some serine-rich motifs masking the nuclear localization signal results in the translocation of NFAT into the nucleus, but that the nuclear export sequence located at the N terminus also needs to, be deleted for NFATx (NFAT4/NFATc3) to exert efficient transactivation function. Here, we report that deletion of the critical serine-rich motifs of NFATx leads to a conformation that efficiently exposes the nuclear localization signal and that has stronger transcription activity compared with the fully activated wild-type protein in the presence of the nuclear export sequence. This also suggests that the regulation of the transactivation domain by phosphorylation observed in NFAT1 may not contribute significantly to the transcription activity of NFATx. The expression of this constitutively nuclear form of NFATx in the CD4(+)CD8(+) T cell line facilitates differentiation into the CD4 single-positive stage upon stimulation with phorbol ester. Our data suggest that NFATx is involved in the regulation of co-receptor expression during differentiation into the CD4 single-positive stage.	Tokyo Metropolitan Inst Med Sci, Dept Immunol, Bunkyo Ku, Tokyo 1138613, Japan; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; Mitsubishi Kagaku Inst Life Sci, Life Sci Res Dept, Tokyo 1948511, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo	Miyatake, S (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Immunol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	smiya@rinshoken.or.jp						Adachi S, 2000, J BIOL CHEM, V275, P14708, DOI 10.1074/jbc.275.19.14708; Adachi S, 2001, BIOCHEM BIOPH RES CO, V288, P1188, DOI 10.1006/bbrc.2001.5912; AIFANTIS L, 2001, NAT IMMUNOL, V2, P463; Amasaki Y, 1998, J IMMUNOL, V160, P2324; ANDERSON G, 1995, J IMMUNOL, V154, P3636; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Imamura R, 1998, J IMMUNOL, V161, P3455; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Kuwata T, 1998, BIOCHEM BIOPH RES CO, V247, P242, DOI 10.1006/bbrc.1998.8767; Liu J, 1997, MOL BIOL CELL, V8, P157, DOI 10.1091/mbc.8.1.157; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Miyatake S, 1997, EUR J IMMUNOL, V27, P1816, DOI 10.1002/eji.1830270733; NAKAYAMA E, 1979, P NATL ACAD SCI USA, V76, P3486, DOI 10.1073/pnas.76.7.3486; Ochoa-Garay J, 1998, J IMMUNOL, V160, P3835; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; URDAHL KB, 1994, J IMMUNOL, V152, P2853; WANG CR, 1995, J EXP MED, V181, P927, DOI 10.1084/jem.181.3.927; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams O, 2001, EUR J IMMUNOL, V31, P1876, DOI 10.1002/1521-4141(200106)31:6<1876::AID-IMMU1876>3.0.CO;2-F; ZHAO Y, 1995, INT IMMUNOL, V7, P1387, DOI 10.1093/intimm/7.9.1387; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	43	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25640	25648		10.1074/jbc.M201860200	http://dx.doi.org/10.1074/jbc.M201860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997392	hybrid, Green Accepted			2022-12-25	WOS:000176747000103
J	Maithal, K; Ravindra, G; Balaram, H; Balaram, P				Maithal, K; Ravindra, G; Balaram, H; Balaram, P			Inhibition of Plasmodium falciparum triose-phosphate isomerase by chemical modification of an interface cysteine - Electrospray ionization mass spectrometric analysis of differential cysteine reactivities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC INHIBITION; TRIOSEPHOSPHATE-ISOMERASE; TRYPANOSOMA-BRUCEI; LEISHMANIA-MEXICANA; CRYSTAL-STRUCTURE; DIMER INTERFACE; ESCHERICHIA-COLI; ENZYME; DEHYDROGENASE; STABILITY	Plasmodium falciparum triose-phosphate isomerase, a homodimeric enzyme, contains four cysteine residues at positions 13, 126, 196, and 217 per subunit. Among these, Cys-13 is present at the dimer interface and is replaced by methionine in the corresponding human enzyme. We have investigated the effect of sulfhydryl labeling on the parasite enzyme, with a view toward developing selective covalent inhibitors by targeting the interface cysteine residue. Differential labeling of the cysteine residues by iodoacetic acid and iodoacetamide has been followed by electrospray ionization mass spectrometry and positions of the labels determined by analysis of tryptic fragments. The rates of labeling follows the order Cys-196 > Cys-13 much greater than Cys-217/Cys-126, which correlates well with surface accessibility calculations based on the enzyme crystal structure. Iodoacetic acid labeling leads to a soluble, largely inactive enzyme, whereas IAM labeling leads to precipitation. Carboxyl methylation of Cys-13 results in formation of monomeric species detectable by gel filtration. Studies with an engineered C13D mutant permitted elucidation of the effects of introducing a negative charge at the interface. The C13D mutant exhibits a reduced stability to denaturants and 7-fold reduction in the enzymatic activity even under the concentrations in which dimeric species are observed.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560004, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Balaram, P (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		Balaram, P./GOG-8417-2022; Maithal, Kapil/GMX-3163-2022	Maithal, Kapil/0000-0003-2375-5804				BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BORCHERT TV, 1995, FEBS LETT, V367, P315, DOI 10.1016/0014-5793(95)00586-X; CASAL JI, 1987, BIOCHEMISTRY-US, V26, P1258, DOI 10.1021/bi00379a009; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Garza-Ramos G, 1998, EUR J BIOCHEM, V253, P684, DOI 10.1046/j.1432-1327.1998.2530684.x; GarzaRamos G, 1996, EUR J BIOCHEM, V241, P114, DOI 10.1111/j.1432-1033.1996.0114t.x; Gokhale RS, 1999, BIOCHEMISTRY-US, V38, P423, DOI 10.1021/bi981087s; GomezPuyou A, 1995, CHEM BIOL, V2, P847, DOI 10.1016/1074-5521(95)90091-8; Gopal B, 1999, BIOCHEMISTRY-US, V38, P478, DOI 10.1021/bi981495w; HOL WGJ, 1991, MOL CONFORMATION BIO, P215; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KOHL L, 1994, EUR J BIOCHEM, V220, P331, DOI 10.1111/j.1432-1033.1994.tb18629.x; KUNTZ DA, 1992, EUR J BIOCHEM, V207, P441, DOI 10.1111/j.1432-1033.1992.tb17069.x; Lambeir AM, 2000, EUR J BIOCHEM, V267, P2516, DOI 10.1046/j.1432-1327.2000.01254.x; LAMBEIR AM, 1987, EUR J BIOCHEM, V168, P69, DOI 10.1111/j.1432-1033.1987.tb13388.x; Li CM, 1999, NAT STRUCT BIOL, V6, P582, DOI 10.1038/9367; LODI PJ, 1994, BIOCHEMISTRY-US, V33, P2809, DOI 10.1021/bi00176a009; Luecke H, 1997, EXP PARASITOL, V87, P203, DOI 10.1006/expr.1997.4243; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; Mainfroid V, 1996, J MOL BIOL, V257, P441, DOI 10.1006/jmbi.1996.0174; Maldonado E, 1998, J MOL BIOL, V283, P193, DOI 10.1006/jmbi.1998.2094; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Perez-Montfort R, 1999, BIOCHEMISTRY-US, V38, P4114, DOI 10.1021/bi982425s; Phillips C, 1998, J MOL BIOL, V282, P667, DOI 10.1006/jmbi.1998.2059; PLAUT B, 1972, BIOCHEM J, V129, P311, DOI 10.1042/bj1290311; RANIE J, 1993, MOL BIOCHEM PARASIT, V61, P159, DOI 10.1016/0166-6851(93)90062-3; Reyes-Vivas H, 2001, BIOCHEMISTRY-US, V40, P3134, DOI 10.1021/bi002619j; Rietveld AWM, 1998, BIOCHEMISTRY-US, V37, P933, DOI 10.1021/bi9721593; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8482, DOI 10.1021/bi00151a014; Schliebs W, 1997, BIOCHEMISTRY-US, V36, P9655, DOI 10.1021/bi963086a; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; Somoza JR, 1998, BIOCHEMISTRY-US, V37, P5344, DOI 10.1021/bi973095z; Subbayya INS, 1997, INDIAN J MED RES, V106, P79; Suresh S, 2000, STRUCT FOLD DES, V8, P541, DOI 10.1016/S0969-2126(00)00135-0; Velanker SS, 1997, STRUCTURE, V5, P751, DOI 10.1016/S0969-2126(97)00230-X; VERLINDE CLMJ, 1994, PROTEIN SCI, V3, P1670, DOI 10.1002/pro.5560031006; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; WALEY SG, 1973, BIOCHEM J, V135, P165, DOI 10.1042/bj1350165; WELCHES WR, 1981, BIOCHEMISTRY-US, V20, P512, DOI 10.1021/bi00506a011; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; WIERENGA RK, 1992, J MOL BIOL, V224, P115; WILLSON M, 1994, BIOCHEMISTRY-US, V33, P214, DOI 10.1021/bi00167a028; ZABORI S, 1980, Z NATURFORSCH C, V35, P999	46	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25106	25114		10.1074/jbc.M202419200	http://dx.doi.org/10.1074/jbc.M202419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006590	hybrid			2022-12-25	WOS:000176747000036
J	Hoyos, B; Imam, A; Korichneva, I; Levi, E; Chua, R; Hammerling, U				Hoyos, B; Imam, A; Korichneva, I; Levi, E; Chua, R; Hammerling, U			Activation of c-Raf kinase by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; SIGNAL-TRANSDUCTION PATHWAYS; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; INSULIN-RECEPTOR; REVERSIBLE REGULATION; CELL-PROLIFERATION; PHOSPHATIDIC-ACID	The present study highlights retinoids as modulators of c-Raf kinase activation by UV light. Whereas a number of retinoids, including retinol, 14-hydroxyretroretinol, anhydroretinol (AR), and retinoic acid bound the c-Raf cysteine-rich domain (CRD) with equal affinity in vitro as well as in vivo, they displayed different, even opposing, effects on UV-mediated kinase activation; retinol and 14-hydroxyretroretinol augmented responses, whereas retinoic acid and AR were inhibitory. Oxidation of thiol groups of cysteines by reactive oxygen, generated during UV irradiation, was the primary event in c-Raf activation, causing the release of zinc ions and, by inference, a change in CRD structure. Retinoids modulated these oxidation events directly: retinol enhanced, whereas AR suppressed, zinc release, precisely mirroring the retinoid effects on c-Raf kinase activation. Oxidation of c-Raf was not sufficient for kinase activation, productive interaction with Ras being mandatory. Further, canonical tyrosine phosphorylation and the action of phosphatase were essential for optimal c-Raf kinase competence. Thus, retinoids bound c-Raf with high affinity, priming the molecule for UV/reactive oxygen species-mediated changes of the CRD that set off GTP-Ras interaction and, in context with an appropriate phosphorylation pattern, lead to full phosphotransferase capacity.	Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hammerling, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA T32 09149, CA89362S1, CA49933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009149, R01CA049933, R01CA089362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chan WH, 2000, J CELL BIOCHEM, V78, P73, DOI 10.1002/(SICI)1097-4644(20000701)78:1<73::AID-JCB7>3.0.CO;2-P; Chen YQ, 1997, P NATL ACAD SCI USA, V94, P10205, DOI 10.1073/pnas.94.19.10205; Chen YQ, 1999, CANCER RES, V59, P3985; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Cunnick JM, 1998, BIOCHEM MOL BIOL INT, V45, P887; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; DERGUINI F, 1995, J BIOL CHEM, V270, P18875, DOI 10.1074/jbc.270.32.18875; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Englaro W, 1998, ONCOGENE, V16, P661, DOI 10.1038/sj.onc.1201536; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Garant MJ, 1999, BIOCHEMISTRY-US, V38, P5896, DOI 10.1021/bi982844p; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; Geilen CC, 1996, J DERMATOL SCI, V12, P255, DOI 10.1016/0923-1811(95)00481-5; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Goldstone SD, 1997, BBA-MOL CELL RES, V1355, P353, DOI 10.1016/S0167-4889(96)00150-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; HUANG Y, 1994, J BIOL CHEM, V269, P31183; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hurley JH, 1997, PROTEIN SCI, V6, P477; Iantomasi T, 2001, BIOCHEM BIOPH RES CO, V280, P1279, DOI 10.1006/bbrc.2001.4274; Imam A, 2001, FASEB J, V15, P28; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Korichneva I, 1999, J CELL SCI, V112, P2521; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; MURAKAMI Y, 1988, CANCER RES, V48, P1587; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Pu MY, 1996, ONCOGENE, V13, P2615; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Sano H, 2001, J IMMUNOL, V166, P3515, DOI 10.4049/jimmunol.166.5.3515; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Tobi SE, 2000, J PHOTOCH PHOTOBIO B, V57, P102, DOI 10.1016/S1011-1344(00)00084-1; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Xia K, 1999, MOL CELL BIOL, V19, P4819; Yasui H, 2000, BIOCHEM BIOPH RES CO, V269, P131, DOI 10.1006/bbrc.2000.2254; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	87	53	55	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23949	23957		10.1074/jbc.M110750200	http://dx.doi.org/10.1074/jbc.M110750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971897	hybrid			2022-12-25	WOS:000176475700110
J	Re, F; Strominger, JL				Re, F; Strominger, JL			Monomeric recombinant MD-2 binds Toll-like receptor 4 tightly and confers lipopolysaccharide responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; RECOGNITION; EXPRESSION; CLEARANCE; ENDOTOXIN; PROTEINS; MOLECULE; CELLS; CD14; TLR4	In order to mediate cellular response to lipopolysaccharide (LPS), Toll-like receptor (TLR) 4 must interact with MD-2, a secreted protein. In this study, a biochemical assay was developed to demonstrate that recombinant MD-2 can interact with the extracellular portion of TLR4 in solution. The ability of MD-2 to multimerize was confirmed, and MD-1 was also shown to possess this ability. Through site-directed mutagenesis, more than two intermolecular disulfide bonds were found to stabilize the MD-2 multimer. MD-2's abilities to confer LPS responsiveness and to bind TLR4 were strongly associated functions. Remarkably, although the majority of recombinant MD-2 exists in multimeric form, monomeric MD-2 was found to preferentially bind TLR4 and to confer LPS responsiveness more efficiently than MD-2 multimers.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University	Re, F (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,Dana 1414, Boston, MA 02115 USA.				NCI NIH HHS [5R35-CA47554] Funding Source: Medline; NIAID NIH HHS [N01-AI45198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Miyake K, 1998, J IMMUNOL, V161, P1348; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098	17	95	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23427	23432		10.1074/jbc.M202554200	http://dx.doi.org/10.1074/jbc.M202554200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976338	hybrid			2022-12-25	WOS:000176475700044
J	Kovacs, M; Malnasi-Csizmadia, A; Woolley, RJ; Bagshaw, CR				Kovacs, M; Malnasi-Csizmadia, A; Woolley, RJ; Bagshaw, CR			Analysis of nucleotide binding to Dictyostelium myosin II motor domains containing a single tryptophan near the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; SMOOTH-MUSCLE MYOSIN; DISCOIDEUM MYOSIN; CONFORMATIONAL-CHANGES; RELAY LOOP; SUBFRAGMENT-1; RESIDUE; ATP; TRANSITION; RESOLUTION	Dictyostelium myosin II motor domain constructs containing a single tryptophan residue near the active sites were prepared in order to characterize the process of nucleotide binding. Tryptophan was introduced at positions 113 and 131, which correspond to those naturally present in vertebrate skeletal muscle myosin, as well as position 129 that is also close to the adenine binding site. Nucleotide (ATP and ADP) binding was accompanied by a large quench in protein fluorescence in the case of the tryptophans at 129 and 131 but a small enhancement for that at 113. None of these residues was sensitive to the subsequent open-closed transition that is coupled to hydrolysis (i.e. ADP and ATP induced similar fluorescence changes). The kinetics of the fluorescence change with the F129W mutant revealed at least a three-step nucleotide binding mechanism, together with formation of a weakly competitive off-line intermediate that may represent a nonproductive mode of nucleotide binding. Overall, we conclude that the local and global conformational changes in myosin IIs induced by nucleotide binding are similar in myosins from different species, but the sign and magnitude of the tryptophan fluorescence changes reflect nonconserved residues in the immediate vicinity of each tryptophan. The nucleotide binding process is at least three-step, involving conformational changes that are quite distinct from the open-closed transition sensed by the tryptophan Trp(501) in the relay loop.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	University of Leicester; Eotvos Lorand University	Bagshaw, CR (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	crb5@le.ac.uk	Kovacs, Mihaly/A-6841-2011; Bagshaw, Clive R./L-5484-2019; Csizmadia, András Málnási/K-7632-2018	Bagshaw, Clive R./0000-0002-5396-153X; Csizmadia, András Málnási/0000-0002-2430-8398; Kovacs, Mihaly/0000-0002-1200-4741				BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 2000, SINGLE MOL, V1, P269; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Kovacs M, 2002, BIOPHYS J, V82, p407A; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MILLAR NC, 1988, BIOCHEM J, V249, P735, DOI 10.1042/bj2490735; Onishi H, 2000, P NATL ACAD SCI USA, V97, P11203, DOI 10.1073/pnas.200362897; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sellers J. R., 1999, MYOSINS; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; WALMSLEY AR, 1989, ANAL BIOCHEM, V176, P313, DOI 10.1016/0003-2697(89)90315-1; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l	27	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28459	28467		10.1074/jbc.M202180200	http://dx.doi.org/10.1074/jbc.M202180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11971905	hybrid			2022-12-25	WOS:000177342600016
J	Marella, M; Lehmann, S; Grassi, J; Chabry, J				Marella, M; Lehmann, S; Grassi, J; Chabry, J			Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; MONOCLONAL-ANTIBODIES; CHOLERA-TOXIN; NORMAL BRAIN; SURFACE; DOMAINS; ISOFORM; CELLS; CAVEOLAE; RECEPTOR	Conversion of the normal membrane-bound prion protein (PrP-sen) to its pathological isoform (PrP-res) is a key event in the pathogenesis of transmissible spongiform encephalopathies. Although the subcellular sites of conversion are poorly characterized, several lines of evidence have suggested the involvement of membrane lipid rafts in the conversion process. Here we report that copper stimulates the endocytosis of PrP-sen via a caveolin-dependent pathway in both microglia and neuroblastoma cells. We show that the polyene antibiotic filipin both limits endocytosis of PrP-sen and dramatically reduces the amount of membrane-bound PrP-sen. This reduction results from a rapid and massive release of full matured PrP-sen into the culture medium. Finally, we demonstrate that filipin is a potent inhibitor of PrP-res formation into chronically infected neuroblastoma cells. Our results reinforce the role of rafts in PrP trafficking and raise the possibility that the release of PrP-sen from the plasma membrane decreases the amount of available substrate PrP-sen at the conversion sites.	CNRS, IPMC, Unite Mixte Rech 6097, F-06560 Valbonne, France; CNRS, Inst Genet Humaine, F-34396 Montpellier, France; CEA, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CEA; UDICE-French Research Universities; Universite Paris Saclay	Chabry, J (corresponding author), CNRS, IPMC, Unite Mixte Rech 6097, 660 Route Lucioles, F-06560 Valbonne, France.		Lehmann, Sylvain/P-1301-2017; Chabry, Joelle/O-2101-2016	Lehmann, Sylvain/0000-0001-6117-562X; 				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Demaimay R, 1997, J VIROL, V71, P9685, DOI 10.1128/JVI.71.12.9685-9689.1997; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; HOLZ RW, 1974, ANN NY ACAD SCI, V235, P469, DOI 10.1111/j.1749-6632.1974.tb43284.x; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KARDOS J, 1989, NEUROSCI LETT, V103, P139, DOI 10.1016/0304-3940(89)90565-X; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; Koo EH, 1996, J CELL SCI, V109, P991; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Lansbury PT, 1996, CURR BIOL, V6, P914, DOI 10.1016/S0960-9822(02)00624-3; Lehmann S, 1999, BIOMED PHARMACOTHER, V53, P39, DOI 10.1016/S0753-3322(99)80059-6; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mange A, 2000, J VIROL, V74, P3135, DOI 10.1128/JVI.74.7.3135-3140.2000; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; UKKONEN P, 1986, J EXP MED, V163, P952, DOI 10.1084/jem.163.4.952; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	50	118	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25457	25464		10.1074/jbc.M203248200	http://dx.doi.org/10.1074/jbc.M203248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994310	hybrid			2022-12-25	WOS:000176747000080
J	Russwurm, M; Mergia, E; Mullershausen, F; Koesling, D				Russwurm, M; Mergia, E; Mullershausen, F; Koesling, D			Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ADENYLYL-CYCLASE; HEME; ACTIVATION; COMPLEX; DISSOCIATION; MECHANISM; BINDING; ENZYME; SYSTEM	Many of the physiological effects of the signaling molecule nitric oxide are mediated by the stimulation of the NO-sensitive guanylyl cyclase. Activation of the enzyme is achieved by binding of NO to the prosthetic heme group of the enzyme and the initiation of conformational changes. So far, the rate of NO dissociation of the purified enzyme has only been determined spectrophotometrically, whereas the respective deactivation, i.e. the decline in enzymatic activity, has only been determined in cytosolic fractions and intact cells. Here, we report on the deactivation of purified NO-sensitive guanylyl cyclase determined after addition of the NO scavenger oxyhemoglobin or dilution. The deactivation rate corresponded to a half-life of the NO/guanylyl cyclase complex of similar to4 s, which is in good agreement with the spectrophotometrically measured NO dissociation rate of the enzyme. The deactivation rate of the enzyme determined in platelets yielded a much shorter half-life indicating either partial damage of the enzyme during the purification procedure or the existence of endogenous deactivation accelerating factors. YC-1, a component causing sensitization of guanylyl cyclase toward NO, inhibited deactivation of guanylyl cyclase, resulting in an extremely prolonged half-life of the NO/guanylyl cyclase complex of more than 10 min. The deactivation of an ATP-utilizing guanylyl cyclase mutant was almost unaffected by YC-1, indicating the existence of a special structure within the catalytic domain required for YC-1 binding or for the transduction of the YC-1 effect. In contrast to the wild type enzyme, YC-1 did not increase NO sensitivity of this mutant, clearly establishing inhibition of deactivation as the underlying mechanism of the NO sensitizer YC-1.	Ruhr Univ Bochum, Fak Med MA N1, D-44780 Bochum, Germany	Ruhr University Bochum	Koesling, D (corresponding author), Ruhr Univ Bochum, Fak Med MA N1, D-44780 Bochum, Germany.							BELLAMY TC, 2000, J BIOL CHEM, V9, P4287; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; Dierks EA, 1998, ARCH BIOCHEM BIOPHYS, V351, P1, DOI 10.1006/abbi.1997.0408; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1998, MOL PHARMACOL, V54, P962, DOI 10.1124/mol.54.6.962; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Margulis A, 2000, BIOCHEMISTRY-US, V39, P1034, DOI 10.1021/bi992040p; MONCADA S, 1991, P NATL ACAD SCI USA, V88, P2166, DOI 10.1073/pnas.88.6.2166; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	27	65	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24883	24888		10.1074/jbc.M110570200	http://dx.doi.org/10.1074/jbc.M110570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978784	hybrid			2022-12-25	WOS:000176747000009
J	Sauvonnet, N; Pradet-Balade, B; Garcia-Sanz, JA; Cornelis, GR				Sauvonnet, N; Pradet-Balade, B; Garcia-Sanz, JA; Cornelis, GR			Regulation of mRNA expression in macrophages after Yersinia enterocolitica infection - Role of different Yop effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 2B; GENE-EXPRESSION; PHOSPHOINOSITIDE 3-KINASE; PLASMINOGEN-ACTIVATOR; EPITHELIAL-CELLS; UP-REGULATION; MAP KINASE; PROTEIN; VIRULENCE; APOPTOSIS	The Yop virulon, which comprises a complete type III secretion system and secreted proteins, allows bacteria from the genus Yersinia to resist the nonspecific immune response of the host. This virulon, which is encoded by a plasmid called pYV in Yersinia enterocolitica, enables extracellular bacteria to inject six Yop effectors (YopE, -H, -T, -O, -P, -M) into the host cell. To investigate the role of YopP, YopM, and the other pYV-encoded factors on the expression of the host cell genes, we characterized the transcriptome alterations in infected mouse macrophages using the microarray technique. PU5-1.8 macrophages were infected either with an avirulent (pYV(-)), a wild type (pYV(+)), or two knockout (yopP(-) and yopM(-)) mutants of Y. enterocolitica. Expression alterations in response to Y. enterocolitica infection were monitored for 6657 genes. Among those, 857 genes were affected, 339 of which were specifically regulated by the action of the Yop virulon. Further analysis of those 339 genes allowed identification of specific targets of YopP, YopM, or the other pYV-encoded factors. According to these results, the main action of the Yop virulon is to counteract the host cell pro-inflammatory response to the infection. YopP participates to this inhibition, whereas another pYV-encoded factor appears to also be involved in this down-regulation. Besides, YopM was found to induce the regulation of genes involved in cell cycle and cell growth, revealing for the first time an in vitro effect for YopM. In addition to YopM, other pYV factors distinct from YopP affected the expression of genes involved in cycling. In conclusion, these results provide new insight into the mechanisms of Yersinia pathogenicity by identifying the changes in host genes expression after infection and highlight the concerted actions of the different Yop effectors.	Christian de Duve Inst Cellular Biol, Microbial Pathogenesis Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	Universite Catholique Louvain; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Basel	Cornelis, GR (corresponding author), Inst Pasteur, Unite Biol Interact Cellulaires, F-75015 Paris, France.	guy.cornelis@unibas.ch	Garcia-Sanz, Jose A/E-7684-2011; Garcia-Sanz, Jose A./AAA-2956-2019	Garcia-Sanz, Jose A/0000-0002-1153-6025; Garcia-Sanz, Jose A./0000-0002-1153-6025; sauvonnet, nathalie/0000-0003-0306-3376				Alberta JA, 1999, J BIOL CHEM, V274, P31062, DOI 10.1074/jbc.274.43.31062; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bies J, 1996, ONCOGENE, V12, P355; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cohen P, 2000, J BIOL CHEM, V275, P11181, DOI 10.1074/jbc.275.15.11181; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Denecker G, 2001, J BIOL CHEM, V276, P19706, DOI 10.1074/jbc.M101573200; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Dube PH, 2001, P NATL ACAD SCI USA, V98, P10880, DOI 10.1073/pnas.191214498; Dukuzumuremyi JM, 2000, J BIOL CHEM, V275, P35281, DOI 10.1074/jbc.M003009200; Dunn SE, 2001, CANCER RES, V61, P1367; Eckmann L, 2000, J BIOL CHEM, V275, P14084, DOI 10.1074/jbc.275.19.14084; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; Grigoryev S, 1996, J BIOL CHEM, V271, P28521, DOI 10.1074/jbc.271.45.28521; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Holmstrom A, 2001, MOL MICROBIOL, V39, P620, DOI 10.1046/j.1365-2958.2001.02259.x; Horikawa I, 2001, J CELL BIOCHEM, V82, P415, DOI 10.1002/jcb.1169; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Lefai E, 2001, BIOCHEM J, V360, P117, DOI 10.1042/0264-6021:3600117; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P389; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P407; Niinobu T, 2000, AM J PHYSIOL-CELL PH, V279, pC504, DOI 10.1152/ajpcell.2000.279.2.C504; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Panetta R, 1999, BIOCHEM BIOPH RES CO, V259, P550, DOI 10.1006/bbrc.1999.0817; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; Ridgway P, 2000, J CELL SCI, V113, P2647; Ruckdeschel K, 2001, J IMMUNOL, V166, P1823, DOI 10.4049/jimmunol.166.3.1823; Sarker MR, 1998, J BACTERIOL, V180, P1207, DOI 10.1128/JB.180.5.1207-1214.1998; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Seipel K, 1999, J CELL SCI, V112, P1825; Sing A, 2002, J IMMUNOL, V168, P1315, DOI 10.4049/jimmunol.168.3.1315; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Subrahmanyam YVBK, 2001, BLOOD, V97, P2457, DOI 10.1182/blood.V97.8.2457; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zavizion B, 1997, J INFECT DIS, V176, P1637, DOI 10.1086/517345; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	56	54	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25133	25142		10.1074/jbc.M203239200	http://dx.doi.org/10.1074/jbc.M203239200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006597	hybrid			2022-12-25	WOS:000176747000039
J	Diakos, C; Prieschl, EE; Saemann, M; Novotny, V; Bohmig, G; Csonga, R; Baumruker, T; Zlabinger, GJ				Diakos, C; Prieschl, EE; Saemann, M; Novotny, V; Bohmig, G; Csonga, R; Baumruker, T; Zlabinger, GJ			Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPORESPONSIVENESS IN-VITRO; SIGNAL-TRANSDUCTION; SODIUM-BUTYRATE; TRANSCRIPTION FACTORS; FATTY-ACIDS; PATHWAYS; NFAT; SUPPRESSION; INHIBITION; EXPRESSION	The transcription factor nuclear factor of activated T-cells (NF-AT) plays an essential role in the activation of many early immune response genes. A dynamic equilibrium between calcineurin and cellular kinases controls its phosphorylation and thus regulates its activity by determining its subcellular localization. Here, we demonstrate that T-cell activation in the presence of the bacterial metabolite n-butyrate, which leads to inhibition of interleukin-2 transcription, is characterized by the maintenance of the activity of counter-regulatory kinases glycogen synthase kinase 3 and protein kinase A as well as persistence of intracellular cAMP levels, whereas calcium response and mitogen-activated protein kinase activation were indistinguishable from cells stimulated in the absence of n-butyrate. Nuclear binding of NF-AT was decreased but other transcription factors implicated in interleukin-2 expression such as AP1 and nuclear factor kappaB were unaffected. The effect on NF-AT binding appeared to be the result of increased nuclear export because the export inhibitor leptomycin B completely restored nuclear binding of NF-AT. We, therefore, provide first evidence for interference with NF-AT regulation alternative to the currently understood inhibition of nuclear import. This mechanism might represent a bacterial strategy to subvert host defense, which could be of particular clinical importance in the gastrointestinal tract where high amounts of n-butyrate are physiologically present.	Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Univ Vienna, Div Nephrol, Dept Internal Med 3, A-1090 Vienna, Austria; Novartis Res Inst, Dept Allerg Dis, A-1235 Vienna, Austria	University of Vienna; University of Vienna; Novartis	Zlabinger, GJ (corresponding author), Univ Vienna, Inst Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	gerhard.zlabinger@univie.ac.at		Zlabinger, Gerhard/0000-0002-7478-4173				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70, DOI 10.1177/014860719902300518; Archer S, 1998, SURGERY, V124, P248, DOI 10.1067/msy.1998.90567; AUGUST A, 1995, TISSUE ANTIGENS, V46, P155, DOI 10.1111/j.1399-0039.1995.tb03114.x; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; Berridge MJ, 1997, CRIT REV IMMUNOL, V17, P155, DOI 10.1615/CritRevImmunol.v17.i2.30; BOHMIG GA, 1995, TRANSPLANTATION, V59, P1500, DOI 10.1097/00007890-199505270-00029; Bohmig GA, 1999, TRANSPL IMMUNOL, V7, P221, DOI 10.1016/S0966-3274(99)80006-9; BOHMIG GA, 1996, TRANSPLANT INT S1, V9, P318; Brodsky FM, 1999, IMMUNOL REV, V168, P5, DOI 10.1111/j.1600-065X.1999.tb01278.x; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chapman MA, 2001, ANN ROY COLL SURG, V83, P75; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Coradini D, 2000, CELL PROLIFERAT, V33, P139, DOI 10.1046/j.1365-2184.2000.00173.x; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; FOSS FM, 1989, ONCOGENE RES, V5, P13; Gilbert KM, 2000, J PHARMACOL EXP THER, V294, P1146; GILBERT KM, 1993, J IMMUNOL, V151, P1245; HENGEL H, 1991, J IMMUNOL, V147, P1115; HERZ F, 1983, BIOCHIM BIOPHYS ACTA, V762, P289, DOI 10.1016/0167-4889(83)90083-6; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LEGROS GS, 1985, LYMPHOKINE RES, V4, P221; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; PALIOGIANNI F, 1993, J EXP MED, V178, P1813, DOI 10.1084/jem.178.5.1813; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ramstad C, 2000, CELL SIGNAL, V12, P557, DOI 10.1016/S0898-6568(00)00097-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saemann MD, 2000, TRANSPLANTATION, V70, P1215; Saemann MD, 2000, FASEB J, V14, P2380; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; SUTHANTHIRAN M, 1982, TRANSPLANTATION, V33, P534, DOI 10.1097/00007890-198205000-00014; TAMIR A, 1994, J IMMUNOL, V152, P3391; Tsuruta L, 1995, J ALLERGY CLIN IMMUN, V96, P1126, DOI 10.1016/S0091-6749(95)70197-4; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Waclavicek M, 1998, J IMMUNOL, V161, P4671; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	50	24	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24243	24251		10.1074/jbc.M200191200	http://dx.doi.org/10.1074/jbc.M200191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983691	hybrid			2022-12-25	WOS:000176611800036
J	Ebert, DH; Deussing, J; Peters, C; Dermody, TS				Ebert, DH; Deussing, J; Peters, C; Dermody, TS			Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSID PROTEIN SIGMA-3; INFECTIOUS SUBVIRION PARTICLES; VIRAL ATTACHMENT PROTEIN; DISTINCT BINDING-SITES; DOUBLE-STRANDED-RNA; MOUSE L-CELLS; PERSISTENT INFECTIONS; MAMMALIAN REOVIRUSES; CHROMIUM RELEASE; SIALIC-ACID	After attachment to receptors, reovirus virions are internalized by endocytosis and exposed to acid-dependent proteases that catalyze viral disassembly. Previous studies using the cysteine protease inhibitor E64 and a mutant cell line that does not support reovirus disassembly suggest a requirement for specific endocytic proteases in reovirus entry. This study identifies the endocytic proteases that mediate reovirus disassembly in murine fibroblast cells. Infection of both L929 cells treated with the cathepsin L inhibitor Z-Phe-Tyr(t-Bu)-diazomethyl ketone and cathepsin L-deficient mouse embryo fibroblasts resulted in inefficient proteolytic disassembly of viral outer-capsid proteins and decreased viral yields. In contrast, both L929 cells treated with the cathepsin B inhibitor CA-074Me and cathepsin B-deficient mouse embryo fibroblasts support reovirus disassembly and growth. However, removal of both cathepsin B and cathepsin L activity completely abrogates disassembly and growth of reovirus. Concordantly, cathepsin L mediates reovirus disassembly more efficiently than cathepsin B in vitro. These results demonstrate that either cathepsin L or cathepsin B is required for reovirus entry into murine fibroblasts and indicate that cathepsin L is the primary mediator of reovirus disassembly. Moreover, these findings suggest that specific endocytic proteases can determine host cell susceptibility to infection by intracellular pathogens.	Vanderbilt Univ, Elizabeth B Lamb Ctr Pediat Res, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Sch Med, Nashville, TN 37232 USA; Univ Freiburg, Inst Mol Med & Zellforsch, D-79106 Freiburg, Germany	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Freiburg	Dermody, TS (corresponding author), Vanderbilt Univ, Elizabeth B Lamb Ctr Pediat Res, Sch Med, D7235 MCN, Nashville, TN 37232 USA.	terry.dermody@mcmail.vanderbilt.edu	Deussing, Jan M/ABB-5993-2021	Deussing, Jan/0000-0002-9329-5252	NIAID NIH HHS [R01 AI32539] Funding Source: Medline; NIGMS NIH HHS [T32 GM07347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSFALGMACHLEIDT I, 1992, BIOL CHEM H-S, V373, P433, DOI 10.1515/bchm3.1992.373.2.433; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barton ES, 2001, J BIOL CHEM, V276, P2200, DOI 10.1074/jbc.M004680200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; BORSA J, 1979, J GEN VIROL, V45, P161, DOI 10.1099/0022-1317-45-1-161; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Chandran K, 1998, J VIROL, V72, P467, DOI 10.1128/JVI.72.1.467-475.1998; CHANG CT, 1971, VIROLOGY, V46, P544, DOI 10.1016/0042-6822(71)90058-4; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Coombs KM, 1998, VIROLOGY, V243, P218, DOI 10.1006/viro.1998.9061; Dean R T, 1976, Essays Biochem, V12, P1; DERMODY TS, 1993, J VIROL, V67, P2055, DOI 10.1128/JVI.67.4.2055-2063.1993; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Ebert DH, 2001, J VIROL, V75, P3197, DOI 10.1128/JVI.75.7.3197-3206.2001; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GENTSCH JR, 1985, J VIROL, V56, P356, DOI 10.1128/JVI.56.2.356-364.1985; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Hooper JW, 1996, J VIROL, V70, P672, DOI 10.1128/JVI.70.1.672-677.1996; Hooper JW, 1996, J VIROL, V70, P459, DOI 10.1128/JVI.70.1.459-467.1996; Jane-Valbuena J, 1999, J VIROL, V73, P2963; JAYASURIYA AK, 1988, VIROLOGY, V163, P591, DOI 10.1016/0042-6822(88)90300-5; KEDL R, 1995, J VIROL, V69, P552, DOI 10.1128/JVI.69.1.552-559.1995; Kothandaraman S, 1998, VIROLOGY, V251, P264, DOI 10.1006/viro.1998.9434; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PWK, 1981, VIROLOGY, V108, P134, DOI 10.1016/0042-6822(81)90533-X; Liemann S, 2002, CELL, V108, P283, DOI 10.1016/S0092-8674(02)00612-8; LUCIAJANDRIS P, 1993, J VIROL, V67, P5339, DOI 10.1128/JVI.67.9.5339-5345.1993; MILLER JE, 1992, J VIROL, V66, P5347, DOI 10.1128/JVI.66.9.5347-5356.1992; Moin K, 2000, ADV EXP MED BIOL, V477, P391; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nason EL, 2001, J VIROL, V75, P6625, DOI 10.1128/JVI.75.14.6625-6634.2001; NIBERT ML, 1995, J VIROL, V69, P5057, DOI 10.1128/JVI.69.8.5057-5067.1995; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Olland AM, 2001, EMBO J, V20, P979, DOI 10.1093/emboj/20.5.979; PACITTI AF, 1987, J VIROL, V61, P1407, DOI 10.1128/JVI.61.5.1407-1415.1987; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; ROTHE G, 1992, BIOL CHEM H-S, V373, P547, DOI 10.1515/bchm3.1992.373.2.547; RUBIN DH, 1992, MICROB PATHOGENESIS, V12, P351, DOI 10.1016/0882-4010(92)90098-9; SCHIFF LA, 1988, MOL CELL BIOL, V8, P273, DOI 10.1128/MCB.8.1.273; SELIGER LS, 1992, VIROLOGY, V187, P202, DOI 10.1016/0042-6822(92)90308-C; SHAW E, 1993, FEBS LETT, V334, P340, DOI 10.1016/0014-5793(93)80707-2; SILVERSTEIN SC, 1972, VIROLOGY, V47, P797, DOI 10.1016/0042-6822(72)90571-5; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; TOSTESON MT, 1993, P NATL ACAD SCI USA, V90, P10549, DOI 10.1073/pnas.90.22.10549; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; Wetzel JD, 1997, J VIROL, V71, P1362, DOI 10.1128/JVI.71.2.1362-1369.1997	59	202	211	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24609	24617		10.1074/jbc.M201107200	http://dx.doi.org/10.1074/jbc.M201107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986312	hybrid			2022-12-25	WOS:000176611800084
J	Liu, MM; Albanese, C; Anderson, CM; Hilty, K; Webb, P; Uht, RM; Price, RH; Pestell, RG; Kushner, PJ				Liu, MM; Albanese, C; Anderson, CM; Hilty, K; Webb, P; Uht, RM; Price, RH; Pestell, RG; Kushner, PJ			Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MAMMARY-GLAND DEVELOPMENT; PROSTATE-CANCER; ER-ALPHA; E-CDK2 ACTIVATION; KINASE-ACTIVITY; MICE; PROMOTER; TRANSCRIPTION; PROGRESSION	Induction of cyclin D1 gene transcription by estrogen receptor alpha (ERalpha) plays an important role in estrogen-mediated proliferation. There is no classical estrogen response element in the cyclin D1 promoter, and induction by ERalpha has been mapped to an alternative response element, a cyclic AMP-response element at -57, with possible participation of an activating protein-1 site at -954. The action of ERbeta at the cyclin D1 promoter is unknown, although evidence suggests that ERbeta may inhibit the proliferative action of ERalpha. We examined the response of cyclin D1 promoter constructs by luciferase assay and the response of the endogenous protein by Western blot in HeLa cells transiently expressing ERalpha, ERalphaK206A (a derivative that is superactive at alternative response elements), or ERbeta. In each case, ER activation at the cyclin D1 promoter is mediated by both the cyclic AMP-response element and the activating protein-1 site, which play partly redundant roles. The activation by ERbeta occurs only with antiestrogens. Estrogens, which activate cyclin D1 gene expression with ERa, inhibit expression with ERbeta. Strikingly, the presence of ERbeta completely inhibits cyclin D1 gene activation by estrogen and ERa or even by estrogen and the superactive ERaK206A. The observation of the opposing action and dominance of ERbeta over ERalpha in activation of cyclin D1 gene expression has implications for the postulated role of ERbeta as a modulator of the proliferative effects of estrogen.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94112 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine	Kushner, PJ (corresponding author), Univ Calif San Francisco, Dept Med, 2200 Post St,Rm C442, San Francisco, CA 94112 USA.	kushner@itsa.ucsf.edu		Anderson, Carol/0000-0002-0308-5447	NCI NIH HHS [R01 CA86072, R01 CA75503, R01 CA80210, R01 CA70896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075503, R01CA070896, R01CA086072, R01CA080210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Altucci L, 1996, ONCOGENE, V12, P2315; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; Dupont S, 2000, DEVELOPMENT, V127, P4277; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Frierson HF, 1996, MODERN PATHOL, V9, P725; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HERBER B, 1994, ONCOGENE, V9, P1295; Horvath LG, 2001, CANCER RES, V61, P5331; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Lukas J, 1996, MOL CELL BIOL, V16, P6917; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pasquali D, 2001, J CLIN ENDOCR METAB, V86, P2051, DOI 10.1210/jc.86.5.2051; Pelletier G, 2000, J CLIN ENDOCR METAB, V85, P4835, DOI 10.1210/jc.85.12.4835; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Prins GS, 2001, CANCER RES, V61, P6089; Risbridger G, 2001, DEV BIOL, V229, P432, DOI 10.1006/dbio.2000.9994; Roger P, 2001, CANCER RES, V61, P2537; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Signoretti S, 2001, AM J PATHOL, V159, P13, DOI 10.1016/S0002-9440(10)61666-5; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Sutherland RL, 1995, CIBA F SYMP, V191, P218; Tonetti DA, 1999, J MAMMARY GLAND BIOL, V4, P401, DOI 10.1023/A:1018722502034; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1998, MOL BASIS SEX HORMON, P121; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936	62	363	375	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24353	24360		10.1074/jbc.M201829200	http://dx.doi.org/10.1074/jbc.M201829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986316	hybrid			2022-12-25	WOS:000176611800051
J	Prajapati, S; Gaynor, RB				Prajapati, S; Gaynor, RB			Regulation of I kappa B kinase (IKK)gamma/NEMO function by IKK beta-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; TAX TRANSFORMING PROTEIN; DEFICIENT MICE; ACTIVATION; COMPLEX; GAMMA; SUBUNIT; ALPHA; RECRUITMENT; COMPONENT	The IkappaB kinase (IKK) complex includes the catalytic components IKKalpha and IKKbeta in addition to the scaffold protein IKKgamma/NEMO. Increases in the activity of the IKK complex result in the phosphorylation and subsequent degradation of IkappaB and the activation of the NF-kappaB pathway. Recent data indicate that the constitutive activation of the NF-kappaB pathway by the human T-cell lymphotrophic virus, type 1, Tax protein leads to enhanced phosphorylation of IKKgamma/NEMO by IKKbeta. To address further the significance of IKKbeta-mediated phosphorylation of IKKgamma/NEMO, we determined the sites in IKKgamma/NEMO that were phosphorylated by IKKbeta, and we assayed whether IKKgamma/NEMO phosphorylation was involved in modulating IKKbeta activity. IKKgamma/NEMO is rapidly phosphorylated following treatment of cells with stimuli such as tumor necrosis factor-alpha and interleukin-1 that activate the NF-kappaB pathway. By using both in vitro and in vivo assays, IKKbeta was found to phosphorylate IKKgamma/NEMO predominantly in its carboxyl terminus on serine residue 369 in addition to sites in the central region of this protein. Surprisingly, mutation of these carboxyl-terminal serine residues increased the ability of IKKgamma/NEMO to stimulate IKKbeta kinase activity. These results indicate that the differential phosphorylation of IKKgamma/NEMO by IKKbeta and perhaps other kinases may be important in regulating IKK activity.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	46	55	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24331	24339		10.1074/jbc.M201393200	http://dx.doi.org/10.1074/jbc.M201393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11971901	hybrid			2022-12-25	WOS:000176611800048
J	Tian, B; Lessan, K; Kahm, J; Kleidon, J; Henke, C				Tian, B; Lessan, K; Kahm, J; Kleidon, J; Henke, C			beta(1) integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3-kinase/Akt/protein kinase B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; GRANULATION-TISSUE; ENDOTHELIAL-CELLS; TYROSINE KINASES; LINKED KINASE; SHEAR-STRESS; APOPTOSIS; SURVIVAL	Integrins regulate cell viability through their interaction with the extracellular matrix. Integrins can sense mechanical forces arising from the matrix and convert these stimuli to chemical signals capable of modulating intracellular signal transduction. The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is a major regulator of cell survival. It is not known, however, whether integrins, acting as mechanoreceptors, regulate cell survival via the PI3K/Akt pathway. Here, we show that in response to a matrix-derived mechanical stimulus, beta(1) integrin regulated cell viability by regulating Akt activity in a PI3K-dependent fashion. To accomplish this, we employed fibroblasts cultured in collagen gels. During contraction of collagen matrices, fibroblasts underwent apoptosis. We demonstrate that ligation of beta(1) integrin with anti-beta(1) integrin antibodies protected fibroblasts from apoptosis. The nature of the survival signal activated by beta(1) integrin engagement with antibody was mediated by PI3K acting through Akt/protein kinase B. We show that Akt phosphorylation decreased during collagen contraction and that this decrease correlated precisely with the onset of fibroblast apoptosis. Fibroblasts transfected with constitutively active PI3H displayed increased Akt phosphorylation and were protected from anoikis and collagen gel contraction-induced apoptosis. Our data identify a novel role for beta(1) integrin in regulating fibroblast viability through a PI3K/Akt/protein kinase B signaling pathway in response to a matrix-derived mechanical stimulus.	Univ Minnesota, Dept Med, Div Pulm & Crit Care, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Henke, C (corresponding author), Univ Minnesota, Dept Med, Div Pulm & Crit Care, FUMC Box 276,420 Delaware St SE, Minneapolis, MN 55455 USA.	henke002@tc.umn.edu			NHLBI NIH HHS [P50 HL50152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Crouch DH, 1996, ONCOGENE, V12, P2689; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DARBY I, 1990, LAB INVEST, V63, P21; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Grinnell F, 1999, CURR TOPICS PATHOL, V93, P61; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Henke C, 1996, AM J PATHOL, V149, P1639; Henke CA, 1996, J CLIN INVEST, V97, P2541, DOI 10.1172/JCI118702; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NAKAGAWA S, 1989, J INVEST DERMATOL, V93, P792, DOI 10.1111/1523-1747.ep12284425; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; POLUNOVSKY VA, 1993, J CLIN INVEST, V92, P388, DOI 10.1172/JCI116578; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Wu CY, 1999, J CELL SCI, V112, P4485; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	46	135	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24667	24675		10.1074/jbc.M203565200	http://dx.doi.org/10.1074/jbc.M203565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986332	hybrid			2022-12-25	WOS:000176611800092
J	Wang, Z; Wilson, GF; Griffith, LC				Wang, Z; Wilson, GF; Griffith, LC			Calcium/calmodulin-dependent protein kinase II phosphorylates and regulates the Drosophila Eag potassium channel.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS; CURRENTS; MELANOGASTER; SUBUNIT; MUSCLE; FAMILY; LOCUS; GENES	Modulation of neuronal excitability is believed to be an important mechanism of plasticity in the nervous system. Calcium/calmodulin-dependent protein kinase 11 (CaMKII) has been postulated to regulate the ether et go-go (eag) potassium channel in Drosophila. Inhibition of CaMKII and mutation of the eag gene both cause hyperexcitability at the larval neuromuscular junction (NMJ) and memory formation defects in the adult. In this study, we identify a single site, threonine 787, as the major CaMKII phosphorylation site in Eag. This site can be phosphorylated by CaMKII both in a heterologous cell system and in vivo at the larval NMJ. Expression of Eag in Xenopus oocytes was used to assess the function of phosphorylation. Injection of either a specific CaMKII inhibitor peptide or lavendustin C, another CaMKII inhibitor, reduced Eag current amplitude acutely. Mutation of threonine 787 to alanine also reduced amplitude. Moreover, both CaMKII inhibition and the alanine mutation accelerated inactivation. The reduction in current amplitudes and the accelerated inactivation of dephosphorylated Eag channels would result in decreased outward potassium currents and hyperexcitability at presynaptic terminals and, thus, are consistent with the NMJ phenotype observed when CaMKII is inhibited. These results show that Eag is a substrate of CaMKII and suggest that direct modulation of potassium channels may be an important function of this kinase.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	Brandeis University; Brandeis University; University of Michigan System; University of Michigan	Griffith, LC (corresponding author), Brandeis Univ, Dept Biol, MS008,415 South St, Waltham, MA 02454 USA.	griffith@brandeis.edu		Wang, Zheng/0000-0001-7678-0072; Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062648] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54408, R01 GM054408] Funding Source: Medline; NIMH NIH HHS [MH62648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cowan T.M., 1984, Journal of Neurogenetics, V1, P333, DOI 10.3109/01677068409107095; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DRYSDALE R, 1991, GENETICS, V127, P497; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARLOW F, 1988, ANTIBODIES LAB MANUA; Jin R, 1998, J NEUROSCI, V18, P8955; KAPLAN WD, 1969, GENETICS, V61, P399; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McCulloch RI, 2001, BIOCHEMISTRY-US, V40, P7273, DOI 10.1021/bi010546d; Moore DD, 1995, GLOB MOB SURV; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PARK D, 2002, IN PRESS J NEUROBIO; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SINGH S, 1990, J EXP BIOL, V152, P59; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang Z, 1998, J NEUROCHEM, V71, P378; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wilson GF, 1998, J BIOL CHEM, V273, P6389, DOI 10.1074/jbc.273.11.6389; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	28	64	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24022	24029		10.1074/jbc.M201949200	http://dx.doi.org/10.1074/jbc.M201949200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980904	hybrid			2022-12-25	WOS:000176611800009
J	Xu, WL; Gauss, P; Shen, JY; Dunn, CA; Bessman, MJ				Xu, WL; Gauss, P; Shen, JY; Dunn, CA; Bessman, MJ			The gene e.1 (nudE.1) of T4 bacteriophage designates a new member of the nudix hydrolase superfamily active on flavin adenine dinucleotide, adenosine 5 '-triphospho-5 '-adenosine, and ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUPINUS-ANGUSTIFOLIUS L; ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATASE; MUTT; PROTEINS; FAMILY; IDENTIFICATION; MECHANISM; ENZYMES; CLONING	The T4 bacteriophage gene e.1 was cloned into an expression vector and expressed in Escherichia coli, and the purified protein was identified as a Nudix hydrolase active on FAD, adenosine 5'-triphospho-5'-adenosine (Ap(3)A), and ADP-ribose. Typical of members of the Nudix hydrolases, the enzyme has an alkaline pH optimum (pH 8) and requires a divalent cation for activity that can be satisfied by Mg2+ or Mn2+. For all substrates, AMP is one of the products, and unlike most of the other enzymes active on Ap(3)A, the T4 enzyme hydrolyzes higher homologues including AP(4-6)A This is the first member of the Nudix hydrolase gene superfamily identified in bacterial viruses and the only one present in T4. Although the protein was predicted to be orthologous to E. coli MutT on the basis of a sequence homology search, the properties of the gene and of the purified protein do not support this notion because of the following. (a) The purified enzyme hydrolyzes substrates not acted upon by MutT, and it does not hydrolyze canonical MutT substrates. (b) The e.1 gene does not complement mutT1 in vivo. (c) The deletion of e.1 does not increase the spontaneous mutation frequency of T4 phage. The properties of the enzyme most closely resemble those of Orf186 of E. coli, the product of the nudE gene, and we therefore propose the mnemonic nudE.1 for the T4 phage orthologue.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, The McCollum Pratt Inst, Baltimore, MD 21218 USA; Western State Coll Colorado, Dept Biol, Gunnison, CO 81231 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM 18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; Jozwik Catherine E., 1994, P464; Kawabata T, 2000, GENE, V259, P223, DOI 10.1016/S0378-1119(00)00442-X; KUTTER E, 1994, MOL BIOL BACTERIOP T, V4, P406; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Sambrook J., 2001, MOL CLONING; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085	23	26	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23181	23185		10.1074/jbc.M203325200	http://dx.doi.org/10.1074/jbc.M203325200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976345	hybrid			2022-12-25	WOS:000176475700013
J	Sers, C; Husmann, K; Nazarenko, I; Reich, S; Wiechen, K; Zhumabayeva, B; Adhikari, P; Schroder, K; Gontarewicz, A; Schafer, R				Sers, C; Husmann, K; Nazarenko, I; Reich, S; Wiechen, K; Zhumabayeva, B; Adhikari, P; Schroder, K; Gontarewicz, A; Schafer, R			The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFN gamma-induced cell death in human ovarian carcinoma cells	ONCOGENE			English	Article						tumour suppressor; H-REV107-1; IRF-1; target gene; IRF gamma; apoptosis	BRCA1 PROMOTER REGION; TRANSCRIPTION FACTOR; LYSYL OXIDASE; DOWN-REGULATION; MESSENGER-RNAS; RETINOIC ACID; EXPRESSION; IRF-1; CANCER; TRANSFORMATION	H-rev107-1 is a growth inhibitory RAS target gene capable of suppressing anchorage independent growth in vitro and in vivo. Using a tumour tissue array with 241 matched tumour and normal tissue cDNA pools, we found down-regulation of H-REV107-1 in 7 out of 14 ovary-derived cDNAs. RT-PCR analysis and immunohistochemical investigation confirmed expression of H-REV107-1 in normal ovarian epithelial cells but down-regulation in high grade ovarian carcinomas. H-REV107-1 is also strongly expressed in immortalized rat and human ovarian epithelial cells in vitro, but suppressed in transformed cells by two different mechanisms. KRAS-transformed rat ovarian cells and PA1 teratocarcinoma cells, reversibly repress H-REV107-1 via MAP/ERK signaling. In contrast, treatment of A27/80 and OVCAR-3 epithelial ovarian cancer cells with IFN-gamma stimulated H-REV107-1 expression. In NIH3T3 cells harbouring an estrogen-inducible IRF-1, H-rev107-1 is directly induced after activation of IRF-1, indicating that H-rev107-1 is a target of IRF-1. Stimulation of H-REV107-1 expression was also observed in ovarian epithelial cells suggesting that IRF-1 is involved in H-REV107-1 regulation in human ovarian epithelium. In the IFNgamma-sensitive cell line A27/80, H-REV107-1 suppresses colony formation. A27/80 and OVCAR-3 cells overexpressing H-REV107-1 protein underwent apoptosis. These results demonstrate down-regulation of the class II tumour suppressor H-REV107-1 in human ovarian carcinomas and suggest an involvement of H-REV107-1 in interferon-dependent cell death.	Univ Hosp Charite, Inst Pathol, D-10117 Berlin, Germany; Natl Res Ctr Biotechnol, Braunschweig, Germany; Clontech Labs, Palo Alto, CA 94303 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sers, C (corresponding author), Univ Hosp Charite, Inst Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	christine.sers@charite.de	Nazarenko, Irina/E-5714-2010; Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010	Nazarenko, Irina/0000-0002-2633-1161; Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Baldwin RL, 2000, CANCER RES, V60, P5329; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Burke F, 1999, BRIT J CANCER, V80, P1236, DOI 10.1038/sj.bjc.6690491; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Demaeyer E., 1988, INTERFERONS OTHER RE; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Green WB, 1999, LEUKEMIA, V13, P1960, DOI 10.1038/sj.leu.2401596; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARADA H, 1994, ONCOGENE, V9, P3313; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; Jiang Ming-Chung, 2001, Molecular Cell Biology Research Communications, V4, P353, DOI 10.1006/mcbr.2001.0303; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; Patton SE, 1998, CANCER RES, V58, P2253; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; RONGLIN X, 2001, J BIOL CHEM, V276, P18624; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; Tnani M, 1999, BBA-MOL CELL RES, V1451, P59, DOI 10.1016/S0167-4889(99)00089-0; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Windbichler GH, 2000, BRIT J CANCER, V82, P1138; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhumabayeva B, 2001, BIOTECHNIQUES, V30, P158, DOI 10.2144/01301pf01; ZHUMABAYEVA B, 2001, CLONTECHNIQUES, V16, P27; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	57	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2829	2839		10.1038/sj.onc.1205377	http://dx.doi.org/10.1038/sj.onc.1205377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973642				2022-12-25	WOS:000175063700007
J	Hafezi, W; Eing, BR; Lorentzen, EU; Thanos, S; Kuhn, JE				Hafezi, W; Eing, BR; Lorentzen, EU; Thanos, S; Kuhn, JE			Reciprocal transmission of herpes simplex virus type 1 (HSV-1) between corneal epithelium and trigeminal neurites in an embryonic chick organ culture	FASEB JOURNAL			English	Article						animal use alternatives; neurons; eye; simplexvirus; coculture	HUMAN FETAL NEURONS; EPIDERMAL-CELLS; ENDOPLASMIC-RETICULUM; ANTEROGRADE TRANSPORT; AXONAL-TRANSPORT; INFECTION; VIRIONS; GROWTH; ENTRY; REENVELOPMENT	Reciprocal transmission between epithelia and sensory neurons of the peripheral nervous system is a crucial step in the life cycle of herpes simplex virus type 1 (HSV-1) and related alphaherpesviruses. In searching for an easy-to-perform and generally applicable experimental approach that enables the direct analysis of virus transfer between primary epithelial cells and sensory neurites, we investigated the spread of HSV-1 in a dual-chamber organ model comprising chick embryonic corneal epithelia and trigeminal sensory neurons. Embryonic chick corneal and trigeminal tissues were found to be permissive for productive infection with HSV-1. Our data show that HSV-1 efficiently enters neurites re-innervating the cornea and reaches the ganglion explant by retrograde axonal transport, with the first antigen-positive cells being detectable 12 h postinfection. After direct infection of trigeminal tissues, the virus is transported by anterograde axonal transport to the corneal epithelium, causing a visible cytopathic effect 48 h postinfection. These results suggest that the organ model presented in this study holds particular promise for the direct observation and molecular analysis of herpes simplex virus spread between primary epithelia and sensory neurons and that it may be an attractive alternative to current experimental approaches based on laboratory animals or human fetal tissues.	Univ Munster, Inst Med Mikrobiol, Abt Klin Virol, D-48151 Munster, Germany; Univ Munster, Klin & Poliklin Augenheilkunde, Abt Expt Ophthalmol, D-48151 Munster, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Munster	Kuhn, JE (corresponding author), Univ Munster, Inst Med Mikrobiol, Abt Klin Virol, Von Stauffenberg Str 36, D-48151 Munster, Germany.	kuehnj@uni-muenster.de		Lorentzen, Eva/0000-0002-5570-1897				Anderson K, 1940, AM J PATHOL, V16, P137; Browne H, 1996, J VIROL, V70, P4311, DOI 10.1128/JVI.70.7.4311-4316.1996; Cleator GM, 2000, PRINCIPLES PRACTICE, P23; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Enquist LW, 1999, ADV VIRUS RES, V51, P237; ERZURUMLU RS, 1993, P NATL ACAD SCI USA, V90, P7235, DOI 10.1073/pnas.90.15.7235; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Holland DJ, 1999, J VIROL, V73, P8503, DOI 10.1128/JVI.73.10.8503-8511.1999; Holland DJ, 1998, J MICROSC-OXFORD, V192, P69, DOI 10.1046/j.1365-2818.1998.00401.x; Immergluck LC, 1998, J GEN VIROL, V79, P549, DOI 10.1099/0022-1317-79-3-549; LOWRY SP, 1971, J GEN VIROL, V10, P1, DOI 10.1099/0022-1317-10-1-1; Miranda-Saksena M, 2000, J VIROL, V74, P1827, DOI 10.1128/JVI.74.4.1827-1839.2000; NAHMIAS AJ, 1983, INFECT DIS, P636; PAVLIDIS C, 1994, INT J DEV NEUROSCI, V12, P587, DOI 10.1016/0736-5748(94)90066-3; PENFOLD MET, 1994, P NATL ACAD SCI USA, V91, P6529, DOI 10.1073/pnas.91.14.6529; Penfold MET, 1996, IN VITRO CELL DEV-AN, V32, P420; RODGERS FG, 1981, BRIT J EXP PATHOL, V62, P317; Roizman B, 1996, FIELDS VIROLOGY, P2231; Skepper JN, 2001, J VIROL, V75, P5697, DOI 10.1128/JVI.75.12.5697-5702.2001; Smith GA, 2001, P NATL ACAD SCI USA, V98, P3466, DOI 10.1073/pnas.061029798; VALYINAGY T, 1991, J VIROL, V65, P4142, DOI 10.1128/JVI.65.8.4142-4152.1991; Whiteley A, 1999, J VIROL, V73, P9515, DOI 10.1128/JVI.73.11.9515-9520.1999; WHITLEY RJ, 1983, PEDIATRICS, V72, P778; Whitley RJ, 1996, FIELDS VIROLOGY, P2297	24	6	6	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					878	+		10.1096/fj.01-0803fje	http://dx.doi.org/10.1096/fj.01-0803fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967226				2022-12-25	WOS:000175425900015
J	Sundaramoorthy, M; Meiyappan, M; Todd, P; Hudson, BG				Sundaramoorthy, M; Meiyappan, M; Todd, P; Hudson, BG			Crystal structure of NC1 domains - Structural basis for type IV collagen assembly in basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPORT SYNDROME; NONCOLLAGENOUS DOMAIN; MOLECULAR RECOGNITION; LENS CAPSULE; CHAIN; IDENTIFICATION; PROCOLLAGEN; GENE; SEQUENCE; NETWORK	Type IV collagen, which is present in all metazoan, exists as a family of six homologous alpha(IV) chains, alpha1-alpha6, in mammals. The six chains assemble into three different triple helical protomers and self-associate as three distinct networks. The network underlies all epithelia as a component of basement membranes, which play important roles in cell adhesion, growth, differentiation, tissue repair and molecular ultrafiltration. The specificity of both protomer and network assembly is governed by amino acid sequences of the C-terminal noncollagenous (NC1) domain of each chain. In this study, the structural basis for protomer and network assembly was investigated by determining the crystal structure of the ubiquitous [(alpha1)(2).alpha2](2) NC1 hexamer of bovine lens capsule basement membrane at 2.0 Angstrom resolution. The NC1 monomer folds into a novel tertiary structure. The (alpha1)(2).alpha2 trimer is organized through the unique three-dimensional domain swapping interactions. The differences in the primary sequences of the hypervariable region manifest in different secondary structures, which determine the chain specificity at the monomer-monomer interfaces. The trimer-trimer interface is stabilized by the extensive hydrophobic and hydrophilic interactions without a need for disulfide cross-linking.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Sundaramoorthy, M (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	msundar@kumc.edu		Hudson, Billy/0000-0002-5420-4100; Meiyappan, Muthuraman/0000-0001-7407-8677	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053763, R37DK018381, R01DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18381, DK 63925, DK 53763] Funding Source: Medline; ORIP NIH HHS [RI 80086] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ORIP NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; Boute N, 1996, BIOL CELL, V88, P37, DOI 10.1016/S0248-4900(97)86829-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; Dauter Z, 1999, J MOL BIOL, V289, P93, DOI 10.1006/jmbi.1999.2744; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; EXPOSITO JY, 1994, J BIOL CHEM, V269, P13167; Fowler SJ, 2000, J BIOL CHEM, V275, P39589, DOI 10.1074/jbc.M005871200; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; GUO XD, 1989, J BIOL CHEM, V264, P17574; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Iwata M, 1996, J BIOCHEM-TOKYO, V120, P133; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADLER K, 1994, PROTEIN PROFILE, V1, P519; KASHTAN CE, 1993, AM J KIDNEY DIS, V22, P627, DOI 10.1016/S0272-6386(12)80424-0; Kashtan CE, 1996, KIDNEY INT, V50, P1445, DOI 10.1038/ki.1996.459; KOIVU J, 1987, J BIOL CHEM, V262, P6159; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PECZON BD, 1982, EXP EYE RES, V35, P643, DOI 10.1016/S0014-4835(82)80076-6; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Pihlajaniemi T, 1996, CONTRIB NEPHROL, V117, P46; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROSENBLOOM J, 1976, J BIOL CHEM, V251, P2070; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; SIBLEY MH, 1994, EMBO J, V13, P3278, DOI 10.1002/j.1460-2075.1994.tb06629.x; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; STUBBS M, 1990, J MOL BIOL, V211, P683, DOI 10.1016/0022-2836(90)90066-U; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1985, ANN NY ACAD SCI, V460, P58, DOI 10.1111/j.1749-6632.1985.tb51157.x; UITTO J, 1973, BIOCHEM BIOPH RES CO, V55, P904, DOI 10.1016/0006-291X(73)91229-1; UITTO VJ, 1981, ARCH BIOCHEM BIOPHYS, V210, P445, DOI 10.1016/0003-9861(81)90208-3; WEBER M, 1992, KIDNEY INT, V41, P620, DOI 10.1038/ki.1992.95; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176; ZHOU J, 1994, J BIOL CHEM, V269, P13193	66	121	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31142	31153		10.1074/jbc.M201740200	http://dx.doi.org/10.1074/jbc.M201740200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	11970952	hybrid			2022-12-25	WOS:000177579800094
J	Penuel, E; Akita, RW; Sliwkowski, MX				Penuel, E; Akita, RW; Sliwkowski, MX			Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; HEREGULIN BINDING-SITE; ERBB SIGNALING NETWORK; TRANSMEMBRANE DOMAIN; EXTRACELLULAR DOMAINS; POINT MUTATION; BREAST-CANCER; ONCOGENE	Ligand-independent ErbB2 activation occurs principally by two distinct mechanisms: overexpression and mutation. Overexpression of ErbB2 at the plasma membrane drives receptor self-association in a concentration-dependent manner, which in turn leads to constitutive receptor activation. Subsets of human breast cancers contain a molecular alteration that leads to erbB2 gene amplification and subsequent protein overexpression. Although not recognized to occur in human cancers, mutation can also lead to increased ErbB2 association. A well characterized mutant of the rodent ortholog neu involves substitution of glutamate for valine within the transmembrane domain. In each case, a number of explanations have been proposed to explain the resulting ErbB2 activation. These include stabilization of receptor oligomers, release of negative constraints, and altered receptor conformations. Here we define a short amino acid segment comprising amino acids 966-968 in the intracellular domain that seemingly disrupts receptor-receptor association that is driven either by overexpression or mutation in the transmembrane region. Because of the hydrophobic nature of these amino acids (VVI), we propose that alteration of this segment likely results in a global conformational change in an area that has been proposed previously to be a dimerization motif for ErbB homomeric association.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Sliwkowski, MX (corresponding author), Genentech Inc, Dept Mol Oncol, Mail Stop 50,1 DNA Way, San Francisco, CA 94080 USA.							Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARTE MT, 1995, ARCH BIOCHEM BIOPHYS, V322, P378, DOI 10.1006/abbi.1995.1478; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; LASKY LA, 1984, DNA-J MOLEC CELL BIO, V3, P23, DOI 10.1089/dna.1.1984.3.23; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	48	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28468	28473		10.1074/jbc.M202510200	http://dx.doi.org/10.1074/jbc.M202510200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12000754	hybrid			2022-12-25	WOS:000177342600017
J	Lindsay, AJ; McCaffrey, MW				Lindsay, AJ; McCaffrey, MW			Rab11-FIP2 functions in transferrin recycling and associates with endosomal membranes via its COOH-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; BINDING PROTEIN RAB4; PLASMA-MEMBRANE; IDENTIFICATION; TRAFFICKING; COMPARTMENT; INTERACTS; EFFECTORS; FUSION; EEA1	Rab11-FIP2 is a recently described member of the Rip11/Rab11-FIP/Rab coupling protein family of Rab11 interacting proteins. Rab11-FIP2 interacts with both Rab11 and myosin Vb and co-localizes with Rab11 in both HeLa and Madin-Darby canine kidney cells (Hales, C. M., Griner, R., Hobdy-Henderson, K. C., Dorn, M. C., Hardy, D., Kumar, R., Navarre, J., Chan, E. K., Lapierre, L. A., and Goldenring, J. R. (2001) J. Biol. Chem. 276, 39067-390751). Here, we characterized the specificity of the interaction between Rab11-FIP2 and Rab11 and report that it does not interact with Rab4, Rab3, Rab5, Rab6, or Rab7. We demonstrate that the COOH-terminal region of Rab11-FIP2, which contains the Rab11 binding domain (11131)), is necessary and sufficient for its early endosomal membrane association. In contrast, the amino-terminal region, which contains a phospholipid binding C2-domain, by itself was insufficient for membrane binding. Expression of a deletion mutant of Rab11-FIP2, containing the RBD, caused tubulation of a transferrin receptor-positive early endosomal compartment in HeLa cells. Endogenous Pab11 was also associated with this compartment. This phenotype cannot be reversed by excess wild-type Rab11, or dominant-positive Rab11 (Rab11Q70L), suggesting that Rab11-FIP2 functions downstream of Rab11 in endosomal trafficking.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Mol Cell Biol Lab, Cork, Ireland	University College Cork	McCaffrey, MW (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Mol Cell Biol Lab, Prospect Row, Cork, Ireland.	m.mccaffrey@ucc.ie	Lindsay, Andrew J/P-9778-2017	Lindsay, Andrew J/0000-0001-9693-7022				Bielli A, 2001, BIOCHEM BIOPH RES CO, V281, P1141, DOI 10.1006/bbrc.2001.4468; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Trischler M, 1999, J CELL SCI, V112, P4773; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	37	96	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27193	27199		10.1074/jbc.M200757200	http://dx.doi.org/10.1074/jbc.M200757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994279	hybrid			2022-12-25	WOS:000177055900064
J	Saxena, A; Saffery, R; Wong, LH; Kalitsis, P; Choo, KHA				Saxena, A; Saffery, R; Wong, LH; Kalitsis, P; Choo, KHA			Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							POLY ADP-RIBOSYLATION; B NULL MICE; NF-KAPPA-B; INNER CENTROMERE; DNA-DAMAGE; OXIDATIVE STRESS; ALPHA-SATELLITE; GENE-DISRUPTION; HISTONE H3; IN-VITRO	Poly(ADP-ribose) polymerase-1 (PARP-1) is activated by DNA strand breaks during cellular genotoxic stress response and catalyzes poly(ADP-ribosyl)ation of acceptor proteins. These acceptor proteins include those involved in modulation of chromatin structure, DNA synthesis, DNA repair, transcription, and cell cycle control. Thus, PARP-1 is believed to play a pivotal role in maintaining genome integrity through modulation of protein-protein and protein-DNA interactions. We previously described the association of PARP-1 with normal mammalian centromeres and human neocentromeres by affinity purification and immunofluorescence. Here we investigated the interaction of this protein with, and poly(ADP-ribosyl)ation of, three constitutive centromere proteins, Cenpa, Cenpb, and Cenpc, and a spindle checkpoint protein, Bub3. Immunoprecipitation and Western blot analyses demonstrate that Cenpa, Cenpb, and Bub3, but not Cenpc, interacted with PARP-1, and are poly(ADP-ribosyl)ated following induction of DNA damage. The results suggest a role of PARP-1 in centromere assembly/disassembly and checkpoint control. Demonstration of PARP-1-binding and poly(ADP-ribosyl)ation in three of the four proteins tested further suggests that many more centromere proteins may behave similarly and implicates PARP-1 as an important regulator of diverse centromere function.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Choo, KHA (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	choo@cryptic.rch.unimelb.edu.au	Saffery, Richard/GLS-1976-2022; Kalitsis, Paul/C-1916-2015; Wong, Lee H/H-9757-2012	Saffery, Richard/0000-0002-9510-4181; Kalitsis, Paul/0000-0001-5569-0609; Wong, Lee H/0000-0002-4005-7330; Saxena, Alka/0000-0001-5683-0618				Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Allshire R, 2001, CURR BIOL, V11, pR454, DOI 10.1016/S0960-9822(01)00278-0; Althaus FR, 1999, MOL CELL BIOCHEM, V193, P5, DOI 10.1023/A:1006975002262; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Amor Y, 1998, FEBS LETT, V440, P1, DOI 10.1016/S0014-5793(98)01408-2; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; Brady DM, 2000, CURR BIOL, V10, P675, DOI 10.1016/S0960-9822(00)00515-7; Burkle A, 1998, EXP GERONTOL, V33, P519, DOI 10.1016/S0531-5565(98)00036-9; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CHEN YM, 1994, EUR J BIOCHEM, V224, P135, DOI 10.1111/j.1432-1033.1994.tb20004.x; Choo KHA, 2001, DEV CELL, V1, P165, DOI 10.1016/S1534-5807(01)00028-4; Choo KHA., 1997, CENTROMERE; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daum JR, 2000, CURR BIOL, V10, pR850, DOI 10.1016/S0960-9822(00)00836-8; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DeMurcia G., 2000, DNA DAMAGE STRESS SI; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; duSart D, 1997, NAT GENET, V16, P144; Earle E, 2000, HUM MOL GENET, V9, P187, DOI 10.1093/hmg/9.2.187; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; Figueroa J, 1998, CHROMOSOMA, V107, P397, DOI 10.1007/s004120050323; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Fukagawa T, 1997, HUM MOL GENET, V6, P2301, DOI 10.1093/hmg/6.13.2301; Fukagawa T, 2001, NUCLEIC ACIDS RES, V29, P3796, DOI 10.1093/nar/29.18.3796; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Hageman GJ, 1998, NUTR CANCER, V32, P113, DOI 10.1080/01635589809514728; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hudson DF, 1998, J CELL BIOL, V141, P309, DOI 10.1083/jcb.141.2.309; Irelan JT, 2001, GENETICS, V157, P1191; Ishida R, 2001, CELL STRUCT FUNCT, V26, P215, DOI 10.1247/csf.26.215; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jacobson EL, 2001, J PHOTOCH PHOTOBIO B, V63, P141, DOI 10.1016/S1011-1344(01)00211-1; Jean L, 1999, FEBS LETT, V446, P6, DOI 10.1016/S0014-5793(99)00173-8; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kapoor M, 1998, CHROMOSOMA, V107, P570, DOI 10.1007/s004120050343; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kipling D, 1997, TRENDS GENET, V13, P141, DOI 10.1016/S0168-9525(97)01098-6; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Lo AWI, 2001, EMBO J, V20, P2087, DOI 10.1093/emboj/20.8.2087; Love S, 1999, BRAIN PATHOL, V9, P119; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; NOZAKI T, 1994, BIOCHEM BIOPH RES CO, V198, P45, DOI 10.1006/bbrc.1994.1007; Oegema K, 2001, J CELL BIOL, V153, P1209, DOI 10.1083/jcb.153.6.1209; Okano S, 2000, J BIOL CHEM, V275, P32635, DOI 10.1074/jbc.M004085200; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Perez-Castro AV, 1998, DEV BIOL, V201, P135, DOI 10.1006/dbio.1998.9005; Pidoux AL, 2000, CURR OPIN CELL BIOL, V12, P308, DOI 10.1016/S0955-0674(00)00094-6; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; Saffery R, 1999, CHROMOSOME RES, V7, P261, DOI 10.1023/A:1009222729850; Saffery R, 2000, HUM MOL GENET, V9, P175, DOI 10.1093/hmg/9.2.175; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sullivan BA, 2001, NAT REV GENET, V2, P584, DOI 10.1038/35084512; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; UCHIDA K, 1994, MOL CELL BIOCHEM, V138, P25, DOI 10.1007/BF00928439; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Van Hooser AA, 2001, J CELL SCI, V114, P3529; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yoda K, 1998, GENES CELLS, V3, P533, DOI 10.1046/j.1365-2443.1998.00210.x; Yoda K, 2000, P NATL ACAD SCI USA, V97, P7266, DOI 10.1073/pnas.130189697; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	108	95	100	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26921	26926		10.1074/jbc.M200620200	http://dx.doi.org/10.1074/jbc.M200620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011073	hybrid			2022-12-25	WOS:000177055900030
J	Cao, Y; Kang, Q; Zhao, ZF; Zolkiewska, A				Cao, Y; Kang, Q; Zhao, ZF; Zolkiewska, A			Intracellular processing of metalloprotease disintegrin ADAM12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ADAM-12 MELTRIN-ALPHA; CYSTEINE-RICH DOMAIN; ENDOPLASMIC-RETICULUM; CONVERTING-ENZYME; CELL-ADHESION; SECRETASE CLEAVAGE; MYOBLAST FUSION; QUALITY-CONTROL; GROWTH-FACTOR	ADAM12 has been implicated in cell-cell interactions in myogenesis and cancer, but the structure of the mature form of ADAM12 is not known, and its localization on the cell surface has been questioned. In this report, we show that full-length ADAM12 is N-glycosylated in the endoplasmic reticulum (ER) and proteolytically processed in the trans-Golgi network to an similar to90-kDa form. The similar to90-kDa form, which lacks the prodomain, was the predominant form present at the cell surface. Replacement of Leu(73) in the putative a-helical region in the prodomain with proline resulted in retention of ADAM12 in the ER and a complete lack of its processing. However, deletion of the entire pro- and metalloprotease domains did not affect the processing and trafficking of ADAM12. In contrast, replacement of the cytoplasmic domain of ADAM12 with that of ADAM9 or adding a c-Myc tag at the C terminus led to a significant increase in transport of the protein to the cell surface. These results suggest that the cytoplasmic domain of ADAM12 plays an important role in regulating ADAM12 exit from the ER. We conclude that properly folded mouse ADAM12, after passing a rate-limiting step of exit from the ER, is processed in the secretory pathway and reaches the cell surface, where it can mediate adhesion-mediated signaling.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewska, A (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045787] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15563] Funding Source: Medline; NIAMS NIH HHS [AR45787] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bornemann A, 2000, J MUSCLE RES CELL M, V21, P475, DOI 10.1023/A:1005657607591; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao Y, 2001, BIOCHEM J, V357, P353, DOI 10.1042/0264-6021:3570353; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kadota N, 2000, J BIOCHEM-TOKYO, V128, P941, DOI 10.1093/oxfordjournals.jbchem.a022845; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	63	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26403	26411		10.1074/jbc.M110814200	http://dx.doi.org/10.1074/jbc.M110814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000744	hybrid			2022-12-25	WOS:000176908700077
J	Weston, CJ; Venning, JD; Jackson, JB				Weston, CJ; Venning, JD; Jackson, JB			The membrane-peripheral subunits of transhydrogenase from Entamoeba histolytica are functional only when dimerized	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING TRANSHYDROGENASE; NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; ESCHERICHIA-COLI; RHODOSPIRILLUM-RUBRUM; CATALYTIC PROPERTIES; SOLUTION SCATTERING; HYDRIDE TRANSFER; MITOCHONDRIAL TRANSHYDROGENASE; BIOLOGICAL MACROMOLECULES; NADP(H)-BINDING DOMAINS	Unlike their bacterial and mammalian counterparts, the NADP(H)- and NAD(H)-binding components of proton-translocating transhydrogenase from the protozoan parasite Entamoeba histolytica (denoted ehdIII and ehdI, respectively) are tethered by a polypeptide linker. The recombinant tethered fragment, ehdIII-ehdI, was prepared without its membrane-spanning dII component. Dimers of ehdIII-ehdI catalyzed transhydrogenation, but monomers were inactive. The addition of ehdIII to ehdIII-ehdI monomers did not lead to an increase in the rate of transhydrogenation, showing that this inactivity is not the result of an unfavorable topology introduced by the linker. The addition of a bacterial dI to ehdIII-ehdI led to an increase in the rate of transhydrogenation, showing that the linker is flexible. A hybrid protein in which ehdIII is tethered to the bacterial dI (denoted ehdIII-rrdI) more readily formed active dimers. Data from small angle x-ray scattering by the hybrid dimers were fitted to models derived from the high-resolution crystal structure of the bacterial dI(2)dIII(1) complex (Cotton, N. P. J., White, S. A., Peake, S. J., McSweeney, S., and Jackson, J. B. (2001) Structure 9, 165-176). The results show that the ehdIII-rrdI dimer is asymmetric; one dIII associates with dI, as in the bacterial complex, but the other is displaced. The results provide evidence for the alternating site, binding change model for proton translocation by intact transhydrogenase.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.							ANDERSON WM, 1981, BIOCHIM BIOPHYS ACTA, V635, P194, DOI 10.1016/0005-2728(81)90018-9; Bizouarn T, 2000, BBA-BIOENERGETICS, V1457, P211, DOI 10.1016/S0005-2728(00)00103-1; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Ghosh S, 2000, INFECT IMMUN, V68, P4319, DOI 10.1128/IAI.68.7.4319-4322.2000; HOEK JB, 1988, BIOCHEM J, V254, P1; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 2002, BIOCHEMISTRY-US, V41, P4173, DOI 10.1021/bi012078d; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1411, P159, DOI 10.1016/S0005-2728(99)00013-4; PERSSON B, 1987, ARCH BIOCHEM BIOPHYS, V259, P341, DOI 10.1016/0003-9861(87)90500-5; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; PHELPS DC, 1985, BIOCHEMISTRY-US, V24, P3503, DOI 10.1021/bi00335a017; Pinheiro TJT, 2001, J BIOL CHEM, V276, P44757, DOI 10.1074/jbc.M109227200; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1999, BIOCHEM J, V341, P329, DOI 10.1042/0264-6021:3410329; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; VERMEULEN AN, 1993, FEMS MICROBIOL LETT, V110, P223, DOI 10.1111/j.1574-6968.1993.tb06324.x; Weston CJ, 2001, FEBS LETT, V488, P51, DOI 10.1016/S0014-5793(00)02386-3; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	42	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26163	26170		10.1074/jbc.M203514200	http://dx.doi.org/10.1074/jbc.M203514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004068	hybrid			2022-12-25	WOS:000176908700045
J	Bavendiek, U; Libby, P; Kilbride, M; Reynolds, R; Mackman, N; Schonbeck, U				Bavendiek, U; Libby, P; Kilbride, M; Reynolds, R; Mackman, N; Schonbeck, U			Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; ACUTE CORONARY SYNDROMES; SHEAR-STRESS INDUCTION; VASCULAR SMOOTH-MUSCLE; HUMAN MONOCYTIC CELLS; EPITHELIAL-CELLS; ARTERY DISEASE; IN-VITRO; LIPOPOLYSACCHARIDE; LIGATION	Induction of tissue factor expression in endothelial cells via ligation of CD40 probably figures prominently in the pathogenesis of prevalent inflammatory diseases, including atherosclerosis. However, the molecular mechanisms of tissue factor gene expression triggered by CD40 ligand (CD40L) in this cell type remain unknown. We demonstrate here that the tissue factor promoter region -278 bp to +121 bp contains the CD40L-responsive elements, consisting of activator protein 1 (AP-1)+/-, nuclear factor (NF) kappaB-, and Egr-1-binding sites. Mutations of either the AP-1- or NF-kappaB-binding sites markedly reduced the CD40L-dependent promoter activation. The AP-1 and NF-kappaB sites displayed constitutive and CD40L-enhanceable DNA binding activity, respectively. Of note, mutation of the Egr-1-binding sites, previously not associated with CD40 signaling, impaired activation of the tissue factor promoter. Accordingly, CD40L strongly induced Egr-1 protein expression and DNA binding activity to all three bindings sites. In contrast to CD40L, other established inducers of tissue factor in endothelial cells, interleukin-1beta or tumor necrosis factor a, did not increase the expression of Egr-1. In conclusion, induction of tissue factor gene expression in human endothelial cells by CD40L involves AP-1 and NF-kappaB as well as Egr-1, a pathway previously not implicated in CD40 signaling and distinct from that employed by certain other proinflammatory cytokines.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Leducq Ctr Cardiovasc Res,Cardiovasc Div, Boston, MA 02115 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Scripps Research Institute	Schonbeck, U (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Leducq Ctr Cardiovasc Res,Cardiovasc Div, 221 Longwood Ave,EBRC 309, Boston, MA 02115 USA.		Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056985, R37HL034636, R01HL034636] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34636, HL-56985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 1999, CIRCULATION, V100, P1215, DOI 10.1161/01.CIR.100.11.1215; Bennett BL, 1996, J BIOL CHEM, V271, P19680, DOI 10.1074/jbc.271.33.19680; Cui MZ, 1999, J BIOL CHEM, V274, P32795, DOI 10.1074/jbc.274.46.32795; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Houston P, 1999, ARTERIOSCL THROM VAS, V19, P281, DOI 10.1161/01.ATV.19.2.281; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Mach F, 1997, CIRCULATION, V96, P396; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Miller DL, 1998, J LEUKOCYTE BIOL, V63, P373, DOI 10.1002/jlb.63.3.373; Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; POTGENS AJG, 1994, THROMB HAEMOSTASIS, V71, P208; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; Schonbeck U, 2000, AM J PATHOL, V156, P7, DOI 10.1016/S0002-9440(10)64699-8; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Schonbeck U, 1999, J EXP MED, V189, P843, DOI 10.1084/jem.189.5.843; Slupsky JR, 1998, THROMB HAEMOSTASIS, V80, P1008; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Zhou L, 1998, THROMB HAEMOSTASIS, V79, P1025	34	116	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25032	25039		10.1074/jbc.M204003200	http://dx.doi.org/10.1074/jbc.M204003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978801	hybrid			2022-12-25	WOS:000176747000027
J	Dineley, KT; Bell, KA; Bui, D; Sweatt, JD				Dineley, KT; Bell, KA; Bui, D; Sweatt, JD			beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CHOLINERGIC HYPOTHESIS; LONGITUDINAL MRI; SENILE DEMENTIA; CONTEXTUAL FEAR; CHANNEL DOMAIN; IN-VITRO; MEMORY	The alpha7 nicotinic acetylcholine receptor is highly expressed in hippocampus and in cholinergic projection neurons from the basal forebrain, structures that are particularly vulnerable to the ravages of Alzheimer's disease. Previous work suggests that beta-amyloid peptide can interact with alpha7 nicotinic acetylcholine receptors, although the nature of this interaction has not been well characterized. To test whether beta-amyloid peptide can activate alpha7 nicotinic acetylcholine receptors, we expressed these receptors in Xenopus oocytes and performed two-electrode voltage clamp recordings, characterizing the response to beta-amyloid peptide 1-42 applied at concentrations ranging from I pm to 100 nM. In alpha7-expressing oocytes, beta-amyloid peptide 1-42 elicits inward currents at low concentrations (1-100 pm), whereas at higher concentrations (nM), less effective receptor activation is observed, indicative of receptor desensitization. Preincubation with the alpha7-selective agents, the antagonist methyllycaconatine, and the agonist 4-OH-GTS-21 blocked beta-amyloid peptide-induced receptor activation. beta-amyloid peptide 1-42 at low concentrations was able to activate the L250T mutant alpha7 receptor. The endogenous Ca2+-activated chloride current in Xenopus oocytes is recruited upon receptor activation since replacing Ca2+ with Ba2+ in the recording solution reduced current amplitude. Thus, when beta-amyloid peptide activation of alpha7 receptors occurs, these currents are comprised, at least in part, of Ca2+.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Dineley, KT (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.	kdineley@cns.bcm.tmc.edu		Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57014] Funding Source: Medline; NINDS NIH HHS [NS13546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Blum S, 1999, J NEUROSCI, V19, P3535; BOWEN DM, 1976, BRAIN, V99, P459, DOI 10.1093/brain/99.3.459; Brining SK, 1997, NEUROBIOL AGING, V18, P581, DOI 10.1016/S0197-4580(97)00153-X; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; DAVIES P, 1976, LANCET, V2, P1403; DEFIEBRE CM, 1995, MOL PHARMACOL, V47, P164; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Dodart JC, 2000, REV NEUROSCIENCE, V11, P75; Fox NC, 1996, BRAIN, V119, P2001, DOI 10.1093/brain/119.6.2001; Fox NC, 1996, ANN NY ACAD SCI, V777, P226, DOI 10.1111/j.1749-6632.1996.tb34423.x; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Meyer EM, 1998, J PHARMACOL EXP THER, V287, P918; PERRY EK, 1977, LANCET, V1, P189; Pettit DL, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-01-j0003.2001; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SEGUELA P, 1993, J NEUROSCI, V13, P596; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2000, J NEUROCHEM, V75, P1155, DOI 10.1046/j.1471-4159.2000.0751155.x	34	200	201	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25056	25061		10.1074/jbc.M200066200	http://dx.doi.org/10.1074/jbc.M200066200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983690	hybrid			2022-12-25	WOS:000176747000030
J	Fukuzawa, J; Nishihira, J; Hasebe, N; Haneda, T; Osaki, J; Saito, T; Nomura, T; Fujino, T; Wakamiya, N; Kikuchi, K				Fukuzawa, J; Nishihira, J; Hasebe, N; Haneda, T; Osaki, J; Saito, T; Nomura, T; Fujino, T; Wakamiya, N; Kikuchi, K			Contribution of macrophage migration inhibitory factor to extracellular signal-regulated kinase activation by oxidative stress in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIS-INDUCING FACTOR; PROTEIN-KINASE; ANGIOTENSIN-II; CRYSTAL-STRUCTURE; CARDIAC MYOCYTES; MESSENGER-RNA; CYTOKINE; MIF; EXPRESSION; MAPK	In response to oxidative stress, the pathogenesis of a number of cardiovascular events and several genes are stimulated by extracellular signal-regulated kinases (ERK1/2). Biphasic (early, 10 min; and delayed, 120 min) ERK1/2 activation by H2O2, a reactive oxygen species, was observed in cultured neonatal rat cardiomyocytes. We investigated the hypothesis that the delayed activation of ERK1/2 depends on a factor secreted by oxidative stress (FSO). The delayed activation was inhibited by calphostin C, a protein kinase C inhibitor. Conditioned medium (CM) obtained from cells stimulated with H2O2 induced rapid and monophasic ERK1/2 activation which was not inhibited by calphostin C. In contrast: calphostin C-pretreated CM did not activate ERK1/2. Macrophage migration inhibitory factor (MIF) was one of the candidate FSOs activating ERK1/2. The existence of MIF in CM, the recombinant MIF-stimulated ERK1/2 rapid activation, and anti-MIF neutralizing antibody-induced inhibition of the delayed activation implied that MIF could be the FSO. Pretreatment of cardiomyocytes with a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor did not suppress the MIF secretion, although it prevented the ERK1/2 activation by H2O2. These results indicate that MIF is secreted from cardiomyocytes as a result of oxidative stress and activates ERK1/2 through a MEK1/2-dependent mechanism, although the secretion is not regulated by ERK1/2 but by protein kinase C.	Asahikawa Med Coll, Dept Med 1, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan; Hokkaido Univ, Sch Med, Cent Res Inst, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Nemuro Municipal Hosp, Nemuro 0878686, Japan	Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical College; Hokkaido University	Fukuzawa, J (corresponding author), Asahikawa Med Coll, Dept Med 1, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	fukuzawa@asahikawa-med.ac.jp						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Booz GW, 1996, HYPERTENSION, V28, P635, DOI 10.1161/01.HYP.28.4.635; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; ERIKSON E, 1986, J BIOL CHEM, V261, P350; Fukuzawa J, 2000, HYPERTENSION, V35, P1191, DOI 10.1161/01.HYP.35.6.1191; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Hunt RA, 1999, HYPERTENSION, V34, P603, DOI 10.1161/01.HYP.34.4.603; IRONS CE, 1993, AM J PHYSIOL, V264, pH282, DOI 10.1152/ajpheart.1993.264.1.H282; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Kaye D, 1996, J CLIN INVEST, V97, P281, DOI 10.1172/JCI118414; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koong AC, 2000, CANCER RES, V60, P883; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin SG, 2000, CIRC RES, V87, P1202, DOI 10.1161/01.RES.87.12.1202; Linke MJ, 1997, AM J PHYSIOL-LUNG C, V272, pL171, DOI 10.1152/ajplung.1997.272.2.L171; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mischke R, 1998, FEBS LETT, V427, P85, DOI 10.1016/S0014-5793(98)00400-1; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; NISHIHIRA J, 1995, BBA-PROTEIN STRUCT M, V1247, P159, DOI 10.1016/0167-4838(94)00215-3; Nishio Y, 1999, BBA-MOL BASIS DIS, V1453, P74, DOI 10.1016/S0925-4439(98)00086-6; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Takahashi M, 2001, CARDIOVASC RES, V52, P438, DOI 10.1016/S0008-6363(01)00408-4; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Tanaki K, 2001, J AM COLL CARDIOL, V37, P676, DOI 10.1016/S0735-1097(00)01123-2; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TURNERS JF, 1980, BIOCHEM J, V156, P434; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yu CM, 2001, AM J CARDIOL, V88, P774, DOI 10.1016/S0002-9149(01)01850-1	47	36	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24889	24895		10.1074/jbc.M112054200	http://dx.doi.org/10.1074/jbc.M112054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978785	hybrid			2022-12-25	WOS:000176747000010
J	Kang, TB; Zhao, YG; Pei, DQ; Sucic, JF; Sang, QXA				Kang, TB; Zhao, YG; Pei, DQ; Sucic, JF; Sang, QXA			Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; CYSTEINE-SWITCH; CONVERTING ENZYME; HUMAN DISINTEGRIN; BETA-SECRETASE; MELTRIN BETA; CLEAVAGE; CLONING; LOCALIZATION; MATURATION	Adamalysin 19 (a disintegrin and metalloproteinase 19, ADAM19, or meltrin beta) is a plasma membrane metalloproteinase. Human ADAM19 zymogen contains two potential furin recognition sites (RX(K/R)R), (KRPRR)-K-196-R-200 and (RRMKR)-R-199-R-203, between its pro- and catalytic domains. Protein N-terminal sequencing revealed that the cellular mature forms of hADAM19 started at (EDLNSMK)-E-204, demonstrating that the preferred furin cleavage site was the (200)RMK(203)Rdown arrow(204)EDLN. Those mature forms were catalytically active. Both Pittsburgh mutant of alpha(1)-proteinase inhibitor and dee-Arg-Val-Lys-Arg-chloromethyl ketone, two specific furin inhibitors, blocked the activation of hADAM19. Activation of hADAM19 was also blocked by brefeldin A, which inhibits protein trafficking from the endoplasmic reticulum to the Golgi, or A23187, a calcium ionophore known to inhibit the autoactivation of furin. When (KR)-K-202 were mutated to AA, the proenzyme was also activated, suggesting that (RPRR)-R-197 is an alternative activation site. Furthermore, only pro-forms of hADAM19 were detected in the (RR)-R-199 to AA mutant, which abolished both furin recognition sites. Moreover, the zymogens were not converted into their active forms in two furin-deficient mammalian cell lines; co-expression of hADAM19 and furin in these two cell lines restored zymogen activation. Finally, co-localization between furin and hADAM19 was identified in the endoplasmic reticulum-Golgi complex and/or the trans-Golgi network. This report is the first thorough investigation of the intracellular activation of adamalysin 19, demonstrating that furin activated pro-hADAM19 in the secretory pathway via one of the two consecutive furin recognition sites.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Michigan, Dept Biol, Flint, MI 48502 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; University of Michigan Flint	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, 303 DLC,Chem Res Bldg,Rm 203, Tallahassee, FL 32306 USA.	sang@chem.fsu.edu			NATIONAL CANCER INSTITUTE [R29CA078646, R29CA076308, R01CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA78646, CA76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; Bass J, 2000, P NATL ACAD SCI USA, V97, P11905, DOI 10.1073/pnas.97.22.11905; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Fritsche J, 2000, BLOOD, V96, P732; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, CANCER RES, V62, P675; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kurohara K, 2000, BIOCHEM BIOPH RES CO, V270, P522, DOI 10.1006/bbrc.2000.2429; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Marchenko ND, 2002, J BIOL CHEM, V277, P18967, DOI 10.1074/jbc.M201197200; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, FEBS LETT, V457, P262, DOI 10.1016/S0014-5793(99)01046-7; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shapiro J, 1997, J HISTOCHEM CYTOCHEM, V45, P3, DOI 10.1177/002215549704500102; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; STEINER DF, 1998, CURR OPIN CHEM BIOL, V84, P45; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; WASLEY CL, 1993, CURR OPIN BIOTECH, V3, P560; Wei P, 2001, BIOCHEM BIOPH RES CO, V280, P744, DOI 10.1006/bbrc.2000.4200; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zhao YG, 2001, BIOCHEM BIOPH RES CO, V289, P288, DOI 10.1006/bbrc.2001.5958	65	54	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25583	25591		10.1074/jbc.M203532200	http://dx.doi.org/10.1074/jbc.M203532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006600	hybrid			2022-12-25	WOS:000176747000096
J	Melvin, VS; Roemer, SC; Churchill, MEA; Edwards, DP				Melvin, VS; Roemer, SC; Churchill, MEA; Edwards, DP			The C-terminal extension (CTE) of the nuclear hormone receptor DNA binding domain determines interactions and functional response to the HMGB-1/-2 co-regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY GROUP PROTEIN-1; ZINC-FINGER REGION; VITAMIN-D-RECEPTOR; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; STRUCTURAL DETERMINANTS; MONOMER-BINDING; RXR-RAR; T-BOX; HMG-1	Previously, we and others reported that the high mobility group proteins, HMGB-1/-2, enhance DNA binding in vitro and transactivation in situ by the steroid hormone subgroup of nuclear receptors but did not influence these functions of class 11 receptors. We show here that the DNA binding domain (DBD) is sufficient to account for the selective influence of HMGB-1/-2 on the steroid class of receptors. Furthermore, the use of chimeric DBDs reveals that this selectivity is dependent on the C-terminal extension (CTE), amino acid sequences adjacent to the zinc finger core DBD. HMGB-1/-2 interact directly with the DBDs of steroid but not class II receptors, and this interaction requires the CTE. This in vitro interaction correlates with a requirement of the CTE for maximal HMGB-1/-2 enhancement of DNA binding in vitro and transcriptional activation in cells. Finally, class II receptor DBDs have a much higher intrinsic affinity for DNA than steroid receptor DBDs, and this affinity difference is also dependent on the CTE. These results reveal the importance of the steroid receptor CTE for DNA binding affinity and functional response to HMGB-1/-2.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Edwards, DP (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, 4200 E 9th Ave,B216, Denver, CO 80262 USA.	dean.edwards@uchsc.edu	Churchill, Mair E. A./C-5549-2014	Churchill, Mair E. A./0000-0003-0862-235X	NATIONAL CANCER INSTITUTE [R01CA046938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059456] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46938] Funding Source: Medline; NIGMS NIH HHS [R01 GM059456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carrozza MJ, 1998, J VIROL, V72, P6752, DOI 10.1128/JVI.72.8.6752-6757.1998; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; Edwards DP, 2000, J MAMMARY GLAND BIOL, V5, P307, DOI 10.1023/A:1009503029176; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HSIEH JC, 1995, BIOCHEM BIOPH RES CO, V215, P1, DOI 10.1006/bbrc.1995.2426; Hsieh JC, 1999, BIOCHEMISTRY-US, V38, P16347, DOI 10.1021/bi9916574; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; Melvin VS, 2001, METH MOL B, V176, P39; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Romine LE, 1998, MOL ENDOCRINOL, V12, P664, DOI 10.1210/me.12.5.664; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Sem DS, 1997, J BIOL CHEM, V272, P18038, DOI 10.1074/jbc.272.29.18038; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	59	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25115	25124		10.1074/jbc.M110400200	http://dx.doi.org/10.1074/jbc.M110400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006575	hybrid			2022-12-25	WOS:000176747000037
J	Vinogradov, E; Frirdich, E; MacLean, LL; Perry, MB; Petersen, BO; Duus, JO; Whitfield, C				Vinogradov, E; Frirdich, E; MacLean, LL; Perry, MB; Petersen, BO; Duus, JO; Whitfield, C			Structures of lipopolysaccharides from Klebsiella pneumoniae - Elucidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIBRIO-CHOLERAE O1; D-GALACTAN-I; CASSETTE TRANSPORT-SYSTEM; RFB GENE-CLUSTER; ESCHERICHIA-COLI; NCTC-5055 LIPOPOLYSACCHARIDE; SEROTYPE O1-K20; ANTIGEN; BIOSYNTHESIS; EXPRESSION	Deamination of LPSs from Klebsiella pneumoniae released O-chain polysaccharides together with a fragment of the core oligosaccharide. The structures of the products from serotypes 01, O2a, O2a,c, 03, 04, 05, and 012 were determined by NMR spectroscopy and chemical methods, identifying the linkage region between the 0 antigens and the core as well as novel residues at the non-reducing ends of the polysaccharides. All serotypes had an identical linkage between the 0 chain and core. [GRAPHICS] where L-glycero-D-manno-heptose is non-stoichiometric. Analysis of the LPSs from a waaL (O-polysaccharide ligase-deficient) mutant showed that the beta-GlcNAc in the linkage region is derived from the O-chain biosynthesis pathway, and the alpha-3-deoxy-D-manno-octulosonic acid represents the core residue to which the 0 chain is ligated. Consistent with the common ligation site, the WaaL proteins from these serotypes are essentially identical. Polysaccharides from serotypes 01, O2a, and O2a,c contain no special groups at the non-reducing end, whereas polysaccharides from serotypes 03,04,05, and 012 have residues at the non-reducing end that are not found in the polymer repeating units.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark	National Research Council Canada; University of Guelph	Vinogradov, E (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.		Duus, Jens Øllgaard/N-4279-2013	Duus, Jens Øllgaard/0000-0003-3625-1250; Vinogradov, Evgeny/0000-0002-5364-1376				BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; BJORNDAL H, 1972, ACTA CHEM SCAND, V26, P1269, DOI 10.3891/acta.chem.scand.26-1269; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; CURVALL M, 1973, ACTA CHEM SCAND, V27, P2645, DOI 10.3891/acta.chem.scand.27-2645; DITTA G, 1985, PLASMID, V13, P149, DOI 10.1016/0147-619X(85)90068-X; ERBING C, 1977, CARBOHYD RES, V56, P377, DOI 10.1016/S0008-6215(00)83359-5; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Guan S, 2001, J BACTERIOL, V183, P3318, DOI 10.1128/JB.183.11.3318-3327.2001; Hansen DS, 1999, J CLIN MICROBIOL, V37, P56, DOI 10.1128/JCM.37.1.56-62.1999; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; JANN K, 1979, BIOCHEM BIOPH RES CO, V86, P1185, DOI 10.1016/0006-291X(79)90242-0; JANN K, 1985, EUR J BIOCHEM, V151, P393, DOI 10.1111/j.1432-1033.1985.tb09114.x; JANN K, 1982, EUR J BIOCHEM, V127, P157, DOI 10.1111/j.1432-1033.1982.tb06850.x; JANSSON PE, 1985, CARBOHYD RES, V145, P59, DOI 10.1016/S0008-6215(00)90412-9; KELLY RF, 1995, J ENDOTOXIN RES, V0002; KELLY RF, 1993, MOL MICROBIOL, V10, P615, DOI 10.1111/j.1365-2958.1993.tb00933.x; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; Kido N, 2000, J BACTERIOL, V182, P2567, DOI 10.1128/JB.182.9.2567-2573.2000; KJAER M, 1994, METHODS ENZYMOL, V239, P288; KOL O, 1992, CARBOHYD RES, V236, P339, DOI 10.1016/0008-6215(92)85028-X; KOL O, 1991, CARBOHYD RES, V217, P117, DOI 10.1016/0008-6215(91)84122-U; LINDBERG B, 1972, ACTA CHEM SCAND, V26, P2231, DOI 10.3891/acta.chem.scand.26-2231; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; MACLEAN LL, 1993, CARBOHYD RES, V239, P325, DOI 10.1016/0008-6215(93)84231-T; MANNING PA, 1995, GENE, V158, P1, DOI 10.1016/0378-1119(95)00124-O; MCCALLUM KL, 1989, CAN J MICROBIOL, V35, P994, DOI 10.1139/m89-166; MCCALLUM KL, 1989, INFECT IMMUN, V57, P3816, DOI 10.1128/IAI.57.12.3816-3822.1989; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; MERINO S, 1992, INFECT IMMUN, V60, P2529, DOI 10.1128/IAI.60.6.2529-2535.1992; Merino S, 2000, INFECT IMMUN, V68, P2435, DOI 10.1128/IAI.68.5.2435-2440.2000; PREHM P, 1976, EUR J BIOCHEM, V67, P53, DOI 10.1111/j.1432-1033.1976.tb10631.x; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; STROEHER UH, 1992, P NATL ACAD SCI USA, V89, P2566, DOI 10.1073/pnas.89.7.2566; Sugiyama T, 1997, GENE, V198, P111, DOI 10.1016/S0378-1119(97)00300-4; Sugiyama T, 1998, J BACTERIOL, V180, P2775, DOI 10.1128/JB.180.10.2775-2778.1998; TRAUTMANN M, 1994, INFECT IMMUN, V62, P1282, DOI 10.1128/IAI.62.4.1282-1288.1994; Trautmann M, 1997, CLIN DIAGN LAB IMMUN, V4, P550, DOI 10.1128/CDLI.4.5.550-555.1997; Unger F. M., 1981, ADV CARBOHYD CHEM BI, V38, P323; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Vinogradov E, 2001, EUR J BIOCHEM, V268, P1722; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; WEISGERBER C, 1984, EUR J BIOCHEM, V140, P553, DOI 10.1111/j.1432-1033.1984.tb08137.x; WEISGERBER C, 1982, EUR J BIOCHEM, V127, P165, DOI 10.1111/j.1432-1033.1982.tb06851.x; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; WHITFIELD C, 1991, J BACTERIOL, V173, P1420, DOI 10.1128/jb.173.4.1420-1431.1991; WHITFIELD C, 1992, J BACTERIOL, V174, P4913, DOI 10.1128/JB.174.15.4913-4919.1992; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9	53	128	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25070	25081		10.1074/jbc.M202683200	http://dx.doi.org/10.1074/jbc.M202683200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986326	hybrid			2022-12-25	WOS:000176747000032
J	Chen, HC; Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, M; Farese, RV; Farese, RV				Chen, HC; Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, M; Farese, RV; Farese, RV			Activation of the ERK pathway and atypical protein kinase C Isoforms in exercise- and aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR)-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; RICH TYROSINE KINASE-2; INSULIN-INDUCED ACTIVATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL REGULATION; GLUT4 TRANSLOCATION; SKELETAL-MUSCLE; PHOSPHOLIPASE-D	Exercise increases glucose transport in muscle by activating 5'-AMP-activated protein kinase (AMPK), but subsequent events are unclear. Presently, we examined the possibility that AMPK increases glucose transport through atypical protein kinase Cs (aPKCs) by activating proline-rich tyrosine kinase-2 (PYK2), ERK pathway components, and phospholipase D (PLD). In mice, treadmill exercise rapidly activated ERK and aPKCs in mouse vastus lateralis muscles. In rat extensor digitorum longus (EDL) muscles, (a) AMPK activator, 5-aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR), activated PYK2, ERK and aPKCs; (b) effects of AICAR on ERK and aPKCs were blocked by tyrosine kinase inhibitor, genistein, and MEK1 inhibitor, PD98059; and (c) effects of AICAR on aPKCs and 2-deoxyglucose (2-DOG) uptake were inhibited by genistein, PD98059, and PLD-inhibitor, 1-butanol. Similarly, in L6 myotubes, (a) AICAR activated PYK2, ERK, PLD, and aPKCs; (b) effects of AICAR on ERK were inhibited by genistein, PD98059, and expression of dominant-negative PYK2; (c) effects of AICAR on PLD were inhibited by MEK1 inhibitor UO126; (d) effects of AICAR on aPKCs were inhibited by genistein, PD98059, 1-butanol, and expression of dominant-negative forms of PYK2, GRB2, SOS, HAS, RAF, and ERK; and (e) effects of AICAR on 2DOG uptake/GLUT4 translocation were inhibited by genistein, PD98059, UO126, I-butanol, cell-permeable myristoylated PKC-zeta pseudosubstrate, and expression of kinase-inactive RAF, ERK, and PKC-zeta. AMPK activator dinitrophenol had effects on ERH, aPKCs, and 2-DOG uptake similar to those of AICAR. Our findings suggest that effects of exercise on glucose transport that are dependent on AMPK are mediated via PYK2, the ERK pathway, PLD, and aPKCs.	Univ S Florida, James A Haley Vet Hosp, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Coll Med, Tampa, FL 33612 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Farese, RV (corresponding author), Univ S Florida, James A Haley Vet Hosp, Coll Med, ACOS 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@hsc.usf.edu	Farese, Robert/B-3605-2015	Chen, Hubert/0000-0002-7599-7218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065969] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balon TW, 2001, BIOCHEM BIOPH RES CO, V282, P1008, DOI 10.1006/bbrc.2001.4677; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Bandyopadhyay G, 2001, J BIOL CHEM, V276, P35537, DOI 10.1074/jbc.M106042200; Bandyopadhyay G, 2000, J BIOL CHEM, V275, P40817, DOI 10.1074/jbc.M007920200; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; CORDERRE L, 1995, J BIOL CHEM, V270, P27584; Hayashi T, 1999, AM J PHYSIOL-CELL PH, V277, pC701, DOI 10.1152/ajpcell.1999.277.4.C701; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1996, ENDOCRINOLOGY, V137, P3014, DOI 10.1210/en.137.7.3014; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wojtaszewski JFP, 1999, AM J PHYSIOL-ENDOC M, V277, pE724, DOI 10.1152/ajpendo.1999.277.4.E724	26	162	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23554	23562		10.1074/jbc.M201152200	http://dx.doi.org/10.1074/jbc.M201152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11978788	hybrid			2022-12-25	WOS:000176475700060
J	He, YW; Cress, WD				He, YW; Cress, WD			E2F-3B is a physiological target of cyclin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F-1; CELL-CYCLE; S-PHASE; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; DNA-REPLICATION; FAMILY MEMBERS; RB/E2F PATHWAY; IN-VIVO; A CDK2	The E2F family of transcription factors controls the expression of numerous genes that are required for the G(1)/S transition. Among the mechanisms that modulate the activity of the E2F proteins, cyclin A has been found to be important for the down-regulation of E2F-1, -2, and -3A activity after cells have progressed through G(1)/S. Specifically, phosphorylation of these E2F proteins by cyclin A/Cdk2 ultimately results in their necessary degradation as cells progress through S phase. E2F-3B was recently identified as an alternatively spliced form of E2F-3A that was predicted to lack a functional cyclin A binding domain. In this paper, we present considerable evidence that contradicts this prediction. First, we demonstrate binding of cyclin A to E2F-3B as bacterially expressed proteins in vitro. Second, we demonstrate binding of cyclin A to E2F-313 in mammalian cells in vivo. Third, we show that co-expression of cyclin A with E2F-3B significantly reduces E2F-3B-mediated transcriptional activity. Finally, in synchronized cells, we observe down-regulation of E2F-3B protein expression coincident with the up-regulation of cyclin A. We conclude that E2F-3B is a physiological target of cyclin A.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33620 USA; Univ S Florida, Coll Med, Dept Interdiciplinary Oncol, Tampa, FL 33620 USA; H Lee Moffitt Comprehens Canc Ctr, Tampa, FL 33612 USA; Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER; NCI NIH HHS [CA78214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Allen KE, 1997, J CELL SCI, V110, P2819; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EBLEN ST, 1995, CELL GROWTH DIFFER, V6, P915; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Jordan-Sciutto KL, 1998, BIOCHEM CELL BIOL, V76, P37; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lavia P, 1999, BIOESSAYS, V21, P221; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; LOGAN TJ, 1995, CANCER RES, V55, P2883; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Magae J, 1996, J CELL SCI, V109, P1717; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Takahashi Y, 2000, GENE DEV, V14, P804; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	52	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23493	23499		10.1074/jbc.M202629200	http://dx.doi.org/10.1074/jbc.M202629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980909	hybrid			2022-12-25	WOS:000176475700053
J	Kitabatake, M; Ali, K; Demain, A; Sakamoto, K; Yokoyama, S; Soll, D				Kitabatake, M; Ali, K; Demain, A; Sakamoto, K; Yokoyama, S; Soll, D			Indolmycin resistance of Streptomyces coelicolor A3(2) by induced expression of one of its two tryptophanyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEVEL MUPIROCIN RESISTANCE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING; REVEALS; RECOGNITION; COMPLEX; PROTEIN; ACID; SITE	Aminoacyl-tRNA synthetases, a family of enzymes essential for protein synthesis, are promising targets of antimicrobials. Indolmycin, a secondary metabolite of Streptomyces griseus and a selective inhibitor of prokaryotic tryptophanyl-tRNA synthetase (TrpRS), was used to explore the mechanism of inhibition and to explain the resistance of a naturally occurring strain. Streptomyces coelicolor A3(2), an indolmycin-resistant strain, contains two trpS genes encoding distinct TrpRS enzymes. We show that TrpRS1 is indolmycin-resistant in vitro and in vivo, whereas TrpRS2 is sensitive. The lysine (position 9) in the enzyme tryptophan binding site is essential for making TrpRS1 indolmycin-resistant. Replacement of lysine 9 by glutamine, which at this position is conserved in most bacterial TrpRS proteins, abolished the ability of the mutant trpS gene to confer indolmycin resistance in vivo. Molecular modeling suggests that lysine 9 sterically hinders indolmycin binding to the enzyme. Tryptophan recognition (assessed by k(cat)/K-M) by TrpRS1 is 4-fold lower than that of TrpRS2. Examination of the mRNA for the two enzymes revealed that only TrpRS2 mRNA is constitutively expressed, whereas mRNA for the indolmycin-resistant TrpRS1 enzyme is induced when the cells are exposed to indolmycin.	RIKEN, Genomic Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Tokyo, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; MIT, Dept Biol, Cambridge, MA 02139 USA	RIKEN; Yale University; University of Tokyo; Massachusetts Institute of Technology (MIT)	Yokoyama, S (corresponding author), RIKEN, Genomic Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp; dieter.soll@yale.edu	Yokoyama, Shigeyuki/N-6911-2015; Sakamoto, Kensaku/N-7496-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Sakamoto, Kensaku/0000-0003-2866-5031	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022854, R01GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnez JG, 1998, COLD SPRING HARBOR M, P465; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BRYANT R, 1982, THESIS YALE U; Bunjun S, 2000, P NATL ACAD SCI USA, V97, P12997, DOI 10.1073/pnas.230444397; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HODGSON JE, 1994, ANTIMICROB AGENTS CH, V38, P1205, DOI 10.1128/AAC.38.5.1205; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 1999, P NATL ACAD SCI USA, V96, P418, DOI 10.1073/pnas.96.2.418; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; Kanamaru T, 2001, ANTIMICROB AGENTS CH, V45, P2455, DOI 10.1128/AAC.45.9.2455-2459.2001; KHORANA HG, 1968, BIOCHEM J, V109, P709, DOI 10.1042/bj1090709c; Kieser T., 2001, PRACTICAL STREPTOMYC; KISSELEV LL, 1993, BIOCHIMIE, V75, P1027, DOI 10.1016/0300-9084(93)90002-A; MARSH W. S., 1960, ANTIBIOT AND CHEMOTHER, V10, P316; Onaka H, 1997, MOL MICROBIOL, V24, P991, DOI 10.1046/j.1365-2958.1997.4081772.x; Praetorius-Ibba M, 2000, BIOCHEMISTRY-US, V39, P13136; PREOBRAZHENSKAYA MN, 1968, TETRAHEDRON, V24, P6131, DOI 10.1016/S0040-4020(01)96345-8; RAHMAN M, 1990, J MED MICROBIOL, V33, P97, DOI 10.1099/00222615-33-2-97; RAO KOPPAKA V., 1960, ANTIBIOT AND CHEMOTHER, V10, P312; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; SIPPONEN P, 1993, SCAND J GASTROENTERO, V28, P3, DOI 10.3109/00365529309098333; Sugiura I, 2000, STRUCTURE, V8, P197, DOI 10.1016/S0969-2126(00)00095-2; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Watanabe H, 2001, J HOSP INFECT, V47, P294, DOI 10.1053/jhin.2000.0931; WERNER RG, 1976, EUR J BIOCHEM, V68, P1, DOI 10.1111/j.1432-1033.1976.tb10758.x; WERNER RG, 1981, J ANTIBIOT, V34, P551, DOI 10.7164/antibiotics.34.551; Witty DR, 1996, BIOORG MED CHEM LETT, V6, P1375, DOI 10.1016/0960-894X(96)00237-5; Witty DR, 1996, TETRAHEDRON LETT, V37, P3067, DOI 10.1016/0040-4039(96)00471-6; Wolf YI, 1999, GENOME RES, V9, P689; ZARGAROVA T A, 1990, Biokhimiya, V55, P1328	40	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23882	23887		10.1074/jbc.M202639200	http://dx.doi.org/10.1074/jbc.M202639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970956	hybrid			2022-12-25	WOS:000176475700102
J	Leong, PL; Xi, SC; Drenning, SD; Dyer, KF; Wentzel, AL; Lerner, EC; Smithgall, TE; Grandis, JR				Leong, PL; Xi, SC; Drenning, SD; Dyer, KF; Wentzel, AL; Lerner, EC; Smithgall, TE; Grandis, JR			Differential function of STAT5 isoforms in head and neck cancer growth control	ONCOGENE			English	Article						STAT5; squamous cell carcinoma of the head and neck epidermal growth factor receptor	SQUAMOUS-CELL CARCINOMA; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; FACTOR RECEPTOR; CONSTITUTIVE ACTIVATION; TGF-ALPHA; TRANSCRIPTION FACTORS; SIGNAL TRANSDUCERS; GENE FAMILY; PROTEINS	Up-regulation of the epidermal growth factor receptor (EGFR) is critical for the loss of growth control in a variety of human cancers, including squamous cell carcinoma of the head and neck (SCCHN). Stimulation of EGFR results in activation of mitogenic signaling pathways including Signal Transducers and Activators of Transcription (STATs). Stat5 activation has been primarily demonstrated in hematopoietic malignancies. Gene disruption studies suggest potentially distinct functions of the Stat5 isoforms, Stat5a and Stat5b, which are encoded by two genes closely linked on human chromosome 17. To determine the function of Stat5 in SCCHN growth control, we studied the expression and constitutive activation of Stat5a and Stat5b in normal and transformed human squamous epithelial cells. Increased constitutive activation of Stat5 was detected in transformed compared with normal squamous cells. Blockade of TGF-alpha or EGFR, abrogated Stat5 activation. Targeting of Stat5b using antisense oligonucleotides inhibited SCCHN growth. In addition, SCCHN cells stably transfected with dominant negative mutant Stat5b failed to proliferate in vitro. In contrast, targeting of Stat5a using either antisense or dominant negative strategies had no effect on cell growth. These results suggest that TGF-alpha/EGFR-mediated autocrine growth of transformed epithelial cells is dependent on activation of Stat5b but not Stat5a.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NCI NIH HHS [CA77308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chai SK, 1997, J IMMUNOL, V159, P4720; CHRISTENSEN ME, 1992, EUR ARCH OTO-RHINO-L, V249, P243, DOI 10.1007/BF00714485; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Endo S, 2000, GENE THER, V7, P1906, DOI 10.1038/sj.gt.3301315; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; GRANDIS JR, 1993, J CELL BIOCHEM, P188; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; HEO DS, 1989, CANCER RES, V49, P5167; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lango MN, 2001, CURR OPIN ONCOL, V13, P168, DOI 10.1097/00001622-200105000-00007; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2000, ONCOGENE, V19, P4117, DOI 10.1038/sj.onc.1203754; Okuda K, 1996, ONCOGENE, V13, P1147; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; SACKS PG, 1988, CANCER RES, V48, P2858; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WeberNordt RM, 1996, BLOOD, V88, P809; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914	53	60	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2846	2853		10.1038/sj.onc.1205385	http://dx.doi.org/10.1038/sj.onc.1205385			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973644				2022-12-25	WOS:000175063700009
J	Meriane, M; Charrasse, S; Comunale, F; Mery, A; Fort, P; Roux, P; Gauthier-Rouviere, C				Meriane, M; Charrasse, S; Comunale, F; Mery, A; Fort, P; Roux, P; Gauthier-Rouviere, C			Participation of small GTPases Rac1 and Cdc42Hs in myoblast transformation	ONCOGENE			English	Article						Rho GTPases; myogenesis; transformations; rhabdomyosarcoma	SKELETAL-MUSCLE DIFFERENTIATION; KINASE PATHWAY; GROWTH-FACTOR; RAS; RHO; P38; ACTIVATION; EXPRESSION; PROLIFERATION; PROTEINS	We have previously shown that expression of active Rac1 and Cdc4Hs inhibits skeletal muscle cell differentiation. We show here, by bromodeoxyuridine incorporation and cyclin D1 expression, that the expression of active Rac1 and Cdc42Hs but not RhoA impairs cell cycle exit of L6 myoblasts cultured in differentiation medium. Furthermore, expression of activated forms of Rac1 and Cdc42Hs elicits the loss of cell contact inhibition and anchorage-dependent growth as measured by focus forming activity and growth in soft agar. RhoA was once again not found to have this effect. We found a constitutive Rac1 and Cdc42Hs activation in three human rhabdomyosarcoma-derived cell lines, one of the most common causes of solid tumours arising from muscle precursors during childhood. Finally, dominant negative forms of Rac1 and Cdc42Hs inhibit cell proliferation of the RD rhabdomyosarcoma cell line. These data suggest an important role for the small GTPases Rac1 and Cdc42Hs in the generation of skeletal muscle tumours.	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Gauthier-Rouviere, C (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier, France.	gauthier@erbm.cnrs.mop.fr	Fort, Philippe/M-9498-2015; Roux, Pierre/D-8833-2017	Fort, Philippe/0000-0001-5997-8722; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Comunale, Franck/0000-0001-8838-2151				Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; HELLER H, 2001, J BIOL CHEM, V6, P6; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Mangues R, 1992, Semin Cancer Biol, V3, P229; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Puri PL, 2000, GENE DEV, V14, P574; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; VAN AL, 1997, GENE DEV, V11, P2295; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	36	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2901	2907		10.1038/sj.onc.1205396	http://dx.doi.org/10.1038/sj.onc.1205396			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973651				2022-12-25	WOS:000175063700016
J	Soldatenkov, VA; Trofimova, IN; Rouzaut, A; McDermott, F; Dritschilo, A; Notario, V				Soldatenkov, VA; Trofimova, IN; Rouzaut, A; McDermott, F; Dritschilo, A; Notario, V			Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1	ONCOGENE			English	Article						antisense apoptosis; ETS transcription factors; poly(ADP-ribose) polymerase	GROWTH-FACTOR-BETA; ANTISENSE RAF OLIGODEOXYRIBONUCLEOTIDE; HUMAN-TUMOR CELLS; EWS GENE; FUSION PROTEINS; DOWN-REGULATION; II RECEPTOR; EWS-FLI1; FAMILY; TRANSCRIPTION	Ewing's sarcoma (EWS) cells contain levels of poly (ADP-ribose) polymerase (PARP) significantly higher than other eukaryotic cells. Previously, we cloned the PARP gene promoter region from EWS cells, showed that it contained multiple ETS-binding sites and demonstrated a positive regulation of PARP by ETS1. We now report that, contrary to ETS1, EWS/FLI-1, an aberrant ETS transcription factor present in most EWS cells, is a negative effector of PARP transcription. Because PARP levels have been associated with cellular resistance or sensitivity to genotoxic agents, we studied the effect of modifying PARP levels in EWS cells on their response to DNA damage by modulating the expression of ETS1 or EWS/FLI-1 using antisense methodology. Results show that stable down-regulation of ETS1 increases the resistance of EWS cells to various genotoxic agents, whereas down-regulation of EWS/FLI-1 has pro-apoptotic effects. Because down-regulation EWS/FLI-1 does not dramatically change PARP levels, these results suggest a direct effect for EWS/FLI-1 in the DNA damage response of EWS cells. Since expression of the aberrant fusion proteins by EWS cells is essential for maintaining their neoplastic phenotype, our results suggest that the use of antisense oligonuleotides in combination with chemotherapeutic agents or radiation may be doubly effective by causing both an increase in sensitivity to therapeutic agents and a simultaneous down-regulation, or reversion, of the neoplastic phenotype of EWS cells.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Expt Carcinogenesis Lab, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20007 USA.	notariov@georgetown.edu	Rouzaut, Ana/I-2576-2017; /AFP-0764-2022; /AAB-6461-2022	Rouzaut, Ana/0000-0003-3226-9162; 	NCI NIH HHS [CA64472, P01-CA74175, P30-CA51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472, P01CA074175, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Gokhale PC, 1997, GENE THER, V4, P1289, DOI 10.1038/sj.gt.3300543; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Im YH, 2000, CANCER RES, V60, P1536; KELLAND LR, 1988, INT J RADIAT ONCOL, V14, P1239, DOI 10.1016/0360-3016(88)90403-8; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LEITH JT, 1988, RADIAT RES, V114, P186, DOI 10.2307/3577154; Lin PP, 1999, CANCER RES, V59, P1428; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PRASAD SC, 1990, CANCER RES, V50, P38; RAO VN, 1993, ONCOGENE, V8, P2167; Raynal S, 1997, INT J CANCER, V72, P356, DOI 10.1002/(SICI)1097-0215(19970717)72:2<356::AID-IJC26>3.3.CO;2-J; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; THRAVES PJ, 1986, INT J RADIAT BIOL, V50, P961, DOI 10.1080/09553008614551381; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2890	2895		10.1038/sj.onc.1205393	http://dx.doi.org/10.1038/sj.onc.1205393			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973649				2022-12-25	WOS:000175063700014
J	Kiyoi, H; Ohno, R; Ueda, R; Saito, H; Naoe, T				Kiyoi, H; Ohno, R; Ueda, R; Saito, H; Naoe, T			Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain	ONCOGENE			English	Article						FLT3; receptor tyrosine kinase; juxtamembrane; internal tandem duplication; leukemia	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; C-KIT RECEPTOR; CELL-LINES; MYELODYSPLASTIC SYNDROME; MOLECULAR CHAPERONES; MYELOGENOUS LEUKEMIA; GENE; MUTATIONS; TRANSFORMATION	Internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 is the most frequent mutation in human acute myeloid leukemia, and is significantly associated with leukocytosis and a poor prognosis. Previously we reported that FLT3 with ITD (FLT3/ ITD) formed a homodimer and was autophosphorylated on tyrosine residues, while the mechanism remains unclear. In this study, we elucidated the role of the JM domain in FLT3 activation. Mutant FLT3 with not only ITD but also an elongating or shortening JM domain transformed murine IL-3-dependent myeloid progenitor cell line 32D regardless of the tyrosine residues in the JM domain. These mutant FLT3s were constitutively tyrosine phosphorylated and activated signal-transduction molecules such as SHC, MAP kinase and STAT5a. Notably, co-transfection of the truncated FLT3/ITD lacking kinase and C-terminal domains with the wild type (Wt)-FLT3 into 32D cells resulted in the autonomous proliferation. In these cells, truncated FLT3/ITD generated a hetero-complex with Wt-FLT3 and Wt-FLT3 was constitutively tyrosine phosphorylated. These findings indicate that the FLT3 JM domain plays an important role in receptor activation, and that the length-mutated JM domain induces ligand-independent receptor activation but also activates Wt-FLT3 in a trans-manner.	Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, Nagoya, Aichi 4668560, Japan; Aichi Canc Ctr Hosp, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Dept Med 2, Nagoya, Aichi 4678601, Japan; Nagoya Natl Hosp, Dept Med, Nagoya, Aichi 4600001, Japan	Nagoya University; Aichi Cancer Center; Nagoya City University	Kiyoi, H (corresponding author), Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	kiyoi@med.nagoya-u.ac.jp	Naoe, Tomoki/I-1888-2012					Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Iwai T, 1999, LEUKEMIA, V13, P38, DOI 10.1038/sj.leu.2401241; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Kondo M, 1999, MED PEDIATR ONCOL, V33, P525; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lam LPY, 1999, BIOCHEM J, V338, P131, DOI 10.1042/0264-6021:3380131; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Tsujimura T, 1996, PATHOL INT, V46, P933, DOI 10.1111/j.1440-1827.1996.tb03571.x; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Xu F, 1999, BRIT J HAEMATOL, V105, P155, DOI 10.1111/j.1365-2141.1999.01284.x; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372; Zhao M, 2000, LEUKEMIA, V14, P374, DOI 10.1038/sj.leu.2401680	34	207	217	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2555	2563		10.1038/sj.onc.1205332	http://dx.doi.org/10.1038/sj.onc.1205332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971190				2022-12-25	WOS:000174918400012
J	Scelfo, RAM; Schwienbacher, C; Veronese, A; Gramantieri, L; Bolondi, L; Querzoli, P; Nenci, I; Calin, GA; Angioni, A; Barbanti-Brodano, G; Negrini, M				Scelfo, RAM; Schwienbacher, C; Veronese, A; Gramantieri, L; Bolondi, L; Querzoli, P; Nenci, I; Calin, GA; Angioni, A; Barbanti-Brodano, G; Negrini, M			Loss of methylation at chromosome 11p15.5 is common in human adult tumors	ONCOGENE			English	Article						chromosome 11p15.5; DNA hypomethylation	BECKWITH-WIEDEMANN-SYNDROME; DNA METHYLATION; IMPRINTED GENE; WILMS-TUMOR; SUPPRESSOR REGIONS; H19; LOCUS; IGF2; EXPRESSION; DISRUPTION	Chromosome 11p15 deletion is frequent in human tumors, suggesting the presence of at least one tumor suppressor gene within this region. While mutation analyses of local genes revealed only rare mutations, we have previously described a mechanism, gain of imprinting, that leads to loss of expression of genes located on the maternal 11p15 chromosome in human hepatocarcinomas. Loss of expression was often associated with loss of maternal-specific methylation at the KvDMR1 locus. Here, we show that loss of the maternal KvDMR1 methylation is common, ranging from 30 to 50%, to a variety of adult neoplasms, including liver, breast, cervical and gastric carcinomas. We found that other 11p15.5 loci were concomitantly hypomethylated, indicating that loss of KvDMR1 methylation occurred in the context of a common mechanism affecting the methylation of a large 11p15 subchromosomal domain. These epigenetic abnormalities were not detected in any normal somatic tissue. Therefore, it seems possible that, contrary to the repression of promoter activity caused by hypermethylation, loss of gene expression at 11p15.5 may result from the activation, by hypomethylation, of one or more negative regulatory elements.	Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Interdipartmentale Ric Canc, I-44100 Ferrara, Italy; Int Canc Ctr, Mol Biol Labs, Rovigo, Italy; Univ Bologna, Dipartimento Med Interna & Gastroenterol, Bologna, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Osped Pediat, Serv Immunotrasfus, Bambino Gesu IRCCS, Rome, Italy	University of Ferrara; University of Ferrara; University of Bologna; Jefferson University; IRCCS Bambino Gesu	Negrini, M (corresponding author), Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, Via Luigi Borsari 46, I-44100 Ferrara, Italy.	ngm@unife.it	Calin, George/E-9390-2011; angioni, adriano/G-1160-2014; Veronese, Angelo/I-4292-2019; Gramantieri, Laura/K-8603-2016; Negrini, Massimo/J-2377-2016; Gramantieri, Laura/J-3862-2019	angioni, adriano/0000-0003-0862-2456; Gramantieri, Laura/0000-0002-5187-9559; Negrini, Massimo/0000-0002-0007-1920; QUERZOLI, Patrizia/0000-0003-2873-8894; Calin, George/0000-0001-6704-5615; Veronese, Angelo/0000-0002-1451-1392				Baffa R, 1996, CANCER RES, V56, P268; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ehrlich Melanie, 2000, P273; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; KIECHLESCHWARZ M, 1993, CANCER, V72, P2423, DOI 10.1002/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P; KOUFOS A, 1989, AM J HUM GENET, V44, P711; Lee MP, 1998, CANCER RES, V58, P4155; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Maniatis T., 1982, MOL CLONING LAB MANU; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Sabbioni S, 1999, CYTOGENET CELL GENET, V86, P214, DOI 10.1159/000015341; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Schwienbacher C, 2000, CANCER RES, V60, P1521; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143	36	45	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2564	2572		10.1038/sj.onc.1205336	http://dx.doi.org/10.1038/sj.onc.1205336			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971191				2022-12-25	WOS:000174918400013
J	Medina, D; Kittrell, FS; Shepard, A; Stephens, LC; Jiang, C; Lu, JX; Allred, DC; McCarthy, M; Ullrich, RL				Medina, D; Kittrell, FS; Shepard, A; Stephens, LC; Jiang, C; Lu, JX; Allred, DC; McCarthy, M; Ullrich, RL			Biological and genetic properties of the p53 null preneoplastic mammary epithelium	FASEB JOURNAL			English	Article						mammary; premalignant; p53 null; immortal; model	GLANDS IN-VIVO; TELOMERASE ACTIVITY; TUMOR-DEVELOPMENT; TRANSGENIC MICE; BREAST-CANCER; MODEL; ESTROGEN; CELLS; TUMORIGENESIS; PROGESTERONE	The absence of the tumor suppressor gene p53 confers an increased tumorigenic risk for mammary epithelial cells. In this report, we describe the biological and genetic properties of the p53 null preneoplastic mouse mammary epithelium in a p53 wild-type environment. Mammary epithelium from p53 null mice was transplanted serially into the cleared mammary fat pads of p53 wild-type BALB/c female to develop stable outgrowth lines. The outgrowth lines were transplanted for 10 generations. The outgrowths were ductal in morphology and progressed through ductal hyperplasia and ductal carcinoma in situ before invasive cancer. The preneoplastic outgrowth lines were immortal and exhibited activated telomerase activity. They are estrogen and progesterone receptor-positive, and aneuploid, and had various levels of tumorigenic potential. The biological and genetic properties of these lines are distinct from those found in most hyperplastic alveolar outgrowth lines, the form of mammary preneoplasia occurring in most traditional models of murine mammary tumorigenesis. These results indicate that the preneoplastic cell populations found in this genetically engineered model are similar in biological properties to a subset of precurser lesions found in human breast cancer and provide a unique model to identify secondary events critical for tumorigenicity and invasiveness.	Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; AMC Canc Res Ctr, Denver, CO USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Microbiol, Galveston, TX 77550 USA; Colorado State Univ, Dept Radiol Hlth Sci, Ft Collins, CO 80523 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; AMC Cancer Research Center; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Colorado State University	Medina, D (corresponding author), Baylor Coll Med, Dept Cellular & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	dmedina@bcm.tmc.edu		Lu, Junxuan/0000-0002-2354-7186				ADAMS LM, 1987, CANCER RES, V47, P4425; BOUFFLER SD, 1994, INT REV CYTOL, V153, P171, DOI 10.1016/S0074-7696(08)62191-9; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Brown P, 2000, CONT ENDOCRINOL, P49; Cardiff RD, 2000, J MAMMARY GLAND BIOL, V5, P421, DOI 10.1023/A:1009534129331; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; Di Carlo E, 1999, LAB INVEST, V79, P1261; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Greer J, 2000, MAT SCI SEMICON PROC, V3, P1, DOI 10.1016/S1369-8001(00)00003-2; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; JERRY DJ, 1993, CANCER RES, V53, P3374; Jiang C, 1997, CARCINOGENESIS, V18, P2085, DOI 10.1093/carcin/18.11.2085; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Maglione JE, 2001, CANCER RES, V61, P8298; MEDINA D, 1976, J NATL CANCER I, V57, P1185, DOI 10.1093/jnci/57.5.1185; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1976, J NATL CANCER I, V57, P331, DOI 10.1093/jnci/57.2.331; MEDINA D, 2000, J MAMMARY GLAND BIOL, V5, P55; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; MEDINA D, 1978, EXPT BREAST CANC, V2, P47; Medina D., 2000, METHODS MAMMARY GLAN, P3; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Meyn RE, 1996, INT J CANCER, V65, P466, DOI 10.1002/(SICI)1097-0215(19960208)65:4<466::AID-IJC13>3.0.CO;2-8; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; TSUKADA T, 1993, ONCOGENE, V8, P3313; Yoshidome K, 2000, CANCER RES, V60, P6901; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	35	82	83	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					881	+		10.1096/fj.01-0885fje	http://dx.doi.org/10.1096/fj.01-0885fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967232				2022-12-25	WOS:000175425900013
J	Bracher, A; Kadlec, J; Betz, H; Weissenhorn, W				Bracher, A; Kadlec, J; Betz, H; Weissenhorn, W			X-ray structure of a neuronal complexin-SNARE complex from squid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; SYNAPTIC EXOCYTOSIS; KINETIC COMPONENTS; CRYSTAL-STRUCTURE; PROTEIN; VESICLE; CALCIUM; CORE; SNAP-25	Nerve terminals release neurotransmitters from vesicles into the synaptic cleft upon transient increases in intracellular Ca2+. This exocytotic process requires the formation of trans SNARE complexes and is regulated by accessory proteins including the complexins. Here we report the crystal structure of a squid core complexin-SNARE complex at 2.95-Angstrom resolution. A helical segment of complexin binds in anti-parallel fashion to the four-helix bundle of the core SNARE complex and interacts at its C terminus with syntaxin and synaptobrevin around the ionic zero layer of the SNARE complex. We propose that this structure is part of a multiprotein fusion machinery that regulates vesicle fusion at a late pre-fusion stage. Accordingly, Ca2+ may initiate membrane fusion by acting directly or indirectly on complexin, thus allowing the conformational transitions of the trans SNARE complex that are thought to drive membrane fusion.	European Mol Biol Lab, F-38042 Grenoble, France; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Weissenhorn, W (corresponding author), European Mol Biol Lab, 6 Rue Jules Horowitz, F-38042 Grenoble, France.	weissen@embl-grenoble.fr	Kadlec, Jan/G-3235-2014	Kadlec, Jan/0000-0002-4853-6918				Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Eastwood SL, 2001, NEUROSCIENCE, V105, P219, DOI 10.1016/S0306-4522(01)00141-5; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Finley MFA, 2002, J NEUROSCI, V22, P1266, DOI 10.1523/JNEUROSCI.22-04-01266.2002; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Graham ME, 2001, J CELL SCI, V114, P4397; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Lonart G, 2000, J BIOL CHEM, V275, P27703; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; Misura KMS, 2000, CURR OPIN STRUC BIOL, V10, P662, DOI 10.1016/S0959-440X(00)00151-2; Morton AJ, 2001, J NEUROCHEM, V76, P166, DOI 10.1046/j.1471-4159.2001.00059.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	60	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26517	26523		10.1074/jbc.M203460200	http://dx.doi.org/10.1074/jbc.M203460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004067	hybrid			2022-12-25	WOS:000176908700091
J	Filling, C; Berndt, KD; Benach, J; Knapp, S; Prozorovski, T; Nordling, E; Ladenstein, R; Jornvall, H; Oppermann, U				Filling, C; Berndt, KD; Benach, J; Knapp, S; Prozorovski, T; Nordling, E; Ladenstein, R; Jornvall, H; Oppermann, U			Critical residues for structure and catalysis in short-chain dehydrogenases/reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURE; TERNARY COMPLEX; ACTIVE-SITE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; CARBONYL REDUCTASE; ALCOHOL; SPECIFICITY; RESOLUTION	Short-chain dehydrogenases/reductases form a large, evolutionarily old family of NAD(P)(H)-dependent enzymes with over 60 genes found in the human genome. Despite low levels of sequence identity (often 10-30%), the three-dimensional structures display a highly similar alpha/beta folding pattern. We have analyzed the role of several conserved residues regarding folding, stability, steady-state kinetics, and coenzyme binding using bacterial 3beta/17beta-hydroxysteroid dehydrogenase and selected mutants. Structure determination of the wildtype enzyme at 1.2-Angstrom resolution by x-ray crystallography and docking analysis was used to interpret the biochemical data. Enzyme kinetic data from mutagenetic replacements emphasize the critical role of residues Thr-12, Asp-60, Asn-86, Asn-87, and Ala-88 in coenzyme binding and catalysis. The data also demonstrate essential interactions of Asn-111 with active site residues. A general role of its side chain interactions for maintenance of the active site configuration to build up a proton relay system is proposed. This extends the previously recognized catalytic triad of Ser-Tyr-Lys residues to form a tetrad of Asn-Ser-Tyr-Lys in the majority of characterized short-chain dehydrogenases/reductase enzymes.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Novum, Ctr Struct Biochem, SE-14157 Huddinge, Sweden; Sodertorns Hogskola, Dept Nat Sci, SE-14104 Huddinge, Sweden; Karolinska Inst, Stockholm Bioinformat Ctr, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Sodertorn University; Karolinska Institutet	Oppermann, U (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	Udo.Oppermann@mbb.ki.se	Berndt, Kurt/J-8574-2015; Knapp, Stefan/AAG-2347-2019	Berndt, Kurt/0000-0002-3049-967X; Knapp, Stefan/0000-0001-5995-6494; Nordling, Erik/0000-0001-9310-7947				Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Benach J, 1996, EUR J BIOCHEM, V236, P144, DOI 10.1111/j.1432-1033.1996.t01-1-00144.x; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; Filling C, 2001, BIOCHEM BIOPH RES CO, V289, P712, DOI 10.1006/bbrc.2001.6032; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Ghosh D, 2001, CHEM-BIOL INTERACT, V130, P637, DOI 10.1016/S0009-2797(00)00255-6; Ghosh D, 2001, J BIOL CHEM, V276, P18457, DOI 10.1074/jbc.M100538200; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Liao DI, 2001, BIOCHEMISTRY-US, V40, P8696, DOI 10.1021/bi0107243; Obeyesekere VR, 1998, BIOCHEM BIOPH RES CO, V250, P469, DOI 10.1006/bbrc.1998.9313; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; Oppermann UCT, 1997, ADV EXP MED BIOL, V414, P403; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Zhou HP, 1999, BIOCHEM BIOPH RES CO, V257, P414, DOI 10.1006/bbrc.1999.0356	26	446	461	5	108	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25677	25684		10.1074/jbc.M202160200	http://dx.doi.org/10.1074/jbc.M202160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976334	hybrid			2022-12-25	WOS:000176747000107
J	Sakurai, K; Goto, Y				Sakurai, K; Goto, Y			Manipulating monomer-dimer equilibrium of bovine beta-lactoglobulin by amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICHIA-PASTORIS; PROTEIN; TRANSITION	Bovine beta-lactoglobulin, a major protein in cow's milk composed of nine beta-strands (betaA-betaI) and one a-helix, exists as a dimer at neutral pH while it dissociates to a native monomer below pH 3.0. It is assumed that the intermolecular beta-sheet formed between I-strands and salt bridges at AB-loops play important roles in dimer formation. Several site-directed mutants in which intermolecular interactions stabilizing the dimer would be removed were expressed in the methylotrophic yeast Pichia pastoris, and their monomer-dimer equilibria were studied by analytical ultracentrifugation. Various I-strand mutants showed decreases in K-alpha, suggesting that the intermolecular beta-sheet is essential for dimer formation. By substituting either Asp(33) or Arg(40) on the AB-loop to oppositely charged residues (i.e. R40D, R40E, and D33R), a large decrease in K-alpha was observed probably because of the charge repulsion, which is consistent with the role of electrostatic attraction between Arg40 on one monomer and Asp(33) on the other monomer in the wild-type dimer. However, when two of these mutants, R40D and D33R, were mixed, a heterodimer was formed by the electrostatic attraction between Arg(33) and Asp(40) of different molecules. These results suggested that protein-protein interactions of bovine beta-lactoglobulin can be manipulated by redesigning the residues on the interface without affecting global folding.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp						Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; CHACKO S, 1995, J MOL BIOL, V245, P261, DOI 10.1006/jmbi.1994.0022; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; Hambling S. G., 1992, ADV DAIRY CHEM, V1, P141; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ikeguchi M, 1997, PROTEINS, V27, P567, DOI 10.1002/(SICI)1097-0134(199704)27:4&lt;567::AID-PROT9&gt;3.0.CO;2-7; Joss LA, 1996, ANAL BIOCHEM, V236, P20, DOI 10.1006/abio.1996.0126; Kim TR, 1997, PROTEIN ENG, V10, P1339, DOI 10.1093/protein/10.11.1339; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuwata K, 1999, PROTEIN SCI, V8, P2541; Kuwata K, 1998, J MOL BIOL, V283, P731, DOI 10.1006/jmbi.1998.2117; PEREZ MD, 1993, J DAIRY RES, V60, P55, DOI 10.1017/S0022029900027345; Qin BY, 1998, FEBS LETT, V438, P272, DOI 10.1016/S0014-5793(98)01199-5; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Sakai K, 2000, PROTEIN SCI, V9, P1719; Sakurai K, 2001, PROTEIN SCI, V10, P2325, DOI 10.1110/ps.17001; Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6; Takano K, 2000, BIOCHEMISTRY-US, V39, P12375, DOI 10.1021/bi000849s; TELLER DC, 1969, ANN NY ACAD SCI, V164, P66, DOI 10.1111/j.1749-6632.1969.tb14033.x; Uhrinova S, 2000, BIOCHEMISTRY-US, V39, P3565, DOI 10.1021/bi992629o; Vaughan CK, 1999, J MOL BIOL, V286, P1487, DOI 10.1006/jmbi.1998.2559; Yamasaki R, 1999, J MOL BIOL, V292, P965, DOI 10.1006/jmbi.1999.3129	25	67	70	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25735	25740		10.1074/jbc.M203659200	http://dx.doi.org/10.1074/jbc.M203659200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006601	hybrid, Green Published			2022-12-25	WOS:000176747000116
J	Mamluk, R; Gechtman, Z; Kutcher, ME; Gasiunas, N; Gallagher, J; Klagsbrun, M				Mamluk, R; Gechtman, Z; Kutcher, ME; Gasiunas, N; Gallagher, J; Klagsbrun, M			Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; CELL-SURFACE; TUMOR-CELLS; SEMAPHORIN-III; NERVOUS-SYSTEM; PROTEIN; IDENTIFICATION; EXPRESSION; SULFATE; MOLECULES	Neuroplin-1 (NRP1), a receptor for vascular endothelial growth factor (VEGF) family members, has three distinct extracellular domains, a1a2, b1b2, and c. To determine the VEGF(165) and placenta growth factor 2 (PIGF-2) -binding sites of NRP1, recombinant NRP1 domains were expressed in mammalian cells as Myc-tagged, soluble proteins, and used in co-precipitation experiments with I-125-VEGF(165) and I-125-PIGF-2. Anti-Myc antibodies immunoprecipitated I-125-VEGF(165) and I-125-PIGF-2 in the presence of the b1b2 but not of the a1a2 and c domains. Neither b1 nor b2 alone was capable of binding I-125-VEGF(165). In competition experiments, VEGF(165) competed PIGF-2 binding to the NRP1 b1b2 domain, suggesting that the binding sites of VEGF(165) and PIGF-2 overlap. The presence of the a1a2 domain greatly enhanced VEGF(165), but not PIGF-2 binding to b1b2. Heparin enhanced the binding of both I-125-VEGF(165) and I-125-PIGF-2 to the b1b2 domain by 20- and 4-fold, respectively. A heparin chain of at least 20-24 monosaccharides was necessary for binding. In addition, the b1b2 domain of NRP1 could bind heparin directly, requiring heparin oligomers of at least 8 monosaccharide units. It was concluded that an intact b1b2 domain serves as the VEGF(165)-, PIGF-2-, and heparin-binding sites in NRP1, and that heparin is a critical component for regulating VEGF(165) and PIGF-2 interactions with NRP1 by physically interacting with both receptor and ligands.	Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA.			Kutcher, Matthew/0000-0003-4566-5359				Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Fuh G, 2000, J BIOL CHEM, V275, P26690; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; MAGLIONE D, 1993, ONCOGENE, V8, P925; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; OLSON ST, 1992, ADV EXP MED BIOL, V313, P155; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	37	196	202	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24818	24825		10.1074/jbc.M200730200	http://dx.doi.org/10.1074/jbc.M200730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986311	hybrid			2022-12-25	WOS:000176611800109
J	Wu, WD; Graves, LM; Gill, GN; Parsons, SJ; Samet, JM				Wu, WD; Graves, LM; Gill, GN; Parsons, SJ; Samet, JM			Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FACTOR EGF RECEPTOR; C-SRC; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; BREAST-CANCER; MITOGENIC RESPONSIVENESS; INTRACELLULAR CA2+; SH3 DOMAINS; KINASE	Previous studies have shown that exposure of cells to Zn2+ ions induces Ras and MAPK activation through the EGF receptor (EGFR). To further determine the role of EGFR in Zn2+-induced signaling, mouse B82L fibroblasts expressing no detectable EGFR protein (B82L-par), wild type EGFR (B82L-wt), kinase-deficient EGFR (B82L-K721M), or COOH-truncated EGFR (B82L-c'958) were tested. Exposure to Zn2+ induced Ras activity in B82L-wt, B82L-K721M, and B82L-c'958 but not in B82L-par cells, indicating that the tyrosine kinase domain and the auto-phosphorylation sites of the EGFR were not required for Zn2+-induced Ras activation. Zn2+ induced Src activation in all B82L cell lines, including B82L-par, indicating that Src activation is independent of the presence of the EGFR. A Src kinase inhibitor blocked Zn2+-induced Ras activation in all the B82L cell lines capable of this response, suggesting the involvement of Src kinase in Zn2+-induced Ras activation via the EGFR. Zn2+ induced the association of the EGFR with Src and specifically increased the phosphorylation of EGFR at tyrosine 845 (Tyr-845), a known Src phosphorylation site. Stably transfected B82L cells with a point mutation of the EGFR at Tyr-845 (B82L-Y845F) exhibited only basal Ras activity following exposure to Zn2+. These data demonstrate that Src-dependent phosphorylation of the EGFR at Tyr-845 is required for EGFR transactivation and Zn2+-induced Ras activation.	US EPA, Human Studies Div, Natl Hlth & Environm Effect Res Lab ORD MD58A, Off Res & Dev, Res Triangle Pk, NC 27711 USA; Univ Virginia, Ctr Hlth, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Hlth, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA	United States Environmental Protection Agency; University of Virginia; University of Virginia; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Samet, JM (corresponding author), US EPA, Human Studies Div, Natl Hlth & Environm Effect Res Lab ORD MD58A, Off Res & Dev, Res Triangle Pk, NC 27711 USA.		Graves, Lee/AAG-5470-2021					Adamson IYR, 2000, TOXICOL APPL PHARM, V166, P111, DOI 10.1006/taap.2000.8955; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P279, DOI 10.1081/CLT-100102426; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kuschner WG, 1997, ENVIRON RES, V75, P7, DOI 10.1006/enrs.1997.3765; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598; Maret W, 2001, P NATL ACAD SCI USA, V98, P12325, DOI 10.1073/pnas.231481398; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Martin CJ, 1999, AM J IND MED, V35, P574, DOI 10.1002/(SICI)1097-0274(199906)35:6<574::AID-AJIM4>3.0.CO;2-L; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; NOGUCHI M, 1993, CANCER RES, V53, P2035; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WELSH JB, 1994, MOL BIOL CELL, V5, P539, DOI 10.1091/mbc.5.5.539; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wong L, 1999, J BIOL CHEM, V274, P8900, DOI 10.1074/jbc.274.13.8900; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924; Wu WD, 2001, AM J PHYSIOL-LUNG C, V281, pL483, DOI 10.1152/ajplung.2001.281.2.L483	66	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24252	24257		10.1074/jbc.M200437200	http://dx.doi.org/10.1074/jbc.M200437200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983694	hybrid, Green Published			2022-12-25	WOS:000176611800037
J	Lu, SM; Hodges, RS				Lu, SM; Hodges, RS			A de novo designed template for generating conformation-specific antibodies that recognize alpha-helices in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; HERPES-SIMPLEX VIRUS; GCN4 LEUCINE-ZIPPER; COILED-COILS; OLIGOMERIZATION STATE; HYDROPHOBIC CORE; PRION PROTEIN; CIRCULAR-DICHROISM; BUNDLE PROTEIN; STABILITY	The generation of antibodies directed toward the surface-exposed regions of a protein using synthetic peptides as immunogens representing surface loops and turns has been widely successful. However, peptides representing a-helical regions are typically unstructured in solution and unable to produce antibodies that recognize a-helices in native proteins. We describe a de novo designed parallel two-stranded a-helical coiled-coil template for immunization to prepare antibodies that recognize a-helical protein sequences in the native protein. This template was designed for maximum stability through an IIe/Leu hydrophobic core and an interchain disulfide bridge. Surface-exposed helical residues are inserted into the template and used for immunization to generate polyclonal antibodies. To demonstrate the feasibility of this approach, 15 residues of the yeast transcription factor GCN4 were inserted into this template, and the resultant antibodies were screened for conformational specificity. Peptide antigens that contain the same surface-exposed residues but differ in structure were used as competitors in a competition assay. Direct competition between the capture peptide immobilized on a biosensor chip, the peptide antigens, and the antibodies generated by the template demonstrated that the antibodies were specific for helical structure in the native coiled-coil (synthetic GCN4 residues 250-280). These antibodies were unable to recognize the same inserted sequence in an unstructured analog. The helix-specific antibodies were also able to identify native GCN4 (31.3 kDa) from yeast whole cell extracts.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA.	robert.hodges@uchsc.edu						Aslam M., 1998, BIOCONJUGATION PROTE; Barthe P, 2000, PROTEIN SCI, V9, P942, DOI 10.1110/ps.9.5.942; Benjamin David C., 1996, Methods (Orlando), V9, P508, DOI 10.1006/meth.1996.0058; Berger C, 1999, FEBS LETT, V450, P149, DOI 10.1016/S0014-5793(99)00458-5; BETZ S, 1995, PHILOS T ROY SOC B, V348, P81, DOI 10.1098/rstb.1995.0048; Bosshard HR, 2001, NEWS PHYSIOL SCI, V16, P171; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cooper JA, 1997, MOL IMMUNOL, V34, P433, DOI 10.1016/S0161-5890(97)00056-4; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DYSON HJ, 1995, FASEB J, V9, P37, DOI 10.1096/fasebj.9.1.7821757; Foster TF, 2001, VIROLOGY, V287, P18, DOI 10.1006/viro.2001.1004; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hay FC., 2001, EPITOPE MAPPING PRAC; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Houston M E Jr, 1995, J Pept Sci, V1, P274; Irving MB, 2001, CURR OPIN CHEM BIOL, V5, P314, DOI 10.1016/S1367-5931(00)00208-8; JIN L, 1996, STRUCTURE ANTIGENS, V3, P21; Kohn WD, 1998, TRENDS BIOTECHNOL, V16, P379, DOI 10.1016/S0167-7799(98)01212-8; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Lee DL, 2001, J MOL BIOL, V306, P539, DOI 10.1006/jmbi.2000.4351; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Miceli R, 1996, Drug Des Discov, V13, P95; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; NEWMAN MA, 1992, J IMMUNOL, V149, P3260; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PARKER JMR, 1984, J PROTEIN CHEM, V3, P465, DOI 10.1007/BF01025065; PARKER JMR, 1984, J PROTEIN CHEM, V3, P479, DOI 10.1007/BF01025066; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8; Rabanal F, 1996, TETRAHEDRON LETT, V37, P1347, DOI 10.1016/0040-4039(96)00019-6; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; STANFIELD RL, 1994, TRENDS BIOTECHNOL, V12, P275, DOI 10.1016/0167-7799(94)90139-2; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Starovasnik MA, 1997, P NATL ACAD SCI USA, V94, P10080, DOI 10.1073/pnas.94.19.10080; STRYNADKA NCJ, 1988, J VIROL, V62, P3474, DOI 10.1128/JVI.62.9.3474-3483.1988; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; TSANG P, 1992, BIOCHEMISTRY-US, V31, P3862, DOI 10.1021/bi00130a018; Van Regenmortel M H, 1995, Biomed Pept Proteins Nucleic Acids, V1, P109; Van Regenmortel MHV, 1998, J MOL RECOGNIT, V11, P163; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Walsh STR, 1999, P NATL ACAD SCI USA, V96, P5486, DOI 10.1073/pnas.96.10.5486; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114; ZHU BY, 1993, PROTEIN SCI, V2, P383	54	26	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23515	23524		10.1074/jbc.M201981200	http://dx.doi.org/10.1074/jbc.M201981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971904	hybrid			2022-12-25	WOS:000176475700056
J	Brinkmann, V; Davis, MD; Heise, CE; Albert, R; Cottens, S; Hof, R; Bruns, C; Prieschl, E; Baumruker, T; Hiestand, P; Foster, CA; Zollinger, M; Lynch, KR				Brinkmann, V; Davis, MD; Heise, CE; Albert, R; Cottens, S; Hof, R; Bruns, C; Prieschl, E; Baumruker, T; Hiestand, P; Foster, CA; Zollinger, M; Lynch, KR			The immune modulator FTY720 targets sphingosine 1-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATING MATURE LYMPHOCYTES; PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; IMMUNOSUPPRESSIVE ACTIVITY; SPHINGOSINE-1-PHOSPHATE; KINASE; LYSOPHOSPHOLIPIDS; SEQUESTRATION; ACCELERATION	Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis. In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation. FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms. Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compound is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis. Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.	Novartis Pharma AG, Dept Transplantat, CH-4002 Basel, Switzerland; Novartis Pharma AG, Dept Arthrit & Bone Metab, CH-4002 Basel, Switzerland; Novartis Pharma AG, Dept Preclin Safety, CH-4002 Basel, Switzerland; Novartis Res Inst, Dept Dermatol & Immunopathol, A-1235 Vienna, Austria; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Novartis; Novartis; Novartis; Novartis; University of Virginia; University of Virginia	Lynch, KR (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, Box 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	krl2z@virginia.edu			NCI NIH HHS [R01 CA88994] Funding Source: Medline; NIGMS NIH HHS [F31 GM64101, R01 GM52722] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722, F31GM064101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Beer MS, 2000, ANN NY ACAD SCI, V905, P118; BOLTON C, 1982, J NEUROL SCI, V56, P147, DOI 10.1016/0022-510X(82)90138-1; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chiba K, 1998, J IMMUNOL, V160, P5037; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Henning G, 2001, J EXP MED, V194, P1875, DOI 10.1084/jem.194.12.1875; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; HOBSON JP, 2001, NATURE, V291, P1800; Im DS, 2001, BIOCHEMISTRY-US, V40, P14053, DOI 10.1021/bi011606i; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kanazawa I, 2001, TRENDS MOL MED, V7, P339, DOI 10.1016/S1471-4914(01)02017-2; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Matsuda S, 1999, J IMMUNOL, V162, P3321; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Miyamoto T, 2001, J AM COLL CARDIOL, V37, P1713, DOI 10.1016/S0735-1097(01)01204-9; Nikolova Z, 2001, TRANSPLANTATION, V72, P168, DOI 10.1097/00007890-200107150-00033; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; PALIK JH, 2001, J BIOL CHEM, V276, P11830; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Steinman L, 1999, NEURON, V24, P511, DOI 10.1016/S0896-6273(00)81107-1; TEDESCO T, 2001, AM J TRANSPLANT, V1, pS243; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	36	1229	1311	2	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21453	21457		10.1074/jbc.C200176200	http://dx.doi.org/10.1074/jbc.C200176200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11967257	hybrid			2022-12-25	WOS:000176286000044
J	Simon, R; Struckmann, K; Schraml, P; Wagner, U; Forster, T; Moch, H; Fijan, A; Bruderer, J; Wilber, K; Mihatsch, MJ; Gasser, T; Sauter, G				Simon, R; Struckmann, K; Schraml, P; Wagner, U; Forster, T; Moch, H; Fijan, A; Bruderer, J; Wilber, K; Mihatsch, MJ; Gasser, T; Sauter, G			Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; MDM2; CDK4; GLI; tissue microarray; TMA	DEPENDENT KINASE 4; CHROMOSOMAL IMBALANCES; TISSUE MICROARRAYS; CYCLIN D1; P53; EXPRESSION; OVEREXPRESSION; PROLIFERATION; P21; COAMPLIFICATION	The chromosomal region 12q13-q15 is recurrently amplified in bladder cancer. Putative target genes located in this region include MDM2, CDK4, and GLI. To evaluate the involvement of these genes in bladder cancer, we screened a tissue microarray (TMA) containing 2317 samples by fluorescence in situ hybridization (FISH). Amplification was found for MDM2 in 5.1%, for CDK4 in 1.1%, and for GLI in 0.4% of interpretable tumors. Among tumors having amplification of at least one of these 12q13-q15 genes, 76.6% had amplification of MDM2 alone and 6.4% had amplification of CDK4 alone. Coamplifications were seen of MDM2 and CDK4 in 10.6%, and of CDK4 and GLI in 6.4%. Neither coamplifications of all three genes nor isolated GLI amplifications were found. These data suggest a prominent role of MDM2 as a 12q13-q15 amplification target in bladder cancer. However, independent CDK4 amplifications do also occur suggesting either two nonoverlapping amplification sites or else a minimal overlapping region between MDM2 and CDK4 perhaps containing another yet unknown oncogene. The frequency of amplification increased significantly from stage pTa to pT1-4 (P<0.04) and from low to high grade (P<0.005). These data are consistent with a high level of genetic instability in invasively growing and high-grade bladder tumors.	Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Basel, Urol Clin, CH-4003 Basel, Switzerland; Vysis Inc, Downers Grove, IL 60515 USA; Cantonal Hosp Liestal, Urol Clin, CH-4410 Liestal, Switzerland	University of Basel; University of Basel; Kantonsspital Baselland	Sauter, G (corresponding author), Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4003 Basel, Switzerland.	Guido.Sauter@unibas.ch		Simon, Ronald/0000-0003-0158-4258				An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Galanis E, 1998, INT J ONCOL, V13, P717; Gamberi G, 2000, CLIN ORTHOP RELAT R, P195; Gisselsson D, 2000, GENE CHROMOSOME CANC, V28, P347; HABUCHI T, 1994, J NATL CANCER I, V86, P1331, DOI 10.1093/jnci/86.17.1331; Ioachim E, 2000, HISTOL HISTOPATHOL, V15, P721, DOI 10.14670/HH-15.721; Jahnson S, 2000, CANCER, V89, P619, DOI 10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.3.CO;2-W; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Kanoe H, 1998, ANTICANCER RES, V18, P2317; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Korkolopoulou P, 1997, PATHOL RES PRACT, V193, P767, DOI 10.1016/S0344-0338(97)80055-6; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; Lu S, 1997, CANCER RES, V57, P4511; Masciullo V, 1997, INT J CANCER, V74, P390, DOI 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Mostofi FK, 1973, HISTOLOGICAL TYPING; Oya M, 1998, JPN J CANCER RES, V89, P719, DOI 10.1111/j.1349-7006.1998.tb03276.x; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pfister C, 1999, CLIN CANCER RES, V5, P4079; Pfister C, 2000, INT J CANCER, V89, P100, DOI 10.1002/(SICI)1097-0215(20000120)89:1<100::AID-IJC16>3.3.CO;2-H; Pilotti S, 2000, BRIT J CANCER, V82, P1271; Reed SI, 1997, CANCER SURV, V29, P7; Reifenberger G, 1996, CANCER RES, V56, P5141; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; SchmitzDrager BJ, 1997, EUR UROL, V32, P487; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Shiina H, 1999, ONCOLOGY-BASEL, V56, P239, DOI 10.1159/000011971; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 1998, J PATHOL, V185, P345; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; UICC/AJCC, 1997, TNM CLASS MAL TUM; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Wolf M, 1997, GENE CHROMOSOME CANC, V18, P66, DOI 10.1002/(SICI)1098-2264(199701)18:1<66::AID-GCC8>3.0.CO;2-#; Zhao JM, 1999, CANCER RES, V59, P4658	46	116	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2476	2483		10.1038/sj.onc.1205304	http://dx.doi.org/10.1038/sj.onc.1205304			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971182				2022-12-25	WOS:000174918400004
J	Horiuchi, T; Taoka, M; Isobe, T; Komano, T; Inouye, S				Horiuchi, T; Taoka, M; Isobe, T; Komano, T; Inouye, S			Role of fruA and csgA genes in gene expression during development of Myxococcus xanthus - Analysis by two-dimensional gel electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUITING BODY MORPHOGENESIS; C-FACTOR; GUANOSINE PENTAPHOSPHATE; SIGNALING PROTEIN; CELL-INTERACTIONS; ESCHERICHIA-COLI; REGULATED GENES; TETRAPHOSPHATE; LOCUS; MYXOBACTERIA	Two genes, fruA and csgA, encoding a putative transcription factor and C-factor, respectively, are essential for fruiting body formation of Myxococcus xanthus. To investigate the role of fruA and csgA genes in developmental gene expression, developing cells as well as vegetative cells of M. xanthus wild-type, fruA::Tc, and csgA731 strains were pulse-labeled with [S-35]methionine, and the whole cell proteins were analyzed using two-dimensional immobilized pH gradient/SDS-PAGE. Differences in protein synthesis patterns among more than 700 protein spots were detected during development of the three strains. Fourteen proteins showing distinctly different expression patterns in mutant cells were analyzed in more detail. Five of the 14 proteins were identified as elongation factor Tu (EF-Tu), Dru, DofA, FruA, and protein S by immunoblot analysis and mass spectroscopy. A gene encoding DofA was cloned and sequenced. Although both fruA and csgA genes regulate early development of M. xanthus, they were found to differently regulate expression of several developmental genes. The production of six proteins, including DofA and protein S, was dependent on fruA, whereas the production of two proteins was dependent on csgA, and one protein was dependent on both fruA and csgA. To explain the present findings, a new model was presented in which different levels of FruA phosphorylation may distinctively regulate the expression of two groups of developmental genes.	Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Dept Chem, Hachioji, Tokyo 1920397, Japan; Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Tokyo Metropolitan University; Tokyo Metropolitan University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Komano, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo 1920397, Japan.		Inouye, Sharon/R-7216-2019; Isobe, Toshiaki/Q-9279-2017	Taoka, Masato/0000-0001-5554-4951				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKER ME, 1994, BIOCHEM J, V301, P311, DOI 10.1042/bj3010311; BRETSCHER AP, 1978, P NATL ACAD SCI USA, V75, P2746; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Crawford EW, 2000, GENE DEV, V14, P483; Davis JM, 1995, MOL MICROBIOL, V18, P943, DOI 10.1111/j.1365-2958.1995.18050943.x; DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; Ellehauge E, 1998, MOL MICROBIOL, V30, P807, DOI 10.1046/j.1365-2958.1998.01113.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GOLLOP R, 1991, J BACTERIOL, V173, P3597, DOI 10.1128/jb.173.11.3597-3600.1991; Gorski L, 2000, J BACTERIOL, V182, P2438, DOI 10.1128/JB.182.9.2438-2444.2000; HAGEN DC, 1978, DEV BIOL, V64, P284, DOI 10.1016/0012-1606(78)90079-9; Harris BZ, 1998, GENE DEV, V12, P1022, DOI 10.1101/gad.12.7.1022; INOUYE M, 1979, DEV BIOL, V68, P579, DOI 10.1016/0012-1606(79)90228-8; INOUYE S, 1983, P NATL ACAD SCI-BIOL, V80, P6829, DOI 10.1073/pnas.80.22.6829; KAISER D, 1993, MYXOBACTERIA, V2, P257; KIM SK, 1991, J BACTERIOL, V173, P1722, DOI 10.1128/jb.173.5.1722-1728.1991; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; KIM SK, 1990, GENE DEV, V4, P896, DOI 10.1101/gad.4.6.896; KROOS L, 1987, GENE DEV, V1, P840, DOI 10.1101/gad.1.8.840; KROOS L, 1986, DEV BIOL, V117, P252, DOI 10.1016/0012-1606(86)90368-4; Kruse T, 2001, MOL MICROBIOL, V40, P156, DOI 10.1046/j.1365-2958.2001.02365.x; LEE BU, 1995, GENE DEV, V9, P2964, DOI 10.1101/gad.9.23.2964; LI SF, 1992, GENE DEV, V6, P401, DOI 10.1101/gad.6.3.401; MANOIL C, 1980, J BACTERIOL, V141, P305, DOI 10.1128/JB.141.1.305-315.1980; MANOIL C, 1980, J BACTERIOL, V141, P297, DOI 10.1128/JB.141.1.297-304.1980; Ogawa M, 1996, MOL MICROBIOL, V22, P757, DOI 10.1046/j.1365-2958.1996.d01-1725.x; Otani M, 2001, J BACTERIOL, V183, P6282, DOI 10.1128/JB.183.21.6282-6287.2001; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMKETS LJ, 1982, J BACTERIOL, V152, P451; SHIMKETS LJ, 1988, MOL GEN GENET, V211, P63, DOI 10.1007/BF00338394; SHIMKETS LJ, 1990, J BACTERIOL, V172, P5299, DOI 10.1128/jb.172.9.5299-5306.1990; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SHIMKETS LJ, 1983, P NATL ACAD SCI-BIOL, V80, P1406, DOI 10.1073/pnas.80.5.1406; SINGER M, 1995, GENE DEV, V9, P1633, DOI 10.1101/gad.9.13.1633; SogaardAndersen L, 1996, GENE DEV, V10, P740, DOI 10.1101/gad.10.6.740; Taoka M, 2000, ELECTROPHORESIS, V21, P1872, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1872::AID-ELPS1872>3.0.CO;2-#	39	32	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26753	26760		10.1074/jbc.M111214200	http://dx.doi.org/10.1074/jbc.M111214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11997385	hybrid			2022-12-25	WOS:000177055900008
J	Saslowsky, DE; Lawrence, J; Ren, XY; Brown, DA; Henderson, RM; Edwardson, JM				Saslowsky, DE; Lawrence, J; Ren, XY; Brown, DA; Henderson, RM; Edwardson, JM			Placental alkaline phosphatase is efficiently targeted to rafts in supported lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; GPI-ANCHORED PROTEINS; MODEL MEMBRANES; PLASMA-MEMBRANE; CHOLESTEROL; DOMAINS; TRANSLOCATION; INSOLUBILITY; RICH	Evidence is growing that biological membranes contain lipid microdomains or "rafts" that may be involved in processes such as cellular signaling and protein trafficking. In this study, we have used atomic force microscopy to examine the behavior of rafts in supported lipid bilayers. We show that bilayers composed of equimolar dioleoylphosphatidylcholine and sphingomyelin spontaneously form rafts, which are detectable as raised features. A comparison of the extents of protrusion of the rafts in monolayers and bilayers indicates that the rafts in the two leaflets of the bilayer coincide. The rafts were observed both in the absence and presence of cholesterol (33 mol %). Cholesterol reduced raft protrusion presumably by increasing the thickness of the non-raft bilayer. PLAP (glycosylphosphatidylinositol-anchored protein placental alkaline phosphatase) was purified and shown to exist as a dimer. Following its incorporation into supported lipid bilayers, PLAP was found to be targeted efficiently to rafts, both in the absence and presence of cholesterol. We suggest that atomic force microscopy provides a powerful tool for the study of raft structure and properties.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	University of Cambridge; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Edwardson, JM (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.				NIGMS NIH HHS [GM 47987] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Berge T, 2000, BIOPHYS J, V79, P479, DOI 10.1016/S0006-3495(00)76309-0; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; EDSTROM RD, 1990, BIOPHYS J, V58, P1437, DOI 10.1016/S0006-3495(90)82489-9; Ellis DJ, 1999, NAT STRUCT BIOL, V6, P15; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; MOU JX, 1995, J MOL BIOL, V248, P507, DOI 10.1006/jmbi.1995.0238; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0	22	137	139	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26966	26970		10.1074/jbc.M204669200	http://dx.doi.org/10.1074/jbc.M204669200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011066	hybrid			2022-12-25	WOS:000177055900036
J	Tamura, M; Sebastian, S; Yang, SJ; Gurates, B; Ferrer, K; Sasano, H; Okamura, K; Bulun, SE				Tamura, M; Sebastian, S; Yang, SJ; Gurates, B; Ferrer, K; Sasano, H; Okamura, K; Bulun, SE			Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells - A paracrine effect mediated by prostaglandin E-2 and nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER CELLS; VASCULAR ENDOTHELIAL-CELLS; MESSENGER-RNA DEGRADATION; TRANSCRIPTION FACTOR; SYNTHASE-2 GENE; IMMUNOHISTOCHEMICAL LOCALIZATION; ENDOPEROXIDE SYNTHASE-2; CARCINOMA-CELLS; HUMAN-UTERUS; FACTOR-ALPHA	We investigated the regulation of prostaglandin production in normal endometrial stromal cells (ESC) by malignant endometrial epithelial cells. We found that cyclooxygenase (COX)-2 mRNA and protein levels and prostaglandin (PG)E, production in ESC were significantly increased by Ishikawa malignant endometrial epithelial cell conditioned medium (MECM). By using transient transfection assays, we found that the -360/-218-bp region of the COX-2 promoter gene was critical for MECM induction of promoter activity. This MECM-responsive region contained a variant nuclear factor (NF)-kappaB site at -222 to -213 that, when mutated, completely abolished COX-2 promoter activation by MECM. Employing electrophoretic mobility shift assays, we further demonstrated that binding of NF-kappaB p65 to this NF-kappaB-binding site is, in part, responsible for the COX-2 promoter activation by MECM. To investigate further the potential effects of MECM on COX-2 mRNA stability, ESC were treated with MECM in the absence or presence of actinomycin D, a general transcription inhibitor. We found that MECM significantly increased COX-2 mRNA stability. Intriguingly, we found that PGE(2) was one of the major factors in MECM, which was responsible for up-regulating COX-2 expression in ESC. ECC-1 and HEC-1A malignant endometrial epithelial cell lines also produced significantly increased quantities of PGE(2). In conclusion, malignant endometrial epithelial cells secrete PGE(2) that induces COX-2 expression in normal endometrial stromal cells in a paracrine fashion through activation of transcription and stabilization of COX-2 mRNA.	Univ Illinois, Dept Obstet & Gynecol, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 9808574, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Tohoku University; Tohoku University	Bulun, SE (corresponding author), Univ Illinois, Dept Obstet & Gynecol, 820 S Wood St,M-C 808, Chicago, IL 60612 USA.	sbulun@uic.edu			NICHD NIH HHS [HD38691] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD038691] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038691] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; ARICI A, 1999, REPROD ENDOCRINOLOGY, P134; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Bonazzi A, 2000, AM J RESP CRIT CARE, V162, P2272, DOI 10.1164/ajrccm.162.6.2003127; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Denkert C, 2001, CANCER RES, V61, P303; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Hinz B, 2000, BIOCHEM BIOPH RES CO, V272, P744, DOI 10.1006/bbrc.2000.2859; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Huang JC, 1998, J CLIN ENDOCR METAB, V83, P538, DOI 10.1210/jc.83.2.538; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kotani T, 2000, J CLIN ENDOCR METAB, V85, P4315; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Milne SA, 2001, J CLIN ENDOCR METAB, V86, P4453, DOI 10.1210/jc.86.9.4453; Munir I, 2000, BIOL REPROD, V63, P933, DOI 10.1095/biolreprod63.3.933; Ota H, 2001, HUM REPROD, V16, P561, DOI 10.1093/humrep/16.3.561; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; REES MCP, 1982, PROSTAGLANDINS, V23, P207, DOI 10.1016/0090-6980(82)90047-8; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Souza RF, 2000, CANCER RES, V60, P5767; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; TAMURA M, 2002, IN PRESS J CLIN ENDO; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Tjandrawinata RR, 1997, ADV EXP MED BIOL, V407, P163; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tucker ON, 1999, CANCER RES, V59, P987; VANVOORHIS BJ, 1990, AM J OBSTET GYNECOL, V163, P57, DOI 10.1016/S0002-9378(11)90667-X; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zimmermann KC, 1999, CANCER RES, V59, P198	54	59	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26208	26216		10.1074/jbc.M201347200	http://dx.doi.org/10.1074/jbc.M201347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006564	hybrid			2022-12-25	WOS:000176908700051
J	Wang, HX; Hays, JB				Wang, HX; Hays, JB			Mismatch repair in human nuclear extracts - Quantitative analyses of excision of nicked circular mismatched DNA substrates, constructed by a new technique employing synthetic oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTS-ALPHA; TUMOR-CELLS; IN-VITRO; CISPLATIN; ADDUCTS; DAMAGE; HETERODIMER; RESISTANCE; TOLERANT; LESIONS	Mammalian mismatch repair (MMR) systems respond to broad ranges of DNA mismatches and lesions. Kinetic analyses of MMR processing in vitro have focused on base mismatches in a few sequence contexts, because of a lack of general and quantitative MMR assays and because of the difficulty of constructing a multiplicity of MMR substrates, particularly those with DNA lesions. We describe here simple and efficient construction of 11 different MMR substrates, by ligating synthetic oligomers into gapped plasmids generated using sequence-specific N.BstNBI nicking endonuclease, then using sequence-specific nicking endonuclease N.AlwI to introduce single nicks for initiation of 3' to 5' or 5' to 3' excision. To quantitatively assay MMR excision gaps in base-mispaired substrates, generated in human nuclear extracts lacking exogenous dNTPs, we used position- and strand-specific oligomer probes. Mispair-provoked excision along the shorter path from the pre-existing nick toward the mismatch, either 3' to 5' or 5' to T, predominated over longer path excision by roughly 10:1 to 20:1. MMR excision was complete within 7 min, was highly specific (90:1) for the nicked strand, and was strongly mispair-dependent (at least 40:1). Nonspecific (mismatch-independent) 5' to 3' excision was considerably greater than nonspecific 3' to 5' excision, especially at pre-existing gaps, but was not processive. These techniques can be used to construct and analyze MMR substrates with DNA mismatches or lesions in any sequence context.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, ALS 1007, Corvallis, OR 97331 USA.				NIEHS NIH HHS [ES09848] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009848] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fink D, 1997, CANCER RES, V57, P1841; Fritzell JA, 1997, CANCER RES, V57, P5143; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HELIG JS, 1998, CURRENT PROTOCOL MOL; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; JONES M, 1987, GENETICS, V115, P605; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu HB, 2000, GENETICS, V154, P503; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nara K, 2001, CANCER RES, V61, P50; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wang HX, 2000, MOL BIOTECHNOL, V15, P97, DOI 10.1385/MB:15:2:97; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; Wang HX, 2002, J BIOL CHEM, V277, P26143, DOI 10.1074/jbc.M200358200; Wang HX, 2001, MOL BIOTECHNOL, V19, P133, DOI 10.1385/MB:19:2:133; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Xu Y, 2001, P NATL ACAD SCI USA, V98, P12990, DOI 10.1073/pnas.241215698	33	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26136	26142		10.1074/jbc.M200357200	http://dx.doi.org/10.1074/jbc.M200357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006560	hybrid			2022-12-25	WOS:000176908700041
J	Wang, Z; Frederick, J; Garabedian, MJ				Wang, Z; Frederick, J; Garabedian, MJ			Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; PROTEIN; ACTIVATION; TRANSCRIPTION; COMPLEXES; SITES; ACID	The glucocorticoid receptor (GR) is phosphorylated at multiple serine residues in a hormone-dependent manner, yet progress on elucidating the function of GR phosphorylation has been hindered by the lack of a simple assay to detect receptor phosphorylation in vivo. We have produced antibodies that specifically recognize phosphorylation sites within human GR at Ser(203) and Ser(211). In the absence of hormone, the level of GR phosphorylation at Ser(211) was low compared with phosphorylation at Ser(203). Phosphorylation of both residues increased upon treatment with the GR agonist dexamethasone. Using a battery of agonists and antagonists, we found that the transcriptional activity of GR correlated with the amount of phosphorylation at Ser(211), suggesting that Ser(211) phosphorylation is a biomarker for activated GR in vivo. Mechanistically, the kinetics of Ser(203) and Ser(211) phosphorylation in response to hormone differed, with Ser(211) displaying a more robust and sustained phosphorylation relative to Ser(203). Analysis of GR immunoprecipitates with phospho-GR-specific antibodies indicated that the receptor was phosphorylated heterogeneously at Ser(203) in the absence of hormone, whereas in the presence of hormone, a subpopulation of receptors was phosphorylated at both Ser(203) and Ser(211). Interestingly, biochemical fractionation studies following hormone treatment indicated that the Ser(203)-phosphorylated form of the receptor was predominantly cytoplasmic, whereas Ser(211)-phosphorylated GR was found in the nucleus. Likewise, by immunofluorescence, Ser(203)-phosphorylated GR was located in the cytoplasm and perinuclear regions of the cell, but not in the nucleoplasm, whereas strong phospho-Ser(211) staining was evident in the nucleoplasm of hormone-treated cells. Our results suggest that differentially phosphorylated receptor species are located in unique subcellular compartments, likely modulating distinct aspects of receptor function.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	garabm01@med.nyu.edu			NCI NIH HHS [P30 CA16087] Funding Source: Medline; NIDDK NIH HHS [R01 DK54836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; BODWELL JE, 1993, J STEROID BIOCHEM, V47, P31, DOI 10.1016/0960-0760(93)90054-Z; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Garabedian Michael J., 1998, P237; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MARIDOR G, 1993, J CELL SCI, V106, P535; MASON SA, 1993, J BIOL CHEM, V268, P21501; ORTI E, 1993, J BIOL CHEM, V268, P7779; Pocuca N, 1998, J STEROID BIOCHEM, V66, P303, DOI 10.1016/S0960-0760(98)00057-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Reichardt HM, 2000, Z RHEUMATOL, V59, P1; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; Webster JC, 1997, J BIOL CHEM, V272, P9287; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	32	227	234	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26573	26580		10.1074/jbc.M110530200	http://dx.doi.org/10.1074/jbc.M110530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000743	hybrid			2022-12-25	WOS:000176908700098
J	Dickinson, LA; Edgar, AJ; Ehley, J; Gottesfeld, JM				Dickinson, LA; Edgar, AJ; Ehley, J; Gottesfeld, JM			Cyclin L is an RS domain protein involved in pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CDK-ACTIVATING KINASE; C-TERMINAL DOMAIN; MESSENGER-RNA; DEPENDENT KINASES; SR PROTEINS; IN-VIVO; P-TEFB; TRANSCRIPTION; CTD	We report the cDNA cloning and functional characterization of human cyclin L, a novel cyclin related to the C-type cyclins that are involved in regulation of RNA polymerase II (pol II) transcription. Cyclin L also contains a COOH-terminal dipeptide repeat of alternating arginines and serines, a hallmark of the SR family of splicing factors. We show that recombinant cyclin L interacts with p110 PITSLRE kinase, and that cyclin L antibody co-immunoprecipitates a kinase activity from HeLa nuclear extracts that phosphorylates the carboxyl-terminal domain (CTD) of pol II and splicing factor SC35, and is inhibited by the cdk inhibitor p21. Cyclin L antibody inhibits the second step of RNA splicing in vitro, and recombinant cyclin L protein stimulates splicing under suboptimal conditions. Significantly, the lC(50) for splicing inhibition by p21 is similar to the lC(50) for inhibition of the cyclin L-associated kinase activity. Cyclin L and its associated kinase are thus new members of the pre-mRNA processing machinery.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Chelsea & Westminster Hosp, Imperial Coll Sch Med, Div Invest Sci, Tissue Engn Ctr, London SW10 9NH, England	Scripps Research Institute; Imperial College London	Gottesfeld, JM (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.			Gottesfeld, Joel/0000-0002-4643-5777				Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Boucher L, 2001, RNA, V7, P1693; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; FU XD, 1995, RNA, V1, P663; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8126; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Reichert V, 2000, NUCLEIC ACIDS RES, V28, P416, DOI 10.1093/nar/28.2.416; Rickert P, 1996, ONCOGENE, V12, P2631; Riedl T, 2000, GENE EXPRESSION, V9, P3; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SOLOVYEV V, 1997, P 5 INT C INT SYST M, P294; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	43	87	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25465	25473		10.1074/jbc.M202266200	http://dx.doi.org/10.1074/jbc.M202266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980906	hybrid			2022-12-25	WOS:000176747000081
J	Lim, S; Jin, K; Friedman, E				Lim, S; Jin, K; Friedman, E			Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1; DOWN-SYNDROME; COLON-CANCER; CELLS; SPECIFICITY; MINIBRAIN; DIFFERENTIATION; SUBSTRATE; COFACTOR; DYRK1A	Mirk/Dyrk1B is an arginine-directed serine/threonine protein kinase that is expressed at low levels in most normal tissues but at elevated levels in many tumor cell lines and in normal skeletal muscle. Colon carcinoma cell lines stably overexpressing Mirk proliferated in serum-free medium, but the mechanism of Mirk action is unknown. DCoHm (dimerization cofactor of hepatocyte nuclear factor 1alpha (HNF1alpha) from muscle), a novel gene of the DCoH family with 78% amino acid identity to DCoH, was identified as a Mirk-binding protein by yeast two-hybrid analysis and cloned. Mirk co-immunoprecipitated with DCoHm and bound to DCoHm in glutathione S-transferase pull-down assays. DCoH stabilizes HNF1alpha as a dimer and enhances its transcriptional activity on the beta-fibrinogen promoter reporter, and DCoHm had similar activity. Mirk enhanced HNF1alpha transcriptional activity in a dose-dependent manner, whereas two kinase-inactive Mirk mutants and a Mirk N-terminal deletion mutant did not. Mirk, DCoHm, and HNF1alpha formed a complex. Mirk bound to a specific region within the CREB-binding protein-binding region of HNF1alpha and phosphorylated HNF1alpha at a site adjacent to the Mirk-binding region. Conversely, the HNF1alpha binding domain was located within the first five conserved kinase subdomains of Mirk. Mirk co-immunoprecipitated with the MAPK kinase MKK3, an upstream activator of p38. MKK3 enhanced Mirk kinase activity and the transcriptional activation of HNF1alpha by Mirk, suggesting that Mirk, like p38, is activated by certain environmental stress agents. The Mirk-binding protein DCoH has been shown to be selectively expressed in colon carcinomas but not in normal tissue. Mirk may function as an HNF1alpha transcriptional activator in response to an MKK3-mediated stress signal, and the selective expression of DCoH could restrict the Mirk response to carcinoma cells.	Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.			Lim, Seunghwan/0000-0001-8920-0890	NCI NIH HHS [R01 CA67405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Bonham K, 2000, J BIOL CHEM, V275, P37604, DOI 10.1074/jbc.M004882200; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Erickson RH, 2000, BIOCHEM BIOPH RES CO, V270, P235, DOI 10.1006/bbrc.2000.2420; Eskinazi R, 1999, AM J PATHOL, V155, P1105, DOI 10.1016/S0002-9440(10)65213-3; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Johnen G, 1997, P NATL ACAD SCI USA, V94, P13469, DOI 10.1073/pnas.94.25.13469; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee K, 2000, CANCER RES, V60, P3631; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; NOLTEN LA, 1995, MOL ENDOCRINOL, V9, P1488, DOI 10.1210/me.9.11.1488; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	28	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25040	25046		10.1074/jbc.M203257200	http://dx.doi.org/10.1074/jbc.M203257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980910	hybrid			2022-12-25	WOS:000176747000028
J	Reed, RC; Zheng, TL; Nicchitta, CV				Reed, RC; Zheng, TL; Nicchitta, CV			GRP94-associated enzymatic activities - Resolution by chromatographic fractionation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; RETICULUM CHAPERONE GRP94; TUMOR REJECTION ANTIGENS; ENDOPLASMIC-RETICULUM; CLASS-I; MAJOR HISTOCOMPATIBILITY; DENDRITIC CELLS; CASEIN KINASE; PEPTIDES; GP96	GRP94 (gp96), which performs established functions as a molecular chaperone and immune system modulator, has been reported to display a number of intrinsic enzymatic activities, including ATP hydrolysis, protein phosphorylation, and aminopeptidase. In observing that GRP94 co-purified with bacterial beta-galactosidase through multiple chromatographic steps, we have examined the hypothesis that the reported enzymatic activities of GRP94 may reflect co-purification of contaminant enzymes, rather than intrinsic catalytic functions. In subjecting GRP94 to increasingly stringent chromatographic purification, we report that a GRP94 carboxyl-terminal directed protein kinase activity could be separated from GRP94 by heparin affinity chromatography. Analysis of the kinase substrate specificity indicates that this kinase is distinct from casein kinase II, which is known to co-purify with GRP94. Electrophoretically pure GRP94 displayed low, but significant levels of aminopeptidase activity. Further purification of GRP94 by anion exchange and heparin affinity chromatography yielded resolution of GRP94 from the aminopeptidase activity. Furthermore, exhaustive trypsinolysis of GRP94 preparations displaying aminopeptidase activity yielded complete proteolysis of GRP94 but did not affect aminopeptidase activity. These results are discussed with respect to current models for GRP94 function and the role of such co-purifying (poly)peptides in the generation of GRP94-dependent cellular immune responses.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	c.nicchitta@cellbio.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Berwin B, 2001, J BIOL CHEM, V276, P21083, DOI 10.1074/jbc.M101836200; Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; CALA SE, 1994, J BIOL CHEM, V269, P5926; Cala SE, 2000, BBA-MOL CELL RES, V1496, P296, DOI 10.1016/S0167-4889(00)00028-8; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Fruci D, 2001, IMMUNITY, V15, P467, DOI 10.1016/S1074-7613(01)00203-5; GRAHAM LD, 1994, BIOCHEM J, V301, P917, DOI 10.1042/bj3010917; Ishiguro S, 2002, EMBO J, V21, P898, DOI 10.1093/emboj/21.5.898; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; KORNBERG A, 1990, METHOD ENZYMOL, V182, P1; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Lobigs M, 2000, EUR J IMMUNOL, V30, P1496, DOI 10.1002/(SICI)1521-4141(200005)30:5<1496::AID-IMMU1496>3.0.CO;2-6; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; MELNICK J, 1992, J BIOL CHEM, V267, P21303; Menoret A, 2001, J BIOL CHEM, V276, P33313, DOI 10.1074/jbc.M103383200; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Riera M, 1999, MOL CELL BIOCHEM, V191, P97, DOI 10.1023/A:1006810311743; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, BIOCHEM J, V301, P919, DOI 10.1042/bj3010919; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Srivastava PK, 1997, METHODS, V12, P165, DOI 10.1006/meth.1997.0464; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; UDONO H, 1994, J IMMUNOL, V152, P5398; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152	39	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25082	25089		10.1074/jbc.M203195200	http://dx.doi.org/10.1074/jbc.M203195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983709	hybrid			2022-12-25	WOS:000176747000033
J	Zeng, QH; Chen, SQ; You, ZB; Yang, F; Carey, TE; Saims, D; Wang, CY				Zeng, QH; Chen, SQ; You, ZB; Yang, F; Carey, TE; Saims, D; Wang, CY			Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SCATTER FACTOR; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; ONCOGENIC RAS; ORAL-CANCER; MAP KINASE; C-MET; EXPRESSION	Hepatocyte growth factor (HGF), also known as a scatter factor, regulates a variety of biological activities including cell proliferation, survival, migration, and angiogenesis. Importantly, HGF and its receptor c-Met have been found to be associated with metastasis of human head and neck squamous cell carcinoma (HNSCC). Because anoikis resistance plays an important role in tumor progression and metastasis, here we examined whether HGF suppressed suspension-induced apoptosis (anoikis) in HNSCC cells, and if so, we assessed downstream signaling pathways mediated by HGF. We found that HNSCC cells underwent anoikis upon loss of matrix contact, whereas HGF provided protection against it. HGF-induced anoikis resistance was found to be dependent on both ERK and Akt signaling pathways. The inhibition of either ERK or Akt activation abolished HGF-mediated survival. Furthermore, we found that HGF did not activate NFkappaB transcription in HNSCC cells and that HGF-mediated anoikis resistance was independent of NFkappaB. Taken together, our results suggest that anoikis resistance induced by HGF may also play an important role in the progression and metastasis of HNSCC.	Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signalling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Oral Pathol Oral Med & Oral Oncol, Ann Arbor, MI 48109 USA; NE Normal Univ, Sch Life Sci, Inst Cytol & Genet, Changchun 130021, Peoples R China	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Northeast Normal University - China	Wang, CY (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signalling & Apoptosis, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.			Carey, Thomas/0000-0002-5202-7518	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013848, R01DE013788] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE13788, R01-DE13848] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Dong G, 2001, CANCER RES, V61, P5911; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kang MK, 2001, CRIT REV ORAL BIOL M, V12, P38, DOI 10.1177/10454411010120010301; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kuechle MK, 2000, CELL DEATH DIFFER, V7, P566, DOI 10.1038/sj.cdd.4400687; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Qian CN, 2002, CANCER RES, V62, P589; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Shillitoe EJ, 2000, ORAL ONCOL, V36, P1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	56	123	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25203	25208		10.1074/jbc.M201598200	http://dx.doi.org/10.1074/jbc.M201598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994287	hybrid			2022-12-25	WOS:000176747000047
J	Barchowsky, A; Soucy, NV; O'Hara, KA; Hwa, J; Noreault, TL; Andrew, AS				Barchowsky, A; Soucy, NV; O'Hara, KA; Hwa, J; Noreault, TL; Andrew, AS			A novel pathway for nickel-induced interleukin-8 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; FACTOR-KAPPA-B; IDIOPATHIC PULMONARY FIBROSIS; INDUCIBLE FACTOR 1-ALPHA; AIRWAY EPITHELIAL-CELLS; GENE-EXPRESSION; BINDING-PROTEIN; FACTOR-I; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL EXPRESSION	Inhalation of particulate nickel subsulfide (Ni3S2) causes chronic active inflammation and fibrosis of the lungs. However, the mechanisms for these effects are not well understood. Therefore, cell culture experiments with BEAS-2B human airway epithelial cells were conducted to test the hypothesis that exposure to noncytotoxic levels of Ni3S2 induces expression of inflammatory cytokines such as interleukin-8 (IL-8). Exposure to Ni3S2 for 48 h was required to significantly increase IL-8 protein levels. Transcriptional stimulation of IL-8 mRNA levels preceded the increase in protein. Transient exposure to soluble nickel sulfate failed to increase IL-8 mRNA. Transfection with truncated IL-8 promoter constructs linked to the luciferase gene demonstrated that nickel-induced IL-8 transcription required -272 bp of the promoter relative to the transcriptional start site. A -133-bp construct, containing cytokine and hypoxia-sensitive AP-1, NF-IL6, and NF-kappaB sites, was insufficient for induction by nickel. Transfection with a dominant negative AP-1 construct or mutation of the AP-1, GATA, or C/EBP sites in the -272-bp IL-8 promoter construct blocked induction by nickel. Inhibiting ERK, phosphatidylinositol 3-kinase, but not p38 kinase, diacylglycerol kinase, or hypoxia-inducible factor-1alpha, attenuated nickel induction of IL-8. These studies indicate that nickel induced IL-8 transcription through a novel pathway that requires both AP-1 and non-traditional transcription factors.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Barchowsky, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NIEHS NIH HHS [ES07373] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007373] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM T, 1992, J BIOL CHEM, V267, P5021; Andrew A, 2000, TOXICOL APPL PHARM, V168, P50, DOI 10.1006/taap.2000.9009; Andrew AS, 2001, AM J PHYSIOL-LUNG C, V281, pL607, DOI 10.1152/ajplung.2001.281.3.L607; Andrew AS, 2001, AM J PHYSIOL-LUNG C, V281, pL616, DOI 10.1152/ajplung.2001.281.3.L616; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; English AM, 2001, MET IONS BIOL SYST, V38, P313; Entingh AJ, 2001, ENDOCRINOLOGY, V142, P221, DOI 10.1210/en.142.1.221; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Haber LT, 2000, REGUL TOXICOL PHARM, V31, P210, DOI 10.1006/rtph.2000.1377; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hetland RB, 2000, J TOXICOL ENV HEAL A, V60, P47, DOI 10.1080/009841000156583; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Kayyali US, 2001, J BIOL CHEM, V276, P14359, DOI 10.1074/jbc.M010100200; Keane MP, 1997, J IMMUNOL, V159, P1437; Kelleher P, 2000, ENVIRON HEALTH PERSP, V108, P685, DOI 10.2307/3454405; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Mori N, 1998, CANCER RES, V58, P3993; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; Ogushi Fumitaka, 1997, Journal of Medical Investigation, V44, P53; Oller AR, 1997, TOXICOL APPL PHARM, V143, P152, DOI 10.1006/taap.1996.8075; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; ROSENTHAL GI, 1994, J IMMUNOL, V153, P3237; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Schmalz G, 2000, EUR J ORAL SCI, V108, P442, DOI 10.1034/j.1600-0722.2000.108005442.x; Shumilla JA, 1999, TOXICOL APPL PHARM, V158, P288, DOI 10.1006/taap.1999.8704; Shumilla JA, 1999, J BIOL CHEM, V274, P36207, DOI 10.1074/jbc.274.51.36207; Sodhi A, 2000, CANCER RES, V60, P4873; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Terunuma A, 2001, J DERMATOL SCI, V26, P85, DOI 10.1016/S0923-1811(00)00165-1; White ES, 2001, J IMMUNOL, V166, P7549, DOI 10.4049/jimmunol.166.12.7549; Wu GD, 1997, J BIOL CHEM, V272, P2396; Xu L, 1999, CANCER RES, V59, P5822; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Ziegenhagen MW, 1998, J INVEST MED, V46, P223	46	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24225	24231		10.1074/jbc.M202941200	http://dx.doi.org/10.1074/jbc.M202941200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978798	hybrid			2022-12-25	WOS:000176611800034
J	Berkowitz, B; Huang, DB; Chen-Park, FE; Sigler, PB; Ghosh, G				Berkowitz, B; Huang, DB; Chen-Park, FE; Sigler, PB; Ghosh, G			The x-ray crystal structure of the NF-kappa B p50 center dot p65 heterodimer bound to the interferon beta-kappa B site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN HMG-I(Y); TRANSCRIPTION FACTORS; DNA-BINDING; P50/P65 HETERODIMER; VIRUS INDUCTION; HMG I(Y); IN-VITRO; HOMODIMER; ENHANCEOSOME; EXPRESSION	We have determined the x-ray crystal structure of the transcription factor NF-kappaB p50-p65 heterodimer complexed to kappaB DNA from the cytokine interferon beta enhancer (IFNbeta-kappaB). To better understand how the binding modes of NF-kappaB on its two best studied DNA targets might contribute to promoter-specific transcription, this structure is compared with the previously determined complex crystal structure containing NF-kappaB bound to the Ig kappa light chain gene enhancer as well as to a second NF-kappaB-Ig kappa light chain gene enhancer complex also reported in this paper. The global binding modes of all NF-kappaB.DNA complex structures are similar, although crystal-packing interactions lead to differences between identical complexes of the same crystallographic asymmetric unit. An extensive network of stacked amino acid side chains that contribute to base-specific DNA contacts is conserved among the three complexes. Consistent with earlier reports, however, the IFNbeta-kappaB DNA is bent significantly less by NF-kappaB than is the Ig K light chain gene enhancer. This and other small structural changes may play a role in explaining why NF-kappaB-directed transcription is sensitive to the context of specific promoters. The precise molecular mechanism behind the involvement of the high mobility group protein I(Y) in interferon beta enhanceosome formation remains elusive.	Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Biol, San Diego, CA 92103 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Yale University	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,9500 Gilman Dr, San Diego, CA 92103 USA.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; BRUNGER AT, 1998, ACTA CRYSTALLOGR D, V10, P25; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Chen-Park FE, 2002, J BIOL CHEM, V277, P24701, DOI 10.1074/jbc.M200007200; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074	37	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24694	24700		10.1074/jbc.M200006200	http://dx.doi.org/10.1074/jbc.M200006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11970948	hybrid			2022-12-25	WOS:000176611800095
J	Koistinen, P; Heino, J				Koistinen, P; Heino, J			The selective regulation of alpha(v)beta(1) integrin expression is based on the hierarchical formation of alpha(v)-containing heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-ADHESION DOMAIN; ALPHA-V-INTEGRINS; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; GENE-EXPRESSION; ALPHA-V-BETA-1; MIGRATION; COLLAGEN	The integrin beta(1) subunit can form a heterodimer with 12 different alpha subunits. According to the present model, the expression level of any alphabeta complex is regulated by the availability of the specific alpha subunit, whereas beta(1) subunit is constantly present in a large excess. The expression of several heterodimers containing the alpha(V) subunit seems to be regulated by an identical mechanism. The fact that many cells express alpha(V)beta(1) heterodimer, and that this fibronectin/vitronectin receptor may be selectively regulated, compromises the present model of the regulation of beta(1) and alpha(V) integrins. We have tried to solve this problem by assuming that distinct alphabeta heterodimers are formed with different tendency. To test the hypothesis, we analyzed WM-266-4 melanoma cells transfected with a cDNA construct coding for an intracellular single-chain anti-alpha(V) integrin antibody. We could see 70-80% reduction in the cell surface expression of alpha(V) subunit. However, the only one of the alpha(V) integrins reduced on the cell surface was alpha(V)beta(1). This suggests that the cell surface expression level of alpha(V)beta(1) is dependent on the number of alpha(V) subunits available after the formation of other alpha(V)-containing heterodimers. Thus, there seems to be a hierarchy in the complex formation between alpha(V) and its different beta-partners. These observations explain how alpha(V)beta(1) can be specifically regulated without concomitant changes in the expression of other alpha(V) or beta(1) integrins.	Univ Jyvaskyla, Dept Biol, FIN-40351 Jyvaskyla, Finland; Turku Univ, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Turku Univ, MediC Res Lab, FIN-20520 Turku, Finland; Turku Univ, Dept Biochem Med, FIN-20520 Turku, Finland	University of Jyvaskyla; University of Turku; University of Turku; University of Turku	Heino, J (corresponding author), Univ Jyvaskyla, Dept Biol & Envrionm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.							AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BODARY SC, 1990, J BIOL CHEM, V265, P5938; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Dahm LM, 1998, J CELL SCI, V111, P1175; DELANNET M, 1994, DEVELOPMENT, V120, P2687; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gailit J, 1996, J INVEST DERMATOL, V106, P102, DOI 10.1111/1523-1747.ep12328177; GOLDBERG HA, 1986, CONNECT TISSUE RES, V15, P209, DOI 10.3109/03008208609001980; Gouon V, 1996, INT J CANCER, V68, P650; HEINO J, 1989, J BIOL CHEM, V264, P380; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Jackson T, 2002, J VIROL, V76, P935, DOI 10.1128/JVI.76.3.935-941.2002; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; Koivisto L, 2000, EXP CELL RES, V255, P10, DOI 10.1006/excr.1999.4769; Li E, 2001, J VIROL, V75, P5405, DOI 10.1128/JVI.75.11.5405-5409.2001; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MARASCO WA, 1992, J CLIN INVEST, V90, P1467, DOI 10.1172/JCI116014; Milner R, 1996, J NEUROSCI, V16, P7240; MILNER R, 1994, DEVELOPMENT, V120, P3497; Milner R, 2001, MOL CELL NEUROSCI, V18, P108, DOI 10.1006/mcne.2001.1003; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; PISCHEL KD, 1987, J IMMUNOL, V138, P226; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856-5862.2000; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	35	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24835	24841		10.1074/jbc.M203149200	http://dx.doi.org/10.1074/jbc.M203149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11997396	hybrid			2022-12-25	WOS:000176611800111
J	Chen, YY; Cross, KJ; Paolini, RA; Fielding, JE; Slakeski, N; Reynolds, EC				Chen, YY; Cross, KJ; Paolini, RA; Fielding, JE; Slakeski, N; Reynolds, EC			CPG70 is a novel basic metallocarboxypeptidase with C-terminal polycystic kidney disease domains from Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LESION MODEL; CYSTEINE PROTEINASES; PERIODONTAL-DISEASE; CRYSTAL-STRUCTURE; VIRULENCE; BACTERIAL; GENE; RGPA; W50; KGP	In a search for a basic carboxypeptidase that might work in concert with the major virulence factors, the Arg- and Lys-specific cysteine endoproteinases of Porphyromonas gingivalis, a novel 69.8-kDa metallocarboxypeptidase CPG70 was purified to apparent homogeneity from the culture fluid of P. gingivalis HG66. Carboxypeptidase activity was measured by matrix-assisted laser desorption ionization-mass spectrometry using peptide substrates derived from a tryptic digest of hemoglobin. CPG70 exhibited activity with peptides containing C-terminal Lys and Arg residues. The k(cat)/K-m values for the hydrolysis of the synthetic dipeptides FA-Ala-Lys and FA-Ala-Arg by CPG70 were 99 and 56 mM(-1)s(-1), respectively. The enzyme activity was strongly inhibited by the Arg analog (2-guanidinoethylmercapto)-succinic acid and 1,10-phenanthroline. High resolution inductively coupled plasma-mass spectrometry demonstrated that I mol of CPG70 was associated with 0.6 mol of zinc, 0.2 mol of nickel, and 0.2 mol of copper. A search of the P. gingivalis W83 genomic data base (TIGR) with the N-terminal amino acid sequence determined for CPG70 revealed that the enzyme is an N- and C-terminally truncated form of a predicted 91.5-kDa protein (PG0232). Analysis of the deduced amino acid sequence of the full-length protein revealed an N-terminal signal sequence followed by a pro-segment, a metallocarboxypeptidase catalytic domain, three tandem polycystic kidney disease domains, and an 88-residue C-terminal segment. The catalytic domain exhibited the highest sequence identity with the duck metallocarboxypeptidase D domain II. Insertional inactivation of the gene encoding CPG70 resulted in a P. gingivalis isogenic mutant that was avirulent in the murine lesion model under the conditions tested.	Univ Melbourne, Sch Dent Sci, Melbourne, Vic 3000, Australia	University of Melbourne	Reynolds, EC (corresponding author), Univ Melbourne, Sch Dent Sci, 711 Elizabeth St, Melbourne, Vic 3000, Australia.		Cross, Keith/F-4566-2012; Cross, Keith J/N-4602-2013	Cross, Keith/0000-0002-4079-2132; Slakeski, Nada/0000-0001-9776-6018; Fielding, James/0000-0003-2995-9576; Reynolds, Eric/0000-0002-6618-4856; Paolini, Rita/0000-0002-2170-4723				Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; [Anonymous], 1993, SPSS WINDOWS BASE SY; AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; Banbula A, 2001, J BIOL CHEM, V276, P6299, DOI 10.1074/jbc.M008789200; Bhogal PS, 1997, MICROBIOL-SGM, V143, P2485, DOI 10.1099/00221287-143-7-2485; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Canaff L, 1999, MOL CELL ENDOCRINOL, V156, P1, DOI 10.1016/S0303-7207(99)00129-X; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; FLETCHER HM, 1995, INFECT IMMUN, V63, P1521, DOI 10.1128/IAI.63.4.1521-1528.1995; Fox C H, 1992, Curr Opin Dent, V2, P5; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; MALEY J, 1992, FEMS MICROBIOL LETT, V15, P75; MCKEE AS, 1986, INFECT IMMUN, V52, P349, DOI 10.1128/IAI.52.2.349-355.1986; Mikolajczyk-Pawlinska J, 1998, BIOL CHEM, V379, P205, DOI 10.1515/bchm.1998.379.2.205; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; O'Brien-Simpson NM, 2001, INFECT IMMUN, V69, P7527, DOI 10.1128/IAI.69.12.7527-7534.2001; O'Brien-Simpson NM, 2000, INFECT IMMUN, V68, P4055, DOI 10.1128/IAI.68.7.4055-4063.2000; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Shi Y, 1999, J BIOL CHEM, V274, P17955, DOI 10.1074/jbc.274.25.17955; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; Slakeski N, 1998, MICROBIOL-UK, V144, P1583, DOI 10.1099/00221287-144-6-1583; SOCRANSKY SS, 1992, J PERIODONTOL, V63, P322, DOI 10.1902/jop.1992.63.4s.322; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Travis J, 2000, ADV EXP MED BIOL, V477, P455; Urban S, 2000, EMBO J, V19, P1217, DOI 10.1093/emboj/19.6.1217; van Adelsberg J, 1999, DEV GENET, V24, P299, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<299::AID-DVG13>3.0.CO;2-J; Veith PD, 2002, BIOCHEM J, V363, P105, DOI 10.1042/0264-6021:3630105; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0	35	49	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23433	23440		10.1074/jbc.M200811200	http://dx.doi.org/10.1074/jbc.M200811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976326	hybrid			2022-12-25	WOS:000176475700045
J	Vilar, M; Sauri, A; Monne, M; Marcos, JF; von Heijne, G; Perez-Paya, E; Mingarro, I				Vilar, M; Sauri, A; Monne, M; Marcos, JF; von Heijne, G; Perez-Paya, E; Mingarro, I			Insertion and topology of a plant viral movement protein in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO MOSAIC-VIRUS; RNA-BINDING DOMAIN; CELL-TO-CELL; AMINO-ACIDS; CYTOSKELETON; PLASMODESMATA; TRAFFICKING; TRANSPORT; INFECTION; TOMBUSVIRIDAE	Virus-encoded movement proteins (MPs) mediate cell-to-cell spread of viral RNA through plant membranous intercellular connections, the plasmodesmata. The molecular pathway by which MPs interact with viral genomes and target plasmodesmata channels is largely unknown. The 9-kDa MP from carnation mottle carmovirus (CarMV) contains two potential transmembrane domains. To explore the possibility that this protein is in fact an intrinsic membrane protein, we have investigated its insertion into the endoplasmic reticulum membrane. By using in vitro translation in the presence of dog pancreas microsomes, we demonstrate that CarMV p9 inserts into the endoplasmic reticulum without the aid of any additional viral or plant host components. We further show that the membrane topology of CarMV p9 is N-cyt-C-cyt (N and C termini of the protein facing the cytoplasm) by in vitro translation of a series of truncated and full-length constructs with engineered glycosylation sites. Based on these results, we propose a topological model in which CarMV p9 is anchored in the membrane with its N- and C-terminal tail segments interacting with its soluble, RNA-bound partner CarMV p7, to accomplish the viral cell-to-cell movement function.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; CSIC, Inst Agroquim & Tecnol Alimentos, Dept Ciencia Alimentos, E-46100 Burjassot, Spain	University of Valencia; Stockholm University; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Mingarro, I (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain.	Ismael.Mingarro@uv.es	von Heijne, Gunnar/F-5576-2011; Marcos, Jose F./A-7121-2011; Monné, Magnus/D-5642-2012; Mingarro, Ismael/B-4745-2014; Vilar, Marçal/B-4581-2016; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Marcos, Jose F./0000-0003-3339-2584; Monné, Magnus/0000-0003-2344-3878; Mingarro, Ismael/0000-0002-1910-1229; Vilar, Marçal/0000-0002-9376-6544; 				Aaziz R, 2001, TRENDS PLANT SCI, V6, P326, DOI 10.1016/S1360-1385(01)01981-1; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Brill LM, 2000, P NATL ACAD SCI USA, V97, P7112, DOI 10.1073/pnas.130187897; Canizares MC, 2001, ARCH VIROL, V146, P2039, DOI 10.1007/s007050170051; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; Chen MH, 2000, EMBO J, V19, P913, DOI 10.1093/emboj/19.5.913; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; DEOM CM, 1991, VIROLOGY, V180, P251, DOI 10.1016/0042-6822(91)90029-B; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Ghoshroy S, 1997, ANNU REV PLANT PHYS, V48, P25; Grieco F, 1999, J GEN VIROL, V80, P1103, DOI 10.1099/0022-1317-80-5-1103; HACKER DL, 1992, VIROLOGY, V186, P1, DOI 10.1016/0042-6822(92)90055-T; Heinlein M, 1998, PLANT CELL, V10, P1107, DOI 10.1105/tpc.10.7.1107; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; KOONIN EV, 1991, J GEN VIROL, V72, P2895, DOI 10.1099/0022-1317-72-12-2895; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lazarowitz SG, 1999, PLANT CELL, V11, P535, DOI 10.1105/tpc.11.4.535; Li VZ, 1998, VIROLOGY, V244, P405, DOI 10.1006/viro.1998.9125; Marcos JF, 1999, VIROLOGY, V255, P354, DOI 10.1006/viro.1998.9596; Mas P, 1999, J CELL BIOL, V147, P945, DOI 10.1083/jcb.147.5.945; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; Melcher U, 2000, J GEN VIROL, V81, P257, DOI 10.1099/0022-1317-81-1-257; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Oparka KJ, 1997, PLANT J, V12, P781, DOI 10.1046/j.1365-313X.1997.12040781.x; Oparka KJ, 1999, CELL, V97, P743, DOI 10.1016/S0092-8674(00)80786-2; Pickard BG, 1999, CELL, V98, P5, DOI 10.1016/S0092-8674(00)80600-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Qu F, 1999, ENCY VIROLOGY, P243; Reichel C, 1998, P NATL ACAD SCI USA, V95, P11169, DOI 10.1073/pnas.95.19.11169; Reichel C, 1999, TRENDS PLANT SCI, V4, P458, DOI 10.1016/S1360-1385(99)01490-9; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; RUSSO M, 1994, ADV VIRUS RES, V44, P381, DOI 10.1016/S0065-3527(08)60334-6; Solovyev AG, 2000, VIROLOGY, V269, P113, DOI 10.1006/viro.2000.0200; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Tzfira T, 2000, ANNU REV MICROBIOL, V54, P187, DOI 10.1146/annurev.micro.54.1.187; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; Vilar M, 2001, J BIOL CHEM, V276, P18122, DOI 10.1074/jbc.M100706200; Ward BM, 1997, J VIROL, V71, P3726, DOI 10.1128/JVI.71.5.3726-3733.1997; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; YANG JT, 1986, METHOD ENZYMOL, V130, P208	44	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23447	23452		10.1074/jbc.M202935200	http://dx.doi.org/10.1074/jbc.M202935200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976343	Green Published, hybrid			2022-12-25	WOS:000176475700047
J	Wang, XL; Gjernes, E; Prydz, H				Wang, XL; Gjernes, E; Prydz, H			Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in a human keratinocyte line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; MESSENGER-RNA DEGRADATION; FACTOR EXPRESSION; BLOOD-COAGULATION; GENE-EXPRESSION; MELANOMA-CELLS; SIGNAL-TRANSDUCTION; BINDING; METASTASIS	Tissue factor (TF), a transmembrane receptor for the serine protease coagulation factor VII(a) (FVIIa), is the main initiator of the coagulation cascade. Through incompletely elucidated mechanisms, TF serves additional functions in tumor-associated angiogenesis and metastasis. We have studied interleukin-8 (IL-8) as a possible link between TF-FYIIa complex formation and subsequent processes. Recombinant human FVIIa induced the up-regulation of both IL-8 mRNA and protein in a FYIIa dose- and time-dependent fashion. A neutralizing antibody to TF reduced this induction by 93 +/- 5%. Active site-inhibited FYIIa had no stimulatory effect and completely blocked that of FVIIa. This confirms that the increased IL-8 production was dependent on the formation of TF-FYIIa complexes and the proteolytic activity of FYIIa. The IL-8 promoter contains DNA binding sites for nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1). In response to FVIIa, the DNA binding activity of both NF-kappaB and AP-1 was enhanced in an electrophoretic mobility shift assay. In addition, the IL-8 promoter was transcriptionally activated both in a luciferase reporter system and a nuclear run-off assay. Moreover, IL-8 mRNA stability was significantly enhanced by FVIIa-induced activation of the mitogen-activated protein kinases ERK1/2 and p38. Taken together, TF-FVIIa signaling induced increased transcription as well as mRNA stabilization leading to the significant up-regulation of IL-8 protein synthesis.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Gaustadalleen 21, N-0349 Oslo, Norway.							Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; BARTALENA L, 1992, MOL ENDOCRINOL, V6, P935, DOI 10.1210/me.6.6.935; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; CARSON SD, 1987, BLOOD, V70, P490; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Dunwiddie Christopher T., 1993, Methods in Enzymology, V223, P291; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Inoue K, 2000, CANCER RES, V60, P2290; Kakkar AK, 1999, BRIT J SURG, V86, P890, DOI 10.1046/j.1365-2168.1999.01153.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Koomagi R, 1998, INT J CANCER, V79, P19, DOI 10.1002/(SICI)1097-0215(19980220)79:1<19::AID-IJC4>3.3.CO;2-9; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Martin DMA, 1998, THROMB RES, V90, P1, DOI 10.1016/S0049-3848(98)00015-2; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Ollivier V, 2000, ARTERIOSCL THROM VAS, V20, P1374, DOI 10.1161/01.ATV.20.5.1374; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Ruf W, 1996, Curr Opin Hematol, V3, P379; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shoji M, 1998, AM J PATHOL, V152, P399; SICA A, 1990, IMMUNOLOGY, V69, P548; SINGH RK, 1994, CANCER RES, V54, P3242; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STRIETER RM, 1992, AM J PATHOL, V141, P1279; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Ueno T, 2000, BRIT J CANCER, V83, P164; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; Yatsunami J, 1997, CANCER LETT, V120, P101, DOI 10.1016/S0304-3835(97)00296-6; Zandi E, 1999, MOL CELL BIOL, V19, P4547	55	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23620	23626		10.1074/jbc.M202242200	http://dx.doi.org/10.1074/jbc.M202242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973337	hybrid			2022-12-25	WOS:000176475700068
J	Oehler, MK; Hague, S; Rees, MCP; Bicknell, R				Oehler, MK; Hague, S; Rees, MCP; Bicknell, R			Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis	ONCOGENE			English	Article						adrenomedullin; angiogenesis; tumorigenesis; tamoxifen; endometrial cancer	INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; CELL LINES; HYPOXIA; CANCER; TAMOXIFEN; ESTROGEN; MECHANISM; RECEPTOR; PEPTIDE	The angiogenic peptide adrenomedullin (ADM) has been implicated as a mediator of the increased risk of endometrial hyperplasia and cancer resulting from the use of tamoxifen for the treatment and prevention of breast cancer. ADM has been shown to be induced by tamoxifen in the endometrium and to be a growth factor for endometrial endothelial cells in vitro. We have now shown ADM to be strongly angiogenic in the mouse subcutaneous sponge angiogenesis assay. To examine the role of ADM in tumor growth, the ADM cDNA was transfected into endometrial carcinoma cells followed by xenografting into athymic mice. Two endometrial cancer cell lines were employed, those in which transfection and expression of ADM resulted in no effect on growth in vitro (Ishikawa cells) and those in which expression of exogenous ADM stimulated in virtro growth (RL95.2 cells). A clear enhancement of tumor growth was seen with both cell lines but the effect was far greater with the RL95.2 cells. We conclude that ADM is pro-tumorigenic by stimulating either angiogenesis alone or by stimulating angiogenesis and carcinoma cell growth directly. The combined activities lead to a striking increase in tumor growth. These results provide the first direct evidence of tumorigenic activity of ADM and provide further support for ADMs involvement in tamoxifen induced endometrial neoplasia.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford; University of Oxford	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England.	r.bicknell@cancer.org.uk		Bicknell, Roy/0000-0002-0941-8919				Ali SH, 2000, CANCER RES, V60, P7094; ATTIA MAM, 1966, CANCER RES, V26, P1787; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Bilimoria MM, 1996, J STEROID BIOCHEM, V58, P479, DOI 10.1016/0960-0760(96)00078-7; Birner P, 2000, CANCER RES, V60, P4693; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; Dalton RR, 2001, SOUTH MED J, V94, P7; FOX SB, 1995, J PATHOL, V177, P275, DOI 10.1002/path.1711770310; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Hata K, 2000, MOL HUM REPROD, V6, P867, DOI 10.1093/molehr/6.10.867; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lal A, 1999, CANCER RES, V59, P5403; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; NIKITENKO LL, 2002, IN PRESS TRENDS PHAR; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; PIO R, 2000, BIOL CHEM, V486, P3; Rocchi P, 2001, CANCER RES, V61, P1196; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SUNDARESHAN P, 1992, IN VITRO CELL DEV-AN, V28A, P544; Walsh DA, 1996, HISTOCHEM J, V28, P759, DOI 10.1007/BF02272149; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; White INH, 1999, CARCINOGENESIS, V20, P1153, DOI 10.1093/carcin/20.7.1153; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213; ZHANG L, 1995, J CELL SCI, V108, P323; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zhong H, 1999, CANCER RES, V59, P5830	36	94	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2815	2821		10.1038/sj.onc.1205374	http://dx.doi.org/10.1038/sj.onc.1205374			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973640				2022-12-25	WOS:000175063700005
J	Park, WS; Lee, JH; Shin, MS; Park, JY; Kim, HS; Lee, JH; Kim, YS; Lee, SN; Xiao, WH; Park, CH; Lee, SH; Yoo, NJ; Lee, JY				Park, WS; Lee, JH; Shin, MS; Park, JY; Kim, HS; Lee, JH; Kim, YS; Lee, SN; Xiao, WH; Park, CH; Lee, SH; Yoo, NJ; Lee, JY			Inactivating mutations of the caspase-10 gene in gastric cancer	ONCOGENE			English	Article						caspase-10; mutation; LOH; gastric cancer; apoptosis	FAS APO-1/CD95 GENE; DEATH DOMAIN; APOPTOSIS; LUNG; AMPLIFICATION; CARCINOMA; DELETION; LIGAND	We have analysed the genetic alteration of the entire coding region and all splice sites of caspase-8 and -10 genes in 99 gastric cancers by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and sequencing. We found LOH of the caspase-8 and -10 in nine (28%) of 32 and in four (15%) of 26 informative cases, respectively. Overall, three of 99 gastric cancers (3%) were found to have the caspase-10 mutations, which were identified in the coding regions of the death effector domain (codon 147) and the p17 large protease domain (codons 257 and 410), whereas no mutation was detected in caspase-8. In vitro expression studies, the M147T and Q257stop mutants severely impaired caspase-10-mediated apoptosis, whereas the V410I which was the same mutation detected in ALPS patient had a significant, albeit less severe, effect on apoptosis. The data presented here suggest that somatic alterations of the caspase-10 gene might contribute to the pathogenesis in a subset of gastric cancers through the loss of their apoptotic function.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Lee, JY (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.	stingray@cmc.cuk.ac.kr	kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022					FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gronbaek K, 2000, BLOOD, V95, P2184; Gronbaek K, 1998, BLOOD, V92, P3018; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; KOHNO T, 1994, ONCOGENE, V9, P103; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1998, LAB INVEST, V78, P453; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Park WS, 2001, J PATHOL, V193, P162; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wyllie AH, 1999, BRIT J CANCER, V80, P34	25	73	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2919	2925		10.1038/sj.onc.1205394	http://dx.doi.org/10.1038/sj.onc.1205394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973654				2022-12-25	WOS:000175063700019
J	Yamamoto, Y; Mandai, K; Okabe, N; Hoshino, T; Nakanishi, H; Takai, Y				Yamamoto, Y; Mandai, K; Okabe, N; Hoshino, T; Nakanishi, H; Takai, Y			Localization of mLin-7 at nectin-based cell-cell junctions	ONCOGENE			English	Article						cell-cell junctions; nectin; afadin; cadherin; mLin-7	ADHESION MOLECULE UVOMORULIN; SYNAPTIC VESICLE EXOCYTOSIS; POLARIZED EPITHELIAL-CELLS; POLIOVIRUS RECEPTOR GENE; ALPHA-CATENIN; E-CADHERIN; ADHERENS JUNCTIONS; CYTOPLASMIC DOMAIN; ARMADILLO PROTEIN; NMDA RECEPTOR	In C. elegans, lin-7 as well as lin-2/lin-10 is involved in the proper localization of the LET-23 receptor tyrosine kinase that regulates vulval induction. The mammalian homologue, mLin-7, forms a ternary complex with the mammalian homologues of LIN-2 and LIN-10 and localizes at cell-cell junctions in epithelial cells, but the mechanism of this localization of mLin-7 is unknown. Nectin is an immunoglobulin-like cell-cell adhesion molecule that is involved in organization of adherens and tight junctions in epithelial cells. Nectin is indirectly associated with the cadherin-catenin system and the actin cytoskeleton through afadin, an actin filament-binding protein. We showed here that mLin-7 localized at the nectin-based cell-cell junctions. This localization of mLin-7 required the interaction of nectin with afadin, but not the cadherin-catenin system or the actin cytoskeleton. mLin-7 did not directly interact with nectin or afadin. The results indicate that mLin-7 localizes at cell-cell junctions through the nectin-afadin system.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Nakanishi, Hiroyuki/0000-0002-9765-0266; Mandai, Kenji/0000-0002-0115-6635				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hata Y, 1996, J NEUROSCI, V16, P2488; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kemler R, 1992, Semin Cell Biol, V3, P149; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YONEMURA S, 1995, J CELL SCI, V108, P127; Zhang Y, 2001, FEBS LETT, V497, P99, DOI 10.1016/S0014-5793(01)02450-4	69	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2545	2554		10.1038/sj.onc.1205335	http://dx.doi.org/10.1038/sj.onc.1205335			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971189				2022-12-25	WOS:000174918400011
J	Back, SH; Shin, SJ; Jang, SK				Back, SH; Shin, SJ; Jang, SK			Polypyrimidine tract-binding proteins are cleaved by caspase-3 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-ENTRY-SITE; INITIATION-FACTOR 4G; MOUTH-DISEASE VIRUS; CAP-INDEPENDENT TRANSLATION; 5' NONTRANSLATED REGION; PROGRAMMED CELL-DEATH; MESSENGER-RNA; INTERNAL INITIATION; FUNCTIONAL REQUIREMENT; MEDIATED TRANSLATION	The polypyrimidine tract-binding protein (PTB), an RNA-binding protein, is required for efficient translation of some mRNAs containing internal ribosomal entry sites (IRESs). Here we provide evidence that the addition of apoptosis-inducing agents to cells results in the cleavage of PTB isoforms 1, 2, and 4 by caspase-3. This cleavage of PTB separated the N-terminal region, containing NLS-RRM1, from the C-terminal region, containing RRM2-3-4. Our data indicate that there are three noncanonical caspase-3 target sites in PTBs, namely Ile-Val-Pro-Asp(7) down arrow Ile, Leu-Tyr-Thr-Asp(139) down arrow Ser, and Ala-Ala-Val-Asp(172) down arrow Ala. The C-terminal PTB fragments localized to the cytoplasm, as opposed to the nucleus where most intact PTBs are found. Moreover, these G terminal PTB fragments inhibited translation of polio-viral mRNA, which contains an IRES element requiring PTB for its activation. This suggests that translation of some IRES-containing mRNAs is regulated by proteolytic cleavage of PTB during apoptosis.	Pohang Univ Sci & Technol, Div Mol Life Sci, Dept Life Sci, Natl Creat Res Ctr Biomol Interact, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Natl Res Lab, Pohang 790784, Kyungbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Jang, SK (corresponding author), Pohang Univ Sci & Technol, Div Mol Life Sci, Dept Life Sci, Natl Creat Res Ctr Biomol Interact, San31, Pohang 790784, Kyungbuk, South Korea.	sungkey@postech.ac.kr	Jang, Sung K/P-1230-2017					Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Back SH, 2002, J VIROL, V76, P2529, DOI 10.1128/JVI.76.5.2529-2542.2002; Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; Belsham GJ, 2000, TRENDS MICROBIOL, V8, P330, DOI 10.1016/S0966-842X(00)01788-1; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Buendia B, 1999, J CELL SCI, V112, P1743; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; CHANG KH, 1993, J VIROL, V67, P6716, DOI 10.1128/JVI.67.11.6716-6725.1993; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Flygare J, 2000, EUR J BIOCHEM, V267, P5977, DOI 10.1046/j.1432-1327.2000.01675.x; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; Giraud S, 2001, J BIOL CHEM, V276, P5668, DOI 10.1074/jbc.M005928200; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Hermann Ralph, 2001, Human Antibodies, V10, P83; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; Hunt SL, 1999, RNA, V5, P344, DOI 10.1017/S1355838299981414; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; Kaminski A, 1995, RNA, V1, P924; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kim YK, 2000, J MOL BIOL, V304, P119, DOI 10.1006/jmbi.2000.4179; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LIN CH, 1995, RNA, V1, P234; LUZ N, 1991, J VIROL, V65, P6486, DOI 10.1128/JVI.65.12.6486-6494.1991; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARTIN SJ, 1993, SCIENCE, V262, P1355; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; Niepmann M, 1996, FEBS LETT, V388, P39, DOI 10.1016/0014-5793(96)00509-1; Oh YL, 1998, BIOCHEM J, V331, P169, DOI 10.1042/bj3310169; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Romanelli MG, 1997, EXP CELL RES, V235, P300, DOI 10.1006/excr.1997.3677; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Sella O, 1999, MOL CELL BIOL, V19, P5429; Shav-Tal Y, 2000, EXP HEMATOL, V28, P1029, DOI 10.1016/S0301-472X(00)00510-5; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000	85	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27200	27209		10.1074/jbc.M203887200	http://dx.doi.org/10.1074/jbc.M203887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004072	hybrid			2022-12-25	WOS:000177055900065
J	Langer, MR; Fry, CJ; Peterson, CL; Denu, JM				Langer, MR; Fry, CJ; Peterson, CL; Denu, JM			Modulating acetyl-CoA binding in the GCN5 family of histone acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; YEAST HO GENE; P300/CBP-ASSOCIATED FACTOR; KINETIC MECHANISM; CRYSTAL-STRUCTURE; COENZYME-A; IN-VIVO; CHROMATIN; TRANSCRIPTION; PROTEIN	The histone acetyltransferase (HAT) GCN5 is the founding member for a family of chromatin remodeling enzymes. GCN5 is the catalytic subunit of a large multi-subunit complex that functions in the regulation of gene activation via acetylation of lysine residues within the N-terminal tails of core histone proteins. Using acetylCoA as a co-substrate, the high affinity binding of acetylCoA is a critical first step in the reaction. Here, we examine the biochemical and biological importance of a conserved hydroxyl-bearing residue in signature motif A. Interestingly, one major exception is the Saccharomyces cerevisiae GCN5, where an alanine (Ala(190)) is located in the corresponding position. In related GCN5 family structures, a hydroxyl-containing side chain residue is hydrogen-bonded to the alpha-phosphate oxygen of CoA. We demonstrate that this key hydrogen bond contributes similar to10-fold to the binding affinity of GCN5 HATs for acetylCoA. Human p300/CBP-associating factor, human GCN5, and tetrahymena GCN5 displayed dissociation constants (K-d) for acetyl-CoA of 0.64 +/- 0.12, 0.56 +/- 0.15, and 0.62 +/- 0.17 muM, respectively. In contrast, S. cerevisiae GCN5 displayed a Kd of 8.5 mum. When Ala(190) was replaced with threonine, the A190T derivative yielded a K-d value of 0.56 +/- 0.1 muM for acetyl-CoA, completely restoring the higher affinity binding seen with the GCN5 homologs that naturally harbor a threonine at this position. Detailed kinetic analyses revealed that the A190T derivative was otherwise catalytically indistinguishable from wild type GCN5. We also demonstrate that the A190T allele rescued the slow growth phenotype and the defect in HO transcription caused by a deletion of GCN5. Furthermore, the A190T allele supported wild type levels of transcriptionally targeted and global histone H3 acetylation. In each case, the A190T derivative behaved similarly to wild type GCN5, suggesting that the efficacy of HAT activity by GCN5 is not limited by the availability of nuclear acetyl-CoA pools.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Oregon Health & Science University; University of Massachusetts System; University of Massachusetts Worcester	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785, R01GM049650, R37GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59785, R01 GM049650, R37 GM049650, GM 49650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Kim Y, 2000, ANAL BIOCHEM, V280, P308, DOI 10.1006/abio.2000.4546; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1974, J BIOL CHEM, V249, P5163; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	43	33	33	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27337	27344		10.1074/jbc.M203251200	http://dx.doi.org/10.1074/jbc.M203251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994311	hybrid			2022-12-25	WOS:000177055900082
J	Hansen, JB; Petersen, RK; Jorgensen, C; Kristiansen, K				Hansen, JB; Petersen, RK; Jorgensen, C; Kristiansen, K			Deregulated MAPK activity prevents adipocyte differentiation of fibroblasts lacking the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; 3T3-L1 ADIPOGENESIS; KINASE ACTIVATION; GENE-EXPRESSION; C/EBP-ALPHA; PPAR-GAMMA; CELL-CYCLE; RAS; BINDING; PHOSPHORYLATION	A functional retinoblastoma protein (pRB) is required for adipose conversion of preadipocyte cell lines and primary mouse embryo fibroblasts (MEFs) in response to treatment with standard adipogenic inducers. Interestingly, lack of functional pRB in AMFs was recently linked to elevated Ras activity. Ras-dependent signaling plays a significant, although incompletely understood, role in adipocyte differentiation, because activated Ras has been reported to either promote or inhibit adipogenesis depending on the cellular context. In various cell types activation of Ras leads to activation of the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase 1/2 (ERK1/2), and protein kinase B (PKB)/Akt, which exert opposing effects on adipogenesis, with ERK1/2 inhibiting and PKB/Akt promoting terminal differentiation. Here we report that the levels of activated ERK1/2 and PKB/Akt are significantly increased in pRB-deficient MEFs both before and after the addition of adipogenic inducers. Consistently, we detected higher levels of activated Ras in AMFs lacking pRB. Suppression of ERKI/2 activation by the MEK inhibitor UO126 restored the ability of pRB-deficient MEFs to undergo adipocyte differentiation, as manifested by expression of adipocyte marker genes and lipid accumulation. Furthermore and reflecting the elevated levels of activated PKB/Akt in the pRB-deficient MEFs, differentiation proceeded in an insulin-independent manner. In conclusion, we suggest that pRB plays a pivotal role in adipogenesis by suppressing MAPK activity.	Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Rheosci AS, DK-2610 Rodovre, Denmark	University of Southern Denmark	Kristiansen, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.		Kristiansen, Karsten/J-5148-2014; Hansen, Jacob B/F-3775-2010	Kristiansen, Karsten/0000-0002-6024-0917; Hansen, Jacob B/0000-0001-5249-2586; Jorgensen, Claus/0000-0002-7841-943X				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee KY, 1999, MOL CELL BIOL, V19, P7724; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Page BD, 2001, MOL CELL, V7, P451, DOI 10.1016/S1097-2765(01)00193-9; PORRAS A, 1992, J BIOL CHEM, V267, P21124; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Raptis L, 1997, CELL GROWTH DIFFER, V8, P11; Raptis L, 1997, EXP CELL RES, V235, P188, DOI 10.1006/excr.1997.3646; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Rosen ED, 2000, GENE DEV, V14, P1293; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEARS R, 2000, GENE DEV, V14, P2105; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	41	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26335	26339		10.1074/jbc.M203870200	http://dx.doi.org/10.1074/jbc.M203870200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000769	hybrid			2022-12-25	WOS:000176908700068
J	Liu, J; Yao, F; Wu, RP; Morgan, M; Thorburn, A; Finley, RL; Chen, YQ				Liu, J; Yao, F; Wu, RP; Morgan, M; Thorburn, A; Finley, RL; Chen, YQ			Mediation of the DCC apoptotic signal by DIP13 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; PTB DOMAIN; NETRIN-1; RECEPTOR; IDENTIFICATION; CARCINOMAS; MIGRATION; MECHANISM; SURVIVAL	DCC (deleted in colorectal cancer) is a candidate tumor suppressor gene. However the function of DCC remains elusive. Previously, we demonstrated that forced expression of DCC induces apoptosis or cell cycle arrest (Chen, Y. Q., Hsieh, J. T., Yao, F., Fang, B., Pong, R. C., Cipriano, S. C. & Krepulat, F. (1999) Oncogene 18,27472754). To delineate the DCC-induced apoptotic pathway, we have identified a protein, DIP13alpha, which interacts with DCC. The DIP13alpha protein has a pleckstrin homology domain and a phosphotyrosine binding domain. It interacts with a region on the DCC cytoplasmic domain that is required for the induction of apoptosis. Although ectopic expression of DIP13alpha alone causes only a slight increase in apoptosis, co-expression of DCC and DIP13alpha results in an similar to5-fold increase in apoptosis. Removal of the DCC-interacting domain on DIP13alpha abolishes its ability to enhance DCC-induced apoptosis. Inhibition of endogenous DIP13alpha expression by small interfering RNA blocks DCC-induced apoptosis. Our data suggest that DIP13alpha is a mediator of the DCC apoptotic pathway.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wake Forest University; Wayne State University; Wayne State University	Chen, YQ (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708; Finley, Russ/0000-0003-1144-6887	NCI NIH HHS [R01CA77489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bloch-Gallego E, 1999, J NEUROSCI, V19, P4407; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; GAO X, 1993, CANCER RES, V53, P2723; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; Hilgers W, 2000, GENE CHROMOSOME CANC, V27, P353, DOI 10.1002/(SICI)1098-2264(200004)27:4<353::AID-GCC3>3.3.CO;2-X; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Margolis B, 1999, TRENDS ENDOCRIN MET, V10, P262, DOI 10.1016/S1043-2760(99)00168-X; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Yee KT, 1999, NEURON, V24, P607, DOI 10.1016/S0896-6273(00)81116-2	25	85	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26281	26285		10.1074/jbc.M204679200	http://dx.doi.org/10.1074/jbc.M204679200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011067	hybrid			2022-12-25	WOS:000176908700061
J	Biemel, KM; Friedl, DA; Lederer, MO				Biemel, KM; Friedl, DA; Lederer, MO			Identification and quantification of major Maillard cross-links in human serum albumin and lens protein - Evidence for glucosepane as the dominant compound	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLGLYOXAL; LYSINE; GLYOXAL; MECHANISM; GLYCATION; SENESCENCE; INCREASE; PENTOSES	Glycation reactions leading to protein modifications (advanced glycation end products) contribute to various pathologies associated with the general aging process and long term complications of diabetes. However, only few relevant compounds have so far been detected in vivo. We now report on the first unequivocal identification of the lysine-arginine cross-links glucosepane 5, DOGDIC 6, MODIC 7, and GODIC 8 in human material. For their accurate quantification by coupled liquid chromatography-electrospray ionization mass spectrometry, C-13-labeled reference compounds were synthesized independently. Compounds 5-8 are formed via the a-dicarbonyl compounds N-6-(2,3-dihydroxy-5,6-dioxohexyl)-L-lysinate (1a,b), 3-deoxyglucosone (2), methylglyoxal (3), and glyoxal (4), respectively. The protein-bound dideoxyosone la,b seems to be of prime significance for cross-linking because it presumably is not detoxified by mammalian enzymes as readily as 2-4. Hence, the follow-up product glucosepane 5 was found to be the dominant compound. Up to 42.3 pmol of 5/mg of protein was identified in human serum albumin of diabetics; the level of 5 correlates markedly with the glycated hemoglobin HbA(1c). In the water-insoluble fraction of lens proteins from normoglycemics, concentration of 5 ranges between 132.3 and 241.7 pmol/mg. The advanced glycoxidation end product GODIC 8 is elevated significantly in brunescent lenses, indicating enhanced oxidative stress in this material. Compounds 5-8 thus appear predestined as markers for pathophysiological processes.	Univ Hohenheim, Inst Lebensmittelchem 170, D-70593 Stuttgart, Germany; Burger Hosp, ZIM, Klinikum Stuttgart, Med Klin 3, D-70191 Stuttgart, Germany	University Hohenheim; Klinikum Stuttgart	Lederer, MO (corresponding author), Univ Hohenheim, Inst Lebensmittelchem 170, Garbenstr 28, D-70593 Stuttgart, Germany.	ledererm@uni-hohenheim.de						Beisswenger PJ, 2001, DIABETES CARE, V24, P726, DOI 10.2337/diacare.24.4.726; Biemel KM, 2002, ANGEW CHEM INT EDIT, V41, P801, DOI 10.1002/1521-3773(20020301)41:5<801::AID-ANIE801>3.0.CO;2-I; Biemel KM, 2001, J BIOL CHEM, V276, P23405, DOI 10.1074/jbc.M102035200; BRINKMANN E, 1995, J CHEM SOC PERK T 1, P2817, DOI 10.1039/p19950002817; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291; EBLE AS, 1983, J BIOL CHEM, V258, P9406; FEATHER MS, 1995, BBA-GEN SUBJECTS, V1244, P10, DOI 10.1016/0304-4165(94)00156-R; Friedman M, 1996, J AGR FOOD CHEM, V44, P631, DOI 10.1021/jf950394r; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200; HAYASE F, 1991, Amino Acids (Vienna), V1, P307, DOI 10.1007/BF00814000; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LO TWC, 1994, J BIOL CHEM, V269, P32299; LOIDLSTAHLHOFEN A, 1994, BBA-LIPID LIPID MET, V1211, P156, DOI 10.1016/0005-2760(94)90264-X; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NAKAMURA K, 1992, J CHEM SOC CHEM COMM, P992, DOI 10.1039/c39920000992; Obayashi H, 1996, BIOCHEM BIOPH RES CO, V226, P37, DOI 10.1006/bbrc.1996.1308; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; Odani H, 1999, BIOCHEM BIOPH RES CO, V256, P89, DOI 10.1006/bbrc.1999.0221; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RAY M, 1987, J BIOL CHEM, V262, P5974; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; Reiser KM, 1998, P SOC EXP BIOL MED, V218, P23; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; Sachs L, 1993, STAT METHODEN PLANUN; SACHS L, 1978, ANGEWANDTE STAT STAT; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shamsi FA, 1999, CURR EYE RES, V19, P276, DOI 10.1076/ceyr.19.3.276.5315; Skovsted IC, 1998, CELL MOL BIOL, V44, P1159; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; WALTER HF, 1991, RUCKSTANDSANALYTIK P, P1; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; Yamaguchi M, 1998, DIABETIC MED, V15, P458, DOI 10.1002/(SICI)1096-9136(199806)15:6<458::AID-DIA601>3.0.CO;2-Q	39	173	183	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24907	24915		10.1074/jbc.M202681200	http://dx.doi.org/10.1074/jbc.M202681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978796	hybrid			2022-12-25	WOS:000176747000012
J	Conti, LR; Radeke, CM; Vandenberg, CA				Conti, LR; Radeke, CM; Vandenberg, CA			Membrane targeting of ATP-sensitive potassium channel - Effects of glycosylation on surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; INSULIN-SECRETING CELLS; SULFONYLUREA RECEPTOR; K+ CHANNELS; FAMILIAL HYPERINSULINISM; ENDOPLASMIC-RETICULUM; SUBUNIT STOICHIOMETRY; PLASMA-MEMBRANE; P-GLYCOPROTEIN; TRAFFICKING	Oligosaccharides play significant roles in trafficking, folding, and sorting of membrane proteins. Sulfonylurea receptors (SURx), members of the ATP binding cassette family of proteins, associate with the inward rectifier Kir6.x to form ATP-sensitive potassium channels (K-ATP). These channels are found on the plasma membrane in many tissues and play a pivotal role in synchronizing electrical excitability with cell metabolic state. Trafficking defects resulting from three independent SUR1 mutations involved in the disease persistent hyperinsulinemic hypoglycemia of infancy have been described. Two of these mutations displayed notable decreases in glycosylation. Here we have investigated the relationship between the two N-linked glycosylation sites (Asn(10) and Asn(1050)) and SUR1 trafficking. Using patch clamp analysis, surface biotinylation, and immunofluorescence microscopy, we demonstrate a significant decrease in surface expression of SUR1 single or double glycosylation site mutants (N10Q,N1050Q) when co-expressed with Kir6.2. Additionally, we show prominent retention within the ER of the SUR1 double glycosylation mutant under the same conditions. Further investigation revealed that mutation of the ER retention signal was able to partially restore surface expression of the SUR1 double glycosylation mutant. These studies suggest that SUR1 glycosylation is a key element for the proper trafficking and surface expression of K-ATP channels.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041656, R29HL041656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; ASHCROFT SJH, 1993, ADV EXP MED BIOL, V334, P47; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Makhina EN, 1998, J BIOL CHEM, V273, P3369, DOI 10.1074/jbc.273.6.3369; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; OConnor SE, 1996, CHEM BIOL, V3, P803, DOI 10.1016/S1074-5521(96)90064-2; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; Pabon A, 2000, J BIOL CHEM, V275, P30677, DOI 10.1074/jbc.M005338200; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	38	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25416	25422		10.1074/jbc.M203109200	http://dx.doi.org/10.1074/jbc.M203109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994306	hybrid			2022-12-25	WOS:000176747000075
J	Kristich, CJ; Ordal, GW				Kristich, CJ; Ordal, GW			Bacillus subtilis CheD is a chemoreceptor modification enzyme required for chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; COVALENT MODIFICATION; GENE-PRODUCT; PROTEINS; METHYLATION; PHOSPHORYLATION; ADAPTATION; RECEPTORS	The chemotaxis machinery of Bacillus subtilis is similar to that of the well characterized system of Escherichia coli. However, B. subtilis contains several chemotaxis genes not found in the E. coli genome, such as cheC and cheD, indicating that the B. subtilis chemotactic system is more complex. In B. subtilis, CheD is required for chemotaxis; the cheD mutant displays a tumbly phenotype, has abnormally methylated chemoreceptors, and responds poorly to most chemical stimuli. Homologs of B. subtilis CheD have been found in chemotaxis-like operons of a large number of bacteria and archaea, suggesting that CheD plays an important role in chemotactic sensory transduction for many organisms. However, the molecular function of CheD has remained unknown. In this study, we show that CheD catalyzes amide hydrolysis of specific glutaminyl side chains of the B. subtilis chemoreceptor McpA. In addition, we present evidence that CheD deamidates other B. subtilis chemoreceptors including McpB and McpC. Previously, deamidation of B. subtilis receptors was thought to be catalyzed by the CheB methylesterase, as is the case for E. coli receptors. Because cheD mutant cells do not respond to most chemoattractants, we conclude that deamidation by CheD is required for B. subtilis chemoreceptors to effectively transduce signals to the CheA kinase.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Liberal Arts, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Sci, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GW (corresponding author), Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM54365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM054365, R01GM054365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOYD A, 1980, J BACTERIOL, V143, P809, DOI 10.1128/JB.143.2.809-815.1980; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; CHELSKY D, 1980, P NATL ACAD SCI-BIOL, V77, P2434, DOI 10.1073/pnas.77.5.2434; GARRITY LF, 1995, PHARMACOL THERAPEUT, V68, P87, DOI 10.1016/0163-7258(95)00027-5; GueroutFleury AM, 1996, GENE, V180, P57, DOI 10.1016/S0378-1119(96)00404-0; HANLON DW, 1994, J BIOL CHEM, V269, P14038; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Karatan E, 2001, J BIOL CHEM, V276, P43618, DOI 10.1074/jbc.M104955200; KEHRY MR, 1982, CELL, V29, P761, DOI 10.1016/0092-8674(82)90438-X; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; Kirby JR, 2001, MOL MICROBIOL, V42, P573, DOI 10.1046/j.1365-2958.2001.02581.x; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; MOUNTAIN A, 1989, BACILLUS, P73; PARKINSON JS, 1977, ANNU REV GENET, V11, P397, DOI 10.1146/annurev.ge.11.120177.002145; ROLLINS C, 1981, CELL, V25, P333, DOI 10.1016/0092-8674(81)90051-9; Rosario MML, 1996, MOL MICROBIOL, V21, P511, DOI 10.1111/j.1365-2958.1996.tb02560.x; ROSARIO MML, 1995, BIOCHEMISTRY-US, V34, P3823, DOI 10.1021/bi00011a040; Sambrook J., 2002, MOL CLONING LAB MANU; SCHON U, 1994, GENE, V147, P91, DOI 10.1016/0378-1119(94)90044-2; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; SUN Y, 1996, PROTEIN PEPTIDE ANAL, P185; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; Wang H, 1996, MOL MICROBIOL, V19, P695, DOI 10.1046/j.1365-2958.1996.393934.x; WARRICK HM, 1977, J BACTERIOL, V130, P223, DOI 10.1128/JB.130.1.223-231.1977; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; Zimmer MA, 2000, J BIOL CHEM, V275, P24264, DOI 10.1074/jbc.M004001200	40	53	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25356	25362		10.1074/jbc.M201334200	http://dx.doi.org/10.1074/jbc.M201334200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12011078	hybrid, Green Submitted			2022-12-25	WOS:000176747000067
J	Solecki, DJ; Gromeier, M; Mueller, S; Bernhardt, G; Wimmer, E				Solecki, DJ; Gromeier, M; Mueller, S; Bernhardt, G; Wimmer, E			Expression of the human poliovirus Receptor/CD155 gene is activated by sonic-hedgehog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; RESPIRATORY FACTOR-I; HUMAN HOMOLOG; CHROMOSOMAL LOCALIZATION; ADHESION MOLECULE; CORE PROMOTER; NTERA-2 CELLS; MOUSE HOMOLOG	The human poliovirus receptor/CD155 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. The ectodomain of CD155 mediates cell attachment to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1. CD155 is a primate-restricted gene that is expressed during development in mesenchymal tissues and ventrally derived structures within the CNS. Its function in adults is as yet unknown, but significantly, CD155 is aberrantly expressed in neuroectodermal tumors. We show that the expression of CD155 mRNA is up-regulated when human Ntera2 cells are treated with purified Sonic hedgehog (Shh) protein. Reporter gene expression driven by the CD155 core promoter is activated by Shh in transient co-transfection assays. Analysis of the CD155 core promoter indicates that an intact GLI binding site is required for Shh activation. In addition, overexpression of Gli1 or Gli3 potently activates reporter gene expression driven by the CD155 core promoter. These data identify the CD155 gene as a transcriptional target of Shh, a finding that has significance for the normal function of CD155 during development and the expression of CD155 in neuroectodermal tumors.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Solecki, DJ (corresponding author), Rockefeller Univ, Dev Neurobiol Lab, 1230 York Ave, New York, NY 10021 USA.	soleckd@mail.rockefeller.edu	Solecki, David/N-8080-2018; Bernhardt, Günter/F-6946-2012; Mueller, Steffen/HGE-0738-2022	Bernhardt, Günter/0000-0002-0510-2853; Mueller, Steffen/0000-0003-2660-258X	NIAID NIH HHS [AI39485] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI039485, R01AI039485] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; Becker TS, 1998, DEVELOPMENT, V125, P4369; BERNHARDT G, 1994, VIROLOGY, V199, P105, DOI 10.1006/viro.1994.1102; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Gromeier M, 2000, VIROLOGY, V273, P248, DOI 10.1006/viro.2000.0418; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jensen AM, 1997, DEVELOPMENT, V124, P363; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1994, ARCH VIROL, V139, P351, DOI 10.1007/BF01310797; Lange R, 2001, VIROLOGY, V285, P218, DOI 10.1006/viro.2001.0943; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Martinez-Morales JR, 1997, DEVELOPMENT, V124, P5139; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Miller LAD, 2001, J HISTOCHEM CYTOCHEM, V49, P1593, DOI 10.1177/002215540104901213; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Pons S, 2000, DEVELOPMENT, V127, P333; Raffel C, 1997, CANCER RES, V57, P842; REIFENBERGER G, 1995, CANCER RES, V55, P731; Reifenberger J, 1998, CANCER RES, V58, P1798; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Schaefer L, 2000, MAMM GENOME, V11, P104, DOI 10.1007/s003350010021; SEIFFERT D, 1995, DEV DYNAM, V203, P71, DOI 10.1002/aja.1002030108; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Solecki D, 1999, J BIOL CHEM, V274, P1791, DOI 10.1074/jbc.274.3.1791; Solecki D, 2000, J BIOL CHEM, V275, P12453, DOI 10.1074/jbc.275.17.12453; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; van Tuyl M, 2000, Respir Res, V1, P30, DOI 10.1186/rr9; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WIMMER E, 1994, COLD SPRING HARBOR M, P101; Wolter M, 1997, CANCER RES, V57, P2581; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang XM, 2001, DEVELOPMENT, V128, P943	62	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25697	25702		10.1074/jbc.M201378200	http://dx.doi.org/10.1074/jbc.M201378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983699	hybrid			2022-12-25	WOS:000176747000110
J	Carrozza, MJ; John, S; Sil, AK; Hopper, JE; Workman, JL				Carrozza, MJ; John, S; Sil, AK; Hopper, JE; Workman, JL			Gal80 confers specificity on HAT complex interactions with activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; RNA-POLYMERASE-II; CHROMATIN-REMODELING COMPLEXES; SACCHAROMYCES-CEREVISIAE; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; REGULATORY PROTEINS; YEAST; PROMOTER; GENE	Several yeast transcription activators have been shown to interact with and recruit histone acetyltransferase complexes to promoters in chromatin. The promiscuity of activator/RAT interactions suggests that additional factors temporally regulate these interactions in response to signaling pathways. In this study, we demonstrate that the negative regulator, Gal80, blocks interactions between the SAGA and NuA4 HAT complexes and the Gal4 activator. By contrast, Gal80 did not inhibit SAGA and NuA4 interaction with another activator Gcn4. The function of Gal80 prevented Gal4 targeting of SAGA and displaced SAGA targeted by Gal4 to a promoter within a nucleosome array. In the same set of experiments, targeting of SAGA by Gcn4 was unaffected by Gal80. These studies demonstrate that the specificity of HAT/activator interactions can be dictated by cofactors that modulate activation domain function in response to cellular signals.	Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.				NIGMS NIH HHS [GM027925, GM047867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047867, R37GM047867, R01GM027925] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Ansari AZ, 1998, P NATL ACAD SCI USA, V95, P13543, DOI 10.1073/pnas.95.23.13543; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhat PJ, 2001, MOL MICROBIOL, V40, P1059, DOI 10.1046/j.1365-2958.2001.02421.x; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DICKSON RC, 1990, NUCLEIC ACIDS RES, V18, P5213, DOI 10.1093/nar/18.17.5213; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; Ikeda K, 1999, MOL CELL BIOL, V19, P855; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Owen-Hughes T, 1999, METH MOL B, V119, P319; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; Peng G, 2000, MOL CELL BIOL, V20, P5140, DOI 10.1128/MCB.20.14.5140-5148.2000; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Roberts SM, 1997, GENETICS, V147, P451; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SALMERON JM, 1990, GENETICS, V125, P21; Sil AK, 1999, MOL CELL BIOL, V19, P7828; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Steger DJ, 1999, METHODS, V19, P410, DOI 10.1006/meth.1999.0877; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; YUN SJ, 1991, J BIOL CHEM, V266, P693	59	30	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24648	24652		10.1074/jbc.M201965200	http://dx.doi.org/10.1074/jbc.M201965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986320	hybrid			2022-12-25	WOS:000176611800089
J	Saegusa, C; Fukuda, M; Mikoshiba, K				Saegusa, C; Fukuda, M; Mikoshiba, K			Synaptotagmin V is targeted to dense-core vesicles that undergo calcium-dependent exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; PANCREATIC BETA-CELLS; C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; ENDOPLASMIC-RETICULUM; REGULATED EXOCYTOSIS; PHOSPHOLIPID-BINDING; TRANSMITTER RELEASE; SYNAPTIC VESICLES; NEURITE OUTGROWTH	Synaptotagmins (Syts) III, V, VI, and X are classified as a subclass of Syt, based on their sequence similarities and biochemical properties (Ibata, K., Fukuda, M., and Mikoshiba, K. (1998) J. Biol. Chem. 273, 12267-12273; Fukuda, M., Kanno, E., and Mikoshiba, K. (1999) J. Biol. Chem 274, 31421-31427). Although they have been suggested to be involved in vesicular trafficking, as in the role of the Syt I isoform in synaptic vesicle exocytosis, their exact functions remain to be clarified, and even their precise subcellular localization is still a matter of controversy. In this study, we established rat pheochromocytoma (PC12) cell lines that stably express Syts III-, V-, VI-, and X-GFP (green fluorescence protein) fusion proteins, respectively, to deter-mine their precise subcellular localizations. Surprisingly, Syts III-, V-, VI-, and X-GFP proteins were found to be targeted to specific organelles: Syt III-GFP to near the plasma membrane, Syt V-GFP to dense-core vesicles, Syt VI-GFP to endoplasmic reticulum-like structures, and Syt X-GFP to vesicles (other than dense-core vesicles) present in cytoplasm. We showed that Syt V-containing vesicles at the neurites of PC12 cells were processed to exocytosis in a Ca2+-dependent manner. Immunohistochemical analysis further showed that endogenous Syt V was also localized on dense-core vesicles in the mouse brain and specifically expressed in glucagon-positive a-cells in mouse pancreatic islets, but not in beta- or delta-cells. Based on these results, we propose that Syt V is a dense-core vesicle-specific Syt isoform that controls a specific type of Ca2+-regulated secretion.	RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				ARVIDSSON U, 1995, J NEUROSCI, V15, P1215; Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; Bennett MR, 1999, PROG NEUROBIOL, V59, P243, DOI 10.1016/S0301-0082(99)00004-0; Berton F, 2000, EUR J NEUROSCI, V12, P1294, DOI 10.1046/j.1460-9568.2000.00013.x; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; Brown H, 2000, DIABETES, V49, P383, DOI 10.2337/diabetes.49.3.383; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Craxton M, 1999, FEBS LETT, V460, P417, DOI 10.1016/S0014-5793(99)01382-4; Craxton M, 2001, GENOMICS, V77, P43, DOI 10.1006/geno.2001.6619; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; Ding YQ, 1996, J COMP NEUROL, V367, P375; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; Fukuda M, 2000, NEUROSCI LETT, V295, P33, DOI 10.1016/S0304-3940(00)01585-8; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V270, P528, DOI 10.1006/bbrc.2000.2434; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Gut A, 2001, J CELL SCI, V114, P1709; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; Kabayama H, 1999, NEUROSCIENCE, V88, P999, DOI 10.1016/S0306-4522(98)00547-8; Kasai H, 1999, P NATL ACAD SCI USA, V96, P945, DOI 10.1073/pnas.96.3.945; Kida Y, 2000, J CELL BIOL, V150, P719, DOI 10.1083/jcb.150.4.719; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schneggenburger R, 2000, NATURE, V406, P889, DOI 10.1038/35022702; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Thomas DM, 1999, MOL BIOL CELL, V10, P2285, DOI 10.1091/mbc.10.7.2285; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895	62	63	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24499	24505		10.1074/jbc.M202767200	http://dx.doi.org/10.1074/jbc.M202767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006594	hybrid			2022-12-25	WOS:000176611800070
J	Wang, YD; De Vos, J; Jourdan, M; Couderc, G; Lu, ZY; Rossi, JF; Klein, B				Wang, YD; De Vos, J; Jourdan, M; Couderc, G; Lu, ZY; Rossi, JF; Klein, B			Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells	ONCOGENE			English	Article						CD9; HB-EGF; ErbB1; IL-6; myeloma	HUMAN MULTIPLE-MYELOMA; DIPHTHERIA-TOXIN RECEPTOR; FACTOR (EGF)-LIKE DOMAIN; SIGNAL TRANSDUCER GP130; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; SURVIVAL FACTOR; IFN-ALPHA; LINES; PROLIFERATION	Interleukin-6 (IL-6) is a major survival and proliferation factor of human malignant plasma cells and IL-6 dependent myeloma cell lines can be obtained from patients with terminal disease. We show here that mutated diphtheria toxin, a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF), blocked the IL-6-induced growth of two myeloma cell lines (XG-1 and XG-14) and did not significantly affect that of two other cell lines (XG-6 and XG-13). The IL-6 mediated growth of myeloma cells was also inhibited by antibodies to ErbB1, a receptor for HB-EGF. The XG-1 and XG-14 cell lines that are sensitive to HB-EGF inhibitors overexpressed HB-EGF and EGF receptor (ErbB1) genes. They also overexpressed CD9, a tetraspanin that binds to the heparin-binding domain of HB-EGF and is critical for promoting ErbB1 activation by HB-EGF. The XG-6 and XG-13 myeloma cells that were not significantly sensitive to HB-EGF antagonists, poorly expressed HB-EGF, ErbB1 and CD9 genes or proteins. We demonstrated that recombinant HB-EGF supported the long-term growth of myeloma cells, as did IL-6. The myeloma cell growth factor activity of HB-EGF was completely inhited by antibodies to ErbB1, but also by antibodies to gp130 IL-6 transducer or to IL-6. These data indicate that in the XG-1 and XG-14 IL-6-dependent myeloma cell lines, the CD9/HB-EGF/erbB1 and the IL-6/IL-6R/ gp130 pathways cooperate synergistically to trigger myeloma cell growth. They suggest that inhibitors of the EGF receptor or HB-EGF may be useful for inducing myeloma cell apoptosis in patients with multiple myeloma.	CHU Montpellier, INSERM, U475, F-34197 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34197 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), CHU Montpellier, INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	Klein@montp.inserm.fr	DE VOS, John/A-5703-2010	DE VOS, John/0000-0003-1880-4130				Badache A, 2001, CANCER RES, V61, P383; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; DAVISFLEISCHER KM, 1998, FRONT BIOSCI, V3, P288; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Ferlin-Bezombes M, 1998, J IMMUNOL, V161, P2692; Gaillard JP, 1997, EUR J IMMUNOL, V27, P3332, DOI 10.1002/eji.1830271232; Garcia-Sanz R, 1999, BLOOD, V93, P1032, DOI 10.1182/blood.V93.3.1032.403a15_1032_1037; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Jelinek DF, 1997, J IMMUNOL, V159, P487; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Kaefer M, 2000, J UROLOGY, V163, P580, DOI 10.1016/S0022-5347(05)67936-0; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LOKHORST HM, 1994, BLOOD, V84, P2269; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; PORTIER M, 1993, BRIT J HAEMATOL, V85, P514; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; SHIMIZU S, 1989, J EXP MED, V169, P339, DOI 10.1084/jem.169.1.339; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHANG XG, 1994, BLOOD, V83, P3654	41	53	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2584	2592		10.1038/sj.onc.1205355	http://dx.doi.org/10.1038/sj.onc.1205355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971193				2022-12-25	WOS:000174918400015
J	den Dekker, E; Gorter, G; Heemskerk, JWM; Akkerman, JWN				den Dekker, E; Gorter, G; Heemskerk, JWM; Akkerman, JWN			Development of platelet inhibition by cAMP during megakaryocytopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CELL-LINE; IN-VITRO; SIGNAL-TRANSDUCTION; ANCHORING PROTEIN; CATALYTIC SUBUNIT; INTACT-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; PROSTACYCLIN RECEPTOR; REGULATORY SUBUNITS	Prostacyclin is a potent inhibitor of agonist-induced Ca2+ increases in platelets, but in the megakaryocytic cell line MEG-01 this inhibition is absent. Using human megakaryocytic cell lines representing different stages in megakaryocyte (Mk) maturation as well as stem cells and immature and mature megakaryocytes, we show that the inhibition by prostacyclin develops at a late maturation stage shortly before platelets are formed. This late appearance is not caused by insufficient cAMP formation or absent protein kinase A (PKA) activity in immature cells. Instead, the appearance of Ca2+ inhibition by prostacyclin is accompanied by a sharp increase in the expression of the catalytic subunit of PKA (PKA-C) but not by changes in the expression of the PKA-regulatory subunits Ialpha/beta, IIalpha, and IIbeta. Overexpression of PKA-C in the megakaryocytic cell line CHRF-288-11 potentiates the Ca2+ inhibition by prostacyclin. Thus, up-regulation of PKA-C appears to be a key step in the development of Ca2+ inhibition by prostacyclin in platelets.	Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3508 GA Utrecht, Netherlands; Maastricht Univ, Dept Biochem & Human Biol, NL-6200 MD Maastricht, Netherlands	Utrecht University; Utrecht University; Maastricht University	Akkerman, JWN (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, POB 85500, NL-3508 GA Utrecht, Netherlands.		Heemskerk, Johan/AAM-8323-2021	Heemskerk, Johan/0000-0002-2848-5121				BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; den Dekker E, 2002, ARTERIOSCL THROM VAS, V22, P179, DOI 10.1161/hq0102.101515; den Dekker E, 2001, BBA-MOL CELL RES, V1539, P243, DOI 10.1016/S0167-4889(01)00112-4; den Dekker E, 2001, THROMB HAEMOSTASIS, V86, P1106; Dodge KL, 1999, ENDOCRINOLOGY, V140, P5165, DOI 10.1210/en.140.11.5165; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; FOSS KB, 1994, EUR J BIOCHEM, V220, P217, DOI 10.1111/j.1432-1033.1994.tb18617.x; FUGMAN DA, 1990, BLOOD, V75, P1252; GREENBERG SM, 1988, BLOOD, V72, P1968; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; HOWARD P, 1991, J BIOL CHEM, V266, P10189; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Kahn NN, 1997, P NATL ACAD SCI USA, V94, P8779, DOI 10.1073/pnas.94.16.8779; KAHN NN, 1990, CIRC RES, V66, P932, DOI 10.1161/01.RES.66.4.932; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Kim SN, 1997, BIOCHEM BIOPH RES CO, V232, P469, DOI 10.1006/bbrc.1997.6313; Lacabaratz-Porret C, 2000, BIOCHEM J, V350, P723, DOI 10.1042/0264-6021:3500723; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; OGURA M, 1985, BLOOD, V66, P1384; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Sasaki Y, 1997, BLOOD, V90, P1039, DOI 10.1182/blood.V90.3.1039.1039_1039_1046; SCHWANER I, 1992, BIOCHEM J, V281, P301, DOI 10.1042/bj2810301; SERNERI GGN, 1984, LANCET, V2, P838; Siddiqua A, 1999, THROMB HAEMOSTASIS, P635; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SUGIYAMA H, 1992, J BIOL CHEM, V267, P25256; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; UHLER MD, 1987, J BIOL CHEM, V262, P15202; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023; Zauli G, 1998, BLOOD, V92, P472, DOI 10.1182/blood.V92.2.472.414k30_472_480	46	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29321	29329		10.1074/jbc.M111390200	http://dx.doi.org/10.1074/jbc.M111390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11997386	hybrid, Green Published			2022-12-25	WOS:000177342600122
J	Collet, JF; Riemer, J; Bader, MW; Bardwell, JCA				Collet, JF; Riemer, J; Bader, MW; Bardwell, JCA			Reconstitution of a disulfide isomerization system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; ESCHERICHIA-COLI; PROTEIN DSBD; ISOMERASE; MEMBRANE; IDENTIFICATION; ELECTRONS; RESIDUES	Isomerization of disulfide bonds is vital for the proper folding of proteins that possess multiple disulfides. In prokaryotes, the catalytic pathway responsible for disulfide isomerization involves thioredoxin, thioredoxin reductase, and the DsbC, DsbG, and DsbD proteins. To be active as isomerases, DsbC and DsbG must be kept reduced. This task is performed by the cytoplasmic membrane protein DsbD. DsbD in turn is reduced by the cytoplasmic thioredoxin and is composed of three domains. The beta domain is membrane-embedded, whereas the a and gamma domains are localized to the periplasm. It had been proposed that electrons are transferred within DsbD by a succession of disulfide exchange reactions between the three domains. To test this model using biochemical methods, we purified to homogeneity different polypeptides corresponding to the alpha, beta, gamma, and betagamma domains. Using these domains, we could reconstitute a DsbD activity and, for the first time, reconstitute in vitro the electron transport pathway from NADPH and thioredoxin to DsbC and DsbG. We showed that electrons are transferred from thioredoxin to the beta domain then successively to the gamma domain, the alpha domain, and finally on to DsbC or DsbG. We also determined the redox potential of the gamma domain to be -241 mV, and that of the a domain was found to be -229 mV. This shows that the direction of electron flow within DsbD is thermodynamically driven.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Catholique Louvain, Chim Physiol Lab, B-1200 Brussels, Belgium	University of Michigan System; University of Michigan; Universite Catholique Louvain	Bader, MW (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.		Collet, Jean Francois/F-2105-2010; Riemer, Jan/B-3340-2012; Riemer, Jan/AAC-1072-2021	Riemer, Jan/0000-0002-7574-8457; Collet, Jean-Francois/0000-0001-8069-7036				Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Goldstone D, 2001, P NATL ACAD SCI USA, V98, P9551, DOI 10.1073/pnas.171315498; Gordon EHJ, 2000, MOL MICROBIOL, V35, P1360, DOI 10.1046/j.1365-2958.2000.01796.x; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Krupp R, 2001, J BIOL CHEM, V276, P3696, DOI 10.1074/jbc.M009500200; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	17	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26886	26892		10.1074/jbc.M203028200	http://dx.doi.org/10.1074/jbc.M203028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004064	hybrid			2022-12-25	WOS:000177055900026
J	Ma, YL; Taylor, S				Ma, YL; Taylor, S			A 15-residue bifunctional element in D-AKAP1 is required for both endoplasmic reticulum and mitochondrial targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SITE-DIRECTED MUTAGENESIS; GREEN FLUORESCENT PROTEIN; REGULATORY SUBUNITS; ANCHOR PROTEIN; CYCLIC-AMP; GERM-CELLS; IDENTIFICATION; DIFFERENTIATION; HEXOKINASE-1	The cAMP-dependent protein kinase anchoring protein, D-AKAP1, has two N-terminal splice variants. The shorter forms (NO, D-AKAP1a, and -1c) target to mitochondria, and the longer forms (N1, D-AKAP1b, and -1d) with 33 additional residues N-terminal to NO target to the endoplasmic reticulum (ER) (Huang, L. J., Wang, L., Ma, Y., Durick, K., Perkins, G., Deerinck, T. J., Ellisman, M. H., and Taylor, S. S. (1999) J. Cell Biol. 145, 951-959). In D-AKAP1a, translation may initiate from both Met-34 or Met-49 producing two molecules both targeted to mitochondria. The shorter molecule contains the 15-residue targeting motif, homologous to the N-terminal mitochondrial targeting motif of hexokinase I. Extensive mutagenesis showed that one hydrophobic surface of the 15-residue hexokinase-homologous segment contained the key elements for mitochondrial targeting. The same 15 residues are also part of the ER-targeting signal, but for ER targeting multiple hydrophobic residues are required that encompass both surfaces of the helix. The different involvement of the same helical motif for targeting to the two organelles appears to reflect different modes of interaction with the two organelles. This is the first example of a bifunctional helical element that is required for both ER and mitochondrion targeting.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, S (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr,MC 0658, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; Kehrer-Sawatzki H, 1999, GENE, V235, P1, DOI 10.1016/S0378-1119(99)00222-X; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Ma Y, 1999, CANCER RES, V59, P5341; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scott JD, 2000, ADV PHARMACOL, V47, P175; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Steen RL, 2001, J CELL BIOL, V153, P621, DOI 10.1083/jcb.153.3.621; Steenaart NAE, 1996, BIOCHEMISTRY-US, V35, P3764, DOI 10.1021/bi9528053; Sui DX, 1997, ARCH BIOCHEM BIOPHYS, V345, P111, DOI 10.1006/abbi.1997.0241; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; XIE GC, 1988, ARCH BIOCHEM BIOPHYS, V267, P803, DOI 10.1016/0003-9861(88)90090-2; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	47	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27328	27336		10.1074/jbc.M201421200	http://dx.doi.org/10.1074/jbc.M201421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994283	hybrid			2022-12-25	WOS:000177055900081
J	Nielsen, KJ; Watson, M; Adams, DJ; Hammarstrom, AK; Gage, PW; Hill, JM; Craik, DJ; Thomas, L; Adams, D; Alewood, PF; Lewis, RJ				Nielsen, KJ; Watson, M; Adams, DJ; Hammarstrom, AK; Gage, PW; Hill, JM; Craik, DJ; Thomas, L; Adams, D; Alewood, PF; Lewis, RJ			Solution structure of mu-conotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; RAT VENTRICULAR MYOCYTES; COMMON AMINO-ACIDS; HIPPOCAMPAL-NEURONS; NA+ CHANNELS; CONUS-GEOGRAPHUS; NMR-SPECTROSCOPY; BINDING-SITE; PROTEIN; CURRENTS	mu-Conotoxins are peptide inhibitors of voltage-sensitive sodium channels (VSSCs). Synthetic forms of mu-conotoxins PIIIA and PIIIA42-22) were found to inhibit tetrodotoxin (TTX)-sensitive VSSC current but had little effect on TTX-resistant VSSC current in sensory ganglion neurons. In rat brain neurons, these peptides preferentially inhibited the persistent over the transient VSSC current. Radioligand binding assays revealed that PIIIA PIIIA-(2-22), and mu-conotoxin GIIIB discriminated among TTX-sensitive VSSCs in rat brain, that these and GIIIC discriminated among the corresponding VSSCs in human brain, and GIIIA had low affinity for neuronal VSSCs. H-1 NMR studies found that PIIIA adopts two conformations in solution due to cis/trans isomerization at hydroxyproline 8. The major trans conformation results in a three-dimensional structure that is significantly different from the previously identified conformation of mu-conotoxins GIIIA and GIIIB that selectively target TTX-sensitive muscle VSSCs. Comparison of the structures and activity of PIIIA to muscle-selective mu-conotoxins provides an insight into the structural requirements for inhibition of different TTX-sensitive sodium channels by mu-conotoxins.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	University of Queensland; University of Queensland; Australian National University; John Curtin School of Medical Research	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Watson, Michael/H-3909-2011; Lewis, Richard J/E-8674-2013; Adams, David John/K-3578-2019; Hill, Justine M/C-5781-2009; Craik, David/B-1695-2010; Adams, David/J-9125-2014; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Adams, David/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Alewood, Paul/0000-0001-7454-6522				Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; ALZHEIMER C, 1993, J NEUROSCI, V13, P660; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bevan MD, 1999, J NEUROSCI, V19, P7617, DOI 10.1523/JNEUROSCI.19-17-07617.1999; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Carter AJ, 1998, AMINO ACIDS, V14, P159, DOI 10.1007/BF01345257; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chahine M, 1995, RECEPTOR CHANNEL, V3, P161; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.physiol.58.1.349; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; Eglen RM, 1999, TRENDS PHARMACOL SCI, V20, P337, DOI 10.1016/S0165-6147(99)01372-3; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; FRENCH CR, 1985, NEUROSCI LETT, V56, P289, DOI 10.1016/0304-3940(85)90257-5; FRENCH CR, 1990, J GEN PHYSIOL, V95, P1139, DOI 10.1085/jgp.95.6.1139; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; GREISINGER C, 1987, J MAGN RESON, V75, P474; Hammarstrom AKM, 2000, J PHYSIOL-LONDON, V529, P107, DOI 10.1111/j.1469-7793.2000.00107.x; Hammarstrom AKM, 1999, J PHYSIOL-LONDON, V520, P451, DOI 10.1111/j.1469-7793.1999.t01-1-00451.x; Hammarstrom AKM, 1998, J PHYSIOL-LONDON, V510, P735, DOI 10.1111/j.1469-7793.1998.735bj.x; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jeglitsch G, 1998, J PHARMACOL EXP THER, V284, P516; Ju YK, 1996, J PHYSIOL-LONDON, V497, P337, DOI 10.1113/jphysiol.1996.sp021772; JU YK, 1992, BRIT J PHARMACOL, V107, P311, DOI 10.1111/j.1476-5381.1992.tb12743.x; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; MADDISON JE, 1987, GASTROENTEROLOGY, V93, P1062, DOI 10.1016/0016-5085(87)90570-1; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Nielsen KJ, 1999, J MOL BIOL, V289, P1405, DOI 10.1006/jmbi.1999.2817; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Ragsdale DS, 1998, BRAIN RES REV, V26, P16, DOI 10.1016/S0165-0173(97)00054-4; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rho JM, 1999, EPILEPSIA, V40, P1471, DOI 10.1111/j.1528-1157.1999.tb02029.x; Safo P, 2000, J NEUROSCI, V20, P76, DOI 10.1523/JNEUROSCI.20-01-00076.2000; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Shon KJ, 1998, J NEUROSCI, V18, P4473; Smith MR, 1998, J NEUROSCI, V18, P6093; Taylor C P, 1997, Adv Pharmacol, V39, P47, DOI 10.1016/S1054-3589(08)60069-1; TAYLOR CP, 1993, TRENDS NEUROSCI, V16, P455, DOI 10.1016/0166-2236(93)90077-Y; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; Whitaker WRJ, 2001, MOL BRAIN RES, V88, P37, DOI 10.1016/S0169-328X(00)00289-8; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009	60	73	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27247	27255		10.1074/jbc.M201611200	http://dx.doi.org/10.1074/jbc.M201611200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12006587	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000177055900071
J	Xu, Y; Keene, DR; Bujnicki, JM; Hook, M; Lukomski, S				Xu, Y; Keene, DR; Bujnicki, JM; Hook, M; Lukomski, S			Streptococcal Scl1 and Scl2 proteins form collagen-like triple helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; GROUP-A STREPTOCOCCUS; CIRCULAR-DICHROISM; ELECTRON-MICROSCOPY; SECONDARY STRUCTURE; SUBCOMPONENT C1Q; SURFACE PROTEIN; SEQUENCE; BINDING; COMPLEMENT	The collagens are a family of animal proteins containing segments of repeated Gly-Xaa-Yaa (GXY) motifs that form a characteristic triple-helical structure. Genes encoding proteins with repeated GXY motifs have also been reported in bacteria and phages; however, it is unclear whether these prokaryotic proteins can form a collagen-like triple-helical structure. Here we used two recently identified streptococcal proteins, Sell and Scl2, containing extended GXY sequence repeats as model proteins. First we observed that prior to heat denaturation recombinant Sel proteins migrated as homotrimers in gel electrophoresis with and without SDS. We next showed that the collagen-like domain of Scl is resistant to proteolysis by trypsin. We further showed that circular dichroism spectra of the Sel proteins contained features characteristic of collagen triple helices, including a positive maximum of ellipticity at 220 nm. Furthermore the triple helices of Scl1 and Scl2 showed a temperature-dependent unfolding with melting temperatures of 36.4 and 37.6degreesC, respectively, which resembles those seen for collagens. We finally demonstrated by electron microscopy that the Scl proteins are organized into "lollipop-like" structures, similar to those seen in human proteins with collagenous domains. This implies that the repeated GXY tripeptide motif is a structural indicator of collagen-like triple helices in proteins from such phylogenetically distant sources as bacteria and humans.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Shriners Hosp Children, Portland, OR 97201 USA; Int Inst Mol & Cellular Biol, Bioinformat Lab, PL-02109 Warsaw, Poland	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Lukomski, S (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 50666] Funding Source: Medline; NIAMS NIH HHS [AR 44415] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACTON S, 1993, J BIOL CHEM, V268, P3530; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; BAMFORD DH, 1990, NATURE, V344, P497, DOI 10.1038/344497b0; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BROWN FR, 1972, J MOL BIOL, V63, P101, DOI 10.1016/0022-2836(72)90524-4; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; CHARALAMBOUS BM, 1988, EMBO J, V7, P2903, DOI 10.1002/j.1460-2075.1988.tb03148.x; Cremer MA, 1998, J MOL MED, V76, P275, DOI 10.1007/s001090050217; DRICKAMER K, 1987, KIDNEY INT, V32, P167; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Gibofsky A, 1998, RHEUM DIS CLIN N AM, V24, P237, DOI 10.1016/S0889-857X(05)70007-7; GIOUD M, 1982, COLLAGEN REL RES, V2, P557; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAAS C, 1991, EUR J BIOCHEM, V197, P799; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; LU J, 1990, J IMMUNOL, V144, P2287; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; MARCIEL AM, 1997, MICROB PATHOG, V22, P202; Ohashi T, 1998, ARCH BIOCHEM BIOPHYS, V360, P223, DOI 10.1006/abbi.1998.0957; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Persikov AV, 2000, BIOPOLYMERS, V55, P436, DOI 10.1002/1097-0282(2000)55:6<436::AID-BIP1019>3.0.CO;2-D; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; REID KBM, 1993, BIOCHEM SOC T, V21, P464, DOI 10.1042/bst0210464; Ruggiero F, 2000, FEBS LETT, V469, P132, DOI 10.1016/S0014-5793(00)01259-X; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Smith MCM, 1998, SCIENCE, V279, P1834; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stevens DL., 2000, STREPTOCOCCAL INFECT; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	53	148	156	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27312	27318		10.1074/jbc.M201163200	http://dx.doi.org/10.1074/jbc.M201163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11976327	hybrid			2022-12-25	WOS:000177055900079
J	Ahn, S; Kim, J; Lucaveche, CL; Reedy, MC; Luttrell, LM; Lefkowitz, RJ; Daaka, Y				Ahn, S; Kim, J; Lucaveche, CL; Reedy, MC; Luttrell, LM; Lefkowitz, RJ; Daaka, Y			Src-dependent tyrosine phosphorylation regulates dynamin self-assembly and ligand-induced endocytosis of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-COUPLED RECEPTORS; KINASE C-SRC; GTPASE ACTIVITY; MEDIATED ENDOCYTOSIS; NERVE-TERMINALS; VESICLE FORMATION; EGF RECEPTOR; CELLULAR SRC; INTERNALIZATION	Endocytosis of ligand-activated receptors requires dynamin-mediated GTP hydrolysis, which is regulated by dynamin self-assembly. Here, we demonstrate that phosphorylation of dynamin I by c-Src induces its self-assembly and increases its GTPase activity. Electron microscopic analyses reveal that tyrosine-phosphorylated dynamin I spontaneously self-assembles into large stacks of rings. Tyrosine 597 was identified as being phosphorylated both in vitro and in cultured cells following epidermal growth factor receptor stimulation. The replacement of tyrosine 597 with phenylalanine impairs Src kinase-induced dynamin I self-assembly and GTPase activity in vitro. Expression of Y597F dynamin I in cells attenuates agonist-driven epidermal growth factor receptor internalization. Thus, c-Src-mediated tyrosine phosphorylation is required for the function of dynamin in ligand-induced signaling receptor internalization.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL16037] Funding Source: Medline; NIGMS NIH HHS [R01 GM66231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; AEBI U, 1987, J ELECTRON MICR TECH, V7, P29, DOI 10.1002/jemt.1060070104; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Barylko B, 2001, METHOD ENZYMOL, V329, P486; Broudy VC, 1999, BLOOD, V94, P1979; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; LAMEZE C, 1993, MOL BIOL CELL, V4, P715; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Liu JP, 1996, J NEUROCHEM, V66, P2074; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Niemann HH, 2001, EMBO J, V20, P5813, DOI 10.1093/emboj/20.21.5813; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Powell KA, 2000, J BIOL CHEM, V275, P11610, DOI 10.1074/jbc.275.16.11610; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SALAMERO J, 1995, EUR J IMMUNOL, V25, P2757, DOI 10.1002/eji.1830251007; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scaife R, 1998, BIOCHEMISTRY-US, V37, P17673, DOI 10.1021/bi981180g; Schmid RS, 2000, J NEUROSCI, V20, P4177; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922	59	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26642	26651		10.1074/jbc.M201499200	http://dx.doi.org/10.1074/jbc.M201499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011079	hybrid			2022-12-25	WOS:000176908700106
J	Babinski, KJ; Ribeiro, AA; Raetz, CRH				Babinski, KJ; Ribeiro, AA; Raetz, CRH			The Escherichia coli gene encoding the UDP-2,3-diacylglucosamine pyrophosphatase of lipid A biosynthesis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; CDP-DIGLYCERIDE HYDROLASE; UDP-N-ACETYLGLUCOSAMINE; GENOME SEQUENCE; A BIOSYNTHESIS; ANTIBACTERIAL AGENTS; 1ST STEP; IDENTIFICATION; MEMBRANE; ACYLTRANSFERASE	UDP-2,3-diacylglucosamine hydrolase is believed to catalyze the fourth step of lipid A biosynthesis in Escherichia coli. This reaction involves pyrophosphate bond hydrolysis of the precursor LTDP-2,3-diacylglucosamine to yield 2,3-diacylglucosamine 1-phosphate and UMP. To identify the gene encoding this hydrolase, E. coli lysates generated with individual A clones of the ordered Kohara library were assayed for overexpression of the enzyme. The sequence of A clone 157[6E7], promoting overproduction of hydrolase activity, was examined for genes encoding hypothetical proteins of unknown function. The amino acid sequence of one such open reading frame, ybbF, is 50.5% identical to a Haemophilus influenzae hypothetical protein and is also conserved in most other Gram-negative organisms, but is absent in Gram-positives. Cell extracts prepared from cells overexpressing ybbF behind the T7lac promoter have similar to540 times more hydrolase activity than cells with vector alone. YbbF was purified to -60% homogeneity, and its catalytic properties were examined. Enzymatic activity is maximal at pH 8 and is inhibited by 0.01% (or more) Triton X-100. The apparent K. for UDP-2,3-diacylglucosamine is 62 gm. YbbF requires a diacylated substrate and does not cleave CDP-diacylglycerol. P-31 NMR studies of the UMP product generated from UDP-2,3-diacylglucosamine in the presence of 40% H(2)(18)0 show that the enzyme attacks the alpha-phosphate group of the UDP moiety. Because ybbF encodes the specific UDP-2,3-diacylglucosamine hydrolase involved in lipid A biosynthesis, it is now designated lpxH.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, NMR Spect Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Babinski KJ, 2002, J BIOL CHEM, V277, P25947, DOI 10.1074/jbc.M204068200; Babinski KJ, 1998, FASEB J, V12, pA1288; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, V2, P1715; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H., 1999, ENDOTOXIN HLTH DIS; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BULAWA CE, 1983, J BIOL CHEM, V258, P4974; BULAWA CE, 1984, J BIOL CHEM, V259, P1257; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COHN M, 1982, ANNU REV BIOPHYS BIO, V11, P23, DOI 10.1146/annurev.bb.11.060182.000323; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; ICHO T, 1985, J BIOL CHEM, V260, P2092; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kaneko T, 1996, DNA Res, V3, P109; KAWAHARA K, 1979, BIOCHIM BIOPHYS ACTA, V572, P1; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1972, J BIOL CHEM, V247, P2245; RAETZ CRH, 1976, J BACTERIOL, V125, P855, DOI 10.1128/JB.125.3.855-863.1976; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER EG, 1976, BIOCHIM BIOPHYS ACTA, V441, P294, DOI 10.1016/0005-2760(76)90172-7; Small D.M., 1986, ALKANES PHOSPHOLIPID; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	65	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25937	25946		10.1074/jbc.M204067200	http://dx.doi.org/10.1074/jbc.M204067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000770	hybrid			2022-12-25	WOS:000176908700017
J	van Alebeek, GJWM; Christensen, TMIE; Schols, HA; Mikkelsen, JD; Voragen, AGJ				van Alebeek, GJWM; Christensen, TMIE; Schols, HA; Mikkelsen, JD; Voragen, AGJ			Mode of action of pectin lyase A of Aspergillus niger on differently C(6)-substituted oligogalacturonides.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-ESTERIFIED OLIGOGALACTURONIDES; FLIGHT MASS-SPECTROMETRY; ENZYMES; PURIFICATION	A thorough investigation of the mode of action of Aspergillus niger (4M-147) pectin lyase A (PIA) on differently C(6)-substituted oligogalacturonides is described. PLA appeared to be very specific for fully methyl-esterified oligogalacturonides: removal of the methyl-ester or changing the type of ester (ethyl esterification) or transamidation resulted in (almost) complete loss of conversion. The PLA activity increased with increasing length of the substrate up to a degree of polymerization (DP) of 8 indicating the presence of at least eight subsites on the enzyme. Product analysis demonstrated the formation of several Delta4,5 unsaturated products and their saturated counterparts. The Delta4,5 unsaturated trimer was the main product up to DP 8. For DP 9 and 10 Delta4,5 unsaturated tetramer was the major product. Based upon the bond cleavage frequencies, a provisional subsite map was calculated, which supports the presence of eight subsites. By limited alkaline de-esterification of fully methyl-esterified pentamer and hexamer two sets of partially methyl-esterified pentamers (x and y methyl groups) and hexamers (a and b methyl groups) were prepared. Matrix-assisted laser desorption/ionization time of flight mass spectroscopy (MALDI-TOF MS) analysis demonstrated that the methyl-ester distribution was fully random. Using these partially methyl-esterified oligogalacturonides as substrates for PLA a 10-fold decrease in reaction rate was recorded compared with the fully methyl-esterified counterparts. Analysis of the methyl-ester distribution of the products showed that PIA tolerates carboxyl groups in the substrate binding cleft. At either subsite +2, +4, or -1 to -4 a free carboxyl group could be tolerated, whereas methyl-esters were obligatory at subsite +1 and +3. So PLA is capable to cleave the bond between a methyl-esterified and a non-esterified galacturonic acid residue, where the newly formed Delta4,5 unsaturated non-reducing end residue always contains a methyl-ester.	Univ Wageningen & Res Ctr, Food Chem Lab, Dept Agrotechnol & Food Sci, NL-6703 HD Wageningen, Netherlands; Danisco Biotechnol, DK-1001 Copenhagen K, Denmark	Wageningen University & Research	Voragen, AGJ (corresponding author), Univ Wageningen & Res Ctr, Food Chem Lab, Dept Agrotechnol & Food Sci, Bomenweg 2, NL-6703 HD Wageningen, Netherlands.	fons.voragen@chem.fdsci.wag-ur.nl	Schols, Henk A/A-1742-2009					Benen JAE, 1999, EUR J BIOCHEM, V259, P577, DOI 10.1046/j.1432-1327.1999.00080.x; Benen JAE, 2000, BIOCHEMISTRY-US, V39, P15563, DOI 10.1021/bi000693w; Coutinho PM, 1999, ROY SOC CH, P3; Daas PJH, 1998, ANAL BIOCHEM, V257, P195, DOI 10.1006/abio.1997.2554; EDSTROM RD, 1964, J BIOL CHEM, V239, P2403; HERI W, 1961, HELV CHIM ACTA, V44, P1945, DOI 10.1002/hlca.19610440716; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; KESTER HCM, 1994, FEMS MICROBIOL LETT, V120, P63, DOI 10.1016/0378-1097(94)00176-6; Korner R, 1998, J MASS SPECTROM, V33, P836; Korner R, 1999, ANAL CHEM, V71, P1421, DOI 10.1021/ac981240o; KUSTERSVANSOMEREN M, 1992, MOL GEN GENET, V234, P113, DOI 10.1007/BF00272352; Limberg G, 2000, CARBOHYD RES, V327, P293, DOI 10.1016/S0008-6215(00)00067-7; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Schols HA, 1996, PROGR BIOTECHNOL, V14, P3, DOI 10.1016/S0921-0423(96)80242-5; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; van Alebeek GJWM, 2000, J MASS SPECTROM, V35, P831, DOI 10.1002/1096-9888(200007)35:7<831::AID-JMS7>3.0.CO;2-4; van Alebeek GJWM, 2000, CARBOHYD POLYM, V43, P39, DOI 10.1016/S0144-8617(99)00207-6; van Alebeek GJWM, 2001, CARBOHYD POLYM, V46, P311, DOI 10.1016/S0144-8617(00)00330-1; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; Voragen A. G. J., 1995, V67, P287; VORAGEN AGJ, 1972, THESIS WAGENINGEN	24	38	39	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25929	25936		10.1074/jbc.M202250200	http://dx.doi.org/10.1074/jbc.M202250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000753	hybrid			2022-12-25	WOS:000176908700016
J	Kong, XD; Li, ZQ; Gou, XJ; Zhu, SZ; Zhang, HY; Wang, XP; Zhang, J				Kong, XD; Li, ZQ; Gou, XJ; Zhu, SZ; Zhang, HY; Wang, XP; Zhang, J			A monomeric L-aspartase obtained by in vitro selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN EVOLUTION; ESCHERICHIA-COLI; MOLECULAR EVOLUTION; AMMONIA-LYASE; SPECIFICITY; STABILIZATION; INTERMEDIATE; MUTAGENESIS; ENHANCEMENT; EXPRESSION	By mimicking the partial spatial structure of the dimer of the L-aspartase subunit, the central ten-helix bundle, and an "active site" between the cleft of domain 1 (D1) and domain 3 (D3) from different subunits, we designed L-aspartase variants, in which D1D2 and D2D3 were ligated with a random hexapeptide loop. As expected, we obtained the variant with the highest activity (relative activity is 21.3% of the native enzyme, named as drAsp017) by in vitro selection. The molecular weight of this variant, obtained from size-exclusion column chromatography, is about 81 kDa, which indicates that it is indeed a monomer, whereas native L-aspartase is a tetramer. The activity-reversibility of drAsp017 (10(-7) m) was 80% after incubation for 30 min at 50degreesC, while native enzyme only retained about 17% under the same conditions. Reactivation of drAsp017 denatured in 4 m guanidine HCl was independent of protein concentration at up to 20 x 10(-8) m at 25 degreesC, whereas the protein concentration of native enzyme strongly affected its reactivation under the above conditions. The sensitivity of drAsp017 (10-7 M) to effective factors in the fumarateamination reaction compared with native enzyme was also determined. Half-saturating concentrations of the activator L-aspartate and Mg2+ for drAsp017 (0.8 and 0.5 mm, respectively) are much higher than that of the native enzyme (0.10 and 0.15 mm, respectively). The data show that a monomeric L-aspartase is obtained by in vitro selection. Thus, the conversion of oligomeric proteins into their functional monomers could have important applications.	Jilin Univ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China; Jilin Univ, Minist Educ, Changchun 130023, Peoples R China	Jilin University; Jilin University	Zhang, J (corresponding author), Jilin Univ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China.							Beck C, 2001, BIOCHEMISTRY-US, V40, P10956, DOI 10.1021/bi0155450; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; Chirumamilla RR, 2001, MOL CELL BIOCHEM, V224, P159, DOI 10.1023/A:1011904405002; Collinet B, 2001, EUR J BIOCHEM, V268, P5107, DOI 10.1046/j.0014-2956.2001.02439.x; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gershenson A, 2000, Genet Eng (N Y), V22, P55; Gonzalez-Blasco G, 2000, J BIOL CHEM, V275, P13708, DOI 10.1074/jbc.275.18.13708; IMAISHI H, 1989, PHYSIOL CHEM PHYS ME, V21, P221; Jayasekera MMK, 1997, BIOCHEMISTRY-US, V36, P9145, DOI 10.1021/bi970452x; KARSTEN WE, 1991, ARCH BIOCHEM BIOPHYS, V287, P60, DOI 10.1016/0003-9861(91)90388-Y; Kolkman JA, 2001, NAT BIOTECHNOL, V19, P423, DOI 10.1038/88084; Kong XD, 2001, BIOCHEM BIOPH RES CO, V289, P137, DOI 10.1006/bbrc.2001.5937; Kurtzman AL, 2001, CURR OPIN BIOTECH, V12, P361, DOI 10.1016/S0958-1669(00)00228-7; Lehmann M, 2001, CURR OPIN BIOTECH, V12, P371, DOI 10.1016/S0958-1669(00)00229-9; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; Meyer A, 2002, J BIOL CHEM, V277, P5575, DOI 10.1074/jbc.M110018200; Morawski B, 2001, BIOTECHNOL BIOENG, V76, P99, DOI 10.1002/bit.1149; MURASE S, 1993, J BIOCHEM, V114, P393, DOI 10.1093/oxfordjournals.jbchem.a124187; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; Saab-Rincon G, 2001, PROTEIN ENG, V14, P149, DOI 10.1093/protein/14.3.149; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; Shi WX, 1997, BIOCHEMISTRY-US, V36, P9136, DOI 10.1021/bi9704515; Suenaga H, 2001, J BACTERIOL, V183, P5441, DOI 10.1128/JB.183.18.5441-5444.2001; Sun LH, 2001, PROTEIN ENG, V14, P699, DOI 10.1093/protein/14.9.699; Viola RE, 2000, ADV ENZYMOL RAMB, V74, P295; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; Wang CW, 2001, J BIOL CHEM, V276, P41161, DOI 10.1074/jbc.M105786200; Wang LJ, 2000, BIOCHEM BIOPH RES CO, V276, P346, DOI 10.1006/bbrc.2000.3472; Wiseman A, 2001, TRENDS BIOTECHNOL, V19, P382, DOI 10.1016/S0167-7799(01)01736-X; ZHANG HY, 1993, BIOCHEM BIOPH RES CO, V192, P15, DOI 10.1006/bbrc.1993.1375	31	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24289	24293		10.1074/jbc.M200370200	http://dx.doi.org/10.1074/jbc.M200370200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983692	hybrid			2022-12-25	WOS:000176611800042
J	Palackal, NT; Lee, SH; Harvey, RG; Blair, IA; Penning, TM				Palackal, NT; Lee, SH; Harvey, RG; Blair, IA; Penning, TM			Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHO-QUINONES; DEHYDROGENASE ISOFORMS; DIOL EPOXIDES; FJORD-REGION; DNA-ADDUCTS; METABOLITES; OXIDATION; BENZO<A>PYRENE-7,8-DIONE; BENZO<G>CHRYSENE; REACTIVITY	Polycyclic aromatic hydrocarbons (PAH) are environmental pollutants and suspected human lung carcinogens. In patients with non-small cell lung carcinoma, differential display shows that aldo-keto reductase (AKR1C) transcripts are dramatically overexpressed. However, whether AKR1C isoforms contribute to the carcinogenic process and oxidize potent PAH trans-dihydrodiols (proximate carcinogens) to reactive and redox active o-quinones is unknown; nor is it known whether these reactions occur in human lungs. We now show that four homogeneous human recombinant aldo-keto reductases (AKR1C1-AKR1C4) are regioselective and oxidize only the relevant non-K region trans-dihydrodiols. However, these enzymes are not stereo-selective, since they oxidized 100%, of these racemic substrates. The highest utilization ratios (V-max/K-m) were observed for some of the most potent proximate carcinogens known (e.g. 7,12-dimethylbenz[a]anthracene-3,4-diol (DMBA-3,4-diol) and benzo[g]chrysene-11,12-diol). In vitro, DMBA-3,4-diol was oxidized by AKR1C4 to the highly reactive 7,12-dimethylbenz[a]anthracene-3,4-dione (DMBA-3,4-dione), which was trapped in situ as its mono- and bis-thioether conjugates, which arise from the sequential 1,6- and 1,4-Michael addition of thiol nucleophiles. Human multiple tissue expression array analysis showed that AKR1C isoform. transcripts were highly expressed in the human lung carcinoma cell line A549. Isoform-specific reverse transcriptase-PCR showed that AKR1C1, AKR1C2, and AKR1C3 transcripts were all expressed. Western blot analysis and functional assays confirmed high expression of AKR1C protein and enzyme activity in these lung cells. A549 cell lysates were found to convert DMBA-3,4-diol to the corresponding o-quinone. In trapping experiments, LC/MS analysis identified peaks in the cell lysates that corresponded to the synthetically prepared mono- and bis-thioether conjugates of DMBA-3,4-dione. This quinone is one of the most electrophilic and redox-active o-quinones produced by AKRs. Its unique ability to form bis-thioether conjugates parallels the formation of bis- and tris-glutathionyl conjugates of hydroquinone, which display end organ toxicity. The ability to measure DMBA-3,4-dione formation in A549 cells implicates the AKR pathway in the metabolic activation of PAH in human lung.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Pennsylvania; University of Pennsylvania; University of Chicago	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Blair, Ian A/B-3320-2010	Lee, Seon Hwa/0000-0003-1095-5516; Penning, Trevor/0000-0002-3937-1066	NATIONAL CANCER INSTITUTE [R01CA039504] Funding Source: NIH RePORTER; NCI NIH HHS [CA39504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN S, 1995, CARCINOGENESIS, V16, P2813, DOI 10.1093/carcin/16.11.2813; Amin S, 1996, POLYCYCL AROMAT COMP, V11, P365, DOI 10.1080/10406639608544688; Burczynski ME, 1998, BIOCHEMISTRY-US, V37, P6781, DOI 10.1021/bi972725u; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; Burczynski ME, 1999, CANCER RES, V59, P607; BUSHMAN DR, 1989, J ORG CHEM, V54, P3533, DOI 10.1021/jo00276a009; CAVALIERI EL, 1995, XENOBIOTICA, V25, P677, DOI 10.3109/00498259509061885; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; CIACCIO PJ, 1994, J BIOL CHEM, V269, P15558; CROISYDELCEY M, 1979, TETRAHEDRON LETT, P2849; FlowersGeary L, 1996, CHEM-BIOL INTERACT, V99, P55, DOI 10.1016/0009-2797(95)03660-1; FLOWERSGEARY L, 1992, BIOCH LIFE SCI ADV, V11, P49; FRENKEL K, 1995, FREE RADICAL BIO MED, V19, P373, DOI 10.1016/0891-5849(95)00046-Z; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; FU PP, 1979, J ORG CHEM, V44, P3778, DOI 10.1021/jo01336a008; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GLAZE ER, 2001, P AM ASSOC CANC RES, V42, P2540; HARVEY RG, 1975, J AM CHEM SOC, V97, P3468, DOI 10.1021/ja00845a032; HARVEY RG, 1977, TETRAHEDRON LETT, P2387; Hsu NY, 2001, CANCER RES, V61, P2727; Hukkanen J, 2000, AM J RESP CELL MOL, V22, P360, DOI 10.1165/ajrcmb.22.3.3845; ISLAM NB, 1990, J AM CHEM SOC, V112, P6363, DOI 10.1021/ja00173a026; KHANNA M, 1995, J BIOL CHEM, V270, P20162, DOI 10.1074/jbc.270.34.20162; Lang DS, 1998, CELL BIOL TOXICOL, V14, P23, DOI 10.1023/A:1007412404180; LEE H, 1986, J ORG CHEM, V51, P3502, DOI 10.1021/jo00368a021; LEE HM, 1979, J ORG CHEM, V44, P4948, DOI 10.1021/jo00394a043; MANAM S, 1992, MOL CARCINOGEN, V6, P68, DOI 10.1002/mc.2940060111; McCoull KD, 1999, CHEM RES TOXICOL, V12, P237, DOI 10.1021/tx980182z; Monks TJ, 1997, CHEM RES TOXICOL, V10, P1296, DOI 10.1021/tx9700937; MURTY VS, 1992, CHEM-BIOL INTERACT, V84, P169, DOI 10.1016/0009-2797(92)90077-X; Nair J, 2000, CHEM RES TOXICOL, V13, P703, DOI 10.1021/tx000045d; PATAKI J, 1983, CARCINOGENESIS, V4, P399, DOI 10.1093/carcin/4.4.399; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; Penning TM, 1996, CHEM RES TOXICOL, V9, P84, DOI 10.1021/tx950055s; PLATT KL, 1983, J ORG CHEM, V48, P265, DOI 10.1021/jo00150a027; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SHOU M, 1993, CARCINOGENESIS, V14, P475, DOI 10.1093/carcin/14.3.475; SMITHGALL TE, 1988, BIOCHEM J, V254, P715, DOI 10.1042/bj2540715; SMITHGALL TE, 1988, CANCER RES, V48, P1227; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SMITHGALL TE, 1988, J BIOL CHEM, V263, P1814; SUKUMARAN KB, 1979, J AM CHEM SOC, V101, P1353, DOI 10.1021/ja00499a086; SUKUMARAN KB, 1980, J ORG CHEM, V45, P4407, DOI 10.1021/jo01310a029; Todorovic R, 1997, CHEM RES TOXICOL, V10, P941, DOI 10.1021/tx970003y; YU D, 2002, IN PRESS CHEM RES TO, V15; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717	46	179	191	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24799	24808		10.1074/jbc.M112424200	http://dx.doi.org/10.1074/jbc.M112424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978787	hybrid			2022-12-25	WOS:000176611800107
J	Wommer, S; Rival, S; Heinz, U; Galleni, M; Frere, JM; Franceschini, N; Amicosante, G; Rasmussen, B; Bauer, R; Adolph, HW				Wommer, S; Rival, S; Heinz, U; Galleni, M; Frere, JM; Franceschini, N; Amicosante, G; Rasmussen, B; Bauer, R; Adolph, HW			Substrate-activated zinc binding of metallo-beta-lactamases - Physiological importance of the mononuclear enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-HYDROPHILA AE036; STENOTROPHOMONAS-MALTOPHILIA; MECHANISM; THIONEIN; L1	We have investigated the influence of substrate binding on the zinc ion affinity of representatives from the three metallo-g-lactamase subclasses, B1 (BcII from Bacillus cereus and BlaB from Chryseobacterium meningosepticum), B2 (CphA from Aeromonas hydrophila), and B3 (L1 from Stenotrophomonas maltophilia). By competition experiments with metal-free apoenzymes and chromophoric zinc chelators or EDTA, we determined the dissociation constants in the absence and presence of substrates. For the formation of the monozine enzymes we determined constants of 1.8, 5.1, 0.007, and 2.6 nm in the absence and 13.6, 1.8, 1.2, and 5.7 pm in the presence of substrates for Bell, BlaB, CphA, and L1, respectively. A second zinc ion binds in the absence (presence) of substrates with considerably higher dissociation constants, namely 1.8 (0.8), 0.007 (0.025), 50 (1.9), and 0.006 (0.12) mum for BcII, BlaB, CphA, and L1, respectively. We have concluded that the apo form might be the prevailing state of most of the metallo-beta-lactamases under physiological conditions in the absence of substrates. Substrate availability induces a spontaneous self-activation due to a drastic decrease of the dissociation constants, resulting in the formation of active mononuclear enzymes already at picomolar free zinc ion concentrations. In the presence of substrates, the binuclear state of the enzymes only exists at unphysiologic high zinc concentrations and might be of no biological relevance. From the competition experiments with EDTA it is further concluded that the reactivation rate does not depend on the pool of free zinc ions but proceeds via the EDTA-Zn(II)-enzyme ternary complexes.	Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany; Univ Saarland, Dept Biochem, D-66041 Saarbrucken, Germany; Univ Liege, Ctr Ingn Prot, B-4000 Liege, Belgium; Univ Aquila, Dipartimento Sci & Technol Biomed & Biometria, I-67100 Laquila, Italy; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Royal Vet & Agr Univ, Dept Math & Phys, DK-1871 Frederiksberg, Denmark; Max Planck Inst Informat, D-66123 Saarbrucken, Germany	Saarland University; Saarland University; University of Liege; University of L'Aquila; University of Copenhagen; University of Copenhagen; Max Planck Society	Adolph, HW (corresponding author), Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany.		Adolph, Hans W/A-2104-2008	FRANCESCHINI, Nicola/0000-0003-2237-0355; amicosante, gianfranco/0000-0002-6813-2101				Boschi L, 2000, ANTIMICROB AGENTS CH, V44, P1538, DOI 10.1128/AAC.44.6.1538-1543.2000; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; BRUNETTI AP, 1969, J AM CHEM SOC, V91, P4680, DOI 10.1021/ja01045a014; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DYE JL, 1960, J AM CHEM SOC, V82, P314, DOI 10.1021/ja01487a016; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Rhazi N, 1999, BIOCHEM J, V341, P409, DOI 10.1042/0264-6021:3410409; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; SKOCHDOPOLE R, 1959, J INORG NUCL CHEM, V11, P222, DOI 10.1016/0022-1902(59)80248-7; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; VALLADARES MH, 1996, MICROB DRUG RESIST, V2, P253; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Yang Y, 2001, P NATL ACAD SCI USA, V98, P5556, DOI 10.1073/pnas.101123298	25	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24142	24147		10.1074/jbc.M202467200	http://dx.doi.org/10.1074/jbc.M202467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967267	hybrid			2022-12-25	WOS:000176611800023
J	Yonkovich, J; McKenndry, R; Shi, XL; Zhu, ZW				Yonkovich, J; McKenndry, R; Shi, XL; Zhu, ZW			Copper ion-sensing transcription factor Mac1p post-translationally controls the degradation of its target gene product Ctr1p.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; TRANSPORT; PROTEIN; BINDING; PHOSPHORYLATION; COMPLEMENTATION; IDENTIFICATION; REPRESSION; ACTIVATION	Copper ion uptake must be regulated to avoid both deficiency and excess because its essential yet toxic biological nature depends on the concentration. Yeast copper uptake is controlled at both the transcriptional and post-translational levels. The transcription of CTR1 and CTR3, encoding high affinity copper ion transporters, is regulated by the copper ion-sensing transcription factor Mac1p through the cis-acting copper ion-responsive elements in CTR1 and CTR3 promoters. Ctr1p is known to undergo degradation in cells exposed to high copper levels. We report that Mac1p is also required for copper-dependent Ctr1p degradation. Both mutations within a conserved copper ion binding motif, the "Cufist" in the Mac1p DNA-binding domain, and within a metal ion binding motif, REP-III located in the cytosolic domain of Ctr1p, cause defects in Ctr1p turnover. Furthermore, we show that the Mac1p limits intracellular copper accumulation likely by controlling Ctr1p degradation. The findings have uncovered an unprecedented mechanism by which a transcription factor not only regulates its target gene transcription but also controls the degradation of its target gene product.	Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Zhu, ZW (corresponding author), Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA.	zhu@biology.ucsc.edu						BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Heredia J, 2001, J BIOL CHEM, V276, P8793, DOI 10.1074/jbc.M008179200; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; LINDER MC, 1991, BIOCHEMISTRY COPPER; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; ZHU Z, 1996, STRESS INDUCIBLE CEL, P307	28	25	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					23981	23984		10.1074/jbc.C200203200	http://dx.doi.org/10.1074/jbc.C200203200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12011036	hybrid			2022-12-25	WOS:000176611800003
J	Gigoux, V; L'Hoste, S; Raynaud, F; Camonis, J; Garbay, C				Gigoux, V; L'Hoste, S; Raynaud, F; Camonis, J; Garbay, C			Identification of Aurora kinases as RasGAP Src homology 3 domain-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SH3 DOMAIN; GAP; PHOSPHORYLATION; APOPTOSIS; GENE; INHIBITION; INDUCTION; SURVIVIN	The GTPase-activating protein RasGAP functions as both a negative regulator and an effector of Ras proteins. In tumor cells, RasGAP is no longer able to deactivate oncogenic Ras proteins, and its effector function becomes predominant. As RasGAP itself has no obvious enzymatic function that may explain this effector function, we looked for downstream RasGAP effectors that could fulfill this role. We looked for the existence of RasGAP Src homology 3 (SH3) domain partners as this domain is involved in the regulation of cell proliferation and has an anti-apoptotic effect. We report here the identification of a new RasGAP SH3 domain-binding protein, named Aurora. This Drosophila melanogaster Ser/Thr kinase has three human orthologs called Aurora/Ipl1-related kinase or HsAIRK-1, -2, and -3. Coimmunoprecipitation experiments in COS cells confirmed that HsAIRK-1 and HsAIRK-2 both interact with RasGAP. RasGAP pull-down experiments showed that it interacts with HsAIRK-1 in G(2)/M HeLa cells. We also demonstrated that RasGAP binds to the kinase domain of Aurora and that this interaction inhibits the kinase activity of HsAIRK-1 and HsAIRK-2. Finally we showed that RasGAP forms a ternary complex with HsAIRK and survivin. This complex may be involved in the regulation of the balance between cell division and apoptosis.	Inst Curie, INSERM U528, Lab Transduct Signal & Oncogenese, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Garbay, C (corresponding author), CNRS, Lab Pharmacochim Mol & Struct, FRE2463, INSERM U266,UFR Sci Pharmaceut & Biol, 4 Ave Observ, F-75270 Paris 06, France.	garbay@pharmacie.univ-paris5.fr	Gigoux, Véronique/AAE-6090-2020	Gigoux, Véronique/0000-0003-1408-5335				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; Giet R, 1999, J CELL SCI, V112, P3591; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; YANG YS, 1994, EMBO J, V13, P1270, DOI 10.1002/j.1460-2075.1994.tb06379.x	30	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23742	23746		10.1074/jbc.C200121200	http://dx.doi.org/10.1074/jbc.C200121200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976319	hybrid			2022-12-25	WOS:000176475700084
J	van Dooren, GG; Su, V; D'Ombrain, C; McFadden, GI				van Dooren, GG; Su, V; D'Ombrain, C; McFadden, GI			Processing of an apicoplast leader sequence in Plasmodium falciparum and the identification of a putative leader cleavage enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; SMALL-SUBUNIT; SUBCELLULAR-LOCALIZATION; MALARIAL PARASITE; TRANSIT PEPTIDE; SITE SELECTION; COMMON ORIGIN; BLOOD STAGES; ACTIVE-SITE; PROTEIN	The plastid (apicoplast) of the malaria-causing parasite Plasmodium falciparum was derived via a secondary endosymbiotic process. As in other secondary endosymbionts, numerous genes for apicoplast proteins are located in the nucleus, and the encoded proteins are targeted to the organelle courtesy of a bipartite N-terminal extension. The first part of this leader sequence is a signal peptide that targets proteins to the secretory pathway. The second, so-called transit peptide region is required to direct proteins from the secretory pathway across the multiple membranes surrounding the apicoplast. In this paper we perform a pulse-chase experiment and N-terminal sequencing to show that the transit peptide of an apicoplast-targeted protein is cleaved, presumably upon import of the protein into the apicoplast. We identify a gene whose product likely performs this cleavage reaction, namely a stromal-processing peptidase (SPP) homologue. In plants SPP cleaves the transit peptides of plastid-targeted proteins. The P. falciparum SPP homologue contains a bipartite N-terminal apicoplast-targeting leader. Interestingly, it shares this leader sequence with a A-aminolevulinic acid dehydratase homologue via an alternative splicing event.	Univ Melbourne, Plant Cell Biol Res Ctr, Sch Bot, Melbourne, Vic 3010, Australia	University of Melbourne	McFadden, GI (corresponding author), Univ Melbourne, Plant Cell Biol Res Ctr, Sch Bot, Melbourne, Vic 3010, Australia.	gim@unimelb.edu.au	McFadden, Geoffrey McFadden I/F-7667-2014; van Dooren, Giel G/A-8896-2012	McFadden, Geoffrey McFadden I/0000-0002-5351-1627; van Dooren, Giel G/0000-0003-2455-9821				BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; Bonday ZQ, 2000, NAT MED, V6, P898, DOI 10.1038/78659; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Cheresh P, 2002, J BIOL CHEM, V277, P16265, DOI 10.1074/jbc.M109331200; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Deane JA, 2000, PROTIST, V151, P239, DOI 10.1078/1434-4610-00022; DeRocher A, 2000, J CELL SCI, V113, P3969; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; Figueroa P, 2000, BIOCHEM BIOPH RES CO, V271, P380, DOI 10.1006/bbrc.2000.2644; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Glaser E, 1996, BBA-BIOENERGETICS, V1275, P33, DOI 10.1016/0005-2728(96)00046-1; Henze K, 2001, TRENDS GENET, V17, P383, DOI 10.1016/S0168-9525(01)02312-5; Hopkins J, 1999, PROTIST, V150, P283, DOI 10.1016/S1434-4610(99)70030-1; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Koussevitzky S, 1998, J BIOL CHEM, V273, P27064, DOI 10.1074/jbc.273.42.27064; Kubo N, 1999, P NATL ACAD SCI USA, V96, P9207, DOI 10.1073/pnas.96.16.9207; Kumar AM, 1996, TRENDS PLANT SCI, V1, P371, DOI 10.1016/S1360-1385(96)80311-6; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang M, 1998, J BIOL CHEM, V273, P30973, DOI 10.1074/jbc.273.47.30973; Liaud MF, 1997, J MOL EVOL, V44, pS28, DOI 10.1007/PL00000050; Lingelbach K, 1998, J CELL SCI, V111, P1467; McFadden GI, 1999, J EUKARYOT MICROBIOL, V46, P339, DOI 10.1111/j.1550-7408.1999.tb04613.x; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205; Reumann S, 1999, TRENDS PLANT SCI, V4, P302, DOI 10.1016/S1360-1385(99)01449-1; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; ROJAS MO, 1995, J BIOCHEM, V118, P1118, DOI 10.1093/oxfordjournals.jbchem.a124996; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; Sato S, 2000, INT J PARASITOL, V30, P427, DOI 10.1016/S0020-7519(99)00185-X; Sato S, 2002, CURR GENET, V40, P391, DOI 10.1007/s00294-002-0273-3; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SCHMIDT RJ, 1985, MOL CELL BIOL, V5, P1093, DOI 10.1128/MCB.5.5.1093; SMITH AG, 1988, BIOCHEM J, V249, P423, DOI 10.1042/bj2490423; SMITH SM, 1979, NATURE, V278, P662, DOI 10.1038/278662a0; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Srivastava P, 1998, EXP PARASITOL, V88, P60, DOI 10.1006/expr.1998.4193; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Sulli C, 1996, PLANT CELL, V8, P43; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; van Dooren GG, 2001, BBA-MOL CELL RES, V1541, P34, DOI 10.1016/S0167-4889(01)00154-9; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WHO, 1999, WORLD HLTH REP 1999, P49; Wilson CM, 1996, MOL BIOCHEM PARASIT, V79, P135, DOI 10.1016/0166-6851(96)02690-4; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; YAMAUCHI K, 1980, J BIOL CHEM, V255, P1746; Yung S, 2001, MOL BIOCHEM PARASIT, V118, P11, DOI 10.1016/S0166-6851(01)00359-0; Zhang ZD, 2000, J MOL EVOL, V51, P26, DOI 10.1007/s002390010064; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zuegge J, 2001, GENE, V280, P19, DOI 10.1016/S0378-1119(01)00776-4	64	135	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23612	23619		10.1074/jbc.M201748200	http://dx.doi.org/10.1074/jbc.M201748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976331	hybrid			2022-12-25	WOS:000176475700067
J	Ameye, L; Aria, D; Jepsen, K; Oldberg, A; Xu, TS; Young, MF				Ameye, L; Aria, D; Jepsen, K; Oldberg, A; Xu, TS; Young, MF			Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis	FASEB JOURNAL			English	Article						leucine-rich; proteoglycans; cartilage; bone; matrix	DEGENERATIVE JOINT DISEASE; PROTEOGLYCANS BIGLYCAN; TARGETED DISRUPTION; SKIN FRAGILITY; KNEE-JOINT; FIBROMODULIN; DECORIN; LUMICAN; GENE; EXPRESSION	Small leucine-rich proteoglycans (SLRPs) regulate extracellular matrix organization, a process essential in development, tissue repair, and metastasis. In vivo interactions of biglycan and fibromodulin, two SLRPs highly expressed in tendons and bones, were investigated by generating biglycan/fibromodulin double-deficient mice. Here we show that collagen fibrils in tendons from mice deficient in biglycan and/or fibromodulin are structurally and mechanically altered resulting in unstable joints. As a result, the mice develop successively and progressively 1) gait impairment, 2) ectopic tendon ossification, and 3) severe premature osteoarthritis. Forced use of the joints increases ectopic ossification and osteoarthritis in the double-deficient mice, further indicating that structurally weak tendons cause the phenotype. The study shows that mutations in SLRPs may predispose to osteoarthritis and offers a valuable and unique animal model for spontaneous osteoarthritis characterized by early onset and a rapid progression of the disease.	NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA; CUNY Mt Sinai Sch Med, Dept Orthopaed, New York, NY 10029 USA; Lund Univ, Dept Cell & Mol Biol, Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Lund University	Ameye, L (corresponding author), Nestle Res Ctr, Dept Nutr, G35 Vers Chez Blanc,POB 44, CH-1000 Lausanne 26, Switzerland.	Laurent.Ameye@rdls.nestle.com		Young, Marian F/0000-0003-0929-8854	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson-MacKenzie JM, 1999, BIOCHEM BIOPH RES CO, V258, P763, DOI 10.1006/bbrc.1999.0713; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331; Cipolla M, 1995, Knee Surg Sports Traumatol Arthrosc, V3, P21, DOI 10.1007/BF01553521; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; HELMINEN HJ, 1993, J CLIN INVEST, V92, P582, DOI 10.1172/JCI116625; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Lapvetelainen T, 2001, OSTEOARTHR CARTILAGE, V9, P152, DOI 10.1053/joca.2000.0370; Malaviya P, 2000, J ORTHOP RES, V18, P116, DOI 10.1002/jor.1100180117; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Nuki G, 1999, Z RHEUMATOL, V58, P142, DOI 10.1007/s003930050164; PRITCHETT JW, 1984, J BONE JOINT SURG AM, V66A, P1379, DOI 10.2106/00004623-198466090-00009; REINHOLT FP, 1982, J ULTRA MOL STRUCT R, V80, P270, DOI 10.1016/S0022-5320(82)80040-3; Saamanen AMK, 2001, BIOCHEM J, V355, P577; Saamanen AMK, 2000, OSTEOARTHR CARTILAGE, V8, P248, DOI 10.1053/joca.2000.0298; Sarin VK, 1999, ANAT RECORD, V257, P174, DOI 10.1002/(SICI)1097-0185(19991015)257:5<174::AID-AR6>3.0.CO;2-O; Schwartz S T, 1999, Med Health R I, V82, P321; SEEGMILLER RE, 2001, OSTEOARTHR CARTILAGE, V9, pS15; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; Vikkula M, 1996, ANN MED, V28, P301, DOI 10.3109/07853899608999084; Wada M, 1996, BRIT J RHEUMATOL, V35, P560; WALTON M, 1977, J PATHOL, V123, P109, DOI 10.1002/path.1711230207; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	30	252	263	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0673	10.1096/fj.01-0848com	http://dx.doi.org/10.1096/fj.01-0848com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978731				2022-12-25	WOS:000175973900021
J	Tsuruta, D; Gonzales, M; Hopkinson, SB; Otey, C; Khuon, S; Goldman, RD; Jones, JCR				Tsuruta, D; Gonzales, M; Hopkinson, SB; Otey, C; Khuon, S; Goldman, RD; Jones, JCR			Microfilament-dependent movement of the beta 3 integrin subunit within focal contacts of endothelial cells	FASEB JOURNAL			English	Article						matrix adhesion; matrix receptors; FRAP; actin cytoskeleton; actinin	INTERMEDIATE FILAMENT NETWORKS; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; LATERAL MOBILITY; ALPHA-ACTININ; ADHESION; FIBROBLASTS; DYNAMICS; GROWTH; ALPHA(V)BETA(3)	To gain insight into the dynamic properties of focal contacts, we induced expression of green fluorescent protein-tagged beta3 integrin (GFP-beta3) and actinin-1 (GFP-actinin-1) in endothelial cells. Both tagged proteins localize with alphavbeta3 integrin in focal contacts distributed towards the periphery of transfected cells. Labeled focal contacts migrate at about 0.1 mum/min in stationary live endothelial cells. We compared beta3 integrin and actinin-1 dynamics in focal contacts by using fluorescence recovery after photobleaching. Recovery of signal in bleached focal contacts that have incorporated actinin-1 is rapid and occurs within less than 4 min. This recovery is energy-dependent. In contrast, recovery of bleached focal contacts that contain GFP-beta3 integrin takes longer than 30 min. Yet, when a narrow stripe of fluorescence is bleached across a beta3 integrin-labeled focal contact, recovery is complete within 16 min. The latter recovery is energy-dependent and is blocked not only by actin-filament disrupting drugs but also by a myosin light chain kinase inhibitor. Thus, integrins are not immobile when incorporated into focal contacts, as some have suggested. We propose that integrins are mobile within the confines of focal contacts and that this mobility is supported by an actin-associated molecular motor.	Northwestern Univ, Sch Med, Dept Mol & Cell Biol, Chicago, IL 60611 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill	Jones, JCR (corresponding author), Northwestern Univ, Sch Med, Dept Mol & Cell Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	j-jones3@nwu.edu	Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922				Broday DM, 2000, B MATH BIOL, V62, P891, DOI 10.1006/bulm.2000.0183; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dogic D, 1999, CURR TOPICS PATHOL, V93, P75; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; GEIGER B, 1982, J CELL BIOL, V93, P495, DOI 10.1083/jcb.93.2.495; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOLDMAN RD, 1973, COLD SPRING HARB SYM, V37, P523, DOI 10.1101/SQB.1973.037.01.063; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KREIS TE, 1982, CELL, V29, P835, DOI 10.1016/0092-8674(82)90445-7; PLANCON S, 2001, BIOCHEM J, V15, P529; Ren XD, 2000, J CELL SCI, V113, P3673; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; SCHLESSINGER J, 1983, CELL MOTIL CYTOSKEL, V3, P399, DOI 10.1002/cm.970030508; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schootemeijer A, 1997, THROMB HAEMOSTASIS, V77, P143; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schweitzer KM, 1997, LAB INVEST, V76, P25; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Simon K. O., 1994, INTEGRINS MOL BIOL R, P49; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STICKEL SK, 1987, J CELL BIOL, V104, P1521, DOI 10.1083/jcb.104.6.1521; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655	41	61	63	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					866	+		10.1096/fj.01-0878fje	http://dx.doi.org/10.1096/fj.01-0878fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967230				2022-12-25	WOS:000175425900014
J	Zhao, M; Pu, J; Forrester, JV; McCaig, CD				Zhao, M; Pu, J; Forrester, JV; McCaig, CD			Membrane lipids, EGF receptors, and intracellular signals colocalize and are polarized in epithelial cells moving directionally in a physiological electric field	FASEB JOURNAL			English	Article						directional cell migration; electric fields; EGF receptor; MAP kinase ERK1/2; wound healing; eletrotaxis/galvanotaxis	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; DIRECTED MIGRATION; CHEMOATTRACTANT RECEPTOR; NEUTROPHIL CHEMOTAXIS; LEADING-EDGE; MOTILITY; KERATINOCYTES; PATHWAY; ORIENTATION	Directed cell migration is essential for tissue formation, inflammation, and wound healing. Chemotaxis plays a major role in these situations and is underpinned by asymmetric intracellular signaling. Endogenous electric fields (EFs) are common where cell movement occurs, such as in wound healing, and cells respond to electric field gradients by reorienting and migrating directionally (galvanotaxis/electrotaxis). We show that a physiological EF redistributed both EGF (epidermal growth factor) receptors and detergent-insoluble membrane lipids asymmetrically, leading to cathodal polarization and enhanced activation of the MAP kinase, ERK1/2. This induced leading-edge actin polymerization in directionally migrating mammalian epithelial cells. Inhibiting the EGF receptor-MAP kinase signaling pathway significantly decreased leading edge actin asymmetry and directional migration. We propose a model in which EF-polarized membrane lipid domains and EGF receptors cause asymmetric signaling through MAP kinase, which drives directional cell migration. A comparison is made with the mechanisms underpinning chemotaxis.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Inst Med Sci, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk; c.mccaig@abdn.ac.uk						AHMED T, 1992, J PHYSIOL-LONDON, V446, pP42; BORGENS RB, 1995, DEV DYNAM, V203, P456, DOI 10.1002/aja.1002030408; BORGENS RB, 1983, J EXP ZOOL, V228, P491, DOI 10.1002/jez.1402280309; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; Fang KS, 1999, J CELL SCI, V112, P1967; Fang KS, 1998, J INVEST DERMATOL, V111, P751, DOI 10.1046/j.1523-1747.1998.00366.x; Gipson I K, 1995, Curr Opin Ophthalmol, V6, P3; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Hirotsu T, 2000, NATURE, V404, P289, DOI 10.1038/35005101; HOTARY KB, 1992, DEVELOPMENT, V114, P985; HOTARY KB, 1994, DEV BIOL, V166, P789, DOI 10.1006/dbio.1994.1357; Iglesia DDS, 1996, J EXP ZOOL, V274, P56, DOI 10.1002/(SICI)1097-010X(19960101)274:1<56::AID-JEZ6>3.0.CO;2-E; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MESSERLI M, 1997, MOL BIOL CELL S, V8, P129; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NUCCITELLI R, 1993, CELL MOTIL CYTOSKEL, V24, P54, DOI 10.1002/cm.970240107; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SHI RY, 1995, DEV DYNAM, V202, P101, DOI 10.1002/aja.1002020202; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; Wang YW, 1998, J CELL SCI, V111, P373; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1997, CURR EYE RES, V16, P973, DOI 10.1076/ceyr.16.10.973.9014; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942; Zieske JD, 2000, INVEST OPHTH VIS SCI, V41, P1346	47	143	153	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					857	+		10.1096/fj.01-0811fje	http://dx.doi.org/10.1096/fj.01-0811fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967227				2022-12-25	WOS:000175425900021
J	Huang, QH; Lerner-Marmarosh, N; Che, WY; Ohta, S; Osawa, M; Yoshizumi, M; Glassman, M; Yan, C; Berk, BC; Abe, J				Huang, QH; Lerner-Marmarosh, N; Che, WY; Ohta, S; Osawa, M; Yoshizumi, M; Glassman, M; Yan, C; Berk, BC; Abe, J			The novel role of the C-terminal region of SHP-2 - Involvement of Gab1 and Shp-2 phosphatase activity in Elk-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; JNK ACTIVATION; SMOOTH-MUSCLE; SH2 DOMAINS; CELLS; STIMULATION; RECEPTORS; BINDING	SHP-2, a nontransmembrane-type protein-tyrosine phosphatase that contains two Src homology 2 (SH2) domains, is thought to participate in growth factor signal transduction pathways via SH2 domain interactions. To determine the role of each region of SHP-2 in platelet-derived growth factor signaling assayed by Elk-1 activation, we generated six deletion mutants of SHP-2. The large SH2 domain deletion SHP-2 mutant composed of amino acids 198-593 (SHP-2-(198-593)), but not the smaller SHP-2-(399-593), showed significantly higher SHP-2 phosphatase activity in vitro. In contrast, SHP-2(198-593) mutant inhibited wild type SHP-2 phosphatase activity, whereas SHP-2-(399-593) mutant increased activity. To understand these functional changes, we focused on the docking protein Gab1 that assembles signaling complexes. Pull-down experiments with Gab1 suggested that the C-terminal region of SHP-2 as well as the SH2 domains (N-terminal region) associated with Gab1, but the SHP-2-(198-593) mutant did not associate with Gab1. SHP-2-(1-202) or SHP-2-(198-593) inhibited platelet-derived growth factorinduced Elk-1 activation, but SHP-2-(399-593) increased Elk-1 activation. Co-expression of SHP-2-(1-202) with SHP-2-(399-593) inhibited SHP-2-(399-593)/Gab1 interaction, and the SHP-2-(399593) mutant induced SHP-2 phosphatase and Elk-1 activation, supporting the autoinhibitory effect of SH2 domains on the C-terminal region of SHP-2. These data suggest that both SHP-2/Gab1 interaction in the C-terminal region of SHP-2 and increased SHP-2 phosphatase activity are important for Elk-1 activation. Furthermore, we identified a novel sequence for SHP-2/Gab1 interactions in the C-terminal region of SHP-2.	Univ Rochester, Sch Med & Dent, Cardiol Unit, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Yokohama City Univ, Dept Oral Surg, Yokohama, Kanagawa 2360004, Japan; Univ Tokushima, Dept Pharmacol, Tokushima 7708503, Japan	University of Rochester; Yokohama City University; Tokushima University	Abe, J (corresponding author), Univ Rochester, Sch Med & Dent, Cardiol Unit, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49192, HL44721, HL61319] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Xu FP, 2001, J BIOL CHEM, V276, P29479, DOI 10.1074/jbc.M104428200; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	24	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29330	29341		10.1074/jbc.M112450200	http://dx.doi.org/10.1074/jbc.M112450200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12011040	hybrid			2022-12-25	WOS:000177342600123
J	Polderman-Tijmes, JJ; Jekel, PA; Jeronimus-Stratingh, CM; Bruins, AP; van der Laan, JM; Sonke, T; Janssen, DB				Polderman-Tijmes, JJ; Jekel, PA; Jeronimus-Stratingh, CM; Bruins, AP; van der Laan, JM; Sonke, T; Janssen, DB			Identification of the catalytic residues of alpha-amino acid ester hydrolase from Acetobacter turbidans by labeling and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACYLASE; AMINOPEPTIDASE; EXPRESSION; CLONING; GENE	The alpha-amino acid ester hydrolase from Acetobacter turbidans ATCC 9325 is capable of hydrolyzing and synthesizing the side chain peptide bond in beta-lactam antibiotics. Data base searches revealed that the enzyme contains an active site serine consensus sequence Gly-X-Ser-Tyr-X-Gly that is also found in X-prolyl dipeptidyl aminopeptidase. The serine hydrolase inhibitor p-nitro-phenyl-p'-guanidino-benzoate appeared to be an active site titrant and was used to label the alpha-amino acid ester hydrolase. Electrospray mass spectrometry and tandem mass spectrometry analysis of peptides from a CNBr digest of the labeled protein showed that Ser(205), situated in the consensus sequence, becomes covalently modified by reaction with the inhibitor. Extended sequence analysis showed alignment of this Ser(205) with the catalytic nucleophile of some alpha/beta-hydrolase fold enzymes, which posses a catalytic triad composed of a nucleophile, an acid, and a base. Based on the alignments, 10 amino acids were selected for site-directed mutagenesis (Arg(85), Asp(86), Tyr(143), Ser(156), Ser(205), Tyr(206), Asp(338), His(370), Asp(509), and His(610)). Mutation of Ser(205), Asp(338), or His(370) to an alanine almost fully inactivated the enzyme, whereas mutation of the other residues did not seriously affect the enzyme activity. Circular dichroism measurements showed that the inactivation was not caused by drastic changes in the tertiary structure. Therefore, we conclude that the catalytic domain of the alpha-amino acid ester hydrolase has an alpha/beta-hydrolase fold structure with a catalytic triad of Ser(205), Asp(338), and His(370). This distinguishes the a-amino acid ester hydrolase from the Ntn-hydrolase family of beta-lactam antibiotic acylases.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Mass Spectrometry Core Facil, NL-9716 AV Groningen, Netherlands; DSM Food Specialties, NL-2600 MA Delft, Netherlands; DSM Res & Patents, NL-6160 MD Geleen, Netherlands	University of Groningen; University of Groningen; DSM NV; DSM NV	Janssen, DB (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	D.B.Janssen@chem.rug.nl						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARAMORI I, 1991, J BACTERIOL, V173, P7848, DOI 10.1128/jb.173.24.7848-7855.1991; BLINKOVSKY AM, 1993, ENZYME MICROB TECH, V15, P965, DOI 10.1016/0141-0229(93)90173-Y; BRUINS AP, 1991, MASS SPECTROM REV, V10, P53, DOI 10.1002/mas.1280100104; CHICH JF, 1992, FEBS LETT, V314, P139, DOI 10.1016/0014-5793(92)80960-O; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; Huynen M, 1998, J MOL BIOL, V280, P323, DOI 10.1006/jmbi.1998.1884; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; Larsen NA, 2002, NAT STRUCT BIOL, V9, P17, DOI 10.1038/nsb742; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Polderman-Tijmes JJ, 2002, APPL ENVIRON MICROB, V68, P211, DOI 10.1128/AEM.68.1.211-218.2002; RYU YW, 1988, ENZYME MICROB TECH, V10, P239, DOI 10.1016/0141-0229(88)90073-7; Suresh CG, 1999, NAT STRUCT BIOL, V6, P414, DOI 10.1038/8213; TAKAHASHI T, 1972, J AM CHEM SOC, V94, P4035, DOI 10.1021/ja00766a076; TAKAHASHI T, 1974, BIOCHEM J, V137, P497, DOI 10.1042/bj1370497; Yoshimoto T, 1999, J BIOCHEM, V126, P559, DOI 10.1093/oxfordjournals.jbchem.a022486	22	16	21	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28474	28482		10.1074/jbc.M204143200	http://dx.doi.org/10.1074/jbc.M204143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12011065	hybrid			2022-12-25	WOS:000177342600018
J	Baillie, GS; Huston, E; Scotland, G; Hodgkin, M; Gall, I; Peden, AH; MacKenzie, C; Houslay, ES; Currie, R; Pettitt, TR; Walmsley, AR; Wakelam, MJO; Warwicker, J; Houslay, MD				Baillie, GS; Huston, E; Scotland, G; Hodgkin, M; Gall, I; Peden, AH; MacKenzie, C; Houslay, ES; Currie, R; Pettitt, TR; Walmsley, AR; Wakelam, MJO; Warwicker, J; Houslay, MD			TAPAS-1, a novel microdomaln within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PHOSPHOLIPASE-D; PROTEIN-KINASE; MOLECULAR TARGETS; COS7 CELLS; BINDING; DOMAIN; ACTIVATION; RD1	Here we identify an 11-residue helical module in the unique N-terminal region of the cyclic AMP-specific phosphodiesterase PDE4A1 that determines association with phospholipid bilayers and shows a profound selectivity for interaction with phosphatidic acid (PA). This module contains a core bilayer insertion unit that is formed by two tryptophan residues, Trp(19) and Trp(20), whose orientation is optimized for bilayer insertion by the Leu(16):Val(17) pairing. Ca2+, at submicromolar levels, interacts with Asp(21) in this module and serves to gate bilayer insertion, which is completed within 10 ms. Selectivity for interaction with PA is suggested to be achieved primarily through the formation of a charge network of the form (Asp(21-):Ca2+:PA(2-):Lys(24+)) with overall neutrality at the bilayer surface. This novel phospholipid-binding domain, which we call TAPAS-1 (tryptophan anchoring phosphatidic acid selective-binding domain 1), is here identified as being responsible for membrane association of the PDE4A1 cAMP-specific phosphodiesterase. TAPAS-1 may not only serve as a paradigm for other PA-binding domains but also aid in detecting related phospholipid-binding domains and in generating simple chimeras for conferring membrane association and intracellular targeting on defined proteins.	Univ Glasgow, IBLS, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Birmingham, Sch Med, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Glasgow, IBLS, Div Infect & Immunol, Glasgow G12 8QQ, Lanark, Scotland; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Glasgow; University of Manchester; University of Birmingham; University of Glasgow; University of Dundee	Houslay, MD (corresponding author), Univ Glasgow, IBLS, Div Biochem & Mol Biol, Mol Pharmacol Grp, Wolfson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	M.Houslay@bio.gla.ac.uk	Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020; Currie, Richard/N-6074-2017	Warwicker, Jim/0000-0002-1302-0815; Wakelam, Michael/0000-0003-4059-9276; Houslay, Miles/0000-0002-3826-8091; Baillie, George/0000-0003-2469-6316; Currie, Richard/0000-0002-6528-3326				Beard MB, 1999, FEBS LETT, V460, P173, DOI 10.1016/S0014-5793(99)01335-6; Beard MB, 2002, CELL SIGNAL, V14, P453, DOI 10.1016/S0898-6568(01)00264-9; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bolger GB, 1997, BIOCHEM J, V328, P539; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Grange Muriel, 1998, Cell Biochemistry and Biophysics, V29, P1, DOI 10.1007/BF02737825; HITCHCOCK PB, 1974, P NATL ACAD SCI USA, V71, P3036, DOI 10.1073/pnas.71.8.3036; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Huston E, 2000, J BIOL CHEM, V275, P28063; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kimber MS, 2000, MOL CELL, V5, P1043, DOI 10.1016/S1097-2765(00)80269-5; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pettitt TR, 2001, BIOCHEM J, V360, P707, DOI 10.1042/0264-6021:3600707; Pooley L, 1997, BIOCHEM J, V321, P177, DOI 10.1042/bj3210177; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Savany A, 1996, CELL SIGNAL, V8, P511, DOI 10.1016/S0898-6568(96)00107-6; Scotland G, 1998, METH MOL B, V88, P141; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; Spina D, 1998, ADV PHARMACOL, V44, P33, DOI 10.1016/S1054-3589(08)60125-8; Sullivan M, 1998, BIOCHEM J, V333, P693, DOI 10.1042/bj3330693; SZABO AG, 2000, SPECTROPHOTOMETRY SP, V2, P33; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Vasudevan C, 1998, J CELL SCI, V111, P1277; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Walmsley AR, 2000, PRACT APPROACH SER, P167; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458; Wolfe C, 1998, MOL MEMBR BIOL, V15, P221, DOI 10.3109/09687689709044324; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	71	127	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28298	28309		10.1074/jbc.M108353200	http://dx.doi.org/10.1074/jbc.M108353200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11994273	hybrid			2022-12-25	WOS:000177189800089
J	Boix, E; Zhang, YN; Swaminathan, GJ; Brew, K; Acharya, KR				Boix, E; Zhang, YN; Swaminathan, GJ; Brew, K; Acharya, KR			Structural basis of ordered binding of donor and acceptor substrates to the retaining glycosyltransferase, alpha-1,3-galactosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTO-BLOOD GROUP; PROTEIN-STRUCTURE REFINEMENT; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; EXPRESSION CLONING; CATALYTIC DOMAIN; MECHANISM; COMPLEX; UDP-GALACTOSE-BETA-GALACTOSIDE-ALPHA-1,3-GALACTOSYLTRANSFERASE; GALACTOSYLTRANSFERASE	Bovine alpha-1,3-galactosyltransferase (alpha3GT) catalyzes the synthesis of the a-galactose (alpha-Gal) epitope, the target of natural human antibodies. It represents a family of enzymes, including the histo blood group A and B transferases, that catalyze retaining glycosyltransfer reactions of unknown mechanism. An initial study of alpha3GT in a crystal form with limited resolution and considerable disorder suggested the possible formation of a beta-galactosyl-enzyme covalent intermediate (Gastinel, L. N., Bignon, C., Misra, A. K., Hindsgaul, O., Shaper, J. H., and Joziasse, D. H. (2001) EMBO J. 20, 638-649). Highly ordered structures are described for complexes of alpha3GT with donor substrate, UDP-galactose, UDPglucose, and two acceptor substrates, lactose and N-acetyllactosamine, at resolutions up to 1.46 Angstrom. Structural and calorimetric binding studies suggest an obligatory ordered binding of donor and acceptor substrates, linked to a donor substrate-induced conformational change, and the direct participation of UDP in acceptor binding. The monosaccharide-UDP bond is cleaved in the structures containing UDP-galactose and UDPglucose, producing non-covalent complexes containing buried beta-galactose and alpha-glucose. The location of these monosaccharides and molecular modeling suggest that binding of a distorted conformation of UDP-galactose may be important in the catalytic mechanism of alpha3GT.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33341 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	State University System of Florida; Florida Atlantic University; University of Bath	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33341 USA.	kbrew@fau.edu; K.R.Acharya@bath.ac.uk	Brew, Keith/A-6746-2009; Boix, Ester/B-9038-2012; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Boix, Ester/0000-0003-1790-2142; Acharya, K. Ravi/0000-0002-3009-4058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58773] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Breton C, 1998, J BIOCHEM, V123, P1000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davies GJ, 2001, NAT STRUCT BIOL, V8, P98, DOI 10.1038/84198; Drickamer K, 1997, STRUCTURE, V5, P465, DOI 10.1016/S0969-2126(97)00202-5; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; Indyk L, 1998, METHOD ENZYMOL, V295, P350; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joziasse DH, 1999, BBA-MOL BASIS DIS, V1455, P403, DOI 10.1016/S0925-4439(99)00056-3; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; MERITT EA, 1997, METHOD ENZYMOL, V277, P505; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; Morris PJ, 1999, BRIT MED BULL, V55, P446, DOI 10.1258/0007142991902367; Muramatsu T, 2000, J BIOCHEM, V127, P171, DOI 10.1093/oxfordjournals.jbchem.a022590; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; SHEDRICK GM, 1997, METHOD ENZYMOL, V277, P317; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Watson KA, 1999, EMBO J, V18, P4619, DOI 10.1093/emboj/18.17.4619; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Zhang YN, 2001, J BIOL CHEM, V276, P11567, DOI 10.1074/jbc.M006530200	35	104	107	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28310	28318		10.1074/jbc.M202631200	http://dx.doi.org/10.1074/jbc.M202631200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011052	hybrid			2022-12-25	WOS:000177189800090
J	Jedrzejas, MJ; Mello, LV; de Groot, BL; Li, SL				Jedrzejas, MJ; Mello, LV; de Groot, BL; Li, SL			Mechanism of hyaluronan degradation by Streptococcus pneumoniae hyaluronate lyase - Structures of complexes with the substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; ACTIVE-SITE; BINDING; ENZYME; PURIFICATION; PNEUMOLYSIN; REFINEMENT	Hyaluronate lyase enzymes degrade hyaluronan, the main polysaccharide component of the host connective tissues, predominantly into unsaturated disaccharide units, thereby destroying the normal connective tissue structure and exposing the tissue cells to various endo-and exogenous factors, including bacterial toxins. The crystal structures of Streptococcus pneumoniae hyaluronate lyase with tetra- and hexasaccharide hyaluronan substrates bound in the active site were determined at 1.52- and 2.0-Angstrom resolution, respectively. Hexasaccharide is the longest substrate segment that binds entirely within the active site of these enzymes. The enzyme residues responsible for substrate binding, positioning, catalysis, and product release were thereby identified and their specific roles characterized. The involvement of three residues in catalysis, Asn(349), His(399), and Tyro(408), is confirmed, and the details of proton acceptance and donation within the catalytic machinery are described. The mechanism of processivity of the enzyme is analyzed. The flexibility (allosteric) behavior of the enzyme may be understood in terms of the results of flexibility analysis of this protein, which identified two modes of motion that are also proposed to be involved in the hyaluronan degradation process. The first motion describes an opening and closing of the catalytic cleft located between the alpha- and beta-domains. The second motion demonstrates the mobility of a binding cleft, which may facilitate the binding of the negatively charged hyaluronan to the enzyme.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Natl Ctr Genet Resources & Biotechnol, BR-70770900 Brasilia, DF, Brazil; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Alabama System; University of Alabama Birmingham; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Max Planck Society	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Baker JR, 2000, BIOCHEM J, V348, P465, DOI 10.1042/0264-6021:3480465; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COURTISS EH, 1995, PLAST RECONSTR SURG, V95, P876, DOI 10.1097/00006534-199595050-00017; DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; de Groot BL, 1999, J MOL BIOL, V286, P1241, DOI 10.1006/jmbi.1998.2568; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; Ducruix A., 1992, CRYSTALLIZATION NUCL; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GREILING H, 1975, CONNECT TISSUE RES, V3, P135, DOI 10.3109/03008207509152171; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Kleinjung J, 2000, FEBS LETT, V470, P257, DOI 10.1016/S0014-5793(00)01295-3; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P15125, DOI 10.1074/jbc.M011102200; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LOCK RA, 1988, MICROB PATHOGENESIS, V5, P461, DOI 10.1016/0882-4010(88)90007-1; McCourt PAG, 1999, MATRIX BIOL, V18, P427, DOI 10.1016/S0945-053X(99)00045-1; MCDANIEL LS, 1991, INFECT IMMUN, V59, P222, DOI 10.1128/IAI.59.1.222-228.1991; McPherson A., 1999, CRYSTALLIZATION BIOL; Mello LV, 1997, PROTEIN ENG, V10, P381, DOI 10.1093/protein/10.4.381; Mello LV, 1998, BIOCHEMISTRY-US, V37, P3137, DOI 10.1021/bi971402v; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; MUFSON MA, 1990, PRINCIPLES PRACTICE; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; PATON JC, 1986, INFECT IMMUN, V54, P50, DOI 10.1128/IAI.54.1.50-55.1986; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; PRITCHARD DG, 1994, ARCH BIOCHEM BIOPHYS, V315, P431, DOI 10.1006/abbi.1994.1521; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P1015, DOI 10.1093/oxfordjournals.jbchem.a133052; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, P11; TOOLE BP, 1984, ROLE EXTRACELLULAR M; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	55	99	102	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28287	28297		10.1074/jbc.M112009200	http://dx.doi.org/10.1074/jbc.M112009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11991948	Green Submitted, hybrid			2022-12-25	WOS:000177189800088
J	Fu, LH; Wang, XF; Eyal, Y; She, YM; Donald, LJ; Standing, KG; Ben-Hayyim, G				Fu, LH; Wang, XF; Eyal, Y; She, YM; Donald, LJ; Standing, KG; Ben-Hayyim, G			A selenoprotein in the plant kingdom. Mass spectrometry confirms that an opal codon (UGA) encodes selenocysteine in Chlamydomonas reinhardtii glutathione peroxidase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION-SEQUENCE SECIS; MAMMALIAN-CELLS; TRANSFER-RNAS; SELENIUM; EXPRESSION; PROTEIN; ACID; GENE; IDENTIFICATION; PURIFICATION	Selenoproteins that contain the rare amino acid selenocysteine in their primary structure have been identified in diverse organisms such as viruses, bacteria, archea, and mammals, but so far not in yeast or plants. Among the most thoroughly investigated families of selenoenzymes are the animal glutathione peroxidases (GPXs). In the last few years, genes encoding GPX-like homologues from Chlamydomonas and higher plants have been isolated, but, unlike the animal ones, all of them have cysteine (rather than selenocysteine) residues in their catalytic site. In all organisms investigated that contain selenoproteins, selenocysteine is encoded by a UGA opal codon, which is usually a stop codon. We report here that, in Chlamydomonas reinhardtii, the cDNA-cloned sequence of a GPX homologue contains an internal TGA codon in frame to the ATG. Specific mRNA expression, protein production, and enzyme activity are selenium-dependent. Sequence analysis of the peptides produced by proteolytic digestion, performed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), confirmed the presence of a selenocysteine residue at the predicted site and suggest its location in the mitochondria. Thus, our data present the first direct proof that a UGA opal codon is decoded in the plant kingdom to incorporate selenocysteine.	Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, IL-50250 Bet Dagan, Israel; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Manitoba, Dept Phys & Astron, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba; University of Manitoba	Ben-Hayyim, G (corresponding author), Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, IL-50250 Bet Dagan, Israel.	vhgozal@agri.gov.il	Standing, Kenneth/E-2416-2011	She, Yi-Min/0000-0002-0571-4630; Eyal, Yoram/0000-0003-4332-1616				Aho EL, 1995, DNA SEQUENCE, V6, P55, DOI 10.3109/10425179509074701; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; Avsian-Kretchmer O, 1999, PLANTA, V209, P469, DOI 10.1007/s004250050750; BARTLING D, 1993, EUR J BIOCHEM, V216, P579, DOI 10.1111/j.1432-1033.1993.tb18177.x; BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Chernushevich IV, 1999, ANAL CHEM, V71, p452A, DOI 10.1021/ac990524l; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU FF, 1993, J BIOL CHEM, V268, P2571; COOKSON E, 1992, P NATL ACAD SCI USA, V89, P5837, DOI 10.1073/pnas.89.13.5837; Engelberg-Kulka H, 2001, BIOFACTORS, V14, P61, DOI 10.1002/biof.5520140109; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; Eyal Y, 1999, BIOTECHNIQUES, V27, P656, DOI 10.2144/99274bm04; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Flohe L., 1982, LIPID PEROXIDES BIOL, P149; Gamain B, 1996, MOL BIOCHEM PARASIT, V78, P237, DOI 10.1016/S0166-6851(96)02632-1; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; Hazebrouck S, 2000, J BIOL CHEM, V275, P28715, DOI 10.1074/jbc.M004985200; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; HUANG KX, 1994, BIOL TRACE ELEM RES, V46, P173, DOI 10.1007/BF02790077; Kohrer C, 2001, P NATL ACAD SCI USA, V98, P14310, DOI 10.1073/pnas.251438898; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; LAUCHLI A, 1993, BOT ACTA, V106, P455; Leisinger U, 1999, PLANT SCI, V149, P139, DOI 10.1016/S0168-9452(99)00151-X; LI WJ, 2000, BIOCHIM BIOPHYS ACTA, V1943, P225; Liu ZS, 1998, NUCLEIC ACIDS RES, V26, P896, DOI 10.1093/nar/26.4.896; Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Ma SG, 2002, J BIOL CHEM, V277, P12749, DOI 10.1074/jbc.M111462200; Miyasaka H, 2000, WORLD J MICROB BIOT, V16, P23, DOI 10.1023/A:1008982332139; Mullineaux PM, 1998, PLANT J, V13, P375, DOI 10.1046/j.1365-313X.1998.00052.x; OVERBAUGH JM, 1985, PLANT PHYSIOL, V77, P437, DOI 10.1104/pp.77.2.437; PRICE NM, 1988, PLANT PHYSIOL, V86, P192, DOI 10.1104/pp.86.1.192; ROCHE C, 1994, GENE, V138, P149, DOI 10.1016/0378-1119(94)90798-6; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SABEH F, 1993, ENZYME PROTEIN, V47, P92, DOI 10.1159/000468662; Sachdev SW, 2001, BIOCHEM J, V357, P851; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEN QC, 1993, J BIOL CHEM, V268, P11463; SHIGEOKA S, 1991, BIOCHEM J, V275, P623, DOI 10.1042/bj2750623; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; SUNDE RA, 1993, BIOCHEM BIOPH RES CO, V193, P905, DOI 10.1006/bbrc.1993.1711; TAKEDA T, 1993, PLANT SCI, V94, P81, DOI 10.1016/0168-9452(93)90009-O; Terry N, 2000, ANNU REV PLANT PHYS, V51, P401, DOI 10.1146/annurev.arplant.51.1.401; TOYODA H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P213, DOI 10.1016/0167-4781(90)90042-Z; URSINI F, 1995, METHOD ENZYMOL, V252, P38; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; VERENTCHIKOV AN, 1994, ANAL CHEM, V66, P126, DOI 10.1021/ac00073a022; Vernet P, 1996, BIOCHEM CELL BIOL, V74, P125, DOI 10.1139/o96-014; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; YOKOTA A, 1988, PLANT PHYSIOL, V86, P649, DOI 10.1104/pp.86.3.649; Zhang W, 1999, BIOL TRACE ELEM RES, V70, P97, DOI 10.1007/BF02783852	58	123	135	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25983	25991		10.1074/jbc.M202912200	http://dx.doi.org/10.1074/jbc.M202912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11973339	hybrid			2022-12-25	WOS:000176908700023
J	Graichen, R; Liu, DX; Sun, Y; Lee, KO; Lobie, PE				Graichen, R; Liu, DX; Sun, Y; Lee, KO; Lobie, PE			Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; D1 PROMOTER; TUMOR-CELLS; MORPHOGENETIC PROTEIN; HEMATOPOIETIC-CELLS; DNA-DAMAGE; FACTOR-I; EXPRESSION; P53; PROLIFERATION	Multiple cellular effects of human growth hormone (hGH) are mediated by an indirect mechanism requiring transcriptional activation of genes encoding protein effector molecules such as insulin-like growth factor-1. Such protein effector molecules then act directly to mediate the cellular functions of hGH. We report here that autocrine hGH production by mammary carcinoma cells specifically results in the transcriptional repression of the p53-regulated placental transforming growth factor-beta (PTGF-beta) gene. Transcriptional repression of the PTGF-beta gene does not require the p53-binding sites in the PTGF-beta promoter, and autocrine hGH also desensitized the response of the PTGF-beta promoter to p53 overexpression. Transcriptional repression of the PTGF-beta gene is accompanied by consequent decreases in its protein product, Smad-mediated transcription, and its cellular effects that include cell cycle arrest and apoptosis. PTGF-beta specifically inhibited the autocrine hGH-stimulated expression of cyclin D1 required for autocrine hGH-stimulated mammary carcinoma cell cycle progression. Thus, one mechanism by which autocrine hGH promotes an increase in mammary carcinoma cell number is by transcriptional repression of protein effector molecules that promote cell cycle arrest and apoptosis. Such transcriptional repression of negative regulatory factors, such as PTGF-beta, may also be requisite for direct stimulation of mammary carcinoma cell mitogenesis by hGH.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Med, Singapore 119074, Singapore; Pfizer Global Res & Dev, Ann Arbor Labs, Canc Mol Sci, Ann Arbor, MI 48105 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Pfizer	Lobie, PE (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Lee, Kok-Onn/E-9874-2011	Lee, Kok-Onn/0000-0002-3040-1185				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carlsson C, 1997, ENDOCRINOLOGY, V138, P3940, DOI 10.1210/en.138.9.3940; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Del Bino G, 1999, CELL PROLIFERAT, V32, P25, DOI 10.1046/j.1365-2184.1999.00130.x; EKBERG S, 1992, J ENDOCRINOL, V135, P59, DOI 10.1677/joe.0.1350059; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Fawcett TW, 1997, CELL STRESS CHAPERON, V2, P104, DOI 10.1379/1466-1268(1997)002<0104:POHSIH>2.3.CO;2; Friedrichsen BN, 2001, MOL ENDOCRINOL, V15, P136, DOI 10.1210/me.15.1.136; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; IZUMI T, 1995, MOL CELL ENDOCRINOL, V112, P95, DOI 10.1016/0303-7207(95)03591-T; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jeay S, 2001, ENDOCRINOLOGY, V142, P147, DOI 10.1210/en.142.1.147; Kato Y, 1996, ENDOCR J, V43, P177, DOI 10.1507/endocrj.43.177; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; KLAPPER DG, 1983, ENDOCRINOLOGY, V112, P2215, DOI 10.1210/endo-112-6-2215; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Li H, 1998, ENDOCRINOLOGY, V139, P3855, DOI 10.1210/en.139.9.3855; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Liu ND, 1997, EXP CELL RES, V237, P196, DOI 10.1006/excr.1997.3789; Liu XP, 2001, CANCER LETT, V170, P183, DOI 10.1016/S0304-3835(01)00589-4; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; ROGERS SA, 1994, AM J PHYSIOL, V267, pF208, DOI 10.1152/ajprenal.1994.267.2.F208; Salatino M, 2001, EXP CELL RES, V265, P152, DOI 10.1006/excr.2001.5175; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Swolin D, 1996, J CLIN ENDOCR METAB, V81, P4329, DOI 10.1210/jc.81.12.4329; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	58	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26662	26672		10.1074/jbc.M109931200	http://dx.doi.org/10.1074/jbc.M109931200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994274	hybrid			2022-12-25	WOS:000176908700108
J	Koh, SS; Li, HW; Lee, YH; Widelitz, RB; Chuong, CM; Stallcup, MR				Koh, SS; Li, HW; Lee, YH; Widelitz, RB; Chuong, CM; Stallcup, MR			Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; PATHWAY; TARGET; WNT; ACETYLTRANSFERASES; METHYLATION; SPECIFICITY; EXPRESSION; CHROMATIN; CBP/P300	The androgen receptor (AR) binds to and activates transcription of specific genes in response to its cognate steroid hormone, dihydrotestosterone. Transcriptional activation by the DNA-bound AR is accomplished with the help of a variety of coactivator proteins. For example, the p160 coactivators bind directly to AR and recruit additional coactivators such as the histone acetyltransferase p300 and the histone methyltransferase CARM1. The current study tested whether CARM1 can cooperate with other types of coactivator proteins. Recently it was shown that beta-catenin can also bind directly to and serve as a coactivator for AR. Here it is shown that CARM1 binds to beta-catenin and can function in synergy with beta-catenin and p300 as coactivators for AR. The methyltransferase activity of CARM1 is important for its synergistic coactivator function with beta-catenin. The synergistic coactivator function of beta-catenin and CARM1 is not restricted to steroid receptors because these two coactivators can also act synergistically with another type of DNA binding transcriptional activator, LEF-1/TCF-4.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Lee, Young-Ho/G-2361-2014	Lee, Young-Ho/0000-0001-6415-4912	NCI NIH HHS [CA83716, R01 CA083716] Funding Source: Medline; NIAMS NIH HHS [R01 AR042177-06S1, R01 AR042177-06, R01 AR042177, R01 AR042177-05, AR42177, R01 AR042177-07, R01 AR042177-07S1] Funding Source: Medline; NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [R01 DK043093, DK43093] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker N, 2000, BIOESSAYS, V22, P961; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chuong CM, 2000, CURR OPIN GENET DEV, V10, P449, DOI 10.1016/S0959-437X(00)00111-8; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Lu JF, 1997, GENE, V196, P201, DOI 10.1016/S0378-1119(97)00228-X; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Truica CI, 2000, CANCER RES, V60, P4709; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2	33	105	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26031	26035		10.1074/jbc.M110865200	http://dx.doi.org/10.1074/jbc.M110865200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11983685	Green Accepted, hybrid			2022-12-25	WOS:000176908700028
J	Chou, CF; Lai, CL; Chang, YC; Duester, G; Yin, SJ				Chou, CF; Lai, CL; Chang, YC; Duester, G; Yin, SJ			Kinetic mechanism of human class IV alcohol dehydrogenase functioning as retinol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STOMACH ALCOHOL; OMEGA-HYDROXYFATTY ACIDS; FIRST-PASS METABOLISM; SUBSTRATE-SPECIFICITY; EXPRESSION PATTERNS; STRUCTURAL BASIS; LIGAND SYNTHESIS; MOLECULAR-BASIS; MOUSE EMBRYOS; ETHANOL	Molecular genetic studies have indicated that alcohol dehydrogenase may be involved in the synthesis of retinoic acid, a hormonal molecule regulating diverse cellular functions at the transcriptional level. Class IV alcohol dehydrogenase (ADH) has been reported to be the most efficient enzyme catalyzing oxidation of retinol in human ADH family. Initial velocity, product inhibition, and dead-end inhibition experiments were performed with the recombinant human class IV ADH to elucidate kinetic mechanism with all-trans-retinol and all-trans-retinal as natural substrates. Fluorescence quenching was titrated in formation of the binary and abortive ternary enzyme complexes. The minimal mechanism deduced from steady-state kinetic and equilibrium binding studies is best described as an asymmetric rapid equilibrium random mechanism with two dead-end ternary complexes for retinol oxidation and a rapid equilibrium ordered mechanism with one dead-end ternary complex for retinal reduction, a unique mechanistic form for zinc-containing ADHs in the medium chain dehydrogenase/reductase superfamily. Dissociation constants for the binary complexes as well as the productive and abortive ternary complexes determined from different experimental approaches are in reasonable agreement. Kinetic isotope effect studies suggest rate-limiting isomerization of the central ternary complexes in both reaction directions. The potential interference of retinol metabolism by ethanol through the ADH pathway may play a significant role in the pathogenesis of fetal alcohol syndrome and alcohol-related upper digestive tract cancer.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Natl Def Med Ctr, Dept Biochem, Taipei 114, Taiwan; Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	National Defense Medical Center; National Defense Medical Center; Sanford Burnham Prebys Medical Discovery Institute	Yin, SJ (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.			Lai, Ching-Long/0000-0001-7401-362X; Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adolph HW, 2000, BIOCHEMISTRY-US, V39, P12885, DOI 10.1021/bi001376s; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AllaliHassani A, 1997, FEBS LETT, V405, P26, DOI 10.1016/S0014-5793(97)00151-8; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Ang HL, 1997, DEV DYNAM, V208, P536; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHA S, 1968, J BIOL CHEM, V243, P820; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cleland W W, 1979, Methods Enzymol, V63, P103; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; DALZIEL K, 1962, BIOCHEM J, V84, P240, DOI 10.1042/bj0840240; DALZIEL K, 1963, J BIOL CHEM, V238, P2850; DALZIEL K, 1966, BIOCHEM J, V100, P36; De Luca LM, 1997, J NUTR BIOCHEM, V8, P426, DOI 10.1016/S0955-2863(97)00063-6; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1997, BIOL REPROD, V56, P102, DOI 10.1095/biolreprod56.1.102; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Edenberg HJ, 2000, PROG NUCLEIC ACID RE, V64, P295, DOI 10.1016/S0079-6603(00)64008-4; EFTINK MR, 1986, BIOCHEMISTRY-US, V25, P6631, DOI 10.1021/bi00369a045; EFTINK MR, 1982, BIOCHEMISTRY-US, V21, P117, DOI 10.1021/bi00530a021; Estonius M, 1996, FEBS LETT, V397, P338, DOI 10.1016/S0014-5793(96)01204-5; Foglio MH, 1999, BBA-PROTEIN STRUCT M, V1432, P239, DOI 10.1016/S0167-4838(99)00104-1; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; HANES CS, 1972, CAN J BIOCHEM CELL B, V50, P1385, DOI 10.1139/o72-182; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1998, ALCOHOL CLIN EXP RES, V22, P1607, DOI 10.1111/j.1530-0277.1998.tb03955.x; Haselbeck RJ, 1997, DEV DYNAM, V208, P447, DOI 10.1002/(SICI)1097-0177(199704)208:4<447::AID-AJA1>3.0.CO;2-I; HOOG JO, 1995, ADV EXP MED BIOL, V372, P355; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JORNVALL H, 1970, EUR J BIOCHEM, V16, P41, DOI 10.1111/j.1432-1033.1970.tb01050.x; Jornvall H, 2000, PHARMACOLOGY, V61, P184, DOI 10.1159/000028399; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kedishvili NY, 1997, J BIOL CHEM, V272, P7494, DOI 10.1074/jbc.272.11.7494; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Peralba JM, 1999, J BIOL CHEM, V274, P26021, DOI 10.1074/jbc.274.37.26021; Plapp BV, 2001, CHEM-BIOL INTERACT, V130, P445, DOI 10.1016/S0009-2797(00)00284-2; POCKER Y, 1993, ADV EXP MED BIOL, V328, P411; SCHIMERLIK MI, 1973, J BIOL CHEM, V248, P8418; Segel I. H., 1975, ENZYME KINETICS, P273; SEKHAR VC, 1990, BIOCHEMISTRY-US, V29, P4289, DOI 10.1021/bi00470a005; SILVERSTEIN E, 1964, J BIOL CHEM, V239, P3908; Sund H., 1963, ENZYMES, V7, P25; Szalai G, 2002, EUR J BIOCHEM, V269, P224, DOI 10.1046/j.0014-2956.2001.02642.x; THEORELL H, 1951, ACTA CHEM SCAND, V5, P1127, DOI 10.3891/acta.chem.scand.05-1127; THEORELL H, 1971, ARCH BIOCHEM BIOPHYS, V142, P69, DOI 10.1016/0003-9861(71)90260-8; Ulven SM, 2000, DEV BIOL, V220, P379, DOI 10.1006/dbio.2000.9634; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; Yin SJ, 1997, GASTROENTEROLOGY, V112, P766, DOI 10.1053/gast.1997.v112.pm9041238; Yin SJ, 1997, ADV EXP MED BIOL, V414, P347; Yin SJ, 1999, ADV EXP MED BIOL, V463, P265; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZHENG YW, 1993, J BIOL CHEM, V268, P24933	63	36	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25209	25216		10.1074/jbc.M201947200	http://dx.doi.org/10.1074/jbc.M201947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997393	hybrid			2022-12-25	WOS:000176747000048
J	Deregibus, MC; Cantaluppi, V; Doublier, S; Brizzi, MF; Deambrosis, I; Albini, A; Camussi, G				Deregibus, MC; Cantaluppi, V; Doublier, S; Brizzi, MF; Deambrosis, I; Albini, A; Camussi, G			HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; TAT PROTEIN; ENDOTHELIAL-CELLS; HIV-TAT; COUPLED RECEPTOR; TRANSGENIC MICE; KINASE-B; IN-VIVO; APOPTOSIS; LESIONS	In this study we found that Tat protected vincristine-treated Kaposi's sarcoma cells from apoptosis and from down-regulation of several anti-apoptotic genes such as AKT-1, AKT-2, BCL2, BCL-XL, and insulin-like growth factor I and induced the de novo expression of the interleukin-3 gene. Moreover, we found that Tat enhanced phosphorylation of AKT and BAD proteins. The inhibition of phosphatidylinositol 3-kinase with two unrelated pharmacological inhibitors, wortmannin and LY294002, abrogated both the anti-apoptotic effect and the phosphorylation of AKT induced by Tat. After treatment with Tat, the AKT enzymatic activity showed a biphasic increase: an early activation (15 min), independent from protein synthesis; and a delayed activation (24 h), which was significantly decreased upon blockage of protein synthesis. Experiments with a function blocking anti-vascular endothelial cell growth factor receptor-2 antibody suggested that both the early and delayed AKT activation and the protection from apoptosis were triggered by the interaction of Tat with vascular endothelial cell growth factor receptor-2. Moreover, experiments with function-blocking antibodies directed against insulin-like growth factor I/insulin-like growth factor I receptor or interleukin-3 indicated their involvement in the delayed activation of AKT and their contribution to the anti-apoptotic effect of Tat on vincristine-treated Kaposi's sarcoma cells.	Univ Turin, Dipartimento Med Interna, Cattedra Nefrol, CeRMS, I-10126 Turin, Italy; Ist Nazl Ric Canc, I-16100 Genoa, Italy	University of Turin; University of Genoa; IRCCS AOU San Martino IST	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.		Brizzi, Maria Felice/J-7882-2016; Camussi, Giovanni/J-7624-2016; Cantaluppi, Vincenzo/K-8531-2016	Camussi, Giovanni/0000-0003-2795-232X; Cantaluppi, Vincenzo/0000-0002-4120-3555; Albini, Adriana/0000-0002-9624-5103				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CANTALUPPI V, 2001, AIDS, V10, P965; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chokunonga E, 2000, INT J CANCER, V85, P54, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;54::AID-IJC10&gt;3.0.CO;2-D; CORALLINI A, 1993, CANCER RES, V53, P5569; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1991, ADV EXP MED BIOL, V303, P27; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Lee FC, 1996, HEMATOL ONCOL CLIN N, V10, P1051, DOI 10.1016/S0889-8588(05)70384-1; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Mitsuyasu RT, 2000, CURR OPIN ONCOL, V12, P174, DOI 10.1097/00001622-200003000-00013; Montaner S, 2001, CANCER RES, V61, P2641; Mori S, 1996, CANCER RES, V56, P1874; Morini M, 2000, BIOCHEM BIOPH RES CO, V273, P267, DOI 10.1006/bbrc.2000.2941; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Samaniego F, 1997, J IMMUNOL, V158, P1887; St Croix B, 2000, SCIENCE, V289, P1197; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEIHUA W, 2000, J BIOL CHEM, V275, P40113; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; ZAULI G, 1993, CANCER RES, V53, P4481; Zauli G, 2001, FASEB J, V15, P483, DOI 10.1096/fj.00-0354com; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	53	84	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25195	25202		10.1074/jbc.M200921200	http://dx.doi.org/10.1074/jbc.M200921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994280	hybrid			2022-12-25	WOS:000176747000046
J	Gonzalez-Perrett, S; Batelli, M; Kim, K; Essafi, M; Timpanaro, G; Moltabetti, N; Reisin, IL; Arnaout, MA; Cantiello, HF				Gonzalez-Perrett, S; Batelli, M; Kim, K; Essafi, M; Timpanaro, G; Moltabetti, N; Reisin, IL; Arnaout, MA; Cantiello, HF			Voltage dependence and pH regulation of human polycystin-2-mediated cation channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; CALCIUM CHANNELS; PERMEANT IONS; PROTEIN; PROTONS; PKD2; GENE	Polycystin-2, the product of the human PKD2 gene, whose mutations cause autosomal dominant polycystic kidney disease, is a large conductance, Ca2+-permeable non-selective cation channel. Polycystin-2 is functionally expressed in the apical membrane of the human syncytiotrophoblast, where it may play a role in the control of fetal electrolyte homeostasis. Little is known, however, about the mechanisms that regulate polycystin-2 channel function. In this study, the role of pH in the regulation of polycystin-2 was assessed by ion channel reconstitution of both apical membranes of human syncytiotrophoblast and the purified FIAG-tagged protein from in vitro transcribed/translated material. A kinetic analysis of single channel currents, including dwell time histograms, confirmed two open and two close states for spontaneous channel behavior and a strong voltage dependence of the open probability of the channel (P-o). A reduction of cis pH (pH(cis)) decreased P-o and shifted the voltage dependence of channel function but had no effect on the single channel conductance. An increase in pH(cis), in contrast, increased NPo (channel number times P-o). Elimination of the H+ chemical gradient did not reverse the low pH(cis) inhibition of polycystin-2. Similar findings confirmed the pH effect on the in vitro translated, FLAG-tagged purified polycystin-2. The data indicate the presence of an H+ ion regulatory site in the channel protein, which is accessible from the cytoplasmic side of the protein. This protonation site controls polycystin-2 cation-selective channel activity.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Fac Farm & Bioquim, Dept Fisicoquim & Quim Analit, Lab Canales Ion, RA-1113 Buenos Aires, DF, Argentina; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Fac Med, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina	University of Buenos Aires; Harvard University; Harvard Medical School	Cantiello, HF (corresponding author), Massachusetts Gen Hosp E, Renal Unit, 149 13th St, Charlestown, MA 02129 USA.		Essafi, Makram/V-8411-2019; Montalbetti, Nicolas/T-4212-2019	Montalbetti, Nicolas/0000-0003-2897-9540	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez O., 1986, ION CHANNEL RECONSTI, P115; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; Eyring H., 1963, MODERN CHEM KINETICS; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grosman C, 1997, J MEMBRANE BIOL, V157, P83, DOI 10.1007/s002329900218; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HANKE W, ION CHANNEL RECONSTI, P141; HESS P, 1989, ANN NY ACAD SCI, V560, P80, DOI 10.1111/j.1749-6632.1989.tb24082.x; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; PATLAK JB, 1988, J GEN PHYSIOL, V92, P413, DOI 10.1085/jgp.92.4.413; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; SNEDECOR GW, 1973, STATISTICAL METHODS, P59; Stulc J, 1997, PHYSIOL REV, V77, P805, DOI 10.1152/physrev.1997.77.3.805; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	19	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24959	24966		10.1074/jbc.M105084200	http://dx.doi.org/10.1074/jbc.M105084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991947	hybrid			2022-12-25	WOS:000176747000017
J	Liu, S; Carrillo, JJ; Pediani, JD; Milligan, G				Liu, S; Carrillo, JJ; Pediani, JD; Milligan, G			Effective information transfer from the alpha(1b)-adrenoceptor to G alpha(11) requires both beta/gamma interactions and an aromatic group four amino acids from the C terminus of the G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; ALPHA-SUBUNITS; ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; PHOSPHOLIPASE-C; CHO CELLS; ACTIVATION; AGONIST	Co-expression of the alpha(1b)-adrenoreceptor and Galpha(11) in cells derived from a Galpha(q)/Galpha(11) knock-out mouse allows agonist-mediated elevation of intracellular Ca2+ levels that is transduced by beta/gamma released from the G protein a subunit. Mutation of Tyr(356) of Galpha(11) to Phe, within a receptor contact domain, had little effect on function but this was reduced greatly by alteration to Ser and virtually eliminated by conversion to Asp. This pattern was replicated following incorporation of each form of Ga-11 into fusion proteins with the alpha(1b)-adrenoreceptor. Following a [S-35] guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) binding assay, immunoprecipitation of the wild type alpha(1b)-adrenoreceptor-Galpha(11) fusion protein indicated that the agonist phenylephrine stimulated guanine nucleotide exchange on Galpha(11) more than 30-fold. Information transfer by agonist was controlled in residue 356 Galpha(11) mutants with rank order Tyr > Phe > Trp > Ile > Ala = Gln = Arg > Ser > Asp, although these alterations did not alter the binding affinity of either phenylephrine or an antagonist ligand. Mutation of a beta/gamma contact interface in the alpha(1b)-adrenoreceptor-Tyr(356) Gat, fusion protein did not alter ligand binding affinity but did reduce greatly beta/gamma binding and phenylephrine stimulation of [S-35]GTPgammas binding. It also prevented agonist elevation of intracellular Ca2+ levels, as did a mutation in Galpha(11) that prevents G protein subunit dissociation. These results indicate that a bulky aromatic group is required four amino acids from the C terminus of Galpha(11) to maximize information transfer from an agonist-occupied receptor and disprove the hypothesis that tyrosine phosphorylation of this residue is required for G protein activation (Umemori, H., Inoue, T., Kume, S., Seldyama, N., Nagao, M, Itoh, H., Nakanishi, S., Mikoshiba, K, and Yamamoto, T. (1997) Science 276,1878-1881). This is distinct from Galpha(i1) where hydrophobicity of the amino acid is the key determinant at this location. They also further demonstrate a key role for the IVY complex in enhancing receptor to G protein a subunit information transfer.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Milligan, Graeme/F-9426-2011; Pediani, John/F-2708-2019	Milligan, Graeme/0000-0002-6946-3519; Pediani, John/0000-0001-6615-537X				Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CARRILLO JJ, 2002, IN PRESS J PHARM EXP; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; DeLapp NW, 1999, J PHARMACOL EXP THER, V289, P946; Dupuis DS, 2001, NEUROPHARMACOLOGY, V40, P36, DOI 10.1016/S0028-3908(00)00098-8; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; KIM GD, 1994, J BIOL CHEM, V269, P19933; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Milligan G, 1999, TRENDS PHARMACOL SCI, V20, P118, DOI 10.1016/S0165-6147(99)01320-6; MILLIGAN G, 1998, BIOCHEM J, V255, P1; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; Stevens PA, 2000, MOL PHARMACOL, V58, P438, DOI 10.1124/mol.58.2.438; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WIELAND T, 1994, METHOD ENZYMOL, V237, P1; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745	40	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25707	25714		10.1074/jbc.M201015200	http://dx.doi.org/10.1074/jbc.M201015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994281	hybrid			2022-12-25	WOS:000176747000112
J	Szkodowska, A; Muller, MCM; Linke, C; Scholze, H				Szkodowska, A; Muller, MCM; Linke, C; Scholze, H			Annexin XXI (ANX21) of Giardia lamblia has sequence motifs uniquely shared by giardial annexins and is specifically localized in the flagella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; BINDING; IDENTIFICATION; PURIFICATION; NUCLEOTIDE; GENES; CELLS	We have identified a novel annexin, ANX21, in trophozoites of Giardia lamblia. The nucleotide sequence encoding this protein deviated from a published sequence in predicting an additional endonexin fold in the fourth annexin domain. In addition, several motifs exclusively shared by other annexins of G. lamblia in their predicted fourth repeat and predicted to be localized on the opposite (concave) surface of the molecule became apparent. Western blots of trophozoite fractions probed with antiserum against the recombinant protein indicated that this annexin, like the other giardial annexins ANX19 and ANX20, associates with phospholipids in the presence of Ca2+. Finally, confocal laser scanning of trophozoites showed that the protein, apart from the median body, was exclusively localized in the eight flagella. Together, these data suggest that ANX21 may function as a Ca2+-regulated structural element linking phospholipid bilayer and underlying axoneme.	Univ Osnabruck, Dept Biochem, D-49069 Osnabruck, Germany; Univ Osnabruck, Dept Zool, D-49069 Osnabruck, Germany	University Osnabruck; University Osnabruck	Scholze, H (corresponding author), Fac Biol Chem, Barbarastr 11, D-49069 Osnabruck, Germany.	scholze@biologie.uni-osnabrueck.de						Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; ALONSO RA, 1992, MOL BIOCHEM PARASIT, V50, P95, DOI 10.1016/0166-6851(92)90247-H; [Anonymous], 1995, PARASIT PROTOZ; Bauer B, 1999, FEMS MICROBIOL LETT, V173, P147, DOI 10.1111/j.1574-6968.1999.tb13496.x; BOUSTEAD CM, 1988, FEBS LETT, V233, P233, DOI 10.1016/0014-5793(88)80433-2; CLARK JT, 1988, PARASITOL RES, V74, P415, DOI 10.1007/BF00535140; CROSSLEY R, 1985, J CELL SCI, V78, P205; Douglas M, 1979, Methods Enzymol, V56, P58; FEINBERG JM, 1991, J HISTOCHEM CYTOCHEM, V39, P955, DOI 10.1177/39.7.1830893; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GRUNDMANN U, 1988, P NATL ACAD SCI USA, V85, P3708, DOI 10.1073/pnas.85.11.3708; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jost M, 1997, J CELL SCI, V110, P221; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYRAN N, 1996, AM J PHYSIOL, V270, P863; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MORGAN RO, 1995, MOL BIOL EVOL, V12, P967; Morgan RO, 1997, J MOL EVOL, V44, P178, DOI 10.1007/PL00006134; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nohynkova E, 2000, EUR J CELL BIOL, V79, P438, DOI 10.1078/0171-9335-00066; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; PEATTIE DA, 1990, PARASITOL TODAY, V6, P52, DOI 10.1016/0169-4758(90)90070-K; Ridgley E, 2000, MOL BIOCHEM PARASIT, V109, P195, DOI 10.1016/S0166-6851(00)00246-2; Roger AJ, 1999, AM NAT, V154, pS146, DOI 10.1086/303290; Seaton BA, 1996, ANNEXINS MOL STRUCTU, P15; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Townson SM, 1996, MOL BIOCHEM PARASIT, V79, P183, DOI 10.1016/0166-6851(96)02661-8; WU YM, 1992, BIOCHEM J, V287, P187, DOI 10.1042/bj2870187	31	16	19	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25703	25706		10.1074/jbc.M203260200	http://dx.doi.org/10.1074/jbc.M203260200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006598	hybrid			2022-12-25	WOS:000176747000111
J	Beinke, S; Belich, MP; Ley, SC				Beinke, S; Belich, MP; Ley, SC			The death domain of NF-kappa B1 p105 is essential for signal-induced p105 proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCINE-RICH REGION; DIFFERENTIAL REGULATION; PRECURSOR P105; KINASE COMPLEX; PROTEINS; PHOSPHORYLATION; BETA; P50; UBIQUITINATION	Stimulation of cells with tumor necrosis factor a (TNFalpha) triggers NF-kappaB1 p105 proteolysis, releasing associated Rel subunits to translocate into the nucleus and modulate target gene expression. Phosphorylation of serine 927 within the p105 PEST region by the IkappaB kinase (IKK) complex is required to promote p105 proteolysis in response to TNFalpha stimulation. In this study, the role of the p105 death domain (DD) in signal-induced p105 proteolysis is investigated. Endogenous p105 is shown to interact with the IKK complex in HeLa cells, and transient transfection experiments in 293 cells indicate that each of the catalytic components of the IKK complex, IKK1 and IKK2, can bind to p105. Interaction of p105 with both IKK1 and IKK2 is substantially reduced by deletion of the p105 DD or introduction of a specific point mutation (L841A) into the p105 DD homologous to the lpr mutation in Fas. Phosphorylation of immunoprecipitated p105 on serine 927 by purified recombinant IKK1 or IKK2 protein in vitro is dramatically reduced in both DD mutants relative to wild type. Furthermore, both of the DD mutations significantly impair the ability of low concentrations of IKK2 to induce p 105 serine 927 phosphorylation and proteolysis in transiently transfected 3T3 cells. However, high levels of transiently expressed IKK2 bypass the requirement for the p105 DD to induce p105 serine 927 phosphorylation. Finally, p105 serine 927 phosphorylation by the endogenous IKK complex after TNFalpha stimulation and subsequent p105 proteolysis is blocked in both p105 DD mutants when stably expressed in HeLa cells. Thus, the p105 DD acts as a docking site for IKK, increasing its local concentration in the vicinity of the p105 PEST region and facilitating efficient serine 927 phosphorylation.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Ley, SC (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Mill Hill, London NW7 1AA, England.	sley@nimr.mrc.ac.uk						ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Syrovets T, 2001, BLOOD, V97, P3941, DOI 10.1182/blood.V97.12.3941; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24162	24168		10.1074/jbc.M201576200	http://dx.doi.org/10.1074/jbc.M201576200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976329	hybrid			2022-12-25	WOS:000176611800026
J	Bottini, N; Stefanini, L; Williams, S; Alonso, A; Jascur, T; Abraham, RT; Couture, C; Mustelin, T				Bottini, N; Stefanini, L; Williams, S; Alonso, A; Jascur, T; Abraham, RT; Couture, C; Mustelin, T			Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE-COMMON ANTIGEN; T-CELLS; SIGNAL-TRANSDUCTION; ACID-PHOSPHATASE; KINASE PP56LCK; GROWTH-FACTOR; PHOSPHORYLATION; CD45	The ZAP-70 protein-tyrosine kinase plays a central role in signaling from the T cell antigen receptor. Recruitment and activation of ZAP-70 are transient and are terminated by phosphorylation of negative regulatory tyrosine residues and dephosphorylation of positively acting sites. We report that the low molecular weight protein-tyrosine phosphatase (LMPTP) specifically dephosphorylates the negative regulatory Tyr-292 of ZAP-70, thereby counteracting inactivation of ZAP-70. Expression of low levels of LMPTP resulted in increased ZAP-70 phosphorylation, presumably at the activating Tyr-493 and other sites, increased kinase activity, and augmented downstream signaling to the mitogen-activated protein kinase pathway. The ZAP-70 Y292F mutant was not affected by LMPTP. Our results indicate that LMPTP, like CD45, dephosphorylates a negative regulatory tyrosine site in a protein-tyrosine kinase and thereby strengthens T cell receptor signaling.	Burnham Inst, Program Signal Transduct, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), Burnham Inst, Program Signal Transduct, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Alonso, Andrés/L-7523-2014; Ingegnoli, Francesca/B-6226-2017	Alonso, Andrés/0000-0001-8674-9378; Ingegnoli, Francesca/0000-0002-6727-1273; Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI40552, AI48032, AI35603] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603, R01AI040552, R01AI048032, R21AI040552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; DISSING J, 1987, BIOCHEM GENET, V25, P901, DOI 10.1007/BF00502609; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Gibson S, 1996, J IMMUNOL, V156, P2716; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Han SL, 2000, EUR J IMMUNOL, V30, P1318, DOI 10.1002/(SICI)1521-4141(200005)30:5<1318::AID-IMMU1318>3.0.CO;2-G; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD85, DOI 10.2741/mustelin; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; TURKA LA, 1992, EUR J IMMUNOL, V22, P551, DOI 10.1002/eji.1830220238; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WO YYP, 1992, J BIOL CHEM, V267, P10856; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	49	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24220	24224		10.1074/jbc.M202885200	http://dx.doi.org/10.1074/jbc.M202885200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976341	hybrid			2022-12-25	WOS:000176611800033
J	Chen-Park, FE; Huang, DB; Noro, B; Thanos, D; Ghosh, G				Chen-Park, FE; Huang, DB; Noro, B; Thanos, D; Ghosh, G			The kappa B DNA sequence from the HIV long terminal repeat functions as an allosteric regulator of HIV transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; P50/P65 HETERODIMER; BETA ENHANCEOSOME; ACTIVATION; BINDING; HOMODIMER; MECHANISM; RECEPTOR; CBP/P300; PROMOTER	NF-kappaB is an inducible transcription factor involved in the immune response, inflammation, and viral transcription. To address how the two NF-kappaB and three Sp1 binding sites of the human immunodeficiency virus (HIV) long terminal repeat (LTR) control multiple activator assembly and transcription, we first observed and compared unique conformations between the crystallographic structure of the NF-kappaB p50-p65 heterodimer bound to the uPA-kappaB target site to that of the p50-p65-HIV-kappaB complex. Next, cooperativity between two NF-kappaB molecules bound to tandem HIV-kappaB sequences was measured as well as that of NF-kappaB and transcription factor Sp1 when bound to adjacent sites. The cooperativity of hybrid HIV-LTR enhancers was measured with the 3' kappaB site converted to uPA-kappaB or to interferon beta gene enhancer kappaB. The hybrids were defective in transcriptional activator assembly and less active transcriptionally. These functional differences correlate with observed conformational differences and demonstrate that distinct kappaB DNA sequences function as allosteric regulators in a gene-specific manner.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Columbia University	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,9500 Gilman Dr, La Jolla, CA 92093 USA.		Thanos, Dimitris/AAE-5720-2019					BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1998, ACTA CRYSTALLOGR D, V10, P25; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; Holmbeck SMA, 1998, J MOL BIOL, V284, P533, DOI 10.1006/jmbi.1998.2207; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P219; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; Roebuck KA, 1999, INT J MOL MED, V4, P223; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Tisne C, 1999, J MOL BIOL, V293, P139, DOI 10.1006/jmbi.1999.3157; Tisne C, 1998, J MOL BIOL, V279, P127, DOI 10.1006/jmbi.1998.1757; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	41	73	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24701	24708		10.1074/jbc.M200007200	http://dx.doi.org/10.1074/jbc.M200007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11970949	hybrid			2022-12-25	WOS:000176611800096
J	Donelan, MJ; Morfini, G; Julyan, R; Sommers, S; Hays, L; Kajio, H; Briaud, I; Easom, RA; Molkentin, JD; Brady, ST; Rhodes, CJ				Donelan, MJ; Morfini, G; Julyan, R; Sommers, S; Hays, L; Kajio, H; Briaud, I; Easom, RA; Molkentin, JD; Brady, ST; Rhodes, CJ			Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells - Implications for regulated beta-granule transport and insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGHT-CHAIN; IN-VIVO; PHOSPHORYLATION; SECRETION; GLUCOSE; ISLETS; RAT; CALCINEURIN; INHIBITION	The specific biochemical steps required for glucose-regulated insulin exocytosis from beta-cells are not well defined. Elevation of glucose leads to increases in cytosolic [Ca2+](i) and biphasic release of insulin from both a readily releasable and a storage pool of beta-granules. The effect of elevated [Ca2+](i) on phosphorylation of isolated beta-granule membrane proteins was evaluated, and the phosphorylation of four proteins was found to be altered by [Ca2+](i). One (a 18/20-kDa doublet) was a Ca2+-dependent increase in phosphorylation, and, surprisingly, three others (138, 42, and 36 kDa) were Ca2+-dependent dephosphorylations. The 138-kDa beta-granule phosphoprotein was found to be kinesin heavy chain (KHC). At low levels of [Ca2+](i) KHC was phosphorylated by casein kinase 2, but KHC was rapidly dephosphorylated by protein phosphatase 2B beta (PP2Bbeta) as [Ca2+](i) increased. Inhibitors of PP2B specifically reduced the second, microtubule-dependent, phase of insulin secretion, suggesting that dephosphorylation of KHC was required for transport of beta-granules from the storage pool to replenish the readily releasable pool of beta-granules. This is distinct from synaptic vesicle exocytosis, because neurotransmitter release from synaptosomes did not require a Ca2+-dependent KHC dephosphorylation. These results suggest a novel mechanism for regulating KHC function and beta-granule transport in beta-cells that is mediated by casein kinase 2 and PP2B. They also implicate a novel regulatory role for PP2B/calcineurin in the control of insulin secretion downstream of a rise in [Ca2+](i).	Pacific NW Res Inst, Seattle, WA 98112 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98112 USA	Cincinnati Children's Hospital Medical Center; University of North Texas System; University of North Texas Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98112 USA.	cjr@pnri.org	Morfini, Gerardo/AAP-8070-2021	Morfini, Gerardo/0000-0001-6059-5518; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041170, R56NS023868, R01NS023868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG012646] Funding Source: NIH RePORTER; NIA NIH HHS [AG12646] Funding Source: Medline; NIDDK NIH HHS [DK47919] Funding Source: Medline; NINDS NIH HHS [NS41170, NS23868] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ALARCON C, 1995, J CLIN INVEST, V95, P1032, DOI 10.1172/JCI117748; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; BALCZON R, 1992, ENDOCRINOLOGY, V131, P331, DOI 10.1210/en.131.1.331; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BOYD AE, 1982, J CELL BIOL, V92, P425, DOI 10.1083/jcb.92.2.425; BRADY ST, 1995, TRENDS CELL BIOL, V5, P159, DOI 10.1016/S0962-8924(00)88980-1; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEROLD KC, 1993, TRANSPLANTATION, V55, P186, DOI 10.1097/00007890-199301000-00035; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; Kajio H, 2001, DIABETES, V50, P2029, DOI 10.2337/diabetes.50.9.2029; Kenyon NS, 1998, DIABETES METAB REV, V14, P303, DOI 10.1002/(SICI)1099-0895(199812)14:4<303::AID-DMR243>3.0.CO;2-E; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Meng YX, 1997, ENDOCRINOLOGY, V138, P1979, DOI 10.1210/en.138.5.1979; MONTAGUE W, 1975, BIOCHEM J, V148, P237, DOI 10.1042/bj1480237; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; OLSZEWSKI S, 1994, J BIOL CHEM, V269, P27987; PENN EJ, 1982, FEBS LETT, V139, P4, DOI 10.1016/0014-5793(82)80474-2; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Seiler S, 2000, NAT CELL BIOL, V2, P333, DOI 10.1038/35014022; Sistiaga A, 2000, NEUROPHARMACOLOGY, V39, P1544, DOI 10.1016/S0028-3908(00)00034-4; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Thaler C D, 1996, Int Rev Cytol, V164, P269; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Woehlke G, 2000, NAT REV MOL CELL BIO, V1, P50, DOI 10.1038/35036069; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	57	80	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24232	24242		10.1074/jbc.M203345200	http://dx.doi.org/10.1074/jbc.M203345200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978799	hybrid			2022-12-25	WOS:000176611800035
J	Sekine, K; Hase, T; Sato, N				Sekine, K; Hase, T; Sato, N			Reversible DNA compaction by sulfite reductase regulates transcriptional activity of chloroplast nucleoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTIANA-TABACUM-L; DEPENDENT RNA-POLYMERASE; PROPLASTID-NUCLEI; CULTURED-CELLS; MOLECULAR CHARACTERIZATION; ENVELOPE MEMBRANE; PLASTID NUCLEOIDS; ESCHERICHIA-COLI; BINDING PROTEIN; PEND PROTEIN	The transcriptional activity of nucleoids changes during plastid development, presumably due to the morphological and molecular differences of the nucleoids. Pea chloroplast nucleoids have an abundant 70-kDa protein identified as sulfite reductase (SiR) that can compact DNA. Using an in vitro transcription assay, we show here that heparin increased the transcriptional activity of chloroplast nucleoids with concomitant release of SiR. Using a fluorometric method we developed for analyzing DNA compaction, we found that the fluorescence intensity of chloroplast DNA stained with 4',6-diamidino-2-phenylindole was decreased by the addition of SiR and increased by the subsequent addition of heparin. Addition of exogenous SiR increased the compaction of isolated nucleoids, and the addition of heparin relaxed it. SiR effectively repressed the in vitro transcription activity of nucleoids and counteracted the activation by heparin. These results suggest that SiR regulates the transcriptional activity of chloroplast nucleoids through changes in DNA compaction.	Saitama Univ, Fac Sci, Dept Mol Biol, Saitama, Saitama 3388570, Japan; Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Saitama University; Osaka University	Sato, N (corresponding author), Saitama Univ, Fac Sci, Dept Mol Biol, 255 Shimo Ohkubo, Saitama, Saitama 3388570, Japan.	naokisat@molbiol.saitama-u.ac.jp	Hase, Toshiharu/H-9271-2013	Sato, Naoki/0000-0001-6230-0410				Allison LA, 2000, BIOCHIMIE, V82, P537, DOI 10.1016/S0300-9084(00)00611-8; Baba K, 2001, PLANT PHYSIOL, V125, P595, DOI 10.1104/pp.125.2.595; BLINGLY M, 2000, EMBO J, V19, P1851; BRIAT JF, 1980, EUR J BIOCHEM, V111, P503, DOI 10.1111/j.1432-1033.1980.tb04966.x; Cannon GC, 1999, PLANT MOL BIOL, V39, P835, DOI 10.1023/A:1006135615924; Frenkiel-Krispin D, 2001, EMBO J, V20, P1184, DOI 10.1093/emboj/20.5.1184; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Ideguchi T, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P713; KADESCH TR, 1980, J MOL BIOL, V136, P79, DOI 10.1016/0022-2836(80)90367-8; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; KUROIWA T, 1991, INT REV CYTOL, V128, P1; MADON J, 1983, EUR J BIOCHEM, V135, P279, DOI 10.1111/j.1432-1033.1983.tb07649.x; MARRISON JL, 1992, PLANT J, V2, P783, DOI 10.1111/j.1365-313X.1992.tb00147.x; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; McLeod SM, 2001, CURR OPIN MICROBIOL, V4, P152, DOI 10.1016/S1369-5274(00)00181-8; Murakami S, 2000, FEBS LETT, V468, P15, DOI 10.1016/S0014-5793(00)01186-8; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; NEMOTO Y, 1990, PLANT CELL PHYSIOL, V31, P767; NEMOTO Y, 1989, PLANT CELL PHYSIOL, V30, P445; NEMOTO Y, 1988, PLANT CELL PHYSIOL, V29, P167; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Ringrose L, 2001, NATURE, V412, P493, DOI 10.1038/35087692; Sakai A, 1998, PLANT CELL PHYSIOL, V39, P928, DOI 10.1093/oxfordjournals.pcp.a029456; SAKAI A, 1991, PLANT CELL PHYSIOL, V32, P835; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Sato N, 1999, BIOCHIMIE, V81, P619, DOI 10.1016/S0300-9084(99)80119-9; Sato N, 2001, NUCLEIC ACIDS RES, V29, P2244, DOI 10.1093/nar/29.11.2244; Sato N, 2001, TRENDS PLANT SCI, V6, P151, DOI 10.1016/S1360-1385(01)01888-X; Sato N, 1998, PLANT CELL, V10, P859, DOI 10.1105/tpc.10.5.859; SATO N, 1993, EMBO J, V12, P555, DOI 10.1002/j.1460-2075.1993.tb05687.x; Sato N, 1997, PROTOPLASMA, V200, P163, DOI 10.1007/BF01283292; Sato N, 2001, FEBS LETT, V487, P347, DOI 10.1016/S0014-5793(00)02342-5; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; Wolffe AP, 2001, CELL, V104, P631, DOI 10.1016/S0092-8674(02)01453-8; Yonekura-Sakakibara K, 1998, J BIOCHEM, V124, P615, DOI 10.1093/oxfordjournals.jbchem.a022156; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010	38	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24399	24404		10.1074/jbc.M201714200	http://dx.doi.org/10.1074/jbc.M201714200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11997391	hybrid			2022-12-25	WOS:000176611800057
J	Virumae, K; Saarma, U; Horowitz, J; Remme, J				Virumae, K; Saarma, U; Horowitz, J; Remme, J			Functional importance of the 3 '-terminal adenosine of tRNA in ribosomal translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA BINDING; UNMODIFIED TRANSFER-RNA; ELONGATION-FACTOR TU; A-SITE; 3'-CCA END; P-SITE; TRANSLOCATION; NUCLEOTIDES; 3'-END	The, universally conserved T-terminal CCA sequence of tRNA interacts with large ribosomal subunit RNA during translation. The functional importance of the interaction between the T-terminal nucleotide of tRNA and the ribosome was studied in vitro using mutant in vitro transcribed tRNA(Val) A76G. Val-tRNA(CCG)., does not support polypeptide synthesis on poly(GUA) as a message. However, in a co-translation system, where Val-tRNA(CCG), represented only a small fraction of total Val-tRNA(CCG) the mutant tRNA is able to transfer valine into a polypeptide chain, albeit at a reduced level. The A76G mutation does not affect binding of Val- or NAcVal-tRNA(CCG) to the A- or P-sites as shown by efficient peptide bond formation, although the donor activity of the mutant NAcVal-tRNA(CCG) in the peptidyl transfer reaction is slightly reduced compared with wild-type NAeVal-tRNA. Translocation of 3'-CCG-tRNA from the P-to the E-site is not significantly influenced. However, the A76G mutation drastically inhibits translocation of peptidyl-tRNA G 76 from the ribosomal A-site to the P-site, which apparently explains its failure to support cell-free protein synthesis. Our results indicate that the identity of the T-terminal nucleotide of tRNA is critical for tRNA movement in the ribosome.	Univ Tartu, Inst Mol & Cell Biol, EE-51010 Tartu, Estonia; Estonian Bioctr, EE-51010 Tartu, Estonia; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	University of Tartu; Estonian Biocentre; Iowa State University	Remme, J (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Riia 23, EE-51010 Tartu, Estonia.		Remme, Jaanus/A-4614-2011; Saarma, Urmas/AAC-9813-2019; Remme, Jaanus/L-1830-2019; Saarma, Urmas/J-6448-2015	Remme, Jaanus/0000-0002-4011-6580; Saarma, Urmas/0000-0002-3222-571X; Remme, Jaanus/0000-0002-4011-6580; Saarma, Urmas/0000-0002-3222-571X	FIC NIH HHS [TW00870] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; Bocchetta M, 2001, RNA, V7, P54, DOI 10.1017/S1355838201001650; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; BOURD SB, 1983, EUR J BIOCHEM, V135, P465, DOI 10.1111/j.1432-1033.1983.tb07674.x; CHLADEK S, 1985, ANGEW CHEM INT EDIT, V24, P371, DOI 10.1002/anie.198503711; CHU WC, 1989, NUCLEIC ACIDS RES, V17, P7241, DOI 10.1093/nar/17.18.7241; CLAESSON C, 1990, FEBS LETT, V273, P173, DOI 10.1016/0014-5793(90)81077-2; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Feinberg JS, 2001, P NATL ACAD SCI USA, V98, P11120, DOI 10.1073/pnas.211184098; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAENNI AL, 1966, BIOCHIM BIOPHYS ACTA, V114, P135, DOI 10.1016/0005-2787(66)90261-9; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; Khaitovich P, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P229; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; Leder P, 1973, Adv Protein Chem, V27, P213, DOI 10.1016/S0065-3233(08)60448-9; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Liu JCH, 1998, RNA, V4, P639, DOI 10.1017/S1355838298980013; LIU MS, 1994, P NATL ACAD SCI USA, V91, P10389, DOI 10.1073/pnas.91.22.10389; LIU MS, 1993, BIOTECHNIQUES, V15, P264; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; NAZARENKO IA, 1994, EMBO J, V13, P2464, DOI 10.1002/j.1460-2075.1994.tb06531.x; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SAMUELSSON T, 1988, J BIOL CHEM, V263, P13692; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; Spahn CMT, 1996, J BIOL CHEM, V271, P32849, DOI 10.1074/jbc.271.51.32849; STRELTSOV S, 1979, FEBS LETT, V104, P279, DOI 10.1016/0014-5793(79)80832-7; TAMURA K, 1994, FEBS LETT, V353, P173, DOI 10.1016/0014-5793(94)01038-2; TAMURA K, 1994, J BIOL CHEM, V269, P22173; TEZUKA M, 1990, BIOCHEMISTRY-US, V29, P667, DOI 10.1021/bi00455a011; WAGNER T, 1983, BIOCHEMISTRY-US, V22, P94, DOI 10.1021/bi00270a013; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; Wower J, 2000, J BIOL CHEM, V275, P37887, DOI 10.1074/jbc.M005031200; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	43	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24128	24134		10.1074/jbc.M200393200	http://dx.doi.org/10.1074/jbc.M200393200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967262	hybrid			2022-12-25	WOS:000176611800021
J	Drachman, JG; Miyakawa, Y; Luthi, JN; Dahlen, DD; Raney, A; Geddis, AE; Kaushansky, K				Drachman, JG; Miyakawa, Y; Luthi, JN; Dahlen, DD; Raney, A; Geddis, AE; Kaushansky, K			Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; THROMBOPOIETIN SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; KINASE ACTIVATION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; FUNCTIONAL-ANALYSIS; C-MYC; ERYTHROPOIETIN RECEPTOR; SHC PHOSPHORYLATION	The thrombopoietin (TPO) receptor c-Mpl, like other members of the cytokine receptor superfamily, requires the association and activation of Janus kinases (JAKs) for normal signal transduction. The membrane-proximal portion of the signaling domain, containing conserved box1 and box2 motifs, is sufficient to support the proliferation of cytokine-dependent cell lines and basal megakaryocytopoiesis in vivo. We hypothesized that activation of the JAK2 kinase alone might be sufficient for proliferative signaling. To test this premise, we constructed chimeric receptors in which the extracellular and transmembrane portions of Mpl were fused to the pseudokinase and kinase domains of murine JAK2 kinase. When expressed in the interleukin-3-dependent cell line Ba/F3, the chimeric receptors were appropriately expressed on the cell surface and were able to initiate tyrosine kinase activity upon exposure to TPO. However, chimeric receptors lacking an intact box2 domain of Mpl were unable to support proliferation at any concentration of TPO. Only chimeric receptors containing both JAK2 kinase activity and the box2 region initiated proliferative signaling. Within the box2 motif, we determined that the sequence Glu(56)-Ile(57)-Leu(58) of the Mpl cytoplasmic domain is critical for proliferation of the chimeric receptors. Furthermore, TPO-dependent induction of c-myc transcription is also dependent on this motif. These results indicate that JAK2 activation alone is not sufficient for TPO-induced proliferation and that one or more essential signaling pathways must arise from the cytoplasmic domain of Mpl that includes box2. Although the nature of the signal transduction pathway is not yet known, this second proliferative event is likely to regulate c-myc expression.	Puget Sound Blood Ctr, Seattle, WA 98104 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Puget Sound Blood Center; University of Washington; University of Washington Seattle	Drachman, JG (corresponding author), Puget Sound Blood Ctr, 921 Terry Ave, Seattle, WA 98104 USA.				NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003498, R01HL065498] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA31615] Funding Source: Medline; NHLBI NIH HHS [R01 HL65498, K08 HL03498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BENIT L, 1994, J VIROL, V68, P5270; Bondurant MC, 1996, J CELL PHYSIOL, V168, P255, DOI 10.1002/(SICI)1097-4652(199608)168:2<255::AID-JCP4>3.0.CO;2-O; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Dahlen DD, 2000, BLOOD, V96, p571A; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Kaushansky K, 1999, BIOESSAYS, V21, P353, DOI 10.1002/(SICI)1521-1878(199904)21:4<353::AID-BIES12>3.0.CO;2-P; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Porteu F, 1996, MOL CELL BIOL, V16, P2473; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sayeski PP, 1999, CIRC RES, V84, P1332, DOI 10.1161/01.RES.84.11.1332; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; Thompson A, 1996, J BIOL CHEM, V271, P22976, DOI 10.1074/jbc.271.38.22976; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	45	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23544	23553		10.1074/jbc.M201120200	http://dx.doi.org/10.1074/jbc.M201120200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980901	hybrid			2022-12-25	WOS:000176475700059
J	Woulfe, D; Jiang, H; Mortensen, R; Yang, J; Brass, LF				Woulfe, D; Jiang, H; Mortensen, R; Yang, J; Brass, LF			Activation of Rap1B by G(i) family members in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE; G-PROTEIN; RECEPTOR; IDENTIFICATION; ADP; THROMBOEMBOLISM; INTEGRIN; SIGNAL; AGGREGATION; RESISTANCE	It has become increasingly appreciated that receptors coupled to Galpha(i) family members can stimulate platelet aggregation, but the mechanism for this has remained unclear. One possible mediator is the small GTPase, Rap1, which has been shown to contribute to integrin activation in several cell lines and to be activated by a calcium-dependent mechanism in platelets. Here, we demonstrate that Rap1 is also activated by Gai family members in platelets. First, we show that platelets from mice lacking the Gai family member Galpha(z) (which couples to the alpha(2A) adrenergic receptor) are deficient in epinephrine-stimulated Rap1 activation. We also show that platelets from mice lacking Galpha(i2), which couples to the ADP receptor, P2Y12, exhibit reduced Rap1 activation in response to ADP. In contrast, platelets from mice that lack Galpha(q) show no decrease in the ability to activate Rap1 in response to epinephrine but show a partial reduction in ADP-stimulated Rap1 activation. This result, combined with studies of human platelets treated with ADP` receptor-selective inhibitors, indicates that ADP-stimulated Rap1 activation in human platelets is dependent on both the Galpha(i)-coupled P2Y12 receptor and the Galpha(q)-coupled P2Y1 receptor. Galpha(i)-dependent activation of Rap1 in platelets does not appear to be mediated by enhanced intracellular calcium release because no increase in intracellular calcium concentration was detected in response to epinephrine and because the calcium response to ADP` was not diminished in platelets from the Galpha(12)-/- mouse. Finally, using human platelets treated with selective inhibitors of phosphatidylinositol 3-kinase (PI3K) and mouse platelets selectively lacking the Goy-activated form of his enzyme (PI3Kgamma), we show that G(i)-mediated Rap1 activation is PI3K-dependent. In summary, activation of Rap1 can be stimulated by G(q)- and PI3K-dependent mechanisms in platelets and by G(q)- and Ca2+-dependent mechanisms, both of which may play a role in promoting platelet activation.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Michigan, Dept Physiol & Med Endocrine, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan	Brass, LF (corresponding author), Univ Penn, Dept Med, Rm 913 BRB-II,421 Curie Blvd, Philadelphia, PA 19104 USA.	Brass@mail.med.upenn.edu			NHLBI NIH HHS [HL-45181, HL-40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL045181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTONI A, 2002, IN PRESS J BIOL CHEM, V277; Brass LF, 1999, J CLIN INVEST, V104, P1663, DOI 10.1172/JCI8944; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Daniel JL, 1999, THROMB HAEMOSTASIS, V82, P1322; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gabbeta J, 1997, P NATL ACAD SCI USA, V94, P8750, DOI 10.1073/pnas.94.16.8750; GAGNON AW, 1991, BLOOD, V78, P1247; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kauffenstein G, 2001, FEBS LETT, V505, P281, DOI 10.1016/S0014-5793(01)02824-1; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Koziak K, 2001, BRIT J HAEMATOL, V114, P134, DOI 10.1046/j.1365-2141.2001.02894.x; Larson MK, 2001, BLOOD, V98, p751A; Leon C, 2001, CIRCULATION, V103, P718; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; MARTI KB, 1992, P NATL ACAD SCI USA, V89, P2784, DOI 10.1073/pnas.89.7.2784; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Nagano T, 2000, J NEUROCHEM, V75, P1, DOI 10.1046/j.1471-4159.2000.0750001.x; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; WILLIAMS AG, 1990, BLOOD, V76, P721; Woulfe D, 2001, J CLIN INVEST, V107, P1503, DOI 10.1172/JCI13361; WOULFE D, 2002, IN PRESS PLATELETS; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	36	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23382	23390		10.1074/jbc.M202212200	http://dx.doi.org/10.1074/jbc.M202212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970953	hybrid			2022-12-25	WOS:000176475700038
J	Agellon, LB; Drover, VAB; Cheema, SK; Gbaguidi, GF; Walsh, A				Agellon, LB; Drover, VAB; Cheema, SK; Gbaguidi, GF; Walsh, A			Dietary cholesterol fails to stimulate the human cholesterol 7 alpha-hydroxylase gene (CYP7A1) in transgenic mice.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; RECEPTOR LXR-ALPHA; BILE-ACID BIOSYNTHESIS; THYROID-HORMONE; HYPOPHYSECTOMIZED RATS; NUCLEAR RECEPTORS; PATHWAY; EXPRESSION; LIVER; MOUSE	Dietary cholesterol has been shown to have a stimulatory effect on the murine cholesterol 7alpha-hydroxylase gene (Cyp7a1), but its effect on human cholesterol 7alpha-hydroxylase gene (CYP7A1) expression in vivo is not known. A transgenic mouse strain harboring the human CYP7A1 gene and homozygous for the disrupted murine Cyp7a1 gene was created. Cholesterol feeding increased the expression of the endogenous modified Cyp7a1 allele but failed to stimulate the human CYP7A1 transgene. In transfected hepatoma cells, 25-hydroxycholesterol increased murine Cyp7a1 gene promoter activity, whereas the human CYP7A1 gene promoter was unresponsive. Electrophoretic mobility shift assays demonstrated the interaction of the liver X receptor alpha (LXRalpha): retinoid X receptor (RXR) heterodimer, a transcription factor complex that is activated by oxysterols, with the murine Cyp7a1 gene promoter, whereas no binding to the human CYP7A1 gene promoter was detected. The results demonstrate that the human CYP7A1 gene is not stimulated by dietary cholesterol in the intact animal, and this is attributable to the inability of the CYP7A1 gene promoter to interact with LXRalpha:RXR.	Univ Alberta, Heritage Med Res Ctr 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	University of Alberta; University of Alberta; Rockefeller University	Agellon, LB (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada.							Agellon LB, 1997, BIOCHEM CELL BIOL, V75, P255, DOI 10.1139/bcb-75-3-255; Agellon LB, 2000, BBA-MOL CELL BIOL L, V1486, P198, DOI 10.1016/S1388-1981(00)00057-3; Cheema SK, 2000, J BIOL CHEM, V275, P12530, DOI 10.1074/jbc.275.17.12530; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Drover VAB, 2002, MOL ENDOCRINOL, V16, P14, DOI 10.1210/me.16.1.14; Goodart SA, 1999, BIOCHEM BIOPH RES CO, V266, P454, DOI 10.1006/bbrc.1999.1799; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; NESS GC, 1994, BBA-LIPID LIPID MET, V1214, P229, DOI 10.1016/0005-2760(94)90068-X; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Qiu Y, 2001, GENOMICS, V73, P66, DOI 10.1006/geno.2000.6467; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 2001, J LIPID RES, V42, P1594; Torchia EC, 1996, BIOCHEM BIOPH RES CO, V225, P128, DOI 10.1006/bbrc.1996.1141; WOOD TG, 1984, P NATL ACAD SCI USA, V24, P7817	24	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20131	20134		10.1074/jbc.C200105200	http://dx.doi.org/10.1074/jbc.C200105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11967256	hybrid			2022-12-25	WOS:000176204500006
J	Claij, N; Riele, HT				Claij, N; Riele, HT			Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level	ONCOGENE			English	Article						mismatch repair; methylation tolerance; microsatellite instability; mutation frequency; homologous recombination	GENE; PREDISPOSITION; HMSH2-HMSH6; DEFICIENCY; EXPRESSION; RESISTANCE; MUTATIONS; FREQUENCY; HMLH1; HMSH2	Loss of DNA mismatch repair has been found in tumors associated with the familial cancer predisposition syndrome HNPCC (hereditary non-polyposis colorectal cancer) and a subset of sporadic cancers. MSH2 deficiency abolishes the action of the mismatch repair system, resulting in a phenotype which is characterized by an increased accumulation of base substitutions and frameshifts, enhanced recombination between homologous but non-identical DNA sequences, and tolerance to the cytotoxic effects of methylating agents. In this study we describe an embryonic stem cell line in which the level of MSH2 protein is 10-fold reduced compared to that in wild-type cells. Remarkably, these MSH2-low cells were as resistant to killing by methylating agents as cells completely lacking MSH2, while they had retained almost maximal mismatch repair capacity as judged from their anti-mutagenic and anti-recombinogenic capacity and the absence of microsatellite instability. In contrast, MSH2-low cells were highly sensitive to methylation-damage induced mutagenesis. Thus, 10-fold reduced MSH2 protein levels render cells resistant to the toxic and highly sensitive to the mutagenic effects of methylating agents. This condition is not manifested by microsatellite instability and may have implications four both the etiology and treatment of cancer.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl						Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Berardini M, 2000, J BIOL CHEM, V275, P27851; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Friedman HS, 1997, CANCER RES, V57, P2933; Fritzell JA, 1997, CANCER RES, V57, P5143; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Kane MF, 1997, CANCER RES, V57, P808; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; Lynch HT, 2000, J CLIN ONCOL, V18, p19S; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Shin KH, 2000, EUR J CANCER, V36, P925, DOI 10.1016/S0959-8049(00)00025-3; Shin KH, 1998, J CANCER RES CLIN, V124, P421, DOI 10.1007/s004320050194; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1998, GENETICS, V148, P1637; Zhu WB, 1998, MUTAT RES-FUND MOL M, V398, P93, DOI 10.1016/S0027-5107(97)00244-3	24	48	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2873	2879		10.1038/sj.onc.1205395	http://dx.doi.org/10.1038/sj.onc.1205395			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973647				2022-12-25	WOS:000175063700012
J	Shiratori, M; Suzuki, T; Itoh, C; Goto, M; Furuichi, Y; Matsumoto, T				Shiratori, M; Suzuki, T; Itoh, C; Goto, M; Furuichi, Y; Matsumoto, T			WRN helicase accelerates the transcription of ribosomal RNA as a component of an RNA polymerase I-associated complex	ONCOGENE			English	Article						nucleolar localization; RNA polymerase 1; rRNA transcription; senescence; Werner syndrome; WRN	WERNER-SYNDROME PROTEIN; SYNDROME GENE; DNA HELICASE; NUCLEAR-LOCALIZATION; GENOMIC STRUCTURE; YEAST SGS1; TOPOISOMERASE; REPLICATION; INTERACTS; HOMOLOG	Werner syndrome (WS) is a rare autosmomal recessive genetic disorder causing premature aging. The gene (WRN) responsible for WS encodes a protein homologous to the RecQ-type helicase. WRN has a nucleolar localization signal and shows intranuclear trafficking between the nucleolus and the nucleoplasm. WRN is recruited into the nucleolus when rRNA transcription is reactivated in quiescent cells. Inhibition of mRNA transcription with alpha-amanitin has no effect on nucleolar localization of WRN whereas inhibition of rRNA transcription with actinomycin D releases WRN from nucleoli, suggesting that nucleolar WRN is closely related to rRNA transcription by RNA polymerase I (RPI). A possible function of WRN on rRNA transcription through interaction with RPI is supported by the results described here showing that WRN is co-immunoprecipitated with an RPI subunit, RPA40. Here we show that WS fibroblasts are characterized by a decreased level of rRNA transcription compared with wild-type cells, and that the decreased level of rRNA transcription in WS fibroblasts recovers when wild-type WRN is exogenously expressed. By contrast, exogenously expressed mutant-type WRN lacking an ability to migrate into the nucleolus fails to stimulate rRNA transcription. These results suggest that WRN promotes rRNA transcription as a component of an RPI-associated complex in the nucleolus.	AGENE Res Inst, Kanagawa 2470063, Japan; Tokyo Metropolitan Otsuka Hosp, Dept Rheumatol, Toshima Ku, Tokyo 1700005, Japan		Matsumoto, T (corresponding author), Japanese Fdn Canc Res, Genome Ctr, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	takehisa.matsumoto@jfcr.or.jp						Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Dammann R, 1998, BBA-GENE STRUCT EXPR, V1396, P153, DOI 10.1016/S0167-4781(97)00206-6; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; STEIN GH, 1994, METHOD ENZYMOL, V58, P279; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Suzuki T, 2001, ONCOGENE, V20, P2551, DOI 10.1038/sj.onc.1204344; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	44	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2447	2454		10.1038/sj.onc.1205334	http://dx.doi.org/10.1038/sj.onc.1205334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971179				2022-12-25	WOS:000174918400001
J	Gilmore, AP; Valentijn, AJ; Wang, PB; Ranger, AM; Bundred, N; O'Hare, MJ; Wakeling, A; Korsmeyer, SJ; Streuli, CH				Gilmore, AP; Valentijn, AJ; Wang, PB; Ranger, AM; Bundred, N; O'Hare, MJ; Wakeling, A; Korsmeyer, SJ; Streuli, CH			Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-KINASE AKT; TYROSINE KINASE; BREAST-CANCER; EGF RECEPTOR; BH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; MAMMARY EPITHELIUM; ANTICANCER THERAPY	Novel cancer chemotherapeutics are required to induce apoptosis by activating pro-apoptotic proteins. Both epidermal growth factor (EGF) and insulin-like growth factor (IGF) provide potent survival stimuli in many epithelia, and activation of their receptors is commonly observed in solid human tumors. Here we demonstrate that blockade of the EGF receptor by a new drug in phase III clinical trails for cancer, ZD1839, potently induces apoptosis in mammary epithelial cell lines and primary cultures, as well as in a primary pleural effusion from a breast cancer patient. We identified the mechanism of apoptosis induction by ZD1839. We showed that it prevents cell survival by activating the pro-apoptotic protein BAD. Moreover, we demonstrate that IGF transactivates the EGF receptor and that ZD1839 blocks IGF-mediated phosphorylation of MAPK and BAD. Many cancer therapies kill tumor cells by inducing apoptosis as a consequence of targeting DNA; however, the threshold at which apoptosis can be triggered through DNA damage is often different from that in normal cells. Our results indicate that by targeting a growth factor-mediated survival signaling pathway, BAD phosphorylation can be manipulated therapeutically to induce apoptosis.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England; UCL, Ludwig Inst Canc Res, Breast Canc Lab, Dept Surg, London W1P 7LD, England; AstraZeneca, Macclesfield SK10 4TG, Cheshire, England; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Ludwig Institute for Cancer Research; University of London; University College London; AstraZeneca; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gilmore, AP (corresponding author), Univ Manchester, Sch Biol Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	agilmore@man.ac.uk						Auvinen PK, 1996, ACTA ONCOL, V35, P995, DOI 10.3109/02841869609100717; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOS JL, 1989, CANCER RES, V49, P4682; Brooks B, 1997, INT J CANCER, V73, P690, DOI 10.1002/(SICI)1097-0215(19971127)73:5<690::AID-IJC13>3.0.CO;2-A; Chan K. C., 1999, Breast Cancer Research and Treatment, V57, P27; Chan KC, 2001, BRIT J SURG, V88, P412, DOI 10.1046/j.1365-2168.2001.01686.x; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; delPeso L, 1997, SCIENCE, V278, P687; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fahraeus R, 1999, J PATHOL, V187, P138; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; KITTRELL FS, 1992, CANCER RES, V52, P1924; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peruzzi F, 2001, J BIOL CHEM, V276, P25990, DOI 10.1074/jbc.M103188200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pullan S, 1996, J CELL SCI, V109, P631; Pullan Shirley E., 1996, P97; Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schmitt CA, 1999, J PATHOL, V187, P127; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Umekita Y, 2000, INT J CANCER, V89, P484, DOI 10.1002/1097-0215(20001120)89:6<484::AID-IJC3>3.0.CO;2-S; Urso B, 2001, CELL SIGNAL, V13, P279, DOI 10.1016/S0898-6568(01)00130-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; White MF, 1998, RECENT PROG HORM RES, V53, P119; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang XH, 2000, BREAST CANCER RES, V2, P170, DOI 10.1186/bcr50; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	76	181	195	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27643	27650		10.1074/jbc.M108863200	http://dx.doi.org/10.1074/jbc.M108863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011069	hybrid			2022-12-25	WOS:000177189800011
J	Li, SC; Zhao, YG; He, X; Kim, TH; Kuharsky, DK; Rabinowich, H; Chen, J; Du, CY; Yin, XM				Li, SC; Zhao, YG; He, X; Kim, TH; Kuharsky, DK; Rabinowich, H; Chen, J; Du, CY; Yin, XM			Relief of extrinsic pathway inhibition by the bid-dependent mitochondrial release of smac in fas-mediated hepatocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-FREE SYSTEM; CASPASE ACTIVATION; STRUCTURAL BASIS; MOLECULAR CHARACTERIZATION; PROMOTES APOPTOSIS; 2-STEP MECHANISM; FAMILY PROTEINS; DEFICIENT MICE	The mitochondrial pathway is critical for the efficient execution of death receptor-initiated apoptosis in certain cell types. Questions remain as to why the mitochondria are required in that scenario. We investigated the molecular events that determined the need for the mitochondria by using an in vivo model of anti-Fas-induced hepatocyte apoptosis. In wild-type mice, Fas stimulation resulted in normal activation of caspase-3, with the generation of the active p19-p12 complex. In biddeficient mice, caspase-3 activation was arrested after the initial cleavage at Asp(175). This allowed the generation of the p12 small subunit, but the p20 large subunit could not be further processed to the p19 subunit. The p20-p12 complex generated by Fas stimulation in biddeficient hepatocytes was inactive, arresting the death program. Failure of p20/p12 caspase-.3 to mature and to exhibit activity was because of the inhibition by the inhibitor-of-apoptosis proteins (IAPs), such as XIAP, and also to a low caspase-8 activity. This block could be overcome in wild-type mice by two mechanisms. Smac was released from mitochondria early following Fas activation and was competitively bound to the IAPs to reverse their effects. XIAP could also be cleaved, and this occurred later and was likely mediated by enhanced caspase activities. Both mechanisms were dependent on Bid and thus were not operative in bid-deficient hepatocytes. In conclusion, mitochondrial activation by Bid is required for reversing the IAP inhibition through Smac release. It is also required for the alternative activation of caspases through cytochrome c release, as demonstrated previously. Together, these events ensure a successful progression of the death program initiated by the death receptor activation in the hepatocyte.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stowers Institute for Medical Research	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 7th Floor,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu			NCI NIH HHS [R01 CA 83817, K01 CA 74885] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA074885, R01CA083817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bajt ML, 2000, TOXICOL SCI, V58, P109, DOI 10.1093/toxsci/58.1.109; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Johnson DE, 2000, CANCER RES, V60, P1818; Juan TSC, 1996, ONCOGENE, V13, P749; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nguyen M, 1998, J BIOL CHEM, V273, P33099, DOI 10.1074/jbc.273.50.33099; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Woo M, 1999, J IMMUNOL, V163, P4909; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	64	113	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26912	26920		10.1074/jbc.M200726200	http://dx.doi.org/10.1074/jbc.M200726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011074	hybrid			2022-12-25	WOS:000177055900029
J	Sipos, K; Lange, H; Fekete, Z; Ullmann, P; Lill, R; Kispal, G				Sipos, K; Lange, H; Fekete, Z; Ullmann, P; Lill, R; Kispal, G			Maturation of cytosolic iron-sulfur proteins requires glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ABC TRANSPORTER; SACCHAROMYCES-CEREVISIAE; SULFHYDRYL OXIDASE; ESCHERICHIA-COLI; CLUSTER BIOSYNTHESIS; OXIDATIVE STRESS; FE/S PROTEINS; YEAST; METABOLISM; ISCU	Glutathione is the major protective agent against oxidative stress in Saccharomyces cerevisiae. Deletion of the GSH1 gene (strain Deltagsh1) encoding the enzyme that catalyzes the first step of glutathione biosynthesis leads to growth arrest, which can be relieved by either glutathione or reducing agents such as dithiothreitol. Because defects in the biosynthesis of cellular iron-sulfur (Fe/S) proteins are associated with increases in glutathione levels, we examined the consequences of glutathione depletion on this essential process. No significant defects were detected in the amounts, activities, and maturation of mitochondrial Fe/S proteins in glutathione-depleted Deltagsh1 cells. On the contrary, the maturation of extra-mitochondrial Fe/S proteins was decreased substantially. The defect was rectified neither by addition of dithiothreitol nor under anaerobic: conditions excluding oxidative damage of Fe/S clusters. A double mutant in GSH1 and ATM1 encoding a mitochondrial ATP binding cassette (ABC) transporter involved in cytosolic Fe/S protein maturation is nonviable even in the presence of dithiothreitol. Similar to atm1 and other mutants defective in cytosolic Fe/S protein maturation, mitochondria from glutathione-depleted Deltagsh1 cells accumulated high amounts of iron. Together, our data demonstrate that glutathione, in addition to its protective role against oxidative damage, performs a novel and specific function in the maturation of cytosolic Fe/S proteins.	Univ Pecs, Fac Med, Inst Biochem, Pecs 7624, Hungary; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; CNRS, Inst Plant Mol Biol, Dept Plant Stress Response, UPR 2357, F-67083 Strasbourg, France	University of Pecs; Philipps University Marburg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kispal, G (corresponding author), Univ Pecs, Fac Med, Inst Biochem, Szigeti Ut 12, H-7624 Pecs, Hungary.	Gyula.Kispal@AOK.PTE.HU	Sipos, Katalin/B-5242-2015	Sipos, Katalin/0000-0002-6706-2682; Lange, Heike/0000-0002-8222-3448; Lill, Roland/0000-0002-8345-6518; Fekete, Zsuzsanna/0000-0002-4264-2365				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; COMMANDEUR JNM, 1995, PHARMACOL REV, V47, P271; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; INOUE K, 1988, J BIOCHEM-TOKYO, V104, P777, DOI 10.1093/oxfordjournals.jbchem.a122549; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KISPAL G, 1988, J BIOL CHEM, V263, P11145; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lisowsky T, 2001, DIGEST LIVER DIS, V33, P173, DOI 10.1016/S1590-8658(01)80074-8; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Marquet A, 2001, VITAM HORM, V61, P51; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; Penninckx M, 2000, ENZYME MICROB TECH, V26, P737, DOI 10.1016/S0141-0229(00)00165-4; PENNINCKX MJ, 1993, ADV MICROB PHYSIOL, V34, P239, DOI 10.1016/S0065-2911(08)60031-4; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	46	166	170	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26944	26949		10.1074/jbc.M200677200	http://dx.doi.org/10.1074/jbc.M200677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011041	hybrid			2022-12-25	WOS:000177055900033
J	Gelebart, P; Kovacs, T; Brouland, JP; van Gorp, R; Grossmann, J; Rivard, N; Panis, Y; Martin, V; Bredoux, R; Enouf, J; Papp, B				Gelebart, P; Kovacs, T; Brouland, JP; van Gorp, R; Grossmann, J; Rivard, N; Panis, Y; Martin, V; Bredoux, R; Enouf, J; Papp, B			Expression of endomembrane calcium pumps in colon and gastric cancer cells - Induction of SERCA3 expression during differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; HISTONE DEACETYLASE INHIBITORS; RETICULUM CA2+-ATPASE-3 GENE; MESSENGER-RNA LEVELS; LARGE-BOWEL CANCER; CHAIN FATTY-ACIDS; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; DIETARY FIBER	Calcium mobilization from the endoplasmic reticulum (ER) into the cytosol is a key component of several signaling networks controlling tumor cell growth, differentiation, or apoptosis. Sarco/endoplasmic reticulum calcium transport ATPases (SERCA-type calcium pumps), enzymes that accumulate calcium in the ER, play an important role in these phenomena. We report that SERCA3 expression is significantly reduced or lost in colon carcinomas when compared with normal colonic epithelial cells, which express this enzyme at a high level. To study the involvement of SERCA enzymes in differentiation, in this work differentiation of colon and gastric cancer cell lines was initiated, and the change in the expression of SERCA isoenzymes as well as intracellular calcium levels were investigated. Treatment of the tumor cells with butyrate or other established differentiation inducing agents resulted in a marked and specific induction of the expression of SERCA3, whereas the expression of the ubiquitous SERCA2 enzymes did not change significantly or was reduced. A similar marked increase in SERCA3 expression was found during spontaneous differentiation of post-confluent Caco-2 cells, and this closely correlated with the induction of other known markers of differentiation. Analysis of the expression of the SERCA3 alternative splice isoforms revealed induction of all three known iso-SERCA3 variants (3a, 3b, and 3c). Butyrate treatment of the KATO-III gastric cancer cells led to higher resting cytosolic calcium concentrations and, in accordance with the lower calcium affinity of SERCA3, to diminished ER calcium content. These data taken together indicate a defect in SERCA3 expression in colon cancers as compared with normal colonic epithelium, show that the calcium homeostasis of the endoplasmic reticulum may be remodeled during cellular differentiation, and indicate that SERCA3 constitutes an interesting new differentiation marker that may prove useful for the analysis of the phenotype of gastrointestinal adenocarcinomas.	Hop Lariboisiere, U348 INSERM, IFR 6, F-75010 Paris, France; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hop Lariboisiere, Serv Anat Pathol, F-75010 Paris, France; Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany; Univ Sherbrooke, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Hop Lariboisiere, Serv Chirurg Gen & Digest, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Regensburg; University of Sherbrooke; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Papp, B (corresponding author), Hop Lariboisiere, U348 INSERM, IFR 6, 8 Rue Guy Patin, F-75010 Paris, France.	bela.papp@inserm.lrb.ap-hop-paris.fr	Gelebart, Pascal/AAI-1439-2020; Kovács, Tünde/O-6020-2017	Gelebart, Pascal/0000-0003-2434-8987; Kovács, Tünde/0000-0003-1064-2616; Papp, Bela/0000-0002-5025-3087; Brouland, Jean Philippe/0000-0003-3475-0101				ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; AVIRAM A, 1994, INT J CANCER, V56, P906, DOI 10.1002/ijc.2910560625; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Carroll RE, 2000, CELL GROWTH DIFFER, V11, P385; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Choe Gheeyong, 1997, Journal of Korean Medical Science, V12, P433; Conley BA, 1998, CLIN CANCER RES, V4, P629; Cooper GR, 1997, BIOCHEM J, V325, P601, DOI 10.1042/bj3250601; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gilon P, 1999, J BIOL CHEM, V274, P20197, DOI 10.1074/jbc.274.29.20197; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Golovina VK, 2000, GLIA, V31, P15, DOI 10.1002/(SICI)1098-1136(200007)31:1<15::AID-GLIA20>3.0.CO;2-H; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230; HAUCK W, 1991, CANCER RES, V51, P3526; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HEERDT BG, 1994, CANCER RES, V54, P3288; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; INESI G, 1994, J MEMBRANE BIOL, V141, P1; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kovacs T, 2001, BIOCHEM J, V358, P559, DOI 10.1042/0264-6021:3580559; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; KWANDUN W, 1995, AM J PHYSIOL, V269, pC775; Lacabaratz-Porret C, 2000, BIOCHEM J, V350, P723, DOI 10.1042/0264-6021:3500723; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; Launay S, 1997, J BIOL CHEM, V272, P10746; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Litvak DA, 2000, ANTICANCER RES, V20, P779; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Maier S, 2000, INT J CANCER, V88, P245; Mariadason JM, 2000, CANCER RES, V60, P4561; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; McConkey DJ, 2001, METHOD CELL BIOL, V66, P229; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Musashi M, 2000, INT J HEMATOL, V72, P12; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; PINTO M, 1983, BIOL CELL, V47, P323; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REPHAELI A, 1991, INT J CANCER, V49, P66, DOI 10.1002/ijc.2910490113; Sakai A, 2001, CANCER LETT, V168, P183, DOI 10.1016/S0304-3835(01)00531-6; SCHAEFER A, 1994, J BIOL CHEM, V269, P8786; Shack S, 1996, CLIN CANCER RES, V2, P865; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Wang YX, 2001, INT J ONCOL, V18, P617; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; Wu JT, 2001, AM J PHYSIOL-GASTR L, V280, pG482, DOI 10.1152/ajpgi.2001.280.3.G482; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; Zippel R, 2000, EXP CELL RES, V258, P403, DOI 10.1006/excr.2000.4937	87	108	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26310	26320		10.1074/jbc.M201747200	http://dx.doi.org/10.1074/jbc.M201747200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986315	hybrid			2022-12-25	WOS:000176908700065
J	Puig, S; Lee, J; Lau, M; Thiele, DJ				Puig, S; Lee, J; Lau, M; Thiele, DJ			Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; MENKES-DISEASE PROTEIN; SACCHAROMYCES-CEREVISIAE; WILSON-DISEASE; MOLECULAR CHARACTERIZATION; SCHIZOSACCHAROMYCES-POMBE; IRON TRANSPORT; BINDING DOMAIN; EXPRESSION; CHAPERONE	The redox active metal copper is an essential cofactor in critical biological processes such as respiration, iron transport, oxidative stress protection, hormone production, and pigmentation. A widely conserved family of high affinity copper transport proteins (Ctr proteins) mediates copper uptake at the plasma membrane. However, little is known about Ctr protein topology, structure, and the mechanisms by which this class of transporters mediates high affinity copper uptake. In this report, we elucidate the topological orientation of the yeast Ctr1 copper transport protein. We show that a series of clustered methionine residues in the hydrophilic extracellular domain and an MXXXM motif in the second transmembrane domain are important for copper uptake but not for protein sorting and delivery to the cell surface. The conversion of these methionine residues to cysteine, by site-directed mutagenesis, strongly suggests that they coordinate to copper during the process of metal transport. Genetic evidence supports an essential role for cooperativity between monomers for the formation of an active Ctr transport complex. Together, these results support a fundamentally conserved mechanism for high affinity copper uptake through the Ctr proteins in yeast and humans.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	dthiele@umich.edu	Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NCI NIH HHS [1R24CA 86307] Funding Source: Medline; NIGMS NIH HHS [GM41840, GM62555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555, R01GM041840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Harrison MD, 1999, J BIOCHEM MOL TOXIC, V13, P93, DOI 10.1002/(SICI)1099-0461(1999)13:2<93::AID-JBT5>3.0.CO;2-3; HARTTER DE, 1988, SYNAPSE, V2, P412, DOI 10.1002/syn.890020408; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Peterson CW, 1996, FEBS LETT, V379, P85, DOI 10.1016/0014-5793(95)01492-6; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	56	304	314	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26021	26030		10.1074/jbc.M202547200	http://dx.doi.org/10.1074/jbc.M202547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11983704	hybrid			2022-12-25	WOS:000176908700027
J	Yieh, L; Hatzis, H; Kassavetis, G; Sandmeyer, SB				Yieh, L; Hatzis, H; Kassavetis, G; Sandmeyer, SB			Mutational analysis of the transcription factor IIIB-DNA target of Ty3 retroelement integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; POSITION-SPECIFIC INTEGRATION; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; PROMOTER ELEMENT; MULTIPLE ROLES; FACTOR-TFIIIB; U6 GENE; YEAST	The Ty3 retrovirus-like element inserts preferentially at the transcription initiation sites of genes transcribed by RNA polymerase 111. The requirements for transcription factor (TF) IIIC and TFIIIB in Ty3 integration into the two initiation sites of the U6 gene carried on pU6LboxB were previously examined. Ty3 integrates at low but detectable frequencies in the presence of TFIIIB subunits Brf1 and TATA-binding protein. Integration increases in the presence of the third subunit, Bdp1. TFIIIC is not essential, but the presence of TFIIIC specifies an orientation of TFIIIB for transcriptional initiation and directs integration to the U6 gene-proximal initiation site. In the current study, recombinant wild-type TATA-binding protein, wild type and mutant Brf1, and Bdp1 proteins and highly purified TFIIIC were used to investigate the roles of specific protein domains in Ty3 integration. The amino-terminal half of Brf1, which contains a TFIIB-like repeat, contributed more strongly than the carboxyl-terminal half of Brf1 to Ty3 targeting. Each half of Bdp1 split at amino acid 352 enhanced integration. In the presence of TFIIIB and TFIIIC, the pattern of integration extended downstream by several base pairs compared with the pattern observed in vitro in the absence of TFIIIC and in vivo, suggesting that TFIIIC may not be present on genes targeted by Ty3 in vivo. Mutations in Bdp1 that affect its interaction with TFIIIC resulted in TFIIIC-independent patterns of Ty3 integration. Brf1 zinc ribbon and Bdp1 internal deletion mutants that are competent for polymerase III recruitment but defective in promoter opening were competent for Ty3 integration irrespective of the state of DNA supercoiling. These results extend the similarities between the TFIIIB domains required for transcription and Ty3 integration and also reveal requirements that are specific to transcription.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego; University of California System; University of California San Diego	Sandmeyer, SB (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	sbsandme@uci.edu			NIGMS NIH HHS [GM18386, GM33281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033281, R37GM018386, R01GM018386] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Ausubel F., 1999, CURRENT PROTOCOLS MO; Aye M, 2001, MOL CELL BIOL, V21, P7839, DOI 10.1128/MCB.21.22.7839-7851.2001; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Connolly CM, 1997, FEBS LETT, V405, P305, DOI 10.1016/S0014-5793(97)00200-7; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Grove A, 2002, EMBO J, V21, P704, DOI 10.1093/emboj/21.4.704; Hahn S, 2000, GENE DEV, V14, P719; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KAISER MW, 1995, J BIOL CHEM, V270, P11398, DOI 10.1074/jbc.270.19.11398; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; Sandmeyer SB, 1996, CURR TOP MICROBIOL, V214, P261; SANDMEYER SB, 1982, P NATL ACAD SCI-BIOL, V79, P7674, DOI 10.1073/pnas.79.24.7674; SANDMEYER SB, 1988, NUCLEIC ACIDS RES, V16, P1499, DOI 10.1093/nar/16.4.1499; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Yieh L, 2000, J BIOL CHEM, V275, P29800, DOI 10.1074/jbc.M003149200	54	31	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25920	25928		10.1074/jbc.M202729200	http://dx.doi.org/10.1074/jbc.M202729200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994300	Green Published, hybrid			2022-12-25	WOS:000176908700015
J	Caohuy, H; Pollard, HB				Caohuy, H; Pollard, HB			Protein kinase C and guanosine triphosphate combine to potentiate calcium-dependent membrane fusion driven by annexin 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; GTP-GAMMA-S; PERMEABILIZED PC12 CELLS; RAT MAST-CELLS; GUANINE-NUCLEOTIDES; CATECHOLAMINE SECRETION; INSULIN-SECRETION; NEUROTRANSMITTER RELEASE; EXOCYTOTIC SECRETION; HUMAN-NEUTROPHILS	Exocytotic secretion is promoted by the concerted action of calcium, guanine nucleotide, and protein kinase C. We now show that the calcium-dependent membrane fusion activity of annexin 7 in vitro is further potentiated by the combined addition of guanine nucleotide and protein kinase C. The observed increment involves the simultaneous activation of annexin 7 by these two effectors. Guanosine triphosphate (GTP) and its non-hydrolyzable analogues optimally enhance the phosphorylation of annexin 7 by protein kinase C in vitro. Reciprocally, phosphorylation by protein kinase C significantly potentiates the binding and hydrolysis of GTP by annexin 7. Only protein kinase C-dependent phosphorylation has a significant positive effect on annexin 7 GTPase, although other protein kinases, including cAMP-dependent protein kinase, cGMP-dependent protein kinase, and pp60(c-src), have been shown to label the protein with high efficiency. In vivo, the ratio of bound GDP/GTP and phosphorylation of annexin 7 change in direct proportion to the extent of catecholamine release from chromaffin cells in response to stimulation by carbachol, or to inhibition by various protein kinase C inhibitors. These results thus lead us to hypothesize that annexin 7 may serve as a common site of action for calcium, guanine nucleotide, and protein kinase C in the exocytotic membrane fusion process in chromaffin cells.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Pollard, HB (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	hpollard@usuhs.mil						AHNERTHILGER G, 1992, BIOCHEM J, V284, P321, DOI 10.1042/bj2840321; AHNERTHILGER G, 1987, BIOCHEMISTRY-US, V26, P7842, DOI 10.1021/bi00398a046; BADER MF, 1989, J BIOL CHEM, V264, P16426; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BROCKLEHURST KW, 1985, BIOCHEM J, V228, P35, DOI 10.1042/bj2280035; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; BURNS AL, 1990, BIOCHEM SOC T, V18, P1118, DOI 10.1042/bst0181118; CAOHUY H, 2002, IN PRESS ANN NY ACAD; CARLIER MF, 1982, BIOCHEMISTRY-US, V21, P1215, DOI 10.1021/bi00535a017; CARROLL AG, 1990, J NEUROCHEM, V55, P930, DOI 10.1111/j.1471-4159.1990.tb04580.x; CHEEK TR, 1987, J BIOL CHEM, V262, P11663; CHINALI G, 1980, J BIOL CHEM, V255, P7455; CHURCHER Y, 1990, CELL REGUL, V1, P523, DOI 10.1091/mbc.1.7.523; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COORSSEN JR, 1990, CELL REGUL, V1, P1027, DOI 10.1091/mbc.1.13.1027; CREUTZ CE, 1982, J CELL BIOCHEM, V18, P87, DOI 10.1002/jcb.1982.240180108; DOLLY JO, 1994, SEMIN NEUROSCI, V6, P149; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FASANO O, 1982, J BIOL CHEM, V257, P3145; FUNG BKK, 1983, J BIOL CHEM, V258, P495; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HONG K, 1982, P NATL ACAD SCI-BIOL, V79, P4642, DOI 10.1073/pnas.79.15.4642; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; Hung CH, 1996, P NATL ACAD SCI USA, V93, P10797, DOI 10.1073/pnas.93.20.10797; Hung CH, 2001, J BIOL CHEM, V276, P12813, DOI 10.1074/jbc.M008482200; KNIGHT DE, 1985, FEBS LETT, V189, P345, DOI 10.1016/0014-5793(85)81053-X; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; Kumai T, 1998, JPN J PHARMACOL, V77, P205, DOI 10.1254/jjp.77.205; LILLIE TH, 1991, PHILOS T R SOC LOND, V336, P877; LILLIE THW, 1993, CIBA F SYMP, V176, P164; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NIR S, 1987, BIOCHIM BIOPHYS ACTA, V903, P309, DOI 10.1016/0005-2736(87)90221-5; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OETTING M, 1986, FEBS LETT, V208, P99, DOI 10.1016/0014-5793(86)81540-X; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; POLLARD HB, 1992, PROG BRAIN RES, V92, P247, DOI 10.1016/S0079-6123(08)61180-2; Proks P, 1996, J PHYSIOL-LONDON, V496, P255, DOI 10.1113/jphysiol.1996.sp021682; RAFFANIELLO RD, 1993, J BIOL CHEM, V268, P8491; REEVES J, 1968, J CELL PHYSL, V78, P49; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; Shono M, 1997, J CARDIOVASC PHARM, V30, P419, DOI 10.1097/00005344-199710000-00003; Sloan DC, 1997, BIOCHEM J, V328, P13; SMOLEN JE, 1989, CELL SIGNAL, V1, P471, DOI 10.1016/0898-6568(89)90032-6; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; SONTAG JM, 1992, EUR J NEUROSCI, V4, P98, DOI 10.1111/j.1460-9568.1992.tb00112.x; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; YANAGIHARA N, 1979, FEBS LETT, V105, P296, DOI 10.1016/0014-5793(79)80633-X	65	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25217	25225		10.1074/jbc.M202452200	http://dx.doi.org/10.1074/jbc.M202452200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994295	hybrid			2022-12-25	WOS:000176747000049
J	Drocourt, L; Ourlin, JC; Pascussi, JM; Maurel, P; Vilarem, MJ				Drocourt, L; Ourlin, JC; Pascussi, JM; Maurel, P; Vilarem, MJ			Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; RESPONSIVE ENHANCER MODULE; CYCLOSPORINE-A OXIDASE; CYTOCHROME-P450 GENES; 5'-FLANKING REGION; SIGNALING PATHWAY; DRUG-INTERACTIONS; PRIMARY CULTURES; INDUCTION	The fully active dihydroxylated metabolite of vitamin D-3 induces the expression of CYP3A4 and, to a lesser extent, CYP2B6 and CYP2C9 genes in normal differentiated primary human hepatocytes. Electrophoretic mobility shift assays and cotransfection in HepG2 cells using wild-type and mutated oligonucleotides revealed that the vitamin D receptor (VDR) binds and transactivates those xenobiotic-responsive elements (ER6, DR3, and DR4) previously identified in CYP3A4, CYP2B6, and CYP2C9 promoters and shown to be targeted by the pregnane X receptor (PXR) and/or the constitutive androstane receptor (CAR). Full VDR response of various CYP3A4 heterologous/homologous promoter-reporter constructs requires both the proximal ER6 and the distal DR3 motifs, as observed previously with rifampicin-activated PXR. Cotransfection of a CYP3A4 homologous promoter-reporter construct (including distal and proximal PXR-binding motifs) and of PXR or CAR expression vectors in HepG2 cells revealed the ability of these receptors to compete with VDR for transcriptional regulation of CYP3A4. In conclusion, this work suggests that VDR, PXR, and CAR control the basal and inducible expression of several CYP genes through competitive interaction with the same battery of responsive elements.	Inst Federatif Rech 24, INSERM, U128, CNRS, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vilarem, MJ (corresponding author), Inst Federatif Rech 24, INSERM, U128, CNRS, 1919 Route Mende, F-34293 Montpellier 05, France.	vilarem@falbala.erbm.cnrs-mop.fr	pascussi, jean marc/F-9311-2013	pascussi, jean marc/0000-0002-5168-5383				Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Auwerx J, 1999, CELL, V97, P161; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BRODIE MJ, 1982, CLIN PHARMACOL THER, V32, P525, DOI 10.1038/clpt.1982.197; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; BURGOSTRINIDAD M, 1986, BIOCHEMISTRY-US, V25, P2692, DOI 10.1021/bi00357a061; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P10; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P82; Carlberg C., 1997, P 10 INT VIT D WORKS, P268; D'Erasmo Emilio, 1998, Recenti Progressi in Medicina, V89, P529; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Freedman LP, 1999, J NUTR, V129, p581S, DOI 10.1093/jn/129.2.581S; Fujisawa K, 2000, J BIOCHEM-TOKYO, V127, P373, DOI 10.1093/oxfordjournals.jbchem.a022618; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P468; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; OHNUMA N, 1980, ARCH BIOCHEM BIOPHYS, V204, P387, DOI 10.1016/0003-9861(80)90047-8; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pascussi JM, 2001, EUR J BIOCHEM, V268, P6346, DOI 10.1046/j.0014-2956.2001.02540.x; Pascussi JM, 1999, BIOCHEM BIOPH RES CO, V260, P377, DOI 10.1006/bbrc.1999.0745; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; PICHARD L, 1992, MOL PHARMACOL, V41, P1047; SchmiedlinRen P, 1997, MOL PHARMACOL, V51, P741, DOI 10.1124/mol.51.5.741; Segura C, 1999, HISTOCHEM CELL BIOL, V112, P163, DOI 10.1007/s004180050403; Shany S, 2001, STEROIDS, V66, P319, DOI 10.1016/S0039-128X(00)00154-9; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557; Zhou ZF, 1997, J BIOL CHEM, V272, P8227, DOI 10.1074/jbc.272.13.8227	53	290	309	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25125	25132		10.1074/jbc.M201323200	http://dx.doi.org/10.1074/jbc.M201323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991950	hybrid			2022-12-25	WOS:000176747000038
J	Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC				Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC			The location of plastocyanin in vascular plant photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; FLASH ABSORPTION-SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; SYNECHOCYSTIS SP PCC-6803; PSI-H SUBUNIT; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; ELECTRON-TRANSFER; SYNECHOCOCCUS-ELONGATUS; CYTOCHROME C(6)	We have studied the binding sites of the electron donor and acceptor proteins of vascular plant photosystem I by electron microscopy/crystallography. Previously, we identified the binding site for the electron acceptor (ferredoxin). In this paper we complete these studies with the characterization of the electron donor (plastocyanin) binding site. After cross-linking, plastocyanin is detected using Fourier difference analysis of two dimensionally ordered arrays of photosystem I located at the periphery of chloroplast grana. Plastocyanin binds in a small cavity on the lumenal surface of photosystem 1, close to the center and with a slight bias toward the PsaL subunit of the complex. The recent release of the full coordinates for the cyanobacterial photosystem I reaction center has allowed a detailed comparison between the structures of the eukaryotic and prokaryotic systems. This reveals a very close homology, which is particularly striking for the lumenal side of photosystem I.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Exeter, Sch Biol Sci, Exeter EX4 4PS, Devon, England; Texas A&M Univ, Dept Biochem & Biophys, Microscopy & Imaging Ctr, College Stn, TX 77843 USA	University of Manchester; University of Exeter; Texas A&M University System; Texas A&M University College Station	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.			Ford, Robert/0000-0002-0958-1505				AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bottin H, 2001, BIOCHEM BIOPH RES CO, V287, P833, DOI 10.1006/bbrc.2001.5658; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; DelaCerda B, 1997, BIOCHEMISTRY-US, V36, P10125, DOI 10.1021/bi9708601; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; HARRIS JR, 1995, J STRUCT BIOL, V115, P102, DOI 10.1006/jsbi.1995.1034; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1996, ARCH BIOCHEM BIOPHYS, V330, P414, DOI 10.1006/abbi.1996.0270; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V36, P275; Inoue T, 1999, BIOCHEMISTRY-US, V38, P6063, DOI 10.1021/bi9824442; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kitmitto A, 1998, J BIOL CHEM, V273, P29592, DOI 10.1074/jbc.273.45.29592; Kitmitto A, 1997, J BIOL CHEM, V272, P19497, DOI 10.1074/jbc.272.31.19497; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Lagoutte B, 2001, PLANT PHYSIOL, V126, P307, DOI 10.1104/pp.126.1.307; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Mamedov MD, 2001, FEBS LETT, V500, P172, DOI 10.1016/S0014-5793(01)02615-1; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Olesen K, 1999, BIOCHEMISTRY-US, V38, P16695, DOI 10.1021/bi991242i; Ruffle SV, 2000, J BIOL CHEM, V275, P36250, DOI 10.1074/jbc.M006549200; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Setif P, 2001, BBA-BIOENERGETICS, V1507, P161, DOI 10.1016/S0005-2728(01)00205-5; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; Young S, 1997, BBA-BIOENERGETICS, V1322, P106, DOI 10.1016/S0005-2728(97)00064-9; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	39	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25692	25696		10.1074/jbc.M202670200	http://dx.doi.org/10.1074/jbc.M202670200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976339	hybrid			2022-12-25	WOS:000176747000109
J	Llano, E; Adam, G; Pendas, AM; Quesada, V; Sanchez, LM; Santamaria, I; Noselli, S; Lopez-Otin, C				Llano, E; Adam, G; Pendas, AM; Quesada, V; Sanchez, LM; Santamaria, I; Noselli, S; Lopez-Otin, C			Structural and enzymatic characterization of Drosophila Dm2-MMP, a membrane-bound matrix metalloproteinase with tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; COLLAGENASE; ACTIVATION; DOMAIN; GENE; MATRILYSIN; NOTCH; IDENTIFICATION	We report the isolation and characterization of a cDNA encoding Dm2-MMP, the second matrix metalloproteinase (MMP) identified in the Drosophila melanogaster genome. The cloned cDNA codes for a polypeptide of 758 residues that displays a domain organization similar to that of other MMPs, including signal peptide, propeptide, catalytic, and hemopexin domains. However, the structure of Dm2-MMP is unique because of the presence of an insertion of 214 amino acids between the catalytic and hemopexin domains that is not present in any of the previously described MMPs. Dm2-MMP also contains a C-terminal extension predicted to form a cleavable glycosylphosphatidylinositol anchor site. Western blot and immunofluorescence analysis of S2 cells transfected with the isolated cDNA confirmed that Dm2-MMP is localized at the cell surface. Production of the catalytic domain of Dm2-MMP in Escherichia coli and analysis of its enzymatic activity revealed that this proteinase cleaves several synthetic peptides used for analysis of vertebrate MMPs. This proteolytic activity was abolished by MMP inhibitors such as BB-94, confirming that the isolated cDNA codes for an enzymatically active metalloproteinase. Reverse transcription-PCR analysis showed that Dm2-MMP is expressed at low levels in all of the developmental stages of Drosophila as well as in adult flies. However, detailed in situ hybridization at the larval stage revealed a strong tissue-specific expression in discrete regions of the brain and eye imaginal discs. According to these results, we propose that Dm2-MMP plays both general proteolytic functions during Drosophila development and in adult tissues and specific roles in eye development and neural tissues through the degradation and remodeling of the extracellular matrix.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain; CNRS, UMR 6543, Ctr Biochim, Inst Rech Signalisat Dev & Canc, F-06108 Nice 2, France	University of Oviedo; Instituto Universitario de Oncologia de Asturias; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	Llano, Elena/K-1723-2014; López-Otín, Carlos/AAB-2106-2020; Quesada, Víctor/B-6557-2014; Pendas, Alberto M/L-1017-2014; Santamaria, Inigo/H-6727-2015; Llano, Elena/AAS-5517-2021	Llano, Elena/0000-0002-2626-5723; López-Otín, Carlos/0000-0001-6964-1904; Quesada, Víctor/0000-0002-8398-3457; Santamaria, Inigo/0000-0001-8718-5359; Llano, Elena/0000-0002-2626-5723; Pendas, Alberto M/0000-0001-9264-3721; Noselli, stephane/0000-0002-7296-324X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Coates D, 2000, BIOCHEM SOC T, V28, P464, DOI 10.1042/0300-5127:0280464; Couet J, 1996, J BIOL CHEM, V271, P4545; Delorme VGR, 2000, PLANT PHYSIOL, V123, P917, DOI 10.1104/pp.123.3.917; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Leontovich AA, 2000, DEVELOPMENT, V127, P907; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; Llano E, 1999, CANCER RES, V59, P2570; Llano E, 2000, J BIOL CHEM, V275, P35978, DOI 10.1074/jbc.M006045200; Lohi J, 2001, J BIOL CHEM, V276, P10134, DOI 10.1074/jbc.M001599200; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; Maidment JM, 1999, J BIOL CHEM, V274, P34706, DOI 10.1074/jbc.274.49.34706; Marchenko GN, 2001, GENE, V265, P87, DOI 10.1016/S0378-1119(01)00360-2; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Montell DJ, 1999, DEVELOPMENT, V126, P3035; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Oh LYS, 1999, J NEUROSCI, V19, P8464; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Puente XS, 1996, CANCER RES, V56, P944; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SAMBROOK J, 2000, MOL CLONING LAB MANU; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sotillos S, 1997, DEVELOPMENT, V124, P4769; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uria JA, 2000, CANCER RES, V60, P4745; Velasco G, 2000, CANCER RES, V60, P877; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Woolley K, 2000, BIOESSAYS, V22, P911; Yu Q, 2000, GENE DEV, V14, P163; Zuo J, 1998, J NEUROSCI, V18, P5203, DOI 10.1523/JNEUROSCI.18-14-05203.1998	61	78	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23321	23329		10.1074/jbc.M200121200	http://dx.doi.org/10.1074/jbc.M200121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967260	hybrid			2022-12-25	WOS:000176475700031
J	Laird, AD; Christensen, JG; Li, GM; Carver, J; Smith, K; Xin, XH; Moss, KG; Louie, SG; Mendel, DB; Cherrington, JM				Laird, AD; Christensen, JG; Li, GM; Carver, J; Smith, K; Xin, XH; Moss, KG; Louie, SG; Mendel, DB; Cherrington, JM			SU6668 inhibits Flk-1/KDR and PDGFR beta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice	FASEB JOURNAL			English	Article						angiogenesis; kinase inhibitor; VEGF; platelet-derived growth factor	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR; VEGF; CANCER; WITHDRAWAL; INDUCTION; VESSELS; THERAPY	SU6668 is a small molecule inhibitor of the angiogenic receptor tyrosine kinases Flk-1/KDR, PDGFRbeta, and FGFR1. In mice, SU6668 treatment resulted in regression or growth arrest of all large established human tumor xenografts examined associated with loss of tumor cellularity. The events underlying loss of tumor cellularity were elucidated in detail in several tumor models. SU6668 treatment induced apoptosis in tumor microvessels within 6 h of the initiation of treatment. Dose-dependent decreases in tumor microvessel density were observed within 3 days of the first treatment. These changes were accompanied by decreased tumor cell proliferation and increased tumor cell apoptosis. Rapid increases in VEGF transcript levels were seen, consistent with the induction of tumor hypoxia. Using Western blot analyses, we determined that these in vivo antiangiogenic and proapoptotic effects of SU6668 occur at doses comparable to those required to inhibit Flk-1/KDR and PDGFRbeta phosphorylation in tumors. Potent, dose-dependent inhibition of Flk-1/KDR activity in vivo was independently demonstrated using vascular permeability as a readout. These data demonstrate that SU6668-induced inhibition of angiogenic receptor tyrosine kinase activity in vivo is associated with rapid vessel killing in tumors, leading to broad and potent antitumor effects.	SUGEN Inc, Preclin Res & Translat Med, San Francisco, CA 94080 USA	Pfizer	Laird, AD (corresponding author), SUGEN Inc, Preclin Res & Translat Med, 230 E Grand Ave, San Francisco, CA 94080 USA.	Douglas-Laird@sugen.com						Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Boehm-Viswanathan T, 2000, CURR OPIN ONCOL, V12, P89, DOI 10.1097/00001622-200001000-00015; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Fong TAT, 1999, CANCER RES, V59, P99; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KLINT P, 1999, FRONT BIOSCI, V4, P165; Laird AD, 2000, CANCER RES, V60, P4152; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; McMahon G, 1998, Curr Opin Drug Discov Devel, V1, P131; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Millauer B, 1996, CANCER RES, V56, P1615; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shaheen RM, 1999, CANCER RES, V59, P5412	23	150	165	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0681	10.1096/fj.01-0700com	http://dx.doi.org/10.1096/fj.01-0700com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978732				2022-12-25	WOS:000175973900022
J	Robey, IF; Edmundson, AB; Schluter, SF; Yocum, DE; Marchalonis, JJ				Robey, IF; Edmundson, AB; Schluter, SF; Yocum, DE; Marchalonis, JJ			Specificity mapping of human anti-T cell receptor monoclonal natural antibodies: defining the properties of epitope recognition promiscuity	FASEB JOURNAL			English	Article						antigen binding site; polyreactivity; mAbs; affinity	POLYREACTIVE ANTIBODIES; EXQUISITE SPECIFICITY; IGM; AUTOANTIBODIES; BINDING; AUTOIMMUNE; REACTIVITY; AFFINITY; SHARKS; HEAVY	The classical concept of antibody binding is defined as an exclusive and high-affinity interaction with one epitope. The emerging reality about antibody combing sites, however, is that some can bind unrelated determinants. The studies presented here define this quality as epitope recognition promiscuity by analyzing the capacity of monoclonal human auto-antibodies to bind sets of overlapping peptides duplicating the complete structures of T cell receptor (TCR) alpha and beta chains and immunoglobulin lambda chain. We assessed the binding of these monoclonal antibodies (mAbs) to a set of homologous peptides corresponding to the CDR1 segments of human Vbeta gene products, a major epitope used in the selection of the antibodies. We present data on the binding characteristics of four human mAbs selected for the ability to bind TCR epitopes. These mAbs are IgM molecules with V-H and V-L sequences in germline configuration, but have diverse V-H CDR3 regions. These studies aim to characterize the property of epitope promiscuity and show that the relationship between the binding site and its epitope is a complex interaction and unpredictable from antigen sequence alone. Our results support the conclusion that epitope recognition promiscuity is a genuine feature of antibody and TCR recognition.	Univ Arizona, Coll Med, Dept Microbiol & Immunol, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Arizona Arthrit Ctr, Tucson, AZ 85724 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	University of Arizona; University of Arizona; Oklahoma Medical Research Foundation	Marchalonis, JJ (corresponding author), Univ Arizona, Coll Med, Dept Microbiol & Immunol, Tucson, AZ 85724 USA.	marchjj@email.arizona.edu						Adib-Conquy M, 1998, INT IMMUNOL, V10, P341, DOI 10.1093/intimm/10.3.341; ADIBCONQUY M, 1994, MOL IMMUNOL, V31, P555, DOI 10.1016/0161-5890(94)90043-4; Arden Bernhard, 1995, Immunogenetics, V42, P455; BERZOFSKY JA, 1981, MOL IMMUNOL, V18, P751, DOI 10.1016/0161-5890(81)90067-5; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.immunol.7.1.513; Casali P, 1988, Int Rev Immunol, V3, P17, DOI 10.3109/08830188809051180; CHEN C, 1991, J IMMUNOL, V147, P2359; Dehghanpisheh K, 1996, IMMUNOL INVEST, V25, P241, DOI 10.3109/08820139609059306; Deng YJ, 2000, CLIN EXP IMMUNOL, V119, P69, DOI 10.1046/j.1365-2249.2000.01096.x; Diaw L, 1997, J IMMUNOL, V158, P968; EDMUNDSON AB, 1975, BIOCHEMISTRY-US, V14, P3953, DOI 10.1021/bi00689a005; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; ICHIYOSHI Y, 1994, J EXP MED, V180, P885, DOI 10.1084/jem.180.3.885; KAYMAZ H, 1993, INT IMMUNOL, V5, P491, DOI 10.1093/intimm/5.5.491; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Lake DF, 1997, J PROTEIN CHEM, V16, P309, DOI 10.1023/A:1026361110795; Marchalonis JJ, 1997, CRIT REV IMMUNOL, V17, P497; Marchalonis JJ, 1998, IMMUNOL REV, V166, P103, DOI 10.1111/j.1600-065X.1998.tb01256.x; Marchalonis JJ, 2001, ADV EXP MED BIOL, V484, P13; Marchalonis JJ, 2001, J MOL RECOGNIT, V14, P110, DOI 10.1002/jmr.527; Marchalonis JJ, 2000, APPL BIOCHEM BIOTECH, V83, P31, DOI 10.1385/ABAB:83:1-3:31; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Robey IF, 2000, J PROTEIN CHEM, V19, P9, DOI 10.1023/A:1007086608036; ROBEY IF, 2001, IN PRESS IMMUNOLOGY; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Seidl KJ, 1999, P NATL ACAD SCI USA, V96, P2262, DOI 10.1073/pnas.96.5.2262; Van Regenmortel MHV, 1998, J IMMUNOL METHODS, V216, P37, DOI 10.1016/S0022-1759(98)00069-6; Weller S, 1997, J IMMUNOL, V159, P3890; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; YANAGI Y, 1985, P NATL ACAD SCI USA, V82, P3430, DOI 10.1073/pnas.82.10.3430	37	15	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0832-6638/02/0046-0642	10.1096/fj.01-0884com	http://dx.doi.org/10.1096/fj.01-0884com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978728				2022-12-25	WOS:000175973900018
J	Delpuech, O; Trabut, JB; Carnot, F; Feuillard, J; Brechot, C; Kremsdorf, D				Delpuech, O; Trabut, JB; Carnot, F; Feuillard, J; Brechot, C; Kremsdorf, D			Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinomas; hepatitis B Virus; Hepatitis C Virus; cDNA macroarray; distinct gene profiles	HEPATITIS-C VIRUS; BETA-CATENIN GENE; MESSENGER-RNA; CYCLIN D1; PROTEIN; GROWTH; OVEREXPRESSION; CANCER; INDUCTION; APOPTOSIS	It is still unclear as to whether the gene expression profile in HCV- or HBV-related HCC exhibits a degree of specificity and whether the development of HCC in a context of cirrhosis influences this gene profile. To address these issues, the expression profiles of 15 cases of HCC were analysed using cDNA macroarray. A global analysis and hierarchical clustering, demonstrated the heterogeneity of HCC patterns, with a majority of down-regulated genes. Statistical analysis clearly showed a distinction between the gene expression profiles of HCV- and HBV-related HCC. HBV-associated HCC exhibited involvement of different cellular pathways, those controlling apoptosis, p53 signalling and G1/S transition. In HCV-related HCC we identified a more heterogenous pattern with an over-expression of the TGF-beta induced gene. In HCC developing on noncirrhotic tissues, beta-catenin encoding gene and genes implicated in the PKC pathway were specifically up-regulated. In addition, our investigation highlighted a distinct profiles of TGF-beta superfamily encoding genes in well, moderately or poorly differentiated HCC. Overall, our study supports the hypothesis that despite the heterogeneity of the HCC pattern, the large-scale screening of gene expression may provide data significant to our understanding of the mechanism of liver carcinogenesis.	CHU Necker, INSERM, Inst Pasteur, U370, F-75015 Paris, France; Hop Europeen Georges Pompidou, Serv Anatomopathol, F-75015 Paris, France; Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France; Hop Avicenne, EA ATHSCO, F-93009 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Kremsdorf, D (corresponding author), Fac Med Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.	kremsdor@necker.fr	Kremsdorf, Dina/O-9797-2017; Feuillard, Jean/O-8587-2016	Feuillard, Jean/0000-0001-6223-2454				Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Benvegnu L, 2001, ANTIVIR RES, V52, P199, DOI 10.1016/S0166-3542(01)00185-1; Benvegnu L, 2001, GUT, V48, P110, DOI 10.1136/gut.48.1.110; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P250, DOI 10.1159/000134349; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V174, pM43; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Feo F, 2000, CRIT REV ONCOGENESIS, V11, P19; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Garrett SH, 1999, PROSTATE, V41, P196, DOI 10.1002/(SICI)1097-0045(19991101)41:3<196::AID-PROS7>3.0.CO;2-U; Gilles C, 1998, CANCER RES, V58, P5529; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Hidalgo J, 1998, NEUROTOXICOLOGY, V19, P661; Hol FA, 1998, CLIN GENET, V53, P119; Honda M, 2001, GASTROENTEROLOGY, V120, P955, DOI 10.1053/gast.2001.22468; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Juengel JL, 1998, J REPROD FERTIL, V113, P299, DOI 10.1530/jrf.0.1130299; Jungmann RA, 1998, J EXP ZOOL, V282, P188, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2<188::AID-JEZ21>3.0.CO;2-P; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kasai Y, 1996, SEMIN SURG ONCOL, V12, P155, DOI 10.1002/(SICI)1098-2388(199605/06)12:3<155::AID-SSU2>3.0.CO;2-6; Kim Hyung Gun, 2000, Korean Journal of Internal Medicine, V15, P165; Knight J, 2001, NATURE, V410, P860, DOI 10.1038/35073680; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lau WY, 2000, ONCOL RES, V12, P59; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; LeBail B, 1997, J PATHOL, V181, P330; Liu CT, 1998, CANCER GENE THER, V5, P3; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; MIRA L, 1995, ARCH BIOCHEM BIOPHYS, V318, P53, DOI 10.1006/abbi.1995.1203; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; Okabe H, 2001, CANCER RES, V61, P2129; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PATERON D, 1994, J HEPATOL, V20, P65, DOI 10.1016/S0168-8278(05)80468-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porte H, 1998, CLIN CANCER RES, V4, P1375; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schulze K, 1995, EUR HEART J, V16, P64, DOI 10.1093/eurheartj/16.suppl_O.64; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079; Takano T, 2001, CANCER LETT, V168, P51, DOI 10.1016/S0304-3835(01)00509-2; Takayasu H, 2001, CLIN CANCER RES, V7, P901; TERAMOTO T, 1994, CANCER RES, V54, P231; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; Tornillo L, 2000, J PATHOL, V192, P307, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH706&gt;3.0.CO;2-O; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; VENEZIANI BM, 1990, J CELL BIOL, V111, P2703, DOI 10.1083/jcb.111.6.2703; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu L, 2001, CANCER RES, V61, P3176; Yamashita T, 2001, BIOCHEM BIOPH RES CO, V282, P647, DOI 10.1006/bbrc.2001.4610; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; ZHAN QM, 1994, CANCER RES, V54, P2755	80	89	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2926	2937		10.1038/sj.onc.1205392	http://dx.doi.org/10.1038/sj.onc.1205392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973655				2022-12-25	WOS:000175063700020
J	Aiba-Masago, S; Liu, XB; Masago, R; Vela-Roch, N; Jimenez, F; Lau, CMA; Frohlich, VC; Talal, N; Dang, H				Aiba-Masago, S; Liu, XB; Masago, R; Vela-Roch, N; Jimenez, F; Lau, CMA; Frohlich, VC; Talal, N; Dang, H			Bax gene expression alters Ca2+ signal transduction without affecting apoptosis in an epithelial cell fine	ONCOGENE			English	Article						calcium; Bcl-2 family; oxidative stress; glutathione; muscarinic receptor	CYTOCHROME-C RELEASE; GLUTATHIONE DEPLETION; SJOGRENS-SYNDROME; REDOX REGULATION; BCL-2; CALCIUM; DEATH; OVEREXPRESSION; BCL-X(L); ALPHA	Bax is an oncogene that has proapoptotic properties but not all cells that express Bax undergo apoptosis. Bax may have a function unrelated to apoptosis. To elucidate the role of Bax in cell signaling, an epithelial cell line called SMG-C6 was transfected with the human bax gene. Stable transfectants were studied for their response to carbachol, a muscarinic receptor agonist, by measuring the increase in intracellular free Ca2+ and Ca2+ influx. Carbachol-mediated release of Call from intracellular stores was significantly higher in Bax transfectants compared to control transfectants (empty vector). Ca2+ influx was also increased in Bax transfectants. Bax had no affect on the storage operated channels. However, the concentration of Ca2+d in the intracellular stores (i.e., mitochondria and granules) was 40-50% lower in the Bax transfectants. There was no significant difference in thapsigargin-mediated apoptosis in Bax transfectants compared to wild-type and control transfectants. Measurement of glutathione was reduced in the Bax transfectant. Restoration of glutathione levels with glutathione monoethyl ester partially normalized Ca2+ mobilization and storage capacity in the mitochondria to control levels. This study shows that subapoptotic levels of Bax can reduce Ca2+ content in intracellular stores and Ca2+ homeostasis. Bax may mediate these effects by reducing the levels of antioxidants resulting in mild oxidative stress.	Univ Texas, Hlth Sci Ctr, Dept Community Dent, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Harcourt Brace Educ Measurement, San Antonio, TX 78204 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10019 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Columbia University	Dang, H (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Community Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dang@uthscsa.edu			NIDCR NIH HHS [DE12203] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012203] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Azhar G, 1999, MECH AGEING DEV, V112, P5, DOI 10.1016/S0047-6374(99)00048-2; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kong LP, 1998, CLIN IMMUNOL IMMUNOP, V88, P133, DOI 10.1006/clin.1998.4556; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Masago R, 2001, ARTHRITIS RHEUM, V44, P693, DOI 10.1002/1529-0131(200103)44:3<693::AID-ANR119>3.0.CO;2-7; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Naarala J, 1997, LIFE SCI, V60, P1905, DOI 10.1016/S0024-3205(97)00152-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUTT LK, 2002, IN PRESS J BIOL CHEM; Ohlsson M, 2001, LAB INVEST, V81, P95, DOI 10.1038/labinvest.3780215; Olive M, 1999, J NEUROL SCI, V164, P76, DOI 10.1016/S0022-510X(99)00041-6; Penault-Llorca F, 1998, PATHOL RES PRACT, V194, P457, DOI 10.1016/S0344-0338(98)80114-3; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Polihronis M, 1998, CLIN EXP IMMUNOL, V114, P485; Quissell D O, 1997, In Vitro Cell Dev Biol Anim, V33, P164; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; Wei HF, 1998, J NEUROCHEM, V70, P2305; Zhang GH, 1997, P SOC EXP BIOL MED, V216, P117; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340	36	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2762	2767		10.1038/sj.onc.1205369	http://dx.doi.org/10.1038/sj.onc.1205369			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965549				2022-12-25	WOS:000174996500016
J	Grassme, H; Bock, J; Kun, J; Gulbins, E				Grassme, H; Bock, J; Kun, J; Gulbins, E			Clustering of CD40 ligand is required to form a functional contact with CD40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 PROTEIN; T-LYMPHOCYTES; CYTOPLASMIC SEQUESTRATION; COSTIMULATORY SIGNAL; CELL-ACTIVATION; FACTOR RECEPTOR; TNF-ALPHA; SPHINGOMYELINASE; RAFTS; EXPRESSION	Receptor clustering is a key event in the initiation of signaling by many types of receptor molecules. Here, we provide evidence for the novel concept that clustering of a ligand is a prerequisite for clustering of the cognate receptor. We show that clustering of the CD40 receptor depends on reciprocal clustering of the CD40 ligand (gp39, CD154). Clustering of the CD40 ligand is mediated by an association of the ligand with p53, a translocation of acid sphingomyelinase (ASM) to the cell membrane, an activation of the ASM, and a formation of ceramide. Ceramide appears to modify preexisting sphingolipid-rich membrane microdomains to fuse and form ceramide-enriched signaling platforms that serve to cluster CD40 ligand. Genetic deficiency of p53 or ASM or disruption of ceramide-enriched membrane domains prevents clustering of CD40 ligand. The functional significance of CD40 ligand clustering is indicated by the finding that clustering of CD40 on B lymphocytes upon co-incubation with CD40 ligand-expressing T cells depends on clustering of the CD40 ligand and is abrogated by inhibition of CD40 ligand clustering.	Univ Essen Gesamthsch, Dept Mol Biol, D-45147 Essen, Germany; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany	University of Duisburg Essen; St Jude Children's Research Hospital; Eberhard Karls University of Tubingen	Gulbins, E (corresponding author), Univ Essen Gesamthsch, Dept Mol Biol, Hufelandstr 55, D-45147 Essen, Germany.	erich.gulbins@uni-essen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; Blair PJ, 2000, J EXP MED, V191, P651, DOI 10.1084/jem.191.4.651; Blotta MH, 1996, J IMMUNOL, V156, P3133; BOSARI S, 1995, AM J PATHOL, V147, P790; Brenner B, 1997, BIOCHEM BIOPH RES CO, V239, P11, DOI 10.1006/bbrc.1997.7415; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Gulbins E, 2000, METHOD ENZYMOL, V322, P382; Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130; Higuchi M, 1997, CLIN IMMUNOL IMMUNOP, V82, P133, DOI 10.1006/clin.1996.4291; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; HORIUCHI T, 1998, MOL GENETIC APPROACH, V1, P11; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Huang HW, 1999, BIOPHYS J, V77, P1489, DOI 10.1016/S0006-3495(99)76996-1; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Koppenhoefer U, 1997, FEBS LETT, V414, P444, DOI 10.1016/S0014-5793(97)01035-1; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; tenGrotenhuis E, 1996, BIOPHYS J, V71, P1389, DOI 10.1016/S0006-3495(96)79341-4; van Kooten C, 2000, FRONT BIOSCI, V5, pD880, DOI 10.2741/kooten; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304	45	78	78	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30289	30299		10.1074/jbc.M200494200	http://dx.doi.org/10.1074/jbc.M200494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12011072	hybrid			2022-12-25	WOS:000177509300115
J	Balandina, A; Kamashev, D; Rouviere-Yaniv, J				Balandina, A; Kamashev, D; Rouviere-Yaniv, J			The bacterial histone-like protein HU specifically recognizes similar structures in all nucleic acids - DNA, RNA, and their hybrids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC BINDING; ESCHERICHIA-COLI HU; Z-ALPHA DOMAIN; TRANSCRIPTION FACTOR; 5S RNA; CRUCIFORM DNA; BACILLUS-STEAROTHERMOPHILUS; RESOLUTION STRUCTURE; CRYSTAL-STRUCTURE; ZINC FINGERS	HU, a major component of the bacterial nucleoid, shares properties with histones, high mobility group proteins (HMGs), and other eukaryotic proteins. HU, which participates in many major pathways of the bacterial cell, binds without sequence specificity to duplex DNA but recognizes with high affinity DNA repair intermediates. Here we demonstrate that HU binds to double-stranded DNA, double-stranded RNA, and linear DNA-RNA duplexes with a similar low affinity. In contrast to this nonspecific binding to total cellular RNA and to supercoiled DNA, HU specifically recognizes defined structures common to both DNA and RNA. In particular HU binds specifically to nicked or gapped DNA-RNA hybrids and to composite RNA molecules such as DsrA, a small non-coding RNA. HU, which modulates DNA architecture, may play additional key functions in the bacterial machinery via its RNA binding capacity. The simple, straightforward structure of its binding domain with two highly flexible beta-ribbon arms and an alpha-helical platform is an alternative model for the elaborate binding domains of the eukaryotic proteins that display dual DNA- and RNA-specific binding capacities.	Inst Biol Physicochim, CNRS, Lab Physiol Bacterienne, UPR 9073, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS)	Rouviere-Yaniv, J (corresponding author), Inst Biol Physicochim, CNRS, Lab Physiol Bacterienne, UPR 9073, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.		Kamashev, Dmitri/K-6560-2017	Kamashev, Dmitri/0000-0003-4158-5300				Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; Arranz V, 1997, MOL CELL BIOL, V17, P2116, DOI 10.1128/MCB.17.4.2116; Balandina A, 2001, MOL MICROBIOL, V39, P1069, DOI 10.1046/j.1365-2958.2001.02305.x; Basu A, 1997, MOL CELL BIOL, V17, P677, DOI 10.1128/MCB.17.2.677; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BOUBRIK F, 1995, P NATL ACAD SCI USA, V92, P3958, DOI 10.1073/pnas.92.9.3958; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; Brown BA, 2000, P NATL ACAD SCI USA, V97, P13532, DOI 10.1073/pnas.240464097; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; Claret L, 1997, J MOL BIOL, V273, P93, DOI 10.1006/jmbi.1997.1310; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; Grove A, 1996, J MOL BIOL, V260, P196, DOI 10.1006/jmbi.1996.0392; Hamann S, 1998, NUCLEIC ACIDS RES, V26, P4108, DOI 10.1093/nar/26.18.4108; HASELKORN R, 1976, P NATL ACAD SCI USA, V73, P1917, DOI 10.1073/pnas.73.6.1917; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; Kamashev D, 1999, EMBO J, V18, P5434, DOI 10.1093/emboj/18.19.5434; Kamashev D, 2000, EMBO J, V19, P6527, DOI 10.1093/emboj/19.23.6527; Kobryn K, 1999, J MOL BIOL, V289, P777, DOI 10.1006/jmbi.1999.2805; KORNBERG A, 1992, DNA REPLICATION, P475; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Lavoie BD, 1996, CELL, V85, P761, DOI 10.1016/S0092-8674(00)81241-6; Lease RA, 2000, P NATL ACAD SCI USA, V97, P9919, DOI 10.1073/pnas.170281497; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; Li SS, 1998, J BACTERIOL, V180, P3750, DOI 10.1128/JB.180.15.3750-3756.1998; Majdalani N, 1998, P NATL ACAD SCI USA, V95, P12462, DOI 10.1073/pnas.95.21.12462; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Nakamura K, 1999, J BIOL CHEM, V274, P13569, DOI 10.1074/jbc.274.19.13569; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Oberto J, 1996, J BACTERIOL, V178, P293, DOI 10.1128/jb.178.1.293-297.1996; PAINBENI E, 1993, J MOL BIOL, V234, P1021, DOI 10.1006/jmbi.1993.1656; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; Pinson V, 1999, J MOL BIOL, V287, P485, DOI 10.1006/jmbi.1999.2631; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; Rouviere-Yaniv J, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 1, P439; ROUVIEREYANIV J, 1975, P NATL ACAD SCI USA, V72, P3428, DOI 10.1073/pnas.72.9.3428; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; Searles MA, 2000, J MOL BIOL, V301, P47, DOI 10.1006/jmbi.2000.3946; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; Wery M, 2001, BIOCHIMIE, V83, P193, DOI 10.1016/S0300-9084(01)01254-8; White SW, 1999, ACTA CRYSTALLOGR D, V55, P801, DOI 10.1107/S0907444999000578; Wimberly BT, 1997, STRUCTURE, V5, P1187, DOI 10.1016/S0969-2126(97)00269-4	55	84	90	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27622	27628		10.1074/jbc.M201978200	http://dx.doi.org/10.1074/jbc.M201978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12006568	hybrid			2022-12-25	WOS:000177189800008
J	Amieux, PS; Howe, DG; Knickerbocker, H; Lee, DC; Su, T; Laszlo, GS; Idzerda, RL; McKnight, GS				Amieux, PS; Howe, DG; Knickerbocker, H; Lee, DC; Su, T; Laszlo, GS; Idzerda, RL; McKnight, GS			Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RI-BETA SUBUNIT; TYROSINE-PHOSPHATASE SHP-2; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; P21-ACTIVATED KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CARNEY COMPLEX	A targeted disruption of the RIalpha isoform of protein kinase A (PKA) was created by using homologous recombination in embryonic stem cells. Unlike the other regulatory and catalytic subunits of PKA, RIalpha is the only isoform that is essential for early embryonic development. RIalpha homozygous mutant embryos fail to develop a functional heart tube at E8.5 and are resorbed at approximately E10.5. Mutant embryos show significant growth retardation and developmental delay compared with wild type littermates from E7.5 to E10.5. The anterior-posterior axis of RIalpha mutants is well developed, with a prominent head structure but a reduced trunk. PKA activity measurements reveal an increased basal PKA activity in these embryos. Brachyury mRNA expression in the primitive streak of RIalpha mutants is significantly reduced, consistent with later deficits in axial, paraxial, and lateral plate mesodermal derivatives. This defect in the production and migration of mesoderm can be completely rescued by crossing RIa mutants to mice carrying a targeted disruption in the Ca catalytic subunit, demonstrating that unregulated PKA activity rather than a specific loss of RIalpha is responsible for the phenotype. Primary embryonic fibroblasts from RIalpha mutant embryos display an abnormal cytoskeleton and an altered ability to migrate in cell culture. Our results demonstrate that unregulated PKA activity negatively affects growth factor-mediated mesoderm formation during early mouse development.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill	McKnight, GS (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.		Amieux, Paul/AAG-4102-2021	Howe, Douglas/0000-0001-5831-7439	NICHD NIH HHS [U54 HD 12629] Funding Source: Medline; NIGMS NIH HHS [GM 32875] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIEUX PS, 2002, ENCY MOL MED, V4, P2637; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BRANDON EP, 1995, RECENT PROG HORM RES, V50, P403; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Casey M, 2000, J CLIN INVEST, V106, pR31, DOI 10.1172/JCI10841; Catala M, 1996, DEVELOPMENT, V122, P2599; CLEGG CH, 1994, MOL CELL NEUROSCI, V5, P153, DOI 10.1006/mcne.1994.1017; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Clegg CH, 1996, J BIOL CHEM, V271, P1638, DOI 10.1074/jbc.271.3.1638; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; Concordet JP, 1996, DEVELOPMENT, V122, P2835; FURUTA Y, 1995, ONCOGENE, V11, P1989; GeorgesLabouesse EN, 1996, DEV DYNAM, V207, P145, DOI 10.1002/(SICI)1097-0177(199610)207:2<145::AID-AJA3>3.0.CO;2-H; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Hammerschmidt M, 1998, DEV BIOL, V194, P166, DOI 10.1006/dbio.1997.8796; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; Hogan B, 1994, MANIPULATING MOUSE E; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe AK, 2001, J BIOL CHEM, V276, P14541, DOI 10.1074/jbc.C000797200; Huang YZ, 2002, J BIOL CHEM, V277, P19889, DOI 10.1074/jbc.M111412200; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Joore J, 1998, MECH DEVELOP, V79, P5, DOI 10.1016/S0925-4773(98)00152-X; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lin TH, 1997, J BIOL CHEM, V272, P8849; Manes S, 1999, MOL CELL BIOL, V19, P3125; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; POUEYMIROU WT, 1989, DEV BIOL, V133, P588, DOI 10.1016/0012-1606(89)90061-4; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RABINOVITCH PS, 1994, METHOD CELL BIOL, V41, P263; Rocchi S, 2000, BIOCHEM J, V352, P483, DOI 10.1042/0264-6021:3520483; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SCHWARTZ DA, 1992, MOL REPROD DEV, V32, P209, DOI 10.1002/mrd.1080320305; Skalhegg BS, 2002, MOL ENDOCRINOL, V16, P630, DOI 10.1210/me.16.3.630; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; Tam PPL, 1997, DEVELOPMENT, V124, P1631; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEILER K, 1989, HOUSE MOUSE ATLAS EM, P40; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang HB, 1996, DEVELOPMENT, V122, P2977	58	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27294	27304		10.1074/jbc.M200302200	http://dx.doi.org/10.1074/jbc.M200302200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004056	hybrid, Green Published			2022-12-25	WOS:000177055900077
J	Hussain, S; Assender, JW; Bond, M; Wong, LF; Murphy, D; Newby, AC				Hussain, S; Assender, JW; Bond, M; Wong, LF; Murphy, D; Newby, AC			Activation of protein kinase C zeta is essential for cytokine-induced metalloproteinase-1,-3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MATRIX METALLOPROTEINASES; TRANSGENE EXPRESSION; SUBSPECIES BLOCKS; UP-REGULATION; GELATINASE-B; GENE; MIGRATION; REQUIREMENT; INVOLVEMENT	Several matrix metalloproteinases (MMPs), including MMP-1, -3, and -9, mediate matrix destruction during chronic inflammatory diseases such as arthritis and atherosclerosis. AMP up-regulation by inflammatory cytokines involves interactions between several transcription factors, including activator protein-1 and nuclear factor kappaB (NF-kappaB). The upstream regulatory pathways are less well understood. We investigated the role of isoforms of protein kinase C (PKC) in basic fibroblast growth factor- and interleukin-1alpha-mediated MMP production from cultured rabbit aortic smooth muscle cells. A synthetic PKC inhibitor, RO318220, inhibited MMP-1, -3, and -9 production by 89 +/- 3, 75 +/- 18, and 89 +/- 9%, respectively. However, down-regulation of conventional and novel isoforms did not inhibit but rather increased MMP-9 production by 48 +/- 16%, implicating an atypical PKC isoform. Consistent with this, PKC protein levels and activity were stimulated 3.3- and 13-fold, respectively, by basic fibroblast growth factor plus interleukin-la and antisense oligonucleotides to PKCzeta significantly decreased MMP-9 formation by 62 +/- 18% compared with scrambled sequences. Moreover, adenovirus-mediated overexpression of a dominant-negative (DN) PKCzeta reduced MMP-1, -3, and -9 production by 78 +/- 9, 76 +/- 8, and 76 +/- 5%, respectively. DN-PKCzeta inhibited NF-kappaB DNA binding but did not affect ERK1/2 activation or AP-1 binding. Antisense PKC oligonucleotides and DN-PKCzeta stimulated cell proliferation by 89 +/- 14% (n = 4) and 305 +/- 74% (n = 3), respectively (both p < 0.05). Our results show that PKCzeta is essential for cytokine-induced up-regulation of MMP-1, -3, and -9, most likely by activating NF-kappaB Selective inhibition of PKCzeta is therefore a possible strategy to inhibit NIMP production in inflammatory diseases such as atherosclerosis.	Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Univ Bristol, Bristol Royal Infirm, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England; Cardiff Univ, Sch Bio Sci, Cardiff CF10 3XQ, S Glam, Wales	Bristol Royal Infirmary; University of Bristol; Bristol Royal Infirmary; University of Bristol; Cardiff University	Newby, AC (corresponding author), Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.	a.newby@bris.ac.uk	Murphy, David/C-3967-2012; assender, jean/AAK-2210-2021; Bond, Mark/AAG-9293-2019	Murphy, David/0000-0003-2946-0353; assender, jean/0000-0003-2003-4630; Bond, Mark/0000-0003-2788-278X				ASSENDER JW, 1994, FEBS LETT, V342, P76, DOI 10.1016/0014-5793(94)80588-1; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; Carlin S, 2000, AM J RESP CELL MOL, V23, P555, DOI 10.1165/ajrcmb.23.4.4197; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; FINI ME, 1994, J BIOL CHEM, V269, P28620; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Harding TC, 1997, J NEUROCHEM, V69, P2620; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KARIYA K, 1989, BIOCHEM BIOPH RES CO, V161, P1020, DOI 10.1016/0006-291X(89)91345-4; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leng L, 1996, ARTERY, V22, P140; Leszczynski D, 1996, LIFE SCI, V58, P599, DOI 10.1016/0024-3205(95)02329-1; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Morgan KG, 1998, ACTA PHYSIOL SCAND, V164, P495; NEWBY AC, 1995, BRIT J PHARMACOL, V114, P1652, DOI 10.1111/j.1476-5381.1995.tb14953.x; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; SANZ L, 1994, J BIOL CHEM, V269, P10044; SATO H, 1993, ONCOGENE, V8, P395; SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021-9150(90)90150-H; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Woessner JF, 1998, BIOL EXTRAC, P1; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; YU LP, 1991, J RHEUMATOL, V18, P1450; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28	45	54	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27345	27352		10.1074/jbc.M111890200	http://dx.doi.org/10.1074/jbc.M111890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12000746	hybrid			2022-12-25	WOS:000177055900083
J	Takimoto, K; Yang, EK; Conforti, L				Takimoto, K; Yang, EK; Conforti, L			Palmitoylation of KChIP splicing variants is required for efficient cell surface expression of Kv4.3 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; K+ CHANNEL; BETA-SUBUNITS; POTASSIUM CHANNEL; PROTEIN PALMITOYLATION; BINDING PROTEIN; GENE-EXPRESSION; CALCIUM SENSOR; LIPID RAFTS; RAT-BRAIN	The Ca2+-binding proteins KChIP1--4 (KChIP3 is also known as DREAM and calsenilin) act as auxiliary subunits for voltage-gated K+ channels in the Kv4 family. Here we identify three splicing isoforms of rat KChIP2 with variable N-terminal peptides. The two longer isoforms, which contain the 32-amino acid peptide, produce larger increases in Kv4.3 protein. level and current density and more effectively localize themselves and their associated channels at the plasma membrane than the shortest variant. The 32-amino acid peptide contains potential palmitoylation cysteines. Metabolic labeling demonstrates that these cysteines in the KChIP2 isoforms, as well as the corresponding sites in KChIP3, are palmitoylated. Mutating these cysteines reduces their plasma membrane localization and the enhancement of Kv4.3 current density. Thus, palmitoylation of the KChIP auxiliary subunits controls plasma membrane localization of their associated channels.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Kyoungpook Natl Univ, Dept Physiol, Taegu 700422, South Korea; Univ Cincinnati, Dept Internal Med, Div Nephrol & Hypertens, Cincinnati, OH 45267 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyungpook National University; University System of Ohio; University of Cincinnati	Takimoto, K (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063123] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63123] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Bizzozero OA, 1997, NEUROPEDIATRICS, V28, P23, DOI 10.1055/s-2007-973660; BOUVIER M, 1995, BIOCHEM SOC T, V23, P116, DOI 10.1042/bst0230116; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chien AJ, 1998, J BIOENERG BIOMEMBR, V30, P377, DOI 10.1023/A:1021941706726; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; Choi EK, 2001, J BIOL CHEM, V276, P19197, DOI 10.1074/jbc.M008597200; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Decher N, 2001, CARDIOVASC RES, V52, P255, DOI 10.1016/S0008-6363(01)00374-1; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Holmqvist MH, 2001, J NEUROSCI, V21, P4154, DOI 10.1523/JNEUROSCI.21-12-04154.2001; Hurley JF, 2000, P NATL ACAD SCI USA, V97, P9293, DOI 10.1073/pnas.160589697; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; Magee J, 1998, ANNU REV PHYSIOL, V60, P327, DOI 10.1146/annurev.physiol.60.1.327; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; Ohya S, 2001, BIOCHEM BIOPH RES CO, V282, P96, DOI 10.1006/bbrc.2001.4558; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; Petrecca K, 2000, J NEUROSCI, V20, P8736; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Takimoto K, 1996, BIOCHEMISTRY-US, V35, P14149, DOI 10.1021/bi961290s; Tsaur ML, 1997, FEBS LETT, V400, P215, DOI 10.1016/S0014-5793(96)01388-9; Tsaur ML, 2001, CHINESE J PHYSIOL, V44, P133; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	53	114	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26904	26911		10.1074/jbc.M203651200	http://dx.doi.org/10.1074/jbc.M203651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12006572	hybrid			2022-12-25	WOS:000177055900028
J	Lesley, J; English, NM; Gal, I; Mikecz, K; Day, AJ; Hyman, R				Lesley, J; English, NM; Gal, I; Mikecz, K; Day, AJ; Hyman, R			Hyaluronan binding properties of a CD44 chimera containing the link module of TSG-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-STIMULATED GENE-6; CELL-OOCYTE COMPLEXES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; PHYSIOLOGICAL FLOW; PRIMARY ADHESION; T-CELLS; ROLLING INTERACTIONS; CYTOPLASMIC DOMAIN; PROTEIN TSG-6	CD44, a cell-surface receptor for the extracellular matrix glycosaminoglycan hyaluronan, can mediate leukocyte rolling on hyaluronan substrates and has been implicated in leukocyte migration to sites of inflammation. CD44-mediated binding to hyaluronan is of low affinity, and effective cell/matrix interaction depends on multiple interactions with the multivalent ligand. We replaced the Link module of CD44 with the homologous region of TSG-6, a hyaluronan-binding protein secreted in response to inflammation whose Link module has a higher affinity for ligand. Monoclonal antibodies raised against the CD44/TSG-6 chimera recognized recombinant human TSG-6 and native mouse TSG-6 and blocked hyaluronan binding to these proteins. Cells expressing the CD44/TSG-6 molecule bound hyaluronan with higher avidity than cells expressing CD44. This resulted in changes in the hyaluronan binding properties characteristic of cells expressing CD44 such as requirements for threshold levels of receptor expression and for hyaluronan of high molecular mass. In parallel plate flow assays used to model leukocyte rolling, cells expressing CD44/TSG-6 failed to roll on hyaluronan. Instead, they stuck and remained "tethered" to the substrate under fluid How. This result argues that the low affinity of CD44 for its ligand is important for rolling, an early phase of leukocyte extravasation from the blood.	Rush Univ, Dept Orthoped Surg, Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Salk Inst, Mol & Cell Biol Lab, San Diego, CA 92186 USA; Rush Univ, Dept Biochem, Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Univ Oxford, Med Res Council Immunochem Unit, Dept Biochem, Oxford OX1 3QU, England	Rush University; Salk Institute; Rush University; University of Oxford	Mikecz, K (corresponding author), Rush Univ, Dept Orthoped Surg, Rush Presbyterian St Lukes Med Ctr, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	kmikecz@rush.edu	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Mikecz, Katalin/0000-0003-1506-4296	NCI NIH HHS [CA-14195] Funding Source: Medline; NIAID NIH HHS [AI-31613] Funding Source: Medline; NIAMS NIH HHS [AR-45652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Chang KC, 2000, P NATL ACAD SCI USA, V97, P11262, DOI 10.1073/pnas.200240897; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; English NM, 1998, CANCER RES, V58, P3736; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; Friederichs J, 2000, CANCER RES, V60, P6714; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LANG JC, 1988, NUCLEIC ACIDS RES, V16, P7736, DOI 10.1093/nar/16.15.7736; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1992, EUR J IMMUNOL, V22, P2719, DOI 10.1002/eji.1830221036; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 2002, IN PRESS HYALURONAN; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PERSCHL A, 1995, J CELL SCI, V108, P1033; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; UNDERHILL C, 1992, J CELL SCI, V103, P293; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	66	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26600	26608		10.1074/jbc.M201068200	http://dx.doi.org/10.1074/jbc.M201068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011075	hybrid			2022-12-25	WOS:000176908700101
J	Hresko, RC; Mueckler, M				Hresko, RC; Mueckler, M			Identification of pp68 as the tyrosine-phosphorylated form of SYNCRIP/NSAP1 - A cytoplasmic RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOPROTEIN-K PROTEIN; MESSENGER-RNA; POLY(A) TAIL; MAMMALIAN-CELLS; INSULIN ACTION; INITIATION; KINASE; TRANSLATION; ADIPOCYTES; STABILITY	Recently we reported that osmotic shock increased the insulin-stimulated tyrosine phosphorylation of a 68-kDa RNA-binding protein in 3T3-L1 adipocytes (Hresko, R. C., and Mueckler, M. (2000) J. BioL Chem. 275,1811418120). In this present study we have identified, by MALDI mass spectrometry, pp68 as the tyrosine-phosphorylated form of synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP)/NSAP1, a newly discovered cytoplasmic RNA-binding protein. Both SYNCRIP and pp68 were enriched in free polysomes found in low density microsomes isolated from 3T3-L1 adipocytes. In vitro phosphorylation studies revealed that SYNCRIP, once extracted from low density microsomes, can be tyrosine phosphorylated using purified insulin receptor. Binding of RNA to SYNCRIP specifically inhibited its in vitro phosphorylation but had no effect on receptor autophosphorylation or on the ability of the receptor to phosphorylate a model substrate, RCM-lysozyme. These results raise the possibility that regulation of mRNA translation or stability by insulin may involve the phosphorylation of SYNCRIP.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARDELLI J, 1976, J CELL BIOL, V70, P47, DOI 10.1083/jcb.70.1.47; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Harris CE, 1999, J VIROL, V73, P72, DOI 10.1128/JVI.73.1.72-80.1999; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; KELLER SR, 1991, J BIOL CHEM, V266, P12817; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; OBRIEN RM, 1996, PHYSIOL REV, V76, P1110; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PIPER RC, 1991, AM J PHYSIOL, V260, P570; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; WENGLER G, 1972, EUR J BIOCHEM, V27, P162, DOI 10.1111/j.1432-1033.1972.tb01822.x; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	35	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25233	25238		10.1074/jbc.M202556200	http://dx.doi.org/10.1074/jbc.M202556200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994298	hybrid			2022-12-25	WOS:000176747000051
J	Joubert, L; Claeysen, S; Sebben, M; Bessis, AS; Clark, RD; Martin, RS; Bockaert, J; Dumuis, A				Joubert, L; Claeysen, S; Sebben, M; Bessis, AS; Clark, RD; Martin, RS; Bockaert, J; Dumuis, A			A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; STRUCTURAL INSTABILITY; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; 3-DIMENSIONAL MODELS; LIGHT ACTIVATION; RHODOPSIN; BINDING; MUTATION	Activation of G protein-coupled receptors is thought to involve disruption of intramolecular interactions that stabilize their inactive conformation. Such disruptions are induced by agonists or by constitutively active mutations. In the present study, novel potent inverse agonists are described to inhibit the constitutive activity of 5-HT4 receptors. Using these compounds and specific receptor mutations, we investigated the mechanisms by which inverse agonists may reverse the disruption of intramolecular interactions that causes constitutive activation. Two mutations (D100(3.32)A in transmembrane domain (TMD)-III and F275(6.51)A in TMD-VI) were found to completely block inverse agonist effects without impairing their binding properties nor the molecular activation switches induced by agonists. Based on the rhodopsin model, we propose that these mutated receptors are in equilibrium between two states R and R* but are unable to reach a third "silent" state stabilized by inverse agonists. We also found another mutation in TMD-VI (W272(6.48)A) that stabilized this silent state. This mutant remained fully activated by agonists. Molecular modeling indicated that Asp-100, Phe-275, and Trp-272 might constitute a network required for stabilization of the silent state by the described inverse agonists. However, this network is not necessary for agonist activity.	CNRS, UPR 9023, F-34094 Montpellier 05, France; Roche Biosci, Neurobiol Unit, Palo Alto, CA 94304 USA	Centre National de la Recherche Scientifique (CNRS); Roche Holding	Bockaert, J (corresponding author), CNRS, UPR 9023, 141 Rue Cardonile, F-34094 Montpellier 05, France.		Claeysen, Sylvie/C-8599-2014	Claeysen, Sylvie/0000-0002-0576-5518				Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ansanay H, 1996, EUR J PHARMACOL, V298, P165, DOI 10.1016/0014-2999(95)00786-5; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Claeysen S, 2000, MOL PHARMACOL, V58, P136, DOI 10.1124/mol.58.1.136; Claeysen S, 2001, EMBO REP, V2, P61, DOI 10.1093/embo-reports/kve003; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; EBREY T, 1980, FEBS LETT, V116, P217, DOI 10.1016/0014-5793(80)80647-8; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; HIBERT MF, 1993, M S-MED SCI, V9, P31, DOI 10.4267/10608/2784; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Onaran HO, 1997, ANN NY ACAD SCI, V812, P98, DOI 10.1111/j.1749-6632.1997.tb48150.x; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scearce-Levie K, 2001, TRENDS PHARMACOL SCI, V22, P414, DOI 10.1016/S0165-6147(00)01743-0; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Surya A, 1998, TRENDS PHARMACOL SCI, V19, P243; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25502	25511		10.1074/jbc.M202539200	http://dx.doi.org/10.1074/jbc.M202539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976337	Green Published, hybrid			2022-12-25	WOS:000176747000086
J	Strom, M; Hume, AN; Tarafder, AK; Barkagianni, E; Seabra, MC				Strom, M; Hume, AN; Tarafder, AK; Barkagianni, E; Seabra, MC			A family of Rab27-binding proteins - Melanophilin links Rab27a and myosin Va function in melanosome transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASES; GERANYLGERANYLATION; MUTATIONS; COMPLEX; GENE; IDENTIFICATION; EXOCYTOSIS; DYNAMICS; RECEPTOR; PRODUCT	The Rab27a GTPase regulates diverse processes involving lysosome-related organelles, including melanosome motility in melanocytes, and lytic granule release in cytotoxic T lymphocytes. Toward an understanding of Rab27a function, we searched for proteins that interact with Rab27a(GTP) using the yeast two-hybrid system and identified JFCI/Slp1, a protein of unknown function. JFC1/Slp1 and related proteins, including melanophilin, contain a conserved amino-terminal domain similar to the Rab3a-binding domain of Rabphilin-3. We used several methods to demonstrate that this conserved amino-terminal domain is a Rab27-binding domain. We show that this domain interacts directly, and in a GTP-dependent manner with Rab27a. Furthermore, overexpression of this domain in melanocytes results in perinuclear clustering of melanosomes, suggesting that this region is sufficient for interaction with, and perturbation of function of, Rab27a in a physiological context. Thus, we identified a novel family of Rab27-binding proteins. We also show that melanophilin associates with Rab27a and myosin Va on melanosomes in melanocytes, and present evidence that a domain within the carboxylterminal region of melanophilin interacts with the carboxyl-terminal tail of the melanocyte-specific splice isoform of myosin Va. Thus, melanophilin can associate simultaneously with activated Rab27a and myosin Va via distinct regions, and serve as a linker between these proteins.	Univ London Imperial Coll Sci & Technol, Cell & Mol Biol Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Fac Med, Div Biomed Sci, Dept Cell & Mol Biol, London SW7 2AZ, England	Imperial College London; Imperial College London	Seabra, MC (corresponding author), Univ London Imperial Coll Sci & Technol, Cell & Mol Biol Sect, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	m.seabra@ic.ac.uk	Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; Hume, Alistair/0000-0001-9443-1087; Tarafder, Abul/0000-0002-0368-6111				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HERZ J, 1990, J BIOL CHEM, V265, P21355; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; James P, 1996, GENETICS, V144, P1425; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOORE KJ, 1988, GENETICS, V119, P933; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Ramalho JS, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-2; Rose MD., 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Shen F, 1996, J BIOL CHEM, V271, P3692; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	241	251	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25423	25430		10.1074/jbc.M202574200	http://dx.doi.org/10.1074/jbc.M202574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980908	hybrid			2022-12-25	WOS:000176747000076
J	Yao, SYM; Ng, AML; Vickers, MF; Sundaram, M; Cass, EC; Baldwin, SA; Young, JD				Yao, SYM; Ng, AML; Vickers, MF; Sundaram, M; Cass, EC; Baldwin, SA; Young, JD			Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2 - Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE NUCLEOSIDES; HYPOXANTHINE TRANSPORT; EPITHELIAL-CELLS; GUINEA-PIG; CLONING; NITROBENZYLTHIOINOSINE; EXPRESSION; PURINE	The human (h) and rat (r) equilibrative (Na+-independent) nucleoside transporters (ENTs) hENT1, rENT1, hENT2, and rENT2 belong to a family of integral membrane proteins with 11 transmembrane domains (TMs) and are distinguished functionally by differences in sensitivity to inhibition by nitrobenzylthioinosine and coronary vasoactive drugs. Structurally, the proteins have a large glycosylated loop between TMs 1 and 2 and a large cytoplasmic loop between TMs 6 and 7. In the present study, hENT1, rENT1, hENT2, and rENT2 were produced in Xenopus laevis oocytes and investigated for their ability to transport pyrimidine and purine nucleobases. hENT2 and rENT2 efficiently transported radiolabeled hypoxanthine, adenine, guanine, uracil, and thymine (apparent K-m values 0.7-2.6 mm), and hENT2, but not rENT2, also transported cytosine. These findings were independently confirmed by hypoxanthine transport experiments with recombinant hENT2 produced in purine-cytosine permease (FCY2)-deficient Saccharomyces cerevisiae and provide the first direct demonstration that the ENT2 isoform is a dual mechanism for the cellular uptake of nucleosides and nucleobases, both of which are physiologically important salvage metabolites. In contrast, recombinant hENT1 and rENT1 mediated negligible oocyte fluxes of hypoxanthine relative to hENT2 and rENT2. Chimeric experiments between rENT1 and rENT2 using splice sites at rENT1 residues 99 (end of TM 2), 171 (between TMs 4 and 5), and 231 (end of TM 6) identified TMs 5-6 of rENT2 (amino acid residues 172-231) as a determinant of nucleobase transport activity, suggesting that this domain forms part(s) of the ENT2 substrate translocation channel.	Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Prot Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca	Cass, Carol E/F-5861-2010					AGBANYO FR, 1988, MOL PHARMACOL, V33, P332; ARONOW B, 1986, J BIOL CHEM, V261, P2014; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BARROS LF, 1994, AM J OBSTET GYNECOL, V171, P111, DOI 10.1016/S0002-9378(94)70086-9; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; CASS CE, 1995, DRUG TRANSPORT ANTIM, P404; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; GATI WP, 1984, BIOCHEM PHARMACOL, V33, P3325, DOI 10.1016/0006-2952(84)90101-1; GATI WP, 1992, J BIOL CHEM, V267, P22272; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; GRIFFITH DA, 1992, BIOCHIM BIOPHYS ACTA, V1106, P303, DOI 10.1016/0005-2736(92)90010-J; GRIFFITH DA, 1994, BIOCHEM J, V303, P901, DOI 10.1042/bj3030901; GRIFFITH DA, 1993, J BIOL CHEM, V268, P20085; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; GUIMARAES MJ, 1995, DEVELOPMENT, V121, P3335; Hogue DL, 1999, GENOMICS, V59, P18, DOI 10.1006/geno.1999.5847; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1983, BIOCHEM J, V216, P661, DOI 10.1042/bj2160661; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Marshman E, 2001, BIOCHEM PHARMACOL, V61, P477, DOI 10.1016/S0006-2952(00)00574-8; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shayeghi M, 1999, BBA-BIOMEMBRANES, V1416, P109, DOI 10.1016/S0005-2736(98)00213-2; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; ULLMAN B, 1987, MOL CELL BIOL, V7, P97, DOI 10.1128/MCB.7.1.97; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Wagner R, 1998, FEMS MICROBIOL LETT, V159, P69, DOI 10.1111/j.1574-6968.1998.tb12843.x; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; WASHINGTON CB, 1995, J BIOL CHEM, V270, P22816, DOI 10.1074/jbc.270.39.22816; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 2000, PRACT APPROACH SER, P47; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Young JD, 2001, CURR TOP MEMBR, V50, P329	59	145	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24938	24948		10.1074/jbc.M200966200	http://dx.doi.org/10.1074/jbc.M200966200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006583	hybrid			2022-12-25	WOS:000176747000015
J	Cai, SJ; Inouye, M				Cai, SJ; Inouye, M			EnvZ-OmpR interaction and osmoregulation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE KINASE ENVZ; DNA-BINDING DOMAIN; SIGNAL-TRANSDUCTION; TRANSCRIPTION ACTIVATOR; SALMONELLA-TYPHIMURIUM; PHOSPHATASE-ACTIVITIES; BACTERIAL CHEMOTAXIS; POSITIVE REGULATOR; GENETIC-ANALYSIS; OSMOSENSOR ENVZ	EnvZ, a histidine kinase/phosphatase in Escherichia coli, responds to the osmolarity changes in the medium by regulating the phosphorylation state of the transcription factor OmpR, which controls the expression levels of outer membrane porin proteins OmpF and OmpC. Although both ompR and envZ genes are located on the ompB locus under the control of the ompB promoter and transcribed as a single polycistronic mRNA, the expression of envZ is known to be significantly less than ompR. However, to date no accurate estimation for the amounts of EnvZ and OmpR in the cell has been carried out. Here we examined the levels of EnvZ and OmpR in the wild-type strain MC4100 by quantitative Western blot analysis using anti-OmpR and anti-EnvZc (cytoplasmic domain of EnvZ) antisera. It was observed that during exponential growth in L-broth medium there were similar to3500 and 100 molecules per cell of OmpR and EnvZ, respectively. The levels of OmpR and EnvZ in MC4100 cells grown in a high osmolarity medium (nutrient broth with 20% sucrose) were about the same as those grown in L-broth, whereas they were 1.7-fold higher than those in a low osmolarity medium (nutrient broth). With His(10)-OmpR, we also determined that the K-d value for the EnvZc-OmpR complex formation is 1.20 +/- 0.17 mum. On the basis of these results, the molecular mechanism of osmoregulation of ompF and ompC is discussed.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; Bergstrom LC, 1998, GENES CELLS, V3, P777, DOI 10.1046/j.1365-2443.1998.00228.x; BERMAN ML, 1984, J BACTERIOL, V159, P750, DOI 10.1128/JB.159.2.750-756.1984; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Harrison-McMonagle P, 1999, J MOL BIOL, V285, P555, DOI 10.1006/jmbi.1998.2375; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Huang KJ, 1996, J MOL BIOL, V262, P615, DOI 10.1006/jmbi.1996.0540; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KATO M, 1989, FEBS LETT, V249, P168, DOI 10.1016/0014-5793(89)80617-9; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; Kondo H, 1997, NAT STRUCT BIOL, V4, P28, DOI 10.1038/nsb0197-28; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LILJESTROM P, 1988, J MOL BIOL, V201, P663, DOI 10.1016/0022-2836(88)90465-2; Mao WM, 1998, MOL MICROBIOL, V27, P415, DOI 10.1046/j.1365-2958.1998.00690.x; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mattison K, 2002, J BIOL CHEM, V277, P11143, DOI 10.1074/jbc.M111128200; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; Qin L, 2000, MOL MICROBIOL, V36, P24, DOI 10.1046/j.1365-2958.2000.01837.x; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; SHIN S, 1995, J BACTERIOL, V177, P4696, DOI 10.1128/jb.177.16.4696-4702.1995; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VERHOEF C, 1979, MOL GEN GENET, V169, P137, DOI 10.1007/BF00271664; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WANNER BL, 1996, ESCHERICHIA COLI SAL, V1, P1359; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808	48	211	226	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24155	24161		10.1074/jbc.M110715200	http://dx.doi.org/10.1074/jbc.M110715200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11973328	hybrid			2022-12-25	WOS:000176611800025
J	Dai, YS; Cserjesi, P; Markham, BE; Molkentin, JD				Dai, YS; Cserjesi, P; Markham, BE; Molkentin, JD			The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; SERUM RESPONSE FACTOR; TROPONIN-I GENE; ATRIAL-NATRIURETIC-FACTOR; HEART TUBE FORMATION; NEURAL-CREST; VENTRAL MORPHOGENESIS; P300; MUSCLE; COMPLEX	An intricate array of heterogeneous transcription factors participate in programming tissue-specific gene expression through combinatorial interactions that are unique to a given cell-type. The zinc finger-containing transcription factor GATA4, which is widely expressed in mesodermal and endodermal derived tissues, is thought to regulate cardiac myocyte-specific gene expression through combinatorial interactions with other semi-restricted transcription factors such as myocyte enhancer factor 2, nuclear factor of activated T-cells, serum response factor, and Nkx2.5. Here we determined that GATA4 also interacts with the cardiac-expressed basic helix-loop-helix transcription factor dHAND (also known as HAND2). GATA4 and dHAND synergistically activated expression of cardiac-specific promoters from the atrial natriuretic factor gene, the b-type natriuretic peptide gene, and the a-myosin heavy chain gene. Using artificial reporter constructs this functional synergy was shown to be GATA site-dependent, but E-box site-independent. A mechanism for the transcriptional synergy was suggested by the observation that the bHLH domain of dHAND physically interacted with the C-terminal zinc finger domain of GATA4 forming a higher order complex. This transcriptional synergy observed between GATA4 and dHAND was associated with p300 recruitment, but not with alterations in DNA binding activity of either factor. Moreover, the bHLH domain of dHAND directly interacted with the CH3 domain of p300 suggesting the existence of a higher order complex between GATA4, dHAND, and p300. Taken together with previous observations, these results suggest the existence of an enhanceosome complex comprised of p300 and multiple semi-restricted transcription factors that together specify tissue-specific gene expression in the heart.	Pfizer Global Res & Dev, Dept Mol Sci, Ann Arbor, MI 48105 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, New Orleans, LA 70112 USA	Pfizer; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Markham, BE (corresponding author), Pfizer Global Res & Dev, Dept Mol Sci, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Dai, Yanshan/B-8577-2009	Molkentin, Jeffery/0000-0002-3558-6529; Dai, Yanshan/0000-0001-5048-7417				Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; BISHOPRIC NH, 1997, J BIOL CHEM, V272, P20585; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Charite J, 2000, DEVELOPMENT, V127, P2461; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Goodman RH, 2000, GENE DEV, V14, P1553; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Howard M, 1999, DEV BIOL, V215, P62, DOI 10.1006/dbio.1999.9450; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Kuo HC, 1999, DEVELOPMENT, V126, P4223; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; McFadden DG, 2000, DEVELOPMENT, V127, P5331; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Murphy AM, 1997, BIOCHEM J, V322, P393, DOI 10.1042/bj3220393; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; NIHCOLAS SB, 1999, AM J PHYSIOL, V277, pH324; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; Rosoff ML, 1998, J BIOL CHEM, V273, P9124, DOI 10.1074/jbc.273.15.9124; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Srivastava D, 1999, TRENDS CARDIOVAS MED, V9, P11, DOI 10.1016/S1050-1738(98)00033-4; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thomas T, 1998, DEVELOPMENT, V125, P3005; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Yamagishi H, 2000, J CLIN INVEST, V105, P261, DOI 10.1172/JCI8856; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	63	146	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24390	24398		10.1074/jbc.M202490200	http://dx.doi.org/10.1074/jbc.M202490200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11994297	hybrid			2022-12-25	WOS:000176611800056
J	Parkin, SE; Baer, M; Copeland, TD; Schwartz, RC; Johnson, PF				Parkin, SE; Baer, M; Copeland, TD; Schwartz, RC; Johnson, PF			Regulation of CCAAT/enhancer-binding protein (C/EBP) activator proteins by heterodimerization with C/EBP gamma (Ig/EBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; ACUTE-PHASE RESPONSE; DNA-BINDING; TRANSCRIPTION FACTORS; LEUCINE ZIPPER; HEPATOCYTE PROLIFERATION; CELL-PROLIFERATION; MESSENGER-RNA; IN-VITRO; BETA	The CCAAT/enhancer-binding proteins (C/EBPs) are basic leucine zipper transcription factors that play important roles in regulating cell growth and differentiation. C/EBP proteins form leucine zipper-mediated homodimers but are also capable of heterodimerizing with other C/EBPs in vitro. Here we show that C/EBPbeta occurs predominantly as a heterodimer that displays rapid mobility in gel shift assays. Biochemical fractionation and antibody supershift assays demonstrate that the C/EBPbeta heterodimeric partner is C/EBPgamma (Ig/EBP), a C/EBP protein that has been implicated as an inhibitor of other family members. Although most cell types express C/EBPbeta.C/EBPgamma heterodimers, macrophages contain a C/EBPbeta partner that is serologically distinct from C/EBPgamma. We found that C/EBPgamma blocked the ability of C/EBPbeta and C/EBPgamma to activate a reporter gene in L cell fibroblasts but did not inhibit a chimeric C/EBPbeta protein containing the GCN4 leucine zipper. Repression by C/EBPgamma occurs at the level of transactivation and requires heterodimerization with the C/EBP partner. C/EBPgamma was an ineffective repressor in HepG2 hepatoma cells despite forming C/EBP heterodimers, and C/EBPalpha was not effectively inhibited in either L or HepG2 cells. Our findings demonstrate that C/EBPgamma modulates C/EBP activity in a cell- and isoform-specific manner.	NCI Frederick, Basic Res Lab, Regulat Cell Growth Lab, Frederick, MD 21702 USA; NCI Frederick, Basic Res Lab, Eukaryot Transcript Regulat Sect, Frederick, MD 21702 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Michigan State University	Johnson, PF (corresponding author), NCI Frederick, Basic Res Lab, Regulat Cell Growth Lab, Frederick, MD 21702 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; An MR, 1996, MOL CELL BIOL, V16, P2295; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COOPER C, 1992, J IMMUNOL, V149, P3225; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEVELLIS J, 1973, INDUCTION ENZYMES GL; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Hu HM, 1998, J IMMUNOL, V160, P2334; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kaisho T, 1999, J EXP MED, V190, P1573, DOI 10.1084/jem.190.11.1573; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE KAW, 1992, J CELL SCI, V103, P9; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V6, P771; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POLL V, 1990, CELL, V63, P643; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WALKER WS, 1975, J IMMUNOL, V114, P765; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zafarana G, 2000, EMBO J, V19, P5856, DOI 10.1093/emboj/19.21.5856; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	51	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23563	23572		10.1074/jbc.M202184200	http://dx.doi.org/10.1074/jbc.M202184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980905	hybrid			2022-12-25	WOS:000176475700061
J	Sasakura, Y; Hirata, S; Sugiyama, S; Suzuki, S; Taguchi, S; Watanabe, M; Matsui, T; Sagami, I; Shimizu, T				Sasakura, Y; Hirata, S; Sugiyama, S; Suzuki, S; Taguchi, S; Watanabe, M; Matsui, T; Sagami, I; Shimizu, T			Characterization of a direct oxygen sensor heme protein from Escherichia coli - Effects of the heme redox states and mutations at the heme-binding site on catalysis and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PHOSPHODIESTERASE; REGULATOR; BACTERIA; MELILOTI; ARCHAEA; SUBUNIT; FIXL; COOA	A protein containing a heme-binding PAS (PAS is from the protein names in which imperfect repeat sequences were first recognized: (P) under bar ER, (A) under bar RNT, and (S) under bar IM) domain from Escherichia coli has been implied a direct oxygen sensor (Ec DOS) enzyme. In the present study, we isolated cDNA for the Ec DOS full-length protein, expressed it in E. coli, and examined its structure-function relationships for the first time. Ec DOS was found to be tetrameric and was obtained as a 6-coordinate low spin ferric heme complex. Its a-helix content was calculated as 53% by CD spectroscopy. The redox potential of the heme was found to be +67 mV versus SHE. Mutation of His-77 of the isolated PAS domain abolished heme binding, whereas mutation of His-83 did not, suggesting that His-77 is one of the heme axial ligands. Ferrous, but not ferric, Ec DOS had phosphodiesterase (PDE) activity of nearly 0.15 min(-1) with cAMP, which was optimal at pH 8.5 in the presence of Mg2+ and was strongly inhibited by CO, NO, and etazolate, a selective cAMP PDE inhibitor. Absorption spectral changes indicated tight CO and NO bindings to the ferrous heme. Therefore, the present study unequivocally indicates for the first time that Ec DOS exhibits PDE activity with cAMP and that this is regulated by the heme redox state.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp	Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Fasman G.D., 1996, CIRCULAR DICHROISM C; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P5500, DOI 10.1021/bi00475a013; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; HIRATSUKA T, 1982, J BIOL CHEM, V257, P13354; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Imamura R, 1996, J BIOL CHEM, V271, P25423, DOI 10.1074/jbc.271.41.25423; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lahiri S, 2000, OXYGEN SENSING MOL M; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Mukai M, 2000, BIOCHEMISTRY-US, V39, P13810, DOI 10.1021/bi001184x; MYER YP, 1978, BIOCHEMISTRY-US, V17, P3723, DOI 10.1021/bi00611a008; Nakajima H, 2001, J BIOL CHEM, V276, P37895; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; ROGERS KR, 1999, CURR OPIN CHEM BIOL, V3, P158; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Tuckerman JR, 2001, J MOL BIOL, V308, P449, DOI 10.1006/jmbi.2001.4591; Tuominen EKJ, 2001, J BIOL CHEM, V276, P19356, DOI 10.1074/jbc.M100853200; VanDyke BR, 1996, J AM CHEM SOC, V118, P3490, DOI 10.1021/ja954181u; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200	34	100	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23821	23827		10.1074/jbc.M202738200	http://dx.doi.org/10.1074/jbc.M202738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970957	hybrid			2022-12-25	WOS:000176475700095
J	Wang, WL; Campos, AH; Prince, CZ; Mou, YS; Pollman, MJ				Wang, WL; Campos, AH; Prince, CZ; Mou, YS; Pollman, MJ			Coordinate Notch3-hairy-related transcription factor pathway regulation in response to arterial injury - Mediator role of platelet-derived growth factor and ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL FATE; NOTCH3 MUTATIONS; ACTIVATION; INHIBITION; CADASIL; GRIDLOCK; EXPRESSION; ANTIBODY; MEMBERS; KINASE	The Notch family of receptors and downstream effectors plays a critical role in cell fate determination during vascular ontogeny. Moreover, the human cerebral autosomal dominant artriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) syndrome of premature stroke and dementia is a heritable arteriopathy with alterations in vascular smooth muscle cells (VSMCs) resulting from mutations within Notch3. However, the expression and regulation of the Notch and hairy-related transcription factor (HRT) pathway in adult VSMCs in vitro and in vivo remain poorly characterized. The present study documents that the well-described modulation of VSMC fate in response to vascular injury and growth factor activation involves a coordinate regulation of the Notch and HRT pathways. Furthermore, platelet-derived growth factor promotes a similar coordinate down-regulation of the Notch receptors and HRT genes in cultured VSMCs via an ERK-dependent signaling pathway. Moreover, we established that HRT1 and HRT2 are direct downstream target genes of Notch3 signaling in VSMCs and determined that the activity of the nuclear protein RBP-Jk is essential for their regulation. These findings provide initial insight into the context- and cell type-dependent coordinate regulation of Notch3 and downstream HRT transcriptional pathway effector genes in VSMCs in vitro and in vivo that may have important implications for understanding the role of Notch signaling in human health and vascular disease.	Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA	Morehouse School of Medicine	Pollman, MJ (corresponding author), Morehouse Sch Med, Cardiovasc Res Inst, 720 Westview Dr,SW,Res Wing, Atlanta, GA 30310 USA.	mpollman@msm.edu	Campos, Alexandre/E-8258-2010					Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Beatus P, 1999, DEVELOPMENT, V126, P3925; Campos AH, 2001, CIRCULATION, V104, P275; Chandrasekar B, 2000, J AM COLL CARDIOL, V35, P555, DOI 10.1016/S0735-1097(99)00596-3; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; CHITNIS AB, 1995, MOL CELL NEUROSCI, V6, P311, DOI 10.1006/mcne.1995.1024; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; CONLON RA, 1995, DEVELOPMENT, V121, P1533; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Joutel A, 2000, ANN NEUROL, V47, P388, DOI 10.1002/1531-8249(200003)47:3<388::AID-ANA19>3.3.CO;2-H; Joutel A, 1997, ANN NY ACAD SCI, V826, P213, DOI 10.1111/j.1749-6632.1997.tb48472.x; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 2001, LANCET, V358, P2049, DOI 10.1016/S0140-6736(01)07142-2; Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5; KANZAKI T, 1994, EUR J CLIN INVEST, V24, P377, DOI 10.1111/j.1365-2362.1994.tb02179.x; Krebs LT, 2000, GENE DEV, V14, P1343; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; McLaughlin KA, 2000, DEV BIOL, V227, P567, DOI 10.1006/dbio.2000.9913; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Mitani Y, 2000, FASEB J, V14, P805, DOI 10.1096/fasebj.14.5.805; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Pfeifer M, 1998, RESP PHYSIOL, V111, P201, DOI 10.1016/S0034-5687(97)00102-3; Pyles JM, 1997, CIRC RES, V81, P904; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rubin P, 1998, INT J RADIAT ONCOL, V40, P929, DOI 10.1016/S0360-3016(97)00937-1; Shuster CB, 1998, MICROCIRCULATION, V5, P239; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	43	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23165	23171		10.1074/jbc.M201409200	http://dx.doi.org/10.1074/jbc.M201409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971902	hybrid			2022-12-25	WOS:000176475700011
J	Shao, CS; Yin, MY; Deng, L; Stambrook, PJ; Doetschman, T; Tischfield, JA				Shao, CS; Yin, MY; Deng, L; Stambrook, PJ; Doetschman, T; Tischfield, JA			Loss of heterozygosity and point mutation at Aprt locus in T cells and fibroblasts of Pms2(-/-) mice	ONCOGENE			English	Article						mismatch repair; PMS2; APRT; mouse model; somatic mutation; loss of heterozygosity	DNA MISMATCH REPAIR; MITOTIC RECOMBINATION; DEFICIENT; GENE; APOPTOSIS; TRANSITIONS; MLH1	Mice null for the Pms2 mismatch repair (MMR) gene exhibit a predisposition to lymphoma, microsatellite repeat instability, and failure of spermatogenesis. To study the role of Pms2 in the maintenance of in vivo genomic integrity in somatic cells, we characterized Aprt mutations in T cells and fibroblasts of 129 x C3H Pms2(-/-)Aprt(+/-) mice. The spontaneous frequency of DAP-resistant T lymphocytes, as a consequence of APRT-deficiency, was increased threefold. Point mutation, which accounted for less than 20% of the DAP(r) mutant clones in Pms2(+/+) mice, was predominant in the mutant T cell clones from Pms2(-/-) mice. These point mutations were predominantly TA to CG transitions. Fibroblasts of Pms2(-/-) mice exhibited only a modest increase in the frequency of clones with point mutations, such that mitotic recombination was still the primary cause of APRT deficiency. Thus, the mutator phenotype as a consequence of PMS2 deficiency is tissue-dependent, which may be related to the tissue-specific tumor proneness of Pms2(-/-)Aprt(+/-) mice.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Tischfield, JA (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.		Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NIDDK NIH HHS [R01DK38185] Funding Source: Medline; NIEHS NIH HHS [P01ES05652, P30ES05022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005652, P30ES005022] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Bielas JH, 2000, P NATL ACAD SCI USA, V97, P11391, DOI 10.1073/pnas.190330997; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Gong JG, 1999, NATURE, V399, P806; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; Meng QX, 1998, ENVIRON MOL MUTAGEN, V32, P236, DOI 10.1002/(SICI)1098-2280(1998)32:3<236::AID-EM6>3.3.CO;2-P; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rose JA, 2000, CANCER RES, V60, P3404; Shaddock J. G., 2001, Environmental and Molecular Mutagenesis, V37, P68; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 1999, CANCER RES, V59, P3021	26	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2840	2845		10.1038/sj.onc.1205358	http://dx.doi.org/10.1038/sj.onc.1205358			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973643				2022-12-25	WOS:000175063700008
J	Horie, R; Watanabe, T; Morishita, Y; Ito, K; Ishida, T; Kanegae, Y; Saito, I; Higashihara, M; Mori, S; Kadin, ME; Watanabe, T				Horie, R; Watanabe, T; Morishita, Y; Ito, K; Ishida, T; Kanegae, Y; Saito, I; Higashihara, M; Mori, S; Kadin, ME; Watanabe, T			Ligand-independent signaling by overexpressed CD30 drives NF-kappa B activation in Hodgkin-Reed-Sternberg cells	ONCOGENE			English	Article						Hodgkin-Reed-Sternberg cells; CD30; TRAF proteins; NF-kappa B; adenovirus vector	TNF RECEPTOR SUPERFAMILY; IMMUNOGLOBULIN GENE REARRANGEMENTS; CYTOPLASMIC DOMAIN; BINDING-SITES; TUMOR-CELLS; DISEASE; DEATH; EXPRESSION; PROTEINS; FAMILY	Overexpression of CD30 and constitutive NF-kappaB activation characterizes tumor cells of Hodgkin's disease (HD), Hodgkin and Reed-Sternberg (H-RS) cells. We report that in H-RS cells overexpression of CD30 leads to self-aggregation, recruitment of TRAF2 and TRAF5, and NF-kappaB activation, independent of CD30 ligand. CD30 and TRAF proteins co-localized in H-RS cell lines and in lymph nodes of HD. An adenovirus-vector carrying a decoy CD30 lacking the cytoplasmic region or a dominant negative IkappaBalpha mutant blocks NF-kappaB activation, down regulates IL-13 expression and induces apoptosis. Thus, in H-RS cells, ligand-independent activation of CD30 signaling drives NF-kappaB activation and this leads to constitutive cytokine expression, which provides a molecular basis for HD. Inhibition of NF-kappaB activation by adenovirus vector-mediated gene transfer may provide a novel strategy of cell- and target molecule-specific therapy for patients with HD.	Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan; Kitasato Univ, Fac Med, Dept Hematol, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Mol Genet Lab, Minato Ku, Tokyo 1088639, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Tokyo; Kitasato University; University of Tokyo; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Watanabe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tnabe@ims.u-tokyo.ac.jp						ADAM D, 1995, J BIOL CHEM, V270, P17482; Aizawa S, 1997, J BIOL CHEM, V272, P2042; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cantwell MJ, 1996, BLOOD, V88, P4676, DOI 10.1182/blood.V88.12.4676.bloodjournal88124676; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; FALINI B, 1995, BLOOD, V85, P1; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; GRUSS HJ, 1994, BLOOD, V83, P2045; Harris NL, 1999, SEMIN HEMATOL, V36, P220; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horie R, 1998, INT IMMUNOL, V10, P203, DOI 10.1093/intimm/10.2.203; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Horie R, 1996, BLOOD, V88, P2422, DOI 10.1182/blood.V88.7.2422.bloodjournal8872422; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; JOSIMOVICALASEVIC O, 1989, EUR J IMMUNOL, V19, P157, DOI 10.1002/eji.1830190125; Kadin ME, 1999, HODGKIN'S DISEASE, P139; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Medina DJ, 1999, BLOOD, V94, P3499; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Pinto A, 1996, BLOOD, V88, P3299, DOI 10.1182/blood.V88.9.3299.bloodjournal8893299; Prince HM, 1998, EXP HEMATOL, V26, P27; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; von Wasielewski R, 2000, BLOOD, V95, P1207, DOI 10.1182/blood.V95.4.1207.004k34_1207_1213; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868	53	163	171	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2493	2503		10.1038/sj.onc.1205337	http://dx.doi.org/10.1038/sj.onc.1205337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971184				2022-12-25	WOS:000174918400006
J	Wittwer, M; Fluck, M; Hoppeler, H; Muller, S; Desplanches, D; Billeter, R				Wittwer, M; Fluck, M; Hoppeler, H; Muller, S; Desplanches, D; Billeter, R			Prolonged unloading of rat soleus muscle causes distinct adaptations of the gene profile	FASEB JOURNAL			English	Review						atrophy; array; hindlimb suspension; L1 regression	DENSITY-LIPOPROTEIN RECEPTOR; RECTIFIER POTASSIUM CHANNEL; GLUCOSE-TRANSPORTER GLUT4; SKELETAL-MUSCLE; HINDLIMB SUSPENSION; MOLECULAR-CLONING; MESSENGER-RNA; SATELLITE CELLS; NEUROPEPTIDE-Y; MYOGENIC DIFFERENTIATION	Using commercially available microarray technology, we investigated a series of transcriptional adaptations caused by atrophy of rat m. soleus due to 35 days of hindlimb suspension. We detected 395 out of 1,200 tested transcripts, which reflected 1%-5% of totally expressed genes. From various cellular functional pathways, we detected multiple genes that spanned a 200-fold range of gene expression levels. Statistical analysis combining L1 regression with the sign test based on the conservative Bonferroni correction identified 105 genes that underwent transcriptional adaptations with atrophy. Generally, expressional changes were discrete (<50%) and pointed in the same direction for genes belonging to the same cellular functional units. In particular, a distinct expressional adaptation of genes involved in fiber transformation; that is, metabolism, protein turnover, and cell regulation were noted and matched to corresponding transcriptional changes in nutrient trafficking. Expressional changes of extracellular proteases, and of genes involved in nerve-muscle interaction and excitation-contraction coupling identify previously not recognized adaptations that occur in atrophic m. soleus. Considerations related to technical and statistical aspects of the array approach for profiling the skeletal muscle genome and the impact of observed novel adaptations of the m. soleus transcriptome are put into perspective of the physiological adaptations occurring with muscular atrophy.	Univ Bern, Inst Anat, CH-3012 Bern, Switzerland; Univ Bern, Dept Math Stat & Actuarial Sci, CH-3012 Bern, Switzerland; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Lyon 1, CNRS, UMR 5123, F-69622 Villeurbanne, France	University of Bern; University of Bern; University of Leeds; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fluck, M (corresponding author), Univ Bern, Inst Anat, Buhlstr 26, CH-3012 Bern, Switzerland.	flueck@ana.unibe.ch	Muller, Samuel/N-1371-2019; Wittwer, Matthias/K-4512-2014; Mueller, Samuel/D-4850-2009	Muller, Samuel/0000-0002-3087-8127; Wittwer, Matthias/0000-0003-4713-8392; Mueller, Samuel/0000-0002-3087-8127				Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Atherton GT, 1996, CELL GROWTH DIFFER, V7, P1059; Attaix D, 1997, MOL BIOL REP, V24, P95, DOI 10.1023/A:1006806103675; Awede B, 1999, FEBS LETT, V461, P263, DOI 10.1016/S0014-5793(99)01469-6; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; Balcerzak D, 2001, J ANIM SCI, V79, P94; Bloomfield P., 1983, LEAST ABSOLUTE DEVIA; BONEN A, 1988, J APPL PHYSIOL, V65, P1833, DOI 10.1152/jappl.1988.65.4.1833; Bonini JA, 1997, BIOCHEM BIOPH RES CO, V234, P190, DOI 10.1006/bbrc.1997.6591; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Catterall W A, 1999, Adv Neurol, V79, P441; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cros N, 1999, AM J PHYSIOL-REG I, V276, pR308, DOI 10.1152/ajpregu.1999.276.2.R308; Delp MD, 2000, AM J PHYSIOL-HEART C, V278, pH1866, DOI 10.1152/ajpheart.2000.278.6.H1866; DESPLANCHES D, 1987, J APPL PHYSIOL, V63, P558, DOI 10.1152/jappl.1987.63.2.558; DESPLANCHES D, 1990, J APPL PHYSIOL, V69, P504, DOI 10.1152/jappl.1990.69.2.504; DESPLANCHES D, 1987, J APPL PHYSIOL, V63, P1739, DOI 10.1152/jappl.1987.63.5.1739; DONOGHUE MJ, 1994, TRENDS GENET, V10, P396, DOI 10.1016/0168-9525(94)90056-6; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Durkin MM, 2000, EXP NEUROL, V165, P90, DOI 10.1006/exnr.2000.7446; ELDER GCB, 1987, J APPL PHYSIOL, V62, P1917, DOI 10.1152/jappl.1987.62.5.1917; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FITTS RH, 1989, AM J PHYSIOL, V256, pC1082, DOI 10.1152/ajpcell.1989.256.5.C1082; Fitts RH, 2000, J APPL PHYSIOL, V89, P823, DOI 10.1152/jappl.2000.89.2.823; Glatz JFC, 1998, ADV EXP MED BIOL, V441, P207; GOLDSPINK DF, 1986, PFLUG ARCH EUR J PHY, V407, P333, DOI 10.1007/BF00585311; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Grichko VP, 2000, J APPL PHYSIOL, V88, P473, DOI 10.1152/jappl.2000.88.2.473; Guidry G, 2000, AUTON NEUROSCI-BASIC, V82, P97, DOI 10.1016/S0165-1838(00)00094-1; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; Haddad F, 1998, J APPL PHYSIOL, V85, P2227, DOI 10.1152/jappl.1998.85.6.2227; Hajduch E, 1999, BIOCHEM BIOPH RES CO, V257, P369, DOI 10.1006/bbrc.1999.0471; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hamilton MT, 1998, AM J PHYSIOL-ENDOC M, V275, pE1016, DOI 10.1152/ajpendo.1998.275.6.E1016; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HENRIKSEN EJ, 1986, J BIOL CHEM, V261, P707; HENRIKSEN EJ, 1993, J APPL PHYSIOL, V74, P1653, DOI 10.1152/jappl.1993.74.4.1653; HENRIKSEN EJ, 1988, METABOLISM, V37, P201, DOI 10.1016/0026-0495(88)90096-0; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HIETANENPELTOLA M, 1992, BRAIN RES, V579, P327, DOI 10.1016/0006-8993(92)90069-L; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; HOWARD G, 1989, J APPL PHYSIOL, V66, P1093, DOI 10.1152/jappl.1989.66.3.1093; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; JOSHUA IG, 1991, PEPTIDES, V12, P37, DOI 10.1016/0196-9781(91)90163-J; JOZSA L, 1988, EXP MOL PATHOL, V49, P267, DOI 10.1016/0014-4800(88)90039-1; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kawano Y, 1999, DIABETOLOGIA, V42, P1071, DOI 10.1007/s001250051273; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; Kraus B, 1997, EUR J BIOCHEM, V247, P98, DOI 10.1111/j.1432-1033.1997.t01-1-00098.x; KRIPPENDORF BB, 1993, MUSCLE NERVE, V16, P99, DOI 10.1002/mus.880160116; KUES WA, 1995, EUR J NEUROSCI, V7, P1376, DOI 10.1111/j.1460-9568.1995.tb01129.x; Langfort J, 1997, BIOCHEM CELL BIOL, V75, P41; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; Leterme D, 1996, PFLUG ARCH EUR J PHY, V432, P313, DOI 10.1007/s004240050138; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu TJ, 2001, CIRC RES, V88, P1231, DOI 10.1161/hh1201.092036; Lluis F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; LOWELL BB, 1986, BIOCHEM J, V234, P237, DOI 10.1042/bj2340237; Luiken JJFP, 1999, LIPIDS, V34, pS169, DOI 10.1007/BF02562278; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Mahns DA, 1998, J AUTONOM NERV SYST, V68, P14, DOI 10.1016/S0165-1838(97)00111-2; MAKITA N, 1994, J BIOL CHEM, V269, P7571; Martin Sally, 1999, Cell Biochemistry and Biophysics, V30, P89, DOI 10.1007/BF02737886; Matteo RG, 2000, CARDIOVASC RES, V45, P961, DOI 10.1016/S0008-6363(99)00409-5; McArthur MJ, 1999, J LIPID RES, V40, P1371; MILLER WC, 1988, P SOC EXP BIOL MED, V189, P183; Morey E R, 1979, Physiologist, V22, pS23; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Muir E, 1998, GLIA, V23, P24, DOI 10.1002/(SICI)1098-1136(199805)23:1<24::AID-GLIA3>3.3.CO;2-J; Nakamura M, 1997, BBA-BIOMEMBRANES, V1328, P83, DOI 10.1016/S0005-2736(97)00131-4; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; O'Harte FPM, 1998, J ENDOCRINOL, V156, P237, DOI 10.1677/joe.0.1560237; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Pol A, 1997, BIOCHEM J, V327, P741, DOI 10.1042/bj3270741; Reid B, 1999, J NEUROSCI, V19, P2511; RILEY DA, 1990, FASEB J, V4, P84, DOI 10.1096/fasebj.4.1.2153085; Roh C, 2001, J BIOL CHEM, V276, P35990, DOI 10.1074/jbc.M102791200; ROSEBOOM PH, 1994, DNA CELL BIOL, V13, P629, DOI 10.1089/dna.1994.13.629; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHULTZ E, 1994, J APPL PHYSIOL, V76, P266, DOI 10.1152/jappl.1994.76.1.266; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; Standaert ML, 1999, ENDOCRINOLOGY, V140, P4470, DOI 10.1210/en.140.10.4470; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; Stohwasser R, 2000, EUR J BIOCHEM, V267, P6221, DOI 10.1046/j.1432-1327.2000.01706.x; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; Suzuki Y, 1998, AM J PHYSIOL-CELL PH, V274, pC1674, DOI 10.1152/ajpcell.1998.274.6.C1674; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; Thompson CB, 1996, J BIOL CHEM, V271, P32653, DOI 10.1074/jbc.271.51.32653; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Tuvim MJ, 2001, NEWS PHYSIOL SCI, V16, P56; Van Nieuwenhoven FA, 1999, INT J BIOCHEM CELL B, V31, P489, DOI 10.1016/S1357-2725(98)00122-8; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; Vernon SD, 2000, J MOL DIAGN, V2, P124, DOI 10.1016/S1525-1578(10)60626-5; Vettor R, 1998, DIABETOLOGIA, V41, P1361, DOI 10.1007/s001250051077; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wildsmith SE, 2001, BIOTECHNIQUES, V30, P202, DOI 10.2144/01301dd04; Willmann R, 2001, AM J PHYSIOL-CELL PH, V280, pC273, DOI 10.1152/ajpcell.2001.280.2.C273; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zhang LF, 1997, J GRAVIT PHYSL, V4, pP97	128	77	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					884	+		10.1096/fj.01-0792fje	http://dx.doi.org/10.1096/fj.01-0792fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967225				2022-12-25	WOS:000175425900012
J	Hwang, GW; Furuchi, T; Naganuma, A				Hwang, GW; Furuchi, T; Naganuma, A			Ubiquitin-proteasome system is responsible for the protection of yeast and human cells against methylmercury	FASEB JOURNAL			English	Article						resistance; Cdc34; Ubc3; ubiquitination	SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; CONJUGATING ENZYME; MERCURY; GENE; INHIBITORS; EXPOSURE; COMPLEX; DISEASE; FISH	The mechanism responsible for the toxic effects of methylmercury (MeHg), an important environmental pollutant, is poorly understood. We have identified a gene, CDC34, that confers resistance to MeHg in Saccharomyces cerevisiae by screening a yeast genomic DNA library. CDC34 encodes a ubiquitin-conjugating enzyme, Cdc34, which is involved in ubiquitin-dependent proteolysis. Overexpression of Cdc34 results in significant resistance to MeHg both in yeast and human cells, and it increases the cellular level of ubiquitinated proteins. The ubiquitin-conjugating activity of Cdc34 is essential for the Cdc34-mediated resistance to MeHg, and the protective effect of the overexpression of Cdc34 is depressed by inhibition of proteasome activity. Our results support the hypothesis that MeHg induces the cellular accumulation of a certain protein(s) that causes cell damage and that this protein(s) is degraded after its ubiquitination in proteasomes.	Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Biochem Toxicol, Sendai, Miyagi 9808578, Japan	Tohoku University	Naganuma, A (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Biochem Toxicol, Sendai, Miyagi 9808578, Japan.	naganuma@mail.pharm.tohoku.ac.jp	NAGANUMA, AKIRA/V-2918-2019					Akagi H, 2000, J HEALTH SCI, V46, P323; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Clarkson T, 1998, SCIENCE, V279, P459; Clarkson T. W., 1972, CRITICAL REV TOXICOL, V1, P203; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FITZGERALD WF, 1991, ENVIRON HEALTH PERSP, V96, P159, DOI 10.2307/3431225; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOYER RA, 1985, ENVIRON HEALTH PERSP, V60, P355, DOI 10.2307/3429982; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN CS, 1993, CURRENT PROTOCOLS MO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LIU Y, 1995, MOL CELL BIOL, V15, P5635; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Naganuma A, 2000, FASEB J, V14, P968, DOI 10.1096/fasebj.14.7.968; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; Schrope M, 2001, NATURE, V409, P124, DOI 10.1038/35051770; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; SKERFVING S, 1974, TOXICOLOGY, V2, P3, DOI 10.1016/0300-483X(74)90038-9; Tsubaki T., 1968, CLIN NEUROL, V8, P511	30	43	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					709	+		10.1096/fj.01-0899fje	http://dx.doi.org/10.1096/fj.01-0899fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978736				2022-12-25	WOS:000174755900017
J	Mills, EM; Xu, D; Fergusson, MM; Combs, CA; Xu, YH; Finkel, T				Mills, EM; Xu, D; Fergusson, MM; Combs, CA; Xu, YH; Finkel, T			Regulation of cellular oncosis by uncoupling protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROTON LEAK; APOPTOSIS; OBESITY; DEATH; GENE; EXPRESSION	Cell death can proceed through at least two distinct pathways. Apoptosis is an energy-dependent process characterized morphologically by cell shrinkage, whereas oncosis is a form of cell death induced by energy depletion and initially characterized by cell swelling. We demonstrate in HeLa cells but not in normal diploid fibroblasts that modest increases in the expression level of uncoupling protein 2 (UCP-2) leads to a rapid and dramatic fall in mitochondrial membrane potential and to a reduction of mitochondrial NADH and intracellular ATP. In HeLa cells, increased UCP-2 expression leads to a form of cell death that is not inhibited by the anti-apoptotic gene product Bcl-2 and that morphologically resembles cellular oncosis. We further describe the creation of a dominant interfering mutant of UCP-2 whose expression increases resting mitochondrial membrane potential and selectively increases the resistance to cell death following oncotic but not apoptotic stimuli. These results suggest that distinct genetic programs may regulate the cellular response to either apoptotic or oncotic stimuli.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, 10 Ctr Dr,Bldg 10-6N-240, Bethesda, MD 20892 USA.	finkelt@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson R, 1998, PANCREAS, V17, P281, DOI 10.1097/00006676-199810000-00010; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Combs CA, 2001, BIOPHYS J, V80, P2018, DOI 10.1016/S0006-3495(01)76172-3; Crisby M, 1997, ATHEROSCLEROSIS, V130, P17, DOI 10.1016/S0021-9150(96)06037-6; ELASSER A, 2001, BASIC RES CONTROL, V96, P219; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jones A, 2000, TRENDS PLANT SCI, V5, P225, DOI 10.1016/S1360-1385(00)01605-8; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Lecoeur H, 2001, CYTOMETRY, V44, P65, DOI 10.1002/1097-0320(20010501)44:1<65::AID-CYTO1083>3.0.CO;2-Q; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Ma FR, 2001, P NATL ACAD SCI USA, V98, P9778, DOI 10.1073/pnas.171322898; MAJNO G, 1995, AM J PATHOL, V146, P3; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; Rial E, 2001, BBA-BIOENERGETICS, V1504, P70, DOI 10.1016/S0005-2728(00)00240-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Ricquier D, 2000, J PHYSIOL-LONDON, V529, P3, DOI 10.1111/j.1469-7793.2000.00003.x; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	30	86	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27385	27392		10.1074/jbc.M111860200	http://dx.doi.org/10.1074/jbc.M111860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011039	hybrid			2022-12-25	WOS:000177055900088
J	Thoden, JB; Holden, HM; Zhuang, ZH; Dunaway-Mariano, D				Thoden, JB; Holden, HM; Zhuang, ZH; Dunaway-Mariano, D			X-ray crystallographic analyses of inhibitor and substrate complexes of wild-type and mutant 4-hydroxybenzoyl-CoA thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTACONATE COA-TRANSFERASE; SARCOPLASMIC-RETICULUM; ACIDAMINOCOCCUS FERMENTANS; MACROMOLECULAR STRUCTURES; CRYSTAL-STRUCTURE; ACTIVE-SITE; BINDING; ATPASE; PHOSPHATE; PATHWAY	The metabolic pathway by which 4-chlorobenzoate is degraded to 4-hydroxybenzoate in the soil-dwelling microbe Pseudomonas sp. strain CBS-3 consists of three enzymes including 4-hydroxybenzoyl-CoA thioesterase. The structure of the unbound form of this thioesterase has been shown to contain the so-called "hot dog" fold with a large helix packed against a five-stranded anti-parallel beta-sheet. To address the manner in which the enzyme accommodates the substrate within the active site, two inhibitors have been synthesized, namely 4-hydroxyphenacyl-CoA and 4-hydroxybenzyl-CoA. Here we describe the structural analyses of the enzyme complexed with these two inhibitors determined and refined to 1.5 and 1.8 Angstrom resolution, respectively. These studies indicate that only one protein side chain, Ser(91), participates directly in ligand binding. All of the other interactions between the protein and the inhibitors are mediated through backbone peptidic NH groups, carbonyl oxygens, and/or solvents. The structures of the enzyme-inhibitor complexes suggest that both a hydrogen bond and the positive end of a helix dipole moment serve to polarize the electrons away from the carbonyl carbon of the acyl group, thereby making it more susceptible to nucleophilic attack. Additionally, these studies demonstrate that the carboxylate group of Asp(17) is similar to3.2 Angstrom from the carbonyl carbon of the acyl group. To address the role of Asp(17), the structure of the site-directed mutant protein D17N with bound substrate has also been determined. Taken together, these investigations suggest that the reaction mechanism may proceed through an acyl enzyme intermediate.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of Wisconsin System; University of Wisconsin Madison; University of New Mexico	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu; dd39@unm.edu	Hu, Ruogu/B-2203-2008		NIGMS NIH HHS [GM 55513] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P1604, DOI 10.1021/bi00405a032; Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P5606; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Jacob U, 1997, STRUCTURE, V5, P415, DOI 10.1016/S0969-2126(97)00198-6; KLAGES U, 1981, J BACTERIOL, V146, P64, DOI 10.1128/JB.146.1.64-68.1981; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Li J, 2000, NAT STRUCT BIOL, V7, P555; Lightstone FC, 1996, J AM CHEM SOC, V118, P2595, DOI 10.1021/ja952589l; Luo LS, 2001, BIOCHEMISTRY-US, V40, P15684, DOI 10.1021/bi011536f; Mack M, 1997, FEBS LETT, V405, P209, DOI 10.1016/S0014-5793(97)00187-7; MISSIAEN L, 1988, BIOCHEM J, V253, P827, DOI 10.1042/bj2530827; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICK U, 1982, J BIOL CHEM, V257, P6111; ROCHET JC, 1994, PROTEIN SCI, V3, P975; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SOLOMON F, 1969, J BIOL CHEM, V244, P1079; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROULLIER A, 1992, J BIOL CHEM, V267, P22821	24	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27468	27476		10.1074/jbc.M203904200	http://dx.doi.org/10.1074/jbc.M203904200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11997398	hybrid			2022-12-25	WOS:000177055900096
J	Buddai, SK; Toulokhonova, L; Bergum, PW; Vlasuk, GP; Krishnaswamy, S				Buddai, SK; Toulokhonova, L; Bergum, PW; Vlasuk, GP; Krishnaswamy, S			Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FACTOR V; ACTIVE-SITE; EXTINCTION COEFFICIENTS; DEPENDENT REACTIONS; BLOOD-COAGULATION; TISSUE FACTOR; HEAVY-CHAIN; FACTOR VIIA; EXOSITE I; ACTIVATION	The binding of recombinant nematode anticoagulant protein c2 (NAPc2) to either factor X or Xa is a requisite step in the pathway for the potent inhibition of VIIa tissue factor. We have used NAPc2 as a tight binding probe of human Xa to investigate protein substrate recognition by the human prothrombinase complex. NAPc2 binds with high affinity (K-d similar to1 nm) to both X and Xa in a way that does not require or occlude the active site of the enzyme. In contrast, NAPc2 is a tight binding, competitive inhibitor of protein substrate cleavage by human Xa incorporated into prothrombinase with saturating concentrations of membranes and Va. By fluorescence binding studies we show that NAPc2 does not interfere with the assembly of human prothrombinase. These are properties expected of an inhibitor that blocks protein substrate recognition by targeting extended macromolecular recognition sites (exosites) on the enzyme complex. A weaker interaction (K-d = 260-500 nm) observed between NAPc2 and bovine X was restored to a high affinity one in a recombinant chimeric bovine X derivative containing 25 residues from the COOH terminus of the proteinase domain of human X. This region implicated in binding NAPc2 is spatially adjacent to a site previously identified as a potential exosite. Despite the weaker interaction with bovine Xa, NAPc2 was a tight binding competitive inhibitor of protein substrate cleavage by bovine prothrombinase as well. Extended enzymic surfaces elucidated with exosite-directed probes, such as NAPc2, may define a unique region of factor Xa that is modulated following its assembly into prothrombinase and in turn determines the binding specificity of the enzyme complex for its protein substrate.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; CORVAS Int Inc, San Diego, CA 92121 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310 Abramson,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL062523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47465, HL-62523] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Bergum PW, 2001, J BIOL CHEM, V276, P10063, DOI 10.1074/jbc.M009116200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; Doyle ML, 1997, CURR OPIN BIOTECH, V8, P31, DOI 10.1016/S0958-1669(97)80154-1; EBY CS, 1992, BLOOD S, V80, P306; Friederich PW, 2001, CIRCULATION, V103, P2555; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gomori G, 1942, J LAB CLIN MED, V27, P955; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Indyk L, 1998, METHOD ENZYMOL, V295, P350; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; KIM DJ, 1994, BIOTECHNOL LETT, V16, P549, DOI 10.1007/BF00128598; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lee A, 2001, CIRCULATION, V104, P74, DOI 10.1161/hc2601.091386; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P27; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; Vlasuk GP, 1998, BLOOD, V92, p361A; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200	58	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26689	26698		10.1074/jbc.M202507200	http://dx.doi.org/10.1074/jbc.M202507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011050	hybrid			2022-12-25	WOS:000176908700111
J	D'Souza, I; Schellenberg, GD				D'Souza, I; Schellenberg, GD			Tau exon 10 expression involves a bipartite intron 10 regulatory sequence and weak 5 ' and 3 ' splice sites.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FAMILIAL FRONTOTEMPORAL DEMENTIA; MICROTUBULE-ASSOCIATED PROTEINS; FTDP-17 MUTATIONS; NEURODEGENERATIVE DISORDERS; U1 SNRNP; GENE; CHROMOSOME-17; PARKINSONISM; PHOSPHORYLATION	tau mutations that deregulate alternative exon 10 (E10) splicing cause frontotemporal dementia with parkinsonism chromosome 17-type by several mechanisms. Previously we showed that E10 splicing involved exon splicing enhancer sequences at the Wand 3' ends of E10, an exon splicing silencer, a weak 5' splice site, and an intron splicing silencer (ISS) within intron 10 (I10). Here, we identify additional regulatory sequences in I10 using both non-neuronal and neuronal cells. The ISS sequence extends from I10 nucleotides 11-18, which is sufficient to inhibit use of a weakened 5' splice site of a heterologous exon. Furthermore, ISS function is location-independent but requires proximity to a weak 5' splice site. Thus, the ISS functions as a linear sequence. A new cis-acting element, the intron splicing modulator (ISM), was identified immediately downstream of the ISS at I10 positions 19-26. The ISM and ISS form a bipartite regulatory element, within which the ISM functions when the ISS is present, mitigating E10 repression by the ISS. Additionally, the 3' splice site of E10 is weak and requires exon splicing enhancer elements for efficient E10 inclusion. Thus far, tau FTDP-17 splicing mutations affect six predicted cis-regulatory sequences.	Univ Washington, Div Gerontol, Dept Med, Seattle, WA 98195 USA; Univ Washington, Div Geriatr Med, Dept Med, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Schellenberg, GD (corresponding author), Univ Washington, Div Gerontol, Dept Med, Seattle, WA 98195 USA.				NATIONAL INSTITUTE ON AGING [R01AG011762] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11762] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CHIUCHAN G, 1998, J NEUROSCI, V18, P5322; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CRISPINO JD, 1995, GENE DEV, V9, P2314, DOI 10.1101/gad.9.18.2314; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Hwang DY, 1996, GENE DEV, V10, P338, DOI 10.1101/gad.10.3.338; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6235; Pastor P, 2001, ANN NEUROL, V49, P263, DOI 10.1002/1531-8249(20010201)49:2<263::AID-ANA50>3.0.CO;2-K; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Poorkaj P, 2001, MAMM GENOME, V12, P700, DOI 10.1007/s00335-001-2044-8; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; Shepard J, 2002, MOL CELL BIOL, V22, P221, DOI 10.1128/MCB.22.1.221-230.2002; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 2000, ANN NEUROL, V48, P939; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yasuda M, 2000, ANN NEUROL, V47, P422, DOI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G; Yean SL, 2000, NATURE, V408, P881, DOI 10.1038/35048617; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581	48	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26587	26599		10.1074/jbc.M203794200	http://dx.doi.org/10.1074/jbc.M203794200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000767	hybrid			2022-12-25	WOS:000176908700100
J	Ishida, A; Fujita, N; Kitazawa, R; Tsuruo, T				Ishida, A; Fujita, N; Kitazawa, R; Tsuruo, T			Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTOGENESIS-INHIBITORY FACTOR; DIFFERENTIATION FACTOR; MESSENGER-RNA; OSTEOPROTEGERIN; MARROW; INTERLEUKIN-1-ALPHA; MODULATION; INDUCTION; CYTOKINES; PATHWAY	Vascular endothelial cells in bone are thought to have significant roles on pathological bone resorption such as bone metastasis and hypercalcemia because this resorption is often seen where blood vessels are abundant. However, the detailed mechanisms have not yet been elucidated. Here, we focused on transforming growth factor-beta (TGF-beta) and studied its effects on vascular endothelial cells because TGF-beta is abundantly stored in bone matrix and is released and activated during bone resorption. We found that TGF-beta up-regulated the expression of receptor activator of NF-kappaB ligand (RANKL) mRNA and protein in bone marrow-derived endothelial cells and in primary vascular endothelial cells but not in osteoblasts. Further analysis revealed that TGF-beta promoted phosphorylation of cAMP response element-binding protein and p38. Protein kinase A inhibitor KT5720 and p38 inhibitor SB203580 significantly reduced the TGF-beta-induced RANKL expression. Moreover, we found two CRE-like domains in murine RANKL promoter region that were critical for TGF-beta-dependent RANKL expression. Therefore, protein kinase A and p38 signaling pathways are involved in TGF-beta-induced RANKL expression by stimulating transcription factors that bind to the CRE-like domains. Our findings indicate that TGF-beta stimulates osteoclastogenesis by promoting RANKL expression in endothelial cells under pathological conditions.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Kobe Univ, Grad Sch Med, Div Mol Pathol, Kobe, Hyogo 6500017, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Kobe University; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; COLLINOSDOBY P, 1994, J CELL BIOCHEM, V55, P304, DOI 10.1002/jcb.240550306; DELANY AM, 1996, GROWTH FACTORS CYTOK, V3, P127; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSON GR, 1990, BONE, V11, P205, DOI 10.1016/8756-3282(90)90215-K; DICKSON GR, 1987, HISTOCHEMISTRY, V87, P569, DOI 10.1007/BF00492472; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Filvaroff E, 1998, CURR BIOL, V8, pR679, DOI 10.1016/S0960-9822(98)70434-8; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ikeda T, 2001, J BONE MINER RES, V16, P1416, DOI 10.1359/jbmr.2001.16.8.1416; Kage K, 1999, BIOCHEM BIOPH RES CO, V254, P259, DOI 10.1006/bbrc.1998.9875; Kaneda T, 2000, J IMMUNOL, V165, P4254, DOI 10.4049/jimmunol.165.8.4254; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SH, 1996, ONCOGENE, V13, P2131; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Marin V, 2001, BLOOD, V98, P667, DOI 10.1182/blood.V98.3.667; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; SASAKI A, 1995, CANCER RES, V55, P3551; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SHINAR DM, 1990, ENDOCRINOLOGY, V126, P3153, DOI 10.1210/endo-126-6-3153; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STREETEN EA, 1989, P NATL ACAD SCI USA, V86, P916, DOI 10.1073/pnas.86.3.916; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Wang LW, 1998, J BIOL CHEM, V273, P8522, DOI 10.1074/jbc.273.14.8522; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZAIDI M, 1993, BONE, V14, P97, DOI 10.1016/8756-3282(93)90234-2; Zhang Y, 1998, ONCOGENE, V16, P693, DOI 10.1038/sj.onc.1201581	48	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26217	26224		10.1074/jbc.M111093200	http://dx.doi.org/10.1074/jbc.M111093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011070	hybrid			2022-12-25	WOS:000176908700052
J	Qiao, JB; Mei, FC; Popov, VL; Vergara, LA; Cheng, XD				Qiao, JB; Mei, FC; Popov, VL; Vergara, LA; Cheng, XD			Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ANCHOR PROTEIN; ADENYLATE-CYCLASE; BINDING PROTEINS; MAP KINASE; RAS; AMP; PATHWAY; FAMILY; PHOSPHORYLATION; INHIBITION	Epac belongs to a new family of proteins that can directly mediate the action of the intracellular second messenger cAMP by activating a downstream small GTPase Rap1. The Epac/Rap1 pathway represents a novel cAMP-signaling cascade that is independent of the cAMP-dependent protein kinase (PKA). In this study, we have used fluorescence microscopy to probe the intracellular targeting of Epac during different stages of the cell division cycle and the structural features that are important for Epac localization. Our results suggest Epac, endogenous or expressed as a green fluorescent protein fusion protein, is mainly localized to the nuclear membrane and mitochondria during interphase in COS-7 cells. Deletion mutagenesis analysis reveals that whereas the DEP domain is responsible for membrane association, the mitochondrial-targeting sequence is located at the N terminus. Although Epac predominantly exhibits perinuclear localization in interphase, the subcellular localization of Epac is cell cycle-dependent. Epac disassociates from the nuclear membrane and localizes to the mitotic spindle and centrosomes in metaphase. At the end of the cell cycle, Epac is observed to reassociate with the nuclear envelope and concentrate around the contractile ring. Furthermore, overexpression of Epac in COS-7 cells leads to an increase in multinuclear cell populations. These results suggest that Epac may play an important role in mitosis.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, World Hlth Org Collaborating Ctr Trop Dis, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Sch Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; World Health Organization; University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Struct Biol, Galveston, TX 77555 USA.	xcheng@utmb.edu	Cheng, Xiaodong/O-8176-2019	Cheng, Xiaodong/0000-0002-3479-1694	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURGER MM, 1972, NATURE-NEW BIOL, V239, P161, DOI 10.1038/newbio239161a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIMINO MJ, 1981, J BIOL CHEM, V256, P876; FINE AS, 1982, J HISTOCHEM CYTOCHEM, V30, P1171, DOI 10.1177/30.11.6292286; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HARTL FU, 1974, SCIENCE, V41, P345; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; INABA T, 1985, ENDOCRINOLOGY, V117, P315, DOI 10.1210/endo-117-1-315; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KULINSKII V I, 1985, Biokhimiya, V50, P1546; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PRIZON V, 1998, ONCOGENE, V3, P201; RALL TW, 1958, J BIOL CHEM, V232, P1065; Roger PP, 1999, EXP CELL RES, V252, P492, DOI 10.1006/excr.1999.4646; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X; SULIMOVICI S, 1974, FEBS LETT, V41, P345, DOI 10.1016/0014-5793(74)81245-7; Thomson M, 1998, BBA-MOL CELL RES, V1403, P211, DOI 10.1016/S0167-4889(98)00069-X; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	44	148	156	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26581	26586		10.1074/jbc.M203571200	http://dx.doi.org/10.1074/jbc.M203571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000763	hybrid			2022-12-25	WOS:000176908700099
J	Temel, RE; Walzem, RL; Banka, CL; Williams, DL				Temel, RE; Walzem, RL; Banka, CL; Williams, DL			Apolipoprotein A-I is necessary for the in vivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; HDL RECEPTOR; TRANSGENIC MICE; APOA-I; CELLULAR-DISTRIBUTION; STEROIDOGENIC CELLS; RICH LIPOPROTEINS; TARGETED MUTATION; HEART-DISEASE; ADRENAL-CELLS	The severe depletion of cholesteryl ester (CE) in steroidogenic cells of apoA-I-/- mice suggests that apolipoprotein (apo) A-I plays a specific role in the high density lipoprotein (HDL) CE-selective uptake process mediated by scavenger receptor BI (SR-BI) in vivo. The nature of this role, however, is unclear because a variety of apolipoproteins bind to SR-BI expressed in transfected cells. In this study the role of apoA-I-/- in SR-BI-mediated HDL CE-selective uptake was tested via analyses of the biochemical properties of apoA-I-/- HDL and its interaction with SR-BI on adrenocortical cells, hepatoma cells, and cells expressing a transfected SR-BI. apoA-I-/- HDL are large heterogeneous particles with a core consisting predominantly of CE and a surface enriched in phospholipid, free cholesterol, apoA-II, and apoE. Functional analysis showed apoA-I-/- HDL to bind to SR-BI with the same or higher affinity as compared with apoA-I+/+ HDL, but apoA-I-/- HDL showed a 2-3-fold decrease in the V-max for CE transfer from the HDL particle to adrenal cells. These results indicate that the absence of apoA-I results in HDL particles with a reduced capacity for SR-BI-mediated CE-selective uptake. The reduced V-max illustrates that HDL properties necessary for binding to SR-BI are distinct from those properties necessary for the transfer of HDL CE from the core of the HDL particle to the plasma membrane. The reduced V-max for HDL CE-selective uptake likely contributes to the severe reduction in CE accumulation in steroidogenic cells of apoA-I-/- mice.	SUNY Stony Brook, Dept Pharmacol Sci, Med Ctr, Stony Brook, NY 11794 USA; La Jolla Inst Mol Med, Div Vasc Biol, San Diego, CA 92121 USA; Texas A&M Univ, Dept Poultry Sci, College Stn, TX 77843 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Texas A&M University System; Texas A&M University College Station	Williams, DL (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Med Ctr, Stony Brook, NY 11794 USA.		Eckhardt, Erik/G-1567-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058012, R01HL060844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60844, HL 58012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; de Beer MC, 2001, J LIPID RES, V42, P309; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GLOMSET JA, 1968, J LIPID RES, V9, P155; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LIU AC, 1994, J LIPID RES, V35, P2263; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; PARKS JS, 1995, J LIPID RES, V36, P349; PARKS JS, 1985, J BIOL CHEM, V260, P3155; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1997, J LIPID RES, V38, P1033; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; REAVEN E, 1989, J LIPID RES, V30, P1551; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RICHARD BM, 1993, J LIPID RES, V34, P571; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; RUBEN EM, 1991, NATURE, V353, P265; SATA T, 1972, J LIPID RES, V13, P757; SCHIMMER BP, 1981, FUNCTIONALLY DIFFERE, P61; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WALZEM RL, 1994, J LIPID RES, V35, P1354; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; Xu SZ, 1997, J LIPID RES, V38, P1289	64	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26565	26572		10.1074/jbc.M203014200	http://dx.doi.org/10.1074/jbc.M203014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000760	hybrid			2022-12-25	WOS:000176908700097
J	Boffa, MB; Hamill, JD; Bastajian, N; Dillon, R; Nesheim, ME; Koschinsky, ML				Boffa, MB; Hamill, JD; Bastajian, N; Dillon, R; Nesheim, ME; Koschinsky, ML			A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROCARBOXYPEPTIDASE-B; NF-KAPPA-B; PRO-CARBOXYPEPTIDASE-R; ACUTE-PHASE RESPONSE; FACTOR-IX PROMOTER; TRANSCRIPTION FACTOR; C/EBP-ALPHA; TAFI LEVELS; GLUCOCORTICOID RECEPTOR; FIBRINOGEN PROMOTER	Thrombin-activable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase B-like zymogen that upon activation by thrombin, thrombin-thrombomodulin, or plasmin attenuates fibrin clot lysis by inhibiting positive feedback in the fibrinolytic cascade. The concentration of TAFI in plasma varies in the human population and thus may constitute a risk factor for thrombotic disorders. In addition, TAFI has been reported to be a positive acute phase reactant in mice. We have initiated molecular analysis of the human TAFI promoter to understand the mechanisms underlying regulation of TAFI gene expression. We identified a putative C/EBP-binding site between -53 and -40 of the promoter. Mutations in this site that abolish C/EBP binding decrease TAFI promoter activity in human hepatoma (HepG2) cells by similar to80%. Get mobility shift analyses indicated that C/EBP-beta present in HepG2 nuclear extracts and C/EBP-a and -beta present in adult rat liver nuclear extracts bind to the C/EBP site. C/EBP-alpha, -beta, and -delta isoforms are all capable of binding to the C/EBP site and activating the TAFI promoter. The identification of a functional C/EBP-binding site in the human TAFI promoter may have important implications for the regulation of expression of this gene during development and in response to inflammatory stimuli.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Rm A208 Botterell Hall, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; An MR, 1996, MOL CELL BIOL, V16, P2295; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAZAAR L, 1995, J BIOL CHEM, V270, P14477; Boccia LM, 1996, MOL CELL BIOL, V16, P1929; Boffa M. B., 2001, Current Drug Targets - Cardiovascular and Haematological Disorders, V1, P59, DOI 10.2174/1568006013337999; Boffa MB, 1999, BIOCHEMISTRY-US, V38, P6547, DOI 10.1021/bi990229v; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Brouwers GJ, 2001, BLOOD, V98, P1992, DOI 10.1182/blood.V98.6.1992; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; Chabloz P, 2001, BRIT J HAEMATOL, V115, P150, DOI 10.1046/j.1365-2141.2001.03082.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chetaille P, 2000, THROMB HAEMOSTASIS, V83, P902, DOI 10.1055/s-0037-1613941; Christoffels VM, 1998, MOL CELL BIOL, V18, P6305, DOI 10.1128/MCB.18.11.6305; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; EATON DL, 1991, J BIOL CHEM, V266, P21833; Franco RF, 2001, HAEMATOLOGICA, V86, P510; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Hendriks D, 1992, Agents Actions Suppl, V38 ( Pt 1), P407; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; Henry M, 2001, BLOOD, V97, P2053, DOI 10.1182/blood.V97.7.2053; HU CH, 1995, J BIOL CHEM, V270, P28342; Juhan-Vague I, 2000, ARTERIOSCL THROM VAS, V20, P2156, DOI 10.1161/01.ATV.20.9.2156; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lisman T, 2001, GASTROENTEROLOGY, V121, P131, DOI 10.1053/gast.2001.25481; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MARI SS, 1999, J BIOL CHEM, V274, P35046; McGlynn LK, 1996, MOL CELL BIOL, V16, P1936; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Nagashima M, 2002, J CLIN INVEST, V109, P101, DOI 10.1172/JCI12119; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ong K, 2000, THROMB HAEMOSTASIS, V84, P1023; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Sato T, 2000, J IMMUNOL, V165, P1053, DOI 10.4049/jimmunol.165.2.1053; Schatteman KA, 1999, CLIN CHEM, V45, P807; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Silveira A, 2000, THROMB HAEMOSTASIS, V84, P364; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Tsay W, 1997, DNA CELL BIOL, V16, P569, DOI 10.1089/dna.1997.16.569; Van Thiel DH, 2001, THROMB HAEMOSTASIS, V85, P667; van Tilburg NH, 2000, BLOOD, V95, P2855, DOI 10.1182/blood.V95.9.2855.009k02_2855_2859; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WHITE JA, 1994, DEVELOPMENT, V120, P1861; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	61	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25329	25336		10.1074/jbc.M203688200	http://dx.doi.org/10.1074/jbc.M203688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000765	hybrid			2022-12-25	WOS:000176747000064
J	Shetzline, MA; Walker, JKL; Valenzano, KJ; Premont, RT				Shetzline, MA; Walker, JKL; Valenzano, KJ; Premont, RT			Vasoactive intestinal polypeptide type-1 receptor regulation - Desensitization, phosphorylation, and sequestration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; SECRETIN RECEPTOR; KINASES; INTERNALIZATION; FAMILY; VIP; IDENTIFICATION; RESPONSIVENESS	The vasoactive intestinal polypeptide type-1 (VPAC(1)) receptor is a class II G protein-coupled receptor, distinct from the adrenergic receptor superfamily. The mechanisms involved in the regulation of the VPAC(1) receptor are largely unknown. We examined agonist-dependent VPAC(1) receptor signaling, phosphorylation, desensitization, and sequestration in human embryonic kidney 293 cells. Agonist stimulation of cells overexpressing this receptor led to a dose-dependent increase in cAMP that peaked within 5-10 min and was completely desensitized after 20 min. Cells cotransfected with the V-PAC(1) receptor (V-PAC(1)R) and G protein-coupled receptor kinases (GRKs) 2, 3, 5, and 6 exhibited enhanced desensitization that was not evident with GRK 4. Immunoprecipitation of the epitope-tagged VPAC(1) receptor revealed dose-dependent phosphorylation that was increased with cotransfection of any GRK. Agonist-stimulated internalization of the VPAC(1)R peaked in 10 min, and neither overexpressed beta-arrestin nor its dominant-negative mutant altered internalization. However, a dynamin-dominant negative mutant did inhibit VPAC(1) receptor internalization. Interestingly, VPAC(1)R specificity in desensitization was not evident by study of the overexpressed receptor; however, we determined that human embryonic kidney 293 cells express an endogenous VPAC(1)R that did demonstrate dose-dependent GRK specificity. Therefore, VPAC(1) receptor regulation involves agonist-stimulated, GRK-mediated phosphorylation, beta-arrestin translocation, and dynamin-dependent receptor internalization. Moreover, study of endogenously expressed receptors may provide information not evident in overexpressed systems.	Duke Univ, Med Ctr, Dept Cell Biol, Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA	Duke University; Duke University	Shetzline, MA (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Div Gastroenterol, Durham, NC 27710 USA.	shetz001@mc.duke.edu	Walker, Julia/R-7585-2017	Premont, Richard/0000-0002-8053-5026	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002544, T32DK007568] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02544, 5T32DK07568] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DOCKRAY GJ, 1994, VASOACTIVE INTENSTIN; FABRE C, 1993, PEPTIDES, V14, P483, DOI 10.1016/0196-9781(93)90136-5; FAROUK M, 1992, GASTROENTEROLOGY, V102, P963, DOI 10.1016/0016-5085(92)90183-Y; Ferguson S S, 1998, Adv Pharmacol, V42, P420; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McDonald TP, 1998, ANN NY ACAD SCI, V865, P64, DOI 10.1111/j.1749-6632.1998.tb11164.x; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Said S I, 1970, Nature, V225, P863, DOI 10.1038/225863a0; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Shetzline MA, 1998, J BIOL CHEM, V273, P6756, DOI 10.1074/jbc.273.12.6756; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	33	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25519	25526		10.1074/jbc.M201815200	http://dx.doi.org/10.1074/jbc.M201815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978791	hybrid			2022-12-25	WOS:000176747000088
J	Wang, Q; Liu, M; Mullah, B; Siderovski, DP; Neubig, RR				Wang, Q; Liu, M; Mullah, B; Siderovski, DP; Neubig, RR			Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; SIGNALING PROTEINS; COUPLED RECEPTORS; TYROSINE-KINASE; HAMMERHEAD RIBOZYMES; CARDIAC MYOCYTES; GAMMA(7) SUBUNIT; PHOSPHOLIPASE-C; CALCIUM-CHANNEL; ALPHA-SUBUNITS	Regulators of G protein signaling (RGS) proteins compose a highly diverse protein family best known for inhibition of G protein signaling by enhancing GTP hydrolysis by Galpha subunits. Little is known about the function of endogenous RGS proteins. In this study, we used synthetic ribozymes targeted to RGS2, RGS3, RGS5, and RGS7 to assess their function. After demonstrating the specificity of in vitro cleavage by the RGS ribozymes, rat aorta smooth muscle cells were used for transient transfection with the RGS-specific ribozymes. RGS3 and RGS5 ribozymes differentially enhanced carbachol- and angiotensin II-induced MAP kinase activity, respectively, whereas RGS2 and RGS7 ribozymes had no effect. This enhancement was pertussis toxin-insensitive. Thus RGS3 is a negative modulator of muscarinic m3 receptor signaling, and RGS5 is a negative modulator of angiotensin AT1a receptor signaling through G(q/11). Also, RGS5 ribozyme enhanced angiotensin-stimulated inositol phosphate release. These results indicate the feasibility of using the ribozyme technology to determine the functional role of endogenous RGS proteins in signaling pathways and to define novel receptor-selective roles of endogenous RGS3 and RGS5 in modulating MAP kinase responses to either carbachol or angiotensin.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA; Appl Biosyst Inc, Foster City, CA 94404 USA; Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Thermo Fisher Scientific; Applied Biosystems; University of North Carolina; University of North Carolina Chapel Hill	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Neubig, Richard/0000-0003-0501-0008	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39561, GM 62338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Alexander RW, 1996, J HYPERTENS, V14, pS51; BENJAMIN CW, 1994, J BIOL CHEM, V269, P31346; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen HM, 2000, P NATL ACAD SCI USA, V97, P12810, DOI 10.1073/pnas.230260397; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Doan TN, 2001, J BIOL CHEM, V276, P20954, DOI 10.1074/jbc.C100199200; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Garzon J, 2001, EUR J NEUROSCI, V13, P801, DOI 10.1046/j.0953-816x.2000.01444.x; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Grassi G, 1997, NUCLEIC ACIDS RES, V25, P3451, DOI 10.1093/nar/25.17.3451; GU JL, 1995, CIRC RES, V77, P14, DOI 10.1161/01.RES.77.1.14; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Kardestuncer T, 1998, FEBS LETT, V438, P285, DOI 10.1016/S0014-5793(98)01319-2; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; SADOSHIMA J, 1995, CIRC RES, V76, P1; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; SCHORB W, 1994, J BIOL CHEM, V269, P19626; Seki N, 1998, J HUM GENET, V43, P202, DOI 10.1007/s100380050071; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; Touyz RM, 1996, J BIOL CHEM, V271, P24353, DOI 10.1074/jbc.271.40.24353; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; Wang Q, 2001, J BIOL CHEM, V276, P39386, DOI 10.1074/jbc.M104981200; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; YALKINOGLU AO, 1995, J RECEPT SIGNAL TR R, V15, P117, DOI 10.3109/10799899509045212; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0	58	101	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24949	24958		10.1074/jbc.M203802200	http://dx.doi.org/10.1074/jbc.M203802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006602	Green Published, hybrid			2022-12-25	WOS:000176747000016
J	Borman, MA; MacDonald, JA; Muranyi, A; Hartshorne, DJ; Haystead, TAJ				Borman, MA; MacDonald, JA; Muranyi, A; Hartshorne, DJ; Haystead, TAJ			Smooth muscle myosin phosphatase-associated kinase induces Ca2+ sensitization via myosin phosphatase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; SIGNAL-TRANSDUCTION; RHO-KINASE; CHICKEN GIZZARD; BINDING SUBUNIT; ZIP KINASE; PHOSPHORYLATION; PROTEIN; CPI-17; CONTRACTION	Smooth muscle calcium sensitization reflects an inhibition of myosin light chain phosphatase (SMPP-1M) activity; however, the underlying mechanisms are not well understood. SMPP-1M activity can be modulated through phosphorylation of the myosin targeting subunit (MYPT1) by the endogenous myosin phosphatase-associated kinase, MYPT1 kinase (MacDonald, J.A., Borman, M. A., Muranyi, A., Somlyo, A. V., Hartshorne, D. J., and Haystead, T. A. (2001) Proc. Natl Acad. Sci. U. S. A 98, 2419-2424). Recombinant chicken gizzard MYPT1 (M130) was phosphorylated in vitro by a recombinant MYPT1 kinase, and the sites of phosphorylation were identified as Thr(654), Ser(808), and Thr(675). Introduction of recombinant MYPT1 kinase elicited a calcium-independent contraction in beta-escin-permeabilized rabbit ileal smooth muscle. Using an antibody that specifically recognizes MYPT1 phosphorylated at Thr(654) (M130 numbering), we determined that this calcium-independent contraction was correlated with an increase in MYPT1 phosphorylation. These results indicate that SMPP-1M phosphorylation by MYPT1 kinase is a mechanism of smooth muscle calcium sensitization.	Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Duke University; University of Virginia; University of Arizona	Haystead, TAJ (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Box 3813, Durham, NC 27710 USA.			MacDonald, Justin/0000-0002-9238-8473	NHLBI NIH HHS [HL23615, HL19242-24] Funding Source: Medline; NIDDK NIH HHS [DK52378-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL023615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HOAR PE, 1979, SCIENCE, V204, P503, DOI 10.1126/science.432654; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Ikebe M, 1996, BIOCHEM BIOPH RES CO, V225, P370, DOI 10.1006/bbrc.1996.1182; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P97; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x	33	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23441	23446		10.1074/jbc.M201597200	http://dx.doi.org/10.1074/jbc.M201597200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976330	hybrid			2022-12-25	WOS:000176475700046
J	Pinakoulaki, E; Gemeinhardt, S; Saraste, M; Varotsis, C				Pinakoulaki, E; Gemeinhardt, S; Saraste, M; Varotsis, C			Nitric-oxide reductase - Structure and properties of the catalytic site from resonance Raman scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-PROTEINS; ACTIVE-SITE; IRON CENTER; SPECTROSCOPY; BINDING; NO; VIBRATIONS; MYOGLOBIN; DIOXYGEN; ADDUCTS	We have applied resonance Raman spectroscopy to investigate the properties of the dinuclear center of oxidized, reduced, and NO-bound nitric-oxide reductase from Paracoccus denitrificans. The spectra of the oxidized enzyme show two distinct nu(as)(Fe-O-Fe) modes at 815 and 833 cm(-1) of the heme/non-heme diiron center. The splitting of the Fe-O-Fe mode suggests that two different conformations (open and closed) are present in the catalytic site of the enzyme. We find evidence from deuterium exchange experiments that in the dominant conformation (833 cm-1 mode, closed), the Fe-O-Fe unit is hydrogen-bonded to distal residue(s). The ferric nitrosyl complex of nitric-oxide reductase exhibits the nu(Fe3+-NO) and nu(N-O) at 594 and 1904 cm(-1), respectively. The nitrosyl species we detect is photolabile and can be photolyzed to generate a new form of oxidized enzyme in which the proximal histidine is ligated to heme b(3), in contrast to the resting form. Photodissociation of the NO ligand yields a five-coordinate high-spin heme b(3). Based on the findings reported here, the structure and properties of the dinuclear center of nitricoxide reductase in the oxidized, reduced, and NO-bound form as well as its photoproduct can be described with certainty.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; European Mol Biol Lab, D-69012 Heidelberg, Germany	University of Crete; European Molecular Biology Laboratory (EMBL)	Varotsis, C (corresponding author), Univ Crete, Dept Chem, L Knossou 300,POB 1470, Iraklion 71409, Crete, Greece.			Pinakoulaki, Eftychia/0000-0003-3320-6112; Varotsis, Constantinos/0000-0003-2771-8891				BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; Hendriks J, 1998, J BIOENERG BIOMEMBR, V30, P15, DOI 10.1023/A:1020547225398; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; HU SZ, 1993, J BIOL CHEM, V268, P6189; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; KIM EK, 1991, J AM CHEM SOC, V113, P4962, DOI 10.1021/ja00013a036; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Laane J, 1980, PROG INORG CHEM, V27, P465, DOI 10.1002/9780470166284.ch6; MACKIN HC, 1983, FEBS LETT, V158, P199, DOI 10.1016/0014-5793(83)80577-8; MARICQ MM, 1989, J CHEM PHYS, V90, P3136, DOI 10.1063/1.455915; Miller LM, 1997, BIOCHEMISTRY-US, V36, P12199, DOI 10.1021/bi962744o; Moenne-Loccoz P, 2000, J AM CHEM SOC, V122, P9344, DOI 10.1021/ja0016295; Moenne-Loccoz P, 1998, J AM CHEM SOC, V120, P5147, DOI 10.1021/ja973671e; NAKAMOTO K, 1990, COORDIN CHEM REV, V100, P363, DOI 10.1016/0010-8545(90)85015-K; Noguchi T, 1996, BIOCHEMISTRY-US, V35, P16777, DOI 10.1021/bi961562r; Obayashi E, 1997, J AM CHEM SOC, V119, P7807, DOI 10.1021/ja9637816; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; ROUSSEAU DL, 1988, J BIOL CHEM, V263, P5681; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; Tomita T, 2001, J AM CHEM SOC, V123, P2666, DOI 10.1021/ja001431k; VAROTSIS C, 1995, J PHYS CHEM-US, V99, P16817, DOI 10.1021/j100046a004; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; ZUMFT WG, 1997, MICROBIOL MOL BIOL R, V61, P553	27	80	80	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23407	23413		10.1074/jbc.M201913200	http://dx.doi.org/10.1074/jbc.M201913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971903	hybrid			2022-12-25	WOS:000176475700041
J	Li, D; Williams, JI; Pietras, RJ				Li, D; Williams, JI; Pietras, RJ			Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression	ONCOGENE			English	Article						VEGF; erb B2/neu; MAP kinase; carboplatin; vascular endothelial cells	HUMAN-BREAST; TUMOR XENOGRAFTS; FACTOR VEGF; IN-VIVO; RECEPTOR; EXPRESSION; KINASE; TRANSFORMATION; AMINOSTEROL; MECHANISMS	Angiogenesis is important for growth and progression of ovarian cancers. Squalamine is a natural antiangiogenic sterol, and its potential role in treatment of ovarian cancers with or without standard cisplatin chemotherapy was assessed. Since HER-2 gene overexpression is associated with cisplatin resistance in vitro and promotion of tumor angiogenesis in vivo, the response of ovarian cancer cells with or without HER-2 gene overexpression to squalamine and cisplatin was evaluated both in tumor xenograft models and in tissue culture. Ovarian cancer cells with or without HER-2 overexpression were grown as subcutaneous xenografts in nude mice. Animals were treated by intraperitoneal injection with control vehicle, cisplatin, squalamine or cisplatin combined with squalamine. At the end of the experiment, tumors were assessed for tumor growth inhibition and for changes in microvessel density and apoptosis. Additional in vitro studies evaluated effects of squalamine on tumor and endothelial cell growth and on signaling pathways in human endothetial cells. Profound growth inhibition was elicited by squalamine alone and by combined treatment with squalamine and cisplatin for both parental and HER-2-overexpressing ovarian tumor xenografts. Immunohistochemical evaluation of tumors revealed decreased microvessel density and increased apoptosis. Although HER-2-overexpressing tumors had more angiogenic and less apoptotic activity than parental cancers, growth of both tumor types was similarly suppressed by treatment with squalamine combined with cisplatin. In in vitro studies, we found that squalamine does not directly affect proliferation of ovarian cells. However, squalamine significantly blocked VEGF-induced activation of MAP kinase and cell proliferation in human vascular endothelial cells. The results suggest that squalamine is anti-angiogenic for ovarian cancer xenografts and appears to enhance cytotoxic effects of cisplatin chemotherapy independent of HER-2 tumor status.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Genaera Corp, Plymouth Meeting, PA 19462 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pietras, RJ (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, 10833 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.	rpietras@ucla.edu		Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [R29CA60835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Akhter S, 1999, AM J PHYSIOL-CELL PH, V276, pC136, DOI 10.1152/ajpcell.1999.276.1.C136; Alvarez AA, 1999, CLIN CANCER RES, V5, P587; BERCHUCK A, 1990, CANCER RES, V50, P4087; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen Q, 1999, CLIN CANCER RES, V5, p3768S; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; Eckhardt SG, 1999, HOSP PRACT, V34, P63, DOI 10.3810/hp.1999.01.124; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOLDMAN JM, 1993, STEM CELLS, V11, P4, DOI 10.1002/stem.5530110903; Hellstrom I, 2001, CANCER RES, V61, P2420; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kolfschoten GM, 2000, GYNECOL ONCOL, V76, P362, DOI 10.1006/gyno.1999.5689; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MOORE KS, 1993, P NATL ACAD SCI USA, V90, P1354, DOI 10.1073/pnas.90.4.1354; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozols RF, 1999, SEMIN ONCOL, V26, P84; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; PATNAIK A, 1999, P AN M AM SOC CLIN, V622, P1999; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIETRAS RJ, 1981, J BIOL CHEM, V256, P8536; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Plumb JA, 2000, CANCER RES, V60, P6039; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schiller JH, 1999, CLIN CANCER RES, V5, P4287; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Teicher BA, 1998, ANTICANCER RES, V18, P2567; WONG YF, 1995, GYNECOL OBSTET INVES, V40, P209, DOI 10.1159/000292337; Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537; Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434-999-0373-0	43	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2805	2814		10.1038/sj.onc.1205410	http://dx.doi.org/10.1038/sj.onc.1205410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973639				2022-12-25	WOS:000175063700004
J	Ghiso, JAA				Ghiso, JAA			Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo	ONCOGENE			English	Article						FAK; uPAR; integrins; MAPK	FOCAL ADHESION KINASE; INTEGRIN-MEDIATED ADHESION; MALIGNANT PHENOTYPE; DOWN-REGULATION; INVASION; FIBRONECTIN; EXPRESSION; REDUCTION; CAVEOLIN; SRC	Activation of focal adhesion kinase (FAK), overexpressed in several human cancers, induces survival, proliferation and motility of cells in culture, but its functional importance in human tumor growth in vivo has not been elucidated. I explored the role of FAK in regulating tumorigenicity of human carcinoma cells, HEp3. These cells overexpress urokinase receptor (uPAR) which, by activating x5beta1 integrin, initiates an intracellular signal through FAK and Src leading to ERK activation and tumorigenicity in vivo. Down regulation of uPAR in these cells led to a similar to3-5-fold reduction in FAK phosphorylation and association with Src and dormancy in vivo. Both FAK phosphorylation and ability to grow in vivo were restored by re-expression of uPAR. The FAK signaling pathway in T-HEp3 cells, measured by FAK phosphorylation, GTP-loaded Ras and ERK activation, was inhibited by transient or stable transfection of FAK related non-kinase (FRNK), known to have a dominant negative function, but not by a FRNK mutant version (S1034-FRNK). Most importantly, while vector- and mutant-S1034-FRNK transfected cells inoculated onto chicken embryo CAMs formed progressively growing tumors, the HA-FRNK-expressing T-HEp3 cells did not proliferate in vivo and remained dormant for at least 6 weeks. Both cell types had similar rate of apoptosis in vivo and the p38(SAPK) or PI3K-Akt signaling pathways were unaffected by FRNK. FRNK induced dormancy could be reverted by expression of an active-R4F-Mek1 mutant. These results show that active FAK is an important mediator of uPAR-regulated tumorigenicity of HEp3 cells and that interruption of FAK mitogenic signaling either through down-regulation of uPAR or by expression of FRNK can force human carcinoma cells into dormancy.	NYU, Mt Sinai Sch Med, Div Med Oncol, Dept Med,Rochelle Belfer Chemotherapy Fdn Lab, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Ghiso, JAA (corresponding author), NYU, Mt Sinai Sch Med, Div Med Oncol, Dept Med,Rochelle Belfer Chemotherapy Fdn Lab, Atran Bldg Room 610,Box 1178, New York, NY 10029 USA.	aguirj01@doc.mssm.edu			NATIONAL CANCER INSTITUTE [R01CA040758] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Bender FC, 2000, CANCER RES, V60, P5870; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARY LA, 1999, FRONT BIOSCI, V4, P102; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; OWENS LV, 1995, CANCER RES, V55, P2752; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SCHILLER JH, 1995, CANCER RES, V55, P6215; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TOOLAN HW, 1954, CANCER RES, V14, P660; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Wang DY, 2000, J CELL SCI, V113, P4221; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	35	192	196	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2513	2524		10.1038/sj/onc/1205342	http://dx.doi.org/10.1038/sj/onc/1205342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971186				2022-12-25	WOS:000174918400008
J	Shaw, G; Morse, S; Ararat, M; Graham, FL				Shaw, G; Morse, S; Ararat, M; Graham, FL			Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells	FASEB JOURNAL			English	Article						neurofilaments; cytoskeleton; viral transformation; cell line; cancer	MALIGNANT RHABDOID-TUMOR; INTERMEDIATE FILAMENT PROTEIN; EMBRYONAL CARCINOMA-CELLS; ACETYLCHOLINE-RECEPTOR; NEUROFILAMENT PROTEINS; STEM-CELLS; LINE; KIDNEY; DIFFERENTIATION; EXPRESSION	The 293 cell line was derived by transformation of primary cultures of human embryonic kidney (HEK) cells with sheared adenovirus (Ad)5 DNA. A combination of immunostaining, immunoblot, and microarray analysis showed that 293 cells express the neurofilament (NF) subunits NF-L, NF-M, NF-H, and alpha-internexin as well as many other proteins typically found in neurons. Three other independently derived HEK lines, two transformed by Ad5 and one by Ad12, also expressed NFs, as did one human embryonic retinal cell line transformed with Ad5. Two rodent kidney lines transformed with Ad12 were also found to express NF proteins, although several rodent kidney cell lines transformed by Ad5 DNA and three HEK cell lines transformed by the SV40 early region did not express NFs. These results suggest that human Ads preferentially transform human neuronal lineage cells. We also demonstrate that the widely used HEK293 cells have an unexpected relationship to neurons, a finding that may require reinterpretation of many previous studies in which it was assumed that HEK293 cells resembled more typical kidney epithelial cells.	Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Mol Med, Hamilton, ON L8S 4K1, Canada	State University System of Florida; University of Florida; McMaster University; McMaster University; McMaster University	Shaw, G (corresponding author), Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA.	shaw@mbi.ufl.edu	, Gerry/X-2377-2019					ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAMJANOV I, 1984, CELL DIFFER DEV, V15, P133, DOI 10.1016/0045-6039(84)90065-4; Dautzenberg FM, 2000, EUR J PHARMACOL, V390, P51, DOI 10.1016/S0014-2999(99)00915-2; Elliott KJ, 1996, J MOL NEUROSCI, V7, P217, DOI 10.1007/BF02736842; Evans J, 2002, J NEUROPHYSIOL, V87, P1076, DOI 10.1152/jn.00088.2001; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FISCHER HP, 1989, PATHOL RES PRACT, V184, P541, DOI 10.1016/S0344-0338(89)80149-9; GALLIMORE PH, 1979, COLD SPRING HARB SYM, V44, P703, DOI 10.1101/SQB.1980.044.01.075; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, P NATL ACAD SCI USA, V76, P6606, DOI 10.1073/pnas.76.12.6606; GREEN M, 1980, VIRUSES NATURALLY OC, V7, P373; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IBELGAUFTS H, 1982, ACTA NEUROPATHOL, V56, P113, DOI 10.1007/BF00690581; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; LEE VMY, 1986, J NEUROSCI, V6, P514; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; Liu L, 1998, NEUROSCI LETT, V251, P161, DOI 10.1016/S0304-3940(98)00513-8; Louis N, 1997, VIROLOGY, V233, P423, DOI 10.1006/viro.1997.8597; LUTHER MA, 1989, J NEUROSCI, V9, P1082; MACKEY JK, 1979, JNCI-J NATL CANCER I, V62, P23; MACKEY JK, 1976, P NATL ACAD SCI USA, V73, P4657, DOI 10.1073/pnas.73.12.4657; MAK S, 1982, INT J CANCER, V30, P697, DOI 10.1002/ijc.2910300604; Makoff A, 1996, MOL BRAIN RES, V37, P239, DOI 10.1016/0169-328X(95)00321-I; MIZOBUCHI K, 1984, ACTA PATHOL JAPON, V34, P1313; MOTOI M, 1985, ACTA NEUROPATHOL, V66, P218, DOI 10.1007/BF00688586; MUKAI N, 1980, SCIENCE, V210, P1023, DOI 10.1126/science.7434012; MUKAI N, 1973, AM J PATHOL, V73, P671; Mukai N, 1975, No Shinkei Geka, V3, P91; NAKAJIMA T, 1979, ACTA NEUROPATHOL, V45, P187, DOI 10.1007/BF00702670; OHTAKI S, 1989, BRIT J EXP PATHOL, V70, P415; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RAJU T, 1981, DEV BIOL, V85, P344, DOI 10.1016/0012-1606(81)90266-9; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; Rolle U, 1999, BJU INT, V83, P1045; SAINIO K, 1994, INT J DEV BIOL, V38, P77; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; Schiedner G, 2000, HUM GENE THER, V11, P2105, DOI 10.1089/104303400750001417; Schmidt U, 1998, AM J DERMATOPATH, V20, P346, DOI 10.1097/00000372-199808000-00004; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; SHAW G, 1998, NEUROFILAMENTS; Soudais C, 2001, FASEB J, V15, P2283, DOI 10.1096/fj.01-0321fje; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Sugimoto T, 1999, INT J CANCER, V82, P678, DOI 10.1002/(SICI)1097-0215(19990827)82:5<678::AID-IJC10>3.0.CO;2-K; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TSOKOS M, 1989, ARCH PATHOL LAB MED, V113, P115; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WOLD WSM, 1979, CANCER RES, V39, P3479; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	62	542	559	5	55	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					869	+		10.1096/fj.01-0995fje	http://dx.doi.org/10.1096/fj.01-0995fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967234				2022-12-25	WOS:000175425900018
J	Tobacman, LS; Nihli, M; Butters, C; Heller, M; Hatch, V; Craig, R; Lehman, W; Homsher, E				Tobacman, LS; Nihli, M; Butters, C; Heller, M; Hatch, V; Craig, R; Lehman, W; Homsher, E			The troponin tail domain promotes a conformational state of the thin filament that suppresses myosin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CARDIAC TROPONIN; HYPERTROPHIC CARDIOMYOPATHY; SKELETAL-MUSCLE; 3-DIMENSIONAL RECONSTRUCTION; T MUTATIONS; STRIATED-MUSCLE; F-ACTIN; TROPOMYOSIN-BINDING; ELECTRON-MICROSCOPY	In cardiac and skeletal muscles tropomyosin binds to the actin outer domain in the absence of Ca2+, and in this position tropomyosin inhibits muscle contraction by interfering sterically with myosin-actin binding. The globular domain of troponin is believed to produce this B-state of the thin filament (Lehman, W., Hatch, V., Korman, V. L., Rosol, M., Thomas, L. T., Maytum, R., Geeves, M. A., Van Eyk, J. E., Tobacman, L. S., and Craig, R. (2000) J. Mol. Biol. 302, 593-606) via troponin I-actin interactions that constrain the tropomyosin. The present study shows that the B-state can be promoted independently by the elongated tail region of troponin (the NH2 terminus (TnT-(1-153)) of cardiac troponin T). In the absence of the troponin globular domain, TnT-(1153) markedly inhibited both myosin S1-actin-tropomyosin MgATPase activity and (at low S1 concentrations) myosin S1-ADP binding to the thin filament. Similarly, TnT-(1-153) increased the concentration of heavy meromyosin required to support in vitro sliding of thin filaments. Electron microscopy and three-dimensional reconstruction of thin filaments containing TnT-(1-153) and either cardiac or skeletal muscle tropomyosin showed that tropomyosin was in the B-state in the complete absence of troponin I. All of these results indicate that portions of the troponin tail domain, and not only troponin I, contribute to the positioning of tropomyosin on the actin outer domain, thereby inhibiting muscle contraction in the absence of Ca2+.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Iowa; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Tobacman, LS (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 200 Hawkins Dr,SE-610 GH, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu		Lehman, William/0000-0002-9430-9521	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008426] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036153, R01HL063774, R01HL036153, R01HL038834, R29HL038834, R55HL036153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988, R01AR034711] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08426] Funding Source: Medline; NHLBI NIH HHS [HL-36153, HL-63774, HL-38834] Funding Source: Medline; NIAMS NIH HHS [AR-34711, AR-30988] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Burhop J, 2001, J BIOL CHEM, V276, P20788, DOI 10.1074/jbc.M101110200; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GREASER ML, 1973, J BIOL CHEM, V248, P2125; GUO XD, 1994, J BIOL CHEM, V269, P15210; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; Hodgkinson JL, 1997, J MOL BIOL, V273, P150, DOI 10.1006/jmbi.1997.1307; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; HORNSHER E, 1996, BIOPHYS J, V70, P1881; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; Korman VL, 1999, J BIOL CHEM, V274, P22191, DOI 10.1074/jbc.274.32.22191; Korman VL, 2000, J BIOL CHEM, V275, P22470, DOI 10.1074/jbc.M002939200; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MAYTUM R, 2002, IN PRESS J BIOL CHEM, V277; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Miki M, 1998, J BIOCHEM-TOKYO, V123, P324; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; NAKAMURA S, 1981, J BIOCHEM-TOKYO, V89, P1639, DOI 10.1093/oxfordjournals.jbchem.a133359; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; ONOYAMA Y, 1986, J BIOCHEM-TOKYO, V100, P517, DOI 10.1093/oxfordjournals.jbchem.a121742; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Smith DA, 2001, J PHYS A-MATH GEN, V34, P4507, DOI 10.1088/0305-4470/34/21/307; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; SYSKA H, 1974, FEBS LETT, V40, P253, DOI 10.1016/0014-5793(74)80238-3; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takeda S, 2002, BIOPHYS J, V82, p170A; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	84	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27636	27642		10.1074/jbc.M201768200	http://dx.doi.org/10.1074/jbc.M201768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011043	hybrid			2022-12-25	WOS:000177189800010
J	Lee, DK; Suh, D; Edenberg, HJ; Hur, MW				Lee, DK; Suh, D; Edenberg, HJ; Hur, MW			POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTION MOTIF; ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; FORMALDEHYDE DEHYDROGENASE; BTB/POZ DOMAIN; HUMAN-LIVER; CHI-ADH; COMPLEX	The POZ domain is a protein-protein interaction motif that is found in many transcription factors, which are important for development, oncogenesis, apoptosis, and transcription repression. We cloned the POZ domain transcription factor, FBI-1, that recognizes the cis-element (bp -38 to -22) located just upstream of the core Sp1 binding sites (bp -22 to +22) of the ADH5/FDH minimal promoter (bp -38 to +61) in vitro and in vivo, as revealed by electrophoretic mobility shift assay and chromatin immunoprecipitation assay. The ADH5/FDH minimal promoter is potently repressed by the FBI-1. Glutathione S-transferase fusion protein pull-down showed that the POZ domains of FBI-1, Plzf, and Bel-6 directly interact with the zinc finger DNA binding domain of Sp1. DNase I footprinting assays showed that the interaction prevents binding of Spl to the GC boxes of the ADH5/FDH promoter. Gal4-POZ domain fusions targeted proximal to the GC boxes repress transcription of the Gal4 upstream activator sequence-Sp1-adenovirus major late promoter. Our data suggest that POZ domain represses transcription by interacting with Sp1 zinc fingers and by interfering with the DNA binding activity of Sp1.	Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Project Med Sci BK21,Inst Genet Sci,SeoDaeMoon Ku, Seoul 120752, South Korea; PoChon CHA Univ, Coll Med, Dept Biochem, Boondang Ku, Songnam 463836, Kyungki Do, South Korea; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Yonsei University; Pochon Cha University; Indiana University System; Indiana University-Purdue University Indianapolis	Hur, MW (corresponding author), Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Project Med Sci BK21,Inst Genet Sci,SeoDaeMoon Ku, 134 Shinchon Dong, Seoul 120752, South Korea.	mwhur2@yumc.yonsei.ac.kr		Edenberg, Howard/0000-0003-0344-9690				ADINOLFI A, 1984, ANN HUM GENET, V48, P1, DOI 10.1111/j.1469-1809.1984.tb00828.x; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DULEY JA, 1985, ALCOHOL CLIN EXP RES, V9, P263, DOI 10.1111/j.1530-0277.1985.tb05747.x; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HUR MW, 1995, J BIOL CHEM, V270, P9002, DOI 10.1074/jbc.270.15.9002; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; Huynh KD, 2000, GENE DEV, V14, P1810; JORNVALL H, 1995, ADV EXP MED BIOL, V372, P281; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Kwon HS, 2001, ARCH BIOCHEM BIOPHYS, V386, P163, DOI 10.1006/abbi.2000.2205; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; UOTILA L, 1974, J BIOL CHEM, V249, P7653; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAGNER FW, 1984, BIOCHEMISTRY-US, V23, P2193, DOI 10.1021/bi00305a014; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334	46	85	92	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26761	26768		10.1074/jbc.M202078200	http://dx.doi.org/10.1074/jbc.M202078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004059	hybrid			2022-12-25	WOS:000177055900009
J	Villard, S; Piquer, D; Raut, S; Leonetti, JP; Saint-Remy, JM; Granier, C				Villard, S; Piquer, D; Raut, S; Leonetti, JP; Saint-Remy, JM; Granier, C			Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY TECHNOLOGY; HEMOPHILIA-A; C2 DOMAIN; MONOCLONAL-ANTIBODY; MAJOR DETERMINANT; BINDING; EPITOPE; RNA; THROMBOSIS; LIBRARIES	Following repeated administration of factor VIII (FVIII), a significant number of hemophilia A patients develop antibodies (Abs), inhibiting the procoagulant activity of infused FVIII. We have designed an approach based on the blocking of the deleterious activity of these Abs by peptide decoys mimicking the anti-FVIII Ab epitopes. Here, the well characterized inhibitory monoclonal Ab ESH8 served as a model. Several phage peptide libraries were screened for specific binding to ESH8. Seven constrained dodecapeptide sequences were obtained. Six sequences carried the consensus motif, hydrophobic-(Y/F)GKTXL. This motif showed a certain similarity with the (2231)QVDFQKTMKV(2240) sequence of the C-2 domain. In the seventh sequence, YCNPSIGDKNCR, the residues GDKN are similar to the sequence (2267)DGHQ(2270). Upon inspection of the C, domain crystallographic structure, the two stretches QVDFQKTMKV and DGHQ appeared close together in space and might constitute a discontinuous epitope. Corresponding synthetic peptides were able to inhibit the binding of ESH8 to FVIII in a specific and dose-dependent manner. Moreover, the ability of the selected peptides to neutralize the inhibitory activity of ESH8 was demonstrated in functional tests as well as in vivo in a murine model of hemophilia A. This study demonstrates the potential of this approach to neutralize the activity of potent inhibitory Abs.	CNRS, UMR 5094, Fac Pharm, F-34093 Montpellier 5, France; Natl Inst Biol Stand & Controls, Div Haematol, Potters Bar EN6 3QG, Herts, England; Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Institute for Biological Standards & Control; Universite Catholique Louvain	Granier, C (corresponding author), CNRS, UMR 5094, Fac Pharm, BP 14491,15 Ave Charles Fiahault, F-34093 Montpellier 5, France.	claude.granier@ibph.pharma.univ-montp1.fr	GRANIER, Claude/A-8841-2008; Raut, Sanj/E-5123-2013	Raut, Sanj/0000-0001-5896-2569				Arza B, 1998, THROMB HAEMOSTASIS, V80, P354, DOI 10.1055/s-0037-1615211; Bi L, 1996, BLOOD, V88, P3446, DOI 10.1182/blood.V88.9.3446.bloodjournal8893446; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; BRIET E, 1994, THROMB HAEMOSTASIS, V72, P162; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; Ferrieres G, 2000, EUR J BIOCHEM, V267, P1819, DOI 10.1046/j.1432-1327.2000.01184.x; Fijnvandraat K, 1998, BLOOD, V91, P2347, DOI 10.1182/blood.V91.7.2347.2347_2347_2352; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GILLES JGG, 1993, BLOOD, V82, P2452; Hay CRM, 1996, VOX SANG, V70, P68, DOI 10.1111/j.1423-0410.1996.tb01353.x; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; Hedner Ulla, 1993, Transfusion Medicine Reviews, V7, P78, DOI 10.1016/S0887-7963(93)70126-1; HOYER LW, 1987, HUM PATHOL, V18, P153, DOI 10.1016/S0046-8177(87)80333-7; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P875, DOI 10.1055/s-0038-1651380; Kreuz W, 1996, VOX SANG, V70, P2, DOI 10.1111/j.1423-0410.1996.tb01341.x; LAMONT AG, 1990, J IMMUNOL, V144, P2493; LARUE C, 1992, MOL IMMUNOL, V29, P271, DOI 10.1016/0161-5890(92)90109-B; Lee SW, 1997, NAT BIOTECHNOL, V15, P41, DOI 10.1038/nbt0197-41; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; LUSHER JM, 1983, BLOOD, V62, P1135; Molina F, 1996, PEPTIDE RES, V9, P151; Nogami K, 1999, BRIT J HAEMATOL, V107, P196, DOI 10.1046/j.1365-2141.1999.01673.x; Nord K, 2001, EUR J BIOCHEM, V268, P4269, DOI 10.1046/j.1432-1327.2001.02344.x; PITNEY WR, 1953, J CLIN PATHOL, V6, P9, DOI 10.1136/jcp.6.1.9; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; Reineke U, 1999, NAT BIOTECHNOL, V17, P271, DOI 10.1038/7018; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; Scandella D, 1999, VOX SANG, V77, P17, DOI 10.1159/000056708; Singh I, 2002, BLOOD, V99, P3235, DOI 10.1182/blood.V99.9.3235; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; TAMURA H, 2001, BIOORG MED CHEM LETT, V11, P1897; Voorberg J, 2000, SEMIN THROMB HEMOST, V26, P143, DOI 10.1055/s-2000-9816	39	26	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27232	27239		10.1074/jbc.M203415200	http://dx.doi.org/10.1074/jbc.M203415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011059	hybrid			2022-12-25	WOS:000177055900069
J	Ahn, T; Oh, DB; Kim, H; Park, C				Ahn, T; Oh, DB; Kim, H; Park, C			The phase provertv of membrane phosholipids is affected by the functionality of signal peptides from the Escherichia coli ribose-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL MEMBRANES; WILD-TYPE; NONBILAYER LIPIDS; PLASMA-MEMBRANE; SEQUENCE; EXPORT; PHOSPHATIDYLSERINE; PHOSPHATIDYLETHANOLAMINE; CONFORMATION; PENETRATION	We examined the effects of synthetic signal peptides from the wild-type, export-defective mutant and its revertant species of ribose-binding protein on the phase properties of lipid bilayers. The lateral segregation of phosphatidylglycerol. (PG) in the lipid bilayer was detected through quenching between NBD-PGs upon the reconstitution of signal peptide into the liposome made with the Escherichia coli inner membrane composition. The tendency of lipid segregation was highly dependent on the export competency of signal peptides in vivo, with a decreasing order of wild-type, revertant, and mutant species. The colocalizations of pyrene-PG with BODIPY-PG were also induced by the signal peptides, confirming the phase separation of the acidic phospholipid. The wildtype and revertant signal peptides predominantly formed a-helical conformations with the presence of acidic phospholipid as determined by circular dichroism spectroscopy. In addition, they restricted the motion of lipid acyl chains as monitored by fluorescence anisotropy of DPH, suggesting a deep penetration of signal peptide into the lipid bilayer. However, the alpha-helical content of mutant signal peptide was only about half that of the wild-type or revertant peptide with a significantly smaller degree of penetration into the bilayer. An association of the defective signal peptides into the membrane was affected by salt extraction, whereas the functional ones were not. The aforementioned results indicate that the functionality of signal peptide is accomplished through its topologies in the membrane and also by its ability to induce lateral segregation of acidic phospholipid. We propose that the clustering of acidic phospholipid by the functional signal peptide is responsible for the formation of non-bilayer membrane structure, thereby promoting an efficient translocation of secretory proteins.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Behav Genet, Dept Biol Sci, Taejon 305701, South Korea; Pai Chai Univ, Res Inst Nat Sci, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Pai Chai University	Park, C (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Behav Genet, Dept Biol Sci, Taejon 305701, South Korea.			Oh, Doo-Byoung/0000-0002-4432-0941				Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; Ahn T, 2000, BIOCHEMISTRY-US, V39, P10147, DOI 10.1021/bi0000622; Ahn T, 1996, J BIOL CHEM, V271, P12372, DOI 10.1074/jbc.271.21.12372; AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; Chi SW, 1995, BIOPHYS J, V69, P2703, DOI 10.1016/S0006-3495(95)80141-4; CHUPIN V, 1995, BIOCHEMISTRY-US, V34, P11617, DOI 10.1021/bi00036a038; FARREN SB, 1980, BIOCHEM BIOPH RES CO, V97, P182, DOI 10.1016/S0006-291X(80)80152-5; GRAHAM I, 1985, BIOCHEMISTRY-US, V24, P7123, DOI 10.1021/bi00346a016; HOEKSTRA D, 1982, BIOCHEMISTRY-US, V21, P1055, DOI 10.1021/bi00534a036; HOYT DW, 1991, J BIOL CHEM, V266, P14406; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; IZARD JW, 1995, BIOCHEMISTRY-US, V34, P9904, DOI 10.1021/bi00031a012; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; LUIRINK J, 1994, MOL MICROBIOL, V11, P9, DOI 10.1111/j.1365-2958.1994.tb00284.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MITTLERNEHER S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P259, DOI 10.1016/0005-2736(93)90257-Z; NAGARAJ R, 1987, BIOCHIM BIOPHYS ACTA, V903, P465, DOI 10.1016/0005-2736(87)90053-8; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; SANKARAM MB, 1994, J BIOL CHEM, V269, P23477; SONG T, 1995, J MOL BIOL, V253, P304, DOI 10.1006/jmbi.1995.0554; TESCHKE CM, 1991, J BIOL CHEM, V266, P11789; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TILCOCK CPS, 1984, BIOCHEMISTRY-US, V23, P2696, DOI 10.1021/bi00307a025; TILCOCK CPS, 1988, BIOCHEMISTRY-US, V27, P1415, DOI 10.1021/bi00405a004; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; VANVENETIE R, 1981, BIOCHIM BIOPHYS ACTA, V645, P262, DOI 10.1016/0005-2736(81)90197-8; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YI GS, 1994, BIOPHYS J, V66, P1604, DOI 10.1016/S0006-3495(94)80952-X; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X	42	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26157	26162		10.1074/jbc.M203445200	http://dx.doi.org/10.1074/jbc.M203445200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004066	hybrid			2022-12-25	WOS:000176908700044
J	Bartoov-Shifman, R; Hertz, R; Wang, HY; Wollheim, CB; Bar-Tana, J; Walker, MD				Bartoov-Shifman, R; Hertz, R; Wang, HY; Wollheim, CB; Bar-Tana, J; Walker, MD			Activation of the insulin gene promoter through a direct effect of hepatocyte nuclear factor 4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; FACTOR-1-ALPHA GENE; FACTOR-4-ALPHA GENE; MISSENSE MUTATION; MAMMALIAN-CELLS; HOMEOBOX FACTOR; MODY1 GENE; EXPRESSION	Maturity onset diabetes of the young, subtype 1 (MODY1), is associated with defective glucose-dependent insulin secretion from pancreatic beta cells. MODY1 is caused by mutation in the transcription factor hepatocyte nuclear factor 4alpha (HNF4alpha). To understand better the MODY1 phenotype, we tested whether HNF4alpha was able to modulate directly the insulin gene promoter. Transfection of cultured 293T cells with an HNF4alpha expression vector led to 10-fold activation of a cotransfected reporter plasmid containing the rat insulin I gene promoter. Computer analysis revealed a potential HNF4alpha-binding site between nucleotides -57 and -69 of the promoter; mutation of this sequence led to reduced ability of HNF4alpha to activate the promoter. The ability of HNF4alpha to bind this sequence was confirmed using gel shift analysis. In transfected INS-1 beta cells, mutation of either the HNF1alpha site or the HNF4alpha site in the insulin gene promoter led to 50-75% reduction in reporter gene activity; expression of dominant negative HNF4alpha led to significant reduction in the activity of wild type and both mutated promoters. Thus, in addition to the previously described indirect action of HNF4alpha on insulin gene expression mediated through elevated HNF1alpha levels, HNF4alpha also activates the insulin gene directly, through a previously unrecognized cis element.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland; Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; University of Geneva; Hebrew University of Jerusalem	Walker, MD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; Bulman MP, 1997, DIABETOLOGIA, V40, P859, DOI 10.1007/s001250050760; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Furuta H, 1997, DIABETES, V46, P1652, DOI 10.2337/diabetes.46.10.1652; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; HERMAN WH, 1994, DIABETES, V43, P40, DOI 10.2337/diabetes.43.1.40; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEFF T, 1989, J BIOL CHEM, V264, P16132; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lindner T, 1997, J CLIN INVEST, V100, P1400, DOI 10.1172/JCI119660; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; Malecki MT, 1999, DIABETIC MED, V16, P193, DOI 10.1046/j.1464-5491.1999.00073.x; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moller AM, 1997, DIABETOLOGIA, V40, P980, DOI 10.1007/s001250050778; Moller AM, 1999, J CLIN ENDOCR METAB, V84, P367, DOI 10.1210/jc.84.1.367; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Shih DQ, 2001, P NATL ACAD SCI USA, V98, P14189, DOI 10.1073/pnas.251558998; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	45	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25914	25919		10.1074/jbc.M201582200	http://dx.doi.org/10.1074/jbc.M201582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994285	hybrid			2022-12-25	WOS:000176908700014
J	Melman, YF; Krumerman, A; McDonald, TV				Melman, YF; Krumerman, A; McDonald, TV			A single transmembrane site in the KCNE-encoded proteins controls the specificity of KvLQT1 channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; CARDIAC POTASSIUM CURRENT; LANGE-NIELSEN-SYNDROME; I-KS CHANNELS; CAUSE JERVELL; MINK; MUTATIONS; SUBUNITS; COMPLEX; ISK	KCNEs are a family of genes encoding small integral membrane proteins whose role in governing voltage-gated potassium channel gating is emerging. Whether each member of this homologous family interacts with channel proteins in the same manner is unknown; however, it is clear that the functional effect of each KCNE on channel gating is different. The specificity of KCNE1 (minK) and KCNE3 control of activation of the potassium channel KvLQT1 maps to a triplet of amino acids within the KCNE transmembrane domain by chimera analysis. We now define the structural determinants of functional specificity within this triplet. The central amino acid of the triplet (Thr-58 of minK and Val-72 of KCNE3) is essential for the specific control of voltage-dependent channel activation characteristics of both minK and KCNE3. Using site-directed mutations that substitute minK and KCNE3 residues, we determined that a hydroxylated central amino acid is necessary for the slow sigmoidal activation produced by minK. The precise spacing of the hydroxyl group was required for minK-like activation. Am aliphatic amino acid substituted at position 58 of minK is capable of reproducing KCNE3-like kinetics and voltage-independent constitutive current activation. The bulk of the central residue is another critical parameter, indicating precise positioning of this portion of the KCNE proteins within the channel complex. An intermediate phenotype produced by several smaller aliphatic-substituted mutants yields conditional voltage independence that is distinct from the voltage-dependent gating process, suggesting that KCNE3 traps the channel in a stable open state. From these results, we propose a model of KCNE-potassium channel interaction where the functional consequence depends on the precise contact at a single amino acid.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Sect Mol Cardiol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	McDonald, TV (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NHLBI NIH HHS [R01 HL57388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 2000, TRENDS PHARMACOL SCI, V21, P199, DOI 10.1016/S0165-6147(00)01475-9; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1989, FASEB J, V5, P331; Tapper AR, 2000, J GEN PHYSIOL, V116, P379, DOI 10.1085/jgp.116.3.379; Tapper AR, 2001, J BIOL CHEM, V276, P38249; TAYLOR RE, 1960, BIOPHYS J, V1, P161, DOI 10.1016/S0006-3495(60)86882-8; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Tzounopoulos T, 1998, BIOPHYS J, V74, P2299, DOI 10.1016/S0006-3495(98)77939-1; VARNUM MD, 1995, NEURON, V14, P407, DOI 10.1016/0896-6273(95)90296-1; Wang HS, 2000, MOL PHARMACOL, V57, P1218; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; Wang WY, 1998, J BIOL CHEM, V273, P34069, DOI 10.1074/jbc.273.51.34069; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	33	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25187	25194		10.1074/jbc.M200564200	http://dx.doi.org/10.1074/jbc.M200564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994278	hybrid			2022-12-25	WOS:000176747000045
J	Sontag, TJ; Parker, RS				Sontag, TJ; Parker, RS			Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism - Novel mechanism of regulation of vitamin E status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-TOCOPHEROL; ALPHA-TOCOPHEROL; HUMAN LIVER; LIPID-PEROXIDATION; TRANSFER PROTEIN; HEPG2 CELLS; HUMAN URINE; METABOLISM; ACID; EXPRESSION	Postabsorptive elimination of the various forms of vitamin E appears to play a key role in regulation of tissue tocopherol concentrations, but mechanisms of tocopherol metabolism have not been elucidated. Here we describe a pathway involving cytochrome P450-mediated omega-hydroxylation of the tocopherol phytyl side chain followed by stepwise removal of two- or three-carbon moieties, ultimately yielding the X-carboxychromanol metabolite that is excreted in urine. All key intermediates of gamma-tocopherol metabolism via this pathway were identified in hepatocyte cultures using gas chromatographymass spectrometry. NADPH-dependent synthesis of the initial gamma- and alpha-tocopherol 13'-hydroxy and -carboxy metabolites was demonstrated in rat and human liver microsomes. Functional analysis of several recombinant human liver P450 enzymes revealed that tocopherol-cohydroxylase activity was associated only with CYP4F2, which also catalyzes omega-hydroxylation of leukotriene B-4 and arachidonic acid. Tocopherol-omega-hydroxylase exhibited similar binding affinities but markedly higher catalytic activities for gamma-tocopherol than alpha-tocopherol, suggesting a role for this pathway in the preferential physiological retention of alpha-tocopherol and elimination of gamma-tocopherol. Sesamin potently inhibited tocopherol-omega-hydroxylase activity exhibited by CYP4F2 and rat or human liver microsomes. Since dietary sesamin also results in elevated tocopherol levels in vivo, this pathway appears to represent a functionally significant means of regulating vitamin E status.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Parker, RS (corresponding author), Cornell Univ, Div Nutr Sci, 113 Savage Hall, Ithaca, NY 14853 USA.	rsp3@cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07158-25] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRENS WA, 1986, J AM COLL NUTR, V5, P91; BIERI JG, 1974, J NUTR, V104, P850, DOI 10.1093/jn/104.7.850; BIERI JG, 1974, AM J CLIN NUTR, V27, P980, DOI 10.1093/ajcn/27.8.980; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; CHIKU S, 1984, J LIPID RES, V25, P40; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Cooney RV, 2001, NUTR CANCER, V39, P66, DOI 10.1207/S15327914nc391_9; Hosomi A, 1997, FEBS LETT, V409, P105, DOI 10.1016/S0014-5793(97)00499-7; HUGHES L, 1990, J LABELLED COMPD RAD, V28, P1049, DOI 10.1002/jlcr.2580280909; Jiang Q, 2001, AM J CLIN NUTR, V74, P714; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; Jin RY, 1998, ARCH BIOCHEM BIOPHYS, V359, P89, DOI 10.1006/abbi.1998.0880; Kamal-Eldin A, 2000, LIPIDS, V35, P427, DOI 10.1007/s11745-000-541-y; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 1999, ARCH BIOCHEM BIOPHYS, V369, P193, DOI 10.1006/abbi.1999.1271; KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Lin HL, 1998, CARCINOGENESIS, V19, P321, DOI 10.1093/carcin/19.2.321; Parker RS, 2000, BIOCHEM BIOPH RES CO, V277, P531, DOI 10.1006/bbrc.2000.3706; Parker RS, 2000, BIOCHEM BIOPH RES CO, V269, P580, DOI 10.1006/bbrc.2000.2319; Pelkonen O, 1998, XENOBIOTICA, V28, P1203, DOI 10.1080/004982598238886; Powell PK, 1996, ARCH BIOCHEM BIOPHYS, V335, P219, DOI 10.1006/abbi.1996.0501; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; Sai Y, 2000, XENOBIOTICA, V30, P327, DOI 10.1080/004982500237541; SCHONFELD A, 1993, NAHRUNG, V37, P498; SHAK S, 1987, METHOD ENZYMOL, V141, P355; Stahl W, 1999, ANAL BIOCHEM, V275, P254, DOI 10.1006/abio.1999.4312; Swanson JE, 1999, J LIPID RES, V40, P665; TAYLOR SL, 1976, LIPIDS, V11, P530, DOI 10.1007/BF02532898; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Traber MG, 1999, ANNU REV NUTR, V19, P343, DOI 10.1146/annurev.nutr.19.1.343; TRABER MG, 1992, J LIPID RES, V33, P1171; VATASSERY GT, 1983, J AM COLL NUTR, V2, P369; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Wechter WJ, 1996, P NATL ACAD SCI USA, V93, P6002, DOI 10.1073/pnas.93.12.6002; YAMASHITA K, 1995, LIPIDS, V30, P1019, DOI 10.1007/BF02536287	39	376	398	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25290	25296		10.1074/jbc.M201466200	http://dx.doi.org/10.1074/jbc.M201466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997390	hybrid, Green Submitted			2022-12-25	WOS:000176747000059
J	Picault, N; Palmieri, L; Pisano, I; Hodges, M; Palmieri, F				Picault, N; Palmieri, L; Pisano, I; Hodges, M; Palmieri, F			Identification of a novel transporter for dicarboxylates and tricarboxylates in plant mitochondria - Bacterial expression, reconstitution, functional characterization, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANICUM-MILIACEUM; CARRIER; PROTEIN; CDNA; PURIFICATION; TRANSLOCATOR; CITRATE; YEAST; OXALOACETATE; MECHANISM	A cDNA from Arabidopsis thaliana and four related cDNAs from Nicotiana tabacum that we have isolated encode hitherto unidentified members of the mitochondrial carrier family. These proteins have been overexpressed in bacteria and reconstituted into phospholipid vesicles. Their transport properties demonstrate that they are orthologs/isoforms of a novel mitochondrial carrier capable of transporting both dicarboxylates (such as malate, oxaloacetate, oxoglutarate, and maleate) and tricarboxylates (such as citrate, isocitrate, cisaconitate, and trans-aconitate). The newly identified dicarboxylate-tricarboxylate carrier accepts only the single protonated form of citrate (H-citrate(2-)) and the unprotonated form of malate (malate(2-)) and catalyzes obligatory, electroneutral exchanges. Oxoglutarate, citrate, and malate are mutually competitive inhibitors, showing K-i close to the respective K-m. The carrier is expressed in all plant tissues examined and is largely spread in the plant kingdom. Furthermore, nitrate supply to nitrogen-starved tobacco plants leads to an increase in its mRNA in roots and leaves. The dicarboxylate-tricarboxylate carrier may play a role in important plant metabolic functions requiring organic acid flux to or from the mitochondria, such as nitrogen assimilation, export of reducing equivalents from the mitochondria, and fatty acid elongation.	Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; Univ Paris 11, CNRS UMR8618, Inst Biotechnol Plantes, F-91405 Orsay, France	Universita degli Studi di Bari Aldo Moro; UDICE-French Research Universities; Universite Paris Saclay	Palmieri, F (corresponding author), Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Via Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	PICAULT, Nathalie/ABB-1755-2021; PISANO, ISABELLA/AAK-5039-2021; Hodges, Michael/A-8883-2008; PICAULT, Nathalie N/M-1476-2015	PICAULT, Nathalie/0000-0003-2770-9688; PICAULT, Nathalie N/0000-0003-2770-9688; PISANO, Isabella/0000-0003-0728-2226				BAKER A, 1985, NUCLEIC ACIDS RES, V13, P5857, DOI 10.1093/nar/13.16.5857; BISACCIA F, 1993, BIOCHIM BIOPHYS ACTA, V1142, P139, DOI 10.1016/0005-2728(93)90095-W; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; Borecky J, 2001, FEBS LETT, V505, P240, DOI 10.1016/S0014-5793(01)02835-6; DAY DA, 1981, ARCH BIOCHEM BIOPHYS, V211, P100, DOI 10.1016/0003-9861(81)90434-3; DOLCE V, 1994, DNA SEQUENCE, V5, P103, DOI 10.3109/10425179409039711; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Galvez S, 1999, TRENDS PLANT SCI, V4, P484, DOI 10.1016/S1360-1385(99)01500-9; Galvez S, 1996, PLANT MOL BIOL, V30, P307, DOI 10.1007/BF00020116; Genchi C, 1999, PLANT PHYSIOL, V120, P841, DOI 10.1104/pp.120.3.841; GENCHI G, 1991, PLANT PHYSIOL, V96, P1003, DOI 10.1104/pp.96.4.1003; Hanning I, 1999, PLANT PHYSIOL, V119, P1025, DOI 10.1104/pp.119.3.1025; Iacobazzi V, 1992, DNA Seq, V3, P79, DOI 10.3109/10425179209034000; JUNG DW, 1979, PLANT PHYSIOL, V63, P591, DOI 10.1104/pp.63.4.591; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Kiiskinen M, 1997, PLANT MOL BIOL, V35, P271, DOI 10.1023/A:1005868715571; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Laloi M, 1999, CELL MOL LIFE SCI, V56, P918, DOI 10.1007/s000180050484; Lancien M, 1999, PLANT PHYSIOL, V120, P717, DOI 10.1104/pp.120.3.717; MCINTOSH CA, 1992, PLANT PHYSIOL, V100, P2030, DOI 10.1104/pp.100.4.2030; OLIVER DJ, 1984, PLANT PHYSIOL, V76, P409, DOI 10.1104/pp.76.2.409; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1971, EUR J BIOCHEM, V22, P66, DOI 10.1111/j.1432-1033.1971.tb01515.x; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 1999, J BIOL CHEM, V274, P22184, DOI 10.1074/jbc.274.32.22184; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PASZKOWSKI J, 1984, EMBO J, V3, P2717, DOI 10.1002/j.1460-2075.1984.tb02201.x; REMY R, 1987, ELECTROPHORESIS, V8, P528, DOI 10.1002/elps.1150081107; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Takabatake R, 1999, PLANT MOL BIOL, V40, P479, DOI 10.1023/A:1006285009435; Taniguchi M, 1996, PLANT MOL BIOL, V30, P51, DOI 10.1007/BF00017802; Taniguchi M, 1997, PLANT PHYSIOL, V114, P285, DOI 10.1104/pp.114.1.285; VANDERREST ME, 1991, EUR J BIOCHEM, V195, P71; VIVEKANANDA J, 1988, J BIOL CHEM, V263, P4782; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WISKICH JT, 1977, ANNU REV PLANT PHYS, V28, P45, DOI 10.1146/annurev.pp.28.060177.000401; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	43	120	126	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24204	24211		10.1074/jbc.M202702200	http://dx.doi.org/10.1074/jbc.M202702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978797	hybrid			2022-12-25	WOS:000176611800031
J	Sigoillot, FD; Evans, DR; Guy, HI				Sigoillot, FD; Evans, DR; Guy, HI			Autophosphorylation of the mammalian multifunctional protein that initiates de novo pyrimidine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; HAMSTER-CELLS; ASPARTATE-TRANSCARBAMYLASE; CREATINE-KINASE; MAP KINASE; CAD; MECHANISM; IDENTIFICATION; DOMAINS	CAD, a large multifunctional protein that carries carbamoyl phosphate synthetase (CPSase), aspartate transcarbamoylase, and dihydroorotase activities, catalyzes the first three steps of de novo pyrimidine biosynthesis in mammalian cells. The CPSase component, which catalyzes the initial, rate-limiting step, exhibits complex regulatory mechanisms involving allosteric effectors and phosphorylation that control the flux of metabolites through the pathway. Incubation of CAD with ATP in the absence of exogenous kinases resulted in the incorporation of 1 mol of P-i/mol of CAD monomer. Mass spectrometry analysis of tryptic digests showed that Thr(1037) located within the CAD CPS.B subdomain was specifically modified. The reaction is specific for MgATP, ADP was a competitive inhibitor, and the native tertiary structure of the protein was required. Phosphorylation occurred after denaturation, further purification of CAD by SDS gel electrophoresis, and renaturation on a nitrocellulose membrane, strongly suggesting that phosphate incorporation resulted from an intrinsic kinase activity and was not the result of contaminating kinases. Chemical modification with the ATP analog, 5'-p-fluorosulfonylbenzoyladenosine, showed that one or both of the active sites that catalyze the ATP-dependent partial reactions are also involved in autophosphorylation. The rate of phosphorylation was dependent on the concentration of CAD, indicating that the reaction was, at least in part, intermolecular. Autophosphorylation resulted in a 2-fold increase in CPSase activity, an increased sensitivity to the feedback inhibitor UTP, and decreased allosteric activation by 5-phosphoribosyl-1-pyrophosphate, functional changes that were distinctly different from those resulting from phosphorylation by either the protein kinase A or mitogen-activated protein kinase cascades.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Guy, HI (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	hguy@cmb.biosci.wayne.edu		Sigoillot, Frederic/0000-0002-8695-4838	NIGMS NIH HHS [GM/CA47399, R01 GM060371, GM/CA60371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399, R01GM060371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; BRAXTON BL, 1992, BIOCHEMISTRY-US, V31, P2309, DOI 10.1021/bi00123a015; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHEN JJ, 1979, J BIOL CHEM, V254, P2697; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; David SSM, 1999, BIOCHEMISTRY-US, V38, P8492, DOI 10.1021/bi990041b; FERNANDEZ R, 1988, J GEN MICROBIOL, V134, P2493; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P23808; GUY HI, 1994, ADV EXP MED BIOL, V370, P729; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; HEMMER W, 1995, BBA-PROTEIN STRUCT M, V1251, P81, DOI 10.1016/0167-4838(95)00083-7; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; KEMLING N, 1994, THESIS WAYNE STATE U; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU X, 1994, J BIOL CHEM, V269, P27747; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; POST LE, 1990, J BIOL CHEM, V265, P7742; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; Sigoillot FD, 2002, J BIOL CHEM, V277, P15745, DOI 10.1074/jbc.M201112200; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TATIBANA M, 1972, BIOCHEM BIOPH RES CO, V46, P491, DOI 10.1016/S0006-291X(72)80165-7; WAHL GM, 1979, J BIOL CHEM, V254, P8679	45	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24809	24817		10.1074/jbc.M203512200	http://dx.doi.org/10.1074/jbc.M203512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986331	hybrid			2022-12-25	WOS:000176611800108
J	Nehrke, K; Arreola, J; Nguyen, HV; Pilato, J; Richardson, L; Okunade, G; Baggs, R; Shull, GE; Melvin, JE				Nehrke, K; Arreola, J; Nguyen, HV; Pilato, J; Richardson, L; Okunade, G; Baggs, R; Shull, GE; Melvin, JE			Loss of hyperpolarization-activated Cl- current in salivary acinar cells from Clcn2 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLC-2 CHLORIDE CHANNEL; SENSITIVE NA+ CURRENT; GRANULAR DUCT CELLS; EPITHELIAL-CELLS; SPLICE VARIANTS; FETAL LUNG; RAT; VOLUME; CALCIUM; SECRETION	ClC-2 is localized to the apical membranes of secretory epithelia where it has been hypothesized to play a role in fluid secretion. Although ClC-2 is clearly the inwardly rectifying anion channel in several tissues, the molecular identity of the hyperpolarization-activated Cl- current in other organs, including the salivary gland, is currently unknown. To determine the nature of the hyperpolarization-activated. Cl- current and to examine the role of ClC-2 in salivary gland function, a mouse line containing a targeted disruption of the Clcn2 gene was generated. The resulting homozygous Clcn2(-/-) mice lacked detectable hyperpolarization-activated chloride currents in parotid acinar cells and, as described previously, displayed postnatal degeneration of the retina and testis. The magnitude and biophysical characteristics of the volume- and calcium-activated chloride currents in these cells were unaffected by the absence of ClC-2. Although ClC-2 appears to contribute to fluid secretion in some cell types, both the initial and sustained salivary flow rates were normal in Clcn2(-/-) mice following in vivo stimulation with pilocarpine, a cholinergic agonist. In addition, the electrolytes and protein contents of the mature secretions were normal. Because ClC-2 has been postulated to contribute to cell volume control, we also examined regulatory volume decrease following cell swelling. However, parotid acinar cells from Clcn2(-/-) mice recovered volume with similar efficiency to wild-type littermates. These data demonstrate that ClC-2 is the hyperpolarization-activated Cl- channel in salivary acinar cells but is not essential for maximum chloride flux during stimulated secretion of saliva or acinar cell volume regulation.	Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Lab Anim Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol & Psysiol, Rochester, NY 14642 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University System of Ohio; University of Cincinnati	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.	james_melvin@urmc.rochester.edu	ARREOLA, JORGE/HGE-4524-2022; Arreola, Jorge/B-1042-2009	ARREOLA, JORGE/0000-0002-5354-3709; Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692, P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13539, DE09692] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arreola J, 1996, J PHYSIOL-LONDON, V490, P351, DOI 10.1113/jphysiol.1996.sp021149; Arreola J, 2002, J PHYSIOL-LONDON, V541, P103, DOI 10.1113/jphysiol.2002.016485; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; ARREOLA J, 1995, J PHYSIOL-LONDON, V484, P677, DOI 10.1113/jphysiol.1995.sp020695; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Brooks HL, 2001, J PHYSIOL-LONDON, V530, P359, DOI 10.1111/j.1469-7793.2001.0359k.x; Chu SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL614, DOI 10.1152/ajplung.1999.276.4.L614; Chu SJ, 1997, NUCLEIC ACIDS RES, V25, P4153, DOI 10.1093/nar/25.20.4153; Cid LP, 2000, AM J PHYSIOL-CELL PH, V279, pC1198, DOI 10.1152/ajpcell.2000.279.4.C1198; Clark S, 1998, J PHYSIOL-LONDON, V506, P665, DOI 10.1111/j.1469-7793.1998.665bv.x; DINUDOM A, 1995, J PHYSIOL-LONDON, V487, P549, DOI 10.1113/jphysiol.1995.sp020899; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DOUGLAS WW, 1963, J PHYSIOL-LONDON, V165, P528, DOI 10.1113/jphysiol.1963.sp007076; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; Fritsch J, 1997, AM J PHYSIOL-CELL PH, V272, pC778, DOI 10.1152/ajpcell.1997.272.3.C778; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kibble JD, 1996, J PHYSIOL-LONDON, V496, P69, DOI 10.1113/jphysiol.1996.sp021666; KOMWATANA P, 1994, PFLUG ARCH EUR J PHY, V428, P641, DOI 10.1007/BF00374588; Komwatana P, 1996, J MEMBRANE BIOL, V150, P133, DOI 10.1007/s002329900038; Komwatana P, 1998, J MEMBRANE BIOL, V162, P225, DOI 10.1007/s002329900360; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; MARTINEZ JR, 1972, EXPERIENTIA, V28, P167, DOI 10.1007/BF01935735; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; Mohammad-Panah R, 2001, J BIOL CHEM, V276, P8306, DOI 10.1074/jbc.M006764200; Murray CB, 1996, AM J PHYSIOL-LUNG C, V271, pL829, DOI 10.1152/ajplung.1996.271.5.L829; MURRAY CB, 1995, AM J RESP CELL MOL, V12, P597, DOI 10.1165/ajrcmb.12.6.7766424; NISHIYAMA A, 1974, J PHYSIOL-LONDON, V242, P173, DOI 10.1113/jphysiol.1974.sp010700; Park K, 2001, J MEMBRANE BIOL, V182, P31, DOI 10.1007/s00232-001-0026-0; Park K, 1998, J MEMBRANE BIOL, V163, P87, DOI 10.1007/s002329900373; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roman RM, 2001, AM J PHYSIOL-GASTR L, V280, pG344, DOI 10.1152/ajpgi.2001.280.3.G344; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; SASAKI T, 1990, FEBS LETT, V264, P130, DOI 10.1016/0014-5793(90)80782-E; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Speake T, 2002, J PHYSIOL-LONDON, V539, P385, DOI 10.1113/jphysiol.2001.014548; Tewari KP, 2000, AM J PHYSIOL-CELL PH, V279, pC40, DOI 10.1152/ajpcell.2000.279.1.C40; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442	53	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23604	23611		10.1074/jbc.M202900200	http://dx.doi.org/10.1074/jbc.M202900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976342	hybrid			2022-12-25	WOS:000176475700066
J	Fabre, S; Reymond, N; Cocchi, F; Menotti, L; Dubreuil, P; Campadelli-Fiume, G; Lopez, M				Fabre, S; Reymond, N; Cocchi, F; Menotti, L; Dubreuil, P; Campadelli-Fiume, G; Lopez, M			Prominent role of the Ig-like V domain in trans-interactions of nectins - Nectin3 and nectin4 bind to the predicted C-C '-C ''-D beta-strands of the nectin1 V domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; HERPESVIRUS ENTRY MEDIATOR; RECEPTOR-RELATED PROTEIN-1; POLIOVIRUS RECEPTOR; GLYCOPROTEIN-D; ADHESION MOLECULE; HOMOPHILIC ADHESION; CLEFT LIP/PALATE; MURINE HOMOLOG; CELL SPREAD	Nectins form a family of integral molecules that belong to the immunoglobulin superfamily. Their ectodomain is made of three Ig-like domains (V, C, C). This family comprises at least five members, namely nectin1, -2, -3, -4, and poliovirus receptor (PVR), that are involved in different physiological and pathological processes. W Nectins are adhesion molecules localized at adherens junctions in epithelial cells. (ii) Some nectins act as poliovirus or alpha-herpesvirus receptors (nectin1). (iii) Nectin1 mutations are involved in orofacial developmental abnormalities in humans. Adhesion properties of nectins are mediated by Ca2+-independent homophilic and heterophilic processes through ectodomain trans-interactions. We have described a nectin trans-hetero-interaction network: nectin3 binds to nectin1, nectin2, and PVR; nectin1 also binds to nectin4. In the present study we compared the affinities of the different trans-interactions mediated by, nectin1. We found that the K-D of nectin1/nectin3 and nectin1/nectin4 interactions is I and 100 nm, respectively, whereas the K-D of the nectin1-mediated homophilic interaction is 1 gm. We show that nectin1/nectin3 and nectin1/nectin4 transhetero-interactions were mediated through trans V to V domain interactions, whereas C domains contributed to increase the affinity of the interaction. Nectin3 and nectin4 share a common binding region in the nectin1 V domain: M nectin3 strongly competed with nectin4 binding, (ii) nectin3 and nectin4 binding to nectin1. was reduced by a number of monoclonal antibodies directed against the nectin1 V domain, and (iii.) the glycoprotein D of herpes simplex virus-1 that binds to the V domain of nectin1 reduced nectin3 and nectin4: binding. Finally, using chimeric nectin1/PVR receptors where PVR V domain beta-strands were substituted with the corresponding regions of nectin1, the nectin3 and nectin4 minimal binding region on nectin1 V domain was mapped to the C-C'-C"-D beta-strands.	INSERM, U119, Inst Canc Biol & Immunol, F-13009 Marseille, France; Univ Bologna, Dept Expt Pathol, Sect Microbiol & Virol, I-40126 Bologna, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Bologna	Lopez, M (corresponding author), INSERM, U119, Inst Canc Biol & Immunol, 27 Bd Lei Roure, F-13009 Marseille, France.		Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; MENOTTI, LAURA/0000-0003-3277-5399; Campadelli-Fiume, Gabriella/0000-0002-6012-6081	Telethon [A.141] Funding Source: Medline	Telethon(Fondazione Telethon)		Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Cocchi F, 2001, J VIROL, V75, P7987, DOI 10.1128/JVI.75.17.7987-7994.2001; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Haarr L, 2001, VIROLOGY, V287, P301, DOI 10.1006/viro.2001.1041; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Krummenacher C, 2002, J VIROL, V76, P2424, DOI 10.1128/JVI.76.5.2424-2433.2002; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; Krummenacher C, 2000, J VIROL, V74, P10863, DOI 10.1128/JVI.74.23.10863-10872.2000; Lange R, 2001, VIROLOGY, V285, P218, DOI 10.1006/viro.2001.0943; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mata M, 2001, J NEUROVIROL, V7, P476, DOI 10.1080/135502801753170336; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Menotti L, 2000, P NATL ACAD SCI USA, V97, P4867, DOI 10.1073/pnas.97.9.4867; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; Ohka S, 2001, BIOCHEM BIOPH RES CO, V287, P941, DOI 10.1006/bbrc.2001.5660; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Sozen MA, 2001, NAT GENET, V29, P141, DOI 10.1038/ng740; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539	36	101	110	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27006	27013		10.1074/jbc.M203228200	http://dx.doi.org/10.1074/jbc.M203228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011057	hybrid			2022-12-25	WOS:000177055900041
J	Schindl, R; Kahr, H; Graz, I; Groschner, K; Romanin, C				Schindl, R; Kahr, H; Graz, I; Groschner, K; Romanin, C			Store depletion-activated CaT1 currents in rat basophilic leukemia mast cells are inhibited by 2-aminoethoxydiphenyl borate - Evidence for a regulatory component that controls activation of both CaT1 and CRAC (Ca2+ release-activated Ca2+ channel) channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE RECEPTOR; CALCIUM-CHANNEL; TRP; PROTEIN; KINASE; ENTRY	The intestinal Ca2+ transport protein CaT1 encoded by TRPV6 has been reported (Yue, L., Peng, J. B., Hediger, M. A., and Clapham, D. E. (2001) Nature 410,705-709) to be all or a part of the Ca2+ release-activated Ca2+ channel (CRAC). The major characteristic of CRAC is its activation following store depletion. We expressed CaT1 in HEK293 cells and rat basophilic leukemia (RBL) mast cells and measured whole-cell currents by the patch clamp technique. In HEK293 cells, the expression of CaT1 consistently yielded a constitutively active current, the size of which was strongly dependent on the holding potential and duration of voltage ramps. In CaT1-expressing RBL cells, the current was either activated by store depletion or was constitutively active at a higher current density. CaT1 currents could be clearly distinguished from endogenous CRAC by their typical current-voltage relationship in divalent free solution. 2-aminoethoxydiphenyl borate (2-APB), which is considered a blocker of CRAC, was tested. for its inhibitory effect on both cell types expressing CaT1. Endogenous CRAC as well as store-dependent CaT1-derived currents of RBL cells were largely blocked by 75 muM 2-APB, whereas constitutively active CaT1 currents in both RBL and HEK293 cells were slightly potentiated. These results indicate that despite the difference in the permeation properties of CRAC and CaT1 channels, the latter are similarly able to form store depletion-activated conductances in RBL mast cells that are inhibited by 2-APB.	Univ Linz, Inst Biophys, A-4040 Linz, Austria; Graz Univ, Inst Pharmacol & Toxicol, A-8010 Graz, Austria	Johannes Kepler University Linz; University of Graz	Romanin, C (corresponding author), Univ Linz, Inst Biophys, A-4040 Linz, Austria.	christoph.romanin@jku.at	Graz, Ingrid/A-7994-2011; Graz, Ingrid/AFP-2308-2022; Schindl, Rainer/V-4205-2019; Romanin, Christoph/D-5399-2009; Schindl, Rainer/E-3959-2013; Groschner, Klaus/A-2550-2010	Graz, Ingrid/0000-0001-7205-4161; Graz, Ingrid/0000-0001-7205-4161; Romanin, Christoph/0000-0003-3756-4136; Schindl, Rainer/0000-0003-0896-8887; Groschner, Klaus/0000-0002-8659-377X				BAKWOSKI D, 2001, J PHYSIOL-LONDON, V532, P55; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoenderop JGJ, 2000, CURR OPIN NEPHROL HY, V9, P335, DOI 10.1097/00041552-200007000-00003; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Montell C., 2001, SCI STKE; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Petersen OH, 2001, CURR BIOL, V11, pR520, DOI 10.1016/S0960-9822(01)00309-8; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; REINSPRECHT M, 1995, MOL PHARMACOL, V47, P1014; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; TREBAK M, IN PRESS J BIOL CHEM, V277; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	34	74	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26950	26958		10.1074/jbc.M203700200	http://dx.doi.org/10.1074/jbc.M203700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011062	hybrid			2022-12-25	WOS:000177055900034
J	Cui, J; Heard, TS; Yu, JH; Lo, JL; Huang, L; Li, Y; Schaeffer, JM; Wright, SD				Cui, J; Heard, TS; Yu, JH; Lo, JL; Huang, L; Li, Y; Schaeffer, JM; Wright, SD			The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLASE GENE CYP7A; NUCLEAR RECEPTOR; BILE-ACIDS; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION DOMAIN; HORMONE-RECEPTOR; LIGAND-BINDING; PROTEIN GENE; CHOLESTEROL; IDENTIFICATION	The critical steps in bile acid metabolism have remarkable differences between humans and mice. It is known that human cholesterol 7alpha-hydroxylase, the enzyme catalyzing the rate-limiting step of bile acid synthesis, is more sensitive to bile acid suppression. In addition, hepatic bile acid export in humans is more dependent on the bile salt export pump (BSEP). To explore the molecular basis for these species differences, we analyzed the function of the ligand-binding domain (LBD) of human and murine farnesoid X receptor (FXR), a nuclear receptor for bile acids. We observed a strong interspecies difference in bile acid-mediated FXR function; in the coactivator association assay, chenodeoxycholate (CDCA) activated human FXR-LBD with 10-fold higher affinity and 3-fold higher maximum response than murine FXR-LBD. Consistently, in HepG2 cells human FXR-LBD increased reporter expression more robustly in the presence of CDCA. The basis for these differences was investigated by preparing chimeric receptors and by site-directed mutagenesis. Remarkably, the double replacements of LyS(366) and Val(384) in murine FXR (corresponding to Asn(354) and Ile(372) in human FXR) with Asn(366) and Ile(384) explained the difference in both potency and maximum activation; compared with the wild-type murine FXR-LBD, the double mutant gained 8-fold affinity and more than 250% maximum response to CDCA in vitro. This mutant also increased reporter expression to an extent comparable with that of human FXR-LBD in HepG2 cells. These results demonstrate that Asn(354) and Ile(372) are critically important for FXR function and that murine FXR can be "humanized" by substituting with the two corresponding residues of human FXR. Consistent with the difference in FXR-LBD transactivation, CDCA induced endogenous expression of human BSEP by 10-12-fold and murine BSEP by 2-3-fold in primary hepatocytes. This study not only provides the identification of critical residues for FXR function but may also explain the species difference in bile acids/cholesterol metabolism.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA	Merck & Company	Cui, J (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000, Rahway, NJ 07065 USA.	jisong_cui@merck.com						Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; DeFabiani E, 1996, BIOCHEM BIOPH RES CO, V226, P663, DOI 10.1006/bbrc.1996.1412; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Greene M. E., 1995, Gene Expression, V4, P281; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Hofmann AF, 2001, HEPATOLOGY, V34, P848, DOI 10.1053/jhep.2001.28197; Jansen PLM, 1999, GASTROENTEROLOGY, V117, P1370, DOI 10.1016/S0016-5085(99)70287-8; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Lobaccaro JMA, 2001, ANN ENDOCRINOL-PARIS, V62, P239; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; POLLARD JW, 1992, METHODS MOL BIOL SER, V75, P145; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; TONE Y, 1994, J BIOL CHEM, V269, P31157; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang DP, 1996, J LIPID RES, V37, P1831; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	42	30	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25963	25969		10.1074/jbc.M200824200	http://dx.doi.org/10.1074/jbc.M200824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004058	hybrid			2022-12-25	WOS:000176908700020
J	Endo, H; Takenaga, K; Kanno, T; Satoh, H; Mori, S				Endo, H; Takenaga, K; Kanno, T; Satoh, H; Mori, S			Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S10OA4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; ANGIOGENESIS INHIBITOR TNP-470; 67-KDA POLYPEPTIDE P67; ENDOTHELIAL-CELLS; S100 PROTEINS; PEL98 PROTEIN; E-CADHERIN; IN-VITRO; GENE; EXPRESSION	S100A4 is an EF-hand type calcium-binding protein that regulates tumor metastasis and a variety of cellular processes via interaction with different target proteins. Here we report that S100A4 physically interacts with methionine aminopeptidase 2 (MetAP2), the primary target for potent angiogenesis inhibitors, fumagillin and ovalicin. Using a yeast two-hybrid screen, S100A4 was found to interact with the N-terminal half of MetAP2. In vitro pull-down assays showed that S100A4 associates with MetAP2 in a calcium-dependent manner. In addition, the binding site of S100A4 was found located within the region between amino acid residues 170 and 229 of MetAP2. In vivo interaction of S100A4 with MetAP2 was verified by co-immunoprecipitation analysis. Immunofluorescent staining revealed that S100A4 and MetAP2 were co-localized in both quiescent and basic fibroblast growth factor-treated murine endothelial MSS31 cells, in the latter of which a significant change of intracellular distribution of both proteins was observed. Although the binding of S100A4 did not affect the in vitro methionine aminopeptidase activity of MetAP2, the cytochemical observation suggests a possible involvement of S100A4 in the regulation of MetAP2 activity through changing its localization, thereby modulating the N-terminal methionine processing of nascent substrates. These results may offer an essential clue for understanding the functional role of S100A4 in regulating endothelial cell growth and tumor metastasis.	Univ Tokyo, Div Pathol, Dept Canc Biol, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Chaba Canc Ctr Res Inst, Div Chemotherapy, Chuoh Ku, Chiba 2608717, Japan	University of Tokyo	Endo, H (corresponding author), Univ Tokyo, Div Pathol, Dept Canc Biol, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	endoh@ims.u-tokyo.ac.jp						ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bjornland K, 1999, CANCER RES, V59, P4702; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COX JV, 1983, CELL, V35, P331, DOI 10.1016/0092-8674(83)90236-2; Cutforth T, 1999, MECH DEVELOP, V82, P23, DOI 10.1016/S0925-4773(99)00006-4; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Datta B, 1999, EXP CELL RES, V250, P223, DOI 10.1006/excr.1999.4508; DATTA B, 1989, J BIOL CHEM, V264, P20620; DAVIES BR, 1993, ONCOGENE, V8, P999; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; Keirsebilck A, 1998, CANCER RES, V58, P4587; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; PARKER C, 1994, DNA CELL BIOL, V13, P1021, DOI 10.1089/dna.1994.13.1021; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; Rudland PS, 2000, CANCER RES, V60, P1595; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tanaka K, 1999, JPN J CANCER RES, V90, P647, DOI 10.1111/j.1349-7006.1999.tb00796.x; Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074-5521(99)80129-X; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; YANASE T, 1993, CANCER RES, V53, P2566; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	48	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26396	26402		10.1074/jbc.M202244200	http://dx.doi.org/10.1074/jbc.M202244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994292	hybrid			2022-12-25	WOS:000176908700076
J	Grimm, M; Spiecker, M; De Caterina, R; Shin, WS; Liao, JK				Grimm, M; Spiecker, M; De Caterina, R; Shin, WS; Liao, JK			Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; DNA-BINDING ACTIVITY; SMOOTH-MUSCLE CELLS; DR-ALPHA GENE; KAPPA-B-ALPHA; OXIDATIVE STRESS; CCAAT-BINDING; NF-Y; PROINFLAMMATORY CYTOKINES; SALMONELLA-TYPHIMURIUM	Interferon (IFN)-gamma facilitates cellular immune response, in part, by inducing the expression of major histocompatibility complex class II (MHC-II) molecules. We demonstrate that IFN-gamma induces the expression of HLA-DRA in vascular endothelial cells via mechanisms involving reactive oxygen species. IFN-gamma-induced HLA-DRA expression was inhibited by nitric oxide (NO) and antioxidants such as superoxide dismutase, catalase, pyrrolidine dithiocarbamate, and N-acetylcysteine. Nuclear run-on assays demonstrated that NO and antioxidants inhibited IFN-gamma-induced HLA-DRA gene transcription. Transient transfection studies using a fully functional HLA-DRA promoter construct ([-300]DRalpha.CAT) showed that inhibition of endogenous NO synthase activity by N-omega-monomethyl-L-arginine or addition of exogenous hydrogen peroxide (11202) augmented basal and IFN-gamma-stimulated [-300]DRalpha.CAT activity. However, H2O2 and N-omega-monomethyl-L-arginine could introduce HLA-DRA expression suggesting that H2O2 is a necessary but not a sufficient mediator of IFN-gamma-induced HLA-DRA expression. Electrophoretic mobility shift assay and Western blotting demonstrated that NO and antioxidants had little or no effect on IFN-gamma-induced IRF-1 activation or MHC-II transactivator (CIITA) expression but did inhibit IFN-gamma-induced activation of STAT1alpha (p91) and Y box transcription factors, NF-Y-A and NF-Y-B. These results indicate that NO and antioxidants may attenuate vascular inflammation by antagonizing the effects of intracellular reactive oxygen species generation by IFN-gamma, which is necessary for MHC-II gene transcription.	Brigham & Womens Hosp, Vasc Med Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, Vasc Med Unit, 221 Longwood Ave,LMRC-322, Boston, MA 02115 USA.		De Caterina, Raffaele/K-3857-2016	De Caterina, Raffaele/0000-0003-1637-574X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233, HL-48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DE CR, 1995, J CLIN INVEST, V96, P60; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GROENEWEGEN G, 1985, NATURE, V316, P361, DOI 10.1038/316361a0; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; Hobart M, 1997, J IMMUNOL, V158, P4260; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; Kielar ML, 2000, INFLAMMATION, V24, P431, DOI 10.1023/A:1007012128392; Labarrere CA, 1997, JAMA-J AM MED ASSOC, V278, P1169, DOI 10.1001/jama.278.14.1169; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LIBBY P, 1994, CLIN TRANSPLANT, V8, P313; Llovera M, 2001, BRIT J PHARMACOL, V132, P419, DOI 10.1038/sj.bjp.0703838; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MARAI N, 1993, J CLIN INVEST, V92, P1866; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PERSSON MG, 1990, BRIT J PHARMACOL, V100, P463, DOI 10.1111/j.1476-5381.1990.tb15829.x; POBER JS, 1983, NATURE, V305, P726, DOI 10.1038/305726a0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; VANDERWAL AC, 1992, AM J PATHOL, V141, P1427; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; Zhang JL, 1997, RES COMMUN MOL PATH, V96, P71	56	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26460	26467		10.1074/jbc.M110538200	http://dx.doi.org/10.1074/jbc.M110538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006557	hybrid			2022-12-25	WOS:000176908700084
J	Haan, GJ; Faber, KN; Baerends, RJS; Koek, A; Krikken, A; Kiel, JAKW; van der Klei, IJ; Veenhuis, M				Haan, GJ; Faber, KN; Baerends, RJS; Koek, A; Krikken, A; Kiel, JAKW; van der Klei, IJ; Veenhuis, M			Hansenula polymorpha Pex3p is a peripheral component of the peroxisomal membrane.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOCKING COMPLEX; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; MONOCLONAL-ANTIBODIES; CANDIDA-BOIDINII; MATRIX PROTEIN; GENE ENCODES; BIOGENESIS; YEAST; IMPORT	Hansenula polymorpha Pex3p plays an essential role in the biogenesis and maintenance of the peroxisomal membrane. In the initial report, bakers' yeast Pex3p was suggested to represent an integral component of the peroxisomal membrane, containing one membrane-spanning region that exposes the N terminus of the protein into the organellar matrix. Biochemically, HpPex3p behaved like an integral membrane protein as it was resistant toward high salt and carbonate treatment. However, urea fully removed Pex3p from the membrane under conditions in which the integral membrane protein Pex10p was resistant to this treatment. Additional experiments, including protease protection assays and pre-embedding labeling experiments on purified organellar fractions from cells that produced Pex3ps carrying Myc epitopes at various selected locations in the protein, revealed that invariably all Myc tags were accessible for externally added proteases and antibodies, independent of the presence of detergents. Also, overproduction of Pex3p failed to demonstrate the typical integral membrane protein structures in fracture faces of freeze-fractured peroxisomes. Taken together, our data suggest that HpPex3p does not span the peroxisomal membrane but instead is tightly associated to the cytosolic face of the organelle where it may be present in focal protein clusters.	Univ Groningen, Groningen Biomol Sci & Biotech Inst, NL-9750 AA Haren, Netherlands	University of Groningen	Veenhuis, M (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotech Inst, POB 14, NL-9750 AA Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679; krikken, arjen/0000-0002-6684-6303				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Baerends RJS, 1997, YEAST, V13, P1437; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Faber KN, 2001, J BIOL CHEM, V276, P36501, DOI 10.1074/jbc.M105828200; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; GOODMAN JM, 1986, J BIOL CHEM, V261, P3464; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Kiel JAKW, 1995, FEBS LETT, V377, P434, DOI 10.1016/0014-5793(95)01385-7; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lolkema JS, 1998, FEMS MICROBIOL REV, V22, P305, DOI 10.1016/S0168-6445(98)00018-7; MERKELBACH A, 1993, APPL MICROBIOL BIOT, V40, P361; MOOR H, 1964, Z ZELLFORSCH MIKROSK, V63, P546; Sambrook J., 2002, MOL CLONING LAB MANU; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; SULTER GJ, 1993, FEBS LETT, V315, P211, DOI 10.1016/0014-5793(93)81166-W; SULTER GJ, 1990, YEAST, V6, P35, DOI 10.1002/yea.320060104; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Titorenko VI, 2001, TRENDS CELL BIOL, V11, P22, DOI 10.1016/S0962-8924(00)01865-1; van der Klei IJ, 1997, TRENDS MICROBIOL, V5, P502, DOI 10.1016/S0966-842X(97)01156-6; van der Klei IJ, 1998, CURR GENET, V34, P1, DOI 10.1007/s002940050360; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Veenhuis M, 2000, MICROSC RES TECHNIQ, V51, P584, DOI 10.1002/1097-0029(20001215)51:6<584::AID-JEMT8>3.0.CO;2-W; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Will GK, 1999, MOL CELL BIOL, V19, P2265	47	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26609	26617		10.1074/jbc.M108569200	http://dx.doi.org/10.1074/jbc.M108569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011037	hybrid			2022-12-25	WOS:000176908700102
J	Malhotra, JD; Koopmann, MC; Kazen-Gillespie, KA; Fettman, N; Hortsch, M; Isom, LL				Malhotra, JD; Koopmann, MC; Kazen-Gillespie, KA; Fettman, N; Hortsch, M; Isom, LL			Structural requirements for interaction of sodium channel beta 1 subunits with ankyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; FEBRILE SEIZURES PLUS; NA+-CHANNEL; CYTOPLASMIC DOMAIN; GENERALIZED EPILEPSY; MESSENGER-RNA; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; ALPHA-SUBUNITS; TENASCIN-R	Sodium channel beta subunits modulate channel kinetic properties and cell surface expression levels and function as cell adhesion molecules. beta1 and beta2 participate in homophilic cell adhesion resulting in ankyrin recruitment to cell contact sites. We hypothesized that a tyrosine residue in the cytoplasmic domain of beta1 may be important for ankyrin recruitment and tested our hypothesis using beta1 mutants replacing Tyr(181) with alanine (beta1Y181A), phenylalanine (beta1Y181F), or glutamate (beta1Y181E), or a truncated construct deleting all residues beyond Tyr(181) (beta1L182(STOP)). Ankyrin recruitment was observed in beta1L182(STOP), showing that residues Ile(166)-Tyr(181) contain the major ankyrin recruiting activity of beta1. Ankyrin recruitment was abolished in beta1Y181E, suggesting that tyrosine phosphorylation of beta1 may inhibit beta1-ankyrin interactions. Ankyrin(G) and beta1 associate in rat brain membranes and in transfected cells expressing beta1 and ankyrin(G) in the absence of sodium channel alpha subunits. beta1 subunits are recognized by anti-phosphotyrosine antibodies following treatment of these cell lines with fibroblast growth factor. beta1 and ankryin(G) association is not detectable in cells following treatment with fibroblast growth factor. Ankyrin(G) and beta1Y181E do not associate even in the absence of fibroblast growth factor treatment. beta1 subunit-mediated cell adhesion and ankyrin recruitment may contribute to sodium channel placement at nodes of Ranvier. The phosphorylation state of beta1Y181 may be a critical regulatory step in these developmental processes.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1150 W Med Dr,1301 MSRB 3, Ann Arbor, MI 48109 USA.			Hortsch, Michael/0000-0002-3750-737X; Isom, Lori/0000-0002-9479-6729	NICHD NIH HHS [R01HD29388] Funding Source: Medline; NIMH NIH HHS [R01MH59980] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; BIEBER AJ, 1994, METHOD CELL BIOL, V44, P683, DOI 10.1016/S0091-679X(08)60938-3; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DibHajj SD, 1996, FEBS LETT, V384, P78, DOI 10.1016/0014-5793(96)00273-6; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; Escayg A, 2001, AM J HUM GENET, V68, P866, DOI 10.1086/319524; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; JOE EH, 1993, J NEUROSCI, V13, P2993; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; Lustig M, 2001, CURR BIOL, V11, P1864, DOI 10.1016/S0960-9822(01)00586-3; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 1998, J BIOL CHEM, V273, P33354, DOI 10.1074/jbc.273.50.33354; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Needham LK, 2001, J NEUROSCI, V21, P1490, DOI 10.1523/JNEUROSCI.21-05-01490.2001; Oh Y, 1997, NEUROSCI LETT, V234, P107, DOI 10.1016/S0304-3940(97)00694-0; OH YS, 1994, P NATL ACAD SCI USA, V91, P9985, DOI 10.1073/pnas.91.21.9985; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; Wallace RH, 2001, AM J HUM GENET, V68, P859, DOI 10.1086/319516; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; Wong EV, 1995, NEUROSCI LETT, V200, P155, DOI 10.1016/0304-3940(95)12100-I; WONG MH, 1994, J CELL BIOL, V126, P1089, DOI 10.1083/jcb.126.4.1089; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	40	119	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26681	26688		10.1074/jbc.M202354200	http://dx.doi.org/10.1074/jbc.M202354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11997395	hybrid			2022-12-25	WOS:000176908700110
J	Wang, HX; Hays, JB				Wang, HX; Hays, JB			Mismatch repair in human nuclear extracts - Time courses and ATP requirements for kinetically distinguishable steps leading to tightly controlled 5 ' to 3 ' and aphidicolin-sensitive 3 ' to 5 ' mispair-provoked excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; SACCHAROMYCES-CEREVISIAE; HMUTS-ALPHA; TRANSLOCATION MECHANISM; MOLECULAR SWITCH; YEAST MSH2-MSH6; SLIDING CLAMP; IN-VITRO; COMPLEX; HETERODUPLEX	Mismatch repair (MMR) systems enhance genomic stability by correcting DNA replication errors. The events in mammalian MMR pathways remain poorly understood. Using HeLa cell nuclear extracts, we analyzed correction of mispairs in circular DNA substrates with single defined nicks and measured excision in the absence of exogenous dNTPs by annealing specific oligonucleotide probes. In reactions initiated by concomitant temperature shift and addition of ATP or Mg2+ to otherwise complete mixtures on ice, ATP-initiated excision and final error correction lagged behind Mg2+-initiated reactions, suggesting a very early requirement for ATP but not its hydrolysis. Subsequent stable commitment (resistance to added excess competitor substrate) began within 30 s, required hydrolyzable ATP, and plateaued after 60-70 s. This may reflect formation of hydrolysis-dependent translocating and/or pre-excision complexes. Excision along shorter nick-mispair paths began 15 s later than commitment. Both 3' to 5' and 5' to 3' excision gaps appeared at rates of similar to0.0055 of final yields per second, respectively, 30 or 2.5 times the nonspecific excision rates. The lag between 3' to 5' excision gaps at two different positions yielded an excision progress rate of 5.2 nucleotides/s. In both substrates, corrected products appeared at fractional rates of 0.0027 of final yield per second. Aphidicolin, known to inhibit both the DNA synthesis and 3' to 5' exonuclease activities of polymerases a and E, reduced appearance of 3' to 5' excision tracts roughly 4-fold at 90 mum but had no effect on 5' to 3' excision.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, ALS 1007, Corvallis, OR 97331 USA.							Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FANG WH, 1993, J BIOL CHEM, V268, P11838; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 2002, J BIOL CHEM, V277, P3673, DOI 10.1074/jbc.M106120200; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Wang HX, 2000, MOL BIOTECHNOL, V15, P97, DOI 10.1385/MB:15:2:97; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200	34	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26143	26148		10.1074/jbc.M200358200	http://dx.doi.org/10.1074/jbc.M200358200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006561	hybrid			2022-12-25	WOS:000176908700042
J	Cervoni, N; Detich, N; Seo, SB; Chakravarti, D; Szyf, M				Cervoni, N; Detich, N; Seo, SB; Chakravarti, D; Szyf, M			The oncoprotein Set/TAF-1 beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; ACETYLATION; NEUROSPORA	Histone hypoacetylation and DNA hypermethylation are hallmarks of gene silencing. Although a role for DNA methylation in regulating histone acetylation has been established, it is not clear how and whether epigenetic histone markings influence DNA modifications in transcriptional silencing. We have previously shown that induction of histone acetylation by trichostatin A promotes demethylation of ectopically methylated DNA (Cervoni, N., and Szyf, M. (2001) J. Biol. Chem. 276, 40778-40787). The oncoprotein Set/TAF-Ibeta is a subunit of the recently identified inhibitor of acetyltransferases complex that inhibits histone acetylation by binding to and masking histone acetyltransferase targets (Seo, S. B., McNamara, P., Heo, S., Turner, A., Lane, W. S., and Chakravarti, D. (2001) Cell 104, 119-130). We show here that the overexpression of Set/TAF-Ibeta, whose expression is up-regulated in multiple tumor tissues, inhibits demethylation of ectopically methylated DNA resulting in gene silencing. Overexpression of a mutant Set/TAF-Ibeta that does not inhibit histone acetylation is defective in inhibiting DNA demethylation. Taken together, these results are consistent with a novel regulatory role for Set/TAF-Ibeta, integrating epigenetic states of histones and DNA in gene regulation and provide a new mechanism that can explain how hypermethylation of specific regions might come about by inhibition of demethylation in cancer cells.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	McGill University; University of Pennsylvania	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.			Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK57079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RAZIN A, 1977, P NATL ACAD SCI USA, V74, P2725, DOI 10.1073/pnas.74.7.2725; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; SZYF M, 1985, J BIOL CHEM, V260, P8653; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508	17	146	160	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25026	25031		10.1074/jbc.M202256200	http://dx.doi.org/10.1074/jbc.M202256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978794	hybrid			2022-12-25	WOS:000176747000026
J	Foster, JD; Pananusorn, B; Vaughan, RA				Foster, JD; Pananusorn, B; Vaughan, RA			Dopamine transporters are phosphorylated on N-terminal serines in rat striatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VESICULAR ACETYLCHOLINE TRANSPORTER; LIGAND-BINDING DOMAINS; SEROTONIN TRANSPORTERS; FUNCTIONAL REGULATION; SYNTAXIN 1A; SUBCELLULAR REDISTRIBUTION; GABA TRANSPORTER; XENOPUS-OOCYTES; PHORBOL ESTERS	Dopamine transporters (DATs) are neuronal phospho-proteins that clear dopamine from the synaptic cleft. Activation of protein kinase C (PKC) and inhibition of protein phosphatases by okadaic acid (OA) increase phosphorylation of DAT and lead to concomitant reduction in DAT activity and cell surface expression. Numerous potential sites for phosphorylation are present on DAT, but the sites utilized and their relationship to transport regulation are currently unknown. We used peptide mapping and epitope-specific immunoprecipitation to identify the region of DAT that undergoes phosphorylation in rat striatal tissue. Phosphoamino acid analysis revealed that basal and stimulated samples were phosphorylated primarily on serine. Digestion of (PO4)-P-32-labeled DAT with trypsin and immunoprecipitation with N- or C-terminal specific antisera failed to isolate phosphopeptide fragments corresponding to photoaffinity-labeled fragments that contain all internal interhelical loops. However, digestion of (PO4)-P-32-labeled DAT with endoproteinase asp-N and immunoprecipitation with an N-terminal antiserum extracted two phosphopeptide fragments from both basal and PKC/OA-stimulated samples, demonstrating that the N-terminal cytoplasmic tail is a major site of phosphorylation. Aminopeptidase treatment of PKC- and/or OA-stimulated DAT cleaved essentially all (PO4)-P-32 label without proteolysis extending past transmembrane domains 1 and 2, providing further evidence that most phosphorylation sites are near the N terminus and not in intracellular loops or C-terminal domains. In situ proteolysis of the N-terminal tail indicates that the majority of stimulated phosphorylation sites are N-terminal to an antibody epitope at residues 42-59. Two-dimensional analysis of purified protein produced three tryptic phosphopeptides that may result from phosphorylation of multiple sites, but the fragments did not co-migrate with synthetic tryptic peptides phosphorylated at serines 2 and 4. These results indicate that most or all of the basal and stimulated phosphorylation of DAT in striatal tissue occurs on one or more residues in a group of six serines clustered near the distal end of the cytoplasmic N terminus.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA	University of North Dakota Grand Forks	Vaughan, RA (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 501 N Columbia Rd, Grand Forks, ND 58203 USA.	rvaughan@medicine.nodak.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013147] Funding Source: NIH RePORTER; NIDA NIH HHS [DA13147] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beckman ML, 1998, J NEUROSCI, V18, P6103; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Cho GW, 2000, J BIOL CHEM, V275, P19942, DOI 10.1074/jbc.M902174199; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FONTANA A, 1986, PRACTICAL PROTEIN CH, P68; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Huff RA, 1997, J NEUROCHEM, V68, P225; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Melikian HE, 1999, J NEUROSCI, V19, P7699; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; SATO K, 1995, J NEUROCHEM, V65, P1967; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuldiner S, 1997, J EXP BIOL, V200, P335; Simon JR, 1997, NEUROSCI LETT, V224, P201, DOI 10.1016/S0304-3940(97)13479-6; Thompson AC, 2000, J NEUROSCI, V20, P9333; Vaughan RA, 1996, J BIOL CHEM, V271, P21672, DOI 10.1074/jbc.271.35.21672; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; Vaughan RA, 2000, CONT NEUROS, P375; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; VAUGHAN RA, 2001, SOC NEUR ABSTR, V27, P1865	40	115	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25178	25186		10.1074/jbc.M200294200	http://dx.doi.org/10.1074/jbc.M200294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994276	hybrid			2022-12-25	WOS:000176747000044
J	Mertens, PR; Steinmann, K; Alfonso-Jaume, MA; En-Nia, A; Sun, Y; Lovett, DH				Mertens, PR; Steinmann, K; Alfonso-Jaume, MA; En-Nia, A; Sun, Y; Lovett, DH			Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE 2; AP-2 TRANSCRIPTION FACTORS; IV COLLAGENASE MMP-2; GROWTH; GENE; TRANSACTIVATION; PROGELATINASE; RADIOTHERAPY; ANGIOGENESIS; INHIBITOR	Gelatinase A, also denoted matrix metalloproteinase 2, plays multiple critical roles in the neoplastic process, including facilitation of neoangiogenesis and formation of distal metastases. The transcriptional regulation of the gelatinase A gene is under the control of strong, evolutionarily conserved cis-acting enhancer elements, designated the r2 (human) or RE-1 (rat), that harbor contiguous binding motifs for the transcription factors activating protein-2 (AP2), p53, and YB-1. Using recombinant transcription factors, complex patterns of RE-1 binding were observed by electrophoretic mobility shift assay. Increased complex formation was detected with the AP2/YB-1 and AP2/p53 combinations, while YB-1 competed with p53 for binding. The combination of AP2, p53, and YB-1 yielded novel ternary complexes, particularly when binding to single-stranded RE-1 probes. Transient transfection of hepatocellular carcinoma cell lines with a series of gelatinase A luciferase reporter constructs were in accordance with the binding patterns determined by electrophoretic mobility shift assay. Combined AP2 and p53 increased gelatinase A luciferase reporter activity significantly, and the inclusion of YB-1 yielded further increase in both reporter activity and secreted levels of gelatinase A protein. YB-1 and p53 expression are increased following multiple genotoxic stresses, including irradiation, and the synergistic interactions of these induced transcription factors with the widely expressed AP2 protein provide a probable pathophysiologic mechanism for the enhanced tumor cell synthesis of gelatinase A induced by radiation.	Rhein Westfal TH Aachen, Dept Nephrol & Immunol, Med Clin 2, D-52057 Aachen, Germany; Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94143 USA; Pfizer Global Res & Dev, Canc Mol Sci, Ann Arbor, MI 48105 USA	RWTH Aachen University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer	Mertens, PR (corresponding author), Rhein Westfal TH Aachen, Dept Nephrol & Immunol, Med Clin 2, Pauwelsstr 30, D-52057 Aachen, Germany.	Pmertens@ukaachen.de	Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araya J, 2001, AM J PHYSIOL-LUNG C, V280, pL30, DOI 10.1152/ajplung.2001.280.1.L30; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Benyon RC, 2000, GUT, V46, P443, DOI 10.1136/gut.46.4.443; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Boulikas T, 1996, ANTICANCER RES, V16, P225; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Furuya M, 2001, HUM PATHOL, V32, P163, DOI 10.1053/hupa.2001.21558; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRIGIONI WF, 1994, DIAGN MOL PATHOL, V3, P163, DOI 10.1097/00019606-199409000-00005; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Itoh T, 1998, CANCER RES, V58, P1048; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Kossakowska AE, 1999, ANN NY ACAD SCI, V878, P578, DOI 10.1111/j.1749-6632.1999.tb07732.x; Kumar A, 2000, BRIT J CANCER, V82, P960, DOI 10.1054/bjoc.1999.1025; LOVETT DH, 1992, AM J PATHOL, V141, P85; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Menke AL, 1997, CANCER RES, V57, P1353; Mertens PR, 1998, HYPERTENSION, V32, P945, DOI 10.1161/01.HYP.32.5.945; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; POULSOM R, 1992, AM J PATHOL, V141, P389; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Sun Y, 1999, MOL CARCINOGEN, V24, P25, DOI 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.3.CO;2-J; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Turck J, 1997, KIDNEY INT, V51, P1397, DOI 10.1038/ki.1997.191; Turner BC, 1998, CANCER RES, V58, P5466; Wang JL, 2000, MOL CARCINOGEN, V27, P252, DOI 10.1002/(SICI)1098-2744(200004)27:4<252::AID-MC2>3.0.CO;2-3; Wild-Bode C, 2001, CANCER RES, V61, P2744; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; Zahner G, 1997, KIDNEY INT, V51, P1116, DOI 10.1038/ki.1997.154	52	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24875	24882		10.1074/jbc.M200445200	http://dx.doi.org/10.1074/jbc.M200445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11973333	hybrid			2022-12-25	WOS:000176747000008
J	Tseng, Y; Schafer, BW; Almo, SC; Wirtz, D				Tseng, Y; Schafer, BW; Almo, SC; Wirtz, D			Functional synergy of actin filament cross-linking proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTININ; MECHANICAL-PROPERTIES; DROSOPHILA BRISTLES; BUNDLING PROTEIN; CELLS LACKING; IN-VIVO; NETWORKS; FASCIN; BINDING; TROPOMYOSIN	The organization of filamentous actin (F-actin) in resilient networks is coordinated by various F-actin cross-linking proteins. The relative tolerance of cells to null mutations of genes that code for a single actin cross-linking protein suggests that the functions of those proteins are highly redundant. This apparent functional redundancy may, however, reflect the limited resolution of available assays in assessing the mechanical role of F-actin cross-linking/bundling proteins. Using reconstituted F-actin networks and rheological methods, we demonstrate how a-actinin and fascin, two F-actin cross-linking/bundling proteins that co-localize along stress fibers and in lamellipodia, could synergistically enhance the resilience of F-actin networks in vitro. These two proteins can generate microfilament arrays that "yield" at a strain amplitude that is much larger than each one of the proteins separately. F-actin/alpha-actinin/fascin networks display strain-induced hardening, whereby the network "stiffens" under shear deformations, a phenomenon that is non-existent in F-actin/fascin networks and much weaker in F-actin/alpha-actinin networks. Strain-hardening is further enhanced at high rates of deformation and high concentrations of actin cross-linking proteins. A simplified model suggests that the optimum results of the competition between the increased stiffness of bundles and their decreased density of cross-links. Our studies support a re-evaluation of the notion of functional redundancy among cytoskeletal regulatory proteins.	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Grad Program Mol Biophys, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Civil Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; Yeshiva Univ, Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, 3400 N Charles St, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010; Schafer, Benjamin/C-9104-2009		NIAID NIH HHS [AI44417] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JC, 1995, J CELL SCI, V108, P1977; ALMO S, 1994, ANN REV CELL BIOL, V10, P207; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CRISFIELD MA, 1998, NONLINEAR FINITE ELE; Critchley David R., 1993, P22; Gere J M, 2001, MECH MAT; GRAZI E, 1994, BIOCHEM J, V298, P129, DOI 10.1042/bj2980129; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; Rivero F, 1996, J CELL BIOL, V135, P965, DOI 10.1083/jcb.135.4.965; Rivero F, 1996, J CELL SCI, V109, P2679; Tilney LG, 2000, J CELL BIOL, V148, P87, DOI 10.1083/jcb.148.1.87; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; Tilney LG, 1996, J CELL BIOL, V135, P1291, DOI 10.1083/jcb.135.5.1291; Tseng Y, 2002, J BIOL CHEM, V277, P18143, DOI 10.1074/jbc.M110868200; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993	33	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25609	25616		10.1074/jbc.M202609200	http://dx.doi.org/10.1074/jbc.M202609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006593	hybrid			2022-12-25	WOS:000176747000099
J	Wu, M; Xu, LG; Li, XY; Zhai, ZH; Shu, HB				Wu, M; Xu, LG; Li, XY; Zhai, ZH; Shu, HB			AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PATHWAYS; ACTIVATION; FADD; IDENTIFICATION; LETHALITY; NECROSIS; CASPER; APAF1; BRAIN	Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein that triggers caspase-independent apoptosis. We describe here the cloning and characterization of a novel AIF-homologous molecule designated AMID (AIF-homologous mitochondrion-associated inducer of death). AMID lacks a mitochondrial localization sequence but shares significant homology with AIF and NADH oxidoreductases from bacteria to mammalian species. Immunofluoreseent staining and biochemical experiments indicated that AMID was co-localized with mitochondria. Overexpression of AMID induced cell death with characteristic apoptotic morphology. Furthermore, AMID-induced apoptosis was independent of caspase activation and p53 and was not inhibited by Bcl-2. These findings suggest that AMID induces a novel caspase-independent apoptotic pathway.	Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Univ Colorado, Ctr Canc, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University; University of Colorado System; University of Colorado Denver	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, K516C,1400 Jackson St, Denver, CO 80206 USA.		Wu, Min/AAE-5066-2021	Wu, Min/0000-0003-1372-4764; Xu, Liangguo/0000-0003-1991-2889				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; LIU X, 1996, CELL, V12, P147; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sambrook J., 2002, MOL CLONING LAB MANU; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	31	143	154	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25617	25623		10.1074/jbc.M202285200	http://dx.doi.org/10.1074/jbc.M202285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980907	hybrid			2022-12-25	WOS:000176747000100
J	Ribbe, MW; Hu, YL; Guo, ML; Schmid, B; Burgess, BK				Ribbe, MW; Hu, YL; Guo, ML; Schmid, B; Burgess, BK			The FeMoco-deficient MoFe protein produced by a nifH deletion strain of Azotobacter vinelandii shows unusual P-cluster features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; ELECTRON-PARAMAGNETIC-RESONANCE; FERROUS FE4S4 CLUSTER; FE-PROTEIN; KLEBSIELLA-PNEUMONIAE; ADENOSINE 5'-TRIPHOSPHATE; DINITROGENASE REDUCTASE; NITROGENASE CATALYSIS; BIOSYNTHESIS; EPR	The His-tag MoFe protein expressed by the nifH deletion strain Azotobacter vinelandii DJ1165 (DeltanifH MoFe protein) was purified in large quantity. The alpha(2)beta(2) tetrameric (DeltanifH MoFe protein is FeMoco-deficient based on metal analysis and the absence of the S = 3/2 EPR signal, which arises from the FeMo cofactor center in wild-type MoFe protein. The DeltanifH MoFe protein contains 18.6 mol Fe/mol and, upon reduction with dithionite, exhibits an unusually strong S = 1/2 EPR signal in the g approximate to 2 region. The indigo disulfonate-oxidized DeltanifH MoFe protein does not show features of the P2+ state of the P-cluster of the DeltanifH MoFe protein. The oxidized AnitH MoFe protein is able to form a specific complex with the Fe protein containing the [4Fe-4S](1+) cluster and facilitates the hydrolysis of MgATP within this complex. However, it is not able to accept electrons from the [4Fe-4S](1+) cluster of the Fe protein. Furthermore, the dithionite-reduced DeltanifH MoFe can be further reduced by WHU citrate, which is quite unexpected. These unusual catalytic and spectroscopic properties might indicate the presence of a P-cluster precursor or a P-cluster trapped in an unusual conformation or oxidation state.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; California Institute of Technology	Ribbe, MW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	markus@nitrolab.bio.uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; CHEN L, 1994, J BIOL CHEM, V269, P3290; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Erickson JA, 1999, BIOCHEMISTRY-US, V38, P14279, DOI 10.1021/bi991389+; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FISKE CH, 1952, J BIOL CHEM, V66, P325; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V223, P783, DOI 10.1042/bj2230783; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER T R, 1988, Biofactors, V1, P199; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; Musgrave KB, 1998, J BIOL INORG CHEM, V3, P344, DOI 10.1007/s007750050243; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Ribbe MW, 2001, P NATL ACAD SCI USA, V98, P5521, DOI 10.1073/pnas.101119498; Ribbe MW, 2000, J BIOL CHEM, V275, P17631, DOI 10.1074/jbc.275.23.17631; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1997, BIOL NITROGEN FIXATI, P51; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TAL S, 1991, J BIOL CHEM, V266, P10654; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WHITE TC, 1992, J BIOL CHEM, V267, P24007; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x	62	57	58	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23469	23476		10.1074/jbc.M202061200	http://dx.doi.org/10.1074/jbc.M202061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11978793	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000176475700050
J	Coll, ML; Rosen, K; Ladeda, V; Filmus, J				Coll, ML; Rosen, K; Ladeda, V; Filmus, J			Increased Bcl-x(L) expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells	ONCOGENE			English	Article						Bcl-x(L); v-Src; anoikis; intestinal epithelial cells	ADVANCED COLORECTAL CANCERS; BCL-X; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; DOWN-REGULATION; ACTIVATED RAS; MAP KINASE; TRANSFORMATION; GROWTH; PP60(C-SRC)	Acquisition of resistance to anoikis (detachment-induced apoptosis) is considered to be a requirement for transformed intestinal epithelial cells to invade surrounding tissues and metastasize to distant organs. Increased Src kinase activity, which is a feature of a large proportion of colorectal cancers, has been identified as one of the factors that can contribute to anoikis resistance. However, the molecular mechanism by which high levels of Src activity contribute to anoikis resistance in intestinal epithelial cells is unknown. Here we show that high Src activity confers resistance to anoikis in intestinal epithelial cells, at least in part, by inducing Bcl-x(L) overexpression, and that this induction is mediated by the MEK/MAPK pathway. Based on the findings reported here. and on our previous study showing that Bcl-x(L), plays a critical role in ras-induced resistance to anoikis, we propose that the increased Bel-x(L) levels found in colorectal cancers play a significant role in the induction of resistance to anoikis during the progression of this disease.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	filmus@sten.sunnybrook.utoronto.ca		Loza Coll, Mariano/0000-0002-3123-1229; Rosen, Kirill/0000-0002-4317-9907				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Daigo Y, 1999, CANCER RES, V59, P4222; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Han NM, 1996, CLIN CANCER RES, V2, P1397; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JAMAL HH, 1994, ONCOGENE, V9, P417; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Krajewska M, 1996, CANCER RES, V56, P2422; Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pories SE, 1998, GASTROENTEROLOGY, V114, P1287, DOI 10.1016/S0016-5085(98)70435-4; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200	41	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2908	2913		10.1038/sj.onc.1205388	http://dx.doi.org/10.1038/sj.onc.1205388			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973652				2022-12-25	WOS:000175063700017
J	Kim, B; Feldman, EL				Kim, B; Feldman, EL			Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED CLEAVAGE; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL REGULATION; RECEPTOR ACTIVATION; INDUCED APOPTOSIS; LIGAND OCCUPANCY; INTEGRIN; OVEREXPRESSION; PROTEINS	In our laboratory, we are interested in hyperosmolarity-induced apoptosis in neuronal cells. We have shown that high concentrations of glucose or mannitol induce apoptotic cell death in dorsal root ganglia in culture and in SH-SH5Y and SH-EP human neuroblastoma cells. Focal adhesion kinase (FAR) is a cytoplasmic tyrosine kinase that has a critical role for transmitting integrin-mediated-signals. In this study, we report that hyperosmolar treatment mediates FAK dephosphorylation and cleavage, which is prevented by insulin-like growth factor I (IGF-I) treatment. Mannitol treatment of SH-EP cells transfected with vector (SH-EP/pSFFV) results in concentration- and time-dependent dephosphorylation and degradation of FAK. Dephosphorylation and degradation of FAK are tightly correlated with apoptotic morphological changes, including the disruption of actin stress fibers, the loss of focal adhesion sites, membrane blebbing, and cell detachment. Treatment of SH-EP/pSFFV cells with IGF-I or transfection of IGF-I receptor prevents these changes. Treatment of cells with pharmacologic inhibitors of the mitogen-activated protein kinase or phosphatidylinositol 3-kinase pathways does not affect mannitol-induced FAK dephosphorylation and degradation. However, phosphatidylinositol 3-kinase is necessary for IGF-I-mediated protection against FAK alteration. Mannitol treatment also results in the degradation of Akt. Mannitol induces the activation of caspases-3 and -9 in a time course similar to the dephosphorylation and degradation of FAK. Treatment of the cells with ZVAD, a general caspase inhibitor, blocks the mannitol-induced FAK and Akt degradation as well as cell detachment and apoptosis. These results suggest that one of the pathways of mannitol-mediated apoptosis is through the degradation of FAK and Akt and that IGF-I protects the cells from apoptosis by blocking the activation of caspases, which may be responsible for the loss of FAK and Akt.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge 3,200 Zina Pitcher Pl, Ann Arbor, MI 48104 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 38849] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delaney CL, 1999, J NEUROBIOL, V41, P540, DOI 10.1002/(SICI)1097-4695(199912)41:4<540::AID-NEU9>3.0.CO;2-P; Delaney CL, 2001, J NEUROPATH EXP NEUR, V60, P147, DOI 10.1093/jnen/60.2.147; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; Francois F, 1999, J NEUROCHEM, V73, P1773, DOI 10.1046/j.1471-4159.1999.731773.x; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Kook S, 2000, CELL BIOCHEM FUNCT, V18, P1; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Russell JW, 1999, HORM METAB RES, V31, P90, DOI 10.1055/s-2007-978704; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wojcik C, 1999, CELL MOL LIFE SCI, V56, P908, DOI 10.1007/s000180050483; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	59	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27393	27400		10.1074/jbc.M201963200	http://dx.doi.org/10.1074/jbc.M201963200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011046	hybrid			2022-12-25	WOS:000177055900089
J	Boskovic, G; Desai, D; Niles, RM				Boskovic, G; Desai, D; Niles, RM			Regulation of retinoic acid receptor alpha by protein kinase C in B16 mouse melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAR-ALPHA; X-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; PHORBOL ESTER; RXR-ALPHA; F9 CELLS; PHOSPHORYLATION; DIFFERENTIATION; PATHWAY; EXPRESSION	We have previously found that retinoic acid stimulates the expression of protein kinase Calpha (PKC) in B16 mouse melanoma cells. Because it has been reported that PKC can phosphorylate retinoic acid receptor (RAR) and alter its function, we determined whether changes in the level and/or activity of PKC could affect the expression or function of the RAR in B16 melanoma. Using in vivo phosphorylation and band shift techniques, we could not demonstrate that altering PKC activity and/or protein level changed the in vivo phosphorylation of RARalpha. However activation of PKC resulted in increased RARalpha protein. Increased receptor protein correlated with a phorbol dibutyrate-stimulated increase in receptor activation function-2 (AF-2)-dependent transcriptional activity. Use of enzyme inhibitors and dominant-negative PKCs indicated that enzyme activity was required for elevation in the RARalpha. The PKC-mediated increase in RARalpha was due to a 2.5-fold increase in the half-life of this protein. In contrast, the down-regulation of PKC diminished RARalpha protein half-life and markedly inhibited AF-2-dependent transcriptional activity. The down-regulation of PKC also inhibited the binding of RAR to a retinoic acid response element and the retinoic acid induction of RARbeta expression. These findings suggest that PKC can influence retinoic acid signaling by altering the stability of RAR protein without directly phosphorylating this receptor.	Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Mol Biol, Huntington, WV 25704 USA; Mayo Clin, Sect Gastroenterol Res, Rochester, MN 55905 USA	Marshall University; Mayo Clinic	Niles, RM (corresponding author), Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Mol Biol, 1542 Spring Valley Dr, Huntington, WV 25704 USA.	niles@marshall.edu			NCI NIH HHS [R01 CA59530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Boudjelal M, 2000, CANCER RES, V60, P2247; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CRETTAZ M, 1990, BIOCHEM J, V272, P91; DE LUCA LM, 1991, FASEB J, V5, P2924; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Desai SH, 2000, BIOCHEM PHARMACOL, V59, P1265, DOI 10.1016/S0006-2952(00)00269-0; DROMS KA, 1991, MOL CARCINOGEN, V4, P1, DOI 10.1002/mc.2940040102; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; HOOPES CW, 1992, GENOMICS, V14, P611, DOI 10.1016/S0888-7543(05)80159-4; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUPULESCU A, 1993, INT J VITAM NUTR RES, V63, P397; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; NILES RM, 1989, CANCER RES, V49, P4483; NILES RM, 1996, J CELL PHYSL, V168, P549; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Xiao YH, 1996, J CELL PHYSIOL, V167, P413, DOI 10.1002/(SICI)1097-4652(199606)167:3<413::AID-JCP5>3.0.CO;2-S; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	47	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26113	26119		10.1074/jbc.M201185200	http://dx.doi.org/10.1074/jbc.M201185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000751	hybrid			2022-12-25	WOS:000176908700038
J	Liu, HY; Meakin, SO				Liu, HY; Meakin, SO			ShcB and ShcC activation by the Trk family of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHOSPHOTYROSINE-BINDING DOMAIN; ADAPTER PROTEIN; RAT TRKA; NEUROTROPHIN RECEPTORS; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; CORTICAL-NEURONS; N-SHC; ASSOCIATION	Activation of the neurotrophin Trk receptors is a key process in the survival and development of the nervous system. The signaling adapters ShcB and ShcC, but not ShcA, are thought to be the primary She adaptor proteins in neurons as both are highly expressed in both the developing and adult nervous system. Although a previous study suggested that ShcB and ShcC do not strongly interact with the Trk receptors (1), we find that ShcB and ShcC bind the Trk receptors in a phosphotyrosine-dependent manner via their N-terminal phosphotyrosine binding domain at Tyr(499) (TrkA) and Tyr(515) (TrkB), they are tyrosine-phosphorylated in response to neurotrophin stimulation, and they enhance the activation of mitogen-activated protein kinase in Trk-expressing cells. Moreover, neurotrophin treatment of primary cortical neurons stimulates ShcB/ShcC-Trk interaction and the tyrosine phosphorylation of ShcB/ShcC, indicating that they are bona fide targets of the Trk receptors in vivo. Interestingly, two proteins (pp60 and pp75) co-immunoprecipitate with ShcB and ShcC in response to neurotrophin stimulation in primary cortical neurons, suggesting a potential role of these unknown targets in neurotrophin signaling. Collectively, these results demonstrate that ShcB and ShcC, and their co-immunoprecipitating proteins, are activated by the Trk receptors in primary neurons.	John P Robarts Res Inst, Lab Neural Signaling, Cell Biol Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Lab Neural Signaling, Cell Biol Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.	smeakin@robarts.ca	Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BUDAY L, 1995, ONCOGENE, V11, P1327; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Iwasaki Y, 1998, J NEUROCHEM, V71, P106; James P, 1996, GENETICS, V144, P1425; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; MAZZONI IE, 1991, NEUROSCIENCE, V45, P195, DOI 10.1016/0306-4522(91)90115-5; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; Pelicci G, 1996, ONCOGENE, V13, P633; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WIDMER HR, 1992, J NEUROCHEM, V59, P2113; Wiesmann C, 2001, CELL MOL LIFE SCI, V58, P748, DOI 10.1007/PL00000898; WILSON LK, 1995, J BIOL CHEM, V270, P25185, DOI 10.1074/jbc.270.42.25185	46	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26046	26056		10.1074/jbc.M111659200	http://dx.doi.org/10.1074/jbc.M111659200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006576	hybrid			2022-12-25	WOS:000176908700030
J	Qi, XM; Pramanik, R; Wang, JT; Schultz, RM; Maitra, RK; Han, JH; DeLuca, HF; Chen, G				Qi, XM; Pramanik, R; Wang, JT; Schultz, RM; Maitra, RK; Han, JH; DeLuca, HF; Chen, G			The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D-3-induced growth inhibition.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTORS; PROTEIN-KINASE; 1,25-DIHYDROXYVITAMIN D-3; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT PHOSPHORYLATION; GENE-EXPRESSION; AP-1 ACTIVITY; MAP KINASES	The signaling connection between mitogen-activated protein kinases(MAPKS) and nuclear steroid receptors is complex and remains mostly unexplored. Here we report that stress-activated protein kinases p38 and JNK trans-activate nuclear steroid vitamin D receptor (VDR) gene and increase vitamin D-3-dependent growth inhibition in human breast cancer cells. Activation of p38 and JNK by an active MAPK kinase 6 stimulates VDR promoter activity independently of the ligand vitamin D-3 and estrogen receptor expression. Moreover, stimulation of the endogenous stress pathways by adenovirus-mediated delivery of recombinant MAPK kinase 6 also activates VDR and sensitizes MCF-7 cells to vitamin D-3-dependent growth inhibition. Both the p38 and JNK MAPK pathways and the downstream transcription factor c-Jun/AP-1 are required for the VDR stimulation, as revealed by application of their dominant negatives, the specific p38 inhibitor SB203580, and site-directed mutagenesis of the AP-1 element in the VDR promoter. The essential role of the p38 and JNK stress pathways in up-regulation of VDR expression is further confirmed by using the chemical stimulator arsenite. These results establish a signaling connection between the stress MAPK pathways and steroid hormone receptor VDR expression and thereby offer new insights into regulation of cell growth by the MAPK pathways through regulation of vitamin D-3/VDR activity.	Loyola Univ, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Dept Cell Biol Neurobiol & Anat, Div Biochem, Maywood, IL 60153 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Cleveland Clin Fdn, Dept Virol, Cleveland, OH 44195 USA	Loyola University Chicago; Loyola University Chicago; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute; Cleveland Clinic Foundation	Chen, G (corresponding author), Loyola Univ, Dept Radiat Oncol, 114B Bldg,1 Hines,2160 S 1st Ave, Maywood, IL 60153 USA.	gchen1@lume.edu	Han, J/G-4671-2010		NCI NIH HHS [CA91576] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Agadir A, 1999, CARCINOGENESIS, V20, P577, DOI 10.1093/carcin/20.4.577; Andrew AS, 2001, AM J PHYSIOL-LUNG C, V281, pL616, DOI 10.1152/ajplung.2001.281.3.L616; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bagowski CP, 2001, J BIOL CHEM, V276, P37708, DOI 10.1074/jbc.M104582200; BERGER U, 1991, CANCER RES, V51, P239; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BURAS RR, 1994, BREAST CANCER RES TR, V31, P191, DOI 10.1007/BF00666153; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; Chen HC, 1999, CURR BIOL, V9, pR478, DOI 10.1016/S0960-9822(99)80300-5; Davoust N, 1998, J NEUROSCI RES, V52, P210, DOI 10.1002/(SICI)1097-4547(19980415)52:2<210::AID-JNR9>3.0.CO;2-D; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Escaleira MTF, 1999, BREAST CANCER RES TR, V54, P123, DOI 10.1023/A:1006198107805; GALANG CK, 1994, ONCOGENE, V9, P2913; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILLIARD GM, 1944, BIOCHEMISTRY-US, V33, P4300; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jehan F, 2000, ARCH BIOCHEM BIOPHYS, V377, P273, DOI 10.1006/abbi.2000.1788; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; KRISHNAN A, 1991, MOL ENDOCRINOL, V86, P2071; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LoveSchimenti CD, 1996, CANCER RES, V56, P2789; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Musiol IM, 1997, ENDOCRINOLOGY, V138, P12, DOI 10.1210/en.138.1.12; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARK K, 1994, CANCER RES, V54, P6087; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROSS TK, 1993, P NATL ACAD SCI USA, V90, P9257, DOI 10.1073/pnas.90.20.9257; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SEBAG M, 1992, J BIOL CHEM, V267, P12162; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Solomon C, 1998, J BIOL CHEM, V273, P17573, DOI 10.1074/jbc.273.28.17573; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Towers TL, 1999, MOL CELL BIOL, V19, P4191; WALTERS MR, 1981, BIOCHEM BIOPH RES CO, V103, P721, DOI 10.1016/0006-291X(81)90509-X; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	75	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25884	25892		10.1074/jbc.M203039200	http://dx.doi.org/10.1074/jbc.M203039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11983707	hybrid			2022-12-25	WOS:000176908700011
J	Bertoni, A; Tadokoro, S; Eto, K; Pampori, N; Parise, LV; White, GC; Shattil, SJ				Bertoni, A; Tadokoro, S; Eto, K; Pampori, N; Parise, LV; White, GC; Shattil, SJ			Relationships between Rap1b, affinity modulation of integrin alpha(IIb)beta(3), and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	43rd Annual Meeting of the American-Society-of-Hematology	DEC 07-11, 2001	ORLANDO, FL	Amer Soc Hematol			PROTEIN-KINASE-C; SMALL GTPASE; PLATELET-AGGREGATION; EXCHANGE FACTOR; CELL-ADHESION; R-RAS; ACTIVATION; ALPHA-IIB-BETA-3; DETERMINANTS; SPECIFICITY	The affinity of integrin alpha(IIb)beta(3) for fibrinogen is controlled by inside-out signals that are triggered by agonists like thrombin. Agonist treatment of platelets also activates Rap1b, a small GTPase known to promote integrin-dependent adhesion of other cells. Therefore, we nvestigated the role of Rap1b in alpha(IIb)beta(3) function by viral transduction of GFP-Rap1 chimeras into murine megakaryocytes, which exhibit inside-out signaling similar to platelets. Expression of constitutively active GFP-Rap1b (V12) had no effect on unstimulated megakaryocytes, but it greatly augmented fibrinogen binding to alpha(IIb)beta(3), induced by a PAR4 thrombin receptor agonist (p < 0.01). The Rap1b effect was cell-autonomous and was prevented by pre-treating cells with cytochalasin D or latrunculin A to inhibit actin polymerization. Rap1b-dependent fibrinogen binding to megakaryocytes was blocked by POW-2, a novel monovalent antibody Fab fragment specific for high affinity murine alpha(IIb)beta(3) In contrast to GFP-Rap1b (V12), expression of GFP-Rap1GAP, which deactivates endogenous Rap1, inhibited agonist-induced fibrinogen binding (p < 0.01), as did dominant-negative GFP-Rap1b (N17) (p < 0.05). None of these treatments affected surface expression of alpha(IIb)beta(3). These studies establish that Rap1b can augment agonist-induced ligand binding to alpha(IIb)beta(3) through effects on integrin affinity, possibly by modulating aHbP3 interactions with the actin cytoskeleton.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Scripps Research Institute; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Shattil, SJ (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.	shattil@scripps.edu						ABRAMS C, 1994, J BIOL CHEM, V269, P18781; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brass L. F, 2000, HEMATOLOGY BASIC PRI, P1753; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Faraday N, 1999, BLOOD, V94, P4084, DOI 10.1182/blood.V94.12.4084.424k28_4084_4092; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kucik DF, 2001, MOL BIOL CELL, V12, P1509, DOI 10.1091/mbc.12.5.1509; Lengweiler S, 1999, BIOCHEM BIOPH RES CO, V262, P167, DOI 10.1006/bbrc.1999.1172; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shibayama H, 1999, BLOOD, V93, P1540, DOI 10.1182/blood.V93.5.1540.405k10_1540_1548; Shiraga M, 1999, J CELL BIOL, V147, P1419, DOI 10.1083/jcb.147.7.1419; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; WALTER U, 1993, ADV EXP MED BIOL, V344, P237; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; White GC, 1998, THROMB HAEMOSTASIS, V79, P832; Wilcox DA, 2000, BLOOD, V95, P3645; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	53	152	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25715	25721		10.1074/jbc.M202791200	http://dx.doi.org/10.1074/jbc.M202791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	11994301	hybrid			2022-12-25	WOS:000176747000113
J	Dikalov, S; Landmesser, U; Harrison, DG				Dikalov, S; Landmesser, U; Harrison, DG			Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling - Implications for studies of hsp90 and endothelial cell nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN 90; RADICAL GENERATION; ACTIVATION; DISMUTASE; BENZOQUINONE; CONTRIBUTES; INHIBITION; STRESS; ANION; NO	The ansamycin antibiotic geldanamycin has frequently been used as an inhibitor of heat shock protein 90 (Hsp90), and this agent has been widely employed as a probe to examine the interactions of Hsp90 with endothelial nitric-oxide synthase. Geldanamycin contains a quinone group, which may participate in redox cycling. When geldanamycin was exposed to the flavin-containing enzyme cytochrome P-450 reductase, both semiquinone and superoxide (O-2(.-)) radicals were detected using electron spin resonance. The treatment of endothelial cells with geldanamycin resulted in a dramatic increase in 07 generation, which was independent of endothelial nitric oxide synthase, because it was not inhibited by N-nitro-L-arginine methyl ester and also occurred in vascular smooth muscle cells. Diphenylene iodinium inhibited this increase in O-2(.-) by 50%, suggesting that flavin-containing enzymes are involved in geldanamycin-induced O-2(.-) generation. In the absence of cells, geldanamycin directly oxidized ascorbate, consumed oxygen, and produced O-2(.-). Geldanamycin decreased the bioavailable nitric oxide generated by 3,4-dihydrodiazete 1,2-dioxide in smooth muscle cells by 50%, whereas pretreatment with superoxide dismutase inhibited the effect of geldanamycin. These findings demonstrate that geldanamycin generates O-2(.-) which scavenges nitric oxide, leading to loss of its bioavailability. This effect is independent of the inhibition of Hsp90 and indicates that geldanamycin cannot be used as a specific inhibitor of Hsp90. In light of these findings, the studies using geldanamycin as an inhibitor of Hsp90 should be interpreted with caution.	Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA; Atlanta Vet Adm Hosp, Atlanta, GA 30322 USA	Emory University	Dikalov, S (corresponding author), Emory Univ, Sch Med, Div Cardiol, 1639 Pierce Dr,319 WMB, Atlanta, GA 30322 USA.	dikalov@emory.edu		Dikalov, Sergey/0000-0003-2976-6184				ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264; ALEGRIA AE, 1989, BIOCHEMISTRY-US, V28, P8653, DOI 10.1021/bi00447a056; BACHUR NR, 1978, CANCER RES, V38, P1745; BENCHEKROUN MN, 1994, FREE RADICAL BIO MED, V17, P191; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Bucci M, 2000, BRIT J PHARMACOL, V131, P13, DOI 10.1038/sj.bjp.0703549; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; DIKALOV S, 1993, BIOCHEM BIOPH RES CO, V195, P113, DOI 10.1006/bbrc.1993.2017; DIKALOV SI, 1992, BIOCHEMISTRY-US, V31, P8947, DOI 10.1021/bi00152a034; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gusev NB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1112, DOI 10.1023/A:1012480829618; GUTTERIDGE JMC, 1984, BIOCHEM PHARMACOL, V33, P3059, DOI 10.1016/0006-2952(84)90609-9; Harris MB, 2000, GEN PHARMACOL-VASC S, V35, P165, DOI 10.1016/S0306-3623(01)00104-5; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; Khurana VG, 2000, J CEREBR BLOOD F MET, V20, P1563, DOI 10.1097/00004647-200011000-00006; Kleschyov AL, 2000, BIOCHEM BIOPH RES CO, V275, P672, DOI 10.1006/bbrc.2000.3361; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; *NIH, 2001, FEDERAL REGISTER ONL, V66, P35443; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Zwicker K, 1998, ARZNEIMITTEL-FORSCH, V48, P629	31	111	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25480	25485		10.1074/jbc.M203271200	http://dx.doi.org/10.1074/jbc.M203271200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983711	hybrid			2022-12-25	WOS:000176747000083
J	Fryer, LGD; Parbu-Patel, A; Carling, D				Fryer, LGD; Parbu-Patel, A; Carling, D			The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; FATTY-ACID; CELL-LINES; MECHANISM; TROGLITAZONE; STRESS; GAMMA; INHIBITION; DERIVATION; CASCADE	AMP-activated protein kinase (AMPK) is activated within the cell in response to multiple stresses that increase the intracellular AMP:ATP ratio. Here we show that incubation of muscle cells with the thiazolidinedione, rosiglitazone, leads to a dramatic increase in this ratio with the concomitant activation of AMPK. This finding raises the possibility that a number of the beneficial effects of the thiazolidinediones could be mediated via activation of AMPK. Furthermore, we show that in addition to the classical activation pathway, AMPK can also be stimulated without changing the levels of adenine nucleotides. In muscle cells, both hyperosmotic stress and the anti-diabetic agent, metformin, activate AMPK in the absence of any increase in the AMP:ATP ratio. However, although activation is no longer dependent on this ratio, it still involves increased phosphorylation of threonine 172 within the catalytic (a) subunit. AMPK stimulation in response to hyperosmotic stress does not appear to involve phosphatidylinositol 3-phosphate kinase, protein kinase C, mitogen-activated protein (MAP) kinase kinase, or p38 MAP kinase alpha or beta. Our results demonstrate that AMPK can be activated by at least two distinct signaling mechanisms and suggest that it may play a wider role in the cellular stress response than was previously understood.	Hammersmith Hosp, MRC, Ctr Clin Sci, Cellular Stress Grp, London W12 0NN, England	Imperial College London	Carling, D (corresponding author), Hammersmith Hosp, MRC, Ctr Clin Sci, Cellular Stress Grp, DuCane Rd, London W12 0NN, England.	dcarling@csc.mrc.ac.uk	Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830; Parbhu Patel, Asha/0000-0002-7314-4043				Brunmair B, 2001, DIABETES, V50, P2309, DOI 10.2337/diabetes.50.10.2309; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; ELKEBBI IM, 1994, METABOLISM, V43, P953, DOI 10.1016/0026-0495(94)90173-2; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; Hundal RS, 2000, DIABETES, V49, P2063, DOI 10.2337/diabetes.49.12.2063; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kishi K, 2000, BIOCHEM BIOPH RES CO, V276, P16, DOI 10.1006/bbrc.2000.3417; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Mudaliar S, 2001, ANNU REV MED, V52, P239, DOI 10.1146/annurev.med.52.1.239; Schaffler A, 2000, EUR J CLIN INVEST, V30, P586; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	46	869	920	0	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25226	25232		10.1074/jbc.M202489200	http://dx.doi.org/10.1074/jbc.M202489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994296	hybrid			2022-12-25	WOS:000176747000050
J	Alvarez, CE; Sutcliffe, JG; Thomas, EA				Alvarez, CE; Sutcliffe, JG; Thomas, EA			Novel isoform of insulin receptor substrate p53/p58 is generated by alternative splicing in the CRIB/SH3-binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; IRSP53; KINASE; POLYGLUTAMINE; LOCALIZATION; ACTIVATION; INTERACTS	Insulin receptor substrate p53/p58 (IRSp53) is involved in cytoskeletal dynamics and is a candidate disease sensor in polyglutamine expansion neurodegeneration. It is widely expressed throughout the body, but its levels are dramatically elevated in forebrain regions. IRSp53 functions as a signal transducing adaptor between activated Rho family GTPases and their effectors. There are four known alternatively spliced isoforms of IRSp53 that vary by the identity of the T-terminal exon. We report here that there is a fifth alternatively spliced isoform, IRSp53-B, which lacks 40 amino acids abutting the CRIB/SH3 ((C) under bar dc42/(R) under bar ac-(i) under bar nteractive (b) under bar inding/(S) under bar rc (h) under bar omology (3) under bar)-binding site. We speculate that the novel form has an altered function related to the mechanism of autoinactivation. IRSp53-B has an odd history in the mammalian lineage, which may complicate the use of rodent models to study cytoskeletal reorganization.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Scripps Research Institute	Sutcliffe, JG (corresponding author), Scripps Res Inst, Dept Biol Mol, 10550 N Torrey Pines Rd,MB10, La Jolla, CA 92037 USA.	gregor@scripps.edu		Jaramillo Garcia, Luis Fernando/0000-0003-2909-9318	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Mayer BJ, 2001, J CELL SCI, V114, P1253; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Oda K, 1999, CYTOGENET CELL GENET, V84, P75, DOI 10.1159/000015219; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Okamura-Oho Y, 2001, BIOCHEM BIOPH RES CO, V289, P957, DOI 10.1006/bbrc.2001.6102; Thomas EA, 2001, NEUROSCI LETT, V309, P145, DOI 10.1016/S0304-3940(01)02064-X; USUI H, 1994, J NEUROSCI, V14, P4915; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921; Yeh TC, 1998, J CELL BIOCHEM, V68, P139, DOI 10.1002/(SICI)1097-4644(19980201)68:2<139::AID-JCB1>3.0.CO;2-W	17	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24728	24734		10.1074/jbc.M202512200	http://dx.doi.org/10.1074/jbc.M202512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006592	hybrid			2022-12-25	WOS:000176611800099
J	Hlaing, M; Shen, X; Dazin, P; Bernstein, HS				Hlaing, M; Shen, X; Dazin, P; Bernstein, HS			The hypertrophic response in C2C12 myoblasts recruits the G(1) cell cycle machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; DEPENDENT KINASES; ANGIOTENSIN-II; REPRESS TRANSCRIPTION; CARDIAC MYOCYTES; CDK INHIBITORS; MITOTIC ENTRY; PRB; PHOSPHORYLATION	Hypertrophy occurs in postmitotic muscle as an adaptive response to various physiological and pathological stresses. Studies in vascular smooth muscle cells and primary cardiomyocytes suggest that angiotensin II-mediated hypertrophy activates signaling pathways associated with cell proliferation. Regulation of cyclin-dependent kinase (Cdk)-cyclin activities is essential to cell size control in lower eukaryotes, yet their role in the hypertrophic response in muscle is incompletely understood. We describe an in vitro model of hypertrophy in C2C12 skeletal myoblasts and demonstrate that induction of hypertrophy involves transient activation of Cdk4, subsequent phosphorylation of Rb, and release of HDAC I from the Rb inhibitory complex. We also demonstrate that E2F-1 becomes transcriptionally active yet remains associated with Rb. We propose a model whereby partial inactivation of the Rb complex leads to derepression of a subset of E2F-1 targets necessary for cell growth without division during hypertrophy.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bernstein, HS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 505 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07544, HL62174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Douahji M, 1999, KIDNEY INT, V56, P1691, DOI 10.1046/j.1523-1755.1999.00728.x; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Gordon SE, 2001, AM J PHYSIOL-ENDOC M, V280, pE150, DOI 10.1152/ajpendo.2001.280.1.E150; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lei XH, 2000, J CELL SCI, V113, P4523; Lijnen P, 1999, J MOL CELL CARDIOL, V31, P949, DOI 10.1006/jmcc.1999.0934; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf G, 2001, AM J PATHOL, V158, P1091, DOI 10.1016/S0002-9440(10)64056-4; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	33	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23794	23799		10.1074/jbc.M201980200	http://dx.doi.org/10.1074/jbc.M201980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967266	hybrid			2022-12-25	WOS:000176475700091
J	Freemantle, SJ; Kerley, JS; Olsen, SL; Gross, RH; Spinella, MJ				Freemantle, SJ; Kerley, JS; Olsen, SL; Gross, RH; Spinella, MJ			Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma	ONCOGENE			English	Article						retinoic acid; embryonal carcinoma; development; microarray differentiation; mammalian embryogenesis	CELL-LINE; ALL-TRANS; HOMEOBOX GENES; CLONING; IDENTIFICATION; EXPRESSION; MOUSE; CDNA; BIOLOGY; PROTEIN	Embryonal carcinoma is a model of embryonic development as well as tumor cell differentiation. In response to all-trans retinoic acid (RA), the human embryonal carcinoma (EC) cell line, NT2/D1, differentiates toward a neuronal lineage with associated loss of cell growth and tumorigenicity. Through the use of cDNA-based micro-arrays we sought to identify the early downstream targets of RA during differentiation commitment of NT2/D1 cells. A total of 57 genes were induced and 37 genes repressed by RA. RA regulated genes were restricted at 8 h with 27 genes induced and five repressed. The total number of RA-responsive transcripts increased at 24 and 48 h and their pattern of expression was more symmetrical. For a given time point less than 1% of the 128 cDNAs on the expression array were regulated by RA. Many of these gene products are associated with developmental pathways including those of TGF-beta (Lefty A, NMA, follistatin), homeo domain (HoxD1, Meis2, Meis1, Gbx2), IGF (IGFBP3, IGFBP6, CTGF), Notch (manic fringe, ADAM 11), Hedgehog (patched) and Wnt (Frat2, secreted frizzled-related protein 1) signaling. In addition a large cassette of genes induced by RA at 2448 h are associated with cell adhesion, cytoskeletal and matrix remodeling, growth suppression and intracellular signaling cascades. The majority of repressed genes are associated with protein/RNA processing, turnover or metabolism. The early induced genes identified may play a regulatory role in RA-mediated growth suppression and terminal differentiation and may have physiologic or pharmacologic importance during normal human development and retinoid-based cancer therapy or prevention.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA75154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan GJ, 2001, REPRODUCTION, V122, P31, DOI 10.1530/reprod/122.1.31; Altmann CR, 2001, INT REV CYTOL, V203, P447; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bani-Yaghoub M, 2001, BIOCHEM CELL BIOL, V79, P387, DOI 10.1139/bcb-79-4-387; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUILLET P, 1995, DEV DYNAM, V204, P372, DOI 10.1002/aja.1002040404; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Calvo R, 2000, ANN ONCOL, V11, P207, DOI 10.1023/A:1011152704791; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Edwards DP, 1999, VITAM HORM, V55, P165; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Glass CK, 2000, GENE DEV, V14, P121; Gudas Lorraine J., 1994, P443; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Heidenreich A, 2000, EUR UROL, V37, P121, DOI 10.1159/000020128; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; INIGUEZ MA, 1994, MOL BRAIN RES, V27, P205, DOI 10.1016/0169-328X(94)90002-7; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kelly DL, 2000, MOL REPROD DEV, V56, P113, DOI 10.1002/(SICI)1098-2795(200006)56:2&lt;113::AID-MRD1&gt;3.0.CO;2-Q; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KURIE JM, 1993, DIFFERENTIATION, V54, P123; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Leypoldt F, 2001, J NEUROCHEM, V76, P806, DOI 10.1046/j.1471-4159.2001.00079.x; Mangelsdorf David J., 1994, P319; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Matin A, 1998, APMIS, V106, P174, DOI 10.1111/j.1699-0463.1998.tb01333.x; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Nichols J, 2001, DEVELOPMENT, V128, P2333; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; PENG HQ, 1993, CANCER RES, V53, P3574; Pera MF, 2000, J CELL SCI, V113, P5; PERA MF, 1990, CANCER SURV, V9, P243; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; Przyborski SA, 2000, EUR J NEUROSCI, V12, P3521, DOI 10.1046/j.1460-9568.2000.00230.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Satoh J, 2000, J NEUROSCI METH, V94, P155, DOI 10.1016/S0165-0270(99)00143-0; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YUAN SX, 1995, CANCER RES, V55, P3456; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	66	80	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2880	2889		10.1038/sj.onc.1205408	http://dx.doi.org/10.1038/sj.onc.1205408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973648				2022-12-25	WOS:000175063700013
J	Gapuzan, MER; Yufit, PV; Gilmore, TD				Gapuzan, MER; Yufit, PV; Gilmore, TD			Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappa B have a malignantly transformed phenotype	ONCOGENE			English	Article						NF-kappa B; RelA; Rel; malignant transformation; mouse knockout cells; apoptosis	TUMOR-NECROSIS-FACTOR; INCREASED APOPTOSIS; MICE; ACTIVATION; PATHWAY; BINDING; CANCER; GENES; CELLS	The RelA transcription factor is part of dimeric complexes, most commonly either p50-RelA (NF-kappaB) heterodimers or RelA homodimers, that control a variety of cellular processes. Immortalized embryonic fibroblasts established from rela knockout mice have previously been shown to be more sensitive to apoptosis induced by tumor necrosis factor (TNF) than are control fibroblasts. In this report, we show that one line of rela-/- fibroblasts has additional phenotypes that distinguish them from control mouse fibroblasts. As compared to normal 3T3 cells, RelA-deficient fibroblasts have a spindled morphology, are less adherent to culture dishes, grow to a higher saturation density, and can form colonies in soft agar. These properties are consistent with a weakly transformed phenotype for rela-/- cells. Furthermore, RelA-deficient fibroblasts can form tumors in immunodeficient mice, but these tumors regress, probably because of the sensitivity of these cells to TNF. The ability of rela-/- fibroblasts to form colonies in soft agar can be reverted by re-expression of wild-type mouse RelA, but not by expression of RelA mutants that cannot form homodimers. There is no clear correlation between the absence of RelA and the levels of expression of other Rel/NF-kappaB family members or adhesion proteins (ICAM-1 and VCAM-1) whose genes have upstream kappaB sites. Taken together, these results suggest that RelA has tumor suppressing activity under some circumstances and that RelA complexes are involved in the control of a variety of cellular properties associated with oncogenesis.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA 47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANCROFT GJ, 1989, J IMMUNOL, V143, P127; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; GILMORE TD, 2002, IN PRESS CANC LETT; HANNINK M, 1990, ONCOGENE, V5, P1843; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricca A, 2001, BRIT J CANCER, V85, P1914, DOI 10.1054/bjoc.2001.2174; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; Trecca D, 1997, ONCOGENE, V14, P791, DOI 10.1038/sj.onc.1200895; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	27	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2484	2492		10.1038/sj.onc.1205333	http://dx.doi.org/10.1038/sj.onc.1205333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971183				2022-12-25	WOS:000174918400005
J	Huang, SY; Bucana, CD; Van Arsdall, M; Fidler, IJ				Huang, SY; Bucana, CD; Van Arsdall, M; Fidler, IJ			Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells	ONCOGENE			English	Article						Stat1; angiogenesis; tumor growth; metastasis	SIGNAL-TRANSDUCTION PATHWAY; FIBROBLAST-GROWTH-FACTOR; PHASE RESPONSE FACTOR; DNA-BINDING PROTEINS; HUMAN-MELANOMA CELLS; NF-KAPPA-B; INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; GENE-EXPRESSION	Stat1 is deficient or inactive in many types of human tumors whereas some tumors have activated Stat1. Whether Stat1 affects tumor growth and metastasis is unclear. In the present study, we used Stat1 knockout tumor cells to determine (1) whether Stat1 can regulate angiogenesis, growth, and metastasis of tumor cells; and (2) whether Stat1 is required for the inhibitory effect of IFN-beta on the expression of angiogenic factor bFGF. Highly tumorigenic and metastatic RAD-105 tumor cells derived from a fibrosarcoma of a Stat1 knockout mouse were reconstituted with a Stat1 expression vector. The reconstitution of Stat1 suppressed the tumorigenicity and metastasis of RAD-105 cells in nude mice which correlated with a decreased microvessel density and decreased expression of proangiogenic molecules bFGF, MMP-2, and MMP-9 in vivo. Moreover, noncytotoxic concentrations of IFN-beta significantly inhibited the in vitro expression of bFGF in the Stat1-reconstituted cells but not in the Stat1-deficient cells, which was consistent with decreased bFGF expression of Stat1-reconstituted tumors in vivo. Therefore, Stat1 is essential for IFN-mediated inhibition of bFGF production, suggesting that tumor-intrinsic Stat1 is an important mediator for antiangiogenic signals, such as IFN. Collectively, these data demonstrate that Stat1 expressed by tumor cells is a negative regulator of tumor angiogenesis and, hence, tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fidler, IJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	ifidler@mdanderson.org			NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 42107, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BALKWILL FR, 1977, INT J CANCER, V20, P500, DOI 10.1002/ijc.2910200405; Bielenberg DR, 1999, INT J ONCOL, V14, P401; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dinney CPN, 1998, CANCER RES, V58, P808; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FABRA A, 1992, DIFFERENTIATION, V52, P101, DOI 10.1111/j.1432-0436.1992.tb00504.x; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1992, Semin Cancer Biol, V3, P65; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, MOL CELL BIOL, V16, P359; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pestka S, 1997, Semin Oncol, V24, pS9; Qin HW, 1998, J IMMUNOL, V161, P6664; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEN GC, 1992, J BIOL CHEM, V267, P5017; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779	58	135	140	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2504	2512		10.1038/sj.onc.1205341	http://dx.doi.org/10.1038/sj.onc.1205341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971185				2022-12-25	WOS:000174918400007
J	Konig, S; Burkman, J; Fitzgerald, J; Mitchell, M; Su, L; Stedman, H				Konig, S; Burkman, J; Fitzgerald, J; Mitchell, M; Su, L; Stedman, H			Modular organization of phylogenetically conserved domains controlling developmental regulation of the human skeletal myosin heavy chain gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SEQUENCE ALIGNMENT; EXPRESSION; MUSCLE; TRANSCRIPTION; MEF2; MYOD; DNA; ACTIVATION; PATTERNS	The mammalian skeletal myosin heavy chain locus is composed of a six-membered family of tandemly linked genes whose complex regulation plays a central role in striated muscle development and diversification. We have used publicly available genomic DNA sequences to provide a theoretical foundation for an experimental analysis of transcriptional regulation among the six promoters at this locus. After reconstruction of annotated drafts of the human and murine loci from fragmented DNA sequences, phylogenetic footprint analysis of each of the six promoters using standard and Bayesian alignment algorithms revealed unexpected patterns of DNA sequence conservation among orthologous and paralogous gene pairs. The conserved domains within 2.0 kilobases of each transcriptional start site are rich in putative muscle-specific transcription factor binding sites. Experiments based on plasmid transfection in vitro and electroporation in vivo validated several predictions of the bioinformatic analysis, yielding a picture of synergistic interaction between proximal and distal promoter elements in controlling developmental stage-specific gene activation. Of particular interest for future studies of heterologous gene expression is a 650-base pair construct containing modules from the proximal and distal human embryonic myosin heavy chain promoter that drives extraordinarily powerful transcription during muscle differentiation in vitro.	Univ Penn, Med Syst, Dept Surg, Philadelphia, PA 19104 USA	University of Pennsylvania	Stedman, H (corresponding author), Rm 608,Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	hstedman@mail.med.upenn.edu		Koenig, Stephane/0000-0002-0801-279X; Fitzgerald, Julie/0000-0001-9936-9569				Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andreucci JJ, 2002, J BIOL CHEM, V277, P16426, DOI 10.1074/jbc.M110891200; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Desjardins PR, 2002, MOL BIOL EVOL, V19, P375, DOI 10.1093/oxfordjournals.molbev.a004093; Fickett JW, 1996, MOL CELL BIOL, V16, P437; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; Huey KA, 1998, EUR J BIOCHEM, V256, P45, DOI 10.1046/j.1432-1327.1998.2560045.x; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; Martin KA, 1997, DNA CELL BIOL, V16, P653, DOI 10.1089/dna.1997.16.653; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NAUMANN K, 1994, DIFFERENTIATION, V55, P203, DOI 10.1046/j.1432-0436.1994.5530203.x; Perkins KJ, 2001, NUCLEIC ACIDS RES, V29, P4843, DOI 10.1093/nar/29.23.4843; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Santalucia T, 2001, J MOL BIOL, V314, P195, DOI 10.1006/jmbi.2001.5091; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Shrager JB, 2000, J MUSCLE RES CELL M, V21, P345, DOI 10.1023/A:1005635030494; Sun XY, 2002, AM J PHYSIOL-REG I, V282, pR509, DOI 10.1152/ajpregu.00509.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; YOON SJ, 1992, P NATL ACAD SCI USA, V89, P12078, DOI 10.1073/pnas.89.24.12078; Zhu J, 1998, BIOINFORMATICS, V14, P25, DOI 10.1093/bioinformatics/14.1.25	40	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27593	27605		10.1074/jbc.M203162200	http://dx.doi.org/10.1074/jbc.M203162200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11971910	hybrid			2022-12-25	WOS:000177189800005
J	Iancu, CV; Borza, T; Fromm, HJ; Honzatko, RB				Iancu, CV; Borza, T; Fromm, HJ; Honzatko, RB			IMP, GTP, and 6-Phosphoryl-IMP complexes of recombinant mouse muscle adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; AMMONIA PRODUCTION; CRYSTAL-STRUCTURES; SKELETAL-MUSCLE; HYDANTOCIDIN; BINDING; OVEREXPRESSION; PURIFICATION; HERBICIDE	Prokaryotes have a single form of adenylosuccinate synthetase that controls the committed step of AMP biosynthesis, but vertebrates have two isozymes of the synthetase. The basic isozyme, which predominates in muscle, participates in the purine nucleotide cycle, has an active site conformation different from that of the Escherichia coli enzyme, and exhibits significant differences in ligand recognition. Crystalline complexes presented here of the recombinant basic isozyme from mouse show the following. GTP alone binds to the active site without inducing a conformational change. IMP in combination with an acetate anion induces major conformational changes and organizes the active site for catalysis. IMP, in the absence of GTP, binds to the GTP pocket of the synthetase. The combination of GTP and IMP results in the formation of a stable complex of 6-phosphoryl-IMP and GDP in the presence or absence of hadacidin. The response of the basic isozyme to GTP alone differs from that of synthetases from plants, and yet the conformation of the mouse basic and E. coli synthetases in their complexes with GDP, 6-phosphoryl-IMP, and hadacidin are nearly identical. Hence, reported differences in ligand recognition among synthetases probably arise from conformational variations observed in partially ligated enzymes.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Mol Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu	Borza, Tudor/A-8510-2012; Borza, Tudor/M-4937-2019	Borza, Tudor/0000-0002-2527-6551; Borza, Tudor/0000-0002-2527-6551	NINDS NIH HHS [NS 10548] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASS MB, 1984, J BIOL CHEM, V259, P2330; BAUGHER BW, 1980, BIOCHEM BIOPH RES CO, V94, P123, DOI 10.1016/S0006-291X(80)80196-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; GOODMAN MN, 1977, J BIOL CHEM, V252, P5054; Gorrell A, 2002, J BIOL CHEM, V277, P8817, DOI 10.1074/jbc.M111810200; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Honzatko RB, 1999, ARCH BIOCHEM BIOPHYS, V370, P1, DOI 10.1006/abbi.1999.1383; Hou ZL, 2002, J BIOL CHEM, V277, P5970, DOI 10.1074/jbc.M109561200; Hou ZL, 1999, J BIOL CHEM, V274, P17505, DOI 10.1074/jbc.274.25.17505; Iancu CV, 2001, J BIOL CHEM, V276, P42146, DOI 10.1074/jbc.M106294200; JAYARAM HN, 1979, CANCER TREAT REP, V63, P1095; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lipps G, 1999, BIOCHEM J, V341, P537, DOI 10.1042/0264-6021:3410537; LOWENSTEIN JM, 1972, PHYSIOL REV, V52, P382, DOI 10.1152/physrev.1972.52.2.382; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATSUDA Y, 1977, BIOCHEM BIOPH RES CO, V78, P766, DOI 10.1016/0006-291X(77)90245-5; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUIRHEAD KM, 1974, J BIOL CHEM, V249, P459; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGAWA H, 1976, BIOCHEM BIOPH RES CO, V68, P524, DOI 10.1016/0006-291X(76)91177-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; Prade L, 2000, J MOL BIOL, V296, P569, DOI 10.1006/jmbi.1999.3473; Schmitzer PR, 2000, J NAT PROD, V63, P777, DOI 10.1021/np990590i; Siehl DL, 1996, PLANT PHYSIOL, V110, P753, DOI 10.1104/pp.110.3.753; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; SPECTOR T, 1979, J BIOL CHEM, V254, P8422; SPECTOR T, 1976, BIOCHIM BIOPHYS ACTA, V445, P509, DOI 10.1016/0005-2744(76)90104-2; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TYAGI AK, 1980, CANCER RES, V40, P4390; Wang WY, 1997, J BIOL CHEM, V272, P16911, DOI 10.1074/jbc.272.27.16911; Wang WY, 1998, J BIOL CHEM, V273, P16000, DOI 10.1074/jbc.273.26.16000	43	26	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26779	26787		10.1074/jbc.M203730200	http://dx.doi.org/10.1074/jbc.M203730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004071	hybrid			2022-12-25	WOS:000177055900011
J	Pusl, T; Wu, JJ; Zimmerman, TL; Zhang, L; Ehrlich, BE; Berchtold, MW; Hoek, JB; Karpen, SJ; Nathanson, MH; Bennett, AM				Pusl, T; Wu, JJ; Zimmerman, TL; Zhang, L; Ehrlich, BE; Berchtold, MW; Hoek, JB; Karpen, SJ; Nathanson, MH; Bennett, AM			Epidermal growth factor-mediated activation of the ETS domain transcription factor Elk-1 requires nuclear calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; GENE-EXPRESSION; PROTEIN-KINASES; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; PARVALBUMIN CDNA; EPITHELIAL-CELLS; BINDING PROTEIN; RAT HEPATOCYTES	Cytosolic and nuclear Ca2+ have been shown to differentially regulate transcription. However, the impact of spatially distinct Ca2+ signals on mitogen-activated protein kinase-mediated gene expression remains unknown. Here we investigated the role of nuclear and cytosolic Ca2+ signals in epidermal growth factor (EGF)-induced transactivation of the ternary complex factor Elk-1 using a GAL4-Elk-1 construct. EGF increased Ca2+ in both the nucleus and cytosol of HepG2 or 293 cells. Pretreatment with the intracellular Ca2+ chelator bis(2-aminophenyl)ethyleneglycol-N,N N',N'-tetraacetic acid significantly reduced EGF-induced transactivation of Elk-1, indicating that EGF-stimulated Elk-1 transcriptional activity is dependent on intracellular Ca2+. To determine the relative contribution of nuclear and cytosolic Ca2+ signals during EGF-mediated Elk-1 transactivation, Ca2+ signals in either compartment were selectively impaired by targeted expression of the Ca2+ binding protein parvalbumin to either the nucleus or cytosol. Suppression of nuclear but not cytosolic Ca2+ signals inhibited EGF-induced transactivation of Elk-1. However, suppression of nuclear Ca2+ signals did not affect the ability of ERK either to become phosphorylated or to undergo translocation to the nucleus in response to EGF. Elk-1 phosphorylation and nuclear localization following EGF stimulation were also unaffected by suppressing nuclear Ca2+ signals. These results suggest that nuclear Ca2+ is required for EGF-mediated transcriptional activation of Elk-1 and that phosphorylation of Elk-1 alone is not sufficient to induce its transcriptional activation in response to EGF. Thus, subcellular targeting of parvalbumin reveals a distinct role for nuclear Ca2+ signals in mitogen-activated protein kinase-mediated gene transcription.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Yale University; Yale University; Baylor College of Medicine; University of Copenhagen; Jefferson University	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B230,333 Cedar St, New Haven, CT 06520 USA.		Berchtold, Martin/L-1695-2014; /AAX-8408-2021	Berchtold, Martin/0000-0001-8995-9047; /0000-0001-9657-9704; Bennett, Anton/0000-0001-5187-7599; Hoek, Jan/0000-0001-7127-4218				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ANDRESSEN C, 1995, EXP CELL RES, V219, P420, DOI 10.1006/excr.1995.1248; BERCHTOLD MW, 1989, BIOCHIM BIOPHYS ACTA, V1009, P201, DOI 10.1016/0167-4781(89)90104-8; Bernal-Mizrachi E, 2001, AM J PHYSIOL-ENDOC M, V281, pE1286, DOI 10.1152/ajpendo.2001.281.6.E1286; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Caillard O, 2000, P NATL ACAD SCI USA, V97, P13372, DOI 10.1073/pnas.230362997; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cruzalegui FH, 2000, CELL MOL LIFE SCI, V57, P402, DOI 10.1007/PL00000702; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ENDO T, 1985, ENDOCRINOLOGY, V117, P527, DOI 10.1210/endo-117-2-527; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HEIZMANN CW, 1984, EXPERIENTIA, V40, P910, DOI 10.1007/BF01946439; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HILL TD, 1988, J CELL BIOCHEM, V38, P137, DOI 10.1002/jcb.240380208; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Ichikawa J, 2001, CELL BIOCHEM FUNCT, V19, P213, DOI 10.1002/cbf.914; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; Johenning FW, 2002, J NEUROSCI, V22, P5344; KAGI U, 1987, J BIOL CHEM, V262, P7314; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LANINI L, 1992, J BIOL CHEM, V267, P11548; Lee MA, 1998, CELL CALCIUM, V23, P91, DOI 10.1016/S0143-4160(98)90107-5; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; LENORMAND P, 1992, MOL CELL BIOL, V12, P2793, DOI 10.1128/MCB.12.6.2793; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LOZA J, 1995, CELL CALCIUM, V17, P301, DOI 10.1016/0143-4160(95)90076-4; MAGNI M, 1991, J BIOL CHEM, V266, P6329; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUNTENER M, 1995, P NATL ACAD SCI USA, V92, P6504, DOI 10.1073/pnas.92.14.6504; NICOTERA P, 1994, MOL CELL BIOCHEM, V135, P89, DOI 10.1007/BF00925964; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; Nojiri S, 2000, HEPATOLOGY, V32, P947, DOI 10.1053/jhep.2000.18662; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; PAULS TL, 1993, J BIOL CHEM, V268, P20897; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; RASMUSSEN CD, 1989, MOL ENDOCRINOL, V3, P588, DOI 10.1210/mend-3-3-588; Santella L, 1997, CELL CALCIUM, V22, P11, DOI 10.1016/S0143-4160(97)90085-3; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHNEEBERGER PR, 1986, FEBS LETT, V201, P51, DOI 10.1016/0014-5793(86)80569-5; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SHEN SS, 1995, CURR TOP DEV BIOL, V30, P63, DOI 10.1016/S0070-2153(08)60564-5; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; TANAKA Y, 1992, HEPATOLOGY, V16, P479, DOI 10.1002/hep.1840160229; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wagstaff SC, 2000, CARCINOGENESIS, V21, P2175, DOI 10.1093/carcin/21.12.2175; Wahr PA, 1999, P NATL ACAD SCI USA, V96, P11982, DOI 10.1073/pnas.96.21.11982; Webb SE, 2000, BIOESSAYS, V22, P113, DOI 10.1002/(SICI)1521-1878(200002)22:2<113::AID-BIES3>3.0.CO;2-L; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; [No title captured]	91	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27517	27527		10.1074/jbc.M203002200	http://dx.doi.org/10.1074/jbc.M203002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11971908	hybrid			2022-12-25	WOS:000177055900102
J	Gaughan, L; Logan, IR; Cook, S; Neal, DE; Robson, CN				Gaughan, L; Logan, IR; Cook, S; Neal, DE; Robson, CN			Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAINS; TRANSCRIPTIONAL REPRESSION; GENE ACTIVATION; PROTEIN; ACETYLTRANSFERASE; COACTIVATOR; COMPLEX; FAMILY; P300; TRANSACTIVATION	The androgen receptor (AR), a member of the nuclear hormone receptor superfamily, is thought to play an important role in the development of prostate cancer. The AR is a hormone-dependent transcription factor that activates expression of numerous androgen-responsive genes. Histone acetyltransferase-containing proteins have been shown to increase activity of several transcription factors, including nuclear hormone receptors, by eliciting histone acetylation, which facilitates promoter access to the transcriptional machinery. Conversely, histone deacetylases (HDACs) have been identified which reduce levels of histone acetylation and are associated with transcriptional repression by various transcription factors. We have previously shown tat Tip60 (Tat-interactive protein, 60 kDa) is a bona fie co-activator protein for the AR. Here we show that Tip60 directly acetylates the AR, which we demonstrate is a requisite for Tip60-mediated transcription. To define a mechanism for repression of AR function, we demonstrate that AR activity is specifically down-regulated by the histone deacetylase activity of HDAC1. Furthermore, using both mammalian two-hybrid and immunoprecipitation experiments, we show that AR and HDAC1 interact, suggestive of a direct role for down-regulation of AR activity by HDAC1. In chromatin immunoprecipitation assays, we provide evidence that AR, Tip60, and HDAC1 form a trimeric complex upon the endogenous AR-responsive PSA promoter, suggesting that acetylation and deacetylation of the AR is an important mechanism for regulating transcriptional activity.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086				Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRINKMANN AO, 1992, J STEROID BIOCHEM, V41, P361, DOI 10.1016/0960-0760(92)90362-M; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	40	238	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25904	25913		10.1074/jbc.M203423200	http://dx.doi.org/10.1074/jbc.M203423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994312	hybrid			2022-12-25	WOS:000176908700013
J	Seong, IS; Kang, MS; Choi, MK; Lee, JW; Koh, OJ; Wang, JM; Eom, SH; Chung, CH				Seong, IS; Kang, MS; Choi, MK; Lee, JW; Koh, OJ; Wang, JM; Eom, SH; Chung, CH			The C-terminal tails of Hs1U ATPase act as a molecular switch for activation of Hs1V peptidase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-DEPENDENT PROTEASES; CELL-DIVISION INHIBITOR; ESCHERICHIA-COLI; HSLVU PROTEASE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; 20S PROTEASOME; CHAPERONE; PROTEINS; COMPLEX	The bacterial HslVU ATP-dependent protease is a homolog of the eukaryotic 26 S proteasome. HslU ATPase forms a hexameric ring, and HslV peptidase is a dodecamer consisting of two stacked hexameric rings. In HslVU complex, the HslU and HslV central pores are aligned, and the proteolytic active sites are sequestered in an internal chamber of HslV, with access to this chamber restricted to small axial pores. Here we show that the C-terminal tails of HslU play a critical role in the interaction with and activation of HslV peptidase. synthetic tail peptide of 10 amino acids could replace HslU in supporting the HslV-mediated hydrolysis of unfolded polypeptide substrates such as a-casein, as well as of small peptides, suggesting that the HslU C terminus is involved in the opening of the HslV pore for substrate entry. Moreover, deletion of 7 amino acids from the C terminus prevented the ability of HslU to form an HslVU complex with HslV. In addition, deletion of the C-terminal 10 residues prevented the formation of an HslU hexamer, indicating that the C terminus is required for HslU oligomerization. These results suggest that the HslU C-terminal tails act as a molecular switch for the assembly of HslVU complex and the activation of HslV peptidase.	Seoul Natl Univ, Sch Biol Sci, Nalt Res Lab Prot Biochem, Seoul 151742, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Seoul National University (SNU); Gwangju Institute of Science & Technology (GIST); Yale University	Chung, CH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Nalt Res Lab Prot Biochem, Seoul 151742, South Korea.							AMES B, 1996, METHOD ENZYMOL, V8, P115; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; Chung CH, 1997, BIOCHEM BIOPH RES CO, V241, P613, DOI 10.1006/bbrc.1997.7735; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; De Mot R, 1999, TRENDS MICROBIOL, V7, P88, DOI 10.1016/S0966-842X(98)01432-2; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hochstrasser M, 2001, NAT STRUCT BIOL, V8, P294, DOI 10.1038/86153; HOLT C, 1993, J CHEM SOC FARADAY T, V89, P2683, DOI 10.1039/ft9938902683; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Ishikawa T, 2000, NATURE, V408, P667, DOI 10.1038/35047165; Kang MS, 2001, EMBO J, V20, P734, DOI 10.1093/emboj/20.4.734; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MA CP, 1992, J BIOL CHEM, V267, P10515; Neuwald AF, 1999, GENOME RES, V9, P27; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; Pickart CM, 2000, NAT STRUCT BIOL, V7, P999, DOI 10.1038/81018; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Seol JH, 1997, EUR J BIOCHEM, V247, P1143, DOI 10.1111/j.1432-1033.1997.01143.x; Seong IS, 2000, FEBS LETT, V477, P224, DOI 10.1016/S0014-5793(00)01808-1; Seong IS, 1999, FEBS LETT, V456, P211, DOI 10.1016/S0014-5793(99)00935-7; SLACK FJ, 1995, MOL MICROBIOL, V15, P689, DOI 10.1111/j.1365-2958.1995.tb02378.x; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Syme CD, 2002, EUR J BIOCHEM, V269, P148, DOI 10.1046/j.0014-2956.2001.02633.x; Trame CB, 2001, ACTA CRYSTALLOGR D, V57, P1079, DOI 10.1107/S0907444901007673; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wang JM, 1998, J STRUCT BIOL, V124, P151, DOI 10.1006/jsbi.1998.4058; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Yao Y, 1999, J BIOL CHEM, V274, P33921, DOI 10.1074/jbc.274.48.33921; Yoo SJ, 1997, FEBS LETT, V412, P57, DOI 10.1016/S0014-5793(97)00742-4; Yoo SJ, 1997, BIOCHEM BIOPH RES CO, V238, P581, DOI 10.1006/bbrc.1997.7341; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	57	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25976	25982		10.1074/jbc.M202793200	http://dx.doi.org/10.1074/jbc.M202793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011053	hybrid			2022-12-25	WOS:000176908700022
J	Wallace, LJM; Candlish, D; De Koning, HP				Wallace, LJM; Candlish, D; De Koning, HP			Different substrate recognition motifs of human and trypanosome nucleobase transporters - Selective uptake of purine antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; BRUCEI-BRUCEI; HUMAN-ERYTHROCYTES; ASPERGILLUS-NIDULANS; AFRICAN TRYPANOSOMES; HYPOXANTHINE UPTAKE; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; NUCLEOSIDE; EXPRESSION	The therapeutic index of antimetabolites such as purine analogues is in large part determined by the extent to which it is selectively accumulated by the target cell. In the current study we have compared the transport of purine nucleobase analogues by the H2 transporter of bloodstream form Trypanosoma brucei brucei and the equilibrative nucleobase transporter of human erythrocytes. The H2 transporter forms hydrogen bonds with hypoxanthine at positions N3, N7, N(1)H, and N(9)H of the purine ring, with apparent DeltaG(0) of 7.7-12.6 kJ/mol. The transporter also appears to H-bond with the amine group of adenine. The human transporter forms hydrogen bonds that form to (6)NH2 and N1 of adenine. An H-bond is also formed with N3 and the 6-keto and amine groups of guanine but not with the protonated N1, thus explaining the low affinity for hypoxanthine. N7 and N9 do not directly interact with the human transporter in the form of H-bonds, and it is proposed that pi-pi stacking interactions contribute significantly to permeant binding. The potential for selective uptake of antimetabolites by the parasite transporter was demonstrated.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	De Koning, HP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	H.de-koning@bio.gla.ac.uk		De Koning, Harry/0000-0002-9963-1827				Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; Barrett MP, 1999, LANCET, V353, P1113, DOI 10.1016/S0140-6736(98)00416-4; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; De Koning HP, 1999, MOL PHARMACOL, V56, P1162, DOI 10.1124/mol.56.6.1162; de Koning HP, 1998, BIOCHEM CELL BIOL, V76, P853, DOI 10.1139/bcb-76-5-853; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; de Koning HP, 2001, INT J PARASITOL, V31, P512, DOI 10.1016/S0020-7519(01)00167-9; de Koning HP, 2001, ACTA TROP, V80, P245, DOI 10.1016/S0001-706X(01)00177-2; de Koning HP, 2001, MOL PHARMACOL, V59, P586; DeKoning HP, 1997, EUR J BIOCHEM, V247, P1102, DOI 10.1111/j.1432-1033.1997.01102.x; deKoning HP, 1997, MOL BIOCHEM PARASIT, V89, P245, DOI 10.1016/S0166-6851(97)00129-1; del Santo B, 1998, HEPATOLOGY, V28, P1504, DOI 10.1002/hep.510280609; DIALLINAS G, 1995, J BIOL CHEM, V270, P8610; DIALLINAS G, 1989, GENETICS, V122, P341; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; Dragan Y, 2000, HEPATOLOGY, V32, P239, DOI 10.1053/jhep.2000.9546; FISH WR, 1982, BIOCHIM BIOPHYS ACTA, V719, P223, DOI 10.1016/0304-4165(82)90092-7; GATI WP, 1992, J BIOL CHEM, V267, P22272; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; GRIFFITH DA, 1993, J BIOL CHEM, V268, P20085; HADDOCK PS, 1995, CARDIOVASC RES, V30, P130, DOI 10.1016/0008-6363(96)88605-6; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; KAMEN BA, 1991, SEMIN HEMATOL, V28, P12; Kaminsky R, 2000, CURR OP ANTIINF INV, V2, P76; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Kolb V M, 1997, Prog Drug Res, V48, P195; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; KRAUPP M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P157, DOI 10.1016/0005-2736(91)90158-5; Kyritsis A P, 1993, Oncology (Williston Park), V7, P93; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; Lee Chee-Wee, 1994, In Vivo (Attiki), V8, P795; MAGILL JM, 1974, J BACTERIOL, V119, P202, DOI 10.1128/JB.119.1.202-206.1974; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; MAHONY WB, 1991, BIOCHEM PHARMACOL, V41, P263, DOI 10.1016/0006-2952(91)90485-N; MAHONY WB, 1992, J BIOL CHEM, V267, P19792; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; RAZAVI M, 1993, BIOCHEM PHARMACOL, V45, P893, DOI 10.1016/0006-2952(93)90174-U; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Shayeghi M, 1999, BBA-BIOMEMBRANES, V1416, P109, DOI 10.1016/S0005-2736(98)00213-2; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; ULLMAN B, 1987, MOL CELL BIOL, V7, P97, DOI 10.1128/MCB.7.1.97; Vos S, 1998, J MOL BIOL, V282, P875, DOI 10.1006/jmbi.1998.2051	51	86	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26149	26156		10.1074/jbc.M202835200	http://dx.doi.org/10.1074/jbc.M202835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004061	hybrid			2022-12-25	WOS:000176908700043
J	Nichols, J; Rajagopalan, KV				Nichols, J; Rajagopalan, KV			Escherichia coli MoeA and MogA - Function in metal incorporation step of molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; SULFITE OXIDASE; GENE-PRODUCT; MOLYBDOPTERIN; INVOLVEMENT; IDENTIFICATION	Escherichia coli MoeA and MogA are required for molybdenum cofactor biosynthesis and are believed to function in the addition of molybdenum to the dithiolene of molybdopterin to form molybdenum cofactor. Here we show that moeA(-) and mogA(-) cells are able to synthesize molybdopterin, but both are deficient in molybdenum incorporation and, as a consequence, are deficient in the formation of molybdopterin-guanine dinucleotide. Human sulfite oxidase expressed in E. coli moeA(-) could be activated in vitro in the presence of MoeA and low concentrations of molybdate. Sulfite oxidase purified from the moeA(-) lysate was also activated, although to a lesser extent than observed in the presence of lysate. MogA was incapable of activating sulfite oxidase expressed in E. coli mogA(-). These results demonstrate that molybdenum insertion into molybdopterin is required for molybdopterin-guanine dinucleotide formation, and that MoeA facilitates molybdenum incorporation at low levels of molybdate, but MogA has an alternative function, possibly as a carrier for molybdopterin during molybdenum incorporation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Leimkuhler S, 1999, J BACTERIOL, V181, P5930; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan K.V., 1980, MOLYBDENUM MOLYBDENU, P241; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	23	50	53	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24995	25000		10.1074/jbc.M203238200	http://dx.doi.org/10.1074/jbc.M203238200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12006571	hybrid			2022-12-25	WOS:000176747000022
J	Richardson, RT; Starr, R; Angus, LJL; Hilton, DJ				Richardson, RT; Starr, R; Angus, LJL; Hilton, DJ			A somatic cell genetic system for dissecting hemopoietic cytokine signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; KREBS ASCITES-CELLS; DIFFERENTIATION FACTOR; STIMULATING FACTOR; TYROSINE KINASE; C-MYC; RECEPTOR; EXPRESSION; CLONING; BINDING	Somatic cell genetics has proven to be a powerful tool for the dissection of cytokine signal transduction pathways. Here we describe a system in which interleukin-6 (IL-6) signaling may be dissected using myeloid leukemic M1 cells. We utilized two properties of M1 cell differentiation to isolate IL-6-unresponsive mutants. First, M1 differentiation is associated with cessation of cell division. Second, differentiated M1 cells migrate rapidly and form dispersed colonies in agar. Mutant clones that are unresponsive to IL-6 are, therefore, large and compact as compared with clones derived from IL-6-responsive wild type M1 cells. Following spontaneous or chemically induced mutagenesis and selection in a high dose of IL-6, we isolated 27 M1 clones unresponsive to IL-6. Three harbored mutations that acted in a dominant manner, whereas 24 contained recessive mutations. gp130, an IL-6 receptor component, was affected in many mutant clones. We show that these clones display IL-6 and leukemia inhibitory factor receptors with reduced binding affinities and express gp130 at reduced levels. The IL-6-unresponsive phenotype of these mutant clones was fully rescued by the transfection of exogenous gp130 DNA. Therefore, this approach targets components of the IL-6 signaling pathway and may be suitable to study signaling from a variety of cytokines.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Hilton, DJ (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392; Richardson, Rachael/0000-0002-2412-8354	NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; BOYD A, 1982, ANNU REV PHYSIOL, V44, P501, DOI 10.1146/annurev.ph.44.030182.002441; BRASEL K, 1995, LEUKEMIA, V9, P1212; BRUCE AG, 1992, J IMMUNOL, V149, P1271; CHIU CP, 1989, J IMMUNOL, V142, P1909; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FACKLER MJ, 1995, BLOOD, V85, P3040, DOI 10.1182/blood.V85.11.3040.bloodjournal85113040; FELDMAN GM, 1991, BLOOD, V78, P1678; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KRYSTOSEK A, 1976, CELL, V9, P675, DOI 10.1016/0092-8674(76)90131-8; LOTEM J, 1974, P NATL ACAD SCI USA, V71, P3507, DOI 10.1073/pnas.71.9.3507; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; METCALF D, 1989, LEUKEMIA, V3, P349; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NECKERS LM, 1988, J CELL PHYSIOL, V135, P339, DOI 10.1002/jcp.1041350223; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SIMON MA, 1992, COLD SPRING HARB SYM, V57, P375, DOI 10.1101/SQB.1992.057.01.042; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	34	1	1	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25624	25630		10.1074/jbc.M202189200	http://dx.doi.org/10.1074/jbc.M202189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994291	hybrid			2022-12-25	WOS:000176747000101
J	Startchik, I; Morabito, D; Lang, U; Rossier, MF				Startchik, I; Morabito, D; Lang, U; Rossier, MF			Control of calcium homeostasis by angiotensin II in adrenal glomerulosa cells through activation of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEDIATED ALDOSTERONE SECRETION; BOVINE ADRENOCORTICAL-CELLS; SMOOTH-MUSCLE CELLS; INTRACELLULAR CALCIUM; ARACHIDONIC-ACID; INHIBITION; CAFFEINE; CHANNELS; SIGNAL	Angiotensin II-induced activation of aldosterone secretion in adrenal glomerulosa cells is mediated by an increase of intracellular calcium. We describe here a new Ca2+-regulatory pathway involving the inhibition by angiotensin II of calcium extrusion through the Na+/Ca2+ exchanger. Caffeine reduced both the angiotensin II-induced calcium signal and aldosterone production in bovine glomerulosa cells. These effects were independent of cAMP or calcium release from intracellular stores. The calcium response to angiotensin II was more sensitive to caffeine than the response to potassium, suggesting that the drug interacts with a pathway specifically elicited by the hormone. In calcium-free medium, calcium returned more rapidly to basal levels after angiotensin II stimulation in the presence of caffeine. Thapsigargin had no effect on these kinetics, but diltiazem, which inhibits the Na+/Ca2+ exchanger, markedly reduced the rate of calcium decrease and abolished caffeine action. The involvement of this exchanger was supported by the effect of cell depolarization and of a reduction of extracellular sodium on the rate of calcium extrusion. We also determined the mechanism of angiotensin II action on the exchanger. Phorbol esters reduced the rate of calcium extrusion, which was increased by baicalein, an inhibitor of lipoxygenases, and by SB 203580, an inhibitor of the p38 MAPK. Finally, we showed that angiotensin II acutely activates, in a caffeine-sensitive manner, p38 MAPK in glomerulosa cells. In conclusion, in bovine glomerulosa cells, the Na+/Ca2+ exchanger plays a crucial role in extruding calcium, and, by reducing its activity, angiotensin II influences the amplitude of the calcium signal. The hormone exerts its action on the exchanger through a caffeine-sensitive pathway involving the p38 MAPK and lipoxygenase products.	Univ Hosp, Dept Pathol, Clin Chem Lab, CH-1211 Geneva 14, Switzerland	University of Geneva	Rossier, MF (corresponding author), Univ Hosp, Div Endocrinol & Diabetol, Dept Med, 24 rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.		Rossier, Michel/AAW-2895-2021					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BIANCHI CP, 1961, J GEN PHYSIOL, V44, P845, DOI 10.1085/jgp.44.5.845; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CAPPONI AM, 1994, ENDOCRINE, V2, P579; CHABRE O, 1995, ENDOCRINOLOGY, V136, P956, DOI 10.1210/en.136.3.956; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HUGHES AD, 1990, PFLUG ARCH EUR J PHY, V416, P462, DOI 10.1007/BF00370755; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; KOJIMA I, 1986, BIOCHEM J, V237, P253, DOI 10.1042/bj2370253; KOJIMA I, 1985, ENDOCRINOLOGY, V117, P1057, DOI 10.1210/endo-117-3-1057; KRAMER RH, 1994, PFLUG ARCH EUR J PHY, V426, P12, DOI 10.1007/BF00374665; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; LANG U, 1987, J BIOL CHEM, V262, P8047; Makara JK, 2000, ENDOCRINOLOGY, V141, P1705, DOI 10.1210/en.141.5.1705; McNeill H, 1998, ENDOCR RES, V24, P373, DOI 10.3109/07435809809032617; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; NATARAJAN R, 1988, J CLIN ENDOCR METAB, V67, P584, DOI 10.1210/jcem-67-3-584; NATARAJAN R, 1992, ENDOCRINOLOGY, V131, P1174, DOI 10.1210/en.131.3.1174; NATARAJAN R, 1988, BIOCHEM BIOPH RES CO, V156, P717, DOI 10.1016/S0006-291X(88)80902-1; NATARAJAN R, 1990, MOL CELL ENDOCRINOL, V72, P73, DOI 10.1016/0303-7207(90)90096-Q; NATARAJAN R, 1994, MOL CELL ENDOCRINOL, V101, P59, DOI 10.1016/0303-7207(94)90219-4; Niisato N, 1999, BIOCHEM BIOPH RES CO, V266, P547, DOI 10.1006/bbrc.1999.1843; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PRESTWICH SA, 1995, BRIT J PHARMACOL, V114, P602, DOI 10.1111/j.1476-5381.1995.tb17182.x; Roger F, 1999, J BIOL CHEM, V274, P34103, DOI 10.1074/jbc.274.48.34103; ROSSIER MF, 1987, J BIOL CHEM, V262, P4053; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; ROSSIER MF, 1995, J BIOL CHEM, V270, P15137, DOI 10.1074/jbc.270.25.15137; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; STERN N, 1993, ENDOCRINOLOGY, V133, P843, DOI 10.1210/en.133.2.843; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tian Y, 1998, ENDOCRINOLOGY, V139, P1801, DOI 10.1210/en.139.4.1801; VANDERBENT V, 1993, ENDOCRINOLOGY, V133, P1213, DOI 10.1210/en.133.3.1213; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YANG DC, 1999, 81 ANN M END SOC ABS, P361; Zhang Z, 1996, AM J PHYSIOL-RENAL, V271, pF1234, DOI 10.1152/ajprenal.1996.271.6.F1234	47	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24265	24273		10.1074/jbc.M110947200	http://dx.doi.org/10.1074/jbc.M110947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983686	hybrid			2022-12-25	WOS:000176611800039
J	Tardif, M; Savard, M; Flamand, L; Gosselin, J				Tardif, M; Savard, M; Flamand, L; Gosselin, J			Impaired protein kinase C activation/translocation in Epstein-Barr virus-infected monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZLF-1-ENCODED ZEBRA PROTEIN; NF-KAPPA-B; NONSTRUCTURAL PROTEIN-3; INTRACELLULAR RECEPTOR; MEDIATED PHAGOCYTOSIS; HUMAN NEUTROPHILS; GENE-EXPRESSION; BETA-SUBUNIT; CELLS; RACK1	Infection of human monocytes by Epstein-Barr virus (EBV) has been linked to a decrease in the production of proinflammatory mediators as well as an impairment of phagocytosis. Considering the key role of protein kinases C (PKCs) in many biological functions of monocytes, including phagocytosis, we investigated the effects of EBV on the PKC activity in infected monocytes. Our results indicate that infection of monocytes by EBV impairs both phorbol 12-myristate 13-acetate (PMA)-induced translocation of PKC isozymes alpha and beta from cytosol to membrane as well as the PKC enzymatic activity. Similarly, the subcellular distribution of the receptor for activated C kinase (RACK), an anchoring protein essential to PKC translocation, was also found to be reduced in EBV-infected monocytes. Transfection of 293T cells with an expression vector coding for the immediate-early protein ZEBRA of EBV resulted in impaired PMA-induced translocation and activity of PKC. Using co-immunoprecipitation assays, the ZEBRA protein was found to physically interact with the RACK1 protein. Thus interaction of ZEBRA with RACK likely results in the inhibition of PKC activity, which in turn affects functions of monocytes, such as phagocytosis.	CHU Laval, Lab Viral Immunol, Ctr Rech Rhumatol & Immunol, CHUL Res Ctr CHUQ, St Foy, PQ G1V 4G2, Canada; CHU Laval, Virol Lab, Ctr Rech Rhumatol & Immunol, Res Ctr CHUQ, St Foy, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Gosselin, J (corresponding author), CHU Laval, Lab Viral Immunol, Ctr Rech Rhumatol & Immunol, CHUL Res Ctr CHUQ, 2705 Boul Laurier,Rm T 1-49, St Foy, PQ G1V 4G2, Canada.			Flamand, Louis/0000-0001-5010-4586				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Baumann M, 1998, J VIROL, V72, P8105, DOI 10.1128/JVI.72.10.8105-8114.1998; Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; BEAULIEU AD, 1995, BLOOD, V86, P2789; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Borowski P, 2000, BIOL CHEM, V381, P19, DOI 10.1515/BC.2000.003; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; DELSOL G, 1993, AM J PATHOL, V142, P1729; Dieter P, 2000, CELL SIGNAL, V12, P297, DOI 10.1016/S0898-6568(00)00069-3; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; Dreyfus DH, 1999, J IMMUNOL, V163, P6261; Dreyfus DH, 2000, BLOOD, V96, P625; Gallina A, 2001, VIROLOGY, V283, P7, DOI 10.1006/viro.2001.0855; Giroux M, 2000, J IMMUNOL, V165, P3985, DOI 10.4049/jimmunol.165.7.3985; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; Guan MX, 1998, ANTICANCER RES, V18, P3171; Kanegane H, 1998, LEUKEMIA LYMPHOMA, V29, P491, DOI 10.3109/10428199809050908; KARIMI K, 1995, J IMMUNOL, V155, P5786; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KELLEHER CA, 1995, VIROLOGY, V208, P685, DOI 10.1006/viro.1995.1200; KENT SJ, 1994, CLIN EXP IMMUNOL, V95, P450, DOI 10.1111/j.1365-2249.1994.tb07017.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Korchak HM, 2001, J BIOL CHEM, V276, P8910, DOI 10.1074/jbc.M008326200; Larochelle B, 1998, BLOOD, V92, P291, DOI 10.1182/blood.V92.1.291.413k34_291_299; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PRICE P, 1987, J VIROL, V61, P3602, DOI 10.1128/JVI.61.11.3602-3606.1987; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Savard M, 2000, J VIROL, V74, P2612, DOI 10.1128/JVI.74.6.2612-2619.2000; Savard M, 2000, J IMMUNOL, V164, P6467, DOI 10.4049/jimmunol.164.12.6467; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	42	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24148	24154		10.1074/jbc.M109036200	http://dx.doi.org/10.1074/jbc.M109036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11971896	hybrid			2022-12-25	WOS:000176611800024
J	van den Heuvel, RHH; Ferrari, D; Bossi, RT; Ravasio, S; Curti, B; Vanoni, MA; Florencio, FJ; Mattevi, A				van den Heuvel, RHH; Ferrari, D; Bossi, RT; Ravasio, S; Curti, B; Vanoni, MA; Florencio, FJ; Mattevi, A			Structural studies on the synchronization of catalytic centers in glutamate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; MACROMOLECULAR STRUCTURES; ESCHERICHIA-COLI; PROTEIN MODELS; AMMONIA; REFINEMENT; MOLSCRIPT; SUBSTRATE; PROGRAM; ENZYMES	The complex iron-sulfur flavoprotein glutamate synthase (GltS) plays a prominent role in ammonia assimilation in bacteria, yeasts, and plants. GltS catalyzes the formation of two molecules of (L)-glutamate from 2-oxoglutarate and L- glutamine via intramolecular channeling of ammonia. GltS has the impressive ability of synchronizing its distinct catalytic centers to avoid wasteful consumption of (L)-glutamine. We have determined the crystal structure of the ferredoxin-dependent GUS in several ligation and redox states. The structures reveal the crucial elements in the synchronization between the glutaminase site and the 2-iminoglutarate reduction site. The structural data combined with the catalytic properties of GUS indicate that binding of ferredoxin and 2-oxoglutarate to the FMN-binding domain of GUS induce a conformational change in the loop connecting the two catalytic centers. The rearrangement induces a shift in the catalytic elements of the amidotransferase domain, such that it becomes activated. This machinery, over a distance of more than 30 Angstrom. controls the ability of the enzyme to bind and hydrolyze the ammonia-donating substrate L-glutamine.	Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Milan, Dept Gen Physiol & Biochem, I-20133 Milan, Italy; Univ Insubria, Dept Chem Phys & Math Sci, I-22100 Como, Italy; Univ Sevilla, CSIC, Inst Plant Biochem & Photosynthesis, E-41092 Seville, Spain	University of Pavia; University of Parma; University of Milan; University of Insubria; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Mattevi, A (corresponding author), Univ Pavia, Dept Genet & Microbiol, Via Abbiategrasso 207, I-27100 Pavia, Italy.		Vanoni, Maria/AAP-2089-2021; Florencio, Francisco J/K-7716-2014; mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019	Vanoni, Maria/0000-0001-7213-732X; Florencio, Francisco J/0000-0002-2068-7861; mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; ferrari, davide/0000-0001-7084-6800				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BEALE SI, 1996, ESCHERICHIA COLI SAL, P731; Binda C, 2000, STRUCTURE, V8, P1299, DOI 10.1016/S0969-2126(00)00540-2; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navarro F, 2000, ARCH BIOCHEM BIOPHYS, V379, P267, DOI 10.1006/abbi.2000.1894; OVADI J, 1991, J THEOR BIOL, V152, P135, DOI 10.1016/S0022-5193(05)80528-4; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Ravasio S, 2001, BIOCHEMISTRY-US, V40, P5533, DOI 10.1021/bi0100889; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vanoni MA, 1998, BIOCHEMISTRY-US, V37, P1828, DOI 10.1021/bi972342w; Vanoni MA, 1999, CELL MOL LIFE SCI, V55, P617, DOI 10.1007/s000180050319; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; [No title captured]	31	66	67	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24579	24583		10.1074/jbc.M202541200	http://dx.doi.org/10.1074/jbc.M202541200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967268	Green Published, hybrid			2022-12-25	WOS:000176611800080
J	Abe, J; Fukuzawa, T; Hirose, S				Abe, J; Fukuzawa, T; Hirose, S			Cleavage of Ig-Hepta at a "SEA" module and at a conserved G protein-coupled receptor proteolytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; EXTRACELLULAR DOMAIN; SECRETIN FAMILY; CELL-SURFACE; MEMBER; CLONING; 7-TRANSMEMBRANE; GENE; IDENTIFICATION; GLYCOPROTEIN	Ig-Hepta is a member of a new subfamily of the heptahelical receptors and has an unusually long N terminus extending toward the extracellular side of the plasma membrane. Pulse-chase experiments in 293T cells using antisera specifically recognizing its N- and C-terminal regions demonstrated that Ig-Hepta is core-glycosylated cotranslationally and proteolytically processed into a two-chain form in the endoplasmic reticulum, followed by maturation of oligosaccharide chains and dimerization. The cleavage occurs at two highly conserved sites: one in a "SEA" module (a module first identified in sperm protein, enterokinase, and agrin) near the N terminus and the other in the stalk region preceding the first transmembrane span, generating similar to20-, 130-, and 32-kDa fragments. The latter two remain tightly associated non-covalently even after cleavage as revealed by immunoprecipitation of native and myc-tagged Ig-Hepta constructs that were transiently expressed in 293T cells. The dimer consisting of four chains, (130 kDa + 32 kDa)21 is linked by disulfide bonds. A fusion protein of the extracellular domain of Ig-Hepta and the Fe domain of immunoglobulin was found to be a good substrate of the processing enzymes and used for determining the exact cleavage sites in the SEA module and juxtamembrane stalk region.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp						Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Formstone CJ, 2001, MECH DEVELOP, V109, P91, DOI 10.1016/S0925-4773(01)00515-9; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gray JX, 1996, J IMMUNOL, V157, P5438; Hadjantonakis AK, 1997, GENOMICS, V45, P97, DOI 10.1006/geno.1997.4892; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Osterhoff C, 1997, DNA CELL BIOL, V16, P379, DOI 10.1089/dna.1997.16.379; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; WARD CJ, 1994, CELL, V77, P881; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502	36	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23391	23398		10.1074/jbc.M110877200	http://dx.doi.org/10.1074/jbc.M110877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973329	hybrid			2022-12-25	WOS:000176475700039
J	Flinn, EM; Wallberg, AE; Hermann, S; Grant, PA; Workman, JL; Wright, APH				Flinn, EM; Wallberg, AE; Hermann, S; Grant, PA; Workman, JL; Wright, APH			Recruitment of Gen5-containing complexes during c-Myc-dependent gene activation - Structure and function aspects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEXES; BURKITTS-LYMPHOMA CELLS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; IN-VIVO; ESSENTIAL COFACTOR; ACETYLASE COMPLEX	The N-terminal domain of c-Myc plays a key role in cellular transformation and is involved in both activation and repression of target genes as well as in modulated proteolysis of c-Myc via the proteasome. Given this functional complexity, it has been difficult to clarify the structures within the N terminus that contribute to these different processes as well as the mechanisms by which they function. We have used a simplified yeast model system to identify the primary determinants within the N terminus for W chromatin remodeling of a promoter, (ii) gene activation from a chromatin template in vivo, and (iii) interaction with highly purified Gcn5 complexes as well as other chromatin-remodeling complexes in vitro. The results identify two regions that contain autonomous chromatin opening and gene activation activity, but both regions are required for efficient interaction with chromatin-remodeling complexes in vitro. The conserved Myc boxes do not play a direct role in gene activation, and Myc box II is not generally required for in vitro interactions with remodeling complexes. The yeast SAGA complex, which is orthologous to the human GCN5-TRRAP complex that interacts with Myc in human cells, plays a role in Myc-mediated chromatin opening at the promoter but may also be involved in later steps of gene activation.	Sodertorns Hogskola, Sect Nat Sci, S-14104 Huddinge, Sweden; Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Sodertorn University; Karolinska Institutet; University of Virginia; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wright, APH (corresponding author), Sodertorns Hogskola, Sect Nat Sci, Box 4101, S-14104 Huddinge, Sweden.		Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969	NIDDK NIH HHS [DK58646] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058646] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Chen BS, 2001, J BIOL CHEM, V276, P23881, DOI 10.1074/jbc.M102893200; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROUCH DH, 1993, ONCOGENE, V8, P1849; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FISHER F, 1991, ONCOGENE, V6, P1099; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; GREEN JBA, 1988, MOL GEN GENET, V215, P100, DOI 10.1007/BF00331310; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Hermann S, 2001, J BIOL CHEM, V276, P40127, DOI 10.1074/jbc.M103793200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Massari ME, 1996, MOL CELL BIOL, V16, P121; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEYHACK B, 1982, EMBO J, V1, P675, DOI 10.1002/j.1460-2075.1982.tb01229.x; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; Rose MD., 1990, METHODS YEAST GENETI; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHOR J, 1995, ONCOGENE, V10, P1587; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	83	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23399	23406		10.1074/jbc.M201704200	http://dx.doi.org/10.1074/jbc.M201704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973336	hybrid			2022-12-25	WOS:000176475700040
J	Gaultier, A; Cousin, H; Darribere, T; Alfandari, D				Gaultier, A; Cousin, H; Darribere, T; Alfandari, D			ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC INTERACTION; ADAM-12 MELTRIN-ALPHA; CREST-CELL-MIGRATION; METALLOPROTEASE-DISINTEGRIN; INTEGRIN ALPHA-4-BETA-1; PROTEASE DOMAIN; XENOPUS-LAEVIS; MURINE EGGS; ADHESION; EXPRESSION	ADAM13 is a member of the disintegrin and metalloprotease protein family that is expressed on cranial neural crest cells surface and is essential for their migration. ADAM13 is an active protease that can cleave fibronectin in vitro and remodel a fibronectin substrate in vivo. Using a recombinant secreted protein containing both disintegrin and cysteine-rich domains of ADAM13, we show that this "adhesive" region of the protein binds directly to fibronectin. Fibronectin fusion proteins corresponding to the various functional domains were used to define the second heparin-binding domain as the ADAM13 binding site. Mutation of the syndecan-binding site (PPRR --> PPTM) within this domain abolishes binding of the recombinant disintegrin and cysteine-rich domains of ADAM13. We further show that the adhesive disintegrin and cysteine-rich domain of ADAM13 can promote cell adhesion via P, integrins. This adhesion requires integrin activation and can be prevented by antibodies to the cysteine-rich domain of ADAM13 and P, integrin. Finally, wild type, but not the E/A mutant of ADAM13 metalloprotease domain, can be shed from the cell surface, releasing the metalloprotease domain associated with the disintegrin and cysteine-rich domains. This suggests that ADAM13 shedding may involve its own metalloprotease activity and that the released protease may interact with both integrins and extracellular matrix proteins.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Paris 06, Biol Dev Lab, UMR CNRS 7622, F-75005 Paris, France	University of Virginia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Alfandari, D (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA.	da3s@virginia.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014365] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26402] Funding Source: Medline; NIDCR NIH HHS [DE14365] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alfandari D, 1996, MECH DEVELOP, V56, P83, DOI 10.1016/0925-4773(96)00513-8; Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; Alfandari D, 2001, CURR BIOL, V11, P918, DOI 10.1016/S0960-9822(01)00263-9; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Darribere T, 2000, BIOL CELL, V92, P5, DOI 10.1016/S0248-4900(00)88760-2; DZAMBA BD, 2002, CELL ADHESION FRONTI, P100; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Harlow E., 1988, ANTIBODIES LAB MANUA; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MENDRICK DL, 1995, LAB INVEST, V72, P367; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; Nath D, 2000, J CELL SCI, V113, P2319; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Teel AL, 1996, MECH DEVELOP, V59, P115, DOI 10.1016/0925-4773(96)00584-9; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; WHITE JM, 2001, CELL ADHESION FRONTI, P189; Whittaker CA, 1998, ANN NY ACAD SCI, V857, P56, DOI 10.1111/j.1749-6632.1998.tb10107.x; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	44	58	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23336	23344		10.1074/jbc.M201792200	http://dx.doi.org/10.1074/jbc.M201792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967265	hybrid			2022-12-25	WOS:000176475700033
J	Giri, S; Jatana, M; Rattan, R; Won, JS; Singh, I; Singh, AK				Giri, S; Jatana, M; Rattan, R; Won, JS; Singh, I; Singh, AK			Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease	FASEB JOURNAL			English	Article						cerebroside; GLD; iNOS; oligodendrocytes; beta-galactosidase	GLOBOID-CELL LEUKODYSTROPHY; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; TWITCHER MOUSE; PSYCHOSINE GALACTOSYLSPHINGOSINE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; SPINAL-CORD; ACCUMULATION; BETA	Globoid cell leukodystrophy (Krabbe disease) is characterized by the accumulation of a toxic metabolite, psychosine (galactosylsphingosine), which is a substrate for the deficient enzyme (galactocerebroside beta-galactosidase). This study underscores the possible role of psychosine in the effect of inducible nitric oxide synthase (iNOS) -derived NO in the pathophysiology of this demyelinating disease. For the first time, we provide evidence of the expression of iNOS in CNS of Krabbe patient and show that the iNOS-expressing cells in the CNS were astrocytes. Psychosine potentiated the LPS-induced production of proinflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in primary rat astrocytes and regulated the cytokine-mediated production of NO in C6 glioma and primary rat astrocyte. Psychosine induced cytokine-mediated nuclear translocation of AP-1 and C/EBP by potentiating the expression of Fra-1 and C/EBP-delta proteins. This suggests that psychosine maintained or sustained the cytokine-primed expression of iNOS by further potentiating the nuclear translocation of AP-1 and C/EBP without modulating the cytokine-mediated transcription activity of NF-kappaB. This study hypothesizes that accumulated psychosine leads to production of cytokines and iNOS expression. The ensuing excessive production of NO and ONOO- may play a role in pathogenesis of Krabbe disease.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Singh, AK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 316 Clin Sci Bldg, Charleston, SC 29425 USA.	singhi@musc.edu	Singh, Ashok/HGF-2506-2022	Won, Jeseong/0000-0003-2408-0386	NINDS NIH HHS [NS-34741, NS-22576, NS 37766, NS-40810] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022576, R01NS040810, R01NS034741, R37NS022576, R01NS037766] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ANDREWS J M, 1970, Experimental Neurology, V29, P483, DOI 10.1016/0014-4886(70)90075-0; AUSTIN J, 1970, ARCH NEUROL-CHICAGO, V23, P502, DOI 10.1001/archneur.1970.00480300024003; AUSTIN JH, 1963, BRAIN LIPIDS LIPOPRO, P120; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; COSTANTI.E, 1972, LIPIDS, V7, P656, DOI 10.1007/BF02533072; Cross AH, 1996, J NEUROIMMUNOL, V71, P145, DOI 10.1016/S0165-5728(96)00147-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Guan ZH, 1999, J BIOL CHEM, V274, P36200, DOI 10.1074/jbc.274.51.36200; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; IDA H, 1990, BRAIN DEV-JPN, V12, P412, DOI 10.1016/S0387-7604(12)80074-X; IGISU H, 1984, SCIENCE, V224, P753, DOI 10.1126/science.6719111; IGISU H, 1986, BIOCHEM BIOPH RES CO, V137, P323, DOI 10.1016/0006-291X(86)91213-1; JACOBS JM, 1982, J NEUROL SCI, V55, P285, DOI 10.1016/0022-510X(82)90127-7; KOBAYASHI T, 1985, J BIOL CHEM, V260, P4982; KOBAYASHI T, 1987, BIOCHEM BIOPH RES CO, V144, P41, DOI 10.1016/S0006-291X(87)80472-2; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Krabbe K, 1916, BRAIN, V39, P74, DOI 10.1093/brain/39.1-2.74; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LeVine SM, 1997, J NEUROIMMUNOL, V73, P47, DOI 10.1016/S0165-5728(96)00166-X; Luzi P, 1996, ANN NEUROL, V40, P116, DOI 10.1002/ana.410400119; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Merrill JE, 1999, NEUROPATH APPL NEURO, V25, P435; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Merrill JE, 1997, METAB BRAIN DIS, V12, P97, DOI 10.1023/B:MEBR.0000007105.13587.ba; MITROVIC B, 1995, NEUROSCIENCE, V65, P531, DOI 10.1016/0306-4522(94)00491-M; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; SHINODA H, 1987, J NEUROCHEM, V49, P92, DOI 10.1111/j.1471-4159.1987.tb03399.x; Smith KJ, 1999, BRAIN PATHOL, V9, P69; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUGAMA S, 1990, PEDIATR RES, V28, P473, DOI 10.1203/00006450-199011000-00011; SUZUKI K, 1970, P NATL ACAD SCI USA, V66, P302, DOI 10.1073/pnas.66.2.302; Suzuki K, 1998, NEUROCHEM RES, V23, P251, DOI 10.1023/A:1022436928925; SUZUKI K, 1976, CURRENT TRENDS SPHIN, V50, P99; SUZUKI K, 1995, METABOLIC MOL BASES, V2, P2671; SVENNERHOLM L, 1980, J LIPID RES, V21, P53; SVENNERHOLM L, 1963, BRAIN LIPIDS LIPOPRO, P104; SWEET H, 1986, MOUSE NEWSLETTER, V75, P30; TAKAHASHI H, 1984, ACTA NEUROPATHOL, V62, P298, DOI 10.1007/BF00687612; TAKAHASHI H, 1983, ACTA NEUROPATHOL, V59, P159, DOI 10.1007/BF00703199; TANAKA K, 1993, J NEUROPATH EXP NEUR, V52, P490, DOI 10.1097/00005072-199309000-00007; TANAKA K, 1989, BRAIN RES, V482, P347, DOI 10.1016/0006-8993(89)91198-0; TANAKA K, 1988, BRAIN RES, V454, P340, DOI 10.1016/0006-8993(88)90835-9; TANIIKE M, 1995, J NEUROSCI RES, V40, P325, DOI 10.1002/jnr.490400306; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wu YP, 2001, J NEUROPATH EXP NEUR, V60, P1062, DOI 10.1093/jnen/60.11.1062; ZLOTOGORA J, 1990, AM J HUM GENET, V47, P37	62	90	91	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0661	10.1096/fj.01-0798com	http://dx.doi.org/10.1096/fj.01-0798com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978730				2022-12-25	WOS:000175973900020
J	Hiner, ANP; Ruiz, JH; Lopez, JNR; Canovas, FG; Brisset, NC; Smith, AT; Arnao, MB; Acosta, M				Hiner, ANP; Ruiz, JH; Lopez, JNR; Canovas, FG; Brisset, NC; Smith, AT; Arnao, MB; Acosta, M			Reactions of the class II peroxidases, lignin peroxidase and Arthromyces ramosus peroxidase, with hydrogen peroxide - Catalase-like activity, compound III formation, and enzyme inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-CHLOROPEROXYBENZOIC ACID; CYTOCHROME-C PEROXIDASE; HORSERADISH-PEROXIDASE; ASCORBATE PEROXIDASE; ESCHERICHIA-COLI; MECHANISM; OXYGEN; H2O2; IDENTIFICATION; DECOMPOSITION	The reactions of the fungal enzymes Arthromyces ramosus peroxidase (ARP) and Phanerochaete chrysosporium lignin peroxidase (LiP) with hydrogen peroxide (H2O2) have been studied. Both enzymes exhibited catalase activity with hyperbolic H2O2 concentration dependence (K-m approximate to 8-10 mM, k(cat) approximate to 1-3 s(-1)). The catalase and peroxidase activities of LiP were inhibited within 10 min and those of ARP in 1 h. The inactivation constants were calculated using two independent methods; LiP, k(i) approximate to 19 x 10(-3) s(-1); ARP, k(i) approximate to 1.6 x 10(-3) s(-1). Com pound III (oxyperoxidase) was detected as the majority species after the addition of H2O2 to LiP or ARP, and its formation was accompanied by loss of enzyme activity. A reaction scheme is presented which rationalizes the turnover and inactivation of LiP and ARP with H2O2. A similar model is applicable to horseradish peroxidase. The scheme links catalase and compound III forming catalytic pathways and inactivation at the level of the [compound I.H2O2] complex. Inactivation does not occur from compound III. All peroxidases studied to date are sensitive to inactivation by H2O2, and it is suggested that the model will be generally applicable to peroxidases of the plant, fungal, and prokaryotic superfamily.	Univ Murcia, Dept Biol Vegetal Fisiol Vegetal, E-30100 Murcia, Spain; Univ Murcia, Dept Bioquim & Biol Mol A, E-30100 Murcia, Spain; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Murcia; University of Murcia; University of Sussex	Acosta, M (corresponding author), Univ Murcia, Dept Biol Vegetal Fisiol Vegetal, E-30100 Murcia, Spain.	macosta@um.es	Josefa, Hernandez-Ruiz/R-5424-2018; Hu, Ruogu/B-2203-2008; Acosta, Manuel/A-2127-2008; Arnao, Marino B./ABE-9146-2020	Josefa, Hernandez-Ruiz/0000-0002-1847-8809; Acosta, Manuel/0000-0003-0611-6672; Arnao, Marino B./0000-0001-8517-6889; Smith, Andrew/0000-0002-0926-1878				ACOSTA M, 1991, BIOCH MOL PHYSL ASPE, P175; ACOSTA M, 1996, PLANT PEROXIDASES BI, P76; ACOSTA M, 1993, PLANT PEROXIDASES BI, P201; Arnao MB, 1995, J MOL CATAL A-CHEM, V104, P179, DOI 10.1016/1381-1169(95)00114-X; Arnao MB, 1996, BIOCHEM MOL BIOL INT, V39, P97; ARNAO MB, 1990, BIOCHIM BIOPHYS ACTA, V1038, P85, DOI 10.1016/0167-4838(90)90014-7; ARNAO MB, 1990, BIOCHIM BIOPHYS ACTA, V1041, P43, DOI 10.1016/0167-4838(90)90120-5; Baker CJ, 2000, ARCH BIOCHEM BIOPHYS, V382, P232, DOI 10.1006/abbi.2000.2013; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; CAI DY, 1989, BIOCHEM BIOPH RES CO, V162, P464, DOI 10.1016/0006-291X(89)92020-2; CAI DY, 1992, J BIOL CHEM, V267, P11149; CAI DY, 1990, BIOCHEMISTRY-US, V29, P2085, DOI 10.1021/bi00460a018; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; Converso DA, 1998, ARCH BIOCHEM BIOPHYS, V357, P22, DOI 10.1006/abbi.1998.0763; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; Doyle WA, 1996, BIOCHEM J, V315, P15, DOI 10.1042/bj3150015; Dunford H. B., 1999, HEME PEROXIDASES, P281; Dunford H B, 1990, PEROXIDASES CHEM BIO, V2, P1; Garcia-Canovas F, 1989, J Enzyme Inhib, V3, P81, DOI 10.3109/14756368909030367; Hernandez-Ruiz J, 2001, BIOCHEM J, V354, P107, DOI 10.1042/0264-6021:3540107; Hernandez-Ruiz J, 2000, BBA-PROTEIN STRUCT M, V1478, P78, DOI 10.1016/S0167-4838(00)00017-0; Hiner ANP, 1996, BIOTECHNOL BIOENG, V50, P655, DOI 10.1002/(SICI)1097-0290(19960620)50:6<655::AID-BIT6>3.3.CO;2-U; Hiner ANP, 2000, BIOCHEM J, V348, P321, DOI 10.1042/0264-6021:3480321; HINER ANP, 1995, EUR J BIOCHEM, V234, P506, DOI 10.1111/j.1432-1033.1995.506_b.x; Hiner ANP, 2001, ARCH BIOCHEM BIOPHYS, V392, P295, DOI 10.1006/abbi.2001.2460; Hiner ANP, 2001, J BIOL INORG CHEM, V6, P504, DOI 10.1007/s007750100219; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; KJALKE M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P248, DOI 10.1016/0167-4838(92)90244-8; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Obinger C, 1997, BIOCHEM BIOPH RES CO, V235, P545, DOI 10.1006/bbrc.1997.6847; Obinger C, 1999, PHOTOTROPHIC PROKARY, P719; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P13201, DOI 10.1021/bi001150p; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; RODRIGUEZLOPEZ JN, 1992, ANAL BIOCHEM, V202, P356, DOI 10.1016/0003-2697(92)90118-Q; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1990, J BIOL CHEM, V265, P11137; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; YONETANI T, 1966, J BIOL CHEM, V241, P3240	46	47	47	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26879	26885		10.1074/jbc.M200002200	http://dx.doi.org/10.1074/jbc.M200002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11983689	Green Submitted, hybrid			2022-12-25	WOS:000177055900025
J	Grunewald, M; Menaker, D; Kanner, BI				Grunewald, M; Menaker, D; Kanner, BI			Cysteine-scanning mutagenesis reveals a conformationally sensitive reentrant pore-loop in the glutamate transporter GLT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MEMBRANE-VESICLES; ACID TRANSPORTER; CHANNEL; SELECTIVITY; EXPRESSION; SUBSTRATE; TOPOLOGY; RESIDUE; ACCESSIBILITY	Removal of glutamate from the synaptic cleft by (Na+ + K+)-coupled transporters prevents neurotoxicity due to elevated concentrations of the transmitter. These transporters exhibit an unusual topology, including two reentrant loops. Reentrant loop 11 plays a pivotal role in coupling ion and glutamate fluxes. Here we used cysteine-scanning mutagenesis of the GLT-1 transporter to test the idea that this loop undergoes conformational changes following sodium and substrate binding. 15 of 22 consecutive single cysteine mutants in the stretch between Gly-422 and Ser-443 exhibited 30-100% of the transport activity of the cysteine-less transporter when expressed in HeLa cells. The transport activity of 11 of the 15 active mutants including five consecutive residues in the ascending limb was inhibited by small hydrophilic methanethiosulfonate reagents. The sensitivity of seven cysteine mutants, including A438C and S440C, to the reagents was significantly reduced by sodium ions, but the opposite was true for A439C. The non-transportable analogue dihydrokainate protected at almost all positions throughout the loop, and at two of the positions, the analogue protected even in the absence of sodium. Our results indicate that reentrant loop H forms part of an aqueous pore, the access of which is blocked by the glutamate analogue dihydrokainate, and that sodium influences the conformation of this pore-loop.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Diamond JS, 1997, J NEUROSCI, V17, P4672; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; YOUNG VR, 2000, J NUTR, V130, pS829; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26074	26080		10.1074/jbc.M202248200	http://dx.doi.org/10.1074/jbc.M202248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994293	hybrid			2022-12-25	WOS:000176908700033
J	Muller, S; Hanisch, FG				Muller, S; Hanisch, FG			Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin - High density and prevalent core 2-based glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM REPEAT PEPTIDE; SKIM MILK MUCINS; LINKED POLYLACTOSAMINOGLYCANS; EPITHELIAL MUCIN; T-CELLS; ADENOCARCINOMA; REACTIVITY; ANTIBODIES; PROTEIN; SIALYLTRANSFERASE	Knowledge about the O-linked glycan chains of tumor-associated MUC1 is primarily based on enzymatic and immunochemical evidence. To obtain structural information and to overcome limitations by the scarcity of endogenous mucin, we expressed a recombinant glycosylation probe corresponding to six MUC1 tandem repeats in four breast cancer cell lines. Comparative analyses of the O-glycan profiles were performed after hydrazinolysis and normal phase chromatography of 2-aminobenzamide-labeled glycans. Except for a general reduction in the O-glycan chain lengths and a high density glycosylation, no common structural pattern was revealed. T47D fusion protein exhibits an almost complete shift from core 2 to core 1 expression with a preponderance of sialylated glycans. By contrast, MCF-7, MDA-MB231, and ZR75-1 cells glycosylate the MUC1 repeat peptide preferentially with core 2-based glycans terminating mostly with alpha3-linked sialic acid (MDA-MB231, ZR75-1) or alpha2/3-linked fucose (MCF-7). Endogenous MUC1 from T47D and MCF-7 cell supernatants revealed almost identical O-glycosylation profiles compared with the respective recombinant probes, indicating that the fusion proteins reflected the authentic O-glycan profiles of the cells. The structural patterns in the majority of cells under study are in conflict with biosynthetic models of MUC1 O-glycosylation in breast cancer, which claim that the truncation of normal core 2-based polylactosamine structures to short sialylated core 1-based glycans is due to the reduced activity of core 2-forming beta6-N-acetylglucosaminyltransferases and/or to overexpression of competitive alpha3-sialyltransferase.	Univ Cologne, Ins Biochem 2, Fak Med, D-50931 Cologne, Germany	University of Cologne	Hanisch, FG (corresponding author), Univ Cologne, Ins Biochem 2, Fak Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.				NATIONAL CANCER INSTITUTE [R01CA084106] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA84106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal B, 1998, CANCER RES, V58, P4079; AGRAWAL B, 1995, CANCER RES, V55, P2257; APOSTOLOPOULOS V, 1994, CRIT REV IMMUNOL, V14, P293, DOI 10.1615/CritRevImmunol.v14.i3-4.40; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; Bhavanandan VP, 1998, GLYCOCONJUGATE J, V15, P37, DOI 10.1023/A:1006987315827; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; Dent GA, 1999, AM J CLIN PATHOL, V111, P741; Engelmann K, 2001, J BIOL CHEM, V276, P27764, DOI 10.1074/jbc.M103187200; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GIRLING A, 1989, INT J CANCER, V43, P1972; Goydos JS, 1996, J SURG RES, V63, P298, DOI 10.1006/jsre.1996.0264; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1990, GLYCOCONJUGATE J, V7, P525, DOI 10.1007/BF01189075; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; HANISCH FG, 2000, GLYCOBIOLOGY, V9, P1181; HILKENS J, 1986, CANCER RES, V46, P2582; Hiltbold EM, 1999, CELL IMMUNOL, V194, P143, DOI 10.1006/cimm.1999.1512; Hull S R, 1989, Cancer Commun, V1, P261; Karanikas V, 1997, J CLIN INVEST, V100, P2783, DOI 10.1172/JCI119825; Karsten U, 1998, CANCER RES, V58, P2541; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOTERA Y, 1994, CANCER RES, V54, P2856; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Miles DW, 1999, PHARMACOL THERAPEUT, V82, P97, DOI 10.1016/S0163-7258(99)00003-0; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; von Mensdorff-Pouilly S, 2000, INT J CANCER, V86, P702, DOI 10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	38	122	126	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26103	26112		10.1074/jbc.M202921200	http://dx.doi.org/10.1074/jbc.M202921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000758	hybrid			2022-12-25	WOS:000176908700037
J	Wang, YL; De Keulenaer, GW; Lee, RT				Wang, YL; De Keulenaer, GW; Lee, RT			Vitamin D-3-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CARDIAC MYOCYTES; OXIDATIVE STRESS; HEART-FAILURE; IN-VITRO; HYPERTROPHY; EXPRESSION; REDUCTASE; SURVIVAL; DISEASE	The protein-disulfide reductase thioredoxin is critical for redox signaling during apoptosis and growth. In this study, we demonstrate that vitamin D-3-up-regulated protein-1 regulates thioredoxin in conditions of biomechanical or oxidative stress and critically regulates cardiomyocyte viability. Expression of vitamin D-3-up-regulated protein-1 but not of thioredoxin in rat cardiomyocytes was rapidly suppressed by biomechanical strain or hydrogen peroxide at both mRNA and protein levels. Mechanical suppression of vitamin D-3-up-regulated protein-1 gene expression was blocked by N-acetylcysteine. The half-life of vitamin D-3-up-regulated protein-1 transcripts in cardiomyocytes was only 1.1 h and remained unchanged after mechanical stimulation, suggesting that rapid responses in vitamin D-3-up-regulated protein-1 gene expression occur through transcriptional control. Vitamin D-3-up-regulated protein-1 down-regulation by strain or hydrogen peroxide led to increased thioredoxin activity, whereas adenovirus-mediated overexpression of vitamin D-3-up-regulated protein-1 suppressed thioredoxin activity. Overexpression of vitamin D-3-up-regulated protein-1 but not of thioredoxin induced cardiomyocyte apoptosis. Furthermore, overexpression of vitamin D-3-up-regulated protein-1 sensitized cells to hydrogen peroxide-induced apoptosis, whereas overexpression of thioredoxin protected against injury. These data identify vitamin D-3-up-regulated protein-1 as a key stress-responsive inhibitory switch of thioredoxin activity in cardiomyocytes and demonstrate that the vitamin D-3-up-regulated protein-1/thioredoxin axis has an important role in the preservation of cellular viability.	Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital	Lee, RT (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Dept Med, 65 Landsdowne St, Cambridge, MA 02139 USA.		De Keulenaer, Gilles/D-9321-2017	De Keulenaer, Gilles/0000-0002-4238-4183	NHLBI NIH HHS [HL64858, HL67554] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL067554, P01HL064858] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 2001, BIOCHEM BIOPH RES CO, V289, P901, DOI 10.1006/bbrc.2001.6068; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Aota M, 1996, J CARDIOVASC PHARM, V27, P727, DOI 10.1097/00005344-199605000-00016; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BOLLI R, 1988, J AM COLL CARDIOL, V12, P239, DOI 10.1016/0735-1097(88)90381-6; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kishimoto C, 2001, JPN CIRC J, V65, P491, DOI 10.1253/jcj.65.491; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shioji K, 2000, FEBS LETT, V472, P109, DOI 10.1016/S0014-5793(00)01446-0; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; Yamanaka H, 2000, BIOCHEM BIOPH RES CO, V271, P796, DOI 10.1006/bbrc.2000.2699; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221	23	146	150	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26496	26500		10.1074/jbc.M202133200	http://dx.doi.org/10.1074/jbc.M202133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011048	hybrid			2022-12-25	WOS:000176908700088
J	Wong, J; Li, PX; Klamut, HJ				Wong, J; Li, PX; Klamut, HJ			A novel p53 transcriptional repressor element (p53TRE) and the asymmetrical contribution of two p53 binding sites modulate the response of the placental transforming growth factor-beta promoter to p53.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; IMPAIRED APOPTOTIC FUNCTION; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; DIFFERENTIAL ACTIVATION; POTENTIAL MEDIATOR; ARREST; GENE; CONFORMATION; MUTANTS	Previous studies in our laboratory and others identified placental transforming growth factor-beta (PTGF-beta) as an important downstream mediator of DNA damage signaling and a transcriptional target of p53. Here we show that accumulation of PTGF-beta mRNA in response to p53 overexpression is delayed relative to p21(WAF1), whereas the promoters of these genes respond to p53 with similar kinetics. Mutational analyses of two p53 binding sites within the PTGF-beta promoter revealed that site p53-1 (+29 bp) is responsible for as much as 80% of the transcriptional response to p53. This is consistent with electrophoretic mobility shift assays showing that site p53-1 binds p53 with a much higher affinity than site p53-2 (-850 bp). We also describe for the first time a novel 21-bp element (-222 to -242 bp) that acts to down-regulate the PTGF-beta promoter response to p53. Termed the p53 transcriptional repressor element (p53TRE), this sequence was shown to suppress p53 transactivation in a position- and promoter-independent fashion and to associate with a 28-kDa protein expressed in several tumor cell lines. A p53 suppressor element and asymmetric p53 binding sites may participate determining the activation thresholds of p53-responsive promoters in a cell- and context-specific manner.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst,Univ Hlth Network, Princess Margaret Hosp,Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Klamut, HJ (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst,Univ Hlth Network, Princess Margaret Hosp,Div Expt Therapeut, 610 Univ Ave,Rm 10-721, Toronto, ON M5G 2M9, Canada.	hklamut@uhnres.utoronto.ca		Wong, J. Tze-Fei/0000-0001-8539-8537				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Garkavtsev IV, 2001, ONCOGENE, V20, P8276, DOI 10.1038/sj.onc.1205120; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Kong XT, 2001, J BIOL CHEM, V276, P32990, DOI 10.1074/jbc.M103681200; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Li PX, 1998, BREAST CANCER RES TR, V48, P273, DOI 10.1023/A:1005961705860; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yardley G, 1998, FEBS LETT, V430, P171, DOI 10.1016/S0014-5793(98)00650-4; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhao RB, 2000, GENE DEV, V14, P981	54	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26699	26707		10.1074/jbc.M203020200	http://dx.doi.org/10.1074/jbc.M203020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011055	hybrid			2022-12-25	WOS:000176908700112
J	Bishop, AC; Xu, JM; Johnson, RC; Schimmel, P; de Crecy-Lagard, V				Bishop, AC; Xu, JM; Johnson, RC; Schimmel, P; de Crecy-Lagard, V			Identification of the tRNA-dihydrouridine synthase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; POSTTRANSCRIPTIONAL MODIFICATION; BINDING-PROTEIN; DATABASE; LOOP; RECOMBINATION; SEQUENCE; BACTERIA; PATHWAYS	5,6-Dihydrouridine (D) is a modified base found abundantly in the D-loops of tRNA from Archaea, Bacteria, and Eukarya. D is thought to be formed post-transcriptionally by the reduction of uridines in tRNA transcripts. Despite its abundance, no enzymes that catalyze D-formation have been identified. Using comparative genomics and computational methods we have identified members of the cluster of orthologous genes, COG0042, as putative dihydrouridine synthase encoding genes. Escherichia coli contains three COG0042 family members (yjbN, yhdG, and yohI). Strains were created where one, two, or all three of the COG0042 genes were deleted. Purified tRNA samples were investigate from the three single and the three double knockout strains, as well as from the triple deletion strain. The results showed that the COG0042 gene family is responsible for tRNA-dihydrouridine synthase activity in E. coli. They also suggest that the COG0042-encoded family members act site-specifically on the tRNA D-loop and contain non-redundant catalytic functions in vivo.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-379,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Hu, Ruogu/B-2203-2008; de Crecy-Lagard, Valerie/AAN-8995-2020		NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander RW, 1999, BIOCHEMISTRY-US, V38, P16359, DOI 10.1021/bi991948c; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BlondeletRouault MH, 1997, GENE, V190, P315, DOI 10.1016/S0378-1119(97)00014-0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Constantinesco F, 1999, NUCLEIC ACIDS RES, V27, P1308, DOI 10.1093/nar/27.5.1308; Dalluge JJ, 1997, J BACTERIOL, V179, P1918, DOI 10.1128/jb.179.6.1918-1923.1997; Dalluge JJ, 1996, NUCLEIC ACIDS RES, V24, P1073, DOI 10.1093/nar/24.6.1073; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Hendrickson TL, 2001, P NATL ACAD SCI USA, V98, P13473, DOI 10.1073/pnas.251549298; HUNNINGHAKE D, 1966, ANAL BIOCHEM, V16, P200, DOI 10.1016/0003-2697(66)90147-3; JACOBSON M, 1970, ANAL BIOCHEM, V34, P459, DOI 10.1016/0003-2697(70)90130-2; Jensen KF, 1998, PATHS PYRIMIDINES, V6, P20; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOWALAK JA, 1995, J BIOL CHEM, V270, P17758, DOI 10.1074/jbc.270.30.17758; MADISON JT, 1965, BIOCHEM BIOPH RES CO, V18, P153, DOI 10.1016/0006-291X(65)90732-1; Miller J.H., 1972, EXPT MOL GENETICS; MOLINARO M, 1968, J BIOL CHEM, V243, P1277; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Nomanbhoy T, 2001, NAT STRUCT BIOL, V8, P344, DOI 10.1038/86228; Palmeros B, 2000, GENE, V247, P255, DOI 10.1016/S0378-1119(00)00075-5; RICHAUD C, 1993, J BIOL CHEM, V268, P26827; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; Sambrook J., 2002, MOL CLONING LAB MANU; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Swairjo MA, 2000, EMBO J, V19, P6287, DOI 10.1093/emboj/19.23.6287; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; XU JM, 1995, J BACTERIOL, V177, P938, DOI 10.1128/jb.177.4.938-947.1995; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	36	67	73	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25090	25095		10.1074/jbc.M203208200	http://dx.doi.org/10.1074/jbc.M203208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983710	hybrid			2022-12-25	WOS:000176747000034
J	Phillip, D; Hobe, S; Paulsen, H; Molnar, P; Hashimoto, H; Young, AJ				Phillip, D; Hobe, S; Paulsen, H; Molnar, P; Hashimoto, H; Young, AJ			The binding of xanthophylls to the bulk light-harvesting complex of photosystem II of higher plants - A specific requirement for carotenoids with a 3-hydroxy-beta-end group	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							13-CIS VIOLAXANTHIN; IN-VITRO; RECONSTITUTION; PROTEIN; PIGMENT; NEOXANTHIN; SITES	The pigment composition of the light-harvesting complexes (LHCs) of higher plants is highly conserved. The bulk complex (LHCIIb) binds three xanthophyll molecules in combination with chlorophyll (Chl) a and b. The structural requirements for binding xanthophylls to LHCIIb have been examined using an in vitro reconstitution procedure. Reassembly of the monomeric recombinant LHCIIb was performed using a wide range of native and nonnative xanthophylls, and a specific requirement for the presence of a hydroxy group at C-3 on a single beta-end group was identified. The presence of additional substituents (e.g. at C-4) did not interfere with xanthophyll binding, but they could not, on their own, support reassembly. cis isomers of zeaxanthin, violaxanthin, and lutein were not bound, whereas all-trans-neoxanthin and different chiral forms of lutein and zeaxanthin were incorporated into the complex. The C-3 and C-3' diols lactucaxanthin (a carotenoid native to many plant LHCs) and eschscholtzxanthin (a retro-carotenoid) both behaved very differently from lutein and zeaxanthin in that they would not support complex reassembly when used alone. Lactucaxanthin could, however, be bound when lutein was also present, and it showed a high affinity for xanthophyll binding site N1. In the presence of lutein, lactucaxanthin was readily bound to at least one lutein-binding site, suggesting that the ability to bind to the complex and initiate protein folding may be dependent on different structural features of the carotenoid molecule. The importance of carotenoid end group structure and ring-to-chain conformation around the C-6-C-7 torsion angle of the carotenoid molecule in binding and complex reassembly is discussed.	Liverpool John Moores Univ, Sch Biol & Earth Sci, Liverpool L3 3AF, Merseyside, England; Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Univ Pecs, Sch Med, Dept Med Chem, H-7601 Pecs, Hungary; Osaka City Univ, Dept Phys, Osaka 5600043, Japan	Liverpool John Moores University; Johannes Gutenberg University of Mainz; University of Pecs; Osaka Metropolitan University	Young, AJ (corresponding author), Liverpool John Moores Univ, Sch Biol & Earth Sci, Byrom St, Liverpool L3 3AF, Merseyside, England.	a.j.young@livjm.ac.uk	Paulsen, Harald/D-3742-2011	Young, Andrew/0000-0001-6251-0944				Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bialek-Bylka GE, 1998, PHOTOSYNTH RES, V56, P255, DOI 10.1023/A:1006090210001; Britton G, 1997, PURE APPL CHEM, V69, P2075, DOI 10.1351/pac199769102075; Buchecker R., 1996, SPECTROSCOPY-US, V1B, P63; Bungard RA, 1999, P NATL ACAD SCI USA, V96, P1135, DOI 10.1073/pnas.96.3.1135; CAMMARATA KV, 1992, PHOTOSYNTH RES, V33, P235, DOI 10.1007/BF00030034; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Demmig-Adams B, 1999, ADV PHOTOSYNTH, V8, P245; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Goodwin T.W, 1980, BIOCH CAROTENOIDS, V1; Grudzinski W, 2001, BBA-BIOENERGETICS, V1503, P291, DOI 10.1016/S0005-2728(00)00206-1; Hashimoto H, 2002, J MOL STRUCT, V604, P125, DOI 10.1016/S0022-2860(01)00648-2; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 1999, ADV PHOTOSYNTH, V8, P271; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HUNTER CN, 1994, J BACTERIOL, V176, P3692, DOI 10.1128/JB.176.12.3692-3697.1994; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; Koyama Y, 1999, ADV PHOTOSYNTH, V8, P161; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Kumagai MH, 1998, PLANT J, V14, P305, DOI 10.1046/j.1365-313X.1998.00128.x; Lichtenthaler H.K., 1983, ANALYSIS-UK, V11, P591, DOI [10.1042/bst0110591, DOI 10.1042/BST0110591]; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; MEYER M, 1993, Z NATURFORSCH C, V48, P461; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PHILLIP D, 1995, PHOTOSYNTH RES, V43, P273, DOI 10.1007/BF00029940; Phillip D, 1999, J PHOTOCH PHOTOBIO B, V49, P89, DOI 10.1016/S1011-1344(99)00019-6; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; RUBAN AV, 1999, J PHOTOCHEM PHOTOBIO, V68, P829; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; Takaichi S, 1998, PLANT CELL PHYSIOL, V39, P968, DOI 10.1093/oxfordjournals.pcp.a029461; Todd JB, 1998, BIOCHEMISTRY-US, V37, P17458, DOI 10.1021/bi981114e; Young A., 1993, CAROTENOIDS PHOTOSYN, P16, DOI DOI 10.1007/978-94-011-2124-8_2	39	46	47	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25160	25169		10.1074/jbc.M202002200	http://dx.doi.org/10.1074/jbc.M202002200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991953	hybrid			2022-12-25	WOS:000176747000042
J	Ariga, A; Namekawa, J; Matsumoto, N; Inoue, J; Umezawa, K				Ariga, A; Namekawa, J; Matsumoto, N; Inoue, J; Umezawa, K			Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; SIGNAL-TRANSDUCTION; TARGET GENES; CANCER CELLS; TNF; TRANSCRIPTION; JNK; EXPRESSION; APOPTOSIS; INDUCTION	We previously designed and synthesized an NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti-inflammatory activity in vivo. In the present study we looked into its mechanism of inhibition. DHMEQ inhibited tumor necrosis factor-alpha (TNF-alpha)-and 12-O-tetradecanoylphorbol-13-acetate-induced transcriptional activity of NF-kappaB in human T cell leukemia Jurkat cells. It also inhibited the TNF-alpha-induced DNA binding of nuclear NF-kappaB but not the phosphorylation and degradation Of IkappaB. Moreover, DHMEQ inhibited the TNF-alpha-induced nuclear accumulation of p65, a component of NF-kappaB. It also inhibited TNF-alpha-induced nuclear transport of green fluorescent protein-tagged p65. On the other hand, DHMEQ did not inhibit the nuclear transport of Smad2 and large T antigen. Also, it did not inhibit TNF-alpha-induced activation of JNK but synergistically induced apoptosis with TNF-alpha in Jurkat cells. Taken together, these data indicate that DHMEQ is a unique inhibitor of NF-kappaB acting at the level of nuclear translocation.	Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2230061, Japan; Inst Microbial Chem, Shinagawa Ku, Tokyo 1410021, Japan	Keio University	Umezawa, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2230061, Japan.							Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2449; ANTWERP DJV, 1996, SCIENCE, V274, P787; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Erkel G, 1996, BIOCHEM BIOPH RES CO, V226, P214, DOI 10.1006/bbrc.1996.1335; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gehrt A, 1998, J ANTIBIOT, V51, P455, DOI 10.7164/antibiotics.51.455; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Matsumoto N, 2000, BIOORG MED CHEM LETT, V10, P865, DOI 10.1016/S0960-894X(00)00114-1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHACOV AN, 1990, J EXP MED, V171, P35; Shoji S, 1998, BIOCHEM BIOPH RES CO, V249, P745, DOI 10.1006/bbrc.1998.9221; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Umezawa K, 2000, ANTI-CANCER DRUG DES, V15, P239; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xia DX, 2000, BIOCHEM PHARMACOL, V60, P717, DOI 10.1016/S0006-2952(00)00367-1; Yang JM, 2001, CANCER RES, V61, P4901; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	46	198	205	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24625	24630		10.1074/jbc.M112063200	http://dx.doi.org/10.1074/jbc.M112063200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983688	hybrid			2022-12-25	WOS:000176611800086
J	Foury, F; Roganti, T				Foury, F; Roganti, T			Deletion of the mitochondrial carrier genes MRS3 and MRS4 suppresses mitochondrial iron accumulation in a yeast frataxin-deficient strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE HOMOLOG; SPLICING DEFECTS; TRANSPORTER; EXPRESSION; PROTEINS; TRANSCRIPTION; BIOGENESIS; STORAGE; SYSTEM	The mitochondrial solute carriers Mrs3p and Mrs4p were originally isolated as multicopy suppressors of intron splicing defects. We show here that MRS4 is coregulated with the iron regulon genes, and up-regulated in a strain deficient for Yfh1p, the yeast homologue of human frataxin. Using in vivo Fe-55 cell radiolabeling we show that in glucose-grown cells mitochondrial iron accumulation is 5-15 times higher in DeltaYFH1 than in wildtype strain. However, although in a DeltaYFH1DeltaMRS3DeltaMRS4 strain, the intracellular Fe-55 content is extremely high, the mitochondrial iron concentration is decreased to almost wild-type levels. Moreover, DeltaYFH1DeltaMRS3DeltaMRS4 cells grown in high iron media do not lose their mitochondrial genome. Conversely, a DeltaYFH1 strain overexpressing MRS4 has an increased mitochondrial iron content and no mitochondrial genome. Therefore, MRS4 is required for mitochondrial iron accumulation in AYFH1 cells. Expression of the iron regulon and intracellular Fe-55 content are higher in a DeltaMRS3DeltaMRS4 strain than in the wild type. Nevertheless, the mitochondrial Fe-55 content, a balance between iron uptake and exit, is decreased by a factor of two. Moreover, Fe-55 incorporation into heme by ferrochelatase is increased in an MRS4-overexpressing strain. The function of MRS4 in iron import into mitochondria is discussed.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Universite Catholique Louvain	Foury, F (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Pl Croix Sud,2-20, B-1348 Louvain, Belgium.	foury@fysa.ucl.ac.be						Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Belenkiy R, 2000, BBA-BIOMEMBRANES, V1467, P207, DOI 10.1016/S0005-2736(00)00222-4; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; CLAISSE ML, 1970, EUR J BIOCHEM, V16, P430, DOI 10.1111/j.1432-1033.1970.tb01098.x; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gregan J, 2001, GENE DEV, V15, P2229, DOI 10.1101/gad.201301; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	34	139	142	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24475	24483		10.1074/jbc.M111789200	http://dx.doi.org/10.1074/jbc.M111789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12006577	hybrid			2022-12-25	WOS:000176611800067
J	Lu, XQ; Tan, CK; Zhou, JQ; You, M; Carastro, LM; Downey, KM; So, AG				Lu, XQ; Tan, CK; Zhou, JQ; You, M; Carastro, LM; Downey, KM; So, AG			Direct interaction of proliferating cell nuclear antigen with the small subunit of DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; PCNA BINDING; CALF THYMUS; SCHIZOSACCHAROMYCES-POMBE; AUXILIARY PROTEIN; REPLICATION FORK; INHIBITOR; REPAIR; IDENTIFICATION	The interaction between proliferating cell nuclear antigen (PCNA) and DNA polymerase 5 is essential for processive DNA synthesis during DNA replication/repair; however, the identity of the subunit of DNA polymerase 5 that directly interacts with PCNA has not been resolved until now. In the present study we have used reciprocal co-immunoprecipitation experiments to determine which of the two subunits of core DNA polymerase 5, the 125-kDa catalytic subunit or the 50-kDa small subunit, directly interacts with PCNA. We found that PCNA co-immunoprecipitated with human p50, as well as calf thymus DNA polymerase 5 heterodimer, but not with p125 alone, suggesting that PCNA directly interacts with p50 but not with p125. A PCNA-binding motif, similar to the sliding clamp-binding motif of bacteriophage RB69 DNA polymerase, was identified in the N terminus of p50. A 22-amino acid oligopeptide containing this sequence (MRPFL) was shown to bind PCNA by far Western analysis and to compete with p50 for binding to PCNA in co-immunoprecipitation experiments. The binding of p50 to PCNA was inhibited by p21, suggesting that the two proteins compete for the same binding site on PCNA. These results establish that the interaction of PCNA with DNA polymerase 5 is mediated through the small subunit of the enzyme.	Univ Miami, Sch Med, Dept Med R99, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	So, AG (corresponding author), Univ Miami, Sch Med, Dept Med R99, POB 016960, Miami, FL 33101 USA.				NIDDK NIH HHS [DK26206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARROYO MP, 1996, J BIOL CHEM, V271, P1571; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Carastro LM, 2002, NUCLEIC ACIDS RES, V30, P2232, DOI 10.1093/nar/30.10.2232; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Downey KM, 1995, METHOD ENZYMOL, V262, P84; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P6655; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Harlow E, 1999, USING ANTIBODIES LAB, P321; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; He H, 2001, P NATL ACAD SCI USA, V98, P11979, DOI 10.1073/pnas.221452098; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; NG L, 1991, J BIOL CHEM, V266, P11699; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Reynolds N, 1999, GENE, V230, P15, DOI 10.1016/S0378-1119(99)00058-X; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tratner I, 1997, BIOCHEM BIOPH RES CO, V231, P321, DOI 10.1006/bbrc.1997.6082; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG J, 1995, GENOMICS, V29, P179, DOI 10.1006/geno.1995.1229; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; ZHOU JQ, 1997, NUCLEIC ACIDS RES, V25, P1090; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	61	41	48	14	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24340	24345		10.1074/jbc.M200065200	http://dx.doi.org/10.1074/jbc.M200065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986310	hybrid			2022-12-25	WOS:000176611800049
J	Nakamura, J; Tajima, G; Sato, C; Furukohri, T; Konishi, K				Nakamura, J; Tajima, G; Sato, C; Furukohri, T; Konishi, K			Substrate regulation of calcium binding in Ca2+-ATPase molecules of the sarcoplasmic reticulum - I. Effect of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITE; HIGH-AFFINITY; PUMP PROTEIN; PHOSPHORYLATION; CA-2+-ATPASE; MODULATION; KINETICS; VESICLES; ACID	The effect of ATP on calcium binding of the Ca2+-ATPase of the sarcoplasmic reticulum has not been clarified. By comparing the calcium dependence of the ATPase activity and of phosphorylation of the ATPase molecules with that of calcium binding in the absence of ATP, we show the existence of two types of regulatory site of the enzyme molecules at which ATP binding variously improves the calcium binding performance of the molecules depending on the aggregation state of the molecules and pH; the two regulatory sites bind ATP at submillimolar (0.25 mm) and millimolar (5 mm) ATP, respectively. The results are discussed based on a model of two conformational variants (A and B forms) of the chemically equivalent ATPase molecules (Nakamura, J., and Furukohri, T. (1994) J. Biol. Chem. 269, 30818-30821). For example, in the sarcoplasmic reticulum membrane at pH 7.40, submillimolar ATP converted the calcium binding manner of the A form from noncooperative (Hill number (n(H)) of similar to1) to cooperative (n(H) similar to 2), concurrent with a decrease in the apparent calcium affinity (K-0.5) from 2-6 to 0.1-0.3 muM. The binding of the A form became almost the same as that of the B form (n(H) similar to 2), (K-0.5 similar to 0.2 muM), which was not affected by ATP. Millimolar ATP further decreased the K-0.5 of the cooperative binding of the two forms to similar to0.05 muM. Regulation of the calcium binding performance by ATP is discussed in terms of monomeric and oligomeric pathway models.	Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Tohoku Gakuin Univ, Fac Liberal Arts, Izumi Ku, Sendai, Miyagi 9813193, Japan; Kohchi Univ, Fac Sci, Inst Biol, Akebono, Kohchi 7808520, Japan; Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Tsukuba, Ibaraki 3058568, Japan	Tohoku University; Tohoku Gakuin University; Kochi University; National Institute of Advanced Industrial Science & Technology (AIST)	Nakamura, J (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 9808578, Japan.	jun-n@mail.cc.tohoku.ac.jp	Sato, Chikara/M-7183-2016	Sato, Chikara/0000-0001-5543-4496				BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BONTING SL, 1961, ARCH BIOCHEM BIOPHYS, V95, P416, DOI 10.1016/0003-9861(61)90170-9; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CARVALHOALVES PC, 1985, J BIOL CHEM, V260, P4282; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2307; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HOBBS AS, 1983, J BIOL CHEM, V258, P8163; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1967, J BIOL CHEM, V242, P4637; KHAN MMT, 1966, J AM CHEM SOC, V88, P668; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Mignaco JA, 1996, BIOCHEMISTRY-US, V35, P3886, DOI 10.1021/bi9518353; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; Nakamura J, 1997, J BIOL CHEM, V272, P19290, DOI 10.1074/jbc.272.31.19290; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1319, DOI 10.1093/oxfordjournals.jbchem.a121838; OGAWA Y, 1972, J BIOCHEM-TOKYO, V71, P571; Ogawa Y, 1973, ORG ENERGY TRANSDUCI, P127; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TADA M, 1978, PHYSIOL REV, V58, P1; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792	51	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24180	24190		10.1074/jbc.M111834200	http://dx.doi.org/10.1074/jbc.M111834200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976321	hybrid			2022-12-25	WOS:000176611800028
J	Mey, A; Gandrillon, O; McNagny, KM; Clegg, DO; Samarut, J				Mey, A; Gandrillon, O; McNagny, KM; Clegg, DO; Samarut, J			The v-erbA oncogene blocks expression of alpha 2/beta 1 integrin a normal inhibitor of erythroid progenitor proliferation	ONCOGENE			English	Article						erythropoiesis; self-renewal; oncogene; v-erbA; VLA-2	MARROW STROMAL CELLS; GROWTH-FACTOR-BETA; HORMONE-RECEPTOR; HEMATOPOIETIC PROGENITORS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ADHERENT CELLS; SELF-RENEWAL; ADHESION; COLLAGEN	T2EC are chicken erythrocytic progenitors that balance between self-renewal and differentiation as a function of response to specific growth factors. Their transformation by the v-erbA oncogene locks them into the self-renewal program. We show here that the expression of the VLA-2 integrin alpha2 subunit mRNA is downregulated by v-erbA and that VLA-2 engagement and clustering, brought about by treatment with an alpha-specific antibody or by culture on the VLA-2 ligand collagen I, inhibits T2EC proliferation. From competition studies using antibodies, VLA-2 was shown to be involved in the collagen-induced response. While engagement of VLA-2 inhibited proliferation, it was not sufficient to induce differentiation. The transformation of T2EC by v-erbA decreased their interaction with collagen I and the VLA-2 brake on cell proliferation, which may account for the increased proliferation potential of transformed erythrocytic progenitors and for their shedding into the blood of infected chickens. Our data suggest that the interaction between erythroid progenitors and collagen, mediated by VLA-2, play a major role in the control of erythropoiesis in vitro and that this pathway is a target of the v-erbA oncogene.	Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, F-69008 Lyon, France; Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, F-69622 Villeurbanne, France; Univ British Columbia, Dept Med Genet, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of British Columbia; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samarut, J (corresponding author), Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, 46 Allee Italie, F-69008 Lyon, France.	Jacques.Samarut@ens-lyon.fr	McNagny, Kelly/P-5239-2014; Samarut, Jacques/AAD-2587-2019	McNagny, Kelly/0000-0003-4737-3499; MEY, Anne/0000-0002-2643-5702	NEI NIH HHS [EY 09736] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009736] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arroyo AG, 1999, IMMUNITY, V11, P555, DOI 10.1016/S1074-7613(00)80131-4; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENTLEY SA, 1982, BRIT J HAEMATOL, V50, P491, DOI 10.1111/j.1365-2141.1982.tb01945.x; BENTLEY SA, 1980, BLOOD, V56, P1006; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BRADSHAW AD, 1995, DEVELOPMENT, V121, P3593; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; Cann GM, 1996, DEV BIOL, V180, P82, DOI 10.1006/dbio.1996.0286; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; Coulombel L, 1997, ACTA HAEMATOL-BASEL, V97, P13, DOI 10.1159/000203655; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DINNEN RD, 1994, CELL GROWTH DIFFER, V5, P855; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; Goltry KL, 1997, BLOOD, V90, P138; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; Hamamura K, 1996, BLOOD, V87, P2513, DOI 10.1182/blood.V87.6.2513.bloodjournal8762513; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; KERST JM, 1993, BLOOD, V81, P344; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KOENIGSMANN M, 1992, BLOOD, V79, P657; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; Mey A, 1998, INFECT IMMUN, V66, P2547, DOI 10.1128/IAI.66.6.2547-2552.1998; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SPOONCER E, 1983, J CELL BIOL, V96, P510, DOI 10.1083/jcb.96.2.510; STONE EM, 1985, P NATL ACAD SCI USA, V82, P1628, DOI 10.1073/pnas.82.6.1628; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955-0674(98)80113-0; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844; YODER MC, 1995, EXP HEMATOL, V23, P961; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZUCKERMAN KS, 1983, BLOOD, V61, P540	51	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2864	2872		10.1038/sj.onc.1205411	http://dx.doi.org/10.1038/sj.onc.1205411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973646				2022-12-25	WOS:000175063700011
J	Malcangio, M; Getting, S; Grist, J; Cunningham, JR; Bradbury, EJ; Issa, PC; Lever, IJ; Pezet, S; Perretti, M				Malcangio, M; Getting, S; Grist, J; Cunningham, JR; Bradbury, EJ; Issa, PC; Lever, IJ; Pezet, S; Perretti, M			A novel control mechanism based on GDNF modulation of somatostatin release from sensory neurones	FASEB JOURNAL			English	Article						substance P; evoked release; spinal cord; thermal hypersensitivity; inflammation	RAT SPINAL-CORD; DORSAL-HORN NEURONS; SUBSTANCE-P; NEUROTROPHIC FACTOR; RECEPTOR; NEUROPEPTIDES; HYPERALGESIA; ACTIVATION; IMMUNOREACTIVITY; INVOLVEMENT	Small-diameter sensory neurones found in the rat dorsal root ganglia (DRG) include cells sensitive to glial cell line-derived neurotrophic factor (GDNF), which express the inhibitory peptide somatostatin (SOM). Here we addressed the functional relationship between GDNF and sensory neurone-derived SOM. Topical application of GDNF through the rat isolated dorsal horn of the spinal cord promoted activity-induced release of SOM from central terminals of sensory neurones. Once released by sensory neurones, SOM is known to act, at least in part, by opposing the action of Substance P (SP) in neurogenic inflammation. Therefore, we evaluated GDNF ability to modulate two well-documented effects of peripherally and centrally administered SP. Local application of GDNF in the mouse air pouch reduced SP-induced leukocyte migration. This effect of GDNF was mimicked by the SOM analog octreotide (OCT) and required intact SOM neuronal pools. Intrathecal injection of GDNF activated rat lumbar dorsal horn neurones and inhibited intrathecal SP-induced thermal hypersensitivity. This effect of GDNF was reversed by the SOM antagonist c-SOM and mimicked by OCT. In conclusion we propose GDNF regulation of neuronal SOM release as a novel mechanism that, if explored, may lead to new therapeutic strategies based on local release of somatostatin.	Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Ctr Res Neurosci, London WC2R 2LS, England; St Thomas Hosp, Rayne Inst, Vis & Ophthalmol Res Grp, London SE1 7EH, England; William Harvey Res Inst, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; Queen Mary University London	Malcangio, M (corresponding author), KCL, Ctr Neurosci, Hodgkin Bldg,Guys Campus,London Bridge, London SE1 1UL, England.	Marzia.Malcangio@kcl.ac.uk	Issa, Peter Charbel/E-8935-2018; Issa, Peter Charbel/F-9603-2011; PEZET, sophie/AAR-1239-2021	Issa, Peter Charbel/0000-0002-0351-6673; PEZET, sophie/0000-0002-3305-3315; Bradbury, Elizabeth/0000-0003-4252-0234; Malcangio, Marzia/0000-0003-4296-5727				ALVAREZ FJ, 1990, NEUROSCIENCE, V38, P343, DOI 10.1016/0306-4522(90)90033-Z; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Carlton SM, 2001, PAIN, V90, P233, DOI 10.1016/S0304-3959(00)00407-3; CECCATELLI S, 1987, PEPTIDES, V8, P371, DOI 10.1016/0196-9781(87)90114-8; CHAPMAN V, 1992, NEUROPEPTIDES, V23, P147, DOI 10.1016/0143-4179(92)90115-D; CHRUBASIK J, 1984, LANCET, V2, P1208; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; GREEN PG, 1992, NEUROSCIENCE, V50, P745, DOI 10.1016/0306-4522(92)90461-A; GRIFFITHS EC, 1977, ACTA ENDOCRINOL-COP, V85, P1; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; Helyes Z, 2000, NEUROSCI LETT, V278, P185, DOI 10.1016/S0304-3940(99)00936-2; HELYES Z, 2000, BRIT J PHARMACOL, V134, P1571; Heppelmann B, 1997, PAIN, V73, P377, DOI 10.1016/S0304-3959(97)00124-3; HOKFELT T, 1976, NEUROSCIENCE, V1, P131, DOI 10.1016/0306-4522(76)90008-7; Holzer P, 1998, GEN PHARMACOL, V30, P5, DOI 10.1016/S0306-3623(97)00078-5; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Issa PC, 2001, J NEUROCHEM, V78, P221, DOI 10.1046/j.1471-4159.2001.00430.x; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; KARALIS K, 1994, J CLIN INVEST, V93, P2000, DOI 10.1172/JCI117193; KOLASINSKI SL, 1992, ARTHRITIS RHEUM, V35, P369, DOI 10.1002/art.1780350402; Lever IJ, 2001, J NEUROSCI, V21, P4469, DOI 10.1523/JNEUROSCI.21-12-04469.2001; MALCANGIO M, 1993, J PHARMACOL EXP THER, V266, P1490; Malcangio M, 1997, EUR J NEUROSCI, V9, P1101, DOI 10.1111/j.1460-9568.1997.tb01462.x; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANCUSO F, 1995, J IMMUNOL, V155, P377; MORTON CR, 1988, NEUROPEPTIDES, V12, P189, DOI 10.1016/0143-4179(88)90054-6; MURASE K, 1982, BRAIN RES, V234, P170, DOI 10.1016/0006-8993(82)90483-8; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Olson L, 1997, TRENDS NEUROSCI, V20, P277, DOI 10.1016/S0166-2236(97)01098-9; Paice JA, 1996, NEUROSURGERY, V38, P203, DOI 10.1097/00006123-199601000-00047; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PAYAN DG, 1986, J BIOL CHEM, V261, P14321; PERRETTI M, 1993, IMMUNOLOGY, V80, P73; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; PROUDLOCK F, 1993, J COMP NEUROL, V327, P289, DOI 10.1002/cne.903270210; Ren K, 1996, BRIT J PHARMACOL, V117, P196, DOI 10.1111/j.1476-5381.1996.tb15174.x; SANDKUHLER J, 1990, NEUROSCIENCE, V34, P565, DOI 10.1016/0306-4522(90)90165-Z; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; Schindler M, 1998, BRAIN RES, V798, P25, DOI 10.1016/S0006-8993(98)00361-8; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Sluka KA, 1997, BRIT J PHARMACOL, V120, P1263, DOI 10.1038/sj.bjp.0701044; Szolcsanyi J, 1998, BRIT J PHARMACOL, V123, P936, DOI 10.1038/sj.bjp.0701685; Todd AJ, 1998, NEUROSCIENCE, V85, P459, DOI 10.1016/S0306-4522(97)00669-6; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TUCHSCHERER MM, 1989, J NEUROSCI, V9, P195; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	52	18	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					730	+		10.1096/fj.01-0971fje	http://dx.doi.org/10.1096/fj.01-0971fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978739				2022-12-25	WOS:000174755900016
